PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Salim, A; Hadjizacharia, P; DuBose, J; Brown, C; Inaba, K; Chan, L; Margulies, DR				Salim, Ali; Hadjizacharia, Pantelis; DuBose, Joseph; Brown, Carlos; Inaba, Kenji; Chan, Linda; Margulies, Daniel R.			Role of anemia in traumatic brain injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; BLOOD-TRANSFUSION; SUBARACHNOID HEMORRHAGE; OXYGEN CARRIER; HEMOGLOBIN; RESUSCITATION; MANAGEMENT; MORTALITY	BACKGROUND: Few studies have investigated the effects of anemia in patients with traumatic brain injury (TBI). The objective of this study was to examine the role of anemia and blood transfusion on outcomes in TBI patients. STUDY DESIGN: We performed a retrospective review of all blunt trauma patients with TBI admitted to the ICU from July 1998 to December 2005. Admission and daily ICU blood hemoglobin (hemoglobin) levels and blood transfusions during the first week of hospitalization were measured. Anemia was defined as a hemoglobin < 9 g/dL occurring on 3 consecutive blood draws. The role of anemia and blood transfusion was investigated using logistic regression adjusting for factors, with p < 0.2 from the bivariate analysis. RESULTS: During the study period, 1, 150 TBI patients were admitted to the ICU. When both anemia and blood transfusion were included in the full model, blood transfusion was significantly associated with higher mortality (adjusted odds ratio [AOR], 2.19 [95% CI, 1.27, 3.751; p = 0.0044) and more complications (AOR, 3.67 [95% CI, 2.18, 6.171; p < 0.0001), but anemia was not. But when transfusion was not included in the full model, anemia was a significant risk factor for mortality (AOR, 1.59 (95% CI, 1.13, 2.24); p = 0.007) and for complications (AOR, 1.95 [95% CI, 1.42, 2.70]; p < 0.0001). CONCLUSIONS: Blood transfusion is associated with significantly worse outcomes in traumatic brain injured patients. Inaddition, blood transfusion is a major contributing factor to worse outcomes in TBI patients who are anemic. We caution against the liberal use of blood in TBI patients.	[Salim, Ali; Margulies, Daniel R.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Hadjizacharia, Pantelis; DuBose, Joseph; Inaba, Kenji; Chan, Linda] Univ So Calif, Med Ctr, Los Angeles, CA USA; [Hadjizacharia, Pantelis; DuBose, Joseph; Inaba, Kenji; Chan, Linda] Div Trauma, Los Angeles, CA USA; [Brown, Carlos] Brackenridge Hosp, Div Trauma, Austin, TX USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Ste 8215N, Los Angeles, CA 90048 USA.						Berezina TL, 2002, J SURG RES, V102, P6, DOI 10.1006/jsre.2001.6306; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CORWIN HL, 1995, CHEST, V108, P767, DOI 10.1378/chest.108.3.767; Ely EW, 1999, NEW ENGL J MED, V340, P467, DOI 10.1056/NEJM199902113400610; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; Herbert PC, 2001, CRIT CARE MED, V29, P227; JAIN R, 1992, MED CLIN N AM, V76, P727, DOI 10.1016/S0025-7125(16)30350-9; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; Kuriyan M, 2004, CRIT CARE CLIN, V20, P237, DOI 10.1016/j.ccc.2003.12.001; Lane P, 2002, NAT MED, V8, P657, DOI 10.1038/nm0702-657; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; McCrossan L, 2002, BRIT J ANAESTH, V88, P6, DOI 10.1093/bja/88.1.6; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Naidech AM, 2006, NEUROSURGERY, V59, P775, DOI 10.1227/01.NEU.0000232662.86771.A9; Rao SV, 2004, JAMA-J AM MED ASSOC, V292, P1555, DOI 10.1001/jama.292.13.1555; Shackford SR, 2005, J TRAUMA, V59, P560; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	26	95	97	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	SEP	2008	207	3					398	406		10.1016/j.jamcollsurg.2008.03.013			9	Surgery	Surgery	349FD	WOS:000259265800014	18722946				2021-06-18	
J	Bavisetty, S; McArthur, DL; Dusick, JR; Wang, C; Cohan, P; Boscardin, WJ; Swerdloff, R; Levin, H; Chang, DJ; Muizelaar, JP; Kelly, DF				Bavisetty, Sumati; McArthur, David L.; Dusick, Joshua R.; Wang, Christina; Cohan, Pejman; Boscardin, W. John; Swerdloff, Ronald; Levin, Harvey; Chang, Dongwoo J.; Muizelaar, Jan P.; Kelly, Daniel F.			Chronic hypopituitarism after traumatic brain injury: Risk assessment and relationship to outcome	NEUROSURGERY			English	Article						endocrinopathy; growth hormone deficiency; hypopituitarism; injury severity; pituitary failure; traumatic brain injury	QUALITY-OF-LIFE; GROWTH-HORMONE DEFICIENCY; SEVERE HEAD-INJURY; GH REPLACEMENT THERAPY; PATIENT-REPORTED OUTCOMES; LONG-TERM; ADULT PATIENTS; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; SPONTANEOUS-RECOVERY	OBJECTIVE: Chronic pituitary dysfunction is increasingly recognized as a sequela of traumatic brain injury. We sought to define the incidence, risk factors, and neurobehavioral consequences of chronic hormonal deficiencies after complicated mild, moderate, or severe traumatic brain injury. METHODS: Patients aged 14 to 80 years were prospectively enrolled at the time of injury and assessed at 3 and 6 to 9 months after injury for hormonal function and neurobehavioral consequences. Major and minor (subclinical) hormonal deficiencies, including growth hormone deficiency (GHD) and growth hormone insufficiency (GHI), were identified. Acute injury characteristics, neurobehavioral, and quality of life measures were compared in patients with and without major hormonal deficits by the use of multivariate analysis. RESULTS: Out of 70 patients (mean age, 32 yr; median Glasgow Coma Scale score, 7; 19% women) tested at 6 to 9 months after injury, 15 (21 %) had at least one major hormonal deficiency, 20 (29%) had minor deficiencies, and 30 (43%) had major and/or minor deficiencies. Patients with major deficiencies included 16% with GHD or GHI, 10.5% with hypogonadism, and 1.4% with diabetes insipidus. None of the patients required adrenal or thyroid replacement. At 6 to 9 months after injury, patients with major hormonal deficits had more abnormal acute computed tomographic findings (P = 0.014), greater acute and chronic body mass index (P < 0.01), and a worse Disability Rating Scale score (multivariate P = 0.04). Compared with the 59 growth hormone-sufficient patients, the 11 patients with GHD or GHI had worse Disability Rating Scale scores (multivariate P = 0.04), greater rates of depression, (90 versus 53%; multivariate P = 0.06), and worse quality of life in the Short Form-36 domains of energy and fatigue (multivariate P = 0.03), emotional well-being (multivariate P = 0.02), and general health (multivariate P = 0.07). CONCLUSION: Chronic hypopituitarism warranting hormone replacement occurs in approximately 20% of patients after complicated mild, moderate, or severe traumatic brain injury and is associated with more severe brain injuries and increased disability. GHD and GHI are also associated with increased disability, poor quality of life, and a greater likelihood of depression. The clinical significance of minor hormonal deficits, which occur in almost 30% of patients, warrants further study. Given that major deficiencies are readily treatable, routine pituitary hormonal testing within 6 months of injury is indicated for this patient population.	[Kelly, Daniel F.] John Wayne Canc Inst, Neuroendocrine Tumor Ctr, Santa Monica, CA 90404 USA; [Bavisetty, Sumati; Wang, Christina; Swerdloff, Ronald] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [McArthur, David L.; Dusick, Joshua R.] Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; [Wang, Christina] Harbor UCLA Med Ctr, Dept Med, Div Endocrinol, Torrance, CA 90509 USA; [Cohan, Pejman] Univ Calif Los Angeles, Sch Med, Div Endocrinol, Los Angeles, CA USA; [Cohan, Pejman] Univ Calif Los Angeles, Sch Med, Gonda Diabet Ctr, Los Angeles, CA USA; [Boscardin, W. John] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA; [Boscardin, W. John] Univ Calif Los Angeles, Sch Publ Hlth, Dept Med, Los Angeles, CA 90024 USA; [Boscardin, W. John] Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA USA; [Boscardin, W. John] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; [Levin, Harvey] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Chang, Dongwoo J.; Muizelaar, Jan P.] Univ Calif Davis, Davis Med Ctr, Dept Neurosurg, Sacramento, CA 95817 USA	Kelly, DF (corresponding author), John Wayne Canc Inst, Neuroendocrine Tumor Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	kellyd@jwcj.org	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K23 RR 1729801, M01 RR 19975, MO1 RR00425, M01 RR 00865] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 40777, NS30308] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000425, M01RR019975, K23RR017298, M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS040777] Funding Source: NIH RePORTER		Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; Abs R, 2005, GROWTH HORM IGF RES, V15, P349, DOI 10.1016/j.ghir.2005.06.018; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2001, Pituitary, V4, P129, DOI 10.1023/A:1015306705154; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Alexander GM, 1998, HORM BEHAV, V33, P85, DOI 10.1006/hbeh.1998.1439; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Arwert LI, 2005, NEUROENDOCRINOLOGY, V81, P31, DOI 10.1159/000084872; Arwert LI, 2005, HORM BEHAV, V47, P343, DOI 10.1016/j.yhbeh.2004.11.015; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Blum WF, 2003, J CLIN ENDOCR METAB, V88, P4158, DOI 10.1210/jc.2002-021792; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; DANIEL PM, 1959, LANCET, V2, P927; DANIEL PM, 1963, SCI BASIS MED ANN, V84, P83; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Feldt-Rasmussen U, 2004, GROWTH HORM IGF RES, V14, pS51, DOI 10.1016/j.ghir.2004.03.013; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Giusti M, 1998, EUR J CLIN INVEST, V28, P13; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; HOFFMAN DM, 1994, LANCET, V344, P482, DOI 10.1016/S0140-6736(94)91821-X; Howell S, 2001, HORM RES, V56, P86, DOI 10.1159/000048142; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KARLBERG J, 1995, ACTA OBSTET GYN SCAN, V74, P367, DOI 10.3109/00016349509024430; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Koltowska-Haggstrom M, 2005, HORM RES, V64, P46, DOI 10.1159/000087444; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kraus JF, 2003, ANN EMERG MED, V41, P18, DOI 10.1067/mem.2003.1; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mahajan T, 2004, EUR J ENDOCRINOL, V151, P325, DOI 10.1530/eje.0.1510325; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; MCGAULEY GA, 1990, HORM RES, V33, P52, DOI 10.1159/000181584; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Miller KK, 2006, J CLIN ENDOCR METAB, V91, P1683, DOI 10.1210/jc.2005-2596; Mukherjee A, 2005, J CLIN ENDOCR METAB, V90, P1542, DOI 10.1210/jc.2004-0832; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Qoubaitary A, 2006, J ANDROL, V27, P853, DOI 10.2164/jandrol.106.000281; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rollero A, 1998, NEUROPSYCHOBIOLOGY, V38, P73, DOI 10.1159/000026520; Rosen T, 1997, EUR J ENDOCRINOL, V137, P240, DOI 10.1530/eje.0.1370240; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Smith A., 1973, SYMBOL DIGIT MODALIT; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Svensson J, 2004, GROWTH HORM IGF RES, V14, P207, DOI 10.1016/j.ghir.2003.12.001; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomei G, 1991, J Neurosurg Sci, V35, P61; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003-032006; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wiren L, 1998, CLIN ENDOCRINOL, V48, P613, DOI 10.1046/j.1365-2265.1998.00462.x; Zarkovic M, 1999, J CLIN ENDOCR METAB, V84, P3170, DOI 10.1210/jc.84.9.3170	96	95	97	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2008	62	5					1080	1093		10.1227/01.neu.0000325870.60129.6a			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	320FG	WOS:000257218500019	18580806				2021-06-18	
J	Stulemeijer, M; Vos, PE; Bleijenberg, G; van der Werf, SP				Stulemeijer, Maja; Vos, Pieter E.; Bleijenberg, Gijs; van der Werf, Sieberen P.			Cognitive complaints after mild traumatic brain injury: Things are not always what they seem	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						brain injuries; outcome assessment; cognitive functioning; distress; personality; fatigue	CHRONIC-FATIGUE-SYNDROME; POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; SELF-REPORT; NEUROPSYCHOLOGICAL DEFICITS; MEMORY COMPLAINTS; SOCIAL INHIBITION; MAJOR DEPRESSION; TEST-SCORES; PERFORMANCE	Objective: To compare nonreferred, emergency department (ED)-admitted mild traumatic brain injury (MTBI) patients with and without self-reported cognitive complaints on (1) demographic variables and injury characteristics; (2) neuropsychological test performance; (3) 12-day self-monitoring of perceived cognitive problems; and (4) emotional distress, physical functioning, and personality. Methods: (Neuro)psychological assessment was carried out 6 months post-injury in 79 patients out of a cohort of 618 consecutive MTBI patients aged 18-60, who attended the ED of our level I trauma centre. Cognitive complaints were assessed with the Rivermead Postconcussional Symptoms Questionnaire (RPSQ). In addition, patients monitored concentration problems and forgetfulness during 12 consecutive days. Results: Self-reported cognitive complaints were reported by 39% of the patients. These complaints were strongly related to lower educational levels, emotional distress, personality, and poorer physical functioning (especially fatigue) but not to injury characteristics. Severity of self-reported cognitive complaints was neither associated with the patients' daily observations of cognitive problems nor with outcome on a range of neuropsychological tests. Conclusion: Self-reported cognitive complaints were more strongly related to premorbid traits and physical and emotional state factors than to actual cognitive impairments. In line with previous work, this suggests that treatment of emotional distress and fatigue may also reduce cognitive complaints. Cognitive outcome assessment of symptomatic MTBI patients should not be restricted to checklist ratings only, but also include a (neuro) psychological screening. In addition, daily monitoring of complaints is a useful method to gather information about the frequency and pattern of cognitive problems in daily life. (c) 2007 Elsevier Inc. All rights reserved.	[Stulemeijer, Maja; van der Werf, Sieberen P.] Radboud Univ Nijmegen Med Ctr, Dept Med Psychol, Nijmegen, Netherlands; [Vos, Pieter E.] Radboud Univ Nijmegen Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Bleijenberg, Gijs] Radboud Univ Nijmegen Med Ctr, Expert Ctr Chron Fatigue, Nijmegen, Netherlands	Vos, PE (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Neurol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Bleijenberg, Gijs/E-6984-2010				Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Antikainen R, 2001, EUR ARCH PSY CLIN N, V251, P6, DOI 10.1007/s004060170060; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beck AT, 1997, BEHAV RES THER, V35, P785, DOI 10.1016/S0005-7967(97)00025-9; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carter SL, 2003, NEUROPSYCHOLOGY, V17, P410, DOI 10.1037/0894-4105.17.3.410; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; DEGORATIS LR, 1994, SCL90 SYNPTOM CHECKL; Delis DC, 1987, CALIFORNIA VERBAL LE; Denollet J, 2006, EUR HEART J, V27, P171, DOI 10.1093/eurheartj/ehi616; Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Elixhauser A, 1999, EPILEPSY RES, V37, P13, DOI 10.1016/S0920-1211(99)00036-4; Gallo LC, 2005, J BEHAV MED, V28, P433, DOI 10.1007/s10865-005-9010-y; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; HANNINEN T, 1994, J AM GERIATR SOC, V42, P1; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kliegel MK, 2005, INT PSYCHOGERIATR, V17, P499, DOI 10.1017/S1041610205001638; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; McHugh T, 2006, BRAIN COGNITION, V60, P209; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Prouteau A, 2004, SCHIZOPHR RES, V69, P85, DOI 10.1016/j.schres.2003.08.011; RABBITT P, 1990, BRIT J PSYCHOL, V81, P1, DOI 10.1111/j.2044-8295.1990.tb02342.x; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Ross SR, 2006, J CLIN EXP NEUROPSYC, V28, P111, DOI 10.1080/13803390590929270; SANDERMAN R, 1995, HET METEN PERSOONLIJ; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Schmand B, 1991, Tijdschr Gerontol Geriatr, V22, P15; Servaes P, 2002, CANCER-AM CANCER SOC, V95, P2017, DOI 10.1002/cncr.10891; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Thiele C, 2002, CLIN PSYCHOL PSYCHOT, V9, P1; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Werf SP, 2002, NEUROPSY NEUROPSY BE, V15, P2; Vercoulen JHMM, 1996, LANCET, V347, P858, DOI 10.1016/S0140-6736(96)91345-8; Vercoulen JHMM, 1998, J CLIN EXP NEUROPSYC, V20, P144, DOI 10.1076/jcen.20.2.144.1160; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wechsler D, 1997, WAIS 3 ADM SCORING M; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; Zimmermann P., 1996, TESTBATTERIJ AANDACH	67	95	95	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999	1879-1360		J PSYCHOSOM RES	J. Psychosomat. Res.	DEC	2007	63	6					637	645		10.1016/j.jpsychores.2007.06.023			9	Psychiatry	Psychiatry	240XY	WOS:000251622700011	18061755				2021-06-18	
J	Popa-Wagner, A; Badan, I; Walker, L; Groppa, S; Patrana, N; Kessler, C				Popa-Wagner, Aurel; Badan, Irina; Walker, Lary; Groppa, Sergiu; Patrana, Nicoleta; Kessler, Christof			Accelerated infarct development, cytogenesis and apoptosis following transient cerebral ischemia in aged rats	ACTA NEUROPATHOLOGICA			English	Article						stroke; aging; recovery; ischemia; rat; BrdU; GFAP; oligodendrocytes; microglia; CD8+lymphocytes; cytogenesis; vascular tree	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; ARTERY OCCLUSION; GENE-EXPRESSION; DENTATE GYRUS; ADULT RATS; STRUCTURAL PLASTICITY; CELL-PROLIFERATION; OXIDATIVE STRESS	Old age is associated with a deficient recovery from stroke, but the cellular mechanisms underlying such phenomena are poorly understood. To address this issue, focal cerebral ischemia was produced by reversible occlusion of the right middle cerebral artery in 3- and 20-month-old male Sprague-Dawley rats. Aged rats showed a delayed and suboptimal functional recovery in the post-stroke period. Using BrdU-labeling, quantitative immunohistochemistry and 3-D reconstruction of confocal images, we found that aged rats are predisposed to rapidly develop an infarct within the first few days after ischemia. The emergence of the necrotic zone is associated with a high rate of cellular degeneration, premature accumulation of proliferating BrdU-positive cells that appear to emanate from capillaries in the infarcted area, and a large number of apoptotic cells. With double labeling techniques, we were able to identify, for the first time, over 60% of BrdU-positive cells either as reactive microglia (45%), oligodendrocyte progenitors (17%), astrocytes (23%), CD8+ lymphocytes (4%), or apoptotic cells (< 1%). Paradoxically, despite a robust reactive phenotype of microglia and astrocytes in aged rats, at 1-week post-stroke, the number of proliferating microglia and astrocytes was lower in aged rats than in young rats. Our data indicate that aging is associated with rapid infarct development and a poor prognosis for full recovery from stroke that is correlated with premature cellular proliferation and increased cellular degeneration and apoptosis in the infarcted area.	Ernst Moritz Arndt Univ Greifswald, Dept Neurol, D-17487 Greifswald, Germany; Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA USA; Emory Univ, Dept Neurol, Atlanta, GA USA; Univ Med & Pharm, Craiova, Romania; Univ Klinikum Schleswig Holstein, Klin Neuropadiatrie, Kiel, Germany	Popa-Wagner, A (corresponding author), Ernst Moritz Arndt Univ Greifswald, Dept Neurol, Ellernholzstr 1-2, D-17487 Greifswald, Germany.	wagnerap@uni-greifswald.de	Popa-Wagner, Aurel/E-2541-2013; Popa-Wagner, Aurel/I-2581-2019; Groppa, Sergiu/A-5711-2019; Walker, L C/J-6541-2015; Groppa, Sergiu/G-4606-2014	Groppa, Sergiu/0000-0002-2551-5655; Walker, L C/0000-0001-9166-3261; 	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00165] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000165] Funding Source: NIH RePORTER		Adams MM, 2001, EXP NEUROL, V172, P244, DOI 10.1006/exnr.2001.7794; Adams MM, 2001, P NATL ACAD SCI USA, V98, P8071, DOI 10.1073/pnas.141215898; Aliev G, 2002, BRAIN PATHOL, V12, P21; Ardel-Rahman A, 2004, GLIA, V47, P299, DOI 10.1002/glia.20047; Asher RA, 2000, J NEUROSCI, V20, P2427; Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; Barnett HJM, 2002, CLIN EXP HYPERTENS, V24, P563, DOI 10.1081/CEH-120015333; Bondolfi L, 2002, J NEUROSCI, V22, P515, DOI 10.1523/JNEUROSCI.22-02-00515.2002; Brown AW, 2003, NEUROBIOL AGING, V24, P607, DOI 10.1016/S0197-4580(02)00129-X; Bury SD, 2002, J NEUROSCI, V22, P8597; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chen ZJ, 2002, MOL CELL NEUROSCI, V20, P125, DOI 10.1006/mcne.2002.1102; DAVIS M, 1995, STROKE, V26, P1072, DOI 10.1161/01.STR.26.6.1072; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Floyd RA, 2000, ANN NY ACAD SCI, V899, P222; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gozal D, 2003, J NEUROCHEM, V86, P1545, DOI 10.1046/j.1471-4159.2003.01973.x; HAJDU MA, 1990, CIRC RES, V66, P1747, DOI 10.1161/01.RES.66.6.1747; Hess DC, 2004, ARCH NEUROL-CHICAGO, V61, P483, DOI 10.1001/archneur.61.4.483; Hiona A, 2004, ANN NY ACAD SCI, V1019, P96, DOI 10.1196/annals.1297.018; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; HOFF SF, 1982, J COMP NEUROL, V205, P246, DOI 10.1002/cne.902050304; HOWARD CV, 1998, UNBIASED STEREOLOGY; HSU JE, 2006, EXP NEUROL      0621; Jones TA, 1999, J NEUROSCI, V19, P10153; Justicia C, 2006, J CEREBR BLOOD F MET, V26, P421, DOI 10.1038/sj.jcbfm.9600198; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kuan CY, 2004, J NEUROSCI, V24, P10763, DOI 10.1523/JNEUROSCI.3883-04.2004; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Li Y, 2001, CELL TRANSPLANT, V10, P31; Lindner MD, 2003, J NEUROSCI, V23, P10913; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; NICHOLS NR, 1995, NEUROBIOL AGING, V16, P105, DOI 10.1016/0197-4580(95)80013-H; Ohta K, 2003, NEUROSCI LETT, V335, P159, DOI 10.1016/S0304-3940(02)01177-1; Packard D S Jr, 1973, Differentiation, V1, P397, DOI 10.1111/j.1432-0436.1973.tb00137.x; PARHAD IM, 1995, J NEUROSCI RES, V41, P355, DOI 10.1002/jnr.490410308; Petullo D, 1999, LIFE SCI, V64, P1099, DOI 10.1016/S0024-3205(99)00038-7; Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196; Popa-Wagner A, 1999, J CEREBR BLOOD F MET, V19, P425, DOI 10.1097/00004647-199904000-00008; Popa-Wagner A, 1999, NEUROSCIENCE, V94, P395, DOI 10.1016/S0306-4522(99)00204-3; Popa-Wagner A, 2000, J GERONTOL A-BIOL, V55, pB242, DOI 10.1093/gerona/55.5.B242; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Retchkiman I, 1996, NEUROBIOL AGING, V17, P41, DOI 10.1016/0197-4580(95)02022-5; Riddle DR, 2003, AGEING RES REV, V2, P149, DOI 10.1016/S1568-1637(02)00064-8; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Roberts EL, 1997, ADV EXP MED BIOL, V411, P83; SCHAUWECKER PE, 1995, J NEUROSCI, V15, P2462; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Stone DJ, 2000, EXP NEUROL, V165, P46, DOI 10.1006/exnr.2000.7455; Sutherland GR, 1996, STROKE, V27, P1663, DOI 10.1161/01.STR.27.9.1663; Tomimoto H, 2003, ACTA NEUROPATHOL, V106, P527, DOI 10.1007/s00401-003-0749-3; Vallieres L, 2003, J NEUROSCI, V23, P5197; Vogelgesang S, 2002, CLIN NEUROPATHOL, V21, P99; WANG LJC, 1995, STROKE, V26, P2087, DOI 10.1161/01.STR.26.11.2087; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Woods AG, 1998, NEUROSCIENCE, V83, P663; Yu WH, 2002, NEUROBIOL AGING, V23, P105, DOI 10.1016/S0197-4580(01)00258-5	67	95	100	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2007	113	3					277	293		10.1007/s00401-006-0164-7			17	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	134EF	WOS:000244065100006	17131130				2021-06-18	
J	Dahlberg, C; Hawley, L; Morey, C; Newman, J; Cusick, CP; Harrison-Felix, C				Dahlberg, C; Hawley, L; Morey, C; Newman, J; Cusick, CP; Harrison-Felix, C			Social communication skills in persons with post-acute traumatic brain injury: Three perspectives	BRAIN INJURY			English	Article						traumatic brain injury; social communication skills; participation	QUALITY-OF-LIFE; HEAD-INJURY; FOLLOW-UP; COMPETENCE; DISCOURSE; OUTCOMES; SATISFACTION; INDIVIDUALS; DYSFUNCTION; INTEGRATION	Objective: To describe social communication skills problems identified by individuals with traumatic brain injury (TBI) compared to significant other (SO) and clinician ratings; and associations between these skills and participation outcome measures. Design: Cohort study. Methods: Sixty individuals with TBI >= 1 year post-injury were administered measures of social communication, societal participation, social integration and life satisfaction. Clinicians and SOs rated the social communication skills of the subjects. Results: Subjects were able to identify social communication skills problems, associated with lower ratings of community integration and satisfaction with life. Males reported higher scores in social communication and social integration than females. SOs and clinicians identified more social skills problems than subjects. Conclusions: Persons with TBI experience social communication skills deficits, associated with decreased societal participation and life satisfaction. Further research is needed to determine efficacy of social communication skills treatment and association with improved participation and satisfaction with life.	Craig Hosp, CCC, SLP, Englewood, CO USA	Dahlberg, C (corresponding author), Craig Hosp, CCC, SLP, 3425 S Clarkson St, Englewood, CO USA.	cdahlberg@craighospital.org					Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; COEHLO CA, 1991, J HEAD TRAUMA REHAB, V6, P92; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GROHER M, 1999, REHABILITATION ADULT, P87; HAGEN C, 1974, RANCHO AMIGOS SCALES; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; LoBello SC, 2003, J REHABIL RES DEV, V40, P293, DOI 10.1682/JRRD.2003.07.0293; Long K, 1998, J AM GERIATR SOC, V46, P1103, DOI 10.1111/j.1532-5415.1998.tb06648.x; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; SOHLBERG MM, 1989, INTRO COGNITIVEF REH, P214; Sokol K, 1999, 127 ANN M AM PUBL HL; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Ylvisaker M., 1987, COMMUNITY REENTRY HE, P137; Ylvsaker M, 2001, BRAIN INJ SOURCE, V5	38	95	95	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2006	20	4					425	435		10.1080/02699050600664574			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GN	WOS:000237730700007	16716988				2021-06-18	
J	Ke, Y; Chi, LY; Xu, RS; Luo, C; Gozal, D; Liu, RG				Ke, Yan; Chi, Liying; Xu, Renshi; Luo, Chun; Gozal, David; Liu, Rugao			Early response of endogenous adult neural progenitor cells to acute spinal cord injury in mice	STEM CELLS			English	Article						neural progenitor cells; neurogenesis; spinal cord injury; nestin; radial glia	CENTRAL-NERVOUS-SYSTEM; NEWLY GENERATED NEURONS; STEM-CELLS; SUBVENTRICULAR ZONE; PRECURSOR CELLS; RADIAL GLIA; HUNTINGTONS-DISEASE; COMPRESSION INJURY; BRAIN-INJURY; MOUSE MODEL	Adult neural progenitor cells (NPCs) are an attractive source for functional replacement in neurodegenerative diseases and traumatic injury to the central nervous system (CNS). It has been shown that transplantation of neural stem cells or NPCs into the lesioned region partially restores CNS function. However, the capacity of endogenous NPCs in replacement of neuronal cell loss and functional recovery of spinal cord injury (SCI) is apparently poor. Furthermore, the temporal and spatial response of endogenous adult NPCs to SCI remains largely undefined. To this end, we have analyzed the early organization, distribution, and potential function of NPCs in response to SCI, using nestin enhancer (promoter) controlled LacZ reporter transgenic mice. We showed that there was an increase of NPC proliferation, migration, and neurogenesis in adult spinal cord after traumatic compression SCI. The proliferation of NPCs detected by 5-bromodeoxyuridine incorporation and LacZ staining was restricted to the ependymal zone (EZ) of the central canal. During acute SCI, NPCs in the EZ of the central canal migrated vigorously toward the dorsal direction, where the compression lesion is generated. The optimal NPC migration occurred in the adjacent region close to the epicenter. More significantly, there was an increased de novo neurogenesis from NPCs 24 hours after SCI. The enhanced proliferation, migration, and neurogenesis of (from) endogenous NPCs in the adult spinal cord in response to SCI suggest a potential role for NPCs in attempting to restore SCI-mediated neuronal dysfunction.	Univ N Dakota, Sch Med, Dept Anat & Cell Biol, Grand Forks, ND 58202 USA; Univ Louisville, Dept Pediat, Kosair Childrens Hosp, Res Inst, Louisville, KY 40292 USA	Liu, RG (corresponding author), Univ N Dakota, Sch Med, Dept Anat & Cell Biol, Grand Forks, ND 58202 USA.	rliu@medicine.nodak.edu	Gozal, David/M-9492-2017	Xu, Renshi/0000-0003-0313-3434	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL075034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG023923] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL075034, R01 HL075034-01, HL75034] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03 AG023923-01, AG23923, R03 AG023923] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045829-01, NS45829, R01 NS045829] Funding Source: Medline		Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Aoki Y, 2000, FASEB J, V14, P1965, DOI 10.1096/fj.00-0105com; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bedard A, 2004, DEV BRAIN RES, V151, P159, DOI 10.1016/j.devbrainres.2004.03.021; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Blight A, 1988, J Am Paraplegia Soc, V11, P26; BLIGHT AR, 1992, J NEUROTRAUM, V9, P147, DOI 10.1089/neu.1992.9.147; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Clarke D, 2001, CURR OPIN GENET DEV, V11, P575, DOI 10.1016/S0959-437X(00)00235-5; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Farooque M, 2000, ACTA NEUROPATHOL, V100, P13, DOI 10.1007/s004010051187; Fujiwara Y, 2004, NEUROSCI LETT, V366, P287, DOI 10.1016/j.neulet.2004.05.080; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hasegawa K, 2005, EXP NEUROL, V193, P394, DOI 10.1016/j.expneurol.2004.12.024; Hill CE, 2004, EXP NEUROL, V190, P289, DOI 10.1016/j.expneurol.2004.05.043; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Lie DC, 2002, J NEUROSCI, V22, P6639; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Martin D, 1996, J NEUROSCI RES, V45, P588; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Mitsuhashi T, 2001, P NATL ACAD SCI USA, V98, P6435, DOI 10.1073/pnas.111051398; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Romanko MJ, 2004, PROG NEUROBIOL, V74, P77, DOI 10.1016/j.pneurobio.2004.07.001; Roy NS, 2000, NAT MED, V6, P271; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Setoguchi T, 2004, EXP NEUROL, V189, P33, DOI 10.1016/j.expneurol.2003.12.007; Setoguchi T, 2001, BRAIN RES, V921, P219, DOI 10.1016/S0006-8993(01)03123-7; Takahashi M, 2003, J NEUROPATH EXP NEUR, V62, P185, DOI 10.1093/jnen/62.2.185; Tattersfield AS, 2004, NEUROSCIENCE, V127, P319, DOI 10.1016/j.neuroscience.2004.04.061; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; Weiss S, 1996, J NEUROSCI, V16, P7599; Xu W, 2005, SPINAL CORD, V43, P204, DOI 10.1038/sj.sc.3101674; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yaworsky PJ, 1999, DEV BIOL, V205, P309, DOI 10.1006/dbio.1998.9035	45	95	110	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	APR	2006	24	4					1011	1019		10.1634/stemcells.2005-0249			9	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	085WY	WOS:000240636300024	16339643	Green Accepted			2021-06-18	
J	Wall, SE; Williams, WH; Cartwright-Hatton, S; Kelly, TP; Murray, J; Murray, M; Owen, A; Turner, M				Wall, SE; Williams, WH; Cartwright-Hatton, S; Kelly, TP; Murray, J; Murray, M; Owen, A; Turner, M			Neuropsychological dysfunction following repeat concussions in jockeys	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; SPORTS; RECOVERY; SYMPTOMS; YOUNG; MRI	Background: Single and repeat concussions have a high prevalence in sport. However, there is limited research into longterm risks associated with single and repeat concussions. Objectives: To determine the effects of single and repeat historical concussions on the neuropsychological functioning and neurological reports of licensed jockeys. Methods: Six hundred and ninety eight licensed jockeys in the UK were assessed for neurological and neuropsychological symptoms of concussion at least three months after potential episodes. Results: Jockeys reporting multiple historical injuries versus a single injury showed reliable decrements on a measure of response inhibition and, to a less robust degree, on divided attention. Younger adults showed greater vulnerability. Conclusions: Repeated concussion is associated with reliable decrements in cognitive performance - even after a three month window for recent recovery.	Univ Exeter, Sch Psychol, Exeter EX4 4QG, Devon, England; Univ Exeter, Ctr Cognit, Washington Singer Labs, Exeter EX4 4QG, Devon, England; Univ Manchester, Div Clin Psychol, Manchester M13 9PL, Lancs, England; Newcastle Gen Hosp, Dept Neuropsychol, Reg Neurosci Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Surrey, Guildford GU2 7XL, Surrey, England; Astley Ainslie Hosp, NHS Lothian, Edinburgh EH9 2HL, Midlothian, Scotland; S Birmingham Primary Care Trust, Birmingham B13 8JL, W Midlands, England; Jockey Club, London WC2H 8AL, England	Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Exeter EX4 4QG, Devon, England.	w.h.williams@ex.ac.uk	Owen, Adrian M/B-4997-2015	cartwright-hatton, sam/0000-0003-3868-3540; williams, huw/0000-0003-0670-2620	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G108/604] Funding Source: Medline		Baddeley A.D., 1992, SPEED CAPACITY LANGU; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BRADSHAW I, 2001, DEV DISORDERS FRONTO; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; DELIA L, 1989, COLOUR TRAILS 1 2; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Ogden JA, 1998, NEUROPSYCHOL REHABIL, V8, P413; Teasdale TW, 2003, J NEUROL NEUROSUR PS, V74, P933, DOI 10.1136/jnnp.74.7.933; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wills SM, 2001, BRAIN INJURY, V15, P645, DOI 10.1080/02699050010010502	24	95	97	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2006	77	4					518	520		10.1136/jnnp.2004.061044			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	031JT	WOS:000236701400023	16543534	Green Published			2021-06-18	
J	Hornero, R; Aboy, M; Abasolo, D; McNames, J; Goldstein, B				Hornero, R; Aboy, M; Abasolo, D; McNames, J; Goldstein, B			Interpretation of approximate entropy: Analysis of intracranial pressure approximate entropy during acute intracranial hypertension	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						approximate entropy; complex analysis; intracranial hypertension; intracranial pressure irregularity; sample entropy; traumatic brain injury (TBI)	ARTERIAL PULSE PRESSURE; TIME-SERIES; HEART-RATE; RESPIRATORY CHANGES; NEURAL-NETWORKS; QUANTIFICATION; COMPLEXITY; IRREGULARITY; PULSATILITY; REGULARITY	We studied changes in intracranial pressure (ICP) complexity, estimated by the approximate entropy (ApEn) of the ICP signal, as subjects progressed from a state of normal ICP (< 20-25 mmHg) to acutely elevated ICP (an ICP "spike" defined as ICP > 25 mmHg for < 5 m-in). We hypothesized that the measures of intracranial pressure (ICP) complexity and irregularity would decrease during acute elevations in ICP. To test this hypothesis we studied ICP spikes in pediatric subjects with severe traumatic brain injury (TBI). We conclude that decreased complexity of ICP coincides with episodes of intracranial hypertension (ICH) in TBI. This suggests that the complex regulatory mechanisms that govern intracranial pressure are disrupted during acute rises in ICP. Furthermore, we carried out a series of experiments where ApEn was used to analyze synthetic signals of different characteristics with the objective of gaining a better understanding of ApEn itself, especially its interpretation in biomedical signal analysis.	Oregon Inst Technol, Elect Engn Technol Dept, Portland, OR 97229 USA; Univ Valladolid, ETSIT, Dept Signal Theory & Commun, E-47011 Valladolid, Spain; Portland State Univ, Dept Elect & Comp Engn, Biomed Signal Proc Lab, Portland, OR 97201 USA; Portland State Univ, Dept Pediat, Complex Syst Lab, Portland, OR 97201 USA	Aboy, M (corresponding author), Oregon Inst Technol, Elect Engn Technol Dept, Portland, OR 97229 USA.	mateoaboy@ieee.org	Abasolo, Daniel/B-7322-2009; Hornero, Roberto/M-5313-2019; Hornero, Roberto/B-5398-2008; Aboy, Mateo/K-4060-2019	Abasolo, Daniel/0000-0002-4268-2885; Hornero, Roberto/0000-0001-9915-2570; Hornero, Roberto/0000-0001-9915-2570; Aboy, Mateo/0000-0002-5168-4321			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ANDELSON P, 2003, CRIT CARE MED, V31, pS417; BRADA LJ, 2001, AM J PHYSIOL-HEART C, V280, pH2674; Bruhn J, 2000, ANESTHESIOLOGY, V93, P981, DOI 10.1097/00000542-200010000-00018; Caiani EG, 2002, PHYSIOL MEAS, V23, P567, DOI 10.1088/0967-3334/23/3/308; Caiani EG, 2000, PHYSIOL MEAS, V21, P175, DOI 10.1088/0967-3334/21/1/321; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; DZEWCZYKOWSKI J, 1975, INTRACRANIAL PRESSUR, V2, P392; Engoren M, 1998, CRIT CARE MED, V26, P1817, DOI 10.1097/00003246-199811000-00021; FLEISHER LA, 1993, ANESTHESIOLOGY, V78, P683, DOI 10.1097/00000542-199304000-00011; FUSHENG Y, 2001, NONLINEAR BIOMEDICAL, V2; Goldstein B, 2003, CRIT CARE MED, V31, P433, DOI 10.1097/01.CCM.0000050285.93097.52; KAPLAN DT, 1991, BIOPHYS J, V59, P945, DOI 10.1016/S0006-3495(91)82309-8; KOLMOGOROV AN, 1958, DOKL AKAD NAUK SSSR+, V119, P861; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Larsen G Y, 1999, Pediatr Rev, V20, P234, DOI 10.1542/pir.20-7-234; Luerssen T G, 1997, Semin Pediatr Neurol, V4, P146, DOI 10.1016/S1071-9091(97)80033-2; Michard F, 1999, AM J RESP CRIT CARE, V159, P935, DOI 10.1164/ajrccm.159.3.9805077; Michard F, 2000, AM J RESP CRIT CARE, V162, P134, DOI 10.1164/ajrccm.162.1.9903035; Pincus S, 1996, P NATL ACAD SCI USA, V93, P2083, DOI 10.1073/pnas.93.5.2083; PINCUS SM, 1994, AM J PHYSIOL, V266, pH1643, DOI 10.1152/ajpheart.1994.266.4.H1643; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1992, P NATL ACAD SCI USA, V89, P4432, DOI 10.1073/pnas.89.10.4432; PINCUS SM, 1992, AM J PHYSIOL, V262, pE741; Pincus SM, 2001, ANN NY ACAD SCI, V954, P245; PINCUS SM, 1993, AM J PHYSIOL, V264, pR638; Pincus SM, 1996, P NATL ACAD SCI USA, V93, P14100, DOI 10.1073/pnas.93.24.14100; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; Price D, 1980, INTRACRANIAL PRESSUR, P395; Radhakrishnan N, 1998, IEEE ENG MED BIOL, V17, P89, DOI 10.1109/51.677174; Rezek IA, 1998, IEEE T BIO-MED ENG, V45, P1186, DOI 10.1109/10.709563; Swiercz M, 2000, ACTA NEUROCHIR, V142, P401, DOI 10.1007/s007010050449; Tsui F.-C., 1996, Biomedical Engineering, Applications Basis Communications, V8, P566; Tsui FC, 1996, P SOC PHOTO-OPT INS, V2762, P220, DOI 10.1117/12.236039; Turner J, 1976, INTRACRANIAL PRESSUR, P283; Veldhuis JD, 2001, AM J PHYSIOL-REG I, V281, pR1975; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9; Zhang XS, 2001, IEEE T BIO-MED ENG, V48, P312, DOI 10.1109/10.914794	38	95	100	0	11	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	OCT	2005	52	10					1671	1680		10.1109/TBME.2005.855722			10	Engineering, Biomedical	Engineering	967UL	WOS:000232116600006	16235653				2021-06-18	
J	Nagdyman, N; Fleck, T; Schubert, S; Ewert, P; Peters, B; Lange, PE; Abdul-Khaliq, H				Nagdyman, N; Fleck, T; Schubert, S; Ewert, P; Peters, B; Lange, PE; Abdul-Khaliq, H			Comparison between cerebral tissue oxygenation index measured by near-infrared spectroscopy and venous jugular bulb saturation in children	INTENSIVE CARE MEDICINE			English	Article						near-infrared spectroscopy; tissue oxygenation index; cerebral oxygenation; jugular venous oxygen saturation; congenital heart defects; children	HYPOTHERMIC CIRCULATORY ARREST; CLOSED-HEAD INJURY; CARDIOPULMONARY BYPASS; OXYHEMOGLOBIN SATURATION; NIRO 300; OXIMETRY; SURGERY; NEURODEVELOPMENT; ISCHEMIA; INFANTS	Objective: To compare the cerebral tissue oxygenation index (TOI) measured by near-infrared spectroscopy (NIRS) with venous oxygen saturation in the jugular bulb (SjO(2)) during elective cardiac catheterization in children. Design and setting: Prospective observational clinical study in a catheterization laboratory for pediatric cardiology. Patients: Sixty children with congenital heart defects admitted to the catheterization laboratory. Measurements and results: TOI measured noninvasively by NIRS was compared to SjO(2) measured in the jugular bulb during cardiac catheterization. Patients were divided into two groups regarding body weight: below ( n= 29) and above 10 kg ( n= 31). Linear regression analysis and Pearson's correlation coefficient were calculated. Bland-Altman analysis, sensitivity, and specificity calculation for spatially resolved near-infrared spectroscopy with a cutoff level of 60% were performed. Simultaneously measured values for SjO(2) ( 67.3 +/- 9.8%, 40 - 84.1%) and TOI ( 65.7 +/- 7.2%, 39 - 80%) showed a significant correlation; the correlation in children weighing under 10 kg was stronger in children weighing over 10 kg. Bland-Altman analysis showed a mean bias of - 1.8% with limits of agreement between 11.7% and - 15.3% for all children. Sensitivity and specificity of the SRS method were 46% and 91%, respectively, for all children and 53% and 83% respectively in infants weighing under 10 kg. Conclusions: The results demonstrate that despite a significant correlation, sensitivity of spatially resolved spectroscopy is poor, and it is questionable whether TOI can be used reliably to detect low SjO(2).	Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects & Pediat Cardiol, D-13353 Berlin, Germany	Nagdyman, N (corresponding author), Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects & Pediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	nagdyman@dhzb.de	Fleck, Thilo Pierre Karl/H-9073-2019	Fleck, Thilo Pierre Karl/0000-0003-4531-5930			Abdul-Khaliq H, 2002, THORAC CARDIOV SURG, V50, P77, DOI 10.1055/s-2002-26698; ABDULKHALIQ H, 1998, Z HERZ THORAX GEFASS, V12, P65; Adcock LM, 1999, CLIN PERINATOL, V26, P893; Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Ali MS, 2001, CAN J ANAESTH, V48, P497, DOI 10.1007/BF03028317; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BROWN R, 1993, ANAESTHESIA, V48, P697, DOI 10.1111/j.1365-2044.1993.tb07184.x; Buunk G, 1998, ANAESTHESIA, V53, P13, DOI 10.1111/j.1365-2044.1998.00263.x; Chan MTV, 1997, ANAESTHESIA, V52, P705; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Daubeney PEF, 1996, ANN THORAC SURG, V61, P930, DOI 10.1016/0003-4975(95)01186-2; Dittrich H, 2003, HEART, V89, P436, DOI 10.1136/heart.89.4.436; FALLON P, 1993, ANN THORAC SURG, V56, P1473, DOI 10.1016/0003-4975(93)90733-X; Fearn SJ, 1997, ANAESTHESIA, V52, P704; Fortune PM, 2001, INTENS CARE MED, V27, P1401, DOI 10.1007/s001340100994; GAYLE MO, 1989, CRIT CARE MED, V17, P385, DOI 10.1097/00003246-198905000-00001; GERMON TJ, 1994, BRIT J ANAESTH, V73, P503, DOI 10.1093/bja/73.4.503; GERMON TJ, 1995, J NEUROL NEUROSUR PS, V58, P477, DOI 10.1136/jnnp.58.4.477; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Jonas RA, 1998, PEDIATR CARDIOL, V19, P321, DOI 10.1007/s002469900317; Kurth CD, 1997, J THORAC CARDIOV SUR, V113, P71, DOI 10.1016/S0022-5223(97)70401-X; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; MATCHER SJ, 1995, P SOC PHOTO-OPT INS, V2389, P486; Nagdyman N, 2003, BRIT J ANAESTH, V91, P438, DOI 10.1093/bja/aeg181; Nollert G, 2000, THORAC CARDIOV SURG, V48, P247, DOI 10.1055/s-2000-6895; Schulz G, 2002, INTENS CARE MED, V28, P184, DOI 10.1007/s00134-001-1182-5; SUZUKI S, 1999, P SOC PHOTO-OPT INS, V3579, P486; Ter Minassian A, 1999, ANESTHESIOLOGY, V91, P985; Thavasothy M, 2002, ANAESTHESIA, V57, P999, DOI 10.1046/j.1365-2044.2002.02826.x; Wahr JA, 1996, J CARDIOTHOR VASC AN, V10, P406, DOI 10.1016/S1053-0770(96)80107-8; WICKRAMASINGHE YABD, 1993, PEDIATR RES, V34, P15, DOI 10.1203/00006450-199307000-00004; Wypij D, 2003, J THORAC CARDIOV SUR, V126, P1397, DOI 10.1016/S0022-5223(03)00940-1	32	95	95	0	4	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2005	31	6					846	850		10.1007/s00134-005-2618-0			5	Critical Care Medicine	General & Internal Medicine	932UC	WOS:000229578000015	15803294				2021-06-18	
J	Pannu, R; Barbosa, E; Singh, AK; Singh, I				Pannu, R; Barbosa, E; Singh, AK; Singh, I			Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						atorvastatin; SCI; inflammation	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; KAPPA-B ACTIVATION; MESSENGER-RNA; LEWIS RATS; REDUCTASE INHIBITOR; MULTIPLE-SCLEROSIS	Spinal cord injury (SCI) is a devastating and complex clinical condition involving proinflammatory cytokines and nitric oxide toxicity that produces a predictable pattern of progressive injury entailing neuronal loss, axonal destruction, and demyelination at the site of impact. The involvement of proinflammatory cytokines and inducible nitric oxide synthase (iNOS) in exacerbation of SCI pathology is well documented. We have reported previously the antiinflammatory properties and immunomodulatory activities of statins (3-hydroxy-3-methylglutaryl [HMG]-CoA reductase inhibitors) in the animal model of multiple sclerosis, experimental allergic encephalitis (EAE). The present study was undertaken to investigate the efficacy of atorvastatin (Lipitor; ILP) treatment in attenuating SCI-induced pathology. Immunohistochemical detection and real-time PCR analysis showed increased expression of iNOS, tumor necrosis factor alpha (TNFalpha) and interleukin 1beta (IL-1beta) after SCI. In addition, neuronal apoptosis was detected 24 hr after injury followed by a profound increase in ED1-positive inflammatory infiltrates, glial fibrillary acidic protein (GFAP)-positive reactive astrocytes, and oligodendrocyte apoptosis by 1 week after SCI relative to control. LP treatment attenuated the SCI-induced iNOS, TNFalpha, and IL-1beta expression. LP also provided protection against SCI-induced tissue necrosis, neuronal and oligodendrocyte apoptosis, demyelination, and reactive gliosis. Furthermore, rats treated with LP scored much higher on the locomotor rating scale after SCI (19.13 +/- 0.53) than did untreated rats (9.04 +/- 1.22). This study therefore reports the beneficial effect of atorvastatin for the treatment of SCI-related pathology and disability. (C) 2004 Wiley-Liss, Inc.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA; Ralph H Johnson VA Med Ctr, Charleston, SC USA	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 96 Jonathan Lucas St, Charleston, SC 29425 USA.	singhi@musc.edu	Abrams, William R/A-5782-2008				Bal-Price A, 2001, J NEUROSCI, V21, P6480; BALENTINE JD, 1978, LAB INVEST, V39, P236; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bentley David, 1994, Current Opinion in Neurobiology, V4, P43, DOI 10.1016/0959-4388(94)90030-2; Bethea JR, 1998, J NEUROSCI, V18, P3251; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Davies SJA, 1998, TRENDS NEUROSCI, V21, P515, DOI 10.1016/S0166-2236(98)01335-6; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Dergham P, 2002, J NEUROSCI, V22, P6570; Dimitroulakos J, 2001, CLIN CANCER RES, V7, P158; Fawcett JW, 1998, SPINAL CORD, V36, P811, DOI 10.1038/sj.sc.3100769; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; HSU CY, 1985, J NEUROL SCI, V70, P275, DOI 10.1016/0022-510X(85)90169-8; HSU CY, 1986, J NEUROL SCI, V74, P289, DOI 10.1016/0022-510X(86)90114-0; HSU CY, 1989, ANN NY ACAD SCI, V559, P282; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Jin Z, 1997, J NEUROSCI, V17, P6256; KIERNAN JA, 1990, TRENDS PHARMACOL SCI, V11, P316, DOI 10.1016/0165-6147(90)90233-X; Kim GM, 2001, J NEUROSCI, V21, P6617; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; KRONKE M, 1990, CELL SIGNAL, V2, P1, DOI 10.1016/0898-6568(90)90027-8; LASSMANN H, 1979, ARCH NEUROL-CHICAGO, V36, P490, DOI 10.1001/archneur.1979.00500440060011; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Laufs U, 2000, TRENDS CARDIOVAS MED, V10, P143, DOI 10.1016/S1050-1738(00)00044-X; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Letourneau PC, 1996, PERSPECT DEV NEUROBI, V4, P111; Liu XZ, 1997, J NEUROSCI, V17, P5395; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pan WH, 1997, NEUROSCI BIOBEHAV R, V21, P603, DOI 10.1016/S0149-7634(96)00047-4; Pan WH, 1999, J NEUROSCI, V19, P3649; Pan WH, 2003, J NEUROIMMUNOL, V134, P111, DOI 10.1016/S0165-5728(02)00426-5; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Popovich PG, 1997, J NEUROPATH EXP NEUR, V56, P1323, DOI 10.1097/00005072-199712000-00007; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rattan R, 2003, FREE RADICAL BIO MED, V35, P1037, DOI 10.1016/S0891-5849(03)00459-3; Regan RF, 1996, NEUROSCI LETT, V213, P9, DOI 10.1016/0304-3940(96)12823-8; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab ME, 1996, PHYSIOL REV, V76, P319; Sequeira SM, 1997, NITRIC OXIDE-BIOL CH, V1, P315, DOI 10.1006/niox.1997.0144; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Taoka Y, 2000, J NEUROTRAUM, V17, P219, DOI 10.1089/neu.2000.17.219; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Weitz-Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165-6147(02)02077-1; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Wong WWL, 2001, CLIN CANCER RES, V7, P2067; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	77	95	102	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB 1	2005	79	3					340	350		10.1002/jnr.20345			11	Neurosciences	Neurosciences & Neurology	892FG	WOS:000226634800009	15605375				2021-06-18	
J	Varelas, PN; Conti, MM; Spanaki, MV; Potts, E; Bradford, D; Sunstrom, C; Fedder, W; Bey, LH; Jaradeh, S; Gennarelli, TA				Varelas, PN; Conti, MM; Spanaki, MV; Potts, E; Bradford, D; Sunstrom, C; Fedder, W; Bey, LH; Jaradeh, S; Gennarelli, TA			The impact of a neurointensivist-led team on a semiclosed neurosciences intensive care unit	CRITICAL CARE MEDICINE			English	Article						neurointensivist; intensive care unit; neurological; neurosurgical; closed; documentation	SEVERE HEAD-INJURY; RESOURCE UTILIZATION; THERAPEUTIC EFFICACY; PATIENT OUTCOMES; COHORT; DOCUMENTATION; HEMORRHAGE; GUIDELINES; EFFICIENCY; MODELS	Objective: To evaluate the impact of a newly appointed neurointensivist on neurosciences intensive care unit (NICU) patient outcomes and quality of care variables. Design: Observational cohort with historical controls. Setting: Ten-bed neurointensive care unit in tertiary university hospital. Patients: Mortality, length of stay (LOS), and discharge disposition of all patients admitted to the NICU were compared between two 19-month periods, before and after the appointment of a neurointensivist. Data regarding these patients were collected using the hospital database and the University Hospitals Consortium database. Individual patient medical records were reviewed for major complications and important prognostic variable documentation. Interventions: Appointment of a neurointensivist. Measurements and Main Results: We analyzed 1,087 patients before and 1,279 after the neurointensivist's appointment. The unadjusted in-hospital mortality decreased from 10.1% in the before to 9.1% in the after period (95% confidence interval, -1.3 to 3%, relative mortality reduction of 9.9%), but this decrease was significantly different than the expected increase of 1.4% in University Hospitals Consortium mortality during the same period (p = .048). The unadjusted mortality in the NICU decreased from 8% to 6.3% (95% confidence interval, -0.5 to 4, relative mortality reduction 21%) and mean NICU LOS from 3.5 to 2.9 days (95% confidence interval, 0.2 to 0.9, relative NICU LOS reduction 17%). A significant 42% reduction of the risk of death during the first 3 days of NICU admission (p = .003) and a 12% greater risk for NICU discharge (p = .02) were found in the after period in multivariate proportional hazard models. Discharge home increased from 51.7% in the before to 59.7% in the after period (95% confidence interval, 4 to 12, relative increase of 15%) and discharge to a nursing home decreased from 8.1% to 6.8% (95% confidence interval, -1 to 4, relative decrease of 16%). Although a higher total number of complications occurred in the after period, fewer of them occurred in the NICU (odds ratio, 0.2; 95% confidence interval, 0.08 to 0.54, p = .001); this may possibly be due to the better documentation by the NICU team in the after period. Conclusions. The institution of a neurointensivist-led team model was associated with an independent positive impact on patient outcomes, including a lower intensive care unit mortality, LOS, and discharge to a skilled nursing facility and a higher discharge home.	Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA; Froedtert Hosp, Milwaukee, WI USA	Varelas, PN (corresponding author), Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.		Varelas, Panayiotis/V-1702-2019				Arabi Y, 2004, INT J QUAL HEALTH C, V16, P149, DOI 10.1093/intqhc/mzh025; Baggs JG, 1999, CRIT CARE MED, V27, P1991, DOI 10.1097/00003246-199909000-00045; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Carlson RW, 1996, CRIT CARE CLIN, V12, P525, DOI 10.1016/S0749-0704(05)70260-8; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; CHARLSON ME, 1987, J CHRON DIS, V40, P31, DOI 10.1016/0021-9681(87)90094-4; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; COX DR, 1972, J R STAT SOC B, V34, P187; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Goodlin SJ, 1999, JAMA-J AM MED ASSOC, V282, P2333, DOI 10.1001/jama.282.24.2333; GROEGER JS, 1992, CRIT CARE MED, V20, P846, DOI 10.1097/00003246-199206000-00024; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Rapoport J, 1996, AM J RESP CRIT CARE, V153, P185, DOI 10.1164/ajrccm.153.1.8542114; RON A, 1989, ARCH INTERN MED, V149, P338, DOI 10.1001/archinte.149.2.338; Soto CM, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-22; Suarez Jose I., 2003, Neurology, V60, pA360; *U HEALTH SYST CON, 1998, UHC CLIN INF MAN RIS; Vincent JL, 2003, INTENS CARE MED, V29, pS74; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; Wood DL, 2001, AM J MED, V110, P332, DOI 10.1016/S0002-9343(00)00748-8; YEH TS, 1984, PEDIATR RES, V18, P445, DOI 10.1203/00006450-198405000-00011; Young M P, 2000, Eff Clin Pract, V3, P284	34	95	97	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2004	32	11					2191	2198		10.1097/01.CCM.0000146131.03578.21			8	Critical Care Medicine	General & Internal Medicine	872MN	WOS:000225211400003	15640630				2021-06-18	
J	Ringger, NC; O'Steen, BE; Brabham, JG; Silver, X; Pineda, J; Wang, KKW; Hayes, RL; Papa, L				Ringger, NC; O'Steen, BE; Brabham, JG; Silver, X; Pineda, J; Wang, KKW; Hayes, RL; Papa, L			A novel marker for traumatic brain injury: CSF alpha II-spectrin breakdown product levels	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; CSF; injury magnitude; lesion size; spectrin; S100 beta; tau	SEVERE HEAD-INJURY; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; SERUM S-100 PROTEIN; CEREBROSPINAL-FLUID; CALPAIN INHIBITOR; BIOCHEMICAL MARKERS; MITOCHONDRIAL DYSFUNCTION; T-2-WEIGHTED MRI; CARDIAC-SURGERY	Currently, there is no definitive diagnostic test for traumatic brain injury (TBI) to help physicians determine the seriousness of injury or the extent of cellular pathology. Calpain cleaves all-spectrin into breakdown products (SBDP) after TBI and ischemia. Mean levels of both ipsilateral cortex (IC) and cerebral spinal fluid (CSF) SBDP at 2, 6, and 24 h after two levels of controlled cortical impact (1.0 mm and 1.6 mm of cortical deformation) in rats were significantly elevated by injury. CSF and IC SBDP levels were significantly higher after severe (1.6 mm) injury than mild (1.0 mm) injury over time. The correlation between CSF SBDP levels and lesion size from T2-weighted magnetic resonance images 24 hours after TBI as well as correlation of tau and S100beta was assessed. Mean levels of CSF SBDP (r = 0.833) and tau (r = 0.693) significantly correlated with lesion size while levels of CSF S100beta did not (r = 0.188). Although levels of CSF and IC SBDP and lesion size are all significantly higher after 1.6 mm than 1.0 mm injury, the correlation between CSF SBDP and lesion size was not significant following the removal of controls from the analysis. This indicates CSF SBDP is a reliable marker of the presence or absence of injury. Furthermore, larger lesion sizes 24 h after TBI were negatively correlated with motor performance on days 1-5 after TBI (r = -0.708). Based on these data, evaluation of CSF SBDP levels as a biomarker of TBI is warranted in clinical studies.	Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injuries, Gainesville, FL 32610 USA; Univ Florida, AMRIS Facil, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Shands Hosp, Coll Med, Dept Emergency Med, Gainesville, FL USA	Ringger, NC (corresponding author), Univ Florida, McKnight Brain Inst, Dept Neurosci, 100 S Newell Dr,L1-100,POB 100244, Gainesville, FL 32610 USA.	ringger@ufbi.ufl.edu	Pineda, Jose/W-2806-2019; Silver, Xeve/AAP-3398-2021	Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39091, R01 NS40182] Funding Source: Medline		Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Bitsch A, 2002, EUR NEUROL, V47, P45, DOI 10.1159/000047946; Buduhan G, 2000, J TRAUMA, V49, P600, DOI 10.1097/00005373-200010000-00005; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Herrmann M, 1999, EUR J CARDIO-THORAC, V16, P513, DOI 10.1016/S1010-7940(99)00245-6; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Hill MD, 2000, CAN MED ASSOC J, V162, P1139; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McKeating EG, 1998, ACT NEUR S, V71, P117; MIRSKI MA, 1995, CRIT CARE MED, V23, P2038, DOI 10.1097/00003246-199512000-00013; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Palmer GC, 2001, ANN NY ACAD SCI, V939, P283; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; Reiber H, 2001, J NEUROL SCI, V184, P101, DOI 10.1016/S0022-510X(00)00501-3; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wang CZ, 1998, J ASIAN NAT PROD RES, V1, P1, DOI 10.1080/10286029808039839; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	68	95	96	0	3	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2004	21	10					1443	1456		10.1089/neu.2004.21.1443			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	867BT	WOS:000224817800008	15672634				2021-06-18	
J	Wennersten, A; Meijer, X; Holmin, S; Wahlberg, L; Mathiesen, T				Wennersten, A; Meijer, X; Holmin, S; Wahlberg, L; Mathiesen, T			Proliferation, migration, and differentiation of human neural stem/progenitor cells after transplantation into a rat model of traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain injury; neurosphere; differentiation; migration; rat	INTRACEREBRAL INFLAMMATORY RESPONSE; CENTRAL-NERVOUS-SYSTEM; ADULT MAMMALIAN BRAIN; PROGENITOR CELLS; STEM-CELLS; APOPTOTIC NEURODEGENERATION; NEURONAL DIFFERENTIATION; HUMAN CNS; IN-VIVO; HIPPOCAMPUS	Object. Cultures containing human neural stem and progenitor cells (neurospheres) have the capacity to proliferate and differentiate into the major phenotypes of the adult brain. These properties make them candidates for therapeutic transplantation in cases of neurological diseases that involve cell loss. In this study, long-term cultured and cryopreserved cells were transplanted into the traumatically injured rat brain to evaluate the potential for human neural stent/progenitor cells to survive and differentiate following traumatic injury. Methods. Neural stem/progenitor cell cultures were established from 10-week-old human forebrain. Immunosuppressed adult rats received a unilateral parietal cortical contusion injury, which was delivered using the weight-drop method. Immediately following the injury, these animals received transplants of neural stem/progenitor cells, which were placed close to the site of injury. Two or 6 weeks after the procedure, these animals were killed and their brains were examined by immunohistochemical analysis. At both 2 and 6 weeks postoperatively, the transplanted human cells were found in the perilesional zone, hippocampus, corpus callosum, and ipsilateral subependymal zone of the rats. Compared with the 2-week time point, an increased number of HuN-positive cells was observed at 6 weeks. In addition, at 6 weeks post-injury/transplantation, the cells were noted to cross the midline to the contralateral corpus callosum and into the contralateral cortex. Double labeling demonstrated neuronal and astrocytic, but not oligodendrocytic differentiation. Moreover, the cortex appeared to provide an environment that was less hospitable to neuronal differentiation than the hippocampus. Conclusions. This study shows that expandable human neural stem/progenitor cells survive transplantation, and migrate, differentiate, and proliferate in the injured brain. These cells could potentially be developed for transplantation therapy in cases of traumatic brain injury.	Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden; NS Gene AS, Copenhagen, Denmark	Mathiesen, T (corresponding author), Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden.	tiit.mathiesen@ks.se		Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919			Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; Barami K, 2001, J NEUROSURG, V95, P308, DOI 10.3171/jns.2001.95.2.0308; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Edwards AD, 1996, NEUROPATH APPL NEURO, V22, P494, DOI 10.1111/j.1365-2990.1996.tb01122.x; Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; GrasbonFrodl EM, 1996, NEUROSCIENCE, V73, P171, DOI 10.1016/0306-4522(96)00008-5; GrasbonFrodl EM, 1997, NEUROBIOL DIS, V3, P299, DOI 10.1006/nbdi.1996.0124; Gray JA, 2000, CELL TRANSPLANT, V9, P153, DOI 10.1177/096368970000900203; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hurelbrink CB, 2002, EUR J NEUROSCI, V15, P1255, DOI 10.1046/j.1460-9568.2002.01959.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MATHIESEN T, 1989, NEUROSCI LETT, V97, P291, DOI 10.1016/0304-3940(89)90613-7; MATHIESEN T, 1989, CANCER LETT, V44, P151, DOI 10.1016/0304-3835(89)90010-4; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Rosser AE, 2000, EUR J NEUROSCI, V12, P2405, DOI 10.1046/j.1460-9568.2000.00135.x; Rubio FJ, 2000, MOL CELL NEUROSCI, V16, P1, DOI 10.1006/mcne.2000.0854; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; Sinden JD, 1997, NEUROSCIENCE, V81, P599, DOI 10.1016/S0306-4522(97)00330-8; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Zhou FC, 2000, EXP NEUROL, V164, P200, DOI 10.1006/exnr.2000.7425	49	95	109	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2004	100	1					88	96		10.3171/jns.2004.100.1.0088			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	761YQ	WOS:000187943400014	14743917				2021-06-18	
J	Farrin, L; Hull, L; Unwin, C; Wykes, T; David, A				Farrin, L; Hull, L; Unwin, C; Wykes, T; David, A			Effects of depressed mood on objective and subjective measures of attention	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							COGNITIVE FAILURES QUESTIONNAIRE; PERSIAN-GULF-WAR; MAJOR DEPRESSION; CHRONIC FATIGUE; PERFORMANCE; COMPLAINTS; DEFICITS	People with depression report frequent cognitive failures, but objective measures of cognition show mixed results. Some studies show impairment on effortful tasks. The relationship between subjective and objective cognitive failures was studied in 102 "depressed" or "nondepressed" UK servicemen, grouped by Beck Depression Inventory scores with a cutoff score of 10. Participants were administered cognitive tests including the Sustained Attention to Response Task (SART), a laboratory measure of vigilance that has revealed increased attentional lapses in traumatic brain injury patients. The depressed men made more errors on SART than the nondepressed men (P = 0.012) but reported much higher incidences objective cognitive failures on a standardized questionnaire (P = 0.0001). The depressed men's SART reaction times slowed following an error, a pattern different from that of brain-injured subjects. Nonclinical depressed subjects may respond "catastrophically" to errors, heightening the subjective sense of failure and contributing to the strong relationship between subjectively reported cognitive failures and depression.	Inst Psychiat, London SE5 8AF, England; Guys Kings & St Thomas Sch Med, Gulf War Illnesses Res Unit, London, England	David, A (corresponding author), Inst Psychiat, De Crespigny Pk, Denmark Hill, London SE5 8AF, England.		Wykes, Til/B-3812-2011; Wykes, Til H M/B-7894-2008; David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019	Wykes, Til/0000-0002-5881-8003; David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X			Beck A. T., 1993, BECK DEPRESSION INVE; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROWN RG, 1994, PSYCHOL MED, V24, P829, DOI 10.1017/S0033291700028932; COPE H, 1995, BRIT J PSYCHIAT, V167, P86, DOI 10.1192/bjp.167.1.86; CRAWFORD JR, 1987, BRIT J CLIN PSYCHOL, V26, P313, DOI 10.1111/j.2044-8260.1987.tb01366.x; Elliott R, 1996, PSYCHOL MED, V26, P975, DOI 10.1017/S0033291700035303; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GRONWALL DMA, 1975, LANCET, V2, P1452; HARTLAGE S, 1993, PSYCHOL BULL, V113, P247, DOI 10.1037/0033-2909.113.2.247; Johnson S K, 1997, Appl Neuropsychol, V4, P145, DOI 10.1207/s15324826an0403_1; KAHN RL, 1975, ARCH GEN PSYCHIAT, V32, P1569; Mahoney AM, 1998, PSYCHOL REP, V82, P1432, DOI 10.2466/PR0.82.3.1432-1434; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; Merckelbach H, 1996, PERS INDIV DIFFER, V20, P715, DOI 10.1016/0191-8869(96)00024-4; Mialet JP, 1996, PSYCHOL MED, V26, P1009, DOI 10.1017/S0033291700035339; Purcell R, 1997, PSYCHOL MED, V27, P1277, DOI 10.1017/S0033291797005448; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Trenerry MR, 1989, PSYCHOL ASSESSMENT R; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; VANGORP WG, 1991, J CLIN EXP NEUROPSYC, V13, P812, DOI 10.1080/01688639108401091; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Wagle AC, 1999, COMPR PSYCHIAT, V40, P478, DOI 10.1016/S0010-440X(99)90093-7; WARE JE, 1993, HLTH SURVEY MANUNAL; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; Wilson, 1991, NATL ADULT READING T	30	95	110	0	11	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2003	15	1					98	104		10.1176/appi.neuropsych.15.1.98			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	641RH	WOS:000180759300015	12556579				2021-06-18	
J	Penkowa, M; Giralt, M; Lago, N; Camats, J; Caffasco, J; Hernandez, J; Molinero, A; Campbell, IL; Hidalgo, J				Penkowa, M; Giralt, M; Lago, N; Camats, J; Caffasco, J; Hernandez, J; Molinero, A; Campbell, IL; Hidalgo, J			Astrocyte-targeted expression of IL-6 protects the CNS against a focal brain injury	EXPERIMENTAL NEUROLOGY			English	Article						neurotrauma; inflammation; neuroprotection; oxidative stress; neurodegeneration; apoptosis; wound healing	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INCREASED OXIDATIVE STRESS; TUMOR-NECROSIS-FACTOR; METALLOTHIONEIN-I; TRANSGENIC MICE; INFLAMMATORY RESPONSE; NEURODEGENERATIVE DISEASES; NEUROGLIAL ACTIVATION; IL-6-DEFICIENT MICE	The effect of CNS-targeted IL-6 gene expression has been thoroughly investigated in the otherwise nonperturbed brain but not following brain injury. Here we examined the impact of astrocyte-targeted IL-6 production in a traumatic brain injury (cryolesion) model using GFAP-IL6 transgenic mice. This study demonstrated that transgenic IL-6 production significantly increased wound healing following the cryolesion. Thus, at 20 days postlesion (dpl) the GFAP-IL6 mice showed almost complete wound healing compared to litter mate nontransgenic controls. It seems likely that a reduced inflammatory response in the long term could be responsible for this IL-6-related effect. Thus, while in the acute phase following cryolesion (1-6 dpl) the recruitment of macrophages and T lymphocytes was higher in GFAP-IL6 mice, at 10-20 dpl it was significantly reduced compared to controls. Reactive astrogliosis was also significantly increased up to but not including 20 dpl in the GFAP-IL6 mice. Oxidative stress as well as apoptotic cell death was significantly decreased throughout the time period studied in the GFAP-IL6 mice compared to controls. This could be linked to the altered inflammatory response as well as to the transgenic IL-6-induced increase of the antioxidant, neuroprotective proteins metallothionein-I + II. These results indicate that although in the brain the chronic astrocyte-targeted expression of IL-6 spontaneously induces an inflammatory response causing significant damage, during an acute neuropathological insult such as following traumatic injury, a clear neuroprotective role is evident. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Autonoma Barcelona, Fac Ciencias, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Bellaterra 08193, Barcelona, Spain; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Bellaterra 08193, Barcelona, Spain.	Juan.Hidalgo@uab.es	Hernandez, Joaquim/E-1298-2011; Hidalgo, Juan/C-9082-2011; Giralt, Mercedes/K-1626-2014; Carrasco, Javier/C-9732-2011; molinero, amalia/K-2147-2014	Hernandez, Joaquim/0000-0003-1409-5568; Hidalgo, Juan/0000-0003-0921-1122; Giralt, Mercedes/0000-0002-1806-1528; Carrasco, Javier/0000-0001-6436-0863; molinero, amalia/0000-0001-8661-8570; Lago, Natalia/0000-0002-5631-8558			Abdel-Mageed AB, 1998, CANCER RES, V58, P2335; AbdelMageed AB, 1997, CANCER GENE THER, V4, P199; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; Aschner M, 1997, ANN NY ACAD SCI, V825, P334, DOI 10.1111/j.1749-6632.1997.tb48445.x; Aschner M, 1996, FASEB J, V10, P1129; Bensadoun JC, 2001, EUR J NEUROSCI, V14, P1753, DOI 10.1046/j.0953-816x.2001.01802.x; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; Brunello AG, 2000, AM J PATHOL, V157, P1485, DOI 10.1016/S0002-9440(10)64787-6; Cai L, 2000, J BIOL CHEM, V275, P38957, DOI 10.1074/jbc.C000593200; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; Campbell IL, 1998, ANN NY ACAD SCI, V840, P83, DOI 10.1111/j.1749-6632.1998.tb09552.x; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Crowthers KC, 2000, TOXICOL APPL PHARM, V166, P161, DOI 10.1006/taap.2000.8961; De Laurentiis A, 2000, NEUROIMMUNOMODULAT, V7, P77, DOI 10.1159/000026423; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Floyd RA, 1999, LIFE SCI, V65, P1893, DOI 10.1016/S0024-3205(99)00443-9; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; GASULL T, 1993, J IMMUNOASSAY, V14, P209, DOI 10.1080/15321819308019851; Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357; Ghoshal K, 1999, BIOCHEM BIOPH RES CO, V264, P735, DOI 10.1006/bbrc.1999.1563; GIJBELS K, 1995, MOL MED, V1, P795, DOI 10.1007/BF03401894; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; HIDALGO J, 1997, CURR TOPICS NEUROCHE, V1, P1; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kling PG, 2000, FREE RADICAL BIO MED, V28, P1628, DOI 10.1016/S0891-5849(00)00277-X; Kondo Y, 1997, MOL PHARMACOL, V52, P195; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lazo JS, 1998, CHEM-BIOL INTERACT, V112, P255, DOI 10.1016/S0009-2797(97)00165-8; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; Martin LJ, 2001, INT J MOL MED, V7, P455; Martiney JA, 1998, NEUROCHEM RES, V23, P349, DOI 10.1023/A:1022457500700; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; MERRILL JE, 1995, FASEB J, V9, P611; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Murphy PG, 1999, J NEUROSCI, V19, P3791; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5; PENKOWA M, 2002, BIOMED REV, V13, P1; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rana Suresh V. S., 2000, Arhiv za Higijenu Rada i Toksikologiju, V51, P279; Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X; Samoilova EB, 1998, J IMMUNOL, V161, P6480; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Sensi SL, 1999, NEUROREPORT, V10, P1723, DOI 10.1097/00001756-199906030-00018; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sun AY, 1998, J BIOMED SCI, V5, P401; Suzuki Y, 2000, TOXICOLOGY, V145, P51, DOI 10.1016/S0300-483X(99)00220-6; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Umegaki H, 1996, BIOCHEM PHARMACOL, V52, P911, DOI 10.1016/0006-2952(96)00422-4; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Xiao BG, 1998, J NEUROL SCI, V157, P1, DOI 10.1016/S0022-510X(98)00049-5; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; Zheng H, 1996, TOXICOL APPL PHARM, V136, P229, DOI 10.1006/taap.1996.0029	84	95	107	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2003	181	2					130	148		10.1016/S0014-4886(02)00051-1			19	Neurosciences	Neurosciences & Neurology	687RR	WOS:000183391000002	12781987				2021-06-18	
J	Mori, T; Wang, XY; Aoki, T; Lo, EH				Mori, T; Wang, XY; Aoki, T; Lo, EH			Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; mouse; neuroprotection; proteolysis	MATRIX-METALLOPROTEINASE EXPRESSION; FOCAL CEREBRAL-ISCHEMIA; GENE KNOCK-OUT; FOREBRAIN ISCHEMIA; TIGHT JUNCTIONS; CELL-LINE; BARRIER; INCREASE; INVOLVEMENT; PROTEOLYSIS	Emerging data suggest that matrix metalloproteinase-9 (MMP-9) plays a critical role in the pathophysiology of brain injury. However, the regulatory mechanisms involved in vivo remain unclear. In this study, we focus on a mitogen activated protein kinase (MAPK) pathway that may trigger MMP-9 after traumatic brain injury. We aim to show that inhibition of the extracellular signal regulated kinase (ERK) would attenuate MMP-9 levels, reduce blood-brain barrier damage, and attenuate edema after trauma induced by controlled cortical impact in mouse brain. Western blots showed that phospho-ERK was rapidly upregulated after trauma. Treatment with U0126, which inhibits MEK, the kinase upstream of ERK, effectively prevented the activation of ERK. After trauma, gelatin zymography showed an increase in MMP-9. U0126 significantly reduced trauma-induced MMP-9 levels. Correspondingly, U0126 ameliorated the degradation of the tight junction protein ZO-1, which is an MMP-9 substrate, and significantly attenuated tissue edema. At 7 days after trauma, traumatic lesion volumes were significantly reduced by U0126 compared with saline-treated controls. These data indicate that the ERK MAPK pathway triggers the upregulation in MMP-9 after trauma, and further suggest that targeting the upstream signaling mechanisms that regulate deleterious MMP-9 activity may reveal new therapeutic opportunities for traumatic brain injury.	Harvard Univ, MGH,Sch Med, Dept Neurol, Neuroprotect Res Lab, Boston, MA 02129 USA; Harvard Univ, MGH,Sch Med, Dept Radiol, Neuroprotect Res Lab, Boston, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02129 USA	Lo, EH (corresponding author), Harvard Univ, MGH,Sch Med, Dept Neurol, Neuroprotect Res Lab, East 149-2401, Boston, MA 02129 USA.	Lo@helix.mgh.harvard.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS37074, R01-NS40529, R01-NS38731] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040529, R01NS037074, R01NS038731] Funding Source: NIH RePORTER		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Asahi M, 2001, J NEUROSCI, V21, P7724; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferguson TA, 2000, MOL CELL NEUROSCI, V16, P157, DOI 10.1006/mcne.2000.0859; Fini ME, 1998, BIOL EXTRAC, P299; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Genersch E, 2000, J CELL SCI, V113, P4319; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Marmarou A., 1996, NEUROTRAUMA, P413; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Nico B, 1999, DEV BRAIN RES, V114, P161, DOI 10.1016/S0165-3806(99)00008-5; Oh LYS, 1999, J NEUROSCI, V19, P8464; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Regan RF, 2001, J NEUROCHEM, V79, P545, DOI 10.1046/j.1471-4159.2001.00590.x; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; SMITH DH, NEUROTRAUMA, P1445; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vu TH, 1998, BIOL EXTRAC, P115; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Westermarck J, 1999, FASEB J, V13, P781; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zhang ZG, 2001, BRAIN RES, V912, P181, DOI 10.1016/S0006-8993(01)02735-4	59	95	108	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1411	1419		10.1089/089771502320914642			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500002	12490006				2021-06-18	
J	Scheff, SW; Saucier, DA; Cain, ME				Scheff, SW; Saucier, DA; Cain, ME			A statistical method for analyzing rating scale data: The BBB locomotor score	JOURNAL OF NEUROTRAUMA			English	Article						behavioral recovery; data analysis; neurotrauma; spinal cord injury	RATS	The Basso, Beattie and Bresnahan (BBB) locomotor rating scale is widely used to test behavioral consequences of spinal cord injury (SCI) to. the rat. Sensitivity of this rating scale can differentiate hind limb locomotor skills over a wide range of injury severities. While the 21-point BBB scale is ordinal in nature, the present discussion recommends the use of parametric statistics to evaluate the locomotor results. Specifically, it defines appropriate statistical analysis of these data in order to facilitate interpretation of results between laboratories and to provide a common methodology for the correct interpretation of SCI behavioral data.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Psychol, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 233, Lexington, KY 40536 USA.			Cain, Mary/0000-0002-2165-990X			Aron A., 1999, STAT PSYCHOL; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Howell D. C., 2002, STAT METHODS PSYCHOL; Howell D.C., 1999, FUNDAMENTAL STAT BEH, V4th; Lankhorst AJ, 1999, J NEUROTRAUM, V16, P323, DOI 10.1089/neu.1999.16.323; Rosenthal R., 1991, ESSENTIALS BEHAV RES; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594	11	95	106	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1251	1260		10.1089/08977150260338038			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400012	12427332				2021-06-18	
J	Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM				Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM			A prospective study of long-term caregiver and family adaptation following brain injury in children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adaptation; brain injury; burden; family functioning; stress trauma	CLOSED-HEAD-INJURY; ASSESSMENT DEVICE; RELIABILITY; VALIDITY; PREDICTORS; RECOVERY; RELATIVES; BURDEN; HEALTH	Objective: We examined tong-term differences in family, adaptation following traumatic brain Injuries (TBI) and orthopedic injuries. Design: Families of children with severe TBI (n = 53), moderate TBI (n = 56), and orthopedic injuries (n = 80) were assessed at baseline, 6 months,and 12 months post injury and at an extended follow-up an average of 4.1 years post injury. Caregiver and family outcomes were examined using mixed model analysis. Results: Patterns of adaptation over time varied across groups but indicated long-standing injury-related stress and burden in the severe TBI group. Conclusions: Severe TBI results in persistent caregiver stress for a substantial proportion of families.	Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA; Case Western Reserve Univ, Dept Pediat Psychol, Cleveland, OH 44106 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA	Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Dept Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BURCHINAL MR, 1994, J EARLY INTERVENTION, V18, P422; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1993, BSI BRIEF SYMPTOM IN; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1988, LANCET, V14, P480; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos R, 1994, LIFE STRESSORS SOCIA; Noller P, 1988, ICPS FAMILY FUNCTION; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; *SAS I I, 1990, STAT AN SYST VERS 6; Silverberg S. B., 1996, PARENTAL EXPERIENCE, P215; SILVERBERG SB, 1987, J YOUTH ADOLESCENCE, V16, P293, DOI 10.1007/BF02139096; SILVERBERG SB, 1990, DEV PSYCHOL, V26, P658, DOI 10.1037/0012-1649.26.4.658; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 2000, NEUROPSYCHOLOGY, P14; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	47	95	97	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					96	111		10.1097/00001199-200204000-00003			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500003	11909509				2021-06-18	
J	Guskiewicz, KM; Marshall, SW; Broglio, SP; Cantu, RC; Kirkendall, DT				Guskiewicz, KM; Marshall, SW; Broglio, SP; Cantu, RC; Kirkendall, DT			No evidence of impaired neurocognitive performance in collegiate soccer players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; PROTECTIVE HEADGEAR; FOOTBALL PLAYERS; CONCUSSION	A high incidence of cerebral concussion has been reported among soccer players. We studied whether long-term or chronic neuropsychological dysfunction was present in collegiate soccer players. Two hundred forty subjects from a National Collegiate Athletic Association division I institution were stratified into three groups: soccer athletes (91), nonsoccer athletes (96 women's field hockey, women's lacrosse, and baseball players), and controls (53 college students). Subjects completed a concussion history questionnaire and underwent preseason baseline neuropsychological testing before the start of either the freshman or sophomore year. Data were collected on the results of six neuropsychological tests and from a concussion history questionnaire for number of previous concussions, Scholastic Aptitude Test results, and exposure to soccer and heading. Despite an average of 15.3 seasons of soccer exposure and a higher prevalence of previous concussions, the soccer athletes did not demonstrate impaired neurocognitive function or scholastic aptitude when compared with the nonsoccer athletes or the student nonathletes. Additionally, there was no significant relationship between a history of soccer-related concussion and either neurocognitive performance or scholastic aptitude. Neither participation in soccer nor a history of soccer-related concussions was associated with impaired performance of neurocognitive function in high-level United States soccer players.	Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, CB 8700, Chapel Hill, NC 27599 USA.			Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233			Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; Barth JT., 1989, MILD HEAD INJURY, P257; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DAILEY SW, 1992, PHYSICIAN SPORTSMED, V20, P79, DOI 10.1080/00913847.1992.11947468; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; DICK RW, 1994, HEAD NECK INJURIES S; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 2001, NEUROLOGICAL SPORTS, P123; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lovell M, 1999, SPORTS RELATED CONCU; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LUHTANEN P, 1994, HDB SPORTS MED SCI, P59; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641	23	95	98	1	17	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	MAR-APR	2002	30	2					157	162		10.1177/03635465020300020201			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	533FV	WOS:000174519500002	11912081				2021-06-18	
J	Singleton, RH; Zhu, JP; Stone, JR; Povlishock, JT				Singleton, RH; Zhu, JP; Stone, JR; Povlishock, JT			Traumatically induced axotomy adjacent to the soma does not result in acute neuronal death	JOURNAL OF NEUROSCIENCE			English	Article						traumatic brain injury; traumatic axonal injury; axotomy; axon reaction; rat; protein translation; TUNEL	EXPERIMENTAL BRAIN INJURY; FLUID-PERCUSSION MODEL; PIG OPTIC-NERVE; AXONAL INJURY; CORTICOSPINAL NEURONS; STRETCH INJURY; CYTOCHEMICAL EVIDENCE; HEAD-INJURY; CELL-DEATH; IN-VIVO	Traumatic axonal injury (TAI), a consequence of traumatic brain injury (TBI), results from progressive pathologic processes initiated at the time of injury. Studies attempting to characterize the pathology associated with TAI have not succeeded in following damaged and/or disconnected axonal segments back to their individual neuronal somata to determine their fate. To address this issue, 71 adult male Sprague Dawley rats were subjected to moderate central fluid percussion injury and killed between 30 min and 7 d after injury. Antibodies to the C terminus of beta-amyloid precursor protein (APP) identified TAI in continuity with individual neuronal somata in the mediodorsal neocortex, the hilus of the dentate gyrus, and the dorsolateral thalamus. These somata were followed with immunocytochemical markers of neuronal injury targeting phosphorylated 200 kDa neurofilaments (RMO-24), altered protein translation (phosphorylated eukaryotic translation initiation factor 2alpha), and cell death [terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)], with parallel electron microscopic (EM) assessment. Despite the finding of TAI within 20-50 mum of the soma, no evidence of cell death, long associated with proximal axotomy, was seen via TUNEL or routine light microscopy/ electron microscopy. Rather, there was rapid onset (<6 hr after injury) subcellular change associated with impaired protein synthesis identified by EM, immunocytochemical, and Western blot analyses. When followed 7 d after injury, these abnormalities did not reveal dramatic progression. Rather, some somata showed evidence of potential reorganization and repair. This study demonstrates a novel somatic response to TAI in the perisomatic domain and also provides insight into the multifaceted pathology associated with TBI.	Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Anesthesiol, Richmond, VA 23298 USA; Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22904 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01 NS020193, NS20193, T32 NS007288] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, T32NS007288] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Balentine JD, 1985, CENTRAL NERVOUS SYST, P455; Bareyre FM, 2001, J NEUROCHEM, V77, P173, DOI 10.1046/j.1471-4159.2001.t01-1-00215.x; BARRON KD, 1979, J NEUROPATH EXP NEUR, V38, P128, DOI 10.1097/00005072-197903000-00005; BARRON KD, 1983, SPINAL CORD RECONSTR, P7; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brown A, 1998, J CELL SCI, V111, P455; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CONRADI S, 1969, ACTA PHYSIOL SCAND, P53; CONRADI S, 1969, ACTA PHYSIOL SCAND, P65; Conti AC, 1998, J NEUROSCI, V18, P5663; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; DENTINGER MP, 1979, J NEUROPATH EXP NEUR, V38, P551, DOI 10.1097/00005072-197909000-00008; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EGAN DA, 1977, ACTA NEUROPATHOL, V37, P13, DOI 10.1007/BF00684534; Emery DL, 2000, J COMP NEUROL, V424, P521; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; KOLIATSOS VE, 1989, BRAIN RES, V482, P205, DOI 10.1016/0006-8993(89)91183-9; Kreutzberg Georg W., 1995, P355; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.0.CO;2-#; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCBRIDE RL, 1989, J NEUROPATH EXP NEUR, V48, P568, DOI 10.1097/00005072-198909000-00007; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meaney DF, 1993, ASME CRASHWORTHINESS, V25, P169; MERLINE M, 1990, J COMP NEUROL, V296, P506, DOI 10.1002/cne.902960313; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Peters A, 1991, FINE STRUCTURE NERVO; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RINK A, 1995, AM J PATHOL, V147, P1575; ROSENFELD J, 1987, J NEUROPATH EXP NEUR, V46, P269, DOI 10.1097/00005072-198705000-00004; Shields DC, 2000, J NEUROSCI RES, V61, P146; SIEGEL SE, 1999, BASIC NEUROCHEMISTRY; SINGH LP, 1994, ENZYME PROTEIN, V48, P61, DOI 10.1159/000474972; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Teramoto N, 1998, J VIROL METHODS, V73, P89, DOI 10.1016/S0166-0934(98)00048-2; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	61	95	96	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 1	2002	22	3					791	802		10.1523/JNEUROSCI.22-03-00791.2002			12	Neurosciences	Neurosciences & Neurology	518HB	WOS:000173660800029	11826109	Green Published, Bronze			2021-06-18	
J	Leskovar, A; Moriarty, LJ; Turek, JJ; Schoenlein, IA; Borgens, RB				Leskovar, A; Moriarty, LJ; Turek, JJ; Schoenlein, IA; Borgens, RB			The macrophage in acute neural injury: Changes in cell numbers over time and levels of cytokine production in mammalian central and peripheral nervous systems	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						spinal injury; macrophage; neurotrauma; cytokine; inflammation; central nervous system; peripheral nervous system; mammal	STIMULATED HOMOLOGOUS MACROPHAGES; ISCHEMIC BRAIN-DAMAGE; NECROSIS-FACTOR-ALPHA; SPINAL-CORD INJURY; WALLERIAN DEGENERATION; RAT-BRAIN; MESSENGER-RNA; MONONUCLEAR PHAGOCYTES; INFLAMMATORY RESPONSE; BLOOD MONOCYTES	We evaluated the timing and density of ED-1-positive macrophage accumulation (ED 1 is the primary antibody for the macrophage) and measured cytokine production by macrophages in standardized compression injuries to the spinal cord and sciatic nerves of individual rats 3, 5, 10 and 21 days post-injury. The actual site of mechanical damage to the nervous tissue, and a more distant site where Wallerian degeneration had occurred, were evaluated in both the peripheral nervous system (PNS) and the central nervous system (CNS) at these time points. The initial accumulation of activated macrophages was similar at both the central and peripheral sites of damage. Subsequently, macrophage densities at all locations studied were statistically significantly higher in the spinal cord than in the sciatic nerve at every time point but one. The peak concentrations of three cytokines, tumor necrosis factor alpha (TNF alpha), interleukin-1 (IL-1) and interleukin-6 (IL-6), appeared earlier and were statistically significantly higher in injured spinal cord than in injured sciatic nerve. We discuss the meaning of these data relative to the known differences in the reparative responses of the PNS and CNS to injury.	Purdue Univ, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Borgens, RB (corresponding author), Purdue Univ, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	rbb@vet.purdue.edu					AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AVELLINO AM, 1995, EXP NEUROL, V136, P183, DOI 10.1006/exnr.1995.1095; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Ben Zeev-Brann A, 1998, GLIA, V23, P181, DOI 10.1002/(SICI)1098-1136(199807)23:3<181::AID-GLIA1>3.0.CO;2-8; BERRY M, 1979, RECENT ADV NEUROPATH, P67; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Clark R. A., 1995, MOL CELLULAR BIOL WO, P3; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; De Vellis Jean, 1993, P61; DIPIETRO LA, 1995, SHOCK, V4, P233, DOI 10.1097/00024382-199510000-00001; DOWNS TR, 1983, ANAL BIOCHEM, V131, P538, DOI 10.1016/0003-2697(83)90212-9; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; FAN L, 1995, MOL BRAIN RES, V30, P125; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; GRIFFIN JW, 1993, LAB INVEST, V69, P257; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jacobson D R, 1991, PCR Methods Appl, V1, P146; KARAVODIN LM, 1989, EUR J IMMUNOL, V19, P1351, DOI 10.1002/eji.1830190732; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; KIRSNER RS, 1993, DERMATOL CLIN, V11, P629, DOI 10.1016/S0733-8635(18)30216-X; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LAWSON LJ, 1994, J NEUROCYTOL, V23, P729, DOI 10.1007/BF01268086; LazarovSpiegler O, 1996, FASEB J, V10, P1296; LING EA, 1980, J COMP NEUROL, V193, P631, DOI 10.1002/cne.901930304; LING EA, 1978, J ANAT, V126, P111; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; LOTAN M, 1994, FASEB J, V8, P1026; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MIYAKE T, 1984, ACTA NEUROPATHOL, V62, P291, DOI 10.1007/BF00687611; MONACO S, 1992, J NEUROCYTOL, V21, P623, DOI 10.1007/BF01191724; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Perry V H, 1992, Curr Opin Neurobiol, V2, P679, DOI 10.1016/0959-4388(92)90038-M; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Ramon y Cajal S, 1928, DEGENERATION REGENER; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reichert F, 1996, EUR J NEUROSCI, V8, P530, DOI 10.1111/j.1460-9568.1996.tb01237.x; Reier P J, 1988, Adv Neurol, V47, P87; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; ROTSHENKER S, 1992, J NEUROIMMUNOL, V39, P75, DOI 10.1016/0165-5728(92)90176-L; SCHINDLER R, 1990, BLOOD, V75, P40; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Turek JJ, 1996, J NUTR, V126, P1541; Turek JJ, 1998, J NUTR BIOCHEM, V9, P258, DOI 10.1016/S0955-2863(98)00014-X; TUREK JJ, 1991, PROSTAG LEUKOTR ESS, V43, P141, DOI 10.1016/0952-3278(91)90161-W; WAHL LM, 1991, CURRENT PROTOCOLS IM; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; YOUNG W, 1995, CONT MANAGEMENT SPIN, P27	75	95	99	1	11	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0022-0949	1477-9145		J EXP BIOL	J. Exp. Biol.	JUN	2000	203	12					1783	1795					13	Biology	Life Sciences & Biomedicine - Other Topics	329ZR	WOS:000087938800002	10821736				2021-06-18	
J	Lee, KS				Lee, KS			The pathogenesis and clinical significance of traumatic subdural hygroma	BRAIN INJURY			English	Article							FLUID COLLECTIONS; FINE-STRUCTURE; HEMATOMA; SPACE; NEOMEMBRANES; TOMOGRAPHY; EFFUSION; ORIGIN; BLOOD; SCANS	Subdural hygroma (SDG) is a common post-traumatic lesion. Despite its common occurrence, the pathogenesis and clinical significance are uncertain. The author reviewed the literature to clarify the present knowledge on the pathogenic, diagnostic and therapeutic aspects of this controversial lesion. A trivial trauma can cause a separation of the dura-arachnoid interface, which is the basic requirement for the development of a SDG. If the brain shrinks due to brain atrophy, excessive dehydration or decreased intracranial pressure, fluid collection may develop by a passive effusion. Most SDGs resolve when the brain is well expanded. However, a few SDGs become chronic subdural haematomas, when the necessary conditions persist over several weeks. Since the majority of patients with a SDG do not show a mass effect, surgery is rarely required. Outcome is closely related to the primary head injury not to the SDG itself. The complexity of SDG depends on Various factors including the dynamics of absorption and expansion, duration of observation, and indication and rate of surgery, besides variety of the primary head injury in types and severity. SDG is a common epiphenomenon of head injury.	Soonchunhyang Univ, Chonan Hosp, Dept Neurosurg, Chonan 330100, South Korea	Lee, KS (corresponding author), Soonchunhyang Univ, Chonan Hosp, Dept Neurosurg, Bongmyong Dong 23-20, Chonan 330100, South Korea.						AOKI N, 1994, J NEUROSURG, V81, P20, DOI 10.3171/jns.1994.81.1.0020; ARNASON O, 1983, ACTA NEUROCHIR, V67, P231, DOI 10.1007/BF01401424; BAKAY L, 1980, HEAD INJURY, P175; Borzone M, 1983, J Neurosurg Sci, V27, P161; BULLOCK R, 1990, HDB CLIN NEUROLOGY, V57, P249; Cohen I, 1927, ARCH NEURO PSYCHIATR, V18, P709, DOI 10.1001/archneurpsyc.1927.02210050041004; Cooper PR, 1993, HEAD INJURY, P275; da Costa DG, 1941, ARCH SURG-CHICAGO, V43, P559, DOI 10.1001/archsurg.1941.01210160020003; Dandy WE, 1955, PRACTICE SURG, P291; Dandy WE, 1932, PRACTICE SURG, P306; DIERCKX RA, 1989, ACTA NEUROL BELG, V89, P352; DUHAIME A, 1992, COMPLICATIONS SEQUEL, P169; ENDTZ LJ, 1978, SURG NEUROL, V10, P305; FISHER RG, 1958, JAMA-J AM MED ASSOC, V167, P176, DOI 10.1001/jama.1958.02990190030007; FRENCH BN, 1978, SURG NEUROL, V9, P145; FRIEDE RL, 1978, AM J PATHOL, V92, P69; GADE GF, 1990, NEUROLOGICAL SURG, V3, P1965; Gudeman S. K., 1989, TXB HEAD INJURY, P138; GURDJIAN ES, 1978, ACTA NEUROCHIR WIE S, V25, P36; GUTIERREZ FA, 1979, CHILD BRAIN, V5, P216; HAINES DE, 1991, ANAT RECORD, V230, P3, DOI 10.1002/ar.1092300103; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; HEYL H, 1941, J NEUROL NEUROSUR PS, V4, P270; HOFF J, 1973, J TRAUMA, V13, P870, DOI 10.1097/00005373-197313100-00005; HUGHES M, 1993, HEAD INJURY, P65; HYODO A, 1980, Neurological Surgery, V8, P649; Ishibashi Akira, 1994, Kurume Medical Journal, V41, P81; ITO H, 1984, ACTA NEUROCHIR, V72, P211, DOI 10.1007/BF01406871; KAUFMAN HH, 1984, ACTA NEUROCHIR, V72, P197, DOI 10.1007/BF01406870; KAWANO N, 1988, Neurological Surgery, V16, P747; Keller TS, 1982, CORRELATIVE NEUROSUR, P1301; KOIZUMI H, 1981, Neurologia Medico-Chirurgica, V21, P397; KOIZUMI H, 1987, SURG NEUROL, V27, P147, DOI 10.1016/0090-3019(87)90286-2; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Lee Kyeong-Seok, 1996, Journal of Korean Medical Science, V11, P55; LIPPER MH, 1989, TXB HEAD INJURY, P102; MASUZAWA T, 1984, NEURORADIOLOGY, V26, P245, DOI 10.1007/BF00342423; Mayo CH, 1894, NEW YORK M J, V59, P434; MCCLUNEY KW, 1992, AM J NEURORADIOL, V13, P1335; McConnell AA, 1941, J NEUROL PSYCHIATRY, V4, P237, DOI 10.1136/jnnp.4.3-4.237; McLaurin RL, 1990, NEUROLOGICAL SURG, P2149; MILLER JD, 1987, NORTHFIELDS SURG CEN, P795; Miura F, 1975, No Shinkei Geka, V3, P769; Munro D, 1936, ARCH NEURO PSYCHIATR, V35, P64, DOI 10.1001/archneurpsyc.1936.02260010074005; Murata Keiji, 1993, Neurologia Medico-Chirurgica, V33, P691, DOI 10.2176/nmc.33.691; NAFFZIGER HC, 1924, JAMA-J AM MED ASSOC, V82, P1751; NAGANUMA H, 1986, NEUROSURGERY, V19, P794, DOI 10.1227/00006123-198611000-00013; NORMAN D, 1977, RADIOLOGY, V123, P335, DOI 10.1148/123.2.335; OHNO K, 1987, J NEUROL NEUROSUR PS, V50, P1694, DOI 10.1136/jnnp.50.12.1694; OKA H, 1972, ACTA NEUROCHIR, V26, P265, DOI 10.1007/BF01407072; ORLIN JR, 1991, ANAT RECORD, V230, P22, DOI 10.1002/ar.1092300104; PARK CK, 1994, ACTA NEUROCHIR, V127, P41, DOI 10.1007/BF01808545; PARK HB, 1990, J KOREAN NEUROSURG S, V19, P126; Payr E, 1916, MED KLIN, V12, P841; POTT P, 1819, CHIRURG WORKS P POTT, P159; RABE EF, 1968, NEUROLOGY, V18, P559, DOI 10.1212/WNL.18.6.559; RABE EF, 1962, NEUROLOGY, V12, P79, DOI 10.1212/WNL.12.2.79; ROSEN HM, 1987, ANN PLAS SURG, V18, P245, DOI 10.1097/00000637-198703000-00012; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; SCHNEIDER RC, 1961, SURG CLIN N AM, V41, P1255; SCHURR PH, 1969, DEV MED CHILD NEUROL, V11, P108; SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311; STJOHN JN, 1981, NEUROSURGERY, V9, P621, DOI 10.1227/00006123-198112000-00002; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; TAGUCHI Y, 1982, Neurologia Medico-Chirurgica, V22, P276, DOI 10.2176/nmc.22.276; TAKAHASHI Y, 1982, Neurologia Medico-Chirurgica, V22, P395, DOI 10.2176/nmc.22.395; van Dongen K, 1981, Prog Neurol Surg, V10, P198, DOI 10.1159/000384770; VONKOPP W, 1988, FORTSCHRITTE GEBIETE, V148, P530; VONKOPP W, 1990, FORTSCHRITTE GEBIETE, V152, P200; WEIR B, 1980, J NEUROSURG, V53, P512, DOI 10.3171/jns.1980.53.4.0512; WETTERLING T, 1986, ACTA NEUROCHIR, V83, P99, DOI 10.1007/BF01402385; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; WHANG K, 1993, J KOREAN NEUROSURG S, V22, P898; WINESTOCK DP, 1975, RADIOLOGY, V115, P373, DOI 10.1148/115.2.373; Yamada H, 1979, No Shinkei Geka, V7, P55; YAMADA H, 1980, SURG NEUROL, V13, P441	77	95	103	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					595	603		10.1080/026990598122359			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200005	9653522				2021-06-18	
J	WAXWEILER, RJ; THURMAN, D; SNIEZEK, J; SOSIN, D; ONEIL, J				WAXWEILER, RJ; THURMAN, D; SNIEZEK, J; SOSIN, D; ONEIL, J			MONITORING THE IMPACT OF TRAUMATIC BRAIN INJURY - A REVIEW AND UPDATE	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		EPIDEMIOLOGY; BRAIN INJURY; ETIOLOGY; INCIDENCE	HEAD-INJURY; POPULATION; COUNTY; DEATHS		CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,OFF STAT PROGRAMMING & GRAPH,ATLANTA,GA 30341	WAXWEILER, RJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.			Thurman, David/0000-0002-0533-7062			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; [Anonymous], 1989, INT CLASSIFICATION D; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1991, NEUROEPIDEMIOLOGY TR, P333; LAND G, 1994, MISSOURI HEAD SPINAL; LEMIER M, 1994, ASSESSMENT HEAD SPIN; MALLONEE S, 1993, SUMMARY REPORTABLE I; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; Thurman DJ., 1995, GUIDELINES SURVEILLA; THURMAN DJ, 1993, HEAD INJURIES AM IND; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; 1977, INT CLASSIFICATION D	20	95	101	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					509	516		10.1089/neu.1995.12.509			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000002	8683602				2021-06-18	
J	HEINEMANN, AW; HAMILTON, B; LINACRE, JM; WRIGHT, BD; GRANGER, C				HEINEMANN, AW; HAMILTON, B; LINACRE, JM; WRIGHT, BD; GRANGER, C			FUNCTIONAL STATUS AND THERAPEUTIC INTENSITY DURING INPATIENT REHABILITATION	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						TRAUMATIC BRAIN INJURY; SPINAL CORD INJURY; FUNCTIONAL STATUS; THERAPY INTENSITY; MEDICAL REHABILITATION	CONTROLLED TRIAL; STROKE REHABILITATION; RHEUMATOID-ARTHRITIS; INDEPENDENCE MEASURE; PERFORMANCE; TEAM	The objective of this study was to describe the relationships between functional status at discharge and intensity of therapies received during inpatient medical rehabilitation. The sample was comprised of 140 patients with traumatic brain injury and 106 patients with spinal cord injury at eight hospitals that subscribe to the Uniform Data System for Medical Rehabilitation. Data included linear measures of motor and cognitive ability derived from the Functional Independence Measure at admission to and discharge from rehabilitation. Multiple regression was used to predict intensity of therapies, discharge motor and cognitive function, the extent to which potential functional gains were achieved, and the efficiency of gains. Intensities of occupational, physical, and speech therapies were not significant predictors of outcomes for either group, controlling linearly for admission function, psychology intensity, length of stay, onset to admission interval, age, and interrupted stays. Only intensity of psychology services seemed to have any relation to functional gain (in cognition for patients with traumatic brain injury). The apparent lack of benefit related to intensity of therapies may be due to factors such as spontaneous recovery, goals not measured by the Functional Independence Measure, limited modulation of therapy intensity according to likely patient responsiveness, or therapies focused on impairment or other goals rather than disability. We suggest that efficiently staged rehabilitation should vary the intensity and nature of services according to patients' functional status, impairments, comorbid conditions, and other clinical factors.	REHABIL INST CHICAGO,CHICAGO,IL 60611; UNIV CHICAGO,CHICAGO,IL 60637; VET AFFAIRS MED CTR,DURHAM,NC 27705; SUNY BUFFALO,BUFFALO,NY			Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR503609] Funding Source: Medline		AHLMEN M, 1988, ARTHRITIS RHEUM, V31, P471, DOI 10.1002/art.1780310403; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BACHYRITA P, 1989, TRAUMATIC BRAIN INJU, P81; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 1992, REHABILITATION EFFIC; JOHNSTON MV, 1986, ARCH PHYS MED REHAB, V67, P581; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; KEITH RA, 1991, ARCH PHYS MED REHAB, V72, P269; KENNEDY OG, 1972, ARCH PHYS MED REHAB, V53, P461; LIANG MH, 1987, MED CARE, V25, P276, DOI 10.1097/00005650-198704000-00002; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Norusis M.J., 1993, SPSS WINDOWS BASE SY; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; SMITH ME, 1982, ARCH PHYS MED REHAB, V63, P21; SPIEGEL JS, 1986, ARTHRITIS RHEUM-US, V29, P628, DOI 10.1002/art.1780290507; Stolov W., 1981, HDB SEVERE DISABILIT; WEHMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66	27	95	96	0	11	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	1995	74	4					315	326		10.1097/00002060-199507000-00011			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	RP735	WOS:A1995RP73500011	7632391				2021-06-18	
J	DASH, PK; MOORE, AN; DIXON, CE				DASH, PK; MOORE, AN; DIXON, CE			SPATIAL MEMORY DEFICITS, INCREASED PHOSPHORYLATION OF THE TRANSCRIPTION FACTOR CREB, AND INDUCTION OF THE AP-1 COMPLEX FOLLOWING EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROSCIENCE			English	Article						CORTICAL IMPACT; SPATIAL MEMORY DEFICIT; HIPPOCAMPUS; TRANSCRIPTION FACTORS; CREB; AP-1; C-FOS	LONG-TERM POTENTIATION; CAMP RESPONSE ELEMENT; CONTROLLED CORTICAL IMPACT; II MUTANT MICE; C-FOS; NERVOUS-SYSTEM; CYCLIC-AMP; SUPRACHIASMATIC NUCLEUS; SOMATOSTATIN GENE; BINDING PROTEIN	Traumatic brain injury causes both short- and long-term neurological impairments. A cascade of biochemical changes triggered by the injury may increase the expression of several genes, which has been hypothesized to contribute to the observed cognitive deficits. The mechanism(s) of induction for these genes is not yet known. We present evidence that lateral cortical impact injury in rats that produces spatial memory deficits also increases phosphorylation of the transcription factor CREB (cAMP response element binding). Subsequent to the phosphorylation of CREB, c-Fos expression and the AP-1 complex are enhanced. The temporal and spatial activation of c-Fos is consistent with it being induced by phosphorylated CREB proteins. Thus, CREB-mediated gene activation may contribute to the observed behavioral deficits. Further elucidation of the biochemical and pathophysiological changes will be of importance for clinical therapy.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77225	DASH, PK (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROBIOL & ANAT,POB 20708,HOUSTON,TX 77225, USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49 CCR606659] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49962] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31998] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998] Funding Source: NIH RePORTER		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DASH PK, 1993, CELL MOL BIOL, V39, P35; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOUCET JP, 1990, MOL NEUROBIOL, V4, P27, DOI 10.1007/BF02935584; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOELET P, 1986, NATURE, V322, P519; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; HAYES RL, 1992, J NEUROTRAUM, V1, pS173; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; KIM KS, 1993, J BIOL CHEM, V268, P15689; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; MALEEVA NE, 1989, GENETIKA+, V25, P1119; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NIKOLAEV E, 1992, BRAIN RES B, V128, P479; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SASSONECORSI P, 1988, NATURE, V336, P646; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	45	95	97	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513	0270-6474			J NEUROSCI	J. Neurosci.	MAR	1995	15	3	1				2030	2039					10	Neurosciences	Neurosciences & Neurology	QM467	WOS:A1995QM46700032	7891150				2021-06-18	
J	DIXON, CE; HAMM, RJ; TAFT, WC; HAYES, RL				DIXON, CE; HAMM, RJ; TAFT, WC; HAYES, RL			INCREASED ANTICHOLINERGIC SENSITIVITY FOLLOWING CLOSED SKULL IMPACT AND CONTROLLED CORTICAL IMPACT TRAUMATIC BRAIN INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; NORADRENERGIC DEPLETION; MAZE PERFORMANCE; SCOPOLAMINE; DEFICITS; MEMORY; DISRUPTION; MODEL	Evidence suggests that prolonged memory deficits in several neurodegenerative diseases are attributable to deficits in central cholinergic neurotransmission. In traumatic brain injury (TBI), such cholinergic deficits also may contribute to prolonged memory disturbances. This study determined whether moderate magnitudes of TBI produced by controlled cortical impact and mild magnitudes of experimental TBI produced by a new closed head impact technique in rats would produce an enhanced vulnerability to the memory disruptive effects of scopolamine, a muscarinic cholinergic receptor antagonist. Water maze performance was used to determine changes in cholinergic hippocampal function following TBI. In the first experiment, rats received a moderate level of TBI by means of a controlled cortical impact. A Morris water maze task assessed spatial memory function on days 30-34 postinjury. During the 5 day assessment period, statistical analyses showed a group main effect for swim latency. Subsequent post hoc analyses indicated that injured rats had significantly longer latencies on days 30 and 31 (p < 0.05, injury vs sham controls). By days 32-35, injured rats showed no statistically significant deficits in spatial memory performance. On day 35, scopolamine (1 mg/kg, IP) was injected into injured rats and sham-injured rats 15 min prior to being retested in the maze. Results showed that although the scopolamine had no effects on the performance of the sham-injured rats, the same dose significantly (p < 0.05) increased the latency to find the hidden platform in the injured group. In the second experiment, rats received a mild concussive closed head impact. Water maze performance was assessed on days 8-12 postinjury. No significant water maze performance deficits were observed. On day 13, injured and uninjured rats were pharmacologically challenged with scopolamine (1 mg/kg) and retested. Similar to the first experiment, injured rats manifested a significantly greater (p < 0.05) sensitivity to scopolamine than sham controls. The results from both experiments suggest that concussive and more severe levels of TBI can produce an enhanced vulnerability to disruption of cholinergically mediated memory function, even when memory function appears normal in the absence of secondary challenges. These data demonstrate that covert deficits can persist after the recovery of normal function. These deficits may be attributable to a decrease in the ability of cholinergic neurons to function properly. These data also provide important insights into features of receptor-coupled disturbances that could contribute to the maintenance of enduring cognitive deficits following TBI.	VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284	DIXON, CE (corresponding author), UNIV TEXAS,HLTH SCI CTR,DIV NEUROSURG,6431 FANNIN ST,SUITE 7147,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B80029, R49-CCR303547] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER		BEATTIE MS, 1988, PHARM APPROACHES TRE, P43; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; COLLERTON D, 1986, NEUROSCIENCE, V19, P1, DOI 10.1016/0306-4522(86)90002-3; Deangelis M. M., 1992, Society for Neuroscience Abstracts, V18, P172; DECKER MW, 1987, BRAIN RES, V417, P59, DOI 10.1016/0006-8993(87)90179-X; DELAHUNTY TM, 1992, J NEUROTRAUM, V9, P58; Dixon C. E., 1992, Society for Neuroscience Abstracts, V18, P171; Dixon C. E., 1993, Society for Neuroscience Abstracts, V19, P1486; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUBOIS B, 1987, ANN NEUROL, V22, P26, DOI 10.1002/ana.410220108; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hayes RL, 1989, MILD HEAD INJURY, P54; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hornykiewicz O, 1986, ADV NEUROL, V45, P19; HUFF FJ, 1988, DRUG DEVELOP RES, V12, P271; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; ROBINSON S E, 1991, Society for Neuroscience Abstracts, V17, P721; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SPANGLER EL, 1990, BEHAV NEUROSCI, V104, P410, DOI 10.1037/0735-7044.104.3.410; SPENCER DG, 1983, DRUG DEVELOP RES, V3, P489, DOI 10.1002/ddr.430030602; SQUIRE LR, 1981, ANN REV PHARM TOXICO, V21, P325; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SUNDERLAND T, 1985, PSYCHOPHARMACOLOGY, V87, P247, DOI 10.1007/BF00431817; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	57	95	95	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					275	287		10.1089/neu.1994.11.275			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100004	7996582				2021-06-18	
J	RIVARA, JB; FAY, GC; JAFFE, KM; POLISSAR, NL; SHURTLEFF, HA; MARTIN, KM				RIVARA, JB; FAY, GC; JAFFE, KM; POLISSAR, NL; SHURTLEFF, HA; MARTIN, KM			PREDICTORS OF FAMILY FUNCTIONING ONE YEAR FOLLOWING TRAUMATIC BRAIN INJURY IN CHILDREN	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						FAMILY; PEDIATRIC; TRAUMATIC BRAIN INJURY	GLOBAL ASSESSMENT SCALE; SEVERE HEAD-INJURY; HANDICAPPED-CHILDREN; DISABLED-CHILDREN; SPINA-BIFIDA; MOTHERS; RELATIVES; IMPACT; ADOLESCENTS; SEQUELAE	This study examined changes in family functioning and predictors of family outcome during the year following traumatic brain injury (TBI). The families of 94 children with TBI (mild = 50, moderate = 25, severe = 19), ages six to 15, were consecutively enrolled from two regional medical centers. Family interview ratings and standard measures of family and child functioning were completed three weeks after injury (measuring preinjury status), as well as three and 12 months. Two-thirds of families had moderate to good preinjury global functioning and coping resources, but more than half exhibited high levels of stress and at-risk family relationships. No significant preinjury differences by injury severity were seen on any measure. Whereas few changes in family functioning were observed over the year in the mild or moderate groups, greater deterioration occurred in the severe group. From one third to one half noted moderate to severe strain in 13 problem areas often seen in individuals with TBI. Preinjury family global functioning, however, was more strongly predictive of 12-month family functioning (R2 = .38 to.68) than was injury severity (R2 = .05 to .09). In four out of five outcome areas assessed at 12 months, preinjury status in each area was the strongest single predictor. Preinjury coping was the best predictor of stress. Families at risk can be identified and need ongoing support for optimal functioning.	UNIV WASHINGTON,SCH SOCIAL WORK,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; STAT & EPIDEMIOL RES CORP,SEATTLE,WA; CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,SEATTLE,WA				Shurtleff, Hillary/0000-0003-0959-2842			ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; BEGLEITER ML, 1976, SOC BIOL, V23, P260, DOI 10.1080/19485565.1976.9988237; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; BRESLAU N, 1982, AM J DIS CHILD, V136, P682, DOI 10.1001/archpedi.1982.03970440026007; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAIRNS NU, 1979, J PEDIATR-US, V95, P484, DOI 10.1016/S0022-3476(79)80541-7; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CLARRIDGE BR, 1989, MED CARE, V27, P352, DOI 10.1097/00005650-198904000-00003; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; FRIEDRICH WN, 1979, J CONSULT CLIN PSYCH, V47, P1140, DOI 10.1037/0022-006X.47.6.1140; GATH A, 1980, ARCH DIS CHILD, V55, P371, DOI 10.1136/adc.55.5.371; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P54; KAY T, 1988, HEAD INJURY FAMILY I; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KOSKI M, 1975, MOD PROBL PAEDIATR, V12, P348; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; KUPST MJ, 1988, J PEDIATR PSYCHOL, V13, P7, DOI 10.1093/jpepsy/13.1.7; LANSKY SB, 1978, PEDIATRICS, V62, P184; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MARTIN DA, 1988, J LEARN DISABIL, V21, P464, DOI 10.1177/002221948802100803; MCCORMICK MC, 1986, DEV MED CHILD NEUROL, V28, P53; MCCUBBIN H, 1973, STRESS FAMILY, V1, P407; MCCUBBIN H, 1979, FAMILY STRESS COPING; McCubbin H.I., 1982, FAMILY STRESS COPING; MCCUBBIN HI, 1983, SOCIAL STRESS FAMILY; McCubbin HI, 1980, FAMILY ASSESSMENT RE; MCCUBBIN MA, 1989, FAM RELAT, V38, P436, DOI 10.2307/585750; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Moos R. H., 1974, SOCIAL CLIMATE SCALE; MRAZEK D, 1985, 32ND P ANN M AM ACAD; ODDEY M, 1980, J NEUROL NEUROSUR PS, V43, P798; PETERSEN P, 1984, J PSYCHOSOM RES, V28, P337, DOI 10.1016/0022-3999(84)90056-4; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SCHILLING RF, 1984, FAM RELAT, V33, P47, DOI 10.2307/584589; Seligman M, 1989, ORDINARY FAMILIES SP; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; SLATER EJ, 1987, PSYCHIAT ANN, V17, P786, DOI 10.3928/0048-5713-19871201-08; TAVORMINA JB, 1981, J ABNORM CHILD PSYCH, V9, P121, DOI 10.1007/BF00917862; TEW B, 1975, BRIT J PREV SOC MED, V29, P27; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260	49	95	96	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1992	73	10					899	910					12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	JU061	WOS:A1992JU06100003	1417464				2021-06-18	
J	ASARNOW, RF; SATZ, P; LIGHT, R; LEWIS, R; NEUMANN, E				ASARNOW, RF; SATZ, P; LIGHT, R; LEWIS, R; NEUMANN, E			BEHAVIOR PROBLEMS AND ADAPTIVE FUNCTIONING IN CHILDREN WITH MILD AND SEVERE CLOSED HEAD-INJURY	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						MILD CLOSED HEAD INJURY; SEVERE CLOSED HEAD INJURY; BEHAVIOR PROBLEMS; ADAPTIVE FUNCTIONING; CHILDREN	FOLLOW-UP; SEQUELAE		POMONA COLL, CLAREMONT, CA 91711 USA; CASA COLINA HOSP REHABIL MED, POMONA, CA USA	ASARNOW, RF (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT, DIV MENTAL RETARDAT & CHILD PSYCHIAT, LOS ANGELES, CA 90024 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0 1 NS26801] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026801] Funding Source: NIH RePORTER		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ALPERN GD, 1984, DEV PROFILE, V2; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BIJUR PE, 1990, PEDIATRICS, V86, P337; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; HAYS WL, 1963, STATISTICS PSYCHOL; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Horowitz I, 1983, Int Rehabil Med, V5, P32; Jennett B, 1989, MILD HEAD INJURY, P23; Kaufman A. S., 1983, KAUFMAN ASSESSMENT B; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS J, IN PRESS PEDIATRICS; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWIS RS, 1989, UNPUB VERBAL MEMORY; LIGHT R, 1989, UNPUB SUSTAINED SELE; LOEBER R, 1991, J ABNORM CHILD PSYCH, V19, P75, DOI 10.1007/BF00910566; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sparrow S., 1984, VINELAND ADAPTIVE BE	25	95	95	1	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	OCT	1991	16	5					543	555		10.1093/jpepsy/16.5.543			13	Psychology, Developmental	Psychology	GL779	WOS:A1991GL77900002	1744804				2021-06-18	
J	LEVIN, HS; WILLIAMS, D; CROFFORD, MJ; HIGH, WM; EISENBERG, HM; AMPARO, EG; GUINTO, FC; KALISKY, Z; HANDEL, SF; GOLDMAN, AM				LEVIN, HS; WILLIAMS, D; CROFFORD, MJ; HIGH, WM; EISENBERG, HM; AMPARO, EG; GUINTO, FC; KALISKY, Z; HANDEL, SF; GOLDMAN, AM			RELATIONSHIP OF DEPTH OF BRAIN-LESIONS TO CONSCIOUSNESS AND OUTCOME AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article									UNIV TEXAS,MED BRANCH,DEPT RADIOL,GALVESTON,TX 77550; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT RADIOL,HOUSTON,TX 77030; MED CTR DEL ORO,DEPT REHABIL MED,HOUSTON,TX	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D-73,GALVESTON,TX 77550, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; SARPEL G, 1987, ARCH NEUROL-CHICAGO, V44, P725, DOI 10.1001/archneur.1987.00520190035014; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TEASDALE G, 1974, LANCET, V2, P81	11	95	96	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	1988	69	6					861	866		10.3171/jns.1988.69.6.0861			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	R0342	WOS:A1988R034200008	3193191				2021-06-18	
J	Brooks, MA; Peterson, K; Biese, K; Sanfilippo, J; Heiderscheit, BC; Bell, DR				Brooks, M. Alison; Peterson, Kaitlin; Biese, Kevin; Sanfilippo, Jennifer; Heiderscheit, Bryan C.; Bell, David R.			Concussion Increases Odds of Sustaining a Lower Extremity Musculoskeletal Injury After Return to Play Among Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports-related concussion; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; RECURRENT CONCUSSION; RISK	Background: Previous studies have identified abnormalities in brain and motor functioning after concussion that persist well beyond observed clinical recovery. Recent work suggests subtle deficits in neurocognition may impair neuromuscular control and thus potentially increase risk of lower extremity musculoskeletal injury after concussion. Purpose: To determine the odds of sustaining an acute lower extremity musculoskeletal injury during the 90-day period after return to play from concussion in a cohort of National Collegiate Athletic Association (NCAA) Division I collegiate athletes. Study Design: Cohort study; Level of evidence, 3. Methods: Included in this study were 87 cases of concussion among 75 athletes (58 men; 17 women) participating in NCAA Division I football, soccer, hockey, softball, basketball, wrestling, or volleyball at a single institution from 2011 to 2014. The 90-day period after return to play for each case of concussion was reviewed for acute noncontact lower extremity musculoskeletal injury. Each 90-day period after return to play was matched to the same 90-day period in up to 3 controls. Control athletes without a history of concussion in the previous year were matched to concussed athletes by sport team/sex, games played, and position. A total of 182 control (136 men; 46 women) 90-day periods were reviewed for acute injury. Conditional logistic regression was used to assess the association between concussion and subsequent risk of acute lower extremity musculoskeletal injury. Results: The incidence of acute lower extremity musculoskeletal injury was higher among recently concussed athletes (15/87; 17%) compared with matched controls (17/182; 9%). The odds of sustaining an acute lower extremity musculoskeletal injury during the 90-day period after return to play were 2.48 times higher in concussed athletes than controls during the same 90-day period (odds ratio, 2.48; 95% CI, 1.04-5.91; P = .04). Conclusion: Concussed athletes have increased odds of sustaining an acute lower extremity musculoskeletal injury after return to play than their nonconcussed teammates. The study results suggest further investigation of neurocognitive and motor control deficits may be warranted beyond the acute injury phase to decrease risk for subsequent injury.	[Brooks, M. Alison; Peterson, Kaitlin; Biese, Kevin; Sanfilippo, Jennifer; Heiderscheit, Bryan C.; Bell, David R.] Univ Wisconsin, Madison, WI 53705 USA; [Brooks, M. Alison; Heiderscheit, Bryan C.; Bell, David R.] Univ Wisconsin, Dept Orthoped & Rehabil, 1685 Highland Ave, Madison, WI 53705 USA; [Brooks, M. Alison; Sanfilippo, Jennifer; Heiderscheit, Bryan C.; Bell, David R.] Univ Wisconsin, Badger Athlet Performance, 1685 Highland Ave, Madison, WI 53705 USA; [Biese, Kevin] Univ Wisconsin, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA; [Biese, Kevin; Bell, David R.] Univ Wisconsin, Dept Kinesiol, 1685 Highland Ave, Madison, WI 53705 USA; [Sanfilippo, Jennifer] Univ Wisconsin, Div Intercollegiate Athlet, 1685 Highland Ave, Madison, WI 53705 USA	Brooks, MA (corresponding author), Univ Wisconsin, Dept Orthoped & Rehabil, 1685 Highland Ave, Madison, WI 53705 USA.	brooks@ortho.wisc.edu					Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN SPORTS MED, V30, P89; Herman D., 2013, CLIN J SPORT MED, V23, P124; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200	26	94	94	2	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2016	44	3					742	747		10.1177/0363546515622387			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DF9CQ	WOS:000371658300029	26786903				2021-06-18	
J	Papa, L; Silvestri, S; Brophy, GM; Giordano, P; Falk, JL; Braga, CF; Tan, CN; Ameli, NJ; Demery, JA; Dixit, NK; Mendes, ME; Hayes, RL; Wang, KKW; Robertson, CS				Papa, Linda; Silvestri, Salvatore; Brophy, Gretchen M.; Giordano, Philip; Falk, Jay L.; Braga, Carolina F.; Tan, Ciara N.; Ameli, Neema J.; Demery, Jason A.; Dixit, Neha K.; Mendes, Matthew E.; Hayes, Ronald L.; Wang, Kevin K. W.; Robertson, Claudia S.			GFAP Out-Performs S100 beta in Detecting Traumatic Intracranial Lesions on Computed Tomography in Trauma Patients with Mild Traumatic Brain Injury and Those with Extracranial Lesions	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography (CT); fractures; glial fibrillary acidic protein (GFAP); mild traumatic brain injury/concussion; S100 beta	FIBRILLARY ACIDIC PROTEIN; MINOR HEAD-INJURY; SERUM S100B LEVELS; DECISION-MAKING; BIOMARKERS; DAMAGE; MULTICENTER; S-100B; BLOOD; INDEX	Both glial fibrillary acidic protein (GFAP) and S100 beta are found in glial cells and are released into serum following a traumatic brain injury (TBI), however, the clinical utility of S100 beta as a biomarker has been questioned because of its release from bone. This study examined the ability of GFAP and S100 beta to detect intracranial lesions on computed tomography (CT) in trauma patients and also assessed biomarker performance in patients with fractures and extracranial injuries on head CT. This prospective cohort study enrolled a convenience sample of adult trauma patients at a Level I trauma center with and without mild or moderate traumatic brain injury (MMTBI). Serum samples were obtained within 4 h of injury. The primary outcome was the presence of traumatic intracranial lesions on CT scan. There were 397 general trauma patients enrolled: 209 (53%) had a MMTBI and 188 (47%) had trauma without MMTBI. Of the 262 patients with a head CT, 20 (8%) had intracranial lesions. There were 137 (35%) trauma patients who sustained extracranial fractures below the head to the torso and extremities. Levels of S100 beta were significantly higher in patients with fractures, compared with those without fractures (p < 0.001) whether MMTBI was present or not. However, GFAP levels were not significantly affected by the presence of fractures (p > 0.05). The area under the receiver operating characteristics curve (AUC) for predicting intracranial lesions on CT for GFAP was 0.84 (0.73-0.95) and for S100 beta was 0.78 (0.67-0.89). However, in the presence of extracranial fractures, the AUC for GFAP increased to 0.93 (0.86-1.00) and for S100 beta decreased to 0.75 (0.61-0.88). In a general trauma population, GFAP out-performed S100 beta in detecting intracranial CT lesions, particularly in the setting of extracranial fractures.	[Papa, Linda; Silvestri, Salvatore; Giordano, Philip; Falk, Jay L.; Braga, Carolina F.; Tan, Ciara N.; Ameli, Neema J.] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Demery, Jason A.; Dixit, Neha K.] North Floridas Vet Hlth Syst, Dept Psychol, Gainesville, FL USA; [Mendes, Matthew E.] Univ Cent Florida, Orlando, FL 32816 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood S-200, Orlando, FL 32806 USA.	lpstat@aol.com		Brophy, Gretchen/0000-0002-4749-2693; Wang, Kevin/0000-0002-9343-6473	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	This study was supported in part by Award Number R01NS057676 from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.	Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Herrmann M, 2001, NEUROSURGERY, V49, P1272, DOI 10.1097/00006123-200111000-00058; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olsson B, 2011, PROG NEUROBIOL, V95, P520, DOI 10.1016/j.pneurobio.2011.04.006; Papa L, 2012, POTEOMICS HUMAN DIS; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; PHILLIPS JP, 1980, BRIT MED J, V281, P777, DOI 10.1136/bmj.281.6243.777; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00054; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vajtr D., 2013, SOUD LEK, V57, P7; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Xiong H, 2000, Sheng Li Ke Xue Jin Zhan, V31, P217; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	31	94	99	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1815	U11		10.1089/neu.2013.3245			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400001	24903744	Green Published			2021-06-18	
J	Mishra, AM; Bai, XX; Sanganahalli, BG; Waxman, SG; Shatillo, O; Grohn, O; Hyder, F; Pitkanen, A; Blumenfeld, H				Mishra, Asht Mangal; Bai, Xiaoxiao; Sanganahalli, Basavaraju G.; Waxman, Stephen G.; Shatillo, Olena; Grohn, Olli; Hyder, Fahmeed; Pitkanen, Asla; Blumenfeld, Hal			Decreased Resting Functional Connectivity after Traumatic Brain Injury in the Rat	PLOS ONE			English	Article							CHILDHOOD ABSENCE EPILEPSY; TONIC-CLONIC SEIZURES; POSTTRAUMATIC EPILEPSY; WAG/RIJ RATS; FMRI; EPILEPTOGENESIS; MODEL; MRI; FLUCTUATIONS; NETWORKS	Traumatic brain injury (TBI) contributes to about 10% of acquired epilepsy. Even though the mechanisms of post-traumatic epileptogenesis are poorly known, a disruption of neuronal networks predisposing to altered neuronal synchrony remains a viable candidate mechanism. We tested a hypothesis that resting state BOLD-fMRI functional connectivity can reveal network abnormalities in brain regions that are connected to the lesioned cortex, and that these changes associate with functional impairment, particularly epileptogenesis. TBI was induced using lateral fluid-percussion injury in seven adult male Sprague-Dawley rats followed by functional imaging at 9.4T 4 months later. As controls we used six sham-operated animals that underwent all surgical operations but were not injured. Electroencephalogram (EEG)-functional magnetic resonance imaging (fMRI) was performed to measure resting functional connectivity. A week after functional imaging, rats were implanted with bipolar skull electrodes. After recovery, rats underwent pentyleneterazol (PTZ) seizure-susceptibility test under EEG. For image analysis, four pairs of regions of interests were analyzed in each hemisphere: ipsilateral and contralateral frontal and parietal cortex, hippocampus, and thalamus. High-pass and low-pass filters were applied to functional imaging data. Group statistics comparing injured and sham-operated rats and correlations over time between each region were calculated. In the end, rats were perfused for histology. None of the rats had epileptiform discharges during functional imaging. PTZ-test, however revealed increased seizure susceptibility in injured rats as compared to controls. Group statistics revealed decreased connectivity between the ipsilateral and contralateral parietal cortex and between the parietal cortex and hippocampus on the side of injury as compared to sham-operated animals. Injured animals also had abnormal negative connectivity between the ipsilateral and contralateral parietal cortex and other regions. Our data provide the first evidence on abnormal functional connectivity after experimental TBI assessed with resting state BOLD-fMRI.	[Mishra, Asht Mangal; Bai, Xiaoxiao; Waxman, Stephen G.; Blumenfeld, Hal] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; [Blumenfeld, Hal] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA; [Sanganahalli, Basavaraju G.; Hyder, Fahmeed] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA; [Hyder, Fahmeed] Yale Univ, Sch Med, Dept Biomed Engn, New Haven, CT USA; [Mishra, Asht Mangal; Sanganahalli, Basavaraju G.; Hyder, Fahmeed; Blumenfeld, Hal] Yale Univ, Core Ctr Quantitat Neurosci Magnet Resonance, New Haven, CT USA; [Waxman, Stephen G.] Ctr Neurosci & Regenerat Res, West Haven, CT USA; [Grohn, Olli] Univ Eastern Finland, Biomed NMR Res Grp, Biomed Imaging Unit, Kuopio, Finland; [Shatillo, Olena; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Blumenfeld, H (corresponding author), Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA.	hal.blumenfeld@yale.edu	Muthamilarasan, Mehanathan/H-9340-2017; Hyder, Fahmeed/A-2644-2015; Sanganahalli, Basavaraju G/C-3296-2008; Prasad, Manoj/AAE-8540-2019; Waxman, Stephen/Z-2507-2019; khan, yusuf/E-6726-2015; khan, yusuf/AAQ-9470-2021; MISHRA, AWDHESH/U-1920-2019	Muthamilarasan, Mehanathan/0000-0001-7589-6372; Hyder, Fahmeed/0000-0001-7822-4002; Sanganahalli, Basavaraju G/0000-0002-0851-6621; Prasad, Manoj/0000-0003-0691-0163; Waxman, Stephen/0000-0001-5718-7177; khan, yusuf/0000-0001-6986-4657; MISHRA, AWDHESH KUMAR/0000-0002-3312-3264	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049307]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS066974]; Epilepsy Foundation Postdoctoral Research and Training Award [123505]; Yale QNMR Pilot study; Betsy and Jonathan Blattmachr family; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation;  [P30 NS052519]	This work was supported by National Institutes of Health (NIH) R01 NS049307 (HB), NIH R01 NS066974 (HB), Epilepsy Foundation Postdoctoral Research and Training Award ID: 123505 (AMM), Yale QNMR Pilot study (AMM), P30 NS052519 (FH), the Betsy and Jonathan Blattmachr family (HB), the Academy of Finland (AP, OG), and by the Sigrid Juselius Foundation (AP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai X, 2011, NEUROLOGY, V76, P1960, DOI 10.1212/WNL.0b013e31821e54de; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Coggan JS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/065002; Cymerblit-Sabba A, 2010, J NEUROSCI, V30, P1619, DOI 10.1523/JNEUROSCI.5078-09.2010; D'Esposito M, 2003, NAT REV NEUROSCI, V4, P863, DOI 10.1038/nrn1246; DeSalvo MN, 2010, NEUROIMAGE, V50, P902, DOI 10.1016/j.neuroimage.2010.01.006; El-Hassar L, 2007, EPILEPSIA, V48, P131, DOI 10.1111/j.1528-1167.2007.01301.x; Englot DJ, 2008, J NEUROSCI, V28, P9066, DOI 10.1523/JNEUROSCI.2014-08.2008; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Franken ND, 2008, VET ANAESTH ANALG, V35, P424, DOI 10.1111/j.1467-2995.2008.00404.x; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hettinger PC, 2011, J NEUROSCI METH, V200, P106, DOI 10.1016/j.jneumeth.2011.06.018; Immonen R, 2013, J NEUROTRAUM, P1; Jenkins G.M., 1968, SPECTRAL ANAL ITS AP; Karhunen H, 2007, NEUROSCIENCE, V148, P314, DOI 10.1016/j.neuroscience.2007.05.047; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Khubchandani M, 2003, MAGNET RESON MED, V49, P962, DOI 10.1002/mrm.10441; Killory BD, 2011, NEUROIMAGE, V56, P2209, DOI 10.1016/j.neuroimage.2011.03.036; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Lemieux L, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00012; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Makinen S, 2008, J CEREBR BLOOD F MET, V28, P263, DOI 10.1038/sj.jcbfm.9600529; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mishra AM, 2009, EPILEPSIA, V50, P362; Mishra AM, 2011, J NEUROSCI, V31, P15053, DOI 10.1523/JNEUROSCI.0101-11.2011; Nersesyan H, 2004, J CEREBR BLOOD F MET, V24, P589, DOI 10.1097/01.WCB.0000117688.98763.23; Niskanen JP, 2013, J NEUROTRAUM, V30, P546, DOI 10.1089/neu.2012.2416; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Sachdev RNS, 2003, NEUROIMAGE, V19, P742, DOI 10.1016/S1053-8119(03)00093-4; Volman V, 2013, NEURAL COMPUT, V25, P2646, DOI 10.1162/NECO_a_00491; Waites AB, 2006, ANN NEUROL, V59, P335, DOI 10.1002/ana.20733; Weber R, 2006, NEUROIMAGE, V29, P1303, DOI 10.1016/j.neuroimage.2005.08.028; Zhao FQ, 2008, NEUROIMAGE, V39, P248, DOI 10.1016/j.neuroimage.2007.07.063	41	94	98	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2014	9	4							e95280	10.1371/journal.pone.0095280			9	Multidisciplinary Sciences	Science & Technology - Other Topics	AG2DP	WOS:000335226500074	24748279	DOAJ Gold, Green Published			2021-06-18	
J	Bouzat, P; Sala, N; Suys, T; Zerlauth, JB; Marques-Vidal, P; Feihl, F; Bloch, J; Messerer, M; Levivier, M; Meuli, R; Magistretti, PJ; Oddo, M				Bouzat, Pierre; Sala, Nathalie; Suys, Tamarah; Zerlauth, Jean-Baptiste; Marques-Vidal, Pedro; Feihl, Francois; Bloch, Jocelyne; Messerer, Mahmoud; Levivier, Marc; Meuli, Reto; Magistretti, Pierre J.; Oddo, Mauro			Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain	INTENSIVE CARE MEDICINE			English	Article						Brain metabolism; Lactate; Cerebral microdialysis; Traumatic brain injury; Hypertonic	INTRACRANIAL HYPERTENSIVE EPISODES; GLUCOSE-METABOLISM; COMBINED MICRODIALYSIS; AEROBIC GLYCOLYSIS; ENERGY-METABOLISM; SODIUM LACTATE; HEAD-INJURY; FDG-PET; GLUTAMATE; INCREASE	Experimental evidence suggests that lactate is neuroprotective after acute brain injury; however, data in humans are lacking. We examined whether exogenous lactate supplementation improves cerebral energy metabolism in humans with traumatic brain injury (TBI). We prospectively studied 15 consecutive patients with severe TBI monitored with cerebral microdialysis (CMD), brain tissue PO2 (PbtO(2)), and intracranial pressure (ICP). Intervention consisted of a 3-h intravenous infusion of hypertonic sodium lactate (aiming to increase systemic lactate to ca. 5 mmol/L), administered in the early phase following TBI. We examined the effect of sodium lactate on neurochemistry (CMD lactate, pyruvate, glucose, and glutamate), PbtO(2), and ICP. Treatment was started on average 33 +/- A 16 h after TBI. A mixed-effects multilevel regression model revealed that sodium lactate therapy was associated with a significant increase in CMD concentrations of lactate [coefficient 0.47 mmol/L, 95 % confidence interval (CI) 0.31-0.63 mmol/L], pyruvate [13.1 (8.78-17.4) mu mol/L], and glucose [0.1 (0.04-0.16) mmol/L; all p < 0.01]. A concomitant reduction of CMD glutamate [-0.95 (-1.94 to 0.06) mmol/L, p = 0.06] and ICP [-0.86 (-1.47 to -0.24) mmHg, p < 0.01] was also observed. Exogenous supplemental lactate can be utilized aerobically as a preferential energy substrate by the injured human brain, with sparing of cerebral glucose. Increased availability of cerebral extracellular pyruvate and glucose, coupled with a reduction of brain glutamate and ICP, suggests that hypertonic lactate therapy has beneficial cerebral metabolic and hemodynamic effects after TBI.	[Bouzat, Pierre; Sala, Nathalie; Suys, Tamarah; Oddo, Mauro] Univ Lausanne Hosp, Fac Biol & Med, Dept Intens Care Med, Neurosci Crit Care Res Grp, CH-1011 Lausanne, Switzerland; [Bouzat, Pierre] Univ Grenoble 1, Grenoble, France; [Zerlauth, Jean-Baptiste; Meuli, Reto] Univ Lausanne Hosp, Fac Biol & Med, Dept Radiol, CH-1011 Lausanne, Switzerland; [Marques-Vidal, Pedro] Univ Lausanne Hosp, Fac Biol & Med, Inst Social & Prevent Med, CH-1011 Lausanne, Switzerland; [Feihl, Francois] Univ Lausanne Hosp, Fac Biol & Med, Dept Internal Med, Div Clin Pathophysiol, CH-1011 Lausanne, Switzerland; [Bloch, Jocelyne; Messerer, Mahmoud; Levivier, Marc] Univ Lausanne Hosp, Fac Biol & Med, Dept Clin Neurosci, Div Neurosurg, CH-1011 Lausanne, Switzerland; [Magistretti, Pierre J.] Univ Lausanne Hosp, Fac Biol & Med, Ctr Neurosci Psychiat,Lab Neuroenerget & Cellular, Ecole Polytech Fed Lausanne,Brain Mind Inst, CH-1011 Lausanne, Switzerland	Oddo, M (corresponding author), Univ Lausanne Hosp, Fac Biol & Med, Dept Intens Care Med, Neurosci Crit Care Res Grp, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	PBouzat@chu-grenoble.fr; mauro.oddo@chuv.ch	Bouzat, Pierre/AAC-4105-2019; Marques-Vidal, Pedro M/C-9449-2009; Messerer, Mahmoud/AAZ-3527-2020; Oddo, Mauro/R-3370-2016; Bloch, Jocelyne/A-9668-2017; Bouzat, Pierre/L-6881-2014	Bouzat, Pierre/0000-0003-4667-6738; Marques-Vidal, Pedro M/0000-0002-4548-8500; Oddo, Mauro/0000-0002-6155-2525; Bloch, Jocelyne/0000-0002-6405-1590; Levivier, Marc/0000-0002-6273-2595; Magistretti, Pierre Julius/0000-0002-6678-320X	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; European Critical Care Research Network; European Society of Intensive Care Medicine; Gueules Cassees Foundation	The authors thank Beatrice Pellet, from the Division of Pharmacy, for the preparation of sodium lactate, as well as all neurosurgical fellows, ICU physicians, and ICU nurses for their help and support. This work was supported by grants from the Swiss National Science Foundation (Grant Nr. 320030_138191, to M.O.), the European Critical Care Research Network, European Society of Intensive Care Medicine (to M.O.), and the Gueules Cassees Foundation (to P.B.). This work received the best abstract award at the European Society of Intensive Care Medicine congress in Paris, 2013.	Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Ichai C, 2013, INTENS CARE MED, V39, P1413, DOI 10.1007/s00134-013-2978-9; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magistretti P, 2008, FUNDAMENTAL NEUROSCI, P271; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Revelly JP, 2005, CRIT CARE MED, V33, P2235, DOI 10.1097/01.CCM.0000181525.99295.8F; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Roquilly A, 2013, CRIT CARE, V17, DOI 10.1186/cc12686; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 1999, J NEUROSCI, V19, P34; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF	36	94	96	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2014	40	3					412	421		10.1007/s00134-013-3203-6			10	Critical Care Medicine	General & Internal Medicine	AC3YL	WOS:000332457400012	24477453				2021-06-18	
J	Bazarian, JJ; Donnelly, K; Peterson, DR; Warner, GC; Zhu, T; Zhong, JH				Bazarian, Jeffrey J.; Donnelly, Kerry; Peterson, Derick R.; Warner, Gary C.; Zhu, Tong; Zhong, Jianhui			The Relation Between Posttraumatic Stress Disorder and Mild Traumatic Brain Injury Acquired During Operations Enduring Freedom and Iraqi Freedom	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast exposure; combat intensity; diffusion tensor imaging; magnetic resonance imaging; mild traumatic brain injury; Operation Enduring Freedom; Operation Iraqi Freedom; posttraumatic stress disorder	MEDIAL PREFRONTAL CORTEX; WHITE-MATTER; INDUCED NEUROTRAUMA; PTSD; INTEGRITY; MILITARY; IDENTIFICATION; ABNORMALITIES; AFGHANISTAN; VOLUNTEERS	Objective: To understand the relations of mild traumatic brain injury (TBI), blast exposure, and brain white matter structure to severity of posttraumatic stress disorder (PTSD). Design: Nested cohort study using multivariate analyses. Participants: Fifty-two OEF/OIF veterans who served in combat areas between 2001 and 2008 were studied approximately 4 years after the last tour of duty. Main Measures: PTSD Checklist-Military; Combat Experiences Survey, interview questions concerning blast exposure and TBI symptoms; anatomical magnetic resonance imaging (MRI), and diffusion tensor imaging (DTI) scanning of the brain. Results: PTSD severity was associated with higher 1st percentile values of mean diffusivity on DTI (regression coefficient [r] = 4.2, P = .039), abnormal MRI (r = 13.3, P = .046), and the severity of exposure to combat events (r = 5.4, P = .007). Mild TBI was not significantly associated with PTSD severity. Blast exposure was associated with lower 1st percentile values of fractional anisotropy on DTI (odds ratio [OR] = 0.38 per SD; 95% confidence interval [CI], 0.15-0.92), normal MRI (OR = 0.00, 95% likelihood ratio test CI, 0.00-0.09), and the severity of exposure to traumatic events (OR = 3.64 per SD; 95% CI, 1.40-9.43). Conclusions: PTSD severity is related to both the severity of combat stress and underlying structural brain changes on MRI and DTI but not to a clinical diagnosis of mild TBI. The observed relation between blast exposure and abnormal DTI suggests that subclinical TBI may play a role in the genesis of PTSD in a combat environment.	[Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY 14642 USA; [Peterson, Derick R.] Univ Rochester, Sch Med, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Zhong, Jianhui] Univ Rochester, Sch Med, Dept Imaging Sci, Rochester, NY 14642 USA; [Donnelly, Kerry] VA Western New York Healthcare Syst Buffalo, Buffalo, NY USA; [Warner, Gary C.] Canandaigua VAMC, Canandaigua, NY USA	Bazarian, JJ (corresponding author), Univ Rochester, Sch Med, Dept Emergency Med, 601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu	Peterson, Derick/W-5240-2019; Zhong, Jianhui/AAE-6061-2020; Zhu, Tong/A-9402-2011	Peterson, Derick/0000-0001-8603-660X; 	Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs; Health Services Research and Development [SDR 06-162]	This research was supported by a grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and Health Services Research and Development (SDR 06-162). The authors thank Leslie Charles (Canandaigua VA), Samuel Z. Lewis (Canandaigua VA), and Michelle Alt (VA Western New York Healthcare System - Buffalo) for their assistance in subject recruitment and data collection and to P.-L. Westesson, MD, PhD, DDS, for magnetic resonance imaging interpretation.	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BREMNER JD, 1992, AM J PSYCHIAT, V149, P328; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Canive JM, 1997, ANN NY ACAD SCI, V821, P512, DOI 10.1111/j.1749-6632.1997.tb48318.x; CASSIDAY KL, 1992, J TRAUMA STRESS, V5, P627, DOI 10.1007/BF00979230; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cerqueira JJ, 2007, CEREB CORTEX, V17, P1998, DOI 10.1093/cercor/bhl108; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoggard N, 2009, J MED ETHICS, V35, P194, DOI 10.1136/jme.2008.025502; Hull AM, 2002, BRIT J PSYCHIAT, V181, P102; Institute of Medicine, 2009, GULF WAR HLTH, V7; Iverson GL, BRAIN INJ, V25, P1325; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Katzman GL, 1999, JAMA-J AM MED ASSOC, V282, P36, DOI 10.1001/jama.282.1.36; Kim SJ, 2006, NEUROPSYCHOBIOLOGY, V54, P120, DOI 10.1159/000098262; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Kwon S. K. C., 2011, FRONT NEUROL, V2, P1; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lyoo IK, 2004, PSYCHIAT RES-NEUROIM, V131, P135, DOI 10.1016/j.pscychresns.2004.04.001; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Needham C, 2012, CHALLENGES MEASURING; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Radley JJ, 2008, J COMP NEUROL, V507, P1141, DOI 10.1002/cne.21588; Rutland-Brown W, 2008, J HEAD TRAUMA REHAB, V23, P84, DOI 10.1097/01.HTR.0000314527.78134.70; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Talvage TM, 2011, J NEUROTRAUM, DOI [10.1089/neu.2010.1512, DOI 10.1089/NEU.2010.1512]; Tanielian T, 2008, INVISIBLE WOUNDS WAR; van Dijk EJ, 2004, HYPERTENSION, V44, P625, DOI 10.1161/01.HYP.0000145857.98904.20; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941; Zhu T, 2009, J MAGN RESON IMAGING, V29, P422, DOI 10.1002/jmri.21647	55	94	94	1	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					1	12		10.1097/HTR.0b013e318256d3d3			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400001	22647965				2021-06-18	
J	Harch, PG; Andrews, SR; Fogarty, EF; Amen, D; Pezzullo, JC; Lucarini, J; Aubrey, C; Taylor, DV; Staab, PK; Van Meter, KW				Harch, Paul G.; Andrews, Susan R.; Fogarty, Edward F.; Amen, Daniel; Pezzullo, John C.; Lucarini, Juliette; Aubrey, Claire; Taylor, Derek V.; Staab, Paul K.; Van Meter, Keith W.			A Phase I Study of Low-Pressure Hyperbaric Oxygen Therapy for Blast-Induced Post-Concussion Syndrome and Post-Traumatic Stress Disorder	JOURNAL OF NEUROTRAUMA			English	Article						hyperbaric oxygen therapy; post-concussion syndrome; post-traumatic stress disorder; single photon emission computed tomography; traumatic brain injury	TRAUMATIC BRAIN-INJURY; WECHSLER ABBREVIATED SCALE; CLOSED-HEAD INJURY; CONTROLLED-TRIALS; MILD; HIPPOCAMPAL; VALIDITY; INTELLIGENCE; RECOVERY; NEURONS	This is a preliminary report on the safety and efficacy of 1.5 ATA hyperbaric oxygen therapy (HBOT) in military subjects with chronic blast-induced mild to moderate traumatic brain injury (TBI)/post-concussion syndrome (PCS) and post-traumatic stress disorder (PTSD). Sixteen military subjects received 40 1.5 ATA/60 min HBOT sessions in 30 days. Symptoms, physical and neurological exams, SPECT brain imaging, and neuropsychological and psychological testing were completed before and within 1 week after treatment. Subjects experienced reversible middle ear barotrauma (5), transient deterioration in symptoms (4), and reversible bronchospasm (1); one subject withdrew. Post-treatment testing demonstrated significant improvement in: symptoms, neurological exam, full-scale IQ (+14.8 points; p < 0.001), WMS IV Delayed Memory (p = 0.026), WMS-IV Working Memory (p = 0.003), Stroop Test (p < 0.001), TOVA Impulsivity (p = 0.041), TOVA Variability (p = 0.045), Grooved Pegboard (p = 0.028), PCS symptoms (Rivermead PCSQ: p = 0.0002), PTSD symptoms (PCL-M: p < 0.001), depression (PHQ-9: p < 0.001), anxiety (GAD-7: p = 0.007), quality of life (MPQoL: p = 0.003), and self-report of percent of normal (p < 0.001), SPECT coefficient of variation in all white matter and some gray matter ROIs after the first HBOT, and in half of white matter ROIs after 40 HBOT sessions, and SPECT statistical parametric mapping analysis (diffuse improvements in regional cerebral blood flow after 1 and 40 HBOT sessions). Forty 1.5 ATA HBOT sessions in 1 month was safe in a military cohort with chronic blast-induced PCS and PTSD. Significant improvements occurred in symptoms, abnormal physical exam findings, cognitive testing, and quality-of-life measurements, with concomitant significant improvements in SPECT.	[Harch, Paul G.; Staab, Paul K.; Van Meter, Keith W.] Louisiana State Univ, Hlth Sci Ctr, Dept Med, Hyperbar Med Dept,Sect Emergency & Hyperbar Med, New Orleans, LA 70112 USA; [Andrews, Susan R.] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Med & Psychiat, New Orleans, LA 70112 USA; [Fogarty, Edward F.] Univ N Dakota, Dept Radiol, Sch Med & Hlth Sci, Bismarck, ND USA; [Amen, Daniel; Taylor, Derek V.] Univ Calif Irvine, Sch Med, Amen Clin Inc, Newport Beach, CA USA; [Pezzullo, John C.] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; [Lucarini, Juliette; Aubrey, Claire] Adm Off, New Orleans, LA USA	Harch, PG (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Med, Hyperbar Med Dept,Sect Emergency & Hyperbar Med, 1542 Tulane Ave,Room 452,Box T4M2, New Orleans, LA 70112 USA.	paulharchmd@gmail.com					Andrykowski MA, 1998, J CONSULT CLIN PSYCH, V66, P586, DOI 10.1037/0022-006X.66.3.586; [Anonymous], 2008, US NAV DIV MAN REV 6, V1; [Anonymous], 2009, MAST REVISED; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Axelrod BN, 2002, ASSESSMENT, V9, P17, DOI 10.1177/1073191102009001003; Bartels C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-118; Basso MR, 2002, CLIN NEUROPSYCHOL, V16, P57, DOI 10.1076/clin.16.1.57.8329; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Beauregard M, 2009, NORD J PSYCHIAT, V63, P5, DOI 10.1080/08039480802421182; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Calabrese C, 2008, J ALTERN COMPLEM MED, V14, P707, DOI 10.1089/acm.2008.0018; Carlson C. F., 2010, J HEAD TRAUMA R 0713; Centers for Medicare and Medicaid Services, 2006, CTR MED MED SERV P 1; Clark J, 2009, HYPERBARIC OXYGEN TH, P217; CLARK JM, 1993, PHYSL MED DIVING, P121; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cyceron, PLAT IM BIOM; Doraiswamy PM, 2007, PSYCHOPHARMACOL BULL, V40, P54; Dougherty G, 1996, MED ENG PHYS, V18, P557, DOI 10.1016/1350-4533(96)00011-2; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Franzen M D, 1987, Arch Clin Neuropsychol, V2, P265, DOI 10.1016/0887-6177(87)90014-X; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Garcia AJ, 2010, J APPL PHYSIOL, V109, P804, DOI 10.1152/japplphysiol.91429.2008; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; Gesell L. B, 2009, HYPERBARIC OXYGEN TH; Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0; Golden Z, 2006, DISABIL REHABIL, V28, P1379, DOI 10.1080/09638280600638364; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; Greenberg L., 1996, TEST VARIABLES ATTEN; Hampson NB, 1996, UNDERSEA HYPERBAR M, V23, P215; Harch P. G., 2004, TXB HYPERBARIC MED, P471; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Harch Paul G, 2009, Cases J, V2, P6538, DOI 10.4076/1757-1626-2-6538; Harch PG, 1996, TXB HYPERBARIC MED, P480; Harch PG, 2004, TXB HYPERBARIC MED, P223; Harch PG, 2009, TXB HYPERBARIC MED, P505; Harch PG, 1996, UNDERSEA HYPERB ME S, V23, P48; Harch PG, 2009, TXB HYPERBARIC MED, P235; Harch PG, 1994, UNDERSEA HYPERB ME S, V21, P30; Harch PG, 2002, P 2 INT S HYP OX CER, P31; Harch PG, 1999, TXB HYPERBARIC MED, P319; Hardy P, 2007, J NEUROL SCI, V253, P94, DOI 10.1016/j.jns.2006.12.005; Hays JR, 2002, PSYCHOL REP, V90, P355, DOI 10.2466/PR0.90.2.355-359; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; Jarcho JM, 2009, CLIN PHARMACOL THER, V86, P352, DOI 10.1038/clpt.2009.126; Jorge RE, 2010, ARCH GEN PSYCHIAT, V67, P187, DOI 10.1001/archgenpsychiatry.2009.185; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lesak M., 2004, NEUROPSYCHOLOGICAL A, V776, P365; LIDVALL HF, 1975, LANCET, V1, P100; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; NEUBAUER RA, 1990, LANCET, V335, P542, DOI 10.1016/0140-6736(90)90777-3; NEUBAUER RA, 1994, SOUTHERN MED J, V87, P933, DOI 10.1097/00007611-199409000-00015; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; PTSD Checklist-Military, 2009, PTSD CHECKLIST MILIT; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rossignol DA, 2007, MED HYPOTHESES, V68, P1208, DOI 10.1016/j.mehy.2006.09.064; Ryan JJ, 2003, APPL NEUROPSYCHOL, V10, P252, DOI 10.1207/s15324826an1004_8; Siddiqui A, 1997, PLAST RECONSTR SURG, V99, P148, DOI 10.1097/00006534-199701000-00023; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; SYMONDS C, 1962, LANCET, V1, P1; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vorstrup S, 1988, Acta Neurol Scand Suppl, V114, P1; WAIS-IV, 2009, WAIS 4; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; WASI, 2009, WASI; Wechsler D., 2001, WECHSLER TEST ADULT; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; WMS-IV, 2009, WMS 4; Wolfson D., 1993, HALSTEAD REITAN NEUR; Woon FL, 2008, HIPPOCAMPUS, V18, P729, DOI 10.1002/hipo.20437; Wright JK, 2009, UNDERSEA HYPERBAR M, V36, P391; Zhang T, 2010, BRAIN INJURY, V24, P1350, DOI 10.3109/02699052.2010.504525	87	94	98	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					168	185		10.1089/neu.2011.1895			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300020	22026588	Bronze			2021-06-18	
J	Moser, RS; Schatz, P; Neidzwski, K; Ott, SD				Moser, Rosemarie Scolaro; Schatz, Philip; Neidzwski, Katherine; Ott, Summer D.			Group Versus Individual Administration Affects Baseline Neurocognitive Test Performance	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						baseline testing; neurocognitive testing; concussion testing; computerized testing; group administration	SPORTS-RELATED CONCUSSION; NEUROPSYCHOLOGICAL ASSESSMENT; SOCIAL FACILITATION; FOOTBALL; DISTRACTION; ATTENTION; IMPACT; NOISE	Background: Computer-based tests are widely used for the purpose of documenting baseline neurocognitive function, and athletes are often tested in groups. At present, there is limited research on the effects of administering these tests in a group versus individual setting. Hypothesis: Athletes assessed with neurocognitive tests in groups would show decreased performance compared with those assessed individually. Study Design: Cohort study; Level of evidence, 3. Methods: High school athletes completed preseason baseline neurocognitive tests either in groups in their school or individually in a private neuropsychological clinic (with no significant between-group differences in sex, history of concussion, and attention deficit disorder/learning disability). All athletes completed the ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) test battery on 1 occasion, which yielded scores in the area of verbal memory, visual memory, motor processing speed, reaction time, and symptom scores. Results: Athletes in the group setting scored significantly lower on verbal memory (mean 83.4 vs 86.5; P = .003), visual memory (mean 71.6 vs 76.7; P = .0001), motor processing speed (mean 35.6 vs 38.4; P = .0001), and reaction time (mean 0.61 vs 0.57; P = .001), but not symptom scores (mean 6.1 vs 4.4; P = .11), and exhibited a greater rate of invalid baselines. Similar results were obtained after excluding athletes with attention deficit disorder/learning disability and/or a history of concussion. Conclusion: Administering baseline neurocognitive testing to athletes in a group setting may introduce extraneous error, negatively affecting test performance.	[Moser, Rosemarie Scolaro] Sports Concuss Ctr New Jersey, Lawrenceville, NJ 08648 USA; St Josephs Univ, Philadelphia, PA 19131 USA	Moser, RS (corresponding author), Sports Concuss Ctr New Jersey, 3131 Princeton Pike,Bldg 5,110, Lawrenceville, NJ 08648 USA.	moserrs@comcast.net		Schatz, Philip/0000-0002-6222-6545			ALVES WM, 1987, CLIN SPORT MED, V6, P211; BARON RS, 1978, J PERS SOC PSYCHOL, V36, P816, DOI 10.1037/0022-3514.36.8.816; BUSHNELL DD, 1978, ALTERING TEST ENV RE; CARVER CS, 1978, J PERS SOC PSYCHOL, V36, P324, DOI 10.1037/0022-3514.36.3.324; Chen Z, 2006, J EXP PSYCHOL HUMAN, V32, P1452, DOI 10.1037/0096-1523.32.6.1452; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Dashiell JF, 1930, J ABNORM SOC PSYCH, V25, P190, DOI 10.1037/h0075144; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; GOLDSTEIN DJ, 1978, PSYCHOL REP, V42, P111, DOI 10.2466/pr0.1978.42.1.111; Hovey HB, 1928, AM J PSYCHOL, V40, P585, DOI 10.2307/1414337; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, IMPACT ONLINE VERSIO; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; *NEUR SYST, 2000, IMPACT IMM POST CONC; *NJSIAA, CONC ID MAN RET TO P; PFISTER HP, 1995, AUST PSYCHOL, V30, P24, DOI 10.1080/00050069508259599; PIERCE RC, 1963, J CONSULT PSYCHOL, V27, P536, DOI 10.1037/h0038844; ROSZKOWSKI MJ, 1984, PSYCHOL REP, V54, P482, DOI 10.2466/pr0.1984.54.2.482; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; *SPSS INC, 2009, SPSS MAC REL 16; Stevens J.P, 2009, APPL MULTIVARIATE ST; Trimmel M, 2006, ERGONOMICS, V49, P202, DOI 10.1080/00140130500434986; Wechsler D., 1955, MANUAL WECHSLER ADUL; WEINSTEIN ND, 1974, J APPL PSYCHOL, V59, P548, DOI 10.1037/h0037338; ZAJONC RB, 1965, SCIENCE, V149, P269, DOI 10.1126/science.149.3681.269	30	94	94	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	NOV	2011	39	11					2325	2330		10.1177/0363546511417114			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	838KG	WOS:000296287900006	21828367				2021-06-18	
J	Marx, CE; Bradford, DW; Hamer, RM; Naylor, JC; Allen, TB; Lieberman, JA; Strauss, JL; Kilts, JD				Marx, C. E.; Bradford, D. W.; Hamer, R. M.; Naylor, J. C.; Allen, T. B.; Lieberman, J. A.; Strauss, J. L.; Kilts, J. D.			PREGNENOLONE AS A NOVEL THERAPEUTIC CANDIDATE IN SCHIZOPHRENIA: EMERGING PRECLINICAL AND CLINICAL EVIDENCE	NEUROSCIENCE			English	Article						neurosteroid; neuroactive steroid; pregnenolone; allopregnanolone; schizophrenia	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; D-ASPARTATE RECEPTORS; MICROTUBULE-ASSOCIATED PROTEIN-2; STEROID-HORMONE METABOLITES; LINKED-IMMUNOSORBENT-ASSAY; NEUROACTIVE STEROIDS; ALZHEIMERS-DISEASE; BIPOLAR DISORDER; RAT-BRAIN	Emerging preclinical and clinical evidence suggests that pregnenolone may be a promising novel therapeutic candidate in schizophrenia. Pregnenolone is a neurosteroid with pleiotropic actions in rodents that include the enhancement of learning and memory, neuritic outgrowth, and myelination. Further, pregnenolone administration results in elevations in downstream neurosteroids such as allopregnanolone, a molecule with neuroprotective effects that also increases neurogenesis, decreases apoptosis and inflammation, modulates the hypothalamic-pituitary-adrenal axis, and markedly increases GABA(A) receptor responses. In addition, pregnenolone administration elevates pregnenolone sulfate, a neurosteroid that positively modulates NMDA receptors. There are thus multiple mechanistic possibilities for pregnenolone as a potential therapeutic agent in schizophrenia, including the amelioration of NMDA receptor hypofunction (via metabolism to pregnenolone sulfate) and the mitigation of GABA dysregulation (via metabolism to allopregnanolone). Additional evidence consistent with a therapeutic role for pregnenolone in schizophrenia includes neurosteroid changes following administration of certain antipsychotics in rodent models. For example, clozapine elevates pregnenolone levels in rat hippocampus, and these increases may potentially contribute to its superior antipsychotic efficacy [Marx et al. (2006a) Pharmacol Biochem Behav 84:598-608]. Further, pregnenolone levels appear to be altered in postmortem brain tissue from patients with schizophrenia compared to control subjects [Marx et al. (2006c) Neuropsychopharmacology 31:1249-1263], suggesting that neurosteroid changes may play a role in the neurobiology of this disorder and/or its treatment. Although clinical trial data utilizing pregnenolone as a therapeutic agent in schizophrenia are currently limited, initial findings are encouraging. Treatment with adjunctive pregnenolone significantly decreased negative symptoms in patients with schizophrenia or schizo-affective disorder in a pilot proof-of-concept randomized controlled trolled trial, and elevations in pregnenolone and allopregnanolone post-treatment with this intervention were correlated with cognitive improvements [Marx et al. (2009) Neuropsychopharmacology 34:1885-1903]. Another pilot randomized controlled trial recently presented at a scientific meeting demonstrated significant improvements in negative symptoms, verbal memory, and attention following treatment with adjunctive pregnenolone, in addition to enduring effects in a small subset of patients receiving pregnenolone longer-term [Savitz (2010) Society of Biological Psychiatry Annual Meeting New Orleans, LA]. A third pilot clinical trial reported significantly decreased positive symptoms and extrapyramidal side effects following adjunctive pregnenolone, in addition to increased attention and working memory performance [Ritsner et al. (2010) J Clin Psychiatry 71:1351-1362]. Future efforts in larger cohorts will be required to investigate pregnenolone as a possible therapeutic candidate in schizophrenia, but early efforts are promising and merit further investigation. This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain. (C) 2011 Published by Elsevier Ltd on behalf of IBRO.	[Marx, C. E.; Bradford, D. W.; Naylor, J. C.; Allen, T. B.; Strauss, J. L.; Kilts, J. D.] Duke Univ, Med Ctr, Durham VA Med Ctr, Durham, NC 27705 USA; [Hamer, R. M.] Univ N Carolina, Chapel Hill, NC USA; [Lieberman, J. A.] Columbia Coll Phys & Surg, New York, NY USA	Marx, CE (corresponding author), Duke Univ, Med Ctr, Durham VA Med Ctr, 508 Fulton St,MHSL 116A, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Lieberman, Jeffrey/AAY-8239-2020		VA Career Development Transition Award (CDTA); VA Career Development Award (CDA); VA Mid-Atlantic Mental Illness, Research, Education, and Clinical Center (MIRECC); VA Research Enhancement Award Program	This work was supported by the following sources: VA Career Development Transition Award (CDTA; CEM), VA Career Development Award (CDA; JLS), VA Mid-Atlantic Mental Illness, Research, Education, and Clinical Center (MIRECC; PI John Fairbank, PhD), and VA Research Enhancement Award Program (PI Roger Madison, PhD). Dr. Marx discloses that she is a co-applicant on pending U.S. patent applications for the use of neurosteroids and derivatives for the treatment of central nervous system disorders and for lowering cholesterol (no patents issued, no licensing in place). The remaining authors have no potential conflicts of interest related to this work to disclose. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health.	Agis-Balboa RC, 2007, P NATL ACAD SCI USA, V104, P18736, DOI 10.1073/pnas.0709419104; Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; Bartzokis G, 2005, AM J PSYCHIAT, V162, P1229, DOI 10.1176/appi.ajp.162.6.1229-a; Belelli D, 2006, NEUROSCIENCE, V138, P821, DOI 10.1016/j.neuroscience.2005.07.021; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Benes FM, 2001, NEUROPSYCHOPHARMACOL, V25, P1, DOI 10.1016/S0893-133X(01)00225-1; Benes FM, 2007, P NATL ACAD SCI USA, V104, P10164, DOI 10.1073/pnas.0703806104; Benitez-King G, 2004, CNS NEUROL DISORD-DR, V3, P515, DOI 10.2174/1568007043336761; Bergeron R, 1996, J NEUROSCI, V16, P1193; Bernardi F, 2000, EUR J ENDOCRINOL, V142, P466, DOI 10.1530/eje.0.1420466; Buchanan RW, 2008, AM J PSYCHIAT, V165, P82, DOI 10.1176/appi.ajp.2007.07050724; Buchanan RW, 2006, AM J PSYCHIAT, V163, P1867, DOI 10.1176/appi.ajp.163.11.1867; Buchanan RW, 2005, SCHIZOPHRENIA BULL, V31, P5, DOI 10.1093/schbul/sbi020; Charalampopoulos I, 2006, ANN NY ACAD SCI, V1088, P139, DOI 10.1196/annals.1366.003; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Charlet A, 2008, PAIN, V139, P603, DOI 10.1016/j.pain.2008.06.016; CHENEY DL, 1995, NEUROREPORT, V6, P1697, DOI 10.1097/00001756-199508000-00025; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; Conley RR, 2009, CLIN NEUROPHARMACOL, V32, P69, DOI 10.1097/WNF.0b013e31816f2795; CORPECHOT C, 1983, BRAIN RES, V270, P119, DOI 10.1016/0006-8993(83)90797-7; Coyle JT, 2006, CELL MOL NEUROBIOL, V26, P365, DOI 10.1007/s10571-006-9062-8; Darnaudery M, 2002, BRAIN RES, V951, P237, DOI 10.1016/S0006-8993(02)03166-9; Darnaudery M, 1998, J NEUROCHEM, V71, P2018; Davis KL, 2003, ARCH GEN PSYCHIAT, V60, P443, DOI 10.1001/archpsyc.60.5.443; Debonnel G, 1996, NEUROSCIENCE, V71, P977, DOI 10.1016/0306-4522(96)80001-7; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Ebner MJ, 2006, ENDOCRINOLOGY, V147, P179, DOI 10.1210/en.2005-1065; Farb D, 2011, 44 ANN WINT C BRAIN; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; FREEMAN H, 1950, J CLIN ENDOCRINOL, V10, P1523, DOI 10.1210/jcem-10-12-1523; FRYE CA, 1994, BRAIN RES, V643, P194, DOI 10.1016/0006-8993(94)90025-6; George O, 2010, BIOL PSYCHIAT, V68, P956, DOI 10.1016/j.biopsych.2010.03.022; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Glantz LA, 2006, SCHIZOPHR RES, V81, P47, DOI 10.1016/j.schres.2005.08.014; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; Green MF, 2000, SCHIZOPHRENIA BULL, V26, P119, DOI 10.1093/oxfordjournals.schbul.a033430; Green MF, 2006, J CLIN PSYCHIAT, V67, P3; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Guidotti A, 2005, PSYCHOPHARMACOLOGY, V180, P191, DOI 10.1007/s00213-005-2212-8; GUO AL, 1995, GYNECOL ENDOCRINOL, V9, P1; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harvey PD, 2004, J CLIN PSYCHIAT, V65, P361; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Higashi T, 2003, J PHARMACEUT BIOMED, V30, P1907, DOI 10.1016/S0731-7085(02)00534-4; Higashi T, 2003, BIOL PHARM BULL, V26, P709; Hoistad M, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.009.2009; Hsu HJ, 2006, NATURE, V439, P480, DOI 10.1038/nature04436; IRWIN RP, 1994, J PHARMACOL EXP THER, V271, P677; Jarskog LF, 2006, CURR OPIN PSYCHIATR, V19, P307, DOI 10.1097/01.yco.0000218603.25346.8f; Jarskog LF, 2004, AM J PSYCHIAT, V161, P109, DOI 10.1176/appi.ajp.161.1.109; Javitt DC, 2007, INT REV NEUROBIOL, V78, P69, DOI 10.1016/S0074-7742(06)78003-5; Javitt DC, 2004, MOL PSYCHIATR, V9, P984, DOI 10.1038/sj.mp.4001551; Jevtovic-Todorovic Vesna, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS178, DOI 10.1016/j.psyneuen.2009.06.001; Johansson T, 2008, J PHARMACOL EXP THER, V324, P759, DOI 10.1124/jpet.107.130518; KAVALIERS M, 1987, BRAIN RES, V415, P393, DOI 10.1016/0006-8993(87)90228-9; Kavaliers M, 2000, NEUROSCIENCE, V95, P807; Keefe RSE, 2008, NEUROPSYCHOPHARMACOL, V33, P1217, DOI 10.1038/sj.npp.1301499; Kelley MH, 2008, J NEUROCHEM, V107, P668, DOI 10.1111/j.1471-4159.2008.05617.x; Kilts JD, 2010, PAIN MED, V11, P1469, DOI 10.1111/j.1526-4637.2010.00927.x; Knight JG, 2007, MOL PSYCHIATR, V12, P424, DOI 10.1038/sj.mp.4001959; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Korneyev A, 1996, HORM BEHAV, V30, P37, DOI 10.1006/hbeh.1996.0006; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; Ladurelle N, 2000, BRAIN RES, V858, P371, DOI 10.1016/S0006-8993(00)01953-3; Lahti AC, 2001, NEUROPSYCHOPHARMACOL, V25, P455, DOI 10.1016/S0893-133X(01)00243-3; LAHTI AC, 1995, NEUROPSYCHOPHARMACOL, V13, P9, DOI 10.1016/0893-133X(94)00131-I; LANTHIER A, 1986, J STEROID BIOCHEM, V25, P445, DOI 10.1016/0022-4731(86)90259-1; Lencz T, 2007, MOL PSYCHIATR, V12, P572, DOI 10.1038/sj.mp.4001983; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Lewis DA, 2004, PSYCHOPHARMACOLOGY, V174, P143, DOI 10.1007/s00213-003-1673-x; Lewis DA, 2003, ANN NY ACAD SCI, V1003, P102, DOI 10.1196/annals.1300.007; Liao GH, 2009, BRAIN RES, V1270, P140, DOI 10.1016/j.brainres.2009.03.027; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Liu SY, 2003, ANAL CHEM, V75, P5835, DOI 10.1021/ac0346297; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; MacDonald ML, 2005, BIOL PSYCHIAT, V57, P1041, DOI 10.1016/j.biopsych.2005.01.022; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Malhotra AK, 1997, NEUROPSYCHOPHARMACOL, V17, P141; Marder SR, 2004, SCHIZOPHR RES, V72, P5, DOI 10.1016/j.schres.2004.09.010; Marder SR, 2006, J CLIN PSYCHIAT, V67, P31; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2003, NEUROPSYCHOPHARMACOL, V28, P1, DOI 10.1038/sj.npp.1300015; Marx CE, 2010, AM COLL NEUR ANN M M; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P609, DOI 10.1016/j.pbb.2006.07.032; Marx CE, 2006, PSYCHOPHARMACOLOGY, V186, P462, DOI 10.1007/s00213-005-0226-x; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Marx CE, 2008, INT J NEUROPSYCHOPH, V11, P547, DOI 10.1017/S1461145708008444; MATHIS C, 1994, PSYCHOPHARMACOLOGY, V116, P201, DOI 10.1007/BF02245063; Mathis C, 1996, NEUROPHARMACOLOGY, V35, P1057, DOI 10.1016/S0028-3908(96)00041-X; Matsumoto K, 2005, STRESS, V8, P85, DOI 10.1080/10253890500159022; Mayo W, 2005, NEUROBIOL AGING, V26, P103, DOI 10.1016/j.neurobiolaging.2004.03.013; MAYO W, 1993, BRAIN RES, V607, P324, DOI 10.1016/0006-8993(93)91524-V; MCGAVACK TH, 1951, J CLIN ENDOCRINOL, V11, P559, DOI 10.1210/jcem-11-6-559; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; Mendelson JH, 2005, NEUROPSYCHOPHARMACOL, V30, P1751, DOI 10.1038/sj.npp.1300753; Meyer L, 2011, PAIN, V152, P170, DOI 10.1016/j.pain.2010.10.015; Meziane H, 1996, PSYCHOPHARMACOLOGY, V126, P323, DOI 10.1007/BF02247383; Millan MJ, 2005, PSYCHOPHARMACOLOGY, V179, P30, DOI 10.1007/s00213-005-2199-1; MORROW AL, 1990, MOL PHARMACOL, V37, P263; MORROW AL, 1987, EUR J PHARMACOL, V142, P483, DOI 10.1016/0014-2999(87)90094-X; Mtchedlishvili Z, 2003, MOL PHARMACOL, V64, P857, DOI 10.1124/mol.64.4.857; Murakami K, 2000, P NATL ACAD SCI USA, V97, P3579, DOI 10.1073/pnas.97.7.3579; Murphy BEP, 2000, J STEROID BIOCHEM, V74, P137, DOI 10.1016/S0960-0760(00)00098-4; Naylor JC, 2008, J CLIN ENDOCR METAB, V93, P3173, DOI 10.1210/jc.2007-1229; Naylor JC, 2010, BBA-MOL CELL BIOL L, V1801, P951, DOI 10.1016/j.bbalip.2010.05.006; Pallares M, 1998, NEUROSCIENCE, V87, P551, DOI 10.1016/S0306-4522(98)00174-2; Patchev VK, 1996, NEUROPSYCHOPHARMACOL, V15, P533, DOI 10.1016/S0893-133X(96)00096-6; PATCHEV VK, 1994, NEUROSCIENCE, V62, P265, DOI 10.1016/0306-4522(94)90330-1; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; PAUL SM, 1992, FASEB J, V6, P2311; Pibiri F, 2008, P NATL ACAD SCI USA, V105, P5567, DOI 10.1073/pnas.0801853105; Pinna G, 2004, P NATL ACAD SCI USA, V101, P6222, DOI 10.1073/pnas.0401479101; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Pinna G, 2010, BEHAV PHARMACOL, V21, P438, DOI 10.1097/FBP.0b013e32833d8ba0; Rasmusson AM, 2006, BIOL PSYCHIAT, V60, P704, DOI 10.1016/j.biopsych.2006.03.026; Ritsner M, 2007, EUR NEUROPSYCHOPHARM, V17, P358, DOI 10.1016/j.euroneuro.2006.10.001; Ritsner MS, 2010, J CLIN PSYCHIAT, V71, P1351, DOI 10.4088/JCP.09m05031yel; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; ROMEO E, 1994, J PHARMACOL EXP THER, V270, P89; Rujescu D, 2006, BIOL PSYCHIAT, V59, P721, DOI 10.1016/j.biopsych.2005.08.029; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Sadri-Vakili G, 2008, J PHARMACOL EXP THER, V327, P840, DOI 10.1124/jpet.108.143958; Savitz AJ, 2007, SCHIZOPHRENIA BULL, V33, P458; Savitz AJ, 2010, BIOL PSYCHIAT, V67, p22S; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Schumacher M, 2008, NEUROCHEM INT, V52, P522, DOI 10.1016/j.neuint.2007.08.022; Serra M, 2001, PSYCHOPHARMACOLOGY, V158, P48, DOI 10.1007/s002130100853; Sliwinski A, 2004, J NEUROSCI RES, V78, P691, DOI 10.1002/jnr.20332; Smith CD, 2006, PSYCHOPHARMACOLOGY, V186, P481, DOI 10.1007/s00213-005-0186-1; Strous RD, 2003, ARCH GEN PSYCHIAT, V60, P133, DOI 10.1001/archpsyc.60.2.133; Takahashi N, 2011, PROG NEUROBIOL, V93, P13, DOI 10.1016/j.pneurobio.2010.09.004; Tkachev D, 2003, LANCET, V362, P798, DOI 10.1016/S0140-6736(03)14289-4; Tkachev D, 2007, INT J NEUROPSYCHOPH, V10, P557, DOI 10.1017/S1461145706007334; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Vallee M, 2001, EUR J NEUROSCI, V14, P2003, DOI 10.1046/j.0953-816x.2001.01817.x; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wang MD, 1997, J STEROID BIOCHEM, V62, P299, DOI 10.1016/S0960-0760(97)00041-1; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Whittaker MT, 2008, J NEUROCHEM, V107, P510, DOI 10.1111/j.1471-4159.2008.05627.x; WINFREE CJ, 1992, LIFE SCI, V50, P1007, DOI 10.1016/0024-3205(92)90095-7; WU FS, 1991, MOL PHARMACOL, V40, P333; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x	158	94	99	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	SEP 15	2011	191				SI		78	90		10.1016/j.neuroscience.2011.06.076			13	Neurosciences	Neurosciences & Neurology	831RR	WOS:000295749300008	21756978				2021-06-18	
J	Cantu, RC; Gean, AD				Cantu, Robert C.; Gean, Alisa D.			Second-Impact Syndrome and a Small Subdural Hematoma: An Uncommon Catastrophic Result of Repetitive Head Injury with a Characteristic Imaging Appearance	JOURNAL OF NEUROTRAUMA			English	Article						acute subdural hematoma; cerebral swelling; dysautoregulation; non-accidental head trauma; second-impact syndrome; shaken-baby syndrome; vascular brain engorgement	TRAUMATIC BRAIN-INJURY; 2ND IMPACT; SPORTS	There have been a handful of previously published cases of athletes who were still symptomatic from a prior head injury, and then suffered a second injury in which a thin, acute subdural hematoma (SDH) with unilateral hemisphere vascular engorgement was demonstrated on CT scan. In those cases, the cause of the brain swelling/dysautoregulation was ascribed to the presence of the acute SDH rather than to the acceleration/deceleration forces that caused the SDH. We believe that the brain swelling is due to "second-impact dysautoregulation," rather than due to the effect of the SDH on the underlying hemisphere. To support our hypothesis, we present 10 additional cases of acute hemispheric swelling in association with small SDHs in athletes who received a second head injury while still symptomatic from a previous head injury. The clinical history and the unique neuroimaging features of this entity on CT are described and illustrated in detail. The CT findings included an engorged cerebral hemisphere with initial preservation of grey-white matter differentiation, and abnormal mass effect and midline shift that appeared disproportionately greater than the size of the SDH. In addition, the imaging similarities between our patients and those with non-accidental head trauma (shaken-baby syndrome) will be discussed.	[Cantu, Robert C.] Boston Univ, Med Ctr, Dept Neurosurg, Boston, MA USA; [Cantu, Robert C.] Boston Univ, Med Ctr, Ctr Study Traumat Encephalopathy, Boston, MA USA; [Gean, Alisa D.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Brain & Spinal Injury Ctr, San Francisco Gen Hosp, San Francisco, CA 94143 USA	Cantu, RC (corresponding author), Boston Univ, Med Ctr, Ctr Study Traumat Eucephalopathy, Dept Neurosurg, 131 ORNAC,John Cuming Bldg,Suite 820, Concord, MA 01742 USA.	rcantu@emersonhosp.org					BODEN B, 2000, AM J SPORTS MED, V35, P1; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 2000, NEUROLOGICAL ATHLETI, P135; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; MUELLER FO, 2009, 27 NAT CTR CAT SPORT; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F; SCHNITKER MT, 1949, J PEDIATR-US, V35, P557, DOI 10.1016/S0022-3476(49)80138-7; STREETER T, 1997, J COMMUN, V47, P128	19	94	94	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1557	1564		10.1089/neu.2010.1334			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500002	20536318	Green Published			2021-06-18	
J	Laird, MD; Sukumari-Ramesh, S; Swift, AEB; Meiler, SE; Vender, JR; Dhandapani, KM				Laird, Melissa D.; Sukumari-Ramesh, Sangeetha; Swift, Andrew E. B.; Meiler, Steffen E.; Vender, John R.; Dhandapani, Krishnan M.			Curcumin attenuates cerebral edema following traumatic brain injury in mice: a possible role for aquaporin-4?	JOURNAL OF NEUROCHEMISTRY			English	Article						cellular edema; controlled cortical impact; glia; intracranial pressure; neuroinflammation; neurotrauma	NF-KAPPA-B; SEVERE HEAD-INJURY; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; COMA DATA-BANK; REACTIVE ASTROCYTES; RAT-BRAIN; INTRACRANIAL HYPERTENSION; RECEPTOR ANTAGONIST; AQP4 EXPRESSION	P>Traumatic brain injury is a devastating neurological injury associated with significant morbidity and mortality. Medical therapies to limit cerebral edema, a cause of increased intracranial hypertension and poor clinical outcome, are largely ineffective, emphasizing the need for novel therapeutic approaches. In the present study, pre-treatment with curcumin (75, 150 mg/kg) or 30 min post-treatment with 300 mg/kg significantly reduced brain water content and improved neurological outcome following a moderate controlled cortical impact in mice. The protective effect of curcumin was associated with a significant attenuation in the acute pericontusional expression of interleukin-1 beta, a pro-inflammatory cytokine, after injury. Curcumin also reversed the induction of aquaporin-4, an astrocytic water channel implicated in the development of cellular edema following head trauma. Notably, curcumin blocked IL-1 beta-induced aquaporin-4 expression in cultured astrocytes, an effect mediated, at least in part, by reduced activation of the p50 and p65 subunits of nuclear factor kappa B. Consistent with this notion, curcumin preferentially attenuated phosphorylated p65 immunoreactivity in pericontusional astrocytes and decreased the expression of glial fibrillary acidic protein, a reactive astrocyte marker. As a whole, these data suggest clinically achievable concentrations of curcumin reduce glial activation and cerebral edema following neurotrauma, a finding which warrants further investigation.	[Laird, Melissa D.; Sukumari-Ramesh, Sangeetha; Vender, John R.; Dhandapani, Krishnan M.] Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA; [Swift, Andrew E. B.] Med Coll Georgia, Dept Med Illustrat, Augusta, GA 30912 USA; [Meiler, Steffen E.] Med Coll Georgia, Dept Anesthesiol & Perioperat Med, Augusta, GA 30912 USA	Dhandapani, KM (corresponding author), Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA.	kdhandapani@mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; American Heart AssociationAmerican Heart Association [BGIA2300135, PRE2250690]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	This work was supported in part by grants from the National Institute of Health (NS065172) and American Heart Association (BGIA2300135) to KMD and by a fellowship from the American Heart Association (PRE2250690) to MDL. The authors report no conflicts of interest.	Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Bae MK, 2006, BBA-MOL CELL RES, V1763, P282, DOI 10.1016/j.bbamcr.2006.01.005; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Cole GM, 2007, ADV EXP MED BIOL, V595, P197; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024; Di Giorgio AM, 2008, RESTOR NEUROL NEUROS, V26, P501; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FAN L, 1995, MOL BRAIN RES, V30, P125; Garodia Prachi, 2007, J Soc Integr Oncol, V5, P25, DOI 10.2310/7200.2006.029; Griebenow M, 2007, J NEUROTRAUM, V24, P1529, DOI 10.1089/neu.2007.0306; Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074-7742(07)82002-2; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hewett SJ, 2006, J PHARMACOL EXP THER, V319, P1219, DOI 10.1124/jpet.106.109876; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Khan MM, 2005, ENDOCRINOLOGY, V146, P5215, DOI 10.1210/en.2005-0276; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Koch JD, 2008, J CEREBR BLOOD F MET, V28, P1294, DOI 10.1038/jcbfm.2008.15; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lam AGM, 2001, NEUROBIOL AGING, V22, P765, DOI 10.1016/S0197-4580(01)00233-0; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Lee SC, 1995, BRAIN BEHAV IMMUN, V9, P345, DOI 10.1006/brbi.1995.1032; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Lim GP, 2001, J NEUROSCI, V21, P8370; Lin JF, 2006, DIAM RELAT MATER, V15, P1, DOI 10.1016/j.diamond.2005.03.012; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Moynagh PN, 2005, J ANAT, V207, P265, DOI 10.1111/j.1469-7580.2005.00445.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nadjar A, 2003, J NEUROCHEM, V87, P1024, DOI 10.1046/j.1471-4159.2003.02097.x; Nicchia GP, 2004, NEUROSCIENCE, V129, P935, DOI 10.1016/j.neuroscience.2004.07.055; Nielsen S, 1997, J NEUROSCI, V17, P171; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; RICHARDSON RM, 2009, J NEUROSURG; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vallee M, 1997, J NEUROSCI, V17, P2626; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zhao J, 2008, BRAIN RES, V1229, P224, DOI 10.1016/j.brainres.2008.06.117; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	75	94	99	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2010	113	3					637	648		10.1111/j.1471-4159.2010.06630.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	579WD	WOS:000276406600007	20132469	Green Accepted, Bronze			2021-06-18	
J	Simard, JM; Kilbourne, M; Tsymbalyuk, O; Tosun, C; Caridi, J; Ivanova, S; Keledjian, K; Bochicchio, G; Gerzanich, V				Simard, J. Marc; Kilbourne, Michael; Tsymbalyuk, Orest; Tosun, Cigdem; Caridi, John; Ivanova, Svetlana; Keledjian, Kaspar; Bochicchio, Grant; Gerzanich, Volodymyr			Key Role of Sulfonylurea Receptor 1 in Progressive Secondary Hemorrhage after Brain Contusion	JOURNAL OF NEUROTRAUMA			English	Article						contusion; glibenclamide; hemorrhage; sulfonylurea receptor 1; traumatic brain injury	SPINAL-CORD-INJURY; NONSELECTIVE CATION CHANNEL; LATERAL FLUID PERCUSSION; ADULT-RAT BRAIN; ISCHEMIC-STROKE; VASCULAR DISRUPTION; REACTIVE ASTROCYTES; HEAD TRAUMA; GLIBENCLAMIDE; CELLS	An important but poorly understood feature of traumatic brain injury (TBI) is the clinically serious problem of spatiotemporal progression ("blossoming'') of a hemorrhagic contusion, a phenomenon we term progressive secondary hemorrhage (PSH). Molecular mechanisms of PSH are unknown and efforts to reduce it by promoting coagulation have met with equivocal results. We hypothesized that PSH might be due to upregulation and activation of sulfonylurea receptor 1 (SUR1)-regulated NCCa-ATP channels in capillary endothelial cells, predisposing to oncotic death of endothelial cells and catastrophic failure of capillary integrity. Anesthetized adult male rats underwent left parietal craniectomy for induction of a focal cortical contusion. The regulatory subunit of the channel, SUR1, was prominently upregulated in capillaries of penumbral tissues surrounding the contusion. In untreated rats, PSH was characterized by progressive enlargement of the contusion deep into the site of cortical impact, including corpus callosum, hippocampus, and thalamus, by progressive accumulation of extravasated blood, with a doubling of the volume during the first 12 h after injury, and by capillary fragmentation in penumbral tissues. Block of SUR1 using low-dose (non-hypoglycemogenic) glibenclamide largely eliminated PSH and capillary fragmentation, and was associated with a significant reduction in the size of the necrotic lesion and in preservation of neurobehavioral function. Antisense oligodeoxynucleotide against SUR1, administered after injury, reduced both SUR1 expression and PSH, consistent with a requirement for transcriptional upregulation of SUR1. Our findings provide novel insights into molecular mechanisms responsible for PSH associated with hemorrhagic contusions, and point to SUR1 as a potential therapeutic target in TBI.	[Simard, J. Marc; Tsymbalyuk, Orest; Tosun, Cigdem; Caridi, John; Ivanova, Svetlana; Keledjian, Kaspar; Gerzanich, Volodymyr] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Bochicchio, Grant] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Kilbourne, Michael] Walter Reed Army Med Ctr, Dept Surg, Washington, DC 20307 USA; [Bochicchio, Grant] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Tosun, Cigdem/AAG-4026-2020		Department of Veterans Affairs (Baltimore, MD)US Department of Veterans Affairs; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL082517]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS061808, NS060801, NS061934]; Christopher and Dana Reeve Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061808, R01NS061934] Funding Source: NIH RePORTER	This work was supported by grants to J.M.S. from the Department of Veterans Affairs (Baltimore, MD), the National Heart, Lung and Blood Institute (HL082517), the National Institute of Neurological Disorders and Stroke (NS061808 and NS060801), and the Christopher and Dana Reeve Foundation, and to V. G. from the National Institute of Neurological Disorders and Stroke (NS061934).	Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Belayev L, 2002, J NEUROSURG, V96, P1077, DOI 10.3171/jns.2002.96.6.1077; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512; Cooper P R, 1992, Neurosurg Clin N Am, V3, P659; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Frontczak-Baniewicz M, 2007, J PHYSIOL PHARMACOL, V58, P193; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Golstein PE, 1999, PFLUG ARCH EUR J PHY, V437, P652, DOI 10.1007/s004240050829; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; Haseloff RF, 2006, PROTEOMICS, V6, P1803, DOI 10.1002/pmic.200500182; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Kunte H, 2007, STROKE, V38, P2526, DOI 10.1161/STROKEAHA.107.482216; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Payen L, 2001, BRIT J PHARMACOL, V132, P778, DOI 10.1038/sj.bjp.0703863; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Regan RF, 1998, J NEUROTRAUM, V15, P645, DOI 10.1089/neu.1998.15.645; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Simard JM, 2008, CURR OPIN PHARMACOL, V8, P42, DOI 10.1016/j.coph.2007.10.004; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tseng Sheng-Hong, 1992, Journal of the Formosan Medical Association, V91, P585; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109; Yokoshiki H, 1999, PFLUG ARCH EUR J PHY, V437, P400, DOI 10.1007/s004240050794; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	54	94	98	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2257	2267		10.1089/neu.2009.1021			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200013	19604096	Green Published, Bronze			2021-06-18	
J	Szmydynger-Chodobska, J; Strazielle, N; Zink, BJ; Ghersi-Egea, JF; Chodobski, A				Szmydynger-Chodobska, Joanna; Strazielle, Nathalie; Zink, Brian J.; Ghersi-Egea, Jean-Francois; Chodobski, Adam			The role of the choroid plexus in neutrophil invasion after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-cerebrospinal fluid barrier; choroid plexus; CXC chemokines; neutrophils; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; RAT-BRAIN; SALMONELLA-TYPHIMURIUM; INTESTINAL EPITHELIA; ADHESION MOLECULES; REPERFUSION INJURY; GROWTH-FACTOR; KAPPA-B	Traumatic brain injury (TBI) frequently results in neuroinflammation, which includes the invasion of neutrophils. After TBI, neutrophils infiltrate the choroid plexus (CP), a site of the blood-cerebrospinal fluid (CSF) barrier (BCSFB), and accumulate in the CSF space near the injury, from where these inflammatory cells may migrate to brain parenchyma. We have hypothesized that the CP functions as an entry point for neutrophils to invade the injured brain. Using the controlled cortical impact model of TBI in rats and an in vitro model of the BCSFB, we show that the CP produces CXC chemokines, such as cytokine-induced neutrophil chemoattractant (CINC)-1 or CXCL1, CINC-2 alpha or CXCL3, and CINC-3 or CXCL2. These chemokines are secreted both apically and basolaterally from the choroidal epithelium, a prerequisite for neutrophil migration across epithelial barriers. Consistent with these findings, we also provide electron microscopic evidence that neutrophils infiltrate the choroidal stroma and subsequently reach the intercellular space between choroidal epithelial cells. This is the first detailed analysis of the BCSFB function related to neutrophil trafficking. Our observations support the role of this barrier in posttraumatic neutrophil invasion. Journal of Cerebral Blood Flow & Metabolism (2009) 29, 1503-1516; doi:10.1038/jcbfm.2009.71; published online 27 May 2009	[Szmydynger-Chodobska, Joanna; Zink, Brian J.; Chodobski, Adam] Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, Providence, RI 02903 USA; [Strazielle, Nathalie] Brain I, Lyon, France; [Ghersi-Egea, Jean-Francois] Univ Lyon 1, Fac Med Laennec, INSERM, U842, F-69365 Lyon, France	Szmydynger-Chodobska, J (corresponding author), Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, George Bldg,Room 314,593 Eddy St, Providence, RI 02903 USA.	joanna_szmydynger-chodobska@brown.edu		Ghersi-Egea, Jean-Francois/0000-0002-0181-4909	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS49479, R07057CS]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049479] Funding Source: NIH RePORTER	This work was supported by Grant NS49479 from the NIH (to AC) and by ANR R07057CS (to JFGE).	ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Beech JS, 2001, J CEREBR BLOOD F MET, V21, P683, DOI 10.1097/00004647-200106000-00006; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; ERICSSON A, 1995, J COMP NEUROL, V361, P681, DOI 10.1002/cne.903610410; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FAYEIN NA, 1992, BIOL CELL, V76, P1, DOI 10.1016/0248-4900(92)90189-8; Handa O, 2004, J PHARMACOL EXP THER, V309, P670, DOI 10.1124/jpet.103.062216; HUANG S, 1992, AM J PATHOL, V141, P981; HUANG SL, 1992, BIOCHEM BIOPH RES CO, V184, P922, DOI 10.1016/0006-291X(92)90679-F; Kamada Kyousuke, 1995, Neurologia Medico-Chirurgica, V35, P1, DOI 10.2176/nmc.35.1; Kivisakk P, 2003, P NATL ACAD SCI USA, V100, P8389, DOI 10.1073/pnas.1433000100; Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Ling EA, 1998, MICROSC RES TECHNIQ, V41, P43, DOI 10.1002/(SICI)1097-0029(19980401)41:1<43::AID-JEMT5>3.3.CO;2-D; Magnoni S, 2003, J NEUROTRAUM, V20, P251, DOI 10.1089/089771503321532833; Matsumoto T, 1997, LAB INVEST, V77, P119; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; McCormick BA, 1998, J IMMUNOL, V160, P455; Nadeau S, 1999, NEUROSCIENCE, V93, P1449, DOI 10.1016/S0306-4522(99)00225-0; Nagra RM, 1997, J NEUROIMMUNOL, V78, P97, DOI 10.1016/S0165-5728(97)00089-1; NAKAGAWA H, 1994, BIOCHEM J, V301, P545, DOI 10.1042/bj3010545; Praetorius J, 2006, AM J PHYSIOL-CELL PH, V291, pC59, DOI 10.1152/ajpcell.00433.2005; Quan N, 1999, J NEUROIMMUNOL, V93, P72, DOI 10.1016/S0165-5728(98)00193-3; Redzic ZB, 2005, CURR TOP DEV BIOL, V71, P1, DOI 10.1016/S0070-2153(05)71001-2; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; SNOW AD, 1994, AM J PATHOL, V144, P337; Strazielle N, 1999, J NEUROSCI, V19, P6275; Strazielle N, 2000, J NEUROPATH EXP NEUR, V59, P561, DOI 10.1093/jnen/59.7.561; Strazielle N, 2003, J NEUROPATH EXP NEUR, V62, P1254, DOI 10.1093/jnen/62.12.1254; Strazielle Nathalie, 2003, Methods Mol Med, V89, P291; Takaishi K, 2000, J BIOCHEM-TOKYO, V127, P511, DOI 10.1093/oxfordjournals.jbchem.a022634; Wong D, 2007, J NEUROIMMUNOL, V184, P136, DOI 10.1016/j.jneuroim.2006.12.003; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5	40	94	95	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2009	29	9					1503	1516		10.1038/jcbfm.2009.71			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	489UF	WOS:000269447600002	19471279	Green Accepted, Bronze			2021-06-18	
J	Swenson, DM; Yard, EE; Fields, SK; Comstock, RD				Swenson, David M.; Yard, Ellen E.; Fields, Sarah K.; Comstock, R. Dawn			Patterns of Recurrent Injuries Among US High School Athletes, 2005-2008	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						recurrent injury; reinjury; injury; high school; sports; epidemiology; surveillance	STATES HIGH-SCHOOL; UNITED-STATES; PROSPECTIVE COHORT; NORTH-CAROLINA; RISK-FACTORS; EPIDEMIOLOGY; CONCUSSION; FOOTBALL; SPORTS; COLLEGIATE	Background: High school sports participants sustain millions of injuries annually; many are recurrent injuries that can be more severe than new injuries. Hypothesis: Recurrent injury patterns differ from new injury patterns by sport and gender. Study Design: Descriptive epidemiology study. Methods: High school sports injury data for the 2005 through 2008 academic years were collected via High School Reporting Information Online (RIO) from a nationally representative sample of 100 US high schools. Results: From 2005 through 2008, certified athletic trainers reported 13 755 injuries during 5 627 921 athlete exposures (24.4 injuries per 10 000 athlete exposures). Recurrent injuries accounted for 10.5% of all injuries. Football players had the highest rate of recurrent injury (4.36 per 10 000 athlete exposures). Girls had higher rates of recurrent injuries than boys in soccer (injury rate ratio = 1.39; 95% confidence interval, 1.07-1.82). Recurrent injuries most often involved the ankle (28.3%), knee (16.8%), head/face (12.1%), and shoulder (12.0%), and were most often ligament sprains (incomplete tears) (34.9%), muscle strains (incomplete tears) (13.3%), and concussions (11.6%). A greater proportion of recurrent injuries than new injuries resulted in the student choosing to end participation (recurrent = 2.4%, new = 0.7%). Recurrent shoulder injuries were more likely to require surgery than new shoulder injuries (injury proportion ratio = 4.51; 95% confidence interval, 2.82-7.20). Conclusion: Recurrent injury rates and patterns differed by sport. Because recurrent injuries can have severe consequences on an athlete's health and future sports participation, injury prevention must be a priority. Knowledge of injury patterns can drive targeted preventive efforts.	[Swenson, David M.; Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH 43205 USA; [Fields, Sarah K.] Ohio State Univ, Sch Phys Act & Educ Serv, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA	Yard, EE (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	Ellen.Yard@NationwideChildrens.org			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01]; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR025753]; Office of the DirectorNational Science Foundation (NSF)NSF - Office of the Director (OD); National Institutes of Health (OD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; DonJoy Orthotics and EyeBlack; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025755, TL1RR025753] Funding Source: NIH RePORTER	The content of this report was funded in part by the Centers for Disease Control and Prevention (CDC) grant # R49/CE000674-01 and by the National Center for Research Resources (NCRR), award # TL1RR025753, funded by the Office of the Director, National Institutes of Health (OD) and supported by the NIH Roadmap for Medical Research. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the CDC, the NCRR, or the NIH. We would also like to acknowledge the generous research funding contributions of DonJoy Orthotics and EyeBlack.	Agel J, 2007, J ATHL TRAINING, V42, P295; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Collins CL, 2008, INJURY PREV, V14, P34, DOI 10.1136/ip.2007.017277; Collins CL, 2008, PEDIATRICS, V121, P1181, DOI 10.1542/peds.2007-2572; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Elosua R, 2005, REV ESP CARDIOL, V58, P887, DOI 10.1157/13078123; Fernandez WG, 2007, ACAD EMERG MED, V14, P641, DOI [10.1197/j.aem.2007.03.1354, 10.1111/j.1553-2712.2007.tb01851.x]; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gravlee JR, 2007, AM FAM PHYSICIAN, V75, P342; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Ingram JG, 2008, AM J SPORT MED, V36, P1116, DOI 10.1177/0363546508314400; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Kofotolis N, 2007, J ATHL TRAINING, V42, P388; Koplan JP, 2005, J AM DIET ASSOC, V105, P131, DOI 10.1016/j.jada.2004.11.023; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; *NAT FED STAT HIGH, 2005 06 HIGH SCH ATH; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; Powell JW, 1999, J ATHL TRAINING, V34, P277; Rauh MJ, 2007, J ATHL TRAINING, V42, P486; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; SPAKE A, 2004, LEARNING FAT TACKLIN; Tyler TF, 2006, AM J SPORT MED, V34, P471, DOI 10.1177/0363546505280429; US Census Bureau, CENS REG US; Van Tiggelen D, 2004, KNEE SURG SPORT TR A, V12, P434, DOI 10.1007/s00167-003-0479-z; Verhagen EALM, 2004, BRIT J SPORT MED, V38, P477, DOI 10.1136/bjsm.2003.005785	33	94	97	1	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2009	37	8					1586	1593		10.1177/0363546509332500			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	474MY	WOS:000268289400016	19372270				2021-06-18	
J	Lotocki, G; Vaccari, JPD; Perez, ER; Sanchez-Molano, J; Furones-Alonso, O; Bramlett, HM; Dietrich, WD				Lotocki, George; Vaccari, Juan Pablo de Rivero; Perez, Enrique R.; Sanchez-Molano, Juliana; Furones-Alonso, Ofelia; Bramlett, Helen M.; Dietrich, W. Dalton			Alterations in Blood-Brain Barrier Permeability to Large and Small Molecules and Leukocyte Accumulation after Traumatic Brain Injury: Effects of Post-Traumatic Hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; CD68; hypothermia; leukocytes; traumatic brain injury	NERVOUS-SYSTEM INJURY; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; RATS; TEMPERATURE; DISRUPTION; DAMAGE; BREAKDOWN	We investigated the temporal and regional profile of blood-brain barrier (BBB) permeability to both large and small molecules after moderate fluid percussion (FP) brain injury in rats and determined the effects of post-traumatic modest hypothermia (33 degrees C/4h) on these vascular perturbations. The visible tracers biotin-dextrin-amine 3000 (BDA-3K, 3 kDa) and horseradish peroxidase (HRP, 44 kDa) were injected intravenously at 4 h or 3 or 7 days post-TBI. At 30 min after the tracer infusion, both small and large molecular weight tracers were detected in the contusion area as well as remote regions adjacent to the injury epicenter in both cortical and hippocampal structures. In areas adjacent to the contusion site, increased permeability to the small molecular weight tracer (BDA-3K) was evident at 4 h post-TBI and remained visible after 7 days survival. In contrast, the larger tracer molecule (HRP) appeared in these remote areas at acute permeable sites but was not detected at later post-traumatic time periods. A regionally specific relationship was documented at 3 days between the lateoccurring permeability changes observed with BDA-3K and the accumulation of CD68-positive macrophages. Mild hypothermia initiated 30 min after TBI reduced permeability to both large and small tracers and the infiltration of CD68-positive cells. These results indicate that moderate brain injury produces temperature-sensitive acute, as well as more long-lasting vascular perturbations associated with secondary injury mechanisms.	[Lotocki, George; Vaccari, Juan Pablo de Rivero; Perez, Enrique R.; Sanchez-Molano, Juliana; Furones-Alonso, Ofelia; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miami Project Cure Paralysis, Neurotrauma Res Ctr, Dept Neurol Surg,Miller Sch Med, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miami Project Cure Paralysis, Neurotrauma Res Ctr, Dept Neurol Surg,Miller Sch Med, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu		de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, NS42133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER	This work was supported by NIH grants (nos. NS030291 and NS42133). We wish to thank Coleen Atkins for scientific discussions, Beata Frydel for helping with 3-D reconstructions, and Jeremy Lytle for editorial assistance in manuscript preparation.	Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Arican N, 2006, INT J NEUROSCI, V116, P1249, DOI 10.1080/00207450600550303; Asahi M, 2001, J NEUROSCI, V21, P7724; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hartl R, 1997, ACT NEUR S, V70, P240; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; Kumar K, 1997, NEUROREPORT, V8, P947, DOI 10.1097/00001756-199703030-00026; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Morganti-Kossmann MC, 2005, BLOOD BRAIN BARRIER, V457- 479; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Raivich G, 2004, BRAIN RES REV, V46, P261, DOI 10.1016/j.brainresrev.2004.06.006; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; ZILLES L, 1985, CORTEX RAT STEREOTAX	43	94	95	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1123	1134		10.1089/neu.2008.0802			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500017	19558276	Green Published			2021-06-18	
J	Dietrich, WD; Atkins, CM; Bramlett, HM				Dietrich, W. Dalton; Atkins, Coleen M.; Bramlett, Helen M.			Protection in Animal Models of Brain and Spinal Cord Injury with Mild to Moderate Hypothermia	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			hypothermia; regeneration; stem cells; traumatic brain injury; traumatic spinal cord injury	FOCAL CEREBRAL-ISCHEMIA; TRANSIENT GLOBAL-ISCHEMIA; DELAYED POSTISCHEMIC HYPOTHERMIA; MICROTUBULE-ASSOCIATED PROTEIN-2; COMBINATION-DRUG THERAPY; CYTOCHROME-C RELEASE; TRAUMATIC AXONAL INJURY; NITRIC-OXIDE SYNTHESIS; POSTTRAUMATIC HYPOTHERMIA; FOREBRAIN ISCHEMIA	For the past 20 years, various laboratories throughout the world have shown that mild to moderate levels of hypothermia lead to neuroprotection and improved functional outcome in various models of brain and spinal cord injury (SCI). Although the potential neuroprotective effects of profound hypothermia during and following central nervous system (CNS) injury have long been recognized, more recent studies have described clinically feasible strategies for protecting the brain and spinal cord using hypothermia following a variety of CNS insults. In some cases, only a one or two degree decrease in brain or core temperature can be effective in protecting the CNS from injury. Alternatively, raising brain temperature only a couple of degrees above normothermia levels worsens outcome in a variety of injury models. Based on these data, resurgence has occurred in the potential use of therapeutic hypothermia in experimental and clinical settings. The study of therapeutic hypothermia is now an international area of investigation with scientists and clinicians from every part of the world contributing to this important, promising therapeutic intervention. This paper reviews the experimental data obtained in animal models of brain and SCI demonstrating the benefits of mild to moderate hypothermia. These studies have provided critical data for the translation of this therapy to the clinical arena. The mechanisms underlying the beneficial effects of mild hypothermia are also summarized.	[Dietrich, W. Dalton; Atkins, Coleen M.; Bramlett, Helen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace,Suite 2-33, Miami, FL 33136 USA.	ddietrich@miami.edu		Atkins, Coleen/0000-0003-4718-7493	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS42133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER		Akaji K, 2003, BRAIN RES, V975, P149, DOI 10.1016/S0006-8993(03)02622-2; Arican N, 2006, INT J NEUROSCI, V116, P1249, DOI 10.1080/00207450600550303; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bacher A, 1998, ANESTHESIOLOGY, V88, P403, DOI 10.1097/00000542-199802000-00019; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BAKER CJ, 1995, NEUROSURGERY, V36, P994, DOI 10.1227/00006123-199505000-00016; BERGUER R, 1992, J VASC SURG, V15, P62, DOI 10.1016/0741-5214(92)70014-C; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; BUCHAN A, 1990, J NEUROSCI, V10, P311; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; BUSTO R, 1994, J NEUROCHEM, V63, P1095; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CARDELL M, 1991, J NEUROCHEM, V57, P1814, DOI 10.1111/j.1471-4159.1991.tb06387.x; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN H, 1992, ACTA NEUROPATHOL, V84, P184, DOI 10.1007/BF00311393; CHEN H, 1992, J NEUROL SCI, V107, P191, DOI 10.1016/0022-510X(92)90288-V; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHURN SB, 1990, STROKE, V21, P1715, DOI 10.1161/01.STR.21.12.1715; Clark DL, 2008, EXP NEUROL, V212, P386, DOI 10.1016/j.expneurol.2008.04.016; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colbourne F, 1998, BRAIN RES, V803, P69, DOI 10.1016/S0006-8993(98)00612-X; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; COLON R, 1987, ANN THORAC SURG, V43, P639, DOI 10.1016/S0003-4975(10)60238-X; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Corbett D, 1997, STROKE, V28, P2238, DOI 10.1161/01.STR.28.11.2238; DeKosky ST, 2004, J NEUROCHEM, V90, P998, DOI 10.1111/j.1471-4159.2004.02575.x; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dong H, 2001, STROKE, V32, P788, DOI 10.1161/01.STR.32.3.788; Florian B, 2008, NEUROSCI LETT, V438, P180, DOI 10.1016/j.neulet.2008.04.020; Friedman LK, 2001, MOL BRAIN RES, V86, P34, DOI 10.1016/S0169-328X(00)00252-7; Fukui O, 2006, BRAIN RES, V1121, P35, DOI 10.1016/j.brainres.2006.08.121; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; GREEN EJ, 1995, BRAIN RES, V702, P145, DOI 10.1016/0006-8993(95)01034-1; Gressens P, 2008, BRAIN PATHOL, V18, P10, DOI 10.1111/j.1750-3639.2007.00095.x; Ha KY, 2008, SPINE, V33, P2059, DOI 10.1097/BRS.0b013e31818018f6; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Hansebout R R, 1975, Surg Neurol, V4, P531; HANSEBOUT RR, 1985, CAN J NEUROL SCI, V12, P83, DOI 10.1017/S0317167100046758; Haranishi Y, 2005, EUR J ANAESTH, V22, P140, DOI 10.1017/S0265021505000268; Hicks SD, 2000, NEUROSCIENCE, V98, P677, DOI 10.1016/S0306-4522(00)00169-X; HORN M, 1991, ACTA NEUROPATHOL, V81, P443, DOI 10.1007/BF00293466; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; Huang FP, 1998, NEUROL RES, V20, P57; Huang FP, 1998, NEUROCHEM RES, V23, P991, DOI 10.1023/A:1021088523137; Huang ZG, 1999, CAN J NEUROL SCI, V26, P298, DOI 10.1017/S0317167100000421; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Ibayashi S, 2000, NEUROCHEM RES, V25, P369, DOI 10.1023/A:1007593004806; Inamasu J, 2000, ACT NEUR S, V76, P525; Inamasu J, 2001, NEUROL RES, V23, P105, DOI 10.1179/016164101101198217; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; Jia XF, 2008, CRIT CARE MED, V36, P1909, DOI 10.1097/CCM.0b013e3181760eb5; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; KADER A, 1992, NEUROSURGERY, V31, P1056, DOI 10.1227/00006123-199212000-00011; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Karabiyikoglu M, 2003, J NEUROSURG, V98, P1271, DOI 10.3171/jns.2003.98.6.1271; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; Kawai N, 2002, ACT NEUR S, V81, P233; Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kobayashi MS, 2008, BRAIN RES REV, V58, P171, DOI 10.1016/j.brainresrev.2008.03.001; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Kollmar R, 2004, EXP NEUROL, V190, P204, DOI 10.1016/j.expneurol.2004.07.006; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; Kollmar R, 2007, STROKE, V38, P1585, DOI 10.1161/STROKEAHA.106.475897; Kuchner E F, 1976, Surg Neurol, V6, P371; KULUZ JW, 1992, STROKE, V23, P1792, DOI 10.1161/01.STR.23.12.1792; KULUZ JW, 1993, AM J PHYSIOL, V265, pH824; Kumar K, 1996, MOL BRAIN RES, V42, P337, DOI 10.1016/S0169-328X(96)00181-7; Kumar K, 1997, METAB BRAIN DIS, V12, P21, DOI 10.1007/BF02676351; Kumura E, 1996, NEUROSCI LETT, V220, P45, DOI 10.1016/S0304-3940(96)13238-9; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Liebetrau M, 2004, NEUROSCI LETT, V357, P17, DOI 10.1016/j.neulet.2003.12.031; LO EH, 1992, STROKE, V23, P889, DOI 10.1161/01.STR.23.6.889; LO EH, 1993, NEUROL RES, V15, P281; LO TP, 2009, J COMP NEUR IN PRESS; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; MALATOVA Z, 1995, MOL CHEM NEUROPATHOL, V25, P81, DOI 10.1007/BF02960903; Mancuso A, 2000, BRAIN RES, V887, P34, DOI 10.1016/S0006-8993(00)02963-2; Markarian GZ, 1996, NEUROSURGERY, V38, P542; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Morino T, 2008, SPINAL CORD, V46, P425, DOI 10.1038/sj.sc.3102163; Morochovic R, 2008, INT J NEUROSCI, V118, P555, DOI 10.1080/00207450601123456; Mueller-Burke D, 2008, INT J DEV NEUROSCI, V26, P67, DOI 10.1016/j.ijdevneu.2007.08.015; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Nakano H, 2007, ARQ NEURO-PSIQUIAT, V65, P810, DOI 10.1590/S0004-282X2007000500015; NASLUND TC, 1992, ANN SURG, V215, P409, DOI 10.1097/00000658-199205000-00002; Nito C, 2003, ACT NEUR S, V86, P199; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; ONESTI ST, 1991, NEUROSURGERY, V29, P369, DOI 10.1227/00006123-199109000-00005; Pabello NG, 2005, BRAIN RES, V1038, P11, DOI 10.1016/j.brainres.2004.12.047; Pabello NG, 2004, BRAIN RES, V995, P29, DOI 10.1016/j.brainres.2003.09.065; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Park CK, 1998, ACT NEUR S, V71, P225; Pazos AJ, 1999, BRAIN RES, V846, P186, DOI 10.1016/S0006-8993(99)02010-7; Phanithi PB, 2000, NEUROPATHOLOGY, V20, P273, DOI 10.1046/j.1440-1789.2000.00346.x; PRAKASA BP, 2000, NEUROSCI LETT, V291, P196; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROSOMOFF HL, 1959, J NEUROSURG, V16, P177, DOI 10.3171/jns.1959.16.2.0177; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Shimohata T, 2007, J CEREBR BLOOD F MET, V27, P1463, DOI 10.1038/sj.jcbfm.9600450; Shimohata T, 2007, STROKE, V38, P375, DOI 10.1161/01.STR.0000254616.78387.ee; Strauch JT, 2004, EUR J CARDIO-THORAC, V25, P708, DOI 10.1016/j.ejcts.2004.01.007; SUTTON LN, 1991, STROKE, V22, P1567, DOI 10.1161/01.STR.22.12.1567; TABAYASHI K, 1993, ANN THORAC SURG, V56, P494, DOI 10.1016/0003-4975(93)90885-L; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Tetik O, 2002, EUR J VASC ENDOVASC, V24, P540, DOI 10.1053/ejvs.2002.1753; Tohyama Y, 1998, EXP BRAIN RES, V122, P333, DOI 10.1007/s002210050521; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Urrea C, 2004, ACTA NEUROPATHOL, V107, P413, DOI 10.1007/s00401-004-0827-1; Van Hemelrijck A, 2005, EUR J NEUROSCI, V22, P1327, DOI 10.1111/j.1460-9568.2005.04331.x; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wakamatsu H, 1999, ANESTH ANALG, V88, P56, DOI 10.1097/00000539-199901000-00011; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; WELLS JD, 1978, SURG NEUROL, V10, P200; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Whalen MJ, 1997, ACT NEUR S, V70, P260; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; Wu XL, 1995, NEUROREPORT, V7, P302, DOI 10.1097/00001756-199512290-00072; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yanamoto H, 2001, STROKE, V32, P232, DOI 10.1161/01.STR.32.1.232; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; Yenari MA, 2002, J CEREBR BLOOD F MET, V22, P29, DOI 10.1097/00004647-200201000-00004; Yoshitake A, 2007, J THORAC CARDIOV SUR, V134, P1220, DOI 10.1016/j.jtcvs.2007.06.015; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Zausinger S, 2003, STROKE, V34, P1526, DOI 10.1161/01.STR.0000070841.31224.29; Zhang H, 2008, NEUROL RES, V30, P332, DOI 10.1179/174313208X300279; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; Zhang Y, 2001, Acta Anaesthesiol Sin, V39, P65; Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9; Zhao H, 2004, STROKE, V35, P572, DOI 10.1161/01.STR.0000110787.42083.58; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zhao H, 2007, J NEUROSURG, V107, P636, DOI 10.3171/JNS-07/09/0636; Zhu HD, 2005, EXP NEUROL, V193, P361, DOI 10.1016/j.expneurol.2005.01.022; ZIELONKA J S, 1974, Surgical Forum (Chicago), V25, P434	175	94	108	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					301	312		10.1089/neu.2008.0806			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900003	19245308	Green Published			2021-06-18	
J	RangeL-Castilla, L; Gasco, J; Nauta, HJW; Okonkwo, DO; Robertson, CS				RangeL-Castilla, Leonardo; Gasco, Jaime; Nauta, Haring J. W.; Okonkwo, David O.; Robertson, Claudia S.			Cerebral pressure autoregulation in traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						cerebral autoregulation; cerebral vasculature; intracranial hypertension; pressure autoregulation; traumatic brain injury	SEVERE HEAD-INJURY; OXIDE SYNTHASE EXPRESSION; TISSUE OXYGEN-TENSION; BLOOD-FLOW; NITRIC-OXIDE; ERYTHROPOIETIN PROTECTS; PERFUSION-PRESSURE; REACTIVITY; HYPEROXIA; HYPERVENTILATION	An understanding of normal cerebral autoregulation and its response to pathological derangements is helpful in the diagnosis, monitoring, management, and prognosis of severe traumatic brain injury (TBI). Pressure autoregulation is the most common approach in testing the effects of mean arterial blood pressure on cerebral blood flow. A gold standard for measuring cerebral pressure autoregulation is not available, and the literature shows considerable disparity in methods. This fact is not surprising given that cerebral autoregulation is more a concept than a physically measurable entity. Alterations in cerebral autoregulation can vary from patient to patient and over time and are critical during the first 4-5 days after injury. An assessment of cerebral autoregulation as part of bedside neuromonitoring in the neurointensive care unit can allow the individualized treatment of secondary injury in a patient with severe TBI. The assessment of cerebral autoregulation is best achieved with dynamic autoregulation methods. Hyperventilation, hyperoxia, nitric oxide and its derivates, and erythropoietin are some of the therapies that can be helpful in managing cerebral autoregulation. In this review the authors summarize the most important points related to cerebral pressure autoregulation in TBI as applied in clinical practice, based on the literature as well as their own experience.	[RangeL-Castilla, Leonardo; Gasco, Jaime; Nauta, Haring J. W.] Univ Texas Med Branch, Div Neurosurg, Galveston, TX 77555 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	RangeL-Castilla, L (corresponding author), Univ Texas Med Branch, Div Neurosurg, 301 Univ Blvd,Suite 9-121 ZC, Galveston, TX 77555 USA.	lerangel@utmb.edu					AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 2007, NEUROL RES, V29, P672, DOI 10.1179/016164107X240053; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; GROSS PM, 1979, CIRC RES, V44, P288, DOI 10.1161/01.RES.44.2.288; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Heistad D D, 1980, Physiologist, V23, P44; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kajita Y, 1998, NEUROSURGERY, V42, P834, DOI 10.1097/00006123-199804000-00087; Kirkness C J, 2001, Biol Res Nurs, V2, P175, DOI 10.1177/109980040100200303; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Longhi L, 2002, ACT NEUR S, V81, P315; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Matta BF, 1996, BRIT J ANAESTH, V76, P790; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; MELAMED E, 1980, STROKE, V11, P31, DOI 10.1161/01.STR.11.1.31; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; OSOL G, 1985, AM J PHYSIOL, V249, pH914; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; PANNIER JL, 1971, EUR NEUROL, V6, P123, DOI 10.1159/000114479; Puppo C, 2008, NEUROCRIT CARE, V8, P344, DOI 10.1007/s12028-008-9069-8; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Schmidt EA, 2003, J NEUROIMAGING, V13, P248, DOI 10.1177/1051228403013003008; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443	54	94	95	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E7	10.3171/FOC.2008.25.10.E7			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100007	18828705	Bronze			2021-06-18	
J	Zhang, B; West, EJ; Van, KC; Gurkoff, GG; Zhou, J; Zhang, XM; Kozikowski, AP; Lyeth, BG				Zhang, Bin; West, Eric J.; Van, Ken C.; Gurkoff, Gene G.; Zhou, Jia; Zhang, Xiu-Mei; Kozikowski, Alan P.; Lyeth, Bruce G.			HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats	BRAIN RESEARCH			English	Article						traumatic brain injury; microglia; inflammation; histone deacetylase; fluid percussion	LATERAL FLUID-PERCUSSION; ACUTE NEURONAL DEGENERATION; TRANSGENIC MOUSE MODEL; DEACETYLASE INHIBITORS; VALPROIC ACID; NEURODEGENERATIVE DISEASES; BEHAVIORAL DEFICITS; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; SODIUM-BUTYRATE	Traumatic brain injury (TBI) produces a rapid and robust inflammatory response in the brain characterized in part by activation of microglia. A novel histone deacetylase (HDAC) inhibitor, 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pentyl]benzamide (DMA-PB), was administered (0, 0.25, 2.5, 25 mg/kg) systemically immediately after lateral fluid percussion TBI in rats. Hippocampal CA2/3 tissue was processed for acetyl-histone H3 immunolocalization, OX-42 immunolocalization (for microglia), and Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury. Vehicle-treated TBI rats exhibited a significant reduction in acetyl-histone H3 immunostaining in the ipsilateral CA2/3 hippocampus compared to the sham TBI group (p<0.05). The reduction in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups. Vehicle-treated TBI rats exhibited a high density of phagocytic microglia in the ipsilateral CA2/3 hippocampus compared to sham TBI in which none were observed. All doses of DMA-PB significantly reduced the density of phagocytic microglia (P<0.05). There was a trend for DMA-PB to reduce the number of degenerating neurons in the ipsilateral CA2/3 hippocampus (p = 0.076). We conclude that the HDAC inhibitor DMA-PB is a potential novel therapeutic for inhibiting neuroinflammation associated with TBI. (C) 2008 Elsevier B.V. All rights reserved.	[Zhang, Bin; West, Eric J.; Van, Ken C.; Gurkoff, Gene G.; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Zhang, Bin; Zhang, Xiu-Mei] Shandong Univ, Sch Med, Dept Pharmacol, Jinan 250012, Shandong, Peoples R China; [Kozikowski, Alan P.] Univ Illinois, Drug Discovery Program, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA; [Zhou, Jia] PsychoGen Inc, Tarrytown, NY 10591 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS29995, NS45136]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136, R01NS029995] Funding Source: NIH RePORTER	This research was supported by NIH NS29995, NS45136 to BGL.	Adcock IM, 2007, BRIT J PHARMACOL, V150, P829, DOI 10.1038/sj.bjp.0707166; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Butler KV, 2008, CURR PHARM DESIGN, V14, P505; Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen B, 2005, BIOORG MED CHEM LETT, V15, P1389, DOI 10.1016/j.bmcl.2005.01.006; Chen PS, 2007, NEUROSCIENCE, V149, P203, DOI 10.1016/j.neuroscience.2007.06.053; Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525-0016(03)00235-1; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gehrmann Jochen, 1995, P883; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; Huuskonen J, 2004, BRIT J PHARMACOL, V141, P874, DOI 10.1038/sj.bjp.0705682; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; KOZIKOWSKI AP, 2007, J MED CHEM; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; McGeer PL, 1998, ALZ DIS ASSOC DIS, V12, pS1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nishida K, 2004, ARTHRITIS RHEUM-US, V50, P3365, DOI 10.1002/art.20709; Pandey UB, 2007, AUTOPHAGY, V3, P643, DOI 10.4161/auto.5050; Petri S, 2006, NEUROBIOL DIS, V22, P40, DOI 10.1016/j.nbd.2005.09.013; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zhou Y, 2005, MOL CELL PROTEOMICS, V4, P1471, DOI 10.1074/mcp.M500114-MCP200	58	94	97	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 21	2008	1226						181	191		10.1016/j.brainres.2008.05.085			11	Neurosciences	Neurosciences & Neurology	351MG	WOS:000259427800021	18582446	Green Accepted			2021-06-18	
J	Berlac, P; Hyldmo, PK; Kongstad, P; Kurola, J; Nakstad, AR; Sandberg, M				Berlac, P.; Hyldmo, P. K.; Kongstad, P.; Kurola, J.; Nakstad, A. R.; Sandberg, M.			Pre-hospital airway management: guidelines from a task force from the Scandinavian Society for Anaesthesiology and Intensive Care Medicine	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						pre-hospital; airway management; endotracheal intubation; laryngeal mask airway; laryngeal tube airway; combitube; emergency medical systems	LARYNGEAL MASK AIRWAY; RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; ADVANCED LIFE-SUPPORT; BAG-VALVE-MASK; RESUSCITATION-COUNCIL GUIDELINES; ESOPHAGEAL-TRACHEAL COMBITUBE; CARDIOPULMONARY-RESUSCITATION; ENDOTRACHEAL INTUBATION; ANESTHETIZED PATIENTS	This article is intended as a generic guide to evidence-based airway management for all categories of pre-hospital personnel. It is based on a review of relevant literature but the majority of the studies have not been performed under realistic, pre-hospital conditions and the recommendations are therefore based on a low level of evidence (D). The advice given depends on the qualifications of the personnel available in a given emergency medical service (EMS). Anaesthetic training and routine in anaesthesia and neuromuscular blockade is necessary for the use of most techniques in the treatment of patients with airway reflexes. For anaesthesiologists, the Task Force commissioned by the Scandinavian Society of Anaesthesia and Intensive Care Medicine recommends endotracheal intubation (ETI) following rapid sequence induction when securing the pre-hospital airway, although repeated unsuccessful intubation attempts should be avoided independent of formal qualifications. Other physicians, as well as paramedics and other EMS personnel, are recommended the lateral trauma recovery position as a basic intervention combined with assisted mask-ventilation in trauma patients. When performing advanced cardiopulmonary resuscitation, we recommend that non-anaesthesiologists primarily use a supraglottic airway device. A supraglottic device such as the laryngeal tube or the intubation laryngeal mask should also be available as a backup device for anaesthesiologists in failed ETI.	[Berlac, P.] Capital Reg Denmark, Rigshosp, Copenhagen Mobile Intens Care Unit, Copenhagen, Denmark; [Hyldmo, P. K.] Sorlandet Hosp, Div Anaesthesia & Emergency Med, Kristiansand, Norway; [Kurola, J.] Kuopio Univ Hosp, Dept Anaesthesia & Intens Care, SF-70210 Kuopio, Finland; [Nakstad, A. R.] Ullevaal Univ Hosp, Dept Anaesthesiol, Oslo, Norway; [Sandberg, M.] Ullevaal Univ Hosp, Air Ambulance Dept, Lorenskog, Norway	Sandberg, M (corresponding author), Ullevaal Univ Hosp, Air Ambulance Dept, Sykehusveien 19, N-1474 Nordbyhagen, Norway.	marten.sandberg@gmail.com	Hyldmo, Per Kristian/AAF-4896-2020	Sandberg, Marten/0000-0002-4812-0103			Adnet F, 1998, ANN EMERG MED, V32, P454, DOI 10.1016/S0196-0644(98)70175-1; ALEXANDER R, 1993, ANAESTHESIA, V48, P231, DOI 10.1111/j.1365-2044.1993.tb06909.x; Ali J, 1997, J TRAUMA, V42, P786, DOI 10.1097/00005373-199705000-00006; Asai T, 2002, BRIT J ANAESTH, V89, P729, DOI 10.1093/bja/aef241; Blake WED, 2002, RESUSCITATION, V53, P289, DOI 10.1016/S0300-9572(02)00037-0; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Cook TM, 2006, RESUSCITATION, V69, P371, DOI 10.1016/j.resuscitation.2005.10.015; Cook TM, 2003, BRIT J ANAESTH, V91, P678, DOI 10.1093/bja/aeg239; Cook TM, 2003, ANAESTHESIA, V58, P191; Cook TM, 2001, ANAESTHESIA, V56, P660, DOI 10.1046/j.1365-2044.2001.01969.x; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; DAVIES PRF, 1990, LANCET, V336, P977, DOI 10.1016/0140-6736(90)92429-L; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Dickinson E T, 1999, Prehosp Emerg Care, V3, P191, DOI 10.1080/10903129908958935; DiRusso SM, 2005, J TRAUMA, V59, P84, DOI 10.1097/01.TA.0000171462.28379.F3; Doerges V, 1999, RESUSCITATION, V41, P63, DOI 10.1016/S0300-9572(99)00036-2; Donald MJ, 2006, EMERG MED J, V23, P728, DOI 10.1136/emj.2006.037184; Dorph E, 2004, RESUSCITATION, V61, P23, DOI 10.1016/j.resuscitation.2003.12.017; Driscoll P, 2005, EMERG MED J, V22, P2, DOI 10.1136/emj.2004.021212; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; FRASS M, 1988, CHEST, V93, P781, DOI 10.1378/chest.93.4.781; Gatward JJ, 2008, BRIT J ANAESTH, V100, P351, DOI 10.1093/bja/aem364; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Hadorn DC, 1996, J CLIN EPIDEMIOL, V49, P749, DOI 10.1016/0895-4356(96)00019-4; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; Hein C, 2005, ANAESTH INTENS CARE, V33, P756, DOI 10.1177/0310057X0503300609; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Henderson JJ, 2004, ANAESTHESIA, V59, P675, DOI 10.1111/j.1365-2044.2004.03831.x; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Kette F, 2005, RESUSCITATION, V66, P21, DOI 10.1016/j.resuscitation.2004.12.023; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; Kober A, 2004, ANESTH ANALG, V98, P206, DOI 10.1213/01.ANE.0000090145.73834.2F; KOKKINIS K, 1994, RESUSCITATION, V27, P9, DOI 10.1016/0300-9572(94)90015-9; Konrad C, 1998, ANESTH ANALG, V86, P635; Krafft P, 1998, ANESTH ANALG, V87, P1457, DOI 10.1097/00000539-199812000-00059; Kurola J, 2006, ACTA ANAESTH SCAND, V50, P40, DOI 10.1111/j.1399-6576.2005.00852.x; Kurola JO, 2005, ANESTH ANALG, V101, P1477, DOI 10.1213/01.ANE.0000182330.54814.70; Langhelle A, 2004, RESUSCITATION, V61, P9, DOI 10.1016/j.resuscitation.2003.12.008; LEACH A, 1993, RESUSCITATION, V25, P245, DOI 10.1016/0300-9572(93)90121-6; Lefrancois DP, 2002, RESUSCITATION, V52, P77, DOI 10.1016/S0300-9572(01)00441-5; Lockey DJ, 1999, ANAESTHESIA, V54, P1097, DOI 10.1046/j.1365-2044.1999.00754.x; MARTIN PD, 1993, ANAESTHESIA, V48, P33; McGlinch BP, 2004, ANN EMERG MED, V44, P320, DOI 10.1016/j.annemergmed.2004.05.022; Meyer PG, 2000, PAEDIATR ANAESTH, V10, P253, DOI 10.1046/j.1460-9592.2000.00496.x; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Nolan J D, 2001, Curr Opin Crit Care, V7, P413, DOI 10.1097/00075198-200112000-00008; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Ochs M, 2000, Prehosp Emerg Care, V4, P333, DOI 10.1080/10903120090941065; Ocker H, 2002, ANESTH ANALG, V95, P1094, DOI 10.1097/00000539-200210000-00057; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; Pelucio M, 1997, ACAD EMERG MED, V4, P563, DOI 10.1111/j.1553-2712.1997.tb03579.x; PENNANT JH, 1992, ANESTH ANALG, V75, P1074, DOI 10.1213/00000539-199212000-00046; PENNANT JH, 1992, ANESTH ANALG, V74, P531; Puntervoll SA, 2002, ACTA ANAESTH SCAND, V46, P455, DOI 10.1034/j.1399-6576.2002.460422.x; Rabitsch W, 2004, AM J EMERG MED, V22, P4, DOI 10.1016/j.ajem.2003.09.008; REINHART DJ, 1994, ANN EMERG MED, V24, P260, DOI 10.1016/S0196-0644(94)70139-3; Richards Christopher F., 1998, Journal of Emergency Medicine, V16, P37, DOI 10.1016/S0736-4679(97)00239-4; Rocca B, 2000, Prehosp Emerg Care, V4, P164, DOI 10.1080/10903120090941443; SAMARKANDI AH, 1994, RESUSCITATION, V28, P103, DOI 10.1016/0300-9572(94)90080-9; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stone BJ, 1998, RESUSCITATION, V38, P3, DOI 10.1016/S0300-9572(98)00068-9; Stoppacher R, 2004, J FORENSIC SCI, V49, P586; Tanigawa K, 1998, Prehosp Emerg Care, V2, P96, DOI 10.1080/10903129808958850; Vadeboncoeur TF, 2006, J EMERG MED, V30, P131, DOI 10.1016/j.jemermed.2005.04.019; Vaida SJ, 2004, ANESTH ANALG, V99, P124, DOI 10.1213/01.ANE.0000123492.26499.63; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang H E, 2000, Prehosp Emerg Care, V4, P14, DOI 10.1080/10903120090941560; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916	70	94	94	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	AUG	2008	52	7					897	907		10.1111/j.1399-6576.2008.01673.x			11	Anesthesiology	Anesthesiology	323VB	WOS:000257475400004	18702752	Bronze			2021-06-18	
J	Le Gall, F; Carling, C; Reilly, T				Le Gall, Franck; Carling, Christopher; Reilly, Thomas			Injuries in young elite female soccer players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						training; trauma; overuse; women	LOWER-EXTREMITY KINEMATICS; MEDICAL-RESEARCH PROGRAM; RISK-FACTORS; EUROPEAN FOOTBALL; DATA-COLLECTION; HEAD-INJURIES; ANKLE SPRAINS; PREVENTION; CONCUSSION; AUDIT	Background: Epidemiologic data on injuries in young female soccer players at elite levels are scarce. Purpose: The aim of the present study is to investigate the incidence of soccer-related injuries in young elite female French players. Study Design: Cohort study; Level of evidence, 2. Methods: Injuries sustained by players between 15 and 19 years of age, during 8 seasons, were diagnosed and documented by a sports physician according to type, location, severity, the date the injury occurred, and playing position. Results: Altogether 619 injuries were documented for 110 players (92.4%). Of these injuries, 64.6% (4.6/1000 training hours; 95% confidence interval [Cl], 4.2-5.0) and 35.4% (22.4/1000 match hours; 95% Cl, 19.4-25.4) were sustained during training and matches, respectively. The risk of injury was greater in the youngest (under age 15) group compared with the oldest (under 19) group (relative risk 1.7; 95% Cl, 1.3-2.3). Traumatic injuries amounted to 536 (86.4%) and 83 (13.4%) were overuse injuries. There were 51.9% minor injuries, 35.7% moderate injuries, and 12.4% major injuries. Most injuries were located at the lower extremities (83.4%), with the majority affecting the ankle (n = 157). The most commonly diagnosed injury was ankle sprain (16.8%). Twelve anterior cruciate ligament ruptures were sustained, with the majority occurring during matches (n = 10; 1.0/1000 match hours; 95% Cl, 0.4-1.6). Reinjuries accounted for 4.4% of total injuries, and September was the predominant month for injury (14.2%). Conclusions: The results, when compared with those of other investigations on female soccer players, revealed high rates of both traumatic injury and match injury, whereas recurrence of injury was low. Injuries, notably sprains, to the ankle were common, suggesting a need for the implementation of specific injury prevention strategies for this joint.	LOSC Lille Metropole Football Club, Ctr Format, F-59650 Villeneuve Dascq, France; [Le Gall, Franck] Inst Natl Football, Ctr Tech Natl Fernand Sastre, Clairefontaine En Yvelin, France; [Reilly, Thomas] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool L3 5UX, Merseyside, England	Carling, C (corresponding author), LOSC Lille Metropole Football Club, Ctr Format, Stadium Lille Metropole 30 Av Chatellenie, F-59650 Villeneuve Dascq, France.	chris.carling@free.fr					Al-Kashmiri A, 2006, TRAUMA, V8, P189, DOI 10.1177/1460408606071144; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Arnason A, 2004, AM J SPORT MED, V32, p5S, DOI 10.1177/0363546503258912; BACKOUS DD, 1988, AM J DIS CHILD, V142, P839, DOI 10.1001/archpedi.1988.02150080045019; Bennett P, 2006, TRAUMA, V8, P69, DOI 10.1177/1460408606072682; Bjordal JM, 1997, AM J SPORT MED, V25, P341, DOI 10.1177/036354659702500312; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Elias SR, 2001, MED SCI SPORT EXER, V33, P359, DOI 10.1097/00005768-200103000-00004; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408; Faude O, 2006, BRIT J SPORT MED, V40, P785, DOI 10.1136/bjsm.2006.027540; Faude O, 2005, AM J SPORT MED, V33, P1694, DOI 10.1177/0363546505275011; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Gioftsidou A, 2006, PERCEPT MOTOR SKILL, V103, P151, DOI 10.2466/PMS.103.1.151-159; Giza E, 2005, BRIT J SPORT MED, V39, P212, DOI 10.1136/bjsm.2004.011973; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hagglund M, 2005, SCAND J MED SCI SPOR, V15, P21, DOI 10.1111/j.1600-0838.2004.00395.x; Hawkins RD, 1999, BRIT J SPORT MED, V33, P196, DOI 10.1136/bjsm.33.3.196; Hawkins RD, 2001, BRIT J SPORT MED, V35, P43, DOI 10.1136/bjsm.35.1.43; Heidt RS, 2000, AM J SPORT MED, V28, P659, DOI 10.1177/03635465000280050601; Hewett TE, 1996, AM J SPORT MED, V24, P765, DOI 10.1177/036354659602400611; INKLAAR H, 1994, SPORTS MED, V18, P81, DOI 10.2165/00007256-199418020-00002; Jacobson I, 2007, SCAND J MED SCI SPOR, V17, P84, DOI 10.1111/j.1600-0838.2006.00524.x; Jacobson I, 2006, EUR J PHYSIOTHER, V8, P66, DOI 10.1080/14038190600621706; Junge A, 2000, AM J SPORT MED, V28, pS40; Knobloch K, 2005, SPORTVERLETZ SPORTSC, V19, P123, DOI 10.1055/s-2005-858345; Le Gall F, 2006, AM J SPORT MED, V34, P928, DOI 10.1177/0363546505283271; LEGALL F, 2005, TRAUMATISMES FOOTBAL; MAEHLUM S, 1986, PHYSICIAN SPORTSMED, V14, P73, DOI 10.1080/00913847.1986.11709124; McGuine TA, 2006, AM J SPORT MED, V34, P1103, DOI 10.1177/0363546505284191; MURIER A, 2006, MAGAZINE MINISTERE J, V106, P11; Ostenberg A, 2000, SCAND J MED SCI SPOR, V10, P279, DOI 10.1034/j.1600-0838.2000.010005279.x; Peterson L, 2000, AM J SPORT MED, V28, pS51; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; Pollard CD, 2006, CLIN J SPORT MED, V16, P223, DOI 10.1097/00042752-200605000-00006; Price RJ, 2004, BRIT J SPORT MED, V38, P466, DOI 10.1136/bjsm.2003.005165; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; SURVE I, 1994, AM J SPORT MED, V22, P601, DOI 10.1177/036354659402200506; Tol JL, 2002, AM J SPORT MED, V30, P45, DOI 10.1177/03635465020300012101; TROPP H, 1985, AM J SPORT MED, V13, P259, DOI 10.1177/036354658501300408; Yu B, 2005, AM J SPORT MED, V33, P1356, DOI 10.1177/0363546504273049	44	94	97	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2008	36	2					276	284		10.1177/0363546507307866			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	255NE	WOS:000252663900007	17932408				2021-06-18	
J	Bermpohl, D; You, Z; Lo, EH; Kim, HH; Whalen, MJ				Bermpohl, Daniela; You, Zerong; Lo, Eng H.; Kim, Hyung-Hwan; Whalen, Michael J.			TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; genetics; knockout; neuroprotection; Fas; immature	NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; NERVOUS-SYSTEM; DEFICIENT MICE; UP-REGULATION; MOUSE-BRAIN; CELL-DEATH; LIGAND; RAT; NEUTRALIZATION	Tumor necrosis factor-alpha (TNF alpha) and Fas are induced after traumatic brain injury (TBI); however, their functional roles are incompletely understood. Using controlled cortical impact (CCI) and mice deficient in TNF alpha, Fas, or both (TNF alpha/ Fas -/-), we hypothesized that TNF alpha and Fas receptor mediate secondary TBI in a redundant manner. Compared with wild type (WT), TNF alpha/ Fas -/- mice had improved motor performance from 1 to 4 days (P < 0.05), improved spatial memory acquisition at 8 to 14 days (P < 0.05), and decreased brain lesion size at 2 and 6 weeks after CCI (P < 0.05). Protection in TNF alpha/Fas -/- mice from histopathological and motor deficits was reversed by reconstitution with recombinant TNF alpha before CCI, and TNF alpha -/- mice administered anti- Fas ligand antibodies had improved spatial memory acquisition versus similarly treated WT mice ( P < 0.05). Tumor necrosis factor- alpha/Fas -/- mice had decreased the numbers of cortical cells with plasmalemma damage at 6h ( P< 0.05 versus WT), and reduced matrix metalloproteinase- 9 activity in injured brain at 48 and 72 h after CCI. In immature mice subjected to CCI, genetic inhibition of TNF alpha and Fas conferred beneficial effects on histopathology and spatial memory acquisition in adulthood (both P < 0.05 versus WT), suggesting that the beneficial effects of TNF alpha/ Fas inhibition may be permanent. The data suggest that redundant signaling pathways initiated by TNF alpha and Fas play pivotal roles in the pathogenesis of TBI, and that biochemical mechanisms downstream of TNF alpha/ Fas may be novel therapeutic targets to limit neurological sequelae in children and adults with severe TBI.	Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA; Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA; Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA; Brigham & Womens Hosp, Vasc Med Res Unit, Cambridge, MA USA	Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048422, R01NS047447, R01NS040529] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS47447, R01 NS48422, R01 NS40529] Funding Source: Medline		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Albensi BC, 2000, SYNAPSE, V35, P151; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Casha S, 2005, EXP NEUROL, V196, P390, DOI 10.1016/j.expneurol.2005.08.020; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Graham EM, 2004, NEUROBIOL DIS, V17, P89, DOI 10.1016/j.nbd.2004.05.007; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; Landau AM, 2005, J EXP MED, V202, P575, DOI 10.1084/jem.20050163; Lee RC, 1999, ANN NY ACAD SCI, V888, P266, DOI 10.1111/j.1749-6632.1999.tb07961.x; Leib SL, 2001, BRAIN, V124, P1734, DOI 10.1093/brain/124.9.1734; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Qiu JH, 2002, J NEUROSCI, V22, P3504; Sakic B, 1997, NEUROSCI BIOBEHAV R, V21, P327; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Zuliani C, 2006, CELL DEATH DIFFER, V13, P31, DOI 10.1038/sj.cdd.4401720	39	94	99	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2007	27	11					1806	1818		10.1038/sj.jcbfm.9600487			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	222ZP	WOS:000250338700004	17406655	Bronze			2021-06-18	
J	Klose, M; Juul, A; Poulsgaard, L; Kosteljanetz, M; Brennum, J; Feldt-Rasmussen, U				Klose, M.; Juul, A.; Poulsgaard, L.; Kosteljanetz, M.; Brennum, J.; Feldt-Rasmussen, U.			Prevalence and predictive factors of post-traumatic hypopituitarism	CLINICAL ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ANTERIOR-PITUITARY DYSFUNCTION; GROWTH-HORMONE DEFICIENCY; INSULIN-TOLERANCE-TEST; PLUS ARGININE; PROVOCATIVE TESTS; GH DEFICIENCY; LONG-TERM; FACTOR-I; DIAGNOSIS	Objective To estimate the prevalence and predictive factors of hypopituitarism following traumatic brain injury (TBI). Design A cross-sectional cohort study. Patients One hundred and four hospitalized TBI patients (26F/78M), median age 41 (range 18-64) years, body mass index (BMI) 25 (17-39) kg/m(2); severity: mild [Glasgow Coma Scale (GCS) score 13-15) n = 44, moderate (GCS 9-12) n = 20, severe (GCS < 9) n = 40]. Measurements Patients were evaluated 13 (10-27) months post-injury, with measurement of baseline (0800-1000 h) and post-stimulatory hormonal levels during an insulin tolerance test (ITT) (86%) or, if contraindicated, an arginine(arg)-GHRH test + Synacthen test (14%). Insufficiencies were confirmed by retesting. Results Hypopituitarism was found in 16 (15%) patients, affecting one axis in 10, two axes in four and more than two axes in two patients. The GH axis was most frequently affected (15%), followed by secondary hypoadrenalism (5%), hypogonadism (2%), hypothyroidism (2%) and diabetes insipidus (2%). The risk of pituitary insufficiency was increased in patients with severe TBI as opposed to mild TBI [odds ratio (OR) 10.1, 95% confidence interval (CI) 2.1-48.4, P = 0.004], and in those patients with increased intracerebral pressure [OR 6.5, 95% CI 1.0-42.2, P = 0.03]. Patients with only one affected axis were all GH deficient; 60% (n = 6) of these were overweight or obese. Conclusions The prevalence of hypopituitarism was estimated at 16%. Although high, this value was lower than previously reported, and may still be overestimated because of well-known confounding factors, such as obesity. Indicators of increased TBI severity were predictive of hypopituitarism, with a high negative predictive value. Neuroendocrine evaluation should therefore be considered in patients with severe TBI, and in particular in those with increased intracerebral pressure (ICP).	Univ Copenhagen Hosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Neurosurg, KAS Glostrup, DK-2100 Copenhagen, Denmark	Klose, M (corresponding author), Univ Copenhagen Hosp, Dept Med Endocrinol, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	klose@rh.dk	Juul, Anders/F-5864-2013	Juul, Anders/0000-0002-0534-4350; Brennum, Jannick/0000-0002-7961-0156			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; ANDERSSON AM, 1995, EUR J ENDOCRINOL, V132, P340, DOI 10.1530/eje.0.1320340; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bonnefont X, 2005, P NATL ACAD SCI USA, V102, P16880, DOI 10.1073/pnas.0508202102; Ceballos R, 1966, Ala J Med Sci, V3, P185; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; GRANADA ML, 1990, ACTA PAEDIATR SCAND, P63; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Karovitaki N, 2006, J NEUROL NEUROSUR PS, V77, P276, DOI 10.1136/jnnp.2005.070482; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P1407, DOI 10.1210/jc.80.4.1407; Schneider HJ, 2006, EUR J ENDOCRINOL, V155, P553, DOI 10.1530/eje.1.02258; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Vestergaard P, 1997, HORM METAB RES, V29, P106, DOI 10.1055/s-2007-979000	29	94	104	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	AUG	2007	67	2					193	201		10.1111/j.1365-2265.2007.02860.x			9	Endocrinology & Metabolism	Endocrinology & Metabolism	197BH	WOS:000248527600006	17524035				2021-06-18	
J	Lavinio, A; Timofeev, I; Nortje, J; Outtrim, J; Smielewski, P; Gupta, A; Hutchinson, PJ; Matta, BF; Pickard, JD; Menon, D; Czosnyka, M				Lavinio, A.; Timofeev, I.; Nortje, J.; Outtrim, J.; Smielewski, P.; Gupta, A.; Hutchinson, P. J.; Matta, B. F.; Pickard, J. D.; Menon, D.; Czosnyka, M.			Cerebrovascular reactivity during hypothermia and rewarming	BRITISH JOURNAL OF ANAESTHESIA			English	Article						autoregulation; brain, injury; hypothermia; monitoring, critical care	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; INTRACRANIAL-PRESSURE; AUTOREGULATION	Background. Experimental evidence from a murine model of traumatic brain injury (TBI) suggests that hypothermia followed by fast rewarming may damage cerebral microcirculation. The effects of hypothermia and subsequent rewarming on cerebral vasoreactivity in human TBI are unknown. Methods. This is a retrospective analysis of data acquired during a prospective, observational neuromonitoring and imaging data collection project. Brain temperature, intracranial pressure (ICP), and cerebrovascular pressure reactivity index (PRx) were continuously monitored. Results. Twenty-four TBI patients with refractory intracranial hypertension were cooled from 36.0 (0.9) to 34.2 (0.5)degrees C [mean (SD), P < 0.0001] in 3.9 (3.7) h. Induction of hypothermia [average duration 40 (45) h] significantly reduced ICP from 23.1 (3.6) to 18.3 (4.8) mm Hg (P < 0.05). Hypothermia did not impair cerebral vasoreactivity as average PRx changed non-significantly from 0.00 (0.21) to -0.01 (0.21). Slow rewarming up to 37.0 degrees C [rate of rewarming, 0.2 (0.2)degrees C h(-1)] did not increase ICP [18.6 (6.2) mm Hg] or PRx [0.06 (0.18)]. However, in 17 (70. 1%) out of 24 patients, rewarming exceeded the brain temperature threshold of 37 degrees C. In these patients, the average brain temperature was allowed to increase to 37.8 (0.3)degrees C (P < 0.0001), ICP remained stable at 18.3 (8.0) mm Hg (P = 0.74), but average PRx increased to 0.32 (0.24) (P < 0.0001), indicating significant derangement in cerebrovascular reactivity. After rewarming, PRx correlated independently with brain temperature (R = 0.53; P < 0.05) and brain tissue O-2 (R=0.66; P < 0.01). Conclusions. After moderate hypothermia, rewarming exceeding the 37 degrees C threshold is associated with a significant increase in average PRx, indicating temperature-dependent hyperaemic derangement of cerebrovascular reactivity.	Addenbrookes Hosp, Dept Clin Neurosci, Acad Neurosurg Unit, Cambridge, England; Addenbrookes Hosp, Dept Anaesthesiol, Cambridge, England; Univ Brescia, Inst Anasthesiol & Intens Care Med, Brescia, Italy	Czosnyka, M (corresponding author), Addenbrookes Hosp, Dept Clin Neurosci, Acad Neurosurg Unit, Box 167, Cambridge, England.	mc141@medschl.cam.ac.uk	Timofeev, Ivan/AAE-7019-2019; Lavinio, Andrea/M-1778-2016	Timofeev, Ivan/0000-0002-1168-0393; Outtrim, Joanne/0000-0001-8118-6430; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0601025, G0600986, G0001237] Funding Source: Medline		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 2002, ACT NEUR S, V81, P117; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; KINCAID S, 2005, ANESTHESIOLOGY, V103, pA17; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Povoa P, 2002, INTENS CARE MED, V28, P235, DOI 10.1007/s00134-002-1209-6; Ramani R, 2006, CURR OPIN ANESTHESIO, V19, P487, DOI 10.1097/01.aco.0000245272.84539.97; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336	17	94	104	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	AUG	2007	99	2					237	244		10.1093/bja/aem118			8	Anesthesiology	Anesthesiology	199GA	WOS:000248683000014	17510046	Bronze, Green Published			2021-06-18	
J	Sonmez, U; Sonmez, A; Erbil, G; Tekmen, I; Baykara, B				Sonmez, Ulker; Sonmez, Atac; Erbil, Guven; Tekmen, Isil; Baykara, Basak			Neuroprotective effects of resveratrol against traumatic brain injury in immature rats	NEUROSCIENCE LETTERS			English	Article						immature rats; resveratrol; traumatic brain injury; hippocampus; cognition	CEREBRAL-ISCHEMIA; WINE; MECHANISMS; PROTECTS; CHILDREN; MEMORY; DAMAGE; DEFICITS	Childhood trauma resulting in traumatic brain injury (TBI) due to accidents and abuse is the major cause of death and dysfunction in the young. Since there are no approved specific pharmacological agents that block the progression of the secondary injury, the current management of TBI is mainly supportive. We aimed to determine the effect of resveratrol on hippocampal damage and behavioral deficits in 7-day-old rat pups subjected to contusion injury. Resveratrol was injected intraperitoneally at the doses of 100 mg/kg of body weight immediately after induction of traumatic injury. Hippocampal damage was examined by cresyl violet staining and behavioral alterations were evaluated using open field and novel object recognition tests 2 weeks after trauma. Histopathological evaluation showed that treatment with a single dose of 100 mg/kg resveratrol (i.p.) after the trauma significantly ameliorated the trauma induced hippocampal neuron loss at ipsilateral and contralateral hippocampal brain regions of rats. Additionally, treatment with resveratrol decreased anxiety and increased cortex/hippocampus dependent memory of animals subjected to blunt head trauma. These results show that acute treatment of resveratrol has a neuroprotective role against trauma induced hippocampal neuron loss and associated cognitive impairment in rats. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Dokuz Eylul Univ, Sch Med, Learning Resources Ctr, Res Lab, TR-35340 Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Histol & Embryol, TR-35340 Izmir, Turkey	Sonmez, A (corresponding author), Dokuz Eylul Univ, Sch Med, Learning Resources Ctr, Res Lab, TR-35340 Izmir, Turkey.	atac.sonmez@deu.edu.tr	TEKMEN, ISIL/Q-2685-2019; Baykara, Basak/AAC-6504-2019	TEKMEN, ISIL/0000-0003-0521-2654; Baykara, Basak/0000-0002-4178-2235			Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blalock EM, 2003, J NEUROSCI, V23, P3807; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bullock R, 2002, J NEUROTRAUM, V17, P449; Chen RS, 2002, J AGR FOOD CHEM, V50, P1665, DOI 10.1021/jf011134e; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Kontinen VK, 1999, PAIN, V80, P341, DOI 10.1016/S0304-3959(98)00230-9; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Virgili M, 2000, NEUROSCI LETT, V281, P123, DOI 10.1016/S0304-3940(00)00820-X; Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z; Zamin LL, 2006, NEUROBIOL DIS, V24, P170, DOI 10.1016/j.nbd.2006.06.002; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x	32	94	99	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 13	2007	420	2					133	137		10.1016/j.neulet.2007.04.070			5	Neurosciences	Neurosciences & Neurology	180ZC	WOS:000247405500008	17531385				2021-06-18	
J	Dias, CP; De Lima, MNM; Presti-Torres, J; Dornelles, A; Garcia, VA; Scalco, FS; Guimaraes, MR; Constantino, L; Budni, P; Dal-Pizzol, F; Schroder, N				Dias, C. Pieta; De Lima, M. N. Martins; Presti-Torres, J.; Dornelles, A.; Garcia, V. A.; Scalco, F. Siciliani; Guimaraes, M. Rewsaat; Constantino, L.; Budni, P.; Dal-Pizzol, Felipe; Schroder, N.			Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats	NEUROSCIENCE			English	Article						aging; neuroprotection; oxidative stress; protein carbonyl; hippocampus; cortex	NMDA RECEPTOR ANTAGONISTS; SEVERE ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY; COGNITIVE DYSFUNCTION; SYNAPTIC PLASTICITY; RECEIVING DONEPEZIL; PARKINSONS-DISEASE; PROTEIN OXIDATION; CONTROLLED-TRIAL; SPATIAL MEMORY	Many neurodegenerative diseases, including Alzheimer's (AD), Parkinson's (PD) and Huntington's diseases (HD), are caused by different mechanisms but may share a common pathway to neuronal injury as a result of the overstimulation of glutamate receptors. It has been suggested that this pathway can be involved in generation of cognitive deficits associated with normal aging. Previous studies performed in our laboratory have demonstrated that aged rats presented recognition memory deficits. The aim of the present study was to evaluate the effect of memantine, a low-affinity N-methyl-D-aspartate (NMDA) receptor antagonist, on age-induced recognition memory deficits. Additionally, parameters of oxidative damage in cerebral regions related to memory formation were evaluated. In order to do that, male Wistar rats (24 months old) received daily injections of saline solution or memantine (20 mg/kg i.p.) during 21 days. The animals were submitted to a novel object recognition task I week after the last injection. Memantine-treated rats showed normal recognition memory while the saline group showed long-term recognition memory deficits. The results show that memantine is able to reverse age-induced recognition memory deficits. We also demonstrated that memantine reduced the oxidative damage to proteins in cortex and hippocampus, two important brain regions involved in memory formation. Thus, the present findings suggest that, at least in part, age-induced cognitive deficits are related to oxidative damage promoted by NMDA receptor overactivation. (C) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.	Pontifical Catholic Univ, Fac Biosci, Neurobiol & Dev Biol Lab, BR-90619900 Porto Alegre, RS, Brazil; Pontifical Catholic Univ, Sao Lucas Hosp, Inst Geriatr & Gerontol, Grad Program Biomed Gerontol, BR-90619900 Porto Alegre, RS, Brazil; Pontifical Catholic Univ, Fac Biosci, Grad Program Cellular & Mol Biol, BR-90619900 Porto Alegre, RS, Brazil; Univ So Santa Catarina, Dept Med, Phytopathol Lab, BR-88806000 Circiuma, SC, Brazil	Schroder, N (corresponding author), Pontificial Catholic Univ, Fac Biosci, Dept Physiol Sci, Av Ipiranga,6681 Predio 12C,Sala 266, BR-90619900 Porto Alegre, RS, Brazil.	nadja_s@terra.com.br	de Lima, Maria/A-8745-2010; Presti-Torres, Juliana/L-8475-2013; Schroder, Nadja/AAE-9376-2019; Dal-Pizzol, Felipe/F-2756-2015	Presti-Torres, Juliana/0000-0002-3560-0052; Dal-Pizzol, Felipe/0000-0003-3003-8977; Constantino, Larissa/0000-0002-5400-6331; Schroder, Nadja/0000-0002-4227-5702			Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Balu M, 2005, INT J DEV NEUROSCI, V23, P501, DOI 10.1016/j.ijdevneu.2005.06.001; Beal MF, 1998, ANN NEUROL, V44, pS110; Bertaina-Anglade V., 2006, Journal of Pharmacological and Toxicological Methods, V54, P99, DOI 10.1016/j.vascn.2006.04.001; Canzoniero LMT, 2005, J ALZHEIMERS DIS, V8, P147; Castellani Rudy J, 2006, Am J Alzheimers Dis Other Demen, V21, P126, DOI 10.1177/153331750602100213; Castellano C, 2001, CURR DRUG TARGETS, V2, P273, DOI 10.2174/1389450013348515; Chen HSV, 2006, J NEUROCHEM, V97, P1611, DOI 10.1111/j.1471-4159.2006.03991.x; CINI M, 1995, NEUROBIOL AGING, V16, P53, DOI 10.1016/0197-4580(95)80007-E; Clark RE, 2005, CURR OPIN NEUROBIOL, V15, P593, DOI 10.1016/j.conb.2005.08.014; Cowan CM, 2006, CURR TOP DEV BIOL, V75, P25, DOI 10.1016/S0070-2153(06)75002-5; Creeley C, 2006, J NEUROSCI, V26, P3923, DOI 10.1523/JNEUROSCI.4883-05.2006; Cummings JL, 2006, NEUROLOGY, V67, P57, DOI 10.1212/01.wnl.0000223333.42368.f1; Dantoine T, 2006, INT J CLIN PRACT, V60, P110, DOI 10.1111/j.1368-5031.2005.00769.x; Dautzenberg PLJ, 2006, INT PSYCHOGERIATR, V18, P179, DOI 10.1017/S104161020625347x; de Lima MN, 2005, EXP GERONTOL, V40, P506, DOI 10.1016/j.exger.2005.03.004; de Lima MNM, 2005, EXP NEUROL, V196, P177, DOI 10.1016/j.expneurol.2005.07.017; de Lima MNM, 2005, EUR J NEUROSCI, V21, P2521, DOI 10.1111/j.1460-9568.2005.04083.x; de Lima MNM, 2005, BEHAV BRAIN RES, V156, P139, DOI 10.1016/j.bbr.2004.05.016; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; El Mohsen MMA, 2005, BIOCHEM BIOPH RES CO, V336, P386, DOI 10.1016/j.bbrc.2005.07.201; FERRIS S, 2006, IN PRESS INT J GERIA; Foster TC, 1997, HIPPOCAMPUS, V7, P602, DOI 10.1002/(SICI)1098-1063(1997)7:6<602::AID-HIPO3>3.0.CO;2-G; Friguet B, 2006, FEBS LETT, V580, P2910, DOI 10.1016/j.febslet.2006.03.028; Gupta RC, 2007, TOXICOL APPL PHARM, V219, P97, DOI 10.1016/j.taap.2006.10.028; Hartmann S, 2003, INT CLIN PSYCHOPHARM, V18, P81, DOI 10.1097/00004850-200303000-00003; HOYER S, 1995, DRUG AGING, V6, P210, DOI 10.2165/00002512-199506030-00004; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kadar T, 1998, J NEURAL TRANSM, V105, P987, DOI 10.1007/s007020050107; Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384; Kayali R, 2006, CELL BIOCHEM FUNCT, V24, P79, DOI 10.1002/cbf.1190; Kelly KM, 2006, EPILEPSY RES, V68, pS5, DOI 10.1016/j.eplepsyres.2005.07.015; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancuso C, 2007, FRONT BIOSCI-LANDMRK, V12, P1107, DOI 10.2741/2130; Martin I, 2006, MECH AGEING DEV, V127, P411, DOI 10.1016/j.mad.2006.01.008; Martinez M, 2000, BRAIN RES, V855, P100, DOI 10.1016/S0006-8993(99)02349-5; Marvanova M, 2004, NEUROPSYCHOPHARMACOL, V29, P1070, DOI 10.1038/sj.npp.1300398; Minkeviciene R, 2004, J PHARMACOL EXP THER, V311, P677, DOI 10.1124/jpet.104.071027; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Mumby DG, 2001, BEHAV BRAIN RES, V127, P159, DOI 10.1016/S0166-4328(01)00367-9; Nabeshi H, 2006, FREE RADICAL RES, V40, P1173, DOI 10.1080/10715760600847580; Nakamura S, 2006, EUR J PHARMACOL, V548, P115, DOI 10.1016/j.ejphar.2006.07.049; Nicolle MM, 2001, NEUROSCIENCE, V107, P415, DOI 10.1016/S0306-4522(01)00374-8; Peskind ER, 2006, AM J GERIAT PSYCHIAT, V14, P704, DOI 10.1097/01.JGP.0000224350.82719.83; Rammsayer TH, 2001, LEARN MEMORY, V8, P20, DOI 10.1101/lm.33701; Rampon C, 2000, NAT NEUROSCI, V3, P238; Rao VLR, 2001, BRAIN RES, V911, P96; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Riederer P, 2006, J NEURAL TRANSM, V113, P1671, DOI 10.1007/s00702-006-0591-6; Rosi S, 2006, NEUROSCIENCE, V142, P1303, DOI 10.1016/j.neuroscience.2006.08.017; Schroder N, 2003, SYNAPSE, V49, P89, DOI 10.1002/syn.10210; Scott GS, 2007, BIOCHEM PHARMACOL, V73, P228, DOI 10.1016/j.bcp.2006.09.021; Smith-Swintosky V L, 1994, J Neural Transm Suppl, V44, P29; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Toescu EC, 2004, J CELL MOL MED, V8, P181, DOI 10.1111/j.1582-4934.2004.tb00273.x; Topic B, 2002, NEUROBIOL AGING, V23, P135, DOI 10.1016/S0197-4580(01)00241-X; van Damme P, 2005, NEURODEGENER DIS, V2, P147, DOI 10.1159/000089620; Vernon AC, 2005, EUR J NEUROSCI, V22, P1799, DOI 10.1111/j.1460-9568.2005.04362.x; WENK GL, 1994, BRAIN RES, V655, P7, DOI 10.1016/0006-8993(94)91590-3; Wenk GL, 1997, BEHAV BRAIN RES, V83, P129, DOI 10.1016/S0166-4328(97)86056-1; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0; Yamada K, 2005, BEHAV BRAIN RES, V162, P191, DOI 10.1016/j.bbr.2005.02.036; Zajaczkowski W, 1996, EUR J PHARMACOL, V296, P239, DOI 10.1016/0014-2999(95)00716-4; Zoladz PR, 2006, PHARMACOL BIOCHEM BE, V85, P298, DOI 10.1016/j.pbb.2006.08.011	68	94	96	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 8	2007	146	4					1719	1725		10.1016/j.neuroscience.2007.03.018			7	Neurosciences	Neurosciences & Neurology	176RB	WOS:000247101500027	17445991				2021-06-18	
J	Lew, HL; Jerger, JF; Guillory, SB; Henry, JA				Lew, Henry L.; Jerger, James F.; Guillory, Sylvia B.; Henry, James A.			Auditory dysfunction in traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						auditory dysfunction; blast-related injury; hearing loss; non-blast-related injury; OIF; rehabilitation; sensorineural hearing loss; TBI; tinnitus; traumatic brain injury	BLAST INJURIES; EAR; LONDON; BOMB; CARE; NEED	Effective communication is essential for successful rehabilitation, especially in patients with traumatic brain injury (TBI). The authors examined the prevalence and characteristics of auditory dysfunction in patients with TBI who were admitted to a Department of Veterans Affairs TBI inpatient unit before and after the onset of Operation Iraqi Freedom (OIF). In order to delineate the characteristics of the auditory manifestations of patients who had sustained blast-related (BR) TBI, we reviewed the medical records of 252 patients with TBI and categorized them according to admission date, either before (Group I, n = 102) or after (Group II, n = 150) the onset of OIF. We subdivided Group 11 into non-blast-related (NBR) and BR TBI; no subjects in Group I had BR TBI. We found that admissions for TBI have increased 47% since the onset of OIF. In Group I, 28% of patients with TBI complained of hearing loss and 11% reported tinnitus. In Group II-NBR (n = 108), 44% complained of hearing loss and 18% reported tinnitus. In Group II-BR (n = 42), 62% complained of hearing loss and 38% reported tinnitus. Sensorineural loss was the most prevalent type of hearing loss in Group II-BR patients. In light of the high prevalence of hearing loss and tinnitus in this growing population of returning soldiers, we need to develop and implement strategies for diagnosis and management of these conditions.	[Lew, Henry L.; Guillory, Sylvia B.] Vet Affairs Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA 94304 USA; [Lew, Henry L.] Stanford Univ, Sch Med, Div Phys Med & Rehabil, Stanford, CA 94305 USA; [Jerger, James F.] Univ Texas Dallas, Sch Behav & Brain Sci, Dallas, TX 75230 USA; [Henry, James A.] VA Med Ctr, Natl Ctr Rehabil Auditory Res, VA Rehabil Res & Dev, Portland, OR USA; [Henry, James A.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA	Lew, HL (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA 94304 USA.	henrylew@stanford.edu					Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; BRUINS WR, 1991, J LARYNGOL OTOL, V105, P890, DOI 10.1017/S002221510011775X; *CDCP, 2003, CDC INJ PREV EXPL BL; Chandler D W, 1997, J Am Acad Audiol, V8, P81; Davis A., 2000, TINNITUS HDB, P1; Davis PB, 2007, EAR HEARING, V28, P242, DOI 10.1097/AUD.0b013e3180312619; Dobie RobertA., 2004, TINNITUS THEORY MANA, P1; *DVBIC, 2005, DEF VET BRAIN INJ FA; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Fausti SA, 2005, J REHABIL RES DEV, V42, P45, DOI 10.1682/JRRD.2005.02.0039; GARTH RJN, 1995, INJURY, V26, P363, DOI 10.1016/0020-1383(95)00042-8; Henry J, 1998, TINNITUS TREATMENT R, P99; Henry J., 2007, TINNITUS RETRAINING; Henry J. A., 2004, TINNITUS THEORY MANA, P220; Henry JA, 2005, J REHABIL RES DEV, V42, P95, DOI 10.1682/JRRD.2005.01.0005; HENRY JA, 2004, TINNITUS THEORY MANA, P337; Henry James A, 2005, Am J Audiol, V14, P49, DOI 10.1044/1059-0889(2005/005); Henry JA, 2006, J AM ACAD AUDIOL, V17, P104, DOI 10.3766/jaaa.17.2.4; Henry James A, 2005, Am J Audiol, V14, P21, DOI 10.1044/1059-0889(2005/004); HENRY JL, 2001, PSYCHOL MANAGEMENT C; Humes LE, 2006, NOISE MILITARY SERVI; Jastreboff P., 1998, TINNITUS TREATMENT R, V1, P201; Jastreboff P. J., 2004, TINNITUS RETRAINING; KERR AG, 1978, PRACTITIONER, V221, P677; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2004, AM J PHYS MED REHAB, V83, P210, DOI 10.1097/01.PHM.0000113402.85460.59; Martin F, 1986, INTRO AUDIOLOGY; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Newman C W, 1998, J Am Acad Audiol, V9, P153; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; Persaud R, 2003, CLIN OTOLARYNGOL, V28, P203, DOI 10.1046/j.1365-2273.2003.00688.x; ROTH Y, 1989, Harefuah, V117, P297; Schechter Martin A, 2002, J Am Acad Audiol, V13, P545; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Singh D, 1968, J Laryngol Otol, V82, P1017, DOI 10.1017/S0022215100069802; TETER DL, 1970, LARYNGOSCOPE, V80, P1122, DOI 10.1288/00005537-197007000-00010; Tyler RS, 2006, TINNITUS TREATMENT C; Van Campen L E, 1999, J Am Acad Audiol, V10, P231; Vernon J., 2000, TINNITUS HDB, P313; WALSH RM, 1995, J ACCID EMERG MED, V12, P194; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; YETISER S, 1993, MIL MED, V158, P803; ZIV M, 1973, MIL MED, V138, P811	46	94	100	0	11	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					921	927		10.1682/JRRD.2007.09.0140			7	Rehabilitation	Rehabilitation	253NL	WOS:000252524800005	18075949				2021-06-18	
J	Bazarian, JJ; Zemlan, FP; Mookerjee, S; Stigbrand, T				Bazarian, Jeffrey J.; Zemlan, Frank P.; Mookerjee, Sohug; Stigbrand, Torgney			Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury	BRAIN INJURY			English	Article						mild traumatic brain injury; S-100B; cleaved-tau; outcome	MINOR HEAD-INJURY; DIFFUSE AXONAL INJURY; PROTEIN MEASUREMENTS; CEREBROSPINAL-FLUID; NEURONAL DAMAGE; POSSIBLE MARKER; FOLLOW-UP; BLOOD; SYMPTOMS; QUANTIFICATION	Primary objective: To determine the relationship of serum S-100B and C-tau levels to long-term outcome after mild traumatic brain injury (mild TBI). Research design: A prospective study of 35 mild TBI subjects presenting to the emergency department. Methods and procedures: Six hour serum S-100B and C-tau levels compared to 3-month Rivermead Post Concussion Questionnaire (RPCQ) scores and post- concussive syndrome (PCS). Main outcomes and results: The linear correlation between marker levels and RPCQ scores was weak (S-100B: r = 0.071, C-tau: r = -0.21). There was no statistically significant correlation between marker levels and 3-month PCS (S-100B: AUC = 0.589, 95% CI. 038, 0.80; C-tau: AUC = 0.634, 95% CI 0.43, 0.84). The sensitivity of these markers ranged from 43.8-56.3% and the specificity from 35.7-71.4%. Conclusions: Initial serum S-100B and C-tau levels appear to be poor predictors of 3-month outcome after mild TBI.	Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY 14472 USA; Univ Cincinnati, Sch Med, Dept Psychiat, Cincinnati, OH USA; Umea Univ, Dept Immunol, Umea, Sweden	Bazarian, JJ (corresponding author), Univ Rochester, Sch Med, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14472 USA.	jeff_bazarian@urmc.rochester.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS41952-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER		Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Audenaert Kurt, 2003, Med Sci Monit, V9, pMT112; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Berger Rachel, 2003, Pediatr Crit Care Med, V4, P391, DOI 10.1097/01.PCC.0000075324.45784.8A; Biberthaler P, 2004, UNFALLCHIRURG, V107, P197, DOI 10.1007/s00113-004-0730-1; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mao Q, 1995, Hua Xi Yi Ke Da Xue Xue Bao, V26, P135; Marchi N, 2003, J NEUROSCI, V23, P1949; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; Mussack T, 2000, ACT NEUR S, V76, P393; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	52	94	98	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	7					759	765		10.1080/02699050500488207			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200010	16809208				2021-06-18	
J	Chiaretti, A; Genovese, O; Aloe, L; Antonelli, A; Piastra, M; Polidori, G; Di Rocco, C				Chiaretti, A; Genovese, O; Aloe, L; Antonelli, A; Piastra, M; Polidori, G; Di Rocco, C			Interleukin 1 beta and interleukin 6 relationship with paediatric head trauma severity and outcome	CHILDS NERVOUS SYSTEM			English	Article						interleukin 1 beta; interleukin 6; traumatic brain injury; Glasgow Coma Scale; Glasgow Outcome Score	INDUCED NEUTROPHIL CHEMOATTRACTANT; NECROSIS-FACTOR-ALPHA; BRAIN-INJURY; CEREBROSPINAL-FLUID; RAT-BRAIN; IL-6; CYTOKINES; ISCHEMIA; INCREASE; ACCUMULATION	Background: Based on the known inflammatory role of interleukins (IL), we evaluated IL-1beta and IL-6 expressions and their association with the severity of traumatic brain injury (TBI; Glasgow Coma Scale [GCS]) and the outcome (Glasgow Outcome Score [GOS]) recorded in a paediatric population. Design: The design was a perspective observational clinical study carried out in the paediatric intensive care unit of the University Hospital. Methods: We measured the IL-1beta and IL-6 levels in 14 children with severe TBI (patients) and in 12 children with obstructive hydrocephalus (control group). Cerebrospinal fluid (CSF) and plasma samples were collected 2 h (T1) and 24 h (T2) after TBI. Interleukins were assayed using the immunoenzymatic method. Results: The IL-1beta mean level was significantly lower than the IL-6 mean level both in the CSF and plasma of TBI children. In the CSF, the IL-1beta level increased from 55.71+/-72.79 pg/ml at T1 to 106.10+/-142.12 pg/ml at T2 and the IL-6 level increased from 405.43+/-280.28 pg/ml at T1 to 631.57+/-385.35 pg/ml at T2; a similar trend was observed in plasma. We found a statistically significant correlation between the increase in CSF and plasma interleukin levels between T1 and T2 and head injury severity (GCSless than or equal to5) as well as poor outcome (GOSless than or equal to3). Conclusions: The increases in IL-1beta and IL-6 expression were correlated with head injury severity and were indicative of poor clinical outcome, reflecting an endogenous neuroinflammatory response after TBI.	Policlin A Gemelli, I-00168 Rome, Italy; CNR, Inst Neurobiol, Rome, Italy; Univ Cattolica Sacro Cuore, Sch Med, Paediat Neurosurg Dept, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Sch Med, Paediat Intens Care Unit, I-00168 Rome, Italy	Chiaretti, A (corresponding author), Policlin A Gemelli, Largo A Gemelli 1, I-00168 Rome, Italy.	achiaretti@yahoo.it		GENOVESE, Orazio/0000-0002-1989-1363			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BELL M, 1998, CRIT CARE MED, V26, pA86; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fassbender K, 1997, J NEUROIMMUNOL, V74, P130, DOI 10.1016/S0165-5728(96)00214-7; GILLES FH, 1977, ANN NEUROL, V2, P49, DOI 10.1002/ana.410020108; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HACK CE, 1992, INFECT IMMUN, V60, P2835, DOI 10.1128/IAI.60.7.2835-2842.1992; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HANGBERG H, 1999, PEDIATR RES, V40, P603; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hodge CJ, 2001, NEUROSURGERY, V48, P2, DOI 10.1097/00006123-200101000-00002; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; Matsumoto T, 1997, LAB INVEST, V77, P119; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; Oygur N, 1998, ARCH DIS CHILD-FETAL, V79, pF190, DOI 10.1136/fn.79.3.F190; PETTILA V, 2002, INTENS CARE MED, V21, P94; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; Savman K, 1998, PEDIATR RES, V43, P746; Seekamp A, 2002, EUR J TRAUMA, V28, P183; Shalak LF, 2002, PEDIATRICS, V110, P673, DOI 10.1542/peds.110.4.673; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Sherwood ER, 2000, CRIT CARE MED, V28, P1221, DOI 10.1097/00003246-200004000-00054; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Strecker W, 2002, EUR J TRAUMA, V28, P75; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5; YAMASAKI Y, 1995, STROKE, V26, P318, DOI 10.1161/01.STR.26.2.318; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; YOSHIDA S, 1989, NEUROSURGERY, V25, P373, DOI 10.1227/00006123-198909000-00009; Zhang ZG, 1998, BRAIN RES, V784, P210, DOI 10.1016/S0006-8993(97)01317-6	56	94	100	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAR	2005	21	3					185	193		10.1007/s00381-004-1032-1			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	902OY	WOS:000227367600003	15455248				2021-06-18	
J	Chou, LS; Kaufman, KR; Walker-Rabatin, AE; Brey, RH; Basford, JR				Chou, LS; Kaufman, KR; Walker-Rabatin, AE; Brey, RH; Basford, JR			Dynamic instability during obstacle crossing following traumatic brain injury	GAIT & POSTURE			English	Article						traumatic brain injury; center of pressure; GCS	CENTER-OF-MASS; POSTURAL STABILITY; BODY BALANCE; HEAD; FALLS; SWAY; REHABILITATION; INDIVIDUALS; MODERATE; MOTION	Patients with traumatic brain injury (TBI) complain of "imbalance" or "unsteadiness" while walking, despite a normal gait on clinical examination. Thus, the purpose of this study was to determine if it was possible to quantitatively assess dynamic stability that did not have an obvious neuromuscular origin in individuals following TBI. Ten patients with documented TBI and 10 age, gender, and stature-matched healthy individuals participated in the study. All subjects were instructed to perform unobstructed level walking and to step over obstacles corresponding to 2.5%, 5%, 10%, and 15% of their height. A 13-link biomechanical model of the human body was used to compute the kinematics of the whole body center of mass (COM). Subjects with TBI walked with a significantly slower gait speed and shorter stride length than their matched controls. Furthermore, subjects with TBI displayed a significantly greater and faster medio-lateral (M-L) COM motion and maintained a significantly greater M-L separation distance between their COM and center of pressure (COP) than their matched control subjects. These measurements indicate that subjects with TBI have difficulty maintaining dynamic stability in the frontal plane and have a reduced ability to successfully arrest their sagittal momentum. These findings provide an objective measurement that reflects the complaints of instability not observable on clinical examination for individuals who have suffered a TBI. This ability to identify any functional impairment after a traumatic brain injury that may affect patient safety is critical for prevention of re-injury during the recovery period. (C) 2003 Elsevier B.V. All rights reserved.	Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Mot Anal Lab, Rochester, MN 55905 USA; Univ Oregon, Dept Exercise & Movement Sci, Eugene, OR 97403 USA; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Vestibular Balance Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA	Kaufman, KR (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Mot Anal Lab, 200 1st St SW,Charlton N L-110L, Rochester, MN 55905 USA.	kaufman.kenton@mayo.edu		Kaufman, Kenton/0000-0002-7311-3781			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; CAPLAN B, 1982, ARCH PHYS MED REHAB, V63, P362; CDC, 1999, TRAUM BRAIN INJ US R; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Chou LS, 2001, GAIT POSTURE, V13, P17, DOI 10.1016/S0966-6362(00)00087-4; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GOUVIER W D, 1991, Neuropsychology Review, V2, P3, DOI 10.1007/BF01108845; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HAHN ME, 2002, P 4 C BIOM CALG CAN; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JIAN YC, 1993, GAIT POSTURE, V1, P9, DOI DOI 10.1016/0966-6362(93)90038-3; KADABA MP, 1989, J ORTHOPAED RES, V7, P849, DOI 10.1002/jor.1100070611; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; Krebs DE, 1998, ARCH PHYS MED REHAB, V79, P1489, DOI 10.1016/S0003-9993(98)90408-7; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; MACKINNON CD, 1993, J BIOMECH, V26, P633, DOI 10.1016/0021-9290(93)90027-C; Matthews E, 1991, GLOBAL BIOGEOCHEM CY, V5, P3, DOI 10.1029/90GB02311; MEGLAN D, 1991, THESIS OHIO STATE U; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; OVERSTALL PW, 1977, BRIT MED J, V1, P261, DOI 10.1136/bmj.1.6056.261; Pai YC, 1997, J BIOMECH, V30, P347, DOI 10.1016/S0021-9290(96)00165-0; PRINCE F, 1994, GAIT POSTURE, V2, P19, DOI 10.1016/0966-6362(94)90013-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rimmele C T, 1987, Arch Clin Neuropsychol, V2, P353; RUBIN AM, 1995, AM J OTOL, V16, P216; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; Tucker CA, 1998, GAIT POSTURE, V8, P117, DOI 10.1016/S0966-6362(98)00030-7; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	37	94	95	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	DEC	2004	20	3					245	254		10.1016/j.gaitpost.2003.09.007			10	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	874QY	WOS:000225366100003	15531171				2021-06-18	
J	Hirsch, LJ				Hirsch, LJ			Continuous EEG monitoring in the intensive care unit: An overview	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						continuous EEG monitoring; critically ill; intensive care unit; nonconvulsive seizures; seizure detection; ischemia detection	NONCONVULSIVE STATUS EPILEPTICUS; NEURON-SPECIFIC ENOLASE; CONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL; SEIZURES; HEMORRHAGE; MORBIDITY; MORTALITY; MARKER	Due to technological advances, it is now feasible to record continuous digital EEG (CEEG), with or without video, in critically ill patients and review recordings remotely. Nonconvulsive seizures (NCSzs) are more common than previously recognized and are associated with worse outcome. The majority of seizures in ICU patients are nonconvulsive and will be missed without CEEG. Factors associated with an increased risk for NCSzs include coma, prior clinical seizures, CNS infection, brain tumor, recent neurosurgery, and periodic epileptiform discharges. In addition to detecting seizures, CEEG is also useful for characterizing paroxysmal spells such as posturing or autonomic changes, detecting ischemia, assessing level of sedation, following long-term EEG trends, and prognosticating. Most NCSzs will be detected in the first 24 hours of CEEG in noncomatose patients, but longer recording periods may be required in comatose patients or in those with periodic epileptiform discharges. EEG patterns in encephalopathic or comatose patients are often equivocal. How aggressively to treat NCSzs and equivocal EEG patterns in these patients is unclear and requires further research. Real-time detection of ischemia at a reversible stage is technologically feasible with CEEG and should be developed into a practical form for prevention of in-hospital infarction in the near future.	Columbia Univ, Comprehens Epilepsy Ctr, New York, NY 10032 USA	Hirsch, LJ (corresponding author), Columbia Univ, Comprehens Epilepsy Ctr, 710 W 168th St,Box NI-135, New York, NY 10032 USA.	LJH3@columbia.edu		Hirsch, Lawrence/0000-0002-6333-832X			Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DEGIORGIO CM, 1995, NEUROLOGY, V45, P1134, DOI 10.1212/WNL.45.6.1134; DeGiorgio CM, 1996, EPILEPSIA, V37, P606, DOI 10.1111/j.1528-1157.1996.tb00623.x; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Dennis LJ, 2002, NEUROSURGERY, V51, P1136, DOI 10.1097/00006123-200211000-00006; Fountain NB, 2001, J CLIN NEUROPHYSIOL, V18, P345, DOI 10.1097/00004691-200107000-00006; Hirsch LJ, 2004, EPILEPSIA, V45, P109, DOI 10.1111/j.0013-9580.2004.38103.x; IVES J, IN PRESS J CLIN NEUR; Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; KRUMHOLZ A, 1995, NEUROLOGY, V45, P1499, DOI 10.1212/WNL.45.8.1499; Krumholz A, 1999, J CLIN NEUROPHYSIOL, V16, P314, DOI 10.1097/00004691-199907000-00003; KULL L, IN PRESS J CLIN NEUR; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Privitera Michael D., 1994, Emergency Medicine Clinics of North America, V12, P1089; RABINOWICZ AL, 1995, EPILEPSIA, V36, P475, DOI 10.1111/j.1528-1157.1995.tb00489.x; Sankar R, 1997, EPILEPSY RES, V28, P129, DOI 10.1016/S0920-1211(97)00040-5; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Young GB, 1996, NEUROLOGY, V47, P83	27	94	95	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	SEP-OCT	2004	21	5					332	340					9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	878TO	WOS:000225670000004	15592007				2021-06-18	
J	Grossman, KJ; Goss, CW; Stein, DG				Grossman, KJ; Goss, CW; Stein, DG			Effects of progesterone on the inflammatory response to brain injury in the rat	BRAIN RESEARCH			English	Article						progesterone; traumatic brain injury; microglia; astrocyte; edema; neuronal survival	CEREBRAL-ARTERY OCCLUSION; FIBRILLARY ACIDIC PROTEIN; NITRIC-OXIDE SYNTHASE; CONTUSION INJURY; SPINAL-CORD; CORTICAL CONTUSION; REACTIVE GLIOSIS; CORTEX ABLATION; MICROGLIA; CNS	The effects of progesterone on the cellular inflammatory response to frontal cortex in jury were examined on Postsurgical days 1, 3 5, 7 and 9 in male rats treated with progesterone (4 mg/kg) and/or vehicle. Rats with bilateral contusions showed increased levels of edema on days I, 3 and 5, more reactive astrocytes on days 3, 5, 7 and 9, and more macrophages/activated microglia on days 1, 3, 5 and 9 compared to shams. The number of neurons in the medial dorsal nucleus (MDN) of the thalamus reduced on days 5 and 9 after injury compared to shams. Progesterone reduced edema levels and increased the accumulation of macrophages/activated microglia compared to vehicle controls (p<0.025); however, these changes in the inflammatory response were not related to MDN neuronal Survival. Our results Confirm the possibility that one way progesterone mediates its neuroprotective effects following injury is through its actions on the inflammatory response. (C) 2004 Elsevier B.V. All rights reserved.	Emory Univ, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Grossman, KJ (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.	kgrossm@uchicago.edu	Stein, Donald/AAJ-5139-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS3866401A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664] Funding Source: NIH RePORTER		Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BOLOVENTA B, 1992, PROG BRAIN RES, V94, P367; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; HE J, 2001, J NEUROTRAUM, V18, P1140; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; Keppel G, 1991, DESIGN ANAL RES HDB, P169; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kuebler JF, 2003, ARCH SURG-CHICAGO, V138, P727, DOI 10.1001/archsurg.138.7.727; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; MANNEL DN, 1990, IMMUNOL LETT, V26, P89, DOI 10.1016/0165-2478(90)90181-O; MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112; MORALI G, 2002, ABSTR SOC NEUR; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V86, P361, DOI 10.1016/0304-3940(88)90511-3; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Paxinos G., 1982, RAT BRAIN; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Ramos-Remus C, 2002, J INVEST MED, V50, P458, DOI 10.1136/jim-50-06-06; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Smith JS, 2000, NEURAL PLAST, V7, P73, DOI 10.1155/NP.2000.73; SMITH JS, 1998, J NEUROTRAUM, V15, P905; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	64	94	99	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 15	2004	1008	1					29	39		10.1016/j.brainres.2004.02.022			11	Neurosciences	Neurosciences & Neurology	817YD	WOS:000221211900004	15081379				2021-06-18	
J	Biswas, AK; Bruce, DA; Sklar, FH; Bokovoy, JL; Sommerauer, JF				Biswas, AK; Bruce, DA; Sklar, FH; Bokovoy, JL; Sommerauer, JF			Treatment of acute traumatic brain injury in children with moderate hypothermia improves intracranial hypertension	CRITICAL CARE MEDICINE			English	Article						moderate hypothermia; traumatic brain injury; cerebral ischemia; intracranial hypertension; pediatric intensive care unit	SEVERE HEAD-INJURIES; CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; SYSTEMIC HYPOTHERMIA; METABOLISM; PRESSURE; DAMAGE		Univ Texas, SW Med Ctr, Dept Pediat, Div Pediat Crit Care Med, Dallas, TX USA; Childrens Med Ctr, Dallas, TX 75235 USA	Biswas, AK (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, Div Pediat Crit Care Med, 5323 Harry Hines Blvd, Dallas, TX USA.						ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNETT B, 1975, LANCET, V1, P480; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mathew P., 1995, Journal of Neurotrauma, V12, P430; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Munro D, 1928, J AMER MED ASSOC, V90, P1688, DOI 10.1001/jama.1928.02690480010004; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; WELCH K, 1980, J NEUROSURG, V52, P693, DOI 10.3171/jns.1980.52.5.0693; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070	46	94	97	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2002	30	12					2742	2751		10.1097/00003246-200212000-00020			10	Critical Care Medicine	General & Internal Medicine	633AP	WOS:000180257300020	12483067				2021-06-18	
J	Winter, CD; Iannotti, F; Pringle, AK; Trikkas, C; Clough, GF; Church, MK				Winter, CD; Iannotti, F; Pringle, AK; Trikkas, C; Clough, GF; Church, MK			A microdialysis method for the recovery of IL-1 beta, IL-6 and nerve growth factor from human brain in vivo	JOURNAL OF NEUROSCIENCE METHODS			English	Article						microdialysis; human; traumatic brain injury (TBI); extracellular fluid (ECF); interleukin-1 beta; interleukin-6; nerve growth factor	TUMOR-NECROSIS-FACTOR; HEAD-INJURY; HUMAN SKIN; TNF-ALPHA; IN-VIVO; CYTOKINES; TISSUE; INFLAMMATION; HISTAMINE; PLASMA	Intracerebral microdialysis is used extensively as a research tool in the investigation of the neurochemical and metabolic,changes that occur following acute brain injury. Microdialysis has enabled elucidation of intra-cerebral levels of substances such as lactate, pyruvate and glycerol but, as yet, has not been used effectively to recover macromolecules from the human brain. Traumatic brain injury is known to result in the generation of cytokines and neurotrophins into extracellular fluid compartment of the brain, with effects on neuronal damage and repair. We have developed a technique of in vivo sampling of the interstitial fluid of the brain of patients with severe head injuries which has allowed the measurement of IL-1beta, IL-6 and nerve growth factor. This report confirms the safety and effectiveness of this modified microdialysis method in the clinical setting of a neurological intensive care unit. The technique provides a timely addition to the armamentarium of the clinical scientist and will potentially lead to a greater understanding of neuroinflammation following acute traumatic brain injury. (C) 2002 Elsevier Science B.V. All rights reserved.	Southampton Gen Hosp, Wessex Neurol Ctr, Dept Neurosurg, Southampton SO16 6YD, Hants, England; Univ Southampton, Sch Med, Southampton SO16 7PX, Hants, England; Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England	Winter, CD (corresponding author), Southampton Gen Hosp, Wessex Neurol Ctr, Dept Neurosurg, Southampton SO16 6YD, Hants, England.	mkc@soton.ac.uk		Pringle, Ashley/0000-0003-2421-4380			Anderson C, 1995, Curr Probl Dermatol, V23, P121; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; BETZ AL, 1992, NEUROSURGERY SCI BAS, P353; Clapp-Lilly KL, 1999, J NEUROSCI METH, V90, P129, DOI 10.1016/S0165-0270(99)00064-3; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; HAMBERGER A, 1983, GLUTAMINE GLUTAMATE, P473; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Landolt H, 1996, ACT NEUR S, V67, P31; LONNROTH P, 1990, J INTERN MED, V227, P295; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Petersen LJ, 1997, CLIN EXP ALLERGY, V27, P284; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Rukwied R, 2000, BRIT J DERMATOL, V142, P1114, DOI 10.1046/j.1365-2133.2000.03535.x; Schmelz M, 1997, NEUROSCI LETT, V230, P117, DOI 10.1016/S0304-3940(97)00494-1; Schmelz M, 1999, CLIN EXP ALLERGY, V29, P695; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TRIKKAS C, 2001, J VASC RES, V38, P199; Westerink BHC, 2001, J NEUROSCI METH, V109, P53, DOI 10.1016/S0165-0270(01)00401-0; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	26	94	95	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	SEP 15	2002	119	1					45	50	PII S0165-0270(02)00153-X	10.1016/S0165-0270(02)00153-X			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	597DK	WOS:000178206700006	12234634				2021-06-18	
J	Cervantes, M; Gonzalez-Vidal, MD; Ruelas, R; Escobar, A; Morali, G				Cervantes, M; Gonzalez-Vidal, MD; Ruelas, R; Escobar, A; Morali, G			Neuroprotective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus	ARCHIVES OF MEDICAL RESEARCH			English	Article						global cerebral ischemia; neuroprotection; caudate nucleus; progesterone; cat	TRANSIENT FOREBRAIN ISCHEMIA; GAMMA-AMINOBUTYRIC-ACID; SUBSTANTIA-NIGRA-RETICULATA; TRAUMATIC BRAIN-INJURY; SELECTIVE VULNERABILITY; CARDIAC-ARREST; ARTERY OCCLUSION; GENE-EXPRESSION; ANIMAL-MODEL; GABA	Background. In addition to the hippocampus, the dorsolateral caudate nucleus (CN) and the pars reticularis of the substantia nigra (SNr) are among the most vulnerable brain areas to ischemia. A possible association of the neuronal injury in these two subcortical nuclei has been proposed, the primary damage affecting the CN GABAergic neurons innervating the SNr, and secondarily the SNr neurons as a result of an imbalance of GABAergic and glutamatergic input to the SNr. Progesterone (P-4) exerts a GABAergic action on the central nervous system (CNS) and is known to protect neurons in the cat hippocampus from the damaging effect of acute global cerebral ischemia (AGCI). The effects of AGCI on the neuronal populations of the CN and SNr, in addition to the possible neuroprotective effects Of P-4, were assessed in cats in the present study. Methods. Ovariectomized adult cats were treated subcutaneously (s.c.) with either P-4 (10 mg/kg/day) or corn oil during the 7 days before and 7 days after being subjected to a period of AGCI by 15 min of cardiorespiratory arrest followed by 4 min of reanimation. After 14 days of survival, animals were sacrificed and their brains perfused in situ with phosphate-buffered 10% formaldehyde for histologic examination. Results. ACGI resulted in an intense glial reaction in the CN and a significant loss (43%) of medium-sized neurons of the CN, but no difference was found in the densities of SNr neurons between controls and ischemic oil- and P-4-treated cats. Progesterone treatment completely prevented CN neuronal loss. Conclusions. The overall results point to the higher vulnerability of CN neurons to ischemia as compared to neuron, in the SNr and show the protective effects of P-4 upon CN neuronal damage after ischemia. (C) 2002 IMSS. Published by Elsevier Science Inc.	IMSS, Ctr Med Nacl Siglo 21, Unidad Invest Med Farmacol, Mexico City 03020, DF, Mexico; IMSS, Ctr Invest Biomed Michoacan, Lab Neurofarmacol, Morelia, Michoacan, Mexico; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Fisiol, Mexico City 04510, DF, Mexico	Morali, G (corresponding author), IMSS, Ctr Med Nacl Siglo 21, Unidad Invest Med Farmacol, Apdo Postal 73-032, Mexico City 03020, DF, Mexico.	gmorali@hotmail.com	Morali, Gabriela/AAH-8014-2020				Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; BARNEA A, 1990, ENDOCRINOLOGY, V127, P500, DOI 10.1210/endo-127-1-500; BARRON KD, 1977, BRAIN RES, V130, P469, DOI 10.1016/0006-8993(77)90109-3; BITRAN D, 1993, PHARMACOL BIOCHEM BE, V45, P423, DOI 10.1016/0091-3057(93)90260-Z; Cervantes M, 1995, Arch Med Res, V26, P385; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CRAIN BJ, 1988, NEUROSCIENCE, V27, P387; Crumrine RC, 1997, STROKE, V28, P2230, DOI 10.1161/01.STR.28.11.2230; DEARDEN NM, 1985, LANCET, V2, P255; DOWNIE MM, 1983, BASIC STAT METHODS; FISHER RS, 1986, BRAIN RES, V398, P148, DOI 10.1016/0006-8993(86)91260-6; Friess E, 1997, AM J PHYSIOL-ENDOC M, V272, pE885; FRIESS E, 1997, AM J PHYSL, V272; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; FRYE CA, 1995, BRAIN RES, V696, P113, DOI 10.1016/0006-8993(95)00793-P; GEE KW, 1988, J PHARMACOL EXP THER, V246, P803; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GONZALES C, 1992, NEUROSCI LETT, V135, P53, DOI 10.1016/0304-3940(92)90134-S; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; HADDAD GG, 1993, PROG NEUROBIOL, V40, P277, DOI 10.1016/0301-0082(93)90014-J; Hall ED, 1996, BRAIN RES, V742, P80, DOI 10.1016/S0006-8993(96)00968-7; Hall ED, 1997, J CEREBR BLOOD F MET, V17, P875, DOI 10.1097/00004647-199708000-00006; HARA H, 1993, PROG NEUROBIOL, V40, P645, DOI 10.1016/0301-0082(93)90009-H; HASHIMOTO N, 1994, BRAIN RES BULL, V33, P281, DOI 10.1016/0361-9230(94)90195-3; HAWKINSON JE, 1994, EUR J PHARM-MOLEC PH, V269, P157, DOI 10.1016/0922-4106(94)90082-5; HOSSMANN KA, 1985, PROG BRAIN RES, V63, P3; Ito H, 1999, ACTA ANAESTH SCAND, V43, P153, DOI 10.1034/j.1399-6576.1999.430206.x; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JOHANSEN FF, 1991, ACTA NEUROL SCAND, V84, P1; KAPLAN J, 1987, RESUSCITATION, V15, P149, DOI 10.1016/0300-9572(87)90012-8; KAWAI K, 1992, J CEREBR BLOOD F MET, V12, P238, DOI 10.1038/jcbfm.1992.34; KIRINO T, 1985, PROG BRAIN RES, V63, P39; KIRKNESS EF, 1989, TRENDS PHARMACOL SCI, V10, P6, DOI 10.1016/0165-6147(89)90091-6; KOGURE K, 1988, NEUROCHEM PATHOL, V9, P145; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; KORNEYEV A, 1993, J NEUROCHEM, V61, P2041, DOI 10.1111/j.1471-4159.1993.tb07440.x; KRAUSE GS, 1988, CRIT CARE MED, V16, P714, DOI 10.1097/00003246-198807000-00015; KUBLIGARFIAS C, 1976, BRAIN RES, V114, P71, DOI 10.1016/0006-8993(76)91008-8; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165-6147(00)89058-6; LEPEILLET E, 1992, BRAIN RES, V571, P115; LI H, 1993, J CEREBR BLOOD F MET, V13, P933, DOI 10.1038/jcbfm.1993.116; LUNA LG, 1960, MANUAL HISTOLOGIC ST, P185; LYDEN PD, 1994, STROKE, V25, P189, DOI 10.1161/01.STR.25.1.189; Lyden PD, 1997, INT REV NEUROBIOL, V40, P233; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MAKER HS, 1986, NEUROPHARMACOLOGY, V25, P25, DOI 10.1016/0028-3908(86)90054-7; MCGEER PL, 1975, BRAIN RES, V91, P331, DOI 10.1016/0006-8993(75)90558-2; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MORDECAI Y-T, 1991, Stroke, V22, P128; NITSCH C, 1988, BRAIN RES, V461, P127, DOI 10.1016/0006-8993(88)90731-7; POIRIER LJ, 1983, BRAIN RES BULL, V11, P371, DOI 10.1016/0361-9230(83)90173-9; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RAICHLE ME, 1983, ANN NEUROL, V13, P2, DOI 10.1002/ana.410130103; RIBAK CE, 1979, J COMP NEUROL, V187, P261, DOI 10.1002/cne.901870203; Roine R.O., 1997, CURRENT REV CEREBROV, P159; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SAJI M, 1993, NEUROSCI LETT, V155, P47, DOI 10.1016/0304-3940(93)90670-G; SAJI M, 1994, BRAIN RES, V643, P234, DOI 10.1016/0006-8993(94)90030-2; Sarraf-Yazdi S, 1999, NEUROL DIS, V48, P243; SCHWARTZ RD, 1995, J NEUROSCI, V15, P529; SHUAIB A, 1992, BRAIN RES, V590, P13, DOI 10.1016/0006-8993(92)91076-Q; SHUAIB A, 1993, EXP NEUROL, V123, P284, DOI 10.1006/exnr.1993.1160; SHUAIB A, 1995, NEUROSCI LETT, V197, P109, DOI 10.1016/0304-3940(95)11934-O; Siegel S., 1956, NONPARAMETRIC STAT B; SIESJO BK, 1995, J NEUROSURG ANESTH, V7, P47, DOI 10.1097/00008506-199501000-00009; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SLIVKA A, 1988, J NEUROCHEM, V50, P1714, DOI 10.1111/j.1471-4159.1988.tb02468.x; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; SNIDER RS, 1961, STEREOTAXIC ATLAS CA; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; STERNAU LL, 1989, STROKE, V20, P281, DOI 10.1161/01.STR.20.2.281; TATEISHI A, 1989, STROKE, V20, P1044, DOI 10.1161/01.STR.20.8.1044; TODD MM, 1982, ANESTHESIOLOGY, V57, P76, DOI 10.1097/00000542-198208000-00003; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; VONLUBITZ DKEJ, 1989, NEUROSCIENCE, V30, P451, DOI 10.1016/0306-4522(89)90265-0; WHITE BC, 1993, NEUROLOGY, V43, P1656, DOI 10.1212/WNL.43.9.1656; WIELOCH T, 1985, PROG BRAIN RES, V63, P69; Yamada K, 1996, BRAIN RES, V743, P233, DOI 10.1016/S0006-8993(96)01052-9	90	94	97	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0188-4409	1873-5487		ARCH MED RES	Arch. Med. Res.	JAN-FEB	2002	33	1					6	14	PII S0188-4409(01)00347-2	10.1016/S0188-4409(01)00347-2			9	Medicine, Research & Experimental	Research & Experimental Medicine	524DQ	WOS:000173997200002	11825624				2021-06-18	
J	Oishi, M; Toyama, M; Tamatani, S; Kitazawa, T; Saito, M				Oishi, M; Toyama, M; Tamatani, S; Kitazawa, T; Saito, M			Clinical factors of recurrent chronic subdural hematoma	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						chronic subdural hematoma; recurrence; clinical review; computed tomography; burr hole surgery	CLOSED-SYSTEM DRAINAGE; CRANIOSTOMY	The clinical, radiological, and operative factors of recurrent chronic subdural hematoma (CSDH) were retrospectively analyzed in 116 patients with CSDH in 134 hemispheres, treated by one burr hole surgery. The correlation of recurrence was evaluated with personal and clinical factors such as age, sex, history of head injury, and interval from onset of initial symptoms to hospitalization; laboratory findings such as bleeding tendency and liver function; computed tomography (CT) findings such as hematoma density and brain atrophy; and operative findings such as additional procedures and postoperative residual air. The recurrence group (RG) included 10 hemispheres (7.5%) in 10 patients (8.6%). The interval from onset of symptoms to hospitalization was significantly shorter in the RG than in the non-recurrence group (NRG). Headache was more frequently seen in the RG than in the NRG. Density of hematoma on CT was classified into five types: Low, iso, and high density, niveau, and mixed, and the incidence of recurrence was 0%, 2.3%, 17.2%, 12.5%, and 6.5%, respectively. Larger amounts of residual air in the postoperative hematoma cavity were associated with recurrence of CSDH. CSDH that progresses rapidly in the acute stage and appears as high density on preoperative CT is associated with a high incidence of recurrence. Intraoperative air invasion to the hematoma cavity should be avoided to prevent recurrence.	Nagaoka Red Cross Hosp, Dept Neurosurg, Nagaoka, Niigata, Japan	Oishi, M (corresponding author), Natl Nishi Niigata Chuo Hosp, Dept Neurosurg, Niigata, Japan.						ARBIT E, 1981, SURG NEUROL, V15, P175, DOI 10.1016/0090-3019(81)90133-6; Asano Y, 1992, No To Shinkei, V44, P827; CAMEL M, 1986, J NEUROSURG, V65, P183, DOI 10.3171/jns.1986.65.2.0183; Ernestus RI, 1997, SURG NEUROL, V48, P220, DOI 10.1016/S0090-3019(97)80031-6; Fukuhara T, 1996, SURG NEUROL, V45, P570, DOI 10.1016/0090-3019(95)00471-8; HAMILTON MG, 1993, NEUROSURGERY, V33, P67; ITO H, 1978, J NEUROSURG, V48, P197, DOI 10.3171/jns.1978.48.2.0197; LAUMER R, 1989, NEUROSURGERY, V25, P991, DOI 10.1227/00006123-198912000-00026; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; NAGATA K, 1989, Neurological Surgery, V17, P15; NAGATA K, 1988, Neurological Surgery, V16, P1347; OKU Y, 1984, J NEUROSURG, V61, P269, DOI 10.3171/jns.1984.61.2.0269; ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263; SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311; Suzuki K, 1998, SURG NEUROL, V50, P231, DOI 10.1016/S0090-3019(97)00339-X; Takahashi Yoshihiko, 1996, Neurologia Medico-Chirurgica, V36, P627, DOI 10.2176/nmc.36.627; Tsutsumi K, 1997, J NEUROSURG, V87, P870, DOI 10.3171/jns.1997.87.6.0870; WAKAI S, 1990, NEUROSURGERY, V26, P771, DOI 10.1227/00006123-199005000-00006; YOSHII K, 1987, Neurological Surgery, V15, P1065	20	94	103	0	5	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	AUG	2001	41	8					382	386		10.2176/nmc.41.382			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	462FX	WOS:000170411000004	11561348	Bronze			2021-06-18	
J	Rapport, LJ; Hanks, RA; Millis, SR; Deshpande, SA				Rapport, LJ; Hanks, RA; Millis, SR; Deshpande, SA			Executive functioning and predictors of falls in the rehabilitation setting	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; COMA; BIAS	Objective: To examine the incremental utility of executive function tests in the prediction of inpatient falls. Design: Evaluation of neuropsychologic and medical risk factors for fall was completed at admission. Inpatient falls were tabulated following discharge. Setting: A freestanding, urban rehabilitation hospital. Patients: Ninety consecutive admissions to traumatic brain injury, orthopedic, and spinal cord injury wards. Age of the participants ranged from 17 to 73 years old. Main Outcome Measure: Incident reports of inpatient falls. Results: Standard multiple regression analyses indicated that measures of executive functioning sensitive to self-monitoring accounted for unique variance in falls beyond that explained by age and functional motor ability as assessed by the Functional Independence Measure. Visuospatial functioning, although not directly related to falls, was a significant predictor in combination with measures of executive functioning. Together, these variables accounted for 30.3% of the variance in inpatient falls (multiple r = .55; p < .001). Conclusion: The findings suggest that the influence of motor and sensory impairments on falls are moderated, in part, by executive functioning. Patients with intact executive functioning are less likely to act in ways that could result in a fall; thus, aggressive fall prevention measures may be unnecessary. In contrast, executive dysfunction may signal the need for intervention, even among patients whose profiles are unremarkable with regard to traditional risk factors for fall. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Rehabil Inst Michigan, Dept Rehabil Psychol & Neurophychol, Detroit, MI USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.						Baker S P, 1985, Clin Geriatr Med, V1, P501; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Cummings JL, 1985, CLIN NEUROPSYCHIATRY; FLETCHER KR, 1990, RN               JAN, P52; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; Grant J S, 1987, Rehabil Nurs, V12, P74; Heaton R. K., 1982, MANUAL CARD SORTING; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Luria, 1973, WORKING BRAIN INTRO; Millis S R, 1994, Int J Neurosci, V79, P165; Mion L C, 1989, Rehabil Nurs, V14, P17; Moore CA, 1996, REHABIL PSYCHOL, V41, P115; MORGAN VR, 1985, AM J PUBLIC HEALTH, V75, P775, DOI 10.2105/AJPH.75.7.775; Nanna MJ, 1997, J APPL GERONTOL, V16, P120, DOI 10.1177/073346489701600107; Paolucci S, 1996, EUR NEUROL, V36, P385, DOI 10.1159/000117298; Persad C. C., 1995, J GERONTOL B-PSYCHOL, V50, P272, DOI 10.1093/geronb/50B.5.P272.; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; RAPPORT LJ, 1995, CLIN NEUROPSYCHOL, V9, P169, DOI 10.1080/13854049508401599; ROBB SS, 1986, NURS RES, V35, P113; Rubenstein LZ, 1996, CLIN GERIATR MED, V12, P881; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; SEIDEL GK, 1994, ARCH PHYS MED REHAB, V75, P590; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stuss D.T., 1986, FRONTAL LOBES; Tabachnick BG, 2013, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; TUFFNELL C, 1990, World Health Forum, V11, P282; *UN DAT SYST MED R, 1993, UN DAT SYST FUNC DEP; VLAHOV D, 1990, ARCH PHYS MED REHAB, V71, P8; WEBSTER JS, 1995, ARCH PHYS MED REHAB, V76, P924, DOI 10.1016/S0003-9993(95)80068-9; WEBSTER JS, 1994, J CLIN EXP NEUROPSYC, V16, P129, DOI 10.1080/01688639408402623; WESCHLER D, 1987, WECHSLER MEMORY SCAL; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889; Wolfson L I, 1985, Clin Geriatr Med, V1, P649	41	94	94	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1998	79	6					629	633		10.1016/S0003-9993(98)90035-1			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZT554	WOS:000074099500005	9630140				2021-06-18	
J	Dixon, CE; Markgraf, CG; Angileri, F; Pike, BR; Wolfson, B; Newcomb, JK; Bismar, MM; Blanco, AJ; Clifton, GL; Hayes, RL				Dixon, CE; Markgraf, CG; Angileri, F; Pike, BR; Wolfson, B; Newcomb, JK; Bismar, MM; Blanco, AJ; Clifton, GL; Hayes, RL			Protective effects of moderate hypothermia on behavioral deficits but not necrotic cavitation following cortical impact injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; traumatic brain injury; behavior; Morris water maze; rat	TRAUMATIC BRAIN INJURY; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; HIPPOCAMPAL-LESIONS; DAMAGE; MEMORY; IMPAIRMENT; GLUTAMATE; MODEL; MOTOR	A number of experimental studies have reported that moderate hypothermia can produce significant protection against behavioral deficits and/or morphopathological alterations following traumatic brain injury; a Phase 3 clinical trial is currently examining the therapeutic potential for moderate hypothermia (32 degrees C) to improve outcome following severe traumatic brain injury in humans. The current study examined whether hypothermia (32 degrees C) provided behavioral protection following experimental cortical impact injury. The extent of focal cortical contusion was also examined in the same rats. A total of 30 male Sprague-Dawley rats were trained on beam balance and beam walking tasks prior to injury. Under isoflurane anesthesia, cortical impact was produced on the right parietal cortex of 20 rats. Ten rats underwent all surgical procedures but were not impacted (sham-injured rats). Ten of the injured rats were cooled to 32 degrees C (measured in temporalis muscle) beginning 5 min postinjury, maintained for 2 h and rewarmed slowly for 1 h. In the other 10 injured rats, normothermic temperatures (37.5 degrees C) were maintained for the same duration. Beam balance and beam walking performance was assessed daily for 5 days following injury. At 11 days postinjury, rats were assessed for 5 days on acquisition of the Morris water maze task. Following behavioral assessments, rats were perfused and the brain removed. Coronal sections were cut through the site of cortical impact injury and stained with hematoxylin and eosin. Hypothermic treatment resulted in significantly less beam balance and beam walking deficits than observed in normothermic rats. Hypothermia also significantly attenuated spatial memory performance deficits. Quantitative morphometric analyses failed to detect any significant differences in volumes of necrotic tissue cavitation in cortices of hypothermic and normothermic rats. Hypothermic treatment also had no effect on volumes of dorsal hippocampal tissue or numbers of cells in CA1 or CA3 regions of the hippocampus. These data suggest that hypothermia, consistent with the reports of others, can produce significant behavioral protection following cortical impact injury that is not necessarily correlated with changes in focal cortical necrosis within the first 15 days following injury.	Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX 77030 USA; Univ Pittsburgh, Div Neurosurg, Pittsburgh, PA 15260 USA	Hayes, RL (corresponding author), Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, 6431 Fannin,Suite 7-154, Houston, TX 77030 USA.		Angileri, Filippo Flavio/J-3533-2012; Angileri, Filippo/N-8556-2019; Angileri, Filippo/AAL-4851-2021	Angileri, Filippo Flavio/0000-0002-1107-4115; Angileri, Filippo/0000-0002-1107-4115; 			BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1996, NEUROTRAUMA; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1995, P SOC NEUR ANN M SOC, V21, P762; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GENNARELLI TA, 1990, ENHANCEMENT AXONAL D; GENNARELLI TA, 1992, J NEUROTRAUM, V9, P60; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P318; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MEANEY DF, 1992, J NEUROTRAUMA, V9, P393; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; MOSER E, 1993, J NEUROSCI, V13, P3916; Nakamura Michio, 1995, Brain and Nerve (Tokyo), V47, P484; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101	45	94	98	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1998	15	2					95	103		10.1089/neu.1998.15.95			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YZ744	WOS:000072287300001	9512085				2021-06-18	
J	Bleiberg, J; Garmoe, WS; Halpern, EL; Reeves, DL; Nadler, JD				Bleiberg, J; Garmoe, WS; Halpern, EL; Reeves, DL; Nadler, JD			Consistency of within-day and across-day performance after mild brain injury	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						mild TBI; variability; ANAM; sustained performance	REACTION-TIME; HEAD-INJURY	The objective of this study was to determine whether inconsistent and erratic within-day and across-day performance is a symptom of mild to moderate traumatic brain injury (TBI), and to determine whether impaired consistency of performance can coexist, in the same patient, with intact or ''normal'' performance on single administrations of neuropsychological and other cognitive tests. The design was a matched-pair study in which a computerized cognitive test battery was administered 30 times over 4 days to all subjects. Performance patterns between TBI and control subjects were compared. Subjects also received traditional neuropsychological testing. The setting was a rehabilitation hospital outpatient department. The subjects were 12 adult volunteers, six with documented TBI and six with no history of TBI, neurologic illness, or injury. Control subjects showed consistent improvement of performance over days 1 to 4, whereas subjects with TBI showed erratic and inconsistent performance across days. In addition to inconsistent performance, some subjects with TBI showed worsening performance across days. The main outcome measures were performance on the Automated Neuropsychological Assessment Metrics (ANAM) battery and performance on traditional neuropsychological tests. Some patients with TBI in the study who have normal initial performance on traditional clinical neuropsychological tests and newly developed computerized cognitive tests show abnormalities of sustained performance. Such abnormalities are most apparent when performance is observed over multiple days, and are characterized by erratic and inconsistent across-day performance. Inconsistent performance was observed even in those subjects with TBI whose initial performance was equal to or better than that of the control subjects. Deficits in dynamic performance may explain why some patients with TBI who have excellent neuropsychological test performance nonetheless complain of functional decrement from premorbid ability.	MEDLANT RES INST, WASHINGTON, DC USA; USN, MED CTR, SAN DIEGO, CA 92152 USA; FLORIDA HOSP MED CTR, ORLANDO, FL 32803 USA	Bleiberg, J (corresponding author), NATL REHABIL HOSP, PSYCHOL SERV, MEDLANT RES INST, 102 IRVING ST NW, WASHINGTON, DC 20010 USA.						Benton AL, 1978, MULTILINGUAL APHASIA; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; CULLUM CM, 1991, FORENSIC NEUROPSYCHO; DELIS C, 1987, CALIFORNIA VERBAL LE; Golden C., 1978, STROOP COLOR WORD TE; GRONWALL D, 1974, LANCET, V2, P1452; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Hall HV, 1996, DETECTING MALINGERIN; Head H., 1926, APHASIA KINDRED DISO; Jastak S, 1984, WIDE RANGE ACHIEVEME; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KAY T, 1992, REHABILITATION POST, P109; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; REEVES D, 1989, UNITED TRISERVICE CO; Reitan RM., 1985, HALSTEAD REITAN NEUR; RUFF RM, 1987, NEUROBEHAVIORAL RECO, P176; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; THORNE DR, 1991, THROUGHPUT SIMPLE RA; VANZOMEREN AH, 1989, NEUROBEHAVIORAL RECO, P398; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	24	94	94	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	OCT	1997	10	4					247	253					7	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	YD472	WOS:A1997YD47200005	9359122				2021-06-18	
J	Kraus, MF; Maki, PM				Kraus, MF; Maki, PM			Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							ALZHEIMERS-DISEASE; CEREBRAL-CORTEX; FLUENCY TEST; DEMENTIA; THERAPY; EPILEPSY; PROFILE; PATIENT; MILD; PET	Symptoms consistent with dysfunction of the frontal lobes can occur following traumatic brain injury (TBI) or other types of acquired brain injury (stroke, aneurysm). These symptoms can include problems with short-term memory, attention, planning, problem solving, impulsivity, disinhibition, poor motivation, and other behavioral and cognitive deficits (''frontal lobe syndrome''). These symptoms may respond to certain drugs, such as dopaminergic agents. This case series describes results of using amantadine in 7 patients with this type of symptom profile (6 with TBI, 1 with meningitis following sinus surgery). Patients received neuropsychiatric examinations and serial neuropsychological testing. All patients showed some degree of positive response. One had side effects that resolved upon discontinuation of drug. The rationale for using dopaminergics is discussed, and pertinent literature is reviewed.	JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA			Maki, Pauline/AAF-1554-2021	Maki, Pauline/0000-0002-8443-3430	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00149] Funding Source: Medline		ALBERT M, 1992, J AM GERIATR SOC, V40, P449, DOI 10.1111/j.1532-5415.1992.tb02009.x; ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; BROWN RM, 1979, BRAIN RES, V168, P133, DOI 10.1016/0006-8993(79)90132-X; DRAKE ME, 1991, ACTA NEUROL BELG, V91, P159; ERKULWATER S, 1989, SOUTHERN MED J, V82, P550, DOI 10.1097/00007611-198905000-00004; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Halstead WC, 1985, HALSTEAD REITAN NEUR; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MORYL E, 1993, PHARMACOL TOXICOL, V72, P394, DOI 10.1111/j.1600-0773.1993.tb01351.x; MULLER HF, 1979, J AM GERIATR SOC, V27, P9; MURRAY TJ, 1985, CAN J NEUROL SCI, V12, P251, DOI 10.1017/S0317167100047107; *NATL I NEUR DIS S, 1989, INT HEAD INJ TASK FO; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; SCHRETLEN D, 1989, BRIEF TEST ATTENTION; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; SEMLITSCH HV, 1992, J NEURAL TRANSM-PARK, V4, P319, DOI 10.1007/BF02260080; SHAHAR EM, 1992, J PEDIATR-US, V121, P819, DOI 10.1016/S0022-3476(05)81922-5; Suitsu N, 1992, Seishin Shinkeigaku Zasshi, V94, P238; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; WARKENTIN S, 1993, DEMENTIA, V4, P188, DOI 10.1159/000107322; Wechsler D., 1987, WECHSLER MEMORY SCAL; WELLER M, 1992, MED HYPOTHESES, V38, P329, DOI 10.1016/0306-9877(92)90027-A; WOLFE N, 1990, J NEUROL NEUROSUR PS, V53, P915, DOI 10.1136/jnnp.53.10.915	39	94	98	0	7	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	1997	9	2					222	230					9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	WX311	WOS:A1997WX31100004	9144101				2021-06-18	
J	Zafonte, RD; Hammond, FM; Mann, NR; Wood, DL; Black, KL; Millis, SR				Zafonte, RD; Hammond, FM; Mann, NR; Wood, DL; Black, KL; Millis, SR			Relationship between Glasgow Coma Scale and functional outcome	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Glasgow Coma Scaler; trauma; head injury outcome	SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; PREDICTION; RECOVERY; PROGNOSIS; TRAUMA; REHABILITATION; PRESSURE	The Glasgow Coma Scale (GCS) is routinely used in the acute care setting after traumatic brain injury (TBI) to guide decisions in triage, based on its ability to predict morbidity and mortality. Although the CCS has been previously demonstrated to predict mortality, efficacy in prediction of functional outcome has not been I established, The purpose of this study was to assess the value of the acute GCS in predicting functional outcome in survivors of TBI. This study used the Multicenter National Institute on Disability and Rehabilitation Research TBI Model Systems database of 501 patients who had received acute medical care and inpatient rehabilitation within a coordinated neurotrauma program for treatment of TBI. Initial and lowest 24 hr GCS scores were correlated with the following outcome measures: the Disability Rating Scale (DRS), Rancho Los Amigos Levels of Cognitive Functioning Scale (LCFS), and cognitive and motor components of the Functional independence Measure (FIM(SM)-COG and FIM(SM)-M). Outcome data were collected at admission to and discharge from the inpatient TBI rehabilitation unit, Correlation analysis revealed only modest, but statistically significant, relationships between initial and lowest GCS scores and outcome variables. Initial and lowest GCS score comparison with outcome demonstrated the following correlation coefficients; admission DRS, -0.25 and -0.28; discharge DRS, -0.24 and -0.24; admission LCFS, 0.31 and 0.33; discharge LCFS, 0.27 and 0.25; admission FIM-COG, 0.36 and 0.37; discharge FIM-COG, 0.23 and 0.23; admission FIM-M, 0.31 and 0.31; discharge FIM-M, 0.25 and 0.21. The GCS as a single Variable may have limited value as a predictor of functional outcome.	WAYNE STATE UNIV,SCH MED,DETROIT,MI	Zafonte, RD (corresponding author), REHABIL INST MICHIGAN,PHYSICIAN SERV,261 MACK BLVD,DETROIT,MI 48201, USA.						CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FACCO E, 1986, CHILD NERV SYST, V2, P67; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; IMES C, 1983, COGNITIVE REHABILITA, V1, P11; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; *STAT U NEW YORK B, 1990, GUID US UN DAT SET M; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1991, ANN NY ACAD SCI, P82; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140	26	94	98	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP-OCT	1996	75	5					364	369		10.1097/00002060-199609000-00012			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	VP517	WOS:A1996VP51700009	8873704				2021-06-18	
J	Geisler, S; Doan, RA; Strickland, A; Huang, X; Milbrandt, J; DiAntonio, A				Geisler, Stefanie; Doan, Ryan A.; Strickland, Amy; Huang, Xin; Milbrandt, Jeffrey; DiAntonio, Aaron			Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice	BRAIN			English	Article						SARM1; axonal degeneration; chemotherapy-induced peripheral neuropathy; vincristine; CIPN	SPINAL DORSAL-HORN; QUALITY-OF-LIFE; WALLERIAN DEGENERATION; NEUROPROTECTIVE EFFICACY; LYMPHOBLASTIC-LEUKEMIA; AMINOPROPYL CARBAZOLES; AXONAL DEGENERATION; SELF-DESTRUCTION; MOUSE MODEL; CHEMOTHERAPY	Peripheral polyneuropathy is a common and dose-limiting side effect of many important chemotherapeutic agents. Most such neuropathies are characterized by early axonal degeneration, yet therapies that inhibit this axonal destruction process do not currently exist. Recently, we and others discovered that genetic deletion of SARM1 (sterile alpha and TIR motif containing protein 1) dramatically protects axons from degeneration after axotomy in mice. This finding fuels hope that inhibition of SARM1 or its downstream components can be used therapeutically in patients threatened by axonal loss. However, axon loss in most neuropathies, including chemotherapy-induced peripheral neuropathy, is the result of subacute/chronic processes that may be regulated differently than the acute, one time insult of axotomy. Here we evaluate if genetic deletion of SARM1 decreases axonal degeneration in a mouse model of neuropathy induced by the chemotherapeutic agent vincristine. In wild-type mice, 4 weeks of twice-weekly intraperitoneal injections of 1.5 mg/kg vincristine cause pronounced mechanical and heat hyperalgesia, a significant decrease in tail compound nerve action potential amplitude, loss of intraepidermal nerve fibres and significant degeneration of myelinated axons in both the distal sural nerve and nerves of the toe. Neither the proximal sural nerve nor the motor tibial nerve exhibit axon loss. These findings are consistent with the development of a distal, sensory predominant axonal polyneuropathy that mimics vincristine-induced peripheral polyneuropathy in humans. Using the same regimen of vincristine treatment in SARM1 knockout mice, the development of mechanical and heat hyperalgesia is blocked and the loss in tail compound nerve action potential amplitude is prevented. Moreover, SARM1 knockout mice do not lose unmyelinated fibres in the skin or myelinated axons in the sural nerve and toe after vincristine. Hence, genetic deletion of SARM1 blocks the development of vincristine-induced peripheral polyneuropathy in mice. Our results reveal that subacute/chronic axon loss induced by vincristine occurs via a SARM1 mediated axonal destruction pathway, and that blocking this pathway prevents the development of vincristine-induced peripheral polyneuropathy. These findings, in conjunction with previous studies with axotomy and traumatic brain injury, establish SARM1 as the central determinant of a fundamental axonal degeneration pathway that is activated by diverse insults. We suggest that targeting SARM1 or its downstream effectors may be a viable therapeutic option to prevent vincristine-induced peripheral polyneuropathy and possibly other peripheral polyneuropathies.	[Geisler, Stefanie; Doan, Ryan A.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Strickland, Amy; Huang, Xin; Milbrandt, Jeffrey] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Milbrandt, Jeffrey; DiAntonio, Aaron] Washington Univ, Sch Med, Hope Ctr Neurol Dis, St Louis, MO 63130 USA; [DiAntonio, Aaron] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO USA	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.; Milbrandt, J (corresponding author), Washington Univ, Sch Med, Hope Ctr Neurol Dis, St Louis, MO 63130 USA.; DiAntonio, A (corresponding author), Washington Univ, Sch Med, 4523 Clayton Ave CB 8103, St Louis, MO 63110 USA.	jmilbrandt@wustl.edu; diantonio@wustl.edu		Doan, Ryan/0000-0002-6944-3921; Milbrandt, Jeffrey/0000-0002-5477-7689	American Brain Foundation; Foundation for Barnes Jewish Hospital Cancer Frontier Fund; Siteman Cancer Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS087632]; Children's Discovery Institute;  [K08NS091448]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS091448, R01NS087632] Funding Source: NIH RePORTER	This study was funded by a Clinical Research Training Fellowship from the American Brain Foundation and K08NS091448 to S.G., a Foundation for Barnes Jewish Hospital Cancer Frontier Fund and Siteman Cancer Center grant to A.D. and J.M., the NIH NS087632 to J.M. and A.D and a microgrant from the Children's Discovery Institute to A.D.	Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Argyriou AA, 2014, CANCER MANAG RES, V6, P135, DOI 10.2147/CMAR.S44261; Authier N, 2003, NEUROTOXICOLOGY, V24, P797, DOI 10.1016/S0161-813X(03)00043-3; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Boehmerle W, 2014, SCI REP-UK, V4, DOI 10.1038/srep06370; Boyette-Davis JA, 2013, CANCER CHEMOTH PHARM, V71, P619, DOI 10.1007/s00280-012-2047-z; BRADLEY WG, 1970, J NEUROL SCI, V10, P107, DOI 10.1016/0022-510X(70)90013-4; Bruna J, 2011, J PERIPHER NERV SYST, V16, P199, DOI 10.1111/j.1529-8027.2011.00346.x; Carozzi VA, 2015, NEUROSCI LETT, V596, P90, DOI 10.1016/j.neulet.2014.10.014; CASEY EB, 1973, BRAIN, V96, P69, DOI 10.1093/brain/96.1.69; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chaudhry V, 2003, NEUROLOGY, V60, P337, DOI 10.1212/01.WNL.0000043691.53710.53; Chen CY, 2011, J CELL BIOL, V193, P769, DOI 10.1083/jcb.201008050; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Costa TC, 2015, REV ESC ENFERM USP, V49, P332, DOI 10.1590/S0080-623420150000200020; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; DEANGELIS LM, 1991, CANCER-AM CANCER SOC, V67, P2241, DOI 10.1002/1097-0142(19910501)67:9<2241::AID-CNCR2820670905>3.0.CO;2-A; Diouf B, 2015, JAMA-J AM MED ASSOC, V313, P815, DOI 10.1001/jama.2015.0894; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Ebenezer GJ, 2007, BRAIN, V130, P2703, DOI 10.1093/brain/awm199; Ezendam NPM, 2014, GYNECOL ONCOL, V135, P510, DOI 10.1016/j.ygyno.2014.09.016; Gerdts J, 2016, NEURON, V89, P449, DOI 10.1016/j.neuron.2015.12.023; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Gilley J, 2015, CELL REP, V10, P1974, DOI 10.1016/j.celrep.2015.02.060; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; GOTTSCHALK PG, 1968, NEUROLOGY, V18, P875; GUIHENEUC P, 1980, J NEUROL SCI, V45, P355, DOI 10.1016/0022-510X(80)90179-3; HAIM N, 1994, CANCER, V73, P2515, DOI 10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; HIMES RH, 1976, CANCER RES, V36, P3798; Jongen JLM, 2015, J NEURO-ONCOL, V121, P229, DOI 10.1007/s11060-014-1632-x; Kamei J, 2005, PAIN, V117, P112, DOI 10.1016/j.pain.2005.05.026; Kim YH, 2007, J EXP MED, V204, P2063, DOI 10.1084/jem.20070868; LaPointe NE, 2013, NEUROTOXICOLOGY, V37, P231, DOI 10.1016/j.neuro.2013.05.008; Smith EM, 2015, J PERIPHER NERV SYST, V20, P37, DOI 10.1111/jns.12114; Liew E, 2013, LEUKEMIA RES, V37, P1632, DOI 10.1016/j.leukres.2013.09.018; Lin CW, 2014, BRAIN BEHAV IMMUN, V37, P142, DOI 10.1016/j.bbi.2013.12.002; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Massoll C, 2013, INVEST OPHTH VIS SCI, V54, P2771, DOI 10.1167/iovs.12-10973; Milde S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001539; MORESS GR, 1967, ARCH NEUROL-CHICAGO, V16, P377, DOI 10.1001/archneur.1967.00470220041005; Ness KK, 2013, ARCH PHYS MED REHAB, V94, P1451, DOI 10.1016/j.apmr.2013.03.009; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; OWELLEN RJ, 1976, CANCER RES, V36, P1499; Reinders-Messelink H A, 2000, Eur J Paediatr Neurol, V4, P225, DOI 10.1053/ejpn.1999.0310; Saika F, 2009, BIOL PHARM BULL, V32, P1231, DOI 10.1248/bpb.32.1231; SANDLER SG, 1969, NEUROLOGY, V19, P367, DOI 10.1212/WNL.19.4.367; Shen Y, 2015, NEUROBIOL DIS, V79, P100, DOI 10.1016/j.nbd.2015.04.012; Siau C, 2006, EXP NEUROL, V201, P507, DOI 10.1016/j.expneurol.2006.05.007; Szretter KJ, 2009, J VIROL, V83, P9329, DOI 10.1128/JVI.00836-09; Tanner KD, 2003, NEUROSCIENCE, V118, P809, DOI 10.1016/S0306-4522(03)00023-X; Tanner KD, 1998, J NEUROSCI, V18, P6480; Tanner KD, 1998, J COMP NEUROL, V424, P563; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Thibault K, 2013, J MOL NEUROSCI, V51, P880, DOI 10.1007/s12031-013-0095-4; Topp KS, 2000, J COMP NEUROL, V424, P563; Uceyler N, 2016, MUSCLE NERVE; Verstappen CCP, 2005, NEUROLOGY, V64, P1076, DOI 10.1212/01.WNL.0000154642.45474.28; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Wang MS, 2001, ANN NEUROL, V50, P773, DOI 10.1002/ana.10039; Wang MS, 2002, ANN NEUROL, V52, P442, DOI 10.1002/ana.10300; Weng HR, 2003, PAIN, V103, P131, DOI 10.1016/S0304-3959(02)00445-1; Wu G, 2002, J NEUROSCI, V22, P7746; Wu G, 2001, J NEUROSCI, V21; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030	69	93	94	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	DEC	2016	139		12				3092	3108		10.1093/brain/aww251			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EI7US	WOS:000392709800013	27797810	Bronze, Green Published			2021-06-18	
J	Chiu, CC; Liao, YE; Yang, LY; Wang, JY; Tweedie, D; Karnati, HK; Greig, NH; Wang, JY				Chiu, Chong-Chi; Liao, Yi-En; Yang, Ling-Yu; Wang, Jing-Ya; Tweedie, David; Karnati, Hanuma K.; Greig, Nigel H.; Wang, Jia-Yi			Neuroinflammation in animal models of traumatic brain injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury (TBI); Neuroinflammation; Glia cells; Astrocytes; Microglia; Controlled cortical impact; Weight-drop impact; Lateralfluid percussion; Measurements evaluating neuroinflammation	NECROSIS-FACTOR-ALPHA; CONTROLLED CORTICAL IMPACT; PEPTIDE-1 RECEPTOR AGONIST; FLUID PERCUSSION INJURY; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; SIGNALING PATHWAY; OXIDATIVE STRESS; GENE-EXPRESSION; CEREBRAL-CORTEX	Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide. Neuroinflammation is prominent in the short and long-term consequences of neuronal injuries that occur after TBI. Neuroinflammation involves the activation of glia, including microglia and astrocytes, to release inflammatory mediators within the brain, and the subsequent recruitment of peripheral immune cells. Various animal models of TBI have been developed that have proved valuable to elucidate the pathophysiology of the disorder and to assess the safety and efficacy of novel therapies prior to clinical trials. These models provide an excellent platform to delineate key injury mechanisms that associate with types of injury (concussion, contusion, and penetration injuries) that occur clinically for the investigation of mild, moderate, and severe forms of TBI. Additionally, TBI modeling in genetically engineered mice, in particular, has aided the identification of key molecules and pathways for putative injury mechanisms, as targets for development of novel therapies for human TBI. This Review details the evidence showing that neuroinflammation, characterized by the activation of microglia and astrocytes and elevated production of inflammatory mediators, is a critical process occurring in various TBI animal models, provides a broad overview of commonly used animal models of TBI, and overviews representative techniques to quantify markers of the brain inflammatory process. A better understanding of neuroinflammation could open therapeutic avenues for abrogation of secondary cell death and behavioral symptoms that may mediate the progression of TBI. (C) 2016 Elsevier B.V. All rights reserved.	[Chiu, Chong-Chi] Chi Mei Med Ctr, Dept Gen Surg, Tainan, Taiwan; [Chiu, Chong-Chi] Chi Mei Med Ctr, Dept Gen Surg, Liouying, Taiwan; [Liao, Yi-En] Taipei Med Univ, Sch Pharm, Coll Pharm, Taipei, Taiwan; [Yang, Ling-Yu; Wang, Jing-Ya; Wang, Jia-Yi] Taipei Med Univ, Grad Inst Med Sci, Coll Med, 250 Wu Xing St, Taipei 110, Taiwan; [Tweedie, David; Karnati, Hanuma K.; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Wang, Jia-Yi] Taipei Med Univ, Sch Med, Dept Physiol, Coll Med, Taipei, Taiwan	Wang, JY (corresponding author), Taipei Med Univ, Grad Inst Med Sci, Coll Med, 250 Wu Xing St, Taipei 110, Taiwan.	jywang2010@tmu.edu.tw	karnati, Hanuma kumar/ABH-8371-2020; Karnati, Hanuma kumar/V-2002-2019	karnati, Hanuma kumar/0000-0002-1259-6900; Wang, Jia-Yi/0000-0002-9106-3351	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST104-2923-B-038-001-MY3]; Chi Mei Medical Center, Tainan and Liouying, Taiwan [100CM-TMU-05]; Intramural Research Program of the National Institute on Aging, NIH, Baltimore, MD, USA; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000994] Funding Source: NIH RePORTER	This study was supported in part by (i) a grant (MOST104-2923-B-038-001-MY3) from the Ministry of Science and Technology, Taiwan; (ii) a grant (100CM-TMU-05) from Chi Mei Medical Center, Tainan and Liouying, Taiwan; and (iii) the Intramural Research Program of the National Institute on Aging, NIH, Baltimore, MD, USA.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Bar-Or D, 2015, REDOX BIOL, V4, P340, DOI 10.1016/j.redox.2015.01.006; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; Deselms H., 2016, J NEUROSCI METHODS; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dong XQ, 2011, INFLAMM RES, V60, P533, DOI 10.1007/s00011-010-0300-7; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Du YZ, 2002, J NEUROSCI RES, V68, P647, DOI 10.1002/jnr.10245; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Galgano M., 2015, J NEUROL NEUROBIOL, V2; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gervasi NM, 2008, REGEN MED, V3, P907, DOI 10.2217/17460751.3.6.907; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Gunther M, 2012, ACTA NEUROCHIR, V154, P689, DOI 10.1007/s00701-012-1297-1; Gurung P, 2015, TRENDS MOL MED, V21, P193, DOI 10.1016/j.molmed.2014.11.008; Haneklaus M, 2015, IMMUNOL REV, V265, P53, DOI 10.1111/imr.12285; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; He YL, 2012, BRAIN RES, V1433, P127, DOI 10.1016/j.brainres.2011.11.027; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Jin W, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/502564; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Jung CS, 2014, INT J MOL SCI, V15, P4088, DOI 10.3390/ijms15034088; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kappe C, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-276; Karve I.P., 2015, BR J PHARM; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kotter MR, 2011, BRAIN, V134, P1882, DOI 10.1093/brain/awr014; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kumar A., 2016, J NEUROTRAUMA; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Lee HF, 2012, RESP PHYSIOL NEUROBI, V182, P1, DOI 10.1016/j.resp.2012.01.016; Leonardo CC, 2012, TRANSL STROKE RES, V3, P357, DOI 10.1007/s12975-012-0203-8; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; Lopez-Rodriguez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128782; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu XY, 2015, CELL MOL NEUROBIOL, V35, P713, DOI 10.1007/s10571-015-0167-9; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mattiasson G, 2004, CYTOM PART A, V62A, P89, DOI 10.1002/cyto.a.20089; Mayeux JP, 2015, BEHAV BRAIN RES, V279, P22, DOI 10.1016/j.bbr.2014.10.053; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Nimmerjahn A, 2009, J PHYSIOL-LONDON, V587, P1639, DOI 10.1113/jphysiol.2008.167171; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Parekkadan B, 2008, NEUROSCI LETT, V438, P190, DOI 10.1016/j.neulet.2008.03.094; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Probst C, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/136020; Rao JS, 2012, NEUROCHEM RES, V37, P903, DOI 10.1007/s11064-012-0708-2; Rau TF, 2014, INT J MOL SCI, V15, P1402, DOI 10.3390/ijms15011402; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Sajja VSSS, 2014, MOL CELL NEUROSCI, V59, P119, DOI 10.1016/j.mcn.2014.02.004; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Seker E, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/12/125504; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Shi HY, 2013, J NEUROSURG, V118, P732, DOI 10.3171/2012.12.JNS12693; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Singh K., 2015, EXP NEUROL; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Suh HS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-37; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Teng SX, 2014, J NEUROTRAUM, V31, P378, DOI 10.1089/neu.2013.3093; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Tweedie D., 2016, J NEUROSCI METHODS; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wei L, 2014, CLIN EXP PHARMACOL P, V41, P134, DOI 10.1111/1440-1681.12186; Wojtala A, 2014, METHOD ENZYMOL, V542, P243, DOI 10.1016/B978-0-12-416618-9.00013-3; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025; Ye YQ, 2014, INT J MOL SCI, V15, P12651, DOI 10.3390/ijms150712651; Yokobori S, 2014, CNS NEUROL DISORD-DR, V13, P606, DOI 10.2174/187152731304140702112805; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhao GW, 2014, J ETHNOPHARMACOL, V151, P694, DOI 10.1016/j.jep.2013.11.041; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	145	93	96	2	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2016	272				SI		38	49		10.1016/j.jneumeth.2016.06.018			12	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EA6LF	WOS:000386740000005	27382003	Green Accepted			2021-06-18	
J	Jin, X; Zhu, F; Mao, HJ; Shen, M; Yang, KH				Jin, Xin; Zhu, Feng; Mao, Haojie; Shen, Ming; Yang, King H.			A comprehensive experimental study on material properties of human brain tissue	JOURNAL OF BIOMECHANICS			English	Article						Human brain tissue; Material properties; Tension; Compression; Shear	VISCOELASTIC PROPERTIES; MECHANICAL-PROPERTIES; AGE; BEHAVIOR; RAT	A comprehensive study on the biomechanical response of human brain tissue is necessary to investigate traumatic brain injury mechanisms. Published brain material property studies have been mostly performed under a specific type of loading, which is insufficient to develop accurate brain tissue constitutive equations. In addition, inconsistent or contradictory data in the literature made it impossible for computational model developers to create a single brain material model that can fit most, if not all, experimental results. In the current study, a total of 240 brain tissue specimens were tested under tension (n=72), compression (n=72), and shear (n=96) loading modes at varying strain rates. Gray-white matter difference, regional difference, and directional difference within white matter were also investigated. Stress-strain relationships of human brain tissue were obtained up to 50% of engineering strain. Strain rate dependency was observed under all three loading modes. White matter was stiffer than gray matter in compression and shear. Corona radiata was found to be stiffer than cortex, thalamus, and corpus callosum in tension and compression. Directional dependency of white matter was observed under shear loading. (C) 2013 Elsevier Ltd. All rights reserved.	[Jin, Xin; Zhu, Feng; Mao, Haojie; Shen, Ming; Yang, King H.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA	Jin, X (corresponding author), Wayne State Univ, Bioengn Ctr, 818 W Hancock, Detroit, MI 48201 USA.	mail.jinxin@gmail.com	Jin, Xin/J-6476-2015; Shen, Ming/AAN-9002-2020; Mao, Haojie/Q-7514-2018	Shen, Ming/0000-0002-9388-3513; Mao, Haojie/0000-0002-7563-9234	Global Human Body Model Consortium	This study was supported by the Global Human Body Model Consortium. The authors would like to express their appreciation to Abrar Wazir for his assistance with grammar correcting on the manuscript.	Arbogast K.B., 1995, P 39 STAPP CAR CRASH; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; ARBOGAST KB, 1997, P 41 STAPP CAR CRASH, P293; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; CDC, TRAUMATIC BRAIN INJU; Cheng S., 2007, J BIOMECHANICS; Donnelly B.R., 1997, ASME J BIOMECHANICAL; ESTES MS, 1970, 70BHF13 ASME; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Galford J.E., 1970, J BIOMECHANICS; Garo A., 2007, BIORHEOLOGY; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Manduca A, 2001, MED IMAGE ANAL, V5, P237, DOI 10.1016/S1361-8415(00)00039-6; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PRANGE MT, 2000, P 44 STAPP CAR CRASH; Takhounts E.G., 2003, STAPP CAR CRASH J; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9	22	93	95	1	27	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	NOV 15	2013	46	16					2795	2801		10.1016/j.jbiomech.2013.09.001			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	267JH	WOS:000328093200006	24112782				2021-06-18	
J	Guan, J; Zhu, ZH; Zhao, RC; Xiao, ZF; Wu, CX; Han, Q; Chen, L; Tong, WM; Zhang, J; Han, QQ; Gao, J; Feng, M; Bao, XJ; Dai, JW; Wang, RZ				Guan, Jian; Zhu, Zhaohui; Zhao, Robert Chunhua; Xiao, Zhifeng; Wu, Chenxi; Han, Qin; Chen, Lei; Tong, Weimin; Zhang, Jin; Han, Qianqian; Gao, Jun; Feng, Ming; Bao, Xinjie; Dai, Jianwu; Wang, Renzhi			Transplantation of human mesenchymal stem cells loaded on collagen scaffolds for the treatment of traumatic brain injury in rats	BIOMATERIALS			English	Article						Brain trauma; Nuclear imaging; Stem cells; Biomaterials; Differentiation	MARROW STROMAL CELLS; CEREBRAL-ISCHEMIA; PRIMATE MODEL; DIFFERENTIATION; RECOVERY; DISEASE; BIODISTRIBUTION; PHARMACOLOGY; STRATEGIES; APOPTOSIS	Studies have suggested that mesenchymal stem cells (MSCs) have therapeutic effects following traumatic brain injury (TBI). However, cell distribution and survival rate are two major barriers to their success as therapeutic treatment. The improvement of cell therapy using collagen delivery matrices had been reported. However, we know very little about the mechanisms. We labeled human bone marrow-derived mesenchymal stem cells (hMSCs) with a positron emission tomography (PET) tracer, 18F-fluoro-2-deoxy-n-glucose (FDG). hMSCs were transplanted with or without collagen scaffolds into rats with experimental TBI and the whole-body nuclear images were compared. Collagen scaffolds increased the retention of hBMSC in the lesion site and limited its distribution at the transplanted region. Significantly more hMSCs were detected in the brain when transplanted with collagen scaffolds. The results showed collagen scaffolds also efficiently improved cell survival and neurite outgrowth in vivo, resulting in better neural functional recovery. In addition, brain metabolism also improved in the collagen scaffold implanted group, as evaluated by PET. We speculated that collagen scaffolds would improve early engraftment and support the survival of grafted cells post-transplantation. (C) 2013 Elsevier Ltd. All rights reserved.	[Guan, Jian; Gao, Jun; Feng, Ming; Bao, Xinjie; Wang, Renzhi] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing 100730, Peoples R China; [Guan, Jian; Zhu, Zhaohui; Zhao, Robert Chunhua; Wu, Chenxi; Han, Qin; Tong, Weimin; Gao, Jun; Feng, Ming; Bao, Xinjie; Wang, Renzhi] Peking Union Med Coll, Beijing 100730, Peoples R China; [Xiao, Zhifeng; Chen, Lei; Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol Dev Biol, Beijing 100080, Peoples R China; [Zhu, Zhaohui; Wu, Chenxi] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nucl Med, Beijing 100730, Peoples R China; [Zhao, Robert Chunhua; Han, Qin] Chinese Acad Med Sci, Inst Basic Med Sci, Ctr Excellence Tissue Engn, Beijing 100730, Peoples R China; [Zhang, Jin] Dalian Med Univ Hosp, Dept Neurosurg, Dalian 116044, Peoples R China; [Han, Qianqian] Natl Inst Food & Drug Control, Dept Med Devices Testing, Beijing 100050, Peoples R China; [Tong, Weimin] Chinese Acad Med Sci, Dept Pathol, Inst Basic Med Sci, Beijing 100730, Peoples R China; [Tong, Weimin] Chinese Acad Med Sci, Ctr Expt Anim Res, Inst Basic Med Sci, Beijing 100730, Peoples R China	Wang, RZ (corresponding author), Beijing Union Med Coll Hosp, Dept Neurosurg, Beijing 100005, Peoples R China.	jwdai@genetics.ac.cn; wangrz@126.com			National High Technology Research and Development Program ("863" Program) of ChinaNational High Technology Research and Development Program of China [2012AA020501, 2011AA020112]; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2011CB965001]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930032, 81200916, 81171370, 81100869]	This work was supported by National High Technology Research and Development Program ("863" Program) of China (2012AA020501 and 2011AA020112), the Ministry of Science and Technology of China (2011CB965001) and National Natural Science Foundation of China (30930032, 81200916, 81171370 and 81100869).	Bao XJ, 2011, EUR J NEUROSCI, V34, P87, DOI 10.1111/j.1460-9568.2011.07733.x; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen RY, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-13; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Detante O, 2009, CELL TRANSPLANT, V18, P1369, DOI 10.3727/096368909X474230; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doi D, 2012, STEM CELLS, V30, P935, DOI 10.1002/stem.1060; Elhami E, 2011, EUR J NUCL MED MOL I, V38, P1323, DOI 10.1007/s00259-011-1753-9; Feng M, 2011, J NUCL MED, V52, P90, DOI 10.2967/jnumed.110.080325; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Guan J, 2012, BIOMATERIALS, V33, P1386, DOI 10.1016/j.biomaterials.2011.10.073; Han Q, 2007, LEUKEMIA RES, V31, P1469, DOI 10.1016/j.leukres.2006.12.016; Henriksson HB, 2009, SPINE, V34, P141, DOI 10.1097/BRS.0b013e31818f8c20; Jiang Q, 2011, NMR BIOMED, V24, P1119, DOI 10.1002/nbm.1667; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kolacna L, 2007, PHYSIOL RES, V56, pS51; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Otto WR, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-20; Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Savani BN, 2005, BIOL BLOOD MARROW TR, V11, P223, DOI 10.1016/j.bbmt.2004.12.328; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Shi CY, 2011, BIOMATERIALS, V32, P2508, DOI 10.1016/j.biomaterials.2010.12.026; Soler R, 2012, J UROLOGY, V187, P1491, DOI 10.1016/j.juro.2011.11.079; Suuronen EJ, 2006, CIRCULATION, V114, pI138, DOI 10.1161/CIRCULATIONAHA.105.001081; Uemura M, 2010, J NEUROSCI RES, V88, P542, DOI 10.1002/jnr.22223; Wang B, 2007, NEUROSCI LETT, V421, P191, DOI 10.1016/j.neulet.2007.04.081; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Zhang J, 2005, EXP NEUROL, V195, P16, DOI 10.1016/j.expneurol.2005.03.018; Zhang Y, 2008, CIRC-CARDIOVASC IMAG, V1, P197, DOI 10.1161/CIRCIMAGING.108.781120; Zhao YN, 2009, TISSUE ENG PT A, V15, P13, DOI 10.1089/ten.tea.2008.0039; Zhou H, 2010, BIOL BLOOD MARROW TR, V16, P403, DOI 10.1016/j.bbmt.2009.11.006	38	93	102	1	64	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612			BIOMATERIALS	Biomaterials	AUG	2013	34	24					5937	5946		10.1016/j.biomaterials.2013.04.047			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	164SS	WOS:000320430400007	23664090				2021-06-18	
J	Hannon, MJ; Crowley, RK; Behan, LA; O'Sullivan, EP; O'Brien, MMC; Sherlock, M; Rawluk, D; O'Dwyer, R; Tormey, W; Thompson, CJ				Hannon, M. J.; Crowley, R. K.; Behan, L. A.; O'Sullivan, E. P.; O'Brien, M. M. C.; Sherlock, M.; Rawluk, D.; O'Dwyer, R.; Tormey, W.; Thompson, C. J.			Acute Glucocorticoid Deficiency and Diabetes Insipidus Are Common After Acute Traumatic Brain Injury and Predict Mortality	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY INSUFFICIENCY; ANTI-DIURETIC HORMONE; INAPPROPRIATE SECRETION; FREE CORTISOL; NEUROENDOCRINE DYSFUNCTION; ANTIDIURETIC-HORMONE; SEVERE HYPONATREMIA; PLASMA-CORTISOL; SEPTIC SHOCK	Context: Published data demonstrates that hypopituitarism is common after traumatic brain injury (TBI). Hormone deficiencies are transient in many, but the natural history of the acute changes after TBI has not been documented. In addition, it is not clear whether there are any early parameters that accurately predict the development of permanent hypopituitarism. Objectives: There were 3 main objectives of this study: 1) to describe the natural history of plasma cortisol (PC) changes and sodium balance after TBI; 2) to identify whether acute hypocortisolemia or cranial diabetes insipidus (CDI) predict mortality; and 3) to identify whether the acute pituitary dysfunction predicts the development of chronic anterior hypopituitarism. Design: Each TBI patient underwent sequential measurement of PC, plasma sodium, urine osmolality, and fluid balance after TBI. All other anterior pituitary hormones were measured on day 10 after TBI. The results from 15 surgical comparisons defined a PC less than 300 nmol/L as inappropriately low for an acutely ill patient. CDI was diagnosed according to standard criteria. Surviving TBI patients underwent dynamic anterior pituitary testing at least 6 months after TBI. Setting: The patients were recruited from the Irish National Neurosurgery Centre. Patients: One hundred sequential TBI patients were recruited. Fifteen patients admitted to Intensive Therapy Unit (ITU) after major surgery were recruited as comparison patients. Main Outcome Measures: PC in TBI patients was compared with that of comparison patients. The mortality rate was compared between TBI patients with and without acute hypocortisolemia. Results of follow-up dynamic pituitary testing were compared between those with and without acute hypocortisolemia. Results: Most of the TBI patients (78%) developed inappropriately low PC after TBI. Low PC and CDI were predictive of mortality. Thirty-nine percent of the patients who had follow-up testing had at least 1 pituitary hormone deficit, all of whom had had previous acute hypocortisolemia or CDI. Conclusions: Acute hypocortisolemia and CDI are predictive of mortality and long-term pituitary deficits in TBI.	[Hannon, M. J.; Crowley, R. K.; Behan, L. A.; O'Sullivan, E. P.; O'Brien, M. M. C.; Sherlock, M.; Thompson, C. J.] Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Dept Endocrinol, Dublin 9, Ireland; [Rawluk, D.] Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Dept Neurosurg, Dublin 9, Ireland; [O'Dwyer, R.] Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Dept Crit Care, Dublin 9, Ireland; [Tormey, W.] Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Dept Chem Pathol, Dublin 9, Ireland	Hannon, MJ (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Acad Dept Endocrinol, Dublin 9, Ireland.	markjhannon2002@yahoo.co.uk; christhompson@beaumont.ie		Crowley, Rachel/0000-0003-1472-4117	Novo NordiskNovo Nordisk	This work was supported by an unrestricted educational grant from Novo Nordisk.	Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Alharfi IM, 2013, PEDIATR CRIT CARE ME, V14, P203, DOI 10.1097/PCC.0b013e31827127b5; Annane D, 2005, CURR OPIN CRIT CARE, V11, P449, DOI 10.1097/01.ccx.0000176691.95562.43; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; Bendel S, 2008, ANESTH ANALG, V106, P1813, DOI 10.1213/ane.0b013e318172fdba; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Boughey JC, 2004, AM SURGEON, V70, P500; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cohen J, 2012, SHOCK, V37, P28, DOI 10.1097/SHK.0b013e318239b809; COOLENS JL, 1987, J STEROID BIOCHEM, V26, P197, DOI 10.1016/0022-4731(87)90071-9; Davies MJ, 1996, J ROY SOC MED, V89, pP159; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DERENDORF H, 1991, J CLIN PHARMACOL, V31, P473, DOI 10.1002/j.1552-4604.1991.tb01906.x; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; Finucane FM, 2008, CLIN ENDOCRINOL, V69, P603, DOI 10.1111/j.1365-2265.2008.03240.x; Gill G, 2006, CLIN ENDOCRINOL, V65, P246, DOI 10.1111/j.1365-2265.2006.02583.x; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; HAWKER F, 1988, BRIT J HOSP MED, V39, P278; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Ho JT, 2006, J CLIN ENDOCR METAB, V91, P105, DOI 10.1210/jc.2005-0265; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Lanterna LA, J STROKE CEREBROVASC, DOI [10.1016/j.jstrokecerebrovasdis.2012.11.002, DOI 10.1016/J.JSTR0KECEREBR0VASDIS.2012.11.002]; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Maggiore U, 2009, CRIT CARE, V13, DOI 10.1186/cc7953; Marik PE, 2009, CHEST, V135, P181, DOI 10.1378/chest.08-1149; Monson JP, 1997, CLIN ENDOCRINOL, V46, P269, DOI 10.1046/j.1365-2265.1997.87897.x; Moro N, 2007, SURG NEUROL, V68, P387, DOI 10.1016/j.surneu.2006.11.052; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; SECKL J, 1989, BRIT MED J, V298, P2, DOI 10.1136/bmj.298.6665.2; Sherlock M, 2009, POSTGRAD MED J, V85, P171, DOI 10.1136/pgmj.2008.072819; Smith DM, 2000, CLIN ENDOCRINOL, V52, P667, DOI 10.1046/j.1365-2265.2000.01027.x; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Stelfox HT, 2008, CRIT CARE, V12, DOI 10.1186/cc7162; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; THOMAS JP, 1971, LANCET, V1, P623; THOMPSON CJ, 1989, BAILLIERE CLIN ENDOC, V3, P473, DOI 10.1016/S0950-351X(89)80012-6; THOMPSON CJ, 1987, Q J MED, V65, P853; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; VERBALIS JG, 1989, BAILLIERE CLIN ENDOC, V3, P499, DOI 10.1016/S0950-351X(89)80013-8; Wachter D, 2009, J CLIN NEUROSCI, V16, P202, DOI 10.1016/j.jocn.2008.01.009; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; Zilberberg Marya D, 2008, BMC Pulm Med, V8, P16, DOI 10.1186/1471-2466-8-16	63	93	97	0	5	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	AUG	2013	98	8					3229	3237		10.1210/jc.2013-1555			9	Endocrinology & Metabolism	Endocrinology & Metabolism	196NC	WOS:000322781300039	23690314	Bronze			2021-06-18	
J	Hsieh, CL; Kim, CC; Ryba, BE; Niemi, EC; Bando, JK; Locksley, RM; Liu, JL; Nakamura, MC; Seaman, WE				Hsieh, Christine L.; Kim, Charles C.; Ryba, Bryan E.; Niemi, Erene C.; Bando, Jennifer K.; Locksley, Richard M.; Liu, Jialing; Nakamura, Mary C.; Seaman, William E.			Traumatic brain injury induces macrophage subsets in the brain	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						Alternative activation; Inflammation; Macrophage; Traumatic brain injury	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; ALTERNATIVE ACTIVATION; MICROGLIAL ACTIVATION; MICE; INFLAMMATION; RECRUITMENT; RECOVERY; HETEROGENEITY	Traumatic brain injury (TBI) elicits innate inflammatory responses that can lead to secondary brain injury. To better understand the mechanisms involved in TBI-induced inflammation, we examined the nature of macrophages responding to TBI in mice. In this model, brain macrophages were increased >20-fold the day after injury and >77-fold 4 days after injury in the ipsilateral hemisphere compared with sham controls. TBI macrophage subsets were identified by using a reporter mouse strain (YARG) that expresses eYFP from an internal ribosome entry site (IRES) inserted at the 3 end of the gene for arginase-1 (Arg1), a hallmark of alternatively activated (M2) macrophages. One day after TBI, 21 +/- 1.5% of ipsilateral brain macrophages expressed relatively high levels of Arg1 as detected by yellow fluorescent protein, and this subpopulation declined thereafter. Arg1(+) cells localized with macrophages near the TBI lesion. Gene expression analysis of sorted Arg1(+) and Arg1(-) brain macrophages revealed that both populations had profiles that included features of conventional M2 macrophages and classically activated (M1) macrophages. The Arg1(+) cells differed from Arg1(-) cells in multiple aspects, most notably in their chemokine repertoires. Thus, the macrophage response to TBI initially involves heterogeneous polarization toward at least two major subsets.	[Hsieh, Christine L.; Ryba, Bryan E.; Liu, Jialing; Nakamura, Mary C.; Seaman, William E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Hsieh, Christine L.; Kim, Charles C.; Niemi, Erene C.; Bando, Jennifer K.; Locksley, Richard M.; Nakamura, Mary C.; Seaman, William E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Hsieh, Christine L.; Liu, Jialing; Nakamura, Mary C.; Seaman, William E.] Northern Calif Inst Res & Educ, San Francisco, CA USA	Hsieh, CL (corresponding author), San Francisco VA Med Ctr, 4150 Clement St 111R, San Francisco, CA 94121 USA.	christine.hsieh@ucsf.edu	Liu, Jialing/A-8627-2012; Nakamura, Mary/ABI-2887-2020	Liu, Jialing/0000-0003-4420-4382; Nakamura, Mary C./0000-0001-8127-9426; Bando, Jennifer/0000-0002-1331-7424; Ryba, Bryan/0000-0002-2397-9245; Kim, Charles/0000-0001-6474-8227	NIH/NCRR UCSF-CTSIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024131]; Department of Veterans AffairsUS Department of Veterans Affairs; Department of DefenseUnited States Department of Defense; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK063720] Funding Source: NIH RePORTER	The authors thank Ruby Gribi of the San Francisco VA Flow Cytometry core, Dr. David Erle, Andrea Barczak, Rebecca Barbeau, and Joshua Pollack at the Sandler Asthma Basic Research (SABRE) Center Functional Genomics Core Facility (NIH/NCRR UCSF-CTSI grant number UL1 RR024131), and Ivy Hsieh of the San Francisco VA Cell Imaging core for their contributions. This work was supported by the Department of Veterans Affairs and by grants from the Department of Defense to WES and CLH, which were administered by the Northern California Institute for Research and Education.	Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Daley JM, 2010, J LEUKOCYTE BIOL, V87, P59, DOI 10.1189/jlb.0409236; Diet A, 2007, J BIOL CHEM, V282, P36199, DOI 10.1074/jbc.M706420200; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; El Kasmi KC, 2008, NAT IMMUNOL, V9, P1399, DOI 10.1038/ni.1671; Faden AI, 2011, ANN NEUROL, V70, P345, DOI 10.1002/ana.22555; Geissmann F, 2010, NAT REV IMMUNOL, V10, P453, DOI 10.1038/nri2784; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Jin X, 2012, PLOS ONE, V7; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A., 2012, BRAIN BEHAV IMMUN; Levy A, 2009, J NEUROTRAUM, V26, P1521, DOI 10.1089/neu.2008.0746; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Manevich Y, 2005, FREE RADICAL BIO MED, V38, P1422, DOI 10.1016/j.freeradbiomed.2005.02.011; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Nair MG, 2006, J IMMUNOL, V177, P1393, DOI 10.4049/jimmunol.177.3.1393; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; Nishiya T, 2011, J BIOL CHEM, V286, P9009, DOI 10.1074/jbc.M110.190678; Nussler AK, 2010, DIGEST DIS, V28, P792, DOI 10.1159/000324287; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Potts Mathew B, 2006, NeuroRx, V3, P143; Puig-Kroger A, 2009, CANCER RES, V69, P9395, DOI 10.1158/0008-5472.CAN-09-2050; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2011, NAT NEUROSCI, V14, P1098, DOI 10.1038/nn.2917; Ransohoff RM, 2002, ANN NY ACAD SCI, V961, P346, DOI 10.1111/j.1749-6632.2002.tb03120.x; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Reinhardt RL, 2006, J IMMUNOL, V177, P1618, DOI 10.4049/jimmunol.177.3.1618; Santos CRA, 2012, IUBMB LIFE, V64, P126, DOI 10.1002/iub.585; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Vergadi E, 2011, CIRCULATION, V123, P1986, DOI 10.1161/CIRCULATIONAHA.110.978627; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; Wietecha MS, 2011, AM J PHYSIOL-HEART C, V300, pH459, DOI 10.1152/ajpheart.00244.2010; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475; Yang D, 2011, CRIT CARE MED, V39, P756, DOI 10.1097/CCM.0b013e318206befd; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhang JP, 2012, J INVEST DERMATOL, V132, P226, DOI 10.1038/jid.2011.268; Zhang SY, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000648; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056	53	93	96	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0014-2980	1521-4141		EUR J IMMUNOL	Eur. J. Immunol.	AUG	2013	43	8					2010	2022		10.1002/eji.201243084			13	Immunology	Immunology	277SN	WOS:000328839700006	23630120	Green Accepted, Bronze			2021-06-18	
J	Wachter, D; Reineke, K; Behm, T; Rohde, V				Wachter, Dorothee; Reineke, Kim; Behm, Timo; Rohde, Veit			Cranioplasty after decompressive hemicraniectomy: Underestimated surgery-associated complications?	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Decompressive hemicraniectomy; Bone flap reimplantation; Surgery-associated complications; Bone flap resorption	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; LARGE CRANIAL DEFECTS; BONE-GRAFT INFECTION; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; SURGICAL DECOMPRESSION; DELAYED CRANIOPLASTY; MALIGNANT INFARCTION; CASE SERIES	Objective: Decompressive hemicraniectomy (DC) and duroplasty after malignant brain infarction or traumatic brain injury is a common surgical procedure. Usually, preserved bone flaps are being reimplanted after resolution of brain swelling. Alloplast cranioplasties are seldom directly implanted due to the risk of wound healing disorders. While numerous studies deal with DC, little is known about the encountered problems of bone flap reimplantation. Thus, aim of the study was to identify surgery-associated complications after bone flap reimplantation. Methods: We performed a retrospective chart analysis of patients that underwent DC and subsequent bone flap reimplantation between 2001 and 2011 at our institution. We registered demographic data, initial clinical diagnosis and surgery-associated complications. Results: We identified 136 patients that underwent DC and subsequent reimplantation. Forty-one patients (30.1%) had early or late surgery-associated complications after bone flap reimplantation. Most often, bone flap resorption and postoperative wound infections were the underlying causes (73%, n = 30/41). Multivariate analysis identified age (p = 0.045; OR = 16.30), GOS prior to cranioplasty (p = 0.03; OR = 2.38) and nicotine abuse as a prognostic factor for surgery-associated complications (p = 0.043; OR = 4.02). Furthermore, patients with early cranioplasty had a better functional outcome than patients with late cranioplasty (p < 0.05). Conclusions: Almost one-third of the patients that are operated on for bone flap reimplantation after DC suffer from surgery-associated complications. Most often, wound healing disorders as well as bone flap resorption lead to a second or even third operation with the need for artificial bone implantation. These results might raise the question, if subsequent operations can be avoided, if an artificial bone is initially chosen for cranioplasty. (C) 2012 Published by Elsevier B.V.	[Wachter, Dorothee; Reineke, Kim; Behm, Timo; Rohde, Veit] Univ Gottingen, Dept Neurosurg, D-37075 Gottingen, Germany	Wachter, D (corresponding author), Univ Gottingen, Dept Neurosurg, Robert Koch Str 40, D-37075 Gottingen, Germany.	dorothee.wachter@med.uni-goettingen.de					Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; Al-Tamimi YZ, 2012, BRIT J NEUROSURG, V26, P510, DOI 10.3109/02688697.2011.633640; Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bentley JN, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09166; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Coutinho JM, 2009, STROKE, V40, P2233, DOI 10.1161/STROKEAHA.108.543421; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; De Bonis P, 2010, J NEUROSURG, V112, P1150, DOI 10.3171/2009.7.JNS09505; Diedler Jennifer, 2009, J Intensive Care Med, V24, P168, DOI 10.1177/0885066609332808; Dorfer C, 2010, WORLD NEUROSURG, V74, P465, DOI 10.1016/j.wneu.2010.08.001; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hill CS, 2012, BRIT J NEUROSURGERY; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Huang YH, 2011, INJURY; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Lee CH, 2012, J TRAUMA ACUTE CARE, V73, P255, DOI 10.1097/TA.0b013e318256a150; Lu Y, 2012, BRIT J NEUROSURG, V26, P216, DOI 10.3109/02688697.2011.629699; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Meier U, 2008, ACTA NEUROCHIR SUPPL, V102, P29, DOI 10.1007/978-3-211-85578-2_6; Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735; Murthy JMK, 2005, NEUROCRIT CARE, V2, P258, DOI 10.1385/NCC:2:3:258; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Sturiale CL, 2012, J NEUROTRAUMA; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Werndle MC, 2012, CLIN NEUROL NEUROSUR, V114, P962, DOI 10.1016/j.clineuro.2012.02.019; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	42	93	97	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	AUG	2013	115	8					1293	1297		10.1016/j.clineuro.2012.12.002			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	198NJ	WOS:000322929300017	23273384				2021-06-18	
J	Howell, D; Osternig, L; Van Donkelaar, P; Mayr, U; Chou, LS				Howell, David; Osternig, Louis; Van Donkelaar, Paul; Mayr, Ulrich; Chou, Li-Shan			Effects of Concussion on Attention and Executive Function in Adolescents	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						SPORT CONCUSSION; EXECUTIVE FUNCTION; ATTENTION; TASK SWITCH	HIGH-SCHOOL; DEFICITS; RECOVERY; EFFICIENCY; COLLEGIATE; SYMPTOMS; TRACKING	Background: Head trauma in adolescents has been linked with deficits in attention and executive function that can compromise the performance of everyday tasks. Although previous research has examined this issue using computerized neuropsychological testing, little work has been done using laboratory-based measurements of attention and executive function in this population. A longitudinal analysis of recovery patterns of these measures among adolescents is central to understanding the effects of concussions across the age spectrum. Purpose: This study prospectively and longitudinally examined laboratory-based measures of attention and executive function in concussed adolescents sequentially during a 2-month period after injury. Methods: Two measures of attention and executive function, the Attentional Network Test and the Task-Switching Test, were administered to 20 concussed adolescents within 72 h postinjury as well as at 1 wk, 2 wk, 1 month, and 2 months postinjury. Twenty healthy, matched control subjects were similarly assessed at the same time intervals. Data were analyzed by two-way, mixed-effects ANOVA to determine the effect of group and time on the dependent variables. Results: Compared with control subjects, the concussed group exhibited a significantly greater switch cost on the Task-Switching Test (P = 0.038, mean difference value = 38 ms) and a significantly greater reaction time for the Attentional Network Test conflict effect component (P = 0.015, mean difference value = 34 ms) for up to 2 months after injury. Conclusions: Concussed adolescents have difficulty recovering executive function after injury and may require extended recuperation time before full recovery is achieved. Evaluations focusing on attention and executive function can be useful additions in the assessment and follow-up after head injury.	[Howell, David; Osternig, Louis; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA; [Van Donkelaar, Paul] Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Mayr, Ulrich] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA	Chou, LS (corresponding author), Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	National Athletic Trainers Association Master's Level Grant; Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Translational Research Award from the University of Oregon; Translational Research Award from the Peace Health Oregon Region; Department of Defense-TATRC Award [W81XWH-11-1-0717]	This work was supported by the National Athletic Trainers Association Master's Level Grant, the Veterans Administration subcontract awards (grant nos. A4842C8 and A4843C), the Translational Research Award from the University of Oregon and Peace Health Oregon Region, and the Department of Defense-TATRC Award (grant no. W81XWH-11-1-0717).	Anderson V, 2008, EXECUTIVE FUNCTIONS, P24; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DAVID AS, 1992, BRIT J PSYCHIAT, V161, P244, DOI 10.1192/bjp.161.2.244; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Fischer K. W., 1996, DEV NEUROIMAGING MAP, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Ishigami Y, 2011, FRONT AGING NEUROSCI, V3, DOI 10.3389/fnagi.2011.00017; Ishigami Y, 2010, J NEUROSCI METH, V190, P117, DOI 10.1016/j.jneumeth.2010.04.019; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Lezak MD, 2004, NEUROPSYCHOLOGICAL A, P35; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Luna B, 2010, BRAIN COGNITION, V72, P101, DOI 10.1016/j.bandc.2009.08.005; Luria AR, 1976, WORKING BRAIN INTRO, P249; Mayr U, 2006, PSYCHON B REV, V13, P794, DOI 10.3758/BF03193999; Mayr U, 2006, PSYCHOL SCI, V17, P774, DOI 10.1111/j.1467-9280.2006.01781.x; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Minear M, 2008, MEM COGNITION, V36, P1470, DOI 10.3758/MC.336.8.1470; Miyake A, 2012, CURR DIR PSYCHOL SCI, V21, P8, DOI 10.1177/0963721411429458; Norman DA, 1991, COGNITIVE NEUROSCIEN, P376; O'Hare ED, 2008, NEUROIMAGE, V42, P1678, DOI 10.1016/j.neuroimage.2008.05.057; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O, 1995, DEV NEUROPSYCHOL, P50; Stuss DT, 2002, NEUROPSYCHOLOGY, V16, P500, DOI 10.1037//0894-4105.16.4.500; Stuss DT, 2006, ANN NY ACAD SCI, V769, P191; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	38	93	96	1	71	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2013	45	6					1030	1037		10.1249/MSS.0b013e3182814595			8	Sport Sciences	Sport Sciences	149MF	WOS:000319323300002	23274602				2021-06-18	
J	Dams-O'Connor, K; Gibbons, LE; Bowen, JD; McCurry, SM; Larson, EB; Crane, PK				Dams-O'Connor, Kristen; Gibbons, Laura E.; Bowen, James D.; McCurry, Susan M.; Larson, Eric B.; Crane, Paul K.			Risk for late-life re-injury, dementia and death among individuals with traumatic brain injury: a population-based study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; APOLIPOPROTEIN-E; REHABILITATION; AGE	Objectives To determine the association of self-reported traumatic brain injury (TBI) with loss of consciousness (LOC) with late-life re-injury, dementia diagnosis and mortality. Design Ongoing longitudinal population-based prospective cohort study. Setting Seattle-area integrated health system. Participants 4225 dementia-free individuals age 65 and older were randomly selected and enrolled between 1994 and 2010. Participants were seen every 2 years, with mean (range) follow-up of 7.4 (0-16) years. 606 (14%) participants reported a lifetime history of TBI with LOC at enrolment. 3466 participants provided information regarding lifetime history of TBI and completed at least one follow-up visit. Main outcome measures Self-reported TBI with LOC after study entry, incident all-cause dementia and Alzheimer's disease (AD), and all-cause mortality. Results There were 25 567 person-years of follow-up. History of TBI with LOC reported at study enrolment was associated with increased risk for TBI with LOC during follow-up, with adjusted HRs ranging from 2.54 (95% CI 1.42 to 4.52) for those reporting first injury before age 25 to 3.79 (95% CI 1.89 to 7.61) for those with first injury after age 55. History of TBI with LOC was not associated with elevated risk for developing dementia or AD. There was no association between baseline history of TBI with LOC and mortality, though TBI with LOC since the previous study visit ('recent TBI') was associated with increased mortality (HR 2.12, 95% CI 1.62 to 2.78). Conclusions Individuals aged 65 or older who reported a history of TBI with LOC at any time in their lives were at elevated risk of subsequent re-injury. Recent TBI with LOC sustained in older adulthood was associated with increased risk for mortality. Findings support the need for close clinical monitoring of older adults who sustain a TBI with LOC.	[Dams-O'Connor, Kristen] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Gibbons, Laura E.; Larson, Eric B.; Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA; [Bowen, James D.] Swedish Neurosci Inst, Seattle, WA USA; [McCurry, Susan M.] Univ Washington, Sch Nursing, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA; [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA	Dams-O'Connor, K (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org	McCurry, Susan M/E-4731-2015	McCurry, Susan M/0000-0001-8624-3772; Crane, Paul/0000-0003-4278-7465	National Institute on Aging (NIA) of the National Institutes of Health (NIH) [U01 AG006781]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24 HD065702]; NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651, R24HD065702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG006781] Funding Source: NIH RePORTER	This project was supported by Grant Number #U01 AG006781 from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) and Grant Number #R24 HD065702 from the National Institutes of Health (NIH). The NIH did not play any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The authors submit this manuscript independent from the funding source.; EBL and PKC received support from NIH/NIA for the submitted work. EBL is employed by Group Health Research Institute where the Adult Changes in Thought Study is run, and receives royalties from book chapters.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Giza CC, 2001, J ATHL TRAINING, V36, P228; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hill G, 2003, J CLIN EPIDEMIOL, V56, P293, DOI 10.1016/S0895-4356(02)00571-1; Institute of Medicine Committee on Gulf War Health, 2009, GULF WAR HLTH, V7, P197; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; StataCorp, 2011, STAT STAT SOFTW REL; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; Thompson HJ, 2012, J NEUROTRAUM, V29, P1864, DOI 10.1089/neu.2011.2284; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	32	93	93	0	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2013	84	2					177	182		10.1136/jnnp-2012-303938			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	070ZP	WOS:000313554700012	23172868	Green Accepted			2021-06-18	
J	Eskridge, SL; Macera, CA; Galarneau, MR; Holbrook, TL; Woodruff, SI; MacGregor, AJ; Morton, DJ; Shaffer, RA				Eskridge, Susan L.; Macera, Caroline A.; Galarneau, Michael R.; Holbrook, Troy L.; Woodruff, Susan I.; MacGregor, Andrew J.; Morton, Deborah J.; Shaffer, Richard A.			Injuries from combat explosions in Iraq: Injury type, location, and severity	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Explosions; Blasts; Blast injury; Military	TRAUMATIC BRAIN-INJURY; ENDURING FREEDOM; BLAST; POLYTRAUMA; OUTCOMES; CARE	Introduction: Explosions have caused a greater percentage of injuries in Iraq and Afghanistan than in any other large-scale conflict. Improvements in body armour and field medical care have improved survival and changed the injury profile of service personnel. This study's objective was to determine the nature, body region, and severity of injuries caused by an explosion episode in male service personnel. Materials and methods: A descriptive analysis was conducted of 4623 combat explosion episodes in Iraq between March 2004 and December 2007. The Barell matrix was used to describe the nature and body regions of injuries due to a combat explosion. Results: A total of 17,637 International Classification of Diseases, Ninth Revision (ICD-9) codes were assigned to the 4623 explosion episodes, with an average of 3.8 ICD-9 codes per episode. The most frequent single injury type was a mild traumatic brain injury (TBI; 10.8%). Other frequent injuries were open wounds in the lower extremity (8.8%) and open wounds of the face (8.2%), which includes tympanic membrane rupture. The extremities were the body regions most often injured (41.3%), followed by head and neck (37.4%) and torso (8.8%). Conclusion: The results of this study support previous observations of TBI as a pre-eminent injury of the wars in Iraq and Afghanistan, with mild TBI as the most common single injury in this large cohort of explosion episodes. The extremities had the highest frequency of injuries for any one body region. The majority of the explosion episodes resulted in more than one injury, and the variety of injuries across nearly every body region and injury type suggests a complex nature of explosion injuries. Understanding the constellation of injuries commonly caused by explosions will assist in the mitigation, treatment, and rehabilitation of the effects of these injuries. (c) 2012 Elsevier Ltd. All rights reserved.	[Eskridge, Susan L.; Galarneau, Michael R.; Holbrook, Troy L.; MacGregor, Andrew J.] USN, Dept Med Modeling & Simulat, Hlth Res Ctr, San Diego, CA 92106 USA; [Macera, Caroline A.] USN, Dept Warfighter Performance, Hlth Res Ctr, San Diego, CA 92106 USA; [Macera, Caroline A.; Shaffer, Richard A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA; [Woodruff, Susan I.] San Diego State Univ, Sch Social Work, San Diego, CA 92182 USA; [Morton, Deborah J.] Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, San Diego, CA 92103 USA; [Shaffer, Richard A.] USN, Dept Def HIV AIDS Prevent Program, Hlth Res Ctr, San Diego, CA 92106 USA	Eskridge, SL (corresponding author), USN, Dept Med Modeling & Simulat, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	susan.eskridge@med.navy.mil		Eskridge, Susan/0000-0002-1817-8355; MacGregor, Andrew/0000-0003-1020-7390	US Navy Bureau of Medicine and Surgery under the Wounded, Ill; Injured/Psychological Health/Traumatic Brain Injury Programme [60808]	This work was supported by the US Navy Bureau of Medicine and Surgery under the Wounded, Ill, and Injured/Psychological Health/Traumatic Brain Injury Programme, Work Unit No. 60808. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocol NHRC.2009.0023).	Aharonson-Daniel L, 2003, INJURY PREV, V9, P156, DOI 10.1136/ip.9.2.156; [Anonymous], US CAS STAT; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Defense, 2006, MED RES PREV MIT TRE; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Kauvar DS, 2006, BURNS, V32, P853, DOI 10.1016/j.burns.2006.03.008; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; McCracken D, TRAUMATIC BRAIN INJU; Mernoff Stephen T, 2010, Med Health R I, V93, P16; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Muzaffar W, 2000, BRIT J OPHTHALMOL, V84, P626, DOI 10.1136/bjo.84.6.626; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	26	93	96	0	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	OCT	2012	43	10					1678	1682		10.1016/j.injury.2012.05.027			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014OU	WOS:000309386200010	22769977				2021-06-18	
J	Ropper, AH				Ropper, Allan H.			Hyperosmolar Therapy for Raised Intracranial Pressure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID PRESSURE; SEVERE HEAD-INJURY; HYPERTONIC SALINE; MANNITOL; HYPERTENSION; CHILDREN; DEATH; CARE	A 49-year-old female passenger was thrown against the doorframe during an automobile accident. After being pulled from the car, she opened her eyes intermittently, moaned, and had flexion withdrawal of her limbs (Glasgow Coma Scale score, 8). Her pupils were 5 mm in diameter and reactive to light. Her blood pressure was 165/85 mm Hg, her heart rate 112 beats per minute, and her breathing regular. After her spine was stabilized, she was conveyed to an intensive care unit (ICU). In the ICU, she no longer opened her eyes, had flexion posturing of her arms, and made no verbal responses (Glasgow Coma Scale score, 5). There was a contusion on her right frontal scalp but no sign of other organ injury. Computed tomography showed large regions of frontal brain contusion with surrounding edema (Fig. 1). The patient was intubated, and an external ventricular drain was placed in order to measure intracranial pressure, which was 29 mm Hg with periodic elevations to 36 mm Hg. After drainage of cerebrospinal fluid, the intracranial pressure transiently decreased to 26 mm Hg. The serum sodium concentration was 139 mmol per liter. The neurointensivist recommended an intravenous bolus infusion of 23% saline to reduce intracranial pressure and attain a serum sodium concentration of 150 mmol per liter. The patient's weight was 55 kg.	Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA	Ropper, AH (corresponding author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.	aropper@partners.org					Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Baker A, 2006, CAN J ANAESTH, V53, P722, DOI 10.1007/BF03021632; Better OS, 1997, KIDNEY INT, V52, P886, DOI 10.1038/ki.1997.409; Bullock MR, 2007, J NEUROTRAUMA S1, V24, pS14; Bullock MR, 2007, J NEUROTRAUM, V24, pvii; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MCDOWELL ME, 1955, AM J PHYSIOL, V180, P545; Monro A., 1835, OBSERVATIONS STRUCTU, V1835, P5; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Palo J, 1999, LANCET, V354, P1909, DOI 10.1016/S0140-6736(05)76879-3; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; Weed LH, 1919, AM J PHYSIOL, V48, P512; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038	30	93	100	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 23	2012	367	8					746	752		10.1056/NEJMct1206321			7	Medicine, General & Internal	General & Internal Medicine	992CX	WOS:000307754200009	22913684				2021-06-18	
J	Stocchetti, N; Paterno, R; Citerio, G; Beretta, L; Colombo, A				Stocchetti, Nino; Paterno, Rosalia; Citerio, Giuseppe; Beretta, Luigi; Colombo, Angelo			Traumatic Brain Injury in an Aging Population	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; age; geriatric brain injury; outcome measures	HEAD-INJURY; AGE; MORTALITY; OUTCOMES; IMPACT; COMA; CLASSIFICATION; PROGNOSIS; ADULTS; SCALE	The epidemiology of traumatic brain injury (TBI) is changing in several Western countries, with an increasing proportion of elderly TBI patients admitted to the intensive care unit (ICU). We describe a series of 1366 adult patients admitted to three neuro-ICUs in which 44% of cases were 50 years of age or older. The health status before trauma (rated using the APACHE score) was worse in older patients. In all 604 patients had emergency removal of intracranial masses, with extradural hematomas more frequent in young cases and subdural hematomas more frequent in older patients. Outcomes were classified according to the Glasgow Outcome Scale (GOS) 6 months post-trauma, as favorable (GOS score 4-5), or unfavorable (GOS score 1-3). Favorable outcomes were achieved by 50% of patients, but the proportions of unfavorable outcomes rose with age. Mortality was the main cause of unfavorable outcomes 6 months after injury in older patients. Logistic regression analysis indicates that several parameters independently contributed to outcome, including the motor component of the Glasgow Coma Scale (GCS), pupils, CT findings, and early hypotension. Additionally, the odds ratios were very high for age and health status before TBI. Patients admitted to the ICU are increasingly older, have co-morbidities, and have specific types of intracranial lesions. Early rescue, surgical treatment, and intensive care of these patients may produce excellent results up to the age of 59 years, with favorable outcomes still possible for 39% of cases aged 60-69 years, without an excessive burden of severely disabled patients.	[Stocchetti, Nino; Paterno, Rosalia; Colombo, Angelo] Univ Milan, Milan, Italy; [Stocchetti, Nino; Paterno, Rosalia; Colombo, Angelo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, NeuroIntens Care Unit, Milan, Italy; [Citerio, Giuseppe] Osped San Gerardo, NeuroIntens Care Unit, Monza, Italy; [Beretta, Luigi] Osped San Raffaele, NeuroIntens Care Unit, Monza, Italy	Stocchetti, N (corresponding author), Fond IRCCS Ca Granda Osped Maggiore Policlin, Neurointens Care Unit, Via Francesco Sforza 35, I-2122 Milan, Italy.	stocchet@policinico.mi.it	Viani, Rafael/V-1196-2018; Citerio, Giuseppe/B-1839-2015; Stocchetti, Nino/O-7444-2017	Citerio, Giuseppe/0000-0002-5374-3161; Stocchetti, Nino/0000-0003-3250-6834			Beretta L, 2007, ACTA NEUROCHIR, V149, P903, DOI 10.1007/s00701-007-1257-3; Beretta L., 2003, MINERVA ANESTESIOL, V69, P223; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Glorioso C, 2011, PROG NEUROBIOL, V93, P165, DOI 10.1016/j.pneurobio.2010.11.006; Heiden J.S., 1979, NEURAL TRAUMA, P181; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; Lu J, 2005, ACT NEUR S, V95, P281; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McGwin G, 2001, ARCH SURG-CHICAGO, V136, P197, DOI 10.1001/archsurg.136.2.197; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; World Health Organization, 2010, GLOB STAT REP ROAD S	27	93	96	0	17	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1119	1125		10.1089/neu.2011.1995			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100012	22220762				2021-06-18	
J	d'Avila, JC; Lam, TI; Bingham, D; Shi, J; Won, SJ; Kauppinen, TM; Massa, S; Liu, JL; Swanson, RA				d'Avila, Joana C.; Lam, Tina I.; Bingham, Deborah; Shi, Jian; Won, Seok Joon; Kauppinen, Tiina M.; Massa, Stephen; Liu, Jialing; Swanson, Raymond A.			Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor	JOURNAL OF NEUROINFLAMMATION			English	Article						Astrocyte; Behavioral; Forelimb; Inflammation; Microglia; Minocycline; Poly(ADP-ribose) polymerase; traumatic brain injury	NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; NAD(+) DEPLETION; NEURONAL DEATH; MOLECULAR-MECHANISMS; THERAPEUTIC TARGETS; CEREBRAL-ISCHEMIA; INJURY; INFLAMMATION; CNS	Background: Traumatic brain injury (TBI) induces activation of microglia. Activated microglia can in turn increase secondary injury and impair recovery. This innate immune response requires hours to days to become fully manifest, thus providing a clinically relevant window of opportunity for therapeutic intervention. Microglial activation is regulated in part by poly(ADP-ribose) polymerase-1 (PARP-1). Inhibition of PARP-1 activity suppresses NF-kB-dependent gene transcription and thereby blocks several aspects of microglial activation. Here we evaluated the efficacy of a PARP inhibitor, INO-1001, in suppressing microglial activation after cortical impact in the rat. Methods: Rats were subjected to controlled cortical impact and subsequently treated with 10 mg/kg of INO-1001 (or vehicle alone) beginning 20 - 24 hours after the TBI. Brains were harvested at several time points for histological evaluation of inflammation and neuronal survival, using markers for microglial activation (morphology and CD11b expression), astrocyte activation (GFAP), and neuronal survival (NeuN). Rats were also evaluated at 8 weeks after TBI using measures of forelimb dexterity: the sticky tape test, cylinder test, and vermicelli test. Results: Peak microglial and astrocyte activation was observed 5 to 7 days after this injury. INO-1001 significantly reduced microglial activation in the peri-lesion cortex and ipsilateral hippocampus. No rebound inflammation was observed in rats that were treated with INO-1001 or vehicle for 12 days followed by 4 days without drug. The reduced inflammation was associated with increased neuronal survival in the peri-lesion cortex and improved performance on tests of forelimb dexterity conducted 8 weeks after TBI. Conclusions: Treatment with a PARP inhibitor for 12 days after TBI, with the first dose given as long as 20 hours after injury, can reduce inflammation and improve histological and functional outcomes.	[d'Avila, Joana C.; Lam, Tina I.; Shi, Jian; Won, Seok Joon; Kauppinen, Tiina M.; Massa, Stephen; Swanson, Raymond A.] Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA; [d'Avila, Joana C.; Lam, Tina I.; Shi, Jian; Won, Seok Joon; Kauppinen, Tiina M.; Massa, Stephen; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; [Bingham, Deborah; Liu, Jialing] Vet Affairs Med Ctr, Dept Neurosurg, San Francisco, CA 94121 USA; [Bingham, Deborah; Liu, Jialing] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94121 USA; [d'Avila, Joana C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil	Swanson, RA (corresponding author), Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA.	raymond.swanson@ucsf.edu	Liu, Jialing/A-8627-2012; Kauppinen, Tiina/I-1009-2019; d'Avila, Joana/L-8970-2013	Liu, Jialing/0000-0003-4420-4382; d'Avila, Joana/0000-0002-2045-0813; Kauppinen, Tiina/0000-0001-7219-9862; Swanson, Raymond/0000-0002-3664-5359	U.S. Department of DefenseUnited States Department of Defense [W81XWH-05-2-0094]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS041421]; Dept. of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041421] Funding Source: NIH RePORTER	This work was supported by the U.S. Department of Defense (contract number W81XWH-05-2-0094, to RAS) National Institutes of Health (NS041421, to RAS) and by a REAP award from the Dept. of Veterans Affairs Rehabilitation Research and Development program. We thank Ms. Dongmin Wang for excellent technical assistance.	Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; Besson VC, 2009, BRIT J PHARMACOL, V157, P695, DOI 10.1111/j.1476-5381.2009.00229.x; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Carson MJ, 2007, NEUROTHERAPEUTICS, V4, P571, DOI 10.1016/j.nurt.2007.07.002; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Cubeddu LX, 2006, PHARMACOTHERAPY, V26, P1288, DOI 10.1592/phco.26.9.1288; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007; Fink EL, 2008, J CEREBR BLOOD F MET, V28, P1523, DOI 10.1038/jcbfm.2008.52; Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Kauppinen TM, 2007, NEUROSCIENCE, V145, P1267, DOI 10.1016/j.neuroscience.2006.09.034; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen TM, 2009, J CEREBR BLOOD F MET, V29, P820, DOI 10.1038/jcbfm.2009.9; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Koh DW, 2005, CELL MOL LIFE SCI, V62, P760, DOI 10.1007/s00018-004-4508-y; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Morrow DA, 2009, J THROMB THROMBOLYS, V27, P359, DOI 10.1007/s11239-008-0230-1; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pijak MR, 2006, ARCH NEUROL-CHICAGO, V63, P300, DOI 10.1001/archneur.63.2.300-b; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; SHIN KH, 1975, CHEM PHARM BULL, V23, P1137; Stengel PW, 2007, EUR J PHARMACOL, V563, P213, DOI 10.1016/j.ejphar.2007.02.028; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	49	93	97	2	21	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 15	2012	9								31	10.1186/1742-2094-9-31			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	917II	WOS:000302166600002	22335939	DOAJ Gold, Green Published			2021-06-18	
J	Sharp, DJ; Ham, TE				Sharp, David J.; Ham, Timothy E.			Investigating white matter injury after mild traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article						blast injury; diffusion tensor imaging; mild traumatic brain injury; susceptibility-weighted imaging	DIFFUSE AXONAL INJURY; WEIGHTED IMAGING SWI; MINOR HEAD-INJURY; WALLERIAN DEGENERATION; PROSPECTIVE COHORT; CORPUS-CALLOSUM; WATER DIFFUSION; UNITED-STATES; YOUNG-PEOPLE; DAMAGE	Purpose of review Traumatic brain injury (TBI) often results in traumatic axonal injury (TAI). This is difficult to identify using conventional neuroimaging methods. We review recent work that uses advanced imaging methods to identify TAI following mild (m)TBI. Recent findings Susceptibility-weighted imaging (SWI) is a highly sensitive way of identifying microbleeds, which are a marker of TAI. Diffusion tensor imaging (DTI) provides a more flexible way of investigating white matter injury. Recent studies largely confirm that DTI is sensitive to white matter damage after mTBI. Distinct DTI abnormalities are observed in the acute and subacute/chronic stages. DTI measurements change dynamically after an injury, reflecting the evolving pathological processes. DTI abnormalities correlate with cognitive and neuropsychiatric impairments. Importantly, DTI can contribute to the prediction of clinical outcome and has begun to be applied to the study of sports and blast injury. Summary DTI and SWI are important advances in MRI that allow more detailed investigation of white matter injury. SWI is a highly sensitive way of identifying microbleeds. DTI is a flexible way of quantifying white matter integrity, and provides a method of diagnosing clinically significant white matter injury when conventional imaging is normal.	[Sharp, David J.; Ham, Timothy E.] Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Div Expt Med, Ctr Neurosci, London W12 0NN, England	Sharp, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Div Expt Med, Ctr Neurosci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013		Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Imperial College Healthcare Charity; PfizerPfizer; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701951] Funding Source: researchfish	The work was supported by The Medical Research Council (UK) (to D.J.S); D.J.S also holds grants from The Imperial College Healthcare Charity and an Investigator Led Award from Pfizer.	ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Henry LC, 2011, J NEUROTRAUMA; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Sun SW, 2008, NEUROIMAGE, V40, P1, DOI 10.1016/j.neuroimage.2007.11.049; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	60	93	97	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2011	24	6					558	563		10.1097/WCO.0b013e32834cd523			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	845VC	WOS:000296850900007	21986682				2021-06-18	
J	Sollman, MJ; Berry, DTR				Sollman, Myriam J.; Berry, David T. R.			Detection of Inadequate Effort on Neuropsychological Testing: A Meta-Analytic Update and Extension	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Cognitive; Effort testing; Malingering; Feigning; Review	LETTER MEMORY TEST; TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; CLASSIFICATION ACCURACY; CROSS-VALIDATION; MMPI-2; PERFORMANCE; PATTERNS; ISSUES; PAIN	The present meta-analysis provides the first meta-analysis of research on stand-alone neurocognitive feigning tests since publication of the preceding paper by Vickery, Berry, Inman, Harris & Orey (2001). Studies of dedicated neurocognitive feigning test performances in adults appearing in published or unpublished (theses and dissertations) sources through October 2010 were reviewed and subjected to stringent inclusion criteria to maximize the validity of results. Neurocognitive feigning tests were included only if at least three contrasts of criterion-supported honest patient groups and feigners were available. Tests that met criteria for review included the Victoria Symptom Validity Test, used as an anchor to compare Vickery and colleagues' results; Test of Memory Malingering, Word Memory Test, Letter Memory Test, and Medical Symptom Validity Test. Effect sizes and test parameters at published cut scores were compiled and compared. Results reflected large effect sizes for all measures (mean d = 1.55, 95% confidence interval [CI] = 1.48-1.63). Mean specificity was 0.90 (95% CI = 0.85-0.94). Mean sensitivity was 0.69 (95% CI = 0.63-0.75). Several moderators of effect size were identified, with certain manipulations resulting in a weakening of effect size. Unexpectedly, warning simulators to feign believably increased effect sizes.	[Sollman, Myriam J.; Berry, David T. R.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA	Berry, DTR (corresponding author), Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA.	dtrb85@gmail.com					Abramsky A., 2005, DISS ABSTR INT B, V66; Batt K, 2008, J INT NEUROPSYCH SOC, V14, P1074, DOI 10.1017/S135561770808137X; Berry D. T. R., 2007, ASSESSMENT MALINGERE, P226; BERRY DTR, 2002, CLIN PERSONALITY ASS, P269; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Boone, 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Connell K. E., 2005, THESIS CALIFORNIA SC, V65, P5393; Covert J. H., 2010, DISS ABSTR INT B, V70, P6544; Demakis GJ, 2006, CLIN NEUROPSYCHOL, V20, P10, DOI 10.1080/13854040500203282; Farkas M. R., 2009, DISS ABSTR INT B, V69, P7136; Graue LO, 2007, CLIN NEUROPSYCHOL, V21, P929, DOI 10.1080/13854040600932137; Green P., 2003, GREENS WORD MEMORY T; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P., 2004, MED SYMPTOM VALIDITY; Greub B. L., 2005, DISS ABSTR INT, V66, P552; Greub BL, 2006, ARCH CLIN NEUROPSYCH, V21, P249, DOI 10.1016/j.acn.2005.12.006; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Harrison C., 2009, DISS ABSTR INT B, V70, P3782; HEDGES LV, 1985, STAT METHODS META AN; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Hubbard K. L., 2008, DISS ABSTR INT B, V68, P6966; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Johnson B. T., 1993, DSTAT 1 10 MANUAL; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; Lindstrom WA, 2009, ARCH CLIN NEUROPSYCH, V24, P659, DOI 10.1093/arclin/acp071; Lipsey MW, 2001, PRACTICAL META ANAL; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Orey SA, 2000, ARCH CLIN NEUROPSYCH, V15, P335, DOI 10.1016/S0887-6177(99)00024-4; Pivovarova E., 2009, INT J FORENSIC MENT, V8, DOI [https://doi.org/10.1080/14999011003635514, DOI 10.1080/14999011003635514, 10.1080/14999011003635514]; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rosenfeld B., 2010, INT J FORENSIC MENT, V9, P63, DOI DOI 10.1080/14999013.2010.499559; Rosenthal R, 1991, META ANAL PROCEDURES; Samra J., 2004, DISS ABSTR INT, V64, P4061; Schipper LJ, 2008, CLIN NEUROPSYCHOL, V22, P345, DOI 10.1080/13854040701218428; Shandera AL, 2010, PSYCHOL ASSESSMENT, V22, P50, DOI 10.1037/a0016585; Sharpe D, 1997, CLIN PSYCHOL REV, V17, P881, DOI 10.1016/S0272-7358(97)00056-1; Sholtz B. P., 2006, DISS ABSTR INT B, V67, P2243; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Slick D. J., 1996, DISS ABSTR INT, V59, P6114; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sollman MJ, 2010, PSYCHOL ASSESSMENT, V22, P325, DOI 10.1037/a0018857; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vagnini VL, 2008, J CLIN EXP NEUROPSYC, V30, P766, DOI 10.1080/13803390701754746; Vagnini VL, 2006, CLIN NEUROPSYCHOL, V20, P289, DOI 10.1080/13854040590947470; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Viglione DJ, 2001, ASSESSMENT, V8, P237, DOI 10.1177/107319110100800301; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Wolfe P. L., 2004, THESIS ILLINOIS I TE, V64, P6346; Wood S. M., 2009, DISS ABSTR INT B, V70; Youngjohn JR, 1999, ARCH CLIN NEUROPSYCH, V14, P511, DOI 10.1016/S0887-6177(98)00049-3	61	93	93	0	28	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2011	26	8					774	789		10.1093/arclin/acr066			16	Psychology, Clinical; Psychology	Psychology	849UX	WOS:000297151900009	22100969	Bronze			2021-06-18	
J	Sharma, SK; Kharkwal, GB; Sajo, M; Huang, YY; De Taboada, L; McCarthy, T; Hamblin, MR				Sharma, Sulbha K.; Kharkwal, Gitika B.; Sajo, Mari; Huang, Ying-Ying; De Taboada, Luis; McCarthy, Thomas; Hamblin, Michael R.			Dose Response Effects of 810 nm Laser Light on Mouse Primary Cortical Neurons	LASERS IN SURGERY AND MEDICINE			English	Article						low level laser therapy; LLLT; photobiomodulation; cultured cortical neurons; near-infra red laser; reactive oxygen species; nitric oxide; mitochondrial membrane potential; intracellular calcium; ATP; biphasic dose response	HELIUM-NEON LASER; TERM NEUROLOGICAL DEFICITS; TRAUMATIC BRAIN-INJURY; HUMAN SKIN FIBROBLASTS; NITRIC-OXIDE; PROMOTES REGENERATION; FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; INFRARED LIGHT; ATP SYNTHESIS	Background and Objectives: In the past four decades numerous studies have reported the efficacy of low level light (laser) therapy (LLLT) as a treatment for diverse diseases and injuries. Recent studies have shown that LLLT can biomodulate processes in the central nervous system and has been extensively studied as a stroke treatment. However there is still a lack of knowledge on the effects of LLLT at the cellular level in neurons. The present study aimed to study the effect of 810 nm laser on several cellular processes in primary cortical neurons cultured from embryonic mouse brains. Study Design/Materials and Methods: Neurons were irradiated with fluences of 0.03, 0.3, 3, 10, or 30 J/cm(2) of 810-nm laser delivered over varying times at 25 mW/cm(2) and intracellular levels of reactive oxygen species (ROS), nitric oxide and calcium were measured using fluorescent probes within 5 minutes of the end of irradiation. The changes in mitochondrial function in response to light were studied in terms of adenosine triphosphate (ATP) and mitochondrial membrane potential (MMP). Results: Light induced a significant increase in calcium, ATP and MMP at lower fluences and a decrease at higher fluences. ROS was significantly induced at low fluences, followed by a decrease and a second larger increase at 30 J/cm(2). Nitric oxide levels showed a similar pattern of a double peak but values were less significant compared to ROS. Conclusions: The results suggest that LLLT at lower fluences is capable of inducing mediators of cell signaling processes which in turn may be responsible for the beneficial stimulatory effects of the low level laser. At higher fluences beneficial mediators are reduced and high levels of Janus-type mediators such as ROS and NO (beneficial at low concentrations and harmful at high concentrations) may be responsible for the damaging effects of high-fluence light and the overall biphasic dose response. Lasers Surg. Med. 43:851-859, 2011. (C) 2011 Wiley-Liss, Inc.	[Sharma, Sulbha K.; Kharkwal, Gitika B.; Sajo, Mari; Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Sharma, Sulbha K.; Kharkwal, Gitika B.; Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Sajo, Mari] Univ Tokyo, Grad Sch Pharmaceut, Tokyo, Japan; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [De Taboada, Luis; McCarthy, Thomas] Photothera Inc, Carlsbad, CA USA; [Hamblin, Michael R.] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, yingying/J-7329-2012; Hamblin, Michael R/H-2758-2019; Huang, Ying-ying/G-3153-2011	Huang, yingying/0000-0002-4038-0277; Hamblin, Michael R/0000-0001-6431-4605; Huang, Ying-ying/0000-0003-3066-6981; De Taboada, Luis/0000-0002-0153-6419	Photothera, Inc.; Photothera; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [10J10592] Funding Source: KAKEN	This study was partly supported by a sponsored research agreement from Photothera, Inc. Luis De Taboada and Thomas McCarthy are employees and stockholders in Photothera, Inc. Michael R Hamblin has received research support, loan of equipment and consulting fees from Photothera.; Contract grant sponsor: NIH; Contract grant number: R01AI050875; Contract grant sponsor: Center for Integration of Medicine and Innovative Technology; Contract grant number: DAMD17-02-2-0006; Contract grant sponsor: CDMRP Program in TBI; Contract grant number: W81XWH-09-1-0514; Contract grant sponsor: Air Force Office of Scientific Research; Contract grant number: FA9950-04-1-0079.	Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Ball KA, 2011, J PHOTOCH PHOTOBIO B, V102, P182, DOI 10.1016/j.jphotobiol.2010.12.002; Borutaite V, 2000, BBA-BIOENERGETICS, V1459, P405, DOI 10.1016/S0005-2728(00)00178-X; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Chen AC-H, 2009, ROLE REACTIVE OXYGEN; Chen AC-H, 2009, LOW LEVEL LASER THER, V7165, p0B; Chow R, 2006, PHOTOMED LASER SURG, V24, P69, DOI 10.1089/pho.2006.24.69; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Fulop AM, 2010, CLIN J PAIN, V26, P729, DOI 10.1097/AJP.0b013e3181f09713; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Hamblin MR, 2008, P SOC PHOTO-OPT INS, V6846, P84602, DOI 10.1117/12.764918; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Hawkins D, 2006, PHOTOMED LASER SURG, V24, P705, DOI 10.1089/pho.2006.24.705; Hawkins DH, 2006, LASER SURG MED, V38, P74, DOI 10.1002/lsm.20271; Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826; Huang L., 2010, J CELL PHYSL; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Konstantinovic LM, 2010, PAIN MED, V11, P1169, DOI 10.1111/j.1526-4637.2010.00907.x; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lohr NL, 2009, J MOL CELL CARDIOL, V47, P256, DOI 10.1016/j.yjmcc.2009.03.009; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; LUBART R, 1992, J PHOTOCH PHOTOBIO B, V15, P337, DOI 10.1016/1011-1344(92)85139-L; Lubart R, 2006, PHOTOMED LASER SURG, V24, P179, DOI 10.1089/pho.2006.24.179; Lucas C, 2002, LASER MED SCI, V17, P110, DOI 10.1007/s101030200018; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; Morales-Medina JC, 2007, SYNAPSE, V61, P785, DOI 10.1002/syn.20406; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2007, PHOTOMED LASER SURG, V25, P180, DOI 10.1089/pho.2007.2064; PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3; Pastore D, 1996, BIOCHEM MOL BIOL INT, V39, P149; Patel NJ, 2010, EUR J PHARMACOL, V633, P1, DOI 10.1016/j.ejphar.2010.01.012; Peplow PV, 2010, PHOTOMED LASER SURG, V28, P291, DOI 10.1089/pho.2008.2446; Peres MFP, 2010, CEPHALALGIA, V30, P1408, DOI 10.1177/0333102410362121; Poyton RO, 2011, DISCOV MED, V11, P154; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910; Sun XG, 2010, FEBS J, V277, P4789, DOI 10.1111/j.1742-4658.2010.07884.x; Tafur J, 2008, PHOTOMED LASER SURG, V26, P323, DOI 10.1089/pho.2007.2184; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Vincent SR, 2010, PROG NEUROBIOL, V90, P246, DOI 10.1016/j.pneurobio.2009.10.007; Wang F, 2005, LASER SURG MED, V36, P2, DOI 10.1002/lsm.20130; Wu SN, 2009, J CELL PHYSIOL, V218, P603, DOI 10.1002/jcp.21636; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Xavier M, 2010, LASER SURG MED, V42, P553, DOI 10.1002/lsm.20896; Yang WZ, 2007, PHOTOCHEM PHOTOBIOL, V83, P979, DOI 10.1111/j.1751-1097.2007.00116.x; Yasukawa A, 2007, J VET MED SCI, V69, P799, DOI 10.1292/jvms.69.799; Yoshihara Y, 2009, CURR OPIN NEUROBIOL, V19, P146, DOI 10.1016/j.conb.2009.05.013; YOUNG S R, 1990, Laser Therapy, V2, P53; Zhang LL, 2010, J CELL PHYSIOL, V224, P218, DOI 10.1002/jcp.22123; Zhang R, 2009, J MOL CELL CARDIOL, V46, P4, DOI 10.1016/j.yjmcc.2008.09.707	63	93	95	2	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0196-8092	1096-9101		LASER SURG MED	Lasers Surg. Med.	SEP	2011	43	8					851	859		10.1002/lsm.21100			9	Dermatology; Surgery	Dermatology; Surgery	824WG	WOS:000295232300010	21956634	Green Accepted			2021-06-18	
J	VanGuilder, HD; Farley, JA; Yan, H; Van Kirk, CA; Mitschelen, M; Sonntag, WE; Freeman, WM				VanGuilder, Heather D.; Farley, Julie A.; Yan, Han; Van Kirk, Colleen A.; Mitschelen, Matthew; Sonntag, William E.; Freeman, Willard M.			Hippocampal dysregulation of synaptic plasticity-associated proteins with age-related cognitive decline	NEUROBIOLOGY OF DISEASE			English	Article						Nogo; CamkII; Aging; Hippocampus; Synapse; Learning and memory	LONG-TERM POTENTIATION; ACTIVATES TRYPTOPHAN 5-MONOOXYGENASE; TRAUMATIC BRAIN-INJURY; CALMODULIN KINASE-II; RAT CEREBRAL-CORTEX; NOGO-A; SPATIAL MEMORY; DREBRIN-A; TYROSINE 3-MONOOXYGENASE; OUTGROWTH INHIBITOR	Age-related cognitive decline occurs without frank neurodegeneration and is the most common cause of memory impairment in aging individuals. With increasing longevity, cognitive deficits, especially in hippocampus-dependent memory processes, are increasing in prevalence. Nevertheless, the neurobiological basis of age-related cognitive decline remains unknown. While concerted efforts have led to the identification of neurobiological changes with aging, few age-related alterations have been definitively correlated to behavioral measures of cognitive decline. In this work, adult (12 months) and aged (28 months) rats were categorized by Morris water maze performance as Adult cognitively Intact, Aged cognitively Intact or Aged cognitively Impaired, and protein expression was examined in hippocampal synaptosome preparations. Previously described differences in synaptic expression of neurotransmission-associated proteins (Dnm1, Hpca, Stx1, Syn1, Syn2, Syp, SNAP25, VAMP2 and 14-3-3 eta, gamma, and zeta) were confirmed between Adult and Aged rats, with no further dysregulation associated with cognitive impairment. Proteins related to synaptic structural stability (MAP2, drebrin, Nogo-A) and activity-dependent signaling (PSD-95, 14-3-30, CaMKII alpha) were up- and down-regulated, respectively, with cognitive impairment but were not altered with increasing age. Localization of MAP2, PSD-95, and CaMKII alpha demonstrated protein expression alterations throughout the hippocampus. The altered expression of activity- and structural stability-associated proteins suggests that impaired synaptic plasticity is a distinct phenomenon that occurs with age-related cognitive decline, and demonstrates that cognitive decline is not simply an exacerbation of the aging phenotype. (C) 2011 Elsevier Inc. All rights reserved.	[VanGuilder, Heather D.; Van Kirk, Colleen A.; Freeman, Willard M.] Penn State Coll Med, Dept Pharmacol, Hershey Ctr Appl Res, Hershey, PA 17033 USA; [Farley, Julie A.; Yan, Han; Mitschelen, Matthew; Sonntag, William E.] Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK 73104 USA	Freeman, WM (corresponding author), Penn State Coll Med, Dept Pharmacol, Hershey Ctr Appl Res, 500 Univ Dr,Mc R130, Hershey, PA 17033 USA.	wfreeman@psu.edu		Freeman, Willard/0000-0001-7027-999X; sonntag, William/0000-0003-1850-2407	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG026607, P01AG11370]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG026607, P01AG011370] Funding Source: NIH RePORTER	This work was supported by NIA grants #R01AG026607 and #P01AG11370 to W.E.S., and generous support from the Donald W. Reynolds Foundation. We thank Robert Brucklacher and the Penn State Genome Sciences Facility for technical assistance.	Asrican B, 2007, J NEUROSCI, V27, P14007, DOI 10.1523/JNEUROSCI.3587-07.2007; Barnes CA, 1997, NATURE, V388, P272, DOI 10.1038/40859; Beique JC, 2006, P NATL ACAD SCI USA, V103, P19535, DOI 10.1073/pnas.0608492103; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Blalock EM, 2005, AGEING RES REV, V4, P481, DOI 10.1016/j.arr.2005.06.006; Blalock EM, 2003, J NEUROSCI, V23, P3807; Boric K, 2008, J NEUROSCI, V28, P8034, DOI 10.1523/JNEUROSCI.2036-08.2008; Brucklacher RM, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-26; Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809; Butterfield DA, 2006, NEUROBIOL DIS, V22, P223, DOI 10.1016/j.nbd.2005.11.002; Carlisle HJ, 2008, J PHYSIOL-LONDON, V586, P5885, DOI 10.1113/jphysiol.2008.163469; Casadesus G, 2004, NUTR NEUROSCI, V7, P309, DOI 10.1080/10284150400020482; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; Dahle CL, 2009, PSYCHOL AGING, V24, P154, DOI 10.1037/a0014283; De Camilli P, 1984, Neuroscience, V11, P817; Delint-Ramirez I, 2008, J NEUROCHEM, V106, P1658, DOI 10.1111/j.1471-4159.2008.05523.x; Dickson HM, 2010, J NEUROSCI, V30, P13319, DOI 10.1523/JNEUROSCI.1324-10.2010; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; El-Hussein AE, 2000, SCIENCE, V290, P1364; Elgersma Y, 2004, J NEUROSCI, V24, P8410, DOI 10.1523/JNEUROSCI.3622-04.2004; Faul C, 2005, J CELL BIOL, V169, P415, DOI 10.1083/jcb.200411169; Freeman WM, 2010, PHARMACOGENOMICS J, V10, P385, DOI 10.1038/tpj.2009.60; Freeman WM, 2009, NEUROSCIENCE, V159, P183, DOI 10.1016/j.neuroscience.2008.12.004; Freeman Willard M, 2009, J Ocul Biol Dis Infor, V2, P202; GEINISMAN Y, 1986, BRAIN RES, V398, P266, DOI 10.1016/0006-8993(86)91486-1; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Gillani RL, 2010, BEHAV BRAIN RES, V208, P415, DOI 10.1016/j.bbr.2009.12.015; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; Hayashi K, 1996, J NEUROSCI, V16, P7161; Hu FH, 2008, J NEUROSCI, V28, P1262, DOI 10.1523/JNEUROSCI.1068-07.2008; Huber AB, 2002, J NEUROSCI, V22, P3553; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; ISHIKAWA R, 1994, J BIOL CHEM, V269, P29928; Khuchua Z, 2003, NEUROSCIENCE, V119, P101, DOI 10.1016/S0306-4522(03)00094-0; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kojima N, 2007, NEUROSCI RES, V58, P1, DOI 10.1016/j.neures.2007.02.003; Kumar A, 2007, J NEUROPHYSIOL, V98, P594, DOI 10.1152/jn.00249.2007; Lee HJ, 2008, J NEUROSCI, V28, P2753, DOI 10.1523/JNEUROSCI.5586-07.2008; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Liu P, 2008, SYNAPSE, V62, P834, DOI 10.1002/syn.20563; Lu FM, 2006, P NATL ACAD SCI USA, V103, P4264, DOI 10.1073/pnas.0508162103; Maei HR, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.004.2009; Majdi M, 2007, EUR J NEUROSCI, V26, P3583, DOI 10.1111/j.1460-9568.2007.05966.x; Marklund N, 2009, NEUROSCIENCE, V163, P540, DOI 10.1016/j.neuroscience.2009.06.042; Matsuo N, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.020.2009; MATUS A, 1981, P NATL ACAD SCI-BIOL, V78, P3010, DOI 10.1073/pnas.78.5.3010; Migaud M, 1998, NATURE, V396, P433; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Mitschelen M, 2009, NEUROSCIENCE, V164, P918, DOI 10.1016/j.neuroscience.2009.08.070; Mizui T, 2005, MOL CELL NEUROSCI, V30, P630, DOI 10.1016/j.mcn.2005.06.013; NIELANDER HB, 1995, J NEUROCHEM, V65, P1712; Norris CM, 1996, J NEUROSCI, V16, P5382; O'Callaghan RM, 2009, HIPPOCAMPUS, V19, P1019, DOI 10.1002/hipo.20591; Okabe S, 2001, J NEUROSCI, V21, P6105; Okonkwo OC, 2010, CEREBROVASC DIS, V30, P362, DOI 10.1159/000319564; Park CS, 2008, NEUROSCIENCE, V151, P43, DOI 10.1016/j.neuroscience.2007.09.075; Platano D, 2008, REJUV RES, V11, P341, DOI 10.1089/rej.2008.0725; Poon HF, 2006, NEUROBIOL AGING, V27, P1020, DOI 10.1016/j.neurobiolaging.2005.05.014; Poulsen DJ, 2007, J NEUROSCI RES, V85, P735, DOI 10.1002/jnr.21163; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Raiker SJ, 2010, J NEUROSCI, V30, P12432, DOI 10.1523/JNEUROSCI.0895-10.2010; Ramsey MM, 2004, NEUROSCIENCE, V129, P119, DOI 10.1016/j.neuroscience.2004.08.001; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Rountree CB, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-61; Rowe WB, 2007, J NEUROSCI, V27, P3098, DOI 10.1523/JNEUROSCI.4163-06.2007; SHEETZ MP, 1989, TRENDS NEUROSCI, V12, P474, DOI 10.1016/0166-2236(89)90099-4; Shi L, 2005, CEREB CORTEX, V15, P571, DOI 10.1093/cercor/bhh158; SHIRAO T, 1994, EXP CELL RES, V215, P145, DOI 10.1006/excr.1994.1326; SHIRAO T, 1992, NEUROREPORT, V3, P109, DOI 10.1097/00001756-199201000-00029; Shrestha L.B., 2006, CHANGING DEMOGRAPHIC; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; Small GW, 2002, BRIT MED J, V324, P1502, DOI 10.1136/bmj.324.7352.1502; Stein V, 2003, J NEUROSCI, V23, P5503; Swofford JA, 2007, DEV NEUROBIOL, V67, P1457, DOI 10.1002/dneu.20458; Tao-Cheng JH, 2006, BRAIN CELL BIOL, V35, P117, DOI 10.1007/s11068-007-9012-5; Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025; TERRY AV, 2009, SPATIAL NAVIGATION; Tombaugh GC, 2002, J NEUROSCI, V22, P9932; VanGuilder HD, 2010, J NEUROCHEM, V113, P1577, DOI 10.1111/j.1471-4159.2010.06719.x; Vickers CA, 2006, BRAIN RES, V1090, P89, DOI 10.1016/j.brainres.2006.03.075; Wang YF, 2006, BRIT J PHARMACOL, V148, P147, DOI 10.1038/sj.bjp.0706720; Wang ZW, 2008, MOL NEUROBIOL, V38, P153, DOI 10.1007/s12035-008-8039-7; Wilson IA, 2003, NEUROBIOL AGING, V24, P297, DOI 10.1016/S0197-4580(02)00080-5; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404; Zagrebelsky M, 2010, J NEUROSCI, V30, P13220, DOI 10.1523/JNEUROSCI.1044-10.2010; Zha XM, 2009, J NEUROSCI RES, V87, P1969, DOI 10.1002/jnr.22033	90	93	94	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JUL	2011	43	1			SI		201	212		10.1016/j.nbd.2011.03.012			12	Neurosciences	Neurosciences & Neurology	771RZ	WOS:000291179700023	21440628	Green Accepted			2021-06-18	
J	Hinzman, JM; Thomas, TC; Burmeister, JJ; Quintero, JE; Huettl, P; Pomerleau, F; Gerhardt, GA; Lifshitz, J				Hinzman, Jason M.; Thomas, Theresa Currier; Burmeister, Jason J.; Quintero, Jorge E.; Huettl, Peter; Pomerleau, Francois; Gerhardt, Greg A.; Lifshitz, Jonathan			Diffuse Brain Injury Elevates Tonic Glutamate Levels and Potassium-Evoked Glutamate Release in Discrete Brain Regions at Two Days Post-Injury: An Enzyme-Based Microelectrode Array Study	JOURNAL OF NEUROTRAUMA			English	Article						amperometry; hippocampus; microdialysis; synaptic release	EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; PREFRONTAL CORTEX; MULTISITE MICROELECTRODE; EXTRACELLULAR GLUTAMATE; NEUROLOGICAL DISORDERS; MEMORY; EXCITOTOXICITY; IMPAIRMENT; EXPRESSION	Traumatic brain injury (TBI) survivors often suffer from a wide range of post-traumatic deficits, including impairments in behavioral, cognitive, and motor function. Regulation of glutamate signaling is vital for proper neuronal excitation in the central nervous system. Without proper regulation, increases in extracellular glutamate can contribute to the pathophysiology and neurological dysfunction seen in TBI. In the present studies, enzyme-based microelectrode arrays (MEAs) that selectively measure extracellular glutamate at 2Hz enabled the examination of tonic glutamate levels and potassium chloride (KCl)-evoked glutamate release in the prefrontal cortex, dentate gyrus, and striatum of adult male rats 2 days after mild or moderate midline fluid percussion brain injury. Moderate brain injury significantly increased tonic extracellular glutamate levels by 256% in the dentate gyrus and 178% in the dorsal striatum. In the dorsal striatum, mild brain injury significantly increased tonic glutamate levels by 200%. Tonic glutamate levels were significantly correlated with injury severity in the dentate gyrus and striatum. The amplitudes of KCl-evoked glutamate release were increased significantly only in the striatum after moderate injury, with a 249% increase seen in the dorsal striatum. Thus, with the MEAs, we measured discrete regional changes in both tonic and KCl-evoked glutamate signaling, which were dependent on injury severity. Future studies may reveal the specific mechanisms responsible for glutamate dysregulation in the post-traumatic period, and may provide novel therapeutic means to improve outcomes after TBI.	[Hinzman, Jason M.; Thomas, Theresa Currier; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Huettl, Peter; Pomerleau, Francois; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Huettl, Peter; Pomerleau, Francois; Gerhardt, Greg A.] Univ Kentucky, Albert B Chandler Med Ctr, Morris K Udall Parkinsons Dis Res Ctr Excellence, Lexington, KY 40536 USA; [Hinzman, Jason M.; Burmeister, Jason J.; Quintero, Jorge E.; Huettl, Peter; Pomerleau, Francois; Gerhardt, Greg A.] Univ Kentucky, Albert B Chandler Med Ctr, Ctr Microelectrode Technol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Phys Med & Rehabil, Lexington, KY 40536 USA	Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, B463 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	JLifshitz@uky.edu	Thomas, Theresa Currier/K-1979-2019	Thomas, Theresa Currier/0000-0002-9619-7666	U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [DA017186, AG00242, NS3978, AG013494]; National Science Fund [EEC-0310723]; University of Kentucky College of Medicine; Kentucky Spinal Cord and Head Injury Research Trust [7-11]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG013494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA017186] Funding Source: NIH RePORTER	The authors thank Amanda M. Lisembee and Kelley D. Hall for technical assistance with the FPI, Laura C. Crawford and Emily D. Cottrell for assistance with in vivo recordings and MEA placement, and Michelle L. Stephens for providing the coordinates for the hippocampus. Support was provided by U.S. Public Health Service grants DA017186, AG00242, NS3978, and AG013494, National Science Fund grant (ERC) EEC-0310723, and the University of Kentucky College of Medicine, and Kentucky Spinal Cord and Head Injury Research Trust Grant 7-11.	Andersen P., 2007, HIPPOCAMPUS BOOK; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Borland LM, 2005, J NEUROSCI METH, V146, P149, DOI 10.1016/j.jneumeth.2005.02.002; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burmeister JJ, 2002, J NEUROSCI METH, V119, P163, DOI 10.1016/S0165-0270(02)00172-3; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Canales JJ, 2002, BRAIN, V125, P2353, DOI 10.1093/brain/awf239; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Day BK, 2006, J NEUROCHEM, V96, P1626, DOI 10.1111/j.1471-4159.2006.03673.x; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; Delatour B, 2000, BEHAV BRAIN RES, V109, P113, DOI 10.1016/S0166-4328(99)00168-0; Diamond JS, 2005, J NEUROSCI, V25, P2906, DOI 10.1523/JNEUROSCI.5125-04.2005; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FONNUM F, 1981, NEUROSCIENCE, V6, P863, DOI 10.1016/0306-4522(81)90168-8; FRIEDEMANN MN, 1992, NEUROBIOL AGING, V13, P325, DOI 10.1016/0197-4580(92)90046-Z; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hascup KN, 2008, J PHARMACOL EXP THER, V324, P725, DOI 10.1124/jpet.107.131698; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Jabaudon D, 1999, P NATL ACAD SCI USA, V96, P8733, DOI 10.1073/pnas.96.15.8733; Jaquins-Gerstl A, 2009, J NEUROSCI METH, V183, P127, DOI 10.1016/j.jneumeth.2009.06.023; Jensen JB, 2000, INT J DEV NEUROSCI, V18, P309, DOI 10.1016/S0736-5748(99)00099-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lifshitz J, 2008, ANIMAL MODELS ACUTE; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MANGANO RM, 1983, BRAIN RES BULL, V10, P47, DOI 10.1016/0361-9230(83)90073-4; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McIntosh TK, 1996, LAB INVEST, V74, P315; Nickell J, 2007, NEUROBIOL AGING, V28, P1737, DOI 10.1016/j.neurobiolaging.2006.07.015; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Pomerleau F, 2003, ANN NY ACAD SCI, V1003, P454, DOI 10.1196/annals.1300.051; Rao VLR, 1998, J NEUROCHEM, V70, P2020; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rutherford EC, 2007, J NEUROCHEM, V102, P712, DOI 10.1111/j.1471-4159.2007.04596.x; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Steketee JD, 2003, BRAIN RES REV, V41, P203, DOI 10.1016/S0165-0173(02)00233-3; Stephens M.L., 2009, NEUROBIOL AGING; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thomas TC, 2009, NEUROPSYCHOPHARMACOL, V34, P436, DOI 10.1038/npp.2008.74; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wu Y, 2000, NEUROSCIENCE, V96, P65, DOI 10.1016/S0306-4522(99)00539-4; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	66	93	94	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					889	899		10.1089/neu.2009.1238			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400011	20233041	Green Published			2021-06-18	
J	Stein, SC; Georgoff, P; Meghan, S; Mirza, KL; El Falaky, OM				Stein, Sherman C.; Georgoff, Patrick; Meghan, Sudha; Mirza, Kasim L.; El Falaky, Omar M.			Relationship of aggressive monitoring and treatment to improved outcomes in severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; head injury; meta-analysis; intracranial pressure monitoring	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; MULTIMODALITY EVOKED-POTENTIALS; SAN-DIEGO-COUNTY; INTRACRANIAL-PRESSURE; COMPUTERIZED-TOMOGRAPHY; EARLY PREDICTION; PROGNOSTIC VALUE; MORTALITY PREDICTION; HOSPITAL ADMISSIONS	Object. Despite being common practice for decades and being recommended by national guidelines, aggressive monitoring and treatment of patients with severe traumatic brain injury (TBI) have not been supported by convincing evidence. Methods. The authors reviewed trials and case series reported after 1970 in which patients were treated for severe closed TBI, and mortality rates and favorable outcomes at 6 months after injury were analyzed. The patient groups were divided into those with and without intracranial pressure (ICP) monitoring and intensive therapy, and the authors performed a meta-analysis to assess the effects of treatment intensity on outcome. Results. Although the mortality rate fell during the years reviewed, it was consistently similar to 12% lower among patients in the intense treatment group (p < 0.001). Favorable outcomes did not change significantly over time, and were 6% higher among the aggressively treated patients (p = 0.0105). Conclusions. Aggressive ICP monitoring and treatment of patients with severe TBI is associated with a statistically significant improvement in outcome. This improvement occurs independently of temporal effects. (DOI: 10.3171/2009.8.JNS09738)	[Stein, Sherman C.; Georgoff, Patrick; Meghan, Sudha; Mirza, Kasim L.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [El Falaky, Omar M.] Cairo Univ, Dept Neurosurg, Cairo, Egypt	Stein, SC (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3400 Spruce St,3 Silverstein, Philadelphia, PA 19104 USA.	sherman.stein@uphs.upenn.edu					Akopian G, 2007, AM SURGEON, V73, P447; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Athiappan S., 1993, Annals Academy of Medicine Singapore, V22, P452; Auer L, 1979, Acta Neurochir Suppl (Wien), V28, P171; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Bang H, 2007, STAT MED, V26, P954, DOI 10.1002/sim.2663; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Benzer A, 1995, Anasthesiol Intensivmed Notfallmed Schmerzther, V30, P231, DOI 10.1055/s-2007-996481; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRAAKMAN R, 1992, ACTA NEUROCHIR, V116, P161, DOI 10.1007/BF01540870; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; BROWNE LA, 1977, IRISH MED J, V70, P197; BUCHMANN B, 1992, J TRAUMA, V32, P459, DOI 10.1097/00005373-199204000-00009; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; BULLOCK R, 2005, NEUROTRAUMA CRIT FAL, P6; BULLOCK R, 2005, NEUROTRAUMA CRIT FAL, P3; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Cogbill TH, 2008, J TRAUMA, V65, P994, DOI 10.1097/TA.0b013e318184ce12; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; EDDY VA, 1995, AM SURGEON, V61, P24; Edwards P, 2005, LANCET, V365, P1957; Einarson TR, 1997, CLIN THER, V19, P559, DOI 10.1016/S0149-2918(97)80140-3; ESPERSEN JO, 1982, ACTA NEUROCHIR, V65, P81, DOI 10.1007/BF01405444; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Ghogawala Z, 2008, NEUROSURGERY, V62, pN9, DOI 10.1227/01.neu.0000333288.21621.a9; GIBSON RM, 1989, LANCET, V2, P369; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hsiao KY, 2008, EMERG MED J, V25, P670, DOI 10.1136/emj.2007.053405; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; JENNETT B, 1979, BRIT MED J, V2, P955, DOI 10.1136/bmj.2.6196.955; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KAGAN RJ, 1994, AM SURGEON, V60, P394; Kim Y, 2000, J TRAUMA, V48, P280, DOI 10.1097/00005373-200002000-00014; KING JT, 1995, J NEUROSURG, V83, P403, DOI 10.3171/jns.1995.83.3.0403; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lane PL, 2000, CAN J SURG, V43, P442; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lee A, 2003, INJURY, V34, P815, DOI 10.1016/S0020-1383(02)00395-9; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; McConnell KJ, 2005, HEALTH SERV RES, V40, P435, DOI 10.1111/j.1475-6773.2005.0u367.x; Miller J D, 1979, Acta Neurochir Suppl (Wien), V28, P86; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; MURRAY GD, 1986, STAT MED, V5, P103, DOI 10.1002/sim.4780050202; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nathens A B, 2001, Adv Surg, V35, P61; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; Odebode TO, 2008, NIGER J CLIN PRACT, V11, P265; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Pillai SV, 2003, NEUROL INDIA, V51, P345; Ramesh VG, 2008, J CLIN NEUROSCI, V15, P1110, DOI 10.1016/j.jocn.2007.08.033; RIMEL RW, 1981, RESUSCITATION, V9, P75, DOI 10.1016/0300-9572(81)90036-8; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Rudnik A, 1992, Acta Neurochir Suppl (Wien), V55, P33; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sahuquillo J, 2008, EUR J ANAESTH, V25, P83, DOI 10.1017/S0265021507003353; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; Servadei F, 2000, NEUROSURGERY, V46, P70; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; Stranjalis G, 2008, J TRAUMA, V65, P789, DOI 10.1097/TA.0b013e3181469e26; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Sundbarg G, 1989, Brain Inj, V3, P283, DOI 10.3109/02699058909029641; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	150	93	99	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2010	112	5					1105	1112		10.3171/2009.8.JNS09738			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	591BW	WOS:000277273600029	19747054				2021-06-18	
S	Wood, WG; Eckert, GP; Igbayboa, U; Muller, WE		Andrews, RJ; Slikker, W; Trembly, B; Patterson, TA		Wood, W. Gibson; Eckert, Gunter P.; Igbayboa, Urule; Mueller, Walter E.			Statins and neuroprotection A prescription to move the field forward	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	9th International Conference on Neuroprotective Agents	SEP 07-11, 2008	Marine Biol Lab, Woods Hole, MA		Marine Biol Lab	Alzheimer's disease; cerebrovascular disease; cholesterol; HMG-CoA reductase; isoprenoids; neurodegeneration; neuroprotection; statins; stroke	COA-REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORTERS; CULTURED CORTICAL-NEURONS; BLOOD-BRAIN-BARRIER; CELL-DEATH; ALZHEIMERS-DISEASE; IN-VITRO; GERANYLGERANYL-PYROPHOSPHATE; UP-REGULATION; CHOLESTEROL	There is growing interest in the use of statins, HMG-CoA reductase inhibitors, for treating specific neurodegenerative diseases (e.g., cerebrovascular disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis) and possibly traumatic brain injury. Neither is there a consensus on the efficacy of statins in treating the aforementioned diseases nor are the mechanisms of the purported statin-induced neuroprotection well-understood. Part of the support for statin-induced neuroprotection comes from studies using animal models and cell culture. Important information has resulted from that work but there continues to be a lack of progress on basic issues pertaining to statins and brain that impedes advancement in understanding how statins alter brain function. For example, there are scant data on the pharmacokinetics of lipophilic and hydrophilic statins in brain, statin-induced neuroprotection versus cell death, and statins and brain isoprenoids. The purpose of this mini-review will be to examine those aforementioned issues and to identify directions of future research.	[Wood, W. Gibson; Igbayboa, Urule] Univ Minnesota, Dept Pharmacol, Geriatr Res Educ & Clin Ctr, VA Med Ctr, Minneapolis, MN 55455 USA; [Eckert, Gunter P.; Mueller, Walter E.] Goethe Univ Frankfurt, Dept Pharmacol, Bioctr Niederursel, Frankfurt, Germany	Wood, WG (corresponding author), Univ Minnesota, Dept Pharmacol, Geriatr Res Educ & Clin Ctr, VA Med Ctr, 6-120 Jackson Hall,321 Church St, Minneapolis, MN 55455 USA.	woodx002@umn.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-23524, AG-18357]; Department of Veterans AffairsUS Department of Veterans Affairs; Hanna Bragard-Apfel Foundation; Alzheimer Forschung Initiative; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG018357, R01AG023524] Funding Source: NIH RePORTER	This work was supported in part by grants from the National Institutes of Health AG-23524, AG-18357, Department of Veterans Affairs, Hanna Bragard-Apfel Foundation, and Alzheimer Forschung Initiative.	Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Bogman K, 2001, BRIT J PHARMACOL, V132, P1183, DOI 10.1038/sj.bjp.0703920; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; BOTTI RE, 1991, CLIN NEUROPHARMACOL, V14, P256, DOI 10.1097/00002826-199106000-00010; Bucelli RC, 2008, J PHARMACOL EXP THER, V324, P1172, DOI 10.1124/jpet.107.132795; Chochina SV, 2001, J LIPID RES, V42, P1292; Cole SL, 2006, NEUROBIOL DIS, V22, P209, DOI 10.1016/j.nbd.2005.11.007; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Domoki F, 2009, AM J PHYSIOL-CELL PH, V296, pC97, DOI 10.1152/ajpcell.00366.2008; Eckert GP, 2005, J NEURAL TRANSM, V112, P1057, DOI 10.1007/s00702-004-0273-1; Eckert GP, 2007, FUTURE LIPIDOL, V2, P423, DOI 10.2217/17460875.2.4.423; Farooqui AA, 2007, BRAIN RES REV, V56, P443, DOI 10.1016/j.brainresrev.2007.09.004; Franke C, 2007, NEUROBIOL DIS, V25, P438, DOI 10.1016/j.nbd.2006.10.004; Hasegawa M, 2003, J PHARMACOL EXP THER, V305, P1087, DOI 10.1124/jpet.102.046847; Hirrlinger J, 2002, J NEUROCHEM, V82, P716, DOI 10.1046/j.1471-4159.2002.01082.x; Hooff GP, 2008, ANAL BIOANAL CHEM, V392, P673, DOI 10.1007/s00216-008-2306-3; Ishigami M, 2001, DRUG METAB DISPOS, V29, P282; Jacobsen W, 2000, DRUG METAB DISPOS, V28, P1369; Jiang ZH, 2004, J NEUROCHEM, V89, P168, DOI 10.1111/j.1471-4159.2004.02319.x; Johnson-Anuna LN, 2007, J NEUROCHEM, V101, P77, DOI 10.1111/j.1471-4159.2006.04375.x; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Kantola T, 1998, CLIN PHARMACOL THER, V64, P58, DOI 10.1016/S0009-9236(98)90023-6; Klopfleisch S, 2008, J NEUROSCI, V28, P13609, DOI 10.1523/JNEUROSCI.2765-08.2008; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Law MRWNJ, 2003, BRIT MED J, V326, P1; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lim JH, 2006, J NEUROCHEM, V97, P140, DOI 10.1111/j.1471-4159.2006.03715.x; Marz P, 2007, GLIA, V55, P1, DOI 10.1002/glia.20422; McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018-005-5298-6; Michikawa M, 1999, J NEUROCHEM, V72, P2278, DOI 10.1046/j.1471-4159.1999.0722278.x; Nassief A, 2008, STROKE, V39, P1042, DOI 10.1161/STROKEAHA.107.501361; Neuhaus Oliver, 2007, Expert Rev Neurother, V7, P547, DOI 10.1586/14737175.7.5.547; Orr JD, 2008, CURR ATHEROSCLER REP, V10, P11; Ostrowski SM, 2007, J BIOL CHEM, V282, P26832, DOI 10.1074/jbc.M702640200; Pai H. V., 2002, Pharmacogenomics Journal, V2, P243, DOI 10.1038/sj.tpj.6500115; SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Schulz JG, 2004, J NEUROCHEM, V89, P24, DOI 10.1046/j.1471-4159.2003.02305.x; Solomon KR, 2008, TRENDS ENDOCRIN MET, V19, P113, DOI 10.1016/j.tem.2007.12.004; Stepien K, 2005, PHARMACOL REP, V57, P561; Sun HY, 2003, ADV DRUG DELIVER REV, V55, P83, DOI 10.1016/S0169-409X(02)00172-2; Swanson KM, 2006, CURR CANCER DRUG TAR, V6, P15, DOI 10.2174/156800906775471743; Takeda M, 2004, EUR J PHARMACOL, V483, P133, DOI 10.1016/j.ejphar.2003.10.017; Tanaka T, 2000, J NEUROSCI, V20, P2852; Tapia-Perez H, 2007, REV NEUROLOGIA, V45, P359, DOI 10.33588/rn.4506.2007380; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Thelen KM, 2006, J PHARMACOL EXP THER, V316, P1146, DOI 10.1124/jpet.105.094136; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Tong H, 2008, ANAL BIOCHEM, V378, P138, DOI 10.1016/j.ab.2008.04.021; Tong HX, 2005, ANAL BIOCHEM, V336, P51, DOI 10.1016/j.ab.2004.09.024; TSUJI A, 1993, J PHARMACOL EXP THER, V267, P1085; Wahner AD, 2008, NEUROLOGY, V70, P1418, DOI 10.1212/01.wnl.0000286942.14552.51; Wood W. G., 2007, HDB NEUROCHEMISTRY M, P151; Xiang ZM, 2009, EXP NEUROL, V215, P41, DOI 10.1016/j.expneurol.2008.09.010; Zacco A, 2003, J NEUROSCI, V23, P11104	56	93	98	0	11	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-777-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1199						69	76		10.1111/j.1749-6632.2009.05359.x			8	Multidisciplinary Sciences; Neurosciences	Science & Technology - Other Topics; Neurosciences & Neurology	BRJ59	WOS:000282838900007	20633110	Green Accepted			2021-06-18	
J	Sigurdardottir, S; Andelic, N; Roe, C; Schanke, AK				Sigurdardottir, Solrun; Andelic, Nada; Roe, Cecilie; Schanke, Anne-Kristine			Cognitive recovery and predictors of functional outcome 1 year after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Injury severity; Trauma; Neuropsychology; Fatigue; Glasgow Outcome Scale-Extended	SEVERITY SCORE; HEAD-INJURY; EMPLOYMENT; SCALE; PRODUCTIVITY; FATIGUE; POPULATION; RATES; COMA	Outcome studies on traumatic brain injury (TBI) have shown that functional status can be predicted by demographic, injury severity, and trauma-related factors. Concurrent cognitive functions as one of the determinants of functional outcome is less documented. This study evaluated the effects of concurrent neuropsychological measures on functional Outcome I year after injury. Neuropsychological data, employment status, self-reported fatigue, and the Glasgow Outcome Scale-Extended (GOSE) were collected from 115 persons with TBI (ranging from mild to severe) at 3 and 12 months postinjury. Principal components analysis was conducted with the neuropsychological measures and three components emerged. Multiple regression analysis, controlling for demographic and injury severity related factors, was used to test the effects of cognitive components at 12 months on functional outcome (GOSE). One year after injury, 64% were categorized as "good recovery" and 36% as "moderate disability" according to GOSE. Good functional recovery depended on shorter duration of posttraumatic amnesia, less fatigue, absence of intracranial pathology, higher education, and better performance on cognitive measures. The predictive values of Verbal/Reasoning and Visual/Perception components are supported; each added significantly and improved prediction of functional outcome. The Memory/Speed component showed a near-significant relationship to outcome. (JINS, 2009, 15, 740-750.)	[Sigurdardottir, Solrun; Schanke, Anne-Kristine] Univ Oslo, Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; [Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway	Sigurdardottir, S (corresponding author), Univ Oslo, Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@sunnaas.no		Andelic, Nada/0000-0002-3719-4406	South-Eastern Norway Regional Health Authority	This study was supported by grants from the South-Eastern Norway Regional Health Authority. Special thanks to Ivar Reinvang, Professor, University of Oslo, for valuable comments; to Tone Jerstad, neuroradiologist, Department of Neuroradiology, Oslo University Hospital, Ulleval, for the CT and MRI evaluations; to Morten Hestnes and Nils Oddvar Skaga from the Oslo University Hospital's Trauma Registry, Ulleval, for the extraction of trauma scores; to Katrine Frey Froslie, The National University Hospital, for statistical assistance; and to Susan Schanche for the proof reading the English text. Competing interests: None.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL REV 19; Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A., 1976, MULTILINGUAL APHASIA; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2001, DELISKAPLAN EXECUTIV; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lerdal A, 2005, SCAND J PUBLIC HEALT, V33, P123, DOI 10.1080/14034940410028406; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Meyers J., 1995, REY COMPLEX FIGURE T; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reitan RM., 1985, HALSTEAD REITAN NEUR; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; *STAT NORW, 2008, STAT YB NORW 2008; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Taylor LA, 2003, BRAIN INJURY, V17, P295, DOI 10.1080/0269905021000038401; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	48	93	93	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2009	15	5					740	750		10.1017/S1355617709990452			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	489IZ	WOS:000269415100010	19602303				2021-06-18	
J	Oddo, M; Levine, JM; Frangos, S; Carrera, E; Maloney-Wilensky, E; Pascual, JL; Kofke, WA; Mayer, SA; LeRoux, PD				Oddo, M.; Levine, J. M.; Frangos, S.; Carrera, E.; Maloney-Wilensky, E.; Pascual, J. L.; Kofke, W. A.; Mayer, S. A.; LeRoux, P. D.			Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; BLOOD-FLOW; SODIUM-CHLORIDE; FLUID RESUSCITATION; 20-PERCENT MANNITOL; CUSHING RESPONSE; PRESSURE; SHOCK; 7.2-PERCENT	Background: The impact of osmotic therapies on brain oxygen has not been extensively studied in humans. We examined the effects on brain tissue oxygen tension (PbtO(2)) of mannitol and hypertonic saline (HTS) in patients with severe traumatic brain injury (TBI) and refractory intracranial hypertension. Methods: 12 consecutive patients with severe TBI who underwent intracranial pressure (ICP) and PbtO(2) monitoring were studied. Patients were treated with mannitol (25%, 0.75 g/kg) for episodes of elevated ICP (> 20 mm Hg) or HTS (7.5%, 250 ml) if ICP was not controlled with mannitol. PbtO2, ICP, mean arterial pressure, cerebral perfusion pressure (CPP), central venous pressure and cardiac output were monitored continuously. Results: 42 episodes of intracranial hypertension, treated with mannitol (n = 28 boluses) or HTS (n = 14 boluses), were analysed. HTS treatment was associated with an increase in PbtO2 (from baseline 28.3 (13.8) mm Hg to 34.9 (18.2) mm Hg at 30 min, 37.0 (17.6) mm Hg at 60 min and 41.4 (17.7) mm Hg at 120 min; all p < 0.01) while mannitol did not affect PbtO2 (baseline 30.4 (11.4) vs 28.7 (13.5) vs 28.4 (10.6) vs 27.5 (9.9) mm Hg; all p > 0.1). Compared with mannitol, HTS was associated with lower ICP and higher CPP and cardiac output. Conclusions: In patients with severe TBI and elevated ICP refractory to previous mannitol treatment, 7.5% hypertonic saline administered as second tier therapy is associated with a significant increase in brain oxygenation, and improved cerebral and systemic haemodynamics.	[LeRoux, P. D.] Univ Penn, Med Ctr, Dept Neurosurg, Div Clin Res, Philadelphia, PA 19104 USA; [Pascual, J. L.] Univ Penn, Med Ctr, Dept Surg, Philadelphia, PA 19104 USA; [Levine, J. M.] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; [Levine, J. M.; Kofke, W. A.] Univ Penn, Med Ctr, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Carrera, E.; Mayer, S. A.] Columbia Univ, Med Ctr, Dept Neurol, Crit Care Div, New York, NY USA	LeRoux, PD (corresponding author), Univ Penn, Med Ctr, Dept Neurosurg, Div Clin Res, Philadelphia, PA 19104 USA.	Peter.LeRoux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525	SICPA Foundation, Switzerland; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBLAB-119620]; Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	Supported by Research Grants from the SICPA Foundation, Switzerland (to MO and EC), the Swiss National Science Foundation, Grant PBLAB-119620 (EC), the Integra Foundation (PDL) and the Mary Elisabeth Groff Surgical and Medical Research Trust (PDL).	Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; Bermueller C, 2006, J NEUROL SCI, V241, P73, DOI 10.1016/j.jns.2005.10.016; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Chen CH, 2007, NEUROCRIT CARE, V7, P92, DOI 10.1007/s12028-007-0033-9; Chen Y, 2006, AM J PHYSIOL-CELL PH, V290, pC1051, DOI 10.1152/ajpcell.00216.2005; DAUTERMANN C, 1992, ADV EXP MED BIOL, V317, P731; DEFELIPPE J, 1980, LANCET, V2, P1002; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Hartl R, 1997, ACT NEUR S, V70, P40; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Schmidt EA, 2005, ACTA NEUROCHIR SUPPL, V95, P253; SCHRADER H, 1985, ACTA NEUROL SCAND, V72, P283; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; STEENBERGEN JM, 1993, AM J PHYSIOL, V265, pH323; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Toung TJK, 2007, CRIT CARE MED, V35, P526, DOI 10.1097/01.CCM.0000253309.44567.A6; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Zausinger S, 2004, NEUROSURGERY, V55, P679, DOI 10.1227/01.NEU.0000134558.28977.EE	36	93	100	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2009	80	8					916	920		10.1136/jnnp.2008.156596			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	471JT	WOS:000268054300019	19293171				2021-06-18	
J	Li, B; Mahmood, A; Lu, DY; Wu, HT; Xiong, Y; Qu, CS; Chopp, M				Li, Bo; Mahmood, Asim; Lu, Dunyue; Wu, Hongtao; Xiong, Ye; Qu, Changsheng; Chopp, Michael			SIMVASTATIN ATTENUATES MICROGLIAL CELLS AND ASTROCYTE ACTIVATION AND DECREASES INTERLEUKIN-1B LEVEL AFTER TRAUMATIC BRAIN INJURY	NEUROSURGERY			English	Article						Astrocyte; Interleukin-1 beta; Microglia; Simvastatin; Traumatic brain injury	NITRIC-OXIDE SYNTHASE; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; CNS INJURY; KAPPA-B; STATINS; INDUCTION; EXPRESSION; RECEPTOR; SYNAPTOGENESIS	OBJECTIVE: Our previous studies demonstrated that simvastatin promotes neurological functional recovery after traumatic brain injury (TBI) in rat; however, the underlying mechanisms remain poorly understood. The purpose of this study was to investigate the anti-inflammatory effect of simvastatin by measuring the level of cytokines and activation of glial cells. METHODS: Controlled cortical impact injury was performed in adult male Wistar rats. The rats were randomly divided into 3 groups: sham, saline control group, and simvastatin treatment group. Simvastatin was administered orally starting at day 1 after TBI until animals were killed at days 1, 3, 7, 14, and 35 after treatment. Functional outcome was measured using modified neurological severity scores. Enzyme-linked immunosorbent assay and immunohistochemical staining were used to measure the expression of interleukin (IL)-1 beta, IL-6, and tumor necrosis factor-a and to identify activated microglial cells and astrocytes. RESULTS: At days 1 and 3 after simvastatin or saline treatment, cytokine levels in the lesion boundary zone were significantly higher in the simvastatin- and saline-treated rats compared with the sham group, peaking at day 3. Simvastatin only reduced the level of IL-1 beta but not IL-6 and tumor necrosis factor-alpha, compared with the saline group. Also, simvastatin significantly reduced the number of activated microglial cells and astrocytes compared with the saline control animals. There was also a trend toward improvement of modified neurological severity score, reaching statistical significance (P = 0.003) toward the end of the trial. CONCLUSION: Our data demonstrate that TBI causes inflammatory reaction, including increased levels of IL-1 beta, IL-6, and tumor necrosis factor-alpha, as well as activated microglial cells. Simvastatin selectively reduces IL-1 beta expression and inhibits the activation of microglial cells and astrocytes after TBI, which might be one of the mechanisms underlying the therapeutic benefits of simvastatin treatment of TBI.	[Chopp, Michael] Henry Ford Hosp, Dept Neurol, Henry Ford Hlth Syst, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Li, Bo; Mahmood, Asim; Wu, Hongtao; Xiong, Ye; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Li, Bo] Harbin Med Univ, Dept Immunol, Harbin, Peoples R China; [Lu, Dunyue] SUNY Hlth Sci Ctr, Dept Psychiat, Brooklyn, NY 11203 USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, Henry Ford Hlth Syst, E&R Bldg 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	Wu, Hongtao/A-8602-2011	Xiong, Ye/0000-0001-9770-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS05228001A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant R01NS05228001A1. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Devaraj S, 2006, J CLIN ENDOCR METAB, V91, P4489, DOI 10.1210/jc.2006-0299; Endres M, 2005, J CEREBR BLOOD F MET, V25, P1093, DOI 10.1038/sj.jcbfm.9600116; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gibson RM, 2004, VET J, V168, P230, DOI 10.1016/j.tvjl.2003.10.016; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Law M, 2006, AM J CARDIOL, V97, p52C, DOI 10.1016/j.amjcard.2005.12.010; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lindberg C, 2005, J NEUROSCI RES, V82, P10, DOI 10.1002/jnr.20615; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Neuhaus O, 2004, LANCET NEUROL, V3, P369, DOI 10.1016/S1474-4422(04)00770-7; Onusko E, 2008, J FAM PRACTICE, V57, P449; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Raivich G, 2003, J NEUROSCI RES, V72, P726, DOI 10.1002/jnr.10621; Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Wachtel M, 2001, J NEUROCHEM, V78, P155, DOI 10.1046/j.1471-4159.2001.00399.x; Zapolska-Downar D, 2004, LIFE SCI, V75, P1287, DOI 10.1016/j.lfs.2004.03.005	37	93	98	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2009	65	1					179	186		10.1227/01.NEU.0000346272.76537.DC			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	474EP	WOS:000268265600022	19574840	Green Accepted			2021-06-18	
J	Helton, WS				Helton, William S.			Impulsive responding and the sustained attention to response task	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Attention; Impulsivity; Mindlessness; Vigilance	ABBREVIATED VIGILANCE TASK; TRAUMATIC BRAIN-INJURY; PERFORMANCE; SENSITIVITY; PERCEPTION; FAILURES; WORKLOAD; SYSTEMS	Two studies investigated whether the sustained attention to response task (SART) is a better measure of impulsive responding than of sustained attention. Participants performed target detection tasks with global-local letter stimuli using one of two response formats: standard, responding to targets; and SART, withholding to targets. In the first experiment, performance in the SART changed rapidly over time, whereas performance in the standard format was stable over time. In the second experiment, performance in the SART was susceptible to global-local condensation tasks, a result previously found with highly impulsive individuals. Overall the results indicate that the SART is sensitive to impulsive responding.	Michigan Technol Univ, Dept Psychol, Houghton, MI 49931 USA	Helton, WS (corresponding author), Michigan Technol Univ, Dept Psychol, Houghton, MI 49931 USA.	Deak_Helton@yahoo.com			Department of Defense University Research Instrumentation Program (DURIP)United States Department of Defense; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA-9550-07-1-0500]	This work was supported by the Department of Defense University Research Instrumentation Program (DURIP) administered by the Air Force Office of Scientific Research (FA-9550-07-1-0500), W. S. Helton Principal Investigator. The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, Department of Defense, or the U. S. Government.	Ballard JC, 1996, J CLIN EXP NEUROPSYC, V18, P843, DOI 10.1080/01688639608408307; BERCH DB, 1984, SUSTAINED ATTENTION, P143; Boff K. R., 1986, HDB PERCEPTION HUMAN, V2, p[43, 1]; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; DAMOS DL, 1994, J CLIN EXP NEUROPSYC, V16, P713, DOI 10.1080/01688639408402684; Davies D.R., 1982, PSYCHOL VIGILANCE; DICKMAN S, 1985, J PERS SOC PSYCHOL, V48, P133, DOI 10.1037/0022-3514.48.1.133; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Doyon J, 2003, NEUROPSYCHOLOGIA, V41, P252, DOI 10.1016/S0028-3932(02)00158-6; Gazzaniga M.S., 2002, COGNITIVE NEUROSCIEN; HARRINGTON DL, 1991, NEUROPSYCHOLOGIA, V29, P147, DOI 10.1016/0028-3932(91)90017-3; Hellige J. B., 1993, HEMISPHERIC ASYMMETR; Helton W. S., 2002, P HUM FACT ERG SOC A, V46, P1546, DOI DOI 10.1177/154193120204601704; Helton WS, 2007, J CLIN EXP NEUROPSYC, V29, P545, DOI 10.1080/13803390600814757; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Helton WS, 2004, HUMAN PERFORMANCE, SITUATION AWARENESS AND AUTOMATION: CURRENT RESEARCH AND TRENDS, VOL 1, P258; Helton WS, 1999, CURR PSYCHOL, V18, P311, DOI 10.1007/s12144-999-1006-2; HOWELL WC, 1993, ANNU REV PSYCHOL, V44, P231, DOI 10.1146/annurev.ps.44.020193.001311; Kirk R. E., 1995, EXPT DESIGN PROCEDUR; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Mackworth NH, 1948, Q J EXP PSYCHOL, V1, P6, DOI 10.1080/17470214808416738; MACKWORTH NH, 1950, 2680 MED RES COUNC; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; MATTHEWS G, 2001, P HUMAN FACTORS ERGO, V45, P1377; Matthews G, 2000, HUMAN PERFORMANCE CO; Maxwell S. E., 2004, DESIGNING EXPT ANAL; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; NUECHTERLEIN KH, 1983, SCIENCE, V220, P327, DOI 10.1126/science.6836276; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Posner MI., 1978, CHRONOMETRIC EXPLORA; Proctor R., 1994, HUMAN FACTORS SIMPLE; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rose CL, 2002, EUR J PERSONALITY, V16, P185, DOI 10.1002/per.451; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Temple JG, 2000, HUM FACTORS, V42, P183, DOI 10.1518/001872000779656480; TUCKER DM, 1984, PSYCHOL REV, V91, P185, DOI 10.1037/0033-295X.91.2.185; Warm J. S., 1984, SUSTAINED ATTENTION, P1; Warm J. S., 1993, WORKLOAD TRANSITION, P139; Wickens CD, 1998, INTRO HUMAN FACTORS	45	93	93	1	25	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	1					39	47	PII 792057852	10.1080/13803390801978856			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	384IT	WOS:000261739200004	18608658				2021-06-18	
J	Christensen, BK; Colella, B; Illness, E; Hebert, D; Monette, G; Bayley, M; Green, RE				Christensen, Bruce K.; Colella, Brenda; Illness, Elizabeth; Hebert, Deborah; Monette, Georges; Bayley, Mark; Green, Robin E.			Recovery of Cognitive Function After Traumatic Brain Injury: A Multilevel Modeling Analysis of Canadian Outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Longitudinal studies; Neuropsychology; Rehabilitation	SEVERE HEAD-INJURY; FOLLOW-UP; NEUROPSYCHOLOGICAL RECOVERY; COMMUNITY INTEGRATION; POSTTRAUMATIC AMNESIA; PROGNOSTIC VALUE; OLDER-ADULTS; REHABILITATION; SEVERITY; MODERATE	Objective: To ascertain patterns of cognitive recovery during the first year after traumatic brain injury (TBI). Specifically, differential recovery across cognitive domains was investigated. Design: Prospective, longitudinal, naturalistic, 1-year follow-up study. Setting: Large, urban inpatient neurorehabilitation program. Participants: Patients (N=75) with moderate to severe TB I. Interventions: Not applicable. Main Outcome Measures: Patients with TBI were followed over the course of 1 year, during which participants' neuropsychological status was repeatedly evaluated at 3 time points (2, 5, and 12 months postinjury). Results: Multilevel modeling results were consistent with previous research, demonstrating that recovery in the first year postinjury is asymptotic in nature, with more accelerated recovery occurring during the first 5 to 6 months. Importantly, results also suggest that recovery is not uniform across cognitive domains. From 2 to 5 months postinjury, steeper recovery curves were revealed for indices of memory, speeded executive function, verbal abstraction, and manual dexterity relative to untimed tests of executive function and word knowledge. Recovery trajectories did not significantly vary as a function of cognitive domain over the course of the last 5 to 12 months. Conclusions: These results are the first to explore trajectories of recovery directly as a function of multiple cognitive domains. They are expected to have implications for rehabilitative efforts as well as our understanding of the architecture of natural recovery after TBI.	[Colella, Brenda; Illness, Elizabeth; Hebert, Deborah; Bayley, Mark; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Christensen, Bruce K.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8S 4L8, Canada; [Illness, Elizabeth; Hebert, Deborah; Bayley, Mark; Green, Robin E.] Univ Toronto, Toronto, ON, Canada; [Monette, Georges] York Univ, Dept Math & Stat, N York, ON M3J 1P3, Canada	Green, RE (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	green.robin@torontorehab.on.ca		Bayley, Mark/0000-0001-7860-9463; Green, Robin/0000-0001-9451-3963; Inness, Elizabeth L./0000-0002-9217-4619	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians' Services Inc [MOP-67072, 05-50]	Supported by the Canadian Institutes of Health Research and the Physicians' Services Inc (grant nos. MOP-67072, 05-50).	Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; BENE JF, 2007, BRAIN INJURY, V21, P395; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brooks D N, 1979, Int Rehabil Med, V1, P166; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; DeBow SB, 2004, CAN J PHYSIOL PHARM, V82, P231, DOI 10.1139/Y04-013; Deutsch PM, 2006, NEUROREHABILITATION, V21, P305; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Fong KNK, 2001, BRAIN INJURY, V15, P443, DOI 10.1080/02699050010005940; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Galwey N. W., 2006, INTRO MIXED MODELLIN; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Green REA, 2006, BRAIN COGNITION, V60, P199; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Harradine PG, 2004, MED J AUSTRALIA, V181, P130, DOI 10.5694/j.1326-5377.2004.tb06202.x; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hebb MO, 2007, J NEUROTRAUM, V24, P579, DOI 10.1089/neu.2006.0146; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hughes C, 2000, J CHILD PSYCHOL PSYC, V41, P483, DOI 10.1017/S0021963099005533; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; KOLB B, 2004, MECH CORTICAL PLASTI; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; Lau AFC, 2003, INT J REHABIL RES, V26, P251, DOI 10.1097/00004356-200312000-00001; LEVERE ND, 1982, PHYSIOL PSYCHOL, V10, P165; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nelles G, 1999, ANN NEUROL, V46, P901, DOI 10.1002/1531-8249(199912)46:6<901::AID-ANA13>3.0.CO;2-7; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Poon WS, 2005, ACT NEUR S, V93, P207; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Smith A., 1982, SYMBOL DIGIT MODALIT; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Taub E, 2001, Curr Atheroscler Rep, V3, P279, DOI 10.1007/s11883-001-0020-0; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; TOFL S, 1996, BRAIN INJURY, V10, P901; Tombaugh TN, 1996, TEST MEMORY MALINGER; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Warburton E, 1999, J NEUROL NEUROSUR PS, V66, P155, DOI 10.1136/jnnp.66.2.155; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	96	93	94	0	31	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S3	S15		10.1016/j.apmr.2008.10.002			13	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	388DB	WOS:000261999400002	19081439				2021-06-18	
J	Fortuna, GR; Mueller, EW; James, LE; Shutter, LA; Butler, KL				Fortuna, Gerald R.; Mueller, Eric W.; James, Laura E.; Shutter, Lori A.; Butler, Karyn L.			The impact of preinjury antiplatelet and anticoagulant pharmacotherapy on outcomes in elderly patients with hemorrhagic brain injury	SURGERY			English	Article							TRAUMATIC INTRACRANIAL HEMORRHAGE; HEAD-INJURY; OLDER-ADULTS; MORTALITY; PROPHYLAXIS; RISK; AGE; THROMBOSIS; SAFETY	Background. More elderly trauma patients are identified with preinjury use of clopidogrel, aspirin, or warfarin (CAW). The purpose of this study was to determine whether preinjury CAW use was an important predictor of mortality in patients aged >= 50 years with blunt, hemorrhagic brain injury (HBI). Methods. A retrospective review of patients with blunt, HBI aged >= 50 years with subgroup analysis for older (> 70 years) and younger (50-70 years) patients was performed. CAW use was analyzed for differences in age, gender, hospital length of stay (LOS), Injury Severity Score (ISS), Glasgow Coma Score (GCS), mechanism of injury (MOI), platelet transfusion therapy (PLT), disposition at discharge, and in-hospital mortality. Results. From January 2003 to October 2005, 416 patients were identified. The mean age was 69 +/- 1 years. No differences were found for ISS (24 +/- 0.5), GCS (12 +/- 0.2), or LOS (8 +/- 0.4 days). CAW use was present in 40% of patients and significantly higher in older patients. Mortality was not different between older and younger CAW(+) patients, but it significantly increased for older CAW(-) patients. Significant predictors of death included age, ISS, and GCS (P < .02). Conclusions. Preinjury CAW use in older blunt, HBI patients is not associated with increased mortality. Age was a significant predictor of mortality independent of CAW use.	[Fortuna, Gerald R.; James, Laura E.; Butler, Karyn L.] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA; [Mueller, Eric W.] Univ Cincinnati, Dept Pharm Serv, Univ Hosp, Div Pharm Practice, Cincinnati, OH USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA; [Butler, Karyn L.] Univ Cincinnati, Div Trauma Crit Care, Cincinnati, OH USA	Butler, KL (corresponding author), Hartford Hosp, 80 Seymour St, Hartford, CT 06102 USA.	kbutler@harthosp.org	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Dellinger AM, 2006, J SAFETY RES, V37, P519, DOI 10.1016/j.jsr.2006.10.001; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224; Geerts William H, 2006, Hematology Am Soc Hematol Educ Program, P462; Hsiao G, 2005, ARTERIOSCL THROM VAS, V25, P1998, DOI 10.1161/01.ATV.0000174798.25085.d6; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; MATTOX KL, 2000, TRAUMA; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Morales D, 2006, J NEUROTRAUM, V23, P976, DOI 10.1089/neu.2006.23.976; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055	20	93	94	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	OCT	2008	144	4					598	605		10.1016/j.surg.2008.06.009			8	Surgery	Surgery	356AL	WOS:000259751000016	18847644				2021-06-18	
J	Nekludov, M; Bellander, BM; Blomback, M; Wallen, HN				Nekludov, Michael; Bellander, Bo-Michael; Blomback, Margareta; Wallen, Hakan N.			Platelet dysfunction in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						bleeding time; coagulopathy; platelet dysfunction; thromboelastography ( TEG); traumatic brain injury ( TBI)	HEAD-INJURY; COAGULOPATHY; THROMBOCYTOPENIA	Coagulopathy is a common phenomenon in traumatic brain injury (TBI) and a major contributor to a poor outcome. Thrombocytopenia is a strong negative prognostic factor in TBI, but bleeding tendency can be present even with a normal platelet count. We investigated platelet function in patients with TBI by means of modified thromboelastography (i.e., platelet mapping [TEG-PM]). Four groups were studied: (1) patients with severe isolated TBI (n = 20), ( 2) patients with general trauma without TBI (the ICU group, n = 10), (3) patients with chronic alcohol abuse (n = 7; as alcohol abuse is common in patients with TBI), and (4) healthy volunteers (n = 10). We measured platelet counts in venous blood (Plt), Ivy bleeding time, standard TEG parameters, and platelet responses to arachidonic acid (AA) and adenosindiphosphate (ADP), using TEG-PM. TBI patients had a lower Plt (180 +/- 68 x 10(9); mean +/- SD) and a longer bleeding time (674 +/- 230 sec) than healthy controls, (256 +/- 43 x 109, p < 0.01) and (320 +/- 95 sec, p < 0.005), respectively. TBI patients had dramatically lower platelet responses to AA (0-86%, mean 22%) compared to healthy controls (57-89%, mean 73%), the ICU group (4-75%, mean 49%), and the alcohol abusers (17-88%, mean 64%; p < 0.001). Responses to ADP did not differ significantly between the groups. Patients with low responsiveness to AA at admittance to the hospital were likely to develop bleeding complications later. Patients with TBI develop platelet dysfunction, which most likely contributes to bleeding complications. The observed platelet dysfunction appears to involve the cyclooxygenase pathway. TEG-PM analysis can be used to identify patients with a high risk of bleeding complications.	Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Div Cardiol, Stockholm, Sweden	Nekludov, M (corresponding author), Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden.			Nekludov, Michael/0000-0001-9916-7086			ALEKSANDROV VN, 1984, ZH VOPR NEIROKHIR IM, V3, P19; Alstrom U, 2007, THROMB RES, V120, P353, DOI 10.1016/j.thromres.2006.10.009; BELL A, 1958, Am J Med Technol, V24, P264; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Goh KYC, 1997, J NEUROL NEUROSUR PS, V63, P334, DOI 10.1136/jnnp.63.3.334; Hansen Mads Koch, 2006, Ugeskr Laeger, V168, P3535; HARTERT H, 1951, Z GES EXP MED, V117, P189, DOI 10.1007/BF02044776; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Hobson AR, 2006, PLATELETS, V17, P509, DOI 10.1080/09537100600935259; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Maeda T, 1997, ACT NEUR S, V70, P102; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; SCHWARZMAIER S, 2006, 8 INT NEUR TRAUM SOC; Singer AJ, 2003, AM J EMERG MED, V21, P441, DOI 10.1016/S0735-6757(03)00100-1; Stein Deborah M, 2004, Curr Opin Crit Care, V10, P520, DOI 10.1097/01.ccx.0000144770.96342.65; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Tantry US, 2005, J AM COLL CARDIOL, V46, P1705, DOI 10.1016/j.jacc.2005.05.090	20	93	99	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1699	1706		10.1089/neu.2007.0322			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500003	18001200				2021-06-18	
J	Son, AHPWV; Ribbers, GM; Verhagen, AP; Stam, HJ				Son, Agnes H. P. Willemse-van; Ribbers, Gerard M.; Verhagen, Arianne P.; Stam, Henk J.			Prognostic factors of long-term functioning and productivity after traumatic brain injury: a systematic review of prospective cohort studies	CLINICAL REHABILITATION			English	Article							MODERATE HEAD-INJURY; MULTICENTER ANALYSIS; ACUTE PREDICTORS; INDEPENDENCE MEASURE; EVOKED-POTENTIALS; EMPLOYMENT; OUTCOMES; RETURN; VIOLENCE; MOTOR	Objective: To systematically review prospective cohort studies that investigated prognostic factors associated with long-term activity limitations or participation restrictions and productivity after a traumatic brain injury. Data sources: PubMed and Psychinfo were searched from 1995 to April 2005, and references were checked. Review methods: Publications were selected if the study assessed prognostic factors for activity limitations or participation restrictions at least one year post injury; outcome was measured with another or additional measure besides the Glasgow Outcome Scale; the design was a prospective cohort study of adult traumatic brain injury patients; the article was a full-text article written in English, French, German or Dutch. Two reviewers independently assessed methodological quality. A study was considered as 'high quality' if it satisfied at least half of the maximum available quality score. Results: Thirty-five articles reporting on 14 cohorts were included. Due to heterogeneity in prognostic factors and outcome measures, a best-evidence synthesis was performed. All cohorts were of high quality. Strong evidence for predicting disability was found for older age, pre-injury unemployment, pre-injury substance abuse, and more disability at rehabilitation discharge. Strong prognostic factors for being non-productive were pre-injury unemployment, longer post-traumatic amnesia, more disability at rehabilitation admission, and pre-injury substance abuse. Conclusion: Older age, pre-injury unemployment, pre-injury substance abuse and more disability at rehabilitation discharge are important predictors of long-term disability. Pre-injury unemployment, longer post-traumatic amnesia, more disability at rehabilitation admission and pre-injury substance abuse are important predictors of being non-productive.	[Son, Agnes H. P. Willemse-van; Ribbers, Gerard M.; Stam, Henk J.] Erasmus MC, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands; [Ribbers, Gerard M.] Rijndam Rehabil Ctr, Rotterdam, Netherlands; [Verhagen, Arianne P.] Erasmus MC, Dept Gen Practice, Rotterdam, Netherlands	Son, AHPWV (corresponding author), Erasmus MC, Dept Rehabil Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.vanson-willemse@erasmusmc.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; Verhagen, Arianne/0000-0002-6195-0128			Altman DG, 2001, BMJ-BRIT MED J, V323, P224, DOI 10.1136/bmj.323.7306.224; Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; [Anonymous], 2006, ACTA NEUROCHIR WIEN, V148, P255; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Scholten-Peeters GGM, 2003, PAIN, V104, P303, DOI 10.1016/S0304-3959(03)00050-2; Sherer M, 1999, BRAIN INJURY, V13, P973; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Stemmer B, 2000, BRAIN COGNITION, V44, P25; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Naalt J, 2000, BRAIN INJURY, V14, P781; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Woischneck D, 1997, NEUROL RES, V19, P305, DOI 10.1080/01616412.1997.11740817; World Health Organization, 2002, INT CLASS FUNCT DIS	49	93	94	0	9	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	NOV	2007	21	11					1024	1037		10.1177/0269215507077603			14	Rehabilitation	Rehabilitation	240EW	WOS:000251571000006	17984154				2021-06-18	
J	Cavanaugh, JT; Mercer, VS; Stergiou, N				Cavanaugh, James T.; Mercer, Vicki S.; Stergiou, Nicholas			Approximate entropy detects the effect of a secondary cognitive task on postural control in healthy young adults: a methodological report	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							DUAL-TASK; CEREBRAL CONCUSSION; OLDER-ADULTS; ATTENTION; BALANCE; INTERFERENCE; PERFORMANCE; DISORDER; POSTUROGRAPHY; STABILITY	Background: Biomechanical measures of postural stability, while generally useful in neuroscience and physical rehabilitation research, may be limited in their ability to detect more subtle influences of attention on postural control. Approximate entropy (ApEn), a regularity statistic from nonlinear dynamics, recently has demonstrated relatively good measurement precision and shown promise for detecting subtle change in postural control after cerebral concussion. Our purpose was to further explore the responsiveness of ApEn by using it to evaluate the immediate, short-term effect of secondary cognitive task performance on postural control in healthy, young adults. Methods: Thirty healthy, young adults performed a modified version of the Sensory Organization Test featuring single (posture only) and dual (posture plus cognitive) task trials. ApEn values, root mean square (RMS) displacement, and equilibrium scores (ES) were calculated from anterior-posterior (AP) and medial-lateral (ML) center of pressure (COP) component time series. For each sensory condition, we compared the ability of the postural control parameters to detect an effect of cognitive task performance. Results: COP AP time series generally became more random (higher ApEn value) during dual task performance, resulting in a main effect of cognitive task (p = 0.004). In contrast, there was no significant effect of cognitive task for ApEn values of COP ML time series, RMS displacement (AP or ML) or ES. Conclusion: During dual task performance, ApEn revealed a change in the randomness of COP oscillations that occurred in a variety of sensory conditions, independent of changes in the amplitude of COP oscillations. The finding expands current support for the potential of ApEn to detect subtle changes in postural control. Implications for future studies of attention in neuroscience and physical rehabilitation are discussed.	[Cavanaugh, James T.] Univ New England, Dept Phys Therapy, Portland, ME 04103 USA; [Mercer, Vicki S.] Univ N Carolina, Dept Allied Hlth Sci, Chapel Hill, NC USA; [Stergiou, Nicholas] Univ Nebraska, HPER Biomechan Lab, Omaha, NE 68182 USA	Cavanaugh, JT (corresponding author), Univ New England, Dept Phys Therapy, Portland, ME 04103 USA.	jcavanaugh@une.edu; vmercer@med.unc.edu; nstergiou@mail.unomaha.edu	Mercer, Vicki/AAN-6669-2021	Cavanaugh, James/0000-0001-7132-6313			Allain H, 2003, PSYCHOPHARMACOLOGY, V165, P419, DOI 10.1007/s00213-002-1272-2; Andersson G, 1998, AM J OTOL, V19, P632; Barin K, 1997, Biomed Sci Instrum, V33, P388; Buatois S, 2006, GERONTOLOGY, V52, P345, DOI 10.1159/000094983; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Cavanaugh JT, 2004, GAIT POSTURE S1, V20, pS55; Dault MC, 2003, COGNITIVE BRAIN RES, V16, P434, DOI 10.1016/S0926-6410(03)00058-2; Davids K, 2003, SPORTS MED, V33, P245, DOI 10.2165/00007256-200333040-00001; Di Nardo W, 1999, J DIABETES COMPLICAT, V13, P79, DOI 10.1016/S1056-8727(99)00032-X; GRASSBERGER P, 1983, PHYSICA D, V9, P189, DOI 10.1016/0167-2789(83)90298-1; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, ORTHOP PHYS THER CLI, V11, P143; Harbourne RT, 2003, DEV PSYCHOBIOL, V42, P368, DOI 10.1002/dev.10110; Hatta T, 2004, APPL NEUROPSYCHOL, V11, P153, DOI 10.1207/s15324826an1103_3; Huxhold O, 2006, BRAIN RES BULL, V69, P294, DOI 10.1016/j.brainresbull.2006.01.002; Hyndman D, 2006, DISABIL REHABIL, V28, P849, DOI 10.1080/09638280500534994; Lajoie Y, 2004, AGING CLIN EXP RES, V16, P363; Lee D, 1975, J HUMAN MOVEMENT STU, V1, P87, DOI DOI 10.3758/BF03199297; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mitra S, 2004, J EXP PSYCHOL HUMAN, V30, P28, DOI 10.1037/0096-1523.30.1.28; *NEUR INT INC, 1991, NEUROCOM EQ SYST DAT; Newell K., 1998, APPL NONLINEAR DYNAM, P80; Nyberg L, 2006, CYBERPSYCHOL BEHAV, V9, P388, DOI 10.1089/cpb.2006.9.388; Perez N, 2006, EUR ARCH OTO-RHINO-L, V263, P414, DOI 10.1007/s00405-005-1027-x; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; Quant S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-18; Redfern MS, 2001, GAIT POSTURE, V14, P211, DOI 10.1016/S0966-6362(01)00144-8; Roerdink M, 2006, EXP BRAIN RES, V174, P256, DOI 10.1007/s00221-006-0441-7; Schiff Steven J., 1994, Integrative Physiological and Behavioral Science, V29, P246, DOI 10.1007/BF02691329; Schneider M, 2006, EUR ARCH PSY CLIN N, V256, P32, DOI 10.1007/s00406-006-1005-3; SHUMWAYCOOK A, 2000, BIOL SCI MED SCI, V55, pM10; SHUMWAYCOOK A, 1997, BIOL SCI MED SCI, V52, pM232; Stergiou N, 2004, INNOVATIVE ANAL HUMA, P63; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stoffregen TA, 1999, J EXP PSYCHOL HUMAN, V25, P1641; TEASDALE N, 1993, EXP AGING RES, V19, P1, DOI 10.1080/03610739308253919; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Theiler J, 1996, ELECTROEN CLIN NEURO, V98, P213, DOI 10.1016/0013-4694(95)00240-5; Vaillancourt DE, 2000, CLIN NEUROPHYSIOL, V111, P2046, DOI 10.1016/S1388-2457(00)00467-3; Vuillerme N, 2000, NEUROSCI LETT, V291, P77, DOI 10.1016/S0304-3940(00)01374-4; Woollacott M, 2002, GAIT POSTURE, V16, P1, DOI 10.1016/S0966-6362(01)00156-4; Yardley L, 1999, NEUROREPORT, V10, P215, DOI 10.1097/00001756-199902050-00003; Yardley L, 2001, J NEUROL NEUROSUR PS, V71, P48, DOI 10.1136/jnnp.71.1.48	46	93	94	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	OCT 30	2007	4								42	10.1186/1743-0003-4-42			7	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	251YD	WOS:000252411100001	17971209	DOAJ Gold, Green Published			2021-06-18	
J	Qiu, W; Zhang, Y; Sheng, H; Zhang, JM; Wang, WM; Liu, WG; Chen, KY; Zhou, JF; Xu, ZF				Qiu, Wusi; Zhang, Ying; Sheng, Hong; Zhang, Jianmin; Wang, Weiming; Liu, Weiguo; Chen, Keyong; Zhou, Junfu; Xu, Zefeng			Effects of therapeutic mild hypothermia on patients with severe traumatic brain injury after craniotomy	JOURNAL OF CRITICAL CARE			English	Article						traumatic brain injury; hypothermia; craniotomy; intracranial pressure; superoxide dismutase; prognosis	SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; CLINICAL-TRIAL; CRITICAL-CARE; MANAGEMENT; CHILDREN; RODENTS	Purpose: We investigated the effects of therapeutic mild hypothermia on patients with severe traumatic brain injury after craniotomy (TBI). Methods: Eighty patients with severe TBI after unilateral craniotomy were randomized into a therapeutic hypothermia group with the brain temperature maintained at 33 degrees C to 35 degrees C for 4 days, and a normothermia control group in the intensive care unit. Vital signs, intracranial pressure, serum superoxide dismutase level, Glasgow Outcome Scale scores, and complications were prospectively analyzed. Results: The mean intracranial pressure values of the therapeutic hypothermia group at 24, 48, and 72 hours after injury were much lower than those of the control group (23.49 +/- 2.38, 24.68 +/- 1.71, and 22.51 +/- 2.44 vs 25.87 +/- 2.18, 25.90 +/- 1.86, and 24.57 +/- 3.95 mm Hg; P = .000, .000, and .003, respectively). The mean serum superoxide dismutase levels of the therapeutic hypothermia group at days 3 and 7 were much higher than those of the control group at the same time point (533.0 +/- 103.4 and 600.5 +/- 82.9 vs 458.7 +/- 68.1 and 497.0 +/- 57.3 mu g/L, respectively; P = .000). The percentage of favorable neurologic outcome 1 year after injury was 70.0% and 47.5%, respectively (P = .041). Complications, including pulmonary infections (57.5% in the therapeutic hypothermia group vs 32.5% in the control group; P = .025) were managed without severe sequelae. Conclusions: Therapeutic mild hypothermia provides a promising way in the intensive care unit for patients with severe TBI after craniotomy. (C) 2007 Elsevier Inc. All rights reserved.	[Qiu, Wusi; Zhang, Ying; Wang, Weiming] Hangzhou Hosp 2, Dept Neurosurg, Sch Med, Hangzhou Normal Coll, Hangzhou 310012, Peoples R China; [Qiu, Wusi; Sheng, Hong; Zhang, Jianmin; Liu, Weiguo; Zhou, Junfu; Xu, Zefeng] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Brain Ctr, Hangzhou 310009, Peoples R China	Qiu, W (corresponding author), Hangzhou Hosp 2, Dept Neurosurg, Sch Med, Hangzhou Normal Coll, Hangzhou 310012, Peoples R China.	shihai954@163.com; sh_2nd@163.com					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 2005, CRIT CARE MED, V33, P1890, DOI 10.1097/01.CCM.0000174103.99462.1E; Akinci OI, 2005, J CRIT CARE, V20, P66, DOI 10.1016/j.jcrc.2004.11.001; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Brooks AJ, 2005, INJURY, V36, P310, DOI 10.1016/j.injury.2004.09.023; Burger R, 2004, NEUROSURGERY, V54, P701, DOI 10.1227/01.NEU.0000108784.80585.EE; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; Hinerfeld D, 2004, J NEUROCHEM, V88, P657, DOI 10.1046/j.1471-4159.2003.02195.x; Hovland A, 2006, RESUSCITATION, V68, P143, DOI 10.1016/j.resuscitation.2005.05.019; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kinoshita K, 2003, ACTA NEUROCHIR SUPPL, V86, P373; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Yamamoto T, 2002, NEUROL RES, V24, P789, DOI 10.1179/016164102101200906; Yunoki M, 2003, SURG NEUROL, V59, P156, DOI 10.1016/S0090-3019(02)01040-6; Zhou JF, 2002, BIOMED ENVIRON SCI, V15, P233	32	93	98	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	SEP	2007	22	3					229	235		10.1016/j.jcrc.2006.06.011			7	Critical Care Medicine	General & Internal Medicine	256HO	WOS:000252719200008	17869973				2021-06-18	
J	Boden, BP; Tacchetti, RL; Cantu, RC; Knowles, SB; Mueller, FO				Boden, Barry P.; Tacchetti, Robin L.; Cantu, Robert C.; Knowles, Sarah B.; Mueller, Frederick O.			Catastrophic head injuries in high school and college football players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						football; subdural hematoma; severe head injury	ACUTE SUBDURAL-HEMATOMA; BRAIN-INJURY; AMERICAN FOOTBALL; CONCUSSION	Background: Catastrophic head injuries in football are rare but tragic events. Purpose: To update the profile of catastrophic head injuries in high school and college football players and to describe relevant risk factors. Study Design: Case series; Level of evidence, 4. Methods: We reviewed 94 incidents of severe football head injuries reported to the National Center for Catastrophic Sports Injury Research during 13 academic years (September 1989 through June 2002). Results: In the study period there were an average of 7.23 (standard deviation = 2.05) direct high school and college catastrophic head injuries in scholastic football participants per year. There were 0.67 injuries per 100 000 (95% confidence interval: 0.54, 0.81 per 100 000) high school and 0.21 injuries per 100 000 (95% confidence interval: 0.0, 0.49 per 100 000) college participants for a risk ratio of 3.28 (95% confidence interval: 0.81, 13.3). The injuries resulted in subdural hematoma in 75 athletes, subdural hematoma with diffuse brain edema in 10 athletes, diffuse brain edema in 5 athletes, and arteriovenous malformation or aneurysm in 4 athletes. Fifty-nine percent of the contacts reported that the athlete had a history of a previous head injury, of which 71% occurred within the same season as the catastrophic event. Thirty-nine percent of the athletes (21 of 54) were playing with residual neurologic symptoms from the prior head injury. There were 8 (9%) deaths as a result of the injury, 46 (51%) permanent neurologic injuries, and 36 (40%) serious injuries with full recovery. Most players sustained a major impact to the head either from tackling or being tackled. Conclusion: The incidence of catastrophic head injuries in football has remained low since the advent of the modern day football helmet in the early 1970s. The incidence of catastrophic head injuries in football is dramatically higher at the high school level than at the college level. Although the reason for this discrepancy is unclear, an unacceptably high percentage of high school players were playing with residual symptoms from a prior head injury. Coaches, athletes, athletic trainers, and medical personnel need to adhere to the guideline that an athlete with any neurologic symptoms from a head injury should be strongly discouraged from returning to play.	Orthopaed Ctr, Med Ctr 9711, Rockville, MD 20850 USA; Emerson Hosp, Concord, MA USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA	Boden, BP (corresponding author), Orthopaed Ctr, Med Ctr 9711, Dr 201, Rockville, MD 20850 USA.	bboden@starpower.net					Boden BP, 2006, AM J SPORT MED, V34, P1223, DOI 10.1177/0363546506288306; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kersey RD, 1998, J ATHL TRAINING, V33, P264; Logan SM, 2001, J ATHL TRAINING, V36, P433; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; Mueller FO, 1996, CATASTROPHIC INJURIE, P1; *NAT FED STAT HIGH, 2002, PART SURV; *NCCSIR, 2005, NCCSIR 12 ANN REP; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	20	93	93	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2007	35	7					1075	1081		10.1177/0363546507299239			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	186XZ	WOS:000247813200005	17351124				2021-06-18	
J	Jensen, MP; Kuehn, CM; Amtmann, D; Cardenas, DA				Jensen, Mark P.; Kuehn, Carrie M.; Amtmann, Dagmar; Cardenas, Diane A.			Symptom burden in persons with spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						fatigue; pain; rehabilitation; signs and symptoms; spinal cord injuries	COMMUNITY INTEGRATION QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; MILD COGNITIVE IMPAIRMENT; CLOSED HEAD-INJURY; QUALITY-OF-LIFE; CHRONIC PAIN; MEMORY IMPAIRMENT; NEUROPATHIC PAIN; CASE SERIES; PREVALENCE	Objective: To determine (1) the frequency, severity, and reported course of 7 symptoms in persons with spinal cord injury (SCI) and (2) the association between these symptoms and patient functioning. Design: Postal survey. Setting: Community. Intervention: A survey that included measures of the frequency, severity, and recalled course of pain, fatigue, numbness, weakness, shortness of breath, vision loss, and memory loss, as well as a measure of community integration and psychologic functioning was mailed to a sample of persons with SCI. One hundred forty-seven usable surveys were returned (response rate, 43% of surveys mailed). Main Outcome Measures: The frequency and average severity of each symptom was computed, and the frequencies of each type of reported course were noted. Analyses estimated the associations among the symptoms, and between symptom severity and measures of patient functioning. Results: The most common symptoms were pain, weakness, fatigue, and numbness. All symptoms were reported to remain the same or to get worse more often than they were reported to improve once they began. Pain, weakness, fatigue, and memory loss were the symptoms most closely associated with patient functioning. Conclusions: Patients with SCI must deal with a number of secondary complications in addition to any disability caused by the injury itself. Of 7 symptoms studied, pain, weakness, and fatigue appeared to be most common and most closely linked to patient social and mental health functioning. Research is needed to identify the causal relationships between perceived symptoms and quality of life in patients with SCI and to identify effective treatments for those symptoms shown to impact patient functioning.	Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA; Univ Miami, Miller Sch Med, Dept Rehabil Med, Miami, FL 33152 USA	Jensen, MP (corresponding author), Univ Washington, Dept Rehabil Med, Sch Med, Box 356490, Seattle, WA 98195 USA.	mjensen@u.washington.edu		Kuehn, Carrie/0000-0001-5762-1682	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD033988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U01AR052171] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U01 AR052171-01, U01 AR52171-01, U01 AR052171] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD033988-020001, P01 HD033988, P01 HD33988] Funding Source: Medline		Ahn SH, 2003, SPINE, V28, P341, DOI 10.1097/00007632-200302150-00005; ANKE AGW, 1995, PARAPLEGIA, V33, P555, DOI 10.1038/sc.1995.120; Ayas N T, 1999, J Spinal Cord Med, V22, P97; Biering-Sorensen F, 2001, SPINAL CORD, V39, P505, DOI 10.1038/sj.sc.3101197; Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010; Buchholz AC, 2005, SPINAL CORD, V43, P513, DOI 10.1038/sj.sc.3101744; Budh CN, 2005, SPINAL CORD, V43, P85, DOI 10.1038/sj.sc.3101680; Caliri MHL, 2005, NURS CLIN N AM, V40, P337, DOI 10.1016/j.cnur.2004.09.009; Capel ID, 2003, SPINAL CORD, V41, P109, DOI 10.1038/sj.sc.3101401; Capoor Jaishree, 2005, Phys Med Rehabil Clin N Am, V16, P129, DOI 10.1016/j.pmr.2004.06.016; Cardenas DD, 2002, PAIN, V96, P365, DOI 10.1016/S0304-3959(01)00483-3; Castro MJ, 1999, J APPL PHYSIOL, V86, P350; Chen D, 2000, Phys Med Rehabil Clin N Am, V11, P45; CORIA F, 1993, J NEUROL NEUROSUR PS, V56, P973, DOI 10.1136/jnnp.56.9.973; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Donnelly C, 2005, SPINAL CORD, V43, P278, DOI 10.1038/sj.sc.3101702; Dryden DM, 2005, NEUROEPIDEMIOLOGY, V25, P55, DOI 10.1159/000086284; Ehde DM, 2004, REHABIL PSYCHOL, V49, P254, DOI 10.1037/0090-5550.49.3.254; Ehde DM, 2003, CLIN J PAIN, V19, P3, DOI 10.1097/00002508-200301000-00002; Finnerup NB, 2002, PAIN, V96, P375, DOI 10.1016/S0304-3959(01)00484-5; GERHART KA, 1997, AM REHABIL, V23, P19; Go Bette K., 1995, P21; Gordon T, 1995, ADV EXP MED BIOL, V384, P429; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Grandas NF, 2005, ARCH PHYS MED REHAB, V86, P1631, DOI 10.1016/j.apmr.2005.02.006; Haran MJ, 2005, ARCH PHYS MED REHAB, V86, P2290, DOI 10.1016/j.apmr.2005.07.293; Hicks AL, 2003, SPINAL CORD, V41, P34, DOI 10.1038/sj.sc.3101389; Jamil F, 2001, SPINAL CORD, V39, P355, DOI 10.1038/sj.sc.3101132; Jensen MP, 2005, SPINAL CORD, V43, P704, DOI 10.1038/sj.sc.3101777; Jensen MP, 2005, INT J CLIN EXP HYP, V53, P198, DOI 10.1080/00207140590927545; Jensen MP, 2004, PSYCHOLOGICA, V37, P129; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; KOIVISTO K, 1995, NEUROLOGY, V45, P741, DOI 10.1212/WNL.45.4.741; KREUTZER JS, 1988, ARCH PHYS MED REHAB, V69, P764; Leoni MEG, 2003, CLIN MICROBIOL INFEC, V9, P780, DOI 10.1046/j.1469-0691.2003.00643.x; Levendoglu F, 2004, SPINE, V29, P743, DOI 10.1097/01.BRS.0000112068.16108.3A; Liem NR, 2004, ARCH PHYS MED REHAB, V85, P1567, DOI 10.1016/j.apmr.2003.12.038; Linn WS, 2003, J SPINAL CORD MED, V26, P28, DOI 10.1080/10790268.2003.11753657; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385; Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879; McColl MA, 2004, ARCH PHYS MED REHAB, V85, P363, DOI 10.1016/j.apmr.2003.06.022; McColl MA, 2003, ARCH PHYS MED REHAB, V84, P1137, DOI 10.1016/S0003-9993(03)00138-2; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McComas AJ, 1995, ADV EXP MED BIOL, V384, P495; Nissen KR, 2003, OPHTHAL EPIDEMIOL, V10, P279, DOI 10.1076/opep.10.4.279.15909; Panagos A, 2004, J SPINAL CORD MED, V27, P138, DOI 10.1080/10790268.2004.11753745; Rintala DH, 2004, J REHABIL RES DEV, V41, P75, DOI 10.1682/JRRD.2004.01.0075; Rintala DH, 1998, ARCH PHYS MED REHAB, V79, P604, DOI 10.1016/S0003-9993(98)90032-6; Ritchie K, 2001, NEUROLOGY, V56, P37, DOI 10.1212/WNL.56.1.37; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Shapiro S, 2005, J NEUROSURG-SPINE, V2, P3, DOI 10.3171/spi.2005.2.1.0003; Sherman AL, 1997, ARCH PHYS MED REHAB, V78, P1012, DOI 10.1016/S0003-9993(97)90068-X; Shields RK, 2002, J ORTHOP SPORT PHYS, V32, P65, DOI 10.2519/jospt.2002.32.2.65; Song HY, 2005, DISABIL REHABIL, V27, P131, DOI 10.1080/09638280400007372; Spungen AM, 1997, SPINAL CORD, V35, P652, DOI 10.1038/sj.sc.3100489; Stein RB, 2002, PROG BRAIN RES, V137, P27; Stormer S, 1997, SPINAL CORD, V35, P446, DOI 10.1038/sj.sc.3100411; Thomas CK, 1998, J NEUROTRAUM, V15, P149, DOI 10.1089/neu.1998.15.149; Turner JA, 2002, PAIN, V98, P127, DOI 10.1016/S0304-3959(02)00045-3; Turner JA, 2001, ARCH PHYS MED REHAB, V82, P501, DOI 10.1053/apmr.2001.21855; Vaccaro AR, 1998, J SPINAL DISORD, V11, P535; Ware JE., 2000, SF 36 HLTH SURVEY MA; Westgren N, 1998, ARCH PHYS MED REHAB, V79, P1433, DOI 10.1016/S0003-9993(98)90240-4; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	67	93	93	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2007	88	5					638	645		10.1016/j.apmr.2007.02.002			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	164MN	WOS:000246238200015	17466734	Green Accepted			2021-06-18	
J	Dick, R; Hootman, JM; Agel, J; Vela, L; Marshall, SW; Messina, R				Dick, Randall; Hootman, Jennifer M.; Agel, Julie; Vela, Luzita; Marshall, Stephen W.; Messina, Renee			Descriptive epidemiology of collegiate women's field hockey injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2002-2003	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; knee injuries; ankle injuries; concussions	SPORT; PATTERNS; SEX	Objective: To review 15 years of National Collegiate Athletic Association (NCAA) injury surveillance data for women's field hockey and identify potential areas for injury prevention initiatives. Background: Field hockey is one of the most popular sports worldwide and is growing in participation in the United States, particularly among women. From 1988-1989 to 2002-2003, participation in NCAA women's field hockey increased 12%, with the largest growth among Division III programs. In 2002-2003, 253 colleges offered women's field hockey and 5385 women participated. Main Results: Game injury rates showed a significant average annual 2.5% decline over 15 years, most likely fueled by drops in ankle ligament sprain, knee internal derangement, and finger fracture injuries. Despite this, ankle ligament sprains were common (13.7% of game and 15.0% of practice injuries) and a frequent cause of severe injuries (resulting in 10+ days of time-loss activity). Concussion and head laceration injuries increased over this same time, and the risk of sustaining a concussion in a game was 6 times higher than the risk of sustaining one during practice. Overall, injury rates were twice as high in games as in practices (7.87 versus 3.70 injuries per 1000 athlete-exposures, rate ratio = 2.1, 95% confidence interval = 2.0, 2.3). Most head/neck/face (71%) and hand/finger/thumb (68%) injuries occurred when the player was near the goal or within the 25-yd line and were caused by contact with the stick or ball (greater than 77% for both body sites); for 34% of head/neck/ face injuries, a penalty was called on the play. Recommendations: Equipment (requiring helmets and padded gloves) and rule changes (to decrease field congestion near the goal) as well as evidence-based injury prevention interventions (eg, prophylactic ankle taping/bracing, neuromuscular balance exercise programs) may be viable prevention initiatives for reducing injury rates in women's collegiate field hockey players.	Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30341 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA; Univ Minnesota, Minneapolis, MN 55455 USA; W Chester Univ, W Chester, PA USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Penn State Univ, University Pk, PA 16802 USA	Hootman, JM (corresponding author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, 4770 Buford Highway NE,MSK-51, Atlanta, GA 30341 USA.	jhootman@cdc.gov		Marshall, Stephen/0000-0002-2664-9233			Beynnon BD, 2005, AM J SPORT MED, V33, P1485, DOI 10.1177/0363546505275490; Bolhuis J H, 1987, Br J Sports Med, V21, P174; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Dick R, 2007, J ATHL TRAINING, V42, P173; HANDOLL HH, 2001, COCHRANE DB SYST REV, V2; JAGDAY S, NEW OFFSIDE RULE; Junge A, 2006, AM J SPORT MED, V34, P565, DOI 10.1177/0363546505281807; MATTEI A, US OPINION GOGGLES M; Murtaugh K, 2001, MED SCI SPORT EXER, V33, P201; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA; Okafor B, 1997, J BONE JOINT SURG BR, V79B, P544, DOI 10.1302/0301-620X.79B4.7432; Olmsted LC, 2004, J ATHL TRAINING, V39, P95; Powell JW, 1999, J ATHL TRAINING, V34, P277; Rosberg HE, 2005, SCAND J PLAST RECONS, V39, P360, DOI 10.1080/02844310500340046; Stevenson MR, 2000, BRIT J SPORT MED, V34, P188, DOI 10.1136/bjsm.34.3.188; Tully MA, 2003, BRIT J SPORT MED, V37, P373, DOI 10.1136/bjsm.37.4.373; Yard EE, 2006, J ATHL TRAINING, V41, P441	17	93	94	0	28	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					211	220					10	Sport Sciences	Sport Sciences	180RC	WOS:000247382300007	17710169				2021-06-18	
J	Flaada, JT; Leibson, CL; Mandrekar, JN; Diehl, N; Perkins, PK; Brown, AW; Malec, JF				Flaada, Julie Testa; Leibson, Cynthia L.; Mandrekar, Jayawant N.; Diehl, Nancy; Perkins, Patricia K.; Brown, Allen W.; Malec, James F.			Relative risk of mortality after traumatic brain injury: A population-based study of the role of age and injury severity	JOURNAL OF NEUROTRAUMA			English	Article						aging; mortality; TBI	HEAD-INJURIES; TRENDS; EPIDEMIOLOGY; SURVIVAL; SEIZURES	To test if observed vs. expected mortality differs by age among traumatic brain injury (TBI) cases, a population-based, historical cohort study was conducted in Olmsted County, Minnesota. From all residents with any diagnosis suggestive of TBI 1985-1999, we randomly sampled 7,800 and reviewed their medical records to confirm the event. Confirmed incident cases were categorized by age in years (< 16 = pediatric, 16-65 = adult, > 65 = elderly) and severity (moderate/severe vs. mild) and followed for vital status through 6/30/2004. We compared observed 6-month and 10-year mortality with expected and tested if the differences varied by age. Of 1,433 confirmed incident cases, 35% were pediatric; 55% were adult; only 9% were elderly; 11.2% of all cases were moderate/severe; the proportions by increasing age group were 11.4%, 8.5%, 26.7%. The proportions who died within 6 months increased with increasing age group, both for moderate/severe (10.3%, 40.3%, 50.0%) and mild cases (0%, 0%, 9.1%); mortality for moderate/severe cases was nearly 40 times that for mild cases, independent of age. Among 6-month survivors, 10-year mortality differed from expected only for adult cases. For all cases, after adjusting for sex, year of TBI, and severity, the difference between observed and expected 10-year mortality was greater for adult cases than for pediatric cases and similar for adult and elderly cases. Elderly individuals account for < 10% of TBI cases and > 50% of 10-year mortality, yet much of this discrepancy reflects age-associated mortality in general. Findings have implications for (1) reducing the number of excess deaths following TBI and (2) caring for survivors.	Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA	Malec, JF (corresponding author), Mayo Clin, Dept Psychiat & Psychol, 200 1st St SW, Rochester, MN 55905 USA.	malec.james@mayo.edu		Brown, Allen W./0000-0001-7228-3351	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R56HD007447, R01HD007447] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HI33A020507] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-07447] Funding Source: Medline		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; GOLEBURN CR, 2001, J CLIN GEROPSYCHOLOG, V7, P161; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; *NATL CTR INJ PREV, 2003, REPORT CONGRESS MILD; Ogungbo B, 2004, J AM COLL SURGEONS, V198, P852, DOI 10.1016/j.jamcollsurg.2004.02.003; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE GM, 1979, ACTA NEUROCHIR S, V75, pS37; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA	25	93	94	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2007	24	3					435	445		10.1089/neu.2006.0119			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	152RQ	WOS:000245379900001	17402850				2021-06-18	
J	Setnik, L; Bazarian, JJ				Setnik, Lon; Bazarian, Jeffrey J.			The characteristics of patients who do not seek medical treatment for traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; survey; internet	COMPUTED-TOMOGRAPHY; UNITED-STATES; HEAD-INJURY; MILD; INTERNET; PREDICTORS	Primary objective: To identify factors associated with not seeking medical care for traumatic brain injury (TBI). Research Design: Internet survey. Methods and procedures: The survey consisted of 17 questions related to demographics, TBI case ascertainment, location and mechanism of injury, type of treatment sought, and post-concussive (PC) symptoms. Logistic regression was used to identify factors associated with not seeking medical care. Main outcome and results: Of the 1381 survey respondents with TBI, 584 (42%) did not seek medical care. TBI respondents were less likely to seek care if they were older (OR 0.98, 95% CI 0.97-0.99), suffered a mild TBI grade 2/3 (OR 0.42, 95% CI 0.31-0.58), or were injured in the home (OR 0.53, 95% CI 0.36-0.78). Conclusions: Several factors associated with not seeking medical care after TBI were identified. Raising public awareness of the signs and symptoms of TBI, and the benefits of medical care, could help increase the number of TBI patients who seek medical care.	Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA; Elliot Hosp, Manchester, NH USA	Bazarian, JJ (corresponding author), Univ Rochester, Sch Med, Dept Emergency Med, Box 655, Rochester, NY USA.	Jeff_Bazarian@urmc.rochester.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS41952-05] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BOREZUK P, 1997, EMERGENCY MED CLIN N, V15, P563; BOREZUK P, 1995, ANN EMERG MED, V25, P1; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Diaz JA, 2002, J GEN INTERN MED, V17, P180, DOI 10.1046/j.1525-1497.2002.10603.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Houston TK, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e7; Houston TK, 2001, PSYCHIATR SERV, V52, P362, DOI 10.1176/appi.ps.52.3.362; *INT WORLD STAT, US POP STAT; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Nathanson AT, 1999, WILD ENVIRON MED, V10, P218, DOI 10.1580/1080-6032(1999)010[0218:WIROAP]2.3.CO;2; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; J HOPKINS SKIING SNO; ONLINE REPORTING SYS; NIH POLICY REPORTING; 2000, SOCIAL SCI Q, V81, P868	34	93	93	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2007	21	1					1	9		10.1080/02699050601111419			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600001	17364514				2021-06-18	
J	Zhang, T; Yan, YN; Wang, XH; Xiong, Z; Lin, F; Wu, RD; Zhang, RJ				Zhang, Ting; Yan, Yongnian; Wang, Xiaohong; Xiong, Zhuo; Lin, Feng; Wu, Rendong; Zhang, Renj			Three-dimensional gelatin and gelatin/hyaluronan hydrogel structures for traumatic brain injury	JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS			English	Article						cell assembling; gelatin; hyaluronan; central nervous system; biocompatibility; biodegradation	HYALURONIC-ACID; SYSTEM; FABRICATION; SCAFFOLDS; DELIVERY; MATRIX; REPAIR; CELLS; RAT	Brain tissue engineering has now emerged as one of the most promising treatments for the traumatic brain injury. In this article, two groups of three-dimensional (3D) hydrogel structures composed of gelatin and gelatin/hyaluronan have been formed using our 3D cell assembly technique for in vivo study in rats, in order to investigate their effects in reparation of injury in the central nervous system (CNS). The structures were implanted into cortical defects created in rat brains, and their abilities to improve the brain tissue reconstruction were then evaluated. After 4, 8, 10, and 13 weeks of implantation, sections of brains were processed with NISSL staining for observing the immigration of host neural cells into the implanted materials and the degradation property of the materials. The results showed that simplex gelatin and gelatin/hyaluronan (20:1) with 3D structures both have good biocompatibility with brain tissue while gelatin/hyaluronan has a better contiguity with the surrounding tissue. Through our primary study, it seems that 3D gelatin/hyaluronan structures may be useful in brain tissue repair.	Tsing Hua Univ, Key Lab Adv Mfg Mat Proc Technol, Beijing 100084, Peoples R China; Tsing Hua Univ, Dept Engn Mech, Ctr Organ Mfg, Beijing 100084, Peoples R China; Tsing Hua Univ, Inst Life Sci & Med, Beijing 100084, Peoples R China	Wang, XH (corresponding author), Tsing Hua Univ, Key Lab Adv Mfg Mat Proc Technol, Beijing 100084, Peoples R China.	wangxiaohong@tsinghua.edu.cn	Wang, Zhong Lin/E-2176-2011; Lin, Feng/K-7906-2012	Wang, Zhong Lin/0000-0002-5530-0380; Lin, Feng/0000-0003-1855-504X			Choi YS, 1999, BIOMATERIALS, V20, P409, DOI 10.1016/S0142-9612(98)00180-X; CHRISTINE E, 2003, EXPT GERONTOL, V38, P79; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; Landers R, 2002, BIOMATERIALS, V23, P4437, DOI 10.1016/S0142-9612(02)00139-4; Lesny P, 2002, J CHEM NEUROANAT, V23, P243, DOI 10.1016/S0891-0618(02)00011-X; Liu HX, 2006, CHINESE SCI BULL, V51, P1830, DOI 10.1007/s11434-006-2045-9; Luo Y, 2000, J CONTROL RELEASE, V69, P169, DOI 10.1016/S0168-3659(00)00300-X; Ma W, 2005, MACROMOL SYMP, V227, P327, DOI 10.1002/masy.200550933; Mironov V, 2003, TRENDS BIOTECHNOL, V21, P157, DOI 10.1016/S0167-7799(03)00033-7; SANES JR, 1983, ANNU REV PHYSIOL, V45, P581, DOI 10.1146/annurev.ph.45.030183.003053; SECKEL BR, 1995, J NEUROSCI RES, V40, P318, DOI 10.1002/jnr.490400305; Sun W, 2002, COMPUT METH PROG BIO, V67, P85, DOI 10.1016/S0169-2607(01)00116-X; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Wang XH, 2006, TISSUE ENG, V12, P83, DOI 10.1089/ten.2006.12.83; West JL, 1996, J REPROD MED, V41, P149; Woerly S, 1996, NEUROSCI LETT, V205, P197, DOI 10.1016/0304-3940(96)12349-1; Woerly S, 1997, MATER SCI FORUM, V250, P53, DOI 10.4028/www.scientific.net/MSF.250.53; Xiong Z, 2002, SCRIPTA MATER, V46, P771, DOI 10.1016/S1359-6462(02)00071-4; Yan YN, 2005, BIOMATERIALS, V26, P5864, DOI 10.1016/j.biomaterials.2005.02.027; Yan YN, 2005, J BIOACT COMPAT POL, V20, P259, DOI 10.1177/0883911505053658	21	93	94	0	42	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0883-9115			J BIOACT COMPAT POL	J. Bioact. Compat. Polym.	JAN	2007	22	1					19	29		10.1177/0883911506074025			11	Biotechnology & Applied Microbiology; Materials Science, Biomaterials; Polymer Science	Biotechnology & Applied Microbiology; Materials Science; Polymer Science	126BQ	WOS:000243487600002					2021-06-18	
J	Berger, RP; Dulani, T; Adelson, PD; Leventhal, JM; Richichi, R; Kochanek, PM				Berger, RP; Dulani, T; Adelson, PD; Leventhal, JM; Richichi, R; Kochanek, PM			Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: A possible screening tool	PEDIATRICS			English	Article						biomarker; blood and CSF; neuron-specific enolase; child abuse; inflicted traumatic brain injury	COMPUTED-TOMOGRAPHY; PROTEIN S100B; CHILD-ABUSE; HEAD-INJURY; DAMAGE	OBJECTIVE. Inflicted traumatic brain injury (iTBI) is the leading cause of death from TBI in infants. Misdiagnosis of iTBI is common and results in increased morbidity and mortality. Biomarkers may be able to assist in screening infants who are at high risk for iTBI and whose injury might otherwise be missed. We investigated whether serum and/or cerebrospinal fluid (CSF) concentrations of neuron-specific enolase (NSE), S100B, and myelin-basic protein (MBP) are sensitive and specific for iTBI in high-risk infants. METHODS. A prospective case-control study was conducted of 98 well-appearing infants who presented with nonspecific symptoms and no history of trauma. Serum or CSF was collected. NSE, S100B, and MBP concentrations were measured by enzyme-linked immunosorbent assay. Abnormal marker concentrations were defined a priori. Patients were followed for 12 months to assess for subsequent abuse. RESULTS. Fourteen patients received a clinical diagnosis of iTBI. Using preestablished cutoffs, NSE was 77% sensitive and 66% specific and MBP was 36% sensitive and 100% specific for iTBI. S100B was neither sensitive nor specific for iTBI. Five patients who were not identified with iTBI at enrollment were identified at follow-up as being possible victims of abuse; 4 had an increased NSE concentration at enrollment. CONCLUSIONS. Serum and/or CSF concentrations of NSE and MBP may be useful as a screening test to identify infants who are at increased risk for iTBI and may benefit from additional evaluation with a head computed tomography scan. S100B is neither sensitive nor specific for iTBI in this study population. The ability to identify iTBI that might otherwise be missed has important implications for decreasing the morbidity and the mortality from iTBI.	Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Pediat, Pittsburgh, PA 15217 USA; Childrens Hosp Pittsburgh, Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15217 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Stat Anal & Measurement Consultants Inc, Lanexa, VA USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Berger, RP (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15217 USA.	rberger@pitt.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD43843-01] Funding Source: Medline; ODCDC CDC HHS [R49/CCR323155-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER		Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Benz MG, 2004, PEDIATRICS, V114, P205, DOI 10.1542/peds.114.1.205; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2002, NEUROSURG CLIN N AM, V13, P149, DOI 10.1016/S1042-3680(02)00002-5; Ellaway BA, 2004, ARCH DIS CHILD, V89, P845, DOI 10.1136/adc.2003.035493; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Motin VG, 2002, B EXP BIOL MED+, V133, P110, DOI 10.1023/A:1015518015515; Nikitin V P, 2002, Neurosci Behav Physiol, V32, P25, DOI 10.1023/A:1012992124052; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; Pitetti RD, 2002, PEDIATRICS, V110, P557, DOI 10.1542/peds.110.3.557; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; *US DEP HHS, 1986, 872905 NIH; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9	26	93	103	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2006	117	2					325	332		10.1542/peds.2005-0711			8	Pediatrics	Pediatrics	014PC	WOS:000235491100009	16452350				2021-06-18	
J	Pellman, EJ; Viano, DC; Withnall, C; Shewchenko, N; Bir, CA; Halstead, PD				Pellman, EJ; Viano, DC; Withnall, C; Shewchenko, N; Bir, CA; Halstead, PD			Concussion in professional football: Helmet testing to assess impact performance - Part 11	NEUROSURGERY			English	Article						concussion; helmets; protective headgear; recreation and sport; sports equipment	INJURY; BIOMECHANICS; SKULL; HEAD	OBJECTIVE: National Football League (NFL) concussions occur at an impact velocity of 9.3 +/- 1.9 m/s (20.8 +/- 4.2 mph) oblique on the facemask, side, and back of the helmet. There is a need for new testing to evaluate helmet performance for impacts causing concussion. This study provides background on new testing methods that form a basis for supplemental National Operating Committee on Standards for Athletic Equipment (NOCSAE) helmet standards. METHODS: First, pendulum impacts were used to simulate 7.4 and 9.3 m/s impacts causing concussion in NFL players. An instrumented Hybrid III head was helmeted and supported on the neck, which was fixed to a sliding table for frontal and lateral impacts. Second, a linear pneumatic impactor was used to evaluate helmets at 9.3 m/s and an elite impact condition at 11.2 m/s. The upper torso of the Hybrid III dummy was used. It allowed interactions with shoulder pads and other equipment. The severity of the head responses was measured by a severity index, translational and rotational acceleration, and other biomechanical responses. High-speed videos of the helmet kinematics were also recorded. The tests were evaluated for their similarity to conditions causing NFL concussions. Finally, a new linear impactor was developed for use by NOCSAE. RESULTS: The pendulum test closely simulated the conditions causing concussion in NFL players. Newer helmet designs and padding reduced the risk of concussion in 7.4 and 9.3 m/s impacts oblique on the facemask and lateral on the helmet shell. The linear impactor provided a broader speed range for helmet testing and more interactions with safety equipment. NOCSAE has prepared a draft supplemental standard for the 7.4 and 9.3 m/s impacts using a newly designed pneumatic impactor. No helmet designs currently address the elite impact condition at 11.2 m/s, as padding bottoms out and head responses dramatically increase. CONCLUSIONS: The proposed NOCSAE standard is the first to address helmet performance in reducing concussion risks in football. Helmet performance has improved with thicker padding and fuller coverage by the she]L However, there remains a challenge for innovative designs that reduce risks in the 11.2 m/s elite impact condition.	ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; ProHLTH Care Associates LLP, Lake Success, NY USA; Biokinet & Associates Ltd, Ottawa, ON, Canada; Wayne State Univ, Ctr Bioengn, Sport Biomech Lab, Detroit, MI USA; Natl Operating Comm Stand Athlet Equipment, Overland Pk, KS USA; Univ Tennessee, Coll Engn, Impact Res Lab, Knoxville, TN USA	Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net		Bir, Cynthia/0000-0002-0777-0951			*AM SOC TEST MAT, 2001, F42901 ASTM; *AM SOC TEST MAT, 2004, F144604 ASTM; *AM SOC TEST MAT, 1989, F42901 ASTM; BACKAITIS SH, 1994, PT44 SOC AUT ENG; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Gurdjian E S, 1964, Clin Neurosurg, V12, P112; GURDJIAN E S, 1964, J Trauma, V4, P309; Gurdjian E S, 1968, Neurosci Res (N Y), V1, P333; GURDJIAN ES, 1968, GEN PRACT, V37, P78; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; HODGSON VR, 1966, J NEUROSURG, V25, P549, DOI 10.3171/jns.1966.25.5.0549; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hodgson VR, 1980, P 24 STAPP CAR CRASH; HODGSON VR, 1972, P 16 STAPP CAR CRASH, P45; Hodgson VR, 1970, P 14 STAPP CAR CRASH; Mertz H. J., 1978, PHYS SPORTS MED, V6, P95, DOI [10.1080/00913847.1978.11948406, DOI 10.1080/00913847.1978.11948406]; *NAT OP COMM STAND, 1996, 00496M04A NOCSAE; *NAT OP COMM STAND, 71487 NOCSAE; *NAT OP COMM STAND, 1998, 00298M03 NOCSAE; *NAT OP COMM STAND, 1998, 02198M05 NOCSAE; *NAT OP COMM STAND, 1996, 00396M03 NOCSAE; National Operating Committee on Standards for Athletic Equipment, 2004, 00104M05 NOCSAE; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; *SOC AUT ENG, 1994, J1733 SAE; *SOC AUT ENG, 1980, J855 SAE; *SOC AUT ENG, 1995, J2111 SAE; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; VIANO DC, 1989, ACCIDENT ANAL PREV, V21, P553, DOI 10.1016/0001-4575(89)90070-5; WITHNALL C, 2005, Patent No. 6871525	34	93	93	1	35	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2006	58	1					78	95		10.1227/01.NEU.0000196265.35238.7C			18	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	000IF	WOS:000234453800017	16385332				2021-06-18	
J	Yasukawa, A; Patel, P; Sisung, C				Yasukawa, A; Patel, P; Sisung, C			Pilot study: Investigating the effects of Kinesio Taping (R) in an acute pediatric rehabilitation setting	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article							UPPER-LIMB FUNCTION; JOINT PROPRIOCEPTION; ATHLETIC TAPE; IMPINGEMENT; MOVEMENT	OBJECTIVES. The purpose of this pilot study is to describe the use of the Kinesio Taping (R) method for the upper extremity in enhancing functional motor skills in children admitted into an acute rehabilitation program. METHOD. Fifteen children (10 females and 5 males; 4 to 16 years of age), who were receiving rehabilitation services at the Rehabilitation Institute of Chicago participated in this study. For 13 of the inpatients, this was the initial rehabilitation following an acquired disability, which included encephalitis, brain tumor, cerebral vascular accident, traumatic brain injury, and spinal cord injury. The Melbourne Assessment of Unilateral Upper Limb Function (Melbourne Assessment) was used to measure upper-limb functional change prior to use of Kinesio Tape (R), immediately after application of the tape, and 3 days after wearing tape. Children's upper-limb function was compared over the three assessments using analysis of variance. RESULTS. The improvement from pre- to posttaping was statistically significant, F(1, 14) = 18.9; p < .02. CONCLUSION. These results suggest that Kinesio Tape may be associated with improvement in upper-extremity control and function in the acute pediatric rehabilitation setting. The use of Kinesio Tape as an adjunct to treatment may assist with the goal-focused occupational therapy treatment during the child's inpatient stay. Further study is recommended to test the effectiveness of this method and to determine the lasting effects on motor skills and functional performance once the tape is removed.	LaRabida Childrens Hosp, Chicago, IL 60649 USA; Rehabil Inst Chicago, Chicago, IL 60611 USA	Yasukawa, A (corresponding author), LaRabida Childrens Hosp, E 65th St, Chicago, IL 60649 USA.	ayasukawa@larabida.org					BACH TM, 1994, DEV MED CHILD NEUROL, V36, P974; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Bourke-Taylor H, 2003, DEV MED CHILD NEUROL, V45, P92, DOI 10.1017/S0012162203000185; Bragg RW, 2002, MED SCI SPORT EXER, V34, P403, DOI 10.1097/00005768-200203000-00004; Cabri J, 2002, SPORT VERLETZUNG SPO, V16, P595; Callaghan MJ, 2002, J ATHL TRAINING, V37, P19; GRELSAMER RP, 1998, PATELLA TEAM APPROAC; HAMILTON BB, 1987, FUNCTIONAL INDEPENDE; HERTLING D, 1996, MANAGEMENT COMMON MU; HOST HH, 1995, PHYS THER, V75, P803, DOI 10.1093/ptj/75.9.803; JOHNSON LM, 1994, DEV MED CHILD NEUROL, V36, P965; Kase K., 2000, ILLUSTRATED KINESIO; Kase K., 2003, CLIN THERAPEUTIC APP, V2nd ed; KASE K, 1997, UNPUB CHANGES VOLUME; MACDONALD R, 1994, TAPING TECHNIQUES PR; Murray H, 2001, J ORTHOP SPORT PHYS, V31, pA, DOI DOI 10.2519/JOSPT.2001.31.1.A1; Randall M., 1999, MELBOURNE ASSESSMENT; REDDIHOUGH DS, 1990, DEV MED CHILD NEUROL, V33, P902; Schmitt L, 1999, J ORTHOP SPORT PHYS, V29, P31, DOI 10.2519/jospt.1999.29.1.31; SHEPHERD J, 2001, OCCUPATIONAL THERAPY; Shoger M, 2000, J ATHL TRAINING, V35, pS44; Simoneau GG, 1997, J ATHL TRAINING, V32, P141; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED	23	93	110	0	18	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	JAN-FEB	2006	60	1					104	110		10.5014/ajot.60.1.104			7	Rehabilitation	Rehabilitation	003GJ	WOS:000234669500012	16541989				2021-06-18	
J	Yao, XL; Liu, J; Lee, E; Ling, GSF; McCabe, JT				Yao, XL; Liu, J; Lee, E; Ling, GSF; McCabe, JT			Progesterone differentially regulates pro- and anti-apoptotic gene expression in cerebral cortex following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; Bcl-2; brain injury; neuroprotection; neurotrauma; progesterone	CENTRAL-NERVOUS-SYSTEM; BCL-2 MESSENGER-RNA; CELL-DEATH; IN-VIVO; ALTERED EXPRESSION; DNA FRAGMENTATION; ARTERY OCCLUSION; CONTUSION INJURY; UNITED-STATES; ADULT BRAIN	Although the administration of progesterone has been shown to be neuroprotective in experimental models of traumatic brain injury (TBI), the mechanisms for this beneficial effect are still poorly understood. The present study examined the effects of progesterone on mRNA and protein levels of the Bcl-2 apoptosis regulatory genes, bax, bad, bcl-2, and bcl-x(L), in cerebral cortex after TBI. Male Sprague-Dawley rats were subjected to either sham surgery or lateral fluid percussion brain injury of moderate severity (2.4-2.6 atm). Within 1 h post-surgery, progesterone (4 mg/kg) or vehicle (corn oil) administration was initiated for 1-7 days postoperatively. Our results indicate that bax and bad mRNA levels and Bax and Bad protein expression in the ipsilateral, injured cerebral cortex were significantly elevated post-TBI, while mRNA levels of bcl-2 and bcl-XL or Bcl-2 and Bcl-x(L) protein expression were not changed. Under the sham-treated condition, progesterone significantly increased mRNA levels of the anti-apoptotic gene, bcl-2, but down-regulated pro-apoptotic gene expression (bax and bad) in cerebral cortex. After TBI, progesterone treatment reduced bax and bad mRNA levels in the ipsilateral cerebral cortex of TBI rats, and decreased Bax and Bad protein levels. In addition, bcl-2 and bcl-x(L) mRNA levels, as well as Bcl-2 and Bcl-x(L) protein expression, were increased by progesterone in TBI injured cortex. These data indicate that one of the neuroprotective mechanisms of progesterone may be related to its differential regulation of apoptotic signals.	Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Yao, XL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.						Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Ceremuga TE, 2001, ENDOCR RES, V27, P433, DOI 10.1081/ERC-100107867; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen J, 1996, J NEUROCHEM, V67, P64; Clark RSB, 1997, J NEUROSCI, V17, P9172; *CTR DIS CONTR, 2001, TRAUM BRAIN INJ US; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; Dubal DB, 1999, J NEUROSCI, V19, P6385; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GOTSCHALL CS, 1995, J NEUROTRAUM, V12, P611, DOI 10.1089/neu.1995.12.611; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Luo Chun, 2002, Chin J Traumatol, V5, P299; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; Viegas LR, 2004, J BIOL CHEM, V279, P9831, DOI 10.1074/jbc.M312402200; Vis JC, 2001, NEUROPATH APPL NEURO, V27, P68, DOI 10.1046/j.0305-1846.2001.00305.x; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Ye X, 2001, BIOCHEM BIOPH RES CO, V286, P401, DOI 10.1006/bbrc.2001.5396; Zhang SM, 1999, CHINESE MED J-PEKING, V112, P608	51	93	103	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					656	668		10.1089/neu.2005.22.656			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400005	15941375				2021-06-18	
J	Hlatky, R; Valadka, AB; Goodman, JC; Contant, CF; Robertson, CS				Hlatky, R; Valadka, AB; Goodman, JC; Contant, CF; Robertson, CS			Patterns of energy substrates during ischemia measured in the brain by microdialysis	JOURNAL OF NEUROTRAUMA			English	Article						cerebral ischemia; glucose; lactate; microdialysis; traumatic brain injury	CEREBRAL MICRODIALYSIS; TISSUE PO-2; HEAD-INJURY; OXYGEN	The purpose of this study was to examine the patterns of change in microdialysate concentrations of glucose, lactate, pyruvate, and glutamate in the brain during periods of hypoxia/ischemia identified by monitoring brain tissue pO(2) (PbtO(2)). Of particular interest was a better understanding of what additional information could be obtained by the microdialysis parameters that was not available from the PbtO(2). Fifty-seven patients admitted with severe traumatic brain injury who had placement of both a brain tissue pO(2) (PbtO(2)) and microdialysis probe were studied. The microdialysis probe was perfused with Ringer's solution at 0.3 muL/min and dialysate was collected at 1-h intervals. The concentration of glucose, pyruvate, lactate, and glutamate were measured in each dialysate sample. Changes in the microdialysis parameters were examined during episodes where the PbtO(2) decreased to below 10 mm Hg. Ten episodes of tissue hypoxia/ischemia identified by a decrease in PbtO(2) below 10 mm Hg were observed during the period of monitoring. The concentration of the dialysate glucose closely followed the PbtO(2). The dialysate pyruvate concentration was more variable and in some patients transiently increased as the PbtO(2) dropped below 10 mm Hg. The dialysate concentration of lactate was significantly increased as the PbtO(2) decreased to less than 10 mm Hg. Dialysate glutamate was significantly elevated only when PbtO(2) decreased to very low levels. Although changes in the PbtO(2) provided the earliest sign of hypoxia/ischemia, the microdialysis assays provided additional information about the consequences that the reduced tissue pO(2) has on brain metabolism, which may be helpful in managing these critically ill patients.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Charles Univ Prague, Univ Hosp, Dept Neurosurg, Hradec Kralove, Czech Republic	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin,Ste 944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; GOODMAN JC, 1999, CRIT CARE MED, V27, P2337; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; Kett-White R, 2002, ACT NEUR S, V81, P363; Kett-White R, 2002, ACT NEUR S, V81, P327; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; RASBASH J, 2002, MLWIN VERSION 1 20 M; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299	22	93	98	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					894	906		10.1089/0897715041526195			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800007	15307902				2021-06-18	
J	Lavoie, ME; Dupuis, F; Johnston, KM; Leclerc, S; Lassonde, M				Lavoie, ME; Dupuis, F; Johnston, KM; Leclerc, S; Lassonde, M			Visual P300 effects beyond symptoms in concussed college athletes	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; CEREBRAL CONCUSSION; LATENCY; COMPONENT; ATTENTION; FOOTBALL; PERFORMANCE; DYSFUNCTION	In order to assess whether cerebral anomalies may be observed in the absence of clinical symptoms, the current study compared the effects of concussions on attentional capacities (reaction times, accuracy) and Event-Related Potentials (ERPs) in concussed athletes with (n = 10) or without (n = 10) symptoms as well as in athletes who never had a concussion (n = 10). The P300 response was recorded from 28 electrodes during a modified visual oddball paradigm. Participants were instructed to press a key upon the appearance of the frequent stimuli as well as when a rare nontarget stimulus followed the frequent one. The other key was to be pressed when the subsequent rare stimuli (rare target) appeared until a frequent one reappeared. The symptomatic athletes displayed longer reaction times than the other two groups of athletes. The P300 amplitude to the rare target stimuli was significantly more attenuated in the symptomatic athletes than in the other two groups. Moreover, the P300 amplitude varied inversely with the severity of postconcussion symptoms but was not influenced by time elapsed since injury. Although the clinical significance of the P300 differences shown by the symptomatic athletes is still uncertain, the results do indicate that symptom severity may be a crucial indicator of functional impairments following mild traumatic brain injury.	Univ Montreal, Grp Rech Neuropsychol Expt, Canada Res Chair Dev Neuropsychol, Dept Psychol, Montreal, PQ H3W 1W5, Canada; McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ, Canada; Univ Montreal, Hop Louis H Lafontaine, Ctr Rech Fernand Seguin, Dept Psychiat, Montreal, PQ, Canada	Lassonde, M (corresponding author), Univ Montreal, Grp Rech Neuropsychol Expt, Canada Res Chair Dev Neuropsychol, Dept Psychol, CP 6128,Succ Centreville, Montreal, PQ H3W 1W5, Canada.	marc.lavoie@crfs.umontreal.ca; Maryse.Lassonde@umontreal.ca	Lavoie, Marc/G-2941-2013; Lavoie, Marc/M-4771-2019	Lavoie, Marc/0000-0002-3037-3890; Lavoie, Marc/0000-0002-3037-3890			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 1994, J Clin Neurophysiol, V11, P111; BEGLEITER H, 1983, PSYCHOPHYSIOLOGY, V20, P95, DOI 10.1111/j.1469-8986.1983.tb00909.x; Blackwood DHR, 1996, BRIT J PSYCHIAT, V168, P85; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BRETON F, 1990, BIOL PSYCHOL, V31, P57, DOI 10.1016/0301-0511(90)90078-B; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Coles M.G., 1995, OX PSYCH S, P86; Coles M.G.H., 1990, PRINCIPLES PSYCHOPHY, P413; COLES MGH, 1995, OX PSYCH S, P1; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; DUNCANJOHNSON CC, 1982, BIOL PSYCHOL, V14, P1, DOI 10.1016/0301-0511(82)90016-3; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GEETS W, 1985, ACTA NEUROL BELG, V85, P277; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Greenham SL, 2000, BIOL PSYCHOL, V55, P79, DOI 10.1016/S0301-0511(00)00070-3; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; JOHNSON R, 1978, ELECTROEN CLIN NEURO, V44, P424, DOI 10.1016/0013-4694(78)90027-5; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; Katayama J, 1996, INT J PSYCHOPHYSIOL, V23, P33, DOI 10.1016/0167-8760(96)00030-X; Kaustio O, 2002, J AFFECT DISORDERS, V71, P43, DOI 10.1016/S0165-0327(01)00410-4; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KRAIUHIN C, 1990, BIOL PSYCHIAT, V28, P372, DOI 10.1016/0006-3223(90)90406-R; Kramer A., 1991, HDB COGNITIVE PSYCHO, P179; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; LEVIT RA, 1973, PSYCHOL MED, V3, P487, DOI 10.1017/S0033291700054295; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MANDEL S, 1989, POSTGRAD MED, V85, P213; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; NAATANEN R, 1991, PSYCHOPHYSIOLOGY, V28, P478, DOI 10.1111/j.1469-8986.1991.tb00735.x; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; Parkinson D, 1996, SURG NEUROL, V45, P459, DOI 10.1016/0090-3019(95)00210-3; PATTERSON JV, 1988, ELECTROEN CLIN NEURO, V71, P450, DOI 10.1016/0168-5597(88)90049-4; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SARA G, 1994, J AFFECT DISORDERS, V31, P29, DOI 10.1016/0165-0327(94)90124-4; SHAGASS C, 1992, INT J PSYCHOPHYSIOL, V13, P255, DOI 10.1016/0167-8760(92)90075-M; Solbakk AK, 2002, CLIN ELECTROENCEPHAL, V33, P102, DOI 10.1177/155005940203300306; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Sullivan T E, 1994, J Neurosci Nurs, V26, P24; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; Weir N, 1998, SCHIZOPHR RES, V31, P151, DOI 10.1016/S0920-9964(98)00017-6; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	64	93	93	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2004	26	1					55	73		10.1076/jcen.26.1.55.23936			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	769TH	WOS:000188665500006	14972694				2021-06-18	
J	Rekling, JC				Rekling, JC			Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation	NEUROSCIENCE LETTERS			English	Article						hippocampal slice cultures; oxygen/glucose deprivation; anticonvulsants; neuroprotection	IN-VITRO ISCHEMIA; GLUCOSE DEPRIVATION; DAMAGE; INHIBITION; OXYGEN; DRUGS	Some anticonvulsants show neuroprotective effects, and may be of use in reducing neuronal death resulting from stroke or traumatic brain injury. Here I report that a broad range of anticonvulsants protect cells in hippocampal slice cultures from death induced by oxygen/glucose deprivation (OGD). Hippocampal slice cultures were submitted to 1 h OGD and the resulting cell death was quantified 24 h later using a novel automated fluorescent scanning method. The classical anticonvulsants phenobarbital, phenytoin, ethosuximide, chlordiazepoxide and midazolam all significantly and dose-dependently reduced cell death induced by OGD. The newer anticonvulsants carbamazepine, felbamate, lamotrigine, tiagabine, and oxcarbazepine also had significant neuroprotective effects, but gabapentin, valproic acid (10 mM), levetiracetam and retigabine were not neuroprotective at a concentration up to 300 muM. In conclusion, several classical and newer anticonvulsants have neuroprotective properties in an in vitro model that simulates cerebral ischemia. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	H Lundbeck & Co AS, Biol Res, Dept 828, DK-2500 Valby, Denmark	Rekling, JC (corresponding author), H Lundbeck & Co AS, Biol Res, Dept 828, Ottiliavej 9, DK-2500 Valby, Denmark.			Rekling, Jens C./0000-0002-8568-2332			Breder J, 2000, NEUROPHARMACOLOGY, V39, P1779, DOI 10.1016/S0028-3908(00)00027-7; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; Hetka R, 1999, EUR J PHARMACOL, V386, P165, DOI 10.1016/S0014-2999(99)00786-4; Margineanu DG, 2000, PHARMACOL RES, V42, P281; Nicolson A, 2001, CNS DRUGS, V15, P955, DOI 10.2165/00023210-200115120-00005; Obrenovitch TP, 1997, INT REV NEUROBIOL, V40, P109; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; REKLING JC, 1993, J NEUROSCI, V13, P1954; RENKAWEK K, 1989, Neuropatologia Polska, V27, P323; Sills GJ, 2001, EPILEPTIC DISORD, V3, P165; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; Taylor CP, 1999, J NEUROSCI, V19, P619; Thompson SM, 1996, J COMP NEUROL, V372, P515; Velazquez JLP, 1997, J NEUROSCI, V17, P9085; WEBER ML, 1994, BRAIN RES, V664, P167, DOI 10.1016/0006-8993(94)91967-4	17	93	93	0	6	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JAN 2	2003	335	3					167	170	PII S0304-3940(02)01193-X	10.1016/S0304-3940(02)01193-X			4	Neurosciences	Neurosciences & Neurology	635QT	WOS:000180410900005	12531459				2021-06-18	
J	Borgaro, SR; Prigatano, GP; Kwasnica, C; Rexer, JL				Borgaro, SR; Prigatano, GP; Kwasnica, C; Rexer, JL			Cognitive and affective sequelae in complicated and uncomplicated mild traumatic brain injury	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; IMPAIRED AWARENESS; STEM RESPONSES; CONCUSSION; SYMPTOMS; DYSFUNCTION	This study examined cognitive and affective disturbances in patients with complicated (presence of space occupying lesion) vs uncomplicated (absence of space occupying lesion) mild traumatic brain injury (TBI). It was predicted that the complicated group would perform worse in both domains compared to the uncomplicated group. Participants were 28 patients admitted to an inpatient neurorehabilitation unit with mild TBI and assessed within 40 days of their injury. The complicated group (n = 14) was matched to the uncomplicated group (n = 14) on Glasgow Coma Scale score and compared to 14 normal controls on the BNI Screen for Higher Cerebral Functions (BNIS). The complicated group showed greater cognitive disturbances than the uncomplicated and control groups, while both TBI groups performed worse on affective measures. These findings document the role of affective disturbances in mild TBI. They also highlight the importance of early intervention strategies for improving affective communication in patients with mild TBI.	Barrow Neurol Inst, Dept Clin Neuropsychol, Phoenix, AZ 85013 USA	Borgaro, SR (corresponding author), Barrow Neurol Inst, Dept Clin Neuropsychol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.						BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BORGARO S, 2002, BNI Q, V17, P14; BORGARO SR, IN PRESS J HEAD TRAU; CARLIDGE NEF, 1977, SCOTTISH MED J, V23, P103; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; GRONWALL D, 1975, LANCET, V2, P995; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENNETT B, 1974, MANAGEMENT HEAD INJU; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levin HS, 1989, MILD HEAD INJURY; LEVINE MJ, 1988, COGNITIVE REHABILITA, V6, P14; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Prigatano G. P., 1995, BNI Q, V9, P2; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosenstein LD, 1997, NEUROPSY NEUROPSY BE, V10, P113; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	31	93	95	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	3					189	198		10.1080/0269905021000013183			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	645CB	WOS:000180957700001	12623495				2021-06-18	
J	Savva, A; Taylor, MJ; Beatty, CW				Savva, A; Taylor, MJ; Beatty, CW			Management of cerebrospinal fluid leaks involving the temporal bone: Report on 92 patients	LARYNGOSCOPE			English	Article; Proceedings Paper	104th Annual Meeting of the Triological-Society	MAY 12-16, 2001	PALM DESERT, CALIFORNIA	Triol Soc		cerebrospinal fluid; otorrhea; otorhinorrhea; retrospective study; treatment	OTORRHEA; DEFECTS; OTORHINORRHEA; MENINGITIS; DIAGNOSIS	Objective. To investigate the success of different surgical and nonsurgical techniques in the management of cerebrospinal fluid otorrhea or otorhinorrhea. Study Design: Retrospective case analysis. Methods: Ninety-two patients with confirmed diagnosis of cerebrospinal fluid otorrhea or otorhinorrhea treated at our institution between 1976 and 1998 were followed up long-term by retrospective chart review and patient interviews. Results: Conservative treatment was successful in most cases of cerebrospinal fluid otorrhea or otorhinorrhea resulting from head injury (26 of 29 patients). In contrast, surgical intervention was required in all but 1 of 53 patients with cerebrospinal fluid otorrhea or otorhinorrhea caused surgically. The primary operative success rate was 76.9%. When relapse occurred, the interval ranged from 0 days to 24 months (mean interval, 3.9 mo; median, 1.3 mo). All leaks requiring surgery eventually were closed successfully. Surgical results were chronologically dependent. Before 1989, 11 failures occurred in 37 primary procedures. After 1989, only 4 failures occurred in 28 primary procedures. Of seven patients undergoing primary dural closure alone, three (43%) had recurrence of the leak. Closure rates were highest among patients in whom a multilayer technique for leak closure was used: combining a primary graft or sealing material such as bone wax, free muscle, or fascia for closure of the defect with additional autologous free grafts or allogenic materials. This resulted in a 2-year closure rate of 100% compared with a 2-year rate of 75.4% for patients whose primary closure was supported by a single layer of autologous or allogenic material (P = .034). Fibrin glue with primary closure alone did not have additional benefit. Postoperative meningitis occurred in two patients and was treated without sequelae. Conclusions. Conservative treatment should be reserved for cerebrospinal fluid otorrhea or otorhinorrhea resulting from head injury. Postoperative and nontraumatic cerebrospinal fluid otorrhea or otorhinorrhea should have early operative intervention. A multilayer technique combining allogenic materials with free autologous grafts is recommended. Key Words: Cerebrospinal fluid, otorrhea, otorhinorrhea, retrospective study, treatment.	Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55905 USA; Univ Hannover, Dept Otorhinolaryngol, Hannover, Germany	Beatty, CW (corresponding author), Mayo Clin, Dept Otorhinolaryngol, 200 1st St SW, Rochester, MN 55905 USA.						da Cruz MJ, 1998, AM J OTOL, V19, P288; Dandy WE, 1944, ARCH SURG-CHICAGO, V49, P75, DOI 10.1001/archsurg.1944.01230020080001; FERGUSON BJ, 1986, LARYNGOSCOPE, V96, P635; Gacek RR, 1999, AM J OTOL, V20, P770; GIDDINGS NA, 1994, AM J OTOL, V15, P781; HARNER SG, 1982, J NEUROSURG, V57, P258, DOI 10.3171/jns.1982.57.2.0258; Hicks G W, 1980, Laryngoscope, V90, P1, DOI 10.1288/00005537-198011001-00001; Klastersky J, 1976, Surg Neurol, V6, P111; KUHWEIDE R, 1987, Acta Oto-Rhino-Laryngologica Belgica, V41, P453; MACGEE EE, 1970, J NEUROSURG, V33, P312, DOI 10.3171/jns.1970.33.3.0312; MAY JS, 1995, AM J OTOL, V16, P765; Merchant SN, 2000, AM J OTOL, V21, P234, DOI 10.1016/S0196-0709(00)80015-0; Narayan RK, 1991, PRINCIPLES NEUROSURG, P235; NEELY JG, 1982, LARYNGOSCOPE, V92, P609; NEELY JG, 1985, OTOLARYNG HEAD NECK, V93, P625; NELSON DR, 1990, J THORAC CARDIOV SUR, V99, P977; Nuss DW, 1995, OTOLARYNGOL HEAD NEC, V8, P79; OBERASCHER G, 1988, AM J OTOL, V9, P102; OMMAYA AK, 1985, NEUROSURGERY, V2, P1637; PAPPAS DG, 1992, AM J OTOL, V13, P534; Shetty PG, 1997, AM J NEURORADIOL, V18, P478; WETMORE SJ, 1987, AM J OTOL, V8, P96; WINKLER J, 1994, ACTA NEUROL SCAND, V89, P293	23	93	100	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0023-852X			LARYNGOSCOPE	Laryngoscope	JAN	2003	113	1					50	56		10.1097/00005537-200301000-00010			7	Medicine, Research & Experimental; Otorhinolaryngology	Research & Experimental Medicine; Otorhinolaryngology	637EX	WOS:000180499500010	12514382				2021-06-18	
J	Nabors, N; Seacat, J; Rosenthal, M				Nabors, N; Seacat, J; Rosenthal, M			Predictors of caregiver burden following traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; SOCIAL SUPPORT; FAMILY NEEDS; HEALTH; INDIVIDUALS; DIMENSIONS; STRESS; IMPACT	Primary objective: To investigate the relationship of demographic characteristics of the caregiver (i.e. race, age, household income, education) to caregiver burden, family needs, family functioning and social support to assess the predictors of caregiver burden. Research design: Information was obtained through mailed surveys and follow-up phone interviews. Methods and procedures: Participants were 24 African American and 21 White caregivers of individuals with traumatic brain injury who were at least 1-year post-injury. Measures administered included the Head Injury Family Interview, Family Needs Questionnaire, Family Assessment Device and the NON, a measure of social support. Main outcomes and results: Regression analyses revealed that importance of needs and percentage of needs met accounted for a significant amount of the variance in predicting affective/behavioural, cognitive and physical/dependency burden. Conclusions: Rehabilitation professionals need to provide support that includes ongoing assessment of needs and provides a resource for steering caregivers to potential sources for meeting those needs.	Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA	Nabors, N (corresponding author), Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA.						BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; HORWITZ AV, 1995, J HEALTH SOC BEHAV, V36, P138, DOI 10.2307/2137221; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KOSCIULEK JF, 1994, REHABIL COUNS BULL, V37, P244; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Martin CD, 2000, J FAM ISSUES, V21, P986, DOI 10.1177/019251300021008003; MILLER B, 1991, J GERONTOL, V46, pS9, DOI 10.1093/geronj/46.1.S9; MILLER IW, 1983, J MARITAL FAMILY THE, V9, P171; Morey L. C., 1991, PERSONALITY ASSESSME; Moules S, 1999, BRAIN INJURY, V13, P983; Panting A., 1972, REHABILITATION, V38, P33; PERRY CM, 1994, INT J AGING HUM DEV, V38, P41, DOI 10.2190/UQKB-EL57-TN8R-3W1A; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TURNER WL, 1994, J NATL MED ASSOC, V86, P915; Walker A E, 1972, Scand J Rehabil Med, V4, P5; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WITOL AS, 1996, MOD SYST BRAIN INJ C; YOUNG JB, 1995, ABNF J           MAY, P68	40	93	95	0	11	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2002	16	12					1039	1050		10.1080/02699050210155285			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	617KK	WOS:000179360700002	12487718				2021-06-18	
J	Qiu, JH; Whalen, MJ; Lowenstein, P; Fiskum, G; Fahy, B; Darwish, R; Aarabi, B; Yuan, JY; Moskowitz, MA				Qiu, JH; Whalen, MJ; Lowenstein, P; Fiskum, G; Fahy, B; Darwish, R; Aarabi, B; Yuan, JY; Moskowitz, MA			Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans	JOURNAL OF NEUROSCIENCE			English	Article						traumatic brain injury; Fas; death-inducing signaling complex; caspases; human; adenoviral vectors	NEURONAL CELL-DEATH; PC12 CELLS; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; CORTICAL IMPACT; TRANSGENIC MICE; CD95; EXPRESSION; CASPASE-3; PROTEIN	Recent studies have implicated Fas in the pathogenesis of inflammatory, ischemic, and traumatic brain injury (TBI); however, a direct link between Fas activation and caspase-mediated cell death has not been established in injured brain. We detected Fas-Fas ligand binding and assembly of death-inducing signaling complexes (DISCs) [Fas, Fas-associated protein with death domain, and procaspase-8 or procaspase-10; receptor interacting protein (RIP)-RIP-associated interleukin-1beta converting enzyme and CED-3 homolog-1/Ced 3 homologous protein with a death domain-procaspase-2] by immunoprecipitation and immunoblotting within mouse parietal cortex after controlled cortical impact. At the time of DISC assembly, procaspase-8 was cleaved and the cleavage product appeared at 48 hr in terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling-positive neurons. Cleavage of caspase-8 was accompanied by caspase-3 processing detected at 48 hr by immunohistochemistry, and by caspase-specific cleavage of poly( ADP-ribose) polymerase at 12 hr. Fas pathways were also stimulated by TBI in human brain, because Fas expression plus Fas-procaspase-8 interaction were robust in contused cortical tissue samples surgically removed between 2 and 30 hr after injury. To address whether Fas functions as a death receptor in brain cells, cultured embryonic day 17 cortical neurons were transfected with an adenoviral vector containing the gene encoding Fas ligand. After 48 hr in culture, Fas ligand expression and Fas-procaspase-8 DISC assembly increased, and by 72 hr, cell death was pronounced. Cell death was decreased by similar to50% after pan-caspase inhibition (Z-Val-ALa-Asp(Ome)-fluoromethylketone). These data suggest that Fas-associated DISCs assemble in neurons overexpressing Fas ligand as well as within mouse and human contused brain after TBI. Therefore, Fas may function as a death receptor after brain injury.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Charlestown, MA 02129 USA; Cedars Sinai Med Ctr, Gene Therapeut Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90048 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Moskowitz, MA (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, 149 13th St,Room 6403, Charlestown, MA 02129 USA.		Moskowitz, Michael A/D-9916-2011	Darwish, Ribal/0000-0003-0727-0401	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152, K08NS041969] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS010828, 2 RO1 NS34152, K08 NS041969, 2 R01 NS34152, KO8 NS41969-01, R01 NS034152] Funding Source: Medline		Aquaro S, 2000, J LEUKOCYTE BIOL, V68, P429; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Cheema ZF, 1999, J NEUROSCI, V19, P1754; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Holland GN, 2000, OCUL IMMUNOL INFLAMM, V8, P1, DOI 10.1076/0927-3948(200003)8:1;1-S;FT001; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee SJ, 2000, J IMMUNOL, V164, P1277, DOI 10.4049/jimmunol.164.3.1277; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Morelli AE, 1999, J GEN VIROL, V80, P571, DOI 10.1099/0022-1317-80-3-571; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; Rose S, 2000, AM J GASTROENTEROL, V95, P1; Saas P, 1999, J IMMUNOL, V162, P2326; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stefanis L, 1997, J NEUROCHEM, V69, P1425; Troy CM, 1997, J NEUROSCI, V17, P1911; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wang J, 2000, J CELL SCI, V113, P753; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	52	93	100	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 1	2002	22	9					3504	3511					8	Neurosciences	Neurosciences & Neurology	546VN	WOS:000175296200028	11978827				2021-06-18	
J	Stone, JR; Singleton, RH; Povlishock, JT				Stone, JR; Singleton, RH; Povlishock, JT			Intra-axonal neurofilament compaction does not evoke local axonal swelling in all traumatically injured axons	EXPERIMENTAL NEUROLOGY			English	Article						axonal injury; cytoskeleton; axoplasmic transport; ultrastructure; rats	AMYLOID PRECURSOR PROTEIN; DIFFUSE BRAIN INJURY; HEAD-INJURY; AXOLEMMAL PERMEABILITY; RETROGRADE CONVERSION; TRANSPORTED VESICLES; CYTOSKELETAL CHANGES; BETA-APP; DAMAGE; MARKER	Traumatic axonal injury (TAI) contributes to morbidity and mortality following traumatic brain injury (TBI). Single-label immunocytochemical studies employing antibodies to neurofilament compaction (NFC), RM014, and antibodies to APP, a marker of impaired axonal transport (AxT), have shown that TAI involves both NFC and disruption of AxT. Although it may be hypothesized that both events occur within the same injured axon, this has not been confirmed. To determine the relationship between NFC and impaired AxT, dual-label immunofluorescence was employed. To compare and contrast specific changes associated with these two markers of TAI, single-label electron microscopy was also used. Rats were subjected to an impact acceleration injury (30 min-6 h survival), and their brains were prepared for dual-label immunofluorescence and single-label electron microscopy. APP and RM014 were consistently found in two distinct classes of TAL One, which showed only RM014 immunoreactivity, was thin and elongate, was sometimes vacuolated, and revealed little progressive change over time. The second was distinguished by focal axonal swellings containing APP immunoreactivity alone in small-caliber axons or in combination with RM014 immunoreactivity in large-caliber axons. These swellings were localized to either nodal or internodal loci and underwent progressive swelling over time, ultimately leading to secondary axotomy. Ultrastructural examination of these two classes of TAI revealed NFC together with mitochondrial dilation without organelle pooling in the RM014 single-labeled axons. However, the APP single-labeled small-caliber axons and APP/RM014 dual-labeled large-caliber axons revealed a progressive accumulation of organelles associated with increased axonal swelling over time. In contrast to previous thought, it now appears that NFC may occur independent of impaired AxT in TAL This finding underscores the complexity of TAI, suggesting the need for multiple immunocytochemical approaches to fully assess the overall axonal response to TBI. (C) 2001 Elsevier Science.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA	Stone, JR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Campus Virginia Commonwelth Univ, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; IMAJO T, 1984, AM J FOREN MED PATH, V5, P217, DOI 10.1097/00000433-198409000-00005; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; MALBOUISSON AMB, 1985, ANAT EMBRYOL, V171, P339, DOI 10.1007/BF00347022; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; MAXWELL ML, 1998, J NEUROCYTOL, V23, P379; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PRICE RL, 1988, J NEUROCYTOL, V17, P55, DOI 10.1007/BF01735377; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069	46	93	100	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	2001	172	2					320	331		10.1006/exnr.2001.7818			12	Neurosciences	Neurosciences & Neurology	510QK	WOS:000173218600007	11716556				2021-06-18	
J	Kupina, NC; Nath, R; Bernath, EE; Inoue, J; Mitsuyoshi, A; Yuen, PW; Wang, KKW; Hall, ED				Kupina, NC; Nath, R; Bernath, EE; Inoue, J; Mitsuyoshi, A; Yuen, PW; Wang, KKW; Hall, ED			The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury	JOURNAL OF NEUROTRAUMA			English	Article						calpain activation; calpain-mediated spectrin proteolysis; neuroprotection; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD INJURY; CLOSED-HEAD INJURY; AXONAL INJURY; SPECTRIN PROTEOLYSIS; RAT; NEURONS; CALCIUM; DEGRADATION	A principal mechanism of calcium-mediated neuronal injury is the activation of neutral proteases known as calpains. Proteolytic substrates for calpain include receptor and cytoskeletal proteins, signal transduction enzymes and transcription factors. Recently, calpain inhibitors have been shown to provide benefit in rat models of focal head injury and focal cerebral ischemia. The present study sought to investigate, in experiment 1, the time course of calpain-mediated cytoskeletal injury in a mouse model of diffuse head injury by measuring the 150- and 145-kDa alpha -spectrin breakdown products (SBDP). Secondly, in experiment 2, we examined the effect of early (20 min postinjury) administration of the novel calpain inhibitor SJA6017 on functional outcome measured 24 h following injury and its effect on posttraumatic ce-spectrin degradation. Lastly, in experiment 3, we examined the effect of delayed (4 or 6 h postinjury) administration of SJA6017 on 24-h postinjury functional outcome. In experiment 1, isoflurane-anesthetized male CF-1 mice (18-22 g) were subjected to a 750 g-cm weight drop-induced injury and were sacrificed for SBDP analysis at postinjury times of 30 min, and 1, 2, 6, 24 and 48 h (plus sham). In experiments 2 and 3, mice were injured as described, and delivered a single tail vein injection of either SJA6017 (0.3, 1, or 3 mg/kg) or vehicle (administered immediately, 4 or 6 h postinjury [3 mg/kg]). Functional outcome was evaluated in both studies, and, in experiment 2, 24-h postinjury assessment of SBDPs was determined. Following injury, the level of SBDP 145 was significantly different from sham at 24 and 48 h in cortical and at 24 h in the hippocampal tissues and at 48 h in the striatum. Immediate postinjury administration of SJA6017 resulted in a dose-related improvement in 24-h functional outcome (p < 0.05 at 3 mg/kg). Significance was maintained after a 4-h delay of the 3 mg/kg, but was lost after a 6-h delay. Despite improvement in functional outcome at 24 h, SJA6017 did not reduce spectrin breakdown in cortical or hippocampal tissues. These results support a role for calpain-mediated neuronal injury and the potential for a practical therapeutic window for calpain inhibition following traumatic brain injury. However, measurements of regional spectrin degradation may not be the most sensitive marker for determining the effects of calpain inhibition.	Pfizer Global Res & Dev, Ann Arbor Labs, Neurosci Therapeut, Ann Arbor, MI 48015 USA; Senju Pharmaceut Co Ltd, Kobe Creat Ctr, Kobe, Hyogo, Japan; Pfizer Global Res & Dev, Ann Arbor Labs, Neurosci Chem, Ann Arbor, MI 48015 USA	Hall, ED (corresponding author), Pfizer Global Res & Dev, Ann Arbor Labs, Neurosci Therapeut, 2800 Plymouth Rd, Ann Arbor, MI 48015 USA.	edward.hall@pfizer.com	Hall, Edward D/F-8930-2013	Wang, Kevin/0000-0002-9343-6473			Aronowski J, 1999, J CEREBR BLOOD F MET, V19, P652, DOI 10.1097/00004647-199906000-00008; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; Fukiage C, 1997, BBA-MOL BASIS DIS, V1361, P304, DOI 10.1016/S0925-4439(97)00043-4; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hall E.D., 1995, CENTRAL NERVOUS SYST, P213; HALL ED, 1998, CEREBROVASC DIS, P710; HARRIS AS, 1988, J NEUROSCI, V8, P2640; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Li PA, 1998, NEUROSCI LETT, V247, P17, DOI 10.1016/S0304-3940(98)00266-3; Liebetrau M, 1999, NEUROREPORT, V10, P529, DOI 10.1097/00001756-199902250-00016; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NIXON RA, 1989, ANN NY ACAD SCI, V568, P198; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur R, 1997, J NEUROCHEM, V68, P2328; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock JT, 1999, ACT NEUR S, V73, P15; Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SHAPIRA Y, 1989, Neurological Research, V11, P169; Shields DC, 1999, J NEUROSCI RES, V55, P533, DOI 10.1002/(SICI)1097-4547(19990301)55:5<533::AID-JNR1>3.0.CO;2-8; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; VERITY MA, 1992, NEUROTOXICOLOGY, V13, P139; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WANG KKW, 1999, CALPAIN PHARM TOXICO, P77; Yuen Po-Wai, 1998, Drugs of the Future, V23, P741, DOI 10.1358/dof.1998.023.07.858362; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291	61	93	95	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2001	18	11					1229	1240		10.1089/089771501317095269			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	491KC	WOS:000172106700004	11721741				2021-06-18	
J	Platt, SR; Radaelli, ST; McDonnell, JJ				Platt, SR; Radaelli, ST; McDonnell, JJ			The prognostic value of the modified Glasgow Coma Scale in head trauma in dogs	JOURNAL OF VETERINARY INTERNAL MEDICINE			English	Article; Proceedings Paper	14th Annual European-Society-of-Veterinary-Neurology Symposium	SEP 20-23, 2000	LONDON, ENGLAND	European Soc Vet Neurol		oculocephalic reflex; skull fracture; traumatic brain injury	BRAIN INJURY; MANAGEMENT	A clinical coma scale modified from the Glasgow Coma Scale used for humans has been suggested as a useful predictor of outcome in the head trauma patient. The objective of this study was to correlate the modified Glasgow Coma Scale (MGCS) score of dogs with head trauma with their probability of survival. Thirty-eight dogs with head trauma were selected and retrospectively evaluated. The information retrieved from the medical record of each dog included signalment, body weight, cause of head trauma, MGCS, presence of concurrent neck pain, and outcome (dead or alive) after 48 hours. Logistic regression was used to model survival in the Ist 48 hours as a function of MGCS, gender, weight, and calvarial fractures. The MGCS ranged from 5 to 18. Seven dogs died within 48 hours of the head trauma. The MGCS could predict the probability of survival in the 1st 48 hrs after head trauma with 50% probability in a patient with a score of 8. Gender, weight, and presence of skull fractures did not predict survival. In conclusion, the MGCS is a useful index for prediction of outcome in dogs with head trauma.	Ctr Small Anim Studies, Anim Hlth Trust, Newmarket CB8 7UU, Suffolk, England; Leibniz Univ Hannover, Klin Kleine Haustiere, D-30173 Hannover, Germany; Tufts Univ, Coll Vet Med, North Grafton, MA USA	Platt, SR (corresponding author), Ctr Small Anim Studies, Anim Hlth Trust, Newmarket CB8 7UU, Suffolk, England.	simon.platt@aht.org.uk		Platt, Simon/0000-0002-7818-1011			Agresti A., 1990, CATEGORICAL DATA ANA; *BRAIN TRAUM TASK, 2000, J NEUROTRAUM, V17, P557; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Dewey CW, 2000, VET CLIN N AM-SMALL, V30, P207, DOI 10.1016/S0195-5616(00)50010-2; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FENNER WR, 1995, TXB VET INTERNAL MED, P578; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Gruen P, 1998, EMERG MED CLIN N AM, V16, P63, DOI 10.1016/S0733-8627(05)70349-7; Hopkins AL, 1996, VET CLIN N AM-SMALL, V26, P875, DOI 10.1016/S0195-5616(96)50110-5; JOHNSON JA, 2000, KIRKS CURRENT VET TH, V13, P178; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; KOLATA RJ, 1974, J AM VET MED ASSOC, V164, P499; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Shores A., 1983, CURRENT VET THERAPY, P847; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	20	93	94	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1939-1676			J VET INTERN MED	J. Vet. Intern. Med.	NOV-DEC	2001	15	6					581	584		10.1892/0891-6640(2001)015<0581:TPVOTM>2.3.CO;2			4	Veterinary Sciences	Veterinary Sciences	492NF	WOS:000172173900011	11817064	Bronze			2021-06-18	
J	Rao, VLR; Dogan, A; Todd, KG; Bowen, KK; Dempsey, RJ				Rao, VLR; Dogan, A; Todd, KG; Bowen, KK; Dempsey, RJ			Neuroprotection by memantine, a non-competitive antagonist after traumatic brain injury NMDA receptor in rats	BRAIN RESEARCH			English	Article						excitotoxicity; glutamate antagonist; memantine; neuroprotection; secondary neuronal death; traumatic brain injury	CHANNEL BLOCKER MEMANTINE; GLUTAMATE; ISCHEMIA; HYPOTHERMIA; ACTIVATION; EXPRESSION; SYMPTOMS; DEATH	This study investigated whether memantine, a non-competitive NMDA receptor antagonist is neuroprotective after traumatic brain injury (TBI) induced in adult rats with a controlled cortical impact device. TBI led to significant neuronal death in the hippocampal CA2 and CA3 regions (by 50 and 59%, respectively), by 7 days after the injury. Treatment of rats with memantine (10 and 20 mg/Kg, i.p.) immediately after the injury significantly prevented the neuronal loss in both CA2 and CA3 regions. This is the first study showing the neuroprotective potential of memantine to prevent the TBI-induced neuronal damage. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI 53792 USA; Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA; Univ Alberta, Dept Psychiat, Edmonton, AB, Canada	Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, H4-336 CSC,600 Highland Ave, Madison, WI 53792 USA.	dempsey@neurosurg.wisc.edu	Dogan, Aclan/AAF-8305-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28000, NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028000, P01NS031220] Funding Source: NIH RePORTER		Block F, 1996, NEUROSCI LETT, V208, P41, DOI 10.1016/0304-3940(96)12545-3; Chen HSV, 1998, NEUROSCIENCE, V86, P1121, DOI 10.1016/S0306-4522(98)00163-8; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dogan A, 1999, ACTA NEUROCHIR, V141, P1107, DOI 10.1007/s007010050491; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Ehrlich M, 1999, J THORAC CARDIOV SUR, V117, P285, DOI 10.1016/S0022-5223(99)70424-1; ERDO SL, 1991, EUR J PHARMACOL, V198, P215, DOI 10.1016/0014-2999(91)90625-Z; Heidrich A, 1997, FORTSCHR NEUROL PSYC, V65, P108, DOI 10.1055/s-2007-996315; Hesselink MB, 1999, PHARMACEUT RES, V16, P637, DOI 10.1023/A:1018856020583; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Krieglstein J, 1997, EUR J PHARM SCI, V5, P71, DOI 10.1016/S0928-0987(96)00257-6; LODGE D, 1991, TRENDS PHARMACOL SCI, P1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Mukhin A, 1996, J NEUROSCI, V16, P6012; Myseros JS, 1995, ANN NY ACAD SCI, V765, P262, DOI 10.1111/j.1749-6632.1995.tb16583.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Osborne NN, 1999, VISUAL NEUROSCI, V16, P45, DOI 10.1017/S0952523899161017; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; SCHNEIDER E, 1984, DEUT MED WOCHENSCHR, V109, P987, DOI 10.1055/s-2008-1069311; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Stieg PE, 1999, EUR J PHARMACOL, V375, P115, DOI 10.1016/S0014-2999(99)00214-9; WESEMANN W, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1243	30	93	98	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 17	2001	911	1					96	100					5	Neurosciences	Neurosciences & Neurology	468JC	WOS:000170753500012	11489449				2021-06-18	
J	Shavelle, RM; Strauss, D; Whyte, J; Day, SM; Yu, YL				Shavelle, RM; Strauss, D; Whyte, J; Day, SM; Yu, YL			Long-term causes of death after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						cause of death; life expectancy; maladaptive behavior; mortality; standardized mortality ratio	LIFE EXPECTANCY; PHYSICAL-ACTIVITY; CEREBRAL-PALSY; COLLEGE ALUMNI; MORTALITY; CHILDREN; MEN	Objective: To determine which causes of death are more frequent in persons with traumatic brain injury (TBI), and by how much, compared with the general population. Our focus was the period beginning 1 yr after injury. Design: Subjects were 2320 Californians with long-term mental disability after a TBI at age 10 yr or more, followed up between 1988 and 1997. The units of study were person-years, each linked to the subject's age, gender, level of ambulation, time since injury, and cause of death (if any) for the specific year. Observed numbers of cause-specific deaths were compared with numbers expected according to general population mortality rates. Results: Mortality was higher between 1.0 and 5.0 yr postinjury than after 5.0 yr and was strongly related to reduced mobility. Death rates were elevated for circulatory diseases, respiratory diseases, choking/suffocation, and seizures, with seizure deaths being relatively frequent, even among the most ambulatory. Conclusions: Death rates for several causes are elevated in persons with long-term sequelae of TBI, The increased risk of choking/suffocation should be of interest to caregivers. Life expectancy seems to be reduced, even for patients who are fully ambulatory.	Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Univ Hong Kong, Dept Med, Div Neurol, Hong Kong, Hong Kong, Peoples R China	Shavelle, RM (corresponding author), Life Expectancy Project, 1439 17th Ave, San Francisco, CA 94122 USA.		Day, Steven/P-1002-2019	Day, Marc/0000-0002-1711-3963; Day, Steven/0000-0001-8305-5813; Whyte, John/0000-0002-4381-1474			ARIAS M, 1983, PACIFIC STATE ARCH, V8, P28; *CAL DEP DEV SERV, 1978, CLIENT DEV ED REP; *CONT SOFTW SYST I, 1995, INT CLASS DIS; DEVIVO DJ, 1995, SPINAL CORD INJURY C; HARRIS CW, 1982, INTERRATER RELIABILI; HUTTON JL, 1994, BRIT MED J, V309, P431, DOI 10.1136/bmj.309.6952.431; Kahn H. A., 1989, STAT METHODS EPIDEMI; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Lilienfeld A.M., 1980, FDN EPIDEMIOLOGY; MacKenzie E J, 1989, Md Med J, V38, P725; NEWMAN SC, 1991, CAN J PSYCHIAT, V36, P239, DOI 10.1177/070674379103600401; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; SHAVELLE RM, 1998, J INSURANCE MED, V30, P240; SINGER RB, 1992, MED SELECTION LIFE R, P58; *STAT CAL DEP FIN, 1988, RAC ETHN POP AG SEX; Strauss D, 1998, DEV MED CHILD NEUROL, V40, P369; Strauss D, 1999, J INSUR MED, V31, P104; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; STRAUSS DJ, 2000, J INSURANCE MED, V32, P11; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WIDAMAN DF, 1984, 92 ANN M AM PSYCH AS; WIDAMAN KF, 1985, 109 ANN M AM ASS MEN; CALIFORNIA WELFARE I	28	93	93	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2001	80	7					510	516		10.1097/00002060-200107000-00009			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	442ZC	WOS:000169314000006	11421519				2021-06-18	
J	Konrad, K; Gauggel, S; Manz, A; Scholl, M				Konrad, K; Gauggel, S; Manz, A; Scholl, M			Lack of inhibition: A motivational deficit in children with attention deficit/hyperactivity disorder and children with traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							CHOICE REACTION-TIME; HYPERACTIVITY DISORDER; MODEL; REINFORCEMENT; PERFORMANCE; ABILITY; STRESS; ADHD	Recent research has demonstrated that both brain-injured children and children with attention deficit/hyperactivity disorder (ADHD) suffer from response inhibition deficits. To investigate whether these deficits can be influenced by motivational factors, the stop-signal task was performed with and without reward contingencies for successful inhibition. Three groups of children between 8 and 12 years of age, participated in the study: 31 children with ADHD, 37 with traumatic brain injuries (TBI), and 26 normal controls. Results indicated that, although all groups showed comparable learning effects, reward contingencies had different effects on the groups. Whereas the performance of children with ADHD under reward contingencies were brought up to the performance level of normal controls, rewards were found less effective at improving response inhibition in children with TBI The results further support a motivational/energetic explanation of the inhibitory deficit in children with ADHD, and of a primary response inhibition deficit due to structural brain damage in children with TBI.	Rhein Westfal TH Aachen, Clin Child & Adolescent Psychiat, D-52074 Aachen, Germany	Konrad, K (corresponding author), Rhein Westfal TH Aachen, Clin Child & Adolescent Psychiat, Neuenhofer Weg 21, D-52074 Aachen, Germany.		Konrad, Kerstin/H-7747-2013	Konrad, Kerstin/0000-0001-9039-2615; Gauggel, Siegfried/0000-0002-2742-4917			Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Cohen J., 1977, STAT POWER ANAL BEHA, P1; CORKUM PV, 1996, J ATTEN DISORD, V1, P114; Damasio H., 1989, LESION ANAL NEUROPSY; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Dopfner M., 1998, DIAGNOSTIK SYSTEM PS; GOLDBERG E, 1987, FRONTAL LOBES REVISI, P155; Jennings JR, 1997, DEV PSYCHOL, V33, P308, DOI 10.1037/0012-1649.33.2.308; Kahneman D., 1973, ATTENTION EFFORT; KEPPEL G, 1991, DESIGN ANAL; Kluger AN, 1996, PSYCHOL BULL, V119, P254, DOI 10.1037/0033-2909.119.2.254; Konrad KN, 2000, BRAIN INJURY, V14, P859; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan GD., 1981, ATTENTION PERFORMANC, P205; Logan Gordon D., 1994, P189; Oosterlaan J, 1998, J ABNORM CHILD PSYCH, V26, P161, DOI 10.1023/A:1022650216978; OSMAN A, 1986, J EXP PSYCHOL HUMAN, V12, P243, DOI 10.1037/0096-1523.12.3.243; PELHAM WE, 1986, J ABNORM PSYCHOL, V95, P319, DOI 10.1037/0021-843X.95.4.319; Rabbitt P, 1998, METHODOLOGY FRONTAL; Sagvolden T, 1998, BEHAV BRAIN RES, V94, P61, DOI 10.1016/S0166-4328(97)00170-8; Sagvolden T, 1998, BEHAV BRAIN RES, V94, P1; Sagvolden T, 1996, CONTEMPORARY PSYCHOLOGY IN EUROPE, P131; SAGVOLDEN T, 1989, ATTENTION DEFICIT DI, P369; SANDERS AF, 1983, ACTA PSYCHOL, V53, P61, DOI 10.1016/0001-6918(83)90016-1; SANDERS AF, 1970, ACTA PSYCHOL, V33, P414, DOI 10.1016/0001-6918(70)90151-4; SCHACHAR R, 1995, J ABNORM CHILD PSYCH, V23, P411, DOI 10.1007/BF01447206; SCHACHAR R, 1989, UNPUB PARENT INTERVI; Sergeant J, 2000, NEUROSCI BIOBEHAV R, V24, P7, DOI 10.1016/S0149-7634(99)00060-3; SLEATOR EK, 1981, PEDIATRICS, V67, P13; Tabachnick BG, 2013, USING MULTIVARIATE S; UNNEWEHR S, 1995, DIAGNOSTISCHES INTER; VANDERMEERE J, 1995, EUNETHYDIS EUROPEAN, P241; Wells KC, 2000, J ABNORM CHILD PSYCH, V28, P543, DOI 10.1023/A:1005131131159	37	93	93	0	13	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	2000	6	4					286	296		10.1076/chin.6.4.286.3145			11	Clinical Neurology	Neurosciences & Neurology	480DP	WOS:000171447000005	11992192				2021-06-18	
J	Otto, M; Holthusen, S; Bahn, E; Sohnchen, N; Wiltfang, I; Geese, R; Fischer, A; Reimers, CD				Otto, M; Holthusen, S; Bahn, E; Sohnchen, N; Wiltfang, I; Geese, R; Fischer, A; Reimers, CD			Boxing and running lead to a rise in serum levels of S-100B protein	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						boxing; jogging; sports medicine; neurotrauma; S-100B protein	CHRONIC BRAIN-DAMAGE; MINOR HEAD-INJURY; APOLIPOPROTEIN-E EPSILON-4; NEURON-SPECIFIC ENOLASE; CREATINE-KINASE; S100 PROTEIN; STROKE; BLOOD; BOXERS; MRI	Permanent neurological dysfunction is the primary medical concern of boxing. Recently it was reported that patients presenting elevated levels of the glial protein S-100B in serum after minor head injuries are more prone to develop neuropsychological deficits than patients with lower levels of S-100B protein. We assessed this protein before and after amateur boxing competitions (n =10)and sparring bouts (n = 15). In several control groups, we investigated S-100B levels of participants before and after a 25 km race (n=11), jogging (10 km, n=12), shortterm running (n = 12), and heading footballs (n =12). There was an increase in S-100B protein after boxing and the running disciplines but not after ergometer cycling or soft heading of footballs. The increase in S-100B protein concentrations due to competitive boxing and after the 25 km race was significantly higher than that after performing other disciplines (p<0.001). There was no significant difference between the increases caused by sparring and the running disciplines (p = 0.21). The number and severity of the strikes to the head correlated significantly with the increase in the S-100B protein levels. Levels of S-100B protein known to be associated with neuropsychological deficits were not reached in our study. In professional boxing, much higher levels are to be expected and would be worthy of investigation.	Univ Hosp Gottingen, Dept Neurol, Gottingen, Germany; Univ Hosp Gottingen, Dept Clin Neurophysiol, Gottingen, Germany; Univ Hosp Gottingen, Dept Psychiat, Gottingen, Germany; Univ Gottingen, Inst Sport Sci, Gottingen, Germany	Otto, M (corresponding author), Univ Gottingen, Neurol Klin & Poliklin, Robert-Koch-Str 40, D-37075 Gottingen, Germany.		Otto, Markus/F-4304-2015	Otto, Markus/0000-0003-4273-4267			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Barzo P, 1997, ACT NEUR S, V70, P243; BORTZ JJ, 1985, STAT SOZIALWISSENSCH, P259; BRAYNE CEG, 1982, LANCET, V2, P1308; Brayne H, 1998, BRIT MED J, V316, P1813, DOI 10.1136/bmj.316.7147.1813; Fiore DC, 1996, JAMA-J AM MED ASSOC, V276, P954; Gillon R, 1998, J MED ETHICS, V24, P3, DOI 10.1136/jme.24.1.3; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HAIMOTO H, 1987, LAB INVEST, V57, P489; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; HORNER E, 1993, CLIN J SPORT MED, V3, P144; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; JORDAN B, 1989, SPORTS NEUROLOGY, P219; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Nygaard O, 1997, CLIN CHEM, V43, P541; Otto M, 1998, BRIT MED J, V316, P577, DOI 10.1136/bmj.316.7131.577; Pisa EK, 1999, STROKE, V30, P1153; RICKMANN M, 1995, NEUROSCIENCE, V67, P977, DOI 10.1016/0306-4522(94)00615-C; Ryan AJ, 1998, CLIN SPORT MED, V17, P155, DOI 10.1016/S0278-5919(05)70070-3; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Unterharnscheidt F, 1995, Rev Neurol, V23, P1013; Unterharnscheidt F, 1995, Rev Neurol, V23, P833; USUI A, 1989, CLIN CHEM, V35, P1942; Warburton N, 1998, J MED ETHICS, V24, P56, DOI 10.1136/jme.24.1.56; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wiesmann M, 1998, CLIN CHEM, V44, P1056; WOERTGEN C, 1998, 1 INT C BIOCH MARK B, pA43; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; ZIMMER DB, 1987, AM J PHYSIOL, V252, P285; 1997, ASS INT MARATHON JUL, P46	37	93	95	0	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622			INT J SPORTS MED	Int. J. Sports Med.	NOV	2000	21	8					551	555		10.1055/s-2000-8480			5	Sport Sciences	Sport Sciences	383TQ	WOS:000165899300002	11156273				2021-06-18	
J	McCrory, PR; Ariens, M; Berkovic, SF				McCrory, PR; Ariens, M; Berkovic, SF			The nature and duration of acute concussive symptoms in Australian football	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; football; Australian; brain; wounds and injuries	RULES FOOTBALLERS	Objective: The purpose of this pilot study was to document the nature and temporal profile of the clinical symptoms of acute sport-related concussion. Design: Prospective cohort study Patient Population: A total of 303 elite Australian football players participating in a national competition during a single season. Outcome Measures: Number and duration of symptoms, digit symbol substitution test (DSST) scores, time of return to play post injury. Results: A total of 23 concussions were recorded over the course of the 20-week football season. No catastrophic head injuries occurred. Headache was the most common symptom and the most persistent, with 40% of players reporting headache symptoms lasting more than 15 minutes. Ten of the players (43%) returned to sport on the day of the injury with the remainder resuming play within 2 weeks. A low likelihood of return to play on the day of injury was found where 3 or more symptoms were present or where the symptoms lasted more than 15 minutes. These findings were significantly correlated with poor DSST performance. Conclusions: This pilot study suggests that both the number of postconcussive symptoms and their duration may be used as a measure of injury severity and a guide for return to play.	Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med Neurol, Heidelberg, Vic, Australia; Oakleigh Chargers Football Club, Oakleigh, Vic, Australia; Olymp Pk Sports Med Ctr, Melbourne, Vic, Australia	McCrory, PR (corresponding author), 31 Grosvenor Rd, Balwyn, Vic 3004, Australia.		McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			Barth JT., 1989, MILD HEAD INJURY, P257; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; ORCHARD J, 1997, AFL INJURIES SEASON; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; WESCHLER D, 1981, WESCHLER ADULT INTEL	14	93	94	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	OCT	2000	10	4					235	238		10.1097/00042752-200010000-00002			4	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	389HK	WOS:000166232400002	11086747				2021-06-18	
J	Weise, J; Isenmann, S; Klocker, N; Kugler, S; Hirsch, S; Gravel, C; Bahr, M				Weise, J; Isenmann, S; Klocker, N; Kugler, S; Hirsch, S; Gravel, C; Bahr, M			Adenovirus-mediated expression of ciliary neurotrophic factor (CNTF) rescues axotomized rat retinal ganglion cells but does not support axonal regeneration in vivo	NEUROBIOLOGY OF DISEASE			English	Article							CENTRAL-NERVOUS-SYSTEM; IN-VIVO; GENE-TRANSFER; FACTOR PREVENTS; ADULT-RATS; OPTIC-NERVE; REGIONAL DISTRIBUTION; NEURONAL DEATH; MOTOR-NEURONS; MESSENGER-RNA	Rat optic nerve (ON) transection leads to mainly apoptotic cell death of about 85% of the retinal ganglion cell (RGC) population within 14 days after lesion. in the present study, we tested the effect of adenovirally delivered CNTF (Ad-CNTF) on survival and regeneration of axotomized adult RGCs in vivo. Single intravitreal Ad-CNTF injection led to stable CNTF mRNA and protein expression for at least 18 days and significantly enhanced RGC survival by 155% when compared to control animals 14 days after ON transection. ON stump application of Ad-CNTF also resulted in an increased number of surviving RGCs. Ad-CNTF injection led to better preservation of intraretinal RGC axons but did not support regeneration of axotomized RGCs into a peripheral nerve graft. Thus, adenovirus-mediated neurotrophic factor supply is a suitable approach for reducing axotomy-induced RGC death in vivo and may constitute a relevant strategy for clinical treatment of traumatic brain injury. (C) 2000 Academic Press.	Univ Tubingen, Sch Med, Dept Neurol, D-72076 Tubingen, Germany; Univ Laval, Ctr Rech, Quebec City, PQ, Canada	Weise, J (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, D-72076 Tubingen, Germany.		Isenmann, Stefan/AAJ-3788-2020; Baehr, Mathias/K-2188-2014				BAHR M, 1994, TRENDS NEUROSCI, V17, P473, DOI 10.1016/0166-2236(94)90136-8; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BUDENZ DL, 1995, INVEST OPHTH VIS SCI, V36, P2211; Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328; CARTER DA, 1989, J NEUROSCI, V9, P4042; Cayouette M, 1996, INVEST OPHTH VIS SCI, V37, P2022; Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423; Cayouette M, 1998, J NEUROSCI, V18, P9282; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; Clatterbuck RE, 1996, J COMP NEUROL, V369, P543, DOI 10.1002/(SICI)1096-9861(19960610)369:4<543::AID-CNE5>3.0.CO;2-4; Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978; Easton RM, 1998, MOL CELL NEUROSCI, V11, P334, DOI 10.1006/mcne.1998.0690; ESCHWEILER GW, 1993, J NEUROL SCI, V116, P34, DOI 10.1016/0022-510X(93)90086-E; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; Gravel C, 1997, NAT MED, V3, P765, DOI 10.1038/nm0797-765; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Jo SA, 1999, NEUROSCIENCE, V89, P579, DOI 10.1016/S0306-4522(98)00546-6; KAHN MA, 1995, BRAIN RES, V685, P55, DOI 10.1016/0006-8993(95)00411-I; Kahn MA, 1997, DEV BRAIN RES, V98, P221, DOI 10.1016/S0165-3806(96)00180-0; Kermer P, 1998, J NEUROSCI, V18, P4656; KIRSCH M, 1994, NEUROSCI LETT, V180, P163, DOI 10.1016/0304-3940(94)90512-6; Kirsch M, 1997, J NEUROCHEM, V68, P979; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; Kugler S, 1999, GENE THER, V6, P1759, DOI 10.1038/sj.gt.3301000; LE GLS, 1993, SCIENCE, V259, P988; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; Lisovoski F, 1997, J NEUROSCI, V17, P7228; MAYER M, 1994, DEVELOPMENT, V120, P143; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; RAMON PP, 1996, INVEST OPHTH VIS SCI, V37, P489; Reichel MB, 1998, GENE THER, V5, P1038, DOI 10.1038/sj.gt.3300691; ROBAEY SM, 1994, P NATL ACAD SCI USA, V91, P10319; Sakamoto T, 1998, HUM GENE THER, V9, P789, DOI 10.1089/hum.1998.9.6-789; Sawai H, 1996, J NEUROSCI, V16, P3887; SENDTNER M, 1994, J NEUROBIOL, V25, P1436, DOI 10.1002/neu.480251110; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VALENZUELA EG, 1994, J NEUROBIOL, V25, P431; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; VILQUIN JT, 1995, HUM GENE THER, V6, P1391, DOI 10.1089/hum.1995.6.11-1391; Weise J, 2000, MICROSC RES TECHNIQ, V48, P55; WINTER CG, 1995, P NATL ACAD SCI USA, V92, P5865, DOI 10.1073/pnas.92.13.5865	52	93	104	0	5	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JUN	2000	7	3					212	223		10.1006/nbdi.2000.0285			12	Neurosciences	Neurosciences & Neurology	329GW	WOS:000087899900007	10860786				2021-06-18	
J	Heyen, JRR; Ye, SM; Finck, BN; Johnson, RW				Heyen, JRR; Ye, SM; Finck, BN; Johnson, RW			Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF-kappa B	MOLECULAR BRAIN RESEARCH			English	Article						microglia; lipopolysaccharide; NF-kappa B; interleukin-6; interleukin-10	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; TRANSCRIPTION FACTOR; GENE-EXPRESSION; FACTOR-ALPHA; PARKINSONS-DISEASE; TRANSGENIC MICE; LPS FEVER	The purpose of this study was to determine if interleukin (IL)-10 inhibits lipopolysaccharide (LPS)-induced IL-6 production in microglia by inhibiting activation of nuclear factor-kappa B (NF-kappa B). N13 microglia (a murine microglial cell line) and primary microglia from neonatal mice were cultured in the presence or absence of LPS and increasing amounts of murine IL-10 for 24 h. As predicted, LPS treatment increased supernatant IL-6 concentration in both N13 and primary microglia cultures. Pretreatment with IL-10, however, decreased LPS-induced IL-6 secretion in a dose-dependent manner in both culture systems. Likewise, ribonuclease protection assays showed that LPS increased steady-state IL-6 mRNA levels, but that pretreatment with IL-10 blocked the LPS-induced increase in IL-6 mRNA. Because NF-kappa B is the predominant transcription factor responsible for IL-6 transcription in response to inflammatory stimuli, it was hypothesized that IL-10 inhibited IL-6 production by preventing nuclear translocation of NF-kappa B. Consistent with this idea, LPS increased nuclear translocation of NF-kappa B as assessed by gel mobility shift assay. Supershift assays and immunocytochemical staining showed that both the p50 and p65 subunits of NF-kappa B translocated from the cytoplasm to the nucleus upon LPS stimulation. Pretreatment with IL-10, however, inhibited LPS-induced activation of NF-kappa B. Furthermore, inhibition of NF-kappa B activity with tosyl-Phe-chloro-methlyketone (a serine protease inhibitor that prevents degradation of the NF-kappa B-I kappa B complex), completely blocked LPS-induced IL-6 production. These data suggest that IL-10 inhibited IL-6 production in microglia by decreasing the activity of NF-kappa B and, therefore, extend what little is known of the intricate relationship between anti-inflammatory and inflammatory cytokines in the central nervous system. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Illinois, Dept Anim Sci, Lab Integrat Biol, Urbana, IL 61808 USA	Johnson, RW (corresponding author), Univ Illinois, Dept Anim Sci, Lab Integrat Biol, Urbana, IL 61808 USA.	rwjohn@ux6.cso.uiuc.edu		Johnson, Rodney/0000-0002-2376-1852	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R29DK051576] Funding Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK51576] Funding Source: Medline		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; Bluthe RM, 1999, PSYCHONEUROENDOCRINO, V24, P301, DOI 10.1016/S0306-4530(98)00077-8; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; DE WMR, 1991, J EXP MED, V174, P1209; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Dickensheets HL, 1997, BLOOD, V90, P4162, DOI 10.1182/blood.V90.10.4162; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hans VHJ, 1999, NEUROREPORT, V10, P409; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; KIM HK, 1995, J IMMUNOL, V154, P4741; KLIR JJ, 1993, AM J PHYSIOL, V265, pR512; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kozak W, 1997, AM J PHYSIOL-REG I, V272, pR621; LAYE S, 1994, MOL BRAIN RES, V27, P157, DOI 10.1016/0169-328X(94)90197-X; Lenczowski MJP, 1999, AM J PHYSIOL-REG I, V276, pR652; Leon LR, 1999, AM J PHYSIOL-REG I, V276, pR81; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; Nava F, 1997, INT J IMMUNOPHARMACO, V19, P31, DOI 10.1016/S0192-0561(97)00006-4; OKA T, 1995, BRAIN RES, V692, P123, DOI 10.1016/0006-8993(95)00691-I; PERLSTEIN RS, 1993, ENDOCRINOLOGY, V132, P946, DOI 10.1210/en.132.3.946; PlataSalaman R, 1996, NEUROREPORT, V7, P841, DOI 10.1097/00001756-199602290-00038; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SAS, 1990, SAS STAT US GUID VER; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Takeshita S, 1996, J IMMUNOL, V156, P2591; TANABE O, 1988, J IMMUNOL, V141, P3875; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; ToliverKinsky T, 1997, J NEUROSCI RES, V48, P580, DOI 10.1002/(SICI)1097-4547(19970615)48:6<580::AID-JNR11>3.0.CO;2-Z; WANG P, 1994, J IMMUNOL, V153, P811; WONG ML, 1994, P NATL ACAD SCI USA, V90, P227; Yao JH, 1997, MOL BRAIN RES, V51, P170, DOI 10.1016/S0169-328X(97)00235-0; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	50	93	99	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	APR 14	2000	77	1					138	147		10.1016/S0169-328X(00)00042-5			10	Neurosciences	Neurosciences & Neurology	317WX	WOS:000087250900015	10814840				2021-06-18	
J	Neufeld, MY; Vishne, T; Chistik, V; Korczyn, AD				Neufeld, MY; Vishne, T; Chistik, V; Korczyn, AD			Life-long history of injuries related to seizures	EPILEPSY RESEARCH			English	Article						seizure; trauma; seizure-related injury; epilepsy	EPILEPSY; RISK	There is meager information in the literature regarding the characteristics and risk factors for injuries caused during epileptic seizures in adults. Previous studies focused mainly on specific types of injuries incurred, and only few explored associated risk factors. A questionnaire regarding lifetime seizures and their traumatic consequences was administered to 298 consecutive epileptic patients and their caretakers or relatives. Ninety-one of them (30%) have reported trauma: 185 events (age 39.8 +/- 18 years, 54 males), of which 61 were severe. This translates to one seizure-related injury every 21 patient-years, and a serious injury once every 64 patient-years. The most common site of injury was the head (55% of the events). Blunt injuries occurred most frequently (40%), followed by cuts (28%). Severe injuries included fractures and dislocations (17%), burns (6%), brain concussion (6%), subdural hematoma (3%) and intracerebral hematoma (1%). Most injuries occurred at home. The 91 patients with traumatic events were compared with the 207 epileptic patients without previous trauma (age 37.8 +/- 14.7 years, 112 males). Patients with seizure-related trauma had significantly earlier onset age of epilepsy. They more commonly had generalized from onset tonic-clonic, complex partial, myoclonic or absence seizures but fewer had partial seizures with secondary generalization. The risk of trauma was mostly related to seizure type (generalized tonic-clonic from onset and myoclonic seizures). This information may be helpful for better management of epileptic patients. (C) 1999 Elsevier Science B.V. All rights reserved.	Tel Aviv Univ, Tel Aviv Elias Sourasky Med Ctr, Dept Neurol, IL-64239 Tel Aviv, Israel	Neufeld, MY (corresponding author), Tel Aviv Univ, Tel Aviv Elias Sourasky Med Ctr, Dept Neurol, 6 Weizman St, IL-64239 Tel Aviv, Israel.		Korczyn, Amos D/C-3461-2017	Korczyn, Amos D/0000-0003-0125-2579			ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; Buck D, 1997, EPILEPSIA, V38, P439, DOI 10.1111/j.1528-1157.1997.tb01733.x; FINELLI PF, 1989, NEUROLOGY, V39, P858, DOI 10.1212/WNL.39.6.858; HAMPTON KK, 1988, BRIT MED J, V296, P1659, DOI 10.1136/bmj.296.6637.1659; KIRBY S, 1995, EPILEPSIA, V36, P25, DOI 10.1111/j.1528-1157.1995.tb01660.x; NAKKEN KO, 1993, EPILEPSIA, V34, P836, DOI 10.1111/j.1528-1157.1993.tb02099.x; RUSSELLJONES DL, 1989, J NEUROL NEUROSUR PS, V52, P659, DOI 10.1136/jnnp.52.5.659; SPITZ MC, 1994, EPILEPSIA, V35, P764, DOI 10.1111/j.1528-1157.1994.tb02508.x	8	93	96	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	APR	1999	34	2-3					123	127		10.1016/S0920-1211(98)00105-3			5	Clinical Neurology	Neurosciences & Neurology	194MC	WOS:000080196600005	10210026				2021-06-18	
J	Lindner, MD; Plone, MA; Cain, CK; Frydel, B; Francis, JM; Emerich, DF; Sutton, RL				Lindner, MD; Plone, MA; Cain, CK; Frydel, B; Francis, JM; Emerich, DF; Sutton, RL			Dissociable long-term cognitive deficits after frontal versus sensorimotor cortical contusions	JOURNAL OF NEUROTRAUMA			English	Article						attention; cognitive deficits; recovery of function; spatial learning; traumatic brain injury	TRAUMATIC BRAIN INJURY; IMPROVES SPATIAL MEMORY; SEVERE HEAD-INJURY; WATER MAZE; AGED RATS; BEHAVIORAL DEFICITS; NEGLECT; LESIONS; ATTENTION; RECOVERY	Cognitive deficits are the most enduring and disabling sequelae of human traumatic brain injury (TBI), but quantifying the magnitude, duration, and pattern of cognitive deficits produced by different types of TBI has received little emphasis in preclinical animal models. The objective of the present study was to use a battery of behavioral tests to determine if different impact sites produce different patterns of behavioral deficits and to determine how long behavioral deficits can be detected after TBI. Prior to surgery, rats were trained to criteria on delayed nonmatching to position, radial arm maze, and rotarod tasks. Rats received sham surgery (controls), midline frontal contusions (frontal TBI, 2.25 m/sec impact), or unilateral sensorimotor cortex contusions (lateral TBI, 3.22 m/sec impact) at 12 months of age and were tested throughout the next 12 months. Cognitive deficits were more robust and more enduring than sensorimotor deficits for both lateral TBI and frontal TBI groups. Lateral TBI rats exhibited transient deficits in the forelimb placing and in the rotarod test of motor/ambulatory function, but cognitive deficits were apparent throughout the 12-month postsurgery period on tests of spatial learning and memory including: (1)reacquisition of a working memory version of the radial arm maze 6-7 months post-TBI, (2) performance in water maze probe trials 8 months post-TBI, and (3) repeated acquisition of the Morris mater maze 8 and 11 months post-TBI. Frontal TBI rats exhibited a different pattern of deficits, with the most robust deficits in tests of attention/orientation such as: (1) the delayed nonmatching to position task (even with no delays) 1-11 weeks post-TBI, (2) the repeated acquisition version of the water maze--especially on the first "information" trial 8 months post-TBI, (3) a test of sensorimotor neglect or inattention 8.5 months post-TBI, and (4) a DRL20 test of timing and/or sustained attention 11 months after surgery. These results suggest that long-term behavioral deficits can be detected in rodent models of TBI, that cognitive deficits seem to be more robust than sensorimotor deficits, and that different TBI impact sites produce dissociable patterns of cognitive deficits in rats.	CytoTherapeut Inc, Lincoln, RI 02865 USA; Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA	Lindner, MD (corresponding author), CytoTherapeut Inc, 701 George Washington Highway, Lincoln, RI 02865 USA.			Lindner, Mark/0000-0002-8646-2980; Cain, Christopher/0000-0002-3929-6094			AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DENOBLE VJ, 1979, PHARMACOL BIOCHEM BE, V10, P393, DOI 10.1016/0091-3057(79)90203-X; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1979, BRAIN RES, V178, P329, DOI 10.1016/0006-8993(79)90697-8; GAGE FH, 1984, SCIENCE, V225, P533, DOI 10.1126/science.6539949; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1995, J NEUROTRAUM, V12, P307, DOI 10.1089/neu.1995.12.307; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, V1, P86; Heilman K. M., 1979, CLIN NEUROPSYCHOLOGY, P268, DOI DOI 10.1055/S-2008-1041551; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1972, NEUROLOGY, V22, P660, DOI 10.1212/WNL.22.6.660; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOYMAN L, 1979, PHYSIOL BEHAV, V22, P139, DOI 10.1016/0031-9384(79)90415-3; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZMAN R, 1991, J AM GERIATR SOC, V39, P516, DOI 10.1111/j.1532-5415.1991.tb02500.x; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kraus JF, 1993, HEAD INJURY, P1; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LINDNER MD, 1992, BEHAV NEURAL BIOL, V58, P94, DOI 10.1016/0163-1047(92)90303-L; Lindner MD, 1997, NEUROBIOL LEARN MEM, V68, P203, DOI 10.1006/nlme.1997.3782; Lindner MD, 1996, CELL TRANSPLANT, V5, P205, DOI 10.1016/0963-6897(95)02029-2; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MARKOWSKA AL, 1993, BEHAV NEUROSCI, V107, P627; MARKOWSKA AL, 1994, J NEUROSCI, V14, P4815; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MECK WH, 1987, J NEUROSCI, V7, P3505; Meck WH, 1996, COGNITIVE BRAIN RES, V3, P227, DOI 10.1016/0926-6410(96)00009-2; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MITCHELL DE, 1973, LANCET, V2, P215; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; OLTON DS, 1988, NEUROPSYCHOLOGIA, V26, P307, DOI 10.1016/0028-3932(88)90083-8; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; READING PJ, 1995, EXP BRAIN RES, V105, P76; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; *SAS I INC, 1989, SAS STAT US GUID VER, V1; SCHENK F, 1990, EXP BRAIN RES, V82, P641; Seifert W, 1983, NEUROBIOLOGY HIPPOCA, P405; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SOKOLOWSKI JD, 1994, BRAIN RES, V642, P20, DOI 10.1016/0006-8993(94)90901-6; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; SUTTON RL, 1995, CENTRAL NERVOUS SYST, P497; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Teuber HL, 1955, ANNU REV PSYCHOL, V6, P267, DOI 10.1146/annurev.ps.06.020155.001411; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	83	93	94	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					199	216		10.1089/neu.1998.15.199			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500005	9528920				2021-06-18	
J	Asikainen, I; Kaste, M; Sarna, S				Asikainen, I; Kaste, M; Sarna, S			Predicting late outcome for patients with traumatic brain injury referred to a rehabilitation programme: a study of 508 Finnish patients 5 years or more after injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; CHILDREN; POPULATION; PROGNOSIS; SEQUELAE; SEVERITY; COHORT; COMA	Variables were studied which predict at the acute stage the functional and occupational long-term outcome for patients with traumatic brain injury (TBI). Glasgow Coma Scale (GCS) score on hospital admission, length of coma (LOG) and duration of post-traumatic amnesia (PTA) were studied in a group of 508 TBI rehabilitation patients, age 0.8-71, mean age 19, followed up between five and over 20 years, mean of 12 years. information from hospital charts and all data available before and after the injury were gathered and reviewed. The study was carried out among a consecutive sample of Finnish patients with TBI referred to a rehabilitation programme at the out-patient neurological clinic of Kauniala Hospital, which specializes in brain injuries in Finland. The patients came from Various hospital districts in the country for an evaluation of their educational and vocational problems. Main outcome measures were functional outcome, as measured by the Glasgow Outcome scale (GOS) at the end of follow-up, and post-injury occupational outcome. The patients' reemployment on the open job marklet, subsidized employment or inability to work war noted. The GCS score on hospital admission correlated clearly with the functional outcome of the patients at the end of follow-up. Length of coma and duration of post-traumatic amnesia correlated specifically with the patient's work history after the brain injury and with functional outcome measured by the GOS. Outcomes varied among age groups and seemed to be affected by age at injury. Accordingly, the extent of recovery and quality of life for rehabilitation patients with TBI can be estimated early on by prognostic factor reflecting injury severity in the acute phase. The results suggest that the GCS score, LOC and duration of PTA all have a strong predictive Value in assessing functional or occupational outcome for TBI patients.	Kauniala Hosp, Dept Neurol, Kauniainen 02700, Finland; Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland	Asikainen, I (corresponding author), Kauniala Hosp, Dept Neurol, Kylpylantie 19, Kauniainen 02700, Finland.			Sarna, Seppo/0000-0003-3458-1627; Kaste, Markku/0000-0001-6557-6412			AMACHER AL, 1987, NEUROSURGERY, V20, P954; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; DOUGLAS I, 1994, ARCH NEUROL-CHICAGO, V51, P661; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GIBSON RM, 1989, LANCET, V2, P369; GUATIERI CT, 1988, BRAIN INJURY, V2, P101; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; HORN S, 1992, Brain Injury, V6, P321, DOI 10.3109/02699059209034946; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; KIRKPATRICK JB, 1987, J AM GERIATR SOC, V26, P489; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; Marshall SB, 1991, J NEUROSURG S, V75, P14; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAULINE P, 1993, BRAIN INJURY, V4, P283; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RUCKERT RF, 1985, UNFALLCHIRURG, V88, P99; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; Vollmer DG, 1991, J NEUROSURG S, V75, P37; WILSON JTL, 1993, J NEUROL NEUROSUR PS, V56, P198; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	47	93	95	0	12	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1998	12	2					95	107		10.1080/026990598122737			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YV073	WOS:000071786900001	9492958				2021-06-18	
J	Geddes, JF; Vowles, GH; Beer, TW; Ellison, DW				Geddes, JF; Vowles, GH; Beer, TW; Ellison, DW			The diagnosis of diffuse axonal injury: implications for forensic practice	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						head injuries; diffuse axonal injury; beta-amyloid precursor protein; forensic medicine	MILD HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; BRAIN; DAMAGE; HUMANS; TRAUMA	The diagnosis of diffuse axonal injury (DAI), which may be of considerable importance in forensic medicine, necessitates widespread sampling of the brain for histology, Because a limited sampling method for screening brains for axonal damage would be of value for medico-legal work, the authors have tested the findings of an earlier study which suggested that a standard set of three blocks from above and below the tentorium could reliably be used in routine practice as a basis for the diagnosis of DAI, A series of 22 previously diagnosed cases of DAI, with a range of survival times, was studied using immunohistochemistry with antibodies to beta-amyloid precursor protein (beta APP), the microglial-associated antigen CD68 (PG-MI) and for GFAP. Strict histological criteria were used to assess traumatic damage, and the evolution of the histological changes with increasing survival is described, In four cases, the sampling scheme employed yielded evidence of axonal damage in only one block, and a diagnosis of DAI could have been made in only 13/22 cases, In six of the shortest surviving cases, beta APP positivity in the corpus callosum and brainstem outlined areas of early ischaemia, as well as of traumatic damage, so that interpretation of immunolabelling was not always clear-cut. The findings suggest that DAI cannot be reliably diagnosed on a restricted number of blocks from vulnerable areas, and that the use of beta APP and PG-M1 immunocytochemistry may bring interpretative problems that can only be resolved by taking a larger series of tissue samples for histology.	SOUTHAMPTON GEN HOSP,DEPT HISTOPATHOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	Geddes, JF (corresponding author), ROYAL LONDON HOSP,DEPT MORBID ANAT,LONDON E1 1BB,ENGLAND.		Ellison, David/N-4806-2018	Beer, Trevor/0000-0002-3096-3030			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; BAZZAZ AA, 1995, NEUROPATHOL APPL NEU, V21, P446; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; GEAN AD, 1994, IMAGING HEAD TRAUMA, P220; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1993, J EMERG MED, V1, P5; Gennarelli TA, 1996, NEUROPATHOL APPL S1, V22, P44; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAHAM DI, 1996, GREENFIELDS NEUROPAT, P197; GRAHAM DI, 1989, MILD MODERATE HEAD I, P63; MAXSWELL WL, IN PRESS J NEUROTRAU; MCKENZIE KJ, 1996, NEUROPATHOL APPL NEU, V22, P160; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526	29	93	97	2	4	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	AUG	1997	23	4					339	347		10.1046/j.1365-2990.1997.4498044.x			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	XW008	WOS:A1997XW00800010	9292874				2021-06-18	
J	Gentleman, SM; Greenberg, BD; Savage, MJ; Noori, M; Newman, SJ; Roberts, GW; Griffin, WST; Graham, DI				Gentleman, SM; Greenberg, BD; Savage, MJ; Noori, M; Newman, SJ; Roberts, GW; Griffin, WST; Graham, DI			A beta(42) is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury	NEUROREPORT			English	Article						Alzheimer's disease; amyloid beta-protein; head injury; human; immunocytochemistry; vascular	FAMILIAL ALZHEIMERS-DISEASE; DEPOSITION; PRECURSOR; MUTATION; PEPTIDE	Fatal head injury results in the formation of diffuse parenchymal deposits of amyloid beta-protein (A beta) in the brains of approximately 30% of individuals. We used carboxyl terminal-specific antisera to examine the exact nature of these deposits in paraffin sections of neocortex from seven head-injured patients. Immunostaining for A beta(42) was observed in all parenchymal deposits whereas staining for A beta(40), the form of the protein which predominates in serum and cerebrospinal fluid, was seen in only a small proportion of deposits. The relative paucity of A beta(40) suggests that post-traumatic deposits do not arise as a result of passive leakage from damaged cerebral blood vessels but are similar to the early A beta(42) parenchymal deposits seen in Down's syndrome and Alzheimer's disease.	CEPHALON INC,W CHESTER,PA 19380; SMITHKLINE BEECHAM PHARMACEUT,MOL NEUROPATHOL RES,HARLOW CM19 5AW,ESSEX,ENGLAND; MCLELLAN VET AFFAIRS MED CTR,LITTLE ROCK,AR 72205; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,LANARK,SCOTLAND	Gentleman, SM (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,ST DUNSTANS RD,LONDON W6 8RP,ENGLAND.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG012411] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12411] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GREENBERG BD, 1995, AMYLOID, V2, P195, DOI 10.3109/13506129509036927; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAUNDERS AM, 1993, P NATL ACAD SCI USA, V90, P8098; Savage MJ, 1995, AMYLOID, V2, P234, DOI 10.3109/13506129508999005; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEKOE DJ, 1994, ANN REV NEUROSCI, V17, P489; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290	18	93	94	0	2	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	APR 14	1997	8	6					1519	1522		10.1097/00001756-199704140-00039			4	Neurosciences	Neurosciences & Neurology	XB174	WOS:A1997XB17400041	9172166				2021-06-18	
J	Lewis, SB; Myburgh, JA; Thornton, EL; Reilly, PL				Lewis, SB; Myburgh, JA; Thornton, EL; Reilly, PL			Cerebral oxygenation monitoring by near-infrared spectroscopy is not clinically useful in patients with severe closed-head injury: A comparison with jugular venous bulb oximetry	CRITICAL CARE MEDICINE			English	Article						cerebral oxygenation; near-infrared spectroscopy; head injury; oxygen saturation; neurologic emergencies; brain injury; critical illness	ACUTE BRAIN INJURY; NEWBORN-INFANTS; SATURATION; TIME; DESATURATION; HEMODYNAMICS; CIRCULATION	Objective: To compare continuous jugular venous bulb oximetry and cerebral near-infrared spectroscopy in patients with severe closed head injury. Design: A prospective observational study. Setting: Intensive care unit of a major teaching hospital. Patients: Adults (n = 10) with severe closed-head injury (Glasgow Coma Scale score of less than or equal to 8). Interventions: None. Measurements and Main Results: Jugular venous bulb oximetry, cerebral near-infrared spectroscopy, and cerebral perfusion pressure were measured continuously, A total of 3,691 paired measurements of near infrared spectroscopy and jugular venous bulb oximetry were analysed, Poor correlation (r(2) =.04) between paired measurements and wide limits of agreement (-13% to +21%) were demonstrated. The mean difference between measurements was +/-4% and the standard deviation of the mean difference was +/-8.69%. The data were subsequently grouped according to three clinically significant subgroups of jugular venous bulb oxygen saturation reflecting low (<55%), normal (55% to 75%) and high (>75%) saturation values, Poor correlation and wide limits of agreement between the two methods of measurement were observed in all groups, Values recorded by near-infrared spectroscopy did not significantly change between the groups, and 14 clinically significant episodes of jugular venous bulb desaturation were not detected by near-infrared spectroscopy. Conclusions: Tissue oxygen saturation determined by near-infrared spectroscopy does not reflect significant changes in cerebral oxygenation detected by the global measurement of jugular venous bulb oximetry, This finding may be explained by inadequate signal detection and inaccuracies in the algorithm used to filter out extracranial components. Until these technical difficulties are addressed, near infrared spectroscopy, as measured by the machine assessed in this study, cannot be routinely recommended for assessment of cerebral oxygenation in patients with acute head injury.	ROYAL ADELAIDE HOSP,DEPT INTENS CARE,ADELAIDE,SA 5000,AUSTRALIA	Lewis, SB (corresponding author), ROYAL ADELAIDE HOSP,DEPT NEUROSURG,N TERR,ADELAIDE,SA 5000,AUSTRALIA.						ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; Araki R, 1989, Adv Exp Med Biol, V248, P3; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHANCE B, 1988, P NATL ACAD SCI USA, V85, P4971, DOI 10.1073/pnas.85.14.4971; CHANCE B, 1989, CRIT CARE MED, V17, P465, DOI 10.1097/00003246-198905000-00018; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; DUJOVNY M, 1994, NEUROSURGERY, V34, P935; EDWARDS AD, 1988, LANCET, V2, P770; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOPINATH SP, 1994, NEUROSURGERY, V35, P796, DOI 10.1097/00006123-199410000-00043; HAZEKI O, 1988, J APPL PHYSIOL, V64, P799; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; KURTH CD, 1993, J CLIN MONITOR, V9, P163, DOI 10.1007/BF01617023; LEWIS SB, 1995, ANAESTH INTENS CARE, V23, P307, DOI 10.1177/0310057X9502300307; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; PROUGH DS, 1995, CRIT CARE MED, V23, P1624, DOI 10.1097/00003246-199510000-00004; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SMITH DS, 1990, ANESTHESIOLOGY, V73, P12, DOI 10.1097/00000542-199007000-00003; TATEISHI A, 1995, CRIT CARE MED, V23, P1734, DOI 10.1097/00003246-199510000-00019; WYATT JS, 1986, LANCET, V2, P1063, DOI 10.1016/S0140-6736(86)90467-8	28	93	94	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	AUG	1996	24	8					1334	1338		10.1097/00003246-199608000-00011			5	Critical Care Medicine	General & Internal Medicine	VB502	WOS:A1996VB50200011	8706488				2021-06-18	
J	Marion, DW; Leonov, Y; Ginsberg, M; Katz, LM; Kochanek, PM; Lechleuthner, A; Nemoto, EM; Obrist, W; Safar, P; Sterz, F; Tisherman, SA; White, RJ; Xiao, F; Zar, H				Marion, DW; Leonov, Y; Ginsberg, M; Katz, LM; Kochanek, PM; Lechleuthner, A; Nemoto, EM; Obrist, W; Safar, P; Sterz, F; Tisherman, SA; White, RJ; Xiao, F; Zar, H			Resuscitative hypothermia	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	International Resuscitation Research Conference (IRRC 94)	MAY 07-09, 1994	PITTSBURGH, PA			cardiac arrest; brain trauma; cardiopulmonary resuscitation; resuscitation; hypothermia; free radicals, cooling; cerebral resuscitation; cerebral ischemia; cerebral protection	PROLONGED CARDIAC-ARREST; D-ASPARTATE ANTAGONIST; GLOBAL BRAIN ISCHEMIA; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; CEREBRAL-ISCHEMIA; FOREBRAIN ISCHEMIA; HEAD-INJURY; DEEP HYPOTHERMIA; NEURONAL DAMAGE	Resuscitative (postinsult) hypothermia is less well studied than protective-preservative (pre and intra-arrest) hypothermia. The latter is in wide clinical use, particularly for protecting the brain during cardiac surgery. Resuscitative hypothermia was explored in the 1950s and then lay dormant until the 1980s when it was revived. This change occurred through the discoveries of brain damage mitigating effects after cardiac arrest in dogs, and after forebrain ischemia in rats, of mild (34 degrees C) hypothermia (which is safe), and of benefits derived from moderate hypothermia (30 degrees C) after traumatic brain injury or focal brain ischemia in various species. The idea that protection-preservation or resuscitation by hypothermia is mainly explained by its ability to reduce cerebral oxygen demand has been replaced by an increasingly documented synergism of many beneficial mechanisms. Deleterious chemical cascades during and after these insults are suppressed even by mild hypothermia. Prolonged moderate hypothermia carries some risks, e.g., arrhythmias, infection and coagulopathies. These side effects need further study. In global brain ischemia, protective-preservative mild hypothermia provides lasting mitigation of brain damage. Resuscitative mild hypothermia, however, may be beneficial in terms of long-term outcome or may merely delay the inevitable loss of selectively vulnerable neurons. Even if the latter is true, mild hypothermia may extend the therapeutic window for other interventions. This extension of the therapeutic window requires further documentation. After normothermic cardiac arrest of 11 mins in dogs, mild resuscitative hypothermia from 15 mins to 12 hrs after reperfusion plus cerebral blood flow promotion normalized functional recovery with the least histologic damage seen thus far. Optimal duration of, and rewarming methods from, resuscitative hypothermia need clarification. The earliest possible induction of mild hypothermia after cardiac arrest seems desirable. Head-neck surface cooling alone is too slow. Among many clinically feasible rapid cooling methods, carotid cold flush and peritoneal cooling look promising. After traumatic brain injury or focal brain ischemia, which seem to still benefit from even later cooling, surface cooling methods may be adequate. Resuscitative hypothermia after cardiac arrest, traumatic brain injury, or focal brain ischemia should be considered for clinical trials.	ASSAF HAROFE MED CTR, ICU DEPT, IL-70300 YAAKOV, ISRAEL; UNIV MIAMI, SCH MED, DEPT NEUROL D45, MIAMI, FL 33101 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; UNIV MIAMI, JACKSON MEM HOSP, DEPT EMERGENCY MED, MIAMI, FL 33136 USA; MERHEIM HOSP, DEPT SURG, W-5000 COLOGNE, GERMANY; UNIV PITTSBURGH, MED CTR, DEPT ANESTHESIOL, CCM, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, MED CTR, DEPT NEUROL SURG, PITTSBURGH, PA 15261 USA; STADT WIEN UNIV KLIN, ALLGEMEINES KRANKENHAUS, ABT NOTFALLMED, A-1090 VIENNA, AUSTRIA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44109 USA; METROHLTH MED CTR, CLEVELAND, OH 44109 USA; LOUISIANA STATE UNIV, CTR MED, DEPT EMERGENCY MED, SHREVEPORT, LA 71130 USA	Marion, DW (corresponding author), UNIV PITTSBURGH, PRESBYTERIAN HOSP, MED CTR, DEPT NEUROL SURG, B400, PITTSBURGH, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015; Tisherman, Samuel A./AAK-9377-2020; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Tisherman, Samuel A./0000-0003-3810-3729; 			BENSON DW, 1958, ANESTH ANALG, V38, P423; BORISMOLLER F, 1989, NEUROSCI RES COMMUN, V5, P87; BOVERIS A, 1980, P NATL ACAD SCI-BIOL, V77, P347, DOI 10.1073/pnas.77.1.347; BRADER E, 1985, Annals of Emergency Medicine, V14, P510, DOI 10.1016/S0196-0644(85)80398-X; BUCHAN A, 1991, J NEUROSCI, V11, P1049; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DRIPPS RD, 1956, PHYSL INDUCED HYPOTH; EBMEYER U, 1994, RESUSCITATION, V28, pS13; ERNSTER L, 1988, CRIT CARE MED, V16, P947, DOI 10.1097/00003246-198810000-00005; FAY T, 1945, TRAUMA CENTRAL NERVO, P611; GINSBERG MD, 1994, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1994, P255; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; GLOBUS MYT, IN PRESS J NEUROCHEM; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HOSSMANN KA, 1988, CRIT CARE MED, V16, P964, DOI 10.1097/00003246-198810000-00007; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KATZ L, 1994, RESUSCITATION, V28, pS10; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; KUBOYAMA K, 1994, RESUSCITATION, V27, P231, DOI 10.1016/0300-9572(94)90037-X; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; LIN B, 1994, STROKE, V25, P254; MANSFIELD RT, IN PRESS J CEREB BLO; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARION DW, IN PRESS J NEUROTRAU; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; NEMOTO EM, 1977, STROKE, V8, P558, DOI 10.1161/01.STR.8.5.558; NEMOTO EM, IN PRESS J NEUROSURG; OKU K, 1993, STROKE, V24, P1590, DOI 10.1161/01.STR.24.10.1590; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PARADIS NA, 1995, CARDIAC ARREST, pCH49; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; RAVITCH MM, 1961, NEW ENGL J MED, V264, P36, DOI 10.1056/NEJM196101052640109; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; ROSOMOFF HL, 1959, ANN NY ACAD SCI, V80, P475, DOI 10.1111/j.1749-6632.1959.tb49225.x; SAFAR P, 1993, ANN EMERG MED, V22, P324, DOI 10.1016/S0196-0644(05)80463-9; SAFAR P, 1988, CRIT CARE MED, V16, P919; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; STERNAU L, 1991, J CEREB BLOOD FLO S2, V11, pS123; STERZ F, 1989, ANESTHESIOLOGY, V71, P907, DOI 10.1097/00000542-198912000-00014; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; TISHERMAN S, 1991, PREHOSP DISASTER MED, V6, P207; TISHERMAN SA, 1991, J TRAUMA, V31, P1051, DOI 10.1097/00005373-199131080-00002; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; WHITE RJ, 1978, MAYO CLIN PROC, V53, P450; WOLFSON SK, 1973, J SURG RES, V14, P449, DOI 10.1016/0022-4804(73)90053-X; XIAO F, 1995, RESUSCITATION, V30, P51, DOI 10.1016/0300-9572(94)00858-D; XIAO F, 1994, RESUSCITATION, V28, pS21; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZAR H, 1994, FASEB J, V8, pA128	67	93	95	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	1996	24	2		S			S81	S89					9	Critical Care Medicine	General & Internal Medicine	TW260	WOS:A1996TW26000008	8608709				2021-06-18	
J	LANG, DA; TEASDALE, GM; MACPHERSON, P; LAWRENCE, A				LANG, DA; TEASDALE, GM; MACPHERSON, P; LAWRENCE, A			DIFFUSE BRAIN-SWELLING AFTER HEAD-INJURY - MORE OFTEN MALIGNANT IN ADULTS THAN CHILDREN	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; BRAIN SWELLING; OUTCOME; CHILDREN	COMPUTED-TOMOGRAPHY; NEUROSURGICAL UNIT; COMA; MILD	A series of 118 patients with diffuse traumatic brain swelling was studied retrospectively in order to compare the clinical findings in children with those in adults, and to determine the occurrence of neurological deterioration and outcome. The computerized tomography (CT) picture of absent third ventricle and basal cisterns was used to identify the cases. Although this condition has been associated with children, we found the same number of children and adults (59 cases each). Secondary deterioration (decline in consciousness, the development of new focal neurological signs, or an increase in intracranial pressure) occurred in 40% of cases and was more common in adults than children. Features that were significantly associated with deterioration were the presence of prolonged coma (> 1 hour) after the injury, CT signs of diffuse axonal injury or subarachnoid hemorrhage, or a recorded episode of hypotension. A moderate or good recovery at 6 months was achieved by 70 patients (59%), but 45 patients had a poor outcome (severe disability in nine, vegetative state in three, and death in 33) and this was often a consequence of secondary deterioration. In three patients, the outcome was not known. The combination of a severe initial injury, secondary insult, and diffuse swelling is associated with a poor outlook, particularly in adults. The CT appearance of diffuse swelling may develop more readily in children because of the lack of cerebrospinal fluid available for displacement. In children, diffuse swelling may have a relatively benign course unless there is a severe primary injury or a secondary hypotensive insult.	SO GEN HOSP, INST NEUROL SCI, GLASGOW G51 4TF, SCOTLAND							ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BRIGGS M, 1984, BRIT MED J, V288, P983; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DEARDEN NM, 1989, INTRACRANIAL PRESSUR, V7, P474; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GRANT R, 1987, MAGN RESON IMAGING, V5, P465, DOI 10.1016/0730-725X(87)90380-8; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MACPHERSON P, 1990, CLIN RADIOL, V42, P85, DOI 10.1016/S0009-9260(05)82072-0; MARMAROU A, 1990, ACT NEUR S, V51, P123; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; MENDELOW AD, 1983, INTRACRANIAL PRESSUR, V5, P495; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, IN PRESS J NEUROL NE; TEASDALE GM, 1989, INTRACRANIAL PRESSUR, V7, P560; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	28	93	98	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	1994	80	4					675	680		10.3171/jns.1994.80.4.0675			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NC826	WOS:A1994NC82600011	8151346				2021-06-18	
J	CRUZ, J				CRUZ, J			ONLINE MONITORING OF GLOBAL CEREBRAL HYPOXIA IN ACUTE BRAIN INJURY - RELATIONSHIP TO INTRACRANIAL HYPERTENSION	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; INTRACRANIAL PRESSURE; CEREBRAL OXYGENATION; CEREBRAL HYPOXIA; COMA; FIBEROPTIC MONITORING	SEVERE HEAD-INJURY; BLOOD-FLOW; HEMODYNAMIC RESERVE; OXYGENATION; METABOLISM; COMA; HYPERVENTILATION; PRESSURE; TRAUMA	Global cerebral oxygenation, perfusion pressure, and expired CO2 tension were continuously monitored in 69 adults with acute severe closed brain trauma. Cerebral oxygenation was assessed by continuous fiberoptic monitoring of jugular bulb oxyhemoglobin saturation, in conjunction with continuous monitoring of arterial oxyhemoglobin saturation. Jugular desaturation associated with arterial desaturation (hypoxemic cerebral hypoxia) was evaluated and managed. A total of 121 episodes of combined arterial and jugular desaturation were documented, 76 in the presence of gross abnormalities identified on chest roentgenograms. Prolonged episodes that did not respond promptly to treatment occurred 32 times in 12 patients, usually after the initial 72 hours posttrauma. The remaining 89 episodes promptly responded to treatment and occurred predominantly within the initial 72 hours. Profound but brief desaturation was not associated with neurological deterioration, while profound and prolonged desaturation was accompanied by significant decreases in Glasgow Coma Scale scores, even though intracranial pressure levels were not significantly different in these two groups. Global cerebral hypoxia that does not respond promptly to treatment appears to be independently deleterious to neurological function in severely head-injured patients.	HOSP UNIV PENN,CTR HEAD INJURY,PHILADELPHIA,PA 19104	CRUZ, J (corresponding author), HOSP UNIV PENN,DIV NEUROSURG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR303697-04] Funding Source: Medline		BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; CRUZ J, 1992, J TRAUMA, V33, P304, DOI 10.1097/00005373-199208000-00022; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1992, J TRAUMA, V32, P401, DOI 10.1097/00005373-199203000-00020; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1992, J TRAUMA, V32, P629, DOI 10.1097/00005373-199205000-00015; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; CRUZ J, 1993, IN PRESS CRIT CARE M; GARLICK R, 1987, SCAND J CLIN LAB INV, V47, P47; Gibbs EL, 1942, J BIOL CHEM, V144, P325; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81	23	93	95	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	1993	79	2					228	233		10.3171/jns.1993.79.2.0228			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LP276	WOS:A1993LP27600010	8331405				2021-06-18	
J	UNTERBERG, A; KIENING, K; SCHMIEDEK, P; LANKSCH, W				UNTERBERG, A; KIENING, K; SCHMIEDEK, P; LANKSCH, W			LONG-TERM OBSERVATIONS OF INTRACRANIAL-PRESSURE AFTER SEVERE HEAD-INJURY - THE PHENOMENON OF SECONDARY RISE OF INTRACRANIAL-PRESSURE	NEUROSURGERY			English	Article						HEAD INJURY; INTRACRANIAL PRESSURE; LEUKOCYTOSIS; SECONDARY RISE OF INTRACRANIAL PRESSURE	AGGRESSIVE TREATMENT; HYPONATREMIA; MANAGEMENT; COMA	THE LONG-TERM COURSE of intracranial pressure (ICP) was studied in 53 patients from a group of 90 patients with severe head injury treated over a 3-year period. In 49 of these, ICP was significantly elevated during the observation period. The maximum in ICP was usually observed 24 to 96 hours posttrauma. A subgroup of patients developed a second rise of ICP. Such a course was observed in 15 (31%) of the 49 patients with intracranial hypertension. In these cases, ICP increased initially to 20 to 30 mm Hg but could be controlled. Thereafter, ICP was decreased again for at least 12 hours. The secondary ICP rise occurred 3 to 10 days after trauma. In six patients, intracranial hypertension became uncontrollable and eventually caused brain death. The outcome of patients with a secondary rise of ICP was worse when compared with that of patients without this complication. A cause of the secondary ICP rise could only be identified in some cases. Delayed traumatic intracerebral hemorrhage, traumatic vasospasm, hypoxia, and hyponatremia were diagnosed in seven cases. In seven other patients, the secondary ICP rise coincided with a pronounced leukocytosis, which was not associated with apparent infections. Because the occurrence and degree of a secondary rise of ICP after severe head injury are important factors affecting outcome, monitoring of ICP after severe head injury should be prolonged.	UNIV MUNICH, KLINIKUM GROSSHADERN, DEPT NEUROSURG, W-8000 MUNICH 70, GERMANY	UNTERBERG, A (corresponding author), FREE UNIV BERLIN, RUDOLF VIRCHOW MED CTR, AUGUSTENBURGER PL 1, W-1000 BERLIN 65, GERMANY.						AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; BAETHMANN A, 1987, MECHANISM SECONDARY; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; COOPER PR, 1982, HEAD INJURY, P212; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; FREIDENFELT H, 1963, ACTA RADIOL DIAGN, V1, P278, DOI 10.1177/028418516300100221; GAMACHE FW, 1982, NEUROSURGERY, V10, P468, DOI 10.1227/00006123-198204000-00009; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; JOHNSTON I H, 1970, Lancet, V2, P433; LUNDBERG N, 1960, ACTA PSYCHIATR NEU S, V149, P7; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1989, INTRACRANIAL PRESSUR, V7, P549; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1987, MECHANISM SECONDARY, P323; MIZUKAMI M, 1983, HYPERTENSIVE INTRACE, P239; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; Pappius H.M., 1974, HDB CLIN NEUROLOGY 1, V16, P167; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; TEASDALE G, 1974, LANCET, V2, P81; Turner H B, 1988, J Neurosci Nurs, V20, P236; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	34	93	94	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	1993	32	1					17	24		10.1227/00006123-199301000-00003			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KF376	WOS:A1993KF37600003	8421552				2021-06-18	
J	BRAUGHLER, JM; HALL, ED				BRAUGHLER, JM; HALL, ED			INVOLVEMENT OF LIPID-PEROXIDATION IN CNS INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CAT SPINAL-CORD; METHYLPREDNISOLONE SODIUM SUCCINATE; NERVOUS-SYSTEM TRAUMA; (NA+ + K+)-ATPASE; DIETARY VITAMIN-E; RAT-BRAIN; CHEMI-LUMINESCENCE; ENERGY-METABOLISM; CEREBRAL-ISCHEMIA; DOSE-RESPONSE	The generation of oxygen radicals and the process of lipid peroxidation have become a focus of attention for investigators in the fields of central nervous system (CNS) injury and stroke (e.g., ischemia). While absolute proof for their involvement in the pathophysiology of traumatic and ischemic damage to the CNS remains to be established, numerous recent studies have provided considerable support for the occurrence of free radical and lipid peroxidation reactions in the injured or ischemic CNS. Furthermore, the use of antioxidants and free radical scavengers in the treatment of experimental and clinical CNS trauma and ischemia has provided convincing support for the involvement of oxygen radicals and lipid peroxidation in these conditions. In this report we will review some of the history behind the hypothesis for an involvement of oxygen radical-mediated lipid peroxidation in the pathophysiology of CNS injury and look at some of the more recent work conducted in this area.		BRAUGHLER, JM (corresponding author), UPJOHN CO,AQUISIT REVIEW,7223-24-3,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; Anderson D.K., 1983, NEUROCHEM PATHOL, V1, P249; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1985, J NEUROSURG, V62, P806, DOI 10.3171/jns.1985.62.6.0806; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1983, J NEUROSURG, V58, P538; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; DEMOPOULOS HB, 1972, STEROIDS BRAIN EDEMA, P29; DEMOPOULOS HB, 1980, ACTA PHYSL SCAND S, V492, P91; DZHAFAROV A I, 1985, Byulleten' Eksperimental'noi Biologii i Meditsiny, V100, P433; FOLBERGROVA J, 1981, J NEUROCHEM, V36, P1670, DOI 10.1111/j.1471-4159.1981.tb00417.x; FRANCESCO V, 1985, STROKE, V16, P14, DOI 10.1161/01.STR.16.1.14; FUJIMOTO S, 1984, SURG NEUROL, V22, P449, DOI 10.1016/0090-3019(84)90301-X; GRAFF G, 1978, J BIOL CHEM, V253, P7662; Gutteridge J M, 1986, Free Radic Res Commun, V1, P173, DOI 10.3109/10715768609083149; Hall E., 1989, J CEREB BLOOD FLO S1, V19, pS561; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1981, EXP NEUROL, V73, P321, DOI 10.1016/0014-4886(81)90067-4; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HORNING EC, 1978, TOCOPHEROL OXYGEN BI, P273; IMAIZUMI S, 1984, STROKE, V15, P1061, DOI 10.1161/01.STR.15.6.1061; KONAT GW, 1985, J NEUROCHEM, V45, P1113, DOI 10.1111/j.1471-4159.1985.tb05530.x; KRAMER K, 1986, FEBS LETT, V198, P80, DOI 10.1016/0014-5793(86)81188-7; KURIHARA M, 1985, J NEUROSURG, V62, P743, DOI 10.3171/jns.1985.62.5.0743; MCGINLEY PA, 1982, J CHROMATOGR, V230, P29, DOI 10.1016/S0378-4347(00)81427-9; MEANS ED, 1981, J NEUROSURG, V55, P100; MIKEL HS, 1987, STROKE, V18, P426; Murad F, 1979, Adv Cyclic Nucleotide Res, V11, P175; NATALE JE, 1988, STROKE, V19, P1371, DOI 10.1161/01.STR.19.11.1371; OLIVER CN, 1990, FASEB J, V4, P5520; PASCOE GA, 1989, FREE RADICAL BIO MED, V6, P209, DOI 10.1016/0891-5849(89)90118-4; PIETRONIGRO DD, 1983, J NEUROCHEM, V41, P1072, DOI 10.1111/j.1471-4159.1983.tb09053.x; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SELIGMAN ML, 1979, PHOTOCHEM PHOTOBIOL, V29, P549, DOI 10.1111/j.1751-1097.1979.tb07089.x; SUZUKI J, 1985, STROKE, V16, P695, DOI 10.1161/01.STR.16.4.695; TAPPEL AL, 1973, FED PROC, V32, P1870; TRAVIS MA, 1987, BRAIN RES, V418, P366, DOI 10.1016/0006-8993(87)90105-3; WATSON BD, 1984, J NEUROCHEM, V42, P268, DOI 10.1111/j.1471-4159.1984.tb09728.x; WILLMORE LJ, 1982, BRAIN RES, V246, P113, DOI 10.1016/0006-8993(82)90147-0; YOSHIDA S, 1985, NEUROLOGY, V35, P126, DOI 10.1212/WNL.35.1.126; YOSHIDA S, 1982, BRAIN RES, V245, P307, DOI 10.1016/0006-8993(82)90813-7; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667	54	93	94	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S1	S7					7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600002	1588600				2021-06-18	
J	PAPADOPOULOS, SM; DICKMAN, CA; SONNTAG, VKH; REKATE, HL; SPETZLER, RF				PAPADOPOULOS, SM; DICKMAN, CA; SONNTAG, VKH; REKATE, HL; SPETZLER, RF			TRAUMATIC ATLANTOOCCIPITAL DISLOCATION WITH SURVIVAL	NEUROSURGERY			English	Article						ATLANTOOCCIPITAL DISLOCATION; OCCIPITAL ATLANTOAXIAL FUSION; SPINAL CORD INJURY	ATLANTO-OCCIPITAL DISLOCATION; JUNCTION; FRACTURES; SPINE	Survival after traumatic atlantooccipital dislocation is rare. Only long-term survivors have been reported in the literature; however, improved prehospital care is likely responsible for the increase in the number of these patients seen at neurotrauma centers over the last decade. Associated severe and persistent neurological dificits are common in the few survivors. We report the case of a 10-year-old boy with traumatic atlantooccipital dislocation and a severe neurological injury. Low-field magnetic resonance imaging provided the additional diagnosis of an associated cervicomedullary epidural hematoma. The patient underwent emergency operative evacuation of the hematoma and an occipital-cervical fusion with internal fixation. He had a remarkable recovery in neurological function and achieved stable bony fusion 3 months postoperatively. With early recognition of this entity, improved neuroradiological imaging techniques, and aggressive treatment, patients may survive with significant neurological recovery.	BARROW NEUROL INST,DIV NEUROL SURG,350 W THOMAS RD,PHOENIX,AZ 85013							ALKER GJ, 1978, ORTHOP CLIN N AM, V9, P1003; BOOLS JC, 1986, AM J NEURORADIOL, V7, P901; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; COLLALTO PM, 1986, J BONE JOINT SURG AM, V68A, P1106, DOI 10.2106/00004623-198668070-00024; DUBLIN AB, 1980, J NEUROSURG, V52, P541, DOI 10.3171/jns.1980.52.4.0541; DUCKER TB, 1978, SURG NEUROL, V10, P71; EISMONT FJ, 1978, J BONE JOINT SURG AM, V60, P397, DOI 10.2106/00004623-197860030-00024; EVARTS CM, 1970, J BONE JOINT SURG AM, VA 52, P1653, DOI 10.2106/00004623-197052080-00017; FARTHING J W, 1948, N C Med J, V9, P34; FINNEY HL, 1978, J NEUROSURG, V48, P636, DOI 10.3171/jns.1978.48.4.0636; FRUIN AH, 1977, J NEUROSURG, V46, P663, DOI 10.3171/jns.1977.46.5.0663; GABRIELS.TO, 1966, AMER J ROENTGENOL RA, V97, P624, DOI 10.2214/ajr.97.3.624; GERLOCK AJ, 1983, NEUROSURGERY, V13, P316, DOI 10.1227/00006123-198309000-00019; KAUFMAN RA, 1987, AM J NEURORADIOL, V8, P995; KAUFMAN RA, 1982, AM J NEURORADIOL, V3, P415; LEE C, 1984, AM J NEURORADIOL, V5, P775; LEE C, 1987, AM J NEURORADIOL, V8, P19; LEVINE AM, 1989, CLIN ORTHOP RELAT R, V239, P53; PAGE CP, 1973, J NEUROSURG, V39, P394, DOI 10.3171/jns.1973.39.3.0394; PANG D, 1980, NEUROSURGERY, V7, P503, DOI 10.1227/00006123-198011000-00017; POWERS B, 1979, NEUROSURGERY, V4, P12, DOI 10.1097/00006123-197901000-00004; ROCKSWOLD GL, 1979, MINN MED, V62, P151; TRAYNELIS VC, 1986, J NEUROSURG, V65, P863, DOI 10.3171/jns.1986.65.6.0863; VANDENBOUT AH, 1986, SPINE, V11, P174, DOI 10.1097/00007632-198603000-00017; WATRIDGE CB, 1985, NEUROSURGERY, V17, P345, DOI 10.1227/00006123-198508000-00021; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WHITE AA, 1978, ORTHOP CLIN N AM, V9, P867; WOODRING JH, 1981, AM J ROENTGENOL, V137, P21, DOI 10.2214/ajr.137.1.21; 1908, ANN SURG, V47, P654	29	93	102	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	APR	1991	28	4					574	579		10.1227/00006123-199104000-00015			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FC831	WOS:A1991FC83100015	2034353				2021-06-18	
J	ZORNOW, MH; SCHELLER, MS; SHACKFORD, SR				ZORNOW, MH; SCHELLER, MS; SHACKFORD, SR			EFFECT OF A HYPERTONIC LACTATED RINGERS SOLUTION ON INTRACRANIAL-PRESSURE AND CEREBRAL WATER-CONTENT IN A MODEL OF TRAUMATIC BRAIN INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article									UNIV CALIF SAN DIEGO, DEPT SURG, LA JOLLA, CA 92093 USA	ZORNOW, MH (corresponding author), UNIV CALIF SAN DIEGO, DEPT ANESTHESIOL, M-029, LA JOLLA, CA 92093 USA.						CLASEN RA, 1962, J NEUROPATH EXP NEUR, V21, P579, DOI 10.1097/00005072-196210000-00006; CLASEN RA, 1953, SURG GYNECOL OBSTET, V96, P605; DEFELIPPE J, 1980, LANCET, V2, P1002; FENSTERMACHER JD, 1984, EDEMA, P393; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; LEVIN AB, 1979, NEUROSURGERY, V5, P570, DOI 10.1227/00006123-197911000-00005; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARSHALL LF, 1985, CLIN NEUROSURG, V29, P312; MESSMER K, 1969, BRIT J SURG, V56, P626; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; SHENKIN HA, 1962, J NEUROSURG, V19, P897, DOI 10.3171/jns.1962.19.10.0897; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; TROUT JJ, 1986, LAB INVEST, V55, P622; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; 1977, DISEASE DISABILITY S, P483	16	93	94	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	1989	29	4					484	488		10.1097/00005373-198904000-00011			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	U4679	WOS:A1989U467900011	2709456				2021-06-18	
J	Ling, HL; Morris, HR; Neal, JW; Lees, AJ; Hardy, J; Holton, JL; Revesz, T; Williams, DDR				Ling, Helen; Morris, Huw R.; Neal, James W.; Lees, Andrew J.; Hardy, John; Holton, Janice L.; Revesz, Tamas; Williams, David D. R.			Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Soccer; Football; Heading; Traumatic brain injury; Concussion; Tauopathy	ALZHEIMERS-DISEASE; NEUROPATHOLOGIC ASSESSMENT; NATIONAL INSTITUTE; BRAIN; CONCUSSION; INJURIES; AGE; CONSORTIUM; GUIDELINES; DEPOSITION	In retired professional association football (soccer) players with a past history of repetitive head impacts, chronic traumatic encephalopathy (CTE) is a potential neurodegenerative cause of dementia and motor impairments. From 1980 to 2010, 14 retired footballers with dementia were followed up regularly until death. Their clinical data, playing career, and concussion history were prospectively collected. Next-of-kin provided consent for six to have post-mortem brain examination. Of the 14 male participants, 13 were professional and 1 was a committed amateur. All were skilled headers of the ball and had played football for an average of 26 years. Concussion rate was limited in six cases to one episode each during their careers. All cases developed progressive cognitive impairment with an average age at onset of 63.6 years and disease duration of 10 years. Neuropathological examination revealed septal abnormalities in all six post-mortem cases, supportive of a history of chronic repetitive head impacts. Four cases had pathologically confirmed CTE; concomitant pathologies included Alzheimer's disease (N = 6), TDP-43 (N = 6), cerebral amyloid angiopathy (N = 5), hippocampal sclerosis (N = 2), corticobasal degeneration (N = 1), dementia with Lewy bodies (N = 1), and vascular pathology (N = 1); and all would have contributed synergistically to the clinical manifestations. The pathological diagnosis of CTE was established in four individuals according to the latest consensus diagnostic criteria. This finding is probably related to their past prolonged exposure to repetitive head impacts from head-to-player collisions and heading the ball thousands of time throughout their careers. Alzheimer's disease and TDP-43 pathologies are common concomitant findings in CTE, both of which are increasingly considered as part of the CTE pathological entity in older individuals. Association football is the most popular sport in the world and the potential link between repetitive head impacts from playing football and CTE as indicated from our findings is of considerable public health interest. Clearly, a definitive link cannot be established in this clinico-pathological series, but our findings support the need for further systematic investigation, including large-scale case-control studies to identify at risk groups of footballers which will justify for the implementation of protective strategies.	[Ling, Helen; Lees, Andrew J.; Hardy, John; Holton, Janice L.; Revesz, Tamas] UCL, UCL Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England; [Ling, Helen; Lees, Andrew J.; Hardy, John; Holton, Janice L.; Revesz, Tamas] UCL Inst Neurol, Reta Lila Weston Inst Neurol Studies, 1 Wakefield St, London WC1N 1PJ, England; [Ling, Helen; Hardy, John; Holton, Janice L.; Revesz, Tamas] UCL, UCL Inst Neurol, Dept Mol Neurosci, London, England; [Morris, Huw R.] UCL Inst Neurol, Dept Clin Neurosci, London, England; [Neal, James W.] Cardiff Univ, Dept Cellular Pathol, Cardiff, S Glam, Wales; [Williams, David D. R.] Cefn Coed Hosp, Swansea, W Glam, Wales	Holton, JL; Revesz, T (corresponding author), UCL, UCL Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England.; Holton, JL; Revesz, T (corresponding author), UCL Inst Neurol, Reta Lila Weston Inst Neurol Studies, 1 Wakefield St, London WC1N 1PJ, England.; Holton, JL; Revesz, T (corresponding author), UCL, UCL Inst Neurol, Dept Mol Neurosci, London, England.	janice.holton@ucl.ac.uk; t.revesz@ucl.ac.uk	Morris, Huw/B-8527-2008; Hardy, John/C-2451-2009	Morris, Huw/0000-0002-5473-3774; Hardy, John/0000-0002-3122-0423	Drake FoundationSmithsonian InstitutionSmithsonian National Museum of Natural History	The Drake Foundation.	Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P205, DOI 10.1080/17482960902721634; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; Dickson DW, 2002, J NEUROPATH EXP NEUR, V61, P935, DOI 10.1093/jnen/61.11.935; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Grinberg LT, 2016, J ALZHEIMERS DIS, V54, P169, DOI 10.3233/JAD-160312; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Josephs KA, 2016, ACTA NEUROPATHOL, V131, P571, DOI 10.1007/s00401-016-1537-1; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kovacs GG, 2008, DEMENT GERIATR COGN, V26, P343, DOI 10.1159/000161560; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P111, DOI 10.1007/s00401-011-0845-8; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory P, 2002, BRIT J SPORT MED, V36, P157, DOI 10.1136/bjsm.36.3.157; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911, DOI 10.1093/jnen/63.9.911; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364	43	92	94	3	35	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2017	133	3					337	352		10.1007/s00401-017-1680-3			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	EL9ST	WOS:000394961100001	28205009	Green Published, Other Gold			2021-06-18	
J	Jacka, FN; Cherbuin, N; Anstey, KJ; Sachdev, P; Butterworth, P				Jacka, Felice N.; Cherbuin, Nicolas; Anstey, Kaarin J.; Sachdev, Perminder; Butterworth, Peter			Western diet is associated with a smaller hippocampus: a longitudinal investigation	BMC MEDICINE			English	Article						Brain derived neurotrophic factor; Hippocampus; Diet; Magnetic resonance imaging; Neurogenesis; Nutrition	TRAUMATIC BRAIN-INJURY; SATURATED-FAT DIET; NEUROTROPHIC FACTOR; MEDITERRANEAN DIET; COGNITIVE IMPAIRMENT; AMYGDALA VOLUMES; OXIDATIVE STRESS; DEPRESSION; NEUROGENESIS; DISEASE	Background: Recent meta-analyses confirm a relationship between diet quality and both depression and cognitive health in adults. While the biological pathways that underpin these relationships are likely multitudinous, extensive evidence from animal studies points to the involvement of the hippocampus. The aim of this study was to examine the association between dietary patterns and hippocampal volume in humans, and to assess whether diet was associated with differential rates of hippocampal atrophy over time. Methods: Data were drawn from the Personality and Total Health Through Life Study and focused on a subsample of the cohort (n = 255) who were aged 60-64 years at baseline in 2001, completed a food frequency questionnaire, and underwent two magnetic resonance imaging scans approximately 4 years apart. Longitudinal generalized estimating equation linear regression models were used to assess the association between dietary factors and left and right hippocampal volumes over time. Results: Every one standard deviation increase in healthy "prudent" dietary pattern was associated with a 45.7 mm(3) (standard error 22.9 mm(3)) larger left hippocampal volume, while higher consumption of an unhealthy " Western" dietary pattern was (independently) associated with a 52.6 mm(3) (SE 26.6 mm(3)) smaller left hippocampal volume. These relationships were independent of covariates including age, gender, education, labour-force status, depressive symptoms and medication, physical activity, smoking, hypertension and diabetes. While hippocampal volume declined over time, there was no evidence that dietary patterns influenced this decline. No relationships were observed between dietary patterns and right hippocampal volume. Conclusions: Lower intakes of nutrient-dense foods and higher intakes of unhealthy foods are each independently associated with smaller left hippocampal volume. To our knowledge, this is the first human study to demonstrate associations between diet and hippocampal volume concordant with data previously observed in animal models.	[Jacka, Felice N.] Deakin Univ, IMPACT Strateg Res Ctr, Div Nutr Psychiat Res, Geelong, Vic 3217, Australia; [Jacka, Felice N.] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia; [Jacka, Felice N.] Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Melbourne, Vic, Australia; [Jacka, Felice N.] Black Dog Inst, Sydney, NSW, Australia; [Cherbuin, Nicolas; Anstey, Kaarin J.; Butterworth, Peter] Australian Natl Univ, Ctr Res Ageing Hlth & Wellbeing, Res Sch Populat Hlth, Canberra, ACT, Australia; [Sachdev, Perminder] Univ New S Wales, Fac Med, Sch Psychiat, CHeBA, Sydney, NSW, Australia	Jacka, FN (corresponding author), Deakin Univ, IMPACT Strateg Res Ctr, Div Nutr Psychiat Res, Geelong, Vic 3217, Australia.	f.jacka@deakin.edu.au	Anstey, Kaarin/AAB-4870-2020; Sachdev, Perminder/ABC-1137-2020; Anstey, Kaarin J/A-3852-2008; Cherbuin, Nicolas/A-8515-2008; Jacka, Felice/D-9424-2012	Sachdev, Perminder/0000-0002-9595-3220; Anstey, Kaarin/0000-0002-9706-9316; Cherbuin, Nicolas/0000-0001-6481-0748; Butterworth, Peter/0000-0002-1531-3881; Jacka, Felice/0000-0002-9825-0328	Deakin University; Brain and Behaviour Research Institute; National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; Australian Rotary Health; Geelong Medical Research Foundation; Ian Potter Foundation; Eli LillyEli Lilly; Meat and Livestock Board; University of MelbourneUniversity of Melbourne; NHMRC Research FellowshipNational Health and Medical Research Council of Australia [1002560]; ARC Future FellowshipAustralian Research Council [120100227, FT130101444]; NHMRCNational Health and Medical Research Council of Australia [973302, 179805, 350833, 157125, 1063907]	FNJ is funded by Deakin University and has received Grant/Research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council (NHMRC), Australian Rotary Health, the Geelong Medical Research Foundation, the Ian Potter Foundation, Eli Lilly, the Meat and Livestock Board and The University of Melbourne and has received speakers' honoraria from Sanofi-Synthelabo, Janssen Cilag, Servier, Pfizer, Health Ed, Network Nutrition, Angelini Farmaceutica, and Eli Lilly. KJA is funded by NHMRC Research Fellowship No. 1002560. NC is funded by an ARC Future Fellowship No. 120100227. PB is funded by an ARC Future Fellowship # FT130101444. The PATH study was supported by NHMRC Grants No. 973302, Program Grants No. 179805 and 350833, and NHMRC project grant No. 157125 and 1063907. The authors are grateful to Anthony Jorm, Bryan Rodgers, Helen Christensen, Simon Easteal, Patricia Jacomb, Karen Maxwell, and the PATH interviewers and participants. PB had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Adair LS, 2005, OBES RES, V13, P1281, DOI 10.1038/oby.2005.153; ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S; An L, 2008, PROG NEURO-PSYCHOPH, V32, P1484, DOI 10.1016/j.pnpbp.2008.05.005; Anstey KJ, 2012, INT J EPIDEMIOL, V41, P951, DOI 10.1093/ije/dyr025; Anstey KJ, 2004, NEUROREPORT, V15, P2825; Beilharz JE, 2014, BRAIN BEHAV IMMUN, V37, P134, DOI 10.1016/j.bbi.2013.11.016; Berk M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-200; Cherbuin N, 2012, NEUROLOGY, V79, P1019, DOI 10.1212/WNL.0b013e31826846de; Cherbuin N, 2012, AM J GERIAT PSYCHIAT, V20, P635, DOI 10.1097/JGP.0b013e31823032a9; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Dash S, 2015, CURR OPIN PSYCHIATR, V28, P1, DOI 10.1097/YCO.0000000000000117; Dias GP, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/541971; Edwards LM, 2011, FASEB J, V25, P1088, DOI 10.1096/fj.10-171983; Fotuhi M, 2009, NAT CLIN PRACT NEURO, V5, P140, DOI 10.1038/ncpneuro1044; Fraser MA, 2015, NEUROIMAGE, V112, P364, DOI 10.1016/j.neuroimage.2015.03.035; Frodl T, 2008, J PSYCHIATR NEUROSCI, V33, P423; Gardener S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.91; Giannakopoulos P, 2009, STROKE, V40, P983, DOI 10.1161/STROKEAHA.108.530337; GOLDBERG D, 1988, BRIT MED J, V297, P897, DOI 10.1136/bmj.297.6653.897; Granzotto A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00095; Guimaraes LR, 2008, PROG NEURO-PSYCHOPH, V32, P1595, DOI 10.1016/j.pnpbp.2008.06.004; Heyward FD, 2012, NEUROBIOL LEARN MEM, V98, P25, DOI 10.1016/j.nlm.2012.04.005; Jacka FN, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-132; Jacka FN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087657; Jacka FN, 2011, PSYCHOSOM MED, V73, P483, DOI 10.1097/PSY.0b013e318222831a; Jacka FN, 2010, AM J PSYCHIAT, V167, P305, DOI 10.1176/appi.ajp.2009.09060881; Kawakita E, 2006, NEUROSCIENCE, V139, P991, DOI 10.1016/j.neuroscience.2006.01.021; Lai JS, 2014, AM J CLIN NUTR, V99, P181, DOI 10.3945/ajcn.113.069880; Lassale C, 2009, J HUM NUTR DIET, V22, P559, DOI 10.1111/j.1365-277X.2009.00990.x; Lee S, 2010, NEUROCHEM RES, V35, P1725, DOI 10.1007/s11064-010-0235-y; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Maller JJ, 2007, PSYCHIAT RES-NEUROIM, V156, P185, DOI 10.1016/j.pscychresns.2007.06.005; Maller JJ, 2006, HIPPOCAMPUS, V16, P80, DOI 10.1002/hipo.20133; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Martire SI, 2014, BEHAV BRAIN RES, V265, P132, DOI 10.1016/j.bbr.2014.02.027; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Morrison CD, 2010, J NEUROCHEM, V114, P1581, DOI 10.1111/j.1471-4159.2010.06865.x; Moylan S, 2014, NEUROSCI BIOBEHAV R, V45, P46, DOI 10.1016/j.neubiorev.2014.05.007; O'Neil A, 2014, AM J PUBLIC HEALTH, V104, pE31, DOI 10.2105/AJPH.2014.302110; Psaltopoulou T, 2013, ANN NEUROL, V74, P580, DOI 10.1002/ana.23944; Ross AP, 2009, NEUROBIOL LEARN MEM, V92, P410, DOI 10.1016/j.nlm.2009.05.007; Samieri C, 2013, J NUTR, V143, P493, DOI 10.3945/jn.112.169896; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Sarris J, 2015, LANCET PSYCHIAT, V2, P271, DOI 10.1016/S2215-0366(14)00051-0; Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Shi F, 2009, HIPPOCAMPUS, V19, P1055, DOI 10.1002/hipo.20573; Swinburn BA, 2011, LANCET, V378, P804, DOI 10.1016/S0140-6736(11)60813-1; Thompson PM, 2007, ANN NY ACAD SCI, V1097, P183, DOI 10.1196/annals.1379.017; Valente T, 2009, J ALZHEIMERS DIS, V18, P849, DOI 10.3233/JAD-2009-1188; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Williams CM, 2008, FREE RADICAL BIO MED, V45, P295, DOI 10.1016/j.freeradbiomed.2008.04.008; World Health Organization, 2010, GLOBAL STATUS REPORT; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Zainuddin MSA, 2012, BRIT MED BULL, V103, P89, DOI 10.1093/bmb/lds021	59	92	94	0	38	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1741-7015			BMC MED	BMC Med.	SEP 8	2015	13								215	10.1186/s12916-015-0461-x			8	Medicine, General & Internal	General & Internal Medicine	CQ7SU	WOS:000360805300001	26349802	DOAJ Gold, Green Published			2021-06-18	
J	Rochfort, KD; Cummins, PM				Rochfort, Keith D.; Cummins, Philip M.			The blood-brain barrier endothelium: a target for pro-inflammatory cytokines	BIOCHEMICAL SOCIETY TRANSACTIONS			English	Article						blood-brain barrier; endothelial; interleukin-6 (IL-6); NADPH oxidase; neuroinflammation; tumour necrosis factor-alpha (TNF-alpha)	NECROSIS-FACTOR-ALPHA; TIGHT JUNCTION PROTEINS; IN-VITRO MODEL; TNF-ALPHA; OXIDATIVE STRESS; NADPH OXIDASE; NOX ENZYMES; KAPPA-B; CELLS; DYSFUNCTION	An intact functioning blood-brain barrier (BBB) is fundamental to proper homoeostatic maintenance and perfusion of the central nervous system (CNS). Inflammatory damage to the unique microvascular endothelial cell monolayer that constitutes the luminal BBB surface, leading to elevated capillary permeability, has been linked to various neurological disorders ranging from ischaemic stroke and traumatic brain injury, to neurodegenerative disease and CNS infections. Moreover, the neuroinflammatory cascade that typically accompanies BBB failure in these circumstances has been strongly linked to elevated levels of proinflammatory cytokines such as tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). This mini review will examine our current knowledge of how cytokines may dysregulate the interendothelial paracellular pathway leading to elevated BBB permeability. The mechanistic role of nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase)-induced oxidative stress in these events will also be addressed.	[Rochfort, Keith D.; Cummins, Philip M.] Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland; [Cummins, Philip M.] Dublin City Univ, Ctr Prevent Med, Dublin 9, Ireland	Cummins, PM (corresponding author), Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland.	phil.cummins@dcu.ie	Rochfort, Keith/R-7009-2019	Rochfort, Keith/0000-0003-1198-5952	Irish National Development Plan/Higher Education Authority Programme for Research in Third Level Institutes (NDP/HEA-PRTLI Cycle 4: T3 Targeted Therapeutics Theranostics)	This work was supported by the Irish National Development Plan/Higher Education Authority Programme for Research in Third Level Institutes (NDP/HEA-PRTLI Cycle 4: T3 Targeted Therapeutics & Theranostics).	Abdullah Z, 2014, MOL CELL NEUROSCI, V61, P72, DOI 10.1016/j.mcn.2014.06.002; Lopez-Ramirez MA, 2012, J IMMUNOL, V189, P3130, DOI 10.4049/jimmunol.1103460; Altenhofer S., 2014, ANTIOXID RE IN PRESS; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Aslam M, 2012, CYTOKINE, V57, P269, DOI 10.1016/j.cyto.2011.10.016; Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606; Balda MS, 1998, J CELL SCI, V111, P541; Basuroy S, 2006, AM J PHYSIOL-CELL PH, V291, pC897, DOI 10.1152/ajpcell.00032.2006; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Bennett J, 2010, J NEUROIMMUNOL, V229, P180, DOI 10.1016/j.jneuroim.2010.08.011; Borlongan CV, 2012, CURR PHARM DESIGN, V18, P3615; Chaudhuri A, 2008, BLOOD, V111, P2062, DOI 10.1182/blood-2007-05-091207; Chen JY, 2014, J PINEAL RES, V57, P340, DOI 10.1111/jpi.12173; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Cohen SS, 2013, NEUROIMMUNOMODULAT, V20, P264, DOI 10.1159/000350470; Desai TR, 2002, J SURG RES, V104, P118, DOI 10.1006/jsre.2002.6415; Ferrarese C, 1999, J CEREBR BLOOD F MET, V19, P1004, DOI 10.1097/00004647-199909000-00008; Fiala M, 1997, MOL MED, V3, P553, DOI 10.1007/BF03401701; Figiel I, 2008, ACTA NEUROBIOL EXP, V68, P526; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Frey RS, 2009, ANTIOXID REDOX SIGN, V11, P791, DOI [10.1089/ars.2008.2220, 10.1089/ARS.2008.2220]; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Gertzberg N, 2004, AM J PHYSIOL-LUNG C, V286, pL37, DOI 10.1152/ajplung.00116.2003; Griffin W Sue T, 2010, US Neurol, V6, P19; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hou TY, 2008, CURR CARDIOL REV, V4, P179, DOI 10.2174/157340308785160570; Labus J, 2014, J NEUROSCI METH, V228, P35, DOI 10.1016/j.jneumeth.2014.03.002; Lambeth JD, 2008, SEMIN IMMUNOPATHOL, V30, P339, DOI 10.1007/s00281-008-0123-6; Lutgendorf MA, 2014, REPROD SCI, V21, P483, DOI 10.1177/1933719113503410; Lv S, 2010, LIVER INT, V30, P1198, DOI 10.1111/j.1478-3231.2010.02211.x; Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957; Manea A, 2010, ARTERIOSCL THROM VAS, V30, P105, DOI 10.1161/ATVBAHA.109.193896; Marcos-Ramiro B, 2014, THROMB HAEMOSTASIS, V112, P1088, DOI 10.1160/TH14-04-0299; Mark KS, 1999, LIFE SCI, V64, P1941, DOI 10.1016/S0024-3205(99)00139-3; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; Mckenzie JAG, 2007, J CELL PHYSIOL, V213, P221, DOI 10.1002/jcp.21114; Naik P, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-51; Nishioku T, 2010, J PHARMACOL SCI, V112, P251, DOI 10.1254/jphs.09292SC; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Rochfort KD, 2015, J CEREBR BLOOD F MET, V35, P1648, DOI 10.1038/jcbfm.2015.102; Rochfort KD, 2015, MICROVASC RES, V100, P48, DOI 10.1016/j.mvr.2015.04.010; Rochfort KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101815; Schroeder K, 2009, ARTERIOSCL THROM VAS, V29, P239, DOI 10.1161/ATVBAHA.108.174219; SHARIEF MK, 1992, J NEUROIMMUNOL, V38, P27, DOI 10.1016/0165-5728(92)90087-2; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Strazza M, 2011, BRAIN RES, V1399, P96, DOI 10.1016/j.brainres.2011.05.015; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; Voigt A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00042; Walsh TG, 2011, J CELL PHYSIOL, V226, P3053, DOI 10.1002/jcp.22655; Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D; Wilson CM, 2009, INT J RADIAT ONCOL, V74, P934, DOI 10.1016/j.ijrobp.2009.02.035	52	92	96	0	27	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0300-5127	1470-8752		BIOCHEM SOC T	Biochem. Soc. Trans.	AUG	2015	43		4				702	706		10.1042/BST20140319			5	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CO2QJ	WOS:000359001400028	26551716				2021-06-18	
J	Ferguson, AR; Nielson, JL; Cragin, MH; Bandrowski, AE; Martone, ME				Ferguson, Adam R.; Nielson, Jessica L.; Cragin, Melissa H.; Bandrowski, Anita E.; Martone, Maryann E.			Big data from small data: data-sharing in the 'long tail' of neuroscience	NATURE NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; NEURONAL MORPHOLOGY; KNOWLEDGE; SCIENCE; PROJECT; REPLICATION; INFORMATION; FRAMEWORK; IMPACT	The launch of the US BRAIN and European Human Brain Projects coincides with growing international efforts toward transparency and increased access to publicly funded research in the neurosciences. The need for data-sharing standards and neuroinformatics infrastructure is more pressing than ever. However, 'big science' efforts are not the only drivers of data-sharing needs, as neuroscientists across the full spectrum of research grapple with the overwhelming volume of data being generated daily and a scientific environment that is increasingly focused on collaboration. In this commentary, we consider the issue of sharing of the richly diverse and heterogeneous small data sets produced by individual neuroscientists, so-called long-tail data. We consider the utility of these data, the diversity of repositories and options available for sharing such data, and emerging best practices. We provide use cases in which aggregating and mining diverse long-tail data convert numerous small data sources into big data for improved knowledge about neuroscience-related disorders.	[Ferguson, Adam R.; Nielson, Jessica L.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Cragin, Melissa H.] Natl Sci Fdn, Directorate Biol Sci, Arlington, VA 22230 USA; [Bandrowski, Anita E.; Martone, Maryann E.] Univ Calif San Diego, Ctr Res Biol Struct, San Diego, CA 92103 USA; [Martone, Maryann E.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA	Martone, ME (corresponding author), Univ Calif San Diego, Ctr Res Biol Struct, San Diego, CA 92103 USA.	mmartone@ucsd.edu		Martone, Maryann/0000-0002-8406-3871; Bandrowski, Anita/0000-0002-5497-0243; Ferguson, Adam/0000-0001-7102-1608; Nielson, Jessica/0000-0002-3677-3959	NIH Neuroscience Blueprint via the National Institute on Drug Abuse [HHSN271200800035C]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS067092, NS079030]; Craig H. Neilsen foundation; Wings for Life foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067092, F32NS079030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [U24DA039832] Funding Source: NIH RePORTER	We thank the NIF staff, especially B. Ozyurt for his text mining expertise and tools that contributed substantially to Supplementary Table 1. The Neuroscience Information Framework is supported by a contract from the NIH Neuroscience Blueprint HHSN271200800035C via the National Institute on Drug Abuse. VISION-SCI is supported by NIH grants NS067092 (A.R.F.) and NS079030 (J.L.N.), and the Craig H. Neilsen foundation (A.R.F) and Wings for Life foundation (A.R.F). This material is based on (M.H.C.) work supported while serving at the National Science Foundation. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not reflect the views of the National Science Foundation.	Agarwal G, 2014, SCIENCE, V344, P626, DOI 10.1126/science.1250444; Ascoli GA, 2007, J NEUROSCI, V27, P9247, DOI 10.1523/JNEUROSCI.2055-07.2007; Bohannon J, 2014, SCIENCE, V344, P788, DOI 10.1126/science.344.6186.788; Boline J, 2008, FRONT NEUROSCI-SWITZ, V2, P100, DOI 10.3389/neuro.01.012.2008; Boulton G, 2011, LANCET, V377, P1633, DOI 10.1016/S0140-6736(11)60647-8; Chan AW, 2014, LANCET, V383, P257, DOI 10.1016/S0140-6736(13)62296-5; Costa Luciano Da Fontoura, 2010, Front Comput Neurosci, V4, P150, DOI 10.3389/fncom.2010.00150; Cragin MH, 2010, PHILOS T R SOC A, V368, P4023, DOI 10.1098/rsta.2010.0165; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Fernandez JJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-178; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gardner D, 2003, NEUROINFORMATICS, V1, P289, DOI 10.1385/NI:1:3:289; Gardner D, 2008, NEUROINFORMATICS, V6, P149, DOI 10.1007/s12021-008-9024-z; Goodman A, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003542; Gorgolewski KJ, 2013, GIGASCIENCE, V2, DOI 10.1186/2047-217X-2-6; Gorgolewski KJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00009; Halavi M, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00049; Hansen MB, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00031; Heidorn PB, 2008, LIBR TRENDS, V57, P280; HUERTA MF, 1993, TRENDS NEUROSCI, V16, P436, DOI 10.1016/0166-2236(93)90069-X; Kennedy DN, 2014, NEUROINFORMATICS, V12, P361, DOI 10.1007/s12021-014-9239-0; Klein T., 2013, DATA SCI J, V12, P1; Kwon BK, 2010, J NEUROTRAUM, V27, P21, DOI 10.1089/neu.2009.1048; Lemmon VP, 2014, J NEUROTRAUM, V31, P1354, DOI 10.1089/neu.2014.3400; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Martone ME, 2004, NAT NEUROSCI, V7, P467, DOI 10.1038/nn1229; Martone ME, 2002, J STRUCT BIOL, V138, P145, DOI 10.1016/S1047-8477(02)00006-0; Mennes M, 2013, NEUROIMAGE, V82, P683, DOI 10.1016/j.neuroimage.2012.10.064; Mueck L, 2013, NAT NANOTECHNOL, V8, P693, DOI 10.1038/nnano.2013.204; Nielson JL, 2014, J NEUROTRAUM, V31, P1789, DOI 10.1089/neu.2014.3399; Perrino T, 2013, PERSPECT PSYCHOL SCI, V8, P433, DOI 10.1177/1745691613491579; Poldrack RA, 2013, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00012; Poline JB, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00096; Research Data Alliance, 2014, RES DAT SHAR BARR; Roche DG, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001779; Roysam B, 2009, NEUROINFORMATICS, V7, P1, DOI 10.1007/s12021-008-9043-9; Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344; Shepherd GM, 1998, TRENDS NEUROSCI, V21, P460, DOI 10.1016/S0166-2236(98)01300-9; Steward O, 2012, EXP NEUROL, V233, P597, DOI 10.1016/j.expneurol.2011.06.017; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tenopir C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021101; Turner CF, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar043; Turner Jessica A, 2010, Front Neuroinform, V4, DOI 10.3389/fninf.2010.00010; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Van Horn JD, 2013, NEUROIMAGE, V82, P677, DOI 10.1016/j.neuroimage.2012.11.010; Wallis JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067332; WEINBERG AM, 1961, SCIENCE, V134, P161, DOI 10.1126/science.134.3473.161; Wicherts JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026828; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	54	92	96	2	78	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	NOV	2014	17	11					1442	1447		10.1038/nn.3838			6	Neurosciences	Neurosciences & Neurology	AS0LT	WOS:000343969300008	25349910	Green Published, Green Accepted			2021-06-18	
J	Naeser, MA; Zafonte, R; Krengel, MH; Martin, PI; Frazier, J; Hamblin, MR; Knight, JA; Meehan, WP; Baker, EH				Naeser, Margaret A.; Zafonte, Ross; Krengel, Maxine H.; Martin, Paula I.; Frazier, Judith; Hamblin, Michael R.; Knight, Jeffrey A.; Meehan, William P., III; Baker, Errol H.			Significant Improvements in Cognitive Performance Post-Transcranial, Red/Near-Infrared Light-Emitting Diode Treatments in Chronic, Mild Traumatic Brain Injury: Open-Protocol Study	JOURNAL OF NEUROTRAUMA			English	Article						executive function; mTBI; photobiomodulation; treatment for mTBI	LEVEL LASER THERAPY; CYTOCHROME-C-OXIDASE; CEREBRAL-BLOOD-FLOW; CLOSED-HEAD-INJURY; WORKING-MEMORY; NEUROLOGICAL DEFICITS; FUNCTIONAL MRI; FOLLOW-UP; TBI; DYSFUNCTION	This pilot, open-protocol study examined whether scalp application of red and near-infrared (NIR) light-emitting diodes (LED) could improve cognition in patients with chronic, mild traumatic brain injury (mTBI). Application of red/NIR light improves mitochondrial function (especially in hypoxic/compromised cells) promoting increased adenosine triphosphate (ATP) important for cellular metabolism. Nitric oxide is released locally, increasing regional cerebral blood flow. LED therapy is noninvasive, painless, and non-thermal (cleared by the United States Food and Drug Administration [FDA], an insignificant risk device). Eleven chronic, mTBI participants (26-62 years of age, 6 males) with nonpenetrating brain injury and persistent cognitive dysfunction were treated for 18 outpatient sessions (Monday, Wednesday, Friday, for 6 weeks), starting at 10 months to 8 years post-mTBI (motor vehicle accident [MVA] or sports-related; and one participant, improvised explosive device [IED] blast injury). Four had a history of multiple concussions. Each LED cluster head (5.35 cm diameter, 500mW, 22.2 mW/cm(2)) was applied for 10 min to each of 11 scalp placements (13 J/cm(2)). LEDs were placed on the midline from front-to-back hairline; and bilaterally on frontal, parietal, and temporal areas. Neuropsychological testing was performed pre-LED, and at 1 week, and 1 and 2 months after the 18th treatment. A significant linear trend was observed for the effect of LED treatment over time for the Stroop test for Executive Function, Trial 3 inhibition (p = 0.004); Stroop, Trial 4 inhibition switching (p = 0.003); California Verbal Learning Test (CVLT)-II, Total Trials 1-5 (p = 0.003); and CVLT-II, Long Delay Free Recall (p = 0.006). Participants reported improved sleep, and fewer post-traumatic stress disorder (PTSD) symptoms, if present. Participants and family reported better ability to perform social, interpersonal, and occupational functions. These open-protocol data suggest that placebo-controlled studies are warranted.	[Naeser, Margaret A.; Krengel, Maxine H.; Martin, Paula I.; Baker, Errol H.] VA Boston Healthcare Syst, Boston, MA USA; [Naeser, Margaret A.; Krengel, Maxine H.; Martin, Paula I.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Zafonte, Ross; Frazier, Judith] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA; [Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil,Brigham & Womens Hosp, Massachusetts Gen Hosp,Red Sox MGH Home Base Prog, Boston, MA USA; [Hamblin, Michael R.] Harvard Univ, Sch Med, Wellman Ctr Photomed,Massachusetts Gen Hosp, Harvard Mit Div Hlth Sci & Technol,Dept Dermatol, Cambridge, MA 02138 USA; [Knight, Jeffrey A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA	Naeser, MA (corresponding author), VA Boston Healthcare Syst 12A, 150 So Huntington Ave, Boston, MA 02130 USA.	mnaeser@bu.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605	Clinical Sciences Research and Development, Department of Veterans Affairs; United States National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; American Medical Society for Sports Medicine (AMSSM) Young Investigator Award; American College of Sports Medicine-American Medical Society for Sports Medicine Foundation Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	M. Naeser was supported by the Clinical Sciences Research and Development, Department of Veterans Affairs. M. R. Hamblin was supported by United States National Institutes of Health (NIH) grant R01AI050875. W. P. Meehan was supported by an American Medical Society for Sports Medicine (AMSSM) Young Investigator Award and an American College of Sports Medicine-American Medical Society for Sports Medicine Foundation Award. The authors thank Laura Burns for assistance with participant enrollment, Iris Monge for the LED treatments, Anita Saltmarche for assistance with acquisition of the LED units and LED methodology, and Michael D. Ho for assistance with manuscript preparation.	Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Beck A., 1993, MANUAL BECK DEPRESSI; Benton A, 1989, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Faul M., 2013, TRAUMATIC BRAIN INJU; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Levin HS, 2013, J NEUROTRAUM, V30, P625, DOI 10.1089/neu.2012.2627; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Pain Assessment Visual Analog Scale, 2008, PAIN VIS SCAL; Pastore D, 2000, INT J RADIAT BIOL, V76, P863; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Siedentopf CM, 2002, NEUROSCI LETT, V327, P53, DOI 10.1016/S0304-3940(02)00383-X; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Sompol P, 2006, J MOL NEUROSCI, V29, P279, DOI 10.1385/JMN:29:3:279; Spreen O., 1977, NUEROSENSORY CTR COM; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; Weathers F. W., 1993, USING PTSD CHECKLIST; Wechsler D., 2008, WAIS 4 WESCHLSER ADU; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	72	92	93	2	44	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2014	31	11					1008	1017		10.1089/neu.2013.3244			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AJ7RS	WOS:000337895300003	24568233	Green Published			2021-06-18	
J	Cox, CS; Baumgartner, JE; Harting, MT; Worth, LL; Walker, PA; Shah, SK; Ewing-Cobbs, L; Hasan, KM; Day, MC; Lee, D; Jimenez, F; Gee, A				Cox, Charles S., Jr.; Baumgartner, James E.; Harting, Matthew T.; Worth, Laura L.; Walker, Peter A.; Shah, Shinil K.; Ewing-Cobbs, Linda; Hasan, Khader M.; Day, Mary-Clare; Lee, Dean; Jimenez, Fernando; Gee, Adrian			Autologous Bone Marrow Mononuclear Cell Therapy for Severe Traumatic Brain Injury in Children	NEUROSURGERY			English	Article						Cellular therapy; Clinical trial; Mononuclear cell; Pediatric; Stem cell; Traumatic brain injury	STROMAL CELLS; INFLAMMATORY RESPONSE; DIFFUSION-TENSOR; HEAD-INJURY; ISCHEMIA; TRANSPLANTATION; HYPOTHERMIA; VALIDATION; DELIVERY; MODERATE	BACKGROUND: Severe traumatic brain injury (TBI) in children is associated with substantial long-term morbidity and mortality. Currently, there are no successful neuroprotective/neuroreparative treatments for TBI. Numerous preclinical studies suggest that bone marrow-derived mononuclear cells (BMMNCs), their derivative cells (marrow stromal cells), or similar cells (umbilical cord blood cells) offer neuroprotection. OBJECTIVE: To determine whether autologous BMMNCs are a safe treatment for severe TBI in children. METHODS: Ten children aged 5 to 14 years with a postresuscitation Glasgow Coma Scale of 5 to 8 were treated with 6 3 106 autologous BMMNCs/ kg body weight delivered intravenously within 48 hours after TBI. To determine the safety of the procedure, systemic and cerebral hemodynamics were monitored during bone marrow harvest; infusion-related toxicity was determined by pediatric logistic organ dysfunction (PELOD) scores, hepatic enzymes, Murray lung injury scores, and renal function. Conventional magnetic resonance imaging (cMRI) data were obtained at 1 and 6 months postinjury, as were neuropsychological and functional outcome measures. RESULTS: All patients survived. There were no episodes of harvest-related depression of systemic or cerebral hemodynamics. There was no detectable infusion-related toxicity as determined by PELOD score, hepatic enzymes, Murray lung injury scores, or renal function. cMRI imaging comparing gray matter, white matter, and CSF volumes showed no reduction from 1 to 6 months postinjury. Dichotomized Glasgow Outcome Score at 6 months showed 70% with good outcomes and 30% with moderate to severe disability. CONCLUSION: Bone marrow harvest and intravenous mononuclear cell infusion as treatment for severe TBI in children is logistically feasible and safe.	[Cox, Charles S., Jr.; Baumgartner, James E.; Harting, Matthew T.; Walker, Peter A.; Shah, Shinil K.; Ewing-Cobbs, Linda; Day, Mary-Clare; Jimenez, Fernando] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX USA; [Harting, Matthew T.; Walker, Peter A.; Shah, Shinil K.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX USA; [Hasan, Khader M.] Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, Houston, TX USA; Univ Texas Houston, Childrens Mem Hermann Hosp, Houston, TX USA; [Worth, Laura L.; Lee, Dean] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pediat, Div Cell Therapy, Houston, TX 77030 USA; [Gee, Adrian] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA	Cox, CS (corresponding author), 6431 Fannin,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu	Hasan, Khader M./ABB-5767-2020; Lee, Dean Anthony/AAK-8443-2021	Lee, Dean Anthony/0000-0001-6693-5392; Harting, Matthew/0000-0002-8929-8311	Children's Memorial Hermann Foundation, Brown Foundation, Inc., National Institute of Health [R21 HD042659-01A1, UL1 RR024148, 1T32 GM 087-92-01, R01 NS052505]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [NO1-HB-37163]; CBR, Inc.; Athersys, Inc.; KCI, Inc.; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD042659] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052505, R01NS077963] Funding Source: NIH RePORTER	This work was supported by Children's Memorial Hermann Foundation, Brown Foundation, Inc., National Institute of Health Grants R21 HD042659-01A1, UL1 RR024148, 1T32 GM 087-92-01, and R01 NS052505. The cell preparation was supported in part by Production Assistance for Cellular Therapies (National Heart, Lung, and Blood Institute Contract NO1-HB-37163). Dr Cox serves as a consultant and has sponsored research agreements with CBR, Inc., Athersys, Inc., and KCI, Inc. Dr Cox has stock and royalty interests in EMIT Corporation. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Boltze J, 2008, J CEREBR BLOOD F MET, V28, P1951, DOI 10.1038/jcbfm.2008.89; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fink DW, 2009, SCIENCE, V324, P1662, DOI 10.1126/science.1173712; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hasan KM, 2007, NEUROIMAGE, V34, P1497, DOI 10.1016/j.neuroimage.2006.10.029; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qu RJ, 2007, NEUROPATHOLOGY, V27, P355, DOI 10.1111/j.1440-1789.2007.00792.x; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Walker PA, 2009, J TRAUMA, V67, pS120, DOI 10.1097/TA.0b013e3181ad323a; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Willing AE, 2007, HISTOL HISTOPATHOL, V22, P697, DOI 10.14670/HH-22.697	35	92	94	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2011	68	3					588	600		10.1227/NEU.0b013e318207734c			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	719WN	WOS:000287242300021	21192274				2021-06-18	
J	Su, XF; Wang, HD; Zhao, JB; Pan, H; Mao, L				Su, Xingfen; Wang, Handong; Zhao, Jinbing; Pan, Hao; Mao, Lei			Beneficial Effects of Ethyl Pyruvate through Inhibiting High-Mobility Group Box 1 Expression and TLR4/NF-kappa B Pathway after Traumatic Brain Injury in the Rat	MEDIATORS OF INFLAMMATION			English	Article							KAPPA-B; INFLAMMATORY RESPONSE; ISCHEMIC-INJURY; HMGB1; MODEL; MICE; DYSFUNCTION; RECOVERY; RELEASE	Ethyl pyruvate (EP) has demonstrated neuroprotective effects against acute brain injury through its anti-inflammatory action. The nuclear protein high-mobility group box 1 (HMGB1) can activate inflammatory pathways when released from dying cells. This study was designed to investigate the protective effects of EP against secondary brain injury in rats after Traumatic Brain Injury (TBI). Adult male rats were randomly divided into three groups: (1) Sham + vehicle group, (2) TBI + vehicle group, and (3) TBI + EP group (n = 30 per group). Right parietal cortical contusion was made by using a weight-dropping TBI method. In TBI + EP group, EP was administered intraperitoneally at a dosage of 75mg/kg at 5min, 1 and 6 h after TBI. Brain samples were harvested at 24 h after TBI. We found that EP treatment markedly inhibited the expressions of HMGB1 and TLR4, NF-kappa B DNA binding activity and inflammatory mediators, such as IL-1 beta, TNF-alpha and IL-6. Also, EP treatment significantly ameliorated beam walking performance, brain edema, and cortical apoptotic cell death. These results suggest that the protective effects of EP may be mediated by the reduction of HMGB1/TLR4/NF-kappa B-mediated inflammatory response in the injured rat brain.	[Su, Xingfen; Wang, Handong; Zhao, Jinbing; Pan, Hao; Mao, Lei] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_nj@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Jiangsu Provincial Key Subject [X4200722]	This work was supported by grants from the National Natural Science Foundation of China (no. 81070974) and the Jiangsu Provincial Key Subject (no. X4200722). The authors would like to thank Dr. Gengbao Feng for his technical assistance.	Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Cai BL, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/642462; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Genovese T, 2009, SHOCK, V32, P217, DOI 10.1097/SHK.0b013e31818d4073; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Kao KK, 2010, BIOCHEM PHARMACOL, V80, P151, DOI 10.1016/j.bcp.2010.03.007; Kawabata H, 2010, SPINE, V35, P1109, DOI 10.1097/BRS.0b013e3181bd14b6; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mao L, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/238321; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Moro N, 2010, EXP NEUROL, V225, P391, DOI 10.1016/j.expneurol.2010.07.013; PAOLA RD, 2009, CRITICAL CARE MED, V37, P270; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roth P, 2000, Crit Care Nurs Q, V23, P14; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246-200108000-00003; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Wang Q, 2009, ANESTHESIOLOGY, V110, P1279, DOI 10.1097/ALN.0b013e3181a160d6; Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648; Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI 10.1016/j.bbagrm.2009.11.019; Yang R, 2002, AM J PHYSIOL-GASTR L, V283, pG212, DOI 10.1152/ajpgi.00022.2002; Yang RK, 2004, CRIT CARE MED, V32, P1453, DOI 10.1097/01.CCM.0000130835.65462.06; Yu YM, 2005, STROKE, V36, P2238, DOI 10.1161/01.STR.0000181779.83472.35; Zhou Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/142458	38	92	96	0	9	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2011	2011								807142	10.1155/2011/807142			10	Cell Biology; Immunology	Cell Biology; Immunology	802XD	WOS:000293543400001	21772666	DOAJ Gold, Green Published			2021-06-18	
J	Maas, AI; Harrison-Felix, CL; Menon, D; Adelson, PD; Balkin, T; Bullock, R; Engel, DC; Gordon, W; Orman, JL; Lew, HL; Robertson, C; Temkin, N; Valadka, A; Verfaellie, M; Wainwright, M; Wright, DW; Schwab, K				Maas, Andrew I.; Harrison-Felix, Cynthia L.; Menon, David; Adelson, P. David; Balkin, Tom; Bullock, Ross; Engel, Doortje C.; Gordon, Wayne; Orman, Jean Langlois; Lew, Henry L.; Robertson, Claudia; Temkin, Nancy; Valadka, Alex; Verfaellie, Mieke; Wainwright, Mark; Wright, David W.; Schwab, Karen			Common Data Elements for Traumatic Brain Injury: Recommendations From the Interagency Working Group on Demographics and Clinical Assessment	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Clinical protocols; Clinical studies; Data collection; Forms and records control; Rehabilitation; Standardization; Traumatic brain injury	PROGNOSTIC VALUE; INTRACRANIAL-PRESSURE; SECONDARY INSULTS; RACE; RACE/ETHNICITY; ETHNICITY; DESIGN	Comparing results across studies in traumatic brain injury (TB!) has been difficult because of the variability in data coding, definitions, and collection procedures. The global aim of the Working Group on Demographics and Clinical Assessment was to develop recommendations on the coding of clinical and demographic variables for TBI studies applicable across the broad spectrum of TBI, and to classify these as core, supplemental, or emerging. The process was consensus driven, with input from experts over a broad range of disciplines. Special consideration was given to military and pediatric TBI. Categorizing clinical elements as core versus supplemental proved difficult, given the great variation in types of studies and their interests. The data elements are contained in modules, which are grouped together in categories. Three levels of detail for coding data elements were developed: basic, intermediate, and advanced, with the greatest level of detail in the advanced version. In every case, the more detailed coding can be collapsed into the basic version. Templates were produced to summarize coding formats, motivation of choices, and recommendations for procedures. Work is ongoing to include more international participation and to provide an electronic data entry format with pull-down menus and automated data checks. This proposed standardization will facilitate comparison of research findings across studies and encourage high-quality meta-analysis of individual patient data.	[Maas, Andrew I.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Harrison-Felix, Cynthia L.] Craig Hosp, Englewood, CO USA; [Menon, David] Univ Cambridge, Cambridge, England; [Adelson, P. David] Phoenix Childrens Neurosci Inst, Phoenix, AZ USA; [Balkin, Tom] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; [Bullock, Ross] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Engel, Doortje C.] Univ Heidelberg Hosp, Heidelberg, Germany; [Gordon, Wayne] Mt Sinai Sch Med, New York, NY USA; [Orman, Jean Langlois] Rehabil Res & Dev Serv, Dept Vet Affairs, Washington, DC USA; [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Def & Vet Brain Injury Ctr, Richmond, VA USA; [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA; [Robertson, Claudia] Baylor Coll Med, Houston, TX 77030 USA; [Temkin, Nancy] Univ Washington, Seattle, WA 98195 USA; [Valadka, Alex] Seton Brain & Spine Inst, Austin, TX USA; [Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02118 USA; [Verfaellie, Mieke] Boston VA Hlth Care Syst, Boston, MA USA; [Wainwright, Mark] Northwestern Univ, Chicago, IL 60611 USA; [Wright, David W.] Emory Univ, Sch Med, Atlanta, GA USA; [Schwab, Karen] Def & Vet Brain Injury Ctr, Washington, DC USA	Maas, AI (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Maas, Andrew IR/C-5584-2013; Wright, David/F-1209-2013; Adelson, David/W-2083-2019	Maas, Andrew IR/0000-0003-1612-1264; Wright, David/0000-0002-7145-9105; Verfaellie, Mieke/0000-0001-5535-4584	National Institutes of Health-National Institute of Neurological Disorders and Stroke [NIH-NINDS]United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 042691]; National Institute on Disability and Rehabilitation Research; Department of Veterans AffairsUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Defense Centers of Excellence; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	Support for the meetings and activities of the Working Group on Demographics and Clinical Assessment was funded in the context of the interagency initiative toward "an integrated approach to Research in Psychological Health and Traumatic Brain Injury" (National Institutes of Health-National Institute of Neurological Disorders and Stroke [NIH-NINDS]; the National Institute on Disability and Rehabilitation Research; the Department of Veterans Affairs; the Defense and Veterans Brain Injury Center and the Defense Centers of Excellence). The development of CDEs was further supported by a supplemental grant from NIH-NINDS (grant no. NS 042691).	Armed Forces Health Surveillance Center (AFHSC), 2007, MED SURVEILLANCE MON, V14, P2; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bhopal R, 1998, AM J PUBLIC HEALTH, V88, P1303, DOI 10.2105/AJPH.88.9.1303; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Caulfield T, 2009, GENOME MED, V1, DOI 10.1186/gm8; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Haga SB, 2003, SCIENCE, V301, P466, DOI 10.1126/science.1087004; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jorde LB, 2004, NAT GENET, V36, pS28, DOI 10.1038/ng1435; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ma IWY, 2007, J CLIN EPIDEMIOL, V60, P572, DOI 10.1016/j.jclinepi.2006.11.009; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2009, CRIT CARE, V13, DOI 10.1186/cc8163; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; *MED AFTAOA, 1990, ABBR INJ SCAL 1990 R, P15; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Smart A, 2008, SOC STUD SCI, V38, P407, DOI 10.1177/0306312707083759; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Suarez-Kurtz G, 2005, TRENDS PHARMACOL SCI, V26, P196, DOI 10.1016/j.tips.2005.02.008; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tutton R, 2008, J LAW MED ETHICS, V36, P464, DOI 10.1111/j.1748-720X.2008.292.x; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; WILDE EA, ARCH PHYS MED REHABI, P1650; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; WRIGHT L, 1994, NEW YORKER      0725, P46; Wynia MK, 2010, NEW ENGL J MED, V362, P846, DOI 10.1056/NEJMsb0910799	33	92	93	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1641	1649		10.1016/j.apmr.2010.07.232			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400003	21044707				2021-06-18	
J	Moulaert, VRMP; Wachelder, EM; Verbunt, JA; Wade, DT; van Heugten, CM				Moulaert, Veronique R. M. P.; Wachelder, Esther M.; Verbunt, Jeanine A.; Wade, Derick T.; van Heugten, Caroline M.			DETERMINANTS OF QUALITY OF LIFE IN SURVIVORS OF CARDIAC ARREST	JOURNAL OF REHABILITATION MEDICINE			English	Article						heart arrest; quality of life; cognition disorders; hypoxia-ischaemia brain	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; LONG-TERM; CARDIOPULMONARY-RESUSCITATION; COMMUNITY INTEGRATION; EARLY DEFIBRILLATION; EVENT SCALE; VALIDATION; FATIGUE; IMPACT	Objective: To study factors related to quality of life after a hypoxic period due to cardiac arrest. Design: Retrospective cohort study. Subjects: Eighty-eight survivors of out-of-hospital cardiac arrest, admitted to a Dutch academic hospital between 2001 and 2006. Methods: Patients received a set of questionnaires at home. The main outcome measures were physical and mental quality of life (Medical Outcomes Study 36-item Short Form Health Survey; SF-36). Potential determinants were cognitive complaints, emotional problems (depression/anxiety), post-traumatic stress, fatigue, daily functioning and participation in society. Multiple linear regression analyses were performed with physical and mental quality of life as dependent variables. Results: Sixty-three (72%) patients responded. Mean time since cardiac arrest was 36 months (standard deviation (SD) 19). Backward regression analyses showed that physical quality of life was significantly (p<0.001, adjusted R(2)=0.531) related to cognitive complaints (beta=-0.378), instrumental daily life activities (beta=0.262), post-traumatic stress (beta=-0.246) and fatigue (beta=-0.226). Mental quality of life was significantly (p<0.001, adjusted R(2)=0.664) explained by anxiety/depression (beta=-0.609), fatigue (beta=-0.177) and cognitive complaints (beta=-0.175). Conclusion: Quality of life is related to cognitive complaints, fatigue, anxiety/depression, post-traumatic stress and difficulties in daily activities in survivors of out-of-hospital cardiac arrest. Rehabilitation programmes for this group should specifically address these topics.	[van Heugten, Caroline M.] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands; [van Heugten, Caroline M.] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, NL-6200 MD Maastricht, Netherlands; [Verbunt, Jeanine A.; Wade, Derick T.] Maastricht Univ, Care & Publ Hlth Res Inst, NL-6200 MD Maastricht, Netherlands; [Wade, Derick T.] Oxford Ctr Enablement, Oxford, England; [Moulaert, Veronique R. M. P.; Wachelder, Esther M.; Verbunt, Jeanine A.] Adelante, Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands	van Heugten, CM (corresponding author), Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, POB 616, NL-6200 MD Maastricht, Netherlands.	c.vanheugten@np.unimaas.nl			Netherlands Organization for Health Research and Development (ZON/MW)Netherlands Organization for Health Research and Development; Fonds Nuts/Ohra	The study is funded by the Netherlands Organization for Health Research and Development (ZON/MW) and Fonds Nuts/Ohra.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Bekkers SCAM, 2007, AM J EMERG MED, V25, P1078, DOI 10.1016/j.ajem.2007.06.008; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Bunch TJ, 2004, RESUSCITATION, V60, P189, DOI 10.1016/j.resuscitation.2003.09.010; Bunch TJ, 2003, NEW ENGL J MED, V348, P2626, DOI 10.1056/NEJMoa023053; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; de Haan R, 1993, Ned Tijdschr Geneeskd, V137, P917; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; de Vreede-Swagemakers JJM, 1998, HEART, V79, P356, DOI 10.1136/hrt.79.4.356; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Eisenburger P, 1998, RESUSCITATION, V38, P137, DOI 10.1016/S0300-9572(98)00085-9; Gamper G, 2004, CRIT CARE MED, V32, P378, DOI 10.1097/01.CCM.0000108880.97967.C0; Gorgels APM, 2003, EUR HEART J, V24, P1204, DOI 10.1016/S0195-668X(03)00191-X; Hochstenbach JB, 2001, ARCH PHYS MED REHAB, V82, P1360, DOI 10.1053/apmr.2001.25970; Horsted TI, 2007, RESUSCITATION, V72, P214, DOI 10.1016/j.resuscitation.2006.06.029; Kamphuis HCM, 2002, EUROPACE, V4, P417, DOI 10.1053/eupc.2002.0258; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Lundgren-Nilsson A, 2005, RESUSCITATION, V66, P285, DOI 10.1016/j.resuscitation.2005.04.001; Moulaert Veronique R M P, 2007, BMC Cardiovasc Disord, V7, P26, DOI 10.1186/1471-2261-7-26; Moulaert VRMP, 2009, RESUSCITATION, V80, P297, DOI 10.1016/j.resuscitation.2008.10.034; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Noble AJ, 2008, NEUROSURGERY, V63, P1095, DOI 10.1227/01.NEU.0000327580.91345.78; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Turnbull JC, 2000, ARCH PHYS MED REHAB, V81, P1034, DOI 10.1053/apmr.2000.7162; van Alem AP, 2004, AM J CARDIOL, V93, P131, DOI 10.1016/j.amjcard.2003.09.027; van Alem AP, 2004, AM HEART J, V148, P416, DOI 10.1016/j.ahj.2004.01.031; van de Port IGL, 2007, CEREBROVASC DIS, V23, P40, DOI 10.1159/000095757; van der Ploeg E, 2004, PSYCHOL ASSESSMENT, V16, P16, DOI 10.1037/1040-3590.16.1.16; Visser-Meily JMA, 2009, STROKE, V40, P1526, DOI 10.1161/STROKEAHA.108.531277; Wachelder EM, 2009, RESUSCITATION, V80, P517, DOI 10.1016/j.resuscitation.2009.01.020	34	92	94	0	6	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	JUN	2010	42	6					553	558		10.2340/16501977-0547			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	613SQ	WOS:000279001000007	20549160	DOAJ Gold			2021-06-18	
J	Jaeger, M; Dengl, M; Meixensberger, J; Schuhmann, MU				Jaeger, Matthias; Dengl, Markus; Meixensberger, Juergen; Schuhmann, Martin U.			Effects of cerebrovascular pressure reactivity-guided optimization of cerebral perfusion pressure on brain tissue oxygenation after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain injury; brain tissue oxygen; cerebrovascular pressure reactivity; cerebral perfusion pressure; neuromonitoring; cerebral autoregulation	SEVERE HEAD-INJURY; BLOOD-FLOW; TENSION; AUTOREGULATION	Objective: To evaluate the concept of a cerebrovascular pressure reactivity-guided optimal cerebral perfusion pressure after traumatic brain injury by analyzing the relationship between optimal cerebral perfusion pressure and brain tissue oxygen. Design: Prospective observational cohort study. Setting: Neurosurgical intensive care unit of a university hospital. Patients: Thirty-eight patients after head injury. Interventions: Continuous computerized monitoring of mean arterial pressure, intracranial pressure, and brain tissue oxygen for 5.3 +/- 2.6 days. The index of cerebrovascular pressure reactivity was calculated as a moving correlation coefficient between spontaneous low-frequency fluctuations of mean arterial pressure and intracranial pressure. Optimal cerebral perfusion pressure was defined as the cerebral perfusion pressure level with the lowest average index of cerebrovascular pressure reactivity. Measurements and Main Results: Optimal cerebral perfusion pressure could be identified in 32 of 38 patients. Median optimal cerebral perfusion pressure was between 70 and 75 mm Hg (range, 60-100 mm Hg). Below the level of optimal cerebral perfusion pressure, brain tissue oxygen decreased in parallel to cerebral perfusion pressure, whereas brain tissue oxygen reached a plateau above optimal cerebral perfusion pressure. Optimal cerebral perfusion pressure correlated significantly with the cerebral perfusion pressure level, where brain tissue oxygen reached its plateau (r = .79; p < .01). Average brain tissue oxygen at optimal cerebral perfusion pressure was 24.5 +/- 6.0 mm Hg. Conclusions: This study supports the concept of cerebrovascular pressure reactivity-based individual optimal cerebral perfusion pressure. Driving cerebral perfusion pressure in excess of optimal cerebral perfusion pressure does not yield improvements in brain tissue oxygen after head injury and should be avoided, whereas cerebral perfusion pressure below optimal cerebral perfusion pressure may result in secondary cerebral ischemia. (Crit Care Med 2010; 38: 1343-1347)	[Jaeger, Matthias; Dengl, Markus; Meixensberger, Juergen; Schuhmann, Martin U.] Univ Leipzig, Dept Neurosurg, Leipzig, Germany; [Jaeger, Matthias] Univ New S Wales, Liverpool Hosp, Sydney SW Area Hlth Serv, Dept Neurosurg, Liverpool, NSW, Australia; [Schuhmann, Martin U.] Univ Tubingen, Dept Neurosurg, Tubingen, Germany	Jaeger, M (corresponding author), Univ Leipzig, Dept Neurosurg, Leipzig, Germany.	Matthias.Jaeger@sswahs.nsw.gov.au					Andrews PJD, 2005, CRIT CARE, V9, P638, DOI 10.1186/cc3922; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; TEASDALE G, 1974, LANCET, V2, P81; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa P, 2003, NEUROSURG FOCUS, V15, P1, DOI DOI 10.3171/foc.2003.15.6.4; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a	18	92	94	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAY	2010	38	5					1343	1347		10.1097/CCM.0b013e3181d45530			5	Critical Care Medicine	General & Internal Medicine	593JD	WOS:000277449100015	20154598				2021-06-18	
J	Spencer, RJ; Drag, LL; Walker, SJ; Bieliauskas, LA				Spencer, Robert J.; Drag, Lauren L.; Walker, Sara J.; Bieliauskas, Linas A.			Self-reported cognitive symptoms following mild traumatic brain injury are poorly associated with neuropsychological performance in OIF/OEF veterans	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						anxiety; brain injury; cognition; depression; insight; military; neuropsychological assessment; self-report; traumatic psychometrics; veterans	OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; CHRONIC PAIN PATIENTS; MEMORY IMPAIRMENT; HEAD-INJURY; DEPRESSION; COMPLAINTS; DEFICITS; INDIVIDUALS; CONCUSSION	Mild traumatic brain injury (mTBI) is not uncommon among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) veterans, and many individuals within this group report lingering cognitive difficulties following their injury. For Department of Veterans Affairs clinicians, an accurate assessment of cognitive symptoms is important in providing appropriate clinical care. Although self-assessment is commonly employed to screen for difficulties in cognitive functioning, little is known about the accuracy of self-report in this population. This study collected cognitive, psychiatric, and self-report data from 105 OIF/OEF veterans with mTBI to examine the relationship between self-reported cognitive functioning and objective neuropsychological test performance. Additionally, clinicians who frequently work with OIF/OEF veterans were asked to predict the magnitude of these associations. Self-reported cognitive functioning was not significantly correlated with objective cognitive abilities, suggesting that objective neuropsychological testing should be used when cognitive weakness is suspected. Perceived cognitive deficits were associated with depression, anxiety, and posttraumatic stress disorder, illustrating the additional importance of adequate assessment and treatment of psychiatric symptoms. Clinicians tended to overestimate the association between self-report and test performance.	[Spencer, Robert J.; Walker, Sara J.; Bieliauskas, Linas A.] Dept Vet Affairs Ann Arbor Healthcare Syst, Dept Mental Hlth Serv, Ann Arbor, MI USA; [Drag, Lauren L.; Bieliauskas, Linas A.] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI USA	Bieliauskas, LA (corresponding author), 2101 Commonwealth Blvd,Suite C, Ann Arbor, MI 48105 USA.	linas@umich.edu					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arnstein P, 1999, PAIN, V80, P483, DOI 10.1016/S0304-3959(98)00220-6; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Branca B, 1996, HEADACHE, V36, P300, DOI 10.1046/j.1526-4610.1996.3605300.x; Burdick KE, 2005, PSYCHIAT RES, V136, P43, DOI 10.1016/j.psychres.2004.12.009; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; COMUNIAN AL, 1989, PERCEPT MOTOR SKILL, V69, P755, DOI 10.2466/pms.1989.69.3.755; Deckersbach T, 2000, J CLIN EXP NEUROPSYC, V22, P640, DOI 10.1076/1380-3395(200010)22:5;1-9;FT640; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; GAGNON M, 1994, NEUROEPIDEMIOLOGY, V13, P145, DOI 10.1159/000110373; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Julian L, 2007, MULT SCLER J, V13, P81, DOI 10.1177/1352458506070255; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; LEW HL, 2007, J REHABIL RES DEV, V45, pR11; MCCREA MA, 2008, AM ACAD CLIN NEUROPS; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meyers J., 1995, REY COMPLEX FIGURE T; Moore LH, 1997, J NEUROPSYCH CLIN N, V9, P37; Randolph C, 1998, REPEATABLE BATTERY A; Savage CR, 2000, NEUROPSYCHOLOGY, V14, P141, DOI 10.1037/0894-4105.14.1.141; Savage CR, 1999, BIOL PSYCHIAT, V45, P905, DOI 10.1016/S0006-3223(98)00278-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwartz CE, 1996, ANN BEHAV MED, V18, P177, DOI 10.1007/BF02883395; SOUTHWICK SM, 1991, AM J PSYCHIAT, V148, P179; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; SULLIVAN MJL, 1990, J ABNORM PSYCHOL, V99, P260, DOI 10.1037/0021-843X.99.3.260; Tanielian T., 2008, RAND CORPORATION INV; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wechsler D, 2008, WAIS 4 ADM SCORING M; ZACHARY RA, 2000, SHIPLEY I LIVING SCA; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	92	92	0	11	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	6					521	530		10.1682/JRRD.2009.11.0181			10	Rehabilitation	Rehabilitation	657FX	WOS:000282399700003	20848365	Bronze			2021-06-18	
J	Parvizi, J; Coburn, KL; Shillcutt, SD; Coffey, CE; Lauterbach, EC; Mendez, MF				Parvizi, Josef; Coburn, Kerry L.; Shillcutt, Samuel D.; Coffey, C. Edward; Lauterbach, Edward C.; Mendez, Mario F.			Neuroanatomy of Pathological Laughing and Crying: A Report of the American Neuropsychiatric Association Committee on Research	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							FOU RIRE PRODROMIQUE; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; POSTERIOR-FOSSA TUMORS; PSEUDOBULBAR AFFECT; MULTIPLE-SCLEROSIS; SUBTHALAMIC NUCLEUS; ELECTRICAL-STIMULATION; COGNITIVE DYSFUNCTION; PONTINE INFARCTION	Pathological laughing and crying ( PLC) is a clinical condition that occurs in patients with various neurological disorders. It is characterized by the presence of episodic and contextually inappropriate or merely exaggerated outbursts of laughter and/or crying without commensurate feelings. This review provides an in depth analysis of the neuroanatomy of lesions seen in patients with this clinical condition, discusses the relevant functional neuroimaging and electrophysiological stimulation studies in human subjects, and summarizes the current treatment options. It concludes with a presentation of the remaining questions and directions for future research.	[Parvizi, Josef] Stanford Univ, Dept Neurol, Sch Med, Stanford, CA 94305 USA; [Coburn, Kerry L.; Shillcutt, Samuel D.; Lauterbach, Edward C.] Mercer Univ, Sch Med, Dept Psychiat, Macon, GA 31207 USA; [Coffey, C. Edward] Henry Ford Hlth Syst, Dept Psychiat, Detroit, MI USA; [Mendez, Mario F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA	Parvizi, J (corresponding author), Stanford Univ, Dept Neurol, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	jparvizi@stanford.edu					Abrahams S, 1997, J NEUROL NEUROSUR PS, V62, P464, DOI 10.1136/jnnp.62.5.464; ACHARI A N, 1976, Journal of the American Medical Association, V235, P1469, DOI 10.1001/jama.235.14.1469; ALLMAN P, 1989, J NEUROL NEUROSUR PS, V52, P1439, DOI 10.1136/jnnp.52.12.1439; ANDERSEN G, 1994, STROKE, V25, P1050, DOI 10.1161/01.STR.25.5.1050; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; Arif H, 2005, NEUROLOGY, V64, P2154, DOI 10.1212/01.WNL.0000166033.90390.2A; BECHTEREW WV, 1909, FUNKTIONEN NERVENCEN; Bejjani BP, 1999, NEW ENGL J MED, V340, P1476, DOI 10.1056/NEJM199905133401905; Benedetti F, 2004, BRAIN RES BULL, V63, P203, DOI 10.1016/j.brainresbull.2004.01.010; Bhatjiwale MG, 2000, NEUROSURGERY, V47, P469, DOI 10.1097/00006123-200008000-00044; Brissaud E, 1895, LECONS MALADIES NERV; Brissaud E., 1895, RIRE PLEURER SPASMOD, P446; Brooks BR, 2004, NEUROLOGY, V63, P1364; Burns A, 1999, INT J GERIATR PSYCH, V14, P681, DOI 10.1002/(SICI)1099-1166(199908)14:8<681::AID-GPS49>3.0.CO;2-Z; Carel C, 1997, STROKE, V28, P2081, DOI 10.1161/01.STR.28.10.2081; CUMMINGS JL, 2007, CNS SPECTR S5 S6, V12; Damasio A. R., 1994, DESCARTESERROR; Davidson Richard J., 2003, HDB AFFECTIVE SCI; de Gelder B, 2006, NAT REV NEUROSCI, V7, P242, DOI 10.1038/nrn1872; DOORENBOS DI, 1993, NEUROLOGY, V43, P229, DOI 10.1212/WNL.43.1_Part_1.229; EKMAN P, 1992, PHILOS T ROY SOC B, V335, P63, DOI 10.1098/rstb.1992.0008; Famularo G, 2007, EUR J NEUROL, V14, P940, DOI 10.1111/j.1468-1331.2007.01784.x; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Feinstein A, 1999, MULT SCLER, V5, P69, DOI 10.1177/135245859900500201; FERE MC, 1903, REV NEUROL, P11353; Fried I, 1998, NATURE, V391, P650, DOI 10.1038/35536; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; GAVRILESCU T, 1995, CEREBROVAS BRAIN MET, V7, P218; Geday J, 2006, NEUROIMAGE, V33, P706, DOI 10.1016/j.neuroimage.2006.06.056; Ghaffar O, 2008, J NEUROL, V255, P406, DOI 10.1007/s00415-008-0685-1; Gondim FAA, 2004, REV NEUROL-FRANCE, V160, P277; Gordon B, 1996, PROG BRAIN RES, V107, P617; Gross J.J, 2007, HDB EMOTIONAL REGULA; Hargrave DR, 2006, J NEURO-ONCOL, V77, P267, DOI 10.1007/s11060-005-9034-8; HAUPT M, 1996, INT PSYCHOGERIATR S, V8, P3409; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; IRONSIDE R, 1956, BRAIN, V79, P589, DOI 10.1093/brain/79.4.589; Johnston S Claiborne, 2007, Ann Neurol, V61, p11A, DOI 10.1002/ana.21100; Kahane P, 2003, EPILEPTIC DISORD, V5, P205; Kataoka S, 1997, STROKE, V28, P809, DOI 10.1161/01.STR.28.4.809; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; KIM JS, 1995, STROKE, V26, P950, DOI 10.1161/01.STR.26.6.950; Kim JS, 1997, STROKE, V28, P2321; Kosaka H, 2006, J NEUROL NEUROSUR PS, V77, P1376, DOI 10.1136/jnnp.2005.073288; Krack P, 2001, MOVEMENT DISORD, V16, P867, DOI 10.1002/mds.1174; LAL AP, 1992, J NEUROL NEUROSUR PS, V55, P628, DOI 10.1136/jnnp.55.7.628-a; Lanteaume L, 2007, CEREB CORTEX, V17, P1307, DOI 10.1093/cercor/bhl041; Larner AJ, 1998, NEUROLOGY, V51, P916, DOI 10.1212/WNL.51.3.916; LAUTERBACH EC, 1994, BIOL PSYCHIAT, V35, P488, DOI 10.1016/0006-3223(94)90048-5; LeDoux J., 1998, EMOTIONAL BRAIN MYST; Levenson RW, 2003, ANN NY ACAD SCI, V1000, P348, DOI 10.1196/annals.1280.016; Low HL, 2008, ARCH NEUROL-CHICAGO, V65, P264, DOI 10.1001/archneurol.2007.53; Mallet L, 2007, P NATL ACAD SCI USA, V104, P10661, DOI 10.1073/pnas.0610849104; MATSUOKA S, 1993, J NEUROSURG, V79, P428, DOI 10.3171/jns.1993.79.3.0428; McCullagh S, 1999, J NEUROL SCI, V169, P43, DOI 10.1016/S0022-510X(99)00214-2; Meletti S, 2006, EPILEPSIA, V47, P47, DOI 10.1111/j.1528-1167.2006.00877.x; Meyer M, 2007, BEHAV BRAIN RES, V182, P245, DOI 10.1016/j.bbr.2007.04.023; MINDEN SL, 1990, ARCH NEUROL-CHICAGO, V47, P98, DOI 10.1001/archneur.1990.00530010124031; MOUTON P, 1994, REV NEUROL, V150, P302; Muller U, 1999, BRAIN INJURY, V13, P805, DOI 10.1080/026990599121197; Murai T, 2003, PSYCHIAT RES-NEUROIM, V123, P207, DOI 10.1016/S0925-4927(03)00065-9; Nadkarni TD, 1999, BRIT J NEUROSURG, V13, P212, DOI 10.1080/02688699944023; Niedenthal PM, 2007, SCIENCE, V316, P1002, DOI 10.1126/science.1136930; Okuda DT, 2005, MOVEMENT DISORD, V20, P1389, DOI 10.1002/mds.20607; Okun MS, 2004, J NEUROL NEUROSUR PS, V75, P921, DOI 10.1136/jnnp.2003.016485; OPPENHEIM H, 1886, MITTEILUNGEN PSEUDOB; Oppenheim H., 1911, TXB NERVOUS DIS PHYS; Panitch HS, 2006, ANN NEUROL, V59, P780, DOI 10.1002/ana.20828; Panksepp J., 1998, AFFECTIVE NEUROSCIEN; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; PARVIZI J, 2003, BRAIN; Parvizi J, 2007, MOVEMENT DISORD, V22, P798, DOI 10.1002/mds.21348; Parvizi J, 2007, J NEUROPSYCH CLIN N, V19, P187, DOI 10.1176/appi.neuropsych.19.2.187; Parvizi J, 2006, MAYO CLIN PROC, V81, P1482, DOI 10.4065/81.11.1482; POECK K, 1985, CLIN NEUROPSYCHOLOGY, P219; POECK K, 1964, ARCH NEUROL PSYCHIAT, P92323; POECK K, 1985, DISORDERS HIGHER NER, P343; POLLACK IF, 1995, NEUROSURGERY, V37, P885, DOI 10.1227/00006123-199511000-00006; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; SELIGER G M, 1992, Brain Injury, V6, P267, DOI 10.3109/02699059209029668; Shafqat S, 1998, NEUROLOGY, V50, P1918, DOI 10.1212/WNL.50.6.1918; Siddiqui MS, 2006, NEUROLOGY, V66, pA369; Sperli F, 2006, EPILEPSIA, V47, P440, DOI 10.1111/j.1528-1167.2006.00442.x; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Tei H, 1997, NEURORADIOLOGY, V39, P190, DOI 10.1007/s002340050390; VANCALENBERGH F, 1995, NEUROSURGERY, V37, P894, DOI 10.1227/00006123-199511000-00007; VANHILTEN JJ, 1988, ARCH NEUROL-CHICAGO, V45, P936, DOI 10.1001/archneur.1988.00520330010001; WALI GM, 1993, J NEUROL NEUROSUR PS, V56, P209, DOI 10.1136/jnnp.56.2.209; Whitehouse PJ, 2007, NEUROTHERAPEUTICS, V4, P560, DOI 10.1016/j.nurt.2007.03.003; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Wojtecki L, 2007, MOVEMENT DISORD, V22, P1314, DOI 10.1002/mds.21266; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160	96	92	94	0	14	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2009	21	1					75	87		10.1176/jnp.2009.21.1.75			13	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	431ES	WOS:000265044700011	19359455				2021-06-18	
J	Covassin, T; Elbin, RJ; Stiller-Ostrowski, JL; Kontos, AP				Covassin, Tracey; Elbin, Robert J., III; Stiller-Ostrowski, Jennifer L.; Kontos, Anthony P.			Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) Practices of Sports Medicine Professionals	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; baseline testing; computerized neurocognitive testing	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; AGREEMENT STATEMENT; SOCCER PLAYERS; EPIDEMIOLOGY; MANAGEMENT; RECOVERY	Context: Computerized neurocognitive testing is becoming popular among clinicians evaluating sport-related concussions across all levels of sport. Baseline neurocognitive testing has been recommended to provide more accurate representation of the preconcussion cognitive status of individual athletes. However, little is known about the use of baseline neurocognitive testing in concussion assessment and management. Objective: To examine implementation and practice trends of sports medicine professionals using baseline neurocognitive testing at the high school and collegiate levels. Design: Quantitative survey research. Setting: Online survey. Patients or Other Participants: Certified athletic trainers (ATs) from approximately 1209 US institutions listed on the ImPACT Web site were recruited. A total of 399 ATs completed the survey, for a response return rate of 32.7%. Main Outcome Measure(s): Survey questions addressed educational level, years of certification, employment setting, percentage of athletes baseline tested, and accuracy of baseline tests. Other items addressed postconcussive neurocognitive testing protocols and scenarios for return-to-play decisions based on neurocognitive testing. Results: Nearly all ATs (94.7%) administered baseline computerized neurocognitive testing to their athletes. However, only 51.9% examined these baseline tests for validity. The majority of ATs indicated that they administer baseline neurocognitive tests most frequently to football players (88.4%), followed by women's soccer players (78.8%) and men's soccer players (71.2%). Nearly all respondents (95.5%) stated that they would not return a symptomatic athlete to play if the athlete's neurocognitive scores were back to baseline. However, when asked if they would return an athlete who is symptom free but who scores below his or her baseline, 86.5% responded no, 9.8% responded yes, and 3.8% indicated that it depended on the importance of the competition. Conclusions: The use of baseline testing, baseline testing readministration, and postconcussion protocols among ATs is increasing. However, the ATs in this study reported that they relied more on symptoms than on neurocognitive test scores when making return-to-play decisions.	[Covassin, Tracey; Elbin, Robert J., III; Stiller-Ostrowski, Jennifer L.] Michigan State Univ, E Lansing, MI 48823 USA; [Kontos, Anthony P.] Humboldt State Univ, Arcata, CA 95521 USA	Covassin, T (corresponding author), Michigan State Univ, 105 IM Sports Circle, E Lansing, MI 48823 USA.	covassin@msu.edu		Kontos, Anthony/0000-0002-3749-4310			[Anonymous], 2006, MED SCI SPORTS EXERC, V38, P395; [Anonymous], 2006, IMM POSTC ASS COGN T; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT., 1989, MILD HEAD INJURY, P257; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell M., CLIN INTERPRETATION; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	26	92	93	0	22	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2009	44	6					639	644		10.4085/1062-6050-44.6.639			6	Sport Sciences	Sport Sciences	522OU	WOS:000272008400011	19911091	Green Published			2021-06-18	
J	Motherway, JA; Verschueren, P; Van der Perre, G; Sloten, JV; Gilchrist, MD				Motherway, Julie A.; Verschueren, Peter; Van der Perre, Georges; Sloten, Jos Vander; Gilchrist, Michael D.			The mechanical properties of cranial bone: The effect of loading rate and cranial sampling position	JOURNAL OF BIOMECHANICS			English	Article						Skull fracture; Mechanical properties; Dynamic loading; Head impact; Adult human	HUMAN PARIETAL BONE; INFANT SKULL; BRAIN-INJURY; BIOMECHANICS; SUTURE; SHEAR	Linear and depressed skull fractures are frequent mechanisms of head injury and are often associated with traumatic brain injury. Accurate knowledge of the fracture of cranial bone can provide insight into the prevention of skull fracture injuries and help aid the design of energy absorbing head protection systems and safety helmets. Cranial bone is a complex material comprising of a three-layered structure: external layers consist of compact, high-density cortical bone and the central layer consists of a low-density, irregularly porous bone structure. In this study, cranial bone specimens were extracted from 8 fresh-frozen cadavers (F = 4, M = 4; 81 +/- 11 years old). 63 specimens were obtained from the parietal and frontal cranial bones. Prior to testing, all specimens were scanned using a mu CT scanner at a resolution of 56.9 mu m. The specimens were tested in a three-point bend set-up at different dynamic speeds (0.5, 1 and 2.5 m/s). The associated mechanical properties that were calculated for each specimen include the 2nd moment of inertia, the sectional elastic modulus, the maximum force at failure, the energy absorbed until failure and the maximum bending stress. Additionally, the morphological parameters of each specimen and their correlation with the resulting mechanical parameters were examined. It was found that testing speed, strain rate, cranial sampling position and intercranial variation all have a significant effect on some or all of the computed mechanical parameters. A modest correlation was also found between percent bone volume and both the elastic modulus and the maximum bending stress. (C) 2009 Elsevier Ltd. All rights reserved.	[Motherway, Julie A.; Gilchrist, Michael D.] Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 4, Ireland; [Verschueren, Peter; Van der Perre, Georges; Sloten, Jos Vander] Katholieke Univ Leuven, Div Biomech & Engn Design, B-3001 Heverlee, Belgium	Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 4, Ireland.	Michael.Gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X			Caprino G, 2009, COMPOS STRUCT, V88, P360, DOI 10.1016/j.compstruct.2008.04.014; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Delille C., 2003, MEC IND, V4, P119, DOI DOI 10.1016/S1296-2139(03)00029-0; Delille R, 2007, INT J CRASHWORTHINES, V12, P101, DOI 10.1080/13588260701433081; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; EVANS FG, 1957, J APPL PHYSIOL, V10, P493; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; HARDY WN, 2001, STAPP CAR CRASH J, V45, P368; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; HUBBARD RP, 1971, J BIOMECH, V4, P251, DOI 10.1016/0021-9290(71)90031-5; JANS G, 2003, THESIS KATHOLIEKE U; KANEKO T, 1975, J PHYS D, V8, P1927, DOI DOI 10.1088/0022-3727/8/16/003; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Motherway J, 2009, Leg Med (Tokyo), V11 Suppl 1, pS220, DOI 10.1016/j.legalmed.2009.01.072; Peterson J, 2003, ANAT REC PART A, V274A, P785, DOI 10.1002/ar.a.10096; Peterson J, 2002, ANAT REC, V268, P7, DOI 10.1002/ar.10131; PRANGE MT, 2002, J BIOMECHANICAL ENG, V124, P224; Roark R.J., 1986, FORMULAS STRESS STRA; *SKYSCAN, 2008, MORPH PAR CT AN; Timoshenko S.P., 1970, THEORY ELASTICITY, V3rd ed.; Timoshenko SP, 1975, VIBRATION PROBLEMS E; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8	25	92	96	3	39	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 18	2009	42	13					2129	2135		10.1016/j.jbiomech.2009.05.030			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	502RO	WOS:000270478000018	19640538				2021-06-18	
J	Marklund, N; Blennow, K; Zetterberg, H; Ronne-Engstrom, E; Enblad, P; Hillered, L				Marklund, Niklas; Blennow, Kaj; Zetterberg, Henrik; Ronne-Engstrom, Elisabeth; Enblad, Per; Hillered, Lars			Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						amyloid beta; diffuse axonal injury; microdialysis; tau protein; traumatic brain injury	CLOSED-HEAD INJURY; LONG-TERM ACCUMULATION; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN; AXONAL INJURY; ALZHEIMERS-DISEASE; CEREBRAL MICRODIALYSIS; NEUROINTENSIVE CARE; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE	Object. Damage to axons contributes to postinjury disabilities and is commonly observed following traumatic brain injury (TBI). Traumatic brain injury is ail important environmental risk factor for the development of Alzheimer disease (AD). In the present feasibility study, the aim was to use intracerebral rnicrodialysis catheters with a high molecular Cutoff membrane (100 kD) to harvest interstitial total tau (T-tau) and amyloid beta 1-42 (A beta 42) proteins, which are important biomarkers for axonal injury and for AD, following moderate-to-severe TBI. Methods. Eight patients (5 men and 3 women) were included in the Study; 5 of the patients had a focal/mixed TBI and 3 had a diffuse axonal injury (DAI). Following the bedside analysis of the routinely measured energy metabolic markers (that is, glucose, lactate/pyrilvate ratio, glycerol, and glutaniate), the remaining dialysate was pooled and two 12-hour samples per day were used to analyze T-tau and A beta 42 by enzyme-linked immunosorbent assay from Day 1 up to 8 days postinjury. Results. The results show high levels of interstitial T-tau and A beta 42 postinjury. Patients with a predominantly focal lesion had higher interstitial T-tau levels than in the DAI group from Days 1 to 3 postinjury (p < 0.05). In contrast, patients with DAI had consistently higher A beta 42 levels when compared with patients with focal injury, Conclusions. These results suggest that monitoring of interstitial T-tau and A beta 42 by using microdialysis may be an important tool when evaluating the presence and role of axonal injury following TBI (DOI: 10.3171/2008.9.JNS08584)	[Marklund, Niklas; Ronne-Engstrom, Elisabeth; Enblad, Per; Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci, SE-75148 Uppsala, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Univ Hosp Sahlgrenska, Dept Internal Med, Gothenburg, Sweden	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, SE-75148 Uppsala, Sweden.	niklas.marklund@neurokir.uu.se		Hillered, Lars/0000-0002-2808-9292; Marklund, Niklas/0000-0002-9797-5626	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Hospital; Swedish Brain Foundation; Laerdahl Foundation for Acute Medicine	This work was supported by the Swedish Research Council (Drs. Marklund, Enblad, and Hillered); Uppsala University Hospital (Drs. Enblad and Hillered); the Swedish Brain Foundation (Dr. Marklund); and the Laerdahl Foundation for Acute Medicine (Drs. Marklund and Hillered).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hulstaert F, 1999, NEUROLOGY, V52, P1555, DOI 10.1212/WNL.52.8.1555; Hutchinson PJ, 2005, ACTA NEUROCHIR SUPPL, V95, P441; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Marklund N, 2006, J NEUROTRAUM, V23, P754; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Park JH, 2006, J NEUROSCI, V26, P1386, DOI 10.1523/JNEUROSCI.3291-05.2006; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raby CA, 1998, J NEUROCHEM, V71, P2505; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; Servadei F, 2000, NEUROSURGERY, V46, P70; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; STALHAMMAR D, 1988, ACTA NEUROCHIR, V90, P73, DOI 10.1007/BF01560558; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vespa PM, 2006, CURR OPIN CRIT CARE, V12, P119, DOI 10.1097/01.ccx.0000216577.57180.bd; Wang HD, 1998, CHINESE MED J-PEKING, V111, P59; Whittle IR, 1998, NEUROREPORT, V9, P2821, DOI 10.1097/00001756-199808240-00025; Wilhelmsen KC, 1999, P NATL ACAD SCI USA, V96, P7120, DOI 10.1073/pnas.96.13.7120; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	74	92	92	1	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2009	110	6					1227	1237		10.3171/2008.9.JNS08584			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	451HH	WOS:000266460800018	19216653				2021-06-18	
J	Tollard, E; Galanaud, D; Perlbarg, V; Sanchez-Pena, P; Le Fur, Y; Abdennour, L; Cozzone, P; Lehericy, S; Chiras, J; Puybasset, L				Tollard, Eleonore; Galanaud, Damien; Perlbarg, Vincent; Sanchez-Pena, Paola; Le Fur, Yann; Abdennour, Lamine; Cozzone, Patrick; Lehericy, Stephane; Chiras, Jacques; Puybasset, Louis			Experience of diffusion tensor imaging and H-1 spectroscopy for outcome prediction in severe traumatic brain injury: Preliminary results	CRITICAL CARE MEDICINE			English	Article						diffusion tensor imaging; spectroscopy; traumatic brain injury; coma; outcome; fractional anisotropy	MAGNETIC-RESONANCE-SPECTROSCOPY; CLOSED-HEAD INJURY; MINIMALLY CONSCIOUS STATE; PROTON MR SPECTROSCOPY; AXONAL INJURY; VEGETATIVE STATE; IN-VIVO; COMATOSE PATIENTS; PROGNOSTIC VALUE; RECOVERY	Objective: The objective of the study is to test whether multimodal magnetic resonance imaging can provide a reliable outcome prediction of the clinical status, focusing on consciousness at 1 year after severe traumatic brain injury (TBI). Design: Single center prospective cohort with consecutive inclusions. Setting. Critical Care Neurosurgical Unit of a university hospital. Patients: Forty-three TBI patients not responding to simple orders after sedation cessation and 15 healthy controls. Interventions. A multimodal magnetic resonance imaging combining morphologic sequences, diffusion tensor imaging (DTI), and H-1 proton magnetic resonance spectroscopy (MRS) was performed 24 +/- 11 days after severe TBI. The ability of DTI and MRS to predict 1-year outcome was assessed by linear discriminant analysis (LDA). Robustness of the classification was tested using a bootstrap procedure. Measurements and Main Results: Fractional anisotropy (FA) was computed as the mean of values at discrete brain sites in the infratentorial and supratentorial regions. The N-acetyl aspartate/creatine (NAA/Cr) ratio was measured in the thalamus, lenticular nucleus, insular cortex, occipital periventricular white matter, and pons. After 1 year, 19 (44%) patients had unfavorable outcomes (death, persistent vegetative state, or minimally conscious state) and 24 (56%) favorable outcomes (normal consciousness with or without functional impairments). Analysis of variance was performed to compare FA and NAA/Cr in the two outcome groups and controls. FA and MRS findings showed highly significant differences between the outcome groups, with significant variables by LDA being supratentorial FA, NAA/Cr (pons), NAA/Cr (thalamus), NAA/Cr (insula), and infratentorial FA. LDA of combined FA and MRS data clearly separated the unfavorable outcome, favorable outcome, and control groups, with no overlap. Unfavorable outcome was predicted with up to 86% sensitivity and 97% specificity; these values were better than those obtained with DTI or MRS alone. Conclusion: FA and NAA/Cr hold potential as quantitative outcome-prediction tools at the subacute phase of TBI. (Crit Care Med 2009; 37:1448-1455)	[Tollard, Eleonore] Univ Hosp, Dept Neuroradiol, Rouen, France; [Galanaud, Damien] Hop La Pitie Salpetriere, CR ICM, CNRS, UMR 7225, Paris, France; [Tollard, Eleonore; Galanaud, Damien; Chiras, Jacques] Hop La Pitie Salpetriere, Dept Neuroradiol, Paris, France; [Perlbarg, Vincent] Univ Paris 06, INSERM, U678, F-75252 Paris 05, France; [Sanchez-Pena, Paola] Univ Paris 06, Lab Funct Imaging, F-75252 Paris 05, France; [Sanchez-Pena, Paola] Univ Paris 06, Dept Anesthesiol & Crit Care, F-75252 Paris 05, France; [Le Fur, Yann; Cozzone, Patrick] Univ Mediterranee Aix Marseille II, Ctr Magnet Resonance Med Biol, Ctr Natl Rech Sci, Marseille, France; [Abdennour, Lamine] Univ Mediterranee Aix Marseille II, Dept Anesthesiol & Crit Care, Marseille, France; [Lehericy, Stephane] Univ Paris 06, Dept Neuroradiol, Paris, France; [Lehericy, Stephane] Univ Paris 06, Ctr Neuroimaging Res CENIR, Paris, France; [Puybasset, Louis] Hop La Pitie Salpetriere, Dept Anesthesiol, Paris, France; [Puybasset, Louis] Hop La Pitie Salpetriere, Crit Care & Intens Care Neurosurg Unit, Paris, France	Galanaud, D (corresponding author), Univ Hosp, Dept Neuroradiol, Rouen, France.	galanaud@dat.org			Assistance Publique-Hopitaux de Paris; French Health Ministry [ADM 05 101]	This study was funded solely by departmental sources (Assistance Publique-Hopitaux de Paris) and French Health Ministry (ADM 05 101 to LP).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashley MJ, 1997, BRAIN INJURY, V11, P677; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Galanaud D, 2007, CURR OPIN NEUROL, V20, P627, DOI 10.1097/WCO.0b013e3282f169ec; Galanaud D, 2006, MAGN RESON MED, V55, P1236, DOI 10.1002/mrm.20886; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Thierry AGM, 2006, EUR RADIOL, V16, P1651, DOI 10.1007/s00330-006-0175-8; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Karantanas A, 2000, J NEUROSURG, V92, P896; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Nakabayashi M, 2007, J NEUROSURG, V106, P370, DOI 10.3171/jns.2007.106.3.370; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Robinson Lawrence R, 2004, Phys Med Rehabil Clin N Am, V15, P43, DOI 10.1016/S1047-9651(03)00102-5; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Weiss FU, 2008, BEST PRACT RES CL GA, V22, P3, DOI 10.1016/j.bpg.2007.10.017	43	92	100	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2009	37	4					1448	1455		10.1097/CCM.0b013e31819cf050			8	Critical Care Medicine	General & Internal Medicine	426HQ	WOS:000264699000038	19242330				2021-06-18	
J	Hart, T; Seignourel, PJ; Sherer, M				Hart, Tessa; Seignourel, Paul J.; Sherer, Mark			A longitudinal study of awareness of deficit after moderate to severe traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Awareness of deficits; Rehabilitation	IMPAIRED SELF-AWARENESS; DISABILITY RATING-SCALE; CLOSED-HEAD INJURY; REHABILITATION; QUESTIONNAIRE; ADULTS; COMMUNITY; RECOVERY; VALIDITY; ELEMENTS	Lack of awareness of deficits is a common problem after traumatic brain injury (TBI), and is associated with worse functional outcome and poor compliance with rehabilitation. Little is known, however, about the course of awareness of deficits after TBI. Using a longitudinal design, we examined changes in self-awareness between the subacute stage (about 45 days after injury) and one-year follow-up in a sample of 123 individuals with moderate to severe TBI. Awareness of deficits was operationalised as the discrepancy between patient and family ratings on the Awareness Questionnaire (AQ) and Patient Competency Rating Scale (PCRS). Compared to baseline, awareness was improved at one year, as evidenced by smaller discrepancy scores and stronger correlations between participant and family ratings. Changes in awareness were most pronounced for the behavioural/affective domain and least pronounced for the motor/sensory domain, which showed best agreement at baseline. Even at one year, participants rated themselves as higher functioning than did their relatives. Awareness at baseline and, for the AQ, time to follow commands, significantly predicted awareness at one year. These results suggest that awareness of deficits improves between the subacute and post-acute stages after TBI, and highlight the need for effective interventions for persons with impaired awareness and for flexible timing of rehabilitation efforts.	[Hart, Tessa; Seignourel, Paul J.] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Hart, Tessa] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; [Seignourel, Paul J.] Univ Penn, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 60 E Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980035, H133A980067, H133A97033] Funding Source: Medline		ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Flashman L. A., 1998, SEMINARS CLIN NEUROP, V3, P201; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; Newman AC, 2000, BRAIN INJURY, V14, P333; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roberts CB, 2006, BRAIN INJURY, V20, P485, DOI 10.1080/02699050600664665; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; STEIGER JH, 1980, PSYCHOL BULL, V87, P245, DOI 10.1037/0033-2909.87.2.245; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977	42	92	94	0	10	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	2					161	176	PII 794669565	10.1080/09602010802188393			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	412HQ	WOS:000263716300001	18609008				2021-06-18	
J	Tanriverdi, F; De Bellis, A; Bizzarro, A; Sinisi, AA; Bellastella, G; Pane, E; Bellastella, A; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; De Bellis, Annamaria; Bizzarro, Antonio; Sinisi, Antonio Agostino; Bellastella, Giuseppe; Pane, Elena; Bellastella, Antonio; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Antipituitary antibodies after traumatic brain injury: is head trauma-induced pituitary dysfunction associated with autoimmunity?	EUROPEAN JOURNAL OF ENDOCRINOLOGY			Spanish	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; GROWTH-HORMONE DEFICIENCY; ENDOCRINE DISEASES; SECRETING CELLS; HYPOPITUITARISM; INSUFFICIENCY; HYPOPHYSITIS; PREVALENCE; CHILDREN; NEURONS	Objective: Traumatic brain injury (TBI) is a devastating public health problem that may result in hypopituitarism. However, the mechanisms responsible for hypothalamic-pituitary dysfunction due to TBI are still unclear. Although the antibodies against neurons have been demonstrated in injured animal studies, investigations regarding the occurrence of antipituitary antibodies (APAs) in patients with TBI are lacking in the literature. In order to investigate whether autoimmune mechanisms could play a role in the pituitary dysfunction after TBI, we have planned this study aimed at investigating the presence of APA at the third year of TBI and association between the TBI-induced hypopituitarism and APA. Patients and design: Twenty-nine (25 males and 4 females; age 36.5 +/- 2.3 years) patients who had completed a 3-year follow-up after TBI were included in the present study. APA and pituitary function were evaluated in all the patients 3 years after TBI; moreover, APAs were tested also in sera of 60 age-/sex-matched normal controls. The APAs were investigated by an indirect immunofluorescence method. Results: APAs were detected in 13 out of the 29 TBI patients (44.8'%), but in none of the normal controls. Pituitary dysfunction development ratio was significantly higher in APA-positive patients (46.2%) when compared with APA-negative ones (12.5%; P=0.04). There was a significant association between APA positivity and hypopituitarism due to TBI (odds ratio: 2.25, 95% confidence intervals 1.1-4.6). Moreover, there was a significant positive correlation (r = 0.74, P = 0.004) between APA titer ratio and peak GH response to GHRH+GH related peptide (GHRP)-6 test, suggesting that high APA titers were associated with low GH response to GHRH + GHRP-6 test. Conclusions: This study shows for the first time the presence of the APA in TBI patients 3 years after head trauma. Moreover, present investigation indicates preliminary evidence that APA may be associated with the development of TBI-induced pituitary dysfunction, thus suggesting that autoimmunity may contribute in the development of TBI-induced hypopituitarism. The presence of the association between APA and TBI induced hypopituitarism may provide a new point of view in this field and promote further clinical and experimental studies.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [De Bellis, Annamaria; Sinisi, Antonio Agostino; Bellastella, Giuseppe; Pane, Elena; Bellastella, Antonio] Univ Naples 2, Chair Endocrinol, I-80131 Naples, Italy; [Bizzarro, Antonio] Univ Naples 2, Chair Immunol, I-80131 Naples, Italy; [Selcuklu, Ahmet] Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; [Casanueva, Felipe F.] Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain; [Casanueva, Felipe F.] Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr		DE BELLIS, Annamaria/0000-0002-0611-4506			Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011; De Bellis A, 2005, CLIN ENDOCRINOL, V63, P45, DOI 10.1111/j.1365-2265.2005.02296.x; De Bellis A, 2005, BEST PRACT RES CL EN, V19, P67, DOI 10.1016/j.beem.2004.11.007; De Bellis A, 2003, J CLIN ENDOCR METAB, V88, P650, DOI 10.1210/jc.2002-021054; De Bellis A, 2007, J CLIN ENDOCR METAB, V92, P604, DOI 10.1210/jc.2006-1216; De Bellis A, 2006, J CLIN ENDOCR METAB, V91, P2484, DOI 10.1210/jc.2006-0040; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gionis D, 2003, J PEDIATR ENDOCR MET, V16, P49; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Manetti L, 2007, J CLIN ENDOCR METAB, V92, P2176, DOI 10.1210/jc.2006-2748; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	29	92	96	1	5	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	JUL	2008	159	1					7	13		10.1530/EJE-08-0050			7	Endocrinology & Metabolism	Endocrinology & Metabolism	329GU	WOS:000257855800002	18463108	Bronze			2021-06-18	
J	Fleminger, S				Fleminger, S.			Long-term psychiatric disorders after traumatic brain injury	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Brain Annual Meeting	MAY 09-12, 2007	Brescia, ITALY			brain injury; psychosis; trauma; depression; long-term effects	HEAD-INJURY; RISK-FACTOR; FOLLOW-UP; ALZHEIMERS-DISEASE; PROSPECTIVE COHORT; STRESS-DISORDER; EARLY ADULTHOOD; YOUNG-PEOPLE; AXIS-I; SCHIZOPHRENIA	In the long term after traumatic brain injury, the most disabling problems are generally related to neuropsychiatric sequelae, including personality change and cognitive impairment, rather than neurophysical sequelae. Cognitive impairment after severe injury is likely to include impaired speed of information processing, poor memory and executive problems. Personality change may include poor motivation, and a tendency to be self-centred and less aware of the needs of others. Patients may be described as lazy and thoughtless. Some become disinhibited and rude. Agitation and aggression can be very difficult to manage. Anxiety and depression symptoms are quite frequent and play a role in the development of persistent post-concussion syndrome after milder injury. Depression may be associated with a deterioration in disability over time after injury. Psychosis is not unusual though it has been difficult to confirm that traumatic brain injury is a cause of schizophrenia. Head injury may, many years later, increase the risk of Alzheimer's disease. Good rehabilitation probably minimizes the risk of psychiatric sequelae, but specific psychological and pharmacological treatments may be needed.	Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, London SE5 8AZ, England	Fleminger, S (corresponding author), Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, Denmark Hill, London SE5 8AZ, England.	s.fleminger@iop.kcl.ac.uk					Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLUMER D, 1978, PSYCHIAT ASPECTS NEU, P151; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Butler PV, 2000, AUST NZ J PSYCHIAT, V34, P684, DOI 10.1046/j.1440-1614.2000.00758.x; Cassidy John W., 1994, P43; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; Deb S, 1999, AM J PSYCHIAT, V156, P374; Eames P, 2003, NEUROPSYCHOL REHABIL, V13, P241, DOI 10.1080/09602010244000435; Feuchtwanger E., 1923, FUNKTIONEN STIRNHIRN; Fleminger S, 2003, BMJ-BRIT MED J, V327, P4, DOI 10.1136/bmj.327.7405.4; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; FLEMINGER S, 2006, COCHRANE DB SYST REV, V4; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Morris Paul Graham, 2005, BMC Fam Pract, V6, P30, DOI 10.1186/1471-2296-6-30; Mortensen PB, 2003, J AFFECT DISORDERS, V76, P79, DOI 10.1016/S0165-0327(02)00073-3; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; PILOSWKY L, 1982, BRIT J PSYCHIAT, V147, P310; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Silver JM, 2005, TXB TRAUMATIC BRAIN, P259; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P131, DOI 10.1136/jnnp.4.2.131; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	51	92	92	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.		2008	25			42			123	130		10.1017/S0265021507003250			8	Anesthesiology	Anesthesiology	283AY	WOS:000254610100021	18289429				2021-06-18	
J	Chen, SF; Hung, TH; Chen, CC; Lin, KH; Huang, YN; Tsai, HC; Wang, JY				Chen, Szu-Fu; Hung, Tai-Ho; Chen, Chien-Cheng; Lin, Kuei-Han; Huang, Ya-Ni; Tsai, Hung-Chih; Wang, Jia-Yi			Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury	LIFE SCIENCES			English	Article						lovastatin; iniflammation; cytokines; traumatic brain injury	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL NITRIC-OXIDE; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; INTERCELLULAR-ADHESION MOLECULE-1; CONTROLLED CORTICAL IMPACT; COA REDUCTASE INHIBITOR; FACTOR-ALPHA; TNF-ALPHA	Traumatic brain injury (TBI) triggers a complex sequence of inflammatory responses that contribute to secondary injury. Statins have demonstrated neuroprotective effects against brain injury, but the underlying mechanisms remain unclear. This study evaluated the effects of lovastatin on a rat model of controlled cortical impact (CCI) injury. Our two hypotheses were that pre-administration of lovastatin would reduce functional deficits and extent of anatomical brain damage and that lovastatin would attenuate levels of pro-inflammatory cytokines. Rats were injected with lovastatin (4 mg/kg) or vehicle for 5 days and subjected to CCI. Neurological status was evaluated using rotarod and adhesive removal tests. Contusion volume and neuronal degeneration were examined using cresyl violet and FluoroJade B (FJB) histochemistry. Levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin- 1 beta (IL- 1 beta) mRNA and protein were assessed by real-time quantitative reverse transcriptase polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemistry. Lovastatin significantly improved performance on both the rotarod and adhesive removal tests before post-injury day 7. Lovastatin also significantly reduced contusion volume (20%) and number of FJB-positive degenerating neurons (35%) at 4 days. These changes were associated with a significant decrease in levels of TNF-a and IL-I beta. mRNA and protein at the contusion site at 6 It and 4 days, respectively. Our results show that pre-administration of lovastatin improved functional outcomes and reduced extent of brain damage, with a concomitant decrease in tissue levels of TNF-alpha and IL- 1 beta mRNA and protein. These findings suggest that lovastatin's protective mechanisms may be partly attributed to a dampening of the inflammatory response. (c) 2007 Elsevier Inc. All rights reserved.	Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; Chang Gung Univ, Coll Med, Taipei, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan	Wang, JY (corresponding author), Natl Def Med Ctr, Dept Physiol, 161 Sec 6,Ming Chuan E Rd, Taipei, Taiwan.	jywang@ndmctsgh.edu.tw	Chen, Szu-Fu/K-5040-2012; Hung, Tai-Ho/ABD-1800-2020; Hung, Tai-Ho/C-7584-2011	Hung, Tai-Ho/0000-0003-2354-7060; Wang, Jia-Yi/0000-0002-9106-3351			Asahi M, 2005, J CEREBR BLOOD F MET, V25, P722, DOI 10.1038/sj.jcbfm.9600070; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; Boehme MWJ, 1996, IMMUNOLOGY, V87, P134; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen JL, 2004, CHINESE PHYS LETT, V21, P12, DOI 10.1088/0256-307X/21/1/004; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CLAUDIO L, 1994, LAB INVEST, V70, P850; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Daimon M, 2004, NEUROSCI LETT, V362, P122, DOI 10.1016/j.neulet.2004.03.012; Endres M, 2005, J CEREBR BLOOD F MET, V25, P1093, DOI 10.1038/sj.jcbfm.9600116; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Farmer JA, 1998, PROG CARDIOVASC DIS, V41, P71, DOI 10.1016/S0033-0620(98)80006-6; Floris S, 2004, BRAIN, V127, P616, DOI 10.1093/brain/awh068; Fox S, 1998, INFECT MED, V15, P8; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hung TH, 2006, PLACENTA, V27, P996, DOI 10.1016/j.placenta.2005.11.002; Hunter AJ, 1998, TRENDS PHARMACOL SCI, V19, P59, DOI 10.1016/S0165-6147(97)01157-7; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; LASTER SM, 1988, J IMMUNOL, V141, P2629; Li W, 2005, J PHARMACOL EXP THER, V313, P557, DOI 10.1124/jpet.104.080002; Lu DY, 2004, J NEUROSURG, V101, P822, DOI 10.3171/jns.2004.101.5.0822; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Niwa S, 1996, INT J IMMUNOPHARMACO, V18, P669, DOI 10.1016/S0192-0561(96)00068-9; Omi H, 2003, MICROVASC RES, V65, P118, DOI 10.1016/S0026-2862(02)00033-X; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Schmeer C, 2006, RESTOR NEUROL NEUROS, V24, P79; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Sironi L, 2005, ARTERIOSCL THROM VAS, V25, P598, DOI 10.1161/01.ATV.0000157145.98200.55; Soares HD, 1995, J NEUROSCI, V15, P8223; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; SternerKock A, 1996, IMMUNOLOGY, V87, P454; Thal SC, 2005, CURR OPIN ANESTHESIO, V18, P490, DOI 10.1097/01.aco.0000182561.32680.30; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; YAMASAKI Y, 1994, ACTA NEUROCHIR, P300; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zapolska-Downar D, 2004, LIFE SCI, V75, P1287, DOI 10.1016/j.lfs.2004.03.005	71	92	93	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	JUL 4	2007	81	4					288	298		10.1016/j.lfs.2007.05.023			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	199GB	WOS:000248683100004	17612572				2021-06-18	
J	Zlotnik, A; Gurevich, B; Tkachov, S; Maoz, I; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Gurevich, Boris; Tkachov, Sergei; Maoz, Ilana; Shapira, Yoram; Teichberg, Vivian I.			Brain neuroprotection by scavenging blood glutamate	EXPERIMENTAL NEUROLOGY			English	Article						acute brain neurodegeneration; closed head injury; brain glutamate levels; blood glutamate scavenging; oxaloacetate; glutamate-oxaloacetate transaminase; neuroprotection; neurological severity score; spontaneous recovery	EXCITATORY AMINO-ACIDS; HUMAN HEAD-INJURY; RAT CEREBRAL-CORTEX; CEREBROSPINAL-FLUID; ISCHEMIC STROKE; MOUSE-BRAIN; BARRIER; RELEASE; MICRODIALYSIS; RECEPTORS	Excess glutamate in brain fluids characterizes acute brain insults such as traumatic brain injury and stroke. Its removal could prevent the glutamate excitotoxicity that causes long-lasting neurological deficits. As blood glutamate scavenging has been demonstrated to increase the efflux of excess glutamate from brain into blood, we tested the prediction that oxaloacetate-mediated blood glutamate scavenging causes neuroprotection in a pathological situation such as closed head injury (CHI), in which there is a well established deleterious increase of glutamate in brain fluids. We observed highly significant improvements of the neurological status of rats submitted to CHI following an intravenous treatment with 1 mmol oxaloacetate/100 g rat weight which decreases blood glutamate levels by 40%. No detectable therapeutic effect was obtained when rats were treated IV with 1 mmol oxaloacetate together with 1 mmol glutamate/100 g rat. The treatment with 0.005 mmol/100 g rat oxaloacetate was no more effective than saline but when it was combined with the intravenous administration of 0.14 nmol/100 g of recombinant glutamate-oxaloacetate transaminase, recovery was almost complete. Oxaloacetate provided neuroprotection when administered before CHI or at 60 min post CHI but not at 120 min post CHI. Since neurological recovery from CHI was highly correlated with the decrease of blood glutamate levels (r=0.89, P=0.001), we conclude that blood glutamate scavenging affords brain neuroprotection Blood glutamate scavenging may open now new therapeutic options. (c) 2006 Elsevier Inc. All rights reserved.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel	Teichberg, VI (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	vivian.teichberg@weizmann.ac.il					Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burckhardt BC, 2005, AM J PHYSIOL-RENAL, V288, pF792, DOI 10.1152/ajprenal.00360.2004; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Desagher S, 1997, J NEUROSCI, V17, P9060; Engstrom ER, 2005, NEUROSCI LETT, V384, P7, DOI [10.1016/j.neurlet.2005.04.030, 10.1016/j.neulet.2005.04.030]; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; Ferrarese C, 2001, NEUROLOGY, V57, P671, DOI 10.1212/WNL.57.4.671; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hosoya K, 1999, J NEUROCHEM, V73, P1206, DOI 10.1046/j.1471-4159.1999.0731206.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Koura SS, 1998, ACT NEUR S, V71, P244; Margaill I, 1996, J CEREBR BLOOD F MET, V16, P107, DOI 10.1097/00004647-199601000-00013; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; Pajor AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1215; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Phillis JW, 1996, NEUROCHEM INT, V29, P115, DOI 10.1016/0197-0186(95)00154-9; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Serena J, 2001, STROKE, V32, P1154, DOI 10.1161/01.STR.32.5.1154; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; SINGH IN, 2006, J CEREB BLOOD FLOW M; Smith QR, 2000, J NUTR, V130, p1016S, DOI 10.1093/jn/130.4.1016S; Spranger M, 1996, J NEUROL SCI, V143, P126, DOI 10.1016/S0022-510X(96)00197-9; Spreux-Varoquaux O, 2002, J NEUROL SCI, V193, P73, DOI 10.1016/S0022-510X(01)00661-X; Stoffel M, 2002, J NEUROTRAUM, V19, P467, DOI 10.1089/08977150252932415; Takamatsu H, 1998, EUR J PHARMACOL, V352, P165, DOI 10.1016/S0014-2999(98)00353-7; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WESTERGREN I, 1992, BRAIN RES, V573, P324, DOI 10.1016/0006-8993(92)90781-4; WESTERGREN I, 1993, J CEREBR BLOOD F MET, V13, P603, DOI 10.1038/jcbfm.1993.78; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458	48	92	94	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2007	203	1					213	220		10.1016/j.expneurol.2006.08.021			8	Neurosciences	Neurosciences & Neurology	123NU	WOS:000243303400023	17014847				2021-06-18	
J	Siklos, S; Kerns, KA				Siklos, Susan; Kerns, Kimberly A.			Assessing need for social support in parents of children with autism and Down syndrome	JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS			English	Article						autism spectrum disorder; social support; Down syndrome; autism; adaptation; Family Needs Questionnaire	TRAUMATIC BRAIN INJURY; FAMILY NEEDS; SCREENING QUESTIONNAIRE; BEHAVIORAL TREATMENT; SPECTRUM DISORDERS; ASPERGER-SYNDROME; STRESS; ADAPTATION; INDIVIDUALS; PERSPECTIVE	Parents of children with autism frequently turn to the service delivery system to access supports designed to help adapt to the challenges of having a child with a life-long impairment. Although studies have suggested various supports and coping strategies that are effective for adapting, few studies have examined parents' own perceptions of needs.. and whether parents felt their needs were being met. In the present study the Family Needs Questionnaire (FNQ, Waaland et al., 1993) was modified to address needs for children with developmental disorders. A sample of fifty-six parents of children with autism and a comparison group of thirty-two parents of children with Down syndrome completed the FNQ. The groups did not differ significantly on the number of important needs reported nor the number of important needs being met. However, the two groups differed in the types of supports they most frequently endorsed as Important or Unmet.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Kerns, KA (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	kkerns@uvic.ca					Agosta J., 1989, SUPPORT CAREGIVING F; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ARVIDSSON T, 1997, AUTISM, V1, P694; Baird G, 2000, J AM ACAD CHILD PSY, V39, P694, DOI 10.1097/00004583-200006000-00007; Berument SK, 1999, BRIT J PSYCHIAT, V175, P444, DOI 10.1192/bjp.175.5.444; Bristol M.M., 1984, EFFECTS AUTISM FAMIL, P289, DOI DOI 10.1007/978-1-4899-2293-9_17; BRISTOL MM, 1988, DEV PSYCHOL, V24, P441, DOI 10.1037/0012-1649.24.3.441; BRISTOL MM, 1987, J AUTISM DEV DISORD, V17, P469, DOI 10.1007/BF01486964; Chakrabarti S, 2001, JAMA-J AM MED ASSOC, V285, P3093, DOI 10.1001/jama.285.24.3093; COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003; DONENBERG G, 1993, J ABNORM CHILD PSYCH, V21, P179, DOI 10.1007/BF00911315; DONOVAN AM, 1988, AM J MENT RETARD, V92, P502; Ehlers S, 1999, J AUTISM DEV DISORD, V29, P129, DOI 10.1023/A:1023040610384; Erwin W. J., 2002, J MENTAL HLTH COUNSE, V24, P247; Filipek PA, 1999, J AUTISM DEV DISORD, V29, P439, DOI 10.1023/A:1021943802493; FISMAN S, 1991, PSYCHIAT CLIN N AM, V14, P199; Fombonne E, 2001, PEDIATRICS, V107, P411, DOI 10.1542/peds.107.2.411; Freedman RI, 2000, HEALTH SOC WORK, V25, P59, DOI 10.1093/hsw/25.1.59; HENDERSON D, 1992, PSYCHOL REP, V71, P167, DOI 10.2466/PR0.71.5.167-171; Hill R., 1949, FAMILIES STRESS; Honda H, 1996, BRIT J PSYCHIAT, V169, P228, DOI 10.1192/bjp.169.2.228; Kadesjo B, 1999, J AUTISM DEV DISORD, V29, P327, DOI 10.1023/A:1022115520317; KONSTANTAREAS MM, 1989, J CHILD PSYCHOL PSYC, V30, P459, DOI 10.1111/j.1469-7610.1989.tb00259.x; KONSTANTAREAS MM, 1991, CAN J BEHAV SCI, V23, P358, DOI 10.1037/h0079022; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KRUG DA, 1980, J CHILD PSYCHOL PSYC, V21, P221, DOI 10.1111/j.1469-7610.1980.tb01797.x; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Liwag M. E., 1989, PHILIPPINE J PSYCHOL, V22, P3; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; McCubbin H.I., 1983, MARRIAGE FAM REV, V6, P7, DOI [10.1300/J002v06n01_02, DOI 10.1300/J002V06N01_02]; MCEACHIN JJ, 1993, AM J MENT RETARD, V97, P359; MILGRAM NA, 1988, J AUTISM DEV DISORD, V18, P415, DOI 10.1007/BF02212196; MORGAN SB, 1988, J AUTISM DEV DISORD, V18, P263, DOI 10.1007/BF02211952; Phillips KM, 2004, PROF PSYCHOL-RES PR, V35, P281, DOI 10.1037/0735-7028.35.3.281; RODRIGUE JR, 1992, J AUTISM DEV DISORD, V22, P249, DOI 10.1007/BF01058154; Sanders JL, 1997, CHILD FAM BEHAV THER, V19, P15, DOI 10.1300/J019v19n04_02; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SIEGEL B, 1996, WORLD AUTISTIC CHILD; TUNALI B, 1993, J CHILD PSYCHOL PSYC, V34, P945, DOI 10.1111/j.1469-7610.1993.tb01100.x; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; White C, 2002, DRUG-EDUC PREV POLIC, V9, P305, DOI 10.1080/09687630110116470; Wing L, 1988, DIAGNOSIS ASSESSMENT; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; WOLF LC, 1989, J AUTISM DEV DISORD, V19, P157, DOI 10.1007/BF02212727; WORTMAN C, 1984, CANCER, V53, P339	46	92	97	0	23	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0162-3257			J AUTISM DEV DISORD	J. Autism Dev. Disord.	OCT	2006	36	7					921	933		10.1007/s10803-006-0129-7			13	Psychology, Developmental	Psychology	093ME	WOS:000241171600010	16897397				2021-06-18	
J	McCarthy, ML; MacKenzie, EJ; Durbin, DR; Aitken, ME; Jaffe, KM; Paidas, CN; Slomine, BS; Dorsch, AM; Christensen, JR; Ding, R				McCarthy, ML; MacKenzie, EJ; Durbin, DR; Aitken, ME; Jaffe, KM; Paidas, CN; Slomine, BS; Dorsch, AM; Christensen, JR; Ding, R		Children's Hlth After Trauma Stdy	Health-related quality of life during the first year after traumatic brain injury	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							GENERIC CORE SCALES; CLOSED-HEAD-INJURY; FAMILY ASSESSMENT DEVICE; LONG-TERM OUTCOMES; CHILD-HEALTH; INTELLECTUAL ABILITY; BEHAVIOR PROBLEMS; FOLLOW-UP; RELIABILITY; VALIDITY	Objectives: To document health-related quality of life (HRQOL) of children with traumatic brain injury (TBI) and to examine the relationship between TBI severity and HRQOL during the first year after injury. Design: Prospective cohort study. Setting: Four pediatric level I trauma centers. Patients: Children with TBI (n=330). Main Exposure: Traumatic brain injury. Main Outcome Measures: A primary caregiver completed telephone interviews at baseline, 3 months, and 12 months to measure the child's HRQOL using the Pediatric Quality of Life Inventory. The HRQOL outcomes were modeled as a function of injury, patient characteristics, and family characteristics using longitudinal, multivariable regression. Results: A considerable proportion of children had impaired HRQOL at 3 months (42% of children) and 12 months (40% of children) after injury. Multiple dimensions of HRQOL were negatively affected among children with moderate or severe TBI (decrease of 3.7 to 17.6) (P < .05) and did not improve significantly over time. Concomitant lower extremity fractures and spinal injuries resulted in large declines in overall HRQOL, particularly at 3 months after injury (decrease of 12.9 and 8.1, respectively) (P < .05). The HRQOL scores were also reduced by preexisting psychosocial conditions (decrease of 2.9 to 12.3), impaired family functioning (decrease of 5.1 to 6.8), having Medicaid coverage or being uninsured (decrease of 3.1 to 5.5), and single-parent households (decrease of 3.2 to 3.4) (P < .05). Conclusions: Moderate or severe TBI resulted in measurable declines in children's HRQOL after injury. Injury-related factors impacted HRQOL more compared with patient and family characteristics during the first year after injury.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA; Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Rehabil Psychol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA; Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; Kennedy Krieger Inst, Dept Pediat Rehabil Med, Baltimore, MD USA	McCarthy, ML (corresponding author), 5802 Smith Ave,Davis Bldg,Room 220, Baltimore, MD 21209 USA.	mmccarth@jhmi.edu	ding, ru/B-1615-2009	Aitken, Mary/0000-0002-8318-9755	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR319701] Funding Source: Medline		Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bastiaansen D, 2004, QUAL LIFE RES, V13, P489, DOI 10.1023/B:QURE.0000018483.01526.ab; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Broman S. H., 1995, TRAUMATIC HEAD INJUR; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; Daltroy LH, 1998, J PEDIATR ORTHOPED, V18, P561, DOI 10.1097/00004694-199809000-00001; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DING R, IN PRESS J PEDIAT OR; Eiser C, 2003, CHILD CARE HLTH DEV, V29, P95, DOI 10.1046/j.1365-2214.2003.00318.x; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Friefeld S, 2004, CNS SPECTRUMS, V9, P465; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; HALEY SM, 1992, PEDIAT EVALUATION DI; HU XH, 1994, J TRAUMA, V37, P209, DOI 10.1097/00005373-199408000-00010; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KAPLAN RM, 1989, MED CARE, V27, P27; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; KRAUS JF, 1987, PEDIATRICS, V79, P501; Laffel LMB, 2003, DIABETES CARE, V26, P3067, DOI 10.2337/diacare.26.11.3067; LANDGRAF JM, 1996, CHQ USERS MANUAL; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MCCARTHY ML, 1995, J TRAUMA, V39, P828, DOI 10.1097/00005373-199511000-00005; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Pollak AN, 2003, J BONE JOINT SURG AM, V85A, P1893, DOI 10.2106/00004623-200310000-00005; Powers SW, 2004, CEPHALALGIA, V24, P120, DOI 10.1111/j.1468-2982.2004.00652.x; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STARFIELD B, 1993, PEDIATRICS, V91, P430; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Varni JW, 2002, ARTHRITIS RHEUM, V46, P714, DOI 10.1002/art.10095; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Varni JW, 2003, DIABETES CARE, V26, P631, DOI 10.2337/diacare.26.3.631; Varni JW, 2004, J BEHAV MED, V27, P297, DOI 10.1023/B:JOBM.0000028500.53608.2c; Ware JE, 2003, ARCH PHYS MED REHAB, V84, pS43, DOI 10.1053/apmr.2003.50246; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	62	92	93	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAR	2006	160	3					252	260		10.1001/archpedi.160.3.252			9	Pediatrics	Pediatrics	019XK	WOS:000235871300003	16520444	Bronze			2021-06-18	
J	Vlodavsky, E; Palzur, E; Soustiel, JF				Vlodavsky, E; Palzur, E; Soustiel, JF			Hyperbaric oxygen therapy reduces neuroinflammation and expression of matrix metalloproteinase-9 in the rat model of traumatic brain injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						hyperbaric oxygen; neuroinflammation; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; GENE KNOCK-OUT; MATRIX METALLOPROTEINASES; CELL-DEATH; EXTRACELLULAR PROTEOLYSIS; PLASMINOGEN ACTIVATORS; INFLAMMATORY RESPONSE; BARRIER PERMEABILITY; TISSUE INHIBITOR	The acute inflammatory response plays an important role in secondary brain damage after traumatic brain injury (TBI). Neutrophils provide the main source of matrix metalloproteinases (MMPs) which also play a deleterious role in TBI. Numerous preclinical studies have suggested that hyperbaric oxygen therapy (HBOT) may by beneficial in various noncerebral and cerebral inflammatory diseases. The goal of this study was to evaluate the effects of HBOT on inflammatory infiltration and the expression of MMPs in correlation with secondary cell death in the rat model of dynamic cortical deformation (DCD). Twenty animals underwent DCD with subsequent HBOT (2.8 ATA, two sessions of 45 min each); 10 animals: DCD and normobaric oxygenation (1 ATA), 10 animals: not treated after DCD. Cell death was evaluated by TUNEL. Neutrophils were revealed by myeloperoxidase staining. Immunohistochemical staining for MMP-2 and -9 and tissue inhibitors of MMP-1 (TIMP-1) and -2 was also performed and the results were quantitatively evaluated by image analysis. In the animals treated by HBOT, a significant decrease in the number of TUNEL-positive cells and neutrophilic inflammatory infiltration was seen in comparison with nontreated animals and those treated by normobaric oxygen. The expression of MMP-9 was also significantly lower in the treated group. Staining for MMP-2 and TIMP-2 did not change significantly. Our results demonstrate that HBOT decreased the extent of secondary cell death and reactive neuroinflammation in the TBI model. The decline of MMP-9 expression after HBOT may also contribute to protection of brain tissue in the perilesional area. Further research should be centred on the evaluation of long-term functional and morphological results of HBOT.	Rambam Med Ctr, Inst Pathol, IL-31096 Haifa, Israel; Rambam Med Ctr, Div Neurosurg, IL-31096 Haifa, Israel; Rambam Med Ctr, Acute Brain Res Lab, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Haifa, Israel	Vlodavsky, E (corresponding author), Rambam Med Ctr, Inst Pathol, IL-31096 Haifa, Israel.	e_vlodavsky@rambam.health.gov.il					Akin ML, 2002, UNDERSEA HYPERBAR M, V29, P279; Asahi M, 2001, J NEUROSCI, V21, P7724; Barone FC, 2000, EXPERT OPIN INV DRUG, V9, P2281, DOI 10.1517/13543784.9.10.2281; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Buras J, 2000, INT ANESTHESIOL CLIN, V38, P91, DOI 10.1097/00004311-200001000-00007; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Crocker SJ, 2004, J NEUROSCI RES, V75, P1, DOI 10.1002/jnr.10836; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Demchenko IT, 2000, NITRIC OXIDE-BIOL CH, V4, P597, DOI 10.1006/niox.2000.0313; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Garrity MM, 2003, MODERN PATHOL, V16, P389, DOI 10.1097/01.MP.0000062657.30170.92; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hjelde A, 2002, EUR J APPL PHYSIOL, V86, P401, DOI 10.1007/s00421-001-0573-1; Juttner B, 2003, UNDERSEA HYPERBAR M, V30, P305; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kochanek PM, 2001, CRIT CARE MED, V29, P906, DOI 10.1097/00003246-200104000-00050; Kubes P, 2000, BRAIN PATHOL, V10, P127; Larson JL, 2000, PLAST RECONSTR SURG, V105, P1375, DOI 10.1097/00006534-200004040-00017; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Maier CM, 2004, STROKE, V35, P1169, DOI 10.1161/01.STR.0000125861.55804.f2; Miljkovic-Lolic M, 2003, BRAIN RES, V971, P90, DOI 10.1016/S0006-8993(03)02364-3; MORENOFLORES MT, 1993, GLIA, V7, P146, DOI 10.1002/glia.440070204; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; Mun-Bryce S, 2004, BRAIN RES, V1026, P227, DOI 10.1016/j.brainres.2004.08.024; NEWCOMB JK, EXP NEUROL, V999, P76; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; REN H, 2000, CHIN J TRAUMATOL, V4, P239; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Shibayama M, 1997, ACT NEUR S, V70, P220; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Sumen G, 2001, EUR J PHARMACOL, V431, P265, DOI 10.1016/S0014-2999(01)01446-7; Tinianow CL, 2000, BIOMED SCI INSTRUM, V395, P275; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	65	92	112	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	FEB	2006	32	1					40	50		10.1111/j.1365-2990.2005.00698.x			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	999TN	WOS:000234413500005	16409552				2021-06-18	
J	Schwarzbach, E; Bonislawski, DP; Xiong, G; Cohen, AS				Schwarzbach, E.; Bonislawski, D. P.; Xiong, G.; Cohen, A. S.			Mechanisms underlying the inability to induce area CA1 LTP in the mouse after traumatic brain injury	HIPPOCAMPUS			English	Article						NMDA receptor; alpha-calmodulin kinase II (alpha-CaMKII); dendrite spine size; cognition; limbic function	LONG-TERM POTENTIATION; POST-TETANIC POTENTIATION; DENDRITIC SPINE DENSITY; SELECTIVE VULNERABILITY; SYNAPTIC-TRANSMISSION; HIPPOCAMPAL-NEURONS; PYRAMIDAL CELLS; PROTEIN-KINASE; DENTATE GYRUS; MEMORY	Traumatic brain injury (TBI) is a significant health issue that often causes enduring cognitive deficits, in particular memory dysfunction. The hippocampus, a structure crucial in learning and memory, is frequently damaged during TBI. Since long-term potentiation (LTP) is the leading cellular model underlying learning and memory, this study was undertaken to examine how injury affects area CA1 LTP in mice using lateral fluid percussion injury (FPI). Brain slices derived from FPI animals demonstrated an inability to induce LTP in area CA1 7 days postinjury. However, area CA1 long-term depression could be induced in neurons 7 days postinjury, demonstrating that some forms of synaptic plasticity can still be elicited. Using a multidisciplined approach, potential mechanisms underlying the inability to induce and maintain area CA1 LTP were investigated. This study demonstrates that injury leads to significantly smaller N-methyl-D-aspartate potentials and glutamate-induced excitatory currents, increased dendritic spine size, and decreased expression of a-calcium calmodulin kinase II. These findings may underlie the injuryinduced lack of LTP and thus, contribute to cognitive impairments often associated with TBI. Furthermore, these results provide attractive sites for potential therapeutic intervention directed toward alleviating the devastating consequences of human TBI. (c) 2006 Wiley-Liss, Inc.	Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA	Schwarzbach, E (corresponding author), 3615 Civic Ctr Blvd,816H ARC, Philadelphia, PA 19104 USA.	eschwarz@mail.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD059288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045975] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD059288-07, R01 HD059288, R01 HD059288-06] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45975, R01 NS045975] Funding Source: Medline		BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P665, DOI 10.1113/jphysiol.1972.sp010053; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cohen AS, 2000, J NEUROPHYSIOL, V84, P2465; Cohen AS, 1996, J NEUROPHYSIOL, V76, P953; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V126, pP27; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Gazzaley A, 2002, NEUROSCIENCE, V111, P853, DOI 10.1016/S0306-4522(02)00021-0; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HANSE E, 1992, J NEUROSCI, V12, P3226; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HESS G, 1992, NEUROREPORT, V3, P361, DOI 10.1097/00001756-199204000-00018; HIRST GDS, 1981, J PHYSIOL-LONDON, V321, P97, DOI 10.1113/jphysiol.1981.sp013973; Kirov SA, 1999, NAT NEUROSCI, V2, P878; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Leuner B, 2003, J NEUROSCI, V23, P659; Li CY, 2005, J NEUROPHYSIOL, V93, P3001, DOI 10.1152/jn.00546.2004; Liu GS, 2004, NAT NEUROSCI, V7, P373, DOI 10.1038/nn1206; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.neuro.14.1.379; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; MARTIN AR, 1964, J PHYSIOL-LONDON, V175, P17, DOI 10.1113/jphysiol.1964.sp007500; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Neigh GN, 2004, EUR J NEUROSCI, V20, P1865, DOI 10.1111/j.1460-9568.2004.03649.x; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Malley A, 2000, NEUROSCIENCE, V99, P229, DOI 10.1016/S0306-4522(00)00182-2; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; PATEL SN, 1988, BRAIN RES, V463, P168, DOI 10.1016/0006-8993(88)90542-2; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Radley JJ, 2004, NEUROSCIENCE, V125, P1, DOI 10.1016/j.neuroscience.2004.01.006; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Sabatini BL, 2002, NEURON, V33, P439, DOI 10.1016/S0896-6273(02)00573-1; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sandkuhler J, 1998, EUR J NEUROSCI, V10, P2476, DOI 10.1046/j.1460-9568.1998.00278.x; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; Segal M, 2005, NAT REV NEUROSCI, V6, P277, DOI 10.1038/nrn1649; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Toth Z, 1997, J NEUROSCI, V17, P8106; Weitlauf C, 2005, J NEUROSCI, V25, P8386, DOI 10.1523/JNEUROSCI.2388-05.2005; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wong TP, 2004, SCIENCE, V305, p1912C, DOI 10.1126/science.1102399; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547; 1999, MED PEDIAT ONCOL, V33, P357	61	92	94	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus		2006	16	6					541	550		10.1002/hipo.20183			10	Neurosciences	Neurosciences & Neurology	049RH	WOS:000238033700003	16634077	Green Accepted			2021-06-18	
J	Wells, R; Dywan, J; Dumas, J				Wells, R; Dywan, J; Dumas, J			Life satisfaction and distress in family caregivers as related to specific behavioural changes after traumatic brain injury	BRAIN INJURY			English	Article						closed head injury; long-term care; caregiver burden; internalizing symptoms; externalizing symptoms; income change; planning; memory; impulse control; empathy; Brock Adaptive Functioning Questionnaire	BURDEN; IMPACT; PREDICTORS; MEMORY; TBI	Primary objective: To predict long-term outcome of those caring for family members who have sustained a traumatic brain injury (TBI). Methods and procedures: A multivariate approach was used to examine the effectiveness of caregiver coping strategies in the context of TBI-related behavioural change. Self-administered questionnaire packages were collected from 72 adult survivor and family-member pairs who provided information on survivors' altered executive function, behavioural control and emotional sensitivity as well as caregivers' methods of coping, attitudes toward caregiving, indices of distress, mood ratings and quality of life. Main outcomes and results: Family members generally reported higher levels of satisfaction than dissatisfaction with their caregiving role. The type of neurobehavioural deficit and the approaches taken to cope with stress had specific effects on each dimension of caregiver outcome. Conclusions: Adequate family support requires finely tuned assessment of factors relevant to successful coping.	Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada; Ontario Brain Injury Assoc, St Catharines, ON, Canada	Dywan, J (corresponding author), Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada.	jdywan@brocku.ca					Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; [Anonymous], 1998, REH PERS TRAUM BRAIN, P1; Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652; BROADBENT NJ, 2002, NEUROPSYCHOLOGY MEMO, P3; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Connell CM, 2001, J GERIATR PSYCH NEUR, V14, P179, DOI 10.1177/089198870101400403; Derogatis LR, 1983, SCL 90 R ADM SCORING; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P992, DOI 10.1037/0022-3514.50.5.992; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HOLROYD J, 1985, QUESTIONNAIRE RESOUR; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LEVIN HS, 1997, BEHAV NEUROLOGY NEUR, P479; Lezak M. D., 1997, BEHAV NEUROLOGY NEUR, P43; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; MCCUBBIN HI, 1982, FAMILY COPING STRATE; Minnes P, 2000, BRAIN INJURY, V14, P737; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Scheibel RS, 2004, CORTEX, V40, P218, DOI 10.1016/S0010-9452(08)70957-2; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; SCHULZ R, 1988, PSYCHOL AGING, V3, P131, DOI 10.1037/0882-7974.3.2.131; Simpson A, 2002, BRAIN INJURY, V16, P1075, DOI 10.1080/02699050210155249; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; TAYLOR S, 2004, HEAD INJURY ASS ORBI; Torner James C., 1996, P19; Varney NR, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P115; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751	37	92	93	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	13					1105	1115		10.1080/02699050500150062			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZD	WOS:000233270000005	16286324				2021-06-18	
J	Cernak, I; Stoica, B; Byrnes, KR; Di Giovanni, S; Faden, AI				Cernak, I; Stoica, B; Byrnes, KR; Di Giovanni, S; Faden, AI			Role of the cell cycle in the pathobiology of central nervous system trauma	CELL CYCLE			English	Article						cell cycle; apoptosis; neuronal injury; traumatic brain injury; astrocyte proliferation; microglial proliferation; neuroprotection; flavopiridol	BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; STIMULATED HOMOLOGOUS MACROPHAGES; KINASE INHIBITOR FLAVOPIRIDOL; IN-VITRO; ALZHEIMERS-DISEASE; DEPENDENT KINASES; MICROGLIAL ACTIVATION; NEURONAL APOPTOSIS; PARKINSONS-DISEASE	Upregulation of cell cycle proteins occurs in both mitotic and post-mitotic neural cells after central nervous system (CNS) injury in adult animals. In mitotic cells, such as astroglia and microglia, they induce proliferation, whereas in post-mitotic cells such as neurons they initiate caspase-related apoptosis. We recently reported that early central administration of the cell cycle inhibitor flavopiridol after experimental traumatic brain injury (TBI) significantly reduced lesion volume, scar formation and neuronal cell death, while promoting near complete behavioral recovery. Here we show that in primary neuronal or astrocyte cultures structurally different cell cycle inhibitors ( flavopiridol, roscovitine, and olomoucine) significantly reduce upregulation of cell cycle proteins, attenuate neuronal cell death induced by etoposide, and decrease astrocyte proliferation. Flavopiridol, in a concentration dependent manner, also attenuates proliferation/ activation of microglia. In addition, we demonstrate that central administration of flavopiridol improves functional outcome in dose-dependent manner after fluid percussion induced brain injury in rats. Moreover, delayed systemic administration of flavopiridol significantly reduces brain lesion volume and edema development after TBI. These data provide further support for the therapeutic potential of cell cycle inhibitors for the treatment of clinical CNS injury and that protective mechanisms likely include reduction of neuronal cell death, inhibition of glial proliferation and attenuation of microglial activation.	Georgetown Univ, Med Ctr, Dept Neurosci, Lab Study CNS Injury, Washington, DC 20057 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Lab Study CNS Injury, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	fadena@georgetown.edu	Cernak, Ibolja/A-6399-2008; STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734; Ibolja, Cernak/0000-0003-3214-698X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD4-0677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-1-2339] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [36537-03] Funding Source: Medline		ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; AKUNDI RS, 2005, IN PRESS GLIA; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Blagosklonny MV, 2004, CELL CYCLE, V3, P1537, DOI 10.4161/cc.3.12.1278; Blamire AM, 2000, J NEUROSCI, V20, P8153; Bonmann E, 1997, NEUROSCI LETT, V230, P109, DOI 10.1016/S0304-3940(97)00485-0; Boonstra J, 2003, J CELL BIOCHEM, V90, P244, DOI 10.1002/jcb.10617; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; Daly J, 1998, NEUROBIOL AGING, V19, P619, DOI 10.1016/S0197-4580(98)00100-6; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fischer Peter M, 2003, Prog Cell Cycle Res, V5, P235; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; GALLO V, 1995, J NEUROSCI, V15, P394; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GIULIAN D, 1988, Brain Behavior and Immunity, V2, P352, DOI 10.1016/0889-1591(88)90040-2; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Grewal RP, 1999, NEUROSCI LETT, V271, P65, DOI 10.1016/S0304-3940(99)00496-6; Hains BC, 2001, J NEUROTRAUM, V18, P409, DOI 10.1089/089771501750170994; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Harris FM, 2004, J BIOL CHEM, V279, P3862, DOI 10.1074/jbc.M309475200; Hashimoto M, 2005, NEUROREPORT, V16, P99, DOI 10.1097/00001756-200502080-00004; HOEPPNER TJ, 1986, EXP NEUROL, V94, P519, DOI 10.1016/0014-4886(86)90235-9; Hunot S, 2003, ANN NEUROL, V53, pS49, DOI 10.1002/ana.10481; Kato H, 2003, BRAIN RES BULL, V60, P215, DOI 10.1016/S0361-9230(03)00036-4; Kim HRC, 1999, CANCER RES, V59, P4148; Kim SY, 2002, MOL CELLS, V13, P429; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Moore S, 1996, PROG NEUROBIOL, V48, P441, DOI 10.1016/0301-0082(95)00051-8; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Schultz C, 2004, NEUROBIOL AGING, V25, P397, DOI 10.1016/S0197-4580(03)00113-1; Schwartz GK, 2001, J CLIN ONCOL, V19, P1985, DOI 10.1200/JCO.2001.19.7.1985; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; VINK R, 1988, J BIOL CHEM, V263, P757; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Wiessner C, 1996, NEUROSCIENCE, V72, P947, DOI 10.1016/0306-4522(95)00601-X; XU J, 1992, J NEUROTRAUM, V9, P245, DOI 10.1089/neu.1992.9.245; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2	84	92	94	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	SEP	2005	4	9					1286	1293		10.4161/cc.4.9.1996			8	Cell Biology	Cell Biology	959JB	WOS:000231512900030	16082214	Bronze			2021-06-18	
J	Davis, DP; Peay, J; Serrano, JA; Buono, C; Vilke, GM; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, DP; Peay, J; Serrano, JA; Buono, C; Vilke, GM; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB			The impact of aeromedical response to patients with moderate to severe traumatic brain injury	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Conference on Air Medical Transport	2004	Cincinnati, OH				RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; SCENE HELICOPTER TRANSPORT; BLUNT TRAUMA; ENDOTRACHEAL INTUBATION; EMERGENCY CARE; INTERHOSPITAL TRANSPORT; MULTIPLE INJURIES; AIR AMBULANCE; MORTALITY	Study objective: Aeromedical crews offer an advanced level of practice and rapid transport to definitive care; however, their efficacy remains unproven. Previous studies have used relatively small sample sizes or have been unable to adequately control for the effect of other potentially influential variables. Here we explore the impact of aeromedical response in patients, with moderate to severe traumatic brain injury. Methods: This was a retrospective analysis using our county trauma registry. All patients with head Abbreviated Injury Score of 3 or greater were included; interfacility transfers were excluded. The impact of aeromedical response was determined using logistic regression; adjusting for age, sex, mechanism; preadmission Glasgow Coma Scale score, head Abbreviated Injury Score, Injury Severity Score, and the presence of preadmission hypotension. Propensity scores were used to account for variability in selection of patients to undergo air versus ground transport: Patients with moderate and severe traumatic brain injury, as defined by head Abbreviated Injury Score and Glasgow Coma Scale score; were compared. Finally, aeromedical patients undergoing field intubation were compared with ground patients undergoing emergency department (ED) intubation. Results: A total of 10,314 patients meeting all inclusion and exclusion criteria and with complete data sets were identified and included 3,017 transported by aeromedical crews. Overall mortality was 251 in the air- and ground-transported cohorts, but outcomes were significantly better for the aeromedical patients when adjusted for age, sex, mechanism of injury, hypotension; Glasgow Coma Scale score, head Abbreviated Injury Score, and Injury Severity Score (adjusted odds ratio [OR] 1.90; 95% confidence interval [CI] 1.60 to 2.25; P < .0001). Good outcomes (discharge to home, jail, psychiatric facility, rehabilitation, or leaving against medical advice) were also higher in aeromedical patients (adjusted OR 1.36; 95% CI 1.18 to 1.58; P < .0001). The primary benefit appeared to be in more severely injured patients, as reflected by head Abbreviated Injury Score and Glasgow Coma Scale score. Improved survival was also observed for air-transported patients intubated in the field versus ground-transported patients given emergency intubation in the ED (adjusted OR 1.42; 95% CI 1.13 to 1.78; P < .001). Conclusion: Here we analyze a large database of patients with moderate to severe traumatic brain injury. Aeromedical response appears to result in improved outcomes after adjustment for multiple influential factors in patients with moderate to severe traumatic brain injury. In addition, out-of-hospital intubation among air-transported patients resulted in better outcomes,than ED intubation among ground-transported patients. Patients with more severe injuries appeared to derive the greatest benefit from aeromedical transport.	Univ Calif San Diego Emergency Med, San Diego, CA 92103 USA; Mercy Air Med Serv, San Diego, CA USA; UC San Diego, Sch Med, La Jolla, CA USA; Scripps Mercy Hosp, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA; Scripps La Jolla Hosp, La Jolla, CA USA; Palomar Hosp, Escondido, CA USA; UC San Diego Dept Surg, San Diego, CA USA	Davis, DP (corresponding author), Univ Calif San Diego Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Austin P N, 2000, Air Med J, V19, P90, DOI 10.1016/S1067-991X(00)90028-2; Bartolacci RA, 1998, MED J AUSTRALIA, V169, P612, DOI 10.5694/j.1326-5377.1998.tb123435.x; BAXT WG, 1983, JAMA-J AM MED ASSOC, V249, P3047, DOI 10.1001/jama.249.22.3047; BAXT WG, 1985, ANN EMERG MED, V14, P859, DOI 10.1016/S0196-0644(85)80634-X; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Biewener A, 2004, J TRAUMA, V56, P94, DOI 10.1097/01.TA.0000061883.92194.50; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BOYD CR, 1989, J TRAUMA, V29, P789, DOI 10.1097/00005373-198906000-00015; Brathwaite CEM, 1998, J TRAUMA, V45, P140, DOI 10.1097/00005373-199807000-00029; Brazier J, 1996, J Health Serv Res Policy, V1, P232; CAMERON PA, 1993, AUST NZ J SURG, V63, P790, DOI 10.1111/j.1445-2197.1993.tb00342.x; Celli P, 1997, Minerva Chir, V52, P1467; Chappell VL, 2002, J TRAUMA, V52, P486, DOI 10.1097/00005373-200203000-00012; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cocanour CS, 1997, J TRAUMA, V43, P83, DOI 10.1097/00005373-199707000-00019; Cunningham P, 1997, J TRAUMA, V43, P940, DOI 10.1097/00005373-199712000-00013; Dardis R, 2000, Ir Med J, V93, P50; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS DP, 2005, IN PRESS J TRAUMA; De Wing MD, 2000, J BURN CARE REHABIL, V21, P535, DOI 10.1097/00004630-200021060-00011; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Falcone R E, 1998, Air Med J, V17, P161, DOI 10.1016/S1067-991X(98)90043-8; FISCHER RP, 1984, J TRAUMA, V24, P946, DOI 10.1097/00005373-198411000-00004; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gearhart PA, 1997, ANN EMERG MED, V30, P500, DOI 10.1016/S0196-0644(97)70010-6; HAMMAN BL, 1991, J TRAUMA, V31, P490, DOI 10.1097/00005373-199104000-00007; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; Holmen CD, 2002, J TRAUMA, V53, P345, DOI 10.1097/00005373-200208000-00026; Jacobs L M, 1999, Conn Med, V63, P677; KEARNEY PA, 1991, ANN EMERG MED, V20, P882, DOI 10.1016/S0196-0644(05)81431-3; Kerr W A, 1999, Prehosp Disaster Med, V14, P159; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Kurola J, 2002, ACTA ANAESTH SCAND, V46, P779, DOI 10.1034/j.1399-6576.2002.460704.x; Larson JT, 2004, J TRAUMA, V56, P89, DOI 10.1097/01.TA.0000061163.35582.A5; MALACRIDA RL, 1993, INJURY, V24, P451, DOI 10.1016/0020-1383(93)90147-X; Mann NC, 2002, ACAD EMERG MED, V9, P694, DOI 10.1111/j.1553-2712.2002.tb02147.x; Moront ML, 1996, J PEDIATR SURG, V31, P1183, DOI 10.1016/S0022-3468(96)90114-1; MOYLAN JA, 1988, ANN SURG, V207, P679, DOI 10.1097/00000658-198806000-00006; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Nardi G, 1994, Eur J Emerg Med, V1, P69; NICHOLL JP, 1995, BRIT MED J, V311, P217, DOI 10.1136/bmj.311.6999.217; Oppe S, 2001, ACCIDENT ANAL PREV, V33, P129, DOI 10.1016/S0001-4575(00)00023-3; Phillips RT, 1999, MIL MED, V164, P361; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Pitts L H, 1995, New Horiz, V3, P546; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; SCHILLER WR, 1988, J TRAUMA, V28, P1127, DOI 10.1097/00005373-198808000-00004; SCHMIDT U, 1992, J TRAUMA, V33, P548, DOI 10.1097/00005373-199210000-00010; Schwartz R J, 1988, Conn Med, V52, P203; Schwartz R J, 1990, Conn Med, V54, P660; SCHWARTZ RJ, 1989, J TRAUMA, V29, P1611, DOI 10.1097/00005373-198912000-00002; Shatney CH, 2002, J TRAUMA, V53, P817, DOI 10.1097/00005373-200211000-00002; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; THOMAS F, 1990, WESTERN J MED, V153, P40; Thomas SH, 2002, J TRAUMA, V52, P136, DOI 10.1097/00005373-200201000-00023; URDANETA LF, 1987, ARCH SURG-CHICAGO, V122, P992; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wills VL, 2000, AUST NZ J SURG, V70, P506, DOI 10.1046/j.1440-1622.2000.01893.x; Wish John R, 2005, Air Med J, V24, P83, DOI 10.1016/j.amj.2004.12.007; Younge PA, 1997, J TRAUMA, V43, P511, DOI 10.1097/00005373-199709000-00021	70	92	94	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2005	46	2					115	122		10.1016/j.annemergmed.2005.01.024			8	Emergency Medicine	Emergency Medicine	950KD	WOS:000230855100004	16046940				2021-06-18	
J	Channon, S; Pellijeff, A; Rule, A				Channon, S; Pellijeff, A; Rule, A			Social cognition after head injury: Sarcasm and theory of mind	BRAIN AND LANGUAGE			English	Article						social cognition; frontal lobes; theory of mind; mentalising; pragmatic; sarcasm	BRAIN-DAMAGED PATIENTS; VERBAL IRONY; CHILDREN; LANGUAGE; IMPAIRMENTS; DYSFUNCTION; DECEPTION; INFERENCE; MEANINGS; DEFICITS	Closed head injury (CHI) is associated with communication difficulties in everyday social interactions. Previous work has reported impaired comprehension of sarcasm, using sarcastic remarks where the intended meaning is the opposite of the sincere or literal meaning. Participants with CHI in the present study were assessed using two types of sarcastic items, those with a directly opposite meaning and those with an indirect, non-literal but not directly opposite meaning. The CHI group was differentially poorer at comprehending sarcastic versus sincere remarks, although type of sarcastic materials did not influence performance. Errors involved not only literal interpretations, but also incorrect non-literal interpretations. Theory of mind (mentalising) was also assessed by comparing comprehension of human actions with control physical events. The CHI group was selectively impaired on the mentalising component of this task, and mentalising scores correlated with sarcasm comprehension. The implications of the findings for our understanding of impaired sarcastic comprehension after acquired brain injury are discussed. (c) 2004 Elsevier Inc. All rights reserved.	UCL, Dept Psychol, London, ON, Canada	Channon, S (corresponding author), UCL, Dept Psychol, London, ON, Canada.	s.channon@ucl.ac.uk	Channon, Shelley/C-1754-2008				Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bishop D.V.M., 1989, TEST RECEPTION GRAMM; Body R., 1999, COMMUNICATION DISORD; BOSCO F, 2004, 26 ANN M COGN SCI SO; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Channon S, 2004, ACTA PSYCHOL, V115, P235, DOI 10.1016/j.actpsy.2003.12.008; CHANNON S, UNPUB COMPREHENSION; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Creusere MA, 1999, DEV REV, V19, P213, DOI 10.1006/drev.1998.0474; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J AUTISM DEV DISORD, V31, P47, DOI 10.1023/A:1005661613288; Dews S, 1996, CHILD DEV, V67, P3071, DOI 10.2307/1131767; DEWS S, 1995, METAPHOR SYMB ACT, V10, P3, DOI 10.1207/s15327868ms1001_2; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gibbs Jr R.W., 2000, METAPHOR SYMBOL, V15, P5, DOI DOI 10.1080/10926488.2000.9678862; Gibbs RW, 2002, J PRAGMATICS, V34, P457, DOI 10.1016/S0378-2166(01)00046-7; Giora R, 1999, J PRAGMATICS, V31, P919, DOI 10.1016/S0378-2166(98)00100-3; Grice H., 1975, SYNTAX SEMANTICS; Grice H.P, 1989, STUDIES WAY WORDS; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Jennett B, 1981, MANAGEMENT HEAD INJU; Jorgensen J, 1996, J PRAGMATICS, V26, P613, DOI 10.1016/0378-2166(95)00067-4; KATZ AN, 2000, METAPHOR SYMBOL, V15, P1; KREUZ RJ, 1989, J EXP PSYCHOL GEN, V118, P374, DOI 10.1037/0096-3445.118.4.374; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; McDonald S, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Mitchley N.J., 1998, COGNITIVE NEUROPSYCH, V3, P127, DOI [DOI 10.1080/135468098396206, 10.1080/135468098396206]; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Ozonoff S, 1996, BRAIN LANG, V52, P411, DOI 10.1006/brln.1996.0022; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Shamay SG, 2002, BRAIN COGNITION, V48, P558, DOI 10.1006/brcg.2001.1417; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Sullivan K, 2003, DEV NEUROPSYCHOL, V23, P85, DOI 10.1207/S15326942DN231&2_5; Wechsler D., 2001, WECHSLER TEST ADULT; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x	48	92	95	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	MAY	2005	93	2					123	134		10.1016/j.bandl.2004.09.002			12	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	913ZX	WOS:000228195300001	15781300				2021-06-18	
J	Vespa, P				Vespa, P			Continuous EEG monitoring for the detection of seizures in traumatic brain injury, infarction, and intracerebral hemorrhage: "To detect and protect"	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						seizures; brain injury; intracerebral hemorrhage; coma; stroke; continuous electroencephalography	INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; CEREBRAL PERFUSION-PRESSURE; VENOUS OXYGEN-SATURATION; EXCITATORY AMINO-ACIDS; HEAD TRAUMA; MICRODIALYSIS; STROKE; EPILEPSY; INCREASE	Brain injury results in a primary pathophysiologic response that enables the brain to have seizures. Seizures occur frequently after traumatic and nontraumatic intracerebral bleeding. These seizures can be nonconvulsive, and if one does not monitor for seizures, one will not know they are occurring. The use of continuous EEG monitoring (cEEG) to detect brain arrhythmias after a primary insult, much in way that cardiac arrhythmias are detected after myocardial infarction, can influence treatment decisions and mitigate some of the pathophysiologic natural history of brain injuries. Seizures after brain injury worsen clinical outcome and need to be treated. In summary, cEEG is a valuable clinical instrument "to detect and protect," i.e., to detect seizures and protect the brain from seizure-related injury in critically ill patients, whose brains are often in a particularly vulnerable state.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Neurol, Los Angeles, CA 90095 USA	Vespa, P (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Neurol, 10833 Le Conte Ave,CHS 18-218, Los Angeles, CA 90095 USA.	Pvespa@mednet.ucla.edu					ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Black P, 1975, CIBA F S, V34, P215; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DAVALOS A, 1992, CEREBROVASC DIS, V2, P327, DOI 10.1159/000109039; Drislane FW, 2000, EPILEPSY BEHAV, V1, P301, DOI 10.1006/ebeh.2000.0100; Enblad P, 1997, J NEUROL NEUROSUR PS, V62, P512, DOI 10.1136/jnnp.62.5.512; Engstrom ER, 2001, EPILEPSY RES, V43, P135, DOI 10.1016/S0920-1211(00)00191-1; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; Kollevold T, 1976, J Oslo City Hosp, V26, P99; LANCMAN ME, 1993, EPILEPSIA, V34, P141, DOI 10.1111/j.1528-1157.1993.tb02386.x; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; Litt Brian, 1994, Epilepsia, V35, P10; Miller J D, 1994, Neurosurg Clin N Am, V5, P661; OLSEN TS, 1987, NEUROLOGY, V37, P1209, DOI 10.1212/WNL.37.7.1209; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; Scholtes FB, 1996, J NEUROL NEUROSUR PS, V61, P93, DOI 10.1136/jnnp.61.1.93; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHIELDS D, 2004, ANN M AM ASS NEUR SU; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; Si Y, 1998, ELECTROEN CLIN NEURO, V106, P488, DOI 10.1016/S0013-4694(97)00154-5; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Young GB, 1996, NEUROLOGY, V47, P83	35	92	96	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	APR	2005	22	2					99	106		10.1097/01.WNP.0000154919.54202.E0			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	914CH	WOS:000228201800003	15805809				2021-06-18	
J	Whiteneck, GG; Gerhart, KA; Cusick, CP				Whiteneck, GG; Gerhart, KA; Cusick, CP			Identifying environmental factors that influence the outcomes of people with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; environment; environment design; social environment	SPINAL-CORD-INJURY; MODEL SYSTEMS; FOLLOW-UP; MEDICAL COMPLICATIONS; LIFE SCALE; SATISFACTION; PREDICTION; EMPLOYMENT; DISABILITY; COMMUNITY	Objectives: To determine the types of environmental barriers reported by persons with traumatic brain injury (TBI) and to identify the relations between environmental barriers and such components of societal participation as employment, community mobility, social integration, and life satisfaction. Design: Seventy-three persons with TBI who were participating in the TBI Model Systems program at Craig Hospital were surveyed at 1 year, using a new measure of the environment, the Craig Hospital Inventory of Environmental Factors (CHIEF), which rates frequency and impact of 25 barriers. Results: Transportation, the surroundings, government policies, attitudes, and the natural environment were the environmental barriers with the greatest reported impact. Those who were married, older, and unemployed or not in school reported the most barriers overall. Additionally, those reporting a greater impact from environmental barriers also reported lower levels of participation and life satisfaction. Conclusions: Although environmental barriers affect TBI survivors and play a role in their outcomes, their interplay with other, perhaps as yet unidentified, factors requires continued research. CHIEF may be a valuable tool for understanding the environment's role in the lives of people with TBI, and identifying the general environmental domains where interventions are needed to reduce their negative impact.	Craig Hosp, Res Dept, Englewood, CO 80113 USA	Whiteneck, GG (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	gale@craighospital.org					[Anonymous], 1992, INT CLASS DIS ICD 10; Brandt E. N., 1997, ENABLING AM ASSESSIN; Chen D, 1999, ARCH PHYS MED REHAB, V80, P1397, DOI 10.1016/S0003-9993(99)90250-2; *CONS SPIN CORD ME, 1999, OUTC FOLL TRAUM SPIN; Craig Hospital Research Department, 2001, CRAIG HOSP INV ENV F; Creek G., 1987, PERSONAL SOCIAL IMPL; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1982, ARCH PHYS MED REHAB, V65, P66; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; ELGHATIT AZ, 1976, ARCH PHYS MED REHAB, V57, P470; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; ELGHATIT AZ, 1978, J CHRON DIS, V31, P363, DOI 10.1016/0021-9681(78)90053-X; Fougeyrollas P., 2002, TOP SPINAL CORD INJ, V7, P1, DOI DOI 10.1310/QDNN-8FN0-NJMG-TVWB; FUHRER M, 1997, RIMA 8 8 WORLD C INT; Gerhart KA, 1999, SPINAL CORD, V37, P183, DOI 10.1038/sj.sc.3100804; GERHART KA, 1993, ARCH PHYS MED REHAB, V74, P1030, DOI 10.1016/0003-9993(93)90057-H; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; GRANGER CV, 1997, ASSESSING MED REHABI; Gray DB, 2003, J ARCHIT PLAN RES, V20, P29; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; KEMP BJ, 1971, J CHRON DIS, V24, P259, DOI 10.1016/0021-9681(71)90078-6; KRAUSE JS, 1990, PARAPLEGIA, V28, P186, DOI 10.1038/sc.1990.24; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1402, DOI 10.1016/S0003-9993(99)90251-4; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; NOREAU I, 2002, TOP SPINAL CORD INJ, V7, P56; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Rintala D. H., 1997, WOMEN PHYS DISABILIT, P223; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; *US DEP ED OFF SPE, 2000, LONG RANG PLAN 1999; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1992, PARAPLEGIA, V30, P616; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2001, INT CLASS FUNCT DIS; YARDLEY JK, 1991, SOC INDIC RES, V24, P101, DOI 10.1007/BF00292653	46	92	93	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2004	19	3					191	204		10.1097/00001199-200405000-00001			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826JB	WOS:000221824300001	15247842				2021-06-18	
J	Petersen, MA; Dailey, ME				Petersen, MA; Dailey, ME			Diverse microglial motility behaviors during clearance of dead cells in hippocampal slices	GLIA			English	Article						microglia; cell death; phagocytosis; brain slice; time-lapse imaging; cell motility	IN-VITRO MODEL; ADHESION MOLECULE EXPRESSION; COLONY-STIMULATING FACTOR; RAT FACIAL NUCLEUS; NERVOUS-SYSTEM; CULTURED MICROGLIA; RAMIFIED MICROGLIA; BRAIN MACROPHAGES; PROPIDIUM IODIDE; PHAGOCYTOSIS	We used two-channel three-dimensional time-lapse fluorescence confocal imaging in live rat hippocampal slice cultures (1-7 days in vitro) to determine the motility behaviors of activated microglia as they engage dead and dying cells following traumatic brain tissue injury. Live microglia were labeled with a fluorescently conjugated lectin (IB4), and dead neurons were labeled with a membrane-impermeant fluorescent DNA-binding dye (Sytox Orange or To-Pro-3). Tissue injury during the slicing procedure induced neuronal death and microglial activation, but the density of dead cells diminished similar to 10-fold by 7 days in vitro as resident microglia cleared dead cells. In time-lapse movies (4-20 h long), activated microglia exhibited varying levels of motile and locomotory activity. The motility of microglia could change abruptly following contact by other microglia or death of nearby cells. When neighboring cells died, some microglia rapidly moved toward or extended a process to engulf the dead cell, consistent with a chemotactic signaling response. Dead cell nuclei usually were engulfed and carried along by highly motile and locomoting microglia. The mean time to engulfment was similar to 5 times faster for newly deceased cells (33 min) than for extant dead cells (160 min), suggesting that the efficacy of microglial phagocytosis in situ might vary with time after cell death or mode of cell death. These observations demonstrate that activated microglia are heterogeneous with respect to motile activity following traumatic tissue injury and further indicate that cell motility in situ is temporally regulated at the single cell level, possibly by direct cell-cell contact and by diffusible substances emanating from nearby dead cells. (C) 2004 Wiley-Liss, Inc.	Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA	Dailey, ME (corresponding author), Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA.	michael-e-dailey@uiowa.edu	Petersen, Mark/AAN-5634-2020		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10 RR017941] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS43468, R01 NS043468] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR017941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043468] Funding Source: NIH RePORTER		ABDELBASSET EM, 1994, ACTA NEUROPATHOL, V88, P527, DOI 10.1007/BF00296489; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Behl C, 1997, MOL PHARMACOL, V51, P535; Bohatschek M, 2001, J NEUROSCI RES, V64, P508, DOI 10.1002/jnr.1103; BOOTH PL, 1991, CELL TISSUE RES, V266, P541, DOI 10.1007/BF00318596; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Calvo CF, 1996, EUR J NEUROSCI, V8, P1725, DOI 10.1111/j.1460-9568.1996.tb01316.x; Chan A, 2001, GLIA, V33, P87, DOI 10.1002/1098-1136(20010101)33:1<87::AID-GLIA1008>3.0.CO;2-S; Coltman BW, 1996, INT J DEV NEUROSCI, V14, P707, DOI 10.1016/S0736-5748(96)00071-8; Cross AK, 1999, J NEUROSCI RES, V55, P17, DOI 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.3.CO;2-0; Dailey ME, 1999, METHODS, V18, P222, DOI 10.1006/meth.1999.0775; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Grossmann R, 2002, GLIA, V37, P229, DOI 10.1002/glia.10031; HAAPANIEMI H, 1995, NEUROSCI LETT, V193, P121, DOI 10.1016/0304-3940(95)11683-N; Hailer NP, 2001, EUR J NEUROSCI, V14, P315, DOI 10.1046/j.0953-816x.2001.01649.x; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; Hartlage-Rubsamen M, 2001, BRAIN RES, V897, P20, DOI 10.1016/S0006-8993(01)02093-5; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Liu W, 2001, BRAIN RES, V916, P239, DOI 10.1016/S0006-8993(01)03006-2; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; MAJNO G, 1995, AM J PATHOL, V146, P3; MCGLADEMCCULLOH E, 1989, P NATL ACAD SCI USA, V86, P1093, DOI 10.1073/pnas.86.3.1093; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; Milner R, 2002, J NEUROSCI, V22, P1562, DOI 10.1523/JNEUROSCI.22-05-01562.2002; Moller T, 1997, J NEUROSCI, V17, P615; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; Nolte C, 1997, EUR J NEUROSCI, V9, P1690, DOI 10.1111/j.1460-9568.1997.tb01526.x; Ohsawa K, 2000, J CELL SCI, V113, P3073; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SIEVERS J, 1994, GLIA, V12, P245, DOI 10.1002/glia.440120402; Skibo GG, 2000, NEUROSCIENCE, V96, P427, DOI 10.1016/S0306-4522(99)00562-X; Smith ME, 2000, J NEUROIMMUNOL, V102, P154, DOI 10.1016/S0165-5728(99)00218-0; SMITH SJ, 1990, 23 S MED HOECHST BIO, P49; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; Takeda H, 1998, NEUROSCI LETT, V240, P5, DOI 10.1016/S0304-3940(97)00917-8; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Tomia Minoru, 1996, Keio Journal of Medicine, V45, P213; von Zahn J, 1997, NEUROREPORT, V8, P3851, DOI 10.1097/00001756-199712220-00003; WARD SA, 1991, J NEUROSCI RES, V29, P13, DOI 10.1002/jnr.490290103; Witting A, 2000, J NEUROCHEM, V75, P1060, DOI 10.1046/j.1471-4159.2000.0751060.x; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	58	92	95	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR 15	2004	46	2					195	206		10.1002/glia.10362			12	Neurosciences	Neurosciences & Neurology	812RO	WOS:000220856800008	15042586				2021-06-18	
J	Stein, SC; Graham, DI; Chen, XH; Smith, DH				Stein, SC; Graham, DI; Chen, XH; Smith, DH			Association between intravascular microthrombosis and cerebral ischemia in traumatic brain injury	NEUROSURGERY			English	Article						cerebral ischemia; disseminated intravascular coagulation; secondary insult; thrombosis; traumatic brain injury	ACTIVATED PROTEIN-C; SEVERE HEAD TRAUMA; BLOOD-VOLUME; MICROVASCULAR ALTERATIONS; HEMODYNAMIC DEPRESSION; CRANIOCEREBRAL TRAUMA; SEVERE SEPSIS; COAGULATION; RATS; COAGULOPATHY	OBJECTIVE: To determine the association between traumatic cerebral ischemia and intravascular thrombosis, a common finding after traumatic brain injury (TBI). METHODS: We reviewed samples of the frontal cortex and hippocampus from individuals who had sustained a fatal TBI Sections stained with hematoxylin and eosin were reviewed and rated for severity of selective neuronal necrosis (SNN). Because intravascular fibrin microthrombi may lyse within a few days of TBI, we restricted our analysis to patients who had died within 48 hours of injury. Medical records in all cases were reviewed to rule out severe or prolonged hypotension or hypoxemia. Eleven patients with severe or global SNN were compared with 11 patients in whom SNN was mild or absent. Slides adjacent to the hematoxylin and eosin sections were stained with an immunofluorescent antibody to antithrombin III and were reviewed for intravascular microthrombosis. The number of microthrombi on each slide was counted by an investigator blinded to the hematoxylin and eosin findings, and density of intravascular microthrombi was calculated. RESULTS: Intravascular microthrombi were noted in every section, excluding control (non-TBI) brain tissue. However, the density of microthrombi varied with the degree of SNN. We found a highly significant difference in the mean density of microthrombi between patients with severe SNN (7.74 +/- 3.7/cm(2)) and those with little or no SNN (2.58 +/- 1.0/cm(2)). Furthermore, a good correlation was noted between the location of intravascular microthrombi and that of SNN. CONCLUSION: These data support a strong link between intravascular microthrombosis and neuronal death after brain trauma in humans and may have important implications for new therapeutic approaches.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Glasgow, Dept Neuropathol, Glasgow G12 8QQ, Lanark, Scotland	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS38104] Funding Source: Medline		AUER RN, 1997, GREENFIELDS NEUROPAT, P263; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHURLIAEV IA, 2001, ANESTEZIOL REANIMAT, V6, P27; COCCHERI S, 1977, AGGREGATION PATHOGEN, P121; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Goodnight S H Jr, 1977, Compr Ther, V3, P25; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grenander A, 2001, J NEUROSURG ANESTH, V13, P49, DOI 10.1097/00008506-200101000-00010; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Hoots WK, 1997, SEMIN THROMB HEMOST, V23, P3; HOOTS WK, 1996, NEUROTRAUMA, P673; HUBER A, 1993, INT J LEGAL MED, V106, P152, DOI 10.1007/BF01225238; IIZUKA H, 1983, Neurological Surgery, V11, P765; IIZUKA H, 1984, Neurologia Medico-Chirurgica, V24, P696, DOI 10.2176/nmc.24.696; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Lee WL, 2000, INTENS CARE MED, V26, P1701, DOI 10.1007/s001340051349; Levi M, 2001, CRIT CARE MED, V29, pS90, DOI 10.1097/00003246-200107001-00028; Levi M, 2000, CRIT CARE MED, V28, pS20, DOI 10.1097/00003246-200009001-00005; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; Maeda T, 1997, ACT NEUR S, V70, P102; Manns BJ, 2002, NEW ENGL J MED, V347, P993, DOI 10.1056/NEJMsa020969; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1996, NEUROTRAUMA, P767; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schroder ML, 1998, ACT NEUR S, V71, P127; Steiger HJ, 1996, STROKE, V27, P2048, DOI 10.1161/01.STR.27.11.2048; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Takahashi H, 2000, J TRAUMA, V49, P86, DOI 10.1097/00005373-200007000-00013; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; ten Cate H, 2001, CRIT CARE MED, V29, pS95, DOI 10.1097/00003246-200107001-00030; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Ungerstedt JS, 2003, J NEUROSURG ANESTH, V15, P13, DOI 10.1097/00008506-200301000-00003; Utter GH, 2002, J TRAUMA, V52, P1071, DOI 10.1097/00005373-200206000-00008; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vallet B, 2001, CRIT CARE MED, V29, pS36, DOI 10.1097/00003246-200107001-00015; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; WATTS C, 1977, SURG NEUROL, V8, P258; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929	64	92	98	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2004	54	3					687	691		10.1227/01.NEU.0000108641.98845.88			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	802FN	WOS:000220149500047	15028145				2021-06-18	
J	Bonne, O; Gilboa, A; Louzoun, Y; Kempf-Sherf, O; Katz, M; Fishman, Y; Ben-Nahum, Z; Krausz, Y; Bocher, M; Lester, H; Chisin, R; Lerer, B				Bonne, O; Gilboa, A; Louzoun, Y; Kempf-Sherf, O; Katz, M; Fishman, Y; Ben-Nahum, Z; Krausz, Y; Bocher, M; Lester, H; Chisin, R; Lerer, B			Cerebral blood flow in chronic symptomatic mild traumatic brain injury	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						neuropsychological testing; SPECT; statistical parametric mapping; MTBI	HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; CONTUSION INDEX; CT; ABNORMALITIES; PERFORMANCE; MRI	Patients with mild traumatic brain injury (MTBI) (journal of Head Trauma and Rehabilitation, 8, 1993, 83-84) challenge physicians' skills and test their patience. Their manifold symptomatology is often not supported by objective neurological findings. We sought to compare regional cerebral blood flow (rCBF) between symptomatic subjects with longstanding MTBI and healthy controls, and to examine the correspondence between neuropsychological deficit and rCBF compromise. Twenty-eight clinically symptomatic male subjects with MTBI and twenty matched controls underwent neuropsychological testing and Tc-99m-HMPAO brain SPECT imaging. Neuropsychological test data were used to categorize subjects into sub-groups according to the presumed location of lesions based on their neurobehavioral deficits. Image subtraction comparisons were made between controls, all MTBI subjects and sub-groups. MTBI patients demonstrated regions of hypoperfusion in frontal, pre-frontal and temporal cortices, and sub-cortical structures. Hypoperfusion in 'frontal', 'left posterior' and to a lesser extent 'sub-cortical' sub-groups was concordant with neuropsychological localization. This was not the case for the 'right posterior' group, where no concordance was found. The rCBF is reduced in symptomatic patients with longstanding MTBI and unremarkable structural brain imaging. Although group analysis is appropriate for the generation of statistically significant differences, the clinical application of brain SPECT imaging in MTBI calls for a capability to associate clinical examination, neuropsychological assessment and cerebral perfusion at the individual subject level. Such competence is still to be attained. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.	NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA; Hadassah Univ Hosp, Dept Psychiat, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Nucl Med, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Unit Treatment & Rehabil Head Trauma Victims, Jerusalem, Israel	Bonne, O (corresponding author), NIMH, Mood & Anxiety Disorders Program, 15K North Dr,Room 200, Bethesda, MD 20892 USA.	bonneo@intra.nimh.nih.gov	louzoun, yoram/F-5874-2011	louzoun, yoram/0000-0003-1714-6148			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ADAMS RD, 1993, PRINCIPLES NEUROLOGY, P749; Baulieu F, 2001, J NEUROIMAGING, V11, P112, DOI 10.1111/j.1552-6569.2001.tb00020.x; BENSON DF, 1997, BEHAV NEUROLOGY NEUR, P401; Benton AL., 1974, REVISED VISUAL RETEN; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; BRADSHAW JL, 1981, BEHAV BRAIN SCI, V4, P51, DOI 10.1017/S0140525X00007548; Damasio H., 1989, LESION ANAL NEUROPSY; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; DUUS BR, 1994, ANN EMERG MED, V23, P1279, DOI 10.1016/S0196-0644(94)70352-3; First M., 1995, STRUCTURED CLIN INTE; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; FUSTER MY, 1996, NEUROPSYCHIATRY, P407; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HOOPER HE, 1981, HOOPER VISUAL ORG TE; ICHISE M, 1994, J NUCL MED, V35, P217; Jacobs A, 1996, J NUCL MED, V37, P1605; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Mesulam M., 2000, PRINCIPLES BEHAV COG; Meyers J., 1995, MEYERS SCORING SYSTE; *MILD TRAUM BRAIN, 1993, J HEAD TRAUMA REHAB, V8, P83; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Osterrieth PA, 1993, CLIN NEUROPSYCHOL, V7, P9; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; RAVEN JC, 1982, REVISED MANUAL RAVEN; RICHARDSON JTE, 1999, CLIN NEUROPSYCHOLOGI; RUSSELL EW, 1984, CLIN NEUROPSYCHOLOGY; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TALAIRACH J, 1988, ATLAS ANATOMIE STERE; TEASDALE G, 1974, LANCET, V2, P81; TIFFIN J, 1968, PURDUE PEG BOARD EXA; Umile EM, 1998, BRAIN INJURY, V12, P577; Vakil E, 1997, CLIN NEUROPSYCHOL, V11, P356, DOI 10.1080/13854049708400464; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WOODS RP, 1998, J COMPUT ASSIST TOMO, V22, P141	50	92	95	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	NOV 30	2003	124	3					141	152		10.1016/S0925-4927(03)00109-4			12	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	745VU	WOS:000186711900002	14623066				2021-06-18	
J	Maier, B; Schwerdtfeger, K; Mautes, A; Holanda, M; Muller, M; Steudel, WI; Marzi, I				Maier, B; Schwerdtfeger, K; Mautes, A; Holanda, M; Muller, M; Steudel, WI; Marzi, I			Differential release of interleukines 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury	SHOCK			English	Article						brain injury; cytokine; blood-brain barrier	ACUTE-PHASE RESPONSE; RAT-BRAIN; NERVOUS-SYSTEM; ORGAN FAILURE; CYTOKINES; BLOOD; INFLAMMATION; ASTROCYTES; INCREASE; BARRIER	Traumatic brain injury (TBI) is characterized by a high mortality which is largely determined by the initial cerebral trauma, secondary brain injury or indirectly during a Multiple Organ Dysfunction Syndrome (MODS). Therefore, we analyzed IL-6, IL-8, and IL-10 in cerebrospinal fluid (CSF) and in plasma with respect to blood-brain barrier (BBB) integrity in 29 patients suffering from isolated TBI. IL-6 and IL-8 were significantly increased compared to baseline levels early after trauma in CSF and plasma. In all patients CSF IL-6 and IL-8 were found to be higher than corresponding plasma levels. IL-10 in plasma was significantly increased above control plasma values, however, without a significant difference to the corresponding CSF values. BBB dysfunction was temporary present in 23 patients. Significant correlations between BBB dysfunction and cytokines were not found. Thus, alterations of the BBB seems not to influence the distribution pattern of interleukines in CSF and plasma after trauma.	Univ Saarland, Univ Hosp, Sch Med, Dept Trauma Hand & Reconstruct Surg, D-66421 Homburg, Germany; Univ Saarland, Univ Hosp, Sch Med, Dept Neurosurg, D-66421 Homburg, Germany; Univ Saarland, Univ Hosp, Sch Med, Dept Neurol, D-66421 Homburg, Germany	Marzi, I (corresponding author), Univ Frankfurt Klinikum, Dept Trauma Surg, D-60590 Frankfurt, Germany.	marzi@trauma-uni-frankfurt.de					ALOISI F, 1992, J IMMUNOL, V149, P2358; ARAUJO DM, 1993, BRAIN RES, V600, P49, DOI 10.1016/0006-8993(93)90400-H; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Aschner M, 1998, TOXICOL LETT, V103, P283, DOI 10.1016/S0378-4274(98)00324-5; BAGGIOLINI M, 1992, ADV IMMUNOL, V55, P55; BANKS WA, 1994, NEUROSCI LETT, V179, P53, DOI 10.1016/0304-3940(94)90933-4; BANKS WA, 1991, J PHARMACOL EXP THER, V259, P988; BAUE AE, 1994, SHOCK, V2, P385, DOI 10.1097/00024382-199412000-00001; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bell MJ, 1997, ACT NEUR S, V70, P96; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Ertel W, 1998, UNFALLCHIRURG, V101, P520, DOI 10.1007/s001130050304; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GORIS RJA, 1990, INTENS CARE MED, V16, pS192, DOI 10.1007/BF01709699; Handa Shoichi, 1992, Kurume Medical Journal, V39, P257; Heesen M, 1996, ACTA NEUROCHIR, V138, P77, DOI 10.1007/BF01411728; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; LOTAN M, 1994, FASEB J, V8, P1026; MAIER B, 1999, UNFALLCHIRURGIE, V25, P100; MCCLAIN C, 1991, J CLIN LAB MED, V118, P226; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Rose S, 1996, ZBL CHIR, V121, P896; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; TADA M, 1993, J NEURO-ONCOL, V16, P25, DOI 10.1007/BF01324831; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Woiciechowsky C, 1997, ACTA NEUROCHIR, V139, P619, DOI 10.1007/BF01411996; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	35	92	96	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUN	2001	15	6					421	426		10.1097/00024382-200115060-00002			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	433TX	WOS:000168776800002	11386612				2021-06-18	
J	Schneider, WN; Drew-Cates, J; Wong, TM; Dombovy, ML				Schneider, WN; Drew-Cates, J; Wong, TM; Dombovy, ML			Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study	BRAIN INJURY			English	Article							HEAD-INJURY; RECOVERY; SCALE	The objective of the current study was to determine the efficacy of amantadine in improving cognitive and behavioural performance in a traumatic brain injury (TBI) rehabilitation sample. The design was a prospective, randomized, double-blind, placebo-controlled, crossover design. Subjects were 10 adult traumatic brain injury patients in an acute brain injury rehabilitation unit. Subjects received a 2-week trail of amantadine or placebo, followed by a 2-week washout, then a 2-week trail of the alternative (placebo or amantadine). Neuropsychological outcome measures included orientation, attention, executive function, memory, orientation, behaviour, and a composite variable. Results of reheated measurer ANOVA and regression analysis of slope/change showed a main effect of rime, but no significant difference for amantadine versus placebo. In conclusion, although patients generally improved, this initial exploratory study found no differences in rate of cognitive improvement between subjects given amantadine versus those given placebo. However, the small sample size, heterogeneous population, acute time course, and large number of dependent variables limit power and generalizability. Implications are discussed for further research to better answer questions regarding efficacy of amantadine post-TBI.	St Marys Hosp, Unity Hlth Syst, Dept Phys Med & Rehabil, Rochester, NY 14611 USA; Univ Rochester, Dept Phys Med & Rehabil, Rochester, NY USA	Schneider, WN (corresponding author), St Marys Hosp, Unity Hlth Syst, Dept Phys Med & Rehabil, Rochester, NY 14611 USA.	wschneider@unityhealth.org					ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; ATKINSON WL, 1986, ARCH INTERN MED, V146, P1751, DOI 10.1001/archinte.146.9.1751; Benton AL., 1974, REVISED VISUAL RETEN; Bradley PB, 1989, INTRO NEUROPHARMACOL; Chandler M C, 1988, Brain Inj, V2, P309; CORRIGAN JD, 1995, NEUROREHABILITATION, V5, P205, DOI 10.3233/NRE-1995-5303; DILLER L, 1974, REHABILITATION MONOG, V50; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; GAULTIERI CT, 1988, BRAIN INJURY, V2, P273; GAULTIERI CT, 1991, NEUROPSYCHIATRY BEHA, P40; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Graham D. I., 1987, HEAD INJURY, P72; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Halstead WC, 1985, HALSTEAD REITAN NEUR; Kaplan E., 1983, BOSTON NAMING TEST; Kasamatusu T, 1981, J NEUROPHYSIOL, V45, P139; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; *MED EC CO, 1999, PHYS DESK REF, P986; *MMWR, 1987, JAMA-J AM MED ASSOC, V258, P599; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; *PURD RES FDN, 1948, EX MAN PURD PEGB; VANWOERKOM TCAM, 1977, LANCET, V1, P812; VECT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792; Wechsler D., 1987, WECHSLER MEMORY SCAL; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Zafonte RD, 1998, BRAIN INJURY, V12, P617; ZASLER N D, 1992, Brain Injury, V6, P1, DOI 10.3109/02699059209008117	33	92	98	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	1999	13	11					863	872					10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253FZ	WOS:000083547000003	10579658				2021-06-18	
J	Ferguson, RJ; Mittenberg, W; Barone, DF; Schneider, B				Ferguson, RJ; Mittenberg, W; Barone, DF; Schneider, B			Postconcussion syndrome following sports-related head injury: Expectation as etiology	NEUROPSYCHOLOGY			English	Article							SYMPTOMS; TRAUMA; CONCUSSION	Mild head trauma is often complicated by a persistent set of symptoms known as postconcussion syndrome (PCS). Past research has suggested that an expectancy-guided, retrospective-recall bias may account for much of the variance in PCS symptom reporting. The present study examined the influence of symptom expectations on mild head trauma symptom reports among participants in contact sports. Head-injured athletes reported symptom rates that did not differ from those of uninjured athletes but consistently underestimated the preinjury incidence of symptoms. Athletes with no head trauma history overestimated the expected degree of pre- to postinjury change in symptom status. Results suggest that individuals with mild head injury tend to overestimate postconcussion symptom change in a manner consistent with their symptom expectations. A cognitive-behavioral model that explains the persistence of PCS is proposed.	Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Behav Med Sect, Dept Psychiat, Lebanon, NH 03756 USA; Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA	Ferguson, RJ (corresponding author), Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Behav Med Sect, Dept Psychiat, Lebanon, NH 03756 USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barth JT., 1989, MILD HEAD INJURY, P257; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CONWAY M, 1984, J PERS SOC PSYCHOL, V47, P738, DOI 10.1037/0022-3514.47.4.738; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Cook J. B, 1969, LATE EFFECTS HEAD IN, P408; Davis CH, 1999, ARCH CLIN NEUROPSYCH, V14, P28, DOI 10.1093/arclin/14.1.28a; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Farber M, 1994, SPORTS ILLUSTRATED, p[38, 39, 46]; Ferguson R. J., 1996, SOURCEBOOK PSYCHOL T, P615; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1975, LANCET, V2, P995; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; HIRT ER, 1990, J PERS SOC PSYCHOL, V58, P937, DOI 10.1037/0022-3514.58.6.937; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 1989, MILD HEAD INJURY; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LINTON SJ, 1982, PAIN, V13, P281, DOI 10.1016/0304-3959(82)90017-3; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MCFARLAND C, 1989, J PERS SOC PSYCHOL, V57, P522, DOI 10.1037/0022-3514.57.3.522; MCFARLAND C, 1992, J PERS SOC PSYCHOL, V5, P837; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSS M, 1989, PSYCHOL REV, V96, P341, DOI 10.1037/0033-295X.96.2.341; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; WILLIAMS CW, 1993, J SOC BEHAV PERS, V8, P489; World Health Organization, 1992, ICD 10 CLASS MENT BE; WRIGHTSON P, 1989, MILD HEAD INJURY, P245	45	92	95	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	1999	13	4					582	589		10.1037/0894-4105.13.4.582			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	244DC	WOS:000083035700013	10527067				2021-06-18	
J	Gale, SD; Hopkins, RO; Weaver, LK; Bigler, ED; Booth, EJ; Blatter, DD				Gale, SD; Hopkins, RO; Weaver, LK; Bigler, ED; Booth, EJ; Blatter, DD			MRI, quantitative MRI, SPECT, and neuropsychological findings following carbon monoxide poisoning	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; TOMOGRAPHY; DEPRESSION; ENCEPHALOPATHY; INTOXICATION; INTELLIGENCE; SEQUELAE; DEATHS; SLEEP; COPD	Carbon monoxide (CO) poisoning has been shown to result in neuropathologic changes and cognitive impairments due to anoxia and other related biochemical mechanisms. The present study investigated brain-behaviour relationships between neuropsychological outcome and SPECT, MRI, and Quantitative magnetic resonance imaging (QMRI) in 21 patients with CO poisoning. Ninety-three per cent of the patients exhibited a variety of cognitive impairments, including impaired attention, memory, executive function, and mental processing speed. Ninety-five per cent of the patients experienced affective changes including depression and anxiety. The results from the imaging studies revealed that 38% of the patients had abnormal clinical MRI scans, 67% had abnormal SPECT scans, and 67% had QMRI findings including hippocampal atrophy and/or diffuse cortical atrophy evidenced by an enlarged ventricle-to-brain ratio (VBI). Hippocampal atrophy was also found on QMRI. SPECT and QMRI appear to be sensitive tools which can be used to identify the neuropathological changes and cerebral perfusion defects which occur following CO poisoning. Cerebral perfusion defects include frontal and temporal lobe hypoperfusion. Significant relationships existed between the various imaging techniques and neuropsychological impairments. The data from this study indicate that a multi-faceted approach to clinical evaluation of the neuropathological and neurobehavioural changes following CO poisoning may provide comprehensive information regarding the neuroanatomical and neurobehavioural effects of CO poisoning.	Latter Day St Hosp, Dept Med, Crit Care Div, Salt Lake City, UT 84143 USA; Brigham Young Univ, Provo, UT 84602 USA; Univ Virginia, Charlottesville, VA 22903 USA	Hopkins, RO (corresponding author), Latter Day St Hosp, Dept Med, Crit Care Div, 8th Ave & C St, Salt Lake City, UT 84143 USA.		Gale, Shawn/M-3144-2013	Gale, Shawn/0000-0002-8989-0964			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARGER SD, 1991, UNDERSEA BIOMEDICA S, V18, P33; Beck A.T., 1993; Beck A.T., 1987, BECK DEPRESSION INVE; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; CHANG KH, 1992, RADIOLOGY, V184, P117, DOI 10.1148/radiology.184.1.1609067; CHAPEL JL, 1978, PSYCHIAT OPINION MAR, P33; CHOI J, 1992, J KOREAN MED SCI, V7, P11; CHOI S, 1993, J KOREAN MED SCI, V8, P78; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; DEREUCK J, 1993, J NEUROL, V240, P430; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; FASCHINGBAUER TR, 1974, J CONSULT CLIN PSYCH, V42, P645, DOI 10.1037/h0037049; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GARLAND H, 1967, Q J MED, V36, P445; GIFT AG, 1993, HEART LUNG, V22, P289; GRAY BG, 1996, J NUCL MED, V37, P1605; GROLLKNAPP E, 1982, NEUROBEH TOXICOL TER, V4, P709; Guilleminault C., 1978, SLEEP APNEA SYNDROME, P1; HAMPSON NB, 1997, UNDERSEA HYPERBARI S, V24, P21; Heaton R.K., 1991, COMPREHENSIVE NORMS; Hopkins R., 1993, UNDERSEA HYPERBAR M, V20, P15; Hopkins R O, 1995, J Int Neuropsychol Soc, V1, P501; HOPKINS RO, 1991, UNDERSEA BIOMED RES, V18, P34; HOPKINS RO, 1997, UNDERSEA HYPERBAR M, V24, P20; HOPKINS RO, 1994, J INT NEUROPSYCH SOC, V2, P454; JACOB H, 1939, NEUROLOGIE PSYCHIAT, V139, P161; JAECKLE RS, 1985, J NERV MENT DIS, V173, P503, DOI 10.1097/00005053-198508000-00009; Jain K. K., 1990, CARBON MONOXIDE POIS; JARRARD LE, 1993, NEUROPATH APPL NEURO, V19, P381, DOI 10.1111/j.1365-2990.1993.tb00458.x; JEFFERSON JW, 1976, AM J PSYCHIAT, V133, P961; KALES A, 1985, J CHRON DIS, V38, P427, DOI 10.1016/0021-9681(85)90138-9; KELLY D A, 1990, Neuropsychology Review, V1, P323, DOI 10.1007/BF01109028; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LIGHT RW, 1985, CHEST, V87, P35, DOI 10.1378/chest.87.1.35; Mathieu D, 1996, UNDERSEA HYPERBAR M, V23, P7; *MAY FDN, 1993, BIOM IM RES ANALYZE; MYERS RAM, 1985, ANN EMERG MED, V14, P1163, DOI 10.1016/S0196-0644(85)81022-2; NABESHIMA T, 1991, J PHARMACOL EXP THER, V256, P378; NAUGLE RI, 1998, INTRO CLIN NEUROPSYC; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; OKEDA R, 1981, ACTA NEUROPATHOL, V54, P1, DOI 10.1007/BF00691327; PIANTADOSI CA, 1987, J HYPERBARIC MED, V2, P27; Piantidosi CA, 1995, UNDERSEA HYPERBAR M, V22, P15; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; PRIGATANO GP, 1983, J CONSULT CLIN PSYCH, V51, P108, DOI 10.1037/0022-006X.51.1.108; RAPHAEL JC, 1989, LANCET          0819, P414; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; SMITH JS, 1973, BRIT MED J, V1, P318, DOI 10.1136/bmj.1.5849.318; THOM SR, 1993, TOXICOL APPL PHARM, V123, P234, DOI 10.1006/taap.1993.1242; THOM SR, 1990, J APPL PHYSIOL, V68, P997; THOM SR, ANN EMERGENCY MED, V23, P3; Tom T, 1996, J NEUROIMAGING, V6, P161, DOI 10.1111/jon199663161; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson J, 1996, J NUCL MED, V37, P1256; YELLOWLEES PM, 1987, MED J AUSTRALIA, V146, P305, DOI 10.5694/j.1326-5377.1987.tb120267.x; Yoon SS, 1998, JAMA-J AM MED ASSOC, V279, P685, DOI 10.1001/jama.279.9.685	66	92	95	0	10	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1999	13	4					229	243		10.1080/026990599121601			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	186RH	WOS:000079742400002	10230524				2021-06-18	
J	O'Dell, MW; Barr, K; Spanier, D; Warnick, RE				O'Dell, MW; Barr, K; Spanier, D; Warnick, RE			Functional outcome of inpatient rehabilitation in persons with brain tumors	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	American-Academy-of-Physical-Medicine-and-Rehabilitation Annual Assembly	SEP 11-12, 1996	CHICAGO, ILLINOIS	Amer Acad Phys Med & Rehabil			MALIGNANT CEREBRAL GLIOMA; QUALITY-OF-LIFE; INDEPENDENCE MEASURE; CANCER REHABILITATION; STROKE; RADIOTHERAPY; DISABILITY; SURVIVAL; SURGERY	Objective: To document functional outcome in persons with brain tumors undergoing inpatient rehabilitation and to compare outcomes with a group of traumatically brain injured patients. Design: Retrospective, descriptive, and case-matched. Setting: A free-standing inpatient brain injury rehabilitation unit. Participants: Forty consecutive patients with a variety of tumor types (40% were either glioblastoma multiforme or meningioma) and a mean age of 53.1 (SD 15.4) years. Sixty percent were men, 25% had recurrent tumors, and 15% had metastatic disease. Also, 40 patients with traumatic brain injury (TBI) matched for age, gender, and admission functional status. Main Outcome Measures: Change in Functional Independence Measure (FIM) scores, length of rehabilitation stay (LOS) and discharge disposition. Results: The mean LOS for the tumor group was 17.8 (SD 9.9) days, mean FIM gain was 25.4 (SD 20.1) points, and 82.5% were discharged home. No demographic or tumor characteristic was statistically significant in predicting functional outcome at discharge, but greater gains were seen for persons with the diagnosis of meningioma, those with left-sided cerebral lesions, and those not receiving radiation therapy. TBI patients made statistically significant greater gains in total FIM change (34.6 vs 25.4), self-care (12.3 vs 8.5), and social cognition (5.2 vs 3.6). However, FIM efficiency and LOS were not statistically different between the TBI and tumor groups (1.9 vs 1.5 FIM points/day and 22.1 vs 17.8 days, respectively). Conclusions: Daily functional gains made by persons with brain tumor undergoing rehabilitation were similar to those made by a group of persons with TBI matched by age, gender, and admission functional status. Further research should use larger samples and address the impact of psychosocial and team factors on LOS and discharge disposition. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine aad Rehabilitation.	Univ Cincinnati, Coll Med, Dept Phys Med & Rehabil, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Mayfield Clin, Cincinnati, OH USA	O'Dell, MW (corresponding author), Southside Hosp, Brain Injury Rehabil Program, 2440 Brackett Bldg,301 E Main St, Bay Shore, NY 11706 USA.						ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; Batchelor T, 1996, NEUROSURG CLIN N AM, V7, P435; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS37, DOI 10.1016/S0003-9993(98)90120-4; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; Chae J, 1996, AM J PHYS MED REHAB, V75, P177, DOI 10.1097/00002060-199605000-00004; Clinchot DM, 1997, ARCH PHYS MED REHAB, V78, P346, DOI 10.1016/S0003-9993(97)90223-9; Culver KW, 1996, BONE MARROW TRANSPL, V18, pS6; Davies E, 1996, BRIT MED J, V313, P1507, DOI 10.1136/bmj.313.7071.1507; Davies E, 1996, BMJ-BRIT MED J, V313, P1512, DOI 10.1136/bmj.313.7071.1512; ELOVIC E, 1996, MED REHABILITATION T, P1; Fernandez-Vicioso E, 1997, Radiat Oncol Investig, V5, P31, DOI 10.1002/(SICI)1520-6823(1997)5:1<31::AID-ROI5>3.0.CO;2-L; GANZ PA, 1990, CANCER, V65, P742, DOI 10.1002/1097-0142(19900201)65:3+<742::AID-CNCR2820651319>3.0.CO;2-P; GARDEN FH, 1996, TXB PHYSICAL MED REH, P1199; Gerber Lynn, 1997, P2925; GREENBURG MS, 1997, HDB NEUROSURGERY; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HUANG ME, 1997, ARCH PHYS MED REHAB, V78, P1054; LEHMANN JF, 1978, ARCH PHYS MED REHAB, V59, P410; Levinson SF, 1993, REHABILITATION MED P, P916; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Marciniak CM, 1996, ARCH PHYS MED REHAB, V77, P54, DOI 10.1016/S0003-9993(96)90220-8; MELLETTE SJ, 1994, SEMIN ONCOL, V21, P779; Meyers C A, 1990, Oncology (Williston Park), V4, P115; Meyers Christina A., 1993, Cancer Bulletin (Houston), V45, P362; Nussbaum ES, 1996, CANCER-AM CANCER SOC, V78, P1781, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U; Poduri KR, 1996, INT J REHABIL RES, V19, P327, DOI 10.1097/00004356-199612000-00005; REIS LA, 1991, CANC STAT REV 1973 1; Ring H, 1997, ARCH PHYS MED REHAB, V78, P630, DOI 10.1016/S0003-9993(97)90429-9; Scheibel RS, 1996, J NEURO-ONCOL, V30, P61; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; SIPOS EP, 1995, NEUROL CLIN, V13, P813, DOI 10.1016/S0733-8619(18)30019-7; *STAT, 1992, AN SOFTW 4 0; Stewart-Amidei C, 1995, Crit Care Nurs Clin North Am, V7, P125; Takakura K, 1982, METASTATIC TUMORS CE; Weitzner MA, 1996, J NEUROSURG, V84, P29, DOI 10.3171/jns.1996.84.1.0029; Weitzner MA, 1996, BAILLIERE CLIN NEUR, V5, P425; WEN PY, 1995, NEUROL CLIN, V13, P875, DOI 10.1016/S0733-8619(18)30023-9; Whitton AC, 1997, CANCER, V80, P258, DOI 10.1002/(SICI)1097-0142(19970715)80:2<258::AID-CNCR14>3.0.CO;2-T	39	92	92	1	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1998	79	12					1530	1534		10.1016/S0003-9993(98)90414-2			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	146GW	WOS:000077421800007	9862294				2021-06-18	
J	Burleigh, SA; Farber, RS; Gillard, M				Burleigh, SA; Farber, RS; Gillard, M			Community integration and life satisfaction after traumatic brain injury: Long-term findings	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article; Proceedings Paper	Annual Conference of the American-Occupational-Therapy-Association	APR   13, 1997	ORLANDO, FLORIDA	Amer Occupat Therapy Assoc		head injuries; quality of life; social adjustment	HEAD-INJURY; IMPAIRMENT; REHABILITATION; REINTEGRATION; DISABILITY; HANDICAP; INDEX	Objective. This study examines the relationship of the degree of community integration to the life satisfaction of persons with traumatic brain injury (TBI). Method. The responses to two self-administered questionnaires measuring aspects of community integration and life satisfaction were studied for 30 persons with TBI who were 26 to 60 years of age. Results. A significant relationship (rho = .37, p < .05) was found between life satisfaction and social integration (a component of community integration), No significant association was found between the total community integration score and life satisfaction. Conclusion. The results suggest the need for rehabilitation programs to provide long-term assistance with community-based social integration as well as more effective treatment strategies to develop these skills in persons with TBI.	ReMed Recovery Care Ctr, Bryn Mawr, PA 19010 USA; Temple Univ, Coll Allied Hlth Profess, Dept Occupat Therapy, Philadelphia, PA 19122 USA	Burleigh, SA (corresponding author), ReMed Recovery Care Ctr, 780 W Lancaster Ave,Suite 103, Bryn Mawr, PA 19010 USA.						ADAMS DL, 1969, J GERONTOL, V24, P470, DOI 10.1093/geronj/24.4.470; Andrews F. M., 1976, SOCIAL INDICATORS WE; Condeluci A., 1992, J HEAD TRAUMA REHAB, V7, P37; Di Donato B A, 1994, Rehabil Nurs, V19, P219; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; JACKSON JD, 1994, AM J OCCUP THER, V48, P251, DOI 10.5014/ajot.48.3.251; JENNETT B, 1976, LANCET, V1, P1031; JOHNSTON MV, 1994, ARCH PHYSICAL MED RE, V75, P2; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LARSON RJ, 1974, J GERONTOL, V28, P109; LOHMANN N, 1977, J GERONTOL, V32, P73, DOI 10.1093/geronj/32.1.73; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MATTINGLY C, 1991, AM J OCCUP THER, V45, P979, DOI 10.5014/ajot.45.11.979; MCDOWELL I, 1987, MEASURING HLTH GUIDE, P204; *NAT HEAD INJ FDN, 1995, BAS QUEST BRAIN INJ; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; *NIH, 1990, NAT I NEUR DIS STROK; *NIH, 1993, NIH PUBL; OAKLEY F, 1982, THESIS VIRGINIA COMM; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OKUN MA, 1984, INT J AGING HUM DEV, V19, P111, DOI 10.2190/QGJN-0N81-5957-HAQD; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; REILLY M, 1969, AM J OCCUP THER, V23, P299; SCHAAF SV, 1992, NEWSLETTER NATL HEAD, V11, P9; STRAX TE, 1994, ARCH PHYSICAL MED RE, V75, P1; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITENECK GG, 1994, ARCH PHYSICAL MED RE, V73, P1073; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1993, BRAIN INJURY REHABIL, P355; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; World Health Organization, 1980, INT CLASS IMP DIS HA	38	92	92	1	3	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	JAN	1998	52	1					45	52		10.5014/ajot.52.1.45			8	Rehabilitation	Rehabilitation	YL778	WOS:000070991900006	9426858				2021-06-18	
J	DeWitt, DS; Smith, TG; Deyo, DJ; Miller, KR; Uchida, T; Prough, DS				DeWitt, DS; Smith, TG; Deyo, DJ; Miller, KR; Uchida, T; Prough, DS			L-arginine and superoxide dismutase prevent or reverse cerebral hypoperfusion after fluid-percussion traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral circulation; free radicals; head trauma; ischemia; L-arginine; laser Doppler; nitric oxide	BLOOD-FLOW; NITRIC-OXIDE; RELAXING FACTOR; HEAD-INJURY; ARTERY OCCLUSION; RAT; INHIBITION; ISCHEMIA; DAMAGE; MICROCIRCULATION	To determine whether treatment with L-arginine or superoxide dismutase (SOD) would prove effective in reducing cerebral hypoperfusion after traumatic brain injury (TBI), we measured cerebral blood flow (CBF) using laser Doppler flowmetry (LDF) in rats treated before or after moderate (2.2 atm) fluid-percussion (FP) TBI. Rats were anesthetized with isoflurane and prepared for midline FP TBI and then for LDF by thinning the calvaria using an air-cooled drill. Rats were then randomly assigned to receive sham injury, sham injury plus L-arginine (100 mg/kg, 5 min after sham TBI), TBI plus 0.9 % NaCl, TBI plus L-arginine (100 mg/kg, 5 min post-TBI), TBI plus SOD (24,000 U/kg pre-TBI + 1600 units/kg/min for 15 min after TBI), or TBI plus SOD and L-arginine. A second group of rats received TBI plus saline, L-, or D-arginine (100 mg/kg, 5 min after-TBI). After treatment and TBI or sham injury, CBF was measured continuously using LDF for 2 h and CBF was expressed as a percent of the preinjury baseline for 2 h after TBI. Rats treated with saline or D-arginine exhibited significant reductions in CBF that persisted throughout the monitoring period. Rats treated with L-arginine alone or in combination with SOD exhibited no decreases in CBF after TBI. CBF in the SOD-treated group decreased significantly within 15 min after TBI but returned to baseline levels by 45 min after TBI. These studies indicate that L-arginine but not D-arginine administered after TBI prevents posttraumatic hypoperfusion and that pretreatment with SOD will restore CBF after a brief period of hypoperfusion.	UNIV TEXAS, MED BRANCH, DEPT PREVENT MED & COMMUNITY HLTH, GALVESTON, TX 77555 USA	DeWitt, DS (corresponding author), UNIV TEXAS, MED BRANCH, DEPT ANESTHESIOL, CHARLES R ALLEN RES LABS, GALVESTON, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [19355] Funding Source: Medline		ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BECKMAN JS, 1994, PROG BRAIN RES, V103, P371; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BECKMAN JS, 1991, J CEREB BLOOD FLO S2, V11, pS629; BONVENTO G, 1994, J CEREBR BLOOD F MET, V14, P699, DOI 10.1038/jcbfm.1994.90; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Crow J P, 1995, Adv Pharmacol, V34, P17; DEWITT D S, 1992, Anesthesiology (Hagerstown), V77, pA689, DOI 10.1097/00000542-199209001-00689; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; FARACI FM, 1991, AM J PHYSIOL, V261, pH1038; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HABERL RL, 1989, AM J PHYSIOL, V256, pH1247; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; KOZNIEWSKA E, 1992, J CEREBR BLOOD F MET, V12, P311; Langfitt T W, 1981, Prog Neurol Surg, V10, P14, DOI 10.1159/000384767; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MILLER JD, 1990, BRIT J SURG, V77, P241, DOI 10.1002/bjs.1800770302; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Morita K, 1996, ANN THORAC SURG, V61, P1775, DOI 10.1016/0003-4975(96)00146-4; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ODLIND B, 1988, PHARMACOL TOXICOL, V62, P95, DOI 10.1111/j.1600-0773.1988.tb01853.x; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; Prado R, 1996, J CEREBR BLOOD F MET, V16, P612, DOI 10.1097/00004647-199607000-00011; REYES AA, 1994, AM J PHYSIOL, V267, pF331; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822; SZABO C, 1994, CIRC SHOCK, V44, P104; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; YUAN XQ, 1989, J NEUROTRAUMA, V6, P211; ZHANG ZG, 1995, J NEUROL SCI, V128, P22, DOI 10.1016/0022-510X(94)00216-B	50	92	93	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1997	14	4					223	233		10.1089/neu.1997.14.223			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WY593	WOS:A1997WY59300005	9151771				2021-06-18	
J	Togher, L; Hand, L; Code, C				Togher, L; Hand, L; Code, C			Analysing discourse in the traumatic brain injury population: Telephone interactions with different communication partners	BRAIN INJURY			English	Article							HEAD-INJURY; ADULTS; LANGUAGE; DEFICITS; SKILLS	A range of discourse analyses are effective in identifying features which are aberrant following traumatic brain injury (TBI). We examined the exchanges of five traumatically brain-injured subjects and five matched controls across four speaking situations which included speaking to a therapist, to the bus timetable information service, to the police, and to their mothers on the telephone. Transcripts were analysed using the exchange structure analysis of systemic functional grammar. This analysis provided an indication of information giving (K1 moves per minute), information requesting and receiving (K2 moves per minute) and the amount of negotiation that was needed for the messages to be conveyed (dynamic moves per minute). Results indicated that the TBI subjects performed differently across the four conditions, and were differentiated from the matched controls on a number of measures. The role of different communication partners is also addressed. Communication partners were noted to interact differently with TBI subjects when compared with controls. This included increased information-giving to control subjects; more requests for information by police from TBI subjects and a greater use of dynamic moves by therapists with controls. The potential of exchange structure analysis is discussed as a useful way of examining the discourse of TBT subjects and their communication partners. Exchange structure analysis highlighted the dynamic nature of information exchange and the subtle ways speakers responded to familiarity and power imbalance in social interaction. This study has implications for family and community education regarding communication with people with TBI.	LIVERPOOL AREA HLTH SERV,BRAIN INJURY UNIT,SYDNEY,NSW,AUSTRALIA; UNIV SYDNEY,FAC HLTH SCI,SCH COMMUNICAT DISORDERS,SYDNEY,NSW 2006,AUSTRALIA	Togher, L (corresponding author), UNIV SYDNEY,FAC HLTH SCI,BRAIN DAMAGE & COMMUNICAT RES,POB 170,LIDCOMBE,NSW 2141,AUSTRALIA.		Togher, Leanne/AAC-7083-2019; Code, Chris/F-4259-2010				ADAMOVITCH BLB, AM J SPEECH LANGUAGE, P39; Berry M., 1981, STUDIES DISCOURSE AN, P120; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Cameron Deborah, 1989, WOMEN THEIR SPEECH C, P74; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Fairclough N., 1992, DISCOURSE SOCIAL CHA; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Giles G M, 1988, Brain Inj, V2, P75, DOI 10.3109/02699058809150933; Glosser G., 1990, BRAIN LANG, V40, P67; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY LL, 1990, NEUROPSYCHOLOGY EVER, P135; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KENNEDY MRT, 1991, COMMUNICATION DISORD, P123; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; MILTON SB, 1988, J HEAD TRAUMA REHAB, V3, P1; OBARR WM, 1987, LANG COMMUN, P205; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; Penn C, 1988, Brain Inj, V2, P3, DOI 10.3109/02699058809150928; POYNTON C, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Rimel RW, 1990, REHABILITATION ADULT, P8; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; SILVAST M, 1991, APHASIOLOGY, V5, P383, DOI 10.1080/02687039108248540; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THWAITES A, THESIS U SYDNEY SYDN; VENTOLA E, STRUCTURE SOCIAL INT	40	92	95	0	13	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR	1997	11	3					169	189		10.1080/026990597123629			21	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WL158	WOS:A1997WL15800002	9057999				2021-06-18	
J	Kinsella, G; Murtagh, D; Landry, A; Homfray, K; Hammond, M; OBeirne, L; Dwyer, L; Lamont, M; Ponsford, J				Kinsella, G; Murtagh, D; Landry, A; Homfray, K; Hammond, M; OBeirne, L; Dwyer, L; Lamont, M; Ponsford, J			Everyday memory following traumatic brain injury	BRAIN INJURY			English	Article							FUNCTIONING QUESTIONNAIRE; TEST-PERFORMANCE; IMPAIRMENT; COMPLAINT; DEFICITS	Residual memory deficits may represent a problem to the everyday functioning of a large number of people, including those who have sustained traumatic brain injury (TBI). The present exploratory study sought to investigate the interrelationships between subjective memory reports, performance on traditional memory tests, and performance on tests of prospective memory. These interrelationships were contrasted between a group of 24 adults who had sustained TBI and a group of 24 matched control subjects. Prospective memory was hypothesized to be indicative of everyday memory functioning. The results provided preliminary evidence that prospective memory tests are sensitive to TBI-related neurological impairment and, in comparison to traditional tests, may be better indicators of functional memory capacity. This pattern was particularly true for control subjects, possibly because TBI subjects had difficulties in evaluating their memory functioning.	ALBURY BASE HOSP,COGNIT REHABIL PROGRAMME,ALBURY,NSW,AUSTRALIA; BETHESDA HOSP,DEPT PSYCHOL,RICHMOND,VIC,AUSTRALIA	Kinsella, G (corresponding author), LA TROBE UNIV,SCH PSYCHOL,BUNDOORA,VIC 3083,AUSTRALIA.		Murtagh, Donal/F-8694-2011; Kinsella, Glynda/O-6347-2017	Murtagh, Donal/0000-0003-1539-3559; Kinsella, Glynda/0000-0002-5859-0934			BADDELEY A, 1982, ALZHEIMERS DISEASE R, P141; BARBA GD, 1993, HDB NEUROPSYCHOLOGY, V8, P239; BROWN FH, 1991, J CLIN PSYCHOL, V47, P772, DOI 10.1002/1097-4679(199111)47:6<772::AID-JCLP2270470607>3.0.CO;2-P; CROSSEN JR, 1988, CLIN NEUROPSYCHOL, V2, P393; DOBBS AR, 1987, CAN J PSYCHOL, V41, P209, DOI 10.1037/h0084152; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; GILEWSKI MJ, 1986, HDB CLIN MEMORY ASSE, P93, DOI DOI 10.1037/10057-008; Goldstein G., 1992, NEUROPSYCHOL REHABIL, V2, P307, DOI [DOI 10.1080/09602019208401416, 10.1080/09602019208401416]; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; KAHN RL, 1975, ARCH GEN PSYCHIAT, V32, P1569; LARRABEE GJ, 1991, J CLIN EXP NEUROPSYC, V13, P466, DOI 10.1080/01688639108401064; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Rey A, 1964, EXAMEN CLIN PSYCHOL; Schacter D. L., 1990, NEUROPSYCHOLOGY EVER, P231; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Stuss D.T., 1986, FRONTAL LOBES; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; ZELINSKI EM, 1990, PSYCHOL AGING, V5, P388, DOI 10.1037/0882-7974.5.3.388; Zelinski EM, 1980, NEW DIRECTIONS MEMOR, P519	26	92	93	1	25	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1996	10	7					499	507		10.1080/026990596124214			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UU819	WOS:A1996UU81900003	8806010				2021-06-18	
J	RUBIN, AM; WOOLLEY, SM; DAILEY, VM; GOEBEL, JA				RUBIN, AM; WOOLLEY, SM; DAILEY, VM; GOEBEL, JA			POSTURAL STABILITY FOLLOWING MILD HEAD OR WHIPLASH INJURIES	AMERICAN JOURNAL OF OTOLOGY			English	Article							BRAIN INJURY; BALANCE; DEFICITS	Studies of the sequelae of head injury suggest that cochlear and vestibular dysfunctions comprise some of the most frequently reported delayed complications following head trauma. To date, little attention has been given to the relation between post-traumatic subjective symptoms of dizziness and the objective measures of postural stability or balance. The purpose of this study was to quantify the balance deficits in individuals who had developed symptoms of dizziness following mild head and whiplash injuries. The balance abilities of 29 patients, who developed dizziness following some type of mild head or whiplash injury, were compared to those of 51 healthy symptom-free subjects. Balance was assessed by examining the center-of-pressure movements, in the anterior-posterior and medial-lateral directions, and the total movement displacement. The isolated contributions of visual and somatosensory inputs were estimated by comparing the magnitudes of the center-of-pressure movements for the various sensory conditions. Data were collected from three 30-second trials of each combination of three visual conditions (accurate, absent, and inaccurate) and two somatosensory conditions (accurate and inaccurate), with the patient standing on a fixed-force platform. Univariate analyses of variance indicated that the group with head injury, compared to the control group, exhibited significantly greater anterior-posterior movements in four of the six sensory conditions and greater total movement displacement during the inaccurate vision/inaccurate somatosensation condition. These data suggest that patients who have sustained head or neck trauma exhibit increased reliance on accurate visual input and are unable to utilize internal vestibular orienting information to resolve conflicting information from the visual and somatosensory systems.	MED COLL OHIO,DEPT OTOLARYNGOL HEAD & NECK SURG,TOLEDO,OH 43699; MED COLL OHIO,DEPT PHYS MED & REHABIL,MOT ANAL LAB,TOLEDO,OH 43699; WASHINGTON UNIV,SCH MED,DEPT OTOLARYNGOL,ST LOUIS,MO 63110							BARBER HO, 1969, ANN OTO RHINOL LARYN, V78, P239, DOI 10.1177/000348946907800204; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROWN JJ, 1990, NEUROL CLIN, V8, P209, DOI 10.1016/S0733-8619(18)30351-7; CAVENESS WF, 1979, ADV NEUROL, P1; DROULEZ J, 1985, VESTIBULAR VISUAL CO, P14; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; HOUGH JVD, 1980, OTOLARYNGOLOGY, P1956; KIRTANE MV, 1982, J LARYNGOL OTOL, V96, P521, DOI 10.1017/S0022215100092793; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1987, HEAD INJURY, P1; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1989, P AM PHYS THER ASS F, P5; NEWTON RA, 1990, P APTAFORUM NASHVILL, P69; PEARSON BW, 1973, ARCH OTOLARYNGOL, V97, P81; RUBIN W, 1973, ARCH OTOLARYNGOL, V97, P85; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; WARD PH, 1969, ANN OTO RHINOL LARYN, V78, P227, DOI 10.1177/000348946907800203; WILLSON GN, 1981, J LARYNGOL OTOL, V95, P1213, DOI 10.1017/S0022215100092057; WOOLLEY SM, 1993, J OTOLARYNGOL, V22, P368	25	92	94	0	5	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0192-9763			AM J OTOL	Am. J. Otol.	MAR	1995	16	2					216	221					6	Otorhinolaryngology	Otorhinolaryngology	QK481	WOS:A1995QK48100016	8572122				2021-06-18	
J	GOODMAN, JC; CHERIAN, L; BRYAN, RM; ROBERTSON, CS				GOODMAN, JC; CHERIAN, L; BRYAN, RM; ROBERTSON, CS			LATERAL CORTICAL IMPACT INJURY IN RATS - PATHOLOGICAL EFFECTS OF VARYING CORTICAL COMPRESSION AND IMPACT VELOCITY	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; DIFFUSE AXONAL INJURY; HEAD-INJURY; NEUROFILAMENT SUBUNITS; VASCULAR DISRUPTION; DAMAGE; INDEX; CAT	Direct lateral cortical impact through the intact leptomeninges using a pneumatically driven piston produces increasingly severe pathophysiologic derangements with increasing cortical deformation. We studied the histopathologic correlates of cortical impact injury produced by 2 mm, 2.5 mm, and 3 mm deformation in the rat at 5 m/sec. Additionally, the effect of impact velocity at a 2.5 mm deformation was assessed at 1 m/sec, 3 m/sec, and 5 m/sec. The brains were examined 14 days after injury. Cortical contusion maximum cross-sectional area, volume, and the percentage CA1 and CA3 hippocampal neuronal loss correlate with cortical deformation and impactor velocity. Contusion volume increased with increasing cortical deformation. Deformations of 2, 2.5, and 3 mm at 5 m/sec produced contusion volumes of 4.59, 8.9, and 21.68 mm(3), respectively. At a fixed cortical deformation of 2.5 mm, contusion volume increased with increasing impact velocity. Impact velocities of 1, 3, and 5 m/sec produced contusion volumes of 5.79, 7.42, and 8.9 mm(3), respectively. Hippocampal CA3 neuronal loss increased with increasing cortical deformation. Deformations of 2, 2.5, and 3 mm at 5 m/sec produced neuronal loss of 29%, 48.3%, and 79.5%, respectively. At a fixed cortical deformation of 2.5 mm, hippocampal CA3 neuronal loss increased with increasing impact velocity. Impact velocities of 1, 3, and 5 m/sec produced neuronal loss of 18.25%, 33.75%, and 48.3%, respectively. Hippocampal CA1 neuronal loss was also seen and paralleled cortical deformation and impact velocity. Cortical deformation and impact velocity are critical parameters in producing cortical contusion and must be considered when comparing results using this model.	BAYLOR COLL MED, DEPT NEUROSURG, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT ANESTHESIOL, HOUSTON, TX 77030 USA	GOODMAN, JC (corresponding author), BAYLOR COLL MED, DEPT PATHOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [LB14960] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BRYAN RM, 1994, IN PRESS ANESTH ANAL; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1993, J EMERG MED, V1, P5; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hayes R L, 1988, Brain Inj, V2, P31, DOI 10.3109/02699058809150930; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; HOVDA DA, 1990, ACT NEUR S, V51, P331; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marmarou A, 1990, Adv Neurol, V52, P233; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	45	92	96	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1994	11	5					587	597		10.1089/neu.1994.11.587			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PR237	WOS:A1994PR23700011	7861450				2021-06-18	
J	KOTAPKA, MJ; GRAHAM, DI; ADAMS, JH; GENNARELLI, TA				KOTAPKA, MJ; GRAHAM, DI; ADAMS, JH; GENNARELLI, TA			HIPPOCAMPAL PATHOLOGY IN FATAL NONMISSILE HUMAN HEAD-INJURY	ACTA NEUROPATHOLOGICA			English	Article						HIPPOCAMPUS; HEAD INJURY; SELECTIVE VULNERABILITY	RAISED INTRACRANIAL-PRESSURE; ISCHEMIC BRAIN-DAMAGE; VULNERABILITY; SECONDARY; COMMON	The hippocampus has been known to be involved in fatal non-missile human head injury, although detailed histopathology of this lesion has yet to be described. This report documents the frequency and distribution of hippocampal damage in a consecutive series of 112 fatal human non-missile head injuries. Damage to the hippocampus was noted in 94 cases (84%). Lesions always involved the CA1 subfield and were bilateral in 70 cases. Other subfields of the hippocampus were involved less frequently. Lesions were focal in the majority of cases (58%). Pathological evidence of high intracranial pressure was present in 86% of the cases. Hypoxic brain damage in other regions of the brain was present in 74% of cases. Thus, the hippocampus is frequently damaged in fatal non-missile human head injury. The pattern of this damage is similar to that observed in experimental head injury. Hypoxia and high intracranial pressure are likely to contribute to the occurrence of human traumatic hippocampal damage but other mechanisms. such as excitotoxicity, are likely to be operative.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104; UNIV GLASGOW,DEPT NEUROPATHOL,GLASGOW G12 8QQ,SCOTLAND							ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Brierley JB, 1984, GREENFIELDS NEUROPAT, P125; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; BULLOCK R, 1990, ACT NEUR S, V51, P274; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; DUHAIME AC, 1990, BRAIN RES, V512, P169, DOI 10.1016/0006-8993(90)91188-M; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; INGLIS FM, 1990, ACT NEUR S, V51, P277; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1991, INTRACRANIAL PRESSUR, V8; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29	23	92	95	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	APR	1992	83	5					530	534		10.1007/BF00310031			5	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	HQ511	WOS:A1992HQ51100012	1621508				2021-06-18	
J	KLONOFF, PS; COSTA, LD; SNOW, WG				KLONOFF, PS; COSTA, LD; SNOW, WG			PREDICTORS AND INDICATORS OF QUALITY-OF-LIFE IN PATIENTS WITH CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV VICTORIA, VICTORIA V8W 2Y2, BC, CANADA; SUNNYBROOK MED CTR, TORONTO M4N 3M5, ONTARIO, CANADA	KLONOFF, PS (corresponding author), ST JOSEPHS HOSP & MED CTR, BARROW NEUROL INST, DEPT NEUROL, NEUROPSYCHOL SECT, 350 W THOMAS RD, PHOENIX, AZ 85013 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BLACK FW, 1973, J CLIN PSYCHOL, V29, P441; Bond M R, 1975, Ciba Found Symp, P141; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Bruckner F E, 1972, Rheumatol Phys Med, V11, P344, DOI 10.1093/rheumatology/11.7.344; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Christensen AL., 1975, LURIAS NEUROPSYCHOLO; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DYE OA, 1979, ACTA NEUROL SCAND, V59, P10; ESSON ME, 1979, ALBANY DEV ASSESSMEN; Field, 1976, EPIDEMIOLOGY HEAD IN; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRONWALL DMA, 1974, LANCET          1122, P995; Harris A. J., 1958, HARRIS TESTS LATERAL; Hathaway Starke, 1967, MINNESOTA MULTIPHASI; Holbourn AHS, 1943, LANCET, V2, P438; HPAY H, 1971, P INT S HEAD INJURIE, P110; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P160; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1975, CIBA F S, V34; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KERR TA, 1971, BRIT J PREV SOC MED, V25, P179; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF PS, NEUROSURGERY; KLONOFF PS, 1984, THESIS U VICTORIA VI; LEIGH D, 1979, PSYCHIATRY DIGES AUG, P21; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LEZAK MD, 1980, FEB M INT NEUR SOC S; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LISHMAN WA, 1978, ORGANIC PSYCHIATRY P; LUNDHOLM J, 1975, SCAND J REHABIL MED, V7, P97; MACK JL, MMPI CURRENT CLIN RE; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; MINDERHOUD JM, 1982, CLIN NEUROL NEUROSUR, V84, P15, DOI 10.1016/0303-8467(82)90106-8; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Panting A., 1972, REHABILITATION, V38, P33; Porteus SD., 1950, PORTEUS MAZE TEST IN; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Spellacy F. J., 1969, CORTEX, V5, P390, DOI DOI 10.1016/S0010-9452(69)80015-8; Spreen O, 1969, NEUROSENSORY CTR COM; Tabachnick BG, 1983, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VIOLON A, 1978, HEAD INJURIES, P105; Walker A E, 1972, Scand J Rehabil Med, V4, P5; WECHLSER D, 1945, MANUAL WECHSLER MEMO; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; ZAZULA T, 1981, UNPUB VERY EARLY BED	70	92	93	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1986	8	5					469	485		10.1080/01688638608405171			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	E9205	WOS:A1986E920500001	3805248				2021-06-18	
J	LeCount, ER; Apfelbach, CW				LeCount, ER; Apfelbach, CW			Pathologic anatomy of traumatic fractures of cranial bones and concomitant brain injuries	JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																AUVRAY M, 1909, MALADIES CRANE ENCEP; GREENACRE, 1917, B J HOPKINS HOSP, V28, P312; TILMANN, 1902, ARCH KLIN CHIR, V66, P750; TILMANN, 1899, ARCH KLIN CHIR, V59, P236	4	92	92	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0002-9955			J AMER MED ASSOC	J. Am. Med. Assoc.	JAN-MAR	1920	74						501	511		10.1001/jama.1920.02620080003002			11	Medicine, General & Internal	General & Internal Medicine	V24KL	WOS:000201649500152					2021-06-18	
J	Harmon, KG; Clugston, JR; Dec, K; Hainline, B; Herring, S; Kane, SF; Kontos, AP; Leddy, JJ; McCrea, M; Poddar, SK; Putukian, M; Wilson, JC; Roberts, WO				Harmon, Kimberly G.; Clugston, James R.; Dec, Katherine; Hainline, Brian; Herring, Stanley; Kane, Shawn F.; Kontos, Anthony P.; Leddy, John J.; McCrea, Michael; Poddar, Sourav K.; Putukian, Margot; Wilson, Julie C.; Roberts, William O.			American Medical Society for Sports Medicine position statement on concussion in sport	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							KING-DEVICK TEST; HIGH-SCHOOL FOOTBALL; CEREBRAL-BLOOD-FLOW; EXTREMITY MUSCULOSKELETAL INJURY; CHRONIC TRAUMATIC ENCEPHALOPATHY; METABOLIC BRAIN VULNERABILITY; VOLUNTARY EXERCISE; TEMPORAL WINDOW; SCREENING TOOL; NUTRITIONAL SUPPLEMENTS	Sport-related concussion (SRC) is a common injury in recreational and organised sport. Over the past 30 years, there has been significant progress in our scientific understanding of SRC, which in turn has driven the development of clinical guidelines for diagnosis, assessment and management of SRC. In addition to a growing need for knowledgeable healthcare professionals to provide evidence-based care for athletes with SRC, media attention and legislation have created awareness and, in some cases, fear about many issues and unknowns surrounding SRC. The American Medical Society for Sports Medicine (AMSSM) formed a writing group to review the existing literature on SRC, update its previous position statement, and to address current evidence and knowledge gaps regarding SRC. The absence of definitive outcomes-based data is challenging and requires relying on the best available evidence integrated with clinical experience and patient values. This statement reviews the definition, pathophysiology and epidemiology of SRC, the diagnosis and management of both acute and persistent concussion symptoms, the short-term and long-term risks of SRC and repetitive head impact exposure, SRC prevention strategies, and potential future directions for SRC research. The AMSSM is committed to best clinical practices, evidence-based research and educational initiatives that positively impact the health and safety of athletes.	[Harmon, Kimberly G.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA; [Harmon, Kimberly G.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL USA; [Clugston, James R.] Univ Florida, Dept Neurol, Gainesville, FL USA; [Dec, Katherine] Virginia Commonwealth Univ, Dept Phys Med & Rehabil & Orthopaed Surg, Richmond, VA USA; [Hainline, Brian] NCAA, Indianapolis, IN USA; [Herring, Stanley] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Kane, Shawn F.] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27515 USA; [Kontos, Anthony P.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA; [Leddy, John J.] SUNY Buffalo, UBMD Dept Orthopaed & Sports Med, Buffalo, NY USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Poddar, Sourav K.] Univ Colorado, Dept Family Med & Orthoped, Denver, CO 80202 USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Rutgers Robert Wood Johnson Med Sch, Internal Med Sports Med, New Brunswick, NJ USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Wilson, Julie C.] Univ Colorado, Dept Orthoped, Aurora, CO USA; [Roberts, William O.] Univ Minnesota, Dept Family Med & Community Hlth, Minneapolis, MN USA	Harmon, KG (corresponding author), Univ Washington, Dept Family Med, Seattle, WA 98195 USA.; Harmon, KG (corresponding author), Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA.	kharmon@uw.edu		kane, Shawn/0000-0002-9110-5224; Harmon, Kimberly/0000-0002-3670-6609; Clugston, James/0000-0002-2103-1039; Roberts, William O/0000-0003-4517-4330			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Ashbaugh A, 2016, CURR SPORT MED REP, V15, P16, DOI 10.1249/JSR.0000000000000219; Asken BM, 2018, AM J SPORT MED, V46, P1465, DOI 10.1177/0363546518757984; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bernhardt DT, 2010, PREPARTICIPATION PHY; Besnier F, 2017, ANN PHYS REHABIL MED, V60, P27, DOI 10.1016/j.rehab.2016.07.002; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Bretzin AC, 2018, AM J SPORT MED, V46, P2263, DOI 10.1177/0363546518778251; Broglio SP, 2018, SPORTS MED, V48, P1255, DOI 10.1007/s40279-017-0813-0; Broglio SP, 2017, J NEUROTRAUM, V34, P2675, DOI 10.1089/neu.2016.4767; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Davis-Hayes C, 2018, NEUROL-CLIN PRACT, V8, P40, DOI 10.1212/CPJ.0000000000000424; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; Dhawan PS, 2017, NEUROL-CLIN PRACT, V7, P464, DOI 10.1212/CPJ.0000000000000381; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Echemendia RJ, 2018, BRIT J SPORT MED, V52, P1149, DOI 10.1136/bjsports-2016-097090; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Eckner JT, 2011, PM&R, V3, P1092, DOI 10.1016/j.pmrj.2011.04.022; Eddy R, 2020, CLIN J SPORT MED, V30, P239, DOI 10.1097/JSM.0000000000000586; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Emery CA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097452; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Fuller GW, 2019, BRIT J SPORT MED, V53, P1526, DOI 10.1136/bjsports-2017-098560; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Garcia GGP, 2018, SPORTS MED, V48, P1739, DOI 10.1007/s40279-018-0880-x; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hecimoyich M, 2018, J SCI MED SPORT, V21, P1004, DOI 10.1016/j.jsams.2018.03.011; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Hoffman NL, 2020, CLIN J SPORT MED, V30, pS29, DOI 10.1097/JSM.0000000000000538; Houck Z, 2016, AM J SPORT MED, V44, P2269, DOI 10.1177/0363546516645070; Howell DR, 2020, CLIN J SPORT MED, V30, pS42, DOI 10.1097/JSM.0000000000000570; Hugentobler JA, 2015, INT J SPORTS PHYS TH, V10, P676; Iverson GL, 2018, J ALZHEIMERS DIS, V61, P17, DOI 10.3233/JAD-170654; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Janssen PHH, 2017, MAYO CLIN PROC, V92, P66, DOI 10.1016/j.mayocp.2016.09.004; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Kerr ZY, 2017, J ATHL TRAINING, V52, P167, DOI 10.4085/1062-6050-51.6.05; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; Krolikowski MP, 2017, AM J SPORT MED, V45, P468, DOI 10.1177/0363546516669701; Lawrence DW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196062; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2019, CLIN J SPORT MED, V29, P353, DOI 10.1097/JSM.0000000000000663; Leddy JJ, 2018, CURR SPORT MED REP, V17, P262, DOI 10.1249/JSR.0000000000000505; Leddy JJ, 2018, CLIN J SPORT MED, V28, P13, DOI 10.1097/JSM.0000000000000431; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lehman EJ, 2016, AM J SPORT MED, V44, P2486, DOI 10.1177/0363546516645093; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lucas JA, 2019, BRIT J SPORT MED, V53, P495, DOI 10.1136/bjsports-2018-099118; Mainwaring L, 2018, INT J PSYCHOPHYSIOL, V132, P39, DOI 10.1016/j.ijpsycho.2018.01.007; Makdissi M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097470; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAvoy K, 2018, NEUROREHABILITATION, V42, P325, DOI 10.3233/NRE-172381; McCarty CA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0459; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McLeod TCV, 2015, BRAIN INJURY, V29, P175, DOI 10.3109/02699052.2014.965206; Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; National Collegiate Athletic Association (NCAA), 2016, INT CONS DIAGN MAN S; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Norheim N, 2018, BMJ OPEN SPORT EXERC, V4, DOI 10.1136/bmjsem-2018-000412; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; O'Neill JA, 2017, REHABIL PSYCHOL, V62, P300, DOI 10.1037/rep0000155; Oliver JM, 2018, SPORTS MED, V48, pS39, DOI 10.1007/s40279-017-0847-3; Oliver JM, 2016, MED SCI SPORT EXER, V48, P974, DOI 10.1249/MSS.0000000000000875; Patricios J, 2017, BRIT J SPORT MED, V51, P888, DOI 10.1136/bjsports-2016-097441; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Randolph C, 2005, J ATHL TRAINING, V40, P139; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, P000012, DOI [10.1136/bmjsem-2015-000012, DOI 10.1136/BMJSEM-2015-000012]; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schmidt JD, 2017, J NEUROTRAUM, V34, P1571, DOI 10.1089/neu.2016.4668; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Seidman DH, 2015, J NEUROL SCI, V356, P97, DOI 10.1016/j.jns.2015.06.021; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stovitz SD, 2017, CURR SPORT MED REP, V16, P50, DOI 10.1249/JSR.0000000000000326; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Trojian TH, 2017, CURR SPORT MED REP, V16, P247, DOI 10.1249/JSR.0000000000000387; Tsushima WT, 2019, ARCH CLIN NEUROPSYCH, V34, P60, DOI 10.1093/arclin/acy019; Tucker R, 2017, BRIT J SPORT MED, V51, P1147, DOI 10.1136/bjsports-2017-097883; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	128	91	91	2	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2019	53	4					213	225		10.1136/bjsports-2018-100338			13	Sport Sciences	Sport Sciences	HL0BB	WOS:000458357900007	30705232		Y	N	2021-06-18	
J	Echemendia, RJ; Meeuwisse, W; McCrory, P; Davis, GA; Putukian, M; Leddy, J; Makdissi, M; Sullivan, SJ; Broglio, SP; Raftery, M; Schneider, K; Kissick, J; McCrea, M; Dvorak, J; Sills, AK; Aubry, M; Engebretsen, L; Loosemore, M; Fuller, G; Kutcher, J; Ellenbogen, R; Guskiewicz, K; Patricios, J; Herring, S				Echemendia, Ruben J.; Meeuwisse, Willem; McCrory, Paul; Davis, Gavin A.; Putukian, Margot; Leddy, John; Makdissi, Michael; Sullivan, S. John; Broglio, Steven P.; Raftery, Martin; Schneider, Kathryn; Kissick, James; McCrea, Michael; Dvorak, Jiri; Sills, Allen K.; Aubry, Mark; Engebretsen, Lars; Loosemore, Mike; Fuller, Gordon; Kutcher, Jeffrey; Ellenbogen, Richard; Guskiewicz, Kevin; Patricios, Jon; Herring, Stanley			The Sport Concussion Assessment Tool 5th Edition (SCAT5): Background and rationale	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INTERNATIONAL-CONFERENCE; STATEMENT; SCALE	This paper presents the Sport Concussion Assessment Tool 5th Edition (SCAT5), which is the most recent revision of a sport concussion evaluation tool for use by healthcare professionals in the acute evaluation of suspected concussion. The revision of the SCAT3 (first published in 2013) culminated in the SCAT5. The revision was based on a systematic review and synthesis of current research, public input and expert panel review as part of the 5th International Consensus Conference on Concussion in Sport held in Berlin in 2016. The SCAT5 is intended for use in those who are 13 years of age or older. The Child SCAT5 is a tool for those aged 5-12 years, which is discussed elsewhere.	[Echemendia, Ruben J.] Univ Orthoped Ctr, Concuss Care Clin, 101 Regent Ct, State Coll, PA 16801 USA; [Echemendia, Ruben J.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Meeuwisse, Willem] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB, Canada; [McCrory, Paul] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Davis, Gavin A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Davis, Gavin A.; Makdissi, Michael] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Putukian, Margot] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA; [Leddy, John] Univ Buffalo, UBMD Orthopaed & Sports Med, Concuss Management Clin, Buffalo, NY USA; [Leddy, John] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA; [Makdissi, Michael] La Trobe Univ, La Trobe Sport & Exercise Med Res Ctr, Bundoora, Vic, Australia; [Sullivan, S. John] Univ Otago, Sch Physiotherapy, Ctr Hlth & Rehabil Res Act, Dunedin, New Zealand; [Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [Raftery, Martin] World Rugby, Dublin, Ireland; [Schneider, Kathryn] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Schneider, Kathryn] Alberta Childrens Prov Gen Hosp, Res Inst Child & Maternal Hlth, Cumming Sch Med, Calgary, AB, Canada; [Schneider, Kathryn] Univ Calgary, Cuming Sch Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Kissick, James] Univ Ottawa, Dept Family Med, Carleton Univ, Sport Med Clin,Int Paralymp Comm Med Comm, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Dvorak, Jiri] Schulthess Clin, Dept Neurol, Zurich, Switzerland; [Sills, Allen K.] Vanderbilt Univ, Dept Neurosurg, 221 Kirkland Hall, Nashville, TN 37235 USA; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Engebretsen, Lars] Int Olymp Comm, Dept Med Sci, Lausanne, Switzerland; [Engebretsen, Lars] Oslo Univ Hosp, Dept Orthopaed Surg, Oslo, Norway; [Loosemore, Mike] Univ Coll Hosp, Inst Sport Exercise & Hlth, London, England; [Fuller, Gordon] Univ Sheffield, Ctr Urgent & Emergency Care Res, Sheffield, S Yorkshire, England; [Kutcher, Jeffrey] Sports Neurol Clin, Brighton, MI USA; [Ellenbogen, Richard; Herring, Stanley] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Guskiewicz, Kevin] Univ N Carolina, Matthew Gfeller Sport Related TBI Res Ctr, Chapel Hill, NC USA; [Patricios, Jon] Univ Pretoria, Fac Hlth Sci, Sect Sports Med, Pretoria, South Africa; [Patricios, Jon] Univ Witwatersrand, Fac Hlth Sci, Dept Emergency Med, Johannesburg, South Africa; [Herring, Stanley] Univ Washington, Orthopaed & Sports Med, Dept Rehabil Med, Seattle, WA 98195 USA	Echemendia, RJ (corresponding author), Univ Orthoped Ctr, Concuss Care Clin, 101 Regent Ct, State Coll, PA 16801 USA.	rechemendia@comcast.net	McCrory, Paul/Q-8688-2019; Echemendia, Ruben/R-6939-2019	Schneider, Kathryn/0000-0002-5951-5899; McCrory, Paul/0000-0003-4850-0568; Fuller, Gordon Ward/0000-0001-8532-3500; Davis, Gavin/0000-0001-8293-4496; Patricios, Jon/0000-0002-6829-4098	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish		Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Davis GA, 2017, BJ SPORTS MED; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Echemendia RJ, 2017, BJ SPORTS MED; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meeuwisse W, 2017, BR J SPORTS MED; Schneiders AG, 2010, J SCI MED SPORT, V13, P382, DOI 10.1016/j.jsams.2010.01.003; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004	15	91	93	4	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2017	51	11					848	850		10.1136/bjsports-2017-097506			3	Sport Sciences	Sport Sciences	EW3QP	WOS:000402416500004	28446453	Bronze			2021-06-18	
J	Woods, DL; Wyma, JM; Yund, EW; Herron, TJ; Reed, B				Woods, David L.; Wyma, John M.; Yund, E. William; Herron, Timothy J.; Reed, Bruce			Factors influencing the latency of simple reaction time	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						gender; timing; processing speed; motor; foreperiod; handedness; hemisphere; replication	NEUROPSYCHOLOGICAL ASSESSMENT METRICS; TRAUMATIC BRAIN-INJURY; DUTY MILITARY SAMPLE; CHOICE-REACTION-TIME; VISUOSPATIAL ATTENTION; SEX-DIFFERENCES; INTRAINDIVIDUAL VARIABILITY; COMPUTERIZED MEASURES; PROCESSING SPEED; AGE-DIFFERENCES	Simple reaction time (SRI), the minimal time needed to respond to a stimulus, is a basic measure of processing speed. SRTs were first measured by Francis Galton in the 19th century, who reported visual SRI latencies below 190 ms in young subjects. However, recent large-scale studies have reported substantially increased SRI latencies that differ markedly in different laboratories, in part due to timing delays introduced by the computer hardware and software used for SRI measurement. We developed a calibrated and temporally precise SRI test to analyze the factors that influence SRI latencies in a paradigm where visual stimuli were presented to the left or right hemifield at varying stimulus onset asynchronies (SOAs). Experiment 1 examined a community sample of 1469 subjects ranging in age from 18 to 65. Mean SRI latencies were short (231, 213 ms when corrected for hardware delays) and increased significantly with age (0.55 ms/year), but were unaffected by sex or education. As in previous studies, SRTs were prolonged at shorter SOAs and were slightly faster for stimuli presented in the visual field contralateral to the responding hand. Stimulus detection time (SDI) was estimated by subtracting movement initiation time, measured in a speeded finger tapping test, from SRTs. SDI latencies averaged 131 ms and were unaffected by age. Experiment 2 tested 189 subjects ranging in age from 18 to 82 years in a different laboratory using a larger range of SOAs. Both SRTs and SDTs were slightly prolonged (by 7 ms). SRI latencies increased with age while SDI latencies remained stable. Precise computer based measurements of SRI latencies show that processing speed is as fast in contemporary populations as in the Victorian era, and that age-related increases in SRI latencies are due primarily to slowed motor output.	[Woods, David L.; Wyma, John M.; Yund, E. William; Herron, Timothy J.] Vet Affairs Northern Calif Hlth Care Syst, Human Cognit Neurophysiol Lab, Martinez, CA 95553 USA; [Woods, David L.; Reed, Bruce] Calif State Univ Sacramento, Dept Neurol, Davis, CA USA; [Woods, David L.] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; [Woods, David L.] Univ Calif Davis, Ctr Mind & Brain, Davis, CA 95616 USA; [Reed, Bruce] Univ Calif Davis, Dept Neurol, Alzheimers Dis Ctr, Davis, CA 95616 USA	Woods, DL (corresponding author), Vet Affairs Northern Calif Hlth Care Syst, Human Cognit Neurophysiol Lab, 150 Muir Rd, Martinez, CA 95553 USA.	dlwoods@ucdavis.edu		Yund, E./0000-0002-6833-0052; Herron, Timothy/0000-0002-4297-014X; Woods, David/0000-0002-8804-3587	VA Research ServiceUS Department of Veterans Affairs [CX000583, CX001000]; National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES014038]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES014038] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001000, I01CX000583] Funding Source: NIH RePORTER	This research was supported by a VA Research Service Grants CX000583 and CX001000 to DW and Award R01ES014038 from the National Institute of Environmental Health Sciences to Michael Bates. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. We would also like to thank Ben Edwards, Oran Poliva, Masood Younus, Nabeel Rahman, Kerry Hubel, Nerene Lynskey, Kataraina George, and John McKeogh, who helped to gather the data used in this report, and to Robert Hink, who developed the MySQL database.	ANNETT M, 1979, BRIT J PSYCHOL, V70, P393, DOI 10.1111/j.2044-8295.1979.tb01709.x; Anstey KJ, 2005, Q J EXP PSYCHOL-A, V58, P5, DOI 10.1080/02724980443000232; Benwell CSY, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00113; Berlingeri M, 2013, EXP BRAIN RES, V224, P393, DOI 10.1007/s00221-012-3319-x; Bherer L, 2004, J GERONTOL B-PSYCHOL, V59, pP66, DOI 10.1093/geronb/59.2.P66; Bielak AAM, 2014, DEV PSYCHOL, V50, P143, DOI 10.1037/a0032650; BISIACCHI P, 1994, BEHAV BRAIN RES, V64, P173, DOI 10.1016/0166-4328(94)90129-5; BRIZZOLARA D, 1994, BEHAV BRAIN RES, V64, P179, DOI 10.1016/0166-4328(94)90130-9; Bugg JM, 2006, BRAIN COGNITION, V62, P9, DOI 10.1016/j.bandc.2006.02.006; Caminiti R, 2009, P NATL ACAD SCI USA, V106, P19551, DOI 10.1073/pnas.0907655106; Chaumillon R, 2014, CORTEX, V58, P86, DOI 10.1016/j.cortex.2014.05.009; CLARKE JM, 1989, BRAIN, V112, P849, DOI 10.1093/brain/112.4.849; Commodari E, 2008, AGING CLIN EXP RES, V20, P578; Deary IJ, 2011, BEHAV RES METHODS, V43, P258, DOI 10.3758/s13428-010-0024-1; Deary IJ, 2010, PSYCHOL AGING, V25, P219, DOI 10.1037/a0017750; Deary IJ, 2005, AGING NEUROPSYCHOL C, V12, P187, DOI 10.1080/13825580590969235; Deary IJ, 2001, INTELLIGENCE, V29, P389, DOI 10.1016/S0160-2896(01)00062-9; Der G, 2006, PSYCHOL AGING, V21, P62, DOI 10.1037/0882-7974.21.1.62; Dordonova Y. A., 2013, INTELLIGENCE, V41, p674 , DOI 10.1016/j.intell.2013.09.001; Dykiert D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045759; Dykiert D, 2012, DEV PSYCHOL, V48, P1262, DOI 10.1037/a0027550; Eckner JT, 2011, J ATHL TRAINING, V46, P409; EMMERSONHANOVER R, 1994, ELECTROEN CLIN NEURO, V92, P93, DOI 10.1016/0168-5597(94)90049-3; Era P, 2011, AGING CLIN EXP RES, V23, P135, DOI 10.1007/BF03351077; FITTRO KP, 1992, J OCCUP ENVIRON MED, V34, P918; Forstmann BU, 2011, J NEUROSCI, V31, P17242, DOI 10.1523/JNEUROSCI.0309-11.2011; FOZARD JL, 1994, J GERONTOL, V49, pP179, DOI 10.1093/geronj/49.4.P179; Godefroy O, 2010, EXP AGING RES, V36, P169, DOI 10.1080/03610731003613615; GOTTSDANKER R, 1982, J GERONTOL, V37, P342, DOI 10.1093/geronj/37.3.342; GREENWOOD PM, 1993, NEUROPSYCHOLOGIA, V31, P471, DOI 10.1016/0028-3932(93)90061-4; Hubel KA, 2013, PERCEPT MOTOR SKILL, V116, P929, DOI 10.2466/25.29.PMS.116.3.929-952; Hubel KA, 2013, J CLIN EXP NEUROPSYC, V35, P745, DOI 10.1080/13803395.2013.824070; Inui N, 1997, PERCEPT MOTOR SKILL, V84, P219, DOI 10.2466/pms.1997.84.1.219; Jensen AR, 2011, INTELLIGENCE, V39, P171, DOI 10.1016/j.intell.2011.03.004; JOHNSON RC, 1985, AM PSYCHOL, V40, P875, DOI 10.1037/0003-066X.40.8.875; Krieg EF, 2001, NEUROTOXICOL TERATOL, V23, P569, DOI 10.1016/S0892-0362(01)00177-5; Levin O, 2011, NEUROSCI LETT, V487, P53, DOI 10.1016/j.neulet.2010.09.072; Lowe C, 1998, NEUROPSYCHOLOGIA, V36, P915, DOI 10.1016/S0028-3932(98)00036-0; Miller J, 2003, COGNITIVE PSYCHOL, V46, P101, DOI 10.1016/S0010-0285(02)00517-0; Montare A, 2013, PERCEPT MOTOR SKILL, V116, P796, DOI 10.2466/27.24.PMS.116.3.796-805; Montare A, 2010, PERCEPT MOTOR SKILL, V111, P819, DOI 10.2466/03.15.25.PMS.111.6.819-828; Neath I, 2011, BEHAV RES METHODS, V43, P353, DOI 10.3758/s13428-011-0069-9; NIEMI P, 1981, PSYCHOL BULL, V89, P133, DOI 10.1037/0033-2909.89.1.133; Parker S, 2014, INTELLIGENCE, V47, P1, DOI 10.1016/j.intell.2014.08.002; Pins D, 1996, PERCEPT PSYCHOPHYS, V58, P390, DOI 10.3758/BF03206815; Plant RR, 2009, BEHAV RES METHODS, V41, P598, DOI 10.3758/BRM.41.3.598; Ratcliff R, 2001, PSYCHOL AGING, V16, P323, DOI 10.1037//0882-7974.16.2.323; Ratcliff R, 2011, P NATL ACAD SCI USA, V108, P11285, DOI 10.1073/pnas.1100483108; Reed BR, 2014, NEUROTOXICOL TERATOL, V42, P68, DOI 10.1016/j.ntt.2014.02.002; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Reimers S, 2006, AGING NEUROPSYCHOL C, V13, P479, DOI 10.1080/138255890969375; Ritchie SJ, 2013, PSYCHOL AGING, V28, P515, DOI 10.1037/a0030820; ROBINSON DL, 1990, NEUROPSYCHOLOGIA, V28, P291, DOI 10.1016/0028-3932(90)90022-G; Sheppard LD, 2008, PERS INDIV DIFFER, V44, P535, DOI 10.1016/j.paid.2007.09.015; Silverman IW, 2010, AM J PSYCHOL, V123, P39, DOI 10.5406/amerjpsyc.123.1.0039; Silverman IW, 2006, SEX ROLES, V54, P57, DOI 10.1007/s11199-006-8869-6; Vallesi A, 2009, NEUROPSYCHOLOGIA, V47, P2876, DOI 10.1016/j.neuropsychologia.2009.06.013; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; WILKINSON RT, 1989, J GERONTOL, V44, pP29, DOI 10.1093/geronj/44.2.P29; Woodley MA, 2013, INTELLIGENCE, V41, P843, DOI 10.1016/j.intell.2013.04.006; Woods D. L., 2015, FRONT HUM N IN PRESS; Woods DL, 2011, J CLIN EXP NEUROPSYC, V33, P721, DOI 10.1080/13803395.2010.550602; Woods DL, 2011, J CLIN EXP NEUROPSYC, V33, P101, DOI 10.1080/13803395.2010.493149; Yordanova J, 2004, BRAIN, V127, P351, DOI 10.1093/brain/awh042	66	91	93	0	53	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 26	2015	9								131	10.3339/fnhum.2015.00131			12	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CF4AZ	WOS:000352492100001	25859198	DOAJ Gold			2021-06-18	
J	Mierzwa, AJ; Marion, CM; Sullivan, GM; McDaniel, DP; Armstrong, RC				Mierzwa, Amanda J.; Marion, Christina M.; Sullivan, Genevieve M.; McDaniel, Dennis P.; Armstrong, Regina C.			Components of Myelin Damage and Repair in the Progression of White Matter Pathology After Mild Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axon damage; Demyelination; Neuroinflammation; Oligodendrocyte; Redundant myelin; Remyelination; Traumatic axonal injury	CORPUS-CALLOSUM; AXONAL INJURY; EXPERIMENTAL DEMYELINATION; OLIGODENDROCYTE LINEAGE; WALLERIAN DEGENERATION; POSTERIOR FUNICULUS; UNMYELINATED AXONS; DORSAL RHIZOTOMY; ADULT CAT; REMYELINATION	White matter tracts are highly vulnerable to damage from impact-acceleration forces of traumatic brain injury (TBI). Mild TBI is characterized by a low density of traumatic axonal injury, whereas associated myelin pathology is relatively unexplored. We examined the progression of white matter pathology in mice after mild TBI with traumatic axonal injury localized in the corpus callosum. Adult mice received a closed-skull impact and were analyzed from 3 days to 6 weeks post-TBI/sham surgery. At all times post-TBI, electron microscopy revealed degenerating axons distributed among intact fibers in the corpus callosum. Intact axons exhibited significant demyelination at 3 days followed by evidence of remyelination at 1 week. Accordingly, bromodeoxyuridine pulse-chase labeling demonstrated the generation of new oligodendrocytes, identified by myelin proteolipid protein messenger RNA expression, at 3 days post-TBI. Overall oligodendrocyte populations, identified by immunohistochemical staining for CC1 and/or glutathione S-transferase pi, were similar between TBI and sham mice by 2 weeks. Excessively long myelin figures, similar to redundant myelin sheaths, were a significant feature at all post-TBI time points. At 6 weeks post-TBI, microglial activation and astrogliosis were localized to areas of axon and myelin pathology. These studies show that demyelination, remyelination, and excessive myelin are components of white matter degeneration and recovery in mild TBI with traumatic axonal injury.	[Mierzwa, Amanda J.; Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Mierzwa, Amanda J.; Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Marion, Christina M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA; [McDaniel, Dennis P.] Uniformed Serv Univ Hlth Sci, Biomed Instrumentat Ctr, Bethesda, MD 20814 USA	Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	regina.armstrong@usuhs.edu	Sullivan, Genevieve/AAK-7415-2021; Marion, Christina M/B-8120-2015	Sullivan, Genevieve/0000-0002-3561-223X; Marion, Christina M/0000-0003-0381-4109	US Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense	This work was supported by the US Department of Defense in the Center for Neuroscience and Regenerative Medicine.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bruce CC, 2010, HORM BEHAV, V57, P56, DOI 10.1016/j.yhbeh.2009.06.004; BUNGE MB, 1961, J BIOPHYS BIOCHEM CY, V10, P67, DOI 10.1083/jcb.10.1.67; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Conti AC, 1998, J NEUROSCI, V18, P5663; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; FRANSON P, 1989, ANAT EMBRYOL, V180, P273, DOI 10.1007/BF00315885; FRANSON P, 1984, J COMP NEUROL, V223, P138, DOI 10.1002/cne.902230111; Gallo V, 2014, NEURON, V83, P283, DOI 10.1016/j.neuron.2014.06.010; Gallyas F, 2006, ACTA NEUROPATHOL, V111, P229, DOI 10.1007/s00401-006-0034-3; Gibson EM, 2014, SCIENCE, V344, P487, DOI 10.1126/science.1252304; Hibbits N, 2012, ASN NEURO, V4, DOI 10.1042/AN20120062; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Liu J, 2012, NAT NEUROSCI, V15, P1621, DOI 10.1038/nn.3263; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; LUDWIN SK, 1984, J NEUROL SCI, V64, P193, DOI 10.1016/0022-510X(84)90037-6; Maxwell WL, 2015, J NEUROTRAUM, V32, P780, DOI 10.1089/neu.2014.3369; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mierzwa AJ, 2014, ASN NEURO, V6, DOI 10.1177/1759091414551782; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Murtie JC, 2005, NEUROBIOL DIS, V19, P171, DOI 10.1016/j.nbd.2004.12.006; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Peters A, 2002, J NEUROCYTOL, V31, P581, DOI 10.1023/A:1025731309829; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSENBLUTH J, 1966, J CELL BIOL, V28, P73, DOI 10.1083/jcb.28.1.73; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Snaidero N, 2014, CELL, V156, P277, DOI 10.1016/j.cell.2013.11.044; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Tobin JE, 2011, J NEUROPATH EXP NEUR, V70, P157, DOI 10.1097/NEN.0b013e31820937e4; Tomassy GS, 2014, SCIENCE, V344, P319, DOI 10.1126/science.1249766; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Villegas R, 2014, J NEUROSCI, V34, P7179, DOI 10.1523/JNEUROSCI.4784-13.2014; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhou YX, 2012, NEUROBIOL DIS, V45, P196, DOI 10.1016/j.nbd.2011.08.004	62	91	92	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2015	74	3					218	232		10.1097/NEN.0000000000000165			15	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CB7AG	WOS:000349777700004	25668562	Green Published, Other Gold			2021-06-18	
J	Kramer, JH; Mungas, D; Possin, KL; Rankin, KP; Boxer, AL; Rosen, HJ; Bostrom, A; Sinha, L; Berhel, A; Widmeyer, M				Kramer, Joel H.; Mungas, Dan; Possin, Katherine L.; Rankin, Katherine P.; Boxer, Adam L.; Rosen, Howard J.; Bostrom, Alan; Sinha, Lena; Berhel, Ashley; Widmeyer, Mary			NIH EXAMINER: Conceptualization and Development of an Executive Function Battery	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article							TRAUMATIC BRAIN-INJURY; FRONTOTEMPORAL DEMENTIA; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; BASAL GANGLIA; MEMORY SPAN; TASK; DISEASE; DEFICITS; PERFORMANCE		[Kramer, Joel H.; Possin, Katherine L.; Rankin, Katherine P.; Boxer, Adam L.; Rosen, Howard J.; Bostrom, Alan; Sinha, Lena; Berhel, Ashley] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Mungas, Dan] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA; [Widmeyer, Mary] Rosalind Franklin Univ Med & Sci, Chicago, IL USA	Kramer, JH (corresponding author), 675 Nelson Rising Lane,Suite 190,MC 1207, San Francisco, CA 94158 USA.	jkramer@memory.ucsf.edu			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [HHSN271200623661C, P50 AG023501, 1R01AG022983, 1R01AG032289]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010220, P50AG023501, K23AG037566, R01AG022983, R01AG032289, P30AG010129] Funding Source: NIH RePORTER	This work was supported by NINDS contract HHSN271200623661C, P50 AG023501, 1R01AG022983 and 1R01AG032289. None of the authors have any conflicts to disclose.	Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; Arnett PA, 1997, NEUROPSYCHOLOGY, V11, P535, DOI 10.1037/0894-4105.11.4.535; Aron AR, 2003, J COGNITIVE NEUROSCI, V15, P629, DOI 10.1162/089892903322307357; Asimakopulos J, 2012, AUST OCCUP THER J, V59, P402, DOI 10.1111/j.1440-1630.2011.00963.x; Barkley Russell A, 2010, J Clin Psychiatry, V71, pe17, DOI 10.4088/JCP.9066tx1c; Boone KB, 1999, J INT NEUROPSYCH SOC, V5, P616, DOI 10.1017/S1355617799577047; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Caeyenberghs K, 2012, BRAIN STRUCTURE FUNC; Cahn-Weiner Deborah A, 2002, Appl Neuropsychol, V9, P187, DOI 10.1207/S15324826AN0903_8; *CAMBR COGN LTD, 1996, CANTAB; CASE R, 1982, J EXP CHILD PSYCHOL, V33, P386, DOI 10.1016/0022-0965(82)90054-6; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Conway ARA, 2005, PSYCHON B REV, V12, P769, DOI 10.3758/BF03196772; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Flores J., 2008, BATERIA NEUROPSICOLO; Foong J, 1997, BRAIN, V120, P15, DOI 10.1093/brain/120.1.15; Gerstenecker A, 2013, ARCH CLIN NEUROPSYCH, V28, P104, DOI 10.1093/arclin/acs098; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Griffin SL, 2002, ARCH CLIN NEUROPSYCH, V17, P497, DOI 10.1016/S0887-6177(01)00136-6; Hambleton R. K., 1991, FUNDAMENTALS ITEM RE; Hellmuth J, 2012, NEUROLOGY, V78, P1824, DOI 10.1212/WNL.0b013e318258f785; Hutchinson AD, 2007, J NEUROL NEUROSUR PS, V78, P917, DOI 10.1136/jnnp.2006.100669; Kramer Joel H, 2003, Cogn Behav Neurol, V16, P211, DOI 10.1097/00146965-200312000-00002; Kray J, 2000, PSYCHOL AGING, V15, P126, DOI 10.1037//0882-7974.15.1.126; Krueger CE, 2009, NEUROLOGY, V73, P349, DOI 10.1212/WNL.0b013e3181b04b24; Krueger CE, 2011, CLIN NEUROPSYCHOL, V25, P741, DOI 10.1080/13854046.2011.569759; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Luks TL, 2010, NEUROPSYCHOLOGIA, V48, P165, DOI 10.1016/j.neuropsychologia.2009.09.001; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Mirsky JB, 2011, COGN BEHAV NEUROL, V24, P50, DOI 10.1097/WNN.0b013e318223f6c6; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Moorhouse P, 2010, J NEUROL SCI, V288, P142, DOI 10.1016/j.jns.2009.09.017; Mungas D, 2003, NEUROPSYCHOLOGY, V17, P380, DOI 10.1037/0894-4105.17.3.380; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Paulsen JS, 2011, CURR NEUROL NEUROSCI, V11, P474, DOI 10.1007/s11910-011-0215-x; Peters M, 2007, J INT NEUROPSYCH SOC, V13, P626, DOI 10.1017/S1355617707070786; Possin KL, 2013, NEUROLOGY, V80, P2180, DOI 10.1212/WNL.0b013e318296e940; Psychology Software Tools I., 2009, E PRIM 2; Ravizza SM, 2002, J COGNITIVE NEUROSCI, V14, P472, DOI 10.1162/089892902317361985; Reed BR, 2004, ARCH NEUROL-CHICAGO, V61, P1545, DOI 10.1001/archneur.61.10.1545; Reitan RM., 1985, HALSTEAD REITAN NEUR; Schenk A., 2008, J INT NEUROPSYCH SOC, V14, P266; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shany-Ur T, 2011, CURR OPIN NEUROL, V24, P550, DOI 10.1097/WCO.0b013e32834cd42a; Slachevsky A, 2004, ARCH NEUROL-CHICAGO, V61, P1104, DOI 10.1001/archneur.61.7.1104; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Wilson BA, 1996, BEHAV ASSESSMENT DYS	52	91	93	1	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2014	20	1					11	19		10.1017/S1355617713001094			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AC2VC	WOS:000332373400004	24103232	Green Accepted			2021-06-18	
J	Huang, YY; Nagata, K; Tedford, CE; McCarthy, T; Hamblin, MR				Huang, Ying-Ying; Nagata, Kazuya; Tedford, Clark E.; McCarthy, Thomas; Hamblin, Michael R.			Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro	JOURNAL OF BIOPHOTONICS			English	Article							TRAUMATIC BRAIN-INJURY; NEAR-INFRARED LIGHT; TERM NEUROLOGICAL DEFICITS; RAT-LIVER MITOCHONDRIA; BIPHASIC DOSE-RESPONSE; CYTOCHROME-C-OXIDASE; HELIUM-NEON LASER; DIFFERENT WAVELENGTHS; DOPAMINERGIC-NEURONS; COGNITIVE DEFICITS		[Huang, Ying-Ying; Nagata, Kazuya; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Ying-Ying] Guangxi Med Univ, Dept Pathol, Nanning, Guangxi, Peoples R China; [Nagata, Kazuya] Univ Tokyo, Grad Sch Med, Tokyo 1138654, Japan; [Tedford, Clark E.; McCarthy, Thomas] PhotoThera Inc, Carlsbad, CA USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, yingying/J-7329-2012; Hamblin, Michael R/H-2758-2019; Huang, Yingying/G-3153-2011	Huang, yingying/0000-0002-4038-0277; Hamblin, Michael R/0000-0001-6431-4605; Huang, Yingying/0000-0003-3066-6981	Photothera Inc; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by sponsored research funding from Photothera Inc and by NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research (FA9950-04-1-0079)	Albertini R, 2007, J PHOTOCH PHOTOBIO B, V89, P50, DOI 10.1016/j.jphotobiol.2007.08.005; Ando T, 2011, PLOS ONE, V6; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bogeski I, 2006, CELL CALCIUM, V40, P1, DOI 10.1016/j.ceca.2006.03.003; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Callaghan GA, 1996, LASER SURG MED, V19, P201; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Chen X, 2009, MOL CELL BIOCHEM, V332, P85, DOI 10.1007/s11010-009-0177-3; Choi K, 2009, CURR NEUROVASC RES, V6, P213, DOI 10.2174/156720209789630375; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Ciancarelli I, 2012, CURR NEUROVASC RES, V9, P266, DOI 10.2174/156720212803530717; CINI M, 1995, NEUROBIOL AGING, V16, P53, DOI 10.1016/0197-4580(95)80007-E; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; DUNN KW, 1994, FASEB J, V8, P573; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Eichler M, 2007, PHOTOMED LASER SURG, V25, P170, DOI 10.1089/pho.2007.2046; Freestone PS, 2009, EUR J NEUROSCI, V30, P1849, DOI 10.1111/j.1460-9568.2009.06990.x; FRIEDMANN H, 1991, J PHOTOCH PHOTOBIO B, V11, P87, DOI 10.1016/1011-1344(91)80271-I; Giuliani A, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-8; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hool LC, 2007, ANTIOXID REDOX SIGN, V9, P409, DOI 10.1089/ars.2006.1446; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Invitrogen, 2011, BIOPROBES, V64, P6; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kotake-Nara E, 2006, THESCIENTIFICWORLDJO, V6, P176, DOI 10.1100/tsw.2006.37; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lavi R, 2003, J BIOL CHEM, V278, P40917, DOI 10.1074/jbc.M303034200; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Lim J, 2010, J PHOTOCH PHOTOBIO B, V99, P105, DOI 10.1016/j.jphotobiol.2010.03.002; Lim J, 2009, J BIOCHEM MOL TOXIC, V23, P1, DOI 10.1002/jbt.20257; Lim WB, 2011, LASER SURG MED, V43, P344, DOI 10.1002/lsm.21038; Lin HJ, 2004, FEBS LETT, V570, P102, DOI 10.1016/j.febslet.2004.06.019; Liu XG, 2009, PHOTOMED LASER SURG, V27, P863, DOI 10.1089/pho.2008.2443; Silveira PCL, 2011, LASER MED SCI, V26, P125, DOI 10.1007/s10103-010-0839-0; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Menke T, 2003, BIOFACTORS, V18, P65, DOI 10.1002/biof.5520180208; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Moges H, 2009, LASER SURG MED, V41, P52, DOI 10.1002/lsm.20732; Moon Y, 2005, J NEUROCHEM, V93, P1199, DOI 10.1111/j.1471-4159.2005.03112.x; MOORHOUSE CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P261, DOI 10.1016/0304-4165(85)90147-3; Nicholls DG, 2008, ANN NY ACAD SCI, V1147, P53, DOI 10.1196/annals.1427.002; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3; Pouokam E, 2009, EUR J PHARMACOL, V615, P40, DOI 10.1016/j.ejphar.2009.04.066; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Radad K, 2006, NEUROCHEM INT, V49, P379, DOI 10.1016/j.neuint.2006.02.003; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Rubio CR, 2009, PHOTOMED LASER SURG, V27, P79, DOI 10.1089/pho.2007.2232; Rochkind S, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E8; Roediger B, 2003, NEUROBIOL DIS, V13, P222, DOI 10.1016/S0969-9961(03)00038-X; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Scheuer T, 2006, BIOCHEM SOC T, V34, P1299, DOI 10.1042/BST0341299; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Shefer G, 2002, J CELL SCI, V115, P1461; Silveira PCL, 2007, J PHOTOCH PHOTOBIO B, V86, P279, DOI 10.1016/j.jphotobiol.2006.10.002; Tada-Oikawa S, 2003, LIFE SCI, V73, P3277, DOI 10.1016/j.lfs.2003.06.013; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; TOMARO ML, 1991, ARCH BIOCHEM BIOPHYS, V286, P610, DOI 10.1016/0003-9861(91)90088-Z; Verri M, 2012, INT J IMMUNOPATH PH, V25, P345, DOI 10.1177/039463201202500204; Wang GC, 2000, NUCLEIC ACIDS RES, V28, P2135, DOI 10.1093/nar/28.10.2135; WANG XY, 1993, ARCH BIOCHEM BIOPHYS, V306, P402, DOI 10.1006/abbi.1993.1529; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x; Zhang JT, 2008, J CELL PHYSIOL, V217, P518, DOI 10.1002/jcp.21529; Zhang SQ, 2011, MOL CELL BIOCHEM, V354, P161, DOI 10.1007/s11010-011-0815-4; Zou WG, 2001, J NEUROSCI RES, V64, P646, DOI 10.1002/jnr.1118	80	91	92	4	18	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	OCT	2013	6	10			SI		829	838					10	Biochemical Research Methods; Biophysics; Optics	Biochemistry & Molecular Biology; Biophysics; Optics	264NL	WOS:000327884800009	23281261	Green Accepted			2021-06-18	
J	Palacios, EM; Sala-Llonch, R; Junque, C; Roig, T; Tormos, JM; Bargallo, N; Vendrell, P				Palacios, Eva M.; Sala-Llonch, Roser; Junque, Carme; Roig, Teresa; Tormos, Jose M.; Bargallo, Nuria; Vendrell, Pere			Resting-State Functional Magnetic Resonance Imaging Activity and Connectivity and Cognitive Outcome in Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							WHITE-MATTER INTEGRITY; MULTIPLE-SCLEROSIS; WORKING-MEMORY; AXONAL INJURY; NETWORK; IMPAIRMENT; RECOVERY; DEFICITS; HIPPOCAMPAL	IMPORTANCE The study of brain activity and connectivity at rest provides a unique opportunity for the investigation of the brain substrates of cognitive outcome after traumatic axonal injury. This knowledge may contribute to improve clinical management and rehabilitation programs. OBJECTIVE To study functional magnetic resonance imaging abnormalities in signal amplitude and brain connectivity at rest and their relationship to cognitive outcome in patients with chronic and severe traumatic axonal injury. DESIGN Observational study. SETTING University of Barcelona and Hospital Clinic de Barcelona, Barcelona, and Institut Guttmann-Neurorehabilitation Hospital, Badalona, Spain. PARTICIPANTS Twenty patients with traumatic brain injury (TBI) were studied, along with 17 matched healthy volunteers. INTERVENTIONS Resting-state functional magnetic resonance imaging and diffusion tensor imaging data were acquired. After exploring group differences in amplitude of low-frequency fluctuations (ALFF), we studied functional connectivity within the default mode network (DMN) by means of independent component analysis, followed by a dual regression approach and seed-based connectivity analyses. Finally, we performed probabilistic tractography between the frontal and posterior nodes of the DMN. MAIN OUTCOMES AND MEASURES Signal amplitude and functional connectivity during the resting state, tractography related to DMN, and the association between signal amplitudes and cognitive outcome. RESULTS Patients had greater ALFF in frontal regions, which was correlated with cognitive performance. Within the DMN, patients showed increased connectivity in the frontal lobes. Seed-based connectivity analyses revealed augmented connectivity within surrounding areas of the frontal and left parietal nodes of the DMN. Fractional anisotropy of the cingulate tract was correlated with increased connectivity of the frontal node of the DMN in patients with TBI. CONCLUSIONS AND RELEVANCE Increased ALFF is related to better cognitive performance in chronic TBI. The loss of structural connectivity produced by damage to the cingulum tract explained the compensatory increases in functional connectivity within the frontal node of the DMN.	[Palacios, Eva M.; Sala-Llonch, Roser; Junque, Carme; Vendrell, Pere] August Pi & Sunyer Biomed Res Inst, Barcelona, Spain; [Sala-Llonch, Roser; Junque, Carme; Vendrell, Pere] Univ Barcelona, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Roig, Teresa; Tormos, Jose M.] Neurorehabil Hosp, Inst Guttmann, Badalona, Spain; [Bargallo, Nuria] Hosp Clin Barcelona, Ctr Diagnost Imatge, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, C Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Vendrell, Pere/B-4392-2011; Bargallo, Nuria/G-6854-2016; Sala-Llonch, Roser/E-7882-2012; Lang, Steven/AAE-8102-2021; Junque, Carme/B-4400-2011; Sala-Llonch, Roser/L-4135-2015	Vendrell, Pere/0000-0001-8918-5440; Bargallo, Nuria/0000-0001-6284-5402; Sala-Llonch, Roser/0000-0003-3576-0475; Lang, Steven/0000-0003-1669-9146; Junque, Carme/0000-0002-6381-3063; Sala-Llonch, Roser/0000-0003-3576-0475; Tormos Munoz, Jose Maria/0000-0002-8764-2289			Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Arenivas A, 2014, BRAIN IMAGING BEHAV, V8, P407, DOI 10.1007/s11682-012-9191-2; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bonavita S, 2011, MULT SCLER J, V17, P411, DOI 10.1177/1352458510394609; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hawellek DJ, 2011, P NATL ACAD SCI USA, V108, P19066, DOI 10.1073/pnas.1110024108; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Wang ZQ, 2011, HUM BRAIN MAPP, V32, P1720, DOI 10.1002/hbm.21140; Zang YF, 2007, BRAIN DEV-JPN, V29, P83, DOI 10.1016/j.braindev.2006.07.002	36	91	95	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	2168-6149			JAMA NEUROL	JAMA Neurol.	JUL	2013	70	7					845	851		10.1001/jamaneurol.2013.38			7	Clinical Neurology	Neurosciences & Neurology	206YN	WOS:000323563000006	23689958	Bronze			2021-06-18	
J	Hazrati, LN; Tartaglia, MC; Diamandis, P; Davis, KD; Green, RE; Wennberg, R; Wong, JC; Ezerins, L; Tator, CH				Hazrati, Lili-Naz; Tartaglia, Maria C.; Diamandis, Phedias; Davis, Karen D.; Green, Robin E.; Wennberg, Richard; Wong, Janice C.; Ezerins, Leo; Tator, Charles H.			Absence of chronic traumatic encephalopathy in retired football players with multiple concussions and neurological symptomatology	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						chronic traumatic encephalopathy; repetitive brain injury; professional athletes; dementia; neurodegenerative disease	TDP-43	Background: Chronic traumatic encephalopathy (CTE) is the term coined for the neurodegenerative disease often suspected in athletes with histories of repeated concussion and progressive dementia. Histologically, CTE is defined as a tauopathy with a distribution of tau-positive neurofibrillary tangles (NFTs) that is distinct from other tauopathies, and usually shows an absence of beta-amyloid deposits, in contrast to Alzheimer's disease (AD). Although the connection between repeated concussions and CTE-type neurodegeneration has been recently proposed, this causal relationship has not yet been firmly established. Also, the prevalence of CTE among athletes with multiple concussions is unknown. Methods: We performed a consecutive case series brain autopsy study on six retired professional football players from the Canadian Football League (CFL) with histories of multiple concussions and significant neurological decline. Results: All participants had progressive neurocognitive decline prior to death; however, only 3 cases had post-mortem neuropathological findings consistent with CTE. The other 3 participants had pathological diagnoses of AD, amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Moreover, the CTE cases showed co-morbid pathology of cancer, vascular disease, and AD. Discussion: Our case studies highlight that not all athletes with history of repeated concussions and neurological symptomology present neuropathological changes of CTE. These preliminary findings support the need for further research into the link between concussion and CTE as well as the need to expand the research to other possible causes of taupathy in athletes. They point to a critical need for prospective studies with good sampling methods to allow us to understand the relationship between multiple concussions and the development of CTE.	[Hazrati, Lili-Naz; Diamandis, Phedias; Wong, Janice C.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; [Hazrati, Lili-Naz; Tartaglia, Maria C.; Wong, Janice C.] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; [Tartaglia, Maria C.; Wennberg, Richard] Univ Toronto, Univ Hlth Network, Krembil Neurosci Ctr, Div Neurol, Toronto, ON M5S 3H2, Canada; [Davis, Karen D.; Tator, Charles H.] Univ Toronto, Univ Hlth Network, Krembil Neurosci Ctr, Div Neurosurg, Toronto, ON M5S 3H2, Canada; [Davis, Karen D.] Univ Hlth Network, Toronto Western Res Inst, Div Brain Imaging & Behav Syst Neurosci, Toronto, ON, Canada; [Davis, Karen D.] Univ Toronto, Dept Surg, Toronto, ON M5S 3H2, Canada; [Davis, Karen D.; Tator, Charles H.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 3H2, Canada; [Green, Robin E.] Univ Toronto, Toronto Rehabil Inst, Cognit Neurorehabil Sci Lab, Toronto, ON M5S 3H2, Canada; [Ezerins, Leo] Canadian Football League Alumni Assoc, Toronto, ON, Canada	Hazrati, LN (corresponding author), Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent West, Toronto, ON M5S 3H2, Canada.	lilinaz.hazrati@utoronto.ca	hazrati, lili-naz/AAE-7785-2020	hazrati, lili-naz/0000-0003-2715-1485; Green, Robin/0000-0001-9451-3963; Diamandis, Phedias/0000-0001-5291-9068	Physicians' Services Incorporated Foundation	We are grateful and would like to thank Dawn Ross, Vicky Proudfoot, Carol Conroy, Joan Toogood, Mary Kuntz, Siobhan Ribbins, Dan Slee, Bill Sokulski, and Tony Gabriel for facilitating the brain donations and for their time and contribution to the subject's histories. We are thankful to Drs. J.H. Jansen, J. Wolfe, J. Michaud, M.C. Guiot, Angela Genge, and C. Petito for their clinical expertise and help with autopsies, and to all the team members of The Canadian Sports Concussion Project. This research was funded by a generous grant from the Physicians' Services Incorporated Foundation to the Canadian Sports Concussion Project.	Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Davis K. D., 2012, J NEUROIMMUNE PHARM, DOI [10.1007/s11481-012-9386-8, DOI 10.1007/S11481-012-9386-8.[]; Dickson DW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009258; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Pickett William, 2004, Chronic Dis Can, V25, P32; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008	22	91	91	2	72	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 24	2013	7								222	10.3389/fnhum.2013.00222			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	152TL	WOS:000319553900001	23745112	DOAJ Gold, Green Published			2021-06-18	
J	Isquith, PK; Roth, RM; Gioia, G				Isquith, Peter K.; Roth, Robert M.; Gioia, Gerard			Contribution of Rating Scales to the Assessment of Executive Functions	APPLIED NEUROPSYCHOLOGY-CHILD			English	Article						ecological validity; executive function; measurement; psychometric; rating scales	TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; PERFORMANCE-BASED MEASURES; AUTISM SPECTRUM DISORDERS; WORKING-MEMORY; NEUROPSYCHOLOGICAL ASSESSMENT; FUNCTION IMPAIRMENTS; ECOLOGICAL VALIDITY; CORTICAL THICKNESS	Executive functions play a vital role in the everyday functioning of healthy individuals across the lifespan and have been implicated in a wide variety of clinical conditions. Historically, the assessment of executive functions in clinical and research settings relied on performance-based measures. A number of authors have argued, however, that such measures have limited ecological validity. In response to this limitation of performance-based measures, several rating scales have been developed that seek to gauge a person's or their knowledgeable informant's (e. g., parent or teacher) subjective view of executive functioning in everyday life. In this article we review evidence supporting the use of rating scales of executive function including profiles in clinical populations, biological correlates, relationships to relevant outcome measures such as academic performance, and correlations with performance-based measures. We conclude that performance-based and rating scale measures provide complementary information with respect to a child's executive functions, offering a more comprehension view than either approach alone.	[Isquith, Peter K.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Program, Lebanon, NH 03756 USA; [Gioia, Gerard] Childrens Natl Med Ctr, Div Neuropsychol, Washington, DC 20010 USA	Isquith, PK (corresponding author), Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Program, One Med Ctr Dr, Lebanon, NH 03756 USA.	peter@qpsych.com	Isquith, Peter/AAY-4851-2020				Anderson V, 2005, J INT NEUROPSYCH SOC, V11, P817, DOI 10.1017/S1355617705051052; Anderson V., 2008, EXECUTIVE FUNCTIONS, P123; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Antshel KM, 2005, PSYCHIAT RES-NEUROIM, V138, P235, DOI 10.1016/j.pscychresns.2005.02.003; Bernstein J, 2007, EXECUTIVE FUNCTION E, P39; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Brown TM, 2008, CHILD NEUROPSYCHOL, V14, P118, DOI 10.1080/09297040601147605; Burgess P. W., 1997, METHODOLOGY FRONTAL, P81, DOI DOI 10.1024//1016-264X.10.2.123; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Christ SE, 2010, NEUROPSYCHOLOGY, V24, P590, DOI 10.1037/a0019176; Clark CAC, 2010, DEV PSYCHOL, V46, P1176, DOI 10.1037/a0019672; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Culberton W. C., 2000, TOWER LONDON DX; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Diamond A, 1988, THOUGHT LANGUAGE, P337; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Ferrier D, 1886, FUNCTIONS BRAIN; Franzen M.D., 1996, ECOLOGICAL VALIDITY, P91; Garlinghouse MA, 2010, SCHIZOPHR RES, V120, P71, DOI 10.1016/j.schres.2010.02.1067; Ghassabian A, 2013, J CHILD PSYCHOL PSYC, V54, P96, DOI 10.1111/j.1469-7610.2012.02590.x; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Grace J, 2002, FRONTAL SYSTEMS BEHA; Holmes-Bernstein J, 1990, NEUROPSYCHOLOGY, P311; Isquith PK, 2004, DEV NEUROPSYCHOL, V26, P403, DOI 10.1207/s15326942dn2601_3; Jarratt KP, 2005, APPL NEUROPSYCHOL, V12, P83, DOI 10.1207/s15324826an1202_4; Kaplan E, 1988, CLIN NEUROPSYCHOLOGY, P129, DOI DOI 10.1037/10063-000; Kenworthy L, 2009, CHILD NEUROPSYCHOL, V15, P425, DOI 10.1080/09297040802646983; Kenworthy L, 2008, NEUROPSYCHOL REV, V18, P320, DOI 10.1007/s11065-008-9077-7; Kenworthy LE, 2005, DEV NEUROPSYCHOL, V28, P809, DOI 10.1207/s15326942dn2803_4; Kesler SR, 2011, ARCH NEUROL-CHICAGO, V68, P1447, DOI 10.1001/archneurol.2011.245; Locascio G, 2010, J LEARN DISABIL-US, V43, P441, DOI 10.1177/0022219409355476; MacAllister WS, 2012, CHILD NEUROPSYCHOL, V18, P404, DOI 10.1080/09297049.2011.613812; Mahone EM, 2007, CLIN NEUROPSYCHOL, V21, P569, DOI 10.1080/13854040600762724; Mahone EM, 2009, J INT NEUROPSYCH SOC, V15, P31, DOI 10.1017/S1355617708090164; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Mares D, 2007, CAN J PSYCHIAT, V52, P527, DOI 10.1177/070674370705200811; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; McCandless Stephen, 2007, J Atten Disord, V10, P381, DOI 10.1177/1087054706292115; McCauley JL, 2010, J CHILD PSYCHOL PSYC, V51, P84, DOI 10.1111/j.1469-7610.2009.02134.x; McDonald B. C., BRAIN BEHAV IN PRESS; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Parrish J, 2007, DEV MED CHILD NEUROL, V49, P412, DOI 10.1111/j.1469-8749.2007.00412.x; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Reddy LA, 2011, SCHOOL PSYCHOL QUART, V26, P45, DOI 10.1037/a0022585; Reynolds C.R., 1992, BEHAV ASSESSMENT SYS; Rotenberg-Shpigelman S., 2008, ISRAELI J OCCUPATION, V17, P77; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Sullivan Jeremy R, 2007, J Atten Disord, V11, P398, DOI 10.1177/1087054707299399; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Waber DP, 2006, DEV NEUROPSYCHOL, V29, P459, DOI 10.1207/s15326942dn2903_5; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yerys BE, 2009, AUTISM RES, V2, P322, DOI 10.1002/aur.103	69	91	93	1	34	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	2162-2965	2162-2973		APPL NEUROPSYCH-CHIL	Appl. Neuropsychol.-Child		2013	2	2			SI		125	132		10.1080/21622965.2013.748389			8	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	AD0TF	WOS:000332946300007	23442015				2021-06-18	
J	Adamczak, S; Dale, G; Vaccari, JPD; Bullock, MR; Dietrich, WD; Keane, RW				Adamczak, Stephanie; Dale, Gordon; Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.			Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome Clinical article	JOURNAL OF NEUROSURGERY			English	Article						biomarker; traumatic brain injury; inflammation; innate immunity; inflammasome	MOLECULAR PLATFORM; PRACTICAL SCALE; HEAD-INJURY; HYPOTHERMIA; ACTIVATION; NEUTRALIZATION; CASPASE-1; NEURONS; DISEASE; TISSUE	Object. Traumatic brain injury (TBI), the third most common CNS pathology, plagues 5.3 million Americans with permanent TBI-related disabilities. To evaluate injury severity and prognosis, physicians rely on clinical variables. Here, the authors seek objective, biochemical markers reflecting molecular injury mechanisms specific to the CNS as more accurate measurements of injury severity and outcome. One such secondary injury mechanism, the innate immune response, is regulated by the inflammasome, a molecular platform that activates caspase-1 and interleukin-1 beta. Methods. The authors investigated whether inflammasome components were present in the CSF of 23 patients with TBI and whether levels of inflammasome components correlate with outcome. The authors performed an immunoblot analysis of CSF samples from patients who suffered TBI and nontrauma controls and assessed the outcomes 5 months postinjury by using the Glasgow Outcome Scale. Data were analyzed using Mann-Whitney U-tests and linear regression analysis. Results. Patients with severe or moderate cranial trauma exhibited significantly higher CSF levels of the inflammasome proteins ASC, caspase-1, and NALP-1 than nontrauma controls (p < 0.0001, p = 0.0029, and p = 0.0202, respectively). Expression of each protein correlated significantly with the Glasgow Outcome Scale score at 5 months postinjury (p < 0.05). ASC, caspase-1, and NALP-1 were significantly higher in the CSF of patients with unfavorable outcomes, including death and severe disability (p < 0.0001). Conclusions. NALP-1 inflammasome proteins are potential biomarkers to assess TBI severity, outcome, and the secondary injury mechanisms impeding recovery, serving as adjuncts to clinical predictors. (http://thejns.org/doi/abs/10.3171/2012.9.JNS12815)	[Adamczak, Stephanie; Dale, Gordon; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Coral Gables, FL 33124 USA; [Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Coral Gables, FL 33124 USA	Keane, RW (corresponding author), 1600 NW 10th Ave,RMSB 5058, Miami, FL 33136 USA.	rkeane@miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; Dale, Gordon/0000-0002-4995-6017	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS032091]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER	This study was supported by NIH grant NS032091. Stephanie Adamczak, Juan Pablo de Rivero Vaccari, M. Ross Bullock, W. Dalton Dietrich, and Robert W. Keane hold a patent on inflammasome proteins as diagnostic and prognostic indicators following central nervous system trauma.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P463; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HOLM S, 1979, SCAND J STAT, V6, P65; JENNETT B, 1975, LANCET, V1, P480; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; Kumar K, 1997, METAB BRAIN DIS, V12, P21, DOI 10.1007/BF02676351; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; TEASDALE G, 1974, LANCET, V2, P81; Tomura S, 2012, J CEREB BLO IN PRESS; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46	28	91	96	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	2012	117	6					1119	1125		10.3171/2012.9.JNS12815			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	042IC	WOS:000311463900019	23061392	Green Accepted			2021-06-18	
J	Lee, JY; Kim, HS; Choi, HY; Oh, TH; Yune, TY				Lee, Jee Y.; Kim, Hwang S.; Choi, Hye Y.; Oh, Tae H.; Yune, Tae Y.			Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury	BRAIN			English	Article						blood-brain barrier; fluoxetine; matrix metalloprotease; spinal cord injury; tight junction	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; CONTUSION INJURY; INTRACEREBRAL HEMORRHAGE; INFLAMMATORY RESPONSE; ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE; OXIDATIVE STRESS	After spinal cord injury, the disruption of blood-spinal cord barrier by activation of matrix metalloprotease is a critical event leading to infiltration of blood cells, inflammatory responses and neuronal cell death, contributing to permanent neurological disability. Recent evidence indicates that fluoxetine, an anti-depressant drug, is shown to have neuroprotective effects in ischaemic brain injury, but the precise mechanism underlying its protective effects is largely unknown. Here, we show that fluoxetine prevented blood-spinal cord barrier disruption via inhibition of matrix metalloprotease activation after spinal cord injury. After a moderate contusion injury at the T9 level of spinal cord with an infinite horizon impactor in the mouse, fluoxetine (10 mg/kg) was injected intraperitoneally and further administered once a day for indicated time points. Fluoxetine treatment significantly inhibited messenger RNA expression of matrix metalloprotease 2, 9 and 12 after spinal cord injury. By zymography and fluorimetric enzyme activity assay, fluoxetine also significantly reduced matrix metalloprotease 2 and matrix metalloprotease 9 activities after injury. In addition, fluoxetine inhibited nuclear factor kappa B-dependent matrix metalloprotease 9 expression in bEnd.3, a brain endothelial cell line, after oxygen-glucose deprivation/reoxygenation. Fluoxetine also attenuated the loss of tight junction molecules such as zona occludens 1 and occludin after injury in vivo as well as in bEnd.3 cultures. By immunofluorescence staining, fluoxetine prevented the breakdown of the tight junction integrity in endothelial cells of blood vessel after injury. Furthermore, fluoxetine inhibited the messenger RNA expression of chemokines such as Gro alpha, MIP1 alpha and 1 beta, and prevented the infiltration of neutrophils and macrophages, and reduced the expression of inflammatory mediators after injury. Finally, fluoxetine attenuated apoptotic cell death and improved locomotor function after injury. Thus, our results indicate that fluoxetine improved functional recovery in part by inhibiting matrix metalloprotease activation and preventing blood-spinal cord barrier disruption after spinal cord injury. Furthermore, our study suggests that fluoxetine may represent a potential therapeutic agent for preserving blood-brain barrier integrity following ischaemic brain injury and spinal cord injury in humans.	[Yune, Tae Y.] Kyung Hee Univ, Sch Med, Dept Biochem & Mol Biol, Seoul 130701, South Korea; [Lee, Jee Y.; Kim, Hwang S.; Choi, Hye Y.; Oh, Tae H.; Yune, Tae Y.] Kyung Hee Univ, Sch Med, Age Related & Brain Dis Res Ctr, Seoul 130701, South Korea; [Lee, Jee Y.; Yune, Tae Y.] Kyung Hee Univ, Sch Med, Neurodegenerat Control Res Ctr, Seoul 130701, South Korea; [Kim, Hwang S.; Yune, Tae Y.] Kyung Hee Univ, Sch Med, Grad Programme Neurosci, Seoul 130701, South Korea	Yune, TY (corresponding author), Kyung Hee Univ, Sch Med, Dept Biochem & Mol Biol, Med Bldg,10th Floor,Hoegi Dong 1, Seoul 130701, South Korea.	tyune@khu.ac.kr			Brain Research Center of 21st Century Frontier Research Program [2011K000282, 2011K000291]; Pioneer Research Center Program through National Research Foundation of KoreaNational Research Foundation of Korea [20110001692]; Basic Science Research Program through National Research Foundation of Korea [20110000932]; Ministry of Education, Science and Technology (MEST), Republic of KoreaMinistry of Education, Science and Technology, Republic of Korea	This study was supported by Brain Research Center of the 21st Century Frontier Research Program (No. 2011K000282, 2011K000291), the Pioneer Research Center Program through the National Research Foundation of Korea (No. 20110001692), and Basic Science Research Program through the National Research Foundation of Korea grant (No. 20110000932) funded by the Ministry of Education, Science and Technology (MEST), the Republic of Korea.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Anjaneyulu M, 2006, EUR J PHARMACOL, V538, P80, DOI 10.1016/j.ejphar.2006.03.067; Asahi M, 2001, J NEUROSCI, V21, P7724; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Begovic Amra, 2004, Bosn J Basic Med Sci, V4, P79; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; BIANCHI M, 1995, INFLAMM RES, V44, P466, DOI 10.1007/BF01837911; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chang DI, 2003, J CEREBR BLOOD F MET, V23, P1408, DOI 10.1097/01.WCB.0000091765.61714.30; Chen XS, 2008, J NEUROCHEM, V107, P1147, DOI 10.1111/j.1471-4159.2008.05697.x; Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003; Chung ES, 2010, BRAIN RES, V1363, P143, DOI 10.1016/j.brainres.2010.09.049; Chung YC, 2011, NEUROPHARMACOLOGY, V60, P963, DOI 10.1016/j.neuropharm.2011.01.043; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; Diamond M, 2006, EUR NEUROPSYCHOPHARM, V16, P481, DOI 10.1016/j.euroneuro.2005.11.011; Fazzino F, 2009, INT IMMUNOPHARMACOL, V9, P463, DOI 10.1016/j.intimp.2009.01.011; Feng SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020599; Fulcher YG, 2011, BIOCHEMISTRY-US, V50, P9488, DOI 10.1021/bi2009807; Gainotti G, 2010, CURR ALZHEIMER RES, V7, P271, DOI 10.2174/156720510791050858; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Ghirnikar RS, 2001, J NEUROSCI RES, V64, P582, DOI 10.1002/jnr.1110; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Hosokawa T, 2011, J NEUROIMMUNOL, V236, P81, DOI 10.1016/j.jneuroim.2011.04.009; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Jin YJ, 2011, CELL SIGNAL, V23, P125, DOI 10.1016/j.cellsig.2010.08.012; Karpus WJ, 1998, J IMMUNOL, V161, P2667; Lee JY, 2010, ENDOCRINOLOGY, V151, P3815, DOI 10.1210/en.2009-1416; Li XQ, 2011, ACTA PHARMACOL SIN, V32, P217, DOI 10.1038/aps.2010.187; Lim CM, 2009, J NEUROSCI RES, V87, P1037, DOI 10.1002/jnr.21899; Liu WL, 2009, J NEUROCHEM, V108, P811, DOI 10.1111/j.1471-4159.2008.05821.x; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Miyazaki K, 2011, J NEUROSCI RES, V89, P718, DOI 10.1002/jnr.22594; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Noble LJ, 2002, J NEUROSCI, V22, P7526; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Pariente J, 2001, ANN NEUROL, V50, P718, DOI 10.1002/ana.1257; Pellegrino TC, 2002, BRAIN BEHAV IMMUN, V16, P87, DOI 10.1006/brbi.2001.0625; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; ROSENBERG GA, 1994, LAB INVEST, V71, P417; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Roumestan C, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-35; Saiwai H, 2010, AM J PATHOL, V176, P2352, DOI 10.2353/ajpath.2010.090839; Salam OMEA, 2004, PHARMACOL RES, V50, P309, DOI 10.1016/j.phrs.2004.01.010; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Sixt M, 2001, J CELL BIOL, V153, P933, DOI 10.1083/jcb.153.5.933; Sounvoravong S, 2007, ACTA BIOL HUNG, V58, P369, DOI 10.1556/ABiol.58.2007.4.4; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Tahanian E, 2011, DRUG DES DEV THER, V5, P299, DOI 10.2147/DDDT.S19931; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Tian DS, 2009, J NEUROCHEM, V109, P1658, DOI 10.1111/j.1471-4159.2009.06077.x; Toft-Hansen H, 2006, J IMMUNOL, V177, P7242, DOI 10.4049/jimmunol.177.10.7242; Utepbergenov DI, 1998, FEBS LETT, V424, P197, DOI 10.1016/S0014-5793(98)00173-2; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wiart L, 2000, STROKE, V31, P1829, DOI 10.1161/01.STR.31.8.1829; Wu C, 2009, NAT MED, V15, P519, DOI 10.1038/nm.1957; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yu F, 2008, J NEUROTRAUM, V25, P184, DOI 10.1089/neu.2007.0438; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Yune TY, 2009, J NEUROCHEM, V110, P1276, DOI 10.1111/j.1471-4159.2009.06214.x; Yune TY, 2004, J NEUROTRAUM, V21, P1778, DOI 10.1089/0897715042664858; Zhang HQ, 2011, J NEUROSCI, V31, P15894, DOI 10.1523/JNEUROSCI.3943-11.2011; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	85	91	94	2	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	AUG	2012	135		8				2375	2389		10.1093/brain/aws171			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	984DQ	WOS:000307170300017	22798270	Bronze			2021-06-18	
J	Yeates, KO; Kaizar, E; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M; Taylor, HG				Yeates, Keith Owen; Kaizar, Eloise; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha; Taylor, H. Gerry			Reliable Change in Postconcussive Symptoms and Its Functional Consequences Among Children With Mild Traumatic Brain Injury	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							QUALITY-OF-LIFE; FAMILY ASSESSMENT DEVICE; HEAD-INJURY; IMPROVES ACCURACY; SEVERITY SCORE; ADOLESCENTS; VALIDITY; RELIABILITY; RECOVERY; MODELS	Objective: To examine reliable change in postconcussive symptoms and its functional consequences among children with mild traumatic brain injury (TBI) over the first year postinjury as compared with children with orthopedic injuries. Design: Prospective, longitudinal cohort. Setting: Emergency departments at 2 children's hospitals. Participants: Eight-to 15-year-old children with mild TBI (n=186) or orthopedic injuries (n=99). Main Exposure: Closed-head or orthopedic trauma. Main Outcome Measures: Parents rated preinjury symptoms retrospectively shortly after injury and postconcussive symptoms at 2 weeks and 3 and 12 months postinjury. A regression-based approach was used to determine whether each child displayed reliable increases in postconcussive symptoms at each postinjury occasion. Health-related quality of life was assessed at 3 and 12 months postinjury. Information regarding children's educational programming was collected at the initial and 12-month assessments. Results: Children with mild TBI were significantly more likely than those with orthopedic injuries to show reliable increases in both cognitive and somatic symptoms. Group differences in the likelihood of reliable increases became less common with time for somatic symptoms but persisted to 12 months postinjury for cognitive symptoms. Among children with mild TBI, reliable increases in symptoms were more common among children with loss of consciousness or abnormalities on neuroimaging. Reliable increases in symptoms were associated with significant declines in health-related quality of life and an increased likelihood of educational intervention. Conclusion: Many children with mild TBI show reliable increases in postconcussive symptoms that are associated with significant functional impairment in their daily lives.	[Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Kaizar, Eloise] Ohio State Univ, Dept Stat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Bangert, Barbara] Case Western Reserve Univ, Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH 44106 USA; [Bangert, Barbara] Case Western Reserve Univ, Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Wright, Martha; Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Cleveland, OH USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Nuss, Kathryn/0000-0003-2185-7364	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	The work was supported by grants HD44099 and HD39834 from the National Institutes of Health (Dr Yeates).	Achenbach TM., 1991, INTEGRATIVE GUIDE 19; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Ashwal S., 2010, PEDIAT TRAUMATIC BRA, P68; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Derogatis L., 1982, BRIEF SYMPTOM INVENT; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; McSweeny A., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Ouimet LA, 2009, J CLIN EXP NEUROPSYC, V31, P73, DOI 10.1080/13803390801992725; Palermo TM, 2008, J PEDIATR PSYCHOL, V33, P983, DOI 10.1093/jpepsy/jsn038; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Taylor HG., 2006, EXCEPTIONALITY, V14, P141, DOI [10.1207/s15327035ex1403_3, DOI 10.1207/S15327035EX1403_3, DOI 10.1207/S15327035EX1403_]; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	43	91	91	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2012	166	7					615	622		10.1001/archpediatrics.2011.1082			8	Pediatrics	Pediatrics	967HJ	WOS:000305897200007	22393171	Bronze, Green Accepted			2021-06-18	
J	Lucas, S; Hoffman, JM; Bell, KR; Walker, W; Dikmen, S				Lucas, Sylvia; Hoffman, Jeanne M.; Bell, Kathleen R.; Walker, William; Dikmen, Sureyya			Characterization of headache after traumatic brain injury	CEPHALALGIA			English	Article						Headache; traumatic brain injury; TBI; post-traumatic headache; PTH; migraine; probable migraine; tension-type headache; cervicogenic headache; secondary headaches	POSTTRAUMATIC HEADACHE; MIGRAINE; PATHOGENESIS; SOLDIERS; RATES	Background: Headache is a common and persistent symptom following traumatic brain injury (TBI). Headaches following TBI are defined primarily by their temporal association to injury, but have no defining clinical features. To provide a framework for treatment, primary headache symptoms were used to characterize headache. Methods: Three hundred and seventy-eight participants were prospectively enrolled during acute in-patient rehabilitation for TBI. Headaches were classified into migraine/probable migraine, tension-type, or cervicogenic headache at baseline and 3, 6, and 12 months following TBI. Results: Migraine was the most frequent headache type occurring in up to 38% of participants who reported headaches. Probable migraine occurred in up to 25%, tension-type headache in up to 21%, then cervicogenic headache in up to 10%. Females were more likely to have endorsed pre-injury migraine than males, and had migraine or probable migraine at all time points after injury. Those classified with migraine were more likely to have frequent headaches. Conclusions: Our data show that most headache after TBI may be classified using primary headache criteria. Migraine/probable migraine described the majority of headache after TBI across one year post-injury. Using symptom-based criteria for headache following TBI can serve as a framework from which to provide evidence-based treatment for these frequent, severe, and persistent headaches.	[Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Lucas, Sylvia; Hoffman, Jeanne M.; Bell, Kathleen R.; Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Walker, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Lucas, S (corresponding author), Univ Washington, Dept Neurol, Box 356097, Seattle, WA 98195 USA.	lucass@uw.edu		Bell, Kathleen/0000-0002-0928-2046	Department of Education, National Institute on Disability and Rehabilitation Research; TBI Model Systems: University of Washington Traumatic Brain Injury Model System [H133A070032]; Virginia Commonwealth Traumatic Brain Injury Model System [H133A070036]; NIDRR; Wadsworth Foundation; MerckMerck & Company; GSKGlaxoSmithKline; Map; Nupathe; St. Jude MedicalSt. Jude Medical; BiogenIdecBiogen; Sanofi-AventisSanofi-Aventis; John L. Locke Foundation; National Headache Foundation; EMD Serono-PfizerPfizer; Zogenix; NovartisNovartis; Allozyne	This study was funded by the Department of Education, National Institute on Disability and Rehabilitation Research, TBI Model Systems: University of Washington Traumatic Brain Injury Model System H133A070032, Virginia Commonwealth Traumatic Brain Injury Model System H133A070036. Dr Lucas received funding from NIDRR and Wadsworth Foundation for this study. Other research funding has been from Merck, GSK, Map, Nupathe, St. Jude Medical (formerly AGA), BiogenIdec, Sanofi-Aventis, John L. Locke Foundation and the National Headache Foundation. Honoraria, advisory or consulting fees have been received from Merck, GSK, BiogenIdec, EMD Serono-Pfizer, Zogenix, Map, Novartis and Allozyne. Dr Hoffman receives research funding from NIDRR. Dr Bell receives research funding from NIDRR. Dr Walker receives research funding from NIDRR. Dr Dikmen receives research funding from NIDRR.	Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Faul M, TRAUMATIC BRAIN INJU; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; *INT HEAD SOC HEAD, 2004, CEPHALALGIA S1, P9; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lieba-Samal D, 2011, CEPHALALGIA, V31, P1618, DOI 10.1177/0333102411428954; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; STEWART WF, 1991, AM J EPIDEMIOL, V134, P1111, DOI 10.1093/oxfordjournals.aje.a116014; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; Tanielian T., 2008, INVISIBLE WOUNDS WAR, P3; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	18	91	91	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	JUN	2012	32	8					600	606		10.1177/0333102412445224			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	959XS	WOS:000305352100004	22623761				2021-06-18	
J	Zhuang, L; Yang, T; Zhao, HL; Fidalgo, AR; Vizcaychipi, MP; Sanders, RD; Yu, BW; Takata, M; Johnson, MR; Ma, DQ				Zhuang, Lei; Yang, Ting; Zhao, Hailin; Fidalgo, Antonio Rei; Vizcaychipi, Marcela P.; Sanders, Robert D.; Yu, Buwei; Takata, Masao; Johnson, Mark R.; Ma, Daqing			The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats	CRITICAL CARE MEDICINE			English	Article						argon; helium; hypoxia-ischemia; neuroprotection; noble gas; xenon	HYPOXIC-ISCHEMIC ENCEPHALOPATHY; TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; CELL-DEATH; MODERATE HYPOTHERMIA; POTASSIUM CHANNELS; CEREBRAL-ISCHEMIA; NITROUS-OXIDE; CYTOCHROME-C; NOBLE-GASES	Objective: Xenon provides neuroprotection in multiple animal models; however, little is known about the other noble gases. The aim of the current study was to compare xenon, argon, and helium neuroprotection in a neonatal asphyxia model in rats. Design: Randomized controlled trial. Setting: Laboratory. Subjects: Seven-day-old postnatal Sprague-Dawley rats. Interventions: Seventy percent argon, helium, xenon, or nitrogen balanced with oxygen after hypoxic-ischemic brain injury. Measurements and Main Results: Control animals undergoing moderate hypoxic-ischemia endured reduced neuronal survival at 7 days with impaired neurologic function at the juvenile age compared with naive animals. Severe hypoxic-ischemic damage produced a large cerebral infarction in controls. After moderate hypoxic-ischemia, all three noble gases improved cell survival, brain structural integrity, and neurologic function on postnatal day 40 compared with nitrogen. Interestingly, argon improved cell survival to naive levels, whereas xenon and helium did not. When tested against more severe hypoxic-ischemic injury only, argon and xenon reduced infarct volume. Furthermore, postinjury body weight in moderate insult was lower in the helium-treated group compared with the naive, control, and other noble gas treatment groups, whereas in the severe injurious setting, it is lower in both control and helium-treated groups than other groups. In the nondirectly injured hemisphere, argon, helium, and xenon increased the expression of Bcl-2, whereas helium and xenon increased Bcl-xL. In addition, Bax expression was enhanced in the control and helium groups. Conclusions: These studies indicate that argon and xenon provide neuroprotection against both moderate and severe hypoxia-ischemic brain injury likely through prosurvival proteins synthesis. (Crit Care Med 2012; 40:1724-1730)	[Zhuang, Lei; Yang, Ting; Zhao, Hailin; Fidalgo, Antonio Rei; Vizcaychipi, Marcela P.; Sanders, Robert D.; Takata, Masao; Ma, Daqing] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Anaesthet Intens Care & Pain Med, London, England; [Zhuang, Lei; Yu, Buwei] Shanghai Jiao Tong Univ, Sch Med, Dept Anesthesiol, Rui Jin Hosp, Shanghai 200030, Peoples R China; [Johnson, Mark R.] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Surg & Canc, London, England	Ma, DQ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Anaesthet Intens Care & Pain Med, London, England.	d.ma@imperial.ac.uk	Fidalgo, Antonio R/A-7402-2010; Vizcaychipi, Marcela/H-5487-2011; Sanders, Robert/A-7844-2012	Fidalgo, Antonio R/0000-0003-3384-0017; Vizcaychipi, Marcela/0000-0001-7894-873X; Ma, Daqing/0000-0003-1235-0537; Ma, Daqing/0000-0002-0688-2097; Sanders, Robert/0000-0003-0113-0328	SPARKS, London, UK [10IMP01]; Chinese Society of Anesthesiology, Beijing, China; Sparks Charity [10IMP01] Funding Source: researchfish	This work was supported partially by a grant (10IMP01) from SPARKS, London, UK. Drs. Zhuang and Yang were supported by a scholarship from Chinese Society of Anesthesiology, Beijing, China.	Abraini JH, 2003, ANESTH ANALG, V96, P746, DOI 10.1213/01.ANE.0000050282.14291.38; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bantel C, 2009, ANESTHESIOLOGY, V110, P986, DOI 10.1097/ALN.0b013e31819dadc7; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; David HN, 2009, J CEREBR BLOOD F MET, V29, P1159, DOI 10.1038/jcbfm.2009.40; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Heinen A, 2008, ANESTHESIOLOGY, V109, P830, DOI 10.1097/ALN.0b013e3181895aa0; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; Johnson SA, 2008, J NEUROSURG ANESTH, V20, P21, DOI 10.1097/ANA.0b013e3181271850; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2007, ANESTHESIOLOGY, V106, P746, DOI 10.1097/01.anes.0000264762.48920.80; Ma DQ, 2009, J AM SOC NEPHROL, V20, P713, DOI 10.1681/ASN.2008070712; Ma DQ, 2006, J CEREBR BLOOD F MET, V26, P199, DOI 10.1038/sj.jcbfm.9600184; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Ma DQ, 2003, ANESTHESIOLOGY, V98, P690, DOI 10.1097/00000542-200303000-00017; MAJNO G, 1995, AM J PATHOL, V146, P3; Martin JL, 2007, BRIT J ANAESTH, V98, P236, DOI 10.1093/bja/ael340; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Pagel PS, 2008, J CARDIOTHOR VASC AN, V22, P554, DOI 10.1053/j.jvca.2008.04.005; Pagel PS, 2007, ANESTH ANALG, V105, P562, DOI 10.1213/01.ane.0000278083.31991.36; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Ryang YM, 2011, CRIT CARE MED, V39, P1448, DOI 10.1097/CCM.0b013e31821209be; Sanders RD, 2010, ANESTHESIOLOGY, V113, P233, DOI 10.1097/ALN.0b013e3181dc1b84; Schmidt M, 2005, ANESTHESIOLOGY, V102, P929, DOI 10.1097/00000542-200505000-00011; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shindler KS, 1997, J NEUROSCI, V17, P3112; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004	39	91	94	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2012	40	6					1724	1730		10.1097/CCM.0b013e3182452164			7	Critical Care Medicine	General & Internal Medicine	946EZ	WOS:000304335600005	22610177				2021-06-18	
J	Washington, CW; Grubb, RL				Washington, Chad W.; Grubb, Robert L., Jr.			Are routine repeat imaging and intensive care unit admission necessary in mild traumatic brain injury?	JOURNAL OF NEUROSURGERY			English	Article						mild traumatic brain injury; head computed tomography; intensive care unit admission	HEAD COMPUTED-TOMOGRAPHY; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; CT; PROGRESSION; CLASSIFICATION; MORTALITY; TRIAL	Object. More than 1.5 million Americans suffer a traumatic brain injury (TBI) each year. Seventy-five percent of these patients have a mild TBI, with Glasgow Coma Scale (GCS) Score 13-15. At the authors' institution, the usual practice has been to admit those patients with an associated intracranial hemorrhage (ICH) to an ICU and to obtain repeat head CT scans 12-24 hours after admission. The purpose of this study was to determine if there exists a subpopulation of mild TBI patients with an abnormal head CT scan that requires neither repeat brain imaging nor admission to an ICU. This group of patients was further classified based on initial clinical factors and imaging characteristics. Methods. A retrospective review of all patients admitted to a Level I trauma center from January 2007 through December 2008 was performed using the hospital Trauma Registry Database, medical records, and imaging data. The inclusion criteria were as follows: 1) an admission GCS score >= 13; 2) an isolated head injury with no other injury requiring ICU admission; 3) an initial head CT scan positive for ICH; and 4) an initial management plan that was nonoperative. Collected data included age, etiology, initial GCS score, time of injury, duration of ICU stay, duration of hospital stay, and anticoagulation status. Primary outcomes measured were the occurrence of neurological or medical decline and the need for neurosurgical intervention. Imaging data were analyzed and classified based on the predominant blood distribution found on admission imaging. Data were further categorized based on the Marshall CT classification, Rotterdam score, and volume of intraparenchymal hemorrhage (IPH). Progression was defined as an increase in the Marshall classification, an increase in the Rotterdam score, or a 30% increase in IPH volume. Results. Three hundred twenty-one of 1101 reviewed cases met inclusion criteria for the study. Only 4 patients (1%) suffered a neurological decline and 4 (1%) required nonemergent neurosurgical intervention. There was a medical decline in 18 of the patients (6%) as a result of a combination of events such as respiratory distress, myocardial infarction, and sepsis. Both patient age and the transfusion of blood products were significant predictors of medical decline. Overall patient mortality was 1%. Based on imaging data, the rate of injury progression was 6%. The only type of ICH found to have a significant rate of progression (53%) was a subfrontal/temporal intraparenchymal contusion. Other variables found to be significant predictors of progression on head CT scans were the use of anticoagulation, an age over 65 years, and a volume of ICH > 10 ml. Conclusions. Most patients with mild TBI have a good outcome without the necessity of neurosurgical intervention. Mild TBI patients with a convexity SAH, small convexity contusion, small IPH (<= 10 ml), and/or small subdural hematoma do not require admission to an ICU or repeat imaging in the absence of a neurological decline. (DOI: 10.3171/2011.11.JNS111092)	[Washington, Chad W.; Grubb, Robert L., Jr.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA	Washington, CW (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, 660 S Euclid Ave,Campus Box 8057, St Louis, MO 63110 USA.	washingtonc@wudosis.wustl.edu					Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Egol A, 1999, CRIT CARE MED, V27, P633; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GREENBERG MS, 1997, HDB NEUROSURGERY; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; Park HK, 2009, BRIT J NEUROSURG, V23, P617, DOI 10.3109/02688690902999302; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	23	91	91	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2012	116	3					549	557		10.3171/2011.11.JNS111092			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	897LL	WOS:000300652100017	22196096				2021-06-18	
J	Vos, PE; Alekseenko, Y; Battistin, L; Ehler, E; Gerstenbrand, F; Muresanu, DF; Potapov, A; Stepan, CA; Traubner, P; Vecsei, L; von Wild, K				Vos, P. E.; Alekseenko, Y.; Battistin, L.; Ehler, E.; Gerstenbrand, F.; Muresanu, D. F.; Potapov, A.; Stepan, C. A.; Traubner, P.; Vecsei, L.; von Wild, K.			Mild traumatic brain injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						guideline; mild traumatic brain injury	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; VALIDATION; GUIDELINES; RECOMMENDATIONS; RULE; CT; RELIABILITY; PREDICTION; MANAGEMENT	Traumatic Brain Injury (TBI) is among the most frequent neurological disorders. Of all TBIs 90% are considered mild with an annual incidence of 100-300/100.000. Intracranial complications of Mild Traumatic Brain Injury (MTBI) are infrequent (10%), requiring neurosurgical intervention in a minority of cases (1%), but potentially life-threatening (case fatality rate 0,1%). Hence, a true health management problem exists because of the need to exclude the small chance of a life threatening complication in large numbers of individual patients. The 2002 EFNS guidelines used a best evidence approach based on the literature until 2001 to guide initial management with respect to indications for CT, hospital admission, observation and follow up of MTBI patients. This updated EFNS guideline version for initial management in MTBI proposes a more selectively strategy for CT when major(dangerous mechanism, GCS<15, 2 points deterioration on the GCS, clinical signs of (basal) skull fracture, vomiting, anticoagulation therapy, post traumatic seizure) or minor(age, loss of consciousness, persistent anterograde amnesia, focal deficit, skull contusion, deterioration on the GCS) risk factors are present based on published decision rules with a high level of evidence. In addition clinical decision rules for CT now exist for children as well. Since 2001 recommendations, although with a lower level of evidence, have been published for clinical in hospital observation to prevent and treat other potential threads to the patient including behavioral disturbances (amnesia, confusion and agitation) and infection.	[Vos, P. E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Alekseenko, Y.] Vitebsk Med Univ, Vitebsk, BELARUS; [Battistin, L.] Clin Neurol I, Padua, Italy; [Ehler, E.] Neurol Clin, Pradubice, Czech Republic; [Gerstenbrand, F.] Ludwig Boltzmann Inst Restorat Neurol & Neuromodu, Vienna, Austria; [Muresanu, D. F.] Univ Med & Pharm Iuliu Hatieganu, Univ CFR Hosp, Cluj Napoca, Romania; [Potapov, A.] Russian Acad Med Sci, Inst Neurosurg, Moscow 109801, Russia; [Stepan, C. A.] Neurol Hosp Rosenh Gel, Vienna, Austria; [Traubner, P.] Comenius Univ, Sch Med, Bratislava, Slovakia; [Vecsei, L.] Szent Gyorgyi Univ Hosp, Szeged, Hungary; [von Wild, K.] Westphalien Univ Munster, Fac Med, Hannover, Germany; [von Wild, K.] Inst INI, Hannover, Germany	Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Hp 935,Reinier Postlaan 4,POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Inglese, Matilde/AAH-3189-2020; Muresanu, Fior-Dafin/AAI-8120-2021; Alekseenko, Yuri/G-9497-2016; Vecsei, Laszlo/B-2066-2010	Inglese, Matilde/0000-0002-9610-0297; Ehler, Edvard/0000-0001-6212-6301; Alekseenko, Urii Vladimirovic/0000-0002-1356-9496; Ehler, Edvard/0000-0002-0595-7712; Vecsei, Laszlo/0000-0001-8037-3672			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; American College of Surgeons, 1997, ADV TRAUM LIF SUPP D, V6th ed; [Anonymous], 2007, NAT I CLIN EXC HEAD; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brainin M, 2004, EUR J NEUROL, V11, P577, DOI 10.1111/j.1468-1331.2004.00867.x; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; FROWEIN R A, 1989, Neurosurgical Review, V12, P184, DOI 10.1007/BF01790644; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SERVADEI F, 1995, ACTA NEUROCHIR, V133, P50, DOI 10.1007/BF01404947; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P463; Twijnstra A, 2001, COMMISSIE KWALITEITS, V1, P1; Valadka AB, 1996, NEUROTRAUMA, P119; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	34	91	94	0	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	FEB	2012	19	2					191	198		10.1111/j.1468-1331.2011.03581.x			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	878KH	WOS:000299255300006	22260187	Bronze, Green Accepted			2021-06-18	
J	Funk, JR; Rowson, S; Daniel, RW; Duma, SM				Funk, James R.; Rowson, Steven; Daniel, Ray W.; Duma, Stefan M.			Validation of Concussion Risk Curves for Collegiate Football Players Derived from HITS Data	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Injury criteria; Head; Brain; MTBI; Acceleration; Tolerance; Incidence; Exposure	HIGH-SCHOOL FOOTBALL; HEAD IMPACTS; PROFESSIONAL FOOTBALL; DIVISION-I; INJURY; ACCELERATION; EPIDEMIOLOGY	For several years, Virginia Tech and other schools have measured the frequency and severity of head impacts sustained by collegiate American football players in real time using the Head Impact Telemetry (HIT) System of helmet-mounted accelerometers. In this study, data from 37,128 head impacts collected at Virginia Tech during games from 2006 to 2010 were analyzed. Peak head acceleration exceeded 100 g in 516 impacts, and the Head Injury Criterion (HIC) exceeded 200 in 468 impacts. Four instrumented players in the dataset sustained a concussion. These data were used to develop risk curves for concussion as a function of peak head acceleration and HIC. The validity of this biomechanical approach was assessed using epidemiological data on concussion incidence from other sources. Two specific aspects of concussion incidence were addressed: the variation by player position, and the frequency of repeat concussions. The HIT System data indicated that linemen sustained the highest overall number of head impacts, while skill positions sustained a higher number of more severe head impacts (peak acceleration > 100 g or HIC > 200). When weighted using injury risk curves, the HIT System data predicted a higher incidence of concussion in skill positions compared to linemen at rates that were in strong agreement with the epidemiological literature (Pearson's r = 0.72-0.87). The predicted rates of repeat concussions (21-39% over one season and 33-50% over five seasons) were somewhat higher than the ranges reported in the epidemiological literature. These analyses demonstrate that simple biomechanical parameters that can be measured by the HIT System possess a high level of power for predicting concussion.	[Funk, James R.] Biodynam Res Corp, San Antonio, TX 78249 USA; [Rowson, Steven; Daniel, Ray W.; Duma, Stefan M.] Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA	Funk, JR (corresponding author), Biodynam Res Corp, 5711 Univ Hts Blvd,Suite 100, San Antonio, TX 78249 USA.	jfunk@brconline.com	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; 	National Institutes of Health (National Institute for Child Health and Human Development)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The authors gratefully acknowledge the National Institutes of Health (National Institute for Child Health and Human Development) R01HD048638 for sponsoring this research.	Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dick R, 2007, J ATHL TRAINING, V42, P221; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Versace J., 1971, SAE TECHNICAL PAPER; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	32	91	91	2	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		79	89		10.1007/s10439-011-0400-8			11	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700007	21994060				2021-06-18	
J	Lim, JY; Jeong, CH; Jun, JA; Kim, SM; Ryu, CH; Hou, Y; Oh, W; Chang, JW; Jeun, SS				Lim, Jung Yeon; Jeong, Chang Hyun; Jun, Jin Ae; Kim, Seong Muk; Ryu, Chung Heon; Hou, Yun; Oh, Wonil; Chang, Jong Wook; Jeun, Sin-Soo			Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia	STEM CELL RESEARCH & THERAPY			English	Article							MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; NEURAL CELLS; BONE; STROKE; TRANSPLANTATION; DIFFERENTIATION; EXPRESSION; ANGIOGENESIS; PHENOTYPES	Introduction: Stem cell transplantation is a promising therapeutic strategy for the treatment of stroke. Mesenchymal stem cells (MSCs) are a potential cell source for clinical application because they can be easily obtained and cultivated with a high proliferative capacity. The safety and efficacy of cell therapy depends on the mode of cell administration. To determine the therapeutic potential of intrathecal administration of MSCs by lumbar puncture (LP), we administrated human umbilical cord blood-derived MSCs (hUCB-MSCs) intrathecally into the lumbar spinal cord or intravenously into the tail vein in a rat model of stroke, and then investigated whether hUCB-MSCs could enter the brain, survive, and improve post-stroke neurological functional recovery. Methods: hUCB-MSCs (1.0 x 10(6)) were administrated three days after stroke induced by occlusion of the middle cerebral artery. The presence of hUCB-MSCs and their survival and differentiation in the brain tissue of the rats was examined by immunohistochemistry. Recovery of coordination of movement after administration of hUCB-MSCs was examined using a Rotarod test and adhesive-removal test on the 7th, 14th, 21st, and 28th days after ischemia. The volume of ischemic lesions seven days after the experimental procedure was evaluated using 2-3-5-triphenyltetrazolium (TTC) staining. Results: Rats receiving hUCB-MSCs intrathecally by LP had a significantly higher number of migrated cells within the ischemic area when compared with animals receiving cells intravenously. In addition, many of the cells administered intrathecally survived and a subset of them expressed mature neural-lineage markers, including the mature neuron marker NeuN and glial fibrillary acidic protein, typical of astrocytes. Animals that received hUCB-MSCs had significantly improved motor function and reduced ischemic damage when compared with untreated control animals. Regardless of the administration route, the group treated with 1 x 10(6) hUCB-MSCs showed better neurological recovery, without significant differences between the two treatment groups. Importantly, intrathecal administration of 5 x 10(5) hUCB-MSCs significantly reduced ischemic damage, but not in the intravenously treated group. Furthermore, the cells administered intrathecally survived and migrated into the ischemic area more extensively, and differentiated significantly into neurons and astrocytes. Conclusions: Together, these results indicate that intrathecal administration of MSCs by LP may be useful and feasible for MSCs treatment of brain injuries, such as stroke, or neurodegenerative disorders.	[Lim, Jung Yeon; Jeong, Chang Hyun; Jun, Jin Ae; Kim, Seong Muk; Ryu, Chung Heon; Hou, Yun; Jeun, Sin-Soo] Catholic Univ Korea, Dept Biomed Sci, Coll Med, Seoul 137701, South Korea; [Jeun, Sin-Soo] Catholic Univ Korea, Dept Neurosurg, Seoul St Marys Hosp, Seoul 137701, South Korea; [Oh, Wonil; Chang, Jong Wook] MEDIPOST Co Ltd, Medipost Biomed Res Inst, Seoul 137073, South Korea	Jeun, SS (corresponding author), Catholic Univ Korea, Dept Biomed Sci, Coll Med, Seoul 137701, South Korea.	ssjeun@catholic.ac.kr		Oh, Wonil/0000-0002-6349-738X	Ministry for Health, Welfare & Family Affairs, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A092258]; National Research Foundation of Korea (NRF)National Research Foundation of Korea; Ministry of Education, Science and Technology, Republic of KoreaMinistry of Education, Science and Technology, Republic of Korea [2010-0022845]; Korea Food and Drug Administration [10172KFDA993]	This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A092258) and by the Basic Science Research program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0022845), Republic of Korea, and by a grant (10172KFDA993) from Korea Food and Drug Administration in 2011.	Bakshi A, 2006, J NEUROTRAUM, V23, P55, DOI 10.1089/neu.2006.23.55; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brooke G, 2007, SEMIN CELL DEV BIOL, V18, P846, DOI 10.1016/j.semcdb.2007.09.012; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Goodwin HS, 2001, BIOL BLOOD MARROW TR, V7, P581, DOI 10.1053/bbmt.2001.v7.pm11760145; Jeong JA, 2005, STEM CELLS, V23, P584, DOI 10.1634/stemcells.2004-0304; Keating A, 2006, CURR OPIN HEMATOL, V13, P419, DOI 10.1097/01.moh.0000245697.54887.6f; Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038; Le Blanc K, 2003, SCAND J IMMUNOL, V57, P11, DOI 10.1046/j.1365-3083.2003.01176.x; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lim JY, 2008, J NEUROSCI RES, V86, P2168, DOI 10.1002/jnr.21669; Lim JY, 2006, EXP NEUROL, V199, P416, DOI 10.1016/j.expneurol.2006.01.015; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Mueller SM, 2001, J CELL BIOCHEM, V82, P583, DOI 10.1002/jcb.1174; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Shichinohe H, 2006, J NUCL MED, V47, P486; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yang SE, 2004, CYTOTHERAPY, V6, P476, DOI 10.1080/14653240410005041; Yang WZ, 2010, J TRANSL MED, V75, P1; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	40	91	102	0	26	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1757-6512		STEM CELL RES THER	Stem Cell Res. Ther.	SEP 22	2011	2								38	10.1186/scrt79			13	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	889XL	WOS:000300108900001	21939558	DOAJ Gold, Green Published			2021-06-18	
J	Clausen, F; Hanell, A; Israelsson, C; Hedin, J; Ebendal, T; Mir, AK; Gram, H; Marklund, N				Clausen, Fredrik; Hanell, Anders; Israelsson, Charlotte; Hedin, Johanna; Ebendal, Ted; Mir, Anis K.; Gram, Hermann; Marklund, Niklas			Neutralization of interleukin-1 beta reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						behavior; cognition; edema; microglia; traumatic brain injury	CONTROLLED CORTICAL IMPACT; AMYLOID PRECURSOR PROTEIN; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; RECEPTOR ANTAGONIST; SUBARACHNOID HEMORRHAGE; EXPERIMENTAL STROKE; MEMORY PROCESSES	Increasing evidence suggests that interleukin-1 beta (IL-1 beta) is a key mediator of the inflammatory response following traumatic brain injury (TBI). Recently, we showed that intracerebroventricular administration of an IL-1 beta-neutralizing antibody was neuroprotective following TBI in mice. In the present study, an anti-IL-1 beta antibody or control antibody was administered intraperitoneally following controlled cortical injury (CCI) TBI or sham injury in 105 mice and we extended our histological, immunological and behavioral analysis. First, we demonstrated that the treatment antibody reached target brain regions of brain-injured animals in high concentrations (> 11 nm) remaining up to 8 days post-TBI. At 48 h post-injury, the anti-IL-1b treatment attenuated the TBI-induced hemispheric edema (P < 0.05) but not the memory deficits evaluated using the Morris water maze (MWM). Neutralization of IL-1 beta did not influence the TBI-induced increases (P < 0.05) in the gene expression of the Ccl3 and Ccr2 chemokines, IL-6 or Gfap. Up to 20 days post-injury, neutralization of IL-1 beta was associated with improved visuospatial learning in the MWM, reduced loss of hemispheric tissue and attenuation of the microglial activation caused by TBI (P < 0.05). Motor function using the rotarod and cylinder tests was not affected by the anti-IL-1 beta treatment. Our results suggest an important negative role for IL-1 beta in TBI. The improved histological and behavioral outcome following anti-IL-1 beta treatment also implies that further exploration of IL-1 beta-neutralizing compounds as a treatment option for TBI patients is warranted.	[Clausen, Fredrik; Hanell, Anders; Hedin, Johanna; Marklund, Niklas] Uppsala Univ, Univ Uppsala Hosp, Sect Neurosurg, Dept Neurosci, S-75185 Uppsala, Sweden; [Israelsson, Charlotte; Ebendal, Ted] Uppsala Univ, Sect Dev Biol, Dept Neurosci, S-75185 Uppsala, Sweden; [Mir, Anis K.; Gram, Hermann] Novartis Inst Biomed Res, Basel, Switzerland	Marklund, N (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Sect Neurosurg, Dept Neurosci, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	niklas.marklund@neuro.uu.se	Hanell, Anders/E-4776-2011	Hanell, Anders/0000-0001-9369-3886; Marklund, Niklas/0000-0002-9797-5626; Clausen, Fredrik/0000-0003-3592-4417	Swedish Brain Foundation; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Hospital; Jeanssons Foundation; Uppsala University	The authors would like to thank Annika Kylberg for invaluable technical assistance. The work was supported by grants from the Swedish Brain Foundation, The Swedish Research Council, Uppsala University Hospital and Jeanssons Foundation, and funds from Uppsala University.	Alten R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2438; Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Basu A, 2002, J NEUROSCI, V22, P6071; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; Biber K, 2002, NEUROSCIENCE, V112, P487, DOI 10.1016/S0306-4522(02)00114-8; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chapman KZ, 2009, J CEREBR BLOOD F MET, V29, P1764, DOI 10.1038/jcbfm.2009.113; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Clark RSB, 1999, FASEB J, V13, P813; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; FAN L, 1995, MOL BRAIN RES, V30, P125; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Ferrari CC, 2004, AM J PATHOL, V165, P1827, DOI 10.1016/S0002-9440(10)63438-4; Fogal B, 2008, J NEUROCHEM, V106, P1, DOI 10.1111/j.1471-4159.2008.05315.x; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Glasper ER, 2010, HIPPOCAMPUS, V20, P706, DOI 10.1002/hipo.20672; Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hein AM, 2010, BRAIN BEHAV IMMUN, V24, P243, DOI 10.1016/j.bbi.2009.10.002; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; McIntosh TK, 1996, LAB INVEST, V74, P315; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Miller DW, 1999, J NEUROVIROL, V5, P570, DOI 10.3109/13550289909021286; Moore AH, 2009, NEUROSCIENCE, V164, P1484, DOI 10.1016/j.neuroscience.2009.08.073; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murray CA, 1998, J NEUROSCI, V18, P2974; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Price CJS, 2003, J NEUROL NEUROSUR PS, V74, P1476, DOI 10.1136/jnnp.74.11.1476; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sas A, 2008, NEUROCHEM RES, V33, P2281, DOI 10.1007/s11064-008-9715-8; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schilling M, 2009, NEUROSCIENCE, V161, P806, DOI 10.1016/j.neuroscience.2009.04.025; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwab JM, 2002, J NEUROSURG, V96, P892, DOI 10.3171/jns.2002.96.5.0892; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thornton P, 2008, MOL CELL NEUROSCI, V37, P135, DOI 10.1016/j.mcn.2007.09.002; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; Walker CT, 2010, BRAIN RES, V1347, P125, DOI 10.1016/j.brainres.2010.05.075; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Winkler DT, 2010, BIOL PSYCHIAT, V68, P971, DOI 10.1016/j.biopsych.2010.01.030; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xu HP, 2005, J IMMUNOL, V175, P6915, DOI 10.4049/jimmunol.175.10.6915; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	85	91	99	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUL	2011	34	1					110	123		10.1111/j.1460-9568.2011.07723.x			14	Neurosciences	Neurosciences & Neurology	789NO	WOS:000292522400012	21623956				2021-06-18	
J	Kim, JJ; Gean, AD				Kim, Jane J.; Gean, Alisa D.			Imaging for the Diagnosis and Management of Traumatic Brain Injury	NEUROTHERAPEUTICS			English	Article						TBI; hemorrhage; subdural; epidural; contusion; traumatic shear injury	DIFFUSE AXONAL INJURY; SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; WHITE-MATTER INJURY; DECOMPRESSIVE CRANIECTOMY; INTRACEREBRAL HEMATOMA; CONSORTIUM SURVEY; CLINICAL-TRIALS; CT; LESIONS	To understand the role of imaging in traumatic brain injury (TBI), it is important to appreciate that TBI encompasses a heterogeneous group of intracranial injuries and includes both insults at the time of impact and a deleterious secondary cascade of insults that require optimal medical and surgical management. Initial imaging identifies the acute primary insult that is essential to diagnosing TBI, but serial imaging surveillance is also critical to identifying secondary injuries such as cerebral herniation and swelling that guide neurocritical management. Computed tomography (CT) is the mainstay of TBI imaging in the acute setting, but magnetic resonance tomography (MRI) has better diagnostic sensitivity for nonhemorrhagic contusions and shear-strain injuries. Both CT and MRI can be used to prognosticate clinical outcome, and there is particular interest in advanced applications of both techniques that may greatly improve the sensitivity of conventional CT and MRI for both the diagnosis and prognosis of TBI.	[Kim, Jane J.; Gean, Alisa D.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, San Francisco, CA 94143 USA	Kim, JJ (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, 1001 Potrero Ave,Box 1325, San Francisco, CA 94143 USA.	jane.kim@radiology.ucsf.edu					Aiken AH, 2010, SEMIN ROENTGENOL, V45, P63, DOI 10.1053/j.ro.2009.09.007; Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P30; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Centers for Disease Control and Prevention, TRAUM BRAIN INJ; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOKSEY M, 1993, BRIT J NEUROSURG, V7, P611, DOI 10.3109/02688699308995090; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Gean AD, 2010, RADIOLOGY, V257, P212, DOI 10.1148/radiol.10092075; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marion DW, 2006, NEUROSURGERY, V58, P655; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Munch E, 2000, NEUROSURGERY, V47, P315; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Rauscher A, 2005, AM J NEURORADIOL, V26, P736; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2000, NEUROSURGERY, V46, P70; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	57	91	101	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JAN	2011	8	1					39	53		10.1007/s13311-010-0003-3			15	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	750RU	WOS:000289566500006	21274684	Other Gold, Green Published			2021-06-18	
J	High, WM; Briones-Galang, M; Clark, JA; Gilkison, C; Mossberg, KA; Zgaljardic, DJ; Masel, BE; Urban, RJ				High, Walter M. Jrl; Briones-Galang, Maria; Clark, Jessica A.; Gilkison, Charles; Mossberg, Kurt A.; Zgaljardic, Dennis J.; Masel, Brent E.; Urban, Randall J.			Effect of Growth Hormone Replacement Therapy on Cognition after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone deficiency; hypopituitarism; traumatic brain injury	QUALITY-OF-LIFE; FACTOR-I; POSTACUTE REHABILITATION; PITUITARY INSUFFICIENCY; GH DEFICIENCY; HYPOPITUITARISM; ADULTS; PERFORMANCE; DYSFUNCTION; MODERATE	Traumatic brain injury (TBI) is a major public health issue, and yet medical science has little to offer for the persistent symptoms that prevent many of these individuals from fully re-entering society. Post-traumatic hypopituitarism, and specifically growth hormone deficiency (GHD), has been found in a large percentage of individuals with chronic moderate to severe TBI. Presently, there are no published treatment studies of hormone replacement in this population. In this study, 83 subjects with chronic TBI were screened for hypopituitarism. Forty-two subjects were found to have either GHD or GH insufficiency (GHI), of which 23 agreed to be randomized to either a year of GH replacement or placebo. All subjects completed the study with no untoward side effects from treatment. A battery of neuropsychological tests and functional measures were administered before and after treatment. Improvement was seen on the following tests: Dominant Hand Finger Tapping Test, Wechsler Adult Intelligence Scale III-Information Processing Speed Index, California Verbal Learning Test II, and the Wisconsin Card Sorting Test (executive functioning). The findings of this pilot study provide preliminary evidence suggesting that some of the cognitive impairments observed in persons who are GHD/GHI after TBI may be partially reversible with appropriate GH replacement therapy.	[High, Walter M. Jrl; Clark, Jessica A.] Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Lexington, KY 40504 USA; [High, Walter M. Jrl] Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY 40504 USA; [High, Walter M. Jrl; Clark, Jessica A.] Univ Kentucky, Coll Med, Dept Psychol, Lexington, KY 40504 USA; [High, Walter M. Jrl] Univ Kentucky, Coll Med, SCoBIRC, Lexington, KY 40504 USA; [Briones-Galang, Maria] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Gilkison, Charles; Urban, Randall J.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA; [Mossberg, Kurt A.] Univ Texas Med Branch, Dept Phys Therapy, Galveston, TX USA; [Zgaljardic, Dennis J.] Univ Texas Med Branch, Dept Rehabil Sci, Galveston, TX USA; [Zgaljardic, Dennis J.; Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA	High, WM (corresponding author), Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Cardinal Hill Rehabil Hosp,SCoBIRC, 2050 Versailles Rd, Lexington, KY 40504 USA.	walter.high@uky.edu			Moody Endowment; Pfizer, Inc.Pfizer; National Center for Research Resources, National Institutes of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR00073, M01RR00188]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000188, M01RR000073] Funding Source: NIH RePORTER	This work was partially funded by the generous support of the Moody Endowment and Pfizer, Inc. Recombinant growth hormone was supplied by Pfizer, Inc. This study was conducted in the General Clinical Research Center (GCRC) at the University of Texas Medical Branch at Galveston, funded by grant M01RR00073, and on the GCRC at Baylor University, Houston, Texas, funded by grant M01RR00188 from the National Center for Research Resources, National Institutes of Health, U.S. Public Health Service.	Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; ALMQVIST O, 1986, PSYCHONEUROENDOCRINO, V11, P347, DOI 10.1016/0306-4530(86)90020-X; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P416, DOI 10.1016/j.ghir.2005.09.001; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Beca S. G., 2008, PITUITARY; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; BINNERTS A, 1992, CLIN ENDOCRINOL, V37, P79, DOI 10.1111/j.1365-2265.1992.tb02287.x; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; DUSICK JR, 2008, PITUITARY, pCH1, DOI DOI 10.1007/S11102-008-0130-6; EDWARDS OM, 1986, MEDICINE, V65, P281; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Hatton J, 2006, J NEUROSURG, V105, P843, DOI 10.3171/jns.2006.105.6.843; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; High WM, 2005, REHABILITATION TRAUM; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kreitschmann-Andermahr I, 2008, GROWTH HORM IGF RES, V18, P472, DOI 10.1016/j.ghir.2008.08.007; Landis J, 2006, ARCH PHYS MED REHAB, V87, P799, DOI 10.1016/j.apmr.2006.02.017; LE GREVES M, 2006, EXP BRAIN RES, V173, P267; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lichtenwalner RJ, 2006, J NEUROSCI RES, V83, P199, DOI 10.1002/jnr.20719; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lijffijt M, 2003, NEUROSCI LETT, V353, P123, DOI 10.1016/j.neulet.2003.09.028; LITTLEY MD, 1989, CLIN ENDOCRINOL, V31, P527, DOI 10.1111/j.1365-2265.1989.tb01276.x; Mahmoud GS, 2006, J NEUROPHYSIOL, V95, P2962, DOI 10.1152/jn.00947.2005; Maruff P, 2005, HORM RES, V64, P100, DOI 10.1159/000089325; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; Peace KA, 1998, CLIN ENDOCRINOL, V49, P391; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Poole NA, 2008, BRAIN INJURY, V22, P519, DOI 10.1080/02699050802132495; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; SARTORIO A, 1995, HORM RES, V44, P6, DOI 10.1159/000184582; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Tanriverdi F, 2010, PITUITARY, V13, P111, DOI 10.1007/s11102-009-0204-0; VAN DAM PS, 2005, PSYCHONEUROENDOCRINO, V30, P357; Wolf SL, 2007, RESTOR NEUROL NEUROS, V25, P549; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	60	91	96	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1565	1575		10.1089/neu.2009.1253			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500003	20578825	Green Published			2021-06-18	
J	Maruta, J; Suh, M; Niogi, SN; Mukherjee, P; Ghajar, J				Maruta, Jun; Suh, Minah; Niogi, Sumit N.; Mukherjee, Pratik; Ghajar, Jamshid			Visual Tracking Synchronization as a Metric for Concussion Screening	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Attention Network Test (ANT); California Verbal Learning Test; 2nd edition (CVLT-II); diffuse axonal injury (DAI); hemispheric specialization; head injury; neuroimaging; neuropsychology; prefrontal cortex; smooth pursuit; traumatic axonal injury	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; PURSUIT EYE-MOVEMENTS; WHITE-MATTER INJURY; HEAD-INJURY; SMOOTH-PURSUIT; PREFRONTAL CORTEX; WORKING-MEMORY; COGNITIVE CONTROL; REACTION-TIME	Our goal was to determine whether performance variability during predictive visual tracking can provide a screening measure for mild traumatic brain injury (mTBI). Seventeen subjects with chronic postconcussive syndrome and 9 healthy control subjects were included in this study. Eye movements were recorded with video-oculography as the subject visually tracked a target that moved through a circular trajectory. We compared the variability of gaze positional errors relative to the target with the microstructural integrity of white matter tracts as measured by the fractional anisotropy (FA) parameter of diffusion tensor imaging. Gaze error variability was significantly correlated with the mean FA values of the right anterior corona radiata (ACR) and the left superior cerebellar peduncle, tracts that support spatial processing and sustenance of attention, and the genu of the corpus callosum. Because the ACR and the genu are among the most frequently damaged white matter tracts in mTBI, the correlations imply that gaze error variability during visual tracking may provide a useful screening tool for mTBI. Gaze error variability was also significantly correlated with attention and working memory measures in neurocognitive testing; thus, measurement of visual tracking performance is promising as a fast and practical screening tool for mTBI.	[Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Suh, Minah] Sungkyunkwan Univ, Dept Biol Sci, Suwon, South Korea; [Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Niogi, Sumit N.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA	Ghajar, J (corresponding author), Brain Trauma Fdn, 7 World Trade Ctr,34th Floor,250 Greenwich St, New York, NY 10007 USA.	ghajar@braintrauma.org	Maruta, Jun/I-3790-2019; Mukherjee, Pratik/A-5446-2008	Maruta, Jun/0000-0002-5054-6605; Mukherjee, Pratik/0000-0001-7473-7409	Department of DefenseUnited States Department of Defense [W81XWH-08-10646, W81XWH-08-2-0177]; James S. McDonnell Foundation	This study was supported by Department of Defense grants W81XWH-08-10646 and W81XWH-08-2-0177 and James S. McDonnell Foundation grant for the Cognitive Neurobiological Research Consortium in Traumatic Brain Injury. The authors thank Rachel Kolster and Ranjeeta Sarkar for technical assistance with eye movement and cognitive testing, and Drs. Carl Johnson and Robert Zimmerman for the clinicalMRI analyses.	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; BARBAS H, 1984, EXP BRAIN RES, V55, P187; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chen Y, 2002, PROG BRAIN RES, V140, P255; Chua TC, 2008, CURR OPIN NEUROL, V21, P83, DOI 10.1097/WCO.0b013e3282f4594b; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; de Xivry JJO, 2007, J PHYSIOL-LONDON, V584, P11, DOI 10.1113/jphysiol.2007.139881; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghajar J, 2009, NEUROSCIENTIST, V15, P232, DOI 10.1177/1073858408326429; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Holbourn AHS, 1943, LANCET, V2, P438; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; IACONO WG, 1979, PSYCHOPHYSIOLOGY, V16, P94, DOI 10.1111/j.1469-8986.1979.tb01451.x; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jones DK, 1999, STROKE, V30, P393, DOI 10.1161/01.STR.30.2.393; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Kelly RM, 2003, J NEUROSCI, V23, P8432; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krauzlis RJ, 2005, NEUROSCIENTIST, V11, P124, DOI 10.1177/1073858404271196; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lim KO, 1999, ARCH GEN PSYCHIAT, V56, P367, DOI 10.1001/archpsyc.56.4.367; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salo R, 2009, BIOL PSYCHIAT, V65, P122, DOI 10.1016/j.biopsych.2008.08.004; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TUSA RJ, 1988, ANN NEUROL, V23, P174, DOI 10.1002/ana.410230211; Ullen F, 2008, J NEUROSCI, V28, P4238, DOI 10.1523/JNEUROSCI.0825-08.2008; UMEDA Y, 1975, ORL J OTO-RHINO-LARY, V37, P290, DOI 10.1159/000275237; Unsworth N, 2007, PSYCHOL REV, V114, P104, DOI 10.1037/0033-295X.114.1.104; VANDERSTEEN J, 1983, VISION RES, V23, P1655, DOI 10.1016/0042-6989(83)90180-3; VANGELDER P, 1990, COMPR PSYCHIAT, V31, P253, DOI 10.1016/0010-440X(90)90009-H; Weber B, 2005, J COGNITIVE NEUROSCI, V17, P113, DOI 10.1162/0898929052880002; White Tonya, 2008, Top Magn Reson Imaging, V19, P97, DOI 10.1097/RMR.0b013e3181809f1e	74	91	92	0	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					293	305		10.1097/HTR.0b013e3181e67936			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900007	20611047				2021-06-18	
J	Alahmadi, H; Vachhrajani, S; Cusimano, MD				Alahmadi, Hussein; Vachhrajani, Shobhan; Cusimano, Michael D.			The natural history of brain contusion: an analysis of radiological and clinical progression - Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; brain contusion; contusion progression; natural history	SEVERE HEAD-INJURY; COMPUTED-TOMOGRAPHY; CT-SCAN; TRAUMA; HEMORRHAGE; LESION	Object. Although brain contusions are a common neurosurgical condition, surprisingly little has been written about their natural history. The purpose of this study was to identify factors that predict radiological and clinically significant progression of this pattern of traumatic brain injury in patients who did not initially require surgery. On the basis of their results and the available literature, the authors suggest a management algorithm. Methods. The authors performed a retrospective review of clinical and radiological records of consecutive patients with brain contusions who initially underwent conservative treatment. Significant radiological progression was defined as a 30% increase in contusion size on CT scans. Statistical analysis was performed to identify clinical and radiological predictors of CT contusion progression, the significance of progression, and predictors of clinical outcome. Results. Of 98 patients identified with brain contusions who initially received conservative treatment, 44 (45%) had significant progression on CT, and 19 (19%) required surgical intervention. The initial size of the contusion and the presence of subdural hematoma were the only statistically significant predictors of CT progression in the multivariate analysis (p = 0.0212 and 0.05, respectively). Four patients required delayed contusion evacuation (3 had radiological progression on follow-up scans). Good Glasgow Coma Scale (GCS) scores on presentation and younger age were predictors of eventual discharge from the hospital (OR 1.471, CI 1.233-1.755, p < 0.001 and OR 0.949, CI 0.912-0.988, p = 0.011, respectively). No patients with an initial GCS score of 15 or an initial contusion size < 14 ml required delayed evacuation. Conclusions. Contusion progression is a common phenomenon that is seen more commonly in larger contusions. Patients with large contusions and low initial GCS scores are at risk for delayed deterioration. A proposed management algorithm for patients with contusions initially treated conservatively may help practitioners identify the best course of treatment. (DOI: 10.3171/2009.5.JNS081369)	[Alahmadi, Hussein; Vachhrajani, Shobhan; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON M5W 1B6, Canada	Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5W 1B6, Canada.	mountain@smh.toronto.on.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Marion DW, 2006, NEUROSURGERY, V58, P655; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2000, NEUROSURGERY, V46, P70; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	26	91	96	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2010	112	5					1139	1145		10.3171/2009.5.JNS081369			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	591BW	WOS:000277273600033	19575576				2021-06-18	
J	Ventura, T; Harrison-Felix, C; Carlson, N; DiGuiseppi, C; Gabella, B; Brown, A; DeVivo, M; Whiteneck, G				Ventura, Thomedi; Harrison-Felix, Cynthia; Carlson, Nichole; DiGuiseppi, Carolyn; Gabella, Barbara; Brown, Allen; DeVivo, Michael; Whiteneck, Gale			Mortality After Discharge From Acute Care Hospitalization With Traumatic Brain Injury: A Population-Based Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Comorbidity; Mortality; Population surveillance; Rehabilitation	LONG-TERM SURVIVAL; DEATH	Ventura T, Harrison-Felix C, Carlson N, DiGuiseppi C, Gabella B, Brown A, De Vivo M, Whiteneck G. Mortality after discharge from acute care hospitalization with traumatic brain injury: a population-based study. Arch Phys Med Rehabil 2010;91:20-9. Objective: To characterize mortality after acute hospitalization with traumatic brain injury (TBI) in a socioeconomically diverse population. Design: Population-based retrospective cohort study. Setting: Statewide TBI surveillance program. Participants: Colorado residents with TBI discharged alive from acute hospitalization between 1998 and 2003 (N=18,998). Interventions: Not applicable. Main Outcome Measures: Vital status at the end of the study period (December 31, 2005) and statewide population mortality rates were used to calculate all-cause and cause-specific standardized mortality ratios (SMRs) and life expectancy compared with population mortality rates. The influence of demographics, injury severity, and comorbid conditions on time until death was investigated using age-stratified Cox proportional hazards modeling. Results: Patients with TBI carried about 2.5 times the risk of death compared with the general population (SMR=2.47; 95% confidence interval [Cl], 2.31-2.65). Life expectancy reduction averaged 6 years. SMRs were largest for deaths caused by mental/behavioral (SMR=3.84; 95% Cl. 2.67-5.51) and neurologic conditions (SMR=2.79; 95% Cl, 2.07-3.77) and were smaller but significantly higher than 1.0 for an array of other causes. Injury severity and older age increased mortality among young people (age <20y). However, risk factors for mortality among adults age 20 and older involved multiple domains of demographics (eg, metropolitan residence), injury-related measures (eg, falls versus vehicular incidents), and comorbidity (eg, >= 3 comorbid health conditions versus none). Conclusions: TBI confers an increased risk of mortality in the months and years after hospital discharge. Although life expectancy is reduced across the population, the excess in mortality lessens as time since injury increases. Specific risk factors (eg, high injury severity, poor general health) pose an especially high threat to survival and should prompt an increased vigilance of health status, especially among younger patients.	[Harrison-Felix, Cynthia; Whiteneck, Gale] Craig Hosp, Englewood, CO 80113 USA; [Carlson, Nichole] Univ Colorado, Dept Biostat & Informat, Colorado Sch Publ Hlth, Denver, CO 80202 USA; [DiGuiseppi, Carolyn] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Denver, CO 80202 USA; [Ventura, Thomedi] Univ Colorado, MSPH MPH Program, Colorado Sch Publ Hlth, Denver, CO 80202 USA; [Harrison-Felix, Cynthia] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [DiGuiseppi, Carolyn; Whiteneck, Gale] Colorado State Univ, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA; [Gabella, Barbara] Colorado Dept Publ Hlth & Environm, Denver, CO USA; [DeVivo, Michael] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Brown, Allen] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA	Harrison-Felix, C (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	charrison-felix@craighospital.org	DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817; Brown, Allen W./0000-0001-7228-3351	Colorado Traumatic Brain Injury Trust; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR811509]	Supported by the Colorado Traumatic Brain Injury Trust Fund Research Program (Colorado Department of Human Services). DiGuiseppi was supported in part by the Centers for Disease Control and Prevention (grant no. R49/CCR811509). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.	Anderson R N, 2001, Natl Vital Stat Rep, V49, P1; [Anonymous], 1998, ABBR INJ SCAL AIS 19; Baguley I, 2000, BRAIN INJURY, V14, P505; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; COLLETT D, 2003, MODELLING SURVIVAL D; *CTR MED MED SERV, MED ENR STAT AG GROU; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; Donohue JT, 2007, J TRAUMA, V62, P419, DOI 10.1097/01.ta.0000219286.88179.18; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Lai DJ, 1996, AM J EPIDEMIOL, V143, P832; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marr AL., 2004, CENTRAL NERVOUS SYST; *MON CTR HLTH POL, 2008, CONC COMPL COM; National Center for Health Statistics, INT CLASS DIS; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Rosner B., 2006, FUNDAMENTALS BIOSTAT; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SHAVELLE RM, 2006, BRAIN INJURY MED PRI, P247; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; *US BUR CENS, 2008, METR MICR STAT AR; World Health Organization, 2006, INT STAT CLASS DIS R	30	91	91	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2010	91	1					20	29		10.1016/j.apmr.2009.08.151			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	592YG	WOS:000277417300004	20103393				2021-06-18	
J	Williams, WH; Cordan, G; Mewse, AJ; Tonks, J; Burgess, CNW				Williams, W. Huw; Cordan, Giray; Mewse, Avril J.; Tonks, James; Burgess, Crispin N. W.			Self-reported traumatic brain injury in male young offenders: A risk factor for re-offending, poor mental health and violence?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Prisoner health; Traumatic brain injury	POPULATION; PREVALENCE; DISORDERS; ADDICTION; PROFILE	Adolescence is a risk period for offending and for traumatic brain injury (TBI) and TBI is a risk factor for poor mental health and for offending. TBI has been largely neglected from guidance on managing the mental health needs of young offenders. We sought to determine the rate of self-reported TBI, of various severities, in a male, adolescent youth offending population. We also aimed to explore whether TBI was associated with number of convictions, violent offending, mental health problems and drug misuse. Young male offenders aged 11 to 19 years were recruited from a Young Offender Institute, a Youth Offending Team and a special needs school. A total of 197 participants were approached and 186 (94.4%) completed the study. They completed self-reports on TBI, crime history, mental health and drug use. TBI with loss of consciousness (LOC) was reported by 46% of the sample. LOC consistent with mild TBI was reported by 29.6%, and 16.6% reported LOC consistent with moderate to severe TBI. Possible TBI was reported by a further 19.1%. Repeat injury was common - with 32% reporting more than one LOC. Frequency of self-reported TBI was associated with more convictions. Three or more self-reported TBIs were associated with greater violence in offences. Those with self-reported TBI were also at risk of greater mental health problems and of misuse of cannabis. TBI may be associated with offending behaviour and worse mental health outcomes. Addressing TBI within adolescent offenders with neurorehabilitative input may be important for improving well-being and reducing re-offending.	[Williams, W. Huw] Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter EX4 4QG, Devon, England; [Cordan, Giray] W England Forens Mental Hlth Serv, Bristol, Avon, England	Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter EX4 4QG, Devon, England.	w.h.williams@exeter.ac.uk		williams, huw/0000-0003-0670-2620; Tonks, James/0000-0003-3930-9294	UK Brain Injury Forum (BIG Lottery); Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [Res-062-23-0135]; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E002692/1] Funding Source: researchfish	The research was supported by grants to HW from UK Brain Injury Forum (BIG Lottery) and Economic and Social Research Council (Res-062-23-0135).	[Anonymous], 2009, LANCET, V373, P603, DOI 10.1016/S0140-6736(09)60374-3; *CDC, 2009, TRAUM BRAIN INJ PRIS; Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI 10.1001/jama.2008.976; Colantonio A, 2007, BRAIN INJURY, V21, P1353, DOI 10.1080/02699050701785054; Fazel S, 2008, J AM ACAD CHILD PSY, V47, P1010, DOI [10.1097/CHI.0b013e31817eeef3, 10.1097/CHI.ObO13e31817eecf3]; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Forrest CB, 2000, PEDIATRICS, V105, P286; Hux D, 1998, BRAIN INJURY, V12, P667; Jolliffe D, 2004, AGGRESS VIOLENT BEH, V9, P441, DOI 10.1016/j.avb.2003.03.001; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Marsden J, 1998, ADDICTION, V93, P1857, DOI 10.1046/j.1360-0443.1998.9312185711.x; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; Mobbs D, 2007, PLOS BIOL, V5, P693, DOI 10.1371/journal.pbio.0050103; MOORE AD, 1990, BRAIN INJURY, V4, P183; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; *PRIS POP STAT, 2009, SNSG4334 LIB HOUS CO; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Williams P., 1988, USERS GUIDE GEN HLTH; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; WILLIAMS WH, BRAIN INJURY IN PRES; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	28	91	91	1	30	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	6					801	812	PII 929353137	10.1080/09602011.2010.519613			12	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	684GB	WOS:000284537300001	21069616				2021-06-18	
J	Blinman, TA; Houseknecht, E; Snyder, C; Wiebe, DJ; Nance, ML				Blinman, Thane A.; Houseknecht, Eileen; Snyder, Caitlin; Wiebe, Douglas J.; Nance, Michael L.			Postconcussive symptoms in hospitalized pediatric patients after mild traumatic brain injury	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	60th Annual Meeting of the American-Academy-of-Pediatrics	OCT 10-12, 2008	Boston, MA	Amer Acad Pediat		Closed head injury; Concussion; Symptoms; Trauma	HEAD TRAUMA; CONCUSSION; SPORT	Background: Mild traumatic brain injury (MTBI) is common in the pediatric population. The symptom complex that might be expected in children after MTBI is not well documented. We sought to clarify the frequency and severity of concussive symptoms reported by children who required hospitalization for MTBI. Methods: Pediatric blunt trauma patients (age, 11-17 years) admitted for treatment of MTBI (GCS 14-15) were prospectively enrolled over a 2-year period. Consented patients were administered a 22-question Likert-based concussion symptom scale (normal, total score 0-8). The symptom scale was repeated at the time of routine follow-up trauma clinic visit. The frequency and severity of concussive symptoms were analyzed at both time-points. Results: For the 2-year period, 116 children participated in the study including 63 who returned for clinic follow-up. The overall population had mean age of 14.1 years (median 14) and was 69.8% male. The mean symptom score (sum of Likert scores [scale 0-6] for 22 questions) was 27.9 (median, 23.5) at hospitalization and 9.2 (median, 4.0) at follow-up. An abnormal symptom score (>8) was reported in 83.6% of hospitalized patients and 38.1% at follow-up. Girls had a significantly higher mean symptom score at initial testing than boys (33.9 vs 25.3, respectively; P < .05). This difference disappeared by the time of follow-up (girls 9.2 vs boys 9.1, P = .98) The most common initial symptom was headache (71.5% of patients) and most severe (highest mean score) was fatigue (mean, 2.0; median, 2.0). At follow-up, the most common symptom was excess sleep (38.1%) and most severe symptom failing asleep (mean, 1.0; median, 0). There were no significant differences in initial scores based oil reported loss of consciousness, prior concussion history, or GCS 14 vs 15. Conclusions: Symptoms after MTBI are quite common at the time of hospitalization. Symptom scores improve to near normal for most by outpatient follow-up. The most common symptom was headache, but the most severe was fatigue, in this hospitalized pediatric population. Thoughtful assessment and follow-up of this patient Population are warranted. (C) 2009 Elsevier Inc. All rights reserved.	[Blinman, Thane A.; Houseknecht, Eileen; Snyder, Caitlin; Nance, Michael L.] Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; [Wiebe, Douglas J.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	Blinman, TA (corresponding author), Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA.	blinman@email.chop.edu	Wiebe, Douglas J/Q-1168-2017				Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2005, J CLIN EXPER NEUROPS, V27; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Stepanski EJ, 2003, SLEEP MED REV, V7, P215, DOI 10.1053/smrv.2001.0246; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7	10	91	91	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	JUN	2009	44	6					1223	1228		10.1016/j.jpedsurg.2009.02.027			6	Pediatrics; Surgery	Pediatrics; Surgery	462HV	WOS:000267342800036	19524745				2021-06-18	
J	Marion, D; Bullock, MR				Marion, Donald; Bullock, M. Ross			Current and Future Role of Therapeutic Hypothermia	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			adult brain injury; cerebral vascular disease; clinical trial; decompressive craniectomy; guidelines; head trauma; hypothermia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; HOSPITAL CARDIAC-ARREST; ACTIVATED FACTOR-VII; ACUTE LIVER-FAILURE; SEVERE HEAD-INJURY; RANDOMIZED CLINICAL-TRIAL; WHOLE-BODY HYPOTHERMIA; INTENSIVE-CARE-UNIT; MILD HYPOTHERMIA	Therapeutic moderate hypothermia has been advocated for use in traumatic brain injury, stroke, cardiac arrest-induced encephalopathy, neonatal hypoxic-ischemic encephalopathy, hepatic encephalopathy, and spinal cord injury, and as an adjunct to aneurysm surgery. In this review, we address the trials that have been performed for each of these indications, and review the strength of the evidence to support treatment with mild/moderate hypothermia. We review the data to support an optimal target temperature for each indication, as well as the duration of the cooling, and the rate at which cooling is induced and rewarming instituted. Evidence is strongest for prehospital cardiac arrest and neonatal hypoxic-ischemic encephalopathy. For traumatic brain injury, a recent meta-analysis suggests that cooling may increase the likelihood of a good outcome, but does not change mortality rates. For many of the other indications, such as stroke and spinal cord injury, trials are ongoing, but the data are insufficient to recommend routine use of hypothermia at this time.	[Marion, Donald] Childrens Neurobiol Solut Fdn, Santa Barbara, CA USA; [Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA	Marion, D (corresponding author), 35 High Rock Rd, Wayland, MA 01778 USA.	donmarion1@yahoo.com	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702			Abou-Chebl A, 2004, NEUROCRIT CARE, V1, P131, DOI 10.1385/NCC:1:2:131; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Arrich J, 2007, CRIT CARE MED, V35, P1041, DOI 10.1097/01.CCM.0000259383.48324.35; Aslam AF, 2006, AM J MED, V119, P297, DOI 10.1016/j.amjmed.2005.09.062; Axelrod YK, 2006, CRIT CARE CLIN, V22, P767, DOI 10.1016/j.ccc.2006.06.001; Badjatia N, 2006, NEUROLOGY, V66, P1739, DOI 10.1212/01.wnl.0000218166.54150.0a; Badjatia N, 2004, NEUROCRIT CARE, V1, P145, DOI 10.1385/NCC:1:2:145; Bernard S, 2004, CRIT CARE, V8, DOI 10.1186/cc2994; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Boodhwani M, 2007, J THORAC CARDIOV SUR, V134, P1443, DOI 10.1016/j.jtcvs.2007.08.016; Boti ET, 2005, ANN THORAC SURG, V79, P1767, DOI 10.1016/j.athoracsur.2003.10.102; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS26; Cheng H, 2006, ACTA NEUROCHIR, V148, P559, DOI 10.1007/s00701-006-0735-3; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dae MW, 2003, STROKE, V34, P734, DOI 10.1161/01.STR.0000057461.56040.FE; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; den Hertog Heleen, 2007, Expert Rev Neurother, V7, P155, DOI 10.1586/14737175.7.2.155; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Dohi K, 2006, ACTA NEUROCHIR SUPPL, V96, P409; Downey C, 2000, Can Oper Room Nurs J, V18, P9; Edwards AD, 2006, ARCH DIS CHILD-FETAL, V91, pF127, DOI 10.1136/adc.2005.071787; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; FAY T, 1959, J NEUROSURG, V16, P239, DOI 10.3171/jns.1959.16.3.0239; Fehlings MG, 2005, INJURY, V36, P113, DOI 10.1016/j.injury.2005.06.022; Fehrenbacher JW, 2007, ANN THORAC SURG, V83, P1041, DOI 10.1016/j.athoracsur.2006.09.088; Fernandez A, 2007, NEUROLOGY, V68, P1013, DOI 10.1212/01.wnl.0000258543.45879.f5; Feuchtl A., 2007, Intensivmedizin und Notfallmedizin, V44, P37, DOI 10.1007/s00390-007-0740-7; FLEMMING K, 2006, GMS GER MED SCI, V4; Frelinger AL, 2003, AM J CARDIOL, V92, P1099, DOI 10.1016/j.amjcard.2003.06.007; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Goldberg CS, 2007, J THORAC CARDIOV SUR, V133, P880, DOI 10.1016/j.jtcvs.2006.11.029; Gudbjartsson T, 2003, J AM COLL CARDIOL, V41, P849, DOI 10.1016/S0735-1097(02)02923-6; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; Gunn AJ, 2008, J PEDIATR-US, V152, P55, DOI 10.1016/j.jpeds.2007.06.003; Heier T, 2006, ANESTHESIOLOGY, V104, P1070, DOI 10.1097/00000542-200605000-00025; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Higgins RD, 2006, J PEDIATR-US, V148, P170, DOI 10.1016/j.jpeds.2005.12.009; Hildebrand F, 2004, AM J SURG, V187, P363, DOI 10.1016/j.amjsurg.2003.12.016; Hinz J, 2007, J NEUROSURG ANESTH, V19, P130, DOI 10.1097/ANA.0b013e318032a208; Hoedemaekers CW, 2007, CRIT CARE, V11, DOI 10.1186/cc6104; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzer M, 2006, STROKE, V37, P1792, DOI 10.1161/01.STR.0000227265.52763.16; Huang HM, 2007, ASAIO J, V53, P684, DOI 10.1097/MAT.0b013e31815d055d; Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Inderbitzen B, 2002, NEUROSURGERY, V50, P364, DOI 10.1097/00006123-200202000-00023; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jalan R, 2004, GASTROENTEROLOGY, V127, P1338, DOI 10.1053/j.gastro.2004.08.005; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kandzari DE, 2004, AM J CARDIOL, V93, P636, DOI 10.1016/j.amjcard.2003.11.038; Keller E, 2003, INTENS CARE MED, V29, P939, DOI 10.1007/s00134-003-1685-3; Kettner SC, 2003, ANESTH ANALG, V96, P1772, DOI 10.1213/01.ANE.0000062520.65192.C9; Kheirabadi BS, 2007, J TRAUMA, V62, P1352, DOI 10.1097/TA.0b013e318047b805; Kheirabadi BS, 2007, J TRAUMA, V63, P1079, DOI 10.1097/TA.0b013e31815885f1; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim F, 2005, CIRCULATION, V112, P715, DOI 10.1161/CIRCULATIONAHA.105.544528; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kliegel A, 2005, RESUSCITATION, V64, P347, DOI 10.1016/j.resuscitation.2004.09.002; Kliegel A, 2007, RESUSCITATION, V73, P46, DOI 10.1016/j.resuscitation.2006.08.023; Konstas AA, 2006, NEUROCRIT CARE, V4, P168, DOI 10.1385/NCC:4:2:168; Kunihara T, 2005, J THORAC CARDIOV SUR, V130, P712, DOI 10.1016/j.jtcvs.2005.03.043; Laver SR, 2006, ANAESTHESIA, V61, P873, DOI 10.1111/j.1365-2044.2006.04552.x; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Leslie K, 2004, ANAESTH INTENS CARE, V32, P362, DOI 10.1177/0310057X0403200310; LUND LO, 1965, ANESTHESIOLOGY, V26, P45, DOI 10.1097/00000542-196501000-00008; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Ly HQ, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.200502.049; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mayer SA, 2007, STROKE, V38, P763, DOI 10.1161/01.STR.0000254499.46122.22; Meng ZH, 2003, J TRAUMA, V55, P886, DOI 10.1097/01.TA.0000066184.20808.A5; Merchant RM, 2006, CRIT CARE MED, V34, pS490, DOI 10.1097/01.CCM.0000246016.28679.36; Merchant RM, 2006, CRIT CARE MED, V34, P1935, DOI 10.1097/01.CCM.0000220494.90290.92; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; Nara I, 1998, ACT NEUR S, V71, P22; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Oddo M, 2006, CRIT CARE MED, V34, P1865, DOI 10.1097/01.CCM.0000221922.08878.49; Patel HJ, 2006, ANN THORAC SURG, V82, P90, DOI 10.1016/j.athoracsur.2006.02.055; Perlman JM, 2006, PEDIATRICS, V117, pS28, DOI 10.1542/peds.2005-0620E; Pichon N, 2007, CRIT CARE, V11, DOI 10.1186/cc5956; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Rajagopalan S, 2008, ANESTHESIOLOGY, V108, P71, DOI 10.1097/01.anes.0000296719.73450.52; RESNICK DK, 2007, HYPOTHERMIA HUMAN SP; Rizoli SB, 2006, CRIT CARE, V10, DOI 10.1186/cc5133; ROSOMOFF HL, 1959, J NEUROSURG, V16, P177, DOI 10.3171/jns.1959.16.2.0177; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; ROSOMOFF HL, 1956, SURGERY, V40, P328; Rutherford MA, 2005, PEDIATRICS, V116, P1001, DOI 10.1542/peds.2005-0328; Sachs B, 2007, SPINE, V32, P2285, DOI 10.1097/BRS.0b013e3181557d45; Safar PJ, 2002, NEW ENGL J MED, V346, P612, DOI 10.1056/NEJM200202213460811; Schulzke Sven M, 2007, BMC Pediatr, V7, P30; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SEDZIMIR CB, 1955, BRIT J ANAESTH, V27, P93, DOI 10.1093/bja/27.2.93; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Stanley TO, 2003, ANN THORAC SURG, V75, P1140, DOI 10.1016/S0003-4975(02)04545-9; Steinberg GK, 2004, NEUROSURGERY, V55, P307, DOI 10.1227/01.NEU.0000129683.99430.8C; Stravitz RT, 2007, CRIT CARE MED, V35, P2498, DOI 10.1097/01.CCM.0000287592.94554.5F; Su J, 2003, INT J DEV NEUROSCI, V21, P353, DOI 10.1016/S0736-5748(03)00070-4; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Tabayashi K, 2002, ACTA CHIR BELG, V102, P224; Takahashi I, 2000, NEUROL SURG TOKYO, V28, P983; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Tetik O, 2002, EUR J VASC ENDOVASC, V24, P540, DOI 10.1053/ejvs.2002.1753; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Vanden Hoek Terry L, 2004, Crit Care Med, V32, pS425, DOI 10.1097/01.CCM.0000134259.59793.B8; Vaquero J, 2005, J HEPATOL, V43, P1067, DOI 10.1016/j.jhep.2005.05.039; Visconti KJ, 2006, ANN THORAC SURG, V82, P2207, DOI 10.1016/j.athoracsur.2006.06.069; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; Yanagawa Y, 2007, J TRAUMA, V62, P287, DOI 10.1097/01.ta.0000223023.98182.d9; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	137	91	99	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					455	467		10.1089/neu.2008.0582			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900021	19292697				2021-06-18	
J	Loetscher, PD; Rossaint, J; Rossaint, R; Weis, J; Fries, M; Fahlenkamp, A; Ryang, YM; Grottke, O; Coburn, M				Loetscher, Philip D.; Rossaint, Jan; Rossaint, Rolf; Weis, Joachim; Fries, Michael; Fahlenkamp, Astrid; Ryang, Yu-Mi; Grottke, Oliver; Coburn, Mark			Argon: Neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury	CRITICAL CARE			English	Article							ORGANOTYPIC HIPPOCAMPAL CULTURES; NEURONAL CELL-DEATH; SLICE CULTURES; RECEPTOR ANTAGONISTS; GLUCOSE DEPRIVATION; UNITED-STATES; NOBLE-GASES; XENON; DAMAGE; NMDA	Introduction Recently, it has been shown in several experimental settings that the noble gases xenon and helium have neuroprotective properties. In this study we tested the hypothesis that the noble gas argon has a neuroprotective potential as well. Since traumatic brain injury and stroke are widespread and generate an enormous economic and social burden, we investigated the possible neuroprotective effect in in vitro models of traumatic brain injury and cerebral ischemia. Methods Organotypic hippocampal slice cultures from mice pups were subjected to either oxygen-glucose deprivation or to a focal mechanical trauma and subsequently treated with three different concentrations (25, 50 and 74%) of argon immediately after trauma or with a two-or-three-hour delay. After 72 hours of incubation tissue injury assessment was performed using propidium iodide, a staining agent that becomes fluorescent when it diffuses into damaged cells via disintegrated cell membranes. Results We could show argon's neuroprotective effects at different concentrations when applied directly after oxygen-glucose deprivation or trauma. Even three hours after application, argon was still neuroprotective. Conclusions Argon showed a neuroprotective effect in both in vitro models of oxygen-glucose deprivation and traumatic brain injury. Our promising results justify further in vivo animal research.	[Loetscher, Philip D.; Rossaint, Jan; Rossaint, Rolf; Fahlenkamp, Astrid; Ryang, Yu-Mi; Grottke, Oliver; Coburn, Mark] Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, D-52074 Aachen, Germany; [Weis, Joachim] Rhein Westfal TH Aachen, Univ Hosp, Dept Neuropathol, D-52074 Aachen, Germany; [Fries, Michael] Rhein Westfal TH Aachen, Univ Hosp, Dept Surg Intens Care, D-52074 Aachen, Germany; [Ryang, Yu-Mi] Rhein Westfal TH Aachen, Univ Hosp, Dept Neurosurg, D-52074 Aachen, Germany	Coburn, M (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	mcoburn@ukaachen.de	Ryang, Yu-Mi/Q-8373-2016; Weis, Joachim/G-1984-2014; Grottke, Oliver/F-1508-2018	Ryang, Yu-Mi/0000-0002-9045-5038; Weis, Joachim/0000-0003-3280-6773; Grottke, Oliver/0000-0002-0722-3122; Coburn, Mark/0000-0002-7930-0270	START program of the Medical Faculty of the RWTH Aachen	This research was conducted with funding by the START program of the Medical Faculty of the RWTH Aachen.; We thank Rosemarie Blaumeiser-Debarry for her help with data acquisition and the teams at the Departments of Neuropathology, Pathology and Animal Research at the University Hospital Aachen for expert laboratory advice, assistance and help.	AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Abraini JH, 2003, ANESTH ANALG, V96, P746, DOI 10.1213/01.ANE.0000050282.14291.38; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Allen JW, 1999, FASEB J, V13, P1875; [Anonymous], IMAGEJ IMAGE PROCESS; ASCHER P, 1987, TRENDS NEUROL SCI, V10, P8; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Behnke AR, 1939, AM J PHYSIOL, V126, P409; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Crain SM, 1998, METHODS, V16, P228, DOI 10.1006/meth.1998.0681; DIEMER NH, 1993, PROG BRAIN RES, V96, P105; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Fries M, 2008, CRIT CARE MED, V36, P2420, DOI 10.1097/CCM.0b013e3181802874; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Galeffi F, 2000, J NEUROCHEM, V75, P1242, DOI 10.1046/j.1471-4159.2000.0751242.x; Goldberg MP, 1997, INT REV NEUROBIOL, V40, P69, DOI 10.1037/10225-004; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; KENNEDY RR, 1992, ANAESTH INTENS CARE, V20, P66, DOI 10.1177/0310057X9202000113; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Lipton P, 1999, PHYSIOL REV, V79, P1431; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Martin JL, 2007, BRIT J ANAESTH, V98, P236, DOI 10.1093/bja/ael340; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Petzelt C, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-55; Petzelt C, 2003, LIFE SCI, V72, P1909, DOI 10.1016/S0024-3205(02)02439-6; Preckel B, 2000, ANESTH ANALG, V91, P1327, DOI 10.1097/00000539-200012000-00003; Pringle AK, 1996, NEUROSCI LETT, V211, P203, DOI 10.1016/0304-3940(96)12745-2; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rekling JC, 2003, NEUROSCI LETT, V335, P167, DOI 10.1016/S0304-3940(02)01193-X; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Scartabelli T, 2008, NEUROPHARMACOLOGY, V55, P509, DOI 10.1016/j.neuropharm.2008.06.019; Schmidt M, 2005, ANESTHESIOLOGY, V102, P929, DOI 10.1097/00000542-200505000-00011; Schwartz-Bloom RD, 2000, NEUROSCIENCE, V98, P471, DOI 10.1016/S0306-4522(00)00144-5; Soldatov P E, 1998, Aviakosm Ekolog Med, V32, P33; Sosin DM, 1996, BRAIN INJURY, V10, P47; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRASSER U, 1995, BRAIN RES, V687, P167, DOI 10.1016/0006-8993(95)00519-V; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trudell JR, 1998, ANESTH ANALG, V87, P411, DOI 10.1097/00000539-199808000-00034; VORNOV JJ, 1995, EXP NEUROL, V133, P7, DOI 10.1006/exnr.1995.1002; Wise-Faberowski L, 2003, J NEUROSURG ANESTH, V15, P193, DOI 10.1097/00008506-200307000-00006; Xu J, 2008, NEUROPHARMACOLOGY, V54, P1029, DOI 10.1016/j.neuropharm.2008.01.014; Yarin YM, 2005, HEARING RES, V201, P1, DOI 10.1016/j.heares.2004.09.015; Zhang F, 2007, NEUROSCIENCE, V150, P938, DOI 10.1016/j.neuroscience.2007.09.070	57	91	98	0	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	6							R206	10.1186/cc8214			9	Critical Care Medicine	General & Internal Medicine	556DF	WOS:000274567900035	20017934	DOAJ Gold, Green Published			2021-06-18	
J	Sesma, HW; Slomine, BS; Ding, R; McCarthy, ML				Sesma, Heather Whitney; Slomine, Beth S.; Ding, Ru; McCarthy, Melissa L.		CHAT Study Grp	Executive functioning in the first year after pediatric traumatic brain injury	PEDIATRICS			English	Article						executive function/dysfunction; traumatic brain injury; cognitive function	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; QUALITY-OF-LIFE; BEHAVIOR PROBLEMS; WORKING-MEMORY; SHORT-TERM; CHILDREN; CHILDHOOD; ATTENTION; RECOVERY	BACKGROUND AND OBJECTIVE. Children with traumatic brain injuries often show impaired executive function (the ability to carry out goal-directed behavior). The Behavior Rating Inventory of Executive Function, a caregiver-report questionnaire, measures executive function in everyday activities. In this study, our goal was to use the Behavior Rating Inventory of Executive Function to document changes in children's executive function in the first year after traumatic brain injury and identify child, family, and injury variables associated with greater dysfunction. We predicted that children with traumatic brain injury would have more executive dysfunction than children hospitalized for orthopedic fractures and that more severe traumatic brain injury would predict greater dysfunction. Children's premorbid functioning and family characteristics were expected to moderate their executive function. PATIENTS AND METHODS. Caregivers of children aged 5 to 15 years (330 mild-to-severe traumatic brain injury, 103 control orthopedic fractures) enrolled onto a longitudinal study of executive function. Caregivers completed the Behavior Rating Inventory of Executive Function by telephone at baseline (obtained retrospectively) and 3 months and 1 year after the injury. RESULTS. Traumatic brain injury groups and controls showed no baseline differences in Behavior Rating Inventory of Executive Function scores. Three months after the injury, children with traumatic brain injury had more dysfunction than controls on the Global Executive Composite. One year after injury, all traumatic brain injury groups differed from the controls on the Behavioral Regulation Index, Metacognition Index, and Global Executive Composite. The working memory scale was the only scale to discriminate between the control group and all 3 traumatic brain injury severity groups at both 3 and 12 months after injury. Executive-function ratings remained stable from 3 to 12 months after injury. Across time points, preexisting learning/behavior problems, lower respondent education, and poor family functioning predicted greater Global Executive Composite dysfunction. CONCLUSIONS. Between 18% and 38% of the children with traumatic brain injury had significant executive dysfunction in the first year after injury, with greater dysfunction reported for children with more severe traumatic brain injury. Our findings support previous reports that preinjury learning and behavior problems, limited family resources, and poor family functioning adversely affect executive function. These results suggest a need for more systematic screening for executive dysfunction after traumatic brain injury to increase recognition of cognitive disability and improve access to appropriate services.	[Sesma, Heather Whitney] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; [Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Ding, Ru; McCarthy, Melissa L.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA	Sesma, HW (corresponding author), Univ Minnesota, Dept Pediat, Mayo Mail Code 486,420 Delaware St, Minneapolis, MN 55455 USA.	hwsesma@umn.edu	ding, ru/B-1615-2009	Aitken, Mary/0000-0002-8318-9755	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR319701] Funding Source: Medline		Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P842; *COMM INJ SCAL, 1990, ABBR INJ SCAL; CONKLIN H, 2006, 34 ANN M INT NEUR SO; Denckla MB., 1989, INT PEDIAT, V4, P155; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Glang A, 2004, NEUROREHABILITATION, V19, P219; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009	49	91	92	0	51	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2008	121	6					E1686	E1695		10.1542/peds.2007-2461			10	Pediatrics	Pediatrics	307IX	WOS:000256313700031	18519472				2021-06-18	
J	Grasso, G; Sfacteria, A; Meli, F; Fodale, V; Buemi, M; Iacopino, DG				Grasso, Giovanni; Sfacteria, Alessandra; Meli, Francesco; Fodale, Vincenzo; Buemi, Michele; Iacopino, Domenico G.			Neuroprotection by erythropoietin administration after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						erythropoietin; neuroprotection; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; ISCHEMIA-REPERFUSION INJURY; CLOSED-HEAD INJURY; SUBARACHNOID HEMORRHAGE; IN-VITRO; BARRIER PERMEABILITY; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; SPATIAL MEMORY; PROTECTS	A large body of evidence indicates that the hormone erythropoietin (EPO) exerts beneficial effects in the central nervous system (CNS). To date, EPO's effect has been assessed in several experimental models of brain and spinal cord injury. This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI. Experimental TBI was induced in rats by a cryogenic injury model. rHuEPO or placebo was injected intraperitoneally immediately after the injury and then every 8 h until 2 or 14 days. Forty-eight hours after injury brain water content, an indicator of brain edema, was measured with the wet-dry method and blood-brain barrier (BBB) breakdown was evaluated by assay of Evans blue extravasation. Furthermore, extent of cerebral damage was assessed. Administration of rHuEPO markedly improved recovery from motor dysfunction compared with placebo group (P<0.05). Brain edema was significantly reduced in the cortex of the EPO-treated group relative to that in the placebo-treated group (80.6 +/- 0.3% versus 91.8%+/- 0.8% respectively, P<0.05). BBB breakdown was significantly lower in EPO-treated group than in the placebo-treated group (66.2 +/- 18.7 mu g/gversus 181.3 +/- 21 mu g/g, respectively, P<0.05). EPO treatment reduced injury volume significantly compared with placebo group (17.4 +/- 5.4 mm3 versus 37.1 +/- 5.3 mm3, P<0.05). EPO, administered in its recombinant form, affords significant neuroprotection in experimental TBI model and may hold promise for future clinical applications. (C) 2007 Elsevier B.V. All rights reserved.	[Grasso, Giovanni; Meli, Francesco] Univ Palermo, Neurosurg Clin, Dept Clin Neurosci, I-90133 Palermo, Italy; [Sfacteria, Alessandra] Univ Messina, Dept Vet Pathol, I-98100 Messina, Italy; [Fodale, Vincenzo] Univ Messina, Dept Anesthesiol, I-98100 Messina, Italy; [Buemi, Michele] Univ Messina, Dept Internal Med, I-98100 Messina, Italy	Grasso, G (corresponding author), Policlin P Giaccone, Neurosurg Clin, Via Vespro 127, I-90100 Palermo, Italy.	ggrasso@unipa.it	grasso, giovanni/K-3774-2018; GRASSO, GIOVANNI/A-4309-2009; Fodale, Vincenzo/G-5554-2010; Sfacteria, Alessandra/AAK-1839-2020; Iacopino, Domenico/C-1539-2013	grasso, giovanni/0000-0001-5362-0092; Fodale, Vincenzo/0000-0001-9540-5665; Iacopino, Domenico/0000-0003-1685-5209			Amorini AM, 2003, ACT NEUR S, V86, P261; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Buemi M, 2002, J NEPHROL, V15, P97; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; D'Andrea RJ, 2000, EXP HEMATOL, V28, P231, DOI 10.1016/S0301-472X(99)00159-9; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fukui S, 2003, J CEREBR BLOOD F MET, V23, P1212, DOI 10.1097/01.WCB.0000088762.02615.30; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Gorlach C, 1998, J CEREBR BLOOD F MET, V18, P1357; Gove CD, 1997, HEPATOLOGY, V25, P295; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2002, J NEUROSURG, V96, P565, DOI 10.3171/jns.2002.96.3.0565; Grasso G, 2001, J Neurosurg Sci, V45, P7; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Hortobagyi T, 2000, PFLUG ARCH EUR J PHY, V441, P409, DOI 10.1007/s004240000441; Iseki K, 1996, NEPHRON, V72, P30, DOI 10.1159/000188803; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Liu RQ, 2006, J NEUROCHEM, V96, P1101, DOI 10.1111/j.1471-4159.2005.03597.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Martinez-Estrada OM, 2003, EUR J NEUROSCI, V18, P2538, DOI 10.1046/j.1460-9568.2003.02987.x; Mogensen J, 2004, PHARMACOL BIOCHEM BE, V77, P381, DOI 10.1016/j.pbb.2003.11.017; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nag S, 1996, J NEUROPATH EXP NEUR, V55, P880, DOI 10.1097/00005072-199608000-00003; Ozturk Erdogan, 2005, Prog Neuropsychopharmacol Biol Psychiatry, V29, P922, DOI 10.1016/j.pnpbp.2005.04.028; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uzum G, 2006, LIFE SCI, V78, P2571, DOI 10.1016/j.lfs.2005.10.027; VERDONCK O, 2007, J CEREB BLOOD FLOW M; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhao Jingxia, 2003, Sichuan Da Xue Xue Bao Yi Xue Ban, V34, P559	50	91	96	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 28	2007	1182						99	105		10.1016/j.brainres.2007.08.078			7	Neurosciences	Neurosciences & Neurology	242CS	WOS:000251702700010	17935704	Green Published			2021-06-18	
J	Pandya, JD; Pauly, JR; Nukala, VN; Sebastian, AH; Day, KM; Korde, AS; Maragos, WF; Hall, ED; Sullivan, PG				Pandya, Jignesh D.; Pauly, James R.; Nukala, Vidya N.; Sebastian, Andrea H.; Day, Kristen M.; Korde, Amit S.; Maragos, William F.; Hall, Edward D.; Sullivan, Patrick G.			Post-injury administration of mitochondrial uncouplers increases tissue sparing and improves Behavioral outcome following traumatic brain injury in rodents	JOURNAL OF NEUROTRAUMA			English	Article						carbonyl cyanide 4-trifluoromethoxy phenylhydrazone; cortical contusion; 2,4-dinitrophenol; mitochondrial bioenergetics; mitochondrial uncoupling; reactive oxygen species	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; HIPPOCAMPAL-NEURONS; CORTICAL IMPACT; CALCIUM-UPTAKE; NMDA RECEPTOR; CELL-DEATH; DAMAGE; RAT; DYSFUNCTION	Following experimental traumatic brain injury (TBI), a rapid and significant necrosis occurs at the site of injury which coincides with significant mitochondrial dysfunction. The present study is driven by the hypothesis that TBI-induced glutamate release increases mitochondrial Call cycling/overload, ultimately leading to mitochondrial dysfunction. Based on this premise, mitochondrial uncoupling during the acute phases of TBI-induced excitotoxicity should reduce mitochondrial Ca2+ uptake (cycling) and reactive oxygen species (ROS) production since both are mitochondrial membrane potential dependent. In the present study, we utilized a cortical impact model of TBI to assess the potential use of mitochondrial uncouplers (2,4-DNP, FCCP) as a neuroprotective therapy. Young adult male rats were intraperitoneally administered vehicle (DMSO), 2,4-DNP (5 mg/kg), or FCCP (2.5 mg/kg) at 5 min post-injury. All animals treated with the uncouplers demonstrated a significant reduction in the amount of cortical damage and behavioral improvement following TBI. In addition, mitochondria isolated from the injured cortex at 3 or 6 h post-injury demonstrated that treatment with the uncouplers significantly improved several parameters of mitochondrial bioenergetics. These results demonstrate that post-injury treatment with mitochondrial uncouplers significantly (p < 0.01) increases cortical tissue sparing (similar to 12%) and significantly (p < 0.01) improves behavioral outcome following TBI. The mechanism of neuroprotection most likely involves the maintenance of mitochondrial homeostasis by reducing mitochondrial Call loading and subsequent mitochondrial dysfunction. These results further implicate mitochondrial dysfunction as an early event in the pathophysiology of TBI and that targeting acute mitochondrial events can result in long-term neuroprotection and improve behavioral outcome following brain injury.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, 375 BBSRB, Lexington, KY 40536 USA.	PatSullivan@uky.edu	Hall, Edward D/F-8930-2013	Korde, Amit/0000-0003-0702-290X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, R01NS042196] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS48191, NS42196] Funding Source: Medline		Amaral David G., 1995, P443; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Billups B, 2002, J NEUROSCI, V22, P5840; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1992, J NEUROTRAUMA, V9, P1; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; DUGAN LL, 1995, J NEUROSCI, V15, P6377; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HALL ED, 2004, NEUROSCIENCE MOL MED, P35; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kim-Han JS, 2001, J NEUROCHEM, V79, P658, DOI 10.1046/j.1471-4159.2001.00604.x; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Korde AS, 2005, J NEUROTRAUM, V22, P1142, DOI 10.1089/neu.2005.22.1142; Korde AS, 2005, J NEUROCHEM, V94, P1676, DOI 10.1111/j.1471-4159.2005.03328.x; KURT TL, 1986, VET HUM TOXICOL, V28, P574; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Maragos WF, 2003, BRAIN RES, V966, P312, DOI 10.1016/S0006-8993(02)04225-7; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; Pivovarova NB, 2002, J NEUROSCI, V22, P10653; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; White RJ, 1996, J NEUROSCI, V16, P5688; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	59	91	94	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					798	811		10.1089/neu.2006.3673			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300005	17518535				2021-06-18	
J	Diringer, MN; Aiyagari, V; Zazulia, AR; Videen, TO; Powers, WJ				Diringer, Michael N.; Aiyagari, Venkatesh; Zazulia, Allyson R.; Videen, Tom O.; Powers, William J.			Effect of hyperoxia on cerebral metabolic rate for oxygen measured using positron emission tomography in patients with acute severe head injury	JOURNAL OF NEUROSURGERY			English	Article						severe head injury; cerebral metabolism; hyperoxia; oxygen	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; O-15 RADIOTRACERS; INSPIRED OXYGEN; MICRODIALYSIS; HYPERVENTILATION; REDUCTION; THERAPY; LACTATE	Object. Recent observations indicate that traumatic brain injury (TBI) may be associated with mitochondrial dysfunction. This, along with growing use of brain tissue PO, monitors, has led to considerable interest in the potential use of ventilation with 100% oxygen to treat patients who have suffered a TBI. To date, the impact of normobaric hyperoxia has only been evaluated using indirect measures of its impact on brain metabolism. To determine if normobaric hyperoxia improves brain oxygen metabolism following acute TBI, the authors directly measured the cerebral metabolic rate for oxygen (CMRO2) with positron emission tomography before and after ventilation with 100% oxygen. Methods. Baseline measurements of arterial and jugular venous blood gases, mean arterial blood pressure, intracranial pressure, cerebral blood flow (CBF), cerebral blood volume, oxygen extraction fraction, and CNIRO2 were made at baseline while the patients underwent ventilation with a fraction of inspired oxygen (FiO(2)) of 0.3 to 0.5. The FiO(2) was then increased to 1.0, and 1 hour later all measurements were repeated. Five patients were studied a mean of 17.9 +/- 5.8 hours (range 12-23 hours) after trauma. The median admission Glasgow Coma Scale score was 7 (range 3-9). During ventilation with 100% oxygen, there was a marked rise in PaO2 (from 117 +/- 31 to 371 +/- 99 mm Hg, p < 0.0001) and a small rise in arterial oxygen content (12.7 +/- 4.0 to 13.3 +/- 4.6 vol % = 0.03). There were no significant changes in systemic hemodynamic or other blood gas measurements. At the baseline evaluation, bihemispheric CBF was 39 +/- 12 ml/100 g/min and bihemispheric CMRO2 was 1.9 +/- 0.6 ml/100 g/min. During hyperoxia there was no significant change in either of these measurements. (Values are given as the mean +/- standard deviation throughout.) Conclusions. Normobaric hyperoxia did not improve brain oxygen metabolism. In the absence of outcome data from clinical trials, these preliminary data do not support the use of 100% oxygen in patients with acute TBI, although larger confirmatory studies are needed.	Washington Univ, Dept Neurol, St Louis, MO 63130 USA	Diringer, MN (corresponding author), Washington Univ, Dept Neurol, Campus Box 8111,600 S Euclid Ave, St Louis, MO 63130 USA.	diringerm@neuro.wustl.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Aiyagari, Venkatesh/0000-0001-8139-3819	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS044885] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS044885] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [N535966] Funding Source: Medline		[Anonymous], 2000, J NEUROTRAUMA, V17, P463; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; Cruz J, 2003, J NEUROSURG, V99, P1110; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Longhi Luca, 2004, Curr Opin Crit Care, V10, P105, DOI 10.1097/00075198-200404000-00005; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MINTUN MA, 1984, J NUCL MED, V25, P177; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; RAICHLE ME, 1983, J NUCL MED, V24, P790; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; VIDEEN TO, 1987, J CEREBR BLOOD F MET, V7, P513, DOI 10.1038/jcbfm.1987.97; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	26	91	93	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	APR	2007	106	4					526	529		10.3171/jns.2007.106.4.526			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	155OJ	WOS:000245586900003	17432700				2021-06-18	
J	Chen, Y; Samal, B; Hamelink, CR; Xiang, CC; Chen, Y; Chen, M; Vaudry, D; Brownstein, MJ; Hallenbeck, JM; Eiden, LE				Chen, Yun; Samal, Babru; Hamelink, Carol R.; Xiang, Charlie C.; Chen, Yong; Chen, Mei; Vaudry, David; Brownstein, Michael J.; Hallenbeck, John M.; Eiden, Lee E.			Neuroprotection by endogenous and exogenous PACAP following stroke	REGULATORY PEPTIDES			English	Article; Proceedings Paper	Workshop on Signalling Mechanisms of VIP, PACAP and Related Peptides - Contribution of Genomics, Proteomics and Bioinformatics	SEP, 2005	Rouen, FRANCE			pituitary adenylate cyclase activating polypeptide; PACAP; PACAP-deficient mouse; middle cerebral artery occlusion; MCAO; neurological severity score; NSS; cerebral ischerma; infarct volume; cDNA microarray; PACAP responsive gene; neuroprotection; neurotrauma	CYCLASE-ACTIVATING POLYPEPTIDE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; VASOACTIVE-INTESTINAL-PEPTIDE; HIPPOCAMPAL GENE-EXPRESSION; CEREBELLAR GRANULE CELLS; MICROARRAY ANALYSIS; LIGAND/RECEPTOR SYSTEM; PROENKEPHALIN GENE; GENOMIC RESPONSE	We investigated the effects of PACAP treatment, and endogenous PACAP deficiency, on infarct volume, neurological function, and the cerebrocortical transcriptional response in a mouse model of stroke, middle cerebral artery occlusion (MCAO). PACAP-38 administered i.v. or i.e. v. 1 h after MCAO significantly reduced infarct volume, and ameliorated functional motor deficits measured 24 h later in wild-type mice. Infarct volumes and neurological deficits (walking faults) were both greater in PACAP-deficient than in wild-type mice, but treatment with PACAP reduced lesion volume and neurological deficits in PACAP-deficient mice to the same level of improvement as in wild-type mice. A 35,546-clone mouse cDNA microarray was used to investigate cortical transcriptional changes associated with cerebral ischemia in wild-type and PACAP-deficient mice, and with PACAP treatment after MCAO in wild-type mice. 229 known (named) transcripts were increased (228) or decreased (1) in abundance at least 50% following cerebral ischemia, in wild-type mice. 49 transcripts were significantly up-regulated only at 1 h post-MCAO (acute response transcripts), 142 were up-regulated only at 24 h post-MCAO (delayed response transcripts) and 37 transcripts were upregulated at both times (sustained response transcripts). More than half of these are transcripts not previously reported to be altered in ischemia. A larger percentage of genes up-regulated at 24 hr than at 1 hr required endogenous PACAP, suggesting a more prominent role for PACAP in later response to injury than in the initial response. This is consistent with a neuroprotective role for PACAP in late response to injury, i.e., even when administered 1 hr or more after MCAO. Putative injury effector transcripts regulated by PACAP include beta-actin, rnidline 2, and metallothionein 1. Potential neuroprotective transcripts include several demonstrated to be PACAP-regulated in other contexts. Prominent among these were transcripts encoding the PACAP-regulated gene ler3, and the neuropeptides enkephalin, substance P (tachykinin 1), and neurotensin. (c) 2006 Elsevier B.V. All rights reserved.	NIH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA; NIMH, Genet Lab, NIH, Bethesda, MD 20892 USA; NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA	Eiden, LE (corresponding author), NIH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bldg 10, Bethesda, MD 20892 USA.	eidenl@mail.nih.gov	Samal, Babru/ABE-5931-2020; VAUDRY, David/M-1454-2018; Samal, Babru B/C-5563-2008	VAUDRY, David/0000-0003-3567-7452; Eiden, Lee/0000-0001-7524-944X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH002386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002924, Z01NS002856] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 MH002386-22, Z01 MH002386-21] Funding Source: Medline		ALLEN GV, 1995, NEUROSCIENCE, V68, P1037, DOI 10.1016/0306-4522(95)00198-R; Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Bernaudin M, 2002, J BIOL CHEM, V277, P39728, DOI 10.1074/jbc.M204619200; Bowler RP, 2002, FREE RADICAL BIO MED, V33, P1141, DOI 10.1016/S0891-5849(02)01008-0; Campagne MV, 1998, J NEUROSCI RES, V53, P279; Canonico PL, 1996, ANN NY ACAD SCI, V805, P470; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Chen Y, 2004, PROCEEDINGS OF THE 2004 INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND CYBERNETICS, VOLS 1-7, P267; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chuquet J, 2002, J CEREBR BLOOD F MET, V22, P1165; Dawson DA, 1999, J CEREBR BLOOD F MET, V19, P616, DOI 10.1097/00004647-199906000-00004; del Rio G, 2001, FEBS LETT, V509, P230, DOI 10.1016/S0014-5793(01)03165-9; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J IMMUNOL, V162, P1200; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DeWitt D S, 1995, New Horiz, V3, P376; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; Dicicco-Bloom E, 1998, ANN NY ACAD SCI, V865, P274, DOI 10.1111/j.1749-6632.1998.tb11188.x; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; Figiel M, 2000, J NEUROSCI, V20, P3596; FISCHERCOLBRIE R, 1992, J NEUROCHEM, V59, P780, DOI 10.1111/j.1471-4159.1992.tb09440.x; FISCHERCOLBRIE R, 1988, P NATL ACAD SCI USA, V85, P3240, DOI 10.1073/pnas.85.9.3240; Fox S, 1998, INFECT MED, V15, P8; Georg B, 2000, MOL BRAIN RES, V79, P67, DOI 10.1016/S0169-328X(00)00101-7; Gozes I, 2004, J ALZHEIMERS DIS, V6, pS37; Hamelink C, 2002, P NATL ACAD SCI USA, V99, P461, DOI 10.1073/pnas.012608999; HERNANDEZ A, 1995, PEPTIDES, V16, P927, DOI 10.1016/0196-9781(95)00059-S; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; Jin K, 2002, NEUROCHEM RES, V27, P1105, DOI 10.1023/A:1020913123054; Jin KL, 2001, ANN NEUROL, V50, P93, DOI 10.1002/ana.1073; Just L, 1998, J MOL NEUROSCI, V11, P57, DOI 10.1385/JMN:11:1:57; Just L, 2000, GLIA, V30, P242, DOI 10.1002/(SICI)1098-1136(200005)30:3<242::AID-GLIA4>3.0.CO;2-V; Kim YD, 2002, BRAIN RES BULL, V58, P491, DOI 10.1016/S0361-9230(02)00823-7; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Koistinaho J, 1997, NEUROREPORT, V8, pR1; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Lipton P, 1999, PHYSIOL REV, V79, P1431; LOW KG, 1992, ENDOCRINOLOGY, V131, P1908, DOI 10.1210/en.131.4.1908; Lu NR, 1998, J NEUROSCI RES, V53, P651, DOI 10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marciano PG, 2001, RESTOR NEUROL NEUROS, V18, P105; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mizushima H, 1999, PEPTIDES, V20, P1337, DOI 10.1016/S0196-9781(99)00143-6; MORGAN JI, 1995, TRENDS NEUROSCI, V18, P66; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Onoue S, 2002, REGUL PEPTIDES, V107, P43, DOI 10.1016/S0167-0115(02)00065-4; Pan W, 2002, BIOINFORMATICS, V18, P546, DOI 10.1093/bioinformatics/18.4.546; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Ravni A, 2006, J NEUROCHEM, V98, P1229, DOI 10.1111/j.1471-4159.2006.03962.x; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Read SJ, 2001, J CEREBR BLOOD F MET, V21, P755, DOI 10.1097/00004647-200107000-00001; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Rickhag M, 2006, J NEUROCHEM, V96, P14, DOI 10.1111/j.1471-4159.2005.03508.x; Riera M, 2001, TRANSPLANTATION, V72, P1217, DOI 10.1097/00007890-200110150-00006; Sano H, 2002, REGUL PEPTIDES, V109, P107, DOI 10.1016/S0167-0115(02)00193-3; Sharp FR, 2000, J CEREBR BLOOD F MET, V20, P1011, DOI 10.1097/00004647-200007000-00001; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shioda Seiji, 2004, Nihon Yakurigaku Zasshi, V123, P243; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Stumm RK, 2001, J NEUROSCI, V21, P798; Tabuchi A, 2001, NEUROSCI RES, V39, P85, DOI 10.1016/S0168-0102(00)00200-5; Takei N, 1998, J NEUROSCI RES, V54, P698, DOI 10.1002/(SICI)1097-4547(19981201)54:5<698::AID-JNR15>3.0.CO;2-5; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; Tateishi N, 2002, J CEREBR BLOOD F MET, V22, P723, DOI 10.1097/00004647-200206000-00011; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/S0006-8993(96)00716-0; Vaudry D, 2002, J NEUROCHEM, V83, P1272, DOI 10.1046/j.1471-4159.2002.01242.x; Villalba M, 1997, J NEUROSCI, V17, P83; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Xiang CC, 2002, NAT BIOTECHNOL, V20, P738, DOI 10.1038/nb0702-738; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Zhou CJ, 1999, NEUROSCIENCE, V93, P375, DOI 10.1016/S0306-4522(99)00108-6	78	91	92	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-0115	1873-1686		REGUL PEPTIDES	Regul. Pept.	NOV 15	2006	137	1-2					4	19		10.1016/j.regpep.2006.06.016			16	Endocrinology & Metabolism; Physiology	Endocrinology & Metabolism; Physiology	117OD	WOS:000242881700002	17027094	Green Accepted			2021-06-18	
J	Xu, Z; Wang, BR; Wang, X; Kuang, F; Duan, XL; Jiao, XY; Ju, G				Xu, Zhen; Wang, Bai-Ren; Wang, Xi; Kuang, Fang; Duan, Xiao-Li; Jiao, Xi-Ying; Ju, Gong			ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury	LIFE SCIENCES			English	Article						spinal cord injury; microglia; macrophages; inducible nitric oxide synthase; mitogen-activated protein kinase; neuron; rat	NITRIC-OXIDE SYNTHASE; TRANSIENT FOREBRAIN ISCHEMIA; SIGNAL-REGULATED KINASE; NECROSIS-FACTOR-ALPHA; MICROGLIAL ACTIVATION; BRAIN-INJURY; EXPRESSION; APOPTOSIS; PATHOPHYSIOLOGY; EXCITOTOXICITY	The enhanced production of nitric oxide (NO) via inducible nitric oxide synthase (iNOS) has been implicated in the pathogenesis of neuronal apoptosis after acute traumatic spinal cord injury (SCI). In the present study, to further characterize the pathways mediating the synthesis and release of NO, we examined activation of extracellular signal regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinases (p38 MAPK) in microglia/macrophages in the injured area of adult rats subjected to a complete transection at the T 10 vertebrae level and assessed their role in NO production and survival of neurons by using immunohistochemistry, Western blot, RT-PCR and pharmacological interventions. Results showed activation of microglia/macrophages featured by morphological changes, as visualized immunohistochemically with the marker OX-42, in the areas adjacent to the lesion epicenter 1 h after surgery. Concomitantly, iNOS mRNA and its protein in the activated microglia/macrophages were also significantly upregulated at early hours after surgery. Their levels were maximal at 6 It, persisted for at least 24 It, and returned to basal level 72 h after SCI. Furthermore, phosphorylated ERK 1/2 and p38 MAPK were activated as well in microglia/macrophages in injured area with a similar time course as iNOS. With administration Of L-NAME, a NOS inhibitor, the number of apoptotic neurons was clearly decreased, as assessed with TUNEL method at 24 h after SCI. In parallel, loss of neurons induced by SCI, assessed with NeuN immumohistochemistry, was also diminished. Moreover, the effect of inhibition of phosphorylation ERK1/2 and p38 MAPK by corresponding inhibitors PD98059 and SB203580 administered before and after SCI was also investigated. Inhibition of p38 effectively reduced iNOS mRNA expression and rescued neurons from apoptosis and death in the area adjacent to the lesion epicenter; whereas the inhibition of ERK 1/2 had a smaller effect on decrease of iNOS mRNA and no long-term protective effect on cell loss. These results indicate the ERK1/2 and p38 MAPK signaling pathway, especially the latter, play an important role in NO-mediated degeneration of neuron in the spinal cord following SCI. Strategies directed to blocking the initiation of this cascade prove to be beneficial for the treatment of acute SCI. (c) 2006 Elsevier Inc. All rights reserved.	Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China	Wang, BR (corresponding author), Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.	wbrnim@fmmu.edu.cn					Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bhat NR, 1998, J NEUROSCI, V18, P1633; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; CHAO CC, 1992, J IMMUNOL, V149, P2736; Choi SH, 2003, J NEUROSCI, V23, P5877; Combs CK, 2001, J NEUROSCI, V21, P1179; Dawson VL, 1996, J NEUROSCI, V16, P2479; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hauben E, 2003, TRENDS PHARMACOL SCI, V24, P7, DOI 10.1016/S0165-6147(02)00013-5; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kwak EK, 2005, J KOREAN MED SCI, V20, P663, DOI 10.3346/jkms.2005.20.4.663; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; Piao CS, 2003, J NEUROSCI RES, V73, P537, DOI 10.1002/jnr.10671; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang MJ, 2004, J NEUROIMMUNOL, V146, P50, DOI 10.1016/j.jneuroim.2003.10.034; Wang ZQ, 2004, BRAIN RES, V996, P55, DOI 10.1016/j.brainres.2003.09.074; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004	37	91	99	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	OCT 12	2006	79	20					1895	1905		10.1016/j.lfs.2006.06.023			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	097TP	WOS:000241472000002	16978658				2021-06-18	
J	Wu, YL; Tang, Z; Fang, HQ; Gao, SL; Chen, J; Wang, Y; Yan, HC				Wu, Yulian; Tang, Zhe; Fang, Heqing; Gao, Shunliang; Chen, Jian; Wang, Yong; Yan, Haichao			High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer	JOURNAL OF SURGICAL ONCOLOGY			English	Article						pancreatic cancer; radiofrequency ablation (RFA); complication; mortality	BLOOD-FLOW; OCCLUSION; RESECTION; SURVIVAL; LESIONS; TIME	Background and Objectives: To report and discuss the effect, complications and mortality of cool-tip radiofrequency ablation (RFA) for unresectable pancreatic cancer. Methods: During October 2003 to July 2004, sixteen patients with unresectable pancreatic cancer were treated by open cool-tip RFA. One-half of the 16 patients had tumors located in the pancreatic head. A 5-mm minimum safe distance between RFA site and major peripancreatic vessels was kept to avoid injury to the vessels. Results: Six of twelve patients with back pain got pain relief postoperatively. Pancreatic fistula occurred in three patients (18.8%) and healed smoothly in 7-10 days with routine abdominal drainage. The mortality was 25% (4/16). In the four death cases, tumors were all located in the pancreatic head; three patients with tumor close to portal vein died suddenly of massive gastrointestinal hemorrhage on the 4th, 30th, 40th postoperative day respectively and a 79-year-old patient died of acute renal failure on the 2nd postoperative day. Conclusions: Standard use of cool-tip RFA was dangerous for pancreatic head cancer close to portal vein, in which a 5-mm minimum safe distance between RFA site and major peripancreatic vessels might not be enough to avoid injury to the vessels.	Zhejiang Univ, Coll Med, Dept Surg, Affiliated Hosp 2, Hangzhou 310009, Peoples R China	Wu, YL (corresponding author), Zhejiang Univ, Coll Med, Dept Surg, Affiliated Hosp 2, 88 Jiefan Rd, Hangzhou 310009, Peoples R China.	wuyulian@medmail.com.cn					Andren-Sandberg A, 2002, PANCREATOLOGY, V2, P431, DOI 10.1159/000064710; BRAMHALL S, 1998, PANCREAS, P889; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Chen KX, 2003, WORLD J GASTROENTERO, V9, P2557; Elias D, 2004, EJSO, V30, P85, DOI 10.1016/j.ejso.2003.10.013; Friedman M, 2004, CARDIOVASC INTER RAD, V27, P427, DOI 10.1007/s00270-004-0062-0; Heisterkamp J, 1997, BRIT J SURG, V84, P1245; Lowenfels AB, 2004, JPN J CLIN ONCOL, V34, P238, DOI 10.1093/jjco/hyh045; Lu DSK, 2002, AM J ROENTGENOL, V178, P47, DOI 10.2214/ajr.178.1.1780047; Matsui Y, 2000, PANCREAS, V20, P14, DOI 10.1097/00006676-200001000-00002; Mirza AN, 2001, CANCER J, V7, P95; Morrison CP, 2003, MED SCI MONITOR, V9, pBR43; Neoptolemos JP, 1997, BRIT J SURG, V84, P1370; Ng Kelvin Kwok-Chai, 2003, Asian J Surg, V26, P50, DOI 10.1016/S1015-9584(09)60218-9; Ng KKC, 2004, BRIT J SURG, V91, P632, DOI 10.1002/bjs.4500; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Patterson EJ, 1998, ANN SURG, V227, P559, DOI 10.1097/00000658-199804000-00018; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Shore S, 2004, SURG ONCOL, V13, P201, DOI 10.1016/j.suronc.2004.11.001; Wiersinga WJ, 2003, BRIT J SURG, V90, P306, DOI 10.1002/bjs.4040; Yamasaki T, 2002, CANCER-AM CANCER SOC, V95, P2353, DOI 10.1002/cncr.10966	21	91	98	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4790	1096-9098		J SURG ONCOL	J. Surg. Oncol.	OCT 1	2006	94	5					392	395		10.1002/jso.20580			4	Oncology; Surgery	Oncology; Surgery	089AQ	WOS:000240852700008	16967436				2021-06-18	
J	Harwin, WS; Patton, JL; Edgerton, VR				Harwin, William S.; Patton, James L.; Edgerton, V. Reggie			Challenges and opportunities for robot-mediated neurorehabilitation	PROCEEDINGS OF THE IEEE			English	Article						haptic interfaces; neurological injury; neurorehabilitation; rehabilitation; robot; spinal cord injury; stroke; traumatic brain injury; virtual reality	REHABILITATION THERAPY; CASE-FATALITY; STROKE; DESIGN; ENVIRONMENT; ADAPTATION; FORCE	Robot-mediated neurorehabilitation is a rapidly advancing field that seeks to use advances in robotics, virtual realities, and haptic interfaces, coupled with theories in neuroscience and rehabilitation to define new methods for treating neurological injuries such as stroke, spinal cord injury, and traumatic brain injury. The field is nascent and much work is needed to identify efficient hardware, software, and control system designs alongside the most effective methods for delivering treatment in home and hospital settings. This paper identifies the need for robots in neurorehabilitation and identifies important goals that will allow this field to advance.	Univ Reading, Sch Syst Engn, Cybernet Grp, Reading RG6 6AY, Berks, England; Rehabil Inst Chicago, Chicago, IL 60611 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	Harwin, WS (corresponding author), Univ Reading, Sch Syst Engn, Cybernet Grp, Reading RG6 6AY, Berks, England.	W.S.Harwin@readihg.ac.uk; j-patton@northwestern.edu; vre@ucla.edu	Harwin, William S/N-1148-2014	Harwin, William S/0000-0002-3928-3381			Amirabdollahian F, 2002, 2002 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS I-IV, PROCEEDINGS, P3380, DOI 10.1109/ROBOT.2002.1014233; AMIRABODOLLAHIA.F, 2003, THSIS U READING READ; Arbib M. A., 1995, HDB BRAIN THEORY NEU; BAVELIER D, 2000, NATURE REV NEUROSCI, V3, P443; Brewer BR, 2005, IEEE T NEUR SYS REH, V13, P1, DOI 10.1109/TNSRE.2005.843443; Brewer BR, 2004, IEEE INT CONF ROBOT, P2080, DOI 10.1109/ROBOT.2004.1308130; BREWER BR, 2003, P 8 INT C REH ROB DA, P258; Burgar CG, 2000, J REHABIL RES DEV, V37, P663; Cai LL, 2005, INT C REHAB ROBOT, P575; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Colombo G, 2005, INT C REHAB ROBOT, P227; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; DUNNETT S, 2004, ACAD MED SCI      MA, P47; Emken JL, 2005, IEEE T NEUR SYS REH, V13, P33, DOI 10.1109/TNSRE.2004.843173; ERLANDSON RF, 1995, IEEE T REHABIL ENG, V3, P22, DOI 10.1109/86.372889; EYRE J, 2004, RESTORING NEUROLOGIC, P35; Fasoli SE, 2004, ARCH PHYS MED REHAB, V85, P1106, DOI 10.1016/j.apmr.2003.11.028; FLANAGAN JR, 1995, J NEUROPHYSIOL, V74, P2174; Galvez J.A., 2005, TECHNOL STRATEG ENHA, V11, P18, DOI DOI 10.1310/DAMJ-G43A-16EH-1BDK; Galvez JA, 2005, INT C REHAB ROBOT, P231; Goldstein A, 1993, WE AM ELDERLY; Goodbody SJ, 1998, J NEUROPHYSIOL, V79, P1825; HARWIN WS, 1995, IEEE T REHABIL ENG, V3, P3, DOI 10.1109/86.372887; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HOGAN N, 1992, P SPIE C TEL TECHN, P28; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; Johnson MJ, 2003, ROBOTICA, V21, P13, DOI 10.1017/S0263574702004599; KANADE T, 2004, NSF INT ADV ROB PROG; Kearney RE, 1997, IEEE T BIO-MED ENG, V44, P493, DOI 10.1109/10.581944; Kording KP, 2004, P NATL ACAD SCI USA, V101, P9839, DOI 10.1073/pnas.0308394101; Kording KP, 2004, NATURE, V427, P244, DOI 10.1038/nature02169; Kujala T, 2000, TRENDS NEUROSCI, V23, P115, DOI 10.1016/S0166-2236(99)01504-0; Liu J, 2005, INT C REHAB ROBOT, P37; Loureiro R, 2003, AUTON ROBOT, V15, P35, DOI 10.1023/A:1024436732030; *MERCK RES LAB, 1997, MARCK MAN GER WHITH; Miall RC, 1996, NEURAL NETWORKS, V9, P1265, DOI 10.1016/S0893-6080(96)00035-4; Mirbagheri MM, 2005, INT C REHAB ROBOT, P561; Nishitani N, 2000, P NATL ACAD SCI USA, V97, P913, DOI 10.1073/pnas.97.2.913; Patton JL, 2004, IEEE T BIO-MED ENG, V51, P636, DOI 10.1109/TBME.2003.821035; PATTON JL, 2005, EXPT BRAIN RES; Rasmussen, 1950, CEREBRAL CORTEX MAN; REINKENSMEYER D, 1999, BIOMECHANTRONICS, P61; Robles-De-La-Torre G, 2001, NATURE, V412, P445, DOI 10.1038/35086588; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; SANDERCOCK P, 2002, HLTH TECHNOL ASSESS, V6; SRINIVASAN MA, 1995, J NEUROPHYSIOL, V73, P88; Stewart JA, 1999, BRIT MED J, V318, P967, DOI 10.1136/bmj.318.7189.967; *STROK ASS, 2006, STROK STAT FACT SHEE; Taub E, 1999, J REHABIL RES DEV, V36, P237; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Timoszyk WK, 2003, ROBOTICA, V21, P25, DOI 10.1017/S0263574702004605; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Warlow C, 2003, LANCET, V362, P1211, DOI 10.1016/S0140-6736(03)14544-8; WEI Y, 2005, P IEEE INT C ROB AUT; WING A, 2004, RESTORING NEUROLOGIC, P58; Winstein CJ, 1999, NEUROPSYCHOLOGIA, V37, P975, DOI 10.1016/S0028-3932(98)00145-6; Wolfe CDA, 2002, J NEUROL NEUROSUR PS, V72, P211, DOI 10.1136/jnnp.72.2.211	57	91	93	0	12	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9219	1558-2256		P IEEE	Proc. IEEE	SEP	2006	94	9					1717	1726		10.1109/JPROC.2006.880671			10	Engineering, Electrical & Electronic	Engineering	101ZK	WOS:000241780000008					2021-06-18	
J	Pagulayan, KF; Temkin, NR; Machamer, J; Dikmen, SS				Pagulayan, KF; Temkin, NR; Machamer, J; Dikmen, SS			A longitudinal study of health-related quality of life after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; longitudinal studies; quality of life; rehabilitation	CLOSED-HEAD-INJURY; SICKNESS IMPACT PROFILE; FOLLOW-UP; RANDOMIZED-TRIAL; NEUROPSYCHOLOGICAL RECOVERY; DISABILITY; MODERATE; SCALE; MILD; REHABILITATION	Objective: To examine the longitudinal course of health-related quality of life from 1 month to 3 to 5 years after traumatic brain injury (TBI). Design: Longitudinal cohort study with 4 evaluation points. Setting: Level 1 trauma center. Participants: Consecutive hospital admissions of 133 adolescents and adults with complicated mild to severe TBI who completed the Outcome measure at all 4 time points, 111 general trauma patients, and 87 healthy friend controls. Interventions: Not applicable. Main Outcome Measure: Sickness Impact Profile. Results: TBI patients reported significant limitations at I month postinjury, with substantial improvement occurring by 6 months. especially in the physical domain. Psychosocial improvement was smaller, and perceived cognitive, emotional, and communication difficulties did not change over the time period assessed. Persons with TBI had clear difficulties relative to healthy peers, but their reported level of difficulties was very similar to that of the persons who had sustained a general trauma by 1 year postinjury. Conclusions: In this sample, TBI was associated with significant early limitations in most aspects of everyday life. Considerable improvement was noted over the first 6 months postinjury, especially in physical domains. Some aspects of psychosocial functioning also improved, although reported limitations in communication, cognitive, and emotional domains remained constant over time. These findings highlight the persistence of injury-related difficulties that compromise quality of life.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Pagulayan, KF (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	farkat@u.washington.edu	Pagulayan, Kati/AAR-9225-2020		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD048030] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643, R01 NS019643] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD048030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER		Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Brooks D N, 1979, Int Rehabil Med, V1, P166; CARTER WB, 1976, HEALTH SERV RES, V11, P516; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HANNAY HJ, 2004, NEUROPSYCHOLOGICAL A, P157; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SILVER JM, 1992, AM PSYCHIAT PRESS TX, P363; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1999, MILD HEAD INJURY	45	91	93	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2006	87	5					611	618		10.1016/j.apmr.2006.01.018			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	039UW	WOS:000237333900002	16635622				2021-06-18	
J	Erlich, S; Shohami, E; Pinkas-Kramarski, R				Erlich, Shlomit; Shohami, Esther; Pinkas-Kramarski, Ronit			Neurodegeneration induces upregulation of Beclin 1	AUTOPHAGY			English	Article						Beclin 1; autophagy; brain; traumatic brain injury; neurons; astrocytes	CLOSED-HEAD INJURY; AUTOPHAGY; NEURONS; TUMORIGENESIS; MECHANISMS; MICROGLIA; DEATH; GENE	Autophagy, a bulk degradation of subcellular constituents, is activated in normal cell growth and development, and represents the major pathway by which the cell maintains a balance between protein synthesis and protein degradation. Autophagy was documented in several neurodegenerative diseases, and under stress conditions the autophagic process can lead to cell death (type II programmed cell death). Beclin 1 is a Bcl-2 interacting protein that was previously found to promote autophagy. We have used Beclin I protein as a marker for autophagy following traumatic brain injury in mice. We demonstrated a dramatic elevation in Beclin I levels near the injury site. Interestingly Beclin I elevation starts at early stages post injury (4 h) in neurons and 3 days later in astrocytes. In both cell types it lasts for at least three weeks. Neuronal cells, but not astrocytes, that overexpress Beclin I may exhibit damaged DNA but without changes in nuclear morphology. These observations may indicate that not all the Beclin1 overexpressing cells will die. The elevation of Beclin 1 at the site of injury may represent enhanced autophagy as a mechanism to discard injured cells and reduce damage to cells by disposing of injured components.	Tel Aviv Univ, Dept Neurobiochem, Ramat Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel	Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiochem, Ramat Aviv, Israel.	lironit@post.tau.ac.il		Pinkas-Kramarski, Ronit/0000-0002-1000-369X			Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; AKIYAMA H, 1994, BRAIN RES, V635, P257, DOI 10.1016/0006-8993(94)91447-8; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Roizin L, 1974, Trans Am Neurol Assoc, V99, P240; Selimi F, 2003, NEURON, V37, P813, DOI 10.1016/S0896-6273(03)00093-X; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Yu LY, 2003, J CELL BIOL, V163, P987, DOI 10.1083/jcb.200305083; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	28	91	91	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1554-8627	1554-8635		AUTOPHAGY	Autophagy	JAN-MAR	2006	2	1					49	51		10.4161/auto.2156			3	Cell Biology	Cell Biology	056ZP	WOS:000238564200008	16874043	Bronze			2021-06-18	
J	Lee, SH; Chun, W; Kong, PJ; Han, JA; Cho, BP; Kwon, OY; Lee, HJ; Kim, SS				Lee, SH; Chun, W; Kong, PJ; Han, JA; Cho, BP; Kwon, OY; Lee, HJ; Kim, SS			Sustained activation of Akt by melatonin contributes to the protection against kainic acid-induced neuronal death in hippocampus	JOURNAL OF PINEAL RESEARCH			English	Article						Akt; excitotoxicity; glial cell line-derived neurotrophic factor; inducible nitric oxide synthase; kainic acid; melatonin	MESSENGER-RNA EXPRESSION; NEUROTROPHIC FACTOR; IN-VIVO; ANTIBODY-RESPONSE; INDUCED APOPTOSIS; PINEAL-GLAND; BRAIN-DAMAGE; NITRIC-OXIDE; RAT; RECEPTORS	In the present study, the underlying protective mechanism of melatonin on kainic acid (KA)-induced excitotoxicity was examined in the hippocampus of mice. KA, administered intracerebroventricularly (i.c.v.), induced marked neuronal cell death with concurrent microglial activation and subsequent induction of inducible nitric oxide synthase (iNOS) in the hippocampus. Histopathological analysis demonstrated that melatonin (10 mg/kg), administered 1 hr prior to KA, attenuated KA-induced death of pyramidal neurons in the CA3 region. Melatonin obviously suppressed KA-induced microglial activation and consequent iNOS expression that were determined by increased immunoreactivities of microglial marker OX-6 and iNOS, respectively. Increased phosphorylation of Akt in pyramidal neurons was observed as early as 2 hr after administration of melatonin. Further, melatonin resulted in increased expression of astroglial glial cell line-derived neurotrophic factor (GDNF), which started to appear approximately 6 hr after administration of melatonin. The results of the present study demonstrate that melatonin exerts its neuroprotective action against KA-induced excitotoxicity both through the activation of neuronal Akt and via the direct action on hippocampal neurons and through the increased expression of astroglial GDNF, which subsequently activates neuronal PI3K/Akt pathway. Therefore, the present study suggests that melatonin, pineal secretory product, is potentially useful in the treatment of acute brain pathologies associated with excitotoxic neuronal damage such as epilepsy, stroke, and traumatic brain injury.	Kangweon Natl Univ, Coll Med, Dept Pharmacol, Chunchon 200701, South Korea; Kangweon Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chunchon 200701, South Korea; Yonsei Univ, Wonju Coll Med, Dept Anat, Wonju, Kangwon, South Korea	Kim, SS (corresponding author), Kangweon Natl Univ, Coll Med, Dept Pharmacol, Hyoja 2 Chunchon, Chunchon 200701, South Korea.	ksslsy@kangwon.ac.kr		Lee, Sang-Hyun/0000-0002-9682-1473; Min, Jeong-Ki/0000-0003-4924-8739			Anhe GF, 2004, J NEUROCHEM, V90, P559, DOI 10.1111/j.1471-4159.2004.02514.x; Armstrong KJ, 2002, NEUROREPORT, V13, P473, DOI 10.1097/00001756-200203250-00023; BAKER H, 1993, NEUROSCIENCE, V52, P115, DOI 10.1016/0306-4522(93)90187-K; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Conti A, 1995, J PINEAL RES, V19, P103, DOI 10.1111/j.1600-079X.1995.tb00177.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Franceschini D, 1999, ADV EXP MED BIOL, V467, P207; Giusti P, 1996, J PINEAL RES, V20, P226, DOI 10.1111/j.1600-079X.1996.tb00263.x; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; Henshall DC, 2002, J NEUROSCI, V22, P8458; Izquierdo LA, 2000, BEHAV BRAIN RES, V111, P93, DOI 10.1016/S0166-4328(00)00137-6; Joo JY, 1998, RESTOR NEUROL NEUROS, V13, P185; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lezoualch F, 1996, NEUROREPORT, V7, P2071, DOI 10.1097/00001756-199609020-00003; MAESTRONI GJM, 1987, CLIN EXP IMMUNOL, V68, P384; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; Manev H, 1996, FASEB J, V10, P1546; Musshoff U, 2002, HIPPOCAMPUS, V12, P165, DOI 10.1002/hipo.1105; Pong K, 1998, J NEUROCHEM, V71, P1912; Pyo H, 2003, NEUROSCI LETT, V346, P141, DOI 10.1016/S0304-3940(03)00505-6; Reppert SM, 1996, TRENDS PHARMACOL SCI, V17, P100, DOI 10.1016/0165-6147(96)10005-5; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Sarabi A, 2000, BRAIN RES, V877, P262, DOI 10.1016/S0006-8993(00)02682-2; Skaper SD, 1998, FASEB J, V12, P725; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; Stewart LS, 2005, EPILEPSIA, V46, P473, DOI 10.1111/j.0013-9580.2005.30204.x; Tan DX, 1998, J NEUROSCI RES, V54, P382, DOI 10.1002/(SICI)1097-4547(19981101)54:3<382::AID-JNR9>3.0.CO;2-Y; Tang YP, 1998, J NEUROSCI RES, V53, P593; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1996, NATURE, V381, P789; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Zagulska-Szymczak S, 2001, NEUROCHEM INT, V38, P485, DOI 10.1016/S0197-0186(00)00101-7	40	91	99	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	JAN	2006	40	1					79	85		10.1111/j.1600-079X.2005.00283.x			7	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	987PO	WOS:000233530000011	16313502	DOAJ Gold			2021-06-18	
J	Newman, JA; Beusenberg, MC; Shewchenko, N; Withnall, C; Fournier, E				Newman, JA; Beusenberg, MC; Shewchenko, N; Withnall, C; Fournier, E			Verification of biomechanical methods employed in a comprehensive study of mild traumatic brain injury and the effectiveness of American football helmets	JOURNAL OF BIOMECHANICS			English	Article						concussion; mild traumatic brain injury; sports; reconstruction; validation; helmet; kinematics; video analysis; acceleration; impact; football; angular acceleration; video	PROFESSIONAL FOOTBALL; CONCUSSION; IMPACTS	Concussion, or mild traumatic brain injury, occurs in many activities, mostly as a result of the head being accelerated. A comprehensive study has been conducted to understand better the mechanics of the impacts associated with concussion in American football. This study involves a sequence of techniques to analyse and reconstruct many different head impact scenarios. It is important to understand the validity and accuracy of these techniques in order to be able to use the results of the study to improve helmets and helmet standards. Two major categories of potential errors have been investigated. The first category concerns error sources specific to the use of crash test dummy instrumentation (accelerometers) and associated data processing techniques. These are relied upon to establish both linear and angular head acceleration responses. The second category concerns the use of broadcast video data and crash test dummy head-neck-torso systems. These are used to replicate the complex head impact scenarios of whole body collisions that occur on the football field between two living human beings. All acceleration measurement and processing techniques were based on well-established practices and standards. These proved to be reliable and reproducible. Potential errors in the linear accelerations due to electrical or mechanical noise did not exceed 2% for the three different noise sources investigated. Potential errors in the angular accelerations due to noise could be as high as 6.7%, due to error accumulation of multiple linear acceleration measurements. The potential error in the relative impact velocity between colliding heads could be as high as 11%, and was found to be the largest error source in the sequence of techniques to reconstruct the game impacts. Full-scale experiments with complete crash test dummies in staged head impacts showed maximum errors of 17% for resultant linear accelerations and 25% for resultant angular accelerations. (c) 2004 Elsevier Ltd. All rights reserved.	Biokinet & Assoc Ltd, Ottawa, ON K1H 1E1, Canada	Withnall, C (corresponding author), Biokinet & Assoc Ltd, 2470 Don Reid Dr, Ottawa, ON K1H 1E1, Canada.	withnall@biokinetics.com					BACKAITIS SH, 1994, HYBRID 3 1 HUMAN LIK; BEUSENBERG M, 2001, P 2001 IRCOBI C BIOM, P295; deJager M, 1996, STAPP CAR C, VP-30, P269; DIMASI FP, 1995, HS808282 DOT NAT HIG; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; GENNARELLI TA, 1983, HEAD NECK INJ CRIT C, P20; JOHNSON AK, 1977, HS802568 DOT NAT HIG; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Newman J. A., 1999, P INT RESEAR C BIOME, P17; Newman JA, 1998, BIOM HLTH R, V21, P200; Newman JA, 1993, ACCIDENTAL INJURY BI, P292; NEWMAN JA, 2000, P 2000 INT IRCOBI C, P233; NEWMAN JA, 2000, P STAPP CAR CRASH J, V44, P215; NEWMAN JA, 1982, AGARD C P 322 LIMP I; *NOCSAE, 1996, 00196 NOCSAE; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PLANK G, 1989, DOTHS807370 NAT HIGH; *SAE, 1995, SURF VEH REC PRACT 1; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; VIANO DC, 1986, P 30 STAPP CAR CRASH, P269	23	91	91	2	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUL	2005	38	7					1469	1481		10.1016/j.jbiomech.2004.06.025			13	Biophysics; Engineering, Biomedical	Biophysics; Engineering	939WM	WOS:000230103300011	15922758				2021-06-18	
J	Bayir, H; Kagan, VE; Borisenko, GG; Tyurina, YY; Janesko, KL; Vagni, VA; Billar, TR; Williams, DL; Kochanek, PM				Bayir, H; Kagan, VE; Borisenko, GG; Tyurina, YY; Janesko, KL; Vagni, VA; Billar, TR; Williams, DL; Kochanek, PM			Enhanced oxidative stress in iNOS-deficient mice after traumatic brain injury: support for a neuroprotective role of iNOS	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ascorbate; DAF-2; head injury; nitric oxide; nitrosative stress; oxidative stress	NITRIC-OXIDE SYNTHASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CEREBROSPINAL-FLUID; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; S-NITROSYLATION; L-ARGININE; SELECTIVE-INHIBITION; SUPEROXIDE-DISMUTASE; PROTEIN NITRATION	Studies in experimental traumatic brain injury (TBI) suggests both deleterious and protective effects of inducible nitric oxide synthase (iNOS). Early after injury, iNOS may be detrimental via formation of peroxynitrite and iNOS inhibitors are protective. In contrast, we reported impaired long-term functional outcome after TBI in iNOS knockout (ko) versus wild-type (wt) mice. To elucidate potential neuroprotective and neurotoxic mechanisms for iNOS we studied nitric oxide formation by electron paramagnetic resonance (EPR) spectroscopy using diethyldithiocarbamate-iron (DETC-Fe) as a spin trap and markers of nitrosative (S-nitrosothiol (RSNO, Fluorescent assay); nitrotyrosine (3NT, ELISA )) and oxidative stress (ascorbate, HPLC) at 72 h after controlled cortical impact (CCI) in iNOS ko and wt and in uninjured iNOS ko and wt mice. 3NT immunostaining with macrophage and myeloperoxidase (MPO) dual labelling was also assessed in brain sections. Brain DETC-Fe-NO low-temperature EPR signal intensity was similar to 2-fold greater in wt versus iNOS ko at 72h after CCI. Ascorbate levels decreased in injured hemisphere in wt and iNOS ko versus uninjured -this decrease was more pronounced in NOS ko. In wt mice, RSNO and 3NT levels were increased after CCI versus uninjured (50% and 400%, respectively, P < 0.05). RSNO levels were not increased in iNOS ko after CCI. Nitrotyrosine levels increased after CCI in wt and ko versus respective uninjured -this increase was more pronounced in wt (2.34 +/- 0.95 versus 1.27 +/- 0.49 pmol/mg protein, P < 0.05). Increased 3NT immunoreactivity was detected in wt versus iNOS ko at 72 h after CCI, and colocalized with macrophage marker and Ill Our data support a role for iNOS-derived NO as an endogenous antioxidant after CCI. iNOS also contributes protein nitrosylation and nitration. Colocalization of 3NT with macrophages and MPO suggests generation of nitrating agents by macrophages and/or phagocytosis of nitrated proteins.	Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth & Pharmacol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA	Bayir, H (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	bavihx@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885; Tyurina, Yulia/0000-0003-0287-2091	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL64145] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318] Funding Source: NIH RePORTER		Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003; Bolan EA, 2000, J NEUROSCI, V20, P4798; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; BRAU RH, 1984, NEUROSURGERY, V14, P142, DOI 10.1227/00006123-198402000-00004; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Fenyk-Melody JE, 1998, J IMMUNOL, V160, P2940; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; Johnson MA, 2001, J BIOL CHEM, V276, P39872, DOI 10.1074/jbc.M102781200; Kagan VE, 2001, ANTIOXID REDOX SIGN, V3, P189, DOI 10.1089/152308601300185160; Kahl KG, 2004, NEUROSCI LETT, V358, P58, DOI 10.1016/j.neulet.2003.12.095; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1998, J IMMUNOL, V161, P4122; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kojima H, 1998, NEUROREPORT, V9, P3345, DOI 10.1097/00001756-199810260-00001; KUBRINA LN, 1992, BIOCHIM BIOPHYS ACTA, V1099, P233, DOI 10.1016/0005-2728(92)90032-W; Levy D, 2001, J NEUROPATH EXP NEUR, V60, P411, DOI 10.1093/jnen/60.5.411; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; Mohanakumar KP, 2002, ANN NY ACAD SCI, V962, P389, DOI 10.1111/j.1749-6632.2002.tb04083.x; Nagayama M, 1998, J CEREBR BLOOD F MET, V18, P1107, DOI 10.1097/00004647-199810000-00007; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; Okamoto H, 1998, STROKE, V29, P1209, DOI 10.1161/01.STR.29.6.1209; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sahrbacher UC, 1998, EUR J IMMUNOL, V28, P1332, DOI 10.1002/(SICI)1521-4141(199804)28:04<1332::AID-IMMU1332>3.3.CO;2-7; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Schulz JB, 1995, J NEUROSCI, V15, P8419; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sjakste N, 1999, BIOCHEM PHARMACOL, V58, P1955, DOI 10.1016/S0006-2952(99)00281-6; SPECTOR R, 1984, FED PROC, V43, P196; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; Strong MJ, 1998, BIOCHEM BIOPH RES CO, V248, P157, DOI 10.1006/bbrc.1998.8930; TOMINAGA T, 1994, J CEREBR BLOOD F MET, V14, P715, DOI 10.1038/jcbfm.1994.92; Tyurin VA, 2001, CIRC RES, V88, P1210, DOI 10.1161/hh1101.092179; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xu AM, 2000, HYPERTENSION, V36, P291, DOI 10.1161/01.HYP.36.2.291; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; Zhao XR, 2000, BRAIN RES, V872, P215, DOI 10.1016/S0006-8993(00)02459-8; Zhu DY, 2003, J NEUROSCI, V23, P223	71	91	96	2	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2005	25	6					673	684		10.1038/sj.jcbfm.9600068			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	928BK	WOS:000229245900002	15716856	Bronze			2021-06-18	
J	Skold, MK; Von Gertten, C; Sandberg-Nordqvist, AC; Mathiesen, T; Holmin, S				Skold, MK; Von Gertten, C; Sandberg-Nordqvist, AC; Mathiesen, T; Holmin, S			VEGF and VEGF receptor expression after experimental brain contusion in rat	JOURNAL OF NEUROTRAUMA			English	Article						angiogenesis; blood-brain barrier (BBB); brain; contusion; vascular endothelial growth factor (VEGF); Flt-1; Flk-1	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; FOCAL CEREBRAL-ISCHEMIA; STIMULATES AXONAL OUTGROWTH; SPINAL-CORD; INTEGRIN ALPHA(V)BETA(3); NERVOUS-SYSTEM; MESSENGER-RNA; ADULT CATS; IN-VITRO	Angiogenesis following traumatic brain injury (TBI) may be of importance not only for post-traumatic reparative processes but also for the development of secondary injuries. Vascular endothelial growth factor (VEGF) is a major regulator of endothelial cell proliferation, angiogenesis, and vascular permeability, though its possible involvement in secondary injuries after TBI is largely unknown. This study was undertaken to analyze the expression of VEGF and the VEGF receptors in experimental brain contusion in rat. Twenty-three adult female Sprague-Dawley rats were subjected to a focal cerebral contusion injury by use of a weight-drop model. Four additional rats underwent craniotomy only. The animals were sacrificed 6 h, or 1, 2, 4, 6, 8, or 16 days post-injury. Expression of VEGF and the VEGF receptors VEGFR1 (Flt-1) and VEGFR2 (Flk-1) were studied by in situ hybridization and immunohistochemistry. VEGF messenger (m)RNA and protein expression were detected in astrocytes, neutrophils, and macrophages in or adjacent to the injury from 1 day after injury, with a peak expression after 4-6 days. Flt-1 and Flk-1 mRNA and protein were detected in vessels adjacent to the lesion from I day after injury throughout day 6 after injury. It was also noted that Flt-1/Flk-1 and VEGF-positive vessels often were negative for SMI-71, a marker for vessels in areas with blood-brain barrier (BBB). In conclusion, we have demonstrated that TBI leads to an upregulation of VEGF, Flt-1, and Flk-1 mRNA and protein in and around the lesion. The data provide a foundation for future pharmacological intervention studies focusing on posttraumatic angiogenesis and possible injury repair effects of the VEGF system in TBI.	Karolinska Inst, Retzius Lab, Dept Neurosci, S-17177 Stockholm, Sweden; Karolinska Hosp, Neurosurg Sect, Dept Clin Neurosci, Stockholm, Sweden; Karolinska Inst, Swedish Natl Def Res Agcy, Dept Def Med, Stockholm, Sweden	Skold, MK (corresponding author), Karolinska Inst, Retzius Lab, Dept Neurosci, B1-5, S-17177 Stockholm, Sweden.	Mattias.Skold@neuro.ki.se	SkAld, Mattias/AAJ-8253-2020	Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919			Abumiya T, 1999, J CEREBR BLOOD F MET, V19, P1038, DOI 10.1097/00004647-199909000-00012; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; BULLOCK R, 1990, ACT NEUR S, V51, P286; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Fong GH, 1996, DEV DYNAM, V207, P1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Goldman CK, 1997, NEUROSURGERY, V40, P1269, DOI 10.1097/00006123-199706000-00029; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; ImperatoKalmar EL, 1997, EXP NEUROL, V145, P322, DOI 10.1006/exnr.1997.6449; Issa R, 1999, LAB INVEST, V79, P417; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Neufeld G, 1999, FASEB J, V13, P9; Nordqvist ACS, 1997, NEUROREPORT, V8, P455, DOI 10.1097/00001756-199701200-00016; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Okada Y, 1996, AM J PATHOL, V149, P37; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Povlishock J T, 1992, Hum Cell, V5, P345; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; RISLING M, 1983, BRAIN RES, V280, P15, DOI 10.1016/0006-8993(83)91169-1; RISLING M, 1989, BRAIN RES, V494, P13, DOI 10.1016/0006-8993(89)90138-8; Robinson CJ, 2001, J CELL SCI, V114, P853; SANDHU RS, 1996, IEEE COMPUT, V2, P38; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Senger DR, 1996, AM J PATHOL, V149, P293; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STERNBERGER NH, 1987, P NATL ACAD SCI USA, V84, P8169, DOI 10.1073/pnas.84.22.8169; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	61	91	99	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2005	22	3					353	367		10.1089/neu.2005.22.353			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	911QM	WOS:000228019500003	15785231				2021-06-18	
J	Gall, B; Parkhouse, W; Goodman, D				Gall, B; Parkhouse, W; Goodman, D			Heart rate variability of recently concussed athletes at rest and exercise	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						uncoupling; spectral analysis; autonomic nervous system; cardiovascular system	TRAUMATIC BRAIN INJURY; AUTONOMIC CONTROL; DYSFUNCTION; SYMPTOMS	Purpose: The objective of this study was to assess the neuroautonomic cardiovascular regulation in recently concussed athletes at rest and in response to low-moderate steady-state exercise, using heart rate variability (HRV). Methods: A 5-min ECG sample was taken at rest from the 14 concussed athletes at 1.8 (+/- 0.2) days postinjury and again at 5 d later. Once asymptomatic at rest, the concussed athletes and their matched controls (N = 14) participated in an exercise protocol. The protocol consisted of a 2-min warm-up with a pedaling frequency between 50 and 60 rpm against a load of 40 W. After the warm-up, the athletes engaged in a low-moderate intensity steady state 10-min exercise bout where the pedaling frequency and load increased to 80-90 rpm and 1.5 W(.)kg(-1) body weight, respectively. The protocol was repeated 5 d later. A 5-min ECG sample from minutes 4 to 9 of the low-moderate intensity steady state exercise bout was used to assess HRV during exercise. Mixed model ANOVA were used to analyze the data. Results: No difference at rest was detected between the concussed athletes and their matched controls in any of the HRV variables measured. However, across both exercise tests, the concussed group demonstrated a significant decrease in the mean RR interval, and low- and high-frequency power (P < 0.05) in relation to their matched controls. Conclusion: Low-moderate steady-state exercise elicits a neuroautonomic cardiovascular dysfunction in concussed athletes that is not present in a rested state. This dysfunction alludes to an exercise induced uncoupling between the autonomic and cardiovascular systems.	Simon Fraser Univ, Sch Kinesiol, Burnaby, BC V5A 1S6, Canada	Parkhouse, W (corresponding author), Simon Fraser Univ, Sch Kinesiol, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	parkhous@sfu.ca					AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; BREUER HWM, 1993, BRIT HEART J, V70, P144; *CAN HOCK ASS, 1999, GAT CAN HOCK SAF PRO, P85; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Cerutti S, 1995, HEART RATE VARIABILI, P63; FARDY PS, 1969, RES QUART, V40, P502, DOI 10.1080/10671188.1969.10614869; Fries I, 1998, J APICULT RES, V37, P85, DOI 10.1080/00218839.1998.11100959; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; Goldsmith RL, 2000, CORONARY ARTERY DIS, V11, P129, DOI 10.1097/00019501-200003000-00007; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; King ML, 1997, BRAIN INJURY, V11, P445; Korpelainen JT, 1996, ACTA NEUROL SCAND, V94, P337, DOI 10.1111/j.1600-0404.1996.tb07076.x; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; Meglic B, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000047605; Mujika I, 2001, MED SCI SPORT EXER, V33, P413, DOI 10.1097/00005768-200103000-00013; NAKAMURA Y, 1993, J APPL PHYSIOL, V74, P875; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; RIMOLDI O, 1990, AM J PHYSIOL, V258, pH967; RIMOLDI O, 1992, CHEST, V101, pS226, DOI 10.1378/chest.101.5.226S	26	91	93	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	AUG	2004	36	8					1269	1274		10.1249/01.MSS.0000135787.73757.4D			6	Sport Sciences	Sport Sciences	843XC	WOS:000223119300001	15292731				2021-06-18	
J	Harrison-Felix, C; Whiteneck, G; DeVivo, M; Hammond, FM; Jha, A				Harrison-Felix, C; Whiteneck, G; DeVivo, M; Hammond, FM; Jha, A			Mortality following rehabilitation in the Traumatic Brain Injury Model Systems of Care	NEUROREHABILITATION			English	Article						traumatic brain injury; mortality; life expectancy	NATIONAL-DEATH-INDEX; SEVERE HEAD-INJURY; LIFE EXPECTANCY; EMPLOYMENT STATUS; LONGITUDINAL-MORTALITY; EARLY PREDICTORS; VITAL STATUS; SURVIVAL; POPULATION; COMA	While many outcomes after traumatic brain injury (TBI) have been systematically investigated, the most basic of all outcomes - survival - has been neglected. The purpose of this study was to investigate mortality in a cohort of 2,178 individuals with TBI completing inpatient rehabilitation in one of 15 National Institute on Disability and Rehabilitation Research-funded TBI Model Systems of care. The study hypotheses were: (1) relative to the general population, TBI increases mortality and decreases life expectancy in individuals with TBI completing inpatient rehabilitation and surviving to one-year post-injury; and (2) within the TBI population, the risk of death is greater in certain TBI subgroups. Results indicate that individuals with TBI were twice as likely to die compared to individuals in the general population of similar age, gender and race, resulting in an estimated average life expectancy reduction of seven years for individuals with TBI. Within the TBI population, the strongest independent risk factors for death after one-year post-injury were older age and not being employed at injury, and greater disability at rehabilitation discharge. This information is important to guide decision-making for treatment, utilization of limited medical resources, and planning for ongoing health care needs and lifetime planning.	Craig Hosp, Res Dept, Englewood, CO 80113 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA; Charlotte Inst Rehabil, Charlotte, NC USA; Univ Colorado, Denver Hlth Med Ctr, Dept Rehabil Med, Denver, CO 80202 USA	Harrison-Felix, C (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	charrison-felix@craighospital.org					ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Baguley I, 2000, BRAIN INJURY, V14, P505; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; FISHER SG, 1995, AM J EPIDEMIOL, V141, P242, DOI 10.1093/oxfordjournals.aje.a117426; Gordis L., 2000, EPIDEMIOLOGY; GOTSCH K, 2001, BRAIN INJ ASS ANN M; Hammond F. M., 2000, ARCH PHYS MED REHAB, V81, P1260; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; MININO AM, 2002, NATL VITAL STAT REPO, V50; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; *NAT I DIS REH RES, 1996, J HEAD TRAUMA REHAB, V11, P1; *NAT I OCC SAF HLT, 2000, BRIEF REP RES GRANT; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; ROGOT E, 1992, PUBLIC HEALTH REP, V107, P457; Rosner B., 2000, FUNDAMENTALS BIOSTAT; Schnorr TM, 1997, EPIDEMIOLOGY, V8, P321, DOI 10.1097/00001648-199705000-00017; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Sesso HD, 2000, AM J EPIDEMIOL, V152, P107, DOI 10.1093/aje/152.2.107; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SINGH GK, 1996, MONTHLY VITAL STAT S, V45; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SORLIE PD, 1990, AM J EPIDEMIOL, V132, P983, DOI 10.1093/oxfordjournals.aje.a115741; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; STEENLAND K, 1991, EPIDEMIOLOGY, V2, P418, DOI 10.1097/00001648-199111000-00005; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; *TRAUM BRAIN INJ M, 2001, TRAUM BRAIN INJ MOD; *TRAUM BRAIN INJ M, 1993, J HEAD TRAUMA REHAB, V8, P1; *TRAUM BRAIN INJ M, ANN REP TRAUM BRAIN; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; Whiteneck G, 2001, COLORADO TRAUMATIC B; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	62	91	93	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2004	19	1					45	54					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	777KA	WOS:000189176500006	14988587				2021-06-18	
J	Piland, SG; Motl, RW; Ferrara, MS; Peterson, CL				Piland, SG; Motl, RW; Ferrara, MS; Peterson, CL			Evidence for the factorial and construct validity of a self-report concussion symptoms scale	JOURNAL OF ATHLETIC TRAINING			English	Article						confirmatory factor analysis; symptoms	COVARIANCE STRUCTURE-ANALYSIS; MILD HEAD-INJURY; TEST STATISTICS; NEUROPSYCHOLOGICAL ASSESSMENT; PERFORMANCE; RECOVERY; CRITERIA; FIT	Objective: To evaluate the factorial and construct validity of the Head Injury Scale (HIS) among a sample of male and female collegiate athletes. Design and Setting: Using a cross-sectional design, we established the factorial validity of the HIS scale with confirmatory factor analysis and the construct validity of the HIS with Pearson product moment correlation analyses. Using an experimental design, we compared scores on the HIS between concussed and nonconcussed groups with a 2 (groups) x 5 (time) mixed-model analysis of variance. Subjects: Participants (N = 279) in the cross-sectional analyses were predominately male (n = 223) collegiate athletes with a mean age of 19.49 +/- 1.63 years. Participants (N = 33) in the experimental analyses were concussed (n = 17) and nonconcussed control (n = 16) collegiate athletes with a mean age of 19.76 +/- 1.49 years. Measurements: All participants completed baseline measures for the 16-item HIS, neuropsychological testing battery, and posturography. Concussed individuals and paired controls were evaluated on days 1, 2, 3, and 10 postinjury on the same testing battery. Results: Confirmatory factor analysis indicated that a theoretically derived, 3-factor model provided a good but not excellent fit to the 16-item HIS. Hence, the 16-item HIS was modified on the basis of substantive arguments about item-content validity. The subsequent analysis indicated that the 3-factor model provided an excellent fit to the modified 9-item HIS. The 3 factors were best described by a single second-order factor: concussion symptoms. Scores from the 16-item HIS and 9-item HIS were strongly correlated, but there were few significant correlations between HIS scores and scores from the neuropsychological and balance measures. A significant group-by-day interaction was noted on both the 9-item HIS and 16-item HIS, with significant differences seen between groups on days 1 and 2 postconcussion. Conclusions: We provide evidence for the factorial and construct validity of the HIS among collegiate athletes. This scale might aid in return-to-play decisions by physicians and athletic trainers.	Univ Georgia, Dept Exercise Sci, Athens, GA 30602 USA; James Madison Univ, Harrisonburg, VA 22807 USA	Piland, SG (corresponding author), Univ Georgia, Dept Exercise Sci, 300 River Rd, Athens, GA 30602 USA.	spiland@coe.uga.edu					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ALVES WM, 1987, CLIN SPORT MED, V6, P211; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Barth JT, 1989, MILD HEAD INJURY; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bollen K.A., 1989, STRUCTURAL EQUATIONS, P514, DOI 10.1002/9781118619179; BROWNE MW, 2002, TESTING STRUCTURAL E, P136; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CHOU CP, 1991, BRIT J MATH STAT PSY, V44, P347, DOI 10.1111/j.2044-8317.1991.tb00966.x; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; DIKMEN SS, 1998, RECOVERY, V9, P10; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Fouladi RT, 2000, STRUCT EQU MODELING, V7, P356, DOI 10.1207/S15328007SEM0703_2; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; GUSKIEWICZ KM, 1998, J ATHL TRAIN S, V33, pS22; GUSKIEWICZ KM, 1998, J ATHL TRAIN S, V33, pS8; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; HU LT, 1992, PSYCHOL BULL, V112, P351, DOI 10.1037/0033-2909.112.2.351; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Joreskog K., 1993, TESTING STRUCTURAL E; Joreskog KG., 1996, LISREL 8 USERS REFER; Kelly JP, 1997, NEUROLOGY, V48, P581; LARRABEE GJ, 1998, RECOVERY, V9, P12; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; MARDIA KV, 1970, BIOMETRIKA, V57, P519, DOI 10.2307/2334770; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MARUISH ME, 1997, CLIN NEUROPSYCHOLOGY, P132; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; MESSICK S, 1995, AM PSYCHOL, V50, P741, DOI 10.1037/0003-066X.50.9.741; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Motl RW, 2000, MED SCI SPORT EXER, V32, P1007; Motl RW, 2000, MEASUREMENT PHYS ED, V4, P13; MUTHEN B, 1985, BR J MATH STAT PSYCH, V38, P347; Paulhus D.L., 1991, MEASURES PERSONALITY, P17, DOI [DOI 10.1016/B978-0-12-590241-0.50006-X, 10.1016/B978-0-12-590241-0.50006-X, DOI 10.1016/b978-0-12-590241-0.50006-x]; Riemann BL, 1999, J SPORT REHABIL, V8, P171, DOI 10.1123/jsr.8.3.171; Riemann BL, 1998, J ATHL TRAIN S, V33, pS18; ROOS R, 1996, PHYSICIAN SPORTSMED, V24, P31; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SATORRA A, 1989, PSYCHOMETRIKA, V54, P131, DOI 10.1007/BF02294453; SATORRA A, 1988, P BUS EC STAT SECT P; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	52	91	91	0	7	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2003	38	2					104	112					9	Sport Sciences	Sport Sciences	738JW	WOS:000186284300001					2021-06-18	
J	Bombardier, CH; Temkin, NR; Machamer, J; Dikmen, SS				Bombardier, CH; Temkin, NR; Machamer, J; Dikmen, SS			The natural history of drinking and alcohol-related problems after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						alcoholism; brain injuries; natural history; rehabilitation	SUBSTANCE-ABUSE; INTERVENTIONS; RECOVERY	Objective: To describe changes in drinking from before traumatic brain injury (TBI) to 1 year after TBI. Design: Inception cohort with 1-year follow-up. Setting: Level I trauma center. Participants: Adults (N=197) hospitalized with a broad range of head injury severity. Interventions: Not applicable. Main Outcome Measures: Alcohol consumption and alcohol-related problems. Results: Drinking and alcohol-related problems decreased substantially from preinjury to 1 year after TBI. However, about one quarter of the sample reported heavy drinking, significant problems, or both during the first year after TBI. Preinjury alcohol use and problems were highly predictive of heavy use and problems after TBI. Conclusion: Although drinking and alcohol-related problems decreased after TBI, there appears to be an ongoing need for prevention and intervention efforts. Screening for preinjury alcohol problems can be used to identify the vast majority of persons who will develop alcohol-related problems within 1 year after injury.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98104 USA	Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	chb@u.washington.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS005304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS05304] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19643] Funding Source: Medline; ODCDC CDC HHS [R49/CCR011714] Funding Source: Medline		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; Bombardier CH, 1997, REHABIL PSYCHOL, V42, P259; BRADLEY KA, 1993, ARCH INTERN MED, V153, P2734, DOI 10.1001/archinte.153.24.2734; BUCHOLZ KK, 1992, ALCOHOL HLTH RES WOR, V0016; Cahalan D, 1969, AM DRINKING PRACTICE, P131; Cisler RA, 1999, ALCOHOL CLIN EXP RES, V23, P263, DOI 10.1111/j.1530-0277.1999.tb04109.x; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; GRANT BF, 1991, ALCOHOL HLTH RES WOR, V0015; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HUNT WA, 1971, J CLIN PSYCHOL, V27, P455, DOI 10.1002/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Marlatt G. A., 1985, RELAPSE PREVENTION M; Miller WR, 1999, J CONSULT CLIN PSYCH, V67, P688, DOI 10.1037/0022-006X.67.5.688; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; TUCKER JA, 1994, J STUD ALCOHOL, V55, P401, DOI 10.15288/jsa.1994.55.401; Zweben A, 1996, SUBST USE MISUSE, V31, P1783, DOI 10.3109/10826089609064001	28	91	91	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					185	191		10.1053/apmr.2003.50002			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700006	12601648				2021-06-18	
J	Marion, DW; Puccio, A; Wisniewski, SR; Kochanek, P; Dixon, CE; Bullian, L; Carlier, P				Marion, DW; Puccio, A; Wisniewski, SR; Kochanek, P; Dixon, CE; Bullian, L; Carlier, P			Effect of hyperventilation on extracellular concentrations of glutamate, lactate, pyruvate, and local cerebral blood flow in patients with severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						severe traumatic brain injury; hyperventilation; microdialysis; local cerebral blood flow; glutamate; lactate	SEVERE HEAD-INJURY; OXYGEN-SATURATION; MICRODIALYSIS; METABOLISM; HYPOCAPNIA; CARE	Objective., To determine the potential adverse effects of brief periods of hyperventilation commonly used for acute neurologic deterioration. Design: Prospective clinical trial. Setting: University medical school. Patients: Twenty patients with severe traumatic brain injury. Interventions: The effect of 30 mins of hyperventilation (mean PaCO2, 24.6 mm Hg) on the extracellular metabolites associated with ischemia, and on local cerebral blood flow was studied by using microdialysis and local cerebral blood flow techniques. Normal appearing brain adjacent to evacuated hemorrhagic contusions or underlying evacuated subdural hematomas was studied. Hyperventilation trials were done 24-36 hrs after injury and again at 3-4 days after injury. Dialysate concentrations of glutamate, lactate, and pyruvate were measured before and for 4 hrs after the hyperventilation trials. Measurements and Main Results., At 24-36 hrs, hyperventilation led to a greater than or equal to10% increase in the extracellular concentrations of glutamate in 14 of 20 patients, with concentrations in those 14 patients 13.7-395% above baseline; a greater than or equal to10% increase in lactate in 7 of 20 patients (11.6-211% above baseline); and a greater than or equal to10% increase in the lactate/pyruvate ratio in eight of 20 patients (10.8-227% above baseline). At 3-4 days after injury, ten of 13 patients had an increase in glutamate of greater than or equal to10%, while only three of 13 patients had an increase in extracellular lactate and two of 13 patients had an increase in the lactate/pyruvate ratio of this magnitude. The hyperventilation associated increases in extracellular glutamate and lactate concentrations were significant (P <.05; one-sample Student's t-test) at both time points after injury, as was the lactate/pyruvate ratio at 24-36 hrs. A greater than or equal to10% decline in local cerebral blood flow was observed with hyperventilation in five of 20 patients at 24-36 hrs (range, 10.2-18.7% below baseline), and in ten of 13 patients studied at 3-4 days (11.3-54% below baseline). There was no correlation with the presence or absence of local CO2 vasoresponsivity and increases in the extracellular metabolites at either the early or late time points. Conclusions: In brain tissue adjacent to cerebral contusions or underlying subdural hematomas, even brief periods of hyperventilation can significantly increase extracellular concentrations of mediators of secondary brain injury. These hyperventilation-induced changes are much more common during the first 24-36 hrs after injury than at 3-4 days.	Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA	Marion, DW (corresponding author), Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, 200 Lothrop St,Suite B400, Pittsburgh, PA 15213 USA.	dmarion@neuronet.pitt.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860			Ausina A, 1998, ACT NEUR S, V71, P1; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; CROCKARD HA, 1973, BMJ-BRIT MED J, V4, P634, DOI 10.1136/bmj.4.5893.634; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; Dexter F, 1997, J NEUROSURG ANESTH, V9, P217, DOI 10.1097/00008506-199707000-00003; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; Kerr ME, 1997, NURS RES, V46, P195, DOI 10.1097/00006199-199707000-00003; LANGFITT TW, 1966, J NEUROSURG, V24, P975, DOI 10.3171/jns.1966.24.6.0975; Letarte PB, 1999, ACT NEUR S, V75, P45; Lundberg N., 1959, ACTA PSYCHIAT SCAND, V34, P4; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHNEIDER GH, 1995, ACTA NEUROCHIR, V134, P71, DOI 10.1007/BF01428507; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212	24	91	97	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2002	30	12					2619	2625		10.1097/00003246-200212000-00001			7	Critical Care Medicine	General & Internal Medicine	633AP	WOS:000180257300001	12483048				2021-06-18	
J	Colton, CA; Brown, CM; Cook, D; Needham, LK; Xu, Q; Czapiga, M; Saunders, AM; Schmechel, DE; Rasheed, K; Vitek, MP				Colton, CA; Brown, CM; Cook, D; Needham, LK; Xu, Q; Czapiga, M; Saunders, AM; Schmechel, DE; Rasheed, K; Vitek, MP			APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress	NEUROBIOLOGY OF AGING			English	Article; Proceedings Paper	Meeting on Brain Aging - Identifying Accelerators and Brakes	NOV, 2001	SAN DIEGO, CALIFORNIA			nitric oxide; arginine transport; apolipoprotein E; microglia; human macrophages; Alzheimer's disease	BETA-AMYLOID PROTEIN; L-ARGININE TRANSPORT; HUMAN APOLIPOPROTEIN-E; AMINO-ACID-TRANSPORT; ALZHEIMERS-DISEASE; TRANSGENIC MICE; BRAIN INJURY; PERITONEAL-MACROPHAGES; ACTIVATED MICROGLIA; INTERFERON-GAMMA	The mechanism linking the APOE4 gene with increased susceptibility for Alzheimer's disease (AD) and poorer outcomes following closed head injury and stroke is unknown. One potential link is activation of the innate immune system in the CNS. Our previously published data demonstrated that apolipoprotein E regulates production of nitric oxide, a critical cytoactive factor released by immune active macrophages. To determine if immune regulation is different in the presence of apolipoprotein E4 compared to apolipoprotein E3, we have measured NO production by peritoneal and CNS macrophages (microglia) cultured from transgenic mice that only express the human apoE4 or apoE3 protein isoform. Significantly more NO was produced in APOE4 mice compared to APOE3 transgenic mice that only express human apoE3 protein. Similarly, monocyte derived macrophages from humans carrying APOE4 gene alleles also produce significantly greater NO than those individuals with APOE3. The mechanism for this isoform-specific difference in NO production is not known and multiple sites in the NO production pathway may be affected. Expression of inducible nitric oxide synthase (iNOS) mRNA and protein are not significantly different between the APOE3 and APOE4 mice, suggesting that induction of iNOS is not a primary cause of the increased NO production in APOE4 animals. One alternative regulatory mechanism that demonstrates isoform specificity is arginine transport, which is greater in microglia from APOE4 transgenic mice compared to microglia from APOE3 mice. Increased transport is consistent with an increased production of NO and may reflect a direct or indirect effect of the APOE genotype on microglial arginine uptake and microglial activation in general. Overall, greater NO production in APOE4 carriers where characteristically high levels of oxidative/nitrosative stress are found in diseases such as AD provides a mechanism that potentially explains the genetic association between APOE4 and human diseases. (C) 2002 Elsevier Science Inc. All rights reserved.	Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA	Colton, CA (corresponding author), Duke Univ, Med Ctr, Div Neurol, Box 2900, Durham, NC 27710 USA.		Brown, Candice/AAD-4982-2019	Brown, Candice/0000-0001-5845-0221; Colton, Carol/0000-0003-3305-370X; Vitek, Michael/0000-0001-8140-8048			AKIYAMA H, 1994, TOHOKU J EXP MED, V174, P295, DOI 10.1620/tjem.174.295; ALBERTS M, 1995, LANCET, V346, P8974; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; Boschert U, 1999, NEUROBIOL DIS, V6, P508, DOI 10.1006/nbdi.1999.0251; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; Breitner JCS, 1998, ALZ DIS ASSOC DIS, V12, P40, DOI 10.1097/00002093-199803000-00006; Butterfield D.A, 1996, ALZHEIMERS DIS REV, V1, P68; CHAO CC, 1992, J IMMUNOL, V149, P2736; Closs EI, 2000, MOL PHARMACOL, V57, P68; COHEN G, 1996, NEURODEGENERATIVE DI, P139; COLTON C, 1994, NEUROBIOLOGY NO OH, P54; Colton CA, 2000, ANN NY ACAD SCI, V899, P292; Colton CA, 2001, BBA-MOL BASIS DIS, V1535, P134, DOI 10.1016/S0925-4439(00)00092-2; COLTON CA, 1992, J NEUROIMMUNOL, V40, P89, DOI 10.1016/0165-5728(92)90216-8; COLTON CA, 1992, J HISTOCHEM CYTOCHEM, V40, P505, DOI 10.1177/40.4.1372634; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682; Deves R, 1998, PHYSIOL REV, V78, P487; Dugas N, 2001, CYTOKINE, V15, P96, DOI 10.1006/cyto.2001.0896; EGENSPERGER R, 1919, MOL NEUROPATHOL, V8, P439; Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GOODWIN JL, 1995, BRAIN RES, V692, P207, DOI 10.1016/0006-8993(95)00646-8; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Grootendorst J, 2000, BRAIN RES, V868, P165, DOI 10.1016/S0006-8993(00)02250-2; HIBBS JB, 1987, J IMMUNOL, V138, P550; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Ii M, 1996, BRAIN RES, V720, P93, DOI 10.1016/0006-8993(96)00156-4; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P2143; Kakuda DK, 1999, BIOCHEM J, V340, P549, DOI 10.1042/0264-6021:3400549; Kalmar B, 2001, NEUROCHEM INT, V38, P453, DOI 10.1016/S0197-0186(00)00090-5; Klegeris A, 1997, J NEUROSCI RES, V49, P229, DOI 10.1002/(SICI)1097-4547(19970715)49:2<229::AID-JNR11>3.0.CO;2-W; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9; MacLeod CL, 1996, BIOCHEM SOC T, V24, P846, DOI 10.1042/bst0240846; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Maneerat Y, 2000, HISTOPATHOLOGY, V37, P269, DOI 10.1046/j.1365-2559.2000.00989.x; MCGEER PL, 1987, NEUROSCI LETT, V79, P195, DOI 10.1016/0304-3940(87)90696-3; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Ohm TG, 1999, ACTA NEUROPATHOL, V98, P273, DOI 10.1007/s004010051080; PIANI D, 1994, NEWS PHYSIOL SCI, V9, P80; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; PRACTICO D, 2000, AM J MED, V109, P577; Praprotnik D, 1996, ACTA NEUROPATHOL, V91, P1; Roses AD, 1997, NEUROBIOL DIS, V4, P170, DOI 10.1006/nbdi.1997.0161; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SATO H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P46, DOI 10.1016/0005-2736(91)90102-E; Saunders AM, 2000, J NEUROPATH EXP NEUR, V59, P751, DOI 10.1093/jnen/59.9.751; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; SMITH M, 2001, J NEUROCHEM, V70, P2212; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Snell JC, 1997, J LEUKOCYTE BIOL, V62, P369; Stevens BR, 1996, J BIOL CHEM, V271, P24017, DOI 10.1074/jbc.271.39.24017; STREIT WJ, 1995, SCI AM, V273, P38; Styren SD, 1998, J COMP NEUROL, V396, P511; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; vanMuiswinkel FL, 1996, J NEUROCHEM, V66, P2468; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; WEINBERG JB, 1995, BLOOD, V86, P1184; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; Wink David A., 1999, P245; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023	82	91	95	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580			NEUROBIOL AGING	Neurobiol. Aging	SEP-OCT	2002	23	5					777	785	PII S0197-4580(02)00016-7	10.1016/S0197-4580(02)00016-7			9	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	615EA	WOS:000179231800018	12392781				2021-06-18	
J	Lang, EW; Mehdorn, HM; Dorsch, NWC; Czosnyka, M				Lang, EW; Mehdorn, HM; Dorsch, NWC; Czosnyka, M			Continuous monitoring of cerebrovascular autoregulation: a validation study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							DYNAMIC CEREBRAL AUTOREGULATION; TRANSCRANIAL DOPPLER; BLOOD-FLOW; HUMANS; INJURY	Background: Continuous monitoring of dynamic cerebral autoregulation, using a moving correlation index of cerebral perfusion pressure and mean middle cerebral artery flow velocity, may be useful in patients with severe traumatic brain injury to guide treatment, and has been shown to be of prognostic value. Objective: To compare an index of dynamic cerebral autoregulation (Mx) with an index of static cerebral autoregulation (sRoR) Methods: Mx was validated in a prospective comparative study against sRoR, using 83 testing sessions in 17 patients with traumatic brain injury. sRoR and Mx were calculated simultaneously during pharmacologically induced blood pressure variations. Results: Mx was significantly correlated with sRoR (R = -0.78, p < 0.05). Nine patients were found to have failure of cerebral autoregulation, with an sRoR value < 50%. If an Mx value of 0.3 was used as the cut off point for failure of cerebral autoregulation, this index had 100% sensitivity and 90% specificity for demonstrating failure of autoregulation compared with the sRoR. An increase in cerebral blood flow velocity correlated significantly with Mx (R = 0.73, p < 0.05) but not with cerebral perfusion pressure (R = 0,41). Conclusions: Dynamic and static cerebral autoregulation are significantly correlated in traumatic 21 brain injury. Cerebral autoregulation can be monitored continuously, graded, and reliably assessed using a moving correlation analysis of cerebral perfusion pressure and cerebral blood flow velocity (Mx). The Mx index can be used to monitor cerebral blood flow regulation. It is useful in traumatic brain. injury because it does not require any external stimulus.	Univ Kiel, Dept Neurosurg, D-24106 Kiel, Germany; Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Sydney, Westmead Hosp, Dept Neurosurg, Westmead, NSW 2145, Australia	Lang, EW (corresponding author), Westmead Hosp, Dept Neurosurg, Level 5, Sydney, NSW 2145, Australia.		Mehdorn, Maximilian/D-2495-2010				AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1996, STROKE, V27, P829; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Heckmann JG, 1999, NEUROL RES, V21, P457, DOI 10.1080/01616412.1999.11740959; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Lewis SB, 2001, NEUROSURGERY, V48, P369, DOI 10.1097/00006123-200102000-00026; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; STEINMEIER R, 1999, J NEUROSURG, V90, P427; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Tiecks FP, 1996, STROKE, V27, P1177, DOI 10.1161/01.STR.27.7.1177; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014	17	91	91	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2002	72	5					583	586		10.1136/jnnp.72.5.583			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	547QX	WOS:000175344200009	11971041	Green Published, Bronze			2021-06-18	
J	Servadei, F; Murray, GD; Teasdale, GM; Dearden, M; Iannotti, F; Lapierre, F; Maas, AJR; Karimi, A; Ohman, J; Persson, L; Stocchetti, N; Trojanowski, T; Unterberg, A				Servadei, F; Murray, GD; Teasdale, GM; Dearden, M; Iannotti, F; Lapierre, F; Maas, AJR; Karimi, A; Ohman, J; Persson, L; Stocchetti, N; Trojanowski, T; Unterberg, A			Traumatic subarachnoid hemorrhage: Demographic and clinical study of 750 patients from the European Brain Injury Consortium survey of head injuries	NEUROSURGERY			English	Article						computed tomographic classification; moderate and severe head injury; outcome; subarachnoid hemorrhage	TRANSCRANIAL DOPPLER ULTRASOUND; CEREBRAL BLOOD-FLOW; SUBDURAL HEMATOMAS; VASOSPASM; DAMAGE; SPASM; SCAN; COMA	OBJECTIVE: Previous reports identified the presence of traumatic subarachnoid hemorrhage (tSAH) on admission computed tomographic (CT) scans as an independent prognostic factor in worsening outcomes. The mechanism underlying the link between tSAH and prognosis has not been clarified. The aim of this study was to investigate the association between CT evidence of tSAH and outcomes after moderate or severe head injuries. METHODS: In a survey organized by the European Brain Injury Consortium, data on initial severity, treatment, and subsequent outcomes were prospectively collected for 1005 patients with moderate or severe head injuries who were admitted to one of the 67 European neurosurgical units during a 3-month period in 1995. The CT findings were classified according to the Traumatic Coma Data Bank classification system, and the presence or absence of tSAH was recorded separately in the initial CT scan forms. RESULTS: Complete data on early clinical features, CT findings, and outcomes at 6 months were available for 750 patients, of whom 41% exhibited evidence of tSAH on admission CT scans. There was a strong, highly statistically significant association between the presence of tSAH and poor outcomes. In fact, 41% of patients without tSAH achieved the level of good recovery, whereas only 15% of patients with tSAH achieved this outcome. Patients with tSAH were significantly older (median age, 43 yr; standard deviation, 21.1 yr) than those without tSAH (median age, 32 yr; standard deviation, 19.5 yr), and there was a significant tendency for patients with tSAH to exhibit lower Glasgow Coma Scale scores at the time of admission. A logistic regression analysis of favorable/unfavorable outcomes demonstrated that there was still a very strong association between tSAH and outcomes after simultaneous adjustment for age, Glasgow Coma Scale Motor Scores, and admission CT findings (odds ratio, 2.49; 95% confidence interval, 1.74-3.55; P < 0.001). Comparison of the time courses for 164 patients with early (within 14 d after injury) deaths demonstrated very similar patterns, with an early peak and a subsequent decline; there was no evidence of a delayed increase in mortality rates for either group of patients (with or without tSAH). CONCLUSION: These findings for an unselected series of patients confirm previous reports of the adverse prognostic significance of tSAH. The data support the view that death among patients with tSAH is related to the severity of the initial mechanical damage, rather than to the effects of delayed vasospasm and secondary ischemic brain damage.	Osped Maurizio Bufalini, WHO, Neurotrauma Collaborating Ctr, Div Neurochirurg Traumatol, I-47023 Cesena, Italy; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Univ Glasgow, So Gen Hosp, Dept Neurosurg, Inst Neurol Sci, Glasgow, Lanark, Scotland; Leeds Gen Infirmary, Dept Anaesthet, Leeds, W Yorkshire, England; Southampton Gen Hosp, Dept Clin Neurosci, Southampton SO9 4XY, Hants, England; Ctr Hosp Univ Poitiers, Serv Neurochirurg, Poitiers, France; Univ Rotterdam Hosp, Dept Neurosurg, Rotterdam, Netherlands; Univ Cologne, Neurochirurg Klin, Cologne, Germany; Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland; Akad Hosp, Dept Neurosurg, Uppsala, Sweden; Osped Maggiore Policlin, Ist Ricovero & Cura Carattere Sci Milano, Terapia Intens Neurochirug Serv Anestesia & Riani, Milan, Italy; Tech Univ Lublin, Sch Med, Dept Neurosurg, PL-20618 Lublin, Poland; Humboldt Univ, Fak Med, Klinikum Rudolf Virchow, Dept Neurosurg, Berlin, Germany	Servadei, F (corresponding author), Osped Maurizio Bufalini, WHO, Neurotrauma Collaborating Ctr, Div Neurochirurg Traumatol, I-47023 Cesena, Italy.	fservade@ausl-cesena.emr.it	Maas, Andrew IR/C-5584-2013; Stocchetti, Nino/O-7444-2017	Maas, Andrew IR/0000-0003-1612-1264; Stocchetti, Nino/0000-0003-3250-6834; Murray, Gordon/0000-0001-9866-4734; Servadei, Franco/0000-0002-3595-3464; Ohman, Juha/0000-0002-6592-1367; Trojanowski, Tomasz/0000-0002-4914-1838			BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; Domenicucci M, 1998, NEUROSURGERY, V42, P51, DOI 10.1097/00006123-199801000-00010; DORSCH NW, 1993, CAN J NEUROL SCI S1, V20, P28; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; HALEY EC, 1992, STROKE, V23, P205, DOI 10.1161/01.STR.23.2.205; HALEY EC, 1993, J NEUROSURG, V78, P548, DOI 10.3171/jns.1993.78.4.0548; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KAKARIEKA A, 1997, TRAUMATIC SUBARACHNO, P1; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; PERRONE P, 1985, ITAL J NEUROL SCI, V6, P43, DOI 10.1007/BF02229216; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 2000, NEUROSURGERY, V46, P70; SHIGEMORI M, 1990, Neurologia Medico-Chirurgica, V30, P396, DOI 10.2176/nmc.30.396; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Vajramani GV, 1999, BRIT J NEUROSURG, V13, P468, DOI 10.1080/02688699908540620; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; Zubkov ZY, 2000, SURG NEUROL, V53, P126	34	91	99	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2002	50	2					261	267		10.1097/00006123-200202000-00006			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	514FE	WOS:000173427300007	11844260				2021-06-18	
J	Lynch, JR; Pineda, JA; Morgan, D; Zhang, L; Warner, DS; Benveniste, H; Laskowitz, DT				Lynch, JR; Pineda, JA; Morgan, D; Zhang, L; Warner, DS; Benveniste, H; Laskowitz, DT			Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema	ANNALS OF NEUROLOGY			English	Article							CLOSED-HEAD INJURY; TRAUMATIC BRAIN INJURY; COGNITIVE DEFICITS; TNF-ALPHA; ACTIVATION; MICE	Apolipoprotein E has been implicated in modifying neurological outcome after traumatic brain injury, although the mechanisms by which this occurs remain poorly defined. To investigate the role of endogenous apolipoprotein E following acute brain injury, noninvasive magnetic resonance imaging was performed on anesthetized mice following closed head injury. Effacement of the lateral ventricle was used as a radiographic surrogate for cerebral edema. At 24 hours following injury, apolipoprotein E-deficient animals had a greater degree of cerebral edema as compared to matched controls. In addition, the brains of apolipoprotein E-deficient animals had a significantly greater upregulation of tissue necrosis factor alpha messenger ribonuclcic acid as compared to controls as early as 1-hr post injury. Thus, modulation of the endogenous central nervous system inflammatory response may be one mechanism by which apolipoprotein E affects outcome following acute brain injury.	Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Lab, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.		Pineda, Jose/W-2806-2019		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR05959] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM08600] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37235, 1K08NS01949] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR005959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001949, R01NS037235] Funding Source: NIH RePORTER		Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Hu JR, 1998, J NEUROCHEM, V71, P1626; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pineda JA, 2001, J NEUROTRAUM, V18, P625, DOI 10.1089/089771501750291864; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	17	91	97	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0364-5134			ANN NEUROL	Ann. Neurol.	JAN	2002	51	1					113	117		10.1002/ana.10098			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	508JK	WOS:000173084800015	11782990				2021-06-18	
J	Dennis, M; Guger, S; Roncadin, C; Barnes, M; Schachar, R				Dennis, M; Guger, S; Roncadin, C; Barnes, M; Schachar, R			Attentional-inhibitory control and social-behavioral regulation after childhood closed head injury: Do biological, developmental, and recovery variables predict outcome?	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						closed-head injury; childhood; attention; behavior	TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; CHILDREN; ADOLESCENTS; MILD; PERFORMANCE; SEQUELAE; AGE; AVAILABILITY; ADJUSTMENT	Attentional-inhibitory control and social-behavioral regulation are two outcome domains commonly impaired after childhood closed head injury (CHI). We compared neuropsychological tests of attentional-inhibitory control (vigilance, selective attention, response modulation) and social discourse and intentionality (inferencing, figurative language, and speech acts) with parent ratings of attention and behavioral regulation in relation to four injury-related variables: age at CHI, time since CHI, CHI injury severity, and frontal lobe injury moderated by CHI severity. Participants were 105 school-aged children in the chronic stage of CHI, divided into mild, moderate, and severe injury severity groups, and further subdivided according to frontal lobe injury. Outcome indices were imperfectly correlated in the group as a whole, although several relations between neurocognitive tests and parent ratings were observed within CHI subgroups. Different domains of cognitive function had different predictors. For attentional-inhibitory control, age at injury and time since injury were most predictive of outcome; for social discourse, predictors were injury severity and frontal lobe injury moderated by injury severity. Variability in cognitive outcome after childhood CHI is not random, but appear, related to age, time, and biological features of the injury.	Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada; Hosp Sick Children, Dept Psychol, Toronto, ON, Canada	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol Res, Room 6278A,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mdennis@sickkids.on.ca		Schachar, Russell/0000-0002-2015-4395	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS 21889-16] Funding Source: Medline		Achenbach TM., 1991, INTEGRATIVE GUIDE 19; ACKERMAN BP, 1990, CHILD DEV, V61, P230; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 1982, P 7 ANN BRAIN IMP C, P360; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BARKLEY RA, 1991, J ABNORM CHILD PSYCH, V19, P149, DOI 10.1007/BF00909976; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BEUN RJ, 1994, J PRAGMATICS, V21, P191, DOI 10.1016/0378-2166(94)90019-1; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Dennis M., 2000, J INT NEUROPSYCH SOC, V6, P132; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Fletcher JM, 2000, SCI PRACT NEUROPSYCH, P25; GORDON M, 1988, GORDON DIAGNOSTIC SY; Gordon M., 1983, GORDON DIAGNOSTIC SY; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GRONWALL D, 1997, J INT NEUROSCIENCE, V53, P171; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Manly T., 1999, TEST EVERYDAY ATTENT; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MCKOON G, 1992, PSYCHOL REV, V99, P440, DOI 10.1037/0033-295X.99.3.440; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; NORUSIS MJ, 1997, SPSS WINDOWS RELEASE; Oakhill J, 1993, EDUC PSYCHOL REV, V5, P223, DOI 10.1007/BF01323045; Overweg-Plandsoen WCG, 1999, EUR J PEDIATR, V158, P249, DOI 10.1007/s004310051061; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Searle J. R., 1969, SPEECH ACTS ESSAY PH, V626; SINGER M, 1992, MEM COGNITION, V20, P539, DOI 10.3758/BF03199586; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1992, CLIN NEUROPSYCHOL, V6, P259; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Verger K, 2000, BRAIN INJURY, V14, P495; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; Wiig E.H., 1985, TEST LANGUAGE COMPET; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92	79	91	93	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2001	7	6					683	692		10.1017/S1355617701766040			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	471YE	WOS:000170955600004	11575590				2021-06-18	
J	Anderson, VA; Catroppa, C; Haritou, F; Morse, S; Pentland, L; Rosenfeld, J; Stargatt, R				Anderson, VA; Catroppa, C; Haritou, F; Morse, S; Pentland, L; Rosenfeld, J; Stargatt, R			Predictors of acute child and family outcome following traumatic brain injury in children	PEDIATRIC NEUROSURGERY			English	Article						traumatic brain injury; childhood; functional outcome	PEDIATRIC HEAD-INJURY; RECOVERY; SEQUELAE	Objective: To examine the relative contributions of injury severity, level of physical and cognitive disability, child behavior and family function to short-term outcome 6 months following traumatic brain injury (TBI) in children. Design: Prospective, longitudinal, between-group design, comparing preinjury and postinjury measures of functional outcome across three levels of injury severity. Subjects: One hundred and twelve children, aged 2-12 years admitted to the Royal Children's Hospital, Melbourne, with a diagnosis of TBI. The sample was divided into three groups, according to injury severity: mild TBI (n = 31), moderate TBI (n = 52) and severe TBI (n = 29). Children with a history of neurologic, developmental and psychiatric disorder were excluded from participation. Main Outcome Measures: Levels of postinjury functioning in the following domains: physical function, cognitive ability (incorporating intellect, memory and attention), behavioral and family functioning, and level of family burden. Results: A clear dose-response relation ship for physical and cognitive outcomes was found, with severe TBI associated with greater impairment of physical, intellectual, memory and attentional function. For psychosocial outcome, results were less clearly linked to injury severity. Preinjury behavioral and family functioning were closely related to postinjury function in these domains, with an interaction identified between family function and child behavior at 6 months postinjury. Family functioning remained unchanged postinjury, although level of burden was high, and predicted by injury severity, functional impairment and postinjury behavioral disturbance. Conclusions: These results suggest ongoing functional problems for the child and significant family burden 6 months following TBI. The nature and severity of physical and cognitive problems are most closely related to injury severity, with family functioning and child behavior better predicted by psychosocial and premorbid factors. Copyright (C) 2001 S. Karger AG, Basel.	Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; Nurdoch Childrens Res Inst, Melbourne, Vic, Australia	Anderson, VA (corresponding author), Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia.	v.anderson@psych.unimelb.edu.au					ADAMS W, 1989, MANUAL WIDE RANGE AS; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V., 1995, NEUROPSYCHOLOGICAL A; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROOKS N, 1985, CLOSED HEAD INJURY P; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Christensen AL, 1979, LURIAS NEUROPSYCHOLO; DANIEL A, 1983, PRIVILEGE PRESTIGE O; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; Kaufman A. S., 1979, INTELLIGENT TESTING; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P165; Lachar D, 1992, PERSONALITY INVENTOR; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LHERMITTE J, 1972, REV NEUROL, V74, P20; MAX J, 1997, J AM ACAD CHILD ADOL, V36, P83; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Noller P, 1988, ICPS FAMILY FUNCTION; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROWE KJ, 1992, J AM ACAD CHILD PSY, V31, P357, DOI 10.1097/00004583-199203000-00026; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TAYLOR HG, IN PRESS NEUROPSYCHO; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wechsler D, 1991, MANUAL WECHSLER SCAL; WECHSLER D, 1987, MANUAL PRESCHOOL PRI; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	46	91	92	0	12	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	MAR	2001	34	3					138	148		10.1159/000056009			11	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	432YC	WOS:000168722900006	11359102				2021-06-18	
J	Stempien, L; Tsai, T				Stempien, L; Tsai, T			Intrathecal baclofen pump use for spasticity - A clinical survey	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						spasticity; intrathecal baclofen; brain injury; cerebral palsy; spinal cord injury; implantable pump	SEVERE SPINAL SPASTICITY; CEREBRAL-PALSY; GENERALIZED DYSTONIA; PROGRAMMABLE PUMP; BRAIN INJURY; FOLLOW-UP; INFUSION; ORIGIN; DELIVERY; REFLEX	Objective: To obtain information from continuous intrathecal baclofen infusion (CIBI) pump centers regarding specific clinical practices and experiences. Methods: A total of 115 centers were surveyed by mail. Results: Forty centers (35%) responded with information about 1002 test doses and 936 pump placements. Patient diagnoses included cerebral palsy, spinal cord injury, traumatic brain injury, and others. The average test dose was 50 mug. A total of 87% of trials were successful. The most common test dose complications were nausea/vomiting (2.6%) and sedation (2.2%). Pump placement complications included cerebrospinal fluid (CSF) collection (3.3%), constipation (2.9%), headache (2.4%), and CSF leak (2.2%). The most common long-term complications were catheter kink or migration (4%) and infection (1.2%). Improved daily activities including easier diapering, dressing, transfers, orthotic wear and comfort, and sitting tolerance were reported in the majority (>90%) of patients. Mixed results were reported for oral motor function and head, bladder, and bowel control. Conclusions: CIBI is an effective treatment for severe spasticity, with dramatic quality-of-life improvements and a small number of significant complications. Long-term benefits and complications need to be monitored in this complex population.	Univ Colorado, Rehabil Ctr, Childrens Hosp, Dept Rehabil Med, Denver, CO 80218 USA	Stempien, L (corresponding author), Univ Colorado, Rehabil Ctr, Childrens Hosp, Dept Rehabil Med, B285,1056 E 19th Ave, Denver, CO 80218 USA.						ABEL NA, 1994, ARCH PHYS MED REHAB, V75, P54; Albright AL, 1998, J NEUROSURG, V88, P73, DOI 10.3171/jns.1998.88.1.0073; Albright AL, 1996, J CHILD NEUROL, V11, P77, DOI 10.1177/088307389601100202; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; AZOUVI P, 1993, J NEUROL NEUROSUR PS, V56, P515, DOI 10.1136/jnnp.56.5.515; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Diederich NJ, 1997, MOVEMENT DISORD, V12, P1100, DOI 10.1002/mds.870120649; Dressler D, 1997, MOVEMENT DISORD, V12, P585, DOI 10.1002/mds.870120416; Gerszten PC, 1998, J NEUROSURG, V88, P1009, DOI 10.3171/jns.1998.88.6.1009; Gianino J M, 1998, J Neurosci Nurs, V30, P47; KROIN JS, 1984, EXP BRAIN RES, V54, P191; LATASH ML, 1989, EXP NEUROL, V103, P165, DOI 10.1016/0014-4886(89)90078-2; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; MACDONELL RAL, 1989, J NEUROL NEUROSUR PS, V52, P1110, DOI 10.1136/jnnp.52.9.1110; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Middel B, 1997, J NEUROL NEUROSUR PS, V63, P204, DOI 10.1136/jnnp.63.2.204; Ordia JI, 1996, J NEUROSURG, V85, P452, DOI 10.3171/jns.1996.85.3.0452; PARKE B, 1989, ARCH PHYS MED REHAB, V70, P30; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1995, MOVEMENT DISORD, V10, P675, DOI 10.1002/mds.870100524; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Zierski J, 1988, Acta Neurochir Suppl (Wien), V43, P94	26	91	96	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	2000	79	6					536	541		10.1097/00002060-200011000-00010			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	371WF	WOS:000165201700008	11083304				2021-06-18	
J	Kline, AE; Yan, HQ; Bao, JL; Marion, DW; Dixon, E				Kline, AE; Yan, HQ; Bao, JL; Marion, DW; Dixon, E			Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						brain injury; methylphenidate; dopamine; rat; cortical impact	DOUBLE-BLIND; HEAD-INJURY; RECOVERY; AMPHETAMINE; EXPERIENCE; ABLATION; MODERATE	Methylphenidate (MPH), a central nervous system stimulant with dopaminergic activity, facilitates neurobehavioral outcome following cortical suction ablation injury, but its potential efficacy following experimental traumatic brain injury (TBI) is unknown. Thus, beginning 24 h after controlled cortical impact injury or sham surgery, male Sprague-Dawley rats were injected (i.p.) once daily for 18 days with either MPH (5 mg/kg) or saline vehicle (VEH) and motor function assessed on post-operative days 1-4, followed by Morris water maze training to find a hidden platform on days 14-18. The MPH treatment regimen was ineffective in accelerating beam-balance or beam-walk recovery, but did significantly decrease swim latencies when compared to VEH-treated controls. The results are consistent with published studies showing improved outcome with MPH therapy. Furthermore, this positive finding with delayed treatment suggests that strategies that enhance catecholamine neurotransmission during the chronic post injury phase may be a useful adjunct in ameliorating some of the neurobehavioral sequelae following TBI in humans. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA	Dixon, E (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318, NS33150] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR/312296] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P50NS030318, R01NS033150, P20NS030318] Funding Source: NIH RePORTER		Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Zeiner P, 1999, ACTA PAEDIATR, V88, P298, DOI 10.1080/08035259950170060	20	91	92	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 25	2000	280	3					163	166		10.1016/S0304-3940(00)00797-7			4	Neurosciences	Neurosciences & Neurology	290VG	WOS:000085698100003	10675786				2021-06-18	
J	Shum, D; Valentine, M; Cutmore, T				Shum, D; Valentine, M; Cutmore, T			Performance of individuals with severe long-term traumatic brain injury on time-, event-, and activity-based prospective memory tasks	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article								This study investigated the effect of traumatic brain injury (TBI) on time-, event-, and activity-based prospective memory using a laboratory paradigm developed in the literature on ageing (Einstein, McDaniel, Richardson, Guynn, & Cunfer, 1995). The participants were 12 individuals with severe longterm TBI and 12 community controls. Participants were asked to answer general-knowledge questions on a computer for two sessions. The time- and event-based tasks were embedded in this filler activity. Participants were also required to carry out activity-based actions at the end of the two sessions. Participants with TBI performed significantly worse than did controls on all three prospective-memory tasks, indicating that TBI affects not only retrospective but also prospective memory. Implications of these results for the assessment and rehabilitation of memory problems in individuals with TBI are discussed.	Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia; Griffith Univ, Neuropsychol Unit, Brisbane, Qld 4111, Australia	Shum, D (corresponding author), Griffith Univ, Sch Appl Psychol, Nathan, Qld 4111, Australia.		Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; DALLABARBA G, 1993, HDB NEUROPSYCHOLOGY, V8, P239; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; LEVIN HS, 1991, HDB NEUROPSYCOLOGY, V6, P183; MAPOU RL, 1992, HDB HEAD TRAUMA ACUT, P75; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; TEASDALE G, 1974, LANCET, V2, P81	15	91	93	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1999	21	1					49	58		10.1076/jcen.21.1.49.943			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	214VN	WOS:000081348400006	10421001				2021-06-18	
J	GomezHernandez, R; Max, JE; Kosier, T; Paradiso, S; Robinson, RG				GomezHernandez, R; Max, JE; Kosier, T; Paradiso, S; Robinson, RG			Social impairment and depression after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP	Objective: Previous studies have shown that social impairment is associated with major depression throughout the first year after traumatic brain injury (TBI). This study examined the specific social factors that were associated with post-TBI depression. Method: A consecutive series of 65 patients with closed head injuries were cross-sectionally and longitudinally examined using a semistructured psychiatric interview, the Hamilton Depression Rating Scale, and the Social Functioning Exam during in-hospital care and at 3-, 6-, 9-, and 12-month follow-ups. Results: Depressed subjects showed poorer social functioning at the initial evaluation, and at 6, 9, and 12 months. Measures of preinjury job dissatisfaction and fear of job loss were significantly associated with depression at the initial evaluation. Concurrent impaired close personal relationships as well as continued fear of job loss were associated with depression at 6, 9, and 12 months after TBI. Conclusions: These findings suggest that two of the psychosocial factors associated with depression during the acute TBI period (patient's satisfaction with work and fear of job loss) are the same as those operant during the chronic period, but an additional psychosocial factor (close interpersonal relationships) is also operant during the chronic period. These findings support the need for early targeted social intervention in cases of TBI. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	HOSP CLIN, DEPT PSYCHIAT, ZARAGOZA, SPAIN; UNIV IOWA, COLL MED, DEPT PSYCHIAT, IOWA CITY, IA 52242 USA			Paradiso, Sergio/H-9052-2012		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH053592] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH53592] Funding Source: Medline		BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; DIKMEN S, 1977, J NERV MENT DIS, V165, P247, DOI 10.1097/00005053-197710000-00004; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GROSWASSER Z, 1977, SCAND J REHABIL MED, V9, P147; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hathaway SR, 1951, MINNESOTA MULTIPHASI; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KARPMAN T, 1985, J APPL REHABILITATIO, V17, P28; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KRAUS J, 1985, HEAD INJURY, P1; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1984, CLOSED HEAD INJURY, P109; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Sartorius N, 1974, MEASUREMENT CLASSIFI; Silver JM., 1994, NEUROPSYCHIATRY TRAU; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TRIESCHMANN RB, 1990, J HEAD TRAUMA REHAB, V5, P57; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN P, 1990, VOCATIONAL REHABILIT	28	91	93	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1997	78	12					1321	1326		10.1016/S0003-9993(97)90304-X			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	YK894	WOS:A1997YK89400007	9421985				2021-06-18	
J	Kujawa, SG; Liberman, MC				Kujawa, SG; Liberman, MC			Conditioning-related protection from acoustic injury: Effects of chronic deefferentation and sham surgery	JOURNAL OF NEUROPHYSIOLOGY			English	Article							CROSSED OLIVOCOCHLEAR BUNDLE; MIDDLE-EAR MUSCLES; COCHLEAR DE-EFFERENTATION; SUPERIOR OLIVARY COMPLEX; AUDITORY-NERVE RESPONSE; INDUCED HEARING-LOSS; OUTER HAIR-CELLS; GUINEA-PIG; THRESHOLD SHIFT; NOISE EXPOSURE	The inner ear can be made less vulnerable to acoustic injury by a "conditioning" treatment involving exposure to a moderate-level acoustic stimulus before the acoustic overexposure. The present study was designed to explore the role of the olivocochlear (OC) system in this "protection" Guinea pigs were divided into a number of groups: some (trauma-only) were exposed to a traumatic noise for 4 h at 109 dB SPL; others (condition/trauma) were conditioned by daily exposure to the same noise at 85 dB SPL before the traumatic exposure. In OC-intact animals, the condition/trauma group showed significantly less permanent threshold shift (PTS) than the trauma-only group as measured via compound action potentials and distortion-product otoacoustic-emissions (DPOAEs). Other animals with identical noise-exposure regimens underwent deefferentation surgery before the start of conditioning: the OC bundle (OCB) was cut in the brain stem, either at the midline (cutting the crossed OCB to both ears) or at the sulcus limitans (cutting all OC fibers to 1 side). Lesion success was quantified by measuring OC fascicles to the outer hair cell region in each ear. The results from the surgical groups showed that total loss of the OCB significantly increased the noise-induced PTS, whereas loss of the COCB only did not; that the conditioning exposure in deefferented animals increased, rather than decreased, the PTS from the traumatic exposure; and that animals undergoing sham surgery (brain stem cuts that failed to transect the OCB) appeared protected whether or not they received the conditioning noise exposure. The latter result suggests that conditioning-related protection may arise from a generalized stress response, which can be elicited by noise exposure, brain surgery, or a variety of other means. The former results make an OC role in the conditioning process, per se, difficult to assess, given the large effects of OC activity on general acoustic vulnerability.	Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA	Liberman, MC (corresponding author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000188, F32DC000180] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F32 DC-00180, R01 DC-000188] Funding Source: Medline		ARNESEN AR, 1984, ACTA OTOLARYNGOL STO, V98, P225; AVAN P, 1992, HEARING RES, V59, P59, DOI 10.1016/0378-5955(92)90102-S; BOETTCHER FA, 1992, HEARING RES, V62, P217, DOI 10.1016/0378-5955(92)90189-T; BROWN MC, 1989, HEARING RES, V40, P93, DOI 10.1016/0378-5955(89)90103-2; BROWN MC, IN PRESS J NEUROPHYS; CANLON B, 1993, NEUROSCI LETT, V150, P103, DOI 10.1016/0304-3940(93)90118-5; Canlon B, 1996, AUDITORY SYSTEM PLASTICITY AND REGENERATION, P118; CANLON B, 1988, HEARING RES, V34, P197, DOI 10.1016/0378-5955(88)90107-4; CANLON B, 1995, HEARING RES, V84, P112, DOI 10.1016/0378-5955(95)00020-5; CANLON B, 1991, NOISE INDUCED HEARIN, P489; GUINAN JJ, 1984, J COMP NEUROL, V226, P21, DOI 10.1002/cne.902260103; GUINAN JJ, 1983, J COMP NEUROL, V221, P358, DOI 10.1002/cne.902210310; HANDROCK M, 1982, ARCH OTO-RHINO-LARYN, V234, P191, DOI 10.1007/BF00453630; HENDERSON D, 1994, HEARING RES, V74, P22, DOI 10.1016/0378-5955(94)90172-4; KIANG NYS, 1965, MIT RES MONOGRAPH, V35; KUJAWA SG, 1996, ABSTR ASS RES OT, V19, P34; LIBERMAN MC, 1990, J COMP NEUROL, V301, P443, DOI 10.1002/cne.903010309; LIBERMAN MC, 1990, HEARING RES, V49, P209, DOI 10.1016/0378-5955(90)90105-X; LIBERMAN MC, 1979, ACTA OTO-LARYNGOL, V88, P161, DOI 10.3109/00016487909137156; LIBERMAN MC, 1988, J NEUROPHYSIOL, V60, P1779; LIBERMAN MC, 1995, HEARING RES, V90, P158, DOI 10.1016/0378-5955(95)00160-2; LIBERMAN MC, 1978, ACTA OTOLARYNGOL S, V358, P5; LIM HH, 1993, HEARING RES, V69, P146; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MOUNTAIN DC, 1980, SCIENCE, V210, P71, DOI 10.1126/science.7414321; MUCHNIK C, 1992, HEARING RES, V58, P101, DOI 10.1016/0378-5955(92)90013-D; OSEN KK, 1969, BRAIN RES, V16, P165, DOI 10.1016/0006-8993(69)90092-4; PUEL JL, 1988, HEARING RES, V37, P65, DOI 10.1016/0378-5955(88)90078-0; RAJAN R, 1988, J NEUROPHYSIOL, V60, P569; RAJAN R, 1995, J NEUROPHYSIOL, V74, P582; RAJAN R, 1991, NOISE INDUCED HEARIN, P429; RAREY KE, 1995, HEARING RES, V82, P135, DOI 10.1016/0378-5955(94)00171-L; REITER ER, 1995, J NEUROPHYSIOL, V73, P506; REITER ER, 1991, ARO MIDW M, V14, P157; ROBERTSON D, 1987, EXP BRAIN RES, V66, P449, DOI 10.1007/BF00270677; RYAN AF, 1994, HEARING RES, V72, P23, DOI 10.1016/0378-5955(94)90201-1; SCHMIEDT RA, 1984, J ACOUST SOC AM, V76, P1293, DOI 10.1121/1.391446; SIEGEL JH, 1982, J NEUROPHYSIOL, V47, P303; SMITH CA, 1961, ANN OTO RHINOL LARYN, V70, P504, DOI 10.1177/000348946107000216; SMITH CA, 1963, ANN OTO RHINOL LARYN, V72, P489, DOI 10.1177/000348946307200218; SRIDHAR TS, 1995, J NEUROSCI, V15, P3667; Sridhar TS, 1997, J NEUROSCI, V17, P428; Subramaniam M, 1996, AUDITORY SYSTEM PLASTICITY AND REGENERATION, P128; SUBRAMANIAM M, 1991, HEARING RES, V52, P181, DOI 10.1016/0378-5955(91)90197-H; SUBRAMANIAM M, 1991, HEARING RES, V56, P65, DOI 10.1016/0378-5955(91)90154-2; TERAYAMA Y, 1969, ANN OTO RHINOL LARYN, V78, P1254, DOI 10.1177/000348946907800612; TRAHIOTIS C, 1970, J ACOUST SOC AM, V47, P592, DOI 10.1121/1.1911934; Tsuji J, 1997, J COMP NEUROL, V381, P188; WARREN EH, 1989, HEARING RES, V37, P89, DOI 10.1016/0378-5955(89)90032-4; Zheng XY, 1997, HEARING RES, V107, P147, DOI 10.1016/S0378-5955(97)00031-2; Zheng XY, 1997, HEARING RES, V104, P191, DOI 10.1016/S0378-5955(96)00187-6	51	91	94	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	DEC	1997	78	6					3095	3106					12	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	YP840	WOS:000071320900027	9405529				2021-06-18	
J	Marklund, N; Salci, K; Lewen, A; Hillered, L				Marklund, N; Salci, K; Lewen, A; Hillered, L			Glycerol as a marker for post-traumatic membrane phospholipid degradation in rat brain	NEUROREPORT			English	Article						degradation; glycerol; membrane function; microdialysis; phospholipid; rat; traumatic brain injury	FREE FATTY-ACIDS; AMINO-ACIDS; INJURY; ISCHEMIA	Degradation of membrane phospholipids (PLs) is a well known phenomenon in acute brain injuries and is thought to underlie the disturbance of vital cellular membrane functions. In the present study glycerol, an end product of PL degradation, was examined in brain interstitial fluid as a marker of PL breakdown following experimental traumatic brain injury (TBI) using microdialysis. TBI was induced in artificially ventilated rats using the weight-drop technique. The trauma caused a significant, eight-fold increase of dialysate glycerol in the injured cortex, with the peak concentration in the second 10 min fraction after trauma. Glycerol then levelled off but remained significantly above sham-operated controls for the entire 4 h observation period in the perimeter of the injury region where scattered neuronal death is seen. The results support the concept that PL degradation occurs early after TBI and that interstitial glycerol, harvested by microdialysis, may be useful as a marker allowing in vivo monitoring of PL breakdown.	UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN			Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Marklund, Niklas/0000-0002-9797-5626			ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; AGARDH CD, 1981, J NEUROCHEM, V36, P490, DOI 10.1111/j.1471-4159.1981.tb01619.x; Agranoff Bernard W., 1994, P97; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FAROOQUI AA, 1994, INT REV NEUROBIOL, V36, P267, DOI 10.1016/S0074-7742(08)60306-2; FELLANDER G, 1994, J CLIN ENDOCR METAB, V78, P150, DOI 10.1210/jc.78.1.150; FOSTER KJ, 1978, CLIN CHEM, V24, P1568; GARDINER M, 1981, J NEUROCHEM, V36, P1500, DOI 10.1111/j.1471-4159.1981.tb00592.x; GERCKEN G, 1973, PFLUG ARCH EUR J PHY, V344, P207, DOI 10.1007/BF00588461; GERCKEN G, 1969, J NEUROCHEM, V16, P761, DOI 10.1111/j.1471-4159.1969.tb06454.x; HINZEN DH, 1970, PFLUG ARCH EUR J PHY, V318, P117, DOI 10.1007/BF00586491; LLOYD B, 1978, CLIN CHEM, V24, P1724; MARKLUND N, 1996, J NEUROTRAUMA, V13, P600; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NILSSON P, 1994, BRAIN RES, V37, P227; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SLESJO B, 1992, NEUROBIOLOGY ESSENTI, P41; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WESTERGREN I, 1994, J NEUROCHEM, V62, P159	30	91	94	0	1	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	APR 14	1997	8	6					1457	1461		10.1097/00001756-199704140-00026			5	Neurosciences	Neurosciences & Neurology	XB174	WOS:A1997XB17400028	9172153				2021-06-18	
J	Steinmeier, R; Bauhuf, C; Hubner, U; Bauer, RD; Fahlbusch, R; Laumer, R; Bondar, I				Steinmeier, R; Bauhuf, C; Hubner, U; Bauer, RD; Fahlbusch, R; Laumer, R; Bondar, I			Slow rhythmic oscillations of blood pressure, intracranial pressure, microcirculation, and cerebral oxygenation - Dynamic interrelation and time course in humans	STROKE			English	Article						autoregulation; blood pressure; cerebral blood flow; intracranial pressure	LASER-DOPPLER FLOWMETRY; WAVE-FORM ANALYSIS; FLOW VELOCITY; B-WAVES; AUTOREGULATION; MODEL	Background and Purpose Various biological signals show nonpulsatile, slow rhythmic oscillations. These include arterial blood pressure (aBP), blood flow velocity in cerebral arteries, intracranial pressure (ICP), cerebral microflow, and cerebral tissue Po-2. Generation and interrelations between these rhythmic fluctuations remained unclear. The aim of this study was to analyze whether stable dynamic interrelations in the low-frequency range exist between these different variables, and if they do, to analyze their exact time delay. Methods In a clinical study, 16 comatose patients with either higher-grade subarachnoid hemorrhage or severe traumatic brain injury were examined. A multimodal digital data acquisition system was used to simultaneously monitor aBP, flow velocity in the middle cerebral artery (FVMCA), ICP, cerebral microflow, and oxygen saturation in the jugular bulb (Sjo(2)). Cross-correlation as a means to analyze time delay and correlation between two periodic signals was applied to a time series of 30 minutes' duration divided into four segments of 2048 data points (approximate to 436 seconds) each. This resulted in four cross-correlations for each 30-minute time series. If the four cross-correlations were consistent and reproducible, averaging of the original cross-correlations was performed, resulting in a representative time delay and correlation for the complete 30-minute interval. Results Reproducible cross-correlations and stable dynamic interrelations were found between aBP, FVMCA, ICP, and Sjo(2). The mean time delay between aBP and ICP was 6.89 +/- 1.90 sec ends, with a negative correlation in 81%. A mean time delay of 1.50 +/- 1.29 seconds (median, 0.85 seconds) was found between FVMCA and ICP, with a positive correlation in 94%. The mean delay between ICP and Sjo(2) was 9.47 +/- 2.21 seconds, with a positive correlation in 77%. Mean values of aBP and ICP did not influence the time delay and dynamic interrelation between the different parameters. Conclusions These results strongly support Rosner's theory that ICP B-waves are the autoregulatory response of spontaneous fluctuations of cerebral perfusion pressure. There is casuistic evidence that failure of autoregulation significantly modifies time delay and the correlation between aBP and ICP.	UNIV ERLANGEN NURNBERG, INST PHYSIOL & CARDIOL, D-91054 ERLANGEN, GERMANY; UNIV HEIDELBERG, DEPT MED INFORMAT, FACHHSCH HEILBRONN, HEILBRONN, GERMANY	Steinmeier, R (corresponding author), UNIV ERLANGEN NURNBERG, NEUROCHIRURG KLIN, DEPT NEUROSURG, SCHWABACHANLAGE 6, D-91054 ERLANGEN, GERMANY.						AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AUER LM, 1981, EUR NEUROL, V20, P448, DOI 10.1159/000115278; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; BUSSE R, 1982, KREISLAUFPHYSIOLOGIE; CHALLIS RE, 1990, MED BIOL ENG COMPUT, V28, P509, DOI 10.1007/BF02442601; CLARK LC, 1958, J APPL PHYSIOL, V13, P85; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DALEY ML, 1995, IEEE T BIO-MED ENG, V42, P420, DOI 10.1109/10.376137; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; DEOUGEMENT J, 1972, INTRACRANIAL PRESSUR, V1, P232; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; DORA E, 1981, ACTA PHYSIOL HUNG, V57, P261; EINHAUPL KM, 1986, INTRACRANIAL PRESSUR, V6, P290; FLORENCE G, 1992, J CEREBR BLOOD F MET, V12, P674, DOI 10.1038/jcbfm.1992.92; FRIESEN WO, 1984, AM J PHYSIOL, V246, pR847; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Gretchin V B, 1969, Electroencephalogr Clin Neurophysiol, V26, P546; HALSEY J H JR, 1974, Stroke, V5, P219; HAXHIU MA, 1989, AM J PHYSIOL, V257, pR804; HUNDLEY WG, 1988, AM J PHYSIOL, V254, pH67; JONES SC, 1995, AM J PHYSIOL-HEART C, V268, pH569; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; LUNDAR T, 1990, ACTA NEUROCHIR, V102, P85, DOI 10.1007/BF01405419; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; MAUTNER-HUPPERT D, 1989, Neurological Research, V11, P194; MAYEVSKY A, 1991, Neurological Research, V13, P39; MORITATSUZUKI Y, 1992, ACTA PHYSIOL SCAND, V146, P431, DOI 10.1111/j.1748-1716.1992.tb09444.x; NELSON RJ, 1992, NEUROSURGERY, V31, P705; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; OKAWARA SH, 1974, J NEUROSURG, V41, P415, DOI 10.3171/jns.1974.41.4.0415; PETTOROSSI VE, 1978, EUR NEUROL, V17, P216, DOI 10.1159/000114948; PIPER IR, 1993, NEUROSURGERY, V32, P805, DOI 10.1227/00006123-199305000-00014; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; Press W.A., 1988, NUMERICAL RECIPES C; Rosner M., 1986, INTRACRANIAL PRESSUR, P137, DOI [10.1007/978-3-642-70971-5_25, DOI 10.1007/978-3-642-70971-5_25]; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; ROSNER MJ, 1983, INTRACRANIAL PRESSUR, V5, P301; STEARNS SD, 1988, SIGNAL PROCESSDING A; Symon L, 1973, STROKE, V4, P139, DOI 10.1161/01.STR.4.2.139; VENES JL, 1979, CHILD BRAIN, V5, P352; VERN BA, 1988, J CEREBR BLOOD F MET, V8, P215, DOI 10.1038/jcbfm.1988.52; YAMAMOTO S, 1983, INTRACRANIAL PRESSUR, V5, P333	44	91	91	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	1996	27	12					2236	2243		10.1161/01.STR.27.12.2236			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	VY009	WOS:A1996VY00900015	8969787				2021-06-18	
J	Gross, H; Kling, A; Henry, G; Herndon, C; Lavretsky, H				Gross, H; Kling, A; Henry, G; Herndon, C; Lavretsky, H			Local cerebral glucose metabolism in patients with long-term behavioral and cognitive deficits following mild traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							POSITRON EMISSION TOMOGRAPHY; CLOSED HEAD-INJURY; PREFRONTAL CORTEX; RHESUS-MONKEY; BLOOD-FLOW; ATTENTION; LOCALIZATION; SEQUELAE; ANATOMY; SYSTEM	A retrospective study of 20 patients with mild traumatic brain injury (MTBI) examined brain regions of interest by comparing [F-18]-2-deoxyglucose PET, neuropsychological test results, and continuing behavioral dysfunction. Abnormal local cerebral metabolic rates (rLCMs) were most prominent in midtemporal, anterior cingulate, precuneus, anterior temporal, frontal white, and corpus callosum brain regions. Abnormal rLCMs were significantly correlated statistically with 1) overall clinical complaints, most specifically with inconsistent attention/concentration and 2) overall neuropsychological test results. The authors conclude that 1) even mild TBI may result in continuing brain behavioral deficits; 2) PET can help elucidate dysfunctional brain circuitry in neurobehavioral disorders; and 3) specific brain areas may correlate with deficits in daily neurobehavioral functioning and neuropsychological test findings.	VET ADM MED CTR, PSYCHIAT SERV, SEPULVEDA, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT & BEHAV SCI, LOS ANGELES, CA 90024 USA; CHARLES R DREW UNIV MED & SCI, DEPT BEHAV RES, LOS ANGELES, CA 90059 USA			Lavretsky, Helen/M-5711-2015	Lavretsky, Helen/0000-0001-9990-5085			BENCH CJ, 1993, NEUROPSYCHOLOGIA, V31, P907, DOI 10.1016/0028-3932(93)90147-R; BEYER WH, 1985, HDB TABLES PROBABILI; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BUCHSBAUM MS, 1984, ARCH GEN PSYCHIAT, V41, P1159; CUMMINGS JL, 1993, FRONTAL SUBCORTICAL, P873; Damasio A., 1994, DESCARTESERROR EMOTI; DEUTSCH G, 1987, INT J NEUROSCI, V36, P23, DOI 10.3109/00207458709002136; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EVANS RW, 1992, NEUROL CLIN, V10, P815; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; Fuster J, 1989, PREFRONTAL CORTEX; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; GRONWALL D, 1974, LANCET, V2, P605; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HAXBY J, 1993, NEUROPSYCHOLOGIA, V29, P539; Heaton R. K, 1981, WISCONSIN CARD SORTI; Hooper H.E., 1958, HOOPER VISUAL ORG TE; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Kaplan E., 1983, BOSTON NAMING TEST; KLING A, 1981, AMYGDALOID COMPLEX, P271; KLING AS, 1987, BEHAV NEURAL BIOL, V47, P54, DOI 10.1016/S0163-1047(87)90156-7; KLING AS, 1993, BEHAV BRAIN RES, V56, P161, DOI 10.1016/0166-4328(93)90034-N; Laberge D, 1990, J Cogn Neurosci, V2, P358, DOI 10.1162/jocn.1990.2.4.358; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LEZAK MD, 1989, FRONTIERS CLIN NEURO; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; MESULAM MM, 1985, PRINCIPLES BEHAVIORA, P1; Milner B, 1972, Clin Neurosurg, V19, P421; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM., 1969, MANUAL ADM NEUROPSYC; RETSBERG J, 1977, NEUROPSYCHOLOGIA, V15, P793; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; ROLAND PE, 1989, WENNER-GR C, V53, P141; ROLAND PE, 1985, J NEUROPHYSIOL, V53, P1219; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SELEMON LD, 1988, J NEUROSCI, V8, P4049; SELEMON LD, 1995, AM J PSYCHIAT, V152, P5, DOI 10.1176/ajp.152.1.5; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SPERRY R, 1884, NEUROPSYCHOLOGIA, V22, P6; Spreen O, 1969, NEUROSENSORY CTR COM; Stuss D.T., 1986, FRONTAL LOBES; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; UZZELL BP, 1991, INT NEUR SOC SAN ANT; UZZELL BP, 1990, INT NEUR SOC INNSBR; Van Hoesen GW., 1981, AMYGDALOID COMPLEX, P77; VOGT BA, 1987, ENCY NEUROSCIENCE, P244; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; Wilcoxon F., 1949, SOME RAPID APPROXIMA; Yaremko R.M., 1986, HDB RES QUANTITATIVE	65	91	92	0	4	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	1996	8	3					324	334					11	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	VB219	WOS:A1996VB21900011	8854305				2021-06-18	
J	Massaro, F; Lanotte, M; Faccani, G; Triolo, C				Massaro, F; Lanotte, M; Faccani, G; Triolo, C			One hundred and twenty-seven cases of acute subdural haematoma operated on - Correlation between CT scan findings and outcome	ACTA NEUROCHIRURGICA			English	Article						acute subdural haematoma; head injury; outcome	COMATOSE PATIENTS; HEAD-INJURY; HEMATOMA; MORTALITY	Traumatic acute subdural haematoma is one of the most lethal of all head injuries: the mortality rate is reported to be between 50 and 90%. We reviewed the clinical records of 1688 head injured patients admitted to the Department of Neurosurgery at C.T.O. hospital between 1982 and 1992. In 127 cases (7,5%) CTscan on admission showed acute subdural haematoma requiring surgery because the midline shift was greater than 5 mm. The overall mortality rate was 57% and 23% had functional recovery. The following variables were assessed with regard to morbidity and mortality: mechanism of injury, age, neurological presentation, time delay from injury to intervention, CTscan finding on admission. GCS and CTscan findings were found to be the most important prognostic variable. Timing of operative intervention for clot removal with regard to outcome was not statistically significant. But no conclusions regarding the importance of early haematoma evacuation can be drawn from such an oversimplifying statement, because it does not take into account factors like rapidity of haematoma development and related brain decompensation as well as additional direct brain lesions. The results of this study suggest that the extent of primary brain injury underlying the subdural haematoma is the most important factor affecting outcome.	CTO HOSP,DEPT NEUROSURG,TURIN,ITALY			Lanotte, Michele M./I-2647-2012	Lanotte, Michele M./0000-0002-4184-028X			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; CANTORE GP, 1987, ACTA NEUROCHIR WIEN, V41, P349; Cooper P R, 1976, Surg Neurol, V5, P25; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; JENNETT B, 1975, LANCET, V1, P480; KLUN B, 1984, ACTA NEUROCHIR, V71, P171, DOI 10.1007/BF01401312; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; LOEW F, 1960, ACTA NEUROCHIR WIE S, V3; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; MCKISSOCK W, 1960, LANCET, V1, P1365; SCHISANO G, 1964, Acta Chir Scand, V128, P471; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHENKIN HA, 1982, J NEUROSURG, V57, P254, DOI 10.3171/jns.1982.57.2.0254; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TALALLA A, 1971, J TRAUM, V11, P771, DOI 10.1097/00005373-197109000-00008; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WINTZEN AR, 1980, BRAIN, V103, P855, DOI 10.1093/brain/103.4.855; YUE CP, 1983, INJURY, V14, P489, DOI 10.1016/0020-1383(83)90051-7	25	91	92	0	4	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1996	138	2					185	191		10.1007/BF01411359			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TX189	WOS:A1996TX18900012	8686543				2021-06-18	
J	COELHO, CA; LILES, BZ; DUFFY, RJ				COELHO, CA; LILES, BZ; DUFFY, RJ			IMPAIRMENTS OF DISCOURSE ABILITIES AND EXECUTIVE FUNCTIONS IN TRAUMATICALLY BRAIN-INJURED ADULTS	BRAIN INJURY			English	Article							HEAD	Preliminary findings from an ongoing investigation of the potential relationship between narrative discourse performance and executive functions in adults with traumatic brain injuries (TBI) are reported. Narrative stories were elicited from 32 adults with TBI. Stories were analysed at three levels: sentence production, intersentential cohesive adequacy, and story episode structure. These measures were then correlated with scores from the Wisconsin Card Sorting Test (WCST), the primary measure of executive function. A significant correlation was noted between a factor score from the WCST and the measure of story structure, but not sentence production or cohesive adequacy. These results suggest that executive functions may be a promising avenue to pursue in the search for underlying causal factors of narrative discourse dysfunction and, therefore to better delineate the nature of communicative deficits secondary to TBI.	GAYLORD HOSP,WALLINGFORD,CT; UNIV CONNECTICUT,STORRS,CT	COELHO, CA (corresponding author), SO CONNECTICUT STATE UNIV,DEPT COMMUN DISORDERS,501 CRESCENT ST,NEW HAVEN,CT 06515, USA.						BLANK M, 1978, PRESCHOOL LANGUAGE A; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1993, CLIN APHASIOLOGY, V21, P183; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Grant D. A., 1948, WISCONSIN CARD SORTI; HAGAN C, 1980, REHABILITATION HEAD; Halliday MAK, 1989, LANGUAGE CONTEXT TEX; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Heaton R. K, 1981, WISCONSIN CARD SORTI; Kertesz A., 1982, W APHASIA BATTERY; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V23, P123; MATTIS S, 1976, GERIATRIC PSYCHIAT, P148; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stein NL., 1979, NEW DIRECTIONS DISCO; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005	20	91	93	0	10	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1995	9	5					471	477		10.3109/02699059509008206			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100005	7550218				2021-06-18	
J	BRODKEY, JA; LAYWELL, ED; OBRIEN, TF; FAISSNER, A; STEFANSSON, K; DORRIES, HU; SCHACHNER, M; STEINDLER, DA				BRODKEY, JA; LAYWELL, ED; OBRIEN, TF; FAISSNER, A; STEFANSSON, K; DORRIES, HU; SCHACHNER, M; STEINDLER, DA			FOCAL BRAIN INJURY AND UP-REGULATION OF A DEVELOPMENTALLY-REGULATED EXTRACELLULAR-MATRIX PROTEIN	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; WOUND HEALING; CEREBRAL CORTEX; ASTROCYTES; TENASCIN; IMMUNOCYTOCHEMISTRY	MASSIVE CORTICAL REORGANIZATION; NEURAL CREST CELLS; NEURITE OUTGROWTH; ENHANCED EXPRESSION; RAT-BRAIN; TENASCIN; GROWTH; MOLECULES; GLYCOPROTEINS; FIBRONECTIN	Tenascin is an extracellular matrix glycoprotein expressed during both normal development and neoplastic growth in both neural and nonneural tissues. During development of the central nervous system (CNS), tenascin is synthesized by glial cells, in particular by immature astrocytes, and is concentrated in transient boundaries around emerging groups of functionally distinct neurons. In the mature CNS, only low levels of the glycoprotein can be detected. The present study demonstrates that following trauma to the adult human cerebral cortex, discrete populations of reactive astrocytes upregulate their expression of tenascin and dramatically increase their transcription of the tenascin gene. The enhanced expression of tenascin may be involved in CNS wound healing, and may also affect neurite growth within and around a brain lesion.	UNIV TENNESSEE,COLL MED,DEPT ANAT & NEUROBIOL,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT NEUROSURG,MEMPHIS,TN; UNIV HEIDELBERG,DEPT NEUROBIOL,W-6900 HEIDELBERG,GERMANY; HARVARD UNIV,DEPT NEUROL,BOSTON,MA; ETH ZURICH,ZURICH,SWITZERLAND			Stefansson, Kari/AAE-7187-2019; Faissner, Andreas/A-5314-2008; Steindler, Dennis/AAJ-5811-2020	Faissner, Andreas/0000-0002-2211-8259; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20856] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020856] Funding Source: NIH RePORTER		BARTSCH S, 1992, J NEUROSCI, V12, P736; BOURDON MA, 1983, CANCER RES, V43, P2796; BRODKEY JA, 1993, EXP NEUROL, V123, P251, DOI 10.1006/exnr.1993.1158; CHUONG CM, 1991, AM J PATHOL, V138, P427; DACUNHA A, 1993, BRAIN RES, V600, P161, DOI 10.1016/0006-8993(93)90415-J; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAISSNER A, 1988, DIFFERENTIATION, V37, P104, DOI 10.1111/j.1432-0436.1988.tb00802.x; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HALFTER W, 1989, DEV BIOL, V132, P14, DOI 10.1016/0012-1606(89)90200-5; HUSMANN K, 1992, J CELL BIOL, V116, P1475, DOI 10.1083/jcb.116.6.1475; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; NIETOSAMPEDRO M, 1988, PHARM APPROACHES TRE, P331; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; PROBSTMEIER R, 1990, J NEUROCHEM, V54, P1016, DOI 10.1111/j.1471-4159.1990.tb02351.x; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; Ramon y Cajal S, 1928, DEGENERATION REGENER; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; Steindler D., 1992, Society for Neuroscience Abstracts, V18, P1042; STEINDLER DA, 1993, ANNU REV NEUROSCI, V16, P445, DOI 10.1146/annurev.ne.16.030193.002305; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; TERVO K, 1991, INVEST OPHTH VIS SCI, V32, P2912; TUCKER RP, 1991, DEVELOPMENT, V112, P1031; Waller A, 1850, PHILOS T R SOC LOND, V140, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021, 10.1098/rstl.1850.0021]	35	91	92	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	1995	82	1					106	112		10.3171/jns.1995.82.1.0106			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	PZ080	WOS:A1995PZ08000017	7529300				2021-06-18	
J	ORRISON, WW; GENTRY, LR; STIMAC, GK; TARREL, RM; ESPINOSA, MC; COBB, LC				ORRISON, WW; GENTRY, LR; STIMAC, GK; TARREL, RM; ESPINOSA, MC; COBB, LC			BLINDED COMPARISON OF CRANIAL CT AND MR IN CLOSED-HEAD INJURY EVALUATION	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article						HEAD, INJURIES; HEAD, COMPUTED TOMOGRAPHY; HEAD, MAGNETIC RESONANCE; MAGNETIC RESONANCE, COMPARATIVE STUDIES; COMPUTED TOMOGRAPHY, COMPARATIVE STUDIES; EFFICACY STUDIES	MAGNETIC-RESONANCE; COMPUTERIZED-TOMOGRAPHY; FIELD MR; TRAUMA; HEMATOMA; MANAGEMENT; MORTALITY; FEATURES; LESIONS	PURPOSE: To compare CT and MR in the evaluation of acute head injury. METHODS: One hundred seven consecutive patients who were referred to the emergency department and underwent both MR and CT cranial examinations within 48 hours were retrospectively reviewed. The films were interpreted by two neuroradiologists blinded to all patient information. RESULTS: The sensitivity of MR was significantly higher than that of CT for the detection of contusion, shearing injury, subdural and epidural hematoma, and sinus involvement. The sensitivity of CT was significantly higher than that of MR for the evaluation of fracture. The sensitivities of MR and CT were statistically equivalent for the detection of superficial soft-tissue injury. The overall sensitivity of MR for the detection of abnormalities in acute head trauma was 96.4%, and for CT was 63.4%. CONCLUSIONS: CT and MR are complementary studies in the evaluation of acute head trauma. MR is necessary to define or exclude contusions, deep shearing injury, and extraaxial fluid collections in acute head trauma.	UNIV NEW MEXICO,SCH MED,DEPT COMMUNITY MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT NEUROL,ALBUQUERQUE,NM 87131; UNIV WISCONSIN,CTR CLIN SCI,DEPT RADIOL,MADISON,WI; FIRST HILL DIAGNOST CTR,SEATTLE,WA	ORRISON, WW (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT RADIOL,ALBUQUERQUE,NM 87131, USA.						ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; BAKER SP, 1989, JAMA-J AM MED ASSOC, V262, P2284, DOI 10.1001/jama.262.16.2284; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; CHANEY RK, 1992, NEUROIMAG CLIN N AM, V2, P25; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; FRENCH BN, 1977, SURG NEUROL, V7, P171; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HESSELINK JR, 1988, AM J NEURORADIOL, V9, P269; JANOUSEK A, 1991, NEURORADIOLOGY S, V33, P616; JENKINS A, 1986, LANCET, V2, P445; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LANKSCH W, 1978, ADV NEUROSURG, V5, P27; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; MOON KL, 1984, AM J NEURORADIOL, V5, P319; MOSELEY IF, 1976, J NEURORADIOLOGY, V3, P277; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SNOEK J, 1979, J NEUROL NEUROSUR PS, V42, P215, DOI 10.1136/jnnp.42.3.215; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; YOON HC, 1988, AM J NEURORADIOL, V9, P404; ZIMMERMAN RA, 1986, AM J NEURORADIOL, V7, P757; ZIMMERMAN RD, 1982, RADIOL CLIN N AM, V20, P105	27	91	97	0	1	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	1994	15	2					351	356					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	MX594	WOS:A1994MX59400025	8192085				2021-06-18	
J	KIRGIS, A; ALBRECHT, S				KIRGIS, A; ALBRECHT, S			PALSY OF THE DEEP PERONEAL NERVE AFTER PROXIMAL TIBIAL OSTEOTOMY - AN ANATOMICAL STUDY	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article								Iatrogenic, isolated weakness or paralysis of the extensor hallucis longus muscle is a common complication in patients who have had a proximal tibial and fibular osteotomy. To investigate why this complication occurs, we dissected the deep peroneal nerve and neighboring structures, such as the tibia and fibula and the muscles of the leg, in twenty-nine specimens from cadavera, paying special attention to the motor branches supplying the extensor hallucis longus. Of forty-six motor nerves that were identified, eight entered the muscle from the lateral side in an area seventy to 150 millimeters distal to the fibular head; all of them ran close to the fibular periosteum. We suggest that, in some patients, the nerve supply to the extensor hallucis longus is at high risk for injury during a tibial osteotomy because of the proximity of the bone to the motor branches.		KIRGIS, A (corresponding author), FREE UNIV BERLIN,TEACHING HOSP,EV WALDKRANKENHAUS SPANDAU,SCH MED,DEPT ANAT,STADTRANDSTR 55,W-1000 BERLIN 20,GERMANY.						BLAUTH W, 1976, ORTHOP PRAXIIS, V12, P176; LANG J, 1972, PRAKTISCHE ANATOMI 4, V1, P83; LEGAL H, 1987, ORTHOP PRAX, V23, P53; MAQUET P, 1985, CLIN ORTHOP RELAT R, V192, P108; NAUMANN T, 1984, ORTHOP PRAX, V20, P914; NAUMANN T, 1987, ORTHOP PRAX, V23, P466; STURZ H, 1979, Z ORTHOP GRENZGEB, V117, P31; WASMER G, 1987, ORTHOP PRAX, V23, P453; WEINGARDEN SI, 1979, JAMA-J AM MED ASSOC, V241, P1248, DOI 10.1001/jama.241.12.1248	9	91	98	0	2	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	SEP	1992	74A	8					1180	1185		10.2106/00004623-199274080-00007			6	Orthopedics; Surgery	Orthopedics; Surgery	JV595	WOS:A1992JV59500007	1400546				2021-06-18	
J	SCHMOKER, JD; ZHUANG, J; SHACKFORD, SR				SCHMOKER, JD; ZHUANG, J; SHACKFORD, SR			HYPERTONIC FLUID RESUSCITATION IMPROVES CEREBRAL OXYGEN DELIVERY AND REDUCES INTRACRANIAL-PRESSURE AFTER HEMORRHAGIC-SHOCK	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	21ST ANNUAL MEETING OF THE WESTERN TRAUMA ASSOC	FEB 23-MAR 02, 1991	JACKSON HOLE, WY	W TRAUMA ASSOC			SMALL-VOLUME RESUSCITATION; LACTATED RINGERS SOLUTION; SEVERELY INJURED PATIENTS; WATER-CONTENT; SALINE; BRAIN; NACL; PULMONARY; TRAUMA; MODEL	Prospective clinical studies have shown that hypotension from hemorrhage contributes to increased morbidity and mortality in patients with traumatic brain injury. It is implied that poorer outcome is the result of secondary brain injury from impaired cerebral oxygen delivery (cO2del). We studied the early and late effects of hypertonic sodium lactate (HSL: 500 mOsm/L) resuscitation on mean arterial pressure (MAP), cardiac output (CO), systemic oxygen delivery (sO2del), cerebral perfusion pressure (CPP), intracranial pressure (ICP), cO2del, cerebral blood flow (CBF), serum osmolality, and cortical water content (CWC) in a porcine model of hemorrhagic shock. Swine were randomized to receive a bolus (4 mL/kg) of either lactated Ringer's solution (LR: 274 mOsm/L) or HSL after shock, followed by either LR or HSL to return MAP to baseline levels. Shed blood was returned 1 hour after resuscitation, and all animals were studied for 24 hours. Control animals were instrumented only. The HSL resuscitation significantly increased cO2del and CBF for 24 hours postresuscitation when compared with LR. The ICP in the HSL-treated animals was significantly lower throughout the postresuscitation phase when compared with the LR-treated animals (p < 0.05). The CWC was significantly lower in the HSL-treated animals (p < 0.05). We attribute these effects to hypertonic dehydration of both the brain parenchyma and the cerebrovascular endothelium. These data suggest that by decreasing ICP and improving cO2del after shock, HSL could decrease secondary brain injury when brain injury and shock occur together.	UNIV VERMONT,COLL MED,DEPT SURG,BURLINGTON,VT 05405					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1-R01-NS 28637-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028637] Funding Source: NIH RePORTER		DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; GAZITUA S, 1969, AM J PHYSIOL, V217, P1216; GAZITUA S, 1971, AM J PHYSIOL, V220, P384; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; KRAMER GC, 1986, SURGERY, V100, P239; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; MANINGAS PA, 1986, ANN EMERG MED, V15, P1131, DOI 10.1016/S0196-0644(86)80852-6; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; NERLICH M, 1983, CIRC SHOCK, V10, P179; NEWFIELD P, 1980, CRIT CARE MED, V8, P254, DOI 10.1097/00003246-198004000-00123; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; Pasztor E, 1973, STROKE, V4, P556, DOI 10.1161/01.STR.4.4.556; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; READ RC, 1960, CIRC RES, V8, P538, DOI 10.1161/01.RES.8.3.538; SCHMOKER J, 1991, Journal of Trauma, V31, P1038, DOI 10.1097/00005373-199107000-00091; SEELIG JM, 1986, INTRACRANIAL PRESSUR, V6, P675; SHACKFORD SR, 1989, J TRAUMA, V29, P894, DOI 10.1097/00005373-198906000-00035; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; SHACKFORD SR, 1987, SURG GYNECOL OBSTET, V164, P127; SHACKFORD SR, 1988, SURGERY, V104, P553; SHACKFORD SR, IN PRESS J NEUROSURG; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; TRAVERSO LW, 1986, J TRAUMA, V26, P168, DOI 10.1097/00005373-198602000-00014; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; WALSH J, 1990, SURG FORUM, V49, P56; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; 1985, INJURY AM, P18	34	91	92	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1991	31	12					1607	1613		10.1097/00005373-199112000-00007			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	GW885	WOS:A1991GW88500007	1749030				2021-06-18	
J	RAO, N; JELLINEK, HM; WOOLSTON, DC				RAO, N; JELLINEK, HM; WOOLSTON, DC			AGITATION IN CLOSED HEAD-INJURY - HALOPERIDOL EFFECTS ON REHABILITATION OUTCOME	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									UNIV WISCONSIN,SCH MED,DEPT REHABIL MED,MADISON,WI 53792; UNIV WISCONSIN,DEPT GEN ENGN,MADISON,WI 53706							ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GRABOWSKI SW, 1973, DIS NERV SYST, V34, P315; HAGEN C, 1979, 3RD ANN POSTGR COURS; HARVEY RF, 1981, ARCH PHYS MED REHAB, V62, P456; HORVATH TB, 1974, J NEUROL NEUROSUR PS, V37, P416, DOI 10.1136/jnnp.37.4.416; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P160; LEVANN LJ, 1971, AM J MENT DEF, V75, P719; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P172; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; RAO N, 1984, ARCH PHYS MED REHAB, V65, P18; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; SCHNAPER N, 1976, AM J PSYCHIAT, V133, P883; SMITH GR, 1974, PSYCHOSOMATICS, V15, P134; SNYDER SH, 1972, ARCH GEN PSYCHIAT, V27, P169; UZZELL BP, 1979, CORTEX, V15, P391, DOI 10.1016/S0010-9452(79)80066-0; WEINSTEIN GS, 1981, J CLIN PSYCHIAT, V42, P120; YUDOFSKY S, 1981, AM J PSYCHIAT, V138, P218	25	91	91	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.		1985	66	1					30	34					5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AAF50	WOS:A1985AAF5000009	3966865				2021-06-18	
J	Ellis, MJ; Ritchie, LJ; Koltek, M; Hosain, S; Cordingley, D; Chu, S; Selci, E; Leiter, J; Russell, K				Ellis, Michael J.; Ritchie, Lesley J.; Koltek, Mark; Hosain, Shahid; Cordingley, Dean; Chu, Stephanie; Selci, Erin; Leiter, Jeff; Russell, Kelly			Psychiatric outcomes after pediatric sports-related concussion	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						psychiatric disorder; sports-related concussion; postconcussion syndrome; pediatric; depression; anxiety; suicide; trauma	TRAUMATIC BRAIN-INJURY; 1ST 6 MONTHS; PERSONALITY-CHANGE; POSTCONCUSSION SYNDROME; DEPRESSION DIAGNOSIS; ANXIETY DISORDERS; SYMPTOM SEVERITY; HIGH-SCHOOL; CHILDREN; ADOLESCENTS	OBJECT The objectives of this study were twofold: 1) to examine the prevalence of emotional symptoms among children and adolescents with a sports-related concussion (SRC) who were referred to a multidisciplinary pediatric concussion program and 2) to examine the prevalence, clinical features, risk factors, and management of postinjury psychiatric outcomes among those in this clinical population. METHODS The authors conducted a retrospective chart review of all patients with SRC referred to a multidisciplinary pediatric concussion program between September 2013 and October 2014. Clinical assessments carried out by a single neurosurgeon included clinical history, physical examination, and Post-Concussion Symptom Scale (PCSS) scoring. Postinjury psychiatric outcomes were defined as a subjective worsening of symptoms of a preinjury psychiatric disorder or new and isolated suicidal ideation or diagnosis of a novel psychiatric disorder (NPD). An NPD was defined as a newly diagnosed psychiatric disorder that occurred in a patient with or without a lifetime preinjury psychiatric disorder after a concussion. Clinical resources, therapeutic interventions, and clinical and return-to-play outcomes are summarized. RESULTS One hundred seventy-four patients (mean age 14.2 years, 61.5% male) were included in the study. At least 1 emotional symptom was reported in 49.4% of the patients, and the median emotional PCSS subscore was 4 (inter-quartile range 1-8) among those who reported at least 1 emotional symptom. Overall, 20 (11.5%) of the patients met the study criteria for a postinjury psychiatric outcome, including 14 patients with an NPD, 2 patients with isolated suicidal ideation, and 4 patients with worsening symptoms of a preinjury psychiatric disorder. Female sex, a higher initial PCSS score, a higher emotional PCSS subscore, presence of a preinjury psychiatric history, and presence of a family history of psychiatric illness were significantly associated with postinjury psychiatric outcomes. Interventions for patients with postinjury psychiatric outcomes included pharmacological therapy alone in 2 patients (10%), cognitive behavioral therapy alone in 4 (20%), multimodal therapy in 9 (45%), and no treatment in 5 (25%). Overall, 5 (25%) of the patients with postinjury psychiatric disorders were medically cleared to return to full sports participation, whereas 5 (25%) were lost to follow-up and 9 (45%) remained in treatment by the multidisciplinary concussion program at the end of the study period. One patient who was asymptomatic at the time of initial consultation committed suicide. CONCLUSIONS Emotional symptoms were commonly reported among pediatric patients with SRC referred to a multidisciplinary pediatric concussion program. In some cases, these symptoms contributed to the development of an NPD, isolated suicidal ideation, and worsening symptoms of a preexisting psychiatric disorder. Future research is needed to clarify the prevalence, pathophysiology, risk factors, and evidence-based management of postinjury psychiatric outcomes after pediatric SRC. Successful management of these patients requires prompt recognition and multidisciplinary care by experts with clinical training and experience in concussion and psychiatry.	[Ellis, Michael J.; Leiter, Jeff] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.; Chu, Stephanie; Selci, Erin; Russell, Kelly] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Ritchie, Lesley J.] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada; [Koltek, Mark; Hosain, Shahid] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.] Univ Manitoba, Neurosurg Sect, Winnipeg, MB, Canada; [Ellis, Michael J.; Ritchie, Lesley J.; Koltek, Mark; Hosain, Shahid; Cordingley, Dean; Leiter, Jeff] Pan Am Concuss Program, Winnipeg, MB, Canada; [Ellis, Michael J.; Chu, Stephanie; Selci, Erin; Russell, Kelly] Childrens Hosp, Res Inst Manitoba, Winnipeg, MB R3A 1S1, Canada; [Ellis, Michael J.; Ritchie, Lesley J.; Koltek, Mark; Hosain, Shahid; Cordingley, Dean; Chu, Stephanie; Selci, Erin; Leiter, Jeff; Russell, Kelly] Canada North Concuss Network, Winnipeg, MB, Canada	Ellis, MJ (corresponding author), Pan Am Clin, Pan Am Concuss Program, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis3@panamclinic.com	Meijer, Anna/K-5118-2016	Russell, Kelly/0000-0002-9159-9201	Pan Am Clinic Foundation; Manitoba Health Research Council	We thank the Pan Am Clinic Foundation and the Manitoba Health Research Council for their financial support of this study.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis MJ, 2015, J NEUROSURG PEDIAT, V2, P1; Fletcher JM, 2008, HEALTH ECON, V17, P1215, DOI 10.1002/hec.1319; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; LEWINSOHN PM, 1993, J AM ACAD CHILD PSY, V32, P60, DOI 10.1097/00004583-199301000-00009; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 2014, PSYCHIAT CLIN N AM, V37, P125, DOI 10.1016/j.psc.2013.11.003; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P272, DOI 10.1176/appi.neuropsych.12040078; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moore E, 2014, J HEAD TRAUMA REHAB, V29, P239, DOI 10.1097/HTR.0b013e31828f9876; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P378, DOI 10.1097/01.HTR.0000341433.67251.01; Rune V, 1970, ACTA PAEDIATR SC   S, V209, P3; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	56	90	90	0	50	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2015	16	6					709	718		10.3171/2015.5.PEDS15220			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CX0FM	WOS:000365372300013	26359916	Bronze			2021-06-18	
J	Higgins, DM; Kerns, RD; Brandt, CA; Haskell, SG; Bathulapalli, H; Gilliam, W; Goulet, JL				Higgins, Diana M.; Kerns, Robert D.; Brandt, Cynthia A.; Haskell, Sally G.; Bathulapalli, Harini; Gilliam, Wesley; Goulet, Joseph L.			Persistent Pain and Comorbidity Among Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn Veterans	PAIN MEDICINE			English	Article						Anxiety; Depression; Obesity; Pain Management; Persistent Pain; Post-traumatic Stress Syndrome; Substance Abuse	TRAUMATIC BRAIN-INJURY; CHRONIC BACK-PAIN; OLDER-ADULTS; CARE; PREVALENCE; POLYTRAUMA; DEPRESSION; DISORDERS; AFGHANISTAN; MANAGEMENT	ObjectiveChronic pain is a significant concern for the Veterans Health Administration (VHA), with chronic pain conditions among those most frequently reported by Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF)/Operation New Dawn (OND) veterans. The current study examined VHA electronic medical record data to examine variation in demographics and high prevalence and high impact medical and mental health conditions in order to characterize the differences between patients with persistent pain and no pain. DesignA conservative operational definition of chronic or persistent pain based on multiple indicators of pain (i.e., pain intensity ratings, prescription opioids, pain clinic visits, International Classification of Diseases, Ninth Revision codes) was employed. Analyses included the entire roster of longitudinal clinical data on OEF/OIF/OND veterans who used VHA care to compare those with persistent pain with those with no clinical evidence of pain. ResultsResults of logistic regression models suggest that sex, race, education, military variables, body mass index (BMI), traumatic brain injury (TBI), and mental health conditions, but not age, reliably discriminate the two groups. Those with persistent pain were more likely to be Black, female, on active duty, enlisted, Army service members, have a high school education or less, and have diagnoses of mood disorders, post-traumatic stress disorder, substance use disorders, anxiety disorders, TBI, and have a BMI consistent with overweight and obesity. ConclusionsThe operational definition of chronic pain used in this study may have research implications for examining predictors of incident and chronic pain. These data have important clinical implications in that addressing comorbid conditions of persistent pain may improve adaptive coping and functioning in these patients.	[Higgins, Diana M.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Higgins, Diana M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kerns, Robert D.; Brandt, Cynthia A.; Haskell, Sally G.; Goulet, Joseph L.] VA Connecticut Healthcare Syst, West Haven, CT USA; [Kerns, Robert D.; Brandt, Cynthia A.; Haskell, Sally G.; Bathulapalli, Harini; Goulet, Joseph L.] Yale Univ, Sch Med, New Haven, CT USA	Higgins, DM (corresponding author), VA Boston Healthcare Syst, Res Serv Psychol Serv 116B-2,150 South Huntington, Boston, MA 02130 USA.	diana.higgins2@va.gov	Bathulapalli, Harini/B-7451-2015	Bathulapalli, Harini/0000-0002-2531-0238; Goulet, Joseph/0000-0002-0842-804X	VA Health Services Research and Development award [DHI07-065]; Veterans AffairsUS Department of Veterans Affairs [I01HX000915] Funding Source: NIH RePORTER	This research was supported by a VA Health Services Research and Development award (PI: SH & CB), #DHI07-065.	Agency for Healthcare Research and Quality (AHRQ), 2009, CLIN CLASS SOFTW CCS; Bair MJ, 2008, PSYCHOSOM MED, V70, P890, DOI 10.1097/PSY.0b013e318185c510; Buckwalter JA, 2000, CLIN ORTHOP RELAT R, P159; Burgess DJ, 2013, CLIN J PAIN, V29, P118, DOI 10.1097/AJP.0b013e31826a86ae; Carroll LJ, 2004, PAIN, V107, P134, DOI 10.1016/j.pain.2003.10.009; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Cleeland CS, 2003, CLIN J PAIN, V19, P298, DOI 10.1097/00002508-200309000-00003; Currie SR, 2004, PAIN, V107, P54, DOI 10.1016/j.pain.2003.09.015; Department of Veterans Affairs, 1999, VET HLTH ADM MEM PAI; Edlund MJ, 2007, PAIN, V129, P355, DOI 10.1016/j.pain.2007.02.014; Frayne S, 2010, J GEN INTERN MED, V25, P333; GATCHEL RJ, 1995, HEALTH PSYCHOL, V14, P415, DOI 10.1037/0278-6133.14.5.415; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Goulet JL, 2007, CLIN INFECT DIS, V45, P1593, DOI 10.1086/523577; Green CR, 2003, J PAIN, V4, P82, DOI 10.1054/jpai.2003.8; Hagen EM, 2006, SPINE, V31, P1491, DOI 10.1097/01.brs.0000219947.71168.08; Hankin CS, 1999, AM J PSYCHIAT, V156, P1924; Haskell SG, 2011, WOMEN HEALTH ISS, V21, P92, DOI 10.1016/j.whi.2010.08.001; Haskell SG, 2009, PAIN MED, V10, P1167, DOI 10.1111/j.1526-4637.2009.00714.x; Hestbaek L, 2003, J MANIP PHYSIOL THER, V26, P243, DOI 10.1016/S0161-4754(03)00003-4; Institute of Medicine of the National Academies, 2011, REL PAIN AM BLU TRAN; Janke EA, 2007, J REHABIL RES DEV, V44, P245, DOI 10.1682/JRRD.2006.06.0060; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; *NAT HEART LUNG BL, 1998, CLIN GUID ID EV TREA; Quintana JM, 2008, AGING CLIN EXP RES, V20, P329; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; VHA Office of Public Health and Environmental Hazards, 2009, VHA OFF PUBL HLTH EN; Walkup JT, 2004, MED CARE, V42, P756, DOI 10.1097/01.mlr.0000132749.20897.46; Wijnhoven HAH, 2006, CLIN J PAIN, V22, P717, DOI 10.1097/01.ajp.0000210912.95664.53	33	90	91	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAY	2014	15	5					782	790		10.1111/pme.12388			9	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	AH9JS	WOS:000336458900011	24548466	Bronze			2021-06-18	
J	Pham, HP; Shaz, BH				Pham, H. P.; Shaz, B. H.			Update on massive transfusion	BRITISH JOURNAL OF ANAESTHESIA			English	Article						massive transfusion; massive transfusion protocol; paediatric transfusion protocol; transfusion management	PROTHROMBIN COMPLEX CONCENTRATE; FRESH WHOLE-BLOOD; LIFE-THREATENING HEMORRHAGE; RECOMBINANT-FACTOR-VIIA; TRAUMATIC BRAIN-INJURY; ACTIVATED FACTOR-VII; FACTOR-XIII ACTIVITY; GROUP-A PLASMA; TRANEXAMIC ACID; EARLY COAGULOPATHY	Massive haemorrhage requires massive transfusion (MT) to maintain adequate circulation and haemostasis. For optimal management of massively bleeding patients, regardless of aetiology (trauma, obstetrical, surgical), effective preparation and communication between transfusion and other laboratory services and clinical teams are essential. A well-defined MT protocol is a valuable tool to delineate how blood products are ordered, prepared, and delivered; determine laboratory algorithms to use as transfusion guidelines; and outline duties and facilitate communication between involved personnel. In MT patients, it is crucial to practice damage control resuscitation and to administer blood products early in the resuscitation. Trauma patients are often admitted with early trauma-induced coagulopathy (ETIC), which is associated with mortality; the aetiology of ETIC is likely multifactorial. Current data support that trauma patients treated with higher ratios of plasma and platelet to red blood cell transfusions have improved outcomes, but further clinical investigation is needed. Additionally, tranexamic acid has been shown to decrease the mortality in trauma patients requiring MT. Greater use of cryoprecipitate or fibrinogen concentrate might be beneficial in MT patients from obstetrical causes. The risks and benefits for other therapies (prothrombin complex concentrate, recombinant activated factor VII, or whole blood) are not clearly defined in MT patients. Throughout the resuscitation, the patient should be closely monitored and both metabolic and coagulation abnormalities corrected. Further studies are needed to clarify the optimal ratios of blood products, treatment based on underlying clinical disorder, use of alternative therapies, and integration of laboratory testing results in the management of massively bleeding patients.	[Pham, H. P.; Shaz, B. H.] New York Blood Ctr, New York, NY 10021 USA; [Pham, H. P.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA; [Shaz, B. H.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Shaz, BH (corresponding author), New York Blood Ctr, New York, NY 10021 USA.	bshaz@nybloodcenter.org		Shaz, Beth/0000-0002-2270-4821; Pham, Huy/0000-0003-4168-3859			Afshari A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007871.pub2; Ak K, 2009, J CARDIAC SURG, V24, P404, DOI 10.1111/j.1540-8191.2009.00840.x; [Anonymous], 2010, DEATHS MORT; Armand R, 2003, TRANSFUS MED REV, V17, P223, DOI 10.1016/S0887-7963(03)00022-1; Blome M, 2005, THROMB HAEMOSTASIS, V93, P1101, DOI 10.1160/TH04-12-0799; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Bolliger D, 2012, TRANSFUS MED REV, V26, P1, DOI 10.1016/j.tmrv.2011.07.005; Bolliger D, 2010, ANESTHESIOLOGY, V113, P1205, DOI 10.1097/ALN.0b013e3181f22b5a; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Callum JL, 2012, HEMATOL-AM SOC HEMAT, P522, DOI 10.1182/asheducation-2012.1.522; Cancio LC, 2008, J TRAUMA, V64, pS51, DOI 10.1097/TA.0b013e3181608c21; Chandler MH, 2012, SEMIN CARDIOTHORAC V, V16, P153, DOI 10.1177/1089253212452344; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Chidester SJ, 2012, J TRAUMA ACUTE CARE, V73, P1273, DOI 10.1097/TA.0b013e318265d267; Cid J, 2011, TRANSFUSION, V51, P1163, DOI 10.1111/j.1537-2995.2010.02953.x; Coakley M, 2006, J CARDIOTHOR VASC AN, V20, P548, DOI 10.1053/j.jvca.2006.01.016; Cohen B, 2013, BRIT J ANAESTH, V111, P62, DOI 10.1093/bja/aet405; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Cotton BA, 2009, J TRAUMA, V66, P41, DOI 10.1097/TA.0b013e31819313bb; Curry N, 2012, INJURY, V43, P1021, DOI 10.1016/j.injury.2012.03.014; Cushing M, 2011, MINERVA ANESTESIOL, V77, P349; Davenport R, 2011, BRIT J HAEMATOL, V155, P537, DOI 10.1111/j.1365-2141.2011.08885.x; de Moya MA, 2013, J TRAUMA ACUTE CARE, V74, P74; Dente CJ, 2009, J TRAUMA, V66, P1616, DOI 10.1097/TA.0b013e3181a59ad5; Diab YA, 2013, BRIT J HAEMATOL, V161, P15, DOI 10.1111/bjh.12247; Ducloy-Bouthors AS, 2011, CRIT CARE, V15, DOI 10.1186/cc10143; Dzik Walter H, 2004, Curr Hematol Rep, V3, P324; Dzik WH, 2011, CRIT CARE, V15, DOI 10.1186/cc10498; Fenger-Eriksen C, 2009, J THROMB HAEMOST, V7, P795, DOI 10.1111/j.1538-7836.2009.03331.x; Fergusson DA, 2012, JAMA-J AM MED ASSOC, V308, P1443, DOI 10.1001/2012.jama.11953; Floccard B, 2012, INJURY, V43, P26, DOI 10.1016/j.injury.2010.11.003; Friedman AJ, 2013, J CARDIOTHOR VASC AN, V27, pS44, DOI 10.1053/j.jvca.2013.05.016; Fries D, 2013, TRANSFUSION, V53, p91S, DOI 10.1111/trf.12041; Gerlach R, 2002, STROKE, V33, P1618, DOI 10.1161/01.STR.0000017219.83330.FF; Gilstad C, 2012, TRANSFUSION, V52, P930, DOI 10.1111/j.1537-2995.2011.03365.x; Girdauskas E, 2010, J THORAC CARDIOV SUR, V140, P1117, DOI 10.1016/j.jtcvs.2010.04.043; Goodnough LT, 2013, CURR OPIN ANESTHESIO, V26, P208, DOI 10.1097/ACO.0b013e32835d6f8f; Grottke O, 2011, BLOOD, V118, P1943, DOI 10.1182/blood-2011-03-343046; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Guerriero C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018987; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Hendrickson JE, 2012, J PEDIAT, V160; Hendrickson JE, 2012, TRANSFUSION, V52, P1228, DOI 10.1111/j.1537-2995.2011.03458.x; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Ickx BE, 2010, EUR J ANAESTH, V27, P1031, DOI 10.1097/EJA.0b013e32833c30e3; Innerhofer P, 2013, INJURY, V44, P209, DOI 10.1016/j.injury.2012.08.047; Johansson PI, 2010, TRANSFUSION, V50, P701, DOI 10.1111/j.1537-2995.2009.02458.x; Karlsson M, 2009, THROMB HAEMOSTASIS, V102, P137, DOI 10.1160/TH08-09-0587; Kettner SC, 1998, BRIT J ANAESTH, V80, P313; Laverdiere Caroline, 2002, Pediatr Crit Care Med, V3, P335, DOI 10.1097/00130478-200210000-00001; Levi M, 2010, NEW ENGL J MED, V363, P1791, DOI 10.1056/NEJMoa1006221; Levy JH, 2006, SEMIN HEMATOL, V43, pS59, DOI 10.1053/j.seminhematol.2005.11.019; Lier H, 2008, J TRAUMA, V65, P951, DOI 10.1097/TA.0b013e318187e15b; Lin YL, 2011, CAN MED ASSOC J, V183, pE9, DOI 10.1503/cmaj.100408; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2011, VOX SANG, V100, P231, DOI 10.1111/j.1423-0410.2010.01387.x; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; Martini WZ, 2007, ANN SURG, V246, P831, DOI 10.1097/SLA.0b013e3180cc2e94; McLaughlin DF, 2008, J TRAUMA, V64, pS57, DOI 10.1097/TA.0b013e318160a566; Mehr CR, 2013, J TRAUMA ACUTE CARE, V74, P1425, DOI 10.1097/TA.0b013e31828b813e; Mitterlechner T, 2011, J THROMB HAEMOST, V9, P729, DOI 10.1111/j.1538-7836.2011.04211.x; Molnar R, 2002, TRANSFUSION, V42, P177, DOI 10.1046/j.1537-2995.2002.00015.x; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; Nunez TC, 2010, J TRAUMA, V68, P1498, DOI 10.1097/TA.0b013e3181d3cc25; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; O'Keeffe T, 2008, ARCH SURG-CHICAGO, V143, P686, DOI 10.1001/archsurg.143.7.686; Pasquali SK, 2012, J THORAC CARDIOV SUR, V143, P550, DOI 10.1016/j.jtcvs.2011.06.048; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Perkins JG, 2007, J TRAUMA, V62, P1095, DOI 10.1097/TA.0b013e31804798a4; Radwan ZA, 2013, JAMA SURG, V148, P170, DOI 10.1001/jamasurgery.2013.414; Rahe-Meyer N, 2009, BRIT J ANAESTH, V102, P785, DOI 10.1093/bja/aep089; Rahe-Meyer N, 2009, J THORAC CARDIOV SUR, V138, P694, DOI 10.1016/j.jtcvs.2008.11.065; Raymer JM, 2012, SURG CLIN N AM, V92, P221, DOI 10.1016/j.suc.2012.01.008; Reiss R F, 2000, Am J Crit Care, V9, P158; Reiss RF, 2000, AM J CRIT CARE, V9, P66; Ringer SA, 1998, PEDIATRICS, V101, P194, DOI 10.1542/peds.101.2.194; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Roberts I, 2011, LANCET, V377, P1096; Roberts I, 2011, INT J GYNECOL OBSTET, V115, P220, DOI 10.1016/j.ijgo.2011.09.001; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Schreiber MA, 2007, J AM COLL SURGEONS, V205, P541, DOI 10.1016/j.jamcollsurg.2007.05.007; Seghatchian J, 2012, TRANSFUS APHER SCI, V47, P235, DOI 10.1016/j.transci.2012.06.001; Sethna NF, 2005, ANESTHESIOLOGY, V102, P727, DOI 10.1097/00000542-200504000-00006; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shaz BH, 2009, ANESTH ANALG, V108, P1760, DOI 10.1213/ane.0b013e3181a0b6c6; Sihler KC, 2010, CHEST, V137, P209, DOI 10.1378/chest.09-0252; Sorensen B, 2012, BRIT J SURG, V99, P40, DOI 10.1002/bjs.7770; Spinella PC, 2008, WORLD J SURG, V32, P2, DOI 10.1007/s00268-007-9201-5; Spinella PC, 2009, J TRAUMA, V66, pS69, DOI 10.1097/TA.0b013e31819d85fb; Stanworth SJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9394; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Talving P, 2011, J TRAUMA, V71, P1205, DOI 10.1097/TA.0b013e31820d151d; Tanaka KA, 2013, BRIT J ANAESTH, V111, P35, DOI 10.1093/bja/aet380; Tripodi A, 2009, BRIT J HAEMATOL, V147, P77, DOI 10.1111/j.1365-2141.2009.07833.x; Wang D, 2012, TRANSFUSION, V52, P1184, DOI 10.1111/j.1537-2995.2011.03466.x; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wikkelsoe AJ, 2011, ACTA ANAESTH SCAND, V55, P1174, DOI 10.1111/j.1399-6576.2011.02534.x; Yazer MH, 2007, TRANSFUSION, V47, P2197, DOI 10.1111/j.1537-2995.2007.01446.x; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf; Zielinski MD, 2013, J TRAUMA ACUTE CARE, V74, P69, DOI 10.1097/TA.0b013e3182788f8e	106	90	94	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	DEC	2013	111			1			71	82		10.1093/bja/aet376			12	Anesthesiology	Anesthesiology	271HZ	WOS:000328383900007	24335401	Bronze			2021-06-18	
J	Siebenrock, KA; Behning, A; Mamisch, TC; Schwab, JM				Siebenrock, Klaus A.; Behning, Anna; Mamisch, T. Charles; Schwab, Joseph M.			Growth Plate Alteration Precedes Cam-type Deformity in Elite Basketball Players	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							FEMOROACETABULAR IMPINGEMENT; HIP; OSTEOARTHRITIS; EPIPHYSEAL; INJURIES; SALTER	Vigorous sporting activity during the growth years is associated with an increased risk of having a cam-type deformity develop. The underlying cause of this osseous deformity is unclear. One may speculate whether this is caused by reactive bone apposition in the region of the anterosuperior head-neck junction or whether sports activity alters the shape of and growth in the growth plate. If the latter is true, then one would expect athletes to show an abnormal shape of the capital growth plate (specifically, the epiphyseal extension) before and/or after physeal closure. We therefore raised three questions: (1) Do adolescent basketball players show abnormal epiphyseal extension? (2) Does the epiphyseal extension differ before and after physeal closure? (3) Is abnormal epiphyseal extension associated with high alpha angles? We performed a case-control comparative analysis of young (age range, 9-22 years) male elite basketball athletes with age-matched nonathletes, substratified by whether they had open or closed physes. We measured epiphyseal extension on radial-sequence MRI cuts throughout the cranial hemisphere from 9 o'clock (posterior) to 3 o'clock (anterior). Epiphyseal extension was correlated to alpha angle measurements at the same points. Epiphyseal extension was increased in all positions in the athletes compared with the control group. On average, athletes showed epiphyseal extension of 0.67 to 0.83 versus 0.53 to 0.71 in control subjects. In the control group epiphyseal extension was increased at all measurement points in hips after physeal closure compared with before physeal closure. In contrast, the subgroup of athletes with a closed growth plate only had increased epiphyseal extension at the 3 o'clock position compared with the athletes with a closed growth plate (0.64-0.70). We observed a correlation between an alpha angle greater than 55A degrees and greater epiphyseal extension in the anterosuperior femoral head quadrant: the corresponding Spearman r values were 0.387 (all hips) and 0.285 (alpha angle > 55A degrees) for the aggregate anterosuperior quadrant. These findings suggest that a cam-type abnormality in athletes is a consequence of an alteration of the growth plate rather than reactive bone formation. High-level sports activity during growth may be a new and distinct risk factor for a cam-type deformity.	[Siebenrock, Klaus A.; Behning, Anna; Mamisch, T. Charles; Schwab, Joseph M.] Univ Bern, Inselspital, Dept Orthopaed Surg, CH-3010 Bern, Switzerland	Siebenrock, KA (corresponding author), Univ Bern, Inselspital, Dept Orthopaed Surg, Freiburgstr, CH-3010 Bern, Switzerland.	klaus.siebenrock@insel.ch		Siebenrock, Klaus Arno/0000-0003-3627-4313; Schwab, Joseph/0000-0002-7068-5215	Maurice E. Muller Foundation of North America	One of the authors (JMS) has received fellowship funding from the Maurice E. Muller Foundation of North America. Each author certifies that he or she, or a member of his or her immediate family, has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research editors and board members are on file with the publication and can be viewed on request. Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.	ADAMS JE, 1966, CALIF MED, V105, P22; Bharam S, 2006, CLIN SPORT MED, V25, P279, DOI 10.1016/j.csm.2006.01.003; Bizzini M, 2007, AM J SPORT MED, V35, P1955, DOI 10.1177/0363546507304141; Caine D, 2006, BRIT J SPORT MED, V40, P749, DOI 10.1136/bjsm.2005.017822; Ganz R, 2003, CLIN ORTHOP RELAT R, P112, DOI 10.1097/01.blo.0000096804.78689.c2; Ganz R, 2008, CLIN ORTHOP RELAT R, V466, P264, DOI 10.1007/s11999-007-0060-z; JARAMILLO D, 1993, RADIOLOGY, V187, P171, DOI 10.1148/radiology.187.1.8451408; JARAMILLO D, 1995, RADIOLOGY, V197, P767, DOI 10.1148/radiology.197.3.7480754; Keogh MJ, 2008, SPORTS MED, V38, P863, DOI 10.2165/00007256-200838100-00005; Kienle KP, 2012, SKELETAL RADIOL, V41, P1381, DOI 10.1007/s00256-012-1358-9; Leunig M, 2009, CLIN ORTHOP RELAT R, V467, P616, DOI 10.1007/s11999-008-0646-0; MURRAY R O, 1971, Journal of Bone and Joint Surgery British Volume, V53, P406; Nanni M, 2005, SKELETAL RADIOL, V34, P405, DOI 10.1007/s00256-004-0892-5; Notzli HP, 2002, J BONE JOINT SURG BR, V84B, P556, DOI 10.1302/0301-620X.84B4.12014; Philippon M, 2007, KNEE SURG SPORT TR A, V15, P908, DOI 10.1007/s00167-007-0332-x; R Development Core Team, 2011, R LANG ENV STAT COMP; Sato T, 2002, J PEDIATR ORTHOP B, V11, P155, DOI 10.1097/00009957-200204000-00013; Siebenrock KA, 2011, CLIN ORTHOP RELAT R, V469, P3229, DOI 10.1007/s11999-011-1945-4; Siebenrock KA, 2004, CLIN ORTHOP RELAT R, P54	19	90	91	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	APR	2013	471	4					1084	1091		10.1007/s11999-012-2740-6			8	Orthopedics; Surgery	Orthopedics; Surgery	097YW	WOS:000315510400005	23247816	Green Published			2021-06-18	
J	Zafonte, RD; Bagiella, E; Ansel, BM; Novack, TA; Friedewald, WT; Hesdorffer, DC; Timmons, SD; Jallo, J; Eisenberg, H; Hart, T; Ricker, JH; Diaz-Arrastia, R; Merchant, RE; Temkin, NR; Melton, S; Dikmen, SS				Zafonte, Ross D.; Bagiella, Emilia; Ansel, Beth M.; Novack, Thomas A.; Friedewald, William T.; Hesdorffer, Dale C.; Timmons, Shelly D.; Jallo, Jack; Eisenberg, Howard; Hart, Tessa; Ricker, Joseph H.; Diaz-Arrastia, Ramon; Merchant, Randall E.; Temkin, Nancy R.; Melton, Sherry; Dikmen, Sureyya S.			Effect of Citicoline on Functional and Cognitive Status Among Patients With Traumatic Brain Injury Citicoline Brain Injury Treatment Trial (COBRIT)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; CDP-CHOLINE; CLINICAL-TRIALS; MULTIPLE OUTCOMES; HIPPOCAMPAL; SYMPTOMS; RECOVERY; TBI	Context Traumatic brain injury (TBI) is a serious public health problem in the United States, yet no treatment is currently available to improve outcome after TBI. Approved for use in TBI in 59 countries, citicoline is an endogenous substance offering potential neuroprotective properties as well as facilitated neurorepair post injury. Objective To determine the ability of citicoline to positively affect functional and cognitive status in persons with complicated mild, moderate, and severe TBI. Design, Setting, and Patients The Citicoline Brain Injury Treatment Trial (COBRIT), a phase 3, double-blind randomized clinical trial conducted between July 20, 2007, and February 4, 2011, among 1213 patients at 8 US level 1 trauma centers to investigate effects of citicoline vs placebo in patients with TBI classified as complicated mild, moderate, or severe. Intervention Ninety-day regimen of daily enteral or oral citicoline (2000 mg) or placebo. Main Outcome Measures Functional and cognitive status, assessed at 90 days using the TBI-Clinical Trials Network Core Battery. A global statistical test was used to analyze the 9 scales of the core battery. Secondary outcomes were functional and cognitive improvement, assessed at 30, 90, and 180 days, and examination of the long-term maintenance of treatment effects. Results Rates of favorable improvement for the Glasgow Outcome Scale-Extended were 35.4% in the citicoline group and 35.6% in the placebo group. For all other scales the rate of improvement ranged from 37.3% to 86.5% in the citicoline group and from 42.7% to 84.0% in the placebo group. The citicoline and placebo groups did not differ significantly at the 90-day evaluation (global odds ratio [OR], 0.98 [95% CI, 0.83-1.15]); in addition, there was no significant treatment effect in the 2 severity subgroups (global OR, 1.14 [95% CI, 0.88-1.49] and 0.89 [95% CI, 0.72-1.49] for moderate/severe and complicated mild TBI, respectively). At the 180-day evaluation, the citicoline and placebo groups did not differ significantly with respect to the primary outcome (global OR, 0.87 [95% CI, 0.72-1.04]). Conclusion Among patients with traumatic brain injury, the use of citicoline compared with placebo for 90 days did not result in improvement in functional and cognitive status.	[Zafonte, Ross D.] Harvard Univ, Spaulding Rehabil Hosp Network, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bagiella, Emilia] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA; [Ansel, Beth M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Novack, Thomas A.; Melton, Sherry] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Friedewald, William T.] Columbia Univ, Dept Biostat, New York, NY USA; [Hesdorffer, Dale C.] Columbia Univ, Dept Epidemiol, New York, NY USA; [Timmons, Shelly D.] Geisinger Med Ctr, Dept Neurosurg, Danville, PA 17822 USA; [Jallo, Jack] Thomas Jefferson Univ, Div Neurotrauma & Crit Care, Philadelphia, PA 19107 USA; [Eisenberg, Howard] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Hart, Tessa] Moss Rehabil Res Inst, Philadelphia, PA USA; [Ricker, Joseph H.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Rockville, MD USA; [Merchant, Randall E.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Zafonte, RD (corresponding author), Harvard Univ, Spaulding Rehabil Hosp Network, Sch Med, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.	rzafonte@partners.org		Diaz-Arrastia, Ramon/0000-0001-6051-3594; Jallo, Jack/0000-0002-5512-1729; Ricker, Joseph/0000-0003-3415-991X	National Institute of Child Health and Human Development at Temple University [U01HD042738]; National Institute of Child Health and Human Development at University of Alabama at Birmingham [U01HD042687]; National Institute of Child Health and Human Development at University of Maryland [U01HD042736]; National Institute of Child Health and Human Development at University of Pittsburgh [U01HD042678]; National Institute of Child Health and Human Development at University of Tennessee Health Sciences Center [U01HD042686]; National Institute of Child Health and Human Development at University of Texas Southwestern [U01HD042652]; National Institute of Child Health and Human Development grants at University of Washington [U01HD042653]; National Institute of Child Health and Human Development grants at Virginia Commonwealth University [U01HD042689]; National Institute of Child Health and Human Development grants at Columbia University [Columbia University (U01HD042823]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042823, U01HD042686, U01HD042687, U01HD042738, U01HD042736, U01HD042653, U01HD042678, U01HD042689] Funding Source: NIH RePORTER	This study was supported by National Institute of Child Health and Human Development grants at the following institutions: Temple University (U01HD042738); University of Alabama at Birmingham (U01HD042687); University of Maryland (U01HD042736); University of Pittsburgh (U01HD042678); University of Tennessee Health Sciences Center (U01HD042686); University of Texas Southwestern (U01HD042652); University of Washington (U01HD042653); Virginia Commonwealth University (U01HD042689); and Columbia University (U01HD042823). Ferrer Grupo provided the citicoline and identical placebo used in the study.	Adibhatla RM, 2002, J NEUROSCI RES, V70, P133, DOI 10.1002/jnr.10403; Alexandrov A V, 2001, Curr Opin Investig Drugs, V2, P1757; Arenth PM, 2011, PM&R, V3, pS123, DOI 10.1016/j.pmrj.2011.03.012; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; COHADON F, 1982, NEUROCHIRURGIE, V28, P287; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Delis DC, 2000, CALIFORNIA VERBAL LE; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hernandez AV, 2005, NEUROSURGERY, V57, P1244, DOI 10.1227/01.NEU.0000186039.57548.96; Kelso ML, 2011, PROG MOL BIOL TRANSL, V98, P85, DOI 10.1016/B978-0-12-385506-0.00003-X; KENNEDY EP, 1956, J BIOL CHEM, V222, P185; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Little RJA, 1987, STAT ANAL MISSING DA; LoBello S, 2003, ARCH PHYS MED REHAB, V84, pA9; LOZANO R, 1991, J NEUROL SCI, V103, pS43; MALDONADO VC, 1991, J NEUROL SCI, V103, pS15; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Pocock SJ, 1997, CONTROL CLIN TRIALS, V18, P530, DOI 10.1016/S0197-2456(97)00008-1; Reitan R. M., 1992, TRAIL MAKING TEST MA; REITAN RM, 1993, HALSTEAD REITH NEURO; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rubin D.B., 1997, MULTIPLE IMPUTATION; Secades JJ, 2011, REV NEUROLOGIA, V52, pS1, DOI 10.33588/rn.52S02.2010787; Team RDC, 2008, R LANG ENV STAT COMP; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; 2000, J NEUROTRAUMA, V17, P457	40	90	93	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2012	308	19					1993	2000		10.1001/jama.2012.13256			8	Medicine, General & Internal	General & Internal Medicine	040AQ	WOS:000311291400023	23168823	Bronze			2021-06-18	
J	Brenner, M; Stein, D; Hu, P; Kufera, J; Wooford, M; Scalea, T				Brenner, Megan; Stein, Deborah; Hu, Peter; Kufera, Joseph; Wooford, Matthew; Scalea, Thomas			Association Between Early Hyperoxia and Worse Outcomes After Traumatic Brain Injury	ARCHIVES OF SURGERY			English	Article							SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; CEREBRAL METABOLISM; OXYGENATION; HYPOXIA	Objective: To investigate the relationship between oxygenation and short-term outcomes in patients with traumatic brain injury (TBI). Design: Logistic regression analysis was used to determine whether average high (>200mmHg) or low (<100 mm Hg) PaO2 levels within the first 24 hours of hospital admission correlated with patient outcomes relative to patients with average PaO2 levels between 100 and 200 mm Hg. Setting: Level 1 trauma center. Patients: We retrospectively reviewed 1547 consecutive patients with severe TBI who survived past 12 hours after hospital admission. Main Outcome Measures: We measured mortality, intensive care unit length of stay, hospital length of stay, and discharge Glasgow Coma Scale (GCS) score. Results: Of the 1547 patients, 77% were male and 89% sustained blunt trauma. Mean (SD) age, admission GCS score, and Injury Severity Score were 41.3(20.6) years, 8.3(4.7), and 31.9(12.5), respectively. Mean (SD) intensive care unit length of stay and hospital length of stay were 8.7(10.5) days and 13.8(13.7) days, respectively. Mean (SD) discharge GCS score was 10.1(4.7). The mortality rate was 28%. After controlling for age, sex, Injury Severity Score, mechanism of injury, and admission GCS score, patients with high PaO2 levels had significantly higher mortality and lower discharge GCS scores than patients with a normal PaO2 (P < .05). Patients with low PaO2 levels also had increased mortality (P < .05). Conclusions: Hyperoxia within the first 24 hours of hospitalization is associated with worse short-term functional outcomes and higher mortality after TBI. Although the mechanism for this has not been completely elucidated, it may involve hyperoxia-induced oxygenfree radical toxicity with or without vasoconstriction. Hyperoxia and hypoxia were found to be equally detrimental to short-term outcomes in patients with TBI. A narrower therapeutic window for oxygenation may improve mortality and functional outcomes.	[Brenner, Megan; Stein, Deborah; Hu, Peter; Kufera, Joseph; Wooford, Matthew; Scalea, Thomas] Univ Maryland, Sch Med, Div Trauma & Surg Crit Care, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA	Brenner, M (corresponding author), Univ Maryland, Med Ctr, Div Crit Care Program Trauma, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	mbrenner@umm.edu		Stein, Deborah/0000-0003-3683-3963	US Department of DefenseUnited States Department of Defense [W81XWH-07-2-0118, FA8650-11-2-6D01]	This research was funded in part by grants W81XWH-07-2-0118 and FA8650-11-2-6D01 from the US Department of Defense.	Ahn Edward S, 2005, Clin Neurosurg, V52, P348; BISSONNETTE B, 1991, CAN J ANAESTH, V38, P654, DOI 10.1007/BF03008204; Bostek C C, 1989, AANA J, V57, P231; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Li J, 2004, FREE RADICAL BIO MED, V36, P1460, DOI 10.1016/j.freeradbiomed.2004.03.005; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Rangel-Castilla L, 2010, J NEUROTRAUM, V27, P1853, DOI 10.1089/neu.2010.1339; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; SAHUQUILLO J, 1993, ACTA NEUROCHIR, V122, P204, DOI 10.1007/BF01405530; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029	21	90	91	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	NOV	2012	147	11					1042	1046		10.1001/archsurg.2012.1560			5	Surgery	Surgery	055EG	WOS:000312397400014	22801994	Bronze			2021-06-18	
J	Reger, ML; Poulos, AM; Buen, F; Giza, CC; Hovda, DA; Fanselow, MS				Reger, Maxine L.; Poulos, Andrew M.; Buen, Floyd; Giza, Christopher C.; Hovda, David A.; Fanselow, Michael S.			Concussive Brain Injury Enhances Fear Learning and Excitatory Processes in the Amygdala	BIOLOGICAL PSYCHIATRY			English	Article						Concussion; fear conditioning; GAD-67; NMDA; PTSD; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; LATERAL FLUID PERCUSSION; RIGHT PARIETAL CORTEX; CONDITIONED FREEZING DEFICIT; MILD TRAUMATIC LESION; BASOLATERAL AMYGDALA; POTENTIATED STARTLE; COGNITIVE FUNCTION; GABA(A) RECEPTOR; DELTA-SUBUNIT	Background: Mild traumatic brain injury (cerebral concussion) results in cognitive and emotional dysfunction. These injuries are a significant risk factor for the development of anxiety disorders, including posttraumatic stress disorder. However, because physically traumatic events typically occur in a highly emotional context, it is unknown whether traumatic brain injury itself is a cause of augmented fear and anxiety. Methods: Rats were trained with one of five fear-conditioning procedures (n = 105) 2 days after concussive brain trauma. Fear learning was assessed over subsequent days and chronic changes in fear learning and memory circuitry were assessed by measuring N-methyl-D-aspartate receptor subunits and glutamic acid decarboxylase, 67 kDa isoform protein levels in the hippocampus and basolateral amygdala complex (BLA). Results: Injured rats exhibited an overall increase in fear conditioning, regardless of whether fear was retrieved via discrete or contextual-spatial stimuli. Moreover, injured rats appeared to overgeneralize learned fear to both conditioned and novel stimuli. Although no gross histopathology was evident, injury resulted in a significant upregulation of excitatory N-methyl-D-aspartate receptors in the BLA. There was a trend toward decreased gamma-aminobutyric acid-related inhibition (glutamic acid decarboxylase, 67 kDa isoform) in the BLA and hippocampus. Conclusions: These results suggest that mild traumatic brain injury predisposes the brain toward heightened fear learning during stressful postinjury events and provides a potential molecular mechanism by which this occurs. Furthermore, these data represent a novel rodent model that can help advance the neurobiological and therapeutic understanding of the comorbidity of posttraumatic stress disorder and traumatic brain injury.	[Reger, Maxine L.; Poulos, Andrew M.; Fanselow, Michael S.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Reger, Maxine L.; Giza, Christopher C.; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Univ Calif Los Angeles Neurotrauma Lab, Los Angeles, CA 90095 USA; [Fanselow, Michael S.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Dept Pediat, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA; [Buen, Floyd] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	Fanselow, MS (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	fanselow@ucla.edu			University of California at Los Angeles Brain Injury Research Center; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1PO1NS058489, 1RO1NS27544, RC1MH088184, KO2NS057420]; Department of DefenseUnited States Department of Defense [DR080372]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RC1MH088184, R01MH062122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489, K02NS057420, R01NS027544] Funding Source: NIH RePORTER	This research was supported by the University of California at Los Angeles Brain Injury Research Center, National Institutes of Health Grants 1PO1NS058489 (DAH), 1RO1NS27544 (DAH), RC1MH088184 (MSF), and KO2NS057420 (CCG) and the Department of Defense Grant DR080372 (CCG).	Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Centers for Disease Control and Prevention, TRAUM BRAIN INJ; Cordero MI, 1998, BEHAV NEUROSCI, V112, P885, DOI 10.1037/0735-7044.112.4.885; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; Crestani F, 2002, P NATL ACAD SCI USA, V99, P8980, DOI 10.1073/pnas.142288699; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Ehrlich I, 2009, NEURON, V62, P757, DOI 10.1016/j.neuron.2009.05.026; FANSELOW MS, 1979, B PSYCHONOMIC SOC, V14, P88; FANSELOW MS, 1994, BEHAV NEUROSCI, V108, P210, DOI 10.1037/0735-7044.108.1.210; Fendt M, 1999, NEUROSCI BIOBEHAV R, V23, P743, DOI 10.1016/S0149-7634(99)00016-0; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Foa E.B., 2006, PATHOLOGICAL ANXIETY; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gale GD, 2004, J NEUROSCI, V24, P3810, DOI 10.1523/JNEUROSCI.4100-03.2004; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Godsil BP, 1997, ANN M SOC NEUR OCT 2, P1612; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Jacobs NS, 2010, J NEUROSCI METH, V190, P235, DOI 10.1016/j.jneumeth.2010.04.029; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim JJ, 2006, NEUROSCI BIOBEHAV R, V30, P188, DOI 10.1016/j.neubiorev.2005.06.005; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Liu GS, 2004, NAT NEUROSCI, V7, P373, DOI 10.1038/nn1206; Makkar SR, 2010, NEUROPSYCHOPHARMACOL, V35, P1625, DOI 10.1038/npp.2010.53; Maren S, 1998, J NEUROSCI, V18, P3088; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Orr SP, 2000, J ABNORM PSYCHOL, V109, P290, DOI 10.1037//0021-843X.109.2.290; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAND Corporation Center for Military Health Policy Research, 2008, MG720CCF RAND CORP C; Rau V, 2005, NEUROSCI BIOBEHAV R, V29, P1207, DOI 10.1016/j.neubiorev.2005.04.010; Rodrigues SM, 2001, J NEUROSCI, V21, P6889; Rothbaum BO, 2001, J TRAUMA STRESS, V14, P283, DOI 10.1023/A:1011160800958; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shin RM, 2006, NEURON, V52, P883, DOI 10.1016/j.neuron.2006.10.010; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; Stam R, 2007, NEUROSCI BIOBEHAV R, V31, P558, DOI 10.1016/j.neubiorev.2007.01.001; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Walker DL, 2008, LEARN MEMORY, V15, P67, DOI 10.1101/lm.798908; Wiltgen BJ, 2005, LEARN MEMORY, V12, P327, DOI 10.1101/lm.89705; Wiltgen BJ, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.037.2009; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	57	90	92	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	FEB 15	2012	71	4					335	343		10.1016/j.biopsych.2011.11.007			9	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	879FJ	WOS:000299314800012	22169439	Green Accepted			2021-06-18	
J	Spikman, JM; Timmerman, ME; Milders, MV; Veenstra, WS; van der Naalt, J				Spikman, Jacoba M.; Timmerman, Marieke E.; Milders, Maarten V.; Veenstra, Wencke S.; van der Naalt, Joukje			Social Cognition Impairments in Relation to General Cognitive Deficits, Injury Severity, and Prefrontal Lesions in Traumatic Brain Injury Patients	JOURNAL OF NEUROTRAUMA			English	Article						emotion recognition; injury severity; prefrontal lesions; social cognition; traumatic brain injury	EMOTION PERCEPTION DEFICITS; GLASGOW COMA SCALE; CLOSED-HEAD INJURY; CEREBRAL CONTUSIONS; MIND IMPAIRMENTS; FRONTAL-CORTEX; RECOGNITION; PREDICTION; NEUROBIOLOGY; ATTENTION	Impairments in social behavior are frequently found in moderate to severe traumatic brain injury (TBI) patients and are associated with an unfavorable outcome with regard to return to work and social reintegration. Neuropsychological tests measuring aspects of social cognition are thought to be sensitive to these problems. However, little is known about the effect of general cognitive problems on these tests, nor about their sensitivity to injury severity and frontal lesions. In the present study 28 chronic TBI patients with a moderate to severe TBI were assessed with tests for social cognition (emotion recognition, Theory of Mind, and empathy), and for general, non-social cognition (memory, mental speed, attention, and executive function). The patients performed significantly worse than healthy controls on all measures, with the highest effect size for the emotion recognition test, the Facial Expressions of Emotion-Stimuli and Tests (FEEST). Correlation analyses yielded no significant (partial) correlations between social and non-social cognition tests. Consequently, poor performance on social cognition tests was not due to general cognitive deficits. In addition, the emotion recognition test was the only measure that was significantly related to post-traumatic amnesia (PTA) duration, Glasgow Coma Scale (GCS) score, and the presence of prefrontal lesions. Hence, we conclude that social cognition tests are a valuable supplement to a standard neuropsychological examination, and we strongly recommend the incorporation of measurements of social cognition in clinical practice. Preferably, a broader range of social cognition tests would be applied, since our study demonstrated that each of the measures represents a unique aspect of social cognition, but if capacity is limited, at least a test for emotion recognition should be included.	[Spikman, Jacoba M.] Dept Clin & Dev Neuropsychol, Groningen, Netherlands; [Timmerman, Marieke E.] Dept Psychometr & Stat, Groningen, Netherlands; [Timmerman, Marieke E.] Univ Groningen, NL-9700 AB Groningen, Netherlands; [Spikman, Jacoba M.; Veenstra, Wencke S.; van der Naalt, Joukje] Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Milders, Maarten V.] Univ Aberdeen, Sch Psychol, Aberdeen AB9 1FX, Scotland	Spikman, JM (corresponding author), Univ Med Ctr Groningen, Dept Clin Neuropsychol, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.m.spikman@rug.nl		Spikman, Jacoba/0000-0002-6477-0763			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Ahmed S, 2000, BRAIN INJURY, V14, P765; Allain P, 2005, BRAIN COGNITION, V57, P4, DOI 10.1016/j.bandc.2004.08.011; Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Baddeley A, 1998, CURR OPIN NEUROBIOL, V8, P234, DOI 10.1016/S0959-4388(98)80145-1; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Beer JS, 2006, BRAIN RES, V1079, P98, DOI 10.1016/j.brainres.2006.01.002; Beer JS, 2006, BRAIN RES, V1079, P1, DOI 10.1016/j.brainres.2006.02.001; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blair RJR, 2003, PHILOS T R SOC B, V358, P561, DOI 10.1098/rstb.2002.1220; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Cummings JL, 1995, ANN NY ACAD SCI, V769, P1, DOI 10.1111/j.1749-6632.1995.tb38127.x; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; Deelman B, 1980, NEUROPSYCHOLOGIE NED; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Enticott PG, 2008, NEUROPSYCHOLOGIA, V46, P2851, DOI 10.1016/j.neuropsychologia.2008.04.022; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Frith U, 2010, PHILOS T R SOC B, V365, P165, DOI 10.1098/rstb.2009.0160; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gallese V, 2004, TRENDS COGN SCI, V8, P396, DOI 10.1016/j.tics.2004.07.002; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Howard MA, 2003, BRAIN RES PROTOC, V10, P125, DOI 10.1016/S1385-299X(02)00202-7; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Keysers C, 2006, PROG BRAIN RES, V156, P379, DOI 10.1016/S0079-6123(06)56021-2; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lichter DC, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P260; Mah LWY, 2005, J NEUROPSYCH CLIN N, V17, P66, DOI 10.1176/appi.neuropsych.17.1.66; Mathersul D, 2009, J CLIN EXP NEUROPSYC, V31, P278, DOI 10.1080/13803390802043619; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Mendez MF, 2009, CNS SPECTRUMS, V14, P608, DOI 10.1017/S1092852900023853; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Naqvi N, 2006, ORBITOFRONTAL CORTEX, P325; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Repovs G, 2006, NEUROSCIENCE, V139, P5, DOI 10.1016/j.neuroscience.2005.12.061; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Rudebeck PH, 2008, COGN AFFECT BEHAV NE, V8, P485, DOI 10.3758/CABN.8.4.485; Ruffman T, 2008, NEUROSCI BIOBEHAV R, V32, P863, DOI 10.1016/j.neubiorev.2008.01.001; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Salthouse TA, 2007, BRAIN COGNITION, V63, P279, DOI 10.1016/j.bandc.2006.09.006; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; SPSS, 2009, STAT PACK SOC SCI; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Young A., 2002, FACIAL EXPRESSIONS E	91	90	93	1	81	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					101	111		10.1089/neu.2011.2084			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300012	21933011				2021-06-18	
J	Kanno, H; Ozawa, H; Sekiguchi, A; Yamaya, S; Itoi, E				Kanno, Haruo; Ozawa, Hiroshi; Sekiguchi, Akira; Yamaya, Seiji; Itoi, Eiji			Induction of Autophagy and Autophagic Cell Death in Damaged Neural Tissue After Acute Spinal Cord Injury in Mice	SPINE			English	Article						spinal cord injury; autophagy; LC3; apoptosis; autophagic cell death	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; UP-REGULATION; MONITORING AUTOPHAGY; APOPTOSIS; RAPAMYCIN; BECLIN-1; NEURODEGENERATION; ACTIVATION; DISEASE	Study Design. Expression of light chain 3 (LC3), a characteristic marker of autophagy, was examined by immunohistochemistry and Western blot using a spinal cord injury (SCI) model in mice. Electron microscopic analysis was also performed to examine the anatomic formation of autophagy and autophagic cell death in the injured spinal cord. Objective. To examine both biochemically and anatomically the activity of autophagy in the damaged neural tissue after SCI. Summary of Background Data. Autophagy is the bulk degradation of intracellular proteins and organelles, and it is involved in a number of diseases. Autophagy can lead to nonapoptotic programmed cell death, which is called autophagic cell death. Recent researches have revealed the increased expression of LC3 and the anatomic formation of autophagy and autophagic cell death in damaged tissues of various disease models. However, previous studies have focused on apoptotic process but not autophagic activity as mechanism of neural tissue damage after SCI. To date, there has been no study to examine the expression of LC3 and the anatomic formation of autophagy after SCI. Methods. The spinal cord was hemitransected at T10 in adult female C57BL/6J mice. The LC3 expression was examined by immunohistochemistry and Western blot. The anatomic formation of autophagic activity was investigated using electron microscopy. Results. Immunohistochemistry showed that the number of the LC3-positive cells significantly increased at the lesion site after hemisection. The increase of LC3-positive cells was observed from 4 hours and peaked at 3 days, and it lasted for at least 21 days after hemisection. The LC3-positive cells were observed in neurons, astrocytes, and oligodendrocytes. Western blot analysis demonstrated that the level of LC3-II protein expression significantly increased in the injured spinal cord. Electron microscopy showed the formation of autophagic vacuoles to increase in the damaged cells. Furthermore, the nuclei in the transferase-mediated dUTP nick end labeling-positive cells expressed LC3 were round, which is consistent with autophagic cell death, and they were neither shrunken nor fragmented as is observed in apoptotic nuclei. Conclusion. This study suggested both biochemically and anatomically that autophagy was clearly activated and autophagic cell death was induced in the damaged neural tissue after SCI.	[Kanno, Haruo] Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Kanno, Haruo] Univ Miami, Miami Project Cure Paralysis, Coral Gables, FL 33124 USA	Kanno, H (corresponding author), Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808574, Japan.	kanno-h@isis.ocn.ne.jp	Kanno, Haruo/AAA-2187-2020	Kanno, Haruo/0000-0003-1985-2257	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [19591712]; Japan Orthopaedics and Traumatology Foundation, Inc. [0138]; The General insurance Association of Japan; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23592153] Funding Source: KAKEN	Supported by Grant-in-Aid for Scientific Research (19591712) from Japan Society for the Promotion of Science, by Japan Orthopaedics and Traumatology Foundation, Inc. (No. 0138), and by Grant in 2007 from The General insurance Association of Japan.	Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Calle E, 1999, ACTA NEUROPATHOL, V97, P143, DOI 10.1007/s004010050967; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dong HX, 2003, J NEUROSCI, V23, P8682; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11179, DOI 10.1073/pnas.93.20.11179; Kanno H, 2009, AUTOPHAGY, V5, P390, DOI 10.4161/auto.5.3.7724; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Krysko DV, 2008, METHOD ENZYMOL, V442, P307, DOI [10.1016/S0076-6879(08)01416-X, 10.1016/S0070-6879(08)01416-X]; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Lee SJ, 2009, GLIA, V57, P1351, DOI 10.1002/glia.20854; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Suzuki C, 2008, BIOCHEM BIOPH RES CO, V368, P100, DOI 10.1016/j.bbrc.2008.01.059; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Uchiyama Y, 2008, AUTOPHAGY, V4, P404, DOI 10.4161/auto.5598; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	42	90	100	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	OCT 15	2011	36	22					E1427	E1434		10.1097/BRS.0b013e3182028c3a			8	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	833IP	WOS:000295877800001	21304420				2021-06-18	
J	Cheng, D; Jenner, AM; Shui, GH; Cheong, WF; Mitchell, TW; Nealon, JR; Kim, WS; McCann, H; Wenk, MR; Halliday, GM; Garner, B				Cheng, Danni; Jenner, Andrew M.; Shui, Guanghou; Cheong, Wei Fun; Mitchell, Todd W.; Nealon, Jessica R.; Kim, Woojin S.; McCann, Heather; Wenk, Markus R.; Halliday, Glenda M.; Garner, Brett			Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex	PLOS ONE			English	Article							LEWY BODY DISEASE; APOLIPOPROTEIN-D EXPRESSION; TANDEM MASS-SPECTROMETRY; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; LIVER X RECEPTORS; ALPHA-SYNUCLEIN; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA	Background: We present a lipidomics analysis of human Parkinson's disease tissues. We have focused on the primary visual cortex, a region that is devoid of pathological changes and Lewy bodies; and two additional regions, the amygdala and anterior cingulate cortex which contain Lewy bodies at different disease stages but do not have as severe degeneration as the substantia nigra. Methodology/Principal Findings: Using liquid chromatography mass spectrometry lipidomics techniques for an initial screen of 200 lipid species, significant changes in 79 sphingolipid, glycerophospholipid and cholesterol species were detected in the visual cortex of Parkinson's disease patients (n = 10) compared to controls (n = 10) as assessed by two-sided unpaired t-test (p-value <0.05). False discovery rate analysis confirmed that 73 of these 79 lipid species were significantly changed in the visual cortex (q-value < 0.05). By contrast, changes in 17 and 12 lipid species were identified in the Parkinson's disease amygdala and anterior cingulate cortex, respectively, compared to controls; none of which remained significant after false discovery rate analysis. Using gas chromatography mass spectrometry techniques, 6 out of 7 oxysterols analysed from both non-enzymatic and enzymatic pathways were also selectively increased in the Parkinson's disease visual cortex. Many of these changes in visual cortex lipids were correlated with relevant changes in the expression of genes involved in lipid metabolism and an oxidative stress response as determined by quantitative polymerase chain reaction techniques. Conclusions/Significance: The data indicate that changes in lipid metabolism occur in the Parkinson's disease visual cortex in the absence of obvious pathology. This suggests that normalization of lipid metabolism and/or oxidative stress status in the visual cortex may represent a novel route for treatment of non-motor symptoms, such as visual hallucinations, that are experienced by a majority of Parkinson's disease patients.	[Cheng, Danni; Kim, Woojin S.; McCann, Heather; Halliday, Glenda M.; Garner, Brett] Neurosci Res Australia, Sydney, NSW, Australia; [Jenner, Andrew M.; Shui, Guanghou; Cheong, Wei Fun; Wenk, Markus R.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Shui, Guanghou] Natl Univ Singapore, Inst Life Sci, Singapore 117548, Singapore; [Mitchell, Todd W.] Univ Wollongong, Sch Hlth Sci, Wollongong, NSW, Australia; [Mitchell, Todd W.; Garner, Brett] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Nealon, Jessica R.] Univ Wollongong, Sch Chem, Wollongong, NSW, Australia; [Kim, Woojin S.; Halliday, Glenda M.] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Wenk, Markus R.] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Garner, Brett] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia	Cheng, D (corresponding author), Neurosci Res Australia, Sydney, NSW, Australia.	brettg@uow.edu.au	jenner, andrew M/H-4791-2016; Mitchell, Todd/G-7044-2012; Halliday, Glenda M/E-8555-2011; Wenk, Markus Rene/D-1441-2014; McCann, Heather/I-3815-2012	jenner, andrew M/0000-0003-1767-2033; Mitchell, Todd/0000-0002-1372-9963; Halliday, Glenda M/0000-0003-0422-8398; McCann, Heather/0000-0002-8474-8969; Shui, Guanghou/0000-0002-1621-9643	Australian Brain Foundation; Australian Research CouncilAustralian Research Council; Singapore National Research FoundationNational Research Foundation, Singapore [2007-04]; Biomedical Research Council of SingaporeAgency for Science Technology & Research (ASTAR) [R-183-000-211-305]; National Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [R-183-000-224-213]; SystemsX.ch RTD project LipidX; Neuroscience Research Australia; University of New South Wales; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia; University of SydneyUniversity of Sydney; Schizophrenia Research Institute; National Institute of Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	DC is supported by a PhD scholarship from the Australian Brain Foundation. GH and BG are Fellows of the NHMRC. BG holds an Australian Research Council Future Fellowship. Work at the NUS lipidomics laboratory (MRW) is supported by grants from the Singapore National Research Foundation under CRP Award No. 2007-04, the Biomedical Research Council of Singapore (R-183-000-211-305), the National Medical Research Council (R-183-000-224-213) and the SystemsX.ch RTD project LipidX. The Sydney Brain Bank is supported by Neuroscience Research Australia, the University of New South Wales and the National Health and Medical Research Council of Australia (NHMRC). The NSW Tissue Resource Centre is supported by the University of Sydney, the NHMRC, the Schizophrenia Research Institute and the National Institute of Alcohol Abuse and Alcoholism. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bar-On P, 2008, J NEUROCHEM, V105, P1656, DOI 10.1111/j.1471-4159.2008.05254.x; Barcelo-Coblijn G, 2007, J NEUROCHEM, V101, P132, DOI 10.1111/j.1471-4159.2006.04348.x; Barnes J, 2001, J NEUROL NEUROSUR PS, V70, P727, DOI 10.1136/jnnp.70.6.727; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bosco DA, 2006, NAT CHEM BIOL, V2, P249, DOI 10.1038/nchembio782; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Bras J, 2008, FEBS J, V275, P5767, DOI 10.1111/j.1742-4658.2008.06709.x; Brown AJ, 2009, MOL ASPECTS MED, V30, P111, DOI 10.1016/j.mam.2009.02.005; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Burke RE, 2008, ANN NEUROL, V64, P485, DOI 10.1002/ana.21541; Caesar R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011525; Cartagena CM, 2010, BRAIN RES, V1319, P1, DOI 10.1016/j.brainres.2009.12.080; Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08; Cheng D, 2008, NEUROREPORT, V19, P1685, DOI 10.1097/WNR.0b013e32831578b2; DAMIER P, 1993, NEUROSCIENCE, V52, P1, DOI 10.1016/0306-4522(93)90175-F; De Haan EH, 2007, NEUROREPORT, V18, P1177, DOI 10.1097/WNR.0b013e32820049d3; Deeley JM, 2008, BBA-MOL CELL BIOL L, V1781, P288, DOI 10.1016/j.bbalip.2008.04.002; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; Dickson DW, 2009, PARKINSONISM RELAT D, V15, pS1, DOI 10.1016/S1353-8020(09)70769-2; Diederich NJ, 2009, NAT REV NEUROL, V5, P331, DOI 10.1038/nrneurol.2009.62; EBERLING JL, 1994, NEUROBIOL AGING, V15, P329, DOI 10.1016/0197-4580(94)90028-0; Elliott DA, 2011, NEUROBIOL AGING, V32, P257, DOI 10.1016/j.neurobiolaging.2009.02.006; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268; Fasano C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000612; Fedorow H, 2005, J NEUROCHEM, V92, P990, DOI 10.1111/j.1471-4159.2004.02975.x; Forsaa EB, 2010, ARCH NEUROL-CHICAGO, V67, P996, DOI 10.1001/archneurol.2010.166; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Graessler J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006261; Guerrera IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007735; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Halliday G, 2002, ACTA NEUROPATHOL, V104, P72, DOI 10.1007/s00401-002-0529-5; Halliday GM, 2010, ANN NY ACAD SCI, V1184, P188, DOI 10.1111/j.1749-6632.2009.05118.x; Halliday GM, 2005, BRAIN, V128, P2654, DOI 10.1093/brain/awh584; Han XL, 2010, BBA-MOL CELL BIOL L, V1801, P774, DOI 10.1016/j.bbalip.2010.01.010; Han XL, 2002, ANAL BIOCHEM, V302, P199, DOI 10.1006/abio.2001.5536; Harding AJ, 2002, BRAIN, V125, P2431, DOI 10.1093/brain/awf251; Hely MA, 2008, MOVEMENT DISORD, V23, P837, DOI 10.1002/mds.21956; Henchcliffe C, 2008, NAT CLIN PRACT NEURO, V4, P600, DOI 10.1038/ncpneuro0924; Heverin M, 2005, J LIPID RES, V46, P1047, DOI 10.1194/jlr.M500024-JLR200; Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200; Holroyd S, 2006, J NEUROPSYCH CLIN N, V18, P402, DOI 10.1176/appi.neuropsych.18.3.402; Hu CX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013318; Huang Q, 2006, CANCER RES, V66, P5807, DOI 10.1158/0008-5472.CAN-06-0077; Ibarretxe-Bilbao N, 2009, MOVEMENT DISORD, V24, pS748, DOI 10.1002/mds.22670; Jellinger KA, 2008, ACTA NEUROPATHOL, V116, P1, DOI 10.1007/s00401-008-0406-y; JENNER P, 1992, ANN NEUROL, V32, pS82, DOI 10.1002/ana.410320714; Kim HJ, 2008, P NATL ACAD SCI USA, V105, P2094, DOI 10.1073/pnas.0711599105; Kim WS, 2009, J NEUROCHEM, V109, P1053, DOI 10.1111/j.1471-4159.2009.06031.x; Kolsch H, 1999, BRAIN RES, V818, P171, DOI 10.1016/S0006-8993(98)01274-8; Kolsch H, 2000, NEUROCHEM INT, V36, P507, DOI 10.1016/S0197-0186(99)00157-6; Le Lay S, 2009, J LIPID RES, V50, P1609, DOI 10.1194/jlr.M800601-JLR200; Lee CYJ, 2009, ANTIOXID REDOX SIGN, V11, P407, DOI [10.1089/ars.2008.2179, 10.1089/ARS.2008.2179]; Lwin A, 2004, MOL GENET METAB, V81, P70, DOI 10.1016/j.ymgme.2003.11.004; Meppelink AM, 2009, BRAIN, V132, P2980, DOI 10.1093/brain/awp223; Mosconi L, 2008, ANN NY ACAD SCI, V1147, P180, DOI 10.1196/annals.1427.007; Neumann J, 2009, BRAIN, V132, P1783, DOI 10.1093/brain/awp044; Obeso JA, 2010, NAT MED, V16, P653, DOI 10.1038/nm.2165; Ordonez C, 2006, HISTOL HISTOPATHOL, V21, P361, DOI 10.14670/HH-21.361; Owen AD, 1996, ANN NY ACAD SCI, V786, P217, DOI 10.1111/j.1749-6632.1996.tb39064.x; Power JHT, 2009, ACTA NEUROPATHOL, V117, P63, DOI 10.1007/s00401-008-0438-3; Prabhakara JPR, 2008, J NEUROCHEM, V107, P1722, DOI 10.1111/j.1471-4159.2008.05736.x; Ramirez-Ruiz B, 2007, EUR J NEUROL, V14, P750, DOI 10.1111/j.1468-1331.2007.01768.x; Ramirez-Ruiz B, 2008, MOVEMENT DISORD, V23, P2335, DOI 10.1002/mds.22258; Rappley I, 2009, J NEUROCHEM, V111, P15, DOI 10.1111/j.1471-4159.2009.06290.x; Repa JJ, 2007, J NEUROSCI, V27, P14470, DOI 10.1523/JNEUROSCI.4823-07.2007; RUIPEREZ V, 2010, PROG LIPID RES; Sacchetti P, 2009, CELL STEM CELL, V5, P409, DOI 10.1016/j.stem.2009.08.019; Sanchez-Castaneda C, 2010, MOVEMENT DISORD, V25, P615, DOI 10.1002/mds.22873; Sanchez-Mejia RO, 2008, NAT NEUROSCI, V11, P1311, DOI 10.1038/nn.2213; Scholpp J, 2004, J NEUROTRAUM, V21, P667, DOI 10.1089/0897715041269632; Schwab U, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002630; Seet RCS, 2010, FREE RADICAL BIO MED, V48, P560, DOI 10.1016/j.freeradbiomed.2009.11.026; Shui G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011956; Shui GH, 2010, MOL BIOSYST, V6, P1008, DOI 10.1039/b913353d; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; STALLBER.S, 1965, J LIPID RES, V6, P146; STOMMEL A, 1989, MECH AGEING DEV, V48, P1, DOI 10.1016/0047-6374(89)90021-3; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; SVENNERHOLM L, 1994, J NEUROCHEM, V63, P1802; Tong JC, 2010, BRAIN, V133, P172, DOI 10.1093/brain/awp282; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776; Williams DR, 2008, J NEUROL NEUROSUR PS, V79, P652, DOI 10.1136/jnnp.2007.124677; Williams DR, 2005, LANCET NEUROL, V4, P605, DOI 10.1016/S1474-4422(05)70146-0; Wilson RS, 2000, J NEUROL NEUROSUR PS, V69, P172, DOI 10.1136/jnnp.69.2.172; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0	88	90	90	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2011	6	2							e17299	10.1371/journal.pone.0017299			17	Multidisciplinary Sciences	Science & Technology - Other Topics	729EM	WOS:000287931400051	21387008	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Huizinga, M; Smidts, DP				Huizinga, Mariette; Smidts, Diana P.			Age-Related Changes in Executive Function: A Normative Study with the Dutch Version of the Behavior Rating Inventory of Executive Function (BRIEF)	CHILD NEUROPSYCHOLOGY			English	Article						Executive function; Development; Children; Behavior regulation; Metacognition	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; AUTISM SPECTRUM DISORDERS; TRAUMATIC BRAIN-INJURY; INTEGRATIVE THEORY; PREFRONTAL CORTEX; FUNCTION DEFICITS; WORKING-MEMORY; CHILDREN; COGNITION; DIMENSIONS	This study examined age-related change in executive function by using a Dutch translation of the Behavior Rating Inventory of Executive Function (BRIEF; Gioia et al., 2000) that was applied to a normative sample (age range 5-18 years). In addition, we examined the reliability and factorial structures of the Dutch BRIEF. Results with respect to age revealed a decrease in reported executive function problems with increasing age. On the Behavior Regulation Index (BRI), 5- to 8-year-olds showed significantly more executive function problems than 9- to 11-year-olds, as did the 12- to 14-year-olds compared to 15- to 18-year-olds (except on the Shift subscale). On the Metacognition Index, we found that 9- to 11-year-olds differed significantly from 5- to 8-year-olds on the Working Memory subscale. In addition, the current study showed that the internal consistency of the Dutch BRIEF is very high, and that this version of the BRIEF has a high test-retest stability. Item factor analysis confirmed the expected eight common factor model, and factor analysis of the eight test scores confirmed the two-factor model, as proposed by Gioia et al., in the Dutch data.	[Huizinga, Mariette] Univ Amsterdam, Dept Psychol, Dev Psychol Sect, NL-1018 WB Amsterdam, Netherlands	Huizinga, M (corresponding author), Univ Amsterdam, Dept Psychol, Dev Psychol Sect, Roetersstr 15, NL-1018 WB Amsterdam, Netherlands.	m.huizinga@uva.nl		Huizinga, M./0000-0001-7007-8952			Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Amso D, 2006, CURR DIR PSYCHOL SCI, V15, P24, DOI 10.1111/j.0963-7214.2006.00400.x; Anderson PJ, 2004, AUST J PSYCHOL, V56, P156; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Baddeley A. D., 1986, WORKING MEMORY; Best JR, 2009, DEV REV, V29, P180, DOI 10.1016/j.dr.2009.05.002; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Bull R, 2008, COGNITION, V107, P663, DOI 10.1016/j.cognition.2007.07.015; Burden V., 2003, BEHAV ASSESSMENT DYS; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Cronbach LJ, 2004, EDUC PSYCHOL MEAS, V64, P391, DOI 10.1177/0013164404266386; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Happe F, 2006, BRAIN COGNITION, V61, P25, DOI 10.1016/j.bandc.2006.03.004; Heaton R., 1993, WISCONSIN CARD SORTI; Herjanic, 1997, DIAGNOSTIC INTERVIEW; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Joreskog K. G., 1999, LISREL 8 NEW STAT FE, P8; Joreskog KG., 1993, SAGE FOCUS EDITIONS, V154, P294; Kenworthy L, 2008, NEUROPSYCHOL REV, V18, P320, DOI 10.1007/s11065-008-9077-7; Kimberg DY, 1997, CURR DIR PSYCHOL SCI, V6, P185, DOI 10.1111/1467-8721.ep10772959; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lehto JE, 2003, BRIT J DEV PSYCHOL, V21, P59, DOI 10.1348/026151003321164627; Lehto JH, 1996, Q J EXP PSYCHOL-A, V49, P29, DOI 10.1080/027249896392793; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Little TD, 1997, MULTIVAR BEHAV RES, V32, P53, DOI 10.1207/s15327906mbr3201_3; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Marlow N, 2007, PEDIATRICS, V120, P793, DOI 10.1542/peds.2007-0440; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Muthen L. K., 2007, MPLUS USERS GUIDE; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nigg JT, 2005, DEV PSYCHOPATHOL, V17, P785, DOI 10.1017/S0954579405050376; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Nunally J.C., 1994, PSYCHOMETRIC THEORY; Rabbitt P, 2001, EUR J COGN PSYCHOL, V13, P5, DOI 10.1080/09541440042000197; Rothbart MK, 2001, CHILD DEV, V72, P1394, DOI 10.1111/1467-8624.00355; Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23, DOI DOI 10.1002/0470010940; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; Smidts D.P., 2009, BRIEF EXECUTIEVE FUN; STUSS DT, 1995, STRUCTURE FUNCTIONS; Tabacknick B. G., 2001, USING MULTIVARIATE S; Thorell LB, 2008, DEV NEUROPSYCHOL, V33, P536, DOI 10.1080/87565640802101516; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zelazo PD, 2003, MONOGR SOC RES CHILD, V68, P1, DOI 10.1111/j.0037-976X.2003.00261.x	56	90	91	2	57	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.		2011	17	1					51	66	PII 931899940	10.1080/09297049.2010.509715			16	Clinical Neurology	Neurosciences & Neurology	716BK	WOS:000286939700004	21218296	Green Published			2021-06-18	
J	Kovesdi, E; Gyorgy, AB; Kwon, SKC; Wingo, DL; Kamnaksh, A; Long, JB; Kasper, CE; Agoston, DV				Kovesdi, Erzsebet; Gyorgy, Andrea B.; Kwon, Sook-Kyung C.; Wingo, Daniel L.; Kamnaksh, Alaa; Long, Joseph B.; Kasper, Christine E.; Agoston, Denes V.			The effect of enriched environment on the outcome of traumatic brain injury; a behavioral, proteomics, and histological study	FRONTIERS IN NEUROSCIENCE			English	Article						neurogenesis; enriched environment; traumatic brain injury; memory; anxiety; hippocampus; histology; proteomics		De novo hippocampal neurogenesis contributes to functional recovery following traumatic brain injury (TBI). Enriched environment (EEN) can improve the outcome of TBI by positively affecting neurogenesis. Blast induced traumatic brain injury (bTBI) characterized by memory impairment and increased anxiety levels, is a leading cause of chronic disability among soldiers. Using a rodent model of bTBI we asked: (a) whether long-term exposure to EEN after injury can ameliorate behavioral abnormalities and (b) what the effects of EEN are at the molecular and cellular levels and on de novo neurogenesis. We found that housing injured animals in EEN resulted in significantly improved spatial memory while animals in normal housing (NH) showed persistent memory impairment. VEGF and Tau protein but not Interleukin-6 (IL-6) levels were normalized in the dorsal hippocampus (DHC) of EEN rats while all three markers remained elevated in NH rats. Interestingly, after peaking at 6 weeks post-injury, anxiety returned to normal levels at 2 months independent of housing conditions. Housing animals in EEN had no significant effect on VEGF and Tau protein levels in the ventral hippocampus (VHC) and the amygdala (AD). We also found that EEN reduced IL-6 and IFN gamma levels in the VHC; these markers remained elevated following NH. We observed an increase in GFAP and DCX immunoreactivities in the VHC of NH animals at 2 months post-injury. Conversely, injured animals housed in EEN showed no increase in GFAP or DCX immunoreactivity in their VHC. In summary, long-term exposure of injured animals to EEN appears to play a positive role in the restoration of memory functions but not on anxiety, which returned to normal levels after a significant period of time. Cellular and molecular changes in response to EEN appear to be a part of neurogenesis-independent as well as dependent recovery processes triggered by bTBI.	[Kovesdi, Erzsebet; Kasper, Christine E.] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA; [Gyorgy, Andrea B.; Kwon, Sook-Kyung C.; Wingo, Daniel L.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Long, Joseph B.] Walter Reed Army Inst Res, Div Mil Casualty Res, Silver Spring, MD USA	Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu	Kasper, Christine/AAF-2347-2021	Kasper, Christine/0000-0002-7784-2519	VA grant [B5044R]	We thank the Neurotrauma Team (WRAIR) for their technical help during the blast exposures; Dr. David Jacobowitz (USU) for his help in brain micropunch dissections; Ms. Cara Olsen (USU) for her help in statistical analysis; Drs. Neil Grunberg and John Wu (USU) for their input in designing and interpreting the behavioral experiments. The work was supported by VA grant # B5044R.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Aimone JB, 2010, TRENDS COGN SCI, V14, P325, DOI 10.1016/j.tics.2010.04.003; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Barkho BZ, 2006, STEM CELLS DEV, V15, P407, DOI 10.1089/scd.2006.15.407; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Barron KD, 1995, J NEUROL SCI, V134, P57, DOI 10.1016/0022-510X(95)00209-K; Berrocal Y, 2007, J NEUROTRAUM, V24, P1761, DOI 10.1089/neu.2007.0327; Bremner J Douglas, 2007, Expert Rev Neurother, V7, P393, DOI 10.1586/14737175.7.4.393; Briones TL, 2009, J NEUROTRAUM, V26, P613, DOI 10.1089/neu.2008.0707; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buchhold B, 2007, RESTOR NEUROL NEUROS, V25, P467; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cacci E, 2005, J NEUROSCI RES, V80, P789, DOI 10.1002/jnr.20531; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dahlqvist P, 2004, EUR J NEUROSCI, V19, P2288, DOI 10.1111/j.0953-816X.2004.03248.x; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dhanushkodi A, 2007, BEHAV NEUROSCI, V121, P491, DOI 10.1037/0735-7044.121.3.491; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Doll H, 2009, J NEUROTRAUM, V26, P235, DOI 10.1089/neu.2008.0741; Ehninger D, 2003, CEREB CORTEX, V13, P845, DOI 10.1093/cercor/13.8.845; EINON DF, 1980, Q J EXP PSYCHOL, V32, P137, DOI 10.1080/00335558008248239; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fischer FR, 2007, J SPINAL CORD MED, V30, P147, DOI 10.1080/10790268.2007.11753926; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gross C, 2004, NEUROTOX RES, V6, P493, DOI 10.1007/BF03033286; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Harrison FE, 2009, BEHAV BRAIN RES, V198, P247, DOI 10.1016/j.bbr.2008.10.015; Hebb D. O., 1947, AM PSYCHOL, V2, P306, DOI DOI 10.1037/H0028720; Hebb DO., 1949, ORG BEHAV NEUROPSYCH; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; HENKE PG, 1990, BRAIN RES BULL, V25, P691, DOI 10.1016/0361-9230(90)90044-Z; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; JURASKA JM, 1985, BRAIN RES, V333, P73, DOI 10.1016/0006-8993(85)90125-8; JURASKA JM, 1988, BRAIN RES, V450, P1, DOI 10.1016/0006-8993(88)91538-7; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S0006-3223(03)00319-6; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2002, BIPOLAR DISORD, V4, P17, DOI 10.1034/j.1399-5618.2002.40101.x; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kempermann G, 2000, NOVART FDN SYMP, V231, P235; Kempermann G., 2000, NOVART FDN SYMP, V231, P302; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kozorovitskiy Y, 2003, J CLIN EXP NEUROPSYC, V25, P721, DOI 10.1076/jcen.25.5.721.14580; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu QO, 2011, J AFFECT DISORDERS, V128, P309, DOI 10.1016/j.jad.2010.07.007; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mora F, 2007, BRAIN RES REV, V55, P78, DOI 10.1016/j.brainresrev.2007.03.011; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; Mueller FJ, 2005, E SCHERING RES FDN W, V53, P83; Neufeld G, 1999, FASEB J, V13, P9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Paxinos G., 1999, CHEMOARCHITECTONIC A; Pham TM, 1999, BEHAV BRAIN RES, V103, P63, DOI 10.1016/S0166-4328(99)00019-4; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Puurunen K, 2002, REV NEUROSCIENCE, V13, P347; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Salzberg M, 2007, EPILEPSIA, V48, P2079, DOI 10.1111/j.1528-1167.2007.01246.x; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Shum FWF, 2007, LEARN MEMORY, V14, P304, DOI 10.1101/lm.530607; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tashiro A, 2007, J NEUROSCI, V27, P3252, DOI 10.1523/JNEUROSCI.4941-06.2007; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Tischler L, 2006, ANN NY ACAD SCI, V1071, P405, DOI 10.1196/annals.1364.031; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, NEW ENGL J MED, V353, P633; WHISHAW IQ, 1984, BEHAV NEURAL BIOL, V42, P183, DOI 10.1016/S0163-1047(84)91046-X; Wilhelmsen KC, 1999, P NATL ACAD SCI USA, V96, P7120, DOI 10.1073/pnas.96.13.7120; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Woon FL, 2010, PROG NEURO-PSYCHOPH, V34, P1181, DOI 10.1016/j.pnpbp.2010.06.016; Wright RL, 2008, BEHAV BRAIN RES, V187, P41, DOI 10.1016/j.bbr.2007.08.025; Yasuhara T, 2004, EUR J NEUROSCI, V19, P1494, DOI 10.1111/j.1460-9568.2004.03254.x; Yehuda R, 2007, NEURON, V56, P19, DOI 10.1016/j.neuron.2007.09.006; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	124	90	92	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.		2011	5								42	10.3389/fnins.2011.00042			12	Neurosciences	Neurosciences & Neurology	V36GI	WOS:000209200600038	21503146	DOAJ Gold, Green Published			2021-06-18	
J	Singleton, RH; Yan, HQ; Fellows-Mayle, W; Dixon, CE				Singleton, Richard H.; Yan, Hong Q.; Fellows-Mayle, Wendy; Dixon, C. Edward			Resveratrol Attenuates Behavioral Impairments and Reduces Cortical and Hippocampal Loss in a Rat Controlled Cortical Impact Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; contusion; neuroprotection; resveratrol (3,5,4 '-trihydroxystilbene); traumatic brain injury	RED WINE POLYPHENOL; MORRIS WATER MAZE; NF-KAPPA-B; SPINAL-CORD; TRANS-RESVERATROL; COGNITIVE DEFICITS; OXIDATIVE STRESS; INDUCED SEIZURES; PROTECTS; ACTIVATION	Resveratrol (3,5,4'-trihydroxystilbene) is a plant-derived small molecule that is protective against multiple neurological and systemic insults. To date, no studies have explored the potential for resveratrol to provide behavioral protection in adult animals in the setting of traumatic brain injury (TBI). Using 50 male Sprague-Dawley rats, we employed the controlled cortical impact (CCI) model to ascertain whether post-injury administration of resveratrol would reduce the severity of the well-described cognitive and motor deficits associated with the model. Contusion volumes and hippocampal neuronal numbers were also measured to characterize the tissue and neuronal-sparing properties, respectively, of resveratrol. We found that 100 mg/kg, but not 10 mg/kg, of intraperitoneal resveratrol administered after injury provides significant behavioral protection in rats sustaining CCI. Specifically, rodents treated with 100 mg/kg of resveratrol showed improvements in motor performance (beam balance and beam walking) and testing of visuospatial memory (Morris water maze). Behavioral protection was correlated with significantly reduced contusion volumes, preservation of CA1 and CA3 hippocampal neurons, and protection from overt hippocampal loss as a result of incorporation into the overlying cortical contusion in resveratrol-treated animals. Although the mechanisms by which resveratrol mediates its neuroprotection is unclear, the current study adds to the growing literature identifying resveratrol as a potential therapy for human brain injury.	[Singleton, Richard H.; Yan, Hong Q.; Fellows-Mayle, Wendy; Dixon, C. Edward] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.	dixoec@upmc.edu			National Institutes of Health-National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS030318, NS060672]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, R01NS060672, P50NS030318] Funding Source: NIH RePORTER	The authors would like to thank Xiecheng Ma for her help with animal preparation and injury, Sherman Culver and Kristin Macfarlane for their help with animal behavioral testing, and Yue-Fang Chang, Ph.D., for her assistance with statistical analyses. This work was supported by National Institutes of Health-National Institute of Neurological Disorders and Stroke grants NS030318 and NS060672.	[Anonymous], 1996, GUIDE CARE USE LAB A; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Ates O, 2006, ACTA PHARMACOL SIN, V27, P1317, DOI 10.1111/j.1745-7254.2006.00416.x; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Buryanovskyy L, 2004, BIOCHEMISTRY-US, V43, P11417, DOI 10.1021/bi049162o; Chun YJ, 1999, BIOCHEM BIOPH RES CO, V262, P20, DOI 10.1006/bbrc.1999.1152; Ciolino HP, 1998, CANCER RES, V58, P5707; Crowell JA, 2004, TOXICOL SCI, V82, P614, DOI 10.1093/toxsci/kfh263; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dong WP, 2008, J VASC SURG, V48, P709, DOI 10.1016/j.jvs.2008.04.007; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Floreani M, 2003, LIFE SCI, V72, P2741, DOI 10.1016/S0024-3205(03)00179-6; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Freyberger A, 2005, TOXICOL LETT, V155, P1, DOI 10.1016/j.toxlet.2004.06.014; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gupta YK, 2002, PHARMACOLOGY, V65, P170, DOI 10.1159/000058044; Gupta YK, 2002, PHARMACOL BIOCHEM BE, V71, P245, DOI 10.1016/S0091-3057(01)00663-3; Gupta YK, 2001, METHOD FIND EXP CLIN, V23, P241, DOI 10.1358/mf.2001.23.5.662120; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaga S, 2005, J MOL CELL CARDIOL, V39, P813, DOI 10.1016/j.yjmcc.2005.08.003; Kaplan S, 2005, ANN THORAC SURG, V80, P2242, DOI 10.1016/j.athoracsur.2005.05.016; Karlsson J, 2000, J NEUROCHEM, V75, P141, DOI 10.1046/j.1471-4159.2000.0750141.x; Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032; Kline AE, 2001, HEAD TRAUMA, P65; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Li C, 2010, NEUROCHEM INT, V56, P495, DOI 10.1016/j.neuint.2009.12.009; Liu BQ, 2010, BIOCHEM BIOPH RES CO, V391, P778, DOI 10.1016/j.bbrc.2009.11.137; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MOUTON PR, 2002, PRINCIPLES PRACTICES; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Piver B, 2001, TOXICOL LETT, V125, P83, DOI 10.1016/S0378-4274(01)00418-0; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; Viswanathan M, 2005, DEV CELL, V9, P605, DOI 10.1016/j.devcel.2005.09.017; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; West T, 2007, DEV NEUROSCI-BASEL, V29, P363, DOI 10.1159/000105477; Wu Z, 2009, NEUROCHEM RES, V34, P1393, DOI 10.1007/s11064-009-9920-0; Yang YB, 2003, ACTA PHARMACOL SIN, V24, P703; Yu C, 2003, RAPID COMMUN MASS SP, V17, P307, DOI 10.1002/rcm.918	59	90	98	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1091	1099		10.1089/neu.2010.1291			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300012	20560755	Green Published			2021-06-18	
J	Mainwaring, LM; Bisschop, SM; Comper, P; Richards, DW; Hutchison, M				Mainwaring, Lynda M.; Bisschop, Sean M.; Comper, Paul; Richards, Doug W.; Hutchison, Michael			Emotional response to sport concussion compared to ACL injury	BRAIN INJURY			English	Article						Sport concussion; emotional disturbance; profile of mood states; recovery; ACL injury	COLLEGIATE FOOTBALL PLAYERS; COGNITIVE IMPAIRMENT; BETA-ENDORPHIN; HEAD-INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; MILD; DEPRESSION; SYMPTOMS; RECOVERY	Research design: Pre-injury, post-injury and longitudinal emotional functioning of athletes with concussion (n = 16), athletes with ACL injuries (n = 7) and uninjured athletes (n = 28) were compared in a prospective repeated-measures design. Methods and procedures: Participants completed the short version of the Profile of Mood States (POMS). ANOVAs and trend analysis were used to examine between and within group differences across time on two sub-scales, Total Mood Disturbance and Depression. Main outcomes and results: Athletes with ACL injury reported higher levels of depression for a longer duration than athletes with concussion. Relative to un-injured controls, athletes with concussion reported significant changes in Total Mood Disturbance and Depression post-injury, whereas athletes with ACL injuries reported significant changes in Depression scores only. Different patterns of post-injury emotional disturbance for the injured groups were observed by trend analyses. Conclusions: Concussed athletes do not report as much emotional disturbance as athletes with ACL injuries. Differential patterns of emotional disturbance were detected between injured groups. The authors recommended that clinical protocols and educational programmes address emotional sequelae associated with sport concussion and ACL injury.	[Mainwaring, Lynda M.; Richards, Doug W.; Hutchison, Michael] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON M5S 2W6, Canada; [Bisschop, Sean M.; Comper, Paul] Toronto Rehabil Inst, Toronto, ON, Canada	Mainwaring, LM (corresponding author), Univ Toronto, Fac Phys Educ & Hlth, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	lynda.mainwaring@utoronto.ca		Bisschop, Sean/0000-0002-3307-292X			Bechara A, 1999, J NEUROSCI, V19, P5473; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BREWER BW, 1995, CLIN J SPORT MED, V5, P241, DOI 10.1097/00042752-199510000-00006; Brewer BW, 2000, REHABIL PSYCHOL, V45, P20, DOI 10.1037/0090-5550.45.1.20; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CHAN CS, 1988, PERCEPT MOTOR SKILL, V66, P875, DOI 10.2466/pms.1988.66.3.875; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; CHUTE N, 1997, THESIS QUEENS U KING; CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957; DALY JM, 1995, J SPORT REHABIL, V4, P23; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Driver S, 2009, BRAIN INJURY, V23, P203, DOI 10.1080/02699050802695574; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Giza CC, 2001, J ATHL TRAINING, V36, P228; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hoffman P., 1997, PHYS ACTIVITY MENTAL, P163; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jorge R, 2002, NEUROREHABILITATION, V17, P311; KRAEMER WJ, 1993, J APPL PHYSIOL, V74, P450; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mainwaring L, 1999, CAN J REHABIL, V12, P145; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McDonald SA, 1990, SPORT PSYCHOL, V4, P261; MILLER WN, 1998, J APPL SPORT PSYCH S, V10, pS127; Morrey MA, 1999, CLIN J SPORT MED, V9, P63, DOI 10.1097/00042752-199904000-00004; Nixon H.L., 1992, J SPORT SOCIAL ISSUE, V16, P127, DOI [DOI 10.1177/019372359201600208, 10.1177/019372359201600208]; NUNNELY J, 1978, PSYCHOMETRIC THEORY; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pearson L., 1992, PHYSIOTHERAPY, V78, P762, DOI DOI 10.1016/S0031-9406(10)61642-2; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P303; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; ROH J, 1998, J APPL SPORT PSYCH S, V10, pS54; SCHWARZ L, 1990, EUR J APPL PHYSIOL O, V61, P165, DOI 10.1007/BF00357593; SCHWARZ L, 1992, SPORTS MED, V13, P25, DOI 10.2165/00007256-199213010-00003; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9	62	90	90	0	30	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	4					589	597		10.3109/02699051003610508			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	570ML	WOS:000275682300003	20235761				2021-06-18	
J	Williams, C; Wood, RL				Williams, Claire; Wood, Rodger Ll.			Alexithymia and emotional empathy following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						20-Item Toronto Alexithymia Scale; Balanced Emotional Empathy Scale; Traumatic brain injury; Emotional perception; Emotion recognition; Injury severity	HEAD-INJURY; IMPAIRED RECOGNITION; POSTTRAUMATIC AMNESIA; BEHAVIORAL-CHANGES; BILATERAL DAMAGE; DECISION-MAKING; MIND; SCALE; PAIN; FMRI	The frequency of alexithymia and the proportion of cases reporting low emotional empathy after traumatic brain injury (TBI) were compared with a control group. The study also examined the relationship between alexithymia and emotional empathy, controlling for the influence of cognitive ability, severity of head injury, and time since injury. A total of 64 TBI patients and matched controls completed the 20-Item Toronto Alexithymia Scale (TAS-20) and Balanced Emotional Empathy Scale (BEES). The TBI group exhibited a significantly higher frequency of alexithymia (60.9%) and low emotional empathy (64.4%) than did the control group (10.9% and 34.4%). Significant moderate negative correlations were found between TAS-20 and BEES scores, with TAS-20 total scores accounting for a significant amount of variance in BEES scores. However, no significant correlation was obtained between Subscale 1 of the TAS-20 (difficulty identifying feelings) and BEES scores in the TBI group. Additionally, there were no significant relationships between alexithymia, emotional empathy, injury severity, and time since injury. The results suggest an inverse relationship between alexithymia and emotional empathy.	[Williams, Claire; Wood, Rodger Ll.] Swansea Univ, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales	Williams, C (corresponding author), Swansea Univ, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	200528@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X	Brain Injury Rehabilitation Trust, UK	Funding for this research was obtained, in part, from the Brain Injury Rehabilitation Trust, UK.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adolphs R, 2002, J COGNITIVE NEUROSCI, V14, P1264, DOI 10.1162/089892902760807258; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Allerdings MD, 2001, BRAIN COGNITION, V47, P304; Bagby R. M., 1993, ANN M AM PSYCH SOC C; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Berthoz S, 2002, AM J PSYCHIAT, V159, P961, DOI 10.1176/appi.ajp.159.6.961; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Burba B, 2006, CAN J PSYCHIAT, V51, P468, DOI 10.1177/070674370605100709; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Danziger N, 2006, BRAIN, V129, P2494, DOI 10.1093/brain/awl155; Davies M, 1998, J PERS SOC PSYCHOL, V75, P989, DOI 10.1037/0022-3514.75.4.989; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Dougherty DD, 2004, ARCH GEN PSYCHIAT, V61, P795, DOI 10.1001/archpsyc.61.8.795; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; GRATTAN LM, 1994, NEUROPSY NEUROPSY BE, V7, P251; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Guttman H, 2002, COMPR PSYCHIAT, V43, P448, DOI 10.1053/comp.2002.35905; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Heberlein AS, 2008, J COGNITIVE NEUROSCI, V20, P721, DOI 10.1162/jocn.2008.20049; Heberlein AS, 2005, NEUROIMAGE, V28, P770, DOI 10.1016/j.neuroimage.2005.06.064; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; HOGAN R, 1969, J CONSULT CLIN PSYCH, V33, P307, DOI 10.1037/h0027580; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Houtveen JH, 1997, J PSYCHOPHYSIOL, V11, P147; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; KRYSTAL H, 1979, AM J PSYCHOTHER, V33, P17; LAMBERTY GJ, 1995, J NEUROPSYCH CLIN N, V7, P320; Lane RD, 1996, PSYCHOSOM MED, V58, P203, DOI 10.1097/00006842-199605000-00002; Loas G, 2001, J PSYCHOSOM RES, V50, P255, DOI 10.1016/S0022-3999(01)00197-0; Luminet O, 2001, PSYCHOTHER PSYCHOSOM, V70, P254, DOI 10.1159/000056263; Mah LWY, 2005, J NEUROPSYCH CLIN N, V17, P66, DOI 10.1176/appi.neuropsych.17.1.66; Mandal MK, 1999, J NERV MENT DIS, V187, P603, DOI 10.1097/00005053-199910000-00003; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; McDougall J., 1989, THEATRES BODY PSYCHO; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mehrabian A, 1997, AGGRESSIVE BEHAV, V23, P433, DOI 10.1002/(SICI)1098-2337(1997)23:6<433::AID-AB3>3.0.CO;2-H; Mehrabian A, 1997, J PSYCHOL, V131, P101, DOI 10.1080/00223989709603508; Mehrabian A., 2000, MANUAL BALANCED EMOT; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Moriguchi Y, 2007, CEREB CORTEX, V17, P2223, DOI 10.1093/cercor/bhl130; Nummenmaa L, 2008, NEUROIMAGE, V43, P571, DOI 10.1016/j.neuroimage.2008.08.014; PARKER JDA, 1993, EUR J PERSONALITY, V7, P221, DOI 10.1002/per.2410070403; Parker JDA, 2001, PERS INDIV DIFFER, V30, P107, DOI 10.1016/S0191-8869(00)00014-3; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Rastam M, 1997, ACTA PSYCHIAT SCAND, V95, P385, DOI 10.1111/j.1600-0447.1997.tb09650.x; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2007, BRAIN, V130, P1663, DOI 10.1093/brain/awm093; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shuren JE, 2002, ARCH NEUROL-CHICAGO, V59, P916, DOI 10.1001/archneur.59.6.916; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2006, NATURE, V439, P466, DOI 10.1038/nature04271; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Taylor G. J., 1997, DISORDERS AFFECT REG; Taylor G. J., 1987, PSYCHOSOMATIC MED CO; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Wood RL, 2001, NEUROBEHAVIOURAL DIS; WOOD RL, 2006, BRAIN INJURY, V20, P1; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518; Worthington A. D., 2008, PSYCHOL APPROACHES R; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	80	90	91	3	34	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	3					259	267		10.1080/13803390902976940			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	572XY	WOS:000275871900005	19548166				2021-06-18	
J	Galluzzi, L; Morselli, E; Kepp, O; Kroemer, G				Galluzzi, Lorenzo; Morselli, Eugenia; Kepp, Oliver; Kroemer, Guido			Targeting post-mitochondrial effectors of apoptosis for neuroprotection	BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS			English	Article; Proceedings Paper	International Symposium on Mitchondrial Physiology and Pathology	JUN, 2008	Bari, ITALY			Apoptosis-inducing factor (AIF); Caspases; Endonuclease G (EndoG); Ischemia; Omi/HtrA2; Permeability transition pore complex (PTPC); Smac/Diablo	FOCAL CEREBRAL-ISCHEMIA; PERMEABILITY TRANSITION PORE; TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; NEONATAL HYPOXIA-ISCHEMIA; SPINAL-CORD-INJURY; OXYGEN-GLUCOSE DEPRIVATION; CYTOCHROME-C RELEASE; ACTIVATING FACTOR-I; X-LINKED INHIBITOR	Mitochondrial membrane permeabilization (MMP) is commonly regarded as the "point-of-no-return" in the cascade of events that delineate the intrinsic pathway of apoptosis. MMP leads to the functional impairment of mitochondria and to the release into the cytosol of toxic proteins that are normally confined within the mitochondrial intermembrane space. These include direct activators of caspases and caspase-independent effectors of the cell death program. MMP has been implicated in a plethora of pathophysiological settings. In particular, MMP contributes to both the immediate and delayed phases of cell loss that follow acute neuronal injury by ischemia/reperfusion or trauma. Although preventing MMP a priori would be the most desirable therapeutic choice, prophylactic interventions are rarely (if ever) achievable in the treatment of stroke and trauma patients. Conversely, interventions that block the post-mitochondrial phase of apoptosis (if administered within the first few hours after the accident) hold great promises for the development of novel neuroprotective strategies. In animal models of acute neuronal injury, the inhibition of caspases, apoptosis-inducing factor (AIF) and other apoptotic effectors can confer significant neuroprotection. Our review recapitulates the results of these studies and proposes novel strategies of inhibiting post-mitochondrial apoptosis in neurons. (C) 2008 Elsevier B.V. All rights reserved.	[Kroemer, Guido] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; Univ Paris 11, F-94805 Villejuif, France	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Galluzzi, Lorenzo/AAG-6432-2019; KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/K-2709-2012; Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/AAH-3286-2021	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Galluzzi, Lorenzo/0000-0003-2257-8500; 			Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Beere HM, 2000, NAT CELL BIOL, V2, P469; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; BRENNER BM, 2000, J RENIN ANGIOITENS A, V1, P329; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Butcher SP, 1997, J NEUROSCI, V17, P6939; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; David KK, 2006, CELL DEATH DIFFER, V13, P1147, DOI 10.1038/sj.cdd.4401787; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elibol B, 2001, NEUROSCIENCE, V105, P79, DOI 10.1016/S0306-4522(01)00159-2; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Fan YF, 2006, NEUROCHEM INT, V48, P50, DOI 10.1016/j.neuint.2005.07.008; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Galiegue S, 2003, CURR MED CHEM, V10, P1563, DOI 10.2174/0929867033457223; Galluzzi L, 2008, ONCOGENE, V27, P4633, DOI 10.1038/onc.2008.114; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Galluzzi L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000018; Galluzzi L, 2007, NAT CELL BIOL, V9, P487, DOI 10.1038/ncb0507-487; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Genovese T, 2007, SHOCK, V27, P258, DOI 10.1097/01.shk.0000239775.41022.54; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Gill R, 2002, J CEREBR BLOOD F MET, V22, P420, DOI 10.1097/00004647-200204000-00006; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Guan QH, 2006, NEUROSCIENCE, V139, P609, DOI 10.1016/j.neuroscience.2005.11.067; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hetz C, 2005, J BIOL CHEM, V280, P42960, DOI 10.1074/jbc.M505843200; Hisatomi T, 2002, CURR EYE RES, V24, P161, DOI 10.1076/ceyr.24.3.161.8305; Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3; Hisatomi T, 2008, J CLIN INVEST, V118, P2025, DOI 10.1172/JCI34267; Honarpour N, 2001, P NATL ACAD SCI USA, V98, P9683, DOI 10.1073/pnas.171283198; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Joza N, 2005, MOL CELL BIOL, V25, P10261, DOI 10.1128/MCB.25.23.10261-10272.2005; Kalinowska M, 2005, APOPTOSIS, V10, P821, DOI 10.1007/s10495-005-0410-9; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Kermer P, 2000, MOL BRAIN RES, V85, P144, DOI 10.1016/S0169-328X(00)00256-4; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; Kim R, 2005, BIOCHEM BIOPH RES CO, V333, P336, DOI 10.1016/j.bbrc.2005.04.161; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; KROEMER G, 2008, CELL DEATH IN PRESS; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kugler S, 2000, CELL DEATH DIFFER, V7, P815, DOI 10.1038/sj.cdd.4400712; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Lee BI, 2005, NEUROSCI LETT, V386, P23, DOI 10.1016/j.neulet.2005.05.058; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Leonard JR, 2002, J NEUROPATH EXP NEUR, V61, P673, DOI 10.1093/jnen/61.8.673; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; Mondragon L, 2008, J MED CHEM, V51, P521, DOI 10.1021/jm701195j; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Morrison RS, 1996, J NEUROSCI, V16, P1337; Mouw G, 2002, METAB BRAIN DIS, V17, P143, DOI 10.1023/A:1019921904378; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Ness JM, 2006, BRAIN RES, V1099, P150, DOI 10.1016/j.brainres.2006.04.132; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Ota K, 2002, J BIOCHEM, V131, P131, DOI 10.1093/oxfordjournals.jbchem.a003067; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pirianov G, 2007, J CEREBR BLOOD F MET, V27, P1022, DOI 10.1038/sj.jcbfm.9600413; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Plesnila N, 2002, EUR SURG RES, V34, P37, DOI 10.1159/000048885; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rodrigues CMP, 2003, BIOCHEMISTRY-US, V42, P3070, DOI 10.1021/bi026979d; Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ruchalski K, 2006, J BIOL CHEM, V281, P7873, DOI 10.1074/jbc.M513728200; Saito A, 2004, MOL BRAIN RES, V127, P89, DOI 10.1016/j.molbrainres.2004.05.012; Saito A, 2004, STROKE, V35, P1443, DOI 10.1161/01.STR.0000128416.28778.7a; Saito A, 2003, J CEREBR BLOOD F MET, V23, P1010, DOI 10.1097/01.WCB.0000080702.47016.FF; Saleh A, 2000, NAT CELL BIOL, V2, P476; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004; Schulz JB, 1998, CELL DEATH DIFFER, V5, P847, DOI 10.1038/sj.cdd.4400420; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Shibata M, 2002, NEUROREPORT, V13, P1985, DOI 10.1097/00001756-200210280-00031; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siegelin MD, 2005, NEUROCHEM INT, V46, P41, DOI 10.1016/j.neuint.2004.07.009; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Sun HW, 2006, SPECTROSC SPECT ANAL, V26, P950; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Tamura M, 2005, GLIA, V51, P312, DOI 10.1002/glia.20212; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; Vaux DL, 2003, CELL, V115, P251, DOI 10.1016/S0092-8674(03)00851-1; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Verhagen AM, 2001, GENOME BIOL, V2; Verrier F, 2003, ANN NY ACAD SCI, V1010, P126, DOI 10.1196/annals.1299.022; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wang XY, 2004, NEUROBIOL DIS, V16, P179, DOI 10.1016/j.nbd.2004.01.014; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; West T, 2006, NEUROBIOL DIS, V22, P523, DOI 10.1016/j.nbd.2005.12.017; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wu G, 2000, NATURE, V408, P1008; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yamashita D, 2004, NEUROREPORT, V15, P2719; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhang JH, 2003, P NATL ACAD SCI USA, V100, P15782, DOI 10.1073/pnas.2636393100; Zhao H, 2003, J NEUROCHEM, V85, P1026, DOI 10.1046/j.1471-4159.2003.01756.x; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200; Zhu C, 2007, CELL DEATH DIFFER, V14, P775, DOI 10.1038/sj.cdd.4402053; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006	178	90	101	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0005-2728	0006-3002		BBA-BIOENERGETICS	Biochim. Biophys. Acta-Bioenerg.	MAY	2009	1787	5			SI		402	413		10.1016/j.bbabio.2008.09.006			12	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	451MX	WOS:000266475400016	18848916				2021-06-18	
J	O'Connell, RG; Bellgrove, MA; Dockree, PM; Lau, A; Hester, R; Garavan, H; Fitzgerald, M; Foxe, JJ; Robertson, IH				O'Connell, Redmond G.; Bellgrove, Mark A.; Dockree, Paul M.; Lau, Adam; Hester, Robert; Garavan, Hugh; Fitzgerald, Michael; Foxe, John J.; Robertson, Ian H.			The neural correlates of deficient error awareness in attention-deficit hyperactivity disorder (ADHD)	NEUROPSYCHOLOGIA			English	Article						Error awareness; ADHD; ERP; Source analysis; Anterior cingulate cortex	TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE CORTEX; EVENT-RELATED POTENTIALS; MEDIAL FRONTAL-CORTEX; DEFICIT/HYPERACTIVITY DISORDER; FUNCTIONAL-SIGNIFICANCE; ELECTRODERMAL ACTIVITY; SUSTAINED ATTENTION; CHILDREN; PERFORMANCE	The ability to detect and correct errors is critical to adaptive control of behaviour and represents a discrete neuropsychological function. A number of studies have highlighted that attention-deficit hyperactivity disorder (ADHD) is associated with abnormalities in behavioural and neural responsiveness to performance errors. One limitation of previous work has been a failure to determine the extent to which these differences are attributable to failures of conscious error awareness, a process that is dependent on the integrity of the frontal lobes. Recent advances in electrophysiological research make it possible to distinguish unconscious and conscious aspects of error processing. This study constitutes an extensive electrophysiological investigation of error awareness and error processing in ADHD. A Go/No-Go response inhibition task specifically designed to assess error awareness was administered to a group of adults diagnosed with ADHD and a group of matched control participants. The ADHD group made significantly more errors than the control group but was less likely to consciously detect these errors. An analysis of event-related potentials elicited by errors indicated that an early performance monitoring component (early positivity) was significantly attenuated in the ADHD group as was a later component that specifically reflects conscious error processing (Pe). Dipole source modelling suggested that abnormal Pe amplitudes were attributable to decreased activation of the anterior cingulate cortex. Decreased electrodermal activity in the ADHD group also suggested a motivational insensitivity to performance errors. Our data provide evidence that neuropsychological deficits associated with ADHD can be exacerbated by error processing abnormalities. Error awareness may represent an important cognitive and physiological phenotype for ADHD. (c) 2009 Elsevier Ltd. All rights reserved.	[O'Connell, Redmond G.; Dockree, Paul M.; Garavan, Hugh; Robertson, Ian H.] Trinity Coll Dublin, Sch Psychol, Dublin 2, Ireland; [O'Connell, Redmond G.; Dockree, Paul M.; Garavan, Hugh; Robertson, Ian H.] Trinity Coll Dublin, Inst Neurosci, Dublin 2, Ireland; [O'Connell, Redmond G.; Dockree, Paul M.; Foxe, John J.] St Vincents Hosp, Cognit Neurophysiol Lab, Dublin 3, Ireland; [Bellgrove, Mark A.; Hester, Robert] Univ Queensland, Sch Psychol, Cognit Neurosci Lab, Brisbane, Qld, Australia; [Bellgrove, Mark A.; Hester, Robert] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [Lau, Adam; Fitzgerald, Michael] Trinity Coll Dublin, Dept Psychiat, Dublin 2, Ireland; [Foxe, John J.] Nathan S Kline Inst Psychiat Res, Cognit Neurophysiol Lab, Orangeburg, NY 10962 USA; [Foxe, John J.] CUNY City Coll, Dept Psychol, Program Cognit Neurosci, New York, NY 10031 USA	O'Connell, RG (corresponding author), Trinity Coll Dublin, Sch Psychol, Lloyd Bldg, Dublin 2, Ireland.	reoconne@tcd.ie	Hester, Robert/F-2097-2011; Bellgrove, Mark/AAB-3114-2019	Hester, Robert/0000-0003-0982-8026; Foxe, John/0000-0002-4300-3098; Bellgrove, Mark/0000-0003-0186-8349; Robertson, Ian H/0000-0001-8637-561X; O'Connell, Redmond/0000-0001-6949-2793	U.S. National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH65350]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065350] Funding Source: NIH RePORTER	The work reported herein was supported by the Government of Ireland Research Scholarship in the Humanities and Social Sciences to RG O'Connell and is administered by the Irish Research Council for the Humanities and Social Sciences. This work was also supported in part by a grant from the U.S. National Institute of Mental Health (MH65350 to JJF). The authors would like to thank Dr. Sherlyn Yeap and Dr. Simon Kelly for their excellent technical support and all those who participated in this study.	APA, 2000, DIAGN STAT MAN MENT; Barry RJ, 2003, CLIN NEUROPHYSIOL, V114, P184, DOI 10.1016/S1388-2457(02)00363-2; Bechara A, 1999, J NEUROSCI, V19, P5473; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; BERG P, 1994, ELECTROEN CLIN NEURO, V90, P229, DOI 10.1016/0013-4694(94)90094-9; Brazdil M, 2005, J PSYCHOPHYSIOL, V19, P244, DOI 10.1027/0269-8803.19.4.244; Brown JW, 2005, SCIENCE, V307, P1118, DOI 10.1126/science.1105783; Burgio-Murphy A, 2007, BIOL PSYCHOL, V75, P75, DOI 10.1016/j.biopsycho.2006.12.003; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Coles MGH, 2001, BIOL PSYCHOL, V56, P173, DOI 10.1016/S0301-0511(01)00076-X; CONNERS CK, 2003, CORNERS ADULT ADHD R; Critchley HD, 2005, NEUROIMAGE, V27, P885, DOI 10.1016/j.neuroimage.2005.05.047; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Dawson M.E., 2000, HDB PSYCHOPHYSIOLOGY, V2nd; de Bruijn ERA, 2004, PSYCHOPHARMACOLOGY, V177, P151, DOI 10.1007/s00213-004-1915-6; Debener S, 2005, J NEUROSCI, V25, P11730, DOI 10.1523/JNEUROSCI.3286-05.2005; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Falkenstein M., 2004, ERRORS CONFLICTS BRA, P5; Fiehler K, 2004, EUR J NEUROSCI, V19, P3081, DOI 10.1111/j.0953-816X.2004.03414.x; Franken IHA, 2007, BIOL PSYCHOL, V75, P45, DOI 10.1016/j.biopsycho.2006.11.003; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Hajcak G, 2003, PSYCHOPHYSIOLOGY, V40, P895, DOI 10.1111/1469-8986.00107; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hogan AM, 2005, DEVELOPMENTAL SCI, V8, P525, DOI 10.1111/j.1467-7687.2005.00444.x; HOLROYD CB, 2004, COGNITIVE NEUROSCIEN; Jonkman LM, 2007, BIOL PSYCHOL, V76, P217, DOI 10.1016/j.biopsycho.2007.08.004; Lijffijt M, 2005, J ABNORM PSYCHOL, V114, P216, DOI 10.1037/0021-843X.114.2.216; Liotti M, 2005, CORTEX, V41, P377, DOI 10.1016/S0010-9452(08)70274-0; Luu P, 2000, J EXP PSYCHOL GEN, V129, P43, DOI [10.1037/0096-3445.129.1.43, 10.1037//0096-3445.129.1.43]; Mathalon DH, 2002, J ABNORM PSYCHOL, V111, P22, DOI 10.1037//0021-843X.111.1.22; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Morris SE, 2006, J ABNORM PSYCHOL, V115, P239, DOI 10.1037/0021-843X.115.2.239; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nieuwenhuis S, 2007, CEREB CORTEX, V17, P1570, DOI 10.1093/cercor/bhl068; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2004, NEUROREPORT, V15, P2535, DOI 10.1097/00001756-200411150-00021; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; O'Keeffe FM, 2007, BRAIN, V130, P753, DOI 10.1093/brain/awl367; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Overtoom CCE, 2002, BIOL PSYCHIAT, V51, P668, DOI 10.1016/S0006-3223(01)01290-2; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Rubia K, 2005, AM J PSYCHIAT, V162, P1067, DOI 10.1176/appi.ajp.162.6.1067; Ruchsow M, 2006, BIOL PSYCHOL, V72, P133, DOI 10.1016/j.biopsycho.2005.08.006; Ruchsow M, 2005, J PSYCHOPHYSIOL, V19, P298, DOI 10.1027/0269-8803.19.4.298; Schachar RJ, 2004, J ABNORM CHILD PSYCH, V32, P285, DOI 10.1023/B:JACP.0000026142.11217.f2; Seidman LJ, 2006, CLIN PSYCHOL REV, V26, P466, DOI 10.1016/j.cpr.2006.01.004; Seidman LJ, 2005, BIOL PSYCHIAT, V57, P1263, DOI 10.1016/j.biopsych.2004.11.019; Shalgi S, 2007, EXP BRAIN RES, V182, P119, DOI 10.1007/s00221-007-1054-5; Sonuga-Barke EJS, 2003, NEUROSCI BIOBEHAV R, V27, P593, DOI 10.1016/j.neubiorev.2003.08.005; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Tieges Z, 2004, COGNITIVE BRAIN RES, V21, P87, DOI 10.1016/j.cogbrainres.2004.06.001; TURNER GR, 2004, COGNITIVE BEHAV REHA; van Meel CS, 2007, PSYCHIAT RES, V151, P211, DOI 10.1016/j.psychres.2006.05.011; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; Vidal F, 2000, BIOL PSYCHOL, V51, P109, DOI 10.1016/S0301-0511(99)00032-0; Vlamings PHJM, 2008, EUR J NEUROSCI, V28, P399, DOI 10.1111/j.1460-9568.2008.06336.x; WARD MF, 1993, AM J PSYCHIAT, V150, P885; Wiersema JR, 2005, J NEURAL TRANSM, V112, P1417, DOI 10.1007/s00702-005-0276-6; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Woods SP, 2002, CLIN NEUROPSYCHOL, V16, P12, DOI 10.1076/clin.16.1.12.8336; Zahn TP, 1999, NEUROPSYCHOLOGIA, V37, P1227, DOI 10.1016/S0028-3932(99)00020-2; Zirnheld PJ, 2004, J COGNITIVE NEUROSCI, V16, P1098, DOI 10.1162/0898929041502779	69	90	92	2	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	MAR	2009	47	4					1149	1159		10.1016/j.neuropsychologia.2009.01.011			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	423TS	WOS:000264519200022	19350709	Green Published			2021-06-18	
J	Stein, SC; Fabbri, A; Servadei, F; Glick, HA				Stein, Sherman C.; Fabbri, Andrea; Servadei, Franco; Glick, Henry A.			A Critical Comparison of Clinical Decision Instruments for Computed Tomographic Scanning in Mild Closed Traumatic Brain Injury in Adolescents and Adults	ANNALS OF EMERGENCY MEDICINE			English	Article							MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; INTRACRANIAL INJURIES; EMERGENCY-DEPARTMENT; NICE GUIDELINES; CT; RULE; MANAGEMENT; METHODOLOGY; PROPOSAL	Study objective: A number of clinical decision aids have been introduced to limit unnecessary computed tomographic scans in patients with mild traumatic brain injury. These aids differ in the risk factors they use to recommend a scan. We compare the instruments according to their sensitivity and specificity and recommend ones based on incremental benefit of correctly classifying patients as having surgical, nonsurgical, or no intracranial lesions. Methods: We performed a secondary analysis of prospectively collected database from 7,955 patients aged 10 years or older with mild traumatic brain injury to compare sensitivity and specificity of 6 common clinical decision strategies: the Canadian CT Head Rule, the Neurotraumatology Committee of the World Federation of Neurosurgical Societies, the New Orleans, the National Emergency X-Radiography Utilization Study II (NEXUS-II), the National Institute of Clinical Excellence guideline, and the Scandinavian Neurotrauma Committee guideline. Excluded from the database were patients for whom the history of trauma was unclear, the initial Glasgow Coma Scale score was less than 14, the injury was penetrating, vital signs were unstable, or who refused diagnostic tests. Patients revisiting the emergency department within 7 days were counted only once. Results: The percentage of scans that would have been required by applying each of the 6 aids were Canadian CT head rule (high risk only) 53%, Canadian (medium & high risk) 56%, the Neurotraumatology Committee of the World Federation of Neurosurgical Societies 56%, New Orleans 69%, NEXUS-II 56%, National Institute of Clinical Excellence 71%, and the Scandinavian 50%. The 6 decision aids' sensitivities for surgical hematomas could not be distinguished statistically (P>.05). Sensitivity was 100% (95% confidence interval [CI] 96% to 100%) for NEXUS-II, 98.1% (95% Cl 93% to 100%) for National Institute of Clinical Excellence, and 99.1% (95% CI 94% to 100%) for the other 4 clinical decision instruments. Sensitivity for any intracranial lesion ranged from 95.7% (95% CI 93% to 97%) (Scandinavian) to 100% (95% Cl 98% to 100%) (National Institute of Clinical Excellence). In contrast, specificities varied between 30.9% (95% CI 30% to 32%) (National Institute of Clinical Excellence) and 52.9% (95% CI 52% to 54) (Scandinavian). Conclusion: NEXUS-II and the Scandinavian clinical decision aids displayed the best combination of sensitivity and specificity in this patient population. However, we cannot demonstrate that the higher sensitivity of NEXUS-II for surgical hematomas is statistically significant. Therefore, choosing which of the 2 clinical decision instruments to use must be based on decisionmakers' attitudes toward risk. [Ann Emerg Med. 2009;53: 180-188.]	[Stein, Sherman C.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19106 USA; [Fabbri, Andrea] Osped Morgagni Pierantoni, Dept Emergency Med, Forli, Italy; [Servadei, Franco] Osped Maggiore Parma, Dept Neurosurg, Parma, Italy; [Glick, Henry A.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	Stein, SC (corresponding author), Hosp Univ Penn, Dept Neurosurg, 310 Spruce St, Philadelphia, PA 19106 USA.	sherman.stein@uphs.upenn.edu	Fabbri, Andrea/K-9994-2016	Fabbri, Andrea/0000-0002-9837-4638; Servadei, Franco/0000-0002-3595-3464	Manuscript Submission Agreement	Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. The authors have stated that no such relationships exist. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement.	Atzema C, 2004, ANN EMERG MED, V44, P47, DOI 10.1016/j.annemergmed.2004.02.032; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Boyle A, 2004, EMERG MED J, V21, P426, DOI 10.1136/emj.2002.002063; Bramley R, 2002, CLIN RADIOL, V57, P151, DOI 10.1053/crad.2001.0868; Clement CM, 2006, ANN EMERG MED, V48, P245, DOI 10.1016/j.annemergmed.2006.04.008; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Dunning J, 2004, EMERG MED J, V21, P404, DOI 10.1136/emj.2004.014944; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Falimirski ME, 2003, J TRAUMA, V55, P1, DOI 10.1097/01.TA.0000071295.67263.A2; Fleiss J.L., 1981, STAT METHODS RATES P, P14; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; Hollander JE, 2003, ACAD EMERG MED, V10, P830, DOI 10.1111/j.1553-2712.2003.tb00624.x; Huda W, 2007, AM J ROENTGENOL, V188, P540, DOI 10.2214/AJR.06.0101; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lee JB, 2004, EMERG MED J, V21, P125; Linden A, 2006, J EVAL CLIN PRACT, V12, P132, DOI 10.1111/j.1365-2753.2005.00598.x; Macgregor DM, 2005, EMERG MED J, V22, P541, DOI 10.1136/emj.2004.017160; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; Maharaj I, 2001, LANCET, V358, P1013, DOI 10.1016/S0140-6736(01)06139-6; MAHARAJ I, 2001, LANCET, V358, P1014; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Miller L, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-7; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Mower WR, 2002, ANN EMERG MED, V40, P505, DOI 10.1067/mem.2002.129245; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; National Institute for Clinical Excellence, 2007, CLIN GUID; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Qushmaq Ismael, 2006, ACP J Club, V144, P53; REILLY PL, 1975, LANCET, V2, P375; Schwam E, 2006, JAMA-J AM MED ASSOC, V295, P497, DOI 10.1001/jama.295.5.497-a; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shravat BP, 2006, EMERG MED J, V23, P109, DOI 10.1136/emj.2004.022327; Smits M, 2006, JAMA-J AM MED ASSOC, V295, P497, DOI 10.1001/jama.295.5.497-b; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; SOX HC, 1988, MED DECIS MAKING, P135; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2000, CAN MED ASSOC J, V163, P1465; Stiell IG, 2006, JAMA-J AM MED ASSOC, V295, P498, DOI 10.1001/jama.295.5.498-a; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STIELL IG, 2001, LANCET, V358, P1013; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; TEASDALE G, 1974, LANCET, V2, P81; Viola L, 2000, ACTA NEUROCHIR, V142, P1281, DOI 10.1007/s007010070026; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395	54	90	96	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	FEB	2009	53	2					180	188		10.1016/j.annemergmed.2008.01.002			9	Emergency Medicine	Emergency Medicine	405LI	WOS:000263225900006	18339447				2021-06-18	
J	Chang, JJJ; Youn, TS; Benson, D; Mattick, H; Andrade, N; Harper, CR; Moore, CB; Madden, CJ; Diaz-Arrastia, RR				Chang, Jason J. J.; Youn, Teddy S.; Benson, Dan; Mattick, Heather; Andrade, Nicholas; Harper, Caryn R.; Moore, Carol B.; Madden, Christopher J.; Diaz-Arrastia, Ramon R.			Physiologic and functional outcome correlates of brain tissue hypoxia in traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						intracranial pressure; cerebral perfusion pressure; hemoglobin; PaCO2; traumatic brain injury; brain tissue oxygenation	SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; DISABILITY RATING-SCALE; CEREBRAL OXYGENATION; INTRACRANIAL HYPERTENSION; REGIONAL OXYGENATION; PARTIAL-PRESSURE; TENSION; MICRODIALYSIS; ISCHEMIA	Objective: Assess the prevalence of brain tissue hypoxia in patients with severe traumatic brain injuries (TBI), and to characterize the relationship between brain tissue hypoxia and functional outcome. Design: Retrospective review of severe TBI patients. Setting: Intensive care unit of a level I trauma center. Patients: Twenty-seven patients with severe TBI requiring intracranial pressure (ICP) monitoring. Median age was 22 yrs, and a majority (63%) had traumatic subarachnoid hemorrhage. Interventions: Hourly assessments of ICP, brain tissue oxygen, mean arterial pressure, fraction of inspired oxygen (FIO2), partial pressure of arterial carbon dioxide (PaCO2,), and hemoglobin concentration (hemoglobin) were recorded. Outcome was assessed 6-9 months postinjury. Measurements and Main Results: Mean (so) ICP and BTpo(2) were 13.7 (6.6) cm H2O and 30.8 (13.6) mm Hg. A total of 13.5% (379) of the BTpo(2) values recorded were <20 mm Hg, only 86 of which were associated with ICP >= 20 cm H2O. This prevalence was comparable with episodes of ICP elevations above 20 cm H2O (14.1%, 397). Hypoxic episodes were more common when cerebral perfusion pressure was below 60 mm Hg (relative risk = 3.0, p < 0.0001). We did not find an association in hypoxic risk and hemoglobin in the range of 7-12 g/dL or PaCO2 in the range of 25-40 mm Hg. Subjects with hourly episodes (epochs) of hypoxia >20% of the time had poorer scores on outcome measures compared with those with fewer hypoxic epochs. Conclusions: Hypoxic episodes are common after severe TBI, and most are independent of ICP elevations. Most episodes of hypoxia occur while cerebral perfusion pressure and mean arterial pressure are within the accepted target range. There is no clear association between PaCO2 and hemoglobin with BTpo(2),. The young age and high prevalence of traumatic subarachnoid hemorrhage in this cohort may limit its generalizability. Increased frequency of hypoxic episodes is associated with poor functional outcome. (Crit Care Med 2009; 37:283-290)	[Youn, Teddy S.; Benson, Dan; Mattick, Heather; Andrade, Nicholas; Harper, Caryn R.; Moore, Carol B.; Diaz-Arrastia, Ramon R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Chang, Jason J. J.; Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA	Chang, JJJ (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu	Youn, Teddy/AAM-7705-2020; Youn, Teddy Si/ABH-9887-2020; Youn, Teddy Si/N-1535-2017	Youn, Teddy Si/0000-0002-7325-1148; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); NIH-NICDHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; US Department of EducationUS Department of Education [1-1133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	Supported, in part, by the Doris Duke Charitable Foundation (to JJJC, TSY), NIH-NICDH (R01 HD48179, U01 HD42652), and US Department of Education Grant (1-1133 A020526) (to RD-A).	Ang BT, 2007, J NEUROL NEUROSUR PS, V78, P298, DOI 10.1136/jnnp.2005.082735; Artru F, 1998, NEUROL RES, V20, pS48; Bardt TF, 1998, ACT NEUR S, V71, P153; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; DITUNNO JF, 1992, J NEUROTRAUM, V9, pS301; Filippi R, 2000, NEUROSURG REV, V23, P94; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; HALSEY JH, 1968, NEUROLOGY, V18, P282; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENFELD JV, 2006, C NEUR SURG 56 ANN M; SARRAFZADEH AS, 2000, NEUROSURG FOCUS, V9, P1; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	44	90	93	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2009	37	1					283	290		10.1097/CCM.0b013e318192fbd7			8	Critical Care Medicine	General & Internal Medicine	391YK	WOS:000262269900038	19050612				2021-06-18	
J	Cockerham, GC; Goodrich, GL; Weichel, LTCED; Orcutt, JC; Rizzo, JF; Bower, COLKS; Schuchard, RA				Cockerham, Glenn C.; Goodrich, Gregory L.; Weichel, L. T. C. Eric D.; Orcutt, James C.; Rizzo, Joseph F.; Bower, C. O. L. Kraig S.; Schuchard, Ronald A.			Eye and visual function in traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast injury; blindness; eye trauma; oculomotor; quality of life; rehabilitation; traumatic brain injury; vision; visual disturbance; visual field	COMBAT OCULAR TRAUMA; OPTIC NEUROPATHY; BLAST INJURY; IRAQ; WAR; REHABILITATION; DYSFUNCTION; MILITARY; PROGRAM; NEGLECT	Combat blast is an important cause of traumatic brain injury (TBI) in the Department of Veterans Affairs polytrauma population, whereas common causes of TBI in the civilian sector include motor vehicle accidents and falls. Known visual consequences of civilian TBI include compromised visual acuity, visual fields, and oculomotor function. The visual consequences of TBI related to blast remain largely unknown. Blast injury may include open globe (eye) injury, which is usually detected and managed early in the rehabilitation journey. The incidence, locations, and types of ocular damage in eyes without open globe injury after exposure to powerful blast have not been systematically studied. Initial reports and preliminary data suggest that binocular function, visual fields, and other aspects of visual function may be impaired after blast-related TBI, despite relatively normal visual acuity. Damage to the ocular tissues may occur from blunt trauma without rupture or penetration (closed globe injury). Possible areas for research are development of common taxonomy and assessment tools across services, surgical management, and outcomes for blast-related eye injury; the incidence, locations, and natural history of closed globe injury; binocular and visual function impairment; quality of life in affected service-members; pharmacological and visual therapies; and practice patterns for screening, management, and rehabilitation.	[Cockerham, Glenn C.] Dept Vet Affairs VA Palo Alto Hlth Care Syst, Ophthalmol Sect, Palo Alto, CA 94304 USA; [Cockerham, Glenn C.] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA; [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA; [Weichel, L. T. C. Eric D.; Bower, C. O. L. Kraig S.] Walter Reed Army Med Ctr, Ophthalmol Serv, Washington, DC 20307 USA; [Orcutt, James C.] VA Puget Sound Hlth Care Syst, Ophthalmol Sect, Seattle, WA USA; [Orcutt, James C.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; [Rizzo, Joseph F.] VA Jama Plain, Ctr Innovat Visual Restorat, Boston, MA USA; [Rizzo, Joseph F.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA; [Bower, C. O. L. Kraig S.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Schuchard, Ronald A.] Atlanta VA Med Ctr, Res & Dev Ctr Excellence, Atlanta, GA USA; [Schuchard, Ronald A.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA	Cockerham, GC (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, Ophthalmol Sect 112 B1, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	glenn.cockerham@va.gov	Goodrich, Gregory L./AAF-7184-2019		VAUS Department of Veterans Affairs [C5018R]; Quality Enhancement Research Initiative [RRP 07-339]	This material was based in part on work supported by the VA through Merit Review Award C5018R and Quality Enhancement Research Initiative grant RRP 07-339.	Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bochicchio GV, 2008, AM SURGEON, V74, P267; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Ciuffreda K. J., 1996, J BEHAV OPTOM, V7, P31; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HEIER JS, 1993, ARCH OPHTHALMOL-CHIC, V111, P795, DOI 10.1001/archopht.1993.01090060083028; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holmes JM, 2005, OPHTHALMOLOGY, V112, P2035, DOI 10.1016/j.ophtha.2005.06.013; Kasten E, 2007, J CLIN EXP NEUROPSYC, V29, P569, DOI 10.1080/13803390600878919; Klavora P, 1998, PERCEPT MOTOR SKILL, V86, P23, DOI 10.2466/pms.1998.86.1.23; Klavora P, 2000, ARCH PHYS MED REHAB, V81, P701, DOI 10.1053/apmr.2000.6285; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Padula WV, 1996, NEUROREHABILITATION, V6, P165, DOI 10.3233/NRE-1996-6302; PELI E, 2000, VISION REHABILITATIO, P104; PHILLIPS YY, 1991, CONVENTIONAL WARFARE, P221; Pizzamiglio L, 2006, RESTOR NEUROL NEUROS, V24, P337; Raphael BA, 2006, AM J OPHTHALMOL, V142, P1026, DOI 10.1016/j.ajo.2006.06.060; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Schoth F, 2006, NEUROSCI LETT, V398, P178, DOI 10.1016/j.neulet.2005.12.088; STAPCZYNSKI JS, 1982, ANN EMERG MED, V11, P687, DOI 10.1016/S0196-0644(82)80268-0; STARCK T, 2000, LIGHTHOUSE HDB VISIO, P143; Steinsapir KD, 2006, J NEURO-OPHTHALMOL, V26, P65, DOI 10.1097/01.wno.0000204646.94991.68; STONE SP, 1993, AGE AGEING, V22, P46, DOI 10.1093/ageing/22.1.46; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Ueki S, 2006, AM J OPHTHALMOL, V142, P591, DOI 10.1016/j.ajo.2006.05.042; *US GAO, 2008, GAO08276; Verlander D., 2000, VIS IMPAIR RES, V2, P129; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WARREN M, 1993, AM J OCCUP THER, V47, P42, DOI 10.5014/ajot.47.1.42; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; 2007, LANCET, V370, P1879, DOI DOI 10.1016/S0140-6736(07)61785-1	44	90	90	0	34	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					811	818		10.1682/JRRD.2008.08.0109			8	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100012	20104404	Bronze			2021-06-18	
J	Belli, A; Sen, J; Petzold, A; Russo, S; Kitchen, N; Smith, M				Belli, A.; Sen, J.; Petzold, A.; Russo, S.; Kitchen, N.; Smith, M.			Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study	ACTA NEUROCHIRURGICA			English	Article						glutamate; glycerol; ICP; lactate; pyruvate ratio; microdialysis; traumatic brain injury	SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; MEMBRANE PHOSPHOLIPID DEGRADATION; POSITRON-EMISSION-TOMOGRAPHY; INTRACEREBRAL MICRODIALYSIS; MITOCHONDRIAL DYSFUNCTION; CEREBRAL METABOLISM; N-ACETYLASPARTATE; SUBSTRATE DELIVERY; ENERGY-METABOLISM	Background: Cerebral microdialysis (MD) is able to detect markers of tissue damage and cerebral ischaemia and can be used to monitor the biochemical changes subsequent to head injury. In this prospective, observational study we analysed the correlation between microdialysis markers of metabolic impairment and intracranial pressure (ICP) and investigated whether changes in biomarker concentration precede rises in ICP. Methods: MD and ICP monitoring was carried out in twenty-five patients with severe TBI in Neurointensive care. MD samples were analysed hourly for lactate:pyruvate (LP) ratio, glutamate and glycerol. Abnormal values of microdialysis variables in presence of normal ICP were used to calculate the risk of intracranial hypertension developing within the next 3h. Findings: An LP ratio > 25 and glycerol > 100 mu mol/L, but not glutamate > 12 mu mol/L, were associated with significantly higher risk of imminent intracranial hypertension (odds ratio: 9.8, CI 5.8-16.1; 2.2, CI 1.6-3.8; 1.7, CI 0.6-3, respectively). An abnormal LP ratio could predict an ICP rise above normal levels in 89% of cases, whereas glycerol and glutamate had a poorer predictive value. Conclusions: Changes in the compound concentrations in microdialysate are a useful tool to describe molecular events triggered by TBI. These changes can occur before the onset of intracranial hypertension, suggesting that biochemical impairment can be present before low cerebral perfusion pressure is detectable. This early warning could be exploited to expand the window for therapeutic intervention.	[Belli, A.] Southampton Univ Hosp, Div Clin Neurosci, Southampton SO16 6YD, Hants, England; [Sen, J.; Russo, S.; Kitchen, N.] UCL Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, London WC1N 3BG, England; [Smith, M.] UCL Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia, London WC1N 3BG, England; [Petzold, A.] Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England	Belli, A (corresponding author), Southampton Univ Hosp, Div Clin Neurosci, Tremona Rd, Southampton SO16 6YD, Hants, England.	a.belli@soton.ac.uk	Smith, Martin/B-2616-2009; Petzold, Axel/C-1090-2009; Belli, Antonio/I-3799-2015	Petzold, Axel/0000-0002-0344-9749; Belli, Antonio/0000-0002-3211-9933	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701458] Funding Source: Medline		Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; Dohmen C, 2005, BRAIN RES, V1037, P43, DOI 10.1016/j.brainres.2004.12.046; Fiskum G, 2004, J NEUROSURG ANESTH, V16, P108, DOI 10.1097/00008506-200401000-00025; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Kim H, 1996, STROKE, V27, P114, DOI 10.1161/01.STR.27.1.114; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Murphy PS, 1999, MAGNET RESON MED, V42, P1155, DOI 10.1002/(SICI)1522-2594(199912)42:6<1155::AID-MRM21>3.0.CO;2-N; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 1998, NEUROL RES, V20, pS91; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Smith AB, 2003, ORG LETT, V5, P1, DOI 10.1021/ol0202520; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stout AK, 1998, NAT NEUROSCI, V1, P366; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; White RJ, 1996, J NEUROSCI, V16, P5688; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yau YH, 2000, J NEUROSURG, V93, P1072, DOI 10.3171/jns.2000.93.6.1072; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003	44	90	95	0	7	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAY	2008	150	5					461	470		10.1007/s00701-008-1580-3			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	299GS	WOS:000255744700006	18421408				2021-06-18	
J	Solomon, J; Raymont, V; Braun, A; Butman, JA; Grafman, J				Solomon, Jeffrey; Raymont, Vanessa; Braun, Allen; Butman, John A.; Grafman, Jordan			User-friendly software for the analysis of brain lesions (ABLe)	COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE			English	Article						brain lesion; cytoarchitecture; Brodmann areas; computer software; prefrontal cortex	IMAGE REGISTRATION; ATTENTION; INJURY	We previously developed a software package called ABLe (analysis of brain lesions) which characterizes brain lesions in terms of lesion volume and intersection with cytoarchitecture (e.g. Brodmann areas). Since our previous publication, there have been significant improvements to this software package which utilize methods standard to the neuroimaging community. These features include spatial normalization to the MNI template brain (standard of the international consortium for brain mapping), and use of the volume occupancy Talairach labels (VOTL) and automated anatomical labeling (AAL) atlases for full brain quantification of structures impacted by the lesion. Methods for multi-subject studies including lesion-symptom mapping proposed by Bates et al. have been extended in ABLe to produce an exploratory analysis summarizing correlations between subjects with overlapping lesions and behavioral deficit. A subset of data from an ongoing traumatic head injury study correlating deficit with brain anatomy is used to demonstrate the power of this software package. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Med Numer Inc, Germantown, MD USA; Henry M Jackson Fdn, Vietnam Head Injury Study, Bethesda, MD USA; NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; NIDCD, Language Sect, NIH, Bethesda, MD USA; NIH, Ctr Clin, Dept Diagnost Radiol, Bethesda, MD 20892 USA	Solomon, J (corresponding author), 20410 Observ Dr,Suite 210, Germantown, MD 20876 USA.	jsolomon@cc.nih.gov	Butman, John A/A-2694-2008; Butman, John/J-2780-2013	Butman, John/0000-0002-1547-9195; Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [Z01DC000031] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [001-0512-948, Z99 CL999999] Funding Source: Medline		Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; Cuadra MB, 2004, IEEE T MED IMAGING, V23, P1301, DOI 10.1109/TMI.2004.834618; Damasio H., 1989, LESION ANAL NEUROPSY; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; FRACKOWIAK R, 2003, HUMAN BRAIN FUNCTION; Frank RJ, 1997, NEUROIMAGE, V5, P13, DOI 10.1006/nimg.1996.0250; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hill DLG, 2001, PHYS MED BIOL, V46, pR1, DOI 10.1088/0031-9155/46/3/201; Howell DC, 2001, STAT METHODS PSYCHOL; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Mah L, 2004, AM J PSYCHIAT, V161, P1247, DOI 10.1176/appi.ajp.161.7.1247; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rorden C, 2004, NAT REV NEUROSCI, V5, P813, DOI 10.1038/nrn1521; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Sylvester CYC, 2003, NEUROPSYCHOLOGIA, V41, P357, DOI 10.1016/S0028-3932(02)00167-7; Talairach J., 1988, COPLANAR STEREOTAXIC; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wood JN, 2005, CORTEX, V41, P796, DOI 10.1016/S0010-9452(08)70298-3; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P153, DOI 10.1097/00004728-199801000-00028	21	90	90	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-2607			COMPUT METH PROG BIO	Comput. Meth. Programs Biomed.	JUN	2007	86	3					245	254		10.1016/j.cmpb.2007.02.006			10	Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics	Computer Science; Engineering; Medical Informatics	170KV	WOS:000246663200006	17408802	Green Accepted			2021-06-18	
J	Goodrich, GL; Kirby, J; Cockerham, G; Ingalla, SP; Lew, HL				Goodrich, Gregory L.; Kirby, Jennine; Cockerham, Glenn; Ingalla, Shanida P.; Lew, Henry L.			Visual function in patients of a polytrauma rehabilitation center: A descriptive study	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						adult; blast injury; brain injury; mechanism of injury; ocular refraction; polytrauma; rehabilitation; vision; visual impairment; visual perception	TRAUMATIC BRAIN-INJURY; LOW-VISION; IMPAIRMENT; CARE; OUTCOMES; HEALTH; IMPACT	Little is known about the visual function deficits associated with polytrauma injury. In this retrospective descriptive study, we examined the records of a clinic established to assess visual function in patients experiencing deployment-related polytrauma. We describe the clinical findings and present a vision examination protocol that may be useful for screening polytrauma patients in other settings. Data from our sample suggested that self-reported vision complaints were common (74%) and confirmed that visual impairment occurred in 38% of all cases. When examining the mechanism of injury, we found that polytrauma due to blast injuries appeared to more than double the risk of visual impairment compared with all other polytrauma causes (i.e., motor vehicle accidents, gunshot and/or shrapnel, assault, falls, or anoxia). The rate of visual impairment in blast-related injury was 52% compared with 20% for all other sources of injury. Visual complaints and impairments were common in the polytrauma patients studied. This finding suggests that comprehensive eye examinations should be routinely administered, particularly when the mechanism of injury involves a blast.	[Goodrich, Gregory L.; Kirby, Jennine] VAPAHCS, Psychol Serv, Palo Alto, CA 94304 USA; [Goodrich, Gregory L.; Kirby, Jennine] VAPAHCS, Western Blind Rehabil Ctr, Palo Alto, CA 94304 USA; [Cockerham, Glenn; Ingalla, Shanida P.] VAPAHCS, Ophthalmol Serv, Palo Alto, CA 94304 USA; [Cockerham, Glenn; Lew, Henry L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Lew, Henry L.] VAPAHCS, Phys Med & Rehabil Serv, Palo Alto, CA 94304 USA	Goodrich, GL (corresponding author), VAPAHCS, Psychol Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	Gregory.Goodrich@va.gov	Goodrich, Gregory L./AAF-7184-2019				Biehl JW, 1999, MIL MED, V164, P780; Brezin Antoine Pierre, 2005, Health Qual Life Outcomes, V3, P27, DOI 10.1186/1477-7525-3-27; GIANUTSOS R, 1997, FUNCTIONAL VISUAL BE, P267; Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595; Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633; JACK CIA, 1995, GERONTOLOGY, V41, P280; Jacobs JM, 2005, AGING CLIN EXP RES, V17, P281; Kerkhoff G, 2000, J NEUROL NEUROSUR PS, V68, P691, DOI 10.1136/jnnp.68.6.691; Lee DJ, 2005, OPHTHAL EPIDEMIOL, V12, P13, DOI 10.1080/09286580490907751; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Morse AR, 1999, ARCH OPHTHALMOL-CHIC, V117, P943; Nguyen Quan Dong, 2002, International Ophthalmology Clinics, V42, P167; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Stelmack JA, 2006, INVEST OPHTH VIS SCI, V47, P3253, DOI 10.1167/iovs.05-1319; WARD TP, 1999, OPHTHALMOL CLIN N AM, V12, P421; Wong TY, 1997, SURV OPHTHALMOL, V41, P433, DOI 10.1016/S0039-6257(97)00022-2; ZIHL J, 1989, NEUROPSYCHOLOGY VISU, P35	19	90	92	1	6	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					929	936		10.1682/JRRD.2007.01.0003			8	Rehabilitation	Rehabilitation	253NL	WOS:000252524800006	18075950	Bronze			2021-06-18	
J	Urrea, C; Castellanos, DA; Sagen, J; Tsoulfas, P; Bramlett, HM; Dietrich, WD				Urrea, Carlos; Castellanos, Daniel A.; Sagen, Jacqueline; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton			Widespread cellular proliferation and focal neurogenesis after traumatic brain injury in the rat	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						neurogenesis; dentate granular neurons; trauma; subventricular zone; plasticity	NEURAL STEM-CELLS; TRANSIENT GLOBAL-ISCHEMIA; SUBVENTRICULAR ZONE; ENHANCED NEUROGENESIS; DENTATE GYRUS; PROGRESSIVE ATROPHY; CEREBRAL-ISCHEMIA; PROGENITOR CELLS; SPINAL-CORD; ADULT	Purpose: A proliferation of stem/progenitor cells is observed after brain injury. We examined the regional and temporal profile of mitotically active cells to determine whether traumatic brain injury (TBI) would increase neurogenesis in selective brain regions. Methods: Mate Sprague-Dawley rats received injections (IP) of 5-bromo-deoxyuridine (BrdU), a compound used to detect mitotic cells, before and after fluid-percussion brain injury. At 3 hr, 1, 2, 3, 7, and 14 days after moderate fluid percussion, brains were processed for immunocytochemical and confocal analysis. Sections were double-labeled for markers selective for neurons (NeuN), astrocytes (GFAP), olidgodendrocytes (CNPase and MBP) and macrophage/microglia (ED1). Results: At 3 hr post-trauma, the majority of BrdU labeled cells were associated with the subventricular zone of the traumatized hemisphere. At later time points, a significant increase in BrdU positive cells was observed throughout the traumatized cerebral cortex, hippocampus, white matter structures, and some contralateral regions. BrdU labeled cells were observed as late as 14 days post-injury. Double-label studies with confocal microscopy demonstrated that cell phenotypes including astrocytes, macrophage/microglia, oligodendrocytes, and neurons were BrdU positive with the majority of cells appearing glial in nature. Evidence for neurogenesis was seen in the granular cell layer of the hippocampus. Conclusion: These findings indicate that TBI stimulates widespread cellular proliferation for days after injury and results in focal neurogenesis in the dentate gyrus of the hippocampus. These cellular responses to injury may participate in brain repair and functional recovery.	Univ Miami, Miller Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr,Miami Project Cure Paralysis, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr,Miami Project Cure Paralysis, 1095 NW 14th Terrace,LPLC 2-23, Miami, FL 33136 USA.	ddietrich@miami.edu		Tsoulfas, Pantelis/0000-0003-1974-6366	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 PO1 NS30291, 1 RO1 NS42133] Funding Source: Medline		Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barres BA, 1999, CELL, V97, P667, DOI 10.1016/S0092-8674(00)80777-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Felling RJ, 2003, J NEUROSCI RES, V73, P277, DOI 10.1002/jnr.10670; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Yang H, 2006, J NEUROSCI, V26, P2157, DOI 10.1523/JNEUROSCI.4070-05.2005; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	44	90	95	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2007	25	1					65	76					12	Neurosciences	Neurosciences & Neurology	195DP	WOS:000248393000007	17473396				2021-06-18	
J	Vardy, J; Wong, K; Yi, QL; Park, A; Maruff, P; Wagner, L; Tannock, IF				Vardy, Janette; Wong, Karen; Yi, Qi-long; Park, Alison; Maruff, Paul; Wagner, Lynne; Tannock, Ian F.			Assessing cognitive function in cancer patients	SUPPORTIVE CARE IN CANCER			English	Article						cognitive impairment; neuropsychological assessment; adjuvant chemotherapy	RECEIVING ADJUVANT CHEMOTHERAPY; BREAST-CANCER; NEUROPSYCHOLOGICAL ASSESSMENT; MENOPAUSAL SYMPTOMS; VALIDATION; TESTS; WOMEN; IMPAIRMENT; CONCUSSION; WORKSHOP	Goals of work: Some patients with cancer suffer cognitive impairment after chemotherapy. A brief, sensitive instrument is required to screen patients for cognitive impairment. In this study, we compare three possible screening instruments. Materials and methods: Cancer patients (n=31) who had received adjuvant chemotherapy within 2 years underwent cognitive evaluation on three occasions. Fluent English speakers (n=20) completed the High Sensitivity Cognitive Screen (HSCS), the computer-based Headminder and CogHealth, and the Functional Assessment of Cancer Therapy-cognitive function (FACT-COG) questionnaire. Patients not fluent in English (NESB) (n=11) performed CogHealth and Headminder. Results: The patients were aged 31-65 years, and 94% were women with breast cancer. At baseline, 6 of 20 (30%) had moderate-severe cognitive impairment on HSCS, 17 of 31 (55%) had scores greater than one standard deviation (SD) below the mean for normative data in one to two of three domains on Headminder, and on CogHealth, 8 of 31 (26%) were greater than one SD below the mean in at least two of six domains. A large practice effect was seen for the HSCS, with moderate-severe cognitive impairment decreasing from 30 to 5% between the first and second assessment. On FACT-COG, 9 of 19 patients (47%) rated their cognition as greater than one SD below that of a pre-chemotherapy breast cancer control group, with impact on quality of life greater than one SD below for 10 of 19 (53%) patients. No correlation was seen between objective cognitive testing and the FACT-COG. Conclusions: CogHealth and Headminder were suitable for NESB patients. The HSCS is not recommended for longitudinal studies with short intervals between testing due to practice effect. There is poor correlation between the patients' perception of their cognitive impairment and the objective tests.	Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; CogState Ltd, Melbourne, Vic 3000, Australia; Northwestern Univ, Sch Med, Evanston NW Healthcare, Evanston, IL 60201 USA	Vardy, J (corresponding author), Princess Margaret Hosp, Dept Med Oncol & Hematol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	janette.vardy@uhn.on.ca	Maruff, Paul/AAD-2454-2021; Maruff, Paul/ABA-1673-2020	Maruff, Paul/0000-0002-6947-9537; Vardy, Janette/0000-0002-5739-5790			Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bornstein R. A., 1994, NEUROPSYCHOLOGY HIV, P146; Borowicz LM, 1996, J CARDIOTHOR VASC AN, V10, P105, DOI 10.1016/S1053-0770(96)80185-6; Brezden CB, 2000, J CLIN ONCOL, V18, P2695, DOI 10.1200/JCO.2000.18.14.2695; BUTTERS N, 1990, J CLIN EXP NEUROPSYC, V12, P963, DOI 10.1080/01688639008401035; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; FALLETI MG, 2006, IN PRESS J CLIN EXP; Fan HGM, 2005, J CLIN ONCOL, V23, P8025, DOI 10.1200/JCO.2005.01.6550; FAUST D, 1989, J NERV MENT DIS, V177, P25, DOI 10.1097/00005053-198901000-00004; Fogel B S, 1991, Int Psychogeriatr, V3, P273, DOI 10.1017/S1041610291000728; Gonzalez R, 2003, J INT NEUROPSYCH SOC, V9, P64, DOI 10.1017/S1355617703910071; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; MCCAFFREY RJ, 1995, ARCH CLIN NEUROPSYCH, V10, P241, DOI 10.1016/0887-6177(94)00048-U; MILLER EN, 1994, NEUROPSYCHOLOGY HIV, P161; Phillips KA, 2003, JNCI-J NATL CANCER I, V95, P190, DOI 10.1093/jnci/95.3.190; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Silbert BS, 2004, BRIT J ANAESTH, V92, P814, DOI 10.1093/bja/aeh157; Symes E, 2000, AUST NZ J PSYCHIAT, V34, P770, DOI 10.1046/j.1440-1614.2000.00808.x; Tannock IF, 2004, J CLIN ONCOL, V22, P2233, DOI 10.1200/JCO.2004.08.094; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Tchen N, 2003, J CLIN ONCOL, V21, P4175, DOI 10.1200/JCO.2003.01.119; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Wagner L, 2003, ANN BEHAV MED, V25; White D A, 1995, J Int Neuropsychol Soc, V1, P304; WIENEKE MH, 1995, PSYCHO-ONCOL, V4, P61, DOI 10.1002/pon.2960040108; Woods SP, 2003, J CLIN EXP NEUROPSYC, V25, P431, DOI 10.1076/jcen.25.3.431.13800	34	90	91	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	NOV	2006	14	11					1111	1118		10.1007/s00520-006-0037-6			8	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	111PA	WOS:000242464300006	16538498				2021-06-18	
J	Geva, R; Eshel, R; Leitner, Y; Fattal-Valevski, A; Harel, S				Geva, Ronny; Eshel, Rina; Leitner, Yael; Fattal-Valevski, Aviva; Harel, Shaul			Memory functions of children born with asymmetric intrauterine growth restriction	BRAIN RESEARCH			English	Article						IUGR; memory; attention; developmental outcome; digit span	FOR-GESTATIONAL-AGE; CLOSED-HEAD INJURY; SHORT-TERM-MEMORY; LOW-BIRTH-WEIGHT; HUMAN HIPPOCAMPUS; RECOGNITION MEMORY; EVOKED POTENTIALS; BRAIN-DEVELOPMENT; DENTATE GYRUS; FRONTAL-LOBE	Objective: Learning difficulties are frequently diagnosed in children born with intrauterine growth restriction (IUGR). Models of various animal species with IUGR were studied and demonstrated specific susceptibility and alterations of the hippocampal formation and its related neural structures. The main purpose was to study memory functions of children born with asymmetric IUGR in a large-scale cohort using a long-term prospective paradigm. Methods: One hundred and ten infants diagnosed with IUGR were followed-up from birth to 9 years of age. Their performance was compared with a group of 63 children with comparable gestational age and multiple socioeconomic factors. Memory functions (short-term, super-and long-term spans) for different stimuli types (verbal and visual) were evaluated using Visual Auditory Digit Span tasks (VADS), Rey Auditory Verbal Learning Test (Rey-AVLT), and Rey Osterrieth Complex Figure Test (ROCF). Results: Children with IUGR had short-term memory difficulties that hindered both serial verbal processing system and simultaneous processing of high-load visuo-spatial stimuli. The difficulties were not related to prematurity, neonatal complications or growth catch-up, but were augmented by lower maternal education. Recognition skills and benefits from reiteration, typically affected by hippocampal dysfunction, were preserved in both groups. Conclusions: Memory profile of children born with IUGR is characterized primarily by a short-term memory deficit that does not necessarily comply with a typical hippocampal deficit, but rather may reflect an executive short-term memory deficit characteristic of anterior hippocampal-prefrontal network. Implications for cognitive intervention are discussed. (c) 2006 Elsevier B.V. All rights reserved.	Bar Ilan Univ, Dev Neuropsychol Lab, Gonda Goldschmied Multidisciplinary Brain Res Ctr, Dept Psychol, IL-52900 Ramat Gan, Israel; Tel Aviv Univ, Inst Child Dev, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Pediat Neurol Unit, Div Pediat, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel	Geva, R (corresponding author), Bar Ilan Univ, Dev Neuropsychol Lab, Gonda Goldschmied Multidisciplinary Brain Res Ctr, Dept Psychol, IL-52900 Ramat Gan, Israel.	gevaro@mail.biu.ac.il		Geva, Ronny/0000-0002-5724-2153			Bachevalier J, 2005, CURR OPIN NEUROBIOL, V15, P168, DOI 10.1016/j.conb.2005.03.015; Baschat AA, 2004, OBSTET GYNECOL SURV, V59, P617, DOI 10.1097/01.OGX.0000133943.54530.76; BERGER B, 1993, HIPPOCAMPUS, V3, P279, DOI 10.1002/hipo.450030305; BLACK LS, 2004, ELECTROGRAPHIC IMAG; Camm EJ, 2000, REPROD FERT DEVELOP, V12, P165, DOI 10.1071/RD99092; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; CINTRA L, 1990, BRAIN RES, V532, P271, DOI 10.1016/0006-8993(90)91769-D; Cintra L, 1997, HIPPOCAMPUS, V7, P192, DOI 10.1002/(SICI)1098-1063(1997)7:2<192::AID-HIPO6>3.0.CO;2-P; Cohen N.J., 1993, MEMORY AMNESIA HIPPO; Cowan N, 1999, CHILD DEV, V70, P1082, DOI 10.1111/1467-8624.00080; DEADWYLER SA, 1985, BEHAV NEURAL BIOL, V44, P201, DOI 10.1016/S0163-1047(85)90198-0; deUngria M, 2000, PEDIATR RES, V48, P169, DOI 10.1203/00006450-200008000-00009; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Dieni S, 2003, J NEUROBIOL, V55, P41, DOI 10.1002/neu.10194; Ergaz Z, 2005, REPROD TOXICOL, V20, P301, DOI 10.1016/j.reprotox.2005.04.007; Fattal-Valevski A, 1999, J CHILD NEUROL, V14, P724, DOI 10.1177/088307389901401107; Frisk V, 2002, DEV NEUROPSYCHOL, V22, P565, DOI 10.1207/S15326942DN2203_2; Geva R, 2005, INFANT MENT HEALTH J, V26, P481, DOI 10.1002/imhj.20063; Geva R, 2006, PEDIATRICS, V118, P91, DOI 10.1542/peds.2005-2343; Goldenberg RL, 1998, EUR J CLIN NUTR, V52, pS54; GOTLIEB SJ, 1988, INFANT BEHAV DEV, V11, P223, DOI 10.1016/S0163-6383(88)80007-9; Gutbrod T, 2000, ARCH DIS CHILD-FETAL, V82, pF208, DOI 10.1136/fn.82.3.F208; HAREL S, 1985, BRAIN DEV-JPN, V7, P580, DOI 10.1016/S0387-7604(85)80005-X; HAREL S, 1985, BRAIN DEV-JPN, V7, P575, DOI 10.1016/S0387-7604(85)80004-8; HAWDON JM, 1990, DEV MED CHILD NEUROL, V32, P943; Hevner RF, 1996, J COMP NEUROL, V372, P384, DOI 10.1002/(SICI)1096-9861(19960826)372:3<384::AID-CNE4>3.0.CO;2-Z; Hollo O, 2002, ARCH PEDIAT ADOL MED, V156, P179, DOI 10.1001/archpedi.156.2.179; Isaacs EB, 2000, PEDIATR RES, V47, P713, DOI 10.1203/00006450-200006000-00006; Isaacs EB, 2003, P NATL ACAD SCI USA, V100, P13060, DOI 10.1073/pnas.1233825100; Karlsgodt KH, 2005, NEUROIMAGE, V25, P1224, DOI 10.1016/j.neuroimage.2005.01.038; Kilpatrick C, 1997, SEIZURE, V6, P213, DOI 10.1016/S1059-1311(97)80008-8; Kohler S, 1998, NEUROPSYCHOLOGIA, V36, P901, DOI 10.1016/S0028-3932(98)00017-7; KOPPITZ EM, 1981, J LEARN DISABIL, V14, P93, DOI 10.1177/002221948101400212; KOSTOVIC I, 1989, NEUROSCIENCE, V30, P105, DOI 10.1016/0306-4522(89)90357-6; Leitner Y, 2000, J CHILD NEUROL, V15, P781, DOI 10.1177/088307380001501202; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; LOW JA, 1992, AM J OBSTET GYNECOL, V167, P1499, DOI 10.1016/0002-9378(92)91727-R; Makhoul IR, 2004, PEDIATR RES, V55, P877, DOI 10.1203/01.PDR.0000119369.21770.7A; Mallard C, 2000, NEUROSCIENCE, V100, P327, DOI 10.1016/S0306-4522(00)00271-2; Manns JR, 2003, NEURON, V37, P171, DOI 10.1016/S0896-6273(02)01147-9; Nyakas C, 1996, PROG NEUROBIOL, V49, P1; O'Keeffe MJ, 2003, PEDIATRICS, V112, P301, DOI 10.1542/peds.112.2.301; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Posner MI, 2004, CAN PSYCHOL, V45, P265, DOI 10.1037/h0086997; Sami N, 2003, CHILD NEUROPSYCHOL, V9, P237, DOI 10.1076/chin.9.4.237.23514; Schacter DL, 1999, HIPPOCAMPUS, V9, P575, DOI 10.1002/(SICI)1098-1063(1999)9:5<575::AID-HIPO11>3.0.CO;2-K; Scherjon S, 2000, PEDIATRICS, V105, P385, DOI 10.1542/peds.105.2.385; Strange BA, 2002, J NEUROSCI, V22, P523, DOI 10.1523/JNEUROSCI.22-02-00523.2002; SZATMARI P, 1990, DEV MED CHILD NEUROL, V32, P954; Talley J L, 1986, Arch Clin Neuropsychol, V1, P315, DOI 10.1016/0887-6177(86)90135-6; Tolsa CB, 2004, PEDIATR RES, V56, P132, DOI 10.1203/01.PDR.0000128983.54614.7E; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; Vakil E, 2004, CHILD NEUROPSYCHOL, V10, P57, DOI 10.1080/09297040490911078; van Wassenaer Aleid, 2005, Pediatr Endocrinol Rev, V2, P372; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	56	90	94	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 30	2006	1117						186	194		10.1016/j.brainres.2006.08.004			9	Neurosciences	Neurosciences & Neurology	107CB	WOS:000242147200019	16962082				2021-06-18	
J	Van Landeghem, FKH; Weiss, T; Oehmichen, M; Von Deimling, A				Van Landeghem, Frank K. H.; Weiss, Thorsten; Oehmichen, Manfred; Von Deimling, Andreas			Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; glutamate; glutamate transporter; human; traumatic brain injury	AMINO-ACID RELEASE; MICROGLIA; ISCHEMIA; PROTEINS; PATTERNS; REVERSAL; GLT-1; EAAT2	The primary mechanism for eliminating synaptically released glutamate is uptake by astrocytes. In the present study, we examined whether traumatic brain injury (TBI) affects the cellular expression of glutamate transporters EAAT1 and EAAT2. Morphometrical immunohistochemical analysis demonstrated a predominant expression of EAAT1 and EAAT2 in astrocytes of normal human neocortex (n = 10). Following traumatic injury of human brain (n = 55), the number of EAAT2-positive cells was decreased for a prolonged survival period within the traumatized neocortex and the pericontusional region. GFAP-positive astrocytes decreased in number within the first 24 h. Thereafter, the number of GFAP-positive astrocytes increased again, indicating formation of reactive gliosis. Double immunofluorescence examinations revealed a reduction in absolute numbers of GFAP-positive astrocytes coexpressing EAAT1 or EAAT2 at survival times up to 7 days. In addition, the relative fractions of astrocytes coexpressing glutamate transporters decreased following TBI. We conclude that the posttraumatic reduction in cellular EAAT 1 and EAAT2 expression is predominantly due to degeneration of astrocytes and to down-regulation in surviving astrocytes. Our results support the view that reduced glutamate uptake by astrocytes contributes to posttraumatic elevation of extracellular glutamate in humans.	Charite Univ Med Berlin, Inst Neuropathol, D-13353 Berlin, Germany; Univ Kiel, Klinikum Schleswig Holstein, Inst Legal Med, Kiel, Germany	Van Landeghem, FKH (corresponding author), Charite Univ Med Berlin, Inst Neuropathol, Campus Virchow Klinikum,Augustenburger Platz 1, D-13353 Berlin, Germany.	frank.van_landeghem@charite.de	; von Deimling, Andreas/F-7774-2013	van Landeghem, Frank/0000-0002-9404-7031; von Deimling, Andreas/0000-0002-5863-540X			Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Domercq M, 1999, EUR J NEUROSCI, V11, P2226, DOI 10.1046/j.1460-9568.1999.00639.x; Duan SM, 2003, J NEUROSCI, V23, P1320; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Ikematsu K, 2002, FORENSIC SCI INT, V130, P83, DOI 10.1016/S0379-0738(02)00344-4; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; Li S, 1999, J Neurosci, V19, pRC16; LONGUEMARE MC, 1995, J NEUROSCI RES, V40, P379, DOI 10.1002/jnr.490400312; Longuemare MC, 1999, NEUROSCIENCE, V93, P285, DOI 10.1016/S0306-4522(99)00152-9; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Milton ID, 1997, MOL BRAIN RES, V52, P17, DOI 10.1016/S0169-328X(97)00233-7; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; Privat Alain, 1995, P3; Rao VLR, 1998, J NEUROCHEM, V70, P2020; REYNOLDS R, 1986, BRAIN RES, V371, P253, DOI 10.1016/0006-8993(86)90361-6; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; RUTLEDGE EM, 1999, AM J PHYSIOL, V271, pC1511; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Suchak SK, 2003, J NEUROCHEM, V84, P522, DOI 10.1046/j.1471-4159.2003.01553.x; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Takahashi M, 1997, J EXP BIOL, V200, P401; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Vermeiren C, 2005, J NEUROCHEM, V94, P405, DOI 10.1111/j.1471-4159.2005.03216.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Williams SM, 2005, GLIA, V49, P520, DOI 10.1002/glia.20139; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	42	90	91	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1518	1528		10.1089/neu.2006.23.1518			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500011	17020486				2021-06-18	
J	Bakshi, A; Shimizu, S; Keck, CA; Cho, S; LeBold, DG; Morales, D; Arenas, E; Snyder, EY; Watson, DJ; McIntosh, TK				Bakshi, A; Shimizu, S; Keck, CA; Cho, S; LeBold, DG; Morales, D; Arenas, E; Snyder, EY; Watson, DJ; McIntosh, TK			Neural progenitor cells engineered to secrete GDNF show enhanced survival, neuronal differentiation and improve cognitive function following traumatic brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cognition; glial cell line-derived neurotrophic factor; neural progenitor cells; rats; traumatic brain injury	NERVE GROWTH-FACTOR; FLUID-PERCUSSION MODEL; STEM-CELLS; NEUROTROPHIC FACTOR; SPINAL-CORD; C-RET; NEUROLOGICAL MOTOR; NESTIN EXPRESSION; TYROSINE KINASE; AXONAL GROWTH	We sought to evaluate the potential of C17.2 neural progenitor cells (NPCs) engineered to secrete glial cell line-derived neurotrophic factor (GDNF) to survive, differentiate and promote functional recovery following engraftment into the brains of adult male Sprague-Dawley rats subjected to lateral fluid percussion brain injury. First, we demonstrated continued cortical expression of GDNF receptor components (GFR alpha-1, c-Ret), suggesting that GDNF could have a physiological effect in the immediate post-traumatic period. Second, we demonstrated that GDNF over-expression reduced apoptotic NPC death in vitro. Finally, we demonstrated that GDNF over-expression improved survival, promoted neuronal differentiation of GDNF-NPCs at 6 weeks, as compared with untransduced (MT) C17.2 cells, following transplantation into the perilesional cortex of rats at 24 h post-injury, and that brain-injured animals receiving GDNF-C17.2 transplants showed improved learning compared with those receiving vehicle or MT-C17.2 cells. Our results suggest that transplantation of GDNF-expressing NPCs in the acute post-traumatic period promotes graft survival, migration, neuronal differentiation and improves cognitive outcome following traumatic brain injury.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, Stockholm, Sweden; Burnham Inst, Program Dev & Regenerat Cell Biol, La Jolla, CA 92037 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Watson, DJ (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, 371A Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	djw3@mail.med.upenn.edu	Arenas, Ernest/AAO-5231-2020	Arenas, Ernest/0000-0003-0197-6577; Morales, Diego/0000-0001-6672-9046	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978] Funding Source: NIH RePORTER		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Akerud P, 2001, J NEUROSCI, V21, P8108; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Benraiss A, 2001, J NEUROSCI, V21, P6718; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; Blesch A, 2001, J COMP NEUROL, V436, P399, DOI 10.1002/cne.1076; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Boockvar JA, 2003, MOL CELL NEUROSCI, V24, P1116, DOI 10.1016/j.mcn.2003.09.011; Burazin TCD, 1999, MOL BRAIN RES, V73, P151, DOI 10.1016/S0169-328X(99)00217-X; Ceccatelli S, 2004, TOXICOL LETT, V149, P59, DOI 10.1016/j.toxlet.2003.12.060; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Chiba S, 2004, J NEUROL SCI, V219, P107, DOI 10.1016/j.jns.2004.01.006; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fink JS, 2000, CELL TRANSPLANT, V9, P273, DOI 10.1177/096368970000900212; Fujiwara Y, 2004, NEUROSCI LETT, V366, P287, DOI 10.1016/j.neulet.2004.05.080; Golden JP, 1998, J COMP NEUROL, V398, P139, DOI 10.1002/(SICI)1096-9861(19980817)398:1<139::AID-CNE9>3.0.CO;2-2; Heuckeroth RO, 1998, DEV BIOL, V200, P116, DOI 10.1006/dbio.1998.8955; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Hurelbrink CB, 2001, EXP NEUROL, V171, P46, DOI 10.1006/exnr.2001.7749; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Ito H, 2003, J NEUROSCI RES, V71, P648, DOI 10.1002/jnr.10532; Iwai M, 2001, Hum Cell, V14, P27; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Larsson LC, 2001, EXP NEUROL, V172, P100, DOI 10.1006/exnr.2001.7738; Lee CS, 2005, EXP NEUROL, V191, P65, DOI 10.1016/j.expneurol.2004.08.025; Liu WG, 2004, NEUROCHEM RES, V29, P2207, DOI 10.1007/s11064-004-7027-1; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Lynch WP, 1999, J VIROL, V73, P6841, DOI 10.1128/JVI.73.8.6841-6851.1999; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mellodew K, 2004, DEV BRAIN RES, V151, P13, DOI 10.1016/j.devbrainres.2004.03.018; Miyazaki H, 1999, NEUROSCIENCE, V89, P643, DOI 10.1016/S0306-4522(98)00592-2; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; *NAT RES COUNC, 1996, GUID CAR US LAB AN; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Ostenfeld T, 2002, J NEUROSCI RES, V69, P955, DOI 10.1002/jnr.10396; PAXINOS G, 1990, STEREOTACTIC ATLAS R; Pencea V, 2001, J NEUROSCI, V21, P6706; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; RINK A, 1995, AM J PATHOL, V147, P1575; Rosario CM, 1997, DEVELOPMENT, V124, P4213; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sarabi A, 2003, NEUROSCIENCE, V116, P261, DOI 10.1016/S0306-4522(02)00559-6; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; Sun LX, 2004, J CLIN INVEST, V113, P1364, DOI 10.1172/JCI200420001; Tamm C, 2004, EUR J NEUROSCI, V19, P2613, DOI 10.1111/j.0953-816X.2004.03391.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037; Tuszynski MH, 1996, NEUROSCIENCE, V71, P761, DOI 10.1016/0306-4522(95)00440-8; Ugarte SD, 2003, J NEUROSCI RES, V73, P105, DOI 10.1002/jnr.10632; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018-004-4144-6; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	81	90	101	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	APR	2006	23	8					2119	2134		10.1111/j.1460-9568.2006.04743.x			16	Neurosciences	Neurosciences & Neurology	034PQ	WOS:000236943500016	16630059				2021-06-18	
J	Geddes-Klein, DM; Schiffman, KB; Meaney, DF				Geddes-Klein, DM; Schiffman, KB; Meaney, DF			Mechanisms and consequences of neuronal stretch injury in vitro differ with the model of trauma	JOURNAL OF NEUROTRAUMA			English	Article						cytosolic calcium; in vitro models; NMDA receptors; permeability	DIFFUSE AXONAL INJURY; BRAIN-INJURY; CORTICAL-NEURONS; QUANTITATIVE-DETERMINATION; MEMBRANE-PERMEABILITY; GLUTAMATE-RECEPTOR; CALCIUM RESPONSE; MEDIATED CURRENT; NEURAL TRAUMA; STRAIN-RATE	The deformation to the brain that occurs during traumatic brain injury (TBI) results in a complex strain distribution throughout the brain tissue. Recently, many in vitro models of neuronal injury have been developed to simplify the mechanics which occur during TBI. We hypothesized that the type of mechanical insult imparted onto neurons would significantly alter both the mechanism and severity of the neuronal response to injury. In this study, primary cortical neurons were cultured on an elastic substrate and subjected to graded levels (0%, 10%, 30%, 50%) of either uniaxial (cells stretched in one direction only) or biaxial (cells simultaneously stretched in two directions) stretch. We found that neurons stretched in either injury paradigm exhibited immediate increases in intracellular free calcium ([Ca2+](i)), but the magnitude of the [Ca2+](i) rise was nearly an order of magnitude higher in biaxially stretched neurons compared to uniaxially stretched neurons. Moreover, while the [Ca2+](i) transient after uniaxial stretch was blocked with specific channel antagonists (APV, CNQX, nimodipine, TTX), a substantial [Ca2+], transient persisted in biaxially stretched neurons. We theorized that the additional calcium influx after biaxial stretch entered through nonspecific pores/tears formed in the membrane, since biaxially stretched neurons exhibited significant uptake of carboxyfluorescein, a molecule typically impermeant to cell membranes. Despite the large [Ca2+](i) transients, neither injury profile resulted in death within 24 h of injury. Interestingly, though, uniaxially stretched neurons exhibited enhanced [Ca+2](i) influx following NMDA stimulation 24 h after trauma, compared to both control and biaxially stretched neurons. These data point out that the type of mechanical insult will influence the acute mechanisms of injury in vitro, can cause differences in the response to potential secondary excitotoxic injury mechanisms, and emphasizes the need to further study how these mechanical conditions can separately affect cell fate following mechanical injury.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Geddes-Klein, DM (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk,120 Hayden Hall, Philadelphia, PA 19104 USA.	dmgeddes@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35712] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NICHD 41699] Funding Source: Medline		Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; BARTOLETTI DC, 1989, FEBS LETT, V256, P4, DOI 10.1016/0014-5793(89)81707-7; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Furukawa Y, 2000, NEUROSCIENCE, V96, P385, DOI 10.1016/S0306-4522(99)00553-9; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gift EA, 2000, CYTOMETRY, V39, P243; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; Holbourn AHS, 1943, LANCET, V2, P438; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; OMMAYA AK, 1967, 13 STAPP CAR CRASH C; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; SHREIBER DI, 1997, 41 STAPP CAR CRASH C; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	42	90	93	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					193	204		10.1089/neu.2006.23.193			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600008	16503803				2021-06-18	
J	Wade, SL; Michaud, L; Brown, TM				Wade, SL; Michaud, L; Brown, TM			Putting the pieces together - Preliminary efficacy of a family problem-solving intervention for children with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; child adjustment; communication skills; family adaptation; problem solving	PREDICTORS; ADOLESCENTS; SKILLS	Objective: To describe a family-centered problem-solving intervention (FPS) for pediatric traumatic brain injury (TBI), and to assess the efficacy of the intervention in a randomized clinical trial. Participants: Families of 32 school-aged children with moderate to severe TBI randomly assigned to FPS or usual care (UC) group. Main Outcome Measures: Child Behavior Checklist, Brief Symptom Inventory, Conflict Behavior Questionnaire. Intervention: Seven-session problemsolving/skill-building intervention delivered over a 6-month period for the participating families. Results: Parents in the FPS group reported significantly greater improvements in their children in internalizing symptoms, anxiety/depression, and withdrawal than did parents in the UC comparison group. Conclusions: FPS holds promise for reducing child behavior problems, the most common and persistent sequelate of TBI.	Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					ACHENBACH TM, 1991, MANUAL CHILD BEAHV C; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; D'Zurilla T. J., 1999, PROBLEM SOLVING THER; Derogatis L., 1982, BRIEF SYMPTOM INVENT; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Foster SL., 1989, NEGOTIATING PARENT A; Horwitz SM, 2001, PSYCHIAT SERV, V52, P1088, DOI 10.1176/appi.ps.52.8.1088; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; JENNETT B, 1975, LANCET, V1, P480; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; NEZU AM, 1998, HELPING CANC PATIENT; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; Patterson G.R., 1992, ANTISOCIAL BOYS; PATTERSON GR, 1988, STRESS COPING DEV CH, P235; SANDERS MR, 1989, J CLIN CHILD PSYCHOL, V18, P72, DOI 10.1207/s15374424jccp1801_9; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M., 1998, COLLABORATIVE BRAIN	25	90	90	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					57	67		10.1097/00001199-200601000-00006			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300006	16456392				2021-06-18	
J	Jaeger, M; Soehle, M; Schuhmann, MU; Winkler, D; Meixensberger, J				Jaeger, M; Soehle, M; Schuhmann, MU; Winkler, D; Meixensberger, J			Correlation of continuously monitored regional cerebral blood flow and brain tissue oxygen	ACTA NEUROCHIRURGICA			English	Article						brain tissue oxygen; cerebral blood flow; thermal diffusion flowmetry; neuromonitoring	AUTOREGULATION; INJURY; PO2	Background. The purpose of this study was to investigate the relationship between continuously monitored regional cerebral blood flow (CBF) and brain tissue oxygen (PtiO2). Methods. Continuous advanced multimodal neuromonitoring including monitoring of PtiO2 (Licox, GMS) and CBF (QFlow, Hemedex) was performed in eight patients after severe subarachnoid haemorrhage (n = 5) and traumatic brain injury (n = 3) for an average of 9.6 days. Parameters were measured using a flexible polarographic PtiO2-probe and a thermal diffusion CBF-microprobe. Findings. Regarding the whole monitoring period in all patients, the data indicated a significant correlation between CBF and PtiO2 (r = 0.36). In 72% of 400 analysed intervals of 30 minutes duration with PtiO2 changes larger than 5 mmHg, a strong correlation between CBF and PtiO2 existed (r > 0.6). In 19% of intervals a still statistically significant correlation was observed (0.3 < r < 0.6). During the remaining 9% no correlation was found (r < 0.3). Regarding the clinical stability of the monitoring devices, the CBF monitoring system allowed monitoring of CBF in 64% of the time when PtiO2 monitoring was possible only. Phases of non-monitoring were mostly due to fever of the patient, when the system does not allow monitoring to avoid overheating of the cerebral tissue. Conclusions. This study suggests a correlation between CBF and PtiO2. The level of PtiO2 seems to be predominately determined by regional CBF, since changes in PtiO2 were correlated in 90% of episodes to simultaneous changes of CBF.	Univ Leipzig, Dept Neurosurg, D-7010 Leipzig, Germany; Univ Bonn, Dept Anaesthesiol & Intens Care Med, D-5300 Bonn, Germany	Jaeger, M (corresponding author), Univ Klinikum Leipzig, Klin & Poliklin Neurochirurgie, Liebigstr 20, D-04103 Leipzig, Germany.	jaem@medizin.uni-leipzig.de					Bardt TF, 1998, ACT NEUR S, V71, P153; Dings J, 1998, NEUROL RES, V20, pS71; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1996, ZBL NEUROCHIR, V57, P177; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 2003, J NEUROSURG ANESTH, V15, P33, DOI 10.1097/00008506-200301000-00006; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	15	90	90	1	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2005	147	1					51	56		10.1007/s00701-004-0408-z			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	888JL	WOS:000226370100015	15565486				2021-06-18	
J	Lovell, M; Collins, M; Bradley, J				Lovell, M; Collins, M; Bradley, J			Return to play following sports-related concussion	CLINICS IN SPORTS MEDICINE			English	Article							NEUROPSYCHOLOGICAL TEST-PERFORMANCE; HIGH-SCHOOL; CEREBRAL CONCUSSION; RECOVERY; IMPAIRMENT; INJURY	This article provides a review of current important issues in the management of athletes who have sustained a concussion during athletic competition. Recent research in the area of concussion management is reviewed with specific reference to the sideline evaluation of concussion and the follow-up of the athlete during the recovery period. The use of neuropsychological testing in sports is also reviewed. A systematic protocol for the management of sports related concussion is presented.	Univ Pittsburgh, Ctr Med, Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15215 USA; Natl Football League Neuropsychol Testing Program, Pittsburgh, PA 15215 USA; Natl Hockey League Neuropsychol Testing Program, Pittsburgh, PA 15215 USA; Team Phys, Pittsburgh, PA 15215 USA	Bradley, J (corresponding author), Univ Pittsburgh, Ctr Med, Sports Med Concuss Program, Dept Orthopaed Surg, 200 Delafield Rd,Suite 410, Pittsburgh, PA 15215 USA.	bradleyjp@msx.upmc.odu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; Bergschneider M, 2003, J NEUROSURG, V86, P241; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Congress of Neurological Surgeon, 1966, CLIN NEUROSURG, V12, P386; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Schnirring L, 2001, PHYSICIAN SPORTSMED, V29, P11; WOJYTS ED, 1999, AM J SPORTS MED, V27, P676	36	90	92	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JUL	2004	23	3					421	+		10.1016/j.csm.2004.04.001			22	Sport Sciences	Sport Sciences	843DT	WOS:000223056700010	15262380	Green Published			2021-06-18	
J	Adibhatla, RM; Hatcher, JF; Dempsey, RJ				Adibhatla, RM; Hatcher, JF; Dempsey, RJ			Phospholipase A(2), hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia	ANTIOXIDANTS & REDOX SIGNALING			English	Article							TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CDP-CHOLINE; FOREBRAIN ISCHEMIA; ARACHIDONIC-ACID; NEURONAL DEATH; CYTOSOLIC PHOSPHOLIPASE-A(2); POSTISCHEMIC REPERFUSION; NERVOUS-SYSTEM; GERBIL BRAIN	Phospholipid degradation is an important promoter of neuronal death after transient cerebral ischemia. Phospholipid hydrolysis by phospholipase A(2) (PLA(2)) after transient cerebral ischemia releases arachidonic acid. Arachidonic acid metabolism results in formation of reactive oxygen species, lipid peroxides, and toxic aldehydes (malondialdehyde, 4-hydroxynonenal, and acrolein). Citicoline (cytidine-5'-diphosphocholine), an intermediate in phosphatidylcholine synthesis, has undergone 13 phase III clinical trials for stroke, and is being evaluated for treatment of Alzheimer's and Parkinson's diseases. Here we examined the effect of citicoline on PLA(2) activity in relationship to attenuating hydroxyl radical (OH.) generation and lipid peroxidation after transient forebrain ischemia in gerbil. High Ca2+ dependency (millimolar range) of PLA(2) activity suggests that secretory PLA(2) is the predominant isoform in membrane and mitochondria. Citicoline attenuated the increase in PLA(2) activity in both membrane and mitochondrial fractions. In vitro, citicoline and its components choline and cytidine had no effect on the PLA(2) activity. Thus, citicoline is not a "direct PLA(2) inhibitor." Citicoline also significantly attenuated loss of cardiolipin and arachidonic acid release from phosphatidylcholine and phosphatidylethanolamine. Transient cerebral ischemia resulted in significant formation of OH. and malondialdehyde, and citicoline significantly attenuated their formation. These results suggest that citicoline provides neuroprotection by attenuating the stimulation of PLA(2).	Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, Madison, WI 53792 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI 53705 USA	Adibhatla, RM (corresponding author), Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, H4-330,600 Highland Ave, Madison, WI 53792 USA.	adibhatl@neurosurg.wise.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042008] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS42008] Funding Source: Medline		Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; Adibhatla RM, 2003, J NEUROSCI RES, V73, P308, DOI 10.1002/jnr.10672; Adibhatla RM, 2002, J NEUROSCI RES, V70, P133, DOI 10.1002/jnr.10403; Adibhatla RM, 2002, J NEUROCHEM, V80, P12; Adibhatla RM, 2001, STROKE, V32, P2376, DOI 10.1161/hs1001.096010; ADIBHATLA RM, 2002, NEUROLOGY; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; ARRIGONI E, 1987, BIOCHEM PHARMACOL, V36, P3697, DOI 10.1016/0006-2952(87)90022-0; Basavarajappa BS, 1997, ALCOHOL CLIN EXP RES, V21, P1199, DOI 10.1111/j.1530-0277.1997.tb04438.x; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chan CY, 2001, IEEE T INTELL TRANSP, V2, P1, DOI 10.1109/6979.911080; Chi SI, 2000, NEUROSCIENCE, V100, P475, DOI 10.1016/S0306-4522(00)00317-1; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; Clemens JA, 1996, STROKE, V27, P527, DOI 10.1161/01.STR.27.3.527; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Davalos A, 2002, STROKE, V33, P2850, DOI 10.1161/01.STR.0000038691.03334.71; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esterbauer H, 1996, PATHOL BIOL, V44, P25; FRESTA M, 1994, J PHARM PHARMACOL, V46, P974, DOI 10.1111/j.2042-7158.1994.tb03252.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALL ED, 1997, PRIMER CEREBROVASCUL, P200; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8; Kasner SE, 1997, ANN EMERG MED, V30, P642, DOI 10.1016/S0196-0644(97)70084-2; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Kishimoto K, 1999, NEUROSCIENCE, V92, P1061, DOI 10.1016/S0306-4522(99)00051-2; Kontos HA, 2001, STROKE, V32, P2712, DOI 10.1161/hs1101.098653; Kruman I, 1997, J NEUROSCI, V17, P5089; Krupinski J, 2002, NEUROPHARMACOLOGY, V42, P846, DOI 10.1016/S0028-3908(02)00032-1; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; McCabe DR, 1997, J CHROMATOGR B, V691, P23, DOI 10.1016/S0378-4347(96)00416-1; Mir C, 2003, J MOL NEUROSCI, V20, P53, DOI 10.1385/JMN:20:1:53; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; NAKAHARA I, 1992, J NEUROSURG, V76, P244, DOI 10.3171/jns.1992.76.2.0244; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Plataras C, 2003, Z NATURFORSCH C, V58, P277; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rao AM, 1999, J NEUROSCI RES, V58, P697, DOI 10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.3.CO;2-2; Rao AM, 2001, BRAIN RES, V893, P268, DOI 10.1016/S0006-8993(00)03280-7; RAO AM, 1999, RRD NEUROCHEMISTRY 2, V2, P533; Ribardo DA, 2001, J BIOL CHEM, V276, P5467, DOI 10.1074/jbc.M006690200; RORDORF G, 1991, J NEUROSCI, V11, P1829; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; SECADES JJ, 2002, METHODS FIND EXP SB, V24, P1; Seeds MC, 1998, BBA-LIPID LIPID MET, V1389, P273, DOI 10.1016/S0005-2760(97)00151-3; Shimoyama Y, 2001, BIOL PHARM BULL, V24, P1004, DOI 10.1248/bpb.24.1004; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Sobrado M, 2003, NEUROSCIENCE, V118, P107, DOI 10.1016/S0306-4522(02)00912-0; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Uchida K, 1999, TRENDS CARDIOVAS MED, V9, P109, DOI 10.1016/S1050-1738(99)00016-X; Walton M, 1997, MOL BRAIN RES, V50, P165, DOI 10.1016/S0169-328X(97)00181-2; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Wu YL, 1998, J IMMUNOL, V160, P5929; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x; Zhang YP, 1999, J BIOL CHEM, V274, P27726, DOI 10.1074/jbc.274.39.27726	67	90	95	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1523-0864	1557-7716		ANTIOXID REDOX SIGN	Antioxid. Redox Signal.	OCT	2003	5	5					647	654		10.1089/152308603770310329			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	735FF	WOS:000186101200019	14580322				2021-06-18	
J	Iyer, LV; Haley, SM; Watkins, MP; Dumas, HM				Iyer, LV; Haley, SM; Watkins, MP; Dumas, HM			Establishing minimal clinically important differences for scores on the Pediatric Evaluation of Disability Inventory for inpatient rehabilitation	PHYSICAL THERAPY			English	Article						clinical importance; minimal clinically important difference; Pediatric Evaluation of Disability Inventory; responsiveness	QUALITY-OF-LIFE; SELECTIVE DORSAL RHIZOTOMY; TRAUMATIC BRAIN INJURY; VISUAL ANALOG SCALES; CONSTRUCT-VALIDITY; CEREBRAL-PALSY/; MOTOR FUNCTION; HEALTH-STATUS; CHILDREN; PROGRAM	Background and Purpose. Standardized pediatric assessment tools such as the Pediatric Evaluation of Disability Inventory (PEDI) numerically quantify changes during rehabilitation through test scores, but they are unable to provide client-specific information regarding important changes in function. The purpose of this study was to identify the smallest change in PEDI scores during inpatient rehabilitation that was considered to be a minimal clinically important difference (MCID) by physical therapists and other clinicians. Subjects and Methods. A retrospective review was done of the medical charts of 53 children and youth (1-19 years of age) discharged from an inpatient rehabilitation hospital. Fifteen clinicians (5 physical therapists, 6 occupational therapists, and 4 speech and language pathologists) who were masked to the PEDI scores provided ratings of the magnitude of functional changes during inpatient rehabilitation using a Likert scale and a visual analog scale (VAS). Ratings by clinicians were reduced to 4 categories, including the MCID, and compared with PEDI change scores. Results. The MCIDs ranged from 6 to 15 points ((X) over bar =11.5, 95% confidence interval= +/- 2.8) for all PEDI scales. Likert scale and VAS ratings were correlated (tau=.73-.80). Discussion and Conclusion. Across all scales, PEDI change scores on the order of about 11% (0-100 scale) appear to be meaningful to clinicians during a child's or adolescent's inpatient rehabilitation. These data can serve as a starting point for interpreting group and individual changes on the PEDI during physical therapy intervention in inpatient rehabilitation.	Boston Univ, Ctr Rehabil Effectiveness, Boston, MA 02215 USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; Warbasse Nursery Sch, Brooklyn, NY USA; MGH Inst Hlth Profess, Post Profess Grad Program Phys Therapy, Boston, MA USA; Franciscan Childrens Hosp, Res Ctr Children Special Hlth Care Needs, Boston, MA USA; Rehabil Ctr, Boston, MA USA	Haley, SM (corresponding author), Boston Univ, Ctr Rehabil Effectiveness, 635 Commonwealth Ave, Boston, MA 02215 USA.	smhaley@bu.edu					American Physical Therapy Association, 2001, GUID PHYS THER PRACT; Bedell GM, 2002, BRAIN INJURY, V16, P659, DOI 10.1080/02699050210128924; CLARKE PRF, 1964, B BRIT PSYCHOL SOC, V17, P55; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DUDGEON BJ, 1994, ARCH PHYS MED REHAB, V75, P46; Dumas Helene M, 2002, Pediatr Phys Ther, V14, P85, DOI 10.1097/00001577-200214020-00004; Dumas Helene M., 2001, Physical and Occupational Therapy in Pediatrics, V21, P7; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; GUYATT GH, 1987, J CHRON DIS, V40, P1129, DOI 10.1016/0021-9681(87)90080-4; Haley S.M., 1992, PEDIAT EVALUATION DI; Haley SM, 2001, PHYS THER, V81, P1425, DOI 10.1093/ptj/81.8.1425; HALEY SM, 1991, PEDIATRIC PHYSICAL T, V3, P177; Hays RD, 2000, PHARMACOECONOMICS, V18, P419, DOI 10.2165/00019053-200018050-00001; Jacobson NS, 1999, J CONSULT CLIN PSYCH, V67, P300, DOI 10.1037/0022-006X.67.3.300; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; Ketelaar M, 2001, PHYS THER, V81, P1534, DOI 10.1093/ptj/81.9.1534; Liang MH, 2000, MED CARE, V38, P84, DOI 10.1097/00005650-200009002-00013; LIPSEY MW, 1983, PSYCHOL BULL, V94, P152, DOI 10.1037/0033-2909.94.1.152; McAuliffe CA, 1998, PEDIAT PHYS THER, V10, P23; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Nichols D.S., 1996, PEDIATR PHYS THER, V8, DOI [https://doi.org/10.1097/00001577-199600810-00004, DOI 10.1097/00001577-199600810-00004]; Nordmark E, 2000, DEV MED CHILD NEUROL, V42, P245, DOI 10.1017/S0012162200000426; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Rasch G., 1960, PROBABILISTIC MODELS; Reid DT, 1993, PHYSICAL OCCUPATIONA, V13, P57, DOI [DOI 10.1080/J006V13N04_04, 10.1080/J006v13n0404]; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Russell D, 1998, DEV MED CHILD NEUROL, V40, P693; Schneider JW, 2001, DEV MED CHILD NEUROL, V43, P601, DOI 10.1017/S0012162201001098; Singer AJ, 1998, ACAD EMERG MED, V5, P1007, DOI 10.1111/j.1553-2712.1998.tb02781.x; *SPSS INC, 1999, STAT PROGR SOC SCI V; SUNDBERG KB, 1992, INTERRATER RELIABILI; Tokcan Gul, 2003, Pediatr Phys Ther, V15, P16, DOI 10.1097/01.PEP.0000050765.71924.6C; Wright B.D., 1982, RATING SCALE ANAL; Wright FV, 1993, CAN J REHABIL, V7, P41; Wyrwich KW, 1999, MED CARE, V37, P469, DOI 10.1097/00005650-199905000-00006; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91, DOI 10.1080/J006v21n02_08	39	90	93	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	OCT	2003	83	10					888	898		10.1093/ptj/83.10.888			11	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	805XQ	WOS:000220399400002	14519060	Bronze			2021-06-18	
J	Suuronen, T; Huuskonen, J; Pihlaja, R; Kyrylenko, S; Salminen, A				Suuronen, T; Huuskonen, J; Pihlaja, R; Kyrylenko, S; Salminen, A			Regulation of microglial inflammatory response by histone deacetylase inhibitors	JOURNAL OF NEUROCHEMISTRY			English	Article						acetylation; Alzheimer; epigenetics; histone deacetylase; neurodegeneration; nuclear factor kappa B	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; IMMUNE-SYSTEM; CHROMATIN STRUCTURE; GENE-REGULATION; UP-REGULATION; ACETYLATION; ACTIVATION; CYTOKINES	The activation of microglial cells is involved in the pathogenesis of a variety of neurodegenerative diseases, stroke and traumatic brain injuries. Recent studies suggest that protein acetylation can affect the extent of inflammatory responses. Our aim was to elucidate whether histone deacetylase inhibitors, inducers of protein hyperacetylation, regulate the inflammatory response in neural models of inflammation in vitro and whether neurone - glia interactions affect this regulation. Interestingly, we observed that histone deacetylase inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid, strongly potentiated the lipopolysaccharide (LPS)-induced inflammatory response in murine N9 and rat primary microglial cells as well in neural co-cultures and hippocampal slice cultures. TSA clearly potentiated the LPS-induced expression of interleukin (IL)-6 and inducible nitric oxide synthase mRNAs, as well as the secretion of cytokines IL-6, tumour necrosis factor-alpha and macrophage inflammatory protein (MIP)-2, and nitric oxide (NO). Co-culture and slice culture experiments showed that the presence of astrocytes and neurones did not stimulate or prevent the pro-inflammatory potentiation induced by histone deacetylase inhibitor in microglial cells. The potentiation of cytokine and NO responses was blocked by the nuclear factor kappa B (NF-kappaB) inhibitors caffeic acid phenethyl ester and helenalin, demonstrating that the NF-kappaB signalling pathway is involved. The DNA-binding activity of the NF-kappaB complex was strongly increased by LPS treatment but not enhanced by TSA. This suggests that potentiation of the inflammatory response is not dependent on the level of cytoplasmic NF-kappaB activation or DNA-binding activity but that site of action may be at the level of transcriptional regulation. Our results suggest that environmental stresses, ageing, diet and diseases that regulate protein acetylation status may also affect the inflammatory response.	Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Salminen, A (corresponding author), Univ Kuopio, Dept Neurol & Neurosci, Pob 1627, FIN-70211 Kuopio, Finland.	antero.salminen@uku.fi					Ajamian F, 2003, NEUROSCI LETT, V346, P57, DOI 10.1016/S0304-3940(03)00545-7; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Blanchard F, 2002, ONCOGENE, V21, P6264, DOI 10.1038/sj.onc.1205777; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Chang KT, 2002, AGEING RES REV, V1, P313, DOI 10.1016/S1568-1637(02)00003-X; Chang RCC, 2000, BRAIN RES, V853, P236, DOI 10.1016/S0006-8993(99)02255-6; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dutnall RN, 2001, CELL, V105, P161, DOI 10.1016/S0092-8674(01)00305-1; Elenkov IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/j.1749-6632.2002.tb04229.x; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; Helenius M, 1999, EXP CELL RES, V248, P194, DOI 10.1006/excr.1999.4393; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; Helenius M, 2001, ANTIOXID REDOX SIGN, V3, P147, DOI 10.1089/152308601750100669; Holloway AF, 2002, MOL IMMUNOL, V38, P567, DOI 10.1016/S0161-5890(01)00094-3; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jung M, 2001, CURR MED CHEM, V8, P1505, DOI 10.2174/0929867013372058; Kaltschmidt B, 2000, EXP BRAIN RES, V130, P100, DOI 10.1007/s002210050011; Kerokoski P, 2001, NEUROCHEM INT, V38, P127, DOI 10.1016/S0197-0186(00)00071-1; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nakamura Y, 2002, BIOL PHARM BULL, V25, P945, DOI 10.1248/bpb.25.945; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Polevoda B, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-5-reviews0006; Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	47	90	93	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2003	87	2					407	416		10.1046/j.1471-4159.2003.02004.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	726JN	WOS:000185596100014	14511118	Bronze			2021-06-18	
J	Chen, SHA; Kareken, DA; Fastenau, PS; Trexler, LE; Hutchins, GD				Chen, SHA; Kareken, DA; Fastenau, PS; Trexler, LE; Hutchins, GD			A study of persistent post-concussion symptoms in mild head trauma using positron emission tomography	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CEREBRAL GLUCOSE-METABOLISM; LATE WHIPLASH SYNDROME; BRAIN-INJURY; TECHNETIUM-99M-HMPAO SPECT; POSTCONCUSSION SYMPTOMS; WORKING-MEMORY; BLOOD-FLOW; PET; ABNORMALITIES; DEPRESSION	Background: Complaints of persistent cognitive deficits following mild head trauma are often uncorroborated by structural brain imaging and neuropsychological examination. Objective: To investigate, using positron emission tomography (PET), the in vivo changes in regional cerebral uptake of 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) and regional cerebral blood flow (rCBF) in patients with persistent symptoms following mild head trauma. Methods: Five patients with mild head trauma and five age and education matched healthy controls were imaged using FDG-PET to measure differences in resting regional cerebral glucose metabolism. Oxygen-15 labelled water ((H2O)-O-15)-PET was also used to measure group differences in rCBF changes during a spatial working memory task. In addition, neuropsychological testing and self report of dys-executive function and post-concussion symptoms were acquired to characterise the sample. Results: There was no difference between patients and controls in normalised regional cerebral FDG uptake in the resting state in frontal and temporal regions selected a priori. However, during the spatial working memory task, patients had a smaller increase in rCBF than controls in the right prefrontal cortex. Conclusions: Persistent post-concussive symptoms may not be associated with resting state hypometabolism. A cognitive challenge may be necessary to detect cerebral changes associated with mild head trauma.	Stanford Sch Med Radiol, Lucas MRS Imaging Ctr, Stanford, CA 94305 USA	Chen, SHA (corresponding author), Stanford Sch Med Radiol, Lucas MRS Imaging Ctr, 1201 Welch Rd MC 5488, Stanford, CA 94305 USA.		Kareken, David/Z-1960-2019; Chen, SH Annabel/F-3742-2011	Chen, SH Annabel/0000-0002-1540-5516; Kareken, David/0000-0003-0855-8300			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Altrocchi PH, 1996, NEUROLOGY, V46, P278; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAXTER LR, 1985, ARCH GEN PSYCHIAT, V42, P441; BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243; BENCH CJ, 1992, PSYCHOL MED, V22, P607, DOI 10.1017/S003329170003806X; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; CONNERS CK, 1995, MULTI HLTH SYSTEMS S; DELIS D, 1987, CALIFORNIA VERBAL LE; Derogatis L.R., 1975, SYMPTOM CHECKLIST 90; DOLAN RJ, 1992, J NEUROL NEUROSUR PS, V55, P768, DOI 10.1136/jnnp.55.9.768; DREVETS WC, 1992, J NEUROSCI, V12, P3628; DUVERNOY HM, 1995, HUMAN BRAIN SURFACE; Fastenau PS, 2002, EXTENDED COMPLEX FIG; Gold S, 1997, NEUROIMAGE, V5, P280, DOI 10.1006/nimg.1997.0268; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Heaton R. K, 1981, WISCONSIN CARD SORTI; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; HURWITZ TA, 1990, CAN J PSYCHIAT, V35, P684, DOI 10.1177/070674379003500807; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P432; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MARTINOT JL, 1990, AM J PSYCHIAT, V147, P1313; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mesulam M. M., 1985, PRINCIPLES BEHAV NEU, V3, P125; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NORMAN MA, IN PRESS J CLIN EXP; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; Otte A, 1997, J NEUROL NEUROSUR PS, V63, P368, DOI 10.1136/jnnp.63.3.368; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; RUFF RM, 1994, BRAIN INJURY, V8, P197; Spreen O., 1998, COMPENDIUM NEUROPSYC; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Talairach J, 1988, CO PLANAR STEREOTAXI; Taylor L, 1991, COMPENDIUM NEUROPSYC; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Trahan D, 1988, CONTINUOUS VISUAL ME; Wechsler D., 1997, WECHSLER INTELLIGENC; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wolfson D., 1993, HALSTEAD REITAN NEUR	50	90	91	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2003	74	3					326	332		10.1136/jnnp.74.3.326			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	651YC	WOS:000181350400013	12588917	Green Published, Bronze			2021-06-18	
J	Maxwell, WL; Dhillon, K; Harper, L; Espin, J; MacIntosh, TK; Smith, DH; Graham, DI				Maxwell, WL; Dhillon, K; Harper, L; Espin, J; MacIntosh, TK; Smith, DH; Graham, DI			There is differential loss of pyramidal cells from the human hippocampus with survival after blunt head injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						adult head injury; blunt head injury; hippocampus; pyramidal neurons	UNBIASED STEREOLOGICAL ESTIMATION; TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; GERBIL HIPPOCAMPUS; NUMBER; RAT; VULNERABILITY; PATHOLOGY; ISCHEMIA; NEURONS	The experimental literature has shown that neurons within sub-fields of the hippocampus possess differential sensitivities to cell loss after different types of insult to the brain. In humans, after blunt head injury, differential neuronal responses between sub-fields of the hippocampus up to 72 hours after injury have been documented, But, in only a small part of the literature have data for alterations in real numbers of neurons been provided. In this study the hypothesis was tested that, after severe blunt head injury in humans, the total number of neurons within a defined volume of brain tissue differed between different sub-fields of the hippocampus and between groups of patients with differing post-traumatic survivals. Stereological methods were used to measure total cross-sectional area of sub-fields of the hippocampus taken at the level of the lateral geniculate nucleus and count numbers of neurons within each of the CA1, CA2, CA3, and CA4 sub-fields of the hippocampus in patients, The patients used in this study were categorized as follows: Group I (early) had survived for I week or less; Group 2 (late) survived 6 months or longer after fatal severe head injury; and Group 3 (controls) consisted of age-matched patients that had no history of head injury or disease prior to death. There was a significant loss in cross-sectional area in sub-fields CA3 and CA4 at I week or less after injury and in sub-field CA1 at 6 months and greater survival. There was no change in CA2. There was loss of neurons from within a predefined volume of brain tissue in sub-fields CA1, CA3, and CA4 one week or less after injury. But there was no loss in CA2. There was continued loss of neurons from sub-fields CA1 and CA4 between I week and 6 months and greater survival, but there was no loss of neurons in sub-fields CA2 and CA3 within the same period. These novel data show that after human severe head injury there is first an acute loss (I week or less survival) of pyramidal neurons in all hippocampal sub-fields except CA2. Second, there is an ongoing loss of neurons in sub-field CA1 and, most notably, in sub-field CA4, in patients surviving for more than 6 months. However, in neither group of patients is there loss of neurons from sub-field CA2.	Univ Glasgow, IBLS, Dept Anat, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, So Gen NHS Trust, Dept Neuropathol, Glasgow, Lanark, Scotland; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Maxwell, WL (corresponding author), Univ Glasgow, IBLS, Dept Anat, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	wmaxwell@bio.gla.ac.uk	smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS038104, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; BONNEKOH P, 1990, ACTA NEUROPATHOL, V80, P18, DOI 10.1007/BF00294217; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1981, VIRCHOWS ARCH B, V37, P317, DOI 10.1007/BF02892580; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HONAVAR M, 1997, GREENFIELDS NEUROPAT, P942; HOWARD CV, 1998, NUMBER ESTIMATION UN, P69; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; MATHIEU O, 1981, J MICROSC-OXFORD, V121, P75, DOI 10.1111/j.1365-2818.1981.tb01200.x; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; RAISMAN G, 1965, BRAIN, V88, P963, DOI 10.1093/brain/88.5.963; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	36	90	93	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2003	62	3					272	279		10.1093/jnen/62.3.272			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	653QM	WOS:000181448400006	12638731	Bronze			2021-06-18	
J	Goldbaum, O; Richter-Landsberg, C				Goldbaum, O; Richter-Landsberg, C			Stress proteins in oligodendrocytes: differential effects of heat shock and oxidative stress	JOURNAL OF NEUROCHEMISTRY			English	Article						heat shock proteins; heme oxygenase; iron chelator; myelin forming cells; oxidative stress	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; HEME OXYGENASE-1 HO-1; MULTIPLE-SCLEROSIS; BIOCHEMICAL-PROPERTIES; REACTIVE OXYGEN; CELL-DEATH; IRON; EXPRESSION; ACTIVATION	Heat shock proteins (HSP) or stress proteins serve as biomarkers to identify the contribution of stress situations underlying the pathogenesis of degenerative diseases of the CNS. We have analyzed by immunoblot technique the constitutive and inducible occurance of stress proteins in cultured rat brain oligodendrocytes subjected to heat shock or oxidative stress exerted by hydrogen peroxide, or a combination of both. The data demonstrate that oligodendrocytes constitutively express HSP32, HSP60 and the cognate form of the HSP70 family of proteins, HSC70. After heat shock, HSP25, alphaB-crystallin and HSP70 were up-regulated, while after oxidative stress the specific induction of HSP32 and alphaB-crystallin was observed. HSP32 represents heme oxygenase 1 (HO-1), a small stress protein with enzymatic activity involved in the oxidative degradation of heme which participates in iron metabolism. The presence of the iron chelators phenanthroline or deferoxamine (DFO), which previously has been shown to protect oligodendrocytes from oxidative stress-induced onset of apoptosis, caused a marked stimulation of HSP32 without affecting HSP70. This indicates that DFO possibly exerts its protective role by directly influencing the antioxidant capacity of HO-1. In summary, HSP in oligodendrocytes are differentially stimulated by heat stress and oxidative stress. Heme oxygenase-1 has been linked to inflammatory processes and oxidative stress, its specific up-regulation after oxidative stress in oligodendrocytes suggests that it is an ideal candidate to investigate the involvement of oxidative stress in demyelinating diseases.	Univ Oldenburg, Dept Biol Mol Neurobiol, D-2611 Oldenburg, Germany	Richter-Landsberg, C (corresponding author), Univ Oldenburg, Dept Biol Mol Neurobiol, POB 2503, D-2611 Oldenburg, Germany.						Aquino DA, 1997, J NEUROPATH EXP NEUR, V56, P664; BAJRAMOVIC JJ, 1997, J NEUROIMMUNOL, V78, P142; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; BIRNBAUM G, 1995, SPRINGER SEMIN IMMUN, V17, P107; Boccaccio GL, 1996, J NEUROSCI RES, V45, P647; BOELENS WC, 1995, MOL BIOL REP, V21, P75, DOI 10.1007/BF00986495; Brosnan CF, 1996, J NEUROPATH EXP NEUR, V55, P389, DOI 10.1097/00005072-199604000-00001; BROWN IR, 1994, HEAT SHOCK PROTEINS, P31; CHARLES J, 1994, TRENDS NEUROSCI, V17, P135, DOI 10.1016/0166-2236(94)90085-X; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; GALEY JP, 1997, ANTIOXIDANTS DIS MEC, P147; GELMAN BB, 1995, J NEUROPATH EXP NEUR, V54, P477, DOI 10.1097/00005072-199507000-00001; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hartsfield CL, 1998, FASEB J, V12, P1675; Head MW, 2000, NEUROPATH APPL NEURO, V26, P304, DOI 10.1046/j.1365-2990.2000.00269.x; ITOH H, 1995, J BIOL CHEM, V270, P13429, DOI 10.1074/jbc.270.22.13429; Jelinski SE, 1999, BRAIN RES, V815, P150, DOI 10.1016/S0006-8993(98)01053-1; Kvam E, 2000, FREE RADICAL BIO MED, V28, P1191, DOI 10.1016/S0891-5849(00)00205-7; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Ludwin SK, 1997, J NEUROPATH EXP NEUR, V56, P111, DOI 10.1097/00005072-199702000-00001; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCMORRIS FA, 1981, EXP CELL RES, V133, P395, DOI 10.1016/0014-4827(81)90332-3; NEUHOFF V, 1979, H-S Z PHYSIOL CHEM, V360, P1657, DOI 10.1515/bchm2.1979.360.2.1657; NOWAK TS, 1994, HEAT SHOCK PROTEINS, P55; Pedchenko TV, 1998, J NEUROIMMUNOL, V84, P188, DOI 10.1016/S0165-5728(97)00256-7; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Raine CS, 1996, LAB INVEST, V75, P109; Richter-Landsberg C, 1999, J NEUROSCI RES, V56, P259, DOI 10.1002/(SICI)1097-4547(19990501)56:3<259::AID-JNR5>3.0.CO;2-N; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Schipper HM, 2000, EXP GERONTOL, V35, P821, DOI 10.1016/S0531-5565(00)00148-0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Smith KJ, 1999, BRAIN PATHOL, V9, P69; Stuhlmeier KM, 2000, EUR J BIOCHEM, V267, P1161, DOI 10.1046/j.1432-1327.2000.01112.x; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x	45	90	93	1	7	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	2001	78	6					1233	1242		10.1046/j.1471-4159.2001.00507.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	474LF	WOS:000171107900005	11579132	Bronze			2021-06-18	
J	Barth, JT; Freeman, JR; Broshek, DK; Varney, RN				Barth, JT; Freeman, JR; Broshek, DK; Varney, RN			Acceleration-deceleration sport-related concussion: The gravity of it all	JOURNAL OF ATHLETIC TRAINING			English	Article						mild head injury; physics; athletic injury; axonal injury; whiplash	HEAD-INJURY; RECOVERY	Objective: To discuss a newtonian physics model for understanding and calculating acceleration-deceleration forces found in sport-related cerebral concussions and to describe potential applications of this formula, including (1) an attempt to measure the forces applied to the brain during acceleration-deceleration injuries, (2) a method of accruing objective data regarding these forces, and (3) use of these data to predict functional outcome, such as neurocognitive status, recovery curves, and return to play. Background: Mild concussion in sports has gained considerable attention in the last decade. Athletic trainers and team physicians have attempted to limit negative outcomes by gaining a better understanding of the mechanisms and severity of mild head injuries and by developing meaningful return-to-play criteria. Mild head injury in sports has become an even greater area of focus and concern, given the negative neurobehavioral outcomes experienced by several recent high-profile professional athletes who sustained repeated concussions, Applying the principles of physics to characterize injury types, injury severity, and outcomes may further our development of better concussion management techniques and prevention strategies. Description: We describe the search for models to explain neuronal injury secondary to concussion and provide an exploratory method for quantifying acceleration-deceleration forces and their relationship to severity of mild head injury. Implications for injury prevention and reduction of morbidity are also considered.	Univ Virginia, Sch Med, Neuropsychol Lab, Dept Psychiat Med, Charlottesville, VA 22908 USA	Barth, JT (corresponding author), Univ Virginia, Sch Med, Neuropsychol Lab, Dept Psychiat Med, 800203 HSC, Charlottesville, VA 22908 USA.	jtb4y@virginia.edu					BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P81; Barth JT., 1989, MILD HEAD INJURY, P257; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GENNARELLI TA, 1981, ACTA NEUROPATHOL B S, V1, P23; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R.M., 1989, MILD HEAD INJURY, P176; Varney RN, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P39; Winters JE, 2001, J ATHL TRAINING, V36, P339	16	90	90	0	17	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					253	256					4	Sport Sciences	Sport Sciences	557NC	WOS:000175913800007	12937493				2021-06-18	
J	Masanic, CA; Bayley, MT; vanReekum, R; Simard, M				Masanic, CA; Bayley, MT; vanReekum, R; Simard, M			Open-label study of donepezil in traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						acetylcholinesterase inhibitor; brain injuries; memory; rehabilitation	VESICULAR ACETYLCHOLINE TRANSPORTER; HEAD-INJURY; REY-OSTERRIETH; MODERATE; HIPPOCAMPAL; COGNITION; PROTEIN; DISEASE	Objective: To determine preliminarily whether donepezil will improve memory, behavior, and global function after chronic traumatic brain injury (TBI). Design: Sixteen-week open-label study. Setting: Outpatient TBI rehabilitation program. Patients: Four patients with chronic, severe TBI. Interventions: Donepezil 5mg daily for 8 weeks followed by 10mg daily for 4 weeks. Main Outcome Measures: Memory measures included the Rey Auditory Verbal Learning Test (RAVLT), the Complex Figure Test (CFT), items from the Rivermead Behavioural Memory Test (RBMT), and a semantic fluency task. The Neuropsychiatric Inventory (NPI) evaluated behavior and affect. Function was assessed by using the FIM(TM) instrument and a clinical global impression of change. Results: On the RAVLT, the mean scores for learning and short- and long-term recall improved by 0.4, 1.04, and .83 standard deviations (SDs) above baseline respectively. On the CFT, the mean scores for short-term recall and long-term recall improved by 1.56 and 1.38 SDs above baseline, respectively. A positive trend was observed on the RBMT and on the NPI subscales. Conclusions: Donepezil may improve some aspects of memory and behavior in persons with chronic TBI. Randomized clinical trials are required to support these preliminary findings.	Hamilton Hlth Sci Corp, Div Phys Med & Rehabil, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; Baycrest Ctr Geriatr Care, Dept Psychiat, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Univ Toronto, Div Geriatr Psychiat, Toronto, ON, Canada	Masanic, CA (corresponding author), Hamilton Hlth Sci Corp, Div Phys Med & Rehabil, Chedoke Campus,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Simard/Q-9675-2019	Simard/0000-0003-1257-8275; Bayley, Mark/0000-0001-7860-9463			Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CASEY MB, 1991, J CLIN EXP NEUROPSYC, V13, P600, DOI 10.1080/01688639108401074; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; CRAWFORD JR, 1989, J CLIN EXP NEUROPSYC, V11, P975, DOI 10.1080/01688638908400950; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DULEY JF, 1993, CLIN NEUROPSYCHOL, V7, P29, DOI DOI 10.1080/13854049308401885; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; GOLDBERG E, 1982, Journal of Clinical Neuropsychology, V4, P219, DOI 10.1080/01688638208401131; Granger CV, 1986, GUIDE USE UNIFORM DA; KUEHN SM, 1992, ARCH CLIN NEUROPSYCH, V7, P445, DOI 10.1016/0887-6177(92)90157-I; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levy ML, 1999, GERONTOLOGY, V45, P15, DOI 10.1159/000052760; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McLean A Jr, 1987, Brain Inj, V1, P145, DOI 10.3109/02699058709034453; MITRUSHINA M, 1999, HDB NORMATIVE DATA N, P184; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rogers SL, 1999, NEUROLOGY, V52, P218; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; Silver JM., 1994, NEUROPSYCHIATRY TRAU; Spreen O., 1998, COMPENDIUM NEUROPSYC; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Talland G. A., 1965, DERANGED MEMORY PSYC; Taverni JP, 1998, BRAIN INJURY, V12, P77; Taylor E. M., 1959, APPRAISAL CHILDREN C; vanReekum R, 1997, CAN J PSYCHIAT, V42, pS35; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	38	90	92	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2001	82	7					896	901		10.1053/apmr.2001.23833			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	450KV	WOS:000169742800005	11441374				2021-06-18	
J	Wallesch, CW; Curio, N; Kutz, S; Jost, S; Bartels, C; Synowitz, H				Wallesch, CW; Curio, N; Kutz, S; Jost, S; Bartels, C; Synowitz, H			Outcome after mild-to-moderate blunt head injury: effects of focal lesions and diffuse axonal injury	BRAIN INJURY			English	Article							TRAUMA	Primary objective: A comparison of the effects of focal and diffuse axonal injury in mild-to-moderate traumatic brain injury (TBI). Research design: In a prospective longitudinal study of 138 consecutive patients suffering from TBI who were admitted to the Magdeburg University Hospital, 60 could be assessed neuropsychologically 8-31 days after trauma and 18-45 weeks later. Methods and procedures: GCS, CT-analysis, comprehensive neuropsychological assessment. Main results: The initial GCS-score was significantly correlated with outcome impairments of semantic fluency and memory in the Wechsler Similarities and in two clinical scales (Neurobehavioural Rating Scale, Frontal Lobe Score). The presence of CT-signs of DAI corresponded with deficits in tasks of response selection and suppression, the presence of focal contusions with results in the clinical scales, reaching significance for behavioural deficits with frontal contusions. Improvements between first and second assessments were pronounced in patients with signs of DAI. Conclusions: The data indicate that traumatic DAI results in mainly transient neuropsychological deficits. Focal frontal contusions result in more relevant deficits at outcome that affect behaviour and, thus, impair rehabilitation prognosis. It is concluded that even in clinically 'mild' TBI, prognosis and rehabilitation requirements should be established by early imaging and post-acute neuropsychological assessment.	Univ Magdeburg, Dept Neurol, D-39120 Magdeburg, Germany; Univ Magdeburg, Div Neuropsychol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Neurosurg, D-39120 Magdeburg, Germany	Wallesch, CW (corresponding author), Univ Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	wallesch@medizin.uni-magdeburg.de					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; ETTLIN T, 1999, SCI PRACT NEUROPSYCH, P233; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gennarelli TA, 1994, HEAD INJURY, P137; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KESSLER J, 1988, DEMENZTEST; KRAMER J, 1977, KURZE ANLEITUNG ZUM; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCFIE J, 1975, ASSESSMENT ORGANIC I; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OSWALD WD, 1995, NURNBERGER ALTERSINV; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; TEASDALE G, 1974, LANCET, V2, P81; WALLESCH CW, IN PRESS J NEUROTRAU; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; ZIMMERMANN P, 1995, NEUROPSYCHOLOGISCHE	25	90	94	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2001	15	5					401	412		10.1080/02699050010005959			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	431TW	WOS:000168648700003	11350654				2021-06-18	
J	Grant, SA; Bettencourt, K; Krulevitch, P; Hamilton, J; Glass, R				Grant, SA; Bettencourt, K; Krulevitch, P; Hamilton, J; Glass, R			In vitro and in vivo measurements of fiber optic and electrochemical sensors to monitor brain tissue pH	SENSORS AND ACTUATORS B-CHEMICAL			English	Article						sol-gel method; optoelectronics; stroke; brain injury; iridium oxide	OXYGEN; BIOSENSOR; STROKE; INJURY	We report herein the development of fiber optic and electrochemical pH sensors that could become part of an arsenal to quickly and aggressively treat people undergoing a stroke as well as people who have suffered traumatic brain injury. The fiber optic pH sensor design consists of the immobilization of a pH sensitive dye, seminaphthorhodamine-1 carboxylate (SNARF-1C) within a silica sol-gel matrix. A miniature optoelectronics package was developed to acquire data from the fiber optic sensor. The electrochemical sensor consists of a thin film multilayer coating sputtered on a kapton substrate. The sensors were tested in vitro and in vivo. For both sensors, the in vitro results show linear and reproducible responses in human blood in the pH range 6.8-8.0. The results of the in vivo studies which were performed in Spraque-Dawley rats indicate that both the fiber optic and electrochemical sensors monitor pH with very little drift. It was concluded that both types of sensors would be useful in tracking brain tissue pH. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Calif Lawrence Livermore Natl Lab, Chem & Mat Sci Directorate, Livermore, CA 94550 USA	Grant, SA (corresponding author), Michigan Technol Univ, Ctr Biomed Engn, 1400 Townsend Dr, Houghton, MI 49931 USA.						BRONK KS, 1995, ANAL CHEM, V67, P2750, DOI 10.1021/ac00113a005; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; GOLDEN JP, 1994, IEEE T BIO-MED ENG, V41, P585, DOI 10.1109/10.293246; Grant SA, 1997, SENSOR ACTUAT B-CHEM, V45, P35, DOI 10.1016/S0925-4005(97)00263-3; Grant SA, 1999, IEEE T BIO-MED ENG, V46, P1207, DOI 10.1109/10.790497; Johnson G., 1998, TRAUMATIC BRAIN INJU; LEVINE SR, 1992, PROG CARDIOVASC DIS, V34, P235, DOI 10.1016/0033-0620(92)90020-Z; Matchar D. B., 1994, STROKE CLIN UPDATES, V5, P9; McKinley BA, 1996, CRIT CARE MED, V24, P1858, DOI 10.1097/00003246-199611000-00016; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Muller P, 1998, Biomed Instrum Technol, V32, P656; RATNER BD, BIOMATERIALS SCI INT, P105; SOLLER BR, 1994, IEEE ENG MED BIOL, V6, P327; VENKATESH B, 1994, CRIT CARE MED, V22, P588, DOI 10.1097/00003246-199404000-00013; Watson JC, 1997, STROKE, V28, P1624, DOI 10.1161/01.STR.28.8.1624; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Xu Z, 1998, J BIOMED MATER RES, V39, P9, DOI 10.1002/(SICI)1097-4636(199801)39:1<9::AID-JBM2>3.0.CO;2-U; YANG L, 1995, ANAL CHEM, V67, P1307, DOI 10.1021/ac00104a002; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; ZAUNER A, 1995, NEUROSURGERY, V37, P1176	20	90	91	2	41	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0925-4005			SENSOR ACTUAT B-CHEM	Sens. Actuator B-Chem.	JAN 25	2001	72	2					174	179		10.1016/S0925-4005(00)00650-X			6	Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation	Chemistry; Electrochemistry; Instruments & Instrumentation	397HW	WOS:000166688100011					2021-06-18	
J	Kirkendall, DT; Jordan, SE; Garrett, WE				Kirkendall, DT; Jordan, SE; Garrett, WE			Heading and head injuries in soccer	SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; CONTACT-SPORTS; CONCUSSION; DAMAGE; PERFORMANCE; GUIDELINES; RETURN	In the world of sports, soccer is unique because of the purposeful use of the unprotected head for controlling and advancing the ball. This skill obviously places the player at risk of head injury and the game does carry some risk. Head injury can be a result of contact of the head with another head (or other body parts), ground, goal post, other unknown objects or even the ball. Such impacts can lead to contusions, fractures, eye injuries, concussions or even, in rare cases, death. Coaches, players, parents and physicians are rightly concerned about the risk of head injury in soccer, Current research shows that selected soccer players have some degree of cognitive dysfunction. It is important to determine the reasons behind such deficits. Purposeful heading has been blamed, but a closer look at the studies that focus on heading has revealed methodological concerns that question the validity of blaming purposeful heading of the ball. The player's history and age (did they play when the ball was leather and could absorb significant amounts of water), alcohol intake. drug intake. learning disabilities, concussion definition and control group use/composition are all factors that cloud the ability to blame purposeful heading. What does seem clear is that a player's history of concussive episodes is a more likely explanation for cognitive deficits. While it is likely that the subconcussive impact of purposeful heading is a doubtful factor in the noted deficits, it is unknown whether multiple subconcussive impacts might have some lingering effects. In addition, it is unknown whether the noted deficits have any affect on daily life. Proper instruction in the technique is critical because if the ball contacts an unprepared head (as in accidental head-ball contacts), the potential for serious injury is possible. To further our understanding of the relationship of heading, head injury and cognitive deficits, we need to: learn more about the actual impact of a ball on the head, verify the exposure to heading at all ages and competitive levels, determine stable estimates of concussive injury rates across the soccer spectrum, conduct prospective longitudinal studies on soccer players focusing on exposure, injury and cognition, and determine the minimum safe age to begin instruction on the skill of heading. Only then will we be able to speak with some authority on the issue of heading and head injuries in soccer.	Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; US Soccer Federat, Chicago, IL USA; Neurol Associates W Los Angeles, Santa Monica, CA USA	Kirkendall, DT (corresponding author), Univ N Carolina, Dept Orthopaed, CB 7055, Chapel Hill, NC 27599 USA.						Armstrong CW, 1988, SCI FOOTBALL, P394; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Congress of Neurological Surgeon, 1966, CLIN NEUROSURG, V12, P386; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Frith U, 1998, SCAND J PSYCHOL, V39, P191, DOI 10.1111/1467-9450.393078; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Holbourn AHS, 1943, LANCET, V2, P438; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENNET B, 1971, SCI FDN NEUROLOGY; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; JOSEPH J, 2001, SOCCER MAY HAZARDOUS; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LEVENDUKSY TA, SCI FOOTBALL, P385; LOHNES JH, 1994, SPORTS INJURIES MECH; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Luhtanen P, 1994, FOOTBALL SOCCER; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon JC, 1999, SPORTS-RELATED CONCUSSION, P3; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; Neiman J, 1998, ALCOHOL CLIN EXP RES, V22, p346S, DOI 10.1111/j.1530-0277.1998.tb04389.x; *NFL SUBC MILD TRA, 1996, STAT REP MEM; Nigg JT, 1998, J ABNORM PSYCHOL, V107, P468, DOI 10.1037/0021-843X.107.3.468; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKINSON D, 1997, MAYO CLIN P, V52, P492; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Reilly T., 1976, J HUMAN MOVEMENT STU, V2, P87; Report of the Sports Medicine Committee, 1990, GUID MAN CONC SPORTS; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Ruff RM, 1999, BRAIN INJURY, V13, P943; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; STONER LJ, 1980, BIOM S P 1980 OCT BL; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; VICTOR M, 1989, WERNICKE KORSAKOFF R; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; 2000, SPORTS ILLUSTRA 0320, V92, P12	60	90	90	0	25	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.		2001	31	5					369	386		10.2165/00007256-200131050-00006			18	Sport Sciences	Sport Sciences	429FD	WOS:000168504600006	11347686				2021-06-18	
J	Madigan, NK; DeLuca, J; Diamond, BJ; Tramontano, G; Averill, A				Madigan, NK; DeLuca, J; Diamond, BJ; Tramontano, G; Averill, A			Speed of information processing in traumatic brain injury: Modality-specific factors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	10th Annual Meeting of the American-Psychological-Society	MAY 21-24, 1998	WASHINGTON, D.C.	Amer Psychol Soc			CLOSED-HEAD-INJURY; MULTIPLE-SCLEROSIS; SERIAL-ADDITION; WORKING-MEMORY; REACTION-TIME; ATTENTION; DEFICITS; FATIGUE; TASK	Objective: To assess speed of information processing by two serial addition tests (one visual, one auditory) in individuals with moderate-to-severe traumatic brain injuries (TBIs) and in a healthy, normal control group (NC). The tasks were designed to equate and control for accuracy of performance across the TBI and NC groups, thus allowing for quantification of information processing speed. Design: Performance across groups and tasks were compared using 2 x 2 repeated measure analyses of variance (AOVAs). In addition, each individual's processing speed was used to adjust rate of stimulus presentation on a subsequent "rehabilitation" trial to determine further whether this adjustment equated accuracy of performance. setting: Rehabilitation hospital. Patients: 22 outpatients with moderate-to-severe TBI (6 women, 16 men; mean age = 34.6 years; duration of loss of consciousness = 22.6 days) and 20 age- and education-matched healthy controls. Results: Processing speed was slower in TBI subjects, relative to controls and was significantly related to measures of executive functioning for those with TBI. Relative to controls, speed of processing in the TBI group was disproportionately slower when information was presented in the auditor relative to the visual, modality. Conclusions: Speed of information processing is a major impairment in those with TBI when unconfounded by performance accuracy. The modality-specific impairment observed in the TBI group may, in part, be due to a greater within-modality interference effect created by the auditory version of the task. By manipulating information at a pace customized for an individual through compensatory strategies and environmental environmental modifications, information-processing performance of TBI participants can be enhanced significantly.	Kessler Med Rehabil Res & Educ Ctr, Dept Phys Med & Rehabil, Dept Res, W Orange, NJ 07052 USA; Ctr Res Alternat & Complementary Med, W Orange, NJ USA; Kessler Inst Rehabil, Welkin Facil, Dept Neuropsychol & Cognit Remediat, Chester, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Res, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA	DeLuca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	delucajo@umdnj.edu					Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; Baddeley A. D., 1986, WORKING MEMORY; Beck A.T., 1987, BECK DEPRESSION INVE; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; DEARY IJ, 1991, PERS INDIV DIFFER, V12, P983, DOI 10.1016/0191-8869(91)90027-9; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gathercole S., 1994, NEUROPSYCHOLOGY, V8, P494, DOI DOI 10.1037/0894-4105.8.4.494; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; Heaton R. K, 1981, WISCONSIN CARD SORTI; Hiscock M, 1998, J CLIN EXP NEUROPSYC, V20, P463, DOI 10.1076/jcen.20.4.463.1466; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Johnson SK, 1996, PERCEPT MOTOR SKILL, V83, P51, DOI 10.2466/pms.1996.83.1.51; Kewman D G, 1988, Brain Inj, V2, P131, DOI 10.3109/02699058809150937; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1988, SCAND J REHABIL MED, P33; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCLEOD P, 1984, ATTENTION PERFORM, V10, P55; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; ODDY M, 1987, J NEUORL NEUROSURG P, V48, P564; PAPO I, 1982, ACTA NEUROCHIR, V62, P47, DOI 10.1007/BF01402210; PIKE R, 1974, ACTA PSYCHOL, V38, P379, DOI 10.1016/0001-6918(74)90042-0; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Spielberger CD, 1983, STATE TRAIT ANXIETY; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Wechsler, 1981, WAIS R MANUAL	44	90	92	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2000	15	3					943	956		10.1097/00001199-200006000-00007			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	321FL	WOS:000087445400007	10785624				2021-06-18	
J	Lopez-Redondo, F; Nakajima, K; Honda, S; Kohsaka, S				Lopez-Redondo, F; Nakajima, K; Honda, S; Kohsaka, S			Glutamate transporter GLT-1 is highly expressed in activated microglia following facial nerve axotomy	MOLECULAR BRAIN RESEARCH			English	Article						glutamate transporter; GLT-1; microglia; astrocytes; facial nerve axotomy; facial nucleus; rat	AMYOTROPHIC-LATERAL-SCLEROSIS; RAT-BRAIN; MOTOR NEURONS; SPINAL-CORD; ASTROCYTES; NEUROTOXICITY; LOCALIZATION; HIPPOCAMPUS; EPILEPSY; ISCHEMIA	Glutamate transporters play an important role in the re-uptake of glutamate after its release from glutamatergic synapses. So far five of such transporters subtypes have been cloned from rodent and human brains. The densities of glutamate transporters are recognised to be developmentally regulated, but the role of glutamate transporters in the mechanisms underlying the occurrence of neuronal traumatic injury has not been widely Studied. Zn the present study quantitative Western blotting and immunohistochemical technique were employed to study the expression of GLT-1/EAAT2 in the facial nuclei of adult rats following unilateral facial nerve axotomy. The total content of GLT-1 protein decreased in the ipsilateral axotomised rat facial nucleus. However, activated microglia surrounding motoneurons showed high expression of GLT-1 after facial nerve axotomy. Parallel studies revealed that primary cultured microglial cells also showed GLT-1-immunoreactivity. To our knowledge, this is the first direct demonstration of the expression of GLT-1 protein in activated microglial cells, suggesting a neuroprotective role of microglia against glutamate excitotoxicity following nerve axotomy. (C) 2000 Elsevier Science B.V. All rights reserved.	Natl Inst Neurosci, Dept Neurochem, Kodaira, Tokyo 1878502, Japan; Soka Univ, Inst Life Sci, Div Neurochem, Hachioji, Tokyo 1928577, Japan	Kohsaka, S (corresponding author), Natl Inst Neurosci, Dept Neurochem, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.	kohsaka@ncnp.go.jp	Lopez-Redondo, Fernando/V-8224-2019	Lopez-Redondo, Fernando/0000-0002-3836-9239			ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi I, 1997, GLIA, V20, P184, DOI 10.1002/(SICI)1098-1136(199707)20:3<184::AID-GLIA2>3.3.CO;2-U; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GRAEBER MB, 1986, J NEUROCYTOL, V15, P363; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEKIEFFRE D, 1992, NEUROSCI LETT, V137, P78, DOI 10.1016/0304-3940(92)90303-O; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Mennini T, 1998, J NEUROL SCI, V157, P31, DOI 10.1016/S0022-510X(98)00072-0; NAKAJIMA K, 1989, BIOMED RES-TOKYO, V10, P411; Nakajima K, 1998, GLIA, V24, P272, DOI 10.1002/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4; NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x; Northington FJ, 1998, NEUROSCIENCE, V85, P1183, DOI 10.1016/S0306-4522(97)00673-8; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SENBA E, 1991, BRAIN RES BULL, V26, P85, DOI 10.1016/0361-9230(91)90193-N; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; STREIT WJ, 1993, GLIA, V7, P68, DOI 10.1002/glia.440070112; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TORP R, 1995, EXP BRAIN RES, V103, P51; Yamada K, 1998, J NEUROSCI, V18, P5706	37	90	93	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	MAR 29	2000	76	2					429	435		10.1016/S0169-328X(00)00022-X			7	Neurosciences	Neurosciences & Neurology	306ET	WOS:000086584900030	10762723				2021-06-18	
J	Borgens, RB; Shi, R				Borgens, RB; Shi, R			Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol	FASEB JOURNAL			English	Article						nerve fusion; nerve repair; neurotrauma	APPLIED ELECTRIC-FIELDS; FUNCTIONAL RECOVERY; GUINEA-PIGS; FUSION; HEMISECTION; MECHANISM; MODEL	A brief application of the hydrophilic polymer polyethylene glycol (PEG) swiftly repairs nerve membrane damage associated with severe spinal cord injury in adult guinea pigs. A 2 min application of PEG to a standardized compression injury to the cord immediately reversed the loss of nerve impulse conduction through the injury in all treated animals while nerve impulse conduction remained absent in all sham-treated guinea pigs. Physiological recovery was associated with a significant recovery of a quantifiable spinal cord dependent behavior in only PEG-treated animals. The application of PEG could be delayed for similar to 8 h without adversely affecting physiological and behavioral recovery which continued to improve for up to 1 month after PEG treatment.-Borgens, R. B., Shi, R. Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA	Borgens, RB (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA.						AHKONG QF, 1987, J CELL SCI, V88, P389; ALDEWINCKEL TL, 1982, BIOCHIM BIOPHYS ACTA, V689, P548; ASANO T, 1995, J NEUROTRAUM, V12, P993; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BLIGHT AR, 1990, J COMP NEUOL, V60, P446; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; FEHLINGS M, 1995, EXP NEUROL, V132, P123; Griffin John W., 1995, P375; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; Honmou Osamu, 1995, P480; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; MASSENBURG D, 1993, BIOCHEMISTRY-US, V32, P9172, DOI 10.1021/bi00086a024; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; PONTECORVO G, 1975, SOMAT CELL GENET, V1, P397, DOI 10.1007/BF01538671; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; SHI R, 1997, SOC NEUR ABSTR, V108, P16; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; THIERAULT E, 1988, J NEUROPHYSIOL, V60, P446; Tilcock C PS, 1979, BIOCHEMISTRY-US, V688, P645; YAWO H, 1985, J NEUROSCI, V5, P1626; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	39	90	92	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					27	35					9	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	WOS:000084784700005	10627277				2021-06-18	
J	Cherian, L; Chacko, G; Goodman, JC; Robertson, CS				Cherian, L; Chacko, G; Goodman, JC; Robertson, CS			Cerebral hemodynamic effects of phenylephrine and l-arginine after cortical impact injury	CRITICAL CARE MEDICINE			English	Article						hypotension; intracranial hypertension; l-arginine; phenylephrine; traumatic brain injury; cortical impact injury	EXPERIMENTAL BRAIN INJURY; BLOOD-FLOW; ARTERIAL-PRESSURE; RATS; REDUCTION; SYNTHASE; VELOCITY; VOLUME; EDEMA	Objective: To determine the effects of a presser agent (phenylephrine and L-arginine) on the abnormal cerebral hemodynamics and on neurologic outcome after a severe cortical impact injury in rats. Design:Prospective, randomized study. Setting: University laboratory. Subjects: Male Long-Evans rats, weighing 300 to 400 g, fasted overnight. Interventions: The animals were anesthetized with isoflurane, and a severe cortical impact injury (velocity, 5 m/sec; deformation, 3 mm) was produced in the right parietal cortex. Five minutes after impact injury, one of the following three treatments were infused: 1 mL saline intravenously for 10 mins, 300 mg/kg L-arginine in 1 mL saline intravenously for 10 mins, or 0.3 mu g/kg/min phenylephrine intravenously for 3 hrs, Mean arterial pressure, intracranial pressure (ICP), cerebral perfusion pressure (CPP), and laser Doppler flow (IDF) at the impact site and in the contralateral parietal cortex were monitored for 3 hrs after the impact injury. Histologic examination of the brain was performed at 2 wks after injury in a separate group of L-arginine- and saline-treated animals. Measurements and Main Results: The immediate response to the impact injury was an increase in ICP, and a decrease in mean arterial pressure, CPP, and LDF, In the saline-treated animals, LDF decreased to <25% of the baseline values at the impact site and stayed at that level for the entire 3-hr monitoring period. On the contralateral side, LDF decreased initially and recovered gradually to approximately 50% of the preimpact baseline value. Infusion of both phenylephrine and L-arginine increased LDF back to near-baseline levels. However, phenylephrine increased ICP significantly, whereas ICP with L-arginine did not change. L-arginine treatment reduced the contusion volume from a median value of 5.28 mm(3) to 0.63 mm(3). Conclusions: Phenylephrine increased cerebral blood flow (CBF) by increasing CPP, L-arginine, however, increased CBF without changing CPP, The improvement in CBF was accompanied by a decrease in neurologic injury. Although the presser agents are used currently to increase CBF after traumatic brain injury, other strategies may also increase CBF without the potential adverse effects of induced hypertension.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Cherian, L (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; ARNAL JF, 1995, J CLIN INVEST, V95, P2565, DOI 10.1172/JCI117957; BARIE PS, 1993, J TRAUMA, V35, P88, DOI 10.1097/00005373-199307000-00015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; KIMURA M, 1994, STROKE, V25, P2227, DOI 10.1161/01.STR.25.11.2227; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; Micieli G, 1997, J NEUROL SCI, V150, P71, DOI 10.1016/S0022-510X(97)05380-X; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; TREVISANI GT, 1994, J TRAUMA, V37, P452, DOI 10.1097/00005373-199409000-00021; WADA K, 1997, ABSTR J NEUR, V14, P760	29	90	92	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	1999	27	11					2512	2517		10.1097/00003246-199911000-00031			6	Critical Care Medicine	General & Internal Medicine	258AA	WOS:000083814800030	10579273				2021-06-18	
J	Morganti-Kossmann, MC; Hans, VHJ; Lenzlinger, PM; Dubs, R; Ludwig, E; Trentz, O; Kossmann, T				Morganti-Kossmann, MC; Hans, VHJ; Lenzlinger, PM; Dubs, R; Ludwig, E; Trentz, O; Kossmann, T			TGF-beta is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood-brain barrier function	JOURNAL OF NEUROTRAUMA			English	Article						antiinflammatory; blood-brain barrier; interleukin-6; lung; lymphocytes; outcome; transforming growth factor-beta; traumatic brain injury	GROWTH-FACTOR-BETA; TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; VENTRICULAR CEREBROSPINAL-FLUID; RAT-BRAIN; LUNG INJURY; IN-VITRO; CEREBRAL INJURY; TNF-ALPHA; EXPRESSION	Traumatic brain injury (TBI) induces local and systemic immunologic changes, release of cytokines, and cell activation. Perpetuation of these cascades may contribute to secondary damage to the brain. Therefore, the ability of the antiinflammatory mediator transforming growth factor-beta (TGF-beta) to downregulate intrathecal immunoactivation may be of fundamental value for diminishing the incidence and extent of secondary insults. In this study, the release of TGF-beta into cerebrospinal fluid (CSF) and serum of 22 patients with severe TBI was analyzed with respect to the function of the blood-brain barrier (BBB) for 21 days. Levels of TGF-beta in CSF increased to their maximum on the first day (median, 1.26 ng/mL), thereafter decreasing gradually over time. Median TGF-beta values in serum always remained within the reference interval (6.5 to 71.5 ng/mL). Daily assessment of the CSF-serum albumin quotient (Q(A)) and of the CSF-serum TGF-beta quotient (Q(TGF-beta)) showed a strong correlation between maximal Q(TGF-beta) and Q(A), indicating a passage of this cytokine from the periphery to the intrathecal compartment across the BBB. However, calculation of the TGF-beta index (Q(TGF-beta 0)/Q(A)) suggested a cerebral production of TGF-beta in 9 of 22 patients. Levels of TGF-beta could not be correlated with extent of initial injury by computed tomography (CT), CD4/CD8 ratios, acute lung injury, or clinical outcome as rated by the Glasgow Outcome Scale (GOS). Although increased levels of TGF-beta in CSF seem to parallel BBB function, a partial intrathecal production is suggested, possibly modulated by elevation of interleukin-6 (IL-6). Thus, TGF-beta may function as a factor in the complex cytokine network following TBI, acting as an antiinflammatory and neuroprotective mediator.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Hosp Bonn, Inst Neuropathol, Bonn, Germany; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Internal Med, Div Clin Immunol, Zurich, Switzerland	Morganti-Kossmann, MC (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, Raemistr 100, CH-8091 Zurich, Switzerland.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			AYALA A, 1993, IMMUNOLOGY, V79, P479; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; BENVENISTE EN, 1995, HUMAN CYTOKINES THEI, P195; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; CAMPBELL LL, 1998, ANN NY ACAD SCI, V840, P83; CHAO CC, 1995, CLIN IMMUNOL IMMUNOP, V77, P358, DOI 10.1006/clin.1995.1163; DACUNHA A, 1992, J NEUROIMMUNOL, V36, P157; DELPECH B, 1972, CLIN CHIM ACTA, V37, P15, DOI 10.1016/0009-8981(72)90410-X; deLuca A, 1996, J NEUROSCI, V16, P4174; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; FLANDERS KC, 1995, NEUROLOGY, V45, P1561, DOI 10.1212/WNL.45.8.1561; FREI K, 1993, INT REV EXP PATHOL, V34, P183; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GOODING R, 1995, BRIT J CANCER, V72, P452, DOI 10.1038/bjc.1995.354; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; HENRICHNOACK P, 1994, J NEURAL TRANSM-SUPP, P33; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; JENNETT B, 1975, LANCET, V1, P480; JOHNS LD, 1993, J NEUROIMMUNOL, V47, P1, DOI 10.1016/0165-5728(93)90278-7; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KITAZAWA K, 1994, STROKE, V25, P1400, DOI 10.1161/01.STR.25.7.1400; Kossik J, 1997, GENET ENG NEWS, V17, P28; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Marshall SB, 1991, J NEUROSURG S, V75, P14; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; RICOU B, 1996, YB INTENSIVE CARE EM, P375; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, V95, P417; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Rollnik JD, 1997, ACTA NEUROL SCAND, V96, P101; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHENKAR R, 1994, AM J RESP CELL MOL, V11, P351, DOI 10.1165/ajrcmb.11.3.8086171; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Specht H., 1997, Society for Neuroscience Abstracts, V23, P1149; STOCKER R, 1995, INTEGRATED APPROACH, P197; SUZUKI Y, 1994, J APPL PHYSIOL, V77, P1281; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vawter MP, 1996, EXP NEUROL, V142, P313, DOI 10.1006/exnr.1996.0200; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Winkler MK, 1998, GLIA, V22, P171, DOI 10.1002/(SICI)1098-1136(199802)22:2<171::AID-GLIA8>3.0.CO;2-A; ZHOU DH, 1991, FASEB J, V5, P2582	66	90	93	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1999	16	7					617	628		10.1089/neu.1999.16.617			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	220EN	WOS:000081651700006	10447073				2021-06-18	
J	Fox, GB; Fan, L; LeVasseur, RA; Faden, AI				Fox, GB; Fan, L; LeVasseur, RA; Faden, AI			Effect of traumatic brain injury on mouse spatial and nonspatial learning in the Barnes circular maze	JOURNAL OF NEUROTRAUMA			English	Article						Barnes circular maze; brain trauma; cognition; controlled cortical impact	MORRIS WATER MAZE; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; CORTEX LESIONS; RATS; HIPPOCAMPAL; MICE; PERFORMANCE	Controlled cortical impact (CCI) is a relatively new model of traumatic brain injury in the mouse, which, in combination with behavioral and histological methods, has potential for elucidating underlying mechanisms of neurodegeneration using genetically altered animals. Previously, we have demonstrated impaired spatial learning in a water maze task following CCI injury at a moderate level. There are many difficulties associated with this task, however, such as stress, physical demand, and the multiple trials over days required for satisfactory training. As a potential alternative to the water maze, we adapted the Barnes circular maze to our mouse model and assessed spatial/non-spatial learning following injury. Mice were trained to locate a dark tunnel, hidden beneath one of 40 holes positioned around the perimeter of a large, flat, plastic disk, brightly illuminated by four overhead halogen lamps. Sham-operated animals rapidly acquired this task, exhibiting reduced latency to find the tunnel and a more efficient search strategy as compared with injured mice. This difference was not due to visuomotor deficits, as all mice performed equally well in a cued version of the same task. These results demonstrate spatial learning impairment following CCI injury in a task that offers an efficient alternative to the water maze.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Rm EP-04, Washington, DC 20007 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Compton DM, 1997, NEUROBIOL LEARN MEM, V68, P117, DOI 10.1006/nlme.1997.3793; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; Hodges H, 1996, COGNITIVE BRAIN RES, V3, P167, DOI 10.1016/0926-6410(96)00004-3; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; Levin H.S., 1996, TRAUMATIC BRAIN INJU, P105; Logue SE, 1997, BEHAV NEUROSCI, V111, P104, DOI 10.1037/0735-7044.111.1.104; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; NAGAHARA AH, 1995, BEHAV NEUROSCI, V109, P3, DOI 10.1037/0735-7044.109.1.3; Nelson A, 1997, BEHAV BRAIN RES, V85, P93, DOI 10.1016/S0166-4328(96)00167-2; NETTO CA, 1993, NEUROSCIENCE, V54, P69, DOI 10.1016/0306-4522(93)90384-R; Ohta H, 1997, NEUROSCIENCE, V79, P1039, DOI 10.1016/S0306-4522(97)00037-7; Owen AJ, 1997, BRAIN RES, V770, P115, DOI 10.1016/S0006-8993(97)00789-0; Ragozzino ME, 1998, J NEUROSCI, V18, P1595; Rogers DC, 1997, PHARMACOL BIOCHEM BE, V56, P747, DOI 10.1016/S0091-3057(96)00430-3; Rusakov DA, 1997, NEUROSCIENCE, V80, P69, DOI 10.1016/S0306-4522(97)00125-5; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Vorhees CV, 1997, DRUG CHEM TOXICOL, V20, P387, DOI 10.3109/01480549709003895; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamada K, 1996, J PHARMACOL EXP THER, V276, P460; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022	38	90	91	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1998	15	12					1037	1046		10.1089/neu.1998.15.1037			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	148FW	WOS:000077495200004	9872460				2021-06-18	
J	Satz, P; Forney, DL; Zaucha, K; Asarnow, RR; Light, R; McCleary, C; Levin, H; Kelly, D; Bergsneider, M; Hovda, D; Martin, N; Namerow, N; Becker, D				Satz, P; Forney, DL; Zaucha, K; Asarnow, RR; Light, R; McCleary, C; Levin, H; Kelly, D; Bergsneider, M; Hovda, D; Martin, N; Namerow, N; Becker, D			Depression, cognition, and functional correlates of recovery outcome after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; MAJOR DEPRESSION; SELF-REPORT; PERFORMANCE; INDIVIDUALS; DISORDERS; DIAGNOSIS; MOOD	The present study investigated the prevalence and magnitude of depressive symptomatology in a sample of patients who had sustained traumatic brain injury (TBI) six months earlier. Depression was examined as a function of recovery outcome status, and its association with neuropsychological functioning, personal competency, and employability was also explored. Subjects were 100 patients who had previously sustained moderate-to-severe TBI who were enrolled as research subjects in the UCLA Brain Injury Research Center, and 30 matched control subjects who had sustained traumatic injuries other than to the head six months prior to evaluation. The results showed a significant association between depression and recovery status as measured by the Glasgow Outcome Scale (GOS). A significant majority of depressed subjects were found in the poorer dos outcome groups (severe and moderate disability), compared to TBI subjects who had good GOS outcomes, and control subjects. This association was also reflected in the magnitude of the mean depression scores on two self-report measures of depression. However, no association was found between depression status and performance on the neuropsychological measures. Effects of depression were found only on an examiner-rated Patient Competency scale, and a metacognition measure based on self-report. These results are discussed in terms of brain injury severity, recovery status, and metacognition issues in TBI and other disorders.	Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; Daniel Freeman Mem Hosp, Los Angeles, CA USA; USC, Sch Med, Dept Neurol, Los Angeles, CA USA; Univ Texas, Med Ctr, Houston, TX USA	Satz, P (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, NPI Room C8-747,760 Westwood Plaza, Los Angeles, CA 90024 USA.			Martin, Neil/0000-0002-6565-4131			ALOIA MS, 1995, ANN M INT NEUR SOC S; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BINDER LM, 1989, ASSESSMENT BEHAV CON, P37; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS N, 1984, CLOSED HEAD INJURY; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; BURTON LA, 1994, J NEUROLOGICAL REHAB, V8, P63, DOI DOI 10.1177/136140969400800202; Christensen B., 1994, ADV MED PSYCHOTHER, V7, P23; DELIA LF, 1996, COLOR TRAILS TEST AD; DEROGATIS LR, 1983, SYMPTOM CHECKLIST 90; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GASS CS, 1990, PSYCHOL ASSESSMENT J, V2, P175, DOI DOI 10.1037//1040-3590.2.2.175; GAULTIERI C, 1991, BRAIN INJURY, V5, P219; HAMMELL K, 1992, INT J REHABILITATION, V17, P319; HARKER JO, UNPUB MEASURING DEPR; HINKIN C, 1996, J CLIN EXPT NEUROPSY, V18, P1; HINKIN CH, 1992, J CLIN EXP NEUROPSYC, V14, P289, DOI 10.1080/01688639208402829; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MOORE L, IN PRESS J NEUROPSYC; NELSON LD, 1989, J CONSULT CLIN PSYCH, V1, P266; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1984, CLOSED HEAD INJURY; PIRGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; RUSSO A, 1996, C NAT AC NEUR NOV; Sartorius N, 1974, MEASUREMENT CLASSIFI; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; SWEET JJ, 1992, CLIN PSYCHOL REV, V12, P21, DOI 10.1016/0272-7358(92)90090-U; VANGORP WG, 1991, J CLIN EXP NEUROPSYC, V13, P812, DOI 10.1080/01688639108401091; WETZLER S, 1993, J PERS ASSESS, V60, P1, DOI 10.1207/s15327752jpa6001_1; WETZLER S, 1989, J PERS ASSESS, V53, P22, DOI 10.1207/s15327752jpa5301_3; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009; ZEFF K, 1987, MIL MED, V152, P529	50	90	90	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					537	553		10.1080/026990598122313			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200001	9653518				2021-06-18	
J	Giometto, B; An, SF; Groves, M; Scaravilli, T; Geddes, JF; Miller, R; Tavolato, B; Beckett, AAJ; Scaravilli, F				Giometto, B; An, SF; Groves, M; Scaravilli, T; Geddes, JF; Miller, R; Tavolato, B; Beckett, AAJ; Scaravilli, F			Accumulation of beta-amyloid precursor	ANNALS OF NEUROLOGY			English	Article							AIDS DEMENTIA COMPLEX; DEFICIENCY SYNDROME AIDS; TRAUMATIC BRAIN INJURY; FRONTAL-CORTEX; HIV-INFECTION; AXONAL INJURY; HEAD-INJURY; PROTEIN; DAMAGE; CELLS	The pathogenesis of neuropsychological abnormalities in patients with human immunodeficiency virus type 1 (HN-B) encephalitis is obscure because neurons are nor the target of infection and severe neuronal loss occurs only late during the disease. Moreover, there is evidence indicating that HIV dementia is not a homogeneous entity and could partially reverse after treatment with zidovudine, The finding that impaired axonal flow, evidenced by beta-amyloid precursor protein immunoreactivity, could contribute to the neuropsychological deficits prompted the present study. Brains of patients with full-blown acquired immunodeficiency syndrome (AIDS) were studied and findings compared with those of normal and abnormal control subjects. The presence of HIV-1 DNA was investigated by nested polymerase chain reaction; axonal abnormalities were detected by beta-amyloid precursor protein, ubiquitin immunohistochemistry, and silver staining. Accumulation of beta-amyloid precursor protein was observed in all the HIV encephalitis brains studied; the appearance of the immunostaining varied from globular structures to bundles of parallel formations. In 2 AIDS brains without pathological abnormalities, only the latter pattern was detected. The brains with trauma mere strongly reactive with beta-amyloid precursor protein antibody and the different reactivity within them correlated with posttrauma survival, only globular structures being detected in the older cases. No correlation was found between the different pattern of beta-amyloid precursor protein reactivity and dementia in AIDS patients. These results shaw that widespread axonal injury is a constant feature in AIDS brains and suggest that it could play a role in the pathogenesis of the neuropsychological abnormalities of these patients.	UNIV LONDON,INST NEUROL,DEPT NEUROPATHOL,NATL HOSP NEUROL & NEUROSURG,LONDON WC1N 3BG,ENGLAND; UNIV PADUA,DEPT PSYCHIAT & NEUROL,NEUROL CLIN,PADUA,ITALY; UNIV LONDON,DEPT MORBID ANAT & HISTOPATHOL,LONDON,ENGLAND; UNIV LONDON,DEPT SEXUALLY TRANSMITTED DIS,LONDON,ENGLAND			Giometto, Bruno/AAG-3236-2019	Miller, Robert/0000-0003-2067-4291; giometto, bruno/0000-0003-2311-9752			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; AN SF, 1994, J CLIN PATHOL, V47, P990, DOI 10.1136/jcp.47.11.990; An SF, 1996, ACTA NEUROPATHOL, V91, P494, DOI 10.1007/s004010050457; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BUDKA H, 1986, ACTA NEUROPATHOL, V69, P253, DOI 10.1007/BF00688301; BUDKA H, 1993, NEUROPATHOLOGY HIV I, P171; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; CIECHANOVER A, 1993, BRAIN PATHOL, V3, P67, DOI 10.1111/j.1750-3639.1993.tb00727.x; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRIFFIN JW, 1987, J NEUROPATHOL EXP NE, V36, P214; JANSSEN RS, 1991, NEUROLOGY, V41, P778; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLEIHUES P, 1985, ACTA NEUROPATHOL, V68, P333, DOI 10.1007/BF00690837; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PETITO CK, 1995, AM J PATHOL, V146, P1121; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Price RW, 1991, BRAIN PATHOL, V1, P155, DOI 10.1111/j.1750-3639.1991.tb00655.x; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613	33	90	91	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0364-5134			ANN NEUROL	Ann. Neurol.	JUL	1997	42	1					34	40		10.1002/ana.410420108			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	XK106	WOS:A1997XK10600006	9225683				2021-06-18	
J	Adelson, PD; Dixon, CE; Robichaud, P; Kochanek, PM				Adelson, PD; Dixon, CE; Robichaud, P; Kochanek, PM			Motor and cognitive functional deficits following diffuse traumatic brain injury in the immature rat	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Fourteenth Annual Meeting of the Neurotrauma Society	NOV 15-16, 1996	WASHINGTON, DC	Neurotrauma Soc		function; head injury; immature rats	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; HEAD-INJURY; CHILDREN; ADOLESCENTS; MEMORY; CAT	To determine the motor and cognitive deficits following a diffuse severe traumatic brain injury (TBI) in immature Sprague Dawley rats (17 days), four groups of animals were injured at different severity levels using a new closed head weight drop model: (sham, severe injury [SI: 100 g/2 m], SH [SI + hypoxemia (30 min of an FiO(2) of 8% posttrauma)], and ultra severe injury [US: 150 g/2 m]). Latency on beam balance, grip test performance, and maintenance of body position on an inclined board were measured daily after injury to assess vestibulomotor function. Cognitive function was assessed on days 11-22 using the Morris water maze (MWM). Balance beam latency and inclined plane body position were reduced in both SI and SH rats (n = 20) (p < 0.05 vs. sham) (maximally at 24 h), and lasted 3-4 day postinjury; however, SH did not differ from SI. In the US group (n = 10), motor deficits were profound at 24 h (p < 0.05 vs. all other groups) and persisted for 10 days. The groups did not differ on grip test. In cognitive performance, there were no differences between sham, SI, and SH. US, however, produced significant cognitive dysfunction (vs. sham, SI, and SH), specifically, greater latencies to find the hidden platform through 22 days. Swim speeds were not significantly different between any of the injury groups and shams. These data indicate that (1) beam balance, inclined plane and MWM techniques are useful for assessing motor and cognitive function after TBI in immature rats; (2) SI produces motor but not cognitive deficits, which was not augmented by transient hypoxia; and (3) US created a marked but reversible motor deficit up to 10 days, and a sustained cognitive dysfunction for up to 22 days after TBI.	CHILDRENS HOSP PITTSBURGH,DEPT NEUROSURG,PITTSBURGH,PA 15213; CHILDRENS HOSP PITTSBURGH,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA			Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 33150, K08 NS01809] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001809, R01NS033150] Funding Source: NIH RePORTER		ADELSON PD, 1996, J NEUROSURG, V85, P134; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Biagas K. V., 1992, Society for Neuroscience Abstracts, V18, P1088; BOKSA P, 1995, PEDIATR RES, V37, P489, DOI 10.1203/00006450-199504000-00018; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; LEURSSEN TG, 1988, J NEUROSURG, V68, P409; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MANSFIELD RT, 1995, J CEREB BLOOD FLOW M, V16, P244; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; VANNUCCI RC, 1988, STROKE, V19, P245, DOI 10.1161/01.STR.19.2.245; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	34	90	91	1	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1997	14	2					99	108		10.1089/neu.1997.14.99			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WN400	WOS:A1997WN40000004	9069441				2021-06-18	
J	Haas, DC				Haas, DC			Chronic post-traumatic headaches classified and compared with natural headaches	CEPHALALGIA			English	Article						post-traumatic headache; whiplash headache	CHRONIC POSTTRAUMATIC HEADACHE; WHIPLASH INJURY; CLUSTER HEADACHE; BRAIN INJURY; MINOR HEAD; SYMPTOMS; NECK; CONCUSSION; FEATURES	This study sought to determine whether chronic post-traumatic headaches are different from or identical to the naturally occurring headaches. The chronic post-traumatic headaches of 48 patients were classified, as if they were natural headaches, by the diagnostic criteria of the International Headache Society. Thirty-six patients' headaches (75%) were chronic tension-type headache, 10 (21%) were migraine without aura, and 2 (4%) were unclassifiable. The characteristics and accompaniments of the headaches within each diagnostic group were then compared to those in a control group with natural headaches of the same type. Nc notable differences between the post-traumatic and control groups were found. Hence, chronic post-traumatic headaches have no special features, but are symptomatically identical to either chronic tension-type headache or migraine without aura (in this series of patients). This identity suggests that post-traumatic headaches are generated by the same processes causing the natural headaches, not by intracranial derangement from head blows or jolts.	SUNY HLTH SCI CTR,DEPT NEUROL,SYRACUSE,NY 13210							ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; BEHRMAN S, 1977, INJURY, V9, P74, DOI 10.1016/0020-1383(77)90059-6; BENOLIEL R, 1994, J ORAL MAXIL SURG, V52, P1138, DOI 10.1016/0278-2391(94)90530-4; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; CARTLIDGE NEF, 1981, HEAD INJURY, P106; CARTLIDGE NEF, 1981, HEAD INJURY, P110; CARTLIDGE NEF, 1981, HEAD INJURY, P145; CARTLIDGE NEF, 1981, HEAD INJURY, P107; Cook J. B, 1969, LATE EFFECTS HEAD IN, P408; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; DUCKRO PN, 1995, HEADACHE Q-CURR TREA, V6, P34; DUCKRO PN, 1992, HEADACHE Q-CURR TREA, V3, P295; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; FOLETTI G, 1995, PRESSE MED, V24, P1121; Haas DC, 1994, HEADACHE CLASSIFICAT, P155; International Headache Society, 1988, CEPHALALGIA S7, V8, P9; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Lidvall HF, 1974, ACTA NEUROLOGICA S56, V50, P7; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moore KL, 1996, HEADACHE Q-CURR TREA, V7, P21; PACKARD RC, 1993, HEADACHE Q-CURR TREA, V4, P42; PEARCE JMS, 1994, NEUROLOGY, V44, P1993, DOI 10.1212/WNL.44.11.1993; RADANOV BP, 1993, BRIT MED J, V307, P652, DOI 10.1136/bmj.307.6905.652; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; REIK L, 1987, HEADACHE, V27, P509, DOI 10.1111/j.1526-4610.1987.hed2709509.x; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SOLOMON S, 1992, CEPHALALGIA, V12, P365, DOI 10.1111/j.1468-2982.1992.00365.x; TURKEWITZ LJ, 1992, HEADACHE, V32, P504, DOI 10.1111/j.1526-4610.1992.hed3210504.x; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; Young WB, 1996, NEUROLOGY, V46, P1488, DOI 10.1212/WNL.46.5.1488	32	90	91	0	4	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0333-1024			CEPHALALGIA	Cephalalgia	NOV	1996	16	7					486	493		10.1046/j.1468-2982.1996.1607486.x			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	VR956	WOS:A1996VR95600007	8933993				2021-06-18	
J	Kelly, DF; Kordestani, RK; Martin, NA; Nguyen, T; Hovda, DA; Bergsneider, M; McArthur, DL; Becker, DP				Kelly, DF; Kordestani, RK; Martin, NA; Nguyen, T; Hovda, DA; Bergsneider, M; McArthur, DL; Becker, DP			Hyperemia following traumatic brain injury: Relationship to intracranial hypertension and outcome	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; intracranial hypertension; cerebral blood flow; cerebral vasoreactivity; hyperemia	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; PRESSURE; METABOLISM; AUTOREGULATION; VASOREACTIVITY; CIRCULATION; MANAGEMENT	The role of posttraumatic hyperemia in the development of raised intracranial pressure (ICP) has important pathophysiological and therapeutic implications. To determine the relationship between hyperemia (cerebral blood flow (CBF) > 55 ml/100 g/minute), intracranial hypertension (ICP > 20 mm Hg), and neurological outcome, 193 simultaneous measurements of ICP and CBF (xenon-133 method) were obtained in 59 patients with moderate and severe head injury. Hyperemia was associated with an increased incidence of simultaneous intracranial hypertension compared to nonhyperemic CBF measurements (32.2% vs. 21.6%, respectively; p < 0.059). However, in 78% of blood flow studies in which ICP was greater than 20 mm Hg. CBF was less than or equal to 55 ml/100 g/minute. At least one episode of hyperemia was documented in 34% of patients, all of whom had a Glasgow Coma Scale (GCS) score of 9 or below. In 12 individuals with hyperemia without simultaneous intracranial hypertension, ICP was greater than 20 mm Hg for an average of 11 +/- 16 hours and favorable outcomes were seen in 75% of patients. In contrast, in eight individuals with hyperemia and at least one episode of hyperemia-associated intracranial hypertension, ICP was greater than 20 mm Hg for an average of 148 +/- 84 hours (p < 0.001), and a favorable outcome was seen in only one patient (p < 0.001). Compared to the remainder of the cohort, patients with hyperemia-associated intracranial hypertension were distinctive in being the youngest, exhibiting the lowest GCS scores (all less than or equal to 6), and having the highest incidence of effaced basilar cisterns and intractable intracranial hypertension. In the majority of individuals with hyperemia-associated intracranial hypertension, their clinical profile suggests the occurrence of a severe initial insult with resultant gross impairment of metabolic vasoreactivity and pressure antoregulation. In a minority of these patients, however, high CBF may be coupled to a hypermetabolic state, given their responsiveness to metabolic suppressive therapy. In patients with hyperemia but without intracranial hypertension, elevated CBF is also likely to be a manifestation of appropriate coupling to increased metabolic demand consistent with a generally favorable outcome. This study supports the concept that there are multiple etiologies of both elevated blood flow and intracranial hypertension after head injury.	UNIV CALIF LOS ANGELES, SCH MED, CEREBRAL BLOOD FLOW LAB, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, BRAIN INJURY RES CTR, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, BRAIN RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MOL & MED PHARMACOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA 90024 USA	Kelly, DF (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROSURG, BOX 957039, ROOM 18-218A NPI, LOS ANGELES, CA 90095 USA.		McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30308] Funding Source: Medline		AASLID R, 1987, STROKE, V18, P771, DOI 10.1161/01.STR.18.4.771; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; *ASS ADV AUT MED, 1990, ABBR INJ SCALE 1990; BERGSNEIDER M, 1995, J CEREB BLOOD FLO S1, V15, pS26; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARION DW, 1993, J NEUROSURG, V78, pA347; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1992, J NEUROTRAUMA S1, V49, pS327; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Ritter A M, 1994, Neurosurg Clin N Am, V5, P633; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SHALMON E, 1994, INTRACRANIAL PRESSUR, V9, P357; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	43	90	93	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					762	771		10.3171/jns.1996.85.5.0762			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900004	8893712				2021-06-18	
J	Rosenthal, M; Dijkers, M; HarrisonFelix, C; Nabors, N; Witol, AD; Young, ME; Englander, JS				Rosenthal, M; Dijkers, M; HarrisonFelix, C; Nabors, N; Witol, AD; Young, ME; Englander, JS			Impact of minority status on functional outcome and community integration following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; etiology; functional outcome; minority status	HEAD TRAUMA; REHABILITATION; SEVERITY; BLACKS; STROKE; CALIFORNIA; HISPANICS; LESIONS; WHITES; SCALE	Objective: To determine whether minority status affected short-term and 1-year functional outcome and community integration for patients with traumatic brain injury (TBI) in the TBI Model Systems National Data Base. Design: Prospective study, consecutive sample. Setting: Four tertiary care rehabilitation centers. Patients: Five hundred and eighty-six patients with TBI admitted to one of four TBI Model Systems programs from February 1989 through June 1995. Inclusion criteria for the study included evidence of a TBI, admission to the system hospital emergency department within 8 hours of injury, 19 years of age or older, and acute care and inpatient rehabilitation within the system hospitals. Information was collected for demographics such as race, age, gender, education, employment status, marital status, and data related to the injury such as injury severity, etiology of injury, and payer source. Over half of the sample was white (53.4%) with the 46.6% of minorities composed of blacks (37.2%). Hispanics (7.3%), and Asians (2.0%). Main Outcome Measures: Functional outcome was measured with the Functional Independence Measure (FIM). Disability Rating Scale (DRS), and Community Integration Questionnaire (CIQ). The FIM and DRS were measured at inpatient rehabilitation admission, discharge, and 1 year post injury. The CIQ total score and subscale scores for Home Integration, Social integration, and Productivity were obtained at 1-year post injury, It was hypothesized that minority status would not predict functional outcome after acute rehabilitation but would predict functional outcome and community integration at 1 year post injury. Results: There were no significant differences between whites and minorities for DRS and FM scores at acute rehabilitation discharge. There were also no significant differences between whites and minorities on FIM scores 1 year post injury, but there were significant differences between whites and minorities on the Social Integration and Productivity subscales and total score of the CIQ. Multiple regression indicated that minority status predicted functional outcome for CIQ total score (r=-.28) and two subscales, Social Integration (r=-.28) and Productivity (r=-.23) even after controlling for etiology, severity of injury, age, gender, and functional status a rehabilitation discharge. Conclusions: Although minority status does not negatively impact recovery of basic mobility and daily living skills, it may impact long-term outcome related to community integration as measured by productivity and social integration. Greater outreach and access to postdischarge services and support may be needed to optimize community integration outcomes. Further studies are needed to determine how best to serve the needs of this segment of the population with TBI.	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,RICHMOND,VA; INST REHABIL & RES,HOUSTON,TX; SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128	Rosenthal, M (corresponding author), WAYNE STATE UNIV,DEPT PHYS MED & REHABIL,261 MACK BLVD,DETROIT,MI 48201, USA.			Dijkers, Marcel/0000-0002-8362-5596			BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FOULKES MA, 1991, J NEUROSURG S, V75, pS9; FRANKOWSKI RF, 1986, CENTRAL NERVOUS SYST; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; HAGEN C, 1977, LEVELS COGNITIVE FUN; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; HOWARD G, 1994, STROKE, V25, P2120, DOI 10.1161/01.STR.25.11.2120; JENNETT B, 1992, PROGNOSIS NEUROLOGIC; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; JOHNSTON MV, 1996, MED REHABILITATION T; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Keith RA, 1987, ADV CLIN REHABILITAT; KENTON EJ, 1991, ARCH NEUROL-CHICAGO, V48, P480, DOI 10.1001/archneur.1991.00530170040018; KLATSKY AL, 1991, AM J PUBLIC HEALTH, V81, P1423, DOI 10.2105/AJPH.81.11.1423; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KUHLEMEIER KV, 1994, STROKE, V25, P2126, DOI 10.1161/01.STR.25.11.2126; LILLIEBLANTON M, 1995, NATIONS INTEREST EQU; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; SAAB PG, 1991, J HYPERTENS, V9, P249, DOI 10.1097/00004872-199103000-00009; SACCO RL, 1991, STROKE, V22, P305, DOI 10.1161/01.STR.22.3.305; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SKORD KG, 1994, BRAIN INJURY, V8, P383, DOI 10.3109/02699059409150989; Stover S., 1995, SPINAL CORD INJURY C; TEASDALE G, 1974, LANCET, V2, P81; WATERS RL, 1995, ORTHOP CLIN N AM, V26, P117; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WRIGHT TJ, 1988, J APPLIED REHABILITA, V19, P4; ZWEIFLER RM, 1995, STROKE, V26, P245, DOI 10.1161/01.STR.26.2.245; 1994, NIH GUIDE, V23, P2; 1994, FED REG         0603, V59, P29139	40	90	90	0	8	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					40	57		10.1097/00001199-199610000-00005			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300005					2021-06-18	
J	Amirjamshidi, A; Rahmat, H; Abbassioun, K				Amirjamshidi, A; Rahmat, H; Abbassioun, K			Traumatic aneurysms and arteriovenous fistulas of intracranial vessels associated with penetrating head injuries occurring during war: Principles and pitfalls in diagnosis and management	JOURNAL OF NEUROSURGERY			English	Article						traumatic aneurysm; arteriovenous fistula; brain injury; cerebral angiography; cerebral hemorrhage; missile head wound	CRANIOCEREBRAL GUNSHOT WOUNDS; INTERNAL CAROTID-ARTERY; CEREBRAL-ARTERIES; BRAIN; EXPERIENCE; VIETNAM	In the early days of the war between Iran and Iraq, reports of the sudden deaths of soldiers who previously had survived a penetrating head injury suggested the possibility that a late complication, traumatic aneurysm (TA), could be the cause of this catastrophe. In response, the authors planned a prospective study to perform cerebral angiography in victims with penetrating head traumas, especially ill those who had artillery shells or bone fragments passing through areas of dense vasculature. Thirty-one TAs and arteriovenous fistulas were documented. Not all of the lesions, however, were deemed appropriate for surgical intervention. Six aneurysms (19.4%) healed spontaneously and shrank or disappeared on repeated serial angio rams. The authors present their cases and discuss the incidence of TAs, their nato ural course and behavior, and the special problems encountered in managing these interesting and potentially fatal complications of penetrating head injuries.	UNIV TEHRAN MED SCI, DR SHARIATI HOSP, TEHRAN, IRAN	Amirjamshidi, A (corresponding author), SINA HOSP, DEPT NEUROSURG, IMAM AVE, TEHRAN, IRAN.						AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACHRAM M, 1980, BRIT J RADIOL, V53, P1144, DOI 10.1259/0007-1285-53-636-1144; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; AMAGASA M, 1986, Neurological Surgery, V14, P1585; ARAKI C, 1965, J NEUROSURG, V23, P64, DOI 10.3171/jns.1965.23.1.0064; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; Ascroft PB, 1943, LANCET, V2, P211; BANK WO, 1978, AM J ROENTGENOL, V130, P975, DOI 10.2214/ajr.130.5.975; BARATHAM G, 1972, J NEUROL NEUROSUR PS, V35, P698, DOI 10.1136/jnnp.35.5.698; BARD LA, 1964, ARCH OPHTHALMOL-CHIC, V71, P332; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CAMPBELL E, 1950, J NEUROPATH EXP NEUR, V9, P139, DOI 10.1097/00005072-195004000-00002; CAREY ME, 1972, SURG GYNECOL OBSTETR, V135, P386; COCKRILL HH, 1977, J NEUROSURG, V46, P377, DOI 10.3171/jns.1977.46.3.0377; COURVILLE C B, 1960, Bull Los Angel Neuro Soc, V25, P48; CRESSMAN MR, 1966, J NEUROSURG, V24, P102, DOI 10.3171/jns.1966.24.1.0102; CROMPTON MR, 1966, BRIT MED J, V1, P1138, DOI 10.1136/bmj.1.5496.1138; Dharker S R, 1975, Neurol India, V23, P207; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; DITMORE M, 1980, NEUROSURGERY, V6, P293; DUFFY GP, 1969, BRIT J SURG, V56, P685, DOI 10.1002/bjs.1800560912; EICHLER A, 1969, J NEUROSURG, V31, P72, DOI 10.3171/jns.1969.31.1.0072; Endo S, 1974, No Shinkei Geka, V2, P329; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FOX JL, 1983, INTRACRANIAL ANEURYS, V1, P523; HADDAD FS, 1978, CAN J SURG, V21, P233; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; Iob I, 1983, J Neurosurg Sci, V27, P187; ITO H, 1975, NO TO SHINKEI, V27, P787; JACKSON FE, 1974, US NAVY MED, V63, P34; JAKOBSSON KE, 1984, ACTA NEUROCHIR, V71, P91, DOI 10.1007/BF01401153; KAUFMAN HH, 1980, NEUROSURGERY, V6, P181, DOI 10.1227/00006123-198002000-00011; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; KUHN RA, 1964, J NEUROSURG, V21, P92, DOI 10.3171/jns.1964.21.2.0092; LAUN A, 1979, CEREBRAL ANEURYSMS A, P364; LAURENT JP, 1981, NEUROSURGERY, V9, P303, DOI 10.1227/00006123-198109000-00015; LILLARD PL, 1978, SURG NEUROL, V9, P79; MAKI Y, SAIGA IGOKU, V14, P92; Martin E M, 1986, J Neurosci Nurs, V18, P89; Marubayashi T, 1975, No Shinkei Geka, V3, P177; MEIROWSKY AM, 1954, JAMA-J AM MED ASSOC, V154, P666, DOI 10.1001/jama.1954.02940420028008; MELVILL RL, 1977, S AFR MED J, V51, P471; MENEZES AH, 1974, J NEUROSURG, V40, P544, DOI 10.3171/jns.1974.40.4.0544; MEZUE WC, 1991, NEUROSURGERY, V28, P428, DOI 10.1227/00006123-199103000-00015; MOORE D, 1979, SURG NEUROL, V11, P115; NOV AA, 1984, J NEURORADIOLOGY, V11, P3; OVERTON MC, 1966, J NEUROSURG, V24, P672, DOI 10.3171/jns.1966.24.3.0672; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PAUL GA, 1980, J NEUROSURG, V53, P101, DOI 10.3171/jns.1980.53.1.0101; PETTY J M, 1969, Journal of Neurosurgery, V30, P741, DOI 10.3171/jns.1969.30.6.0741; POZZATI E, 1982, J NEUROSURG, V57, P418, DOI 10.3171/jns.1982.57.3.0418; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; RAHMAT H, 1984, J NEUROSURG, V60, P630, DOI 10.3171/jns.1984.60.3.0630; RAIMONDI AJ, 1968, NEUROCHIRURGIA, V11, P219; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; ROBBINS JB, 1976, LARYNGOSCOPE, V86, P893, DOI 10.1288/00005537-197607000-00001; RUMBAUGH CL, 1970, RADIOLOGY, V96, P49, DOI 10.1148/96.1.49; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; SALAR G, 1978, J NEUROSURG, V49, P100, DOI 10.3171/jns.1978.49.1.0100; SARWAR M, 1976, RADIOLOGY, V120, P603, DOI 10.1148/120.3.603; SCHMIDT-VANDERHEYDEN W, 1971, Archiv fuer Psychiatrie und Nervenkrankheiten, V214, P10, DOI 10.1007/BF00344623; SCHORSTEIN J, 1947, BRIT J SURG S, V1, P96; SEDZIMIR CB, 1968, J NEUROSURG, V29, P636, DOI 10.3171/jns.1968.29.6.0636; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHALLAT RF, 1981, NEUROSURGERY, V8, P569, DOI 10.1227/00006123-198105000-00010; SMALL J M, 1947, Br J Surg, V55, P62; SPETZLER RF, 1979, NEUROSURGERY, V4, P334, DOI 10.1227/00006123-197904000-00011; STEINMETZ H, 1988, SURG NEUROL, V30, P305, DOI 10.1016/0090-3019(88)90304-7; TEASDALE G, 1974, LANCET, V2, P81; UMEBAYASHI Y, 1970, Clinical Radiology, V21, P36, DOI 10.1016/S0009-9260(70)80136-2; VANDELLEN JR, 1980, SURG NEUROL, V13, P203; YONAS H, 1980, NEUROSURGERY, V7, P499, DOI 10.1227/00006123-198011000-00016	79	90	90	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	1996	84	5					769	780		10.3171/jns.1996.84.5.0769			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	UG540	WOS:A1996UG54000009	8622150				2021-06-18	
J	Carey, ME				Carey, ME			Analysis of wounds incurred by US Army Seventh Corps personnel treated in corps hospitals during Operation Desert Storm, February 20 to March 10, 1991	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	7th International Symposium of Weapons Traumatology and Wound Ballistics	SEP 20-23, 1994	ST PETERSBURG, RUSSIA	Russian Acad Med Sci, Fed Minister Hlth & Med Ind, Moscow, Mayer St Petersburg		trauma; combat; hemorrhage; brain wounds; missile injury; Operation Desert Storm	VIETNAM	One hundred and forty-three soldiers who received ballistic injury were actively treated at U.S. Army Seventh Corps hospitals during Operation Desert Storm, Ninety-five percent were wounded by fragments, 5% by bullets, Many had wounds of several body parts, including 17.3% who received a head wound; 4.3% a neck wound; 5.8% a chest wound; 9.3% an abdominal wound; and 90% who had extremity wounds, Three hospital deaths occurred-a 2.1% mortality rate, Only two soldiers sustained a brain wound; in both, the missile entered below the skull area protected by the Kevlar helmet, One brain-wounded individual was treated and lived; the other died from hemorrhage and shock from concomitant traumatic lower-extremity amputations, The current U.S. helmet appears to provide significant protection from fragmenting ordnance as does the armored vest. Hemorrhage from proximal extremity wounds caused hospital deaths, Treatment of such wounds will have to be improved to reduce future combat mortality.		Carey, ME (corresponding author), LOUISIANA STATE UNIV,MED CTR,DEPT NEUROSURG,USA RESERVE,MED CORPS,1542 TULANE AVE,NEW ORLEANS,LA 70112, USA.						BEEBE GW, 1952, BATTLE CASUALTIES, P165; BEEBE GW, 1952, BATTLE CASUALTIES, P178; BELLAMY RF, 1984, MIL MED, V149, P55; BOWEN TE, 1988, EMERGENCY WAR SURG, P5; BURNS BD, 1942, 350 RC BRIT MIN SUPP; CAREY ME, 1987, MIL MED, V152, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HEATON LD, 1966, CURR PROB SURG, P5; MAUGHON JS, 1970, MIL MED, V135, P8; OUGHTERSON AW, 1962, WOUND BALLISTICS, P290; REISTER FA, 1973, BATTLE CASUALTIES ME, P35; REISTER FA, 1975, MED STAT WORLD WAR 2, P21; REISTER FA, 1973, BATTLE CASUALTIES ME, P43; SYNDER HGE, 1962, WOUND BALLISTICS, P484; UHORCHAK JM, CASUALTY DATA ASSESS; WHELAN TJ, 1968, ADV SURG, V3, P249; 1970, EVALUATION WOUND DAT, V1	17	90	93	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1996	40	3		S			S165	S169		10.1097/00005373-199603001-00036			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	UB897	WOS:A1996UB89700040	8606402				2021-06-18	
J	KREGOR, PJ; SONG, KM; ROUTT, MLC; SANGEORZAN, BJ; LIDDELL, RM; HANSEN, ST				KREGOR, PJ; SONG, KM; ROUTT, MLC; SANGEORZAN, BJ; LIDDELL, RM; HANSEN, ST			PLATE FIXATION OF FEMORAL-SHAFT FRACTURES IN MULTIPLE INJURED CHILDREN	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							EXTERNAL FIXATION; FEMUR FRACTURES; ADOLESCENT; TRACTION	A study was done of twelve patients (seven boys and five girls) who, because of multiple injuries or a head injury, had been managed with compression plating of a unilateral or bilateral femoral-shaft fracture at a level-I trauma center from 1986 through 1990. The patients had a total of fifteen fractures. The average age at the time of the injuries was eight years (range, five years to nine years and eleven months). There were nine closed fractures and six open fractures; three of the open fractures were Grade I; two, Grade II; and one, Grade IIIA, according to the criteria of Gustilo et al. Each patient had an average of three associated injuries. All fifteen fractures had healed clinically and radiographically at an average of eight weeks (range, six to twelve weeks) after the operation. There were no infections. Anatomical alignment was obtained in fourteen limbs. One fracture healed with 13 degrees of anterior angulation. The compression plates were removed at an average of ten months (range, three to twenty-four months) after the index operation. At the latest follow-up evaluation (average, twenty-six months; range, eleven to fifty-seven months), no patient had restriction of activities due to the femoral fracture. Scanograms revealed overgrowth of the injured femur averaging 0.9 centimeter (range, 0.3 to 1.4 centimeters) in seven patients who had an uninjured contralateral femur. We believe that plate fixation of the femur is a good treatment option for children who have a femoral shaft fracture and a major head injury or multiple injuries, or both.	HARBORVIEW MED CTR,DEPT ORTHOPAED,SEATTLE,WA 98104; CHILDRENS HOSP & MED CTR,SEATTLE,WA 98105							ALLEN BL, 1977, J TRAUMA, V17, P8; ARONSON J, 1992, J PEDIATR ORTHOPED, V12, P157, DOI 10.1097/01241398-199203000-00003; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BELLAMY R, 1974, J TRAUMA, V14, P1021, DOI 10.1097/00005373-197412000-00004; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; DAMERON TB, 1959, J BONE JOINT SURG AM, V41, P1201, DOI 10.2106/00004623-195941070-00004; FRY K, 1976, J TRAUMA, V16, P371, DOI 10.1097/00005373-197605000-00008; GIBSON JMC, 1960, J BONE JOINT SURG BR, V42, P425; GLENN JN, 1973, J TRAUMA, V13, P958, DOI 10.1097/00005373-197311000-00004; GRATZ RR, 1979, J TRAUMA, V19, P551, DOI 10.1097/00005373-197908000-00001; GUSTILO RB, 1984, J TRAUMA, V24, P742, DOI 10.1097/00005373-198408000-00009; GUTTMANN GG, 1988, J PEDIATR ORTHOPED, V8, P699, DOI 10.1097/01241398-198811000-00014; HUMBERGER FW, 1969, J BONE JOINT SURG AM, VA 51, P499, DOI 10.2106/00004623-196951030-00007; IRANI RN, 1976, J BONE JOINT SURG AM, V58, P945, DOI 10.2106/00004623-197658070-00009; KIRBY RM, 1981, J PEDIATR ORTHOPED, V1, P193, DOI 10.1097/01241398-198110000-00010; KIRSCHENBAUM D, 1990, J PEDIATR ORTHOPED, V10, P588, DOI 10.1097/01241398-199009000-00003; MANN DC, 1986, J PEDIATR ORTHOPED, V6, P651, DOI 10.1097/01241398-198611000-00002; PETERSEN EA, 1974, ACTA ORTHOP SCAND, V45, P321, DOI 10.3109/17453677408989152; PORAT S, 1986, J TRAUMA, V26, P81, DOI 10.1097/00005373-198601000-00015; REEVES RB, 1990, J PEDIATR ORTHOPED, V10, P592, DOI 10.1097/01241398-199009000-00004; SHIH HN, 1989, J TRAUMA, V29, P498, DOI 10.1097/00005373-198904000-00014; STAHELI LT, 1977, CLIN ORTHOP RELAT R, P162; Staheli LT, 1984, FRACTURES CHILDREN, V3, P845; TIMMERMAN LA, 1993, J ORTHOP TRAUMA, V7, P331, DOI 10.1097/00005131-199308000-00008; TOLO VT, 1983, J PEDIATR ORTHOPED, V3, P435, DOI 10.1097/01241398-198309000-00004; WARD WT, 1992, J PEDIATR ORTHOPED, V12, P626; ZIV I, 1984, J TRAUMA, V24, P432, DOI 10.1097/00005373-198405000-00011; ZIV I, 1983, J BONE JOINT SURG BR, V65, P276	28	90	95	0	0	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	DEC	1993	75A	12					1774	1780		10.2106/00004623-199312000-00006			7	Orthopedics; Surgery	Orthopedics; Surgery	MN144	WOS:A1993MN14400006	8258547				2021-06-18	
J	TOULMOND, S; SERRANO, A; BENAVIDES, J; SCATTON, B				TOULMOND, S; SERRANO, A; BENAVIDES, J; SCATTON, B			PREVENTION BY ELIPRODIL (SL-82.0715) OF TRAUMATIC BRAIN-DAMAGE IN THE RAT - EXISTENCE OF A LARGE (18-H) THERAPEUTIC WINDOW	BRAIN RESEARCH			English	Article						BRAIN TRAUMA; ELIPRODIL; NEUROPROTECTION; N-METHYL-D-ASPARTATE RECEPTOR	D-ASPARTATE RECEPTOR; EXCITATORY AMINO-ACIDS; SPINAL-CORD INJURY; ANTI-ISCHEMIC AGENTS; NMDA RECEPTOR; CEREBRAL-ISCHEMIA; ANTAGONIST MK-801; POLYAMINE SITE; IFENPRODIL; RELEASE	The neuroprotective potential of eliprodil (SL 82.0715), an N-methyl-D-aspartate (NMDA) receptor antagonist acting at the polyamine modulatory site, in brain trauma was examined in a rat model of lateral fluid-percussion brain injury. The volume of the lesion was assessed histologically by measuring, at 7 days post-injury, the area of brain damage at 10 coronal planes. Eliprodil (10 mg/kg i.p.) when given 15 min, 6 h and 24 h after fluid percussion (1.6 atm) and then b.i.d. fpr the following 6 days, reduced by 60% the volume of cortical damage. A similar neuroprotection was obtained when the first administration of eliprodil was delayed by up to 12 h after the brain insult. Moreover, when the treatment with this compound was started at 18 h post-injury, cortical damage was still significantly reduced by 33%. Autoradiographic studies showed that eliprodil treatment (10 mg/kg, i.p.), initiated 15 min after the trauma, also caused a marked reduction of the loss of the neuronal marker omega1-2 (central benzodiazepine) binding sites and of the increase in the glial/macrophage marker peripheral type benzodiazepine binding sites in the cerebral cortex. In contrast, dizocilpine (a blocker of the cationic channel coupled to the NMDA receptor) when administered 6 h and 24 h after fluid percussion and then b.i.d. for the following 6 days induced a non significant reduction of the volume of the lesion at the highest tolerated dose (0.6 mg/kg i.p.). These results demonstrate the neuroprotective activity of eliprodil in experimental brain trauma using neuropathology as an endpoint and indicate that there is a very large time window for therapeutic intervention, consistent with the delayed nature of the neuronal loss, in this condition.	SYNTHELAB RECH LERS,DEPT BIOL,31 AV PAUL VAILLANT COUTURIER,F-92220 BAGNEUX,FRANCE							BENAVIDES J, 1990, BRAIN RES, V522, P275, DOI 10.1016/0006-8993(90)91472-S; BENAVIDES J, 1988, J PHARMACOL EXP THER, V245, P1033; BONDOLI A, 1989, RESUSCITATION, V9, P119; CARTER C, 1989, EUR J PHARMACOL, V164, P611, DOI 10.1016/0014-2999(89)90275-6; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CHOI DW, 1988, TRENDS NEUROSCI, V11, P165; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DANJOU P, 1991, BIOL PSYCHIAT, V2, P760; DIENEL GA, 1984, J NEUROCHEM, V42, P1053, DOI 10.1111/j.1471-4159.1984.tb12710.x; DUVAL D, 1992, NEUROSCI LETT, V137, P193, DOI 10.1016/0304-3940(92)90402-S; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1989, J NEUROSURG, V70, P578; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; FOSTER AC, 1988, J NEUROSCI, V8, P4745; GILL R, 1987, J NEUROSCI, V7, P3343; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEWIS SJ, 1989, HYPERTENSION, V13, P759, DOI 10.1161/01.HYP.13.6.759; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; MCCULLOCH J, 1991, EXCITATORY AMINO ACI, P287; MCINTOSH T, 1989, J NEUROTRAUM, V4, P247; McINTOSH T., 1988, NEUROL NEUR, P653; MCINTOSH T, 1990, NEUROCHEM INT, V3, P14; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, FIDIA RES F S SERIES, V9, P247; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Sanger D J, 1989, J Psychopharmacol, V3, P198, DOI 10.1177/026988118900300402; SANGER DJ, 1991, PSYCHOPHARMACOLOGY, V104, P27, DOI 10.1007/BF02244550; SANGER DJ, 1991, BEHAV PHARMACOL, V2, P57; SCATTON B, 1991, CEREBROVASC DIS, V1, P121, DOI 10.1159/000108829; SCATTON B, IN PRESS P MANSELL B; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH D H, 1990, FASEB Journal, V4, pA400; SMITH DH, 1991, J CEREB BLOOD FLOW S, V11, P300; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; WAHL F, STROKE, V23, P267; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	57	90	90	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 20	1993	620	1					32	41		10.1016/0006-8993(93)90267-Q			10	Neurosciences	Neurosciences & Neurology	LR731	WOS:A1993LR73100005	8402196				2021-06-18	
J	DUTREVOU, MD; VANDELLEN, JR; CAMINS, MB; CHANDLER, WF				DUTREVOU, MD; VANDELLEN, JR; CAMINS, MB; CHANDLER, WF			PENETRATING STAB WOUNDS TO THE BRAIN - THE TIMING OF ANGIOGRAPHY IN PATIENTS PRESENTING WITH THE WEAPON ALREADY REMOVED	NEUROSURGERY			English	Article						ANGIOGRAPHY; SLOT FRACTURE; STAB WOUND; TRAUMATIC ANEURYSM	TRAUMATIC INTRACRANIAL ANEURYSMS; CEREBRAL-ARTERIES; INJURY; HEAD	ANGIOGRAPHY IS ALWAYS necessary in patients with penetrating stab wounds to the head, to exclude unexpected vascular lesions. The most important, since they are seldom clinically evident, are traumatic aneurysms and arteriovenous fistulae. It has previously been proposed that carotid angiography should be delayed until the start of the second week, to allow for better visualization of these complications. However, traumatic aneurysms can rupture at any time after the injury, and the mortality resulting from a second hemorrhage is unacceptably high. A prospective study was undertaken in which 330 patients with penetrating stab wounds to the head underwent angiography as soon as possible after admission. In 250 of these patients (76%), the weapon had already been removed by the assailant, and there was radiological evidence of penetration of the dura. Of these 250, 130 patients underwent angiography within 7 days of the injury. Another 51 patients, who presented late, underwent angiography more than 7 days after the injury. The timing of angiography did not affect the identification of traumatic aneurysms,the incidence of which was 12% in both groups. Of the patients with cranial stabs and who required urgent evacuation of intracerebral hematomas, 10% had traumatic aneurysms that could be dealt with simultaneously. No patient in this series suffered a secondary hemorrhage. We conclude that it is neither necessary nor safe to delay angiography. In some patients, either because of vasospasm or 'cut-off" of a vessel, a second angiogram may be necessary to further elucidate a vascular abnormality that might not have been evident originally.	UNIV NATAL, FAC MED, DEPT NEUROSURG, DURBAN, SOUTH AFRICA							AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BULLOCK R, 1985, SURG NEUROL, V24, P555, DOI 10.1016/0090-3019(85)90273-3; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CAROTHERS A, 1978, JAMA-J AM MED ASSOC, V239, P1151, DOI 10.1001/jama.239.12.1151; CRESSMAN MR, 1966, J NEUROSURG, V24, P102, DOI 10.3171/jns.1966.24.1.0102; De Villiers JC., 1975, HDB CLIN NEUROLOGY, V23, P477; DEVILLIERS JC, 1985, NEUROSURGERY, V17, P930, DOI 10.1227/00006123-198512000-00010; DUTREVOU M, 1991, INJURY, V22, P237, DOI 10.1016/0020-1383(91)90053-H; EICHLER A, 1969, J NEUROSURG, V31, P72, DOI 10.3171/jns.1969.31.1.0072; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HANDA J, 1970, AMER J ROENTGENOL RA, V109, P127, DOI 10.2214/ajr.109.1.127; HERRING CJ, 1988, NEUROSURGERY, V23, P658, DOI 10.1227/00006123-198811000-00022; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; LUKIN R, 1974, NEURORADIOLOGY, V8, P1, DOI 10.1007/BF00339796; MCDONALD EJ, 1976, AM J ROENTGENOL, V126, P792, DOI 10.2214/ajr.126.4.792; MELVILL RL, 1977, S AFR MED J, V51, P471; MILLER P, 1987, NEUROSURGERY, V21, P92, DOI 10.1227/00006123-198707000-00021; MIZUKAMI M, 1982, NEUROSURGERY, V10, P301, DOI 10.1227/00006123-198203000-00001; PARENT AD, 1981, SURG NEUROL, V15, P229, DOI 10.1016/0090-3019(81)90151-8; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; RUMBAUGH CL, 1970, RADIOLOGY, V96, P49, DOI 10.1148/96.1.49; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163; VANDELLEN JR, 1978, SURG NEUROL, V10, P110; VILLIERS JCD, 1975, BRIT J OPHTHALMOL, V59, P52; YAMAURA A, 1978, SURG NEUROL, V10, P327	32	90	90	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	1992	31	5					905	912		10.1227/00006123-199211000-00012			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JX217	WOS:A1992JX21700012	1436415				2021-06-18	
J	LEVIN, HS; MEYERS, CA; GROSSMAN, RG; SARWAR, M				LEVIN, HS; MEYERS, CA; GROSSMAN, RG; SARWAR, M			VENTRICULAR ENLARGEMENT AFTER CLOSED HEAD-INJURY	ARCHIVES OF NEUROLOGY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEURORADIOL,GALVESTON,TX 77550	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092314] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07377-10, N01-NS-9-2314] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BARRON SA, 1976, NEUROLOGY, V26, P1011, DOI 10.1212/WNL.26.11.1011; BOLLER FC, 1972, J NEUROL NEUROSUR PS, V35, P463, DOI 10.1136/jnnp.35.4.463; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; FRONT D, 1972, NEURORADIOLOGY, V4, P6, DOI 10.1007/BF00344802; GARDEUR D, 1979, J RADIOL ELEC MED N, V60, P79; Granholm L, 1972, Scand J Rehabil Med, V4, P31; GYLDENSTED C, 1977, NEURORADIOLOGY, V14, P183, DOI 10.1007/BF00496982; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; KASS B, 1978, ACTA NEUROL SCAND, V57, P19, DOI 10.1111/j.1600-0404.1978.tb04495.x; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; PENN RD, 1978, ANN NEUROL, V3, P216, DOI 10.1002/ana.410030306; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; TEASDALE G, 1974, LANCET, V2, P81; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; WEINBERGER DR, 1979, ARCH GEN PSYCHIAT, V36, P735	20	90	90	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1981	38	10					623	629		10.1001/archneur.1981.00510100051007			7	Clinical Neurology	Neurosciences & Neurology	ML870	WOS:A1981ML87000005	6975095				2021-06-18	
J	SARNO, MT				SARNO, MT			THE NATURE OF VERBAL IMPAIRMENT AFTER CLOSED HEAD-INJURY	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article										SARNO, MT (corresponding author), NYU,SCH MED,INST REHABIL MED,NEW YORK,NY 10016, USA.			sarno, martha/0000-0001-7649-8691			Benson D. F., 1967, CORTEX MILANO, V3, P373, DOI [10.1016/S0010-9452(67)80025-X, DOI 10.1016/S0010-9452(67)80025-X]; BENTON AL, 1969, J NEUROL SCI, V9, P39, DOI 10.1016/0022-510X(69)90057-4; Benton AL, 1967, CORTEX, V3, P32, DOI [10.1016/S0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; CAIRNS H, 1941, J ROY ARMY MED CORPS, V76, P12; GESCHWIND N, 1971, NEW ENGL J MED, V284, P654, DOI 10.1056/NEJM197103252841206; Geschwind N, 1964, Int J Neurol, V4, P207; Geschwind N., 1967, CORTEX, V3, P97, DOI 10.1016/S0010-9452(67)80007-8; Goldstein K, 1942, EFFECTS BRAIN INJURI; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; LENNEBERG EH, 1967, BIOL F LANGUAGE; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Luria AR., 1970, TRAUMATIC APHASIA; Newcombe F., 1969, MISSILE WOUNDS BRAIN; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Orgass B., 1966, CORTEX, V2, P222, DOI [10.1016/S0010-9452(66)80005-9, DOI 10.1016/S0010-9452(66)80005-9]; RUSSELL WR, 1961, TRAUMATIC APHASIA; SCHILLER F, 1947, J NEUROL NEUROSUR PS, V10, P183, DOI 10.1136/jnnp.10.4.183; Spreen O, 1969, NEUROSENSORY CTR COM; Teuber H-L, 1969, LATE EFFECTS HEAD IN, P13; THOMSEN IV, 1977, SCAND J REHABIL MED, V9, P73; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; THOMSEN IV, 1976, ACTA NEUROL SCAND, V54, P219, DOI 10.1111/j.1600-0404.1976.tb04798.x; THOMSEN IV, 1976, FOLIA PHONIATR, V28, P363	25	90	92	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.		1980	168	11					685	692		10.1097/00005053-198011000-00008			8	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	KQ844	WOS:A1980KQ84400008	7441232				2021-06-18	
J	Kerr, ZY; Marshall, SW; Dompier, TP; Corlette, J; Klossner, DA; Gilchrist, J				Kerr, Zachary Y.; Marshall, Stephen W.; Dompier, Thomas P.; Corlette, Jill; Klossner, David A.; Gilchrist, Julie			College Sports-Related Injuries - United States, 2009-10 Through 2013-14 Academic Years	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article							SURVEILLANCE SYSTEM; DESCRIPTIVE EPIDEMIOLOGY; PREVENTION; CONCUSSION		[Kerr, Zachary Y.; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN 46240 USA; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Corlette, Jill] State Hlth Registry Iowa, Iowa City, IA USA; [Klossner, David A.] Univ Maryland, College Pk, MD 20742 USA; [Gilchrist, Julie] CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA	Dompier, TP (corresponding author), Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN 46240 USA.	tdompier@datalyscenter.org		Kerr, Zachary/0000-0003-1423-1259; Corlette, Jill/0000-0002-9119-487X			Dick R, 2007, J ATHL TRAINING, V42, P278; Gilchrist J, 2008, AM J SPORT MED, V36, P1476, DOI 10.1177/0363546508318188; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kucera KL, 2011, J ATHL TRAINING, V46, P489; Marshall SW, 2007, J ATHL TRAINING, V42, P234; National Collegiate Athletic Association, 2014, SPORTS SPONS PART RA; Parker EM, 2015, J HEAD TRAUMA REHAB, V30, P198, DOI 10.1097/HTR.0000000000000097; Reider B, 2004, AM J SPORT MED, V32, P1383, DOI 10.1177/0363546504268028; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	10	89	88	2	14	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	DEC 11	2015	64	48					1330	+		10.15585/mmwr.mm6448a2			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CZ6LJ	WOS:000367212500002	26655724				2021-06-18	
J	Blanchette, M; Daneman, R				Blanchette, Marie; Daneman, Richard			Formation and maintenance of the BBB	MECHANISMS OF DEVELOPMENT			English	Article						Angiogenesis; Blood-brain barrier; Central nervous system; Embryogenesis; Endothelial cells; Neurovascular unit		The central nervous system (CNS) is vascularized by a dense capillary network that is critical to deliver oxygen and nutrients, and remove carbon dioxide and waste products, from the neural tissue. These blood vessels contain a series of properties, termed the blood-brain barrier (BBB), which distinguishes them from vasculature in other tissues, enabling CNS vessels to stringently regulate the transfer of ions, molecules and cells between the blood and the tissue. This barrier is critical to maintain brain homeostasis which allows for proper neuronal function and also to protect the tissue from injury and disease and many neurological diseases are associated with BBB dysfunction, including traumatic brain injuries, Alzheimer's disease, stroke, epilepsy, and multiple sclerosis. Therefore, a better understanding of the mechanisms controlling the development of the BBB may lead to improved comprehension of the pathophysiology of these diseases, and further aid in the identification of targets to modulate the barrier to treat different neurological diseases. Many of the properties of the BBB are possessed by the endothelial cells that form the walls of the blood vessels but are acquired through a series of complex cellular interactions with the microenvironment throughout its development. We will review what is known about the induction and regulation of BBB properties during development. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA; [Daneman, Richard] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92093 USA	Daneman, R (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, San Diego, CA 92093 USA.	rdaneman@ucsd.edu		Blanchette, Marie/0000-0003-1187-8700			Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Altaba ARI, 2002, NAT REV NEUROSCI, V3, P24; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Anderson KD, 2011, P NATL ACAD SCI USA, V108, P2807, DOI 10.1073/pnas.1019761108; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Bell R. D., 2012, APOLIPOPROTEIN E, P512; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Ben-Zvi A, 2014, NATURE, V509, P507, DOI 10.1038/nature13324; BERTLER A, 1966, PHARMACOL REV, V18, P369; Bjarnegard M, 2004, DEVELOPMENT, V131, P1847, DOI 10.1242/dev.01080; Bolz S, 1996, CELL TISSUE RES, V284, P355, DOI 10.1007/s004410050596; Braniste V, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009759; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243; Correale J, 2009, NEUROCHEM RES, V34, P2067, DOI 10.1007/s11064-009-0081-y; Cucullo L, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-40; Cullen M, 2011, P NATL ACAD SCI USA, V108, P5759, DOI 10.1073/pnas.1017192108; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Daneman R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013741; Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106; Deli MA, 2005, CELL MOL NEUROBIOL, V25, P59, DOI 10.1007/s10571-004-1377-8; Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909; Dohgu S, 2005, BRAIN RES, V1038, P208, DOI 10.1016/j.brainres.2005.01.027; Ek CJ, 2010, TOXICOL LETT, V197, P51, DOI 10.1016/j.toxlet.2010.04.025; Ek CJ, 2006, J COMP NEUROL, V496, P13, DOI 10.1002/cne.20885; El-Bacha RS, 1999, CELL MOL BIOL, V45, P15; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Etchevers HC, 2001, DEVELOPMENT, V128, P1059; Gaillard PJ, 2000, PHARMACEUT RES, V17, P1198, DOI 10.1023/A:1026406528530; Hayashi Y, 1997, GLIA, V19, P13, DOI 10.1002/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Helms HC, 2012, GLIA, V60, P882, DOI 10.1002/glia.22321; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Junge HJ, 2009, CELL, V139, P299, DOI 10.1016/j.cell.2009.07.048; Keller A, 2013, NAT GENET, V45, P1077, DOI 10.1038/ng.2723; Kim MO, 2003, NEUROSCI LETT, V336, P93, DOI 10.1016/S0304-3940(02)01260-0; Korn J, 2002, J COMP NEUROL, V442, P78, DOI 10.1002/cne.1423; Kuhnert F, 2010, SCIENCE, V330, P985, DOI 10.1126/science.1196554; Kurz H, 2009, CELL ADHES MIGR, V3, P205, DOI 10.4161/cam.3.2.7855; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Menezes MJ, 2014, J NEUROSCI, V34, P15260, DOI 10.1523/JNEUROSCI.3678-13.2014; Moon Randall T, 2005, Sci STKE, V2005, pcm1; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Nishitsuji K, 2011, J BIOL CHEM, V286, P17536, DOI 10.1074/jbc.M111.225532; Ohlmann A, 2012, PROG RETIN EYE RES, V31, P243, DOI 10.1016/j.preteyeres.2012.02.002; OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502; Osada T, 2011, J CEREBR BLOOD F MET, V31, P1972, DOI 10.1038/jcbfm.2011.99; Paes KT, 2011, INVEST OPHTH VIS SCI, V52, P6452, DOI 10.1167/iovs.10-7146; Ransohoff RM, 2009, NATURE, V462, P41, DOI 10.1038/462041a; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Reis M, 2012, J EXP MED, V209, P1611, DOI 10.1084/jem.20111580; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Sauvageot CM, 2002, CURR OPIN NEUROBIOL, V12, P244, DOI 10.1016/S0959-4388(02)00322-7; SHEPRO D, 1993, FASEB J, V7, P1031; Siegenthaler JA, 2013, BIOL OPEN, V2, P647, DOI 10.1242/bio.20135009; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; Smallwood PM, 2007, J BIOL CHEM, V282, P4057, DOI 10.1074/jbc.M609618200; Sobue K, 1999, NEUROSCI RES, V35, P155, DOI 10.1016/S0168-0102(99)00079-6; Sohet F, 2015, J CELL BIOL, V208, P703, DOI 10.1083/jcb.201410131; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Tam SJ, 2012, DEV CELL, V22, P403, DOI 10.1016/j.devcel.2011.11.018; Tien AC, 2012, DEVELOPMENT, V139, P2477, DOI 10.1242/dev.077214; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wang YS, 2012, CELL, V151, P1332, DOI 10.1016/j.cell.2012.10.042; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Wosik K, 2007, J NEUROSCI, V27, P9032, DOI 10.1523/JNEUROSCI.2088-07.2007; Yang YJ, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-22; Yao Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4413; Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047; YOSHIDA Y, 1988, DEV BRAIN RES, V44, P211, DOI 10.1016/0165-3806(88)90219-2; Zhou YL, 2014, DEV CELL, V31, P248, DOI 10.1016/j.devcel.2014.08.018; Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431	83	89	91	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0925-4773	1872-6356		MECH DEVELOP	Mech. Dev.	NOV	2015	138		1				8	16		10.1016/j.mod.2015.07.007			9	Developmental Biology	Developmental Biology	CW9MZ	WOS:000365324200003	26215350	Bronze			2021-06-18	
J	Maissan, IM; Dirven, PJAC; Haitsma, IK; Hoeks, SE; Gommers, D; Stolker, RJ				Maissan, Iscander M.; Dirven, Perjan J. A. C.; Haitsma, Iain K.; Hoeks, Sanne E.; Gommers, Diederik; Stolker, Robert Jan			Ultrasonographic measured optic nerve sheath diameter as an accurate and quick monitor for changes in intracranial pressure	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; trauma; head trauma; neurotrauma; ONSD; optic nerve sheath; diagnostic and operative techniques	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; EMERGENCY-DEPARTMENT; OCULAR ULTRASOUND; HYPERTENSION; MANAGEMENT; CRANIOSYNOSTOSIS; CHILDREN	OBJECT Ultrasonographic measurement of the optic nerve sheath diameter (ONSD) is known to be an accurate monitor of elevated intracranial pressure (ICP). However, it is yet unknown whether fluctuations in ICP result in direct changes in ONSD. Therefore, the authors researched whether ONSD and ICP simultaneously change during tracheal manipulation in patients in the intensive care unit (ICU) who have suffered a traumatic brain injury (TBI). MATERIALS The authors included 18 ICP-monitored patients who had sustained TBI and were admitted to the ICU. They examined the optic nerve sheath by performing ultrasound before, during, and after tracheal manipulation, which is known to increase ICP. The correlation between ONSD and ICP measurements was determined, and the diagnostic performance of ONSD measurement was tested using receiver operating characteristic curve analysis. RESULTS In all patients ICP increased above 20 mm Hg during manipulation of the trachea, and this increase was directly associated with a dilation of the ONSD of > 5.0 mm. After tracheal manipulation stopped, ICP as well as ONSD decreased immediately to baseline levels. The correlation between ICP and ONSD was high (R-2 = 0.80); at a cutoff of >= 5.0 mm ONSD, a sensitivity of 94%, a specificity of 98%, and an area under the curve of 0.99 (95% CI 0.97-1.00) for detecting elevated ICP were determined. CONCLUSIONS In patients who have sustained a TBI, ultrasonography of the ONSD is an accurate, simple, and rapid measurement for detecting elevated ICP as well as immediate changes in ICP. Therefore, it might be a useful tool to monitor ICP, especially in conditions in which invasive ICP monitoring is not available, such as at trauma scenes.	[Maissan, Iscander M.; Dirven, Perjan J. A. C.; Hoeks, Sanne E.; Stolker, Robert Jan] Erasmus MC, Dept Anesthesiol, NL-3014 CE Rotterdam, Netherlands; [Haitsma, Iain K.] Erasmus MC, Dept Neurosurg, NL-3014 CE Rotterdam, Netherlands; [Gommers, Diederik] Erasmus MC, Dept Intens Care, NL-3014 CE Rotterdam, Netherlands	Maissan, IM (corresponding author), Erasmus MC, Dept Anesthesiol, Rm H-1386,S Gravedijkwal 230, NL-3014 CE Rotterdam, Netherlands.	i.maissan@erasmusmc.nl	Hoeks, Sanne/AAM-3313-2020				AASLID R, 1986, NEURORADIOLOGY, V28, P11, DOI 10.1007/BF00341759; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Boer C, 2012, CURR OPIN ANESTHESIO, V25, P556, DOI 10.1097/ACO.0b013e328357225c; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; Copetti R, 2009, INTENS CARE MED, V35, P1488, DOI 10.1007/s00134-009-1494-4; Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901; Driessen C, 2012, PLAST RECONSTR SURG, V130, p448E, DOI 10.1097/PRS.0b013e31825dc1f1; Driessen C, 2011, J NEUROSURG-PEDIATR, V8, P329, DOI 10.3171/2011.6.PEDS10547; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Qayyum H, 2013, EUR J EMERG MED, V20, P91, DOI 10.1097/MEJ.0b013e32835105c8; Raboel PH, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/950393; Rajajee V, 2012, CRIT CARE, V16, DOI [10.1186/cc11336, 10.1186/CC11336]; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rosenberg JB, 2011, NEUROCRIT CARE, V15, P599, DOI 10.1007/s12028-011-9545-4; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040	19	89	93	2	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2015	123	3					743	747		10.3171/2014.10.JNS141197			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CP6VZ	WOS:000360027600031	25955869	Bronze			2021-06-18	
J	Bryant, RA; Nickerson, A; Creamer, M; O'Donnell, M; Forbes, D; Galatzer-Levy, I; McFarlane, AC; Silove, D				Bryant, Richard A.; Nickerson, Angela; Creamer, Mark; O'Donnell, Meaghan; Forbes, David; Galatzer-Levy, Isaac; McFarlane, Alexander C.; Silove, Derrick			Trajectory of post-traumatic stress following traumatic injury: 6-year follow-up	BRITISH JOURNAL OF PSYCHIATRY			English	Article							BRAIN-INJURY; RISK-FACTORS; WHOQOL-BREF; DISORDER; RESILIENCE; PTSD; EXTINCTION; DEPRESSION; GROWTH; US	Background Traumatic injuries affect millions of patients each year, and resulting post-traumatic stress disorder (PTSD) significantly contributes to subsequent impairment. Aims To map the distinctive long-term trajectories of PTSD responses over 6 years by using latent growth mixture modelling. Method Randomly selected injury patients (n = 1084) admitted to four hospitals around Australia were assessed in hospital, and at 3, 12, 24 and 72 months. Lifetime psychiatric history and current PTSD severity and functioning were assessed. Results Five trajectories of PTSD response were noted across the 6 years: (a) chronic (4%), (b) recovery (6%), (c) worsening/recovery (8%), (d) worsening (10%) and (e) resilient (73%). A poorer trajectory was predicted by female gender, recent life stressors, presence of mild traumatic brain injury and admission to intensive care unit. Conclusions These findings demonstrate the long-term PTSD effects that can occur following traumatic injury. The different trajectories highlight that monitoring a subset of patients over time is probably a more accurate means of identifying PTSD rather than relying on factors that can be assessed during hospital admission. (C) The Royal College of Psychiatrists 2015.	[Bryant, Richard A.; Nickerson, Angela] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Bryant, Richard A.] Univ Sydney, Brain Dynam Ctr, Sydney, NSW 2006, Australia; [Bryant, Richard A.] Westmead Millennium Inst, Sydney, NSW, Australia; [Creamer, Mark; O'Donnell, Meaghan; Forbes, David] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Melbourne, Vic 3010, Australia; [Galatzer-Levy, Isaac] NYU, Dept Psychiat, New York, NY 10016 USA; [McFarlane, Alexander C.] Univ Adelaide, Ctr Mil & Veteran Hlth, Adelaide, SA, Australia; [Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; Galatzer-Levy, Isaac/0000-0003-1864-064X; O'Donnell, Meaghan/0000-0003-4349-0022; Forbes, David/0000-0001-9145-1605; Nickerson, Angela/0000-0001-9171-4209			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blake DD, 1998, CLIN ADM PTSD SCALE; Bonanno GA, 2012, REHABIL PSYCHOL, V57, P236, DOI 10.1037/a0029256; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; BRESLAU N, 1995, AM J PSYCHIAT, V152, P529; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; BRUGHA T, 1985, PSYCHOL MED, V15, P189, DOI 10.1017/S003329170002105X; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hawthorne G, 2006, SOC INDIC RES, V77, P37, DOI 10.1007/s11205-005-5552-1; Hobfoll SE, 2006, J TRAUMA STRESS, V19, P867, DOI 10.1002/jts.20166; McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Muthen B., 2004, HDB QUANTITATIVE MET, P346, DOI DOI 10.4135/9781412986311.N19; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Norrholm SD, 2006, LEARN MEMORY, V13, P681, DOI 10.1101/lm.393906; Norris FH, 2009, SOC SCI MED, V68, P2190, DOI 10.1016/j.socscimed.2009.03.043; Pietrzak RH, 2013, J PSYCHIATR RES, V47, P520, DOI 10.1016/j.jpsychires.2012.12.005; Post Robert M., 1995, P203; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smid GE, 2012, PSYCHOL MED, V42, P1675, DOI 10.1017/S0033291711002765; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; World Health Organization, 1992, ICD 10 CLASS MENT BE; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943; Zlotnick C, 2002, COMPR PSYCHIAT, V43, P413, DOI 10.1053/comp.2002.35900	34	89	90	1	25	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0007-1250	1472-1465		BRIT J PSYCHIAT	Br. J. Psychiatry	MAY	2015	206	5					417	423		10.1192/bjp.bp.114.145516			7	Psychiatry	Psychiatry	CH6PA	WOS:000354157300010	25657356	Bronze			2021-06-18	
J	Nordstrom, A; Nordstrom, P; Ekstrand, J				Nordstrom, Anna; Nordstrom, Peter; Ekstrand, Jan			Sports-related concussion increases the risk of subsequent injury by about 50% in elite male football players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CONSENSUS STATEMENT; EPIDEMIOLOGY; SOCCER; RECOVERY; OUTCOMES; HEAD	Background Little is known about the short-term and long-term sequelae of concussion, and about when athletes who have sustained such injuries can safely return to play. Purpose To examine whether sports-related concussion increases the risk of subsequent injury in elite male football players. Study design Prospective cohort study. Methods Injuries were registered for 46 male elite football teams in 10 European countries in the 2001/ 2002-2011/ 2102 seasons. Two survival models were used to analyse whether concussion increased the subsequent risk of an injury in the first year. Results During the follow-up period, 66 players sustained concussions and 1599 players sustained other injuries. Compared with the risk following other injuries, concussion was associated with a progressively increased risk of a subsequent injury in the first year (0 to <3 months, HR=1.56, 95% CI 1.09 to 2.23; 3 to <6 months, HR=2.78, 95% CI 1.58 to 4.89; 6-12 months, HR=4.07, 95% CI 2.14 to 7.76). In the second model, after adjustment for the number of injuries in the year preceding the concussion, this injury remained significantly associated with the risk of subsequent injury in the first year (HR=1.47, 95% CI 1.05 to 2.05). Conclusions Concussion was a risk factor for sustaining subsequent injury within the following year. In-depth medical evaluation, which includes neurological and cognitive assessment, is warranted within the concussion management and return-to-play process.	[Nordstrom, Anna] Umea Univ, Dept Surg & Perioperat Sci, S-90185 Umea, Sweden; [Nordstrom, Peter] Umea Univ, Dept Community Med & Rehabil, S-90185 Umea, Sweden; [Ekstrand, Jan] Linkoping Univ, Dept Med & Hlth Sci, Div Community Med, Football Res Grp, Linkoping, Sweden	Nordstrom, A (corresponding author), Umea Univ, Dept Surg & Perioperat Sci, S-90185 Umea, Sweden.	anna.nordstrom@idrott.umu.se	Nordstrom, Anna/O-2504-2018; Nordstrom, Anna/F-2238-2010	Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Peter/0000-0003-2924-508X	UEFA; Swedish National Center for Research in Sports	The study was supported by grants from UEFA and the Swedish National Center for Research in Sports.	Al-Kashmiri A, 2006, TRAUMA, V8, P189, DOI 10.1177/1460408606071144; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ekstrand J, 2013, BRIT J SPORT MED, V47, P732, DOI 10.1136/bjsports-2013-092394; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nilsson M, 2013, CLIN J SPORT MED, V23, P255, DOI 10.1097/JSM.0b013e31827ee6f8; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Nordstrom A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001151; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084	28	89	89	1	47	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT	2014	48	19					1447	1450		10.1136/bjsports-2013-093406			4	Sport Sciences	Sport Sciences	AP3AL	WOS:000341947200011	25082616	Bronze, Green Published			2021-06-18	
J	Maas, AIR; Murray, GD; Roozenbeek, B; Lingsma, HF; Butcher, I; McHugh, GS; Weir, J; Lu, J; Steyerberg, EW				Maas, Andrew I. R.; Murray, Gordon D.; Roozenbeek, Bob; Lingsma, Hester F.; Butcher, Isabella; McHugh, Gillian S.; Weir, James; Lu, Juan; Steyerberg, Ewout W.		Int Mission Prognosis Anal Clinica	Advancing care for traumatic brain injury: findings from the IMPACT studies and perspectives on future research	LANCET NEUROLOGY			English	Article							RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; HEAD-INJURY; COVARIATE ADJUSTMENT; EXTERNAL VALIDATION; ACUTE STROKE; INTERNATIONAL MISSION; STATISTICAL-ANALYSIS; PROGNOSTIC ANALYSIS; OUTCOME PREDICTION	Research in traumatic brain injury (TBI) is challenging for several reasons; in particular, the heterogeneity between patients regarding causes, pathophysiology, treatment, and outcome. Advances in basic science have failed to translate into successful clinical treatments, and the evidence underpinning guideline recommendations is weak. Because clinical research has been hampered by non-standardised data collection, restricted multidisciplinary collaboration, and the lack of sensitivity of classification and efficacy analyses, multidisciplinary collaborations are now being fostered. Approaches to deal with heterogeneity have been developed by the IMPACT study group. These approaches can increase statistical power in clinical trials by up to 50% and are also relevant to other heterogeneous neurological diseases, such as stroke and subarachnoid haemorrhage. Rather than trying to limit heterogeneity, we might also be able to exploit it by analysing differences in treatment and outcome between countries and centres in comparative effectiveness research. This approach has great potential to advance care in patients with TBI.	[Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, B-2650 Edegem, Belgium; [Murray, Gordon D.; Butcher, Isabella; McHugh, Gillian S.; Weir, James] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Roozenbeek, Bob] Univ Med Ctr Rotterdam, Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Lu, Juan] Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth, Richmond, VA USA	Maas, AIR (corresponding author), Univ Antwerp Hosp, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Steyerberg, Ewout W/C-1509-2018	Steyerberg, Ewout W/0000-0002-7787-0122; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734	NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602150]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	This work was supported by NIH-NINDS (NS-042691). AIM, HFL, and EWS are participants in CENTER-TBI, a large collaborative project funded by the European Commission 7th Framework program (602150). We have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Adams HP, 2008, STROKE, V39, P3277, DOI 10.1161/STROKEAHA.107.508853; Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Annane D, 2009, CRIT CARE MED, V37, pS117, DOI 10.1097/CCM.0b013e318192078b; [Anonymous], 2012, LANCET NEUROL, V11, P651, DOI 10.1016/S1474-4422(12)70166-7; Bath P, 2009, STROKE, V40, P888, DOI 10.1161/STROKEAHA.108.519207; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Edwards P, 2005, LANCET, V365, P1957; European Commission, RES INN PART PORT FP; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Harrell Frank E., 2001, REGRESSION MODELING; Hebert PC, 2002, CHEST, V121, P1290, DOI 10.1378/chest.121.4.1290; Hernandez AV, 2006, ANN EPIDEMIOL, V16, P41, DOI 10.1016/j.annepidem.2005.09.007; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JENNETT B, 1975, LANCET, V1, P480; Kidwell CS, 2001, STROKE, V32, P1349, DOI 10.1161/01.STR.32.6.1349; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Li BY, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-77; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-201; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Macdonald RL, 2013, WORLD NEUROSURG, V79, P418, DOI 10.1016/j.wneu.2013.01.006; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease, 2011, PREC MED; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Roozenbeek B, 2009, J NEUROTRAUM, V26, P1069, DOI 10.1089/neu.2008.0569; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; Turner EL, 2012, J CLIN EPIDEMIOL, V65, P474, DOI 10.1016/j.jclinepi.2011.08.012; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; Yue JK, 2013, J NEUROTRAUM, DOI DOI 10.1089/NEU.2013.2970	82	89	90	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2013	12	12					1200	1210		10.1016/S1474-4422(13)70234-5			11	Clinical Neurology	Neurosciences & Neurology	265BG	WOS:000327924100015	24139680	Green Accepted			2021-06-18	
J	Hawkins, BE; Krishnamurthy, S; Castillo-Carranza, DL; Sengupta, U; Prough, DS; Jackson, GR; DeWitt, DS; Kayed, R				Hawkins, Bridget E.; Krishnamurthy, Shashirekha; Castillo-Carranza, Diana L.; Sengupta, Urmi; Prough, Donald S.; Jackson, George R.; DeWitt, Douglas S.; Kayed, Rakez			Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; POSTTRAUMATIC EPILEPSY; PHOSPHORYLATION SITES; NEURONAL LOSS; MOUSE MODEL; HEAD-INJURY; IN-VITRO; TAUOPATHY	Traumatic brain injury (TBI) is a serious problem that affects millions of people in the United States alone. Multiple concussions or even a single moderate to severe TBI can also predispose individuals to develop a pathologically distinct form of tauopathy- related dementia at an early age. No effective treatments are currently available for TBI or TBI-related dementia; moreover, only recently has insight been gained regarding the mechanisms behind their connection. Here, we used antibodies to detect oligomeric and phosphorylated Tau proteins in a non-transgenic rodent model of parasagittal fluid percussion injury. Oligomeric and phosphorylated Tau proteins were detected 4 and 24 h and 2 weeks post-TBI in injured, but not sham control rats. These findings suggest that diagnostic tools and therapeutics that target only toxic forms of Tau may provide earlier detection and safe, more effective treatments for tauopathies associated with repetitive neurotrauma.	[Hawkins, Bridget E.; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA; [Hawkins, Bridget E.; Prough, Donald S.; DeWitt, Douglas S.] Univ Texas Med Branch, Moody Ctr Traumat Brain & Spinal Cord Injury Res, Galveston, TX 77555 USA; [Hawkins, Bridget E.; Prough, Donald S.; DeWitt, Douglas S.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Krishnamurthy, Shashirekha; Castillo-Carranza, Diana L.; Sengupta, Urmi; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, Dept Neurol, Galveston, TX 77555 USA; [Krishnamurthy, Shashirekha; Castillo-Carranza, Diana L.; Sengupta, Urmi; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; [Krishnamurthy, Shashirekha; Castillo-Carranza, Diana L.; Sengupta, Urmi; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, George & Cynthia Mitchell Ctr Neurodegenerat Dis, Galveston, TX 77555 USA	Kayed, R (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	rakayed@utmb.edu	Hawkins, Bridget/H-4933-2015; Prough, Donald S/G-5793-2013	Hawkins, Bridget/0000-0002-1887-3657; Prough, Donald S/0000-0001-7994-532X; Castillo-Carranza, Diana/0000-0003-2511-949X	Cullen Family Trust for Health Care, the Mitchell Center for Neurodegenerative Diseases; Moody Center for Traumatic Brain & Spinal Cord Injury Research/Mission Connect	This work was supported by the Cullen Family Trust for Health Care, the Mitchell Center for Neurodegenerative Diseases, and the Moody Center for Traumatic Brain & Spinal Cord Injury Research/Mission Connect. R.K. has patent applications on the compositions and methods related to Tau oligomers and antibodies.	Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; Castillo-Carranza D. L., 2010, SOC NEUROSCI; Castillo-Carranza Diana L, 2013, Front Biosci (Schol Ed), V5, P426; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cowan CM, 2012, BIOCHEM SOC T, V40, P693, DOI 10.1042/BST20120135; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Goldstein L.E., 2012, SCI TRANSL MED, V4; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Hall GF, 2012, PRION, V6, P223, DOI 10.4161/pri.19912; Haroutunian V, 2007, NEUROBIOL AGING, V28, P1, DOI 10.1016/j.neurobiolaging.2005.11.001; Hawkins BE, 2012, BRAIN RES, V1432, P28, DOI 10.1016/j.brainres.2011.11.009; Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Henkins KM, 2012, BRAIN PATHOL, V22, P826, DOI 10.1111/j.1750-3639.2012.00598.x; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kril JJ, 2002, ACTA NEUROPATHOL, V103, P370, DOI 10.1007/s00401-001-0477-5; Lasagna-Reeves CA, 2011, CURR ALZHEIMER RES, V8, P659; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Lasagna-Reeves CA, 2011, J BIOL CHEM, V286, P22122, DOI 10.1074/jbc.M111.236257; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Le Meghan N, 2012, Am J Neurodegener Dis, V1, P316; Li Y, 2010, BRAIN RES, V1330, P131, DOI 10.1016/j.brainres.2010.03.034; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pooler AM, 2013, EMBO REP, V14, P389, DOI 10.1038/embor.2013.15; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Schneider A, 2008, NEUROTHERAPEUTICS, V5, P443, DOI 10.1016/j.nurt.2008.05.006; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Spires TL, 2006, AM J PATHOL, V168, P1598, DOI 10.2353/ajpath.2006.050840; Tai HC, 2012, AM J PATHOL, V181, P1426, DOI 10.1016/j.ajpath.2012.06.033; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Ubhi K, 2011, EXP NEUROL, V230, P157, DOI 10.1016/j.expneurol.2010.10.007; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang JZ, 2013, J ALZHEIMERS DIS, V33, pS123, DOI 10.3233/JAD-2012-129031; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528	63	89	91	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2013	288	23					17042	17050		10.1074/jbc.M113.472746			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	163ZU	WOS:000320378900075	23632019	Green Published, Other Gold			2021-06-18	
J	McNally, KA; Bangert, B; Dietrich, A; Nuss, K; Rusin, J; Wright, M; Taylor, HG; Yeates, KO				McNally, Kelly A.; Bangert, Barbara; Dietrich, Ann; Nuss, Kathy; Rusin, Jerome; Wright, Martha; Taylor, H. Gerry; Yeates, Keith Owen			Injury Versus Noninjury Factors as Predictors of Postconcussive Symptoms Following Mild Traumatic Brain Injury in Children	NEUROPSYCHOLOGY			English	Article						concussion; pediatric; outcomes; recovery	POST-CONCUSSIVE SYMPTOMS; HEAD-INJURY; CONSEQUENCES; VALIDITY; COHORT; SCALE	Objective: To examine the relative contributions of injury characteristics and noninjury child and family factors as predictors of postconcussive symptoms (PCS) following mild traumatic brain injury (TBI) in children. Method: Participants were 8- to 15-year-old children, 186 with mild TBI and 99 with mild orthopedic injuries (OI). Parents and children rated PCS shortly after injury and at 1, 3, and 12 months postinjury. Hierarchical regression analyses were conducted to predict PCS from (1) demographic variables; (2) premorbid child factors (WASI IQ; WRAT-3 Reading; Child Behavior Checklist; ratings of preinjury PCS); (3) family factors (Family Assessment Device General Functioning Scale; Brief Symptom Inventory; and Life Stressors and Social Resources Inventory); and (4) injury group (OI, mild TBI with loss of consciousness [LOC] and associated injuries [AI], mild TBI with LOC but without AI, mild TBI without LOC but with AI, and mild TBI without LOC or AI). Results: Injury group predicted parent and child ratings of PCS but showed a decreasing contribution over time. Demographic variables consistently predicted symptom ratings across time. Premorbid child factors, especially retrospective ratings of premorbid symptoms, accounted for the most variance in symptom ratings. Family factors, particularly parent adjustment, consistently predicted parent, but not child, ratings of PCS. Conclusions: Injury characteristics predict PCS in the first months following mild TBI but show a decreasing contribution over time. In contrast, noninjury factors are more consistently related to persistent PCS.	[McNally, Kelly A.] Nationwide Childrens Hosp, Sect Pediat Psychol & Neuropsychol, Columbus, OH 43205 USA; [McNally, Kelly A.; Dietrich, Ann; Nuss, Kathy; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathy] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Wright, Martha; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Wright, Martha; Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892; McNally, Kelly/0000-0001-9278-9413	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	The work reported here was supported by grants HD44099 and HD39834 from the National Institutes of Health to Keith Owen Yeates.	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Ayr L. K., 2009, CHILD NEUROPSYCHOL, V2, P213; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MOOS R, 1988, LIFE STRESSORS SOCIA; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; O'Brien RM, 2007, QUAL QUANT, V41, P673, DOI 10.1007/s11135-006-9018-6; Olofsson E, 2009, ACTA PAEDIATR, V98, P17, DOI 10.1111/j.1651-2227.2008.00998.x; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Psychological Corporation, 1999, WECHSLER ABBREVIATED; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TAYLOR HG, 1993, J CLIN CHILD PSYCHOL, V22, P196, DOI 10.1207/s15374424jccp2202_6; TEASDALE G, 1974, LANCET, V2, P81; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	42	89	89	0	23	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2013	27	1					1	12		10.1037/a0031370			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	073QI	WOS:000313757200001	23356592	Green Accepted			2021-06-18	
J	Master, CL; Gioia, GA; Leddy, JJ; Grady, MF				Master, Christina L.; Gioia, Gerard A.; Leddy, John J.; Grady, Matthew F.			Importance of 'Return-to-Learn' in Pediatric and Adolescent Concussion	PEDIATRIC ANNALS			English	Article							SPORT-RELATED CONCUSSION		[Master, Christina L.; Grady, Matthew F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.] Univ Penn, Perelman Sch Med, Div Pediat Orthoped & Sports Med, Dept Surg, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.] Univ Penn, Perelman Sch Med, Div Pediat Orthoped & Sports Med, Dept Pediat, Philadelphia, PA 19104 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, SCORE Program,Childrens Natl Med Ctr, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Psychiat & Behav Sci, Washington, DC 20052 USA; [Leddy, John J.] SUNY Buffalo, UB Orthopaed & Sports Med, Buffalo, NY 14260 USA	Master, CL (corresponding author), Childrens Hosp Philadelphia, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270			DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Gioia GA, 2006, HEADS BRAIN INJURY Y; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Moser RS, 2012, J PEDIAT; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008	8	89	90	0	16	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0090-4481	1938-2359		PEDIATR ANN	Pediatr. Annu.	SEP	2012	41	9					E180	E185		10.3928/00904481-20120827-09			6	Pediatrics	Pediatrics	082NM	WOS:000314398700002	22953975				2021-06-18	
J	Ling, J; Merideth, F; Caprihan, A; Pena, A; Teshiba, T; Mayer, AR				Ling, Josef; Merideth, Flannery; Caprihan, Arvind; Pena, Amanda; Teshiba, Terri; Mayer, Andrew R.			Head injury or head motion? Assessment and quantification of motion artifacts in diffusion tensor imaging studies	HUMAN BRAIN MAPPING			English	Article						mild TBI; DTI; diffusion tensor imaging; gradient sampling schemes; motion; simulations	TRAUMATIC BRAIN-INJURY; PRINCIPAL EIGENVECTOR MEASUREMENTS; STIMULUS-CORRELATED MOTION; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; WEIGHTED MRI; FMRI; DTI; ACQUISITION; SCHEMES	The relationship between head motion and diffusion values such as fractional anisotropy (FA) and mean diffusivity (MD) is currently not well understood. Simulation studies suggest that head motion may introduce either a positive or negative bias, but this has not been quantified in clinical studies. Moreover, alternative measures for removing bias as result of head motion, such as the removal of problematic gradients, has been suggested but not carefully evaluated. The current study examined the impact of head motion on FA and MD across three common pipelines (tract-based spatial statistics, voxelwise, and region of interest analyses) and determined the impact of removing diffusion weighted images. Our findings from a large cohort of healthy controls indicate that while head motion was associated with a positive bias for both FA and MD, the effect was greater for MD. The positive bias was observed across all three analysis pipelines and was present following established protocols for data processing, suggesting that current techniques (i.e., correction of both image and gradient table) for removing motion bias are likely insufficient. However, the removal of images with gross artifacts did not fundamentally change the relationship between motion and DTI scalar values. In addition, Monte Carlo simulations suggested that the random removal of images increases the bias and reduces the precision of both FA and MD. Finally, we provide an example of how head motion can be quantified across different neuropsychiatric populations, which should be implemented as part of any diffusion tensor imaging quality assurance protocol. Hum Brain Mapp, 2012. (C) 2011 Wiley Periodicals, Inc.	[Ling, Josef; Merideth, Flannery; Caprihan, Arvind; Pena, Amanda; Teshiba, Terri; Mayer, Andrew R.] Mind Res Network, Albuquerque, NM 87106 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21-NS064464-01A1, 3R21-NS064464-01A1S1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant numbers: R21-NS064464-01A1 and 3R21-NS064464-01A1S1 (to A.M.).	Aksoy M, 2008, MAGN RESON MED, V59, P1138, DOI 10.1002/mrm.21558; Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Ardekani BA, 2010, HUM BRAIN M IN PRESS; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bullmore E, 1996, MAGN RESON MED, V35, P261, DOI 10.1002/mrm.1910350219; Bullmore ET, 1999, HUM BRAIN MAPP, V7, P38, DOI 10.1002/(SICI)1097-0193(1999)7:1<38::AID-HBM4>3.3.CO;2-H; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Cook PA, 2007, J MAGN RESON IMAGING, V25, P1051, DOI 10.1002/jmri.20905; Cox R, 2006, SEATTL WA INT SOC MA, P349; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Frank LR, 2010, NEUROIMAGE, V49, P1510, DOI 10.1016/j.neuroimage.2009.09.010; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; HAJNAL JV, 1994, MAGNET RESON MED, V31, P283, DOI 10.1002/mrm.1910310307; Horsfield MA, 1999, MAGN RESON IMAGING, V17, P1335, DOI 10.1016/S0730-725X(99)00077-6; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 2002, NEUROIMAGE, V17, P592, DOI 10.1006/nimg.2002.1148; Jones DK, 2002, HUM BRAIN MAPP, V15, P216, DOI 10.1002/hbm.10018; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Landman BA, 2008, MAGN RESON IMAGING, V26, P790, DOI 10.1016/j.mri.2008.01.034; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Liu CL, 2004, MAGN RESON MED, V52, P1388, DOI 10.1002/mrm.20288; Lund TE, 2005, NEUROIMAGE, V26, P960, DOI 10.1016/j.neuroimage.2005.02.021; Marenco S, 2006, PSYCHIAT RES-NEUROIM, V147, P69, DOI 10.1016/j.pscychresns.2006.01.008; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2007, J INT NEUROPSYCH SOC, V13, P839, DOI 10.1017/S1355617707071081; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Norris DG, 2001, J MAGN RESON IMAGING, V13, P486, DOI 10.1002/jmri.1072; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Roosendaal SD, 2009, NEUROIMAGE, V44, P1397, DOI 10.1016/j.neuroimage.2008.10.026; Saad ZS, 2009, NEUROIMAGE, V44, P839, DOI 10.1016/j.neuroimage.2008.09.037; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Sexton CE, 2009, BIOL PSYCHIAT, V66, P814, DOI 10.1016/j.biopsych.2009.05.024; Sijbers J, 2009, NEUROIMAGE, V46, P692; Skare S, 2000, J MAGN RESON, V147, P340, DOI 10.1006/jmre.2000.2209; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Storey P, 2007, MAGN RESON MED, V57, P614, DOI 10.1002/mrm.21132; Tijssen RHN, 2009, HUM BRAIN MAPP, V30, P2641, DOI 10.1002/hbm.20695; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; White Tonya, 2008, Top Magn Reson Imaging, V19, P97, DOI 10.1097/RMR.0b013e3181809f1e; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Yoo SS, 2005, NEUROSCI RES, V53, P84, DOI 10.1016/j.neures.2005.06.004; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; Zollei L, 2010, NEUROIMAGE, V51, P206, DOI 10.1016/j.neuroimage.2010.01.101	51	89	89	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1065-9471			HUM BRAIN MAPP	Hum. Brain Mapp.	JAN	2012	33	1					50	62		10.1002/hbm.21192			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	869IH	WOS:000298591100005	21391258	Green Published			2021-06-18	
J	Karlin, AM				Karlin, Aaron M.			Concussion in the Pediatric and Adolescent Population: "Different Population, Different Concerns"	PM&R			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURY; NEUROCOGNITIVE PERFORMANCE; POSTCONCUSSION SYNDROME; NCAA CONCUSSION; YOUNG ATHLETE; CHILDREN	Sports-related concussions are common among pediatric and adolescent athletes, yet a scarcity of age-specific research often has meant that practitioners use guidelines developed for collegiate or adult populations. This situation is changing, as more studies are being published about this population that bears special attention because of the immaturity of the developing brain. This article describes existing knowledge about the epidemiology and etiology of concussions in youth athletes; discusses issues related to assessment, clinical management, and return to activity; examines special concerns related to the effects of concussion on the developing brain; and discusses prevention and education initiatives related to concussion in youth athletes. PM R 2011;3:S369-S379	[Karlin, Aaron M.] Ochsner Clin & Alton Ochsner Med Fdn, Div Pediat Phys Med & Rehabil, Ochsner Pediat & Adolescent Concuss Management Pr, Med Ctr,Dept Pediat, New Orleans, LA USA; [Karlin, Aaron M.] Ochsner Clin & Alton Ochsner Med Fdn, Med Ctr, Dept Phys Med & Rehabil, New Orleans, LA USA; [Karlin, Aaron M.] Ochsner Clin & Alton Ochsner Med Fdn, Med Ctr, Dept Sports Med, New Orleans, LA USA	Karlin, AM (corresponding author), Childrens Hlth Ctr, 101 Judge Tanner Dr,Suite 302, Covington, LA 70433 USA.	akarlin@ochsner.org					Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; [Anonymous], ATHL TRAIN FILL NEC; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Canadian Pediatric Society, 2006, PAEDIAT CHILD HLTH, V11, P420; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Centers for Disease Control and Prevention, WHAT TRAUM BRAIN INJ; Centers for Disease Control and Prevention, HEADS SCH KNOW YOUR; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cook Rebecca S, 2006, J Trauma Nurs, V13, P58; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gordon Kevin E, 2006, Semin Pediatr Neurol, V13, P243, DOI 10.1016/j.spen.2006.09.005; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kieslich M, 2002, J NEUROL NEUROSUR PS, V73, P13, DOI 10.1136/jnnp.73.1.13; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee Michael A, 2009, Conn Med, V73, P171; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Center for Injury Prevention and Control, 2011, C MILD TRAUM BRAIN I; National Federation of State High School Athletic Associations, 2009 2010 HIGH SCH A; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Patel DR, 2010, PEDIATR CLIN N AM, V57, P649, DOI 10.1016/j.pcl.2010.03.006; Patel DR, 2002, PEDIATR CLIN N AM, V49, P505, DOI 10.1016/S0031-3955(02)00003-2; Patrick Kathleen, 2011, NASN Sch Nurse, V26, P15, DOI 10.1177/1942602X10390372; Pellman EJ, 2007, NEUROSURGERY, V60, P1050; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; U.S. Department of Education, 2007, FREE APPR PUBL ED ST; U.S. Department of Education, 2000, GUID IND ED PROGR; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wallander JL, 2003, HDB PEDIAT PSYCHOL, P141; Washington State Department of Health, CONC MAN SCH; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	89	89	89	0	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S369	S379		10.1016/j.pmrj.2011.07.015			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	966YK	WOS:000305873100004	22035679				2021-06-18	
J	Alford, PW; Dabiri, BE; Goss, JA; Hemphill, MA; Brigham, MD; Parker, KK				Alford, Patrick W.; Dabiri, Borna E.; Goss, Josue A.; Hemphill, Matthew A.; Brigham, Mark D.; Parker, Kevin Kit			Blast-induced phenotypic switching in cerebral vasospasm	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						neurotrauma; mechanotransduction; tissue engineering; vascular mechanics	SMOOTH-MUSCLE-CELLS; MYOSIN LIGHT-CHAIN; EXTRACELLULAR-MATRIX; SUBARACHNOID HEMORRHAGE; GROWTH; MODEL; MODULATION; INJURY; MECHANOTRANSDUCTION; PHOSPHORYLATION	Vasospasm of the cerebrovasculature is a common manifestation of blast-induced traumatic brain injury (bTBI) reported among combat casualties in the conflicts in Afghanistan and Iraq. Cerebral vasospasm occurs more frequently, and with earlier onset, in bTBI patients than in patients with other TBI injury modes, such as blunt force trauma. Though vasospasm is usually associated with the presence of subarachnoid hemorrhage (SAH), SAH is not required for vasospasm in bTBI, which suggests that the unique mechanics of blast injury could potentiate vasospasm onset, accounting for the increased incidence. Here, using theoretical and in vitro models, we show that a single rapid mechanical insult can induce vascular hypercontractility and remodeling, indicative of vasospasm initiation. We employed high-velocity stretching of engineered arterial lamellae to simulate the mechanical forces of a blast pulse on the vasculature. An hour after a simulated blast, injured tissues displayed altered intracellular calcium dynamics leading to hypersensitivity to contractile stimulus with endothelin-1. One day after simulated blast, tissues exhibited blast force dependent prolonged hypercontraction and vascular smooth muscle phenotype switching, indicative of remodeling. These results suggest that an acute, blast-like injury is sufficient to induce a hypercontraction-induced genetic switch that potentiates vascular remodeling, and cerebral vasospasm, in bTBI patients.	[Alford, Patrick W.; Dabiri, Borna E.; Goss, Josue A.; Hemphill, Matthew A.; Brigham, Mark D.; Parker, Kevin Kit] Harvard Univ, Wyss Inst Biologically Inspired Engn, Dis Biophys Grp, Sch Engn & Appl Sci, Cambridge, MA 02138 USA	Parker, KK (corresponding author), Harvard Univ, Wyss Inst Biologically Inspired Engn, Dis Biophys Grp, Sch Engn & Appl Sci, Pierce Hall 321,29 Oxford St, Cambridge, MA 02138 USA.	kkparker@seas.harvard.edu		Brigham, Mark/0000-0002-7196-2261	Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-08-C-2036]; Harvard School of Engineering and Applied Sciences	The authors gratefully acknowledge the use of facilities at the Harvard Center for Nanoscale Systems. This work was funded by the Defense Advanced Research Projects Agency Preventing Violent Explosive Neurologic Trauma (PREVENT) N66001-08-C-2036 (K. K. P.) and Harvard School of Engineering and Applied Sciences.	Alford PW, 2008, COMPUT METHOD BIOMEC, V11, P525, DOI 10.1080/10255840801930710; Alford PW, 2008, BIOMECH MODEL MECHAN, V7, P245, DOI 10.1007/s10237-007-0101-2; Alford PW, 2010, BIOMATERIALS, V31, P3613, DOI 10.1016/j.biomaterials.2010.01.079; Alford PW, 2003, J BIOMECH, V36, P1135, DOI 10.1016/S0021-9290(03)00089-7; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Balasubramanian L, 2007, AM J PHYSIOL-REG I, V293, pR1586, DOI 10.1152/ajpregu.00025.2007; Baldwin ME, 2004, STROKE, V35, P2506, DOI 10.1161/01.STR.0000144654.79393.cf; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Borel CO, 2003, STROKE, V34, P427, DOI 10.1161/01.STR.0000053848.06436.AB; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chesler NC, 1999, AM J PHYSIOL-HEART C, V277, pH2002; COSENTINO F, 1994, STROKE, V25, P904, DOI 10.1161/01.STR.25.4.904; COX RH, 1978, AM J PHYSIOL, V234, pH533; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Feinberg AW, 2007, SCIENCE, V317, P1366, DOI 10.1126/science.1146885; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Humphrey JD, 2007, ANN BIOMED ENG, V35, P1485, DOI 10.1007/s10439-007-9321-y; Humphrey JD, 2003, BIOMECH MODEL MECHAN, V2, P109, DOI [10.1007/s10237-003-0033-4, 10.1007/S10237-003-0033-4]; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Intengan HD, 2001, HYPERTENSION, V38, P581, DOI 10.1161/hy09t1.096249; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; MASAOKA H, 1989, LANCET, V2, P1402; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Peyton SR, 2005, J CELL PHYSIOL, V204, P198, DOI 10.1002/jcp.20274; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Polte TR, 2004, AM J PHYSIOL-CELL PH, V286, pC518, DOI 10.1152/ajpcell.00280.2003; Qin H, 2000, EXP MOL PATHOL, V69, P79, DOI 10.1006/exmp.2000.2321; Ramasubramanian A, 2008, T ASME, V130; RODRIGUEZ EK, 1994, J BIOMECH, V27, P455, DOI 10.1016/0021-9290(94)90021-3; Sato M, 2000, CIRC RES, V87, P195, DOI 10.1161/01.RES.87.3.195; Stegemann JP, 2005, J APPL PHYSIOL, V98, P2321, DOI 10.1152/japplphysiol.01114.2004; Taber LA, 1998, J BIOMECH ENG-T ASME, V120, P348, DOI 10.1115/1.2798001; Taber LA, 1998, J THEOR BIOL, V193, P201, DOI 10.1006/jtbi.1997.0618; Tachibana E, 1999, ACTA NEUROCHIR, V141, P13, DOI 10.1007/s007010050260; Warden DL, 2005, NEW ENGL J MED, V353, P633; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Yamaguchi-Okada M, 2009, CEREBROVASC DIS, V28, P135, DOI 10.1159/000223439; YAMAMOTO M, 1993, EXP CELL RES, V204, P121, DOI 10.1006/excr.1993.1016; Zhang W, 2007, AM J PHYSIOL-HEART C, V293, pH2355, DOI 10.1152/ajpheart.00423.2007; Zhang ZD, 2006, NEUROL RES, V28, P713, DOI 10.1179/016164106X151990	49	89	89	0	9	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 2	2011	108	31					12705	12710		10.1073/pnas.1105860108			6	Multidisciplinary Sciences	Science & Technology - Other Topics	800SC	WOS:000293385700038	21765001	Green Published, Bronze			2021-06-18	
J	Hankin, JA; Farias, SE; Barkley, R; Heidenreich, K; Frey, LC; Hamazaki, K; Kim, HY; Murphy, RC				Hankin, Joseph A.; Farias, Santiago E.; Barkley, Robert M.; Heidenreich, Kim; Frey, Lauren C.; Hamazaki, Kei; Kim, Hee-Yong; Murphy, Robert C.			MALDI Mass Spectrometric Imaging of Lipids in Rat Brain Injury Models	JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY			English	Article						MALDI; IMS; Imaging mass spectrometry; Sublimation; Brain; Phosphatidylcholine; Ceramide; Traumatic brain injury; Ischemia reperfusion; Brain injury; Alkali metal adduct images; CA1; Hippocampus damage	GERBIL HIPPOCAMPUS; FOREBRAIN ISCHEMIA; MATRIX; PHOSPHOLIPIDS; TISSUE; DAMAGE; IMS	Matrix-assisted laser desorption ionization/ionization imaging mass spectrometry (MALDI IMS) with a time-of-flight analyzer was used to characterize the distribution of lipid molecular species in the brain of rats in two injury models. Ischemia/reperfusion injury of the rat brain after bilateral occlusion of the carotid artery altered appearance of the phospholipids present in the hippocampal region, specifically the CA1 region. These brain regions also had a large increase in the ion abundance at m/z 548.5 and collisional activation supported identification of this ion as arising from ceramide (d18:1/18:0), a lipid known to be associated with cellular apoptosis. Traumatic brain injury model in the rat was examined by MALDI IMS and the area of damage also showed an increase in ceramide (d18:1/18:0) and a remarkable loss of signal for the potassium adduct of the most abundant phosphocholine molecular species 16:0/18:1 (PC) with a corresponding increase in the sodium adduct ion. This change in PC alkali attachment ion was suggested to be a result of edema and influx of extracellular fluid likely through a loss of Na/K-ATPase caused by the injury. These studies reveal the value of MALDI IMS to examine tissues for changes in lipid biochemistry and will provide data needed to eventually understand the biochemical mechanisms relevant to tissue injury.	[Hankin, Joseph A.; Farias, Santiago E.; Barkley, Robert M.; Heidenreich, Kim; Murphy, Robert C.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO USA; [Hamazaki, Kei; Kim, Hee-Yong] NIAAA, Lab Mol Signaling, NIH, Bethesda, MD USA; [Frey, Lauren C.] Univ Colorado Denver, Dept Neurol, Aurora, CO USA	Murphy, RC (corresponding author), Univ Colorado Denver, Dept Pharmacol, Aurora, CO USA.	Robert.Murphy@ucdenver.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	General Medical Sciences Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM069338]; Colorado TBI Trust; NIAAA, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM069338] Funding Source: NIH RePORTER	The authors acknowledge that this work was supported, in part, by a grant from the LipidMAPS Large Scale Collaborative grant from General Medical Sciences Institute (GM069338) of the National Institutes of Health and Colorado TBI Trust Fund. A part of this research (Kei H. and H.Y.K.) was supported by the intramural program of NIAAA, NIH. The authors thank Erin Genova (UC Denver Pathology Department) for assistance in preparation of FPI tissue sections.	Astigarraga E, 2008, ANAL CHEM, V80, P9105, DOI 10.1021/ac801662n; Burnum KE, 2009, J LIPID RES, V50, P2290, DOI 10.1194/jlr.M900100-JLR200; Chen YF, 2008, ANAL CHEM, V80, P2780, DOI 10.1021/ac702350g; Cornett DS, 2007, NAT METHODS, V4, P828, DOI 10.1038/NMETH1094; Deeley JM, 2010, J LIPID RES, V51, P2753, DOI 10.1194/jlr.M007716; Drexler Dieter M., 2007, Journal of Pharmacological and Toxicological Methods, V55, P279, DOI 10.1016/j.vascn.2006.11.004; Durmaz R, 2003, CAN J NEUROL SCI, V30, P143, DOI 10.1017/S0317167100053415; Farias S, 2009, J NEUROTRAUM, V26, P1977, DOI 10.1089/neu.2009.0877; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Grey AC, 2010, ANAT REC, V293, P821, DOI 10.1002/ar.21103; Hankin JA, 2007, J AM SOC MASS SPECTR, V18, P1646, DOI 10.1016/j.jasms.2007.06.010; Hankin JA, 2010, ANAL CHEM, V82, P8476, DOI 10.1021/ac101079v; Jackson SN, 2007, J AM SOC MASS SPECTR, V18, P17, DOI 10.1016/j.jasms.2006.08.015; Jackson SN, 2008, J AM SOC MASS SPECTR, V19, P1655, DOI 10.1016/j.jasms.2008.07.005; Jurchen JC, 2005, J AM SOC MASS SPECTR, V16, P1654, DOI 10.1016/j.jasms.2005.06.006; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Koizumi S, 2010, NEUROSCIENCE, V168, P219, DOI 10.1016/j.neuroscience.2010.03.056; Kubota M, 1996, NEUROL RES, V18, P337; MURPHY RC, 2010, MASS SPECTR IN PRESS; Murphy RC, 2009, J LIPID RES, V50, pS317, DOI 10.1194/jlr.R800051-JLR200; Nakane M, 2000, NEUROSCI LETT, V296, P89, DOI 10.1016/S0304-3940(00)01655-4; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Schwamborn K, 2010, NAT REV CANCER, V10, P639, DOI 10.1038/nrc2917; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Spencer SJ, 2006, J CEREBR BLOOD F MET, V26, P456, DOI 10.1038/sj.jcbfm.9600206; Sugiura Y, 2009, J LIPID RES, V50, P1776, DOI 10.1194/jlr.M900047-JLR200; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Vestal ML, 2009, J MASS SPECTROM, V44, P303, DOI 10.1002/jms.1537; Wisztorski M, 2008, DEV NEUROBIOL, V68, P845, DOI 10.1002/dneu.20623; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	32	89	90	0	52	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1044-0305			J AM SOC MASS SPECTR	J. Am. Soc. Mass Spectrom.	JUN	2011	22	6					1014	1021		10.1007/s13361-011-0122-z			8	Biochemical Research Methods; Chemistry, Analytical; Chemistry, Physical; Spectroscopy	Biochemistry & Molecular Biology; Chemistry; Spectroscopy	762DD	WOS:000290451600008	21953042	Green Accepted, Bronze			2021-06-18	
J	Rowson, S; Beckwith, JG; Chu, JJ; Leonard, DS; Greenwald, RM; Duma, SM				Rowson, Steven; Beckwith, Jonathan G.; Chu, Jeffrey J.; Leonard, Daniel S.; Greenwald, Richard M.; Duma, Stefan M.			A Six Degree of Freedom Head Acceleration Measurement Device for Use in Football	JOURNAL OF APPLIED BIOMECHANICS			English	Article						mild traumatic brain injury (MTBI); concussion; biomechanics; angular; linear; rotational	TRAUMATIC BRAIN-INJURIES; PROFESSIONAL FOOTBALL; IMPACT; ACCELEROMETERS; EPIDEMIOLOGY; CONCUSSION; LOCATION	The high incidence rate of concussions in football provides a unique opportunity to collect biomechanical data to characterize mild traumatic brain injury. The goal of this study was to validate a six degree of freedom (6DOF) measurement device with 12 single-axis accelerometers that uses a novel algorithm to compute linear and angular head accelerations for each axis of the head. The 6DOF device can be integrated into existing football helmets and is capable of wireless data transmission. A football helmet equipped with the 6DOF device was fitted to a Hybrid III head instrumented with a 9 accelerometer array. The helmet was impacted using a pneumatic linear impactor. Hybrid III head accelerations were compared with that of the 6DOF device. For all impacts, peak Hybrid III head accelerations ranged from 24 g to 176 g and 1,506 rad/s(2) to 14,431 rad/s(2). Average errors for peak linear and angular head acceleration were 1% +/- 18% and 3% +/- 24%, respectively. The average RMS error of the temporal response for each impact was 12.5 g and 907 rad/s(2).	[Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.; Leonard, Daniel S.; Greenwald, Richard M.] Simbex, Lebanon, NH USA	Rowson, S (corresponding author), Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA.		Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Highway Traffic Safety Administration; Toyota Central Research and Development Laboratories; National Institutes of Health (National Institute for Child Health and Human Development)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The authors gratefully acknowledge our sponsors for this research including the National Highway Traffic Safety Administration, Toyota Central Research and Development Laboratories, and the National Institutes of Health (National Institute for Child Health and Human Development) award R01HD048638.	Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Foster J.K., 1977, P 21 STAPP CAR CRASH; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; HUBBARD RP, 1974, P 18 STAPP CAR CRASH; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Moon D W, 1971, Med Sci Sports, V3, P44; Newman J, 2000, P INT RES C BIOM IMP; Newman J.A., 1999, P INT RES C BIOM IMP; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; *NOCSAE, 2006, 08104M04 ND NOCSAE; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; RATH AL, 2005, 200520010745 SOC AUT; Reid S E, 1974, J Sports Med, V2, P86; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; Rowson S, 2010, CLIN J SPORT MED, V20, P344, DOI 10.1097/JSM.0b013e3181ed7e50; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Walker L., 1973, P 17 STAPP CAR CRASH	28	89	89	0	18	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483			J APPL BIOMECH	J. Appl. Biomech.	FEB	2011	27	1					8	14		10.1123/jab.27.1.8			7	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	748GQ	WOS:000289378400002	21451177				2021-06-18	
J	Covassin, T; Elbin, R; Kontos, A; Larson, E				Covassin, Tracey; Elbin, Robert; Kontos, Anthony; Larson, Elizabeth			Investigating baseline neurocognitive performance between male and female athletes with a history of multiple concussion	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; RECURRENT CONCUSSION; AGREEMENT STATEMENT; FOOTBALL PLAYERS; ESTROGEN; SPORT; SYMPTOMS; IMPACT; RISK	Objective The purpose of this study was to examine, using a dose-response model, sex differences in computerised neurocognitive performance among athletes with a history of multiple concussions. Design Retrospective with randomly selected concussion cases from four levels/numbers of previous concussion. Setting Multicentre analysis of NCAA student-athletes. Participants Subjects included a total of 100 male and 88 female NCAA athletes. Intervention Sex and four mutually exclusive groups of self-reported concussion history: (1) no history of concussion, (2) one previous concussion, (3) two previous concussions, (4) three or more previous concussions. Main outcome measurements Neurocognitive performance as measured by a computerised neurocognitive test battery (Immediate Postconcussion Assessment Cognitive Testing (ImPACT)). Results A dose-response gradient was found for two or more previous concussions and decreased neurocognitive performance. Females with a history of two and three or more concussions performed better than males with a history of two (p=0.001) and three or more concussions (p=0.012) on verbal memory. Females performed better than males with a history of three or more concussions (p=0.021) on visual memory. Finally, there was a significant difference for sex on both motor processing speed and reaction-time composite scores. Specifically, males performed worse than females on both processing speed (p=0.029) and reaction time (p=0.04). Conclusion The current study provided partial support for a dose-response model of concussion and neurocognitive performance decrements beginning at two or more previous concussions. Sex differences should be considered when examining the effects of concussion history on computerised neurocognitive performance.	[Covassin, Tracey; Elbin, Robert] Michigan State Univ, E Lansing, MI 48824 USA; [Kontos, Anthony; Larson, Elizabeth] Humboldt State Univ, Arcata, CA 95521 USA	Covassin, T (corresponding author), Michigan State Univ, 105 Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu		Kontos, Anthony/0000-0002-3749-4310			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Brown CN, 2007, J ATHL TRAINING, V42, P515; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; *CDC, 2006, HEADS SPORTS CONC; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Giza CC, 2001, J ATHL TRAINING, V36, P228; Granito VJ., 2002, J SPORT BEHAV, V25, P243; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halpern DF, 1997, AM PSYCHOL, V52, P1091, DOI 10.1037/0003-066X.52.10.1091; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; JENSEN AR, 1983, PERS INDIV DIFFER, V4, P223, DOI 10.1016/0191-8869(83)90029-6; Kaufman A. S., 1990, ASSESSING ADOLESCENT; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LOVELL M, 2005, IMMEDIATE POSTCONCUS; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; SMITH SS, 1989, BRAIN RES, V503, P354, DOI 10.1016/0006-8993(89)91691-0; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	30	89	89	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2010	81	6					597	601		10.1136/jnnp.2009.193797			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	605NK	WOS:000278354100005	20522868				2021-06-18	
J	Sarmiento, K; Mitchko, J; Klein, C; Wong, S				Sarmiento, Kelly; Mitchko, Jane; Klein, Cynthia; Wong, Sharon			Evaluation of the Centers for Disease Control and Prevention's Concussion Initiative for High School Coaches: "Heads Up: Concussion in High School Sports"	JOURNAL OF SCHOOL HEALTH			English	Article						health communication; concussion prevention; physical fitness and sport; public health; high school coaches; tool kit		METHODS: A mail questionnaire was administered to all eligible high school coaches who received the tool kit. Follow-up focus groups were conducted for additional information. Both quantitative data from the surveys and qualitative data from the focus groups were analyzed to support the objectives of the study. RESULTS: Respondents self-reported favorable changes in knowledge, attitudes, and practices toward the prevention and management of concussions. Qualitative responses augmented the quantitative data. CONCLUSION: Barriers to concussion prevention and management are complex; however, these results highlight the role that coaches can play in school settings in establishing a safe environment for their athletes.	[Sarmiento, Kelly] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, Atlanta, GA 30341 USA; [Klein, Cynthia] SRA Int Inc, Survey & Evaluat Res Div, Atlanta, GA 30329 USA	Sarmiento, K (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, 4770 Buford Hwy NE,Mail Stop F-62, Atlanta, GA 30341 USA.	KSarmiento@cdc.gov; jpmitchko@cdc.gov; Cynthia_Klein@sra.com; SWong1@cdc.gov					*CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Dillman DA., 1999, MAIL INTERNET SURVEY; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; *US I MED, 2002, SOCC BAD CHILDR HEAD	6	89	89	0	11	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-4391			J SCHOOL HEALTH	J. Sch. Health	MAR	2010	80	3					112	118		10.1111/j.1746-1561.2010.00491.x			7	Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health	Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health	557KW	WOS:000274669000002	20236412				2021-06-18	
J	Tillou, A; Gupta, M; Baraff, LJ; Schriger, DL; Hoffman, JR; Hiatt, JR; Cryer, HM				Tillou, Areti; Gupta, Malkeet; Baraff, Larry J.; Schriger, David L.; Hoffman, Jerome R.; Hiatt, Jonathan R.; Cryer, Henry M.			Is the Use of Pan-Computed Tomography for Blunt Trauma Justified? A Prospective Evaluation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Computed tomography; Blunt injury; Trauma; Missed injuries	ABDOMINAL-TRAUMA; EMERGENCY-DEPARTMENT; INJURY; MANAGEMENT; SCAN	Objective: Many trauma centers use the pan-computed tomography (CT) scan (head, neck, chest, and abdomen/pelvis) for the evaluation of blunt trauma. This prospective observational study was undertaken to determine whether a more selective approach could be justified. Methods: We evaluated injuries in blunt trauma victims receiving a pan-CT scan at a level 1 trauma center. The primary outcome was injury needing immediate intervention. Secondary outcome was any injury. The perceived need for each scan was independently recorded by the emergency medicine and trauma surgery service before patients went to CT. A scan was unsupported if at least one of the physicians deemed it unnecessary. Results: Between July, 1, 2007, and December, 28, 2007, 284 blunt trauma patients (average Injury Severity Score = 11) underwent a pan-CT after the survey form was completed. A total of 311 CT scans were judged to be unnecessary in 143 patients (27%), including scans of the head (62), neck (50), chest (116), and abdomen/pelvis (83). Of the 284 patients, 48 (17%) had injuries on 52 unsupported CT scans. An immediate intervention was required in 2 of the 48 patients (4%). Injuries that would have been missed included 5 of 62 unsupported head scans (8%), 2 of 50 neck scans (4%), 33 of 116 chest scans (28%), and 12 of 83 abdominal scans (14%). These missed injuries represent 5 of the 61 patients with closed head injuries (8%) in the series, 2 of the 23 with C-spine injuries (9%), 33 of the 112 with chest injuries (29%), and 12 of the 86 with abdominal injuries (14%). In 19 patients. none of the four CT scans was supported; nine of these had an injury identified, and six were admitted to the hospital (1 to the intensive care unit). Injuries that would have been missed included intraventricular and intracerebral hemorrhage (4), subarachnoid hemorrhage (2), cerebral contusion (1), C1 fracture (1), spinous and transverse process fractures (3), vertebral fracture (6), lung lacerations (1), lung contusions (14), small pneumothoraces (7), grade II-III liver and splenic lacerations (6), and perinephric or mesenteric hematomas (2). Conclusions: In this small sample, physicians were willing to omit 27% of scans. If this was done, two injuries requiring immediate actions would have been missed initially, and other potentially important injuries would have been missed in 17% of patients.	[Tillou, Areti] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Emergency Med, David Geffen Sch Med, Los Angeles, CA 90095 USA	Tillou, A (corresponding author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, 10833 Conte Ave,CHS,Room 72-231, Los Angeles, CA 90095 USA.	atillou@mednet.ucla.edu		Schriger, David/0000-0003-0242-1127			BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; BRIX G, 2008, EUR J RADIOL; Broder J, 2006, EMERG RADIOL, V13, P25, DOI 10.1007/s10140-006-0493-9; Buduhan G, 2000, J TRAUMA, V49, P600, DOI 10.1097/00005373-200010000-00005; DEMETRIADES D, 2008, ARCH SURG-CHICAGO, V133, P1084; Exadaktylos AK, 2001, J TRAUMA, V51, P1173, DOI 10.1097/00005373-200112000-00025; GLABAMAN M, HLTH PLANS STAIN CON; Goldman D, 2005, US HLTH CARE FACTS C; Griffen MM, 2003, J TRAUMA, V55, P222, DOI 10.1097/01.TA.0000083332.93868.E2; Isenhour JL, 2007, EMERG MED CLIN N AM, V25, P713, DOI 10.1016/j.emc.2007.06.002; Kalra MK, 2004, RADIOLOGY, V230, P619, DOI 10.1148/radiol.2303021726; Livingston DH, 1998, J TRAUMA, V44, P273, DOI 10.1097/00005373-199802000-00005; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; MATSUBARA TK, 1990, J TRAUMA, V30, P410, DOI 10.1097/00005373-199030040-00006; McCarthy MC, 1998, J TRAUMA, V44, P280; PEITZMAN AB, 1986, J TRAUMA, V26, P585, DOI 10.1097/00005373-198607000-00001; PEVEC WC, 1991, SURG GYNECOL OBSTET, V173, P262; Pfeifer R, 2008, PATIENT SAF SURG, V2, DOI 10.1186/1754-9493-2-20; Poletti PA, 2004, J TRAUMA, V57, P1072, DOI 10.1097/01.TA.0000092680.73274.E1; RIZZO AG, 1995, J TRAUMA, V38, P338, DOI 10.1097/00005373-199503000-00005; Salim A, 2006, ARCH SURG-CHICAGO, V141, P468, DOI 10.1001/archsurg.141.5.468; Self ML, 2003, AM J SURG, V186, P609, DOI 10.1016/j.amjsurg.2003.08.003; Tien HC, 2007, J TRAUMA, V62, P151, DOI 10.1097/TA.0b013e31802d9700; Tyburski JG, 2006, ARCH SURG-CHICAGO, V141, P473; Vles WJ, 2003, J AM COLL SURGEONS, V197, P596, DOI 10.1016/S1072-7515(03)00601-X; WOLFMAN NT, 1992, AM J ROENTGENOL, V158, P493, DOI 10.2214/ajr.158.3.1738983	28	89	92	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2009	67	4					779	787		10.1097/TA.0b013e3181b5f2eb			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	506BE	WOS:000270747000018	19820586				2021-06-18	
J	Dash, PK; Zhao, J; Orsi, SA; Zhang, M; Moore, AN				Dash, Prarnod K.; Zhao, Jing; Orsi, Sara A.; Zhang, Min; Moore, Anthony N.			Sulforaphane improves cognitive function administered following traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						TBI; Nrf2; Prefrontal cortex; Hippocampus; Spatial memory	CONTROLLED CORTICAL IMPACT; OLIGONUCLEOTIDE MICROARRAY; MEMORY DEFICITS; EXPRESSION; IDENTIFICATION; NEURONS; COMPLEX; PROTEIN; STRESS; MODEL	Recent studies have shown that sulforaphane, a naturally occurring compound that is found in cruciferous vegetables, offers cellular protection in several models of brain injury. When administered following traumatic brain injury (TBI), sulforaphane has been demonstrated to attenuate blood-brain barrier permeability and reduce cerebral edema. These beneficial effects of sulforaphane have been shown to involve induction of a group of cytoprotective, Nrf2-driven genes, whose protein products include free radical scavenging and detoxifying enzymes. However, the influence of sulforaphane on post-injury cognitive deficits has not been examined. In this study, we examined if sulforaphane, when administered following cortical impact injury, can improve the performance of rats tested in hippocampal- and prefrontal cortex-dependent tasks. Our results indicate that sulforaphane treatment improves performance in the Morris water maze task (as indicated by decreased latencies during learning and platform localization during a probe trial) and reduces working memory dysfunction (tested using the delayed match-to-place task). These behavioral improvements were only observed when the treatment was initiated 1 h, but not 6 h, post-injury. These studies support the use of sulforaphane in the treatment of TBI, and extend the previously observed protective effects to include enhanced cognition. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Dash, Prarnod K.; Zhao, Jing; Orsi, Sara A.; Zhang, Min; Moore, Anthony N.] Univ Texas Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH072933, NS053588, NS049160]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053588, R01NS049160] Funding Source: NIH RePORTER	This work was supported, in part, by grants (MH072933, NS053588, NS049160) from the National Institutes of Health to P.K.D.	CALICOS MA, 1996, BRAIN RES, V739, P111; DASH PK, 1995, J NEUROSCI, V15, P2030; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; SHARP FR, 1993, STROKE S, V24, P172; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	18	89	95	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 28	2009	460	2					103	107		10.1016/j.neulet.2009.04.028			5	Neurosciences	Neurosciences & Neurology	469PD	WOS:000267911100001	19515491	Green Accepted			2021-06-18	
J	Rana, AR; Michalsky, MP; Teich, S; Groner, JI; Caniano, DA; Schuster, DP				Rana, Ankur R.; Michalsky, Marc P.; Teich, Steven; Groner, Jonathon I.; Caniano, Donna A.; Schuster, Dara P.			Childhood obesity: a risk factor for injuries observed at a level-1 trauma center	JOURNAL OF PEDIATRIC SURGERY			English	Article						Childhood obesity; Trauma; Outcomes	BODY-MASS INDEX; OVERWEIGHT; MORTALITY; FRACTURES; OUTCOMES; CHILDREN; IMPACT	Purpose: Obesity is ail independent risk factor in trauma-related morbidity in adults. The purpose of this study was to investigate the effect of obesity in the pediatric trauma population. Methods: All patients (6-20 years) between January 2004 and July 2007 were retrospectively reviewed and defined as non-obese (body mass index [BMI] <95th percentile for age) or obese (BMI >= 95th percentile for age). Groups were compared for differences in demographics, initial vital signs, mechanisms of injury, length of stay, intensive care unit stay, ventilator days, Injury Severity Score, operative procedures, and clinical outcomes. Results: Of 1314 patients analyzed, there were 1020 (77%) nonobese patients (mean BMI = 18.8 kg/m(2)) and 294 (23%) obese patients (mean BMI = 29.7 kg/m(2)). There was no significant difference in sex, heart rate, length of stay, intensive care unit days, ventilator days, Injury Severity Score, and mortality between the groups. The obese children were significantly younger than the nonobese children (10.9 +/- 3.3 vs 11.5 +/- 3.5 years; P = .008) and had a higher systolic blood pressure during initial evaluation (128 +/- 17 vs 124 +/- 16 min Hg, P < .001). In addition, the obese group had a higher incidence of extremity fractures (55% vs 40%; P < .001) and orthopedic surgical intervention (42% vs 30%; P < .001) but a lower incidence of closed head injury (12% vs 18%; P =.013) and intraabdominal injuries (6% vs 11%; P = .023). Evaluation of complications showed a higher incidence of decubitus ulcers (P = .043) and deep vein thrombosis (P = .008) in the obese group. Conclusion: In pediatric trauma patients, obesity may be a risk factor for sustaining ail extremity fracture requiring operative intervention and having a higher risk for certain complications (ie, deep venous thrombosis [DVT] and decubitus ulcers) despite having a lower incidence of intracranial and intraabdominal injuries. Results are similar to reports examining the effect(s) of obesity on the adult population. (C) 2009 Elsevier Inc. All rights reserved.	[Rana, Ankur R.; Michalsky, Marc P.; Teich, Steven; Groner, Jonathon I.; Caniano, Donna A.] Ohio State Univ, Coll Med, Div Pediat Surg, Dept Surg, Columbus, OH 43205 USA; [Rana, Ankur R.; Michalsky, Marc P.; Teich, Steven; Groner, Jonathon I.; Caniano, Donna A.; Schuster, Dara P.] Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Schuster, Dara P.] Ohio State Univ, Dept Internal Med, Coll Med, Columbus, OH 43205 USA	Michalsky, MP (corresponding author), Ohio State Univ, Coll Med, Div Pediat Surg, Dept Surg, Columbus, OH 43205 USA.	marc.michalsky@nationwidechildrens.org	Groner, Jonathan/E-3156-2011; Michalsky, Marc/E-3674-2011	Groner, Jonathan/0000-0002-0998-593X; michalsky, marc/0000-0002-7119-3634	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR025755] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025755] Funding Source: NIH RePORTER		Alban RF, 2006, AM SURGEON, V72, P966; Arbabi S, 2003, J TRAUMA, V54, P1090, DOI 10.1097/01.TA.0000064449.11809.48; Belzberg H, 2007, J TRAUMA, V62, P1192, DOI 10.1097/01.ta.0000219701.07295.b8; Bochicchio GV, 2006, J AM COLL SURGEONS, V203, P533, DOI 10.1016/j.jamcollsurg.2006.07.001; BOSTMAN OM, 1995, J BONE JOINT SURG BR, V77B, P101; BOSTMAN OM, 1994, J TRAUMA, V37, P62; BOULANGER BR, 1992, J TRAUMA, V33, P228, DOI 10.1097/00005373-199208000-00011; Brown CVR, 2006, J PEDIATR SURG, V41, P88, DOI 10.1016/j.jpedsurg.2005.10.012; Brown CVR, 2005, J TRAUMA, V58, P102, DOI 10.1097/01.TA.0000105990.05074.4A; Byrnes MC, 2005, J TRAUMA, V58, P232, DOI 10.1097/01.TA.0000152081.67588.10; Duane TM, 2006, J TRAUMA, V61, P1218, DOI 10.1097/01.ta.0000241022.43088.e1; Ferraro KF, 2003, J GERONTOL B-PSYCHOL, V58, pS110, DOI 10.1093/geronb/58.2.S110; Freedman DS, 1999, PEDIATRICS, V103, P1175, DOI 10.1542/peds.103.6.1175; Mei ZG, 2002, AM J CLIN NUTR, V75, P978; Must Aviva, 2003, Nutr Clin Care, V6, P4; Neville AL, 2004, ARCH SURG-CHICAGO, V139, P983, DOI 10.1001/archsurg.139.9.983; Newell MA, 2007, J AM COLL SURGEONS, V204, P1056, DOI 10.1016/j.jamcollsurg.2006.12.042; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Peskin GW, 2003, ARCH SURG-CHICAGO, V138, P354, DOI 10.1001/archsurg.138.4.354; Spaine LA, 1996, INJURY, V27, P687, DOI 10.1016/S0020-1383(96)00136-2; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301	21	89	91	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	AUG	2009	44	8					1601	1605		10.1016/j.jpedsurg.2008.11.060			5	Pediatrics; Surgery	Pediatrics; Surgery	481BA	WOS:000268780300021	19635312	Green Accepted			2021-06-18	
J	Reiff, DA; Haricharan, RN; Bullington, NM; Griffin, RL; McGwin, G; Rue, LW				Reiff, Donald A.; Haricharan, Ramanath N.; Bullington, Nathan M.; Griffin, Russell L.; McGwin, Gerald, Jr.; Rue, Loring W., III			Traumatic Brain Injury Is Associated With the Development of Deep Vein Thrombosis Independent of Pharmacological Prophylaxis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM PROPHYLAXIS; INTRACRANIAL HEMORRHAGIC INJURIES; MAJOR TRAUMA; ENOXAPARIN PROPHYLAXIS; 1602 EPISODES; HEAD-INJURY; DATA-BANK; SAFETY; COAGULATION	Introduction: Deep venous thrombosis (DVT) is common among trauma patients. If left untreated it may result in lethal pulmonary thromboembolism. Previous studies have suggested that intracranial hemorrhage serves as an independent risk factor for the development of DVT. These studies were not able to exclude anticoagulation therapy as a confounding variable in their analysis. Our objective was to determine the association of traumatic brain injury (TBI) to the formation of DVT irrespective of the use of anticoagulation therapy. Methods: All patients admitted to an academic level I Trauma Center between 2000 and 2007 with blunt or penetrating injuries were selected for inclusion in this study. Patients who died or who were discharged within 24 hours of admission were excluded in the analysis. TBI was defined as any intraparenchymal hemorrohage or extra-axial intracranial bleeding identified on radiographic imaging or both. Anticoagulation therapy was defined as the uninterrupted use of either subcutaneous lovenox or heparin. Risk ratios and 95% confidence intervals compared the risk of DVT among patients with and without TBI according to the initiation of anticoagulation therapy (no therapy, <24 hours, 24-48 hours, and >48 hours) adjusted for age, gender, race, injury severity, mechanism of injury, spinal injury, and lower extremity fracture. Results: Irrespective of the time of initiation of pharmacologic prophalaxis, TBI is independently associated with the formation of DVT. A threefold to fourfold increased risk of DVT formation is consistent across all prophylaxis groups among patients with TBI. Conclusion: The incidence of DVT among injured patients with TBI is significantly higher than those patients without head injury independent of anticoagulation therapy. Rigorous surveillance to detect DVT among trauma patients with TBI should be undertaken and where appropriate alternate means for pulmonary thromboembolism prevention used.	[Reiff, Donald A.; Haricharan, Ramanath N.; Bullington, Nathan M.; Griffin, Russell L.] Univ Alabama Birmingham, Dept Surg, Sect Trauma Burns & Surg Crit Care, Sch Med, Birmingham, AL 35294 USA; [Reiff, Donald A.; McGwin, Gerald, Jr.; Rue, Loring W., III] Univ Alabama Birmingham, Sch Publ Hlth, Ctr Injury Sci, Birmingham, AL 35294 USA; [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA	Reiff, DA (corresponding author), Univ Alabama Birmingham, Dept Surg, Sect Trauma Burns & Surg Crit Care, Sch Med, 1922 7th Ave S,KB 110, Birmingham, AL 35294 USA.	donald.reiff@ccc.uab.edu					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Brandt MM, 2007, AM J SURG, V193, P383; Buller HR, 2004, CHEST, V126, p401S, DOI 10.1378/chest.126.3_suppl.401S; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts William H, 2006, Hematology Am Soc Hematol Educ Program, P462; Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Macdonald RL, 2003, SURG NEUROL, V59, P363, DOI 10.1016/S0090-3019(03)00111-3; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Rogers SO, 2007, J TRAUMA, V62, P562; Ruggeri ZM, 2003, J THROMB HAEMOST, V1, P1335, DOI 10.1046/j.1538-7836.2003.00260.x; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Shackford SR, 2004, ANN SURG, V240, P496; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Yablon SA, 2004, NEUROLOGY, V63, P485, DOI 10.1212/01.WNL.0000133009.24727.9F; 2007, J NEUROTRAUMA S1, V24, pS32	35	89	94	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2009	66	5					1436	1440		10.1097/TA.0b013e31817fdf1c			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	445AJ	WOS:000266021700032	19430251				2021-06-18	
J	Summers, CR; Ivins, B; Schwab, KA				Summers, Carl R.; Ivins, Brian; Schwab, Karen A.			Traumatic Brain Injury in the United States: An Epidemiologic Overview	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						epidemiology; head injury; traumatic brain injury	MILD	A basic description of severity and frequency is needed for planning healthcare delivery for any disease process. In the case of trumatic brain injury, severity is typically categorized into mild, moderate, and severe with information from a combination of clinical observation and self-report methodologies. Recent US civilian epidemiological findings measuring the frequency of mortality and morbidity of traumatic brain injury are presented, including demographic and etiological breakdowns of the data. Falls, motor vehicle accidents, and being struck by objects are the major etiologies of traumatic brain injury. US civilian and Army hospitalization trends are discussed and compared. Features of traumatic brain injuries form Operation Iraqi Freedom and Operation Enduring Freedom are discussed. Mt Sinai J Med 76:105-110, 2009 (C) 2009 Mount Sinai School of Medicine	[Summers, Carl R.; Ivins, Brian; Schwab, Karen A.] Def & Vet Brain Injury Ctr, Washington, DC USA	Summers, CR (corresponding author), Def & Vet Brain Injury Ctr, Washington, DC USA.	Carl.Summers@amedd.army.mil					Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Association for the Advancement of Automotive Medicine, 2005, ABBR INJ SCAL 2005; Brundage JF, 1998, MIL MED, V163, P272; CAMEY N, 2007, GUIDELINES PREHOSPIT; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ivins BJ, 2006, NEUROEPIDEMIOLOGY, V27, P154, DOI 10.1159/000096127; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; NAPAOLITANO E, 2007, BRAIN INJURY MED, P57; *NAT CTR INJ PREV, 2006, REP C MILD TRAUM BRA; *NAT CTR INJ PREV, 2006, TRAUM BRAIN INJ US E; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sosin DM, 1996, BRAIN INJURY, V10, P47; TEASDALE G, 1974, LANCET, V2, P81; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 2007, BRAIN INJURY MED; *US ARM PUBL AFF, 1997, ARMY ACHIEVES SAFEST; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	25	89	92	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					105	110		10.1002/msj.20100			6	Medicine, General & Internal	General & Internal Medicine	427OE	WOS:000264787800003	19306375				2021-06-18	
J	Jones, NC; Cardamone, L; Williams, JP; Salzberg, MR; Myers, D; O'Brien, TJ				Jones, Nigel C.; Cardamone, Lisa; Williams, John P.; Salzberg, Michael R.; Myers, Damian; O'Brien, Terence J.			Experimental Traumatic Brain Injury Induces a Pervasive Hyperanxious Phenotype in Rats	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; behavior; depression; rat; traumatic brain injury	OF-THE-LITERATURE; PSYCHIATRIC-DISORDERS; COGNITIVE DEFICITS; AXIS-I; DEPRESSION; BEHAVIOR; ANXIETY; MODEL; ACETYLCHOLINE; RECEPTOR	Mood disturbances, including depression and anxiety disorders, are common and disabling long-term sequelae of traumatic brain injury (TBI). These psychiatric conditions have generally been considered psychosocial consequences of the trauma, but neurobiological alterations and causes have also been implicated. Using a rat model of TBI (lateral fluid-percussion injury), this longitudinal study seeks to assess anxiety and depression-like behaviors following experimental TBI. Male Wistar rats (n=20) received a severe (similar to 3.5 atmosphere) pressure pulse directed to the right sensorimotor cortex, or sham surgery (n=15). At 1, 3, and 6 months following injury, all rats underwent four assessments of anxiety and depression-like behaviors: exposure to an open field, elevated plus maze test, the forced swim test, and the sucrose preference test. Injured animals displayed increased anxiety-like behaviors throughout the study, as evidenced by reduced time spent (p=0.014) and reduced entries (p<0.001) into the center area of the open field, and reduced proportion of time in the open arms of the plus maze (p=0.015), compared to sham-injured controls. These striking changes were particularly evident 1 and 3 months after injury. No differences were observed in depression-like behaviors in the forced swim test (a measure of behavioral despair) and the sucrose preference test (a measure of anhedonia). This report provides the first evidence of persistent anxiety-like disturbances in an experimental model of TBI. This finding indicates that the common occurrence of these symptoms in human sufferers is likely to have, at least in part, a neurobiological basis. Studies in this model could provide insight into the mechanisms underlying affective disturbance in brain-injured patients.	[Jones, Nigel C.; Cardamone, Lisa; Myers, Damian; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia; [Williams, John P.] Howard Florey Inst, Parkville, Vic, Australia; [Salzberg, Michael R.] Univ Melbourne, St Vincents Hosp, Dept Psychiat, Fitzroy, Vic 3065, Australia	Jones, NC (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia.	ncjones@unimelb.edu.au	Myers, Damian E/L-5302-2013; Jones, Nigel C/K-7773-2012; O'Brien, Terence J/L-8102-2013	O'Brien, Terence/0000-0002-7198-8621; Myers, Damian/0000-0002-7569-9907; Jones, Nigel/0000-0002-1080-8439	Victorian Government Transport Accident Commission [DP0023]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [400088]	We wish to acknowledge the assistance of Amelia Koe for analysis of the forced swim test and the administrative support of Rosemary Paxton (Neurosciences Victoria). Funding for this project was provided by the Victorian Government Transport Accident Commission (in the form of a Victorian Neurotrauma Initiative Grant, DP0023). N.J., M.S., and T.O. wish to acknowledge the financial support of the National Health and Medical Research Council of Australia (competitive grant 400088).	APA, 2000, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Cannistraro Paul A, 2003, Psychopharmacol Bull, V37, P8; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Gould TD, 2006, GENES BRAIN BEHAV, V5, P113, DOI 10.1111/j.1601-183X.2005.00186.x; GRANACHER RP, 2003, NEUROPSYCHIATRIC PSY; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JANOWSKY DS, 1994, AM J MED GENET, V54, P335, DOI 10.1002/ajmg.1320540412; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kumar G, 2007, PSYCHONEUROENDOCRINO, V32, P834, DOI 10.1016/j.psyneuen.2007.05.011; Lahmame A, 1997, BRAIN RES, V750, P285, DOI 10.1016/S0006-8993(96)01368-6; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Pitkanen A, 2006, MODELS OF SEIZURES AND EPILEPSY, P465, DOI 10.1016/B978-012088554-1/50039-6; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Salzberg M, 2007, EPILEPSIA, V48, P2079, DOI 10.1111/j.1528-1167.2007.01246.x; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Singh A, 2004, IDRUGS, V7, P1096; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Spalletta G, 2006, MOL PSYCHIATR, V11, P984, DOI 10.1038/sj.mp.4001879; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009	45	89	91	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2008	25	11					1367	1374		10.1089/neu.2008.0641			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	384BP	WOS:000261718900009	19061380				2021-06-18	
J	Kilinc, D; Gallo, G; Barbee, KA				Kilinc, Devrim; Gallo, Gianluca; Barbee, Kenneth A.			Mechanically-induced membrane poration causes axonal beading and localized cytoskeletal damage	EXPERIMENTAL NEUROLOGY			English	Article						diffuse axonal injury; mechanoporation; neuroprotection; Poloxamer 188; axonal bead formation; fluid shear stress injury; plasma membrane	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; NEURONAL INJURY; STRETCH-INJURY; POLOXAMER 188; NERVE-FIBERS; OPTIC-NERVE; HEAD-INJURY; TRANSPORT; CALCIUM	Diffuse axonal injury (DAI), a major component of traumatic brain injury, is a manifestation of microstructural cellular trauma and various ensuing neurochemical reactions that leads to secondary neuronal death. DAI is suggested to result from the initial increase in the membrane permeability caused by the mechanical forces acting on the axons. Permeability increases disturb ion balance and lead to cytoskeletal disruption resulting in the impairment of axonal transport. We present an in vitro model that reproduces important features of in vivo DAI such as membrane permeability changes, focal disruption of microtubules, impaired axonal transport, and focal accumulation of organelles. We induced fluid shear stress injury (FSSI) on Cultured primary chick forebrain neurons and characterized the resulting structural and morphological changes. In addition, we tested the effect of Poloxamer 188 (P188), a tri-block co-polymer that is known to Promote resealing membrane pores. We found that FSSI induces mechanoporation that leads to axonal bead formation, the "hallmark" morphology of DAI. Beads contained accumulated mitochondria and co-localized with focal microtubule disruptions, also a characteristic of DAI. Post-injury P188 treatment prevented FSSI-induced membrane permeability changes and reduced axonal beading to control levels. These results indicate that acute mechanoporation of axons in response to injury is a necessary condition for subsequent axonal pathology, suggesting that membrane integrity is a potential target for therapeutic interventions. P188 provides neuroprotection Via resealing the plasma membrane following injury and prevents focal disruption of microtubules and axonal bead formation. (C) 2008 Published by Elsevier Inc.	[Kilinc, Devrim; Barbee, Kenneth A.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Gallo, Gianluca] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA	Barbee, KA (corresponding author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.	barbee@drexel.edu	Barbee, Kenneth/F-4333-2014; Kilinc, Devrim/I-4180-2019; Kilinc, Devrim/E-8733-2011	Kilinc, Devrim/0000-0003-3321-5203; Kilinc, Devrim/0000-0003-3321-5203	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048090, R56NS048090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS048090] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Baekmark TR, 1997, BIOPHYS J, V73, P1479, DOI 10.1016/S0006-3495(97)78180-3; Barbee KA, 2005, ANN NY ACAD SCI, V1066, P67, DOI 10.1196/annals.1363.006; Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Curry DJ, 2004, NEUROSURGERY, V55, P943, DOI 10.1227/01.NEU.0000137890.29862.2C; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gallo G, 1999, J NEUROSCI, V19, P3860; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hannig J, 2000, IEEE T PLASMA SCI, V28, P97, DOI 10.1109/27.842873; Heidemann SR, 2003, METHOD CELL BIOL, V71, P51, DOI 10.1016/S0091-679X(03)01004-5; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.02745; KILINC D, 2007, EMBC07, P5395; KOENIG E, 1985, J NEUROSCI, V5, P715; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2005, ANN NY ACAD SCI, V1066, P310, DOI 10.1196/annals.1363.018; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McIntosh TK, 1996, LAB INVEST, V74, P315; PADANILAM JT, 1994, ANN NY ACAD SCI, V720, P111, DOI 10.1111/j.1749-6632.1994.tb30439.x; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Sharma V, 1996, BIOPHYS J, V71, P3229, DOI 10.1016/S0006-3495(96)79516-4; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844	55	89	95	1	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2008	212	2					422	430		10.1016/j.expneurol.2008.04.025			9	Neurosciences	Neurosciences & Neurology	334WL	WOS:000258252000025	18572167				2021-06-18	
J	Hokari, M; Kuroda, S; Shichinohe, H; Yano, S; Hida, K; Iwasaki, Y				Hokari, Masaaki; Kuroda, Satoshi; Shichinohe, Hideo; Yano, Shunsuke; Hida, Kazutoshi; Iwasaki, Yoshinobu			Bone marrow stromal cells protect and repair damaged neurons through multiple mechanisms	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						bone marrow stromal cell; neuron; differentiation; neurotrophin; regeneration; coculture	MESENCHYMAL STEM-CELLS; IN-VITRO DIFFERENTIATION; TRAUMATIC BRAIN-INJURY; MICE CEREBRAL INFARCT; SPINAL-CORD-INJURY; NEUROECTODERMAL DIFFERENTIATION; GENE-EXPRESSION; GROWTH-FACTOR; RAT; TRANSPLANTATION	A surprising shortage of information surrounds the mechanism by which bone marrow stromal cells (BMSC) restore lost neurologic functions when transplanted into the damaged central nervous system. To clarify the issue, the BMSC were cocultured with the neurons using two paradigms: the cell-mixing coculture technique and three-dimensional coculture technique. The green fluorescent protein (GFP)-expressing BMSC were cocultured with the PKH-26-labelled neurons, using cell mixing coculture technique. GFP-positive, PKH-26-negative cells morphologically simulated the neurons and significantly increased the expression of AP-2, Tuj-1, nestin, and GFAP GFP/nestin-positive, PKH-26-negative cells increased from 13.6% +/- 6.7% to 32.1 % +/- 15.5% over 7 days of coculture. They further enhanced Tuj-1 expression when cocultured with neurons exposed to 100 mu M of glutamate for 10 min. About 20-30% of GFP-positive cells became positive for PKH-26 through coculture with the neurons, but the doubly positive cells did not increase when cocultured with glutamate-exposed neurons. Alternatively, the BMSC significantly ameliorated glutamate-induced neuronal damage when cocultured with the three-dimensional coculture technique. The protective effect was more prominent when coculture was started prior to glutamate exposure than when coculture was started just after glutamate exposure. ELISA analysis revealed that the BMSC physiologically produce NGF, BDNF, SDF-1 alpha, HGF, TGF beta-1, and IGF-1 and significantly enhanced the production of NGF and BDNF when cocultured with glutamate-exposed neurons. These findings strongly suggest that the BMSC may protect and repair the damaged neurons through multiple mechanisms, including transdifferentiation, cell fusion, and production of growth factors. (C) 2007 Wiley-Liss, Inc.	[Hokari, Masaaki; Kuroda, Satoshi; Shichinohe, Hideo; Yano, Shunsuke; Hida, Kazutoshi; Iwasaki, Yoshinobu] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Kuroda, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, N 15 W 7, Sapporo, Hokkaido 0608638, Japan.	skuroda@med.hokudai.ac.jp	Shichinohe, Hideo/G-5367-2012		Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591572] Funding Source: KAKEN		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bossolasco P, 2005, EXP NEUROL, V193, P312, DOI 10.1016/j.expneurol.2004.12.013; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Gao Q, 2005, NEUROSCIENCE, V136, P123, DOI 10.1016/j.neuroscience.2005.06.091; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Hermann A, 2006, J NEUROSCI RES, V83, P1502, DOI 10.1002/jnr.20840; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Jori FP, 2005, J CELL BIOCHEM, V94, P645, DOI 10.1002/jcb.20315; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Lee JB, 2004, BRAIN RES PROTOC, V14, P37, DOI 10.1016/j.brainresprot.2004.09.004; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Niikura T, 2004, J NEUROSCI RES, V77, P54, DOI 10.1002/jnr.20139; Poupot M, 2003, J IMMUNOL, V171, P2517, DOI 10.4049/jimmunol.171.5.2517; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Rismanchi N, 2003, BRAIN RES, V991, P46, DOI 10.1016/j.brainres.2003.07.004; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Shichinohe H, 2004, BRAIN RES PROTOC, V13, P166, DOI 10.1016/j.brainresprot.2004.04.004; Shichinohe H, 2006, J NUCL MED, V47, P486; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432-0436.2004.07207003.x; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wislet-Gendebien S, 2005, BRAIN RES BULL, V68, P95, DOI 10.1016/j.brainresbull.2005.08.016; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Yano S, 2005, J NEUROTRAUM, V22, P907, DOI 10.1089/neu.2005.22.907; Zhong C, 2003, NEUROSCI LETT, V342, P93, DOI 10.1016/S0304-3940(03)00255-6	46	89	102	0	10	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR	2008	86	5					1024	1035		10.1002/jnr.21572			12	Neurosciences	Neurosciences & Neurology	284QD	WOS:000254720000007	18030676				2021-06-18	
J	Jha, A; Weintraub, A; Allshouse, A; Morey, C; Cusick, C; Kittelson, J; Harrison-Felix, C; Whiteneck, G; Gerber, D				Jha, Amitabh; Weintraub, Alan; Allshouse, Amanda; Morey, Clare; Cusick, Chris; Kittelson, John; Harrison-Felix, Cynthia; Whiteneck, Gale; Gerber, Don			A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; fatigue; modafinil; randomized clinical trial	BECK DEPRESSION INVENTORY; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; HEALTH SURVEY; HEAD-INJURY; PLACEBO; RELIABILITY; SCALE; SPECIFICITY; SENSITIVITY	Background: This study examines the efficacy of modafinil in treating fatigue and excessive daytime sleepiness in individuals with traumatic brain Injury (TBI). Methods: A single-center, double-blind, placebo-controlled cross-over trial, where 53 participants with TBI were randomly assigned to receive up to 400 mg of modafinil, or equal number of inactive placebo tablets. Main eligibility criteria were being at least 1 year post-TBI severe enough to require inpatient rehabilitation. The primary outcome measures were fatigue (Fatigue Severity Scale, FSS) and daytime sleepiness (Epworth Sleepiness Scale, ESS). Results: After adjusting for baseline scores and period effects, there were no statistically siginficant differences between improvements seen with modafinil and placebo in the FSS at week 4 (-0.5 +/- 1.88; P = .80) or week 10 (-1.4 +/- 2.75; P = .61). For ESS, average changes were significantly greater with modafinil than placebo at week 4 (-1.2 +/- 0.49; P = .02) but not at week 10 (-0.5 +/- 0.87; P = .56). Modafinil was safe and well tolerated, although insomnia was reported significantly more often with modafinil than placebo (P = .03). Conclusions: While there were sporadic statistically significant differences identified, a clear beneficial pattern from modafinil was not seen at either week 4 or week 10 for any of the 12 outcomes. There was no consistent and persistent clinically significant difference between treatment with modafinil and placebo.	[Jha, Amitabh; Weintraub, Alan; Morey, Clare; Cusick, Chris; Kittelson, John; Harrison-Felix, Cynthia; Whiteneck, Gale; Gerber, Don] Craig Hosp, Res Dept, Englewood, CO 80110 USA; [Jha, Amitabh; Harrison-Felix, Cynthia; Whiteneck, Gale] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [Allshouse, Amanda; Kittelson, John] Univ Colorado, Dept Prevent Med & Biometr, Denver, CO 80202 USA	Jha, A (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80110 USA.	ajha@craighospital.org		Allshouse, Amanda/0000-0003-0109-7193			[Anonymous], 1998, Ann Neurol, V43, P88; Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406; Beck A. T., 1996, BECK DEPRESSION INVE; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Beusterien KM, 1999, SLEEP, V22, P757, DOI 10.1093/sleep/22.6.757; Black JE, 2005, SLEEP, V28, P464, DOI 10.1093/sleep/28.4.464; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Carter Gregory T, 2006, Am J Hosp Palliat Care, V23, P412, DOI 10.1177/1049909106292169; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chan KM, 2006, MUSCLE NERVE, V33, P138, DOI 10.1002/mus.20437; CHRISTENSEN L, 1995, J CONSULT CLIN PSYCH, V63, P495; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COLLINS M, 2002, MED SCI SPORTS EXE S, V34; COLLINS M, 2002, J ATHLETIC TRAIN S, V37; CONNERS CK, 2000, CONNERS CPT, V2; Czeisler CA, 2005, NEW ENGL J MED, V353, P476, DOI 10.1056/NEJMoa041292; DeBattista C, 2003, J CLIN PSYCHIAT, V64, P1057, DOI 10.4088/JCP.v64n0911; ERICKSEN J, 2001, BRAIN INJ SOURCE, V5, P32; Fava M, 2005, J CLIN PSYCHIAT, V66, P85, DOI 10.4088/JCP.v66n0112; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; HAMMOND F, 1997, PHYS MED REH CLIN N, V8, P801; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HAWN K, 2002, J ATHLETIC TRAIN S, V37; Homack Susan, 2006, J Atten Disord, V9, P556, DOI 10.1177/1087054705283578; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Jones DEJ, 2007, ALIMENT PHARM THER, V25, P471, DOI 10.1111/j.1365-2036.2006.03223.x; KJERULFF KH, 1995, MED CARE, V33, pAS156; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lee K A, 1994, Image J Nurs Sch, V26, P149; LOVELL M, 2002, MED SCI SPORTS EXE S, V34; LOVELL M, 2002, J ATHLETIC TRAIN S, V37; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Newton JL, 2006, HEPATOLOGY, V44, P91, DOI 10.1002/hep.21230; Ninan PT, 2004, J CLIN PSYCHIAT, V65, P414; Okuyama T, 2000, J PAIN SYMPTOM MANAG, V19, P5, DOI 10.1016/S0885-3924(99)00138-4; Ondo WG, 2005, J NEUROL NEUROSUR PS, V76, P1636, DOI 10.1136/jnnp.2005.065870; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pack AI, 2001, AM J RESP CRIT CARE, V164, P1675, DOI 10.1164/ajrccm.164.9.2103032; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PEPPER CM, 1993, J NEUROPSYCH CLIN N, V5, P200; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Roth T, 1996, CLIN THER, V18, P562, DOI 10.1016/S0149-2918(96)80207-4; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Sevy S, 2005, J CLIN PSYCHIAT, V66, P839, DOI 10.4088/JCP.v66n0705; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SMITH S, 2007, SLEEP MED       0517; Stankoff B, 2005, NEUROLOGY, V64, P1139, DOI 10.1212/01.WNL.0000158272.27070.6A; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Taylor RR, 2000, PSYCHOL MED, V30, P849, DOI 10.1017/S0033291799002500; Teitelman E, 2001, AM J PSYCHIAT, V158, P1341, DOI 10.1176/ajp.158.8.1341; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WALKER EA, 1993, J GEN INTERN MED, V8, P436, DOI 10.1007/BF02599621; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Warden DL, 2000, J HEAD TRAUMA REHAB, V15, P1092, DOI 10.1097/00001199-200010000-00003; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; Wolman RL, 1994, CLIN REHABIL, V8, P253; Zifko UA, 2002, J NEUROL, V249, P983, DOI 10.1007/s00415-002-0765-6; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; 2000, NEUROL, V54, P1166	78	89	91	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2008	23	1					52	63		10.1097/01.HTR.0000308721.77911.ea			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	256HS	WOS:000252719800009	18219235				2021-06-18	
J	Klose, M; Juul, A; Struck, J; Morgenthaler, NG; Kosteljanetz, M; Feldt-Rasmussen, U				Klose, M.; Juul, A.; Struck, J.; Morgenthaler, N. G.; Kosteljanetz, M.; Feldt-Rasmussen, U.			Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study	CLINICAL ENDOCRINOLOGY			English	Article							CORTISOL RESPONSE; SEPTIC SHOCK; HYPOPITUITARISM; GH; DYSFUNCTION; PREVALENCE; ARGININE; ADULTS; SENSITIVITY; DEFICIENCY	Objective To assess the prevalence of hypopituitarism following traumatic brain injury (TBI), describe the time-course and assess the association with trauma-related parameters and early post-traumatic hormone alterations. Design A 12-month prospective study. Patients Forty-six consecutive patients with TBI (mild: N = 22; moderate: N = 9; severe: N = 15). Measurements Baseline and stimulated hormone concentrations were assessed in the early phase (0-12 days post-traumatically), and at 3, 6 and 12 months postinjury. Pituitary tests included the Synacthen-test (acute +6 months) and the insulin tolerance test (ITT) or the GHRH + arginine test if the ITT was contraindicated (3 + 12 months). Insufficiencies were confirmed by retesting. Results Early post-traumatic hormone alterations mimicking central hypogonadism or hypothyroidism were present in 35 of the 46 (76%) patients. Three months post-traumatically, 6 of the 46 patients failed anterior pituitary testing. At 12 months, one patient had recovered, whereas none developed new insufficiencies. All insufficient patients had GH deficiency (5 out of 46), followed by ACTH- (3 out of 46), TSH- (1 out of 46), LH/FSH- (1 out of 46) and ADH deficiency (1 out of 46). Hypopituitary patients had more frequently been exposed to severe TBI (4 out of 15) than to mild or moderate TBI (1 out of 31) (P = 0.02). Early endocrine alterations including lowered thyroid and gonadal hormones, and increased total cortisol, free cortisol and copeptin were positively associated to TBI severity (P < 0.05), but not to long-term development of hypopituitarism (P > 0.1), although it was indicative in some. Conclusion Long-term hypopituitarism was frequent only in severe TBI. During the 3-12 months follow-up, recovery but no new insufficiencies were recorded, indicating manifest hypothalamic or pituitary damage already a few months postinjury. Very early hormone alterations were not associated to long-term post-traumatic hypopituitarism. Clinicians should, nonetheless, be aware of potential ACTH deficiency in the early post-traumatic period.	Univ Copenhagen Hosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark; BRAHMS Aktiengesellschaft, Dept Res, Hennigsdorh, Germany	Klose, M (corresponding author), Univ Copenhagen Hosp, Dept Med Endocrinol, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	klose@rh.dk	Juul, Anders/F-5864-2013	Juul, Anders/0000-0002-0534-4350			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Andersen S, 2003, THYROID, V13, P1069, DOI 10.1089/105072503770867237; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Beishuizen A, 2001, INTENS CARE MED, V27, P1584, DOI 10.1007/s001340101073; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Ceballos R, 1966, Ala J Med Sci, V3, P185; COOLENS JL, 1987, J STEROID BIOCHEM, V26, P197, DOI 10.1016/0022-4731(87)90071-9; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; HARRIS EK, 1970, CLIN CHEM, V16, P1022; Hoeck HC, 1999, GROWTH HORM IGF RES, V9, P18, DOI 10.1054/ghir.1998.0085; Hoeck HC, 2000, J CLIN ENDOCR METAB, V85, P1467, DOI 10.1210/jc.85.4.1467; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; Jochberger S, 2006, J CLIN ENDOCR METAB, V91, P4381, DOI 10.1210/jc.2005-2830; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2007, J CLIN ENDOCR METAB, V92, P1326, DOI 10.1210/jc.2006-1791; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MOLIJN GJ, 1995, J CLIN ENDOCR METAB, V80, P1799, DOI 10.1210/jc.80.6.1799; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; VAN BG, 1998, J CLIN ENDOCRINOLOGY, V83, P1827; Vanhorebeek I, 2006, J CLIN ENDOCR METAB, V91, P3803, DOI 10.1210/jc.2005-2089	38	89	95	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	OCT	2007	67	4					598	606		10.1111/j.1365-2265.2007.02931.x			9	Endocrinology & Metabolism	Endocrinology & Metabolism	210VI	WOS:000249483300019	17880406				2021-06-18	
S	Bartfai, T; Sanchez-Alavez, M; Andell-Jonsson, S; Schultzberg, M; Vezzani, A; Danielsson, E; Conti, B		Csermely, P; Korcsmaros, T; Sulyok, K		Bartfai, Tamas; Sanchez-Alavez, Manuel; Andell-Jonsson, Siv; Schultzberg, Marianne; Vezzani, Annamaria; Danielsson, Erik; Conti, Bruno			Interleukin-1 system in CNS stress - Seizures, fever, and neurotrauma	STRESS RESPONSES IN BIOLOGY AND MEDICINE: STRESS OF LIFE IN MOLECULES, CELLS, ORGANISMS, AND PSYCHOSOCIAL COMMUNITIES	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	2nd World Conference on Stress	AUG 23-26, 2007	Budapest, HUNGARY			interleukin-1 beta; interleukin-1 receptor antagonist; neurotrauma; seizure; fever; anticonvulsant	IL-1 RECEPTOR ANTAGONIST; OVEREXPRESSION; MICE; PHASE; IL-1-BETA; BEHAVIOR; STROKE; BRAIN; GENE; RAT	Proteins of the interleukin-1 (IL-1) system include the secreted agonist IL-1 beta, and the receptor antagonist IL-1ra, both competing for binding to the IL-1 receptor (IL-1R). IL-1 beta and IL-1ra are highly inducible under different forms of stress, such as excitatory neurotransmitter excess occurring during seizures, in infection and inflammation, and during neurotrauma. In each of these conditions induction of IL-1 beta precedes that of IL-1ra, resulting in up to 10-20-fold elevation of IL-1 beta concentrations. Consequently, IL-1 beta induces the elevation of other proinflammatory molecules, including IL-6, IL-1R1, COX2, and iNOS, as well as of IL-1ra. Elevation of IL-1ra is of key importance for quenching the inflammatory response at the IL-1R1 as part of an autoregulatory loop. In seizures, IL-1ra is a strong anticonvulsant and in IL-1 beta-dependent fever, a powerful antipyretic. In traumatic brain injury (TBI), the ability of patients to mount an IL-1ra response, as measured in the CSF, strongly correlated with the neurological outcome. Selective induction or pharmacological application of IL-1ra may be sparing neurons in seizures and neurotrauma.	Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA; Stockholm Univ, S-10691 Stockholm, Sweden; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Malmo Almanna Sjukhus, Malmo, Sweden	Bartfai, T (corresponding author), Scripps Res Inst, Mol & Integrat Neurosci Dept, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tbartfai@scripps.edu	Schultzberg, Marianne/E-7076-2014; Vezzani, Annamaria/AAB-1882-2020	Schultzberg, Marianne/0000-0002-8314-0927; Vezzani, Annamaria/0000-0003-0573-6175; Sanchez-Alavez, Manuel/0000-0002-8164-8452; Conti, Bruno/0000-0002-9185-5201			Alheim K, 1998, ANN NY ACAD SCI, V840, P51, DOI 10.1111/j.1749-6632.1998.tb09548.x; Dantzer R, 1998, ANN NY ACAD SCI, V840, P586, DOI 10.1111/j.1749-6632.1998.tb09597.x; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; Lundkvist J, 1999, AM J PHYSIOL-REG I, V276, pR644; Mulcahy NJ, 2003, BRIT J PHARMACOL, V140, P471, DOI 10.1038/sj.bjp.0705462; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; Oprica M, 2005, BRAIN BEHAV IMMUN, V19, P223, DOI 10.1016/j.bbi.2004.07.006; Sanchez-Alavez M, 2006, P NATL ACAD SCI USA, V103, P2904, DOI 10.1073/pnas.0510960103; Shavit Y, 2005, PAIN, V115, P50, DOI 10.1016/j.pain.2005.02.003; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tsai TH, 2003, NEUROREPORT, V14, P803, DOI 10.1097/00001756-200305060-00005; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Viviani B, 2003, J NEUROSCI, V23, P8692; Xia Y, 1999, J CLIN INVEST, V103, P1309, DOI 10.1172/JCI5823	16	89	95	0	12	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-675-0	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2007	1113						173	177		10.1196/annals.1391.022			5	Psychology, Biological; Behavioral Sciences; Biochemistry & Molecular Biology; Immunology; Multidisciplinary Sciences; Psychology, Social	Psychology; Behavioral Sciences; Biochemistry & Molecular Biology; Immunology; Science & Technology - Other Topics	BGX56	WOS:000251158200016	17656565				2021-06-18	
J	Bonislawski, DP; Schwarzbach, EP; Cohen, AS				Bonislawski, David P.; Schwarzbach, Elizabeth P.; Cohen, Akiva S.			Brain injury impairs dentate gyrus inhibitory efficacy	NEUROBIOLOGY OF DISEASE			English	Article						head injury; hippocampus; dentate gyrus; GABA; KCC2; gramacidin; perforated patch; chloride fluorescence	ENDURING MEMORY IMPAIRMENT; KCC2 EXPRESSION; HIPPOCAMPUS; NEURONS; COTRANSPORTER; NEOCORTEX; SEIZURES; SOMA; RAT; CA1	Every 23 s, a person sustains a traumatic brain injury in the United States leaving many patients with substantial cognitive impairment and epilepsy. Injury-induced alterations in the hippocampus underpin many of these disturbances of neurological function. Abnormalities in the dentate gyrus are likely to play a major role in the observed pathophysiology because this subregion functions as a filter impeding excessive or aberrant activity from propagating further into the circuit and following experimental brain injury, the dentate gyrus becomes more excitable. Although alteration in excitation or inhibition could mediate this effect in the dentate gyrus, we show a key role played by an impairment of GABA(A)ergic inhibition. The efficacy of GABA(A)-mediated inhibition depends on a low [CI-](i) that is maintained by neuronal K-Cl co-transporter 2 (KCC2). Using fluid percussion injury (FPI) in the mouse, we demonstrate significant reductions in KCC2 protein and mRNA expression in the dentate gyrus that causes a depolarizing shift in GABA(A) reversal potential, due to impaired chloride clearance, resulting in reduced inhibitory efficiency. This study elucidates a novel mechanism underlying diminished dentate gyrus inhibitory efficacy and provides an innovative target for the development of potential therapeutics to restore the severe pathological consequences of traumatic brain injury. (c) 2006 Elsevier Inc. All rights reserved.	Univ Penn, Childrens Hosp, Sch Med, Div Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Cohen, AS (corresponding author), Abramson Res Ctr 3516, Room 816H,Civic Ctr Blvd, Philadelphia, PA 19104 USA.	cohena@email.chop.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045975] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045975, R01 NS45975] Funding Source: Medline		Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; *BIAUSA, 2004, TBI STAT; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; Cave C B, 1991, Hippocampus, V1, P329, DOI 10.1002/hipo.450010323; Cohen AS, 2003, EUR J NEUROSCI, V17, P1607, DOI 10.1046/j.1460-9568.2003.02597.x; Eldridge LL, 2005, J NEUROSCI, V25, P3280, DOI 10.1523/JNEUROSCI.3420-04.2005; GRADY MS, 1995, ANESTHETIC MANAGEMEN, P87; HEINEMANN U, 1992, EPILEPSY RES, P273; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; KAILA K, 1994, PROG NEUROBIOL, V42, P489, DOI 10.1016/0301-0082(94)90049-3; LOTHMAN EW, 1992, EPILEPSY RES, P301; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516; Plotkin MD, 1997, J NEUROBIOL, V33, P781, DOI 10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NEU6>3.0.CO;2-5; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Rivera C, 1999, NATURE, V397, P251; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Sun MK, 2001, J NEUROPHYSIOL, V85, P269; Toth Z, 1997, J NEUROSCI, V17, P8106; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Zhu L, 2005, J NEUROPHYSIOL, V93, P1557, DOI 10.1152/jn.00616.2004; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	28	89	91	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JAN	2007	25	1					163	169		10.1016/j.nbd.2006.09.002			7	Neurosciences	Neurosciences & Neurology	114KN	WOS:000242665200017	17045484	Green Accepted			2021-06-18	
J	Fan, Y; Liu, ZY; Weinstein, PR; Fike, JR; Liu, JL				Fan, Yang; Liu, Zhengyan; Weinstein, Philip R.; Fike, John R.; Liu, Jialing			Environmental enrichment enhances neurogenesis and improves functional outcome after cranial irradiation	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cognitive impairment; dentate gyrus; gerbil; memory; neural precursor cells; radiation injury	INDUCED COGNITIVE DYSFUNCTION; EARLY-ONSET STIMULATION; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; ADULT NEUROGENESIS; NEURONAL DIFFERENTIATION; NEUROTROPHIN LEVELS; CELL-PROLIFERATION	Radiation therapy is a widely used treatment for brain tumors but it can cause delayed progressive cognitive decline and memory deficits. Previous studies suggested that this neurocognitive dysfunction might be linked to the impairment of hippocampal neurogenesis. However, little is known regarding how to reduce the cognitive impairment caused by radiation therapy. To investigate whether environmental enrichment (EE) promotes neurogenesis and cognitive function after irradiation, irradiated gerbils were housed in EE for 2 months and evaluated by neurobehavioral testing for learning and memory function, and immunohistochemical analysis for neurogenesis. Our results demonstrated that even relatively low doses (5-10 Gy) of irradiation could acutely abolish precursor cell proliferation in the dentate gyrus by more than 90%. This reduction in precursor proliferation was persistent and led to a significant decline in the granule cell population 9 months later. EE housing enhanced the number of newborn neurons and increased residual neurogenesis. EE also significantly increased the total number of immature neurons in the dentate gyrus. Furthermore, irradiated animals after EE housing showed a significant improvement in spatial learning and memory during the water-maze test and in rotorod motor learning over a 5-day training paradigm. In conclusion, EE has a positive impact on hippocampal neurogenesis and functional recovery in irradiated adult gerbils. Our data suggest that there is still a considerable amount of plasticity remaining in the hippocampal progenitor cells in adult animals after radiation injury, which can become a target of therapeutic intervention for radiation-induced cognitive dysfunction.	Univ Calif San Francisco, Dept Neurol Surg 112C, San Francisco, CA 94121 USA; San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Fudan Univ, HuaShan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China	Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS051576, R01 NS46051, R01 NS40469] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046051, R01NS040469, R21NS051576] Funding Source: NIH RePORTER		Abayomi OK, 1996, ACTA ONCOL, V35, P659, DOI 10.3109/02841869609083995; Bauer S, 2005, J CELL BIOL, V171, P641, DOI 10.1083/jcb.200505072; Berman RF, 1996, ALCOHOL, V13, P209, DOI 10.1016/0741-8329(95)02049-7; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Bruel-Jungerman E, 2006, J NEUROSCI, V26, P5888, DOI 10.1523/JNEUROSCI.0782-06.2006; Byrne TN, 2005, CURR OPIN NEUROL, V18, P662, DOI 10.1097/01.wco.0000191511.52745.99; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Coq JO, 1998, EXP BRAIN RES, V121, P191, DOI 10.1007/s002210050452; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Diamond MC, 2001, AN ACAD BRAS CIENC, V73, P211, DOI 10.1590/S0001-37652001000200006; Dorr W, 1997, INT J RADIAT BIOL, V72, P635, DOI 10.1080/095530097142780; During Matthew J., 2006, Current Alzheimer Research, V3, P29, DOI 10.2174/156720506775697133; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Gobbo OL, 2004, BEHAV BRAIN RES, V152, P231, DOI 10.1016/j.bbr.2003.10.017; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Kanzawa T, 2006, ONCOGENE, V25, P3638, DOI 10.1038/sj.onc.1209414; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Klein M, 2002, LANCET, V360, P1361, DOI 10.1016/S0140-6736(02)11398-5; Komitova M, 2005, STROKE, V36, P1278, DOI 10.1161/01.STR.0000166197.94147.59; Laack NN, 2004, SEMIN ONCOL, V31, P702, DOI 10.1053/j.seminoncol.2004.07.013; Lazic SE, 2006, EUR J NEUROSCI, V23, P1829, DOI 10.1111/j.1460-9568.2006.04715.x; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Lehmann K, 2005, EUR J NEUROSCI, V21, P3205, DOI 10.1111/j.1460-9568.2005.04156.x; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Meltzer LA, 2005, TRENDS NEUROSCI, V28, P653, DOI 10.1016/j.tins.2005.09.007; Meshi D, 2006, NAT NEUROSCI, V9, P729, DOI 10.1038/nn1696; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Pham TM, 1999, BEHAV BRAIN RES, V103, P63, DOI 10.1016/S0166-4328(99)00019-4; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Rampon C, 2000, NAT NEUROSCI, V3, P238; Rola R, 2004, RADIAT RES, V162, P442, DOI 10.1667/RR3234; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; Steiner B, 2006, EXP NEUROL, V199, P291, DOI 10.1016/j.expneurol.2005.11.004; Suh SW, 2005, DIABETES, V54, P500, DOI 10.2337/diabetes.54.2.500; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Tozuka Y, 2005, NEURON, V47, P803, DOI 10.1016/j.neuron.2005.08.023; Uberti D, 2001, MOL BRAIN RES, V93, P81, DOI 10.1016/S0169-328X(01)00180-2; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Wojtowicz JM, 2006, HIPPOCAMPUS, V16, P261, DOI 10.1002/hipo.20158; Wong CS, 2004, MOL INTERV, V4, P273, DOI 10.1124/mi.4.5.7; Yoneoka Y, 1999, BRIT J RADIOL, V72, P1196, DOI 10.1259/bjr.72.864.10703477; Young D, 1999, NAT MED, V5, P448; Zhu SW, 2006, BEHAV BRAIN RES, V169, P10, DOI 10.1016/j.bbr.2005.11.024	64	89	97	1	8	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JAN	2007	25	1					38	46		10.1111/j.1460-9568.2006.05269.x			9	Neurosciences	Neurosciences & Neurology	128TQ	WOS:000243682100004	17241265				2021-06-18	
J	Pickelsimer, EE; Selassie, AW; Sample, PL; Heinemann, AW; Gu, JK; Veldheer, LC				Pickelsimer, E. Elisabeth; Selassie, Anbesaw W.; Sample, Pat L.; Heinemann, Allen W.; Gu, Ja K.; Veldheer, Linda C.			Unmet service needs of persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						barriers to receiving services; traumatic brain injury; unmet service needs	SUBSTANCE-ABUSE; MENTAL-HEALTH; LIFE SATISFACTION; HEAD-INJURY; ALCOHOL-USE; CARE; INDIVIDUALS; DISABILITY; AWARENESS; REHABILITATION	Objectives: Assess unmet needs of persons with traumatic brain injury (TBI) 1 year after hospital discharge; compare perceived need with needs based on deficits (unrecognized need); determine major barriers to services; evaluate association of needs with satisfaction with life. Participants: Representative sample of 1830 community-dwelling persons with TBI aged 15 years and older. Measures: Perceived and unrecognized unmet needs, barriers to receiving services, and satisfaction with life as a function of met service needs. Results: 35.2% of participants reported at least 1 unmet need, 51.5% had unrecognized needs, 47% reported at least 1 barrier to receiving help. Receipt of services significantly increased satisfaction with life. Conclusions: Many persons experiencing TBI report having unmet service needs 1 year after hospital discharge.	Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; Colorado State Univ, Dept Occupat Therapy, Ft Collins, CO USA; Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA; Northwestern Univ, Dept Phys Med & Rehabil, Evanston, IL 60208 USA; Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL USA; S Carolina Dept Disabil & Special Needs, Columbia, SC USA	Pickelsimer, EE (corresponding author), Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, POB 250835,135 Cannon Str, Charleston, SC 29425 USA.	pickelse@musc.edu	Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU421926] Funding Source: Medline		Allen SM, 1997, MED CARE, V35, P1132, DOI 10.1097/00005650-199711000-00005; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BARRERA M, 1983, J COMMUNITY PSYCHOL, V11, P133, DOI 10.1002/1520-6629(198304)11:2<133::AID-JCOP2290110207>3.0.CO;2-L; Batavia AI, 2001, ARCH PHYS MED REHAB, V82, P546, DOI 10.1053/apmr.2001.20829; BERK ML, 1995, HEALTH AFFAIR, V14, P139, DOI 10.1377/hlthaff.14.3.139; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; CORRIGAN JD, 2006, PROBLEMATIC SUBSTANC; Craske MG, 2005, PSYCHIAT SERV, V56, P988, DOI 10.1176/appi.ps.56.8.988; DAMIANO AM, 1996, SIP USERS MANUAL; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Greenspan AI, 2000, BRAIN INJURY, V14, P417; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; *INT CLASS DIS, 1996, CLIN MOD; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Kraus J, 2000, HEAD INJURY, P1; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; LaPlante MP, 2004, J GERONTOL B-PSYCHOL, V59, pS98, DOI 10.1093/geronb/59.2.S98; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; *NAT CTR HLTH STAT, 1995, NAT HLTH INT SURV CU; Parslow RA, 2001, AUST NZ J PSYCHIAT, V35, P455, DOI 10.1046/j.1440-1614.2001.00924.x; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; Roy CW, 2002, BRAIN INJURY, V16, P1057, DOI 10.1080/02699050210154231; Sample PL, 2004, BRAIN INJURY, V18, P1177, DOI 10.1080/02699050410001719925; *SAS I INC, 2004, STAT AN SOFTW; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Schatz P, 1996, ARCH CLIN NEUROPSYCH, V11, P444; Schootman M, 1999, BRAIN INJURY, V13, P995; Smith J E, 2000, Care Manag J, V2, P27; SOKOL K, 1999, ARCH PHYS MED REHAB, V80, P974; Sturm R, 2001, J BEHAV HEALTH SER R, V28, P81, DOI 10.1007/BF02287236; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; *TRIAN INC, 1997, ICDMAP 90 SOFTW; US Department of Health and Human Service, 1999, TRAUM BRAIN INJ US R; *US GAO, 2001, GAOHEHS9855; WARE JE, 2000, SF36 HLTH SURVEY MAN; Woods J., 2002, LINKING PEOPLE TRAUM; YEATTS DE, 1992, GERONTOLOGIST, V32, P24, DOI 10.1093/geront/32.1.24	63	89	90	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2007	22	1					1	13		10.1097/00001199-200701000-00001			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130SX	WOS:000243820400001	17235226				2021-06-18	
J	Loscher, W; Schmidt, D				Loescher, Wolfgang; Schmidt, Dieter			New horizons in the development of antiepileptic drugs: Innovative strategies	EPILEPSY RESEARCH			English	Article; Proceedings Paper	3rd Workshop on New Horizons in the Development of Antiepileptic Drugs	NOV 30-DEC 01, 2005	Washington, DC			epilepsy; seizures; drug resistance; drug targets; neurodegeneration; inflammation; epileptogenesis	TEMPORAL-LOBE EPILEPSY; LONG-TERM POTENTIATION; LITHIUM-PILOCARPINE MODEL; SYNAPTIC VESICLE PROTEIN; AMYGDALA-KINDLING MODEL; TRAUMATIC BRAIN-INJURY; SPONTANEOUS RECURRENT SEIZURES; ABC TRANSPORTER SUPERFAMILY; NMDA-RECEPTOR ANTAGONISTS; MAXIMAL ELECTROSHOCK TEST	The past decades have brought many advances to the treatment of epilepsy. However. despite the continued development and release of new antiepileptic drugs, many patients have seizures that do not respond to drug therapy or have related side effects that preclude continued use. Even in patients in whom pharmacotherapy is efficacious, current antiepileptic drugs do not seem to affect the progression or the underlying natural history of epilepsy. Furthermore. there is currently no drug available which prevents the development of epilepsy, e.g. after head trauma or stroke. Thus. there are at least four important goals for the future: (1) development of better antiepileptic ("anti-ictal") drugs with higher efficacy and tolerability to stop seizures compared to current medications; (2) better understanding of processes leading to epilepsy. thus allowing to create therapies aimed at the prevention of epilepsy in patients at risk; (3) development of disease-modifying therapies. interfering with progression of epilepsy, and (4) improved understanding of neurobiological mechanisms of pharmacoresistance, allowing to develop drugs for reversal or prevention of drug resistance. The third Workshop on New Horizons in the Development of Antiepileptic Drugs explored these four goals for improved epilepsy therapy, with a focus on innovative strategies in the search for better anti-ictal drugs, for novel drugs for prevention of epilepsy or its progression, and for drugs overcoming drug resistance in epilepsy. In this conference review, the current status of antiepileptic therapies under development is critically assessed. and innovative approaches for future therapies are highlighted.	Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; Epilepsy Res Grp, Berlin, Germany	Loscher, W (corresponding author), Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01 NS002732-19] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002732] Funding Source: NIH RePORTER		AARTS JHP, 1984, BRAIN, V107, P293, DOI 10.1093/brain/107.1.293; Adamec R, 2005, BEHAV BRAIN RES, V159, P73, DOI 10.1016/j.bbr.2004.10.004; Agrawal M, 2003, CHEM ENG PROG, V99, P9; Altaha R, 2002, CURR PHARM DESIGN, V8, P1707, DOI 10.2174/1381612023394043; Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Arroyo S, 2003, EPILEPSY BEHAV, V4, P457, DOI 10.1016/j.yebeh.2003.07.011; Asarnow RF, 1997, DEV MED CHILD NEUROL, V39, P430; Bailet LL, 2000, EPILEPSIA, V41, P426, DOI 10.1111/j.1528-1157.2000.tb00184.x; Barbarosie M, 2000, J NEUROPHYSIOL, V83, P1115; Barbarosie M, 1997, J NEUROSCI, V17, P9308; Barton ME, 2003, EPILEPSY RES, V56, P17, DOI 10.1016/j.eplepsyres.2003.08.001; Barton ME, 2001, EPILEPSY RES, V47, P217, DOI 10.1016/S0920-1211(01)00302-3; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; Begley CE, 2000, EPILEPSIA, V41, P342, DOI 10.1111/j.1528-1157.2000.tb00166.x; Belliotti TR, 2005, J MED CHEM, V48, P2294, DOI 10.1021/jm049762l; Bender RA, 2004, ADV EXP MED BIOL, V548, P213; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Bialer M, 1999, EPILEPSY RES, V34, P1, DOI 10.1016/S0920-1211(98)00108-9; Bialer M, 2002, EPILEPSY RES, V51, P31, DOI 10.1016/S0920-1211(02)00106-7; Bialer M, 2004, EPILEPSY RES, V61, P1, DOI 10.1016/j.eplepsyres.2004.07.010; Bialer M, 2001, EPILEPSY RES, V43, P11, DOI 10.1016/S0920-1211(00)00171-6; Binder DK, 1999, J NEUROSCI, V19, P4616; Binder DK, 1999, J NEUROSCI, V19, P1424; Binnie C D, 1991, Adv Neurol, V55, P113; Binnie CD, 2003, LANCET NEUROL, V2, P725, DOI 10.1016/S1474-4422(03)00584-2; BINNIE CD, 1992, EPILEPSY RES, P71; Bittigau P, 2002, P NATL ACAD SCI USA, V99, P15089, DOI 10.1073/pnas.222550499; Bjornaes H, 2001, SEIZURE-EUR J EPILEP, V10, P250, DOI 10.1053/seiz.2000.0503; Borowicz KK, 1996, EPILEPSIA, V37, P618, DOI 10.1111/j.1528-1157.1996.tb00625.x; Borowicz KK, 2003, POL J PHARMACOL, V55, P735; BOROWICZ KK, 1995, EUR J PHARMACOL, V281, P319, DOI 10.1016/0014-2999(95)00266-N; Borowicz KK, 1999, EUR J PHARMACOL, V380, P67, DOI 10.1016/S0014-2999(99)00541-5; Borowicz KK, 2002, EPILEPSIA, V43, P956, DOI 10.1046/j.1528-1157.2002.34301.x; BOURGEOIS BFD, 1983, ANN NEUROL, V14, P438, DOI 10.1002/ana.410140407; Brandt C, 2005, EPILEPSIA, V46, P60; Brandt C, 2004, EPILEPSIA, V45, P1488, DOI 10.1111/j.0013-9580.2004.16904.x; Brandt C, 2003, EPILEPSY RES, V55, P83, DOI 10.1016/S0920-1211(03)00114-1; Brandt C, 2003, NEUROSCIENCE, V118, P727, DOI 10.1016/S0306-4522(03)00027-7; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brown JP, 1998, J BIOL CHEM, V273, P25458, DOI 10.1074/jbc.273.39.25458; BROWNING RA, 1985, FED PROC, V44, P2425; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; Burger H, 2004, BLOOD, V104, P2940, DOI 10.1182/blood-2004-04-1398; Buzsaki G, 1996, CEREB CORTEX, V6, P81, DOI 10.1093/cercor/6.2.81; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; Cendes F, 2005, CURR OPIN NEUROL, V18, P173, DOI 10.1097/01.wco.0000162860.49842.90; Chaperon F, 2003, BEHAV PHARMACOL, V14, P477, DOI 10.1097/01.fbp.0000091471.79060.ed; Chenard BL, 1999, CURR PHARM DESIGN, V5, P381; CHIASSON BJ, 1995, MOL BRAIN RES, V29, P191, DOI 10.1016/0169-328X(94)00250-I; Chrobak JJ, 2000, HIPPOCAMPUS, V10, P457, DOI 10.1002/1098-1063(2000)10:4<457::AID-HIPO12>3.0.CO;2-Z; Clayton DA, 2001, NEUROBIOL AGING, V22, P165, DOI 10.1016/S0197-4580(00)00196-2; Coenen AML, 2003, BEHAV GENET, V33, P635, DOI 10.1023/A:1026179013847; Colbert CM, 1997, J NEUROSCI, V17, P6512; Cortez MA, 2001, NEUROLOGY, V56, P341, DOI 10.1212/WNL.56.3.341; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; Cunningham MO, 2004, EUR J NEUROSCI, V20, P1566, DOI 10.1111/j.1460-9568.2004.03625.x; CZUCZWAR SJ, 1995, EUR J PHARMACOL, V281, P327, DOI 10.1016/0014-2999(95)00268-P; Czuczwar SJ, 1998, EUR J PHARMACOL, V359, P103, DOI 10.1016/S0014-2999(98)00632-3; CZUCZWAR SJ, 1982, EUR J PHARMACOL, V83, P335, DOI 10.1016/0014-2999(82)90273-4; Czuczwar SJ, 1996, METAB BRAIN DIS, V11, P143, DOI 10.1007/BF02069501; D'Ambrosio R, 2004, PHARMACOL THERAPEUT, V103, P95, DOI 10.1016/j.pharmthera.2004.05.004; Dalby NO, 1997, NEUROSCI LETT, V229, P135; Danysz W, 2005, IDRUGS, V8, P755; Dean M, 2001, J LIPID RES, V42, P1007; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Donevan SD, 2000, MOL PHARMACOL, V58, P614; Dooley DJ, 2000, J PHARMACOL EXP THER, V295, P1086; Dooley DJ, 2000, NEUROSCI LETT, V280, P107, DOI 10.1016/S0304-3940(00)00769-2; Dooley DJ, 2002, SYNAPSE, V45, P171, DOI 10.1002/syn.10094; DZIKI M, 1992, EUR J PHARMACOL, V222, P273, DOI 10.1016/0014-2999(92)90866-3; Ebert U, 2000, NEUROPHARMACOLOGY, V39, P1893, DOI 10.1016/S0028-3908(00)00039-3; Ebert U, 2002, EPILEPSIA, V43, P86, DOI 10.1046/j.1528-1157.43.s.5.39.x; Ebert U, 1997, EUR J PHARMACOL, V322, P179, DOI 10.1016/S0014-2999(97)00084-8; Eichenbaum H, 1999, BEHAV BRAIN RES, V103, P123, DOI 10.1016/S0166-4328(99)00044-3; Eid T, 2004, J NEUROPATH EXP NEUR, V63, P73, DOI 10.1093/jnen/63.1.73; Elkind NB, 2005, CANCER RES, V65, P1770, DOI 10.1158/0008-5472.CAN-04-3303; Emilien G, 1998, INT J CLIN PHARM TH, V36, P181; Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x; Errante LD, 2003, SEIZURE-EUR J EPILEP, V12, P300, DOI 10.1016/S1059-1311(02)00295-9; Errante LD, 2002, EPILEPSY RES, V49, P203, DOI 10.1016/S0920-1211(02)00034-7; Eskazan E, 2002, EPILEPSIA, V43, P1115, DOI 10.1046/j.1528-1157.2002.35601.x; FARWELL JR, 1985, EPILEPSIA, V26, P395, DOI 10.1111/j.1528-1157.1985.tb05670.x; Fehrenbacher JC, 2003, PAIN, V105, P133, DOI 10.1016/S0304-3959(03)00173-8; Fink K, 2002, NEUROPHARMACOLOGY, V42, P229, DOI 10.1016/S0028-3908(01)00172-1; French JA, 2004, NEUROLOGY, V62, P1252, DOI 10.1212/01.WNL.0000123693.82339.FC; Friedl M, 1999, BRAIN RES, V821, P117, DOI 10.1016/S0006-8993(99)01083-5; Fulda S, 2001, SLEEP MED REV, V5, P423, DOI 10.1053/smrv.2001.0157; Galanopoulou AS, 2005, EPILEPSIA, V46, P107, DOI 10.1111/j.1528-1167.2005.01007.x; GALE K, 1992, J CLIN NEUROPHYSIOL, V9, P264, DOI 10.1097/00004691-199204010-00007; Galvis-Alonso OY, 2004, NEUROSCIENCE, V125, P787, DOI 10.1016/j.neuroscience.2004.01.042; Garcia CC, 2004, J MED GENET, V41, P183, DOI 10.1136/jmg.2003.013680; GARCIACAIRASCO N, 1983, BRAZ J MED BIOL RES, V16, P171; Gilad R, 1996, ARCH NEUROL-CHICAGO, V53, P1149, DOI 10.1001/archneur.1996.00550110089017; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Gloveli T, 2003, NEUROBIOL DIS, V13, P203, DOI 10.1016/S0969-9961(03)00039-1; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; Golarai G, 1996, J NEUROPHYSIOL, V75, P343; GOLDLUST A, 1995, EPILEPSY RES, V22, P1, DOI 10.1016/0920-1211(95)00028-9; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grabenstatter HL, 2005, EPILEPSIA, V46, P8, DOI 10.1111/j.0013-9580.2005.13404.x; Gravius A, 2005, BEHAV PHARMACOL, V16, P113, DOI 10.1097/00008877-200503000-00007; Greenberg DA, 2005, AM J HUM GENET, V76, P139, DOI 10.1086/426735; Gu J, 2004, EUR J NEUROSCI, V19, P334, DOI 10.1111/j.0953-816X.2003.03106.x; Han KJ, 2000, ACTA HAEMATOL-BASEL, V104, P174, DOI 10.1159/000046511; Hannesson DK, 2004, EPILEPSY RES, V58, P145, DOI 10.1016/j.eplepsyres.2004.01.004; Hannesson DK, 2000, NEUROSCI BIOBEHAV R, V24, P725, DOI 10.1016/S0149-7634(00)00033-6; Harkin LA, 2002, AM J HUM GENET, V70, P530, DOI 10.1086/338710; Harty TP, 2000, EPILEPSY RES, V39, P47, DOI 10.1016/S0920-1211(99)00108-4; He XP, 2002, J NEUROSCI, V22, P7502; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Helmstaedter C, 2003, ANN NEUROL, V54, P425, DOI 10.1002/ana.10692; Hernandez TD, 1997, TRENDS PHARMACOL SCI, V18, P59, DOI 10.1016/S0165-6147(96)01027-9; Hesdorffer DC, 2001, ANN NEUROL, V50, P458, DOI 10.1002/ana.1136; Hinz B, 2001, EUR J CELL BIOL, V80, P615, DOI 10.1078/0171-9335-00196; Hirai H, 2001, EUR J NEUROSCI, V14, P73, DOI 10.1046/j.0953-816x.2001.01630.x; Holmes GL, 1998, ANN NEUROL, V44, P845, DOI 10.1002/ana.410440602; Holmes GL, 1997, EPILEPSIA, V38, P12, DOI 10.1111/j.1528-1157.1997.tb01074.x; Holmes GL, 1999, J COMP NEUROL, V404, P537, DOI 10.1002/(SICI)1096-9861(19990222)404:4<537::AID-CNE9>3.0.CO;2-#; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Hovinga CA, 2002, EXPERT OPIN INV DRUG, V11, P1387, DOI 10.1517/13543784.11.10.1387; Hovorka J, 1997, EPILEPSY RES, V28, P225, DOI 10.1016/S0920-1211(97)00048-X; Huang YF, 2002, J NEUROSCI, V22, P8422; Huang YF, 1999, NAT NEUROSCI, V2, P867; Illmer T, 2004, LEUKEMIA, V18, P401, DOI 10.1038/sj.leu.2403257; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; Isoherranen N, 2001, EPILEPSIA, V42, P831, DOI 10.1046/j.1528-1157.2001.042007831.x; Jokeit H, 2002, PROG BRAIN RES, V135, P455; Jung HY, 1997, J NEUROSCI, V17, P6639; Kali S, 2004, NAT NEUROSCI, V7, P286, DOI 10.1038/nn1202; Kaneko S, 2002, NEUROSCI RES, V44, P11, DOI 10.1016/S0168-0102(02)00065-2; KASTELEIJNNOLSTTRENITE DGA, 1988, EPILEPSY RES, V2, P111, DOI 10.1016/0920-1211(88)90027-7; Khalilov I, 2003, NAT NEUROSCI, V6, P1079, DOI 10.1038/nn1125; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; Klodzinska A, 1999, POL J PHARMACOL, V51, P543; Klugbauer N, 2003, J BIOENERG BIOMEMBR, V35, P639, DOI 10.1023/B:JOBB.0000008028.41056.58; Kohling R, 1998, BRAIN, V121, P1073, DOI 10.1093/brain/121.6.1073; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KREINDLER A, 1958, J NEUROPHYSIOL, V21, P430; Kuzniecky R, 2002, NEUROLOGY, V58, P368, DOI 10.1212/WNL.58.3.368; LEBER PD, 1989, EPILEPSIA, V30, pS57, DOI 10.1111/j.1528-1157.1989.tb05816.x; LEITE JP, 1995, EPILEPSY RES, V20, P93, DOI 10.1016/0920-1211(94)00070-D; Leith CP, 1999, BLOOD, V94, P1086; LEMOS T, 1995, EXP BRAIN RES, V102, P423; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; LOISEAU P, 1983, ANN NEUROL, V13, P642, DOI 10.1002/ana.410130610; Lombroso CT, 1997, EPILEPSIA, V38, P797, DOI 10.1111/j.1528-1157.1997.tb01467.x; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; Louie K, 2001, NEURON, V29, P145, DOI 10.1016/S0896-6273(01)00186-6; Luker GD, 1997, J NUCL MED, V38, P369; Luszczki J, 2003, PHARMACOL BIOCHEM BE, V75, P319, DOI 10.1016/S0091-3057(03)00081-9; Luszczki JJ, 2006, EPILEPSIA, V47, P10, DOI 10.1111/j.1528-1167.2006.00364.x; Luszczki JJ, 2005, EUR J PHARMACOL, V515, P54, DOI 10.1016/j.ejphar.2005.03.046; Luszczki JJ, 2005, NEUROPSYCHOPHARMACOL, V30, P958, DOI 10.1038/sj.npp.1300602; Luszczki JJ, 2004, EPILEPSIA, V45, P895, DOI 10.1111/j.0013-9580.2004.05104.x; Luszczki JJ, 2003, NEUROPSYCHOPHARMACOL, V28, P1817, DOI 10.1038/sj.npp.1300243; Luszczki JJ, 2003, EPILEPSIA, V44, P1003, DOI 10.1046/j.1528-1157.2003.10003.x; Luszczki JJ, 2003, EPILEPSIA, V44, P489, DOI 10.1046/j.1528-1157.2003.32702.x; Lynch BA, 2004, P NATL ACAD SCI USA, V101, P9861, DOI 10.1073/pnas.0308208101; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; MARESCAUX C, 1987, EXP NEUROL, V97, P160, DOI 10.1016/0014-4886(87)90290-1; Marson A, 2005, LANCET, V365, P2007, DOI 10.1016/S0140-6736(05)66694-9; Massa R, 2001, NEUROLOGY, V57, P1071, DOI 10.1212/WNL.57.6.1071; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; Matsuzaka T, 2001, EPILEPSIA, V42, P9, DOI 10.1046/j.1528-1157.42.s6.2.x; Matveeva EA, 2003, J NEUROCHEM, V84, P621, DOI 10.1046/j.1471-4159.2003.01589.x; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; MCNAMARA JO, 1988, NEUROPHARMACOLOGY, V27, P563, DOI 10.1016/0028-3908(88)90176-1; MEENCKE HJ, 1983, J NEUROL, V230, P171, DOI 10.1007/BF00313628; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; Minichiello L, 2002, NEURON, V36, P121, DOI 10.1016/S0896-6273(02)00942-X; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORUZZI G, 1995, J NEUROPSYCH CLIN N, V7, P251; MOSHE SL, 1984, DEV BRAIN RES, V13, P305, DOI 10.1016/0165-3806(84)90165-2; Nabbout R, 2003, J CLIN NEUROPHYSIOL, V20, P393, DOI 10.1097/00004691-200311000-00002; Narkilahti S, 2003, NEUROPHARMACOLOGY, V44, P1068, DOI 10.1016/S0028-3908(03)00115-1; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; Neyens LGJ, 1999, EPILEPSY RES, V34, P85, DOI 10.1016/S0920-1211(98)00118-1; NGouemo P, 1997, BRAIN RES, V761, P217, DOI 10.1016/S0006-8993(97)00322-3; Nielsen EO, 1999, J PHARMACOL EXP THER, V289, P1492; Northcott E, 2005, EPILEPSIA, V46, P924, DOI 10.1111/j.1528-1167.2005.62304.x; NOYER M, 1995, EUR J PHARMACOL, V286, P137, DOI 10.1016/0014-2999(95)00436-O; Olney JW, 2004, TRENDS PHARMACOL SCI, V25, P135, DOI 10.1016/j.tips.2004.01.002; Parsons CG, 1998, DRUG NEWS PERSPECT, V11, P523, DOI 10.1358/dnp.1998.11.9.863689; Patel MK, 2000, BRIT J PHARMACOL, V130, P1731, DOI 10.1038/sj.bjp.0703530; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pellock JM, 1999, EPILEPSIA, V40, pS57, DOI 10.1111/j.1528-1157.1999.tb00920.x; PENNELL PB, 1995, NEUROLOGY, V45, P456, DOI 10.1212/WNL.45.3.456; Perucca E, 2003, EPILEPSIA, V44, P41, DOI 10.1046/j.1528-1157.44.s4.1.x; Perucca E, 2002, EUR J PAIN, V6, P35, DOI 10.1053/eujp.2001.0320; Perucca E, 2001, CNS DRUGS, V15, P609, DOI 10.2165/00023210-200115080-00004; Perucca E, 1998, EUR J CLIN PHARMACOL, V54, P1, DOI 10.1007/s002280050411; Petroff OAC, 2001, EPILEPSIA, V42, P543, DOI 10.1046/j.1528-1157.2001.18800.x; Pitkanen A, 2005, EPILEPSY RES, V63, P27, DOI 10.1016/j.eplepsyres.2004.10.003; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/14656566.5.4.777; Postma T, 2000, EPILEPSIA, V41, P1514; Potschka H, 1999, EUR J PHARMACOL, V374, P175, DOI 10.1016/S0014-2999(99)00311-8; Prakriya M, 2000, NEURON, V26, P671, DOI 10.1016/S0896-6273(00)81203-9; Pyle RA, 2000, J BIOL CHEM, V275, P17195, DOI 10.1074/jbc.M000674200; Reid KH, 2001, NEUROSCI LETT, V308, P29, DOI 10.1016/S0304-3940(01)01973-5; Reigada D, 2003, P NATL ACAD SCI USA, V100, P3485, DOI 10.1073/pnas.0336914100; Reis J, 2002, EPILEPSIA, V43, P1149, DOI 10.1046/j.1528-1157.2002.09902.x; Remy S, 2003, ANN NEUROL, V53, P469, DOI 10.1002/ana.10473; Rigoulot MA, 2003, EPILEPSIA, V44, P529, DOI 10.1046/j.1528-1157.2003.50502.x; Robey R, 1999, BLOOD, V93, P306, DOI 10.1182/blood.V93.1.306.401k42_306_314; Roch C, 2002, EPILEPSIA, V43, P1129, DOI 10.1046/j.1528-1157.2002.17802.x; Roch C, 2002, EPILEPSIA, V43, P325, DOI 10.1046/j.1528-1157.2002.11301.x; RODIN E, 1971, ELECTROEN CLIN NEURO, V30, P62, DOI 10.1016/0013-4694(71)90205-7; RODIN EA, 1986, DEV MED CHILD NEUROL, V28, P25; ROGAWSKI MA, 1990, PHARMACOL REV, V42, P223; Roopra A, 2001, Mol Interv, V1, P219; Roth T, 2001, SLEEP MED, V2, P379, DOI 10.1016/S1389-9457(01)00071-5; Roth Thomas, 2003, Clin Cornerstone, V5, P5, DOI 10.1016/S1098-3597(03)90031-7; RUNDFELDT C, 1993, J PHARMACOL EXP THER, V266, P216; Sakaeda T, 2003, PHARMACOGENOMICS, V4, P397, DOI 10.1517/phgs.4.4.397.22747; Sanchez RM, 2001, J NEUROSCI, V21, P8154; Schachter SC, 2000, EXPERT OPIN INV DRUG, V9, P871, DOI 10.1517/13543784.9.4.871; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; Schmidt D, 2005, EPILEPSIA, V46, P858, DOI 10.1111/j.1528-1167.2005.54904.x; SCHWINDT PC, 1995, J NEUROPHYSIOL, V74, P2220; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shen B, 1996, HIPPOCAMPUS, V6, P685; SHEWMON DA, 1988, ELECTROEN CLIN NEURO, V69, P319, DOI 10.1016/0013-4694(88)90004-1; Shimoyama M, 2000, PAIN, V85, P405, DOI 10.1016/S0304-3959(99)00283-3; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; Sills GJ, 2003, EPILEPSIA, V44, P886, DOI 10.1046/j.1528-1157.2003.04203.x; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; SILVERMAN RB, 1991, J MED CHEM, V34, P2295, DOI 10.1021/jm00111a053; Sparreboom A, 2003, DRUG RESIST UPDATE, V6, P71, DOI 10.1016/S1368-7646(03)00005-0; Sperber EF, 1999, DEV BRAIN RES, V116, P59, DOI 10.1016/S0165-3806(99)00075-9; Spigelman I, 1998, NEUROSCIENCE, V86, P109, DOI 10.1016/S0306-4522(98)00028-1; Spooren W, 2003, BEHAV PHARMACOL, V14, P257, DOI 10.1097/01.fbp.0000081783.35927.8f; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stables James P., 2003, Epilepsia, V44, P1472, DOI 10.1111/j.0013-9580.2003.32803.x; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; Stafstrom CE, 2002, INT REV NEUROBIOL, V49, P391; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Steckler T, 2005, BEHAV BRAIN RES, V164, P52, DOI 10.1016/j.bbr.2005.05.010; Stefani A, 1998, NEUROPHARMACOLOGY, V37, P83, DOI 10.1016/S0028-3908(97)00189-5; Stephen LJ, 2002, SEIZURE-EUR J EPILEP, V11, P349, DOI 10.1053/seiz.2002.0711; Stratton SC, 2003, EPILEPSY RES, V53, P95, DOI 10.1016/S0920-1211(02)00254-1; SUMANCHAUHAN N, 1993, EUR J PHARM-MOLEC PH, V244, P293, DOI 10.1016/0922-4106(93)90155-3; SUTULA T, 1987, BRAIN RES, V420, P109, DOI 10.1016/0006-8993(87)90245-9; SVEINBJORNSDOTTIR S, 1993, EPILEPSY RES, V16, P165, DOI 10.1016/0920-1211(93)90031-2; TAYLOR CP, 1993, EPILEPSY RES, V14, P11, DOI 10.1016/0920-1211(93)90070-N; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; THURLOW RJ, 1993, EUR J PHARM-MOLEC PH, V247, P341, DOI 10.1016/0922-4106(93)90204-M; Trinka E, 2004, J NEUROL, V251, P1235, DOI 10.1007/s00415-004-0521-1; Tromp SC, 2003, J CHILD NEUROL, V18, P407, DOI 10.1177/08830738030180060501; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Volk HA, 2005, BRAIN, V128, P1358, DOI 10.1093/brain/awh437; Wakamoto H, 2000, BRAIN DEV-JPN, V22, P246, DOI 10.1016/S0387-7604(00)00121-2; Walker MC, 1996, NEUROLOGY, V46, P912, DOI 10.1212/WNL.46.4.912; Walker MC, 1997, NEUROLOGY, V49, P333, DOI 10.1212/WNL.49.2.333; Wallace RH, 1998, NAT GENET, V19, P366; Wang MH, 1999, BIOCHEM J, V342, P313, DOI 10.1042/0264-6021:3420313; Weglage J, 1997, DEV MED CHILD NEUROL, V39, P646; Westphalen RI, 2003, J PHARMACOL EXP THER, V304, P1188, DOI 10.1124/jpet.102.044685; White H S, 1998, Adv Neurol, V76, P29; White HS, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s7.10.x; Williams J, 1998, SEIZURE-EUR J EPILEP, V7, P223, DOI 10.1016/S1059-1311(98)80040-X; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; Wirrell E, 2001, EPILEPSIA, V42, P760, DOI 10.1046/j.1528-1157.2001.02401.x; Wirrell EC, 1996, NEUROLOGY, V47, P912, DOI 10.1212/WNL.47.4.912; Wirrell EC, 1997, ARCH PEDIAT ADOL MED, V151, P152, DOI 10.1001/archpedi.1997.02170390042008; Wlaz P, 1998, EUR J PHARMACOL, V342, P39, DOI 10.1016/S0014-2999(97)01452-0; Wlaz P, 1997, EPILEPSIA, V38, P1167, DOI 10.1111/j.1528-1157.1997.tb01212.x; Wong M, 2003, EXP NEUROL, V183, P87, DOI 10.1016/S0014-4886(03)00099-2; WONG MW, 1987, RAPID COMMUN MASS SP, V1, P3; Wong N D, 2001, Prev Cardiol, V4, P109, DOI 10.1111/j.1520-037X.2001.00570.x; Xu T, 2001, NAT CELL BIOL, V3, P691, DOI 10.1038/35087000; Zhang Y, 2004, J NEUROSCI, V24, P5239, DOI 10.1523/JNEUROSCI.0992-04.2004; Zhang Y, 2002, MOL THER, V6, P67, DOI 10.1006/mthe.2002.0633; Zupanc ML, 2003, EXPERT OPIN PHARMACO, V4, P2039, DOI 10.1517/14656566.4.11.2039	281	89	95	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUN	2006	69	3					183	272		10.1016/j.eplepsyres.2006.03.014			90	Clinical Neurology	Neurosciences & Neurology	062DO	WOS:000238925000001	16835945	Green Accepted			2021-06-18	
J	Wang, Y; Chan, RCK; Deng, YY				Wang, Ya; Chan, Raymond C. K.; Deng, Yongyu			Examination of postconcussion-like symptoms in healthy university students: Relationships to subjective and objective neuropsychological function performance	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						postconcussion; base rate; neuropsychological performance; brain injury	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; BASE RATES; ATTENTIONAL DEFICITS; WORKING-MEMORY; COMPLAINTS; STRESS; QUESTIONNAIRE; DEPRESSION; DISORDER	This study examined postconcussion-like symptoms in a group of university students and explored their relationships to neuropsychological function performance. A sample of 124 students was recruited. All of the participants received the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) and completed a comprehensive set of neuropsychological tests. They reported a relatively high base rate of postconcussion-like symptoms. The most frequently endorsed items were "fatigue" (76.9%), "longer time to think" (60.3%), "poor concentration" (58.7%), "sleep disturbance" (50.4%), and "frustration" (46.3%). There were no significant differences between low symptom reporters and high symptom reporters, except for self-reported dysexecutive problems. A comparison of the healthy high symptom reporters and a convenient sample of traumatic brain injury patients revealed that the patients performed significantly worse on neuropsychological functions than the high symptom reporters, despite non-significant differences between symptom endorsement. Our findings demonstrate that: (a) the base rate of postconcussion-like symptoms in a group of healthy university students is relatively high and (b) postconcussion symptom (PCS) is not related to neuropsychological functions in normal people. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Sun Yat Sen Univ, Dept Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Guangzhou 510275, Guangdong, Peoples R China; Chinese Acad Sci, Inst Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Beijing 100080, Peoples R China; Zhongkai Univ Agr & Technol, Guangzhou, Guangdong, Peoples R China	Chan, RCK (corresponding author), Sun Yat Sen Univ, Dept Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Guangzhou 510275, Guangdong, Peoples R China.	edschchq@zsu.edu.cn	Chan, Raymond CK/B-6717-2009; Wang, Ya/C-7374-2009	Chan, Raymond CK/0000-0002-3414-450X; Wang, Ya/0000-0001-5764-6740			Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; Beck AT, 1967, DEPRESSION CAUSES TR; BECK AT, 1996, MANUAL BDI, V2; BOHNEN NI, 1995, J NEUROSURG, V70, P509; BOHNEN NI, 1992, NEUROPSYCHOLOGY, V15, P170; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Callicott JH, 1998, NEUROPSYCHOPHARMACOL, V18, P186, DOI 10.1016/S0893-133X(97)00096-1; CHAN CM, 1984, COGNITIVE THER RES, V8, P501, DOI 10.1007/BF01173287; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 1999, ARCH CLIN NEUROPSYCH, V14, P735, DOI 10.1016/S0887-6177(99)80228-5; Chan RCK, 2001, BRAIN INJURY, V15, P71, DOI 10.1080/02699050118215; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; GANGADHAR BN, 1985, NIMHANS J, V3, P147; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GASQUOINE PG, 2000, APPL NEUROPSYCHOL, V2, P83; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Piland SG, 2003, J ATHL TRAINING, V38, P104; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Varney N R, 1995, Appl Neuropsychol, V2, P47, DOI 10.1207/s15324826an0202_1; Wechsler D., 1987, WECHSLER MEMORY SCAL; WONG J. L., 2000, INT J REHABILITATION, V5, P85; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	52	89	92	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2006	21	4					339	347		10.1016/j.acn.2006.03.006			9	Psychology, Clinical; Psychology	Psychology	067GI	WOS:000239289500011	16765018	Bronze			2021-06-18	
J	Kaufman, KR; Brey, RH; Chou, LS; Rabatin, A; Brown, AW; Basford, JR				Kaufman, KR; Brey, RH; Chou, LS; Rabatin, A; Brown, AW; Basford, JR			Comparison of subjective and objective measurements of balance disorders following traumatic brain injury	MEDICAL ENGINEERING & PHYSICS			English	Article						traumatic brain injury; center of mass; dizziness handicap inventory; gait; balance	CENTER-OF-MASS; DYNAMIC POSTUROGRAPHY; DIZZINESS; GAIT; DEFICITS; SUPPORT; MOTION; HEAD	Patients with mild traumatic brain injury (TBI) often complain of dizziness. However, these problems may be undetected by a clinical exam. Therefore, the purpose of this study was to evaluate the relationships between the subjective and objective measures of balance impairment. Ten patients with TBI (6 men and 4 women) and 10 matched controls participated in this study. Average duration since the TBI was 2.8 years (range 0.4-14.4). Six of the 10 subjects with TBI had abnormal imaging studies. All subjects and controls had a normal neuromuscular exam. Tinetti Balance Assessments were obtained and the TBI group was not significantly different from the control group. The Dizziness Handicap Inventory (DHI) score supported their complaints of "unsteadiness" and "imbalance" from the subjects with TBI. The DHI score was 32 +/- 23 (range 4-68) out of a maximum possible score of 100. Balance was tested using computerized dynamic posturography. The Sensory Organization Test score was significantly lower for subjects who had a TBI (70 +/- 12) compared to the control subjects (80 +/- 8), which indicated that the subjects with TBI had poorer balance than the control subjects. A 13-link biomechanical model of the human body was used to compute the kinematics of the whole body center of mass (COM) while walking on a level surface. The subjects with TBI had significantly less displacement in the anterior/posterior direction, walked significantly slower, had significantly greater medial/lateral sway and velocity than the normal controls, and had significantly greater medial/lateral imbalance. There was a significant relationship between the physical aspects of the DHI and posturography. There was also significant relationship between the physical, functional, and total DHI and the motion of the COM. Overall, the motion of the COM predicted between 42 and 69% of the DHI score. The present study has demonstrated that objective measurements can quantify the patient's functional deficits. Therefore, these objective measurement techniques should be used to assess the clinical complaints of imbalance from patients with TBI. (c) 2005 IPEM. Published by Elsevier Ltd. All rights reserved.	Mayo Clin & Mayo Fdn, Dept Orthopaed Surg, Biomech Motion Analysis Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Vestibular Balance Lab, Rochester, MN 55905 USA; Univ Oregon, Dept Exercise & Movement Sci, Eugene, OR 97403 USA; Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA	Kaufman, KR (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthopaed Surg, Biomech Motion Analysis Lab, 200 1st St SW, Rochester, MN 55905 USA.	kaufman.kenton@mayo.edu		Brown, Allen W./0000-0001-7228-3351; Kaufman, Kenton/0000-0002-7311-3781			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; *CDC, 1999, TRAUM BRAIN INJ; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Chou LS, 2001, GAIT POSTURE, V13, P17, DOI 10.1016/S0966-6362(00)00087-4; Dobie RA, 1997, AM J OTOL, V18, P108; *EQUITEST, 1992, SYST OP MAN VERS 4 0; Evans MK, 1999, OTOLARYNG HEAD NECK, V120, P164, DOI 10.1016/S0194-5998(99)70401-8; FREGLY AR, 1968, AEROSPACE MED, V39, P277; FURMAN JM, 1994, BAILLIERE CLIN NEUR, V3, P501; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hillier SL, 1997, BRAIN INJURY, V11, P649; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; JENNETT B, 1975, LANCET, V1, P480; JIAN YC, 1993, GAIT POSTURE, V1, P9, DOI DOI 10.1016/0966-6362(93)90038-3; KADABA MP, 1989, J ORTHOPAED RES, V7, P849, DOI 10.1002/jor.1100070611; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; MEGLAN D, 1991, THESIS OHIO STATE U; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; NASHNER LM, 1982, J NEUROSCI, V2, P536; O'Neill DE, 1998, AM J OTOL, V19, P797; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Palliyath S, 1998, MOVEMENT DISORD, V13, P958, DOI 10.1002/mds.870130616; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Romberg M. H., 1853, MANUAL NERVOUS DIS M, P395; RUBIN AM, 1995, AM J OTOL, V16, P216; Seidel B, 2002, J REHABIL MED, V34, P288, DOI 10.1080/165019702760390392; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	34	89	90	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533	1873-4030		MED ENG PHYS	Med. Eng. Phys.	APR	2006	28	3					234	239		10.1016/j.medengphy.2005.05.005			6	Engineering, Biomedical	Engineering	013WK	WOS:000235440500004	16043377				2021-06-18	
J	Wang, HC; Gao, JL; Lassiter, TF; McDonagh, DL; Sheng, HX; Warner, DS; Lynch, JR; Laskowitz, DT				Wang, Haichen; Gao, Junling; Lassiter, Timothy F.; McDonagh, David L.; Sheng, Huaxin; Warner, David S.; Lynch, John R.; Laskowitz, Daniel T.			Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage	NEUROCRITICAL CARE			English	Article						subarachnoid hemorrhage; traumatic brain injury; posttraumatic epilepsy; levetiracetam; vasospasm; neuroprotection	NITRIC-OXIDE SYNTHASE; DIFFUSE BRAIN-INJURY; CEREBRAL VASOSPASM; ANTIEPILEPTIC DRUGS; PHENYTOIN; SEIZURES; ENDOTHELIUM; PROPHYLAXIS; PREVENTION; MANAGEMENT	Objectives: Prophylactic treatment with antiepileptic drugs is common practice following subarachnoid hemorrhage (SAH) and traumatic brain injury. However, commonly used antiepileptic drugs have multiple drug interactions, require frequent monitoring of serum levels, and are associated with adverse effects that may prompt discontinuation. In the current study, we test the hypothesis that levetiracetam, an anticonvulsant with favorable interaction and adverse event profiles, is neuroprotective in clinically relevant models of SAH and closed head injury (CHI). Methods: A single intravenous dose of vehicle, low-dose (18 mg/kg), or high-dose (54 mg/kg) levetiracetam was administered intravenously followed CHI. Functional assessments were performed on a daily basis, and histological assessments performed at 24 hours. In a separate series of experiments, mice were randomized to receive intravenous administration of vehicle, low-dose, or high-dose levetiracetam every 12 hours for 3 days following SAH. Functional endpoints were assessed daily, followed by measurement of MCA luminal diameter on day 3. Results: A single dose of levetiracetam improved functional and histological outcomes after CHI. This effect appeared specific for levetiracetam and was not associated with fosphenytoin treatment. Treatment with levetiracetam also improved functional outcomes and reduced vasospasm following SAH. Conclusion: Levetiracetam is neuroprotective in clinically relevant animal models of SAH and CHI. Levetiracetam may be a therapeutic alternative to phenytoin following acute brain injury in the clinical setting when seizure prophylaxis is indicated.	Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharm, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; N China Coal Med Coll, Dept Histol & Embryol, Tangshan, Hebei, Peoples R China	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008600] Funding Source: Medline		Briggs Deborah E, 2004, Expert Opin Drug Saf, V3, P415, DOI 10.1517/14740338.3.5.415; BROWNE TR, 1996, NEUROLOGY S, V46, pS7; Cardile V, 2003, BRAIN RES, V976, P227, DOI 10.1016/S0006-8993(03)02720-3; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Conger LA, 1996, CUTIS, V57, P223; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; Dagonnier M, 2005, J NEUROL, V252, P727, DOI 10.1007/s00415-005-0726-y; Dooley M, 2000, DRUGS, V60, P871, DOI 10.2165/00003495-200060040-00004; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gidal BE, 2005, EPILEPSY RES, V64, P1, DOI 10.1016/j.eplepsyres.2005.01.005; Goldstein LB, 1998, ARCH NEUROL-CHICAGO, V55, P454, DOI 10.1001/archneur.55.4.454; HANNON E, 2001, SEIZURE, V10, P287; HASAN D, 1993, ANN NEUROL, V33, P286; Holtzer CD, 1997, ANN PHARMACOTHER, V31, P435, DOI 10.1177/106002809703100409; IGNARRO LJ, 1987, AM J PHYSIOL, V253, pH1074; Ito Y, 2000, J CARDIOVASC PHARM, V35, P45, DOI 10.1097/00005344-200001000-00006; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; KORMAN LB, 1989, CLIN PHARMACY, V8, P514; Lynch BA, 2004, P NATL ACAD SCI USA, V101, P9861, DOI 10.1073/pnas.0308208101; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; Meek PD, 1999, ARCH INTERN MED, V159, P2639, DOI 10.1001/archinte.159.22.2639; Mula M, 2003, NEUROLOGY, V61, P704, DOI 10.1212/01.WNL.0000078031.32904.0D; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Parra A, 2002, NEUROL RES, V24, P510, DOI 10.1179/016164102101200276; Patsalos PN, 2003, LANCET NEUROL, V2, P473, DOI 10.1016/S1474-4422(03)00483-6; Pluta RM, 1997, J NEUROSURG, V87, P746, DOI 10.3171/jns.1997.87.5.0746; Ramsay RE, 1996, NEUROLOGY, V46, P17, DOI 10.1212/WNL.46.6_Suppl_1.17S; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; Rigo JM, 2002, BRIT J PHARMACOL, V136, P659, DOI 10.1038/sj.bjp.0704766; ROSE FC, 1965, BRIT MED J, V1, P18, DOI 10.1136/bmj.1.5426.18; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Wolf EW, 1998, J NEUROSURG, V89, P279, DOI 10.3171/jns.1998.89.2.0279; YANAGISAWA M, 1988, J HYPERTENS, V6, pS188, DOI 10.1097/00004872-198812040-00056	38	89	91	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2006	5	1					71	78		10.1385/NCC:5:1:71			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	073UB	WOS:000239767000015	16960300				2021-06-18	
J	Struve, J; Maher, PC; Li, YQ; Kinney, S; Fehlings, MG; Kuntz, C; Sherman, LS				Struve, J; Maher, PC; Li, YQ; Kinney, S; Fehlings, MG; Kuntz, C; Sherman, LS			Disruption of the hyaluronan-based extracellular matrix in spinal cord promotes astrocyte proliferation	GLIA			English	Article						gliosis; spinal cord; astrocyte; trauma; CD44; hyaluronan	CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER; RAT-BRAIN; REACTIVE ASTROCYTES; CHONDROITINASE ABC; NEURITE OUTGROWTH; BINDING PROTEIN; CARCINOMA-CELLS; ADULT-RAT; IN-VIVO	Astrocyte proliferation is tightly controlled during development and in the adult nervous system. In the present study, we find that a high-molecular-weight (MW) form of the glycosaminoglycan hyaluronan (HA) is found in rat spinal cord tissue and becomes degraded soon after traumatic spinal cord injury. Newly synthesized HA accumulates in injured spinal cord as gliosis proceeds, such that high-MW HA becomes overabundant in the extracellular matrix surrounding glial scars after 1 month. Injection of hyaluronidase, which degrades HA, into normal spinal cord tissue results in increased numbers of glial fibrillary acidic protein (GFAP)-positive cells that also express the nuclear proliferation marker Ki-67, suggesting that HA degradation Promotes astrocyte proliferation. In agreement with this observation, adding high- but not low-MW HA to proliferating astrocytes in vitro inhibits cell growth, while treating confluent, quiescent astrocyte cultures with hyaluronidase induces astrocyte proliferation. Collectively, these data indicate that high-MW HA maintains astrocytes in a state of quiescence, and that degradation of HA following CNS injury relieves growth inhibition, resulting in increased astrocyte proliferation. (c) 2005 Wiley-Liss, Inc.	Univ Cincinnati, Inst Neurosci, Dept Neurosurg, Cincinnati, OH 45221 USA; Mayfield Clin, Cincinnati, OH USA; Spine Inst, Cincinnati, OH USA; Hyaluron Inc, Burlington, MA USA; Univ Toronto, Div Neurosurg, Div Cell & Mol Biol, Toronto Western Res Inst,Krembil Neurosci Ctr, Toronto, ON, Canada	Sherman, LS (corresponding author), Oregon Hlth Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.	shermanl@ohsu.edu		Fehlings, Michael/0000-0002-5722-6364	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00163] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000163] Funding Source: NIH RePORTER		ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267; BIGNAMI A, 1992, INT J DEV NEUROSCI, V10, P45, DOI 10.1016/0736-5748(92)90006-L; BIGNAMI A, 1992, EXP NEUROL, V117, P90, DOI 10.1016/0014-4886(92)90115-7; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Cole R, 2001, PROTOCOLS NEURAL CEL, P117; Davies SJA, 1997, NATURE, V390, P680; EGGLI PS, 1992, NEUROSCIENCE, V48, P737, DOI 10.1016/0306-4522(92)90417-Z; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Fitch MT, 2001, GLIAL CELL DEV, P263; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; GIRGRAH N, 1991, J NEUROPATH EXP NEUR, V50, P779, DOI 10.1097/00005072-199111000-00009; GREENWALD RA, 1980, ARTHRITIS RHEUM-US, V23, P455, DOI 10.1002/art.1780230408; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; Jones LL, 2000, J COMP NEUROL, V426, P468, DOI 10.1002/1096-9861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I; Jones LL, 1997, EUR J NEUROSCI, V9, P1854, DOI 10.1111/j.1460-9568.1997.tb00752.x; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Little AR, 2001, NEUROTOXICOLOGY, V22, P607, DOI 10.1016/S0161-813X(01)00032-8; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Liu Y, 2002, GLIA, V40, P25, DOI 10.1002/glia.10111; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; Moon LDF, 2003, J NEUROSCI RES, V71, P23, DOI 10.1002/jnr.10449; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Mothe AJ, 2005, NEUROSCIENCE, V131, P177, DOI 10.1016/j.neuroscience.2004.10.011; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Rivlin A S, 1978, Surg Neurol, V10, P38; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Sherman LS, 2002, GLIA, V38, P93, DOI 10.1002/glia.10053; Sleeman JP, 1996, CANCER RES, V56, P3134; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; StemmerRachamimov AO, 1997, J NEUROPATH EXP NEUR, V56, P735; Tokita Y, 2001, J NEUROSCI, V21, P1257; TONA A, 1993, J NEUROSCI RES, V36, P191, DOI 10.1002/jnr.490360209; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tuohy TMF, 2004, GLIA, V47, P335, DOI 10.1002/glia.20042; VOGEL H, 1992, J NEUROCYTOL, V21, P363, DOI 10.1007/BF01191704; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3	47	89	91	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	OCT	2005	52	1					16	24		10.1002/glia.20215			9	Neurosciences	Neurosciences & Neurology	964GJ	WOS:000231866800002	15892130				2021-06-18	
J	Iverson, GL; Gaetz, M; Lovell, MR; Collins, MW				Iverson, GL; Gaetz, M; Lovell, MR; Collins, MW			Relation between subjective fogginess and neuropsychological testing following concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						concussion; neuropsychological testing; sports		The purpose of this study was to examine the relation between the subjective report of feeling foggy at one-week post concussion and acute neuropsychological outcome. The outcome variables were derived from a computerized neuropsychological screening battery, Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT). Participants were I 10 high school students who sustained a sports-related concussion and were evaluated 5-10 days post injury (M = 6.8 days). Athletes were divided into two groups on the basis of self-reported fogginess. The first group reported no fogginess (it = 91), whereas the second group reported experiencing some degree of fogginess (n = 19) on a 6-point scale. The athletes with persistent fogginess experienced a large number of other post-concussion symptoms, compared to the athletes with no reported fogginess. In addition, the athletes with persistent fogginess had significantly slower reaction times, reduced memory performance, and slower processing speed. Thus, athletes with any degree of self-reported fogginess at one-week post injury are likely to have adverse effects from their concussions in multiple domains.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2B4, Canada; Riverview Hosp, Vancouver, BC V6T 2B4, Canada; Univ Fraser Valley, Abbotsford, BC, Canada; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2B4, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027	3	89	91	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	OCT	2004	10	6					904	906		10.1017/S1355617704106139			3	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	862PB	WOS:000224502000013	15637782				2021-06-18	
J	Pelsers, MMAL; Hanhoff, T; Van Der Voort, D; Arts, B; Peters, M; Ponds, R; Honig, A; Rudzinski, W; Spener, F; De Kruijk, JR; Twijnstra, A; Hermens, WT; Menheere, PPCA; Glatz, JFC				Pelsers, MMAL; Hanhoff, T; Van Der Voort, D; Arts, B; Peters, M; Ponds, R; Honig, A; Rudzinski, W; Spener, F; De Kruijk, JR; Twijnstra, A; Hermens, WT; Menheere, PPCA; Glatz, JFC			Brain- and heart-type fatty acid-binding proteins in the brain: Tissue distribution and clinical utility	CLINICAL CHEMISTRY			English	Article							NEURON-SPECIFIC ENOLASE; ACUTE MYOCARDIAL-INFARCTION; MYELIN BASIC-PROTEIN; SKELETAL-MUSCLE INJURY; CEREBROSPINAL-FLUID; S-100 PROTEIN; MOUSE-BRAIN; SERUM CONCENTRATIONS; CARDIAC-SURGERY; EARLY MARKER	Background: Detection of brain injury by serum markers is not a standard procedure in clinical practice, although several proteins, such as S100B, neuron-specific enolase (NSE), myelin basic protein, and glial fibrillary acidic protein, show promising results. We investigated the tissue distribution of brain- and heart-type fatty acid-binding proteins (B-FABP and H-FABP) in segments of the human brain and the potential of either protein to serve as plasma marker for diagnosis of brain injury. Methods: B-FABP and H-FABP were measured immunochemically in autopsy samples of the brain (n = 6) and in serum samples from (a) patients with mild traumatic brain injury (MTBI; n = 130) and (b) depressed patients undergoing bilateral electroconvulsive therapy (ECT; n = 14). The protein markers S100B and NSE were measured for comparison. Reference values of B-FABP and H-FABP were established in healthy individuals (n = 92). Results: The frontal, temporal, and occipital lobes, the striatum, the pons, and the cerebellum had different tissue concentrations of B-FABP and of H-FABP. B-FABP ranged from 0.8 mug/g wet weight in striatum tissue to 3.1 mug/g in frontal lobe. H-FABP was markedly higher, ranging from 16.2 mug/g wet weight in cerebellum tissue to 39.5 mug/g in pons. No B-FABP was detected in serum from healthy donors. H-FABP serum reference value was 6 mug/L. In the MTBI study, serum B-FABP was increased in 68% and H-FABP in 70% of patients compared with S100B (increased in 45%) and NSE (increased in 51% of patients). In ECT, serum B-FABP was increased in 6% of all samples (2 of 14 patients), whereas H-FABP was above its upper reference limit (6 mug/L) in 17% of all samples (8 of 14 patients), and S100B was above its upper reference limit (0.3 mug/L) in 0.4% of all samples. Conclusions: B-FABP and H-FABP patterns differ among brain tissues, with the highest concentrations in the frontal lobe and pons, respectively. However, in each part of the brain, the H-FABP concentration was at least 10 times higher than that of B-FABP. Patient studies indicate that B-FABP and H-FABP are more sensitive markers for minor brain injury than the currently used markers S100B and NSE. (C) 2004 American Association for Clinical Chemistry.	Maastricht Univ, Dept Mol Genet, CARIM, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Biophys, CARIM, NL-6200 MD Maastricht, Netherlands; Univ Munster, Dept Biochem, D-4400 Munster, Germany; Med Acad Bialystok, Dept Surg, Bialystok, Poland; Univ Hosp Maastricht, Dept Psychiat, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Clin Chem, Maastricht, Netherlands	Pelsers, MMAL (corresponding author), Maastricht Univ, Dept Mol Genet, CARIM, POB 616, NL-6200 MD Maastricht, Netherlands.	maurice.pelsers@gen.unimaas.nl					AURREL A, 1991, STROKE, V22, P1254; Balendiran GK, 2000, J BIOL CHEM, V275, P27045; BAUDIER J, 1984, BIOCHIM BIOPHYS ACTA, V790, P164, DOI 10.1016/0167-4838(84)90220-6; Broderick JP, 2002, CIRCULATION, V106, P1563, DOI 10.1161/01.CIR.0000030406.47365.26; Carney S, 2003, LANCET, V361, P799; de Groot MJM, 1999, CARDIOVASC RES, V44, P315, DOI 10.1016/S0008-6363(99)00199-6; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DEVANAND DP, 1994, AM J PSYCHIAT, V151, P957; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Glatz JFC, 2002, J CLIN LIGAND ASSAY, V25, P167; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Guillaume E, 2003, PROTEOMICS, V3, P1495, DOI 10.1002/pmic.200300478; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ishii J, 1997, CLIN CHEM, V43, P1372; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; JONSSON H, 2000, VASC ANESTH, V6, P698; Key G, 1999, CLIN BIOCHEM, V32, P229, DOI 10.1016/S0009-9120(98)00108-8; Kilminster S, 1999, STROKE, V30, P1869, DOI 10.1161/01.STR.30.9.1869; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; MyersPayne SC, 1996, J NEUROCHEM, V66, P1648; NAKAGAWA H, 1994, NEUROSURGERY, V34, P825, DOI 10.1227/00006123-199405000-00006; Nooijen PTGA, 1997, DEMENT GERIATR COGN, V8, P169, DOI 10.1159/000106627; Owada Y, 1996, MOL BRAIN RES, V42, P156, DOI 10.1016/S0169-328X(96)00182-9; Pelsers MMAL, 1999, CLIN CHEM, V45, P441; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Pu LX, 1999, MOL CELL BIOCHEM, V198, P69, DOI 10.1023/A:1006946027619; Robers M, 1998, CLIN CHEM, V44, P1564; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; ROOS W, 1995, J IMMUNOL METHODS, V183, P149, DOI 10.1016/0022-1759(95)00043-A; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; SELLNER PA, 1995, DEV BRAIN RES, V89, P33, DOI 10.1016/0165-3806(95)00099-Y; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Sorichter S, 1998, BRIT J SPORT MED, V32, P121, DOI 10.1136/bjsm.32.2.121; van der Voort D, 2003, BIOSENS BIOELECTRON, V19, P465, DOI 10.1016/S0956-5663(03)00205-7; VANNIEUWENHOVEN FA, 1995, CIRCULATION, V92, P2848, DOI 10.1161/01.CIR.92.10.2848; Verbeek MM, 2003, ANN CLIN BIOCHEM, V40, P25, DOI 10.1258/000456303321016141; Watanabe T, 2001, CLIN BIOCHEM, V34, P257, DOI 10.1016/S0009-9120(01)00200-4; Wodzig KWH, 1997, ANN CLIN BIOCHEM, V34, P263, DOI 10.1177/000456329703400307	45	89	99	0	8	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147			CLIN CHEM	Clin. Chem.	SEP	2004	50	9					1568	1575		10.1373/clinchem.2003.030361			8	Medical Laboratory Technology	Medical Laboratory Technology	848YJ	WOS:000223503800014	15217991	Bronze, Green Published			2021-06-18	
J	Reeves, TM; Prins, ML; Zhu, JP; Povlishock, JT; Phillips, LL				Reeves, TM; Prins, ML; Zhu, JP; Povlishock, JT; Phillips, LL			Matrix metalloproteinase inhibition alters functional and structural correlates of deafferentation-induced sprouting in the dentate gyrus	JOURNAL OF NEUROSCIENCE			English	Article						deafferentation; collateral sprouting; synaptogenesis; matrix metalloproteinase; extracellular matrix; synaptic plasticity	ENTORHINAL CORTEX LESION; LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; EXCITATORY SYNAPTIC TRANSMISSION; CENTRAL-NERVOUS-SYSTEM; CURRENT SOURCE-DENSITY; RAT FASCIA-DENTATA; ADULT-RAT; EXTRACELLULAR-MATRIX; HIPPOCAMPAL CA1	Molecules comprising the extracellular matrix (ECM), and the family of matrix metalloproteinases (MMPs) that regulate them, perform essential functions during neuroplasticity in both developing and adult nervous systems, including substrate guidance during neuritogenesis and the establishment of boundaries for axonal terminal fields. MMP proteolysis of ECM molecules may perform a permissive or inductive role in fiber remodeling and synaptogenesis initiated by deafferentation. This study examined functional and structural effects of MMP inhibition during the early phases of deafferentation-induced sprouting, characterizing components of the degeneration/proliferation cycle that may be dependent on MMP activity. Adult rats received unilateral lesions of the entorhinal cortex to induce collateral sprouting of the crossed temporodentate fiber pathway. This was followed by intraventricular infusion of the MMP inhibitor FN-439 (2.9 mg/kg) or saline vehicle. After 7 d postlesion, rats underwent in vivo electrophysiological recording or histological processing for electron microscopic analysis. Lesioned rats receiving vehicle exhibited normal sprouting and synaptogenesis, with the emergence of the capacity for long-term potentiation (LTP) within the sprouting pathway, and the successful clearance of degenerating terminals with subsequent synaptic proliferation. In contrast, lesioned rats receiving the MMP inhibitor failed to develop the capacity for LTP and showed persistent cellular debris. Current source density analysis also revealed an FN-439-induced disruption of the current sink, normally localized to the middle region of the granule cell dendrites, corresponding to the terminal field of the crossed temporodentate fibers. These results establish a role for MMP-dependent processes in the deafferentation/sprouting cycle.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anesthesiol, Richmond, VA 23298 USA; Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90095 USA	Reeves, TM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, 1217 E Marshall St,Room 740,Box 980709, Richmond, VA 23298 USA.		Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS020193, NS44372, R56 NS044372, R01 NS044372, NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS044372, R01NS020193, R01NS044372] Funding Source: NIH RePORTER		Amaral David G., 1995, P443; Amet LEA, 2001, MOL CELL NEUROSCI, V17, P1014, DOI 10.1006/mcne.2001.0998; Anan H, 1996, J ENDODONT, V22, P668, DOI 10.1016/S0099-2399(96)80061-6; Bukalo O, 2001, NEUROSCIENCE, V104, P359, DOI 10.1016/S0306-4522(01)00082-3; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; BURDETTE LJ, 1995, BRAIN RES, V680, P53, DOI 10.1016/0006-8993(95)00231-E; Canning KJ, 1997, HIPPOCAMPUS, V7, P643, DOI 10.1002/(SICI)1098-1063(1997)7:6<643::AID-HIPO6>3.3.CO;2-L; Chang HP, 2001, NEUROSCIENCE, V102, P289, DOI 10.1016/S0306-4522(00)00478-4; CHOI BH, 1994, MICROSC RES TECHNIQ, V28, P193, DOI 10.1002/jemt.1070280304; COTMAN CW, 1981, PHYSIOL REV, V61, P684; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; DAVIS L, 1988, J COMP NEUROL, V267, P190, DOI 10.1002/cne.902670204; Deller T, 1996, NEUROSCIENCE, V71, P651, DOI 10.1016/0306-4522(95)00475-0; Deller T, 1997, NEUROSCIENCE, V81, P829, DOI 10.1016/S0306-4522(97)00194-2; Deller T, 1997, PROG NEUROBIOL, V53, P687, DOI 10.1016/S0301-0082(97)00044-0; DESMOND NL, 1983, BRAIN RES, V265, P21, DOI 10.1016/0006-8993(83)91329-X; DISCENNA PG, 1994, HIPPOCAMPUS, V4, P569, DOI 10.1002/hipo.450040506; ERB DE, 1991, EXP BRAIN RES, V83, P253; Fillmore HL, 2001, J NEURO-ONCOL, V53, P187, DOI 10.1023/A:1012213604731; Forster E, 1997, NEUROSCIENCE, V80, P731, DOI 10.1016/S0306-4522(97)00054-7; FROTSCHER M, 1988, ADV ANAT EMBRYOL CEL, V111, P2; Fujimura M, 1999, BRAIN RES, V842, P92, DOI 10.1016/S0006-8993(99)01843-0; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; Haas CA, 1997, NEUROSCIENCE, V81, P33, DOI 10.1016/S0306-4522(97)00187-5; Haas CA, 1999, J NEUROSCI, V19, P9953; Johnston D., 1995, FDN CELLULAR NEUROPH, V1; KIGASAWA K, 1995, JPN J OPHTHALMOL, V39, P35; Komai S, 2000, EUR J NEUROSCI, V12, P1479, DOI 10.1046/j.1460-9568.2000.00035.x; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Lauri SE, 1999, J NEUROSCI, V19, P1226; Lee MY, 1997, J NEUROSCI, V17, P1137; LEUNG LS, 1994, BRAIN RES, V650, P75; LEUNG LS, 1995, J NEUROPHYSIOL, V73, P2392; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LOMO T, 1971, EXP BRAIN RES, V12, P46; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; PHILLIPS LL, 1990, MOL BRAIN RES, V8, P249, DOI 10.1016/0169-328X(90)90024-8; PHILLIPS LL, 1994, NEUROSCIENCE, V58, P503, DOI 10.1016/0306-4522(94)90076-0; RAMIREZ JJ, 1984, BEHAV BRAIN RES, V13, P53, DOI 10.1016/0166-4328(84)90029-9; Ramirez JJ, 1996, P NATL ACAD SCI USA, V93, P15512, DOI 10.1073/pnas.93.26.15512; REEVES TM, 1987, BEHAV NEUROSCI, V101, P179; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; REEVES TM, 1995, EXP BRAIN RES, V106, P248; REEVES TM, 1986, EXP BRAIN RES, V65, P167; RICHARDSON TL, 1987, J NEUROPHYSIOL, V58, P981; STEWARD O, 1983, J COMP NEUROL, V214, P370, DOI 10.1002/cne.902140403; STEWARD O, 1976, EXP BRAIN RES, V26, P423; STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024; STEWARD O, 1991, CEREB CORTEX, V9, P81; Steward O., 1994, NEUROBIOLOGY CENTRAL, P266; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Vaillant C, 1999, J NEUROSCI, V19, P4994; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; WHITE G, 1990, J NEUROPHYSIOL, V64, P1186; WILSON R C, 1981, Journal of Neurophysiology (Bethesda), V46, P339; WILSON RC, 1981, J NEUROPHYSIOL, V46, P324; WYSS JM, 1981, J COMP NEUROL, V199, P495; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	67	89	94	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 12	2003	23	32					10182	10189					8	Neurosciences	Neurosciences & Neurology	742UH	WOS:000186536100002	14614076				2021-06-18	
J	Michaelson, P; Michaelson, M; Jaric, S; Latash, ML; Sjolander, P; Djupsjobacka, M				Michaelson, P; Michaelson, M; Jaric, S; Latash, ML; Sjolander, P; Djupsjobacka, M			Vertical posture and head stability in patients with chronic neck	JOURNAL OF REHABILITATION MEDICINE			English	Article						neck pain; whiplash injury; work-related myalgia; single-blind method; posture; balance; head stabilization; proprioception	SUSPECTED CERVICAL ORIGIN; LOW-BACK-PAIN; WHIPLASH INJURIES; ARM MOVEMENTS; DISORDERS; DIZZINESS; BALANCE; MUSCLES; CAT	Objective: To evaluate postural performance and head stabilization of patients with chronic neck pain. Design: A single-blind comparative group study. Subjects: Patients with work-related chronic neck pain (n=9), with chronic whiplash associated disorders (n=9) and healthy subjects (n=16). Methods: During quiet standing in different conditions (e.g. 1 and 2 feet standing, tandem standing, and open and closed eyes) the sway areas and the ability to maintain the postures were measured. The maximal peak-to-peak displacement of the centre of pressure and the head translation were analysed during predictable and unpredictable postural perturbations. Results: Patients with chronic neck pain, in particular those with whiplash-associated disorders, showed larger sway areas and reduced ability to successfully execute more challenging balance tasks. They also displayed larger sway areas and reduced head stability during perturbations. Conclusion: The results show that disturbances of postural control in chronic neck pain are dependent on the aetiology, and that it is possible to quantify characteristic postural disturbances in different neck pain conditions. It is suggested that the dissimilarities in postural performance are a reflection of different degrees of disturbances of the proprioceptive input to the central nervous system and/or of the central processing of such input.	So Lapland Res Dept, SE-91232 Vilhelmina, Sweden; Univ Gavle, Ctr Musculoskeletal Res, Gavle, Sweden; Umea Univ, Dept Surg & Perioperat Sci, Div Sports Med, S-90187 Umea, Sweden; Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; Saxnasgardens Rehabil Ctr, Marsfjall, Sweden; Univ Delaware, Human Performance Lab, Newark, DE 19716 USA	Sjolander, P (corresponding author), So Lapland Res Dept, Postgatan 7, SE-91232 Vilhelmina, Sweden.	per.sjolander@vilhelmina.se	salimi, mehdi/D-1192-2009				Alund M, 1993, J Vestib Res, V3, P383; ARUIN AS, 1995, EXP BRAIN RES, V103, P323; ARUIN AS, 1995, EXP BRAIN RES, V106, P291; BRANDT T, 1991, VERTIGO ITS MULTISEN, P277; Branstrom H, 2001, ADV PHYSIOTHER, V3, P120; CORDO PJ, 1982, J NEUROPHYSIOL, V47, P287; DIRNHOFER R, 1977, Z RECHTSMED, V79, P25; FITZRITSON D, 1991, J MANIP PHYSIOL THER, V14, P193; Graybiel A, 1966, Acta Otolaryngol, V61, P292, DOI 10.3109/00016486609127066; Hagg GM, 2000, EUR J APPL PHYSIOL, V83, P159, DOI 10.1007/s004210000274; Hodges PW, 1996, SPINE, V21, P2640, DOI 10.1097/00007632-199611150-00014; Johansson H, 1999, AM J IND MED, P104; JONSSON H, 1991, J SPINAL DISORD, V4, P251, DOI 10.1097/00002517-199109000-00001; Jull GA, 2000, J MUSCULOSKELET PAIN, V8, P143, DOI 10.1300/J094v08n01_12; Karlberg M, 1996, ARCH PHYS MED REHAB, V77, P874, DOI 10.1016/S0003-9993(96)90273-7; Karlberg M, 1996, J VESTIBUL RES-EQUIL, V6, P37; KARLBERG M, 1995, GAIT POSTURE, V3, P241; Lanska DJ, 2000, NEUROLOGY, V55, P1201, DOI 10.1212/WNL.55.8.1201; Latash ML, 1996, BEHAV BRAIN SCI, V19, P55, DOI 10.1017/S0140525X00041467; Luoto S, 1998, SPINE, V23, P2081, DOI 10.1097/00007632-199810010-00008; MASSION J, 1992, PROG NEUROBIOL, V38, P35, DOI 10.1016/0301-0082(92)90034-C; McPartland JM, 1997, J MANIP PHYSIOL THER, V20, P24; MUNRO BH, 1997, STAT METHODS HLTH CA, P162; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; Ordway NR, 1997, SPINE, V22, P501, DOI 10.1097/00007632-199703010-00007; Pedersen J, 1997, PAIN, V70, P83, DOI 10.1016/S0304-3959(96)03305-2; Persson L, 1996, J VESTIBUL RES-EQUIL, V6, P439; ROSSITERFORNOFF JE, 1995, J GERONTOL A-BIOL, V50, pM291, DOI 10.1093/gerona/50A.6.M291; RUBIN AM, 1995, AM J OTOL, V16, P216; Serra L L, 1994, Acta Neurol (Napoli), V16, P262; Sjolander Per, 2002, J Electromyogr Kinesiol, V12, P167, DOI 10.1016/S1050-6411(02)00017-2; SRIVASTAVA M, 1996, REGRESSION ANAL THEO, P158; STONES MJ, 1987, ARCH PHYS MED REHAB, V68, P85; Thunberg J, 2001, PAIN, V91, P15, DOI 10.1016/S0304-3959(00)00415-2	34	89	91	0	13	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2003	35	5					229	235		10.1080/16501970306093			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	712UP	WOS:000184817000006	14582555	DOAJ Gold			2021-06-18	
J	Timonen, M; Miettunen, J; Hakko, H; Zitting, P; Veijola, J; von Wendt, L; Rasanen, P				Timonen, M; Miettunen, J; Hakko, H; Zitting, P; Veijola, J; von Wendt, L; Rasanen, P			The association of preceding traumatic brain injury with mental disorders, alcoholism and criminality: the Northern Finland 1966 Birth Cohort Study	PSYCHIATRY RESEARCH			English	Article						psychiatric disorders; alcohol abuse; alcohol dependence; criminal	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; PSYCHIATRIC-DISORDERS; NERVOUS-SYSTEM; HEAD-INJURY; SUBSTANCE-ABUSE; UNITED-STATES; FOLLOW-UP; SCHIZOPHRENIA; COMORBIDITY	The purpose of this study was to test the hypothesis that traumatic brain injury (TBI) during childhood and adolescence is associated with psychiatric disorders, heavy alcohol use and criminal offenses in adulthood. We made use of an unselected, general population birth cohort (n=12058) in Northern Finland, which was followed up prospectively up to the age of 31. The data on TBIs of the cohort members were collected from the hospital case notes of the outpatient clinics of the hospitals in the region and from the Finnish Hospital Discharge Registers (FHDR). The data on mental disorders including alcohol diagnoses were also collected from the FHDR after a careful validation process. The Ministry of Justice provided information on criminal offenses for all subjects. The final number of subjects in our study was 5589 males and 5345 females. We found that after controlling for confounders, TBI during childhood or adolescence increased the risk of developing mental disorders two-fold (OR 2.1, 95% CI 1.1-3.6) and TBI was significantly related to later mental disorder with coexisting criminality in male cohort members (OR 4.1, 95% CI 1.2-13.6). The results support the TBI's association with psychiatric morbidity, which should not be overlooked when treating psychiatric patients, especially those with comorbid criminality. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Oulu, Dept Psychiat, FIN-90014 Oulu, Finland; Oulu Hlth Ctr, FIN-90015 Oulu, Finland; Univ Oulu, Dept Publ Hlth Sci & Gen Practice, FIN-90220 Oulu, Finland; HUCH Hosp Children & Adolescents, Dept Child Neurol, FIN-00029 Helsinki, HYKS, Finland	Timonen, M (corresponding author), Univ Oulu, Dept Psychiat, POB 5000, FIN-90014 Oulu, Finland.		Miettunen, Jouko/AAC-4334-2019	Miettunen, Jouko/0000-0003-0575-2669			BARNFIELD TV, 1988, BRAIN INJURYU, V12, P455; BIEDERMAN J, 1995, AM J PSYCHIAT, V152, P1652; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; CLONINGER CR, 1995, EUR ARCH PSY CLIN N, V245, P239, DOI 10.1007/BF02191803; Deb S, 1999, AM J PSYCHIAT, V156, P374; Diaz F G, 1995, Med Law, V14, P131; Eyestone L L, 1994, Bull Am Acad Psychiatry Law, V22, P181; Faraone SV, 2000, BIOL PSYCHIAT, V48, P9, DOI 10.1016/S0006-3223(00)00889-1; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HILL AB, 1965, P ROY SOC MED, V58, P293; Isohanni M, 1997, SOC PSYCH PSYCH EPID, V32, P303, DOI 10.1007/BF00789044; JOUKAMAA M, 1991, M10791; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KONDRAD K, 2000, BRAIN INJURY, V14, P859; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEWIS DO, 1982, J ADOLESCENT HEALTH, V3, P160, DOI 10.1016/S0197-0070(82)80119-8; LEWIS DO, 1979, CHILD PSYCHIAT HUM D, V9, P210, DOI 10.1007/BF01433696; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; McAllister TW, 1998, SEMIN CLIN NEUROPSYC, V3, P211; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MILBERGER S, 1995, AM J PSYCHIAT, V152, P1793; Pliszka SR, 2000, CHILD ADOL PSYCH CL, V9, P525; POIKOLAINEN K, 1983, DRUG ALCOHOL DEPEN, V12, P315, DOI 10.1016/0376-8716(83)90002-9; RANTAKALLIO P, 1979, SOC SCI MED-MED SOC, V13, P423, DOI 10.1016/0160-7979(79)90131-0; RANTAKALLIO P, 1995, SOC PSYCH PSYCH EPID, V30, P113, DOI 10.1007/BF00802039; RANTAKALLIO P, 1992, INT J EPIDEMIOL, V21, P1106, DOI 10.1093/ije/21.6.1106; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; RANTAKALLIO P, 1985, J EPIDEMIOL COMMUN H, V39, P353, DOI 10.1136/jech.39.4.353; RANTAKALLIO P, 1969, ACTA PAEDIAT SC S193, V0193; Rantakallio P, 1997, INT J EPIDEMIOL, V26, P837, DOI 10.1093/ije/26.4.837; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SHANOK SS, 1981, ARCH GEN PSYCHIAT, V38, P211; *STAT FINL CRIM NO, 1996, HANDBOOKS, V27; Taylor C.A., 1998, SEMINARS CLIN NEUROP, V3, P224; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	46	89	89	0	20	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	DEC 30	2002	113	3					217	226	PII S0165-1781(02)00269-X	10.1016/S0165-1781(02)00269-X			10	Psychiatry	Psychiatry	643VL	WOS:000180881900001	12559478				2021-06-18	
J	Hartman, RE; Laurer, H; Longhi, L; Bales, KR; Paul, SM; McIntosh, TK; Holtzman, DM				Hartman, RE; Laurer, H; Longhi, L; Bales, KR; Paul, SM; McIntosh, TK; Holtzman, DM			Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; amyloid; APP; traumatic brain injury; apoE; hippocampus	CLOSED-HEAD INJURY; TRANSGENIC MICE; E EPSILON-4; BETA-PROTEIN; PRECURSOR PROTEIN; E-DEFICIENT; ALLELE; NEURODEGENERATION; SUSCEPTIBILITY; ASSOCIATION	The epsilon4 allele of apolipoprotein E (APOE) and traumatic brain injury (TBI) are both risk factors for the development of Alzheimer's disease (AD). These factors may act synergistically, in that APOE4+ individuals are more likely to develop dementia after TBI. Because the mechanism underlying these effects is unclear, we questioned whether APOE4 and TBI interact either through effects on amyloid-beta (Abeta) or by enhancing cell death/tissue injury. We assessed the effects of TBI in PDAPP mice (transgenic mice that develop AD-like pathology) expressing human APOE3 (PDAPP: E3), human APOE4 (PDAPP: E4), or no APOE (PDAPP: E-/-). Mice were subjected to a unilateral cortical impact injury at 9-10 months of age and allowed to survive for 3 months. Abeta load, hippocampal/cortical volumes, and hippocampal CA3 cell loss were quantified using stereological methods. All of the groups contained mice with Abeta-immunoreactive deposits (56% PDAPP: E4, 20% PDAPP: E3, 75% PDAPP: E-/-), but thioflavine-S-positive Abeta (amyloid) was present only in the molecular layer of the dentate gyrus in the PDAPP: E4 mice (44%). In contrast, our previous studies showed that in the absence of TBI, PDAPP: E3 and PDAPP: E4 mice have little to no Abeta deposition at this age. After TBI, all of the Abeta deposits present in PDAPP: E3 and PDAPP: E-/- mice were diffuse plaques. In contrast to the effect of APOE4 on amyloid, PDAPP: E3, PDAPP: E4, and PDAPP: E-/- mice did not differ in the amount of brain tissue or cell loss. These data support the hypothesis that APOE4 influences the neurodegenerative cascade after TBI via an effect on Abeta.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alzheimers Dis Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA; Indiana Univ, Dept Pharmacol Toxicol & Psychiat, Sch Med, Indianapolis, IN 46285 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Holtzman, DM (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.		Longhi, Luca/AAF-9903-2021; Hartman, Richard/C-5767-2008	Longhi, Luca/0000-0001-9894-8788; Hartman, Richard/0000-0001-9235-3169	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG005681, P01 AG011355, R01 AG013956, AG13956, AG05681, AG11355, R37 AG013956] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA07261, T32 DA007261] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, P50 NS008803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005681, R01AG013956, R37AG013956, P01AG011355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007261] Funding Source: NIH RePORTER		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Buttini M, 1999, J NEUROSCI, V19, P4867; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fagan AM, 1998, EXP NEUROL, V151, P314, DOI 10.1006/exnr.1998.6818; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Gouras GK, 1997, ANN NEUROL, V41, P402, DOI 10.1002/ana.410410317; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Holtzman DM, 2001, J MOL NEUROSCI, V17, P147, DOI 10.1385/JMN:17:2:147; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LECLERCQ PD, 2002, NEUROPATHOL APPL NEU, V28, P161; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Macfarlane DP, 1999, NEUROREPORT, V10, P3945, DOI 10.1097/00001756-199912160-00040; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stone DJ, 1998, J NEUROSCI, V18, P3180; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun YL, 1998, J NEUROSCI, V18, P3261; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teter B, 2000, ALZHEIMERS REP, V3, P199; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147	40	89	91	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC 1	2002	22	23					10083	10087					5	Neurosciences	Neurosciences & Neurology	619DE	WOS:000179458100004	12451108				2021-06-18	
J	Oertel, M; Kelly, DF; Lee, JH; McArthur, DL; Glenn, TC; Vespa, P; Boscardin, WJ; Hovda, DA; Martin, NA				Oertel, M; Kelly, DF; Lee, JH; McArthur, DL; Glenn, TC; Vespa, P; Boscardin, WJ; Hovda, DA; Martin, NA			Efficacy of hyperventilation, blood pressure elevation, and metabolic suppression therapy in controlling intracranial pressure after head injury	JOURNAL OF NEUROSURGERY			English	Article						hyperventilation therapy; induced-hypertension therapy; pressure autoregulation; metabolic suppression therapy; propofol; transcranial Doppler ultrasonography; traumatic brain injury; vasoreactivity	TRAUMATIC BRAIN INJURY; CEREBRAL PERFUSION-PRESSURE; CARBON-DIOXIDE REACTIVITY; PROPOFOL ANESTHESIA; PROLONGED HYPERVENTILATION; MODERATE HYPERVENTILATION; BURST SUPPRESSION; BARBITURATE COMA; AUTOREGULATION; HYPERTENSION	Object. Hyperventilation therapy, blood pressure augmentation, and metabolic suppression therapy are often used to reduce intracranial pressure (ICP) and improve cerebral perfusion pressure (CPP) in intubated head-injured patients. In this study, as part of routine vasoreactivity testing, these three therapies were assessed in their effectiveness in reducing ICP. Methods. Thirty-three patients with a mean age of 33 +/- 13 years and a median Glasgow Coma Scale (GCS) score of 7 underwent a total of 70 vasoreactivity testing sessions from postinjury Days 0 to 13. After an initial Xe-133 cerebral blood flow (CBF) assessment, transcranial Doppler ultrasonography recordings of the middle cerebral arteries were obtained to assess blood flow velocity changes resulting from transient hyperventilation (57 studies in 27 patients), phenylephrine-induced hypertension (55 studies in 26 patients), and propofol-induced metabolic suppression (43 studies in 21 patients). Changes in ICP, mean arterial blood pressure (MABP), CPP, PaCO2, and jugular venous oxygen saturation (SjvO(2)) were recorded. With hyperventilation therapy, patients experienced a mean decrease in PaCO2 from 35 +/- 5 to 27 +/- 5 mm Hg and in ICP from 20 +/- 11 to 13 +/- 8 min Hg (p < 0.001). In no patient who underwent hyperventilation therapy did SjvO(2) fall below 55%. With induced hypertension, MABP in patients increased by 14 5 mm Hg and ICP increased from 16 +/- 9 to 19 +/- 9 mm Hg (p = 0.001). With the aid of metabolic suppression, MABP remained stable and ICP decreased from 20 +/- 10 to 16 +/- 11 mm Hg (p < 0.001). A decrease in ICP of more than 20% below the baseline value was observed in 77.2, 5.5, and 48.8% of hyperventilation, induced-hypertension, and metabolic suppression tests, respectively (p < 0.001 for all comparisons). Predictors of an effective reduction in ICP included a high PaCO2 for hyperventilation, a high study GCS score for induced hypertension, and a high PaCO2 and a high CBF for metabolic suppression. Conclusions. Of the three modalities tested to reduce ICP, hyperventilation therapy was the most consistently effective, metabolic suppression therapy was variably effective, and induced hypertension was generally ineffective and in some instances significantly raised ICP. The results of this study suggest that hyperventilation may be used more aggressively to control ICP in head-injured patients, provided it is performed in conjunction with monitoring of SjvO(2).	Univ Calif Los Angeles, Sch Med, Brain Injury Res Ctr, Cerebral Blood Flow Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Ctr Hlth Sci, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA 90024 USA; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Inst Educ, Torrance, CA USA	Kelly, DF (corresponding author), 200 UCLA Med Plaza,Suite 504,Box 718224, Los Angeles, CA 90095 USA.		McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; ARTRU AA, 1992, J NEUROSURG ANESTH, V4, P99, DOI 10.1097/00008506-199204000-00005; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bouma G J, 1995, New Horiz, V3, P384; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRICOLO AP, 1981, J NEUROSURG, V55, P397, DOI 10.3171/jns.1981.55.3.0397; BROWN FD, 1979, J NEUROSURG, V50, P423, DOI 10.3171/jns.1979.50.4.0423; Bullock MR, 1996, J NEUROTRAUM, V13, P699; Bullock MR, 1996, J NEUROTRAUM, V13, P693; COHEN PJ, 1964, ANESTHESIOLOGY, V25, P186; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Doyle PW, 1999, BRIT J ANAESTH, V83, P580; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Goblet W, 1977, Neurochirurgia (Stuttg), V20, P35; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; LASSEN NA, 1990, REV NEUROL, V146, P620; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Letarte PB, 1999, ACT NEUR S, V75, P45; LUNDBERG N, 1960, ACTA PSYCHIATRICA  S, V149, P1; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; NEWMAN MF, 1995, ANESTH ANALG, V81, P452, DOI 10.1097/00000539-199509000-00004; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; ROBERTS I, 2000, COCHRANE DATABASE SY, V136, DOI UNSP CD000033; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; RODENBERG FH, 1976, J NEUROSURG, V44, P347; ROSENBERG AA, 1988, STROKE, V19, P1365, DOI 10.1161/01.STR.19.11.1365; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; ROWED DW, 1975, ARCH NEUROL-CHICAGO, V32, P369, DOI 10.1001/archneur.1975.00490480035003; SADOSHIMA S, 1980, BRAIN RES, V189, P115, DOI 10.1016/0006-8993(80)90011-6; Schneider GH, 1998, ACT NEUR S, V71, P62; SHAPIRO HM, 1974, J NEUROSURG, V40, P90, DOI 10.3171/jns.1974.40.1.0090; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007; UNTERBERG AW, 1997, J TRAUMA S, V42, P32; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Wodey E, 1999, BRIT J ANAESTH, V82, P516; Woodman T, 1996, NEUROTRAUMA, P519	64	89	97	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2002	97	5					1045	1053		10.3171/jns.2002.97.5.1045			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	613BC	WOS:000179109800012	12450025				2021-06-18	
J	Sun, FY; Lin, X; Mao, LZ; Ge, WH; Zhang, LM; Huang, YL; Gu, J				Sun, FY; Lin, X; Mao, LZ; Ge, WH; Zhang, LM; Huang, YL; Gu, J			Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia	JOURNAL OF PINEAL RESEARCH			English	Article						antioxidant; apoptosis; brain; DNA repair; injury; ischemia; neuronal death	TRAUMATIC BRAIN INJURY; CELL-DEATH; FOREBRAIN ISCHEMIA; OXIDATIVE DAMAGE; EXCISION-REPAIR; REPERFUSION; PROTECTS; EXPRESSION; BCL-2; REDUCTION	In the present study, double fluorescence staining combined with confocal laser scanning microscopy analysis were used to examine the effects of melatonin on ischemia-induced neuronal DNA strand breaks and its possible mechanisms in a transient middle cerebral artery (MCA) occlusion model. Results showed that melatonin dose-dependently reduced infarct areas and decreased both DNA double and single strand breaks (DSB and SSB) and enhanced cell viability in the peri-ischemic brain regions. Furthermore, Bcl-2 induction in the ischemic brain was further enhanced by melatonin treatment. Double staining analysis indicated that the cells costained for Bcl-2 and TdT-mediated-deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL), a DSB marker, displayed a relative regular morphology compared with the cells only stained with TUNEL. Transient ischemia induced an expression of excision repair cross-complementing factor 6 (ERCC6) mRNA, a gene essential for the preferential repair of nuclear excision repair, in the injured neurons. Double labeling showed that ERCC6 only co-localized with proliferating cell nuclear antigen (PCNA), a member of the nuclear excision repair complex, but not with TUNEL. Melatonin further and statistical significantly up-regulated ERCC6 mRNA expression in the peri-ischemic region of rat brains. The results suggest that neuroprotection by melatonin against ischemic injury may be related to modulation of apoptosis and DNA repair capacity.	Fudan Univ, Med Ctr, Natl Key Lab Med Neurobiol, Shanghai 200032, Peoples R China	Sun, FY (corresponding author), Fudan Univ, Med Ctr, Natl Key Lab Med Neurobiol, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.						Acuna-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x; Cazevieille C, 1997, BRAIN RES, V755, P91, DOI 10.1016/S0006-8993(97)00090-5; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chang YY, 1999, NEUROSCI LETT, V277, P61, DOI 10.1016/S0304-3940(99)00799-5; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Chen J, 2000, J CEREBR BLOOD F MET, V20, P1033, DOI 10.1097/00004647-200007000-00002; Chen J, 1997, J NEUROCHEM, V69, P232; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Gilad E, 1997, LIFE SCI, V60, P169; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; Li XJ, 2002, J PINEAL RES, V32, P47, DOI 10.1034/j.1600-079x.2002.10831.x; Li XJ, 1999, ACTA PHARMACOL SIN, V20, P201; Li XJ, 1997, ACTA PHARMACOL SIN, V18, P394; Lin LH, 2000, J NEUROCHEM, V74, P1098; Ling X, 1999, ACTA PHARMACOL SIN, V20, P15; Ling X, 1999, ACTA PHARMACOL SIN, V20, P409; Lipton P, 1999, PHYSIOL REV, V79, P1431; Liu PK, 1996, J NEUROSCI, V16, P6795; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Love S, 1999, BRAIN PATHOL, V9, P119; Manev H, 1996, FASEB J, V10, P1546; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Murakami K, 1997, BRAIN RES, V751, P160, DOI 10.1016/S0006-8993(97)00029-2; Nagayama T, 2000, J NEUROCHEM, V75, P1716, DOI 10.1046/j.1471-4159.2000.0751716.x; Pierre C., 1994, LIFE SCI, V55, P271; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter RJ, 1998, P W PHARMACOL SOC, V41, P229; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; Reiter RJ, 1999, BIOL SIGNAL RECEPT, V8, P56; Reiter RJ, 2000, CURR TOP BIOPHYS, V24, P171; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; Tan D-X, 1993, ENDOCR J, V1, P57; Tang L, 1998, MOL CELL BIOCHEM, V178, P299, DOI 10.1023/A:1006815530519; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Wakatsuki A, 2001, J PINEAL RES, V31, P167, DOI 10.1034/j.1600-079x.2001.310211.x; Wakatsuki A, 2001, J PINEAL RES, V30, P22, DOI 10.1034/j.1600-079X.2001.300103.x; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yin KJ, 1999, BRAIN RES, V815, P29, DOI 10.1016/S0006-8993(98)01071-3	45	89	92	0	5	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0742-3098			J PINEAL RES	J. Pineal Res.	AUG	2002	33	1					48	56		10.1034/j.1600-079X.2002.01891.x			9	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	573MF	WOS:000176833300007	12121485				2021-06-18	
J	Leon-Carrion, J; Van Eeckhout, P; Dominguez-Morales, MD; Perez-Santamaria, FJ				Leon-Carrion, J; Van Eeckhout, P; Dominguez-Morales, MD; Perez-Santamaria, FJ			The locked-in syndrome: a syndrome looking for a therapy	BRAIN INJURY			English	Article							MULTI-INFARCT DEMENTIA; ALZHEIMER TYPE	The locked-in syndrome (LIS) is a very severe condition caused by a primary vascular or traumatic injury to the brainstem, normally corresponding to a ventral pons lesion due to an obstruction of the basilar artery, and characterized by upper motor neuron quadriplegia, paralysis of lower cranial nerves, bilateral paresis of horizontal gaze and anarthria, and with preserved consciousness. Patients who have suffered this pontine lesion generally have preserved vertical eye movements and movement of the eyelids (blinking), this being their only means of responding to the outside world. A survey was conducted of 44 people diagnosed with LIS, all of them belonging to the Association of Locked-in Syndrome (ALIS) of France. Results of this survey showed that LIS was equally frequent in men and women (51.2% vs. 48.1%) and had occurred at any age between 22-77 years of age (normally between 41-52 years, the mean age being 46.79 years). The average time that transpired post-insult was 71.35 months. The principal cause of LIS was stroke (86.4%), with traumatic brain injury (TBI) being a distant second cause with an incidence of only 13.6%. The diagnosis of LIS was usually made around the middle of the second month after onset (mean of 78.76 days). The principal treatments, when present, were pharmacological and physiotherapy. However, 47.1% of the patients were not receiving treatment of any kind at the time of the survey. Neuropsychologically, 86% had a good attentional level, 97.6% were temporally oriented and 76.7% could read; 18.6% reported memory problems and 24% showed visual deficit (found mainly in patients with LIS originated by TBI); 47.5% reported a good mood state and 12.5% reported feeling depressed; 61.1% reported having sexual desire, but only 30% maintained sexual relations; 78% were capable of emitting sounds and 65.8% could communicate without technical aid; 73.2% enjoyed going out and 81% met with friends at least twice a month. Only 14.3% participated in social activities and 23.8% watched television regularly. Nearly 100% of the patients reported being sensitive to touch to any part of their bodies. This survey suggests diagnostics and rehabilitation procedures.	Univ Seville, Seville 41018, Spain; Federat Neurol La Pitie Salpetriere, Paris, France; CRECER, Ctr Brain Injury Rehabil, Seville, Spain	Leon-Carrion, J (corresponding author), Univ Seville, San Francisco Javier S-N, Seville 41018, Spain.		Odom, James V/A-1344-2013	Odom, James V/0000-0001-5874-1707			Allain P, 1998, CORTEX, V34, P629, DOI 10.1016/S0010-9452(08)70520-3; ALONI R, 1993, SEX DISABIL, V11, P121; ARBOIX S, 1990, NEUROLOGIA, V5, P137; BOLDRINI P, 1991, ARCH PHYS MED REHAB, V72, P202; BUCHT G, 1984, J AM GERIATR SOC, V32, P491, DOI 10.1111/j.1532-5415.1984.tb02233.x; CUMMINGS JL, 1987, ARCH NEUROL-CHICAGO, V44, P389, DOI 10.1001/archneur.1987.00520160031010; DELACOUR J L, 1988, Annales Francaises d'Anesthesie et de Reanimation, V7, P433, DOI 10.1016/S0750-7658(88)80065-0; GALLO UE, 1989, AM J EMERG MED, V7, P581, DOI 10.1016/0735-6757(89)90278-7; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Griffith ER, 1993, SEXUALITY PERSON TRA; HAIG AJ, 1987, ARCH PHYS MED REHAB, V68, P24; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P403; Markus E, 1992, Rehabilitation (Stuttg), V31, P85; MOINGA TN, 1986, ARCH PHYSICAL MED RE, V67, P19; PLUM F, 1982, DIAGNOSIS STUPOR COM, P9; PROSIEGEL M, 1980, FORTSCHR MED, V98, P1489; SJOGREN K, 1981, INT REHABILITATION M, V15, P55; STARKSTEIN SE, 1991, NEUROBEHAVIORAL ASPE, P150	18	89	93	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2002	16	7					571	582		10.1080/02699050110119781			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	569RN	WOS:000176616100002	12119076				2021-06-18	
J	Stewart, WF; Schwartz, BS; Simon, D; Kelsey, K; Todd, AC				Stewart, WF; Schwartz, BS; Simon, D; Kelsey, K; Todd, AC			ApoE genotype, past adult lead exposure, and neurobehavioral function	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						apolipoprotein E; bone lead; cognitive function; neurobehavioral tests; X-ray fluorescence	AMYLOID PROTEIN DEPOSITION; RAT HIPPOCAMPAL-NEURONS; TRAUMATIC BRAIN-INJURY; E EPSILON 4; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; INORGANIC LEAD; HEAD-INJURY; INDUCED NEUROTOXICITY; BONE-LEAD	Our objective in this study was to determine if the known relation between tibia bone lead levels and neurobehavioral test scores are influenced by the apolipoprotein E (ApoE) genotype. We collected data on 20 neurobehavioral tests in 529 former organolead workers who had an average of 16 years since last occupational exposure to lead. We used linear regression to model the relations between each of 20 neurobehavioral test scores and tibia lead, a binary variable for ApoE genotype (i.e., at least one epsilon4 allele vs. none), and an interaction term between tibia lead and the binary term for ApoE genotype. At the time of testing, former lead workers were an average of 57.6 years of age; 82% were younger than 65 years. In regression analysis, we observed one statistically significant and one borderline significant coefficient for ApoE genotype alone. Coefficients for the ApoE and tibia lead interaction term were negative in 19 of the 20 regression models. This indicates that the slope for the relation between tibia lead and each neurobehavioral test was more negative for individuals with at least one epsilon4 allele than for those who did not have an epsilon4 allele. Four of 19 negative coefficients for the interaction term were statistically significant (digit symbol, Purdue pegboard assembly, Purdue pegboard-dominant hand, complex reaction time); another three of the remaining 16 coefficients (symbol digit, trail-making A, Stroop) were borderline significant (i.e., p < 0.10). This study suggests that individuals may vary in susceptibility to the long-term effects of lead on the central nervous system (CNS). In particular, the persistent CNS effect of lead may be more toxic in individuals who have at least one ApoE-epsilon4 allele.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Div Occupat & Environm Hlth, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA; Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Mt Sinai Med Ctr, Dept Community & Prevent Med, New York, NY USA	Stewart, WF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Room 6027,615 N Wolfe St, Baltimore, MD 21205 USA.	wstewart@jhsph.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG10785] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P42 ES-05947, ES00002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES000002, P42ES005947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010785] Funding Source: NIH RePORTER		Chen HH, 1998, BIOMED ENVIRON SCI, V11, P61; CORYSIECHTA DA, 1967, HDB NEUROTOXICOLOGY, P61; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; Finkelstein Y, 1998, BRAIN RES REV, V27, P168, DOI 10.1016/S0165-0173(98)00011-3; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GERHARDSSON L, 1993, ARCH ENVIRON HEALTH, V48, P147, DOI 10.1080/00039896.1993.9940813; Gong Zhaolong, 1995, Arhiv za Higijenu Rada i Toksikologiju, V46, P381; Gutowski M, 1998, TOXICOL LETT, V95, P195, DOI 10.1016/S0378-4274(98)00036-8; Harry GJ, 1996, TOXICOL APPL PHARM, V139, P84, DOI 10.1006/taap.1996.0145; HIXSON JE, 1990, J LIPID RES, V31, P541; Hu H, 1998, ENVIRON HEALTH PERSP, V106, P1, DOI 10.2307/3433626; Jones PM, 1998, GROUP DECIS NEGOT, V7, P249, DOI 10.1023/A:1008635500191; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALA SV, 1995, NEUROTOXICOLOGY, V16, P297; KERN M, 1995, TOXICOL APPL PHARM, V134, P111, DOI 10.1006/taap.1995.1174; KONAT G, 1984, NEUROTOXICOLOGY, V5, P87; KONAT G, 1979, J NEUROCHEM, V32, P187, DOI 10.1111/j.1471-4159.1979.tb04526.x; Links JM, 2001, ENVIRON HEALTH PERSP, V109, P361, DOI 10.2307/3454895; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; Marchioro M, 1996, J PHARMACOL EXP THER, V279, P143; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCCULLOUGH P, 1983, GEN LINEAR MODELS; Murphy KJ, 1995, TOXICOL LETT, V82-3, P271, DOI 10.1016/0378-4274(95)03561-3; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NIKLOWITZ WJ, 1975, NEUROLOGY, V25, P927, DOI 10.1212/WNL.25.10.927; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sahota A, 1997, ANN NEUROL, V42, P659, DOI 10.1002/ana.410420418; SCHWARTZ BS, 1993, AM J EPIDEMIOL, V137, P1006, DOI 10.1093/oxfordjournals.aje.a116757; Schwartz BS, 2000, NEUROLOGY, V55, P1144, DOI 10.1212/WNL.55.8.1144; SELVINTESTA A, 1994, NEUROTOXICOLOGY, V15, P389; SLOMIANKA L, 1989, NEUROTOXICOLOGY, V10, P177; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Southgate GS, 1998, J CHEM NEUROANAT, V14, P151, DOI 10.1016/S0891-0618(98)00026-X; Stewart WF, 1999, NEUROLOGY, V52, P1610, DOI 10.1212/WNL.52.8.1610; TIAN X, 1995, DEV BRAIN RES, V86, P268, DOI 10.1016/0165-3806(95)00038-F; Todd AC, 2000, ENVIRON HEALTH PERSP, V108, P383, DOI 10.2307/3454376; TODD AC, 1993, BASIC LIFE SCI, P299; TODD AC, 1992, ENVIRON RES, V57, P117, DOI 10.1016/S0013-9351(05)80073-8; WALSH TJ, 1984, NEUROTOXICOLOGY, V5, P67; WALSH TJ, 1986, NEUROTOXICOLOGY, V7, P21; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Xu YZ, 1998, NEUROTOXICOL TERATOL, V20, P69, DOI 10.1016/S0892-0362(97)00072-X; Zaiser AE, 1997, NEUROSCI LETT, V239, P128, DOI 10.1016/S0304-3940(97)00895-1; Zhang HS, 1998, BIOMED ENVIRON SCI, V11, P81; ZIMMERMANN HP, 1988, MUTAT RES, V201, P293, DOI 10.1016/0027-5107(88)90018-8	47	89	92	0	2	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2002	110	5					501	505		10.1289/ehp.02110501			5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	552NL	WOS:000175626400025	12003753	DOAJ Gold, Green Published			2021-06-18	
J	Shi, R; Pryor, JD				Shi, R; Pryor, JD			Pathological changes of isolated spinal cord axons in response to mechanical stretch	NEUROSCIENCE			English	Article						axon; membrane sealing; spinal cord injury; neurotrauma; elongation; nerve repair	CNS WHITE MATTER; NA+-CA2+ EXCHANGER; MORPHOMETRIC ANALYSIS; POLYETHYLENE-GLYCOL; CONDUCTION-BLOCK; IN-VITRO; INJURY; 4-AMINOPYRIDINE; MODEL; TETRODOTOXIN	White matter strips extracted from adult guinea-pig spinal cords were maintained in vitro and studied physiologically using a double sucrose gap technique and anatomically using a horseradish peroxidase assay. The amplitude of compound action potentials was monitored continuously before, during, and after elongation. Three types of conduction blocks resulting from stretch injury were identified: an immediate, spontaneously reversible component. which may result from a transient increase in membrane permeability and consequent disturbance of ionic distributions a second component that was irreversible within 30 60 min of recording, perhaps resulting from profound axolemmal disruption; and a third component, which may be due to perturbation of the myelin sheath, that was reversible with application of 100 muM of the potassium channel blocker, 4-aminopyridine. The intensity of the conduction deficits correlated with the extent of initial stretch over a Call range of severity. Stimulus-response data indicate that mechanical damage to axons in stretch was evenly distributed across the caliber spectrum, Morphological examinations revealed that a small portion of axons exhibited membrane damage at 2 min following stretch and appeared to be largely sealed at 30 min after injury. Further, in the entire length of the cord strip subjected to stretch. axons closer to the surface were found to be more likely to suffer membrane damage, which distinguished stretch injury from compression injury. In summary. we have developed an in vitro model of axonal stretch that provides the ability to monitor changes in the properties of central myelinated axons following stretch injury in the absence of pathological variables related to vascular damage. This initial investigation found no evidence of secondary deterioration of axons in the first 30 min after stretch in vitro, although there was evidence of both transient and lasting physiological and anatomical damage to axons and their myelin sheaths. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Ctr Paralysis Res,Inst Appl Neurol, W Lafayette, IN 47907 USA	Shi, R (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Ctr Paralysis Res,Inst Appl Neurol, W Lafayette, IN 47907 USA.						Agrawal SK, 1996, J NEUROSCI, V16, P545; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; BEMENT SL, 1969, EXP NEUROL, V24, P147, DOI 10.1016/0014-4886(69)90012-0; Blight A, 1988, J Am Paraplegia Soc, V11, P26; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; BOENING JA, 1989, NEUROSCIENCE, V33, P263, DOI 10.1016/0306-4522(89)90205-4; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GOLDBERG WJ, 1986, J NEUROSCI, V6, P3144; GORDON TR, 1990, NEUROSCIENCE, V37, P829, DOI 10.1016/0306-4522(90)90112-H; KOESIS JD, 1986, NEUROBIOLOGY, V36, P117; Kuffler S., 1984, NEURON BRAIN; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Rosenberg LJ, 1996, BRAIN RES, V734, P349; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Shi RY, 1997, EXP NEUROL, V148, P495, DOI 10.1006/exnr.1997.6706; Smith DH, 1999, J NEUROSCI, V19, P4263; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; STYS PK, 1992, J NEUROSCI, V12, P430; Teng YD, 1997, J NEUROSCI, V17, P4359; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; WEST DC, 1983, J PHYSIOL-LONDON, V337, P37, DOI 10.1113/jphysiol.1983.sp014610	31	89	96	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	110	4					765	777	PII S0306-4522(01)00596-6	10.1016/S0306-4522(01)00596-6			13	Neurosciences	Neurosciences & Neurology	545YN	WOS:000175245300016	11934483				2021-06-18	
J	Steiner, T; Ringleb, P; Hacke, W				Steiner, T; Ringleb, P; Hacke, W			Treatment options for large hemispheric stroke	NEUROLOGY			English	Article							SEVERE HEAD-INJURY; CEREBRAL-ARTERY OCCLUSION; INCREASED INTRACRANIAL-PRESSURE; TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; TRANSTENTORIAL HERNIATION; DECOMPRESSIVE CRANIECTOMY; FUNCTIONAL RECOVERY; MILD HYPOTHERMIA; BARBITURATE COMA	Some stroke patients suffering acute middle cerebral artery (MCA) infarction develop massive brain edema and herniation, a condition known as malignant MCA infarction. Severe swelling increases intracranial pressure (ICP) and leads to progressive brainstem dysfunction. Once ICP reaches critical values (> 30 mm Hg) herniation occurs, usually within 2 to 5 days. Patients rarely survive (80% mortality) with standard treatment, and those who do are often severely disabled. Malignant MCA infarction is often missed by neurologists, despite well-defined clinical and neuroimaging (CT scan) diagnostic criteria. After diagnosis, conventional treatments such as osmotherapy, barbiturates, buffers, and hyperventilation center on reducing ICP. The goal of hyperosmolar therapy is to increase the serum osmolarity to approximately 315-320 mOsm/L. Enteric glycerol is used routinely to reduce ICP. In more severe cases and when glycerol fails, mannitol may be administered. Other therapies are also available, including hypertonic saline solution, THAM (Tris-hydroxy-methyl-aminomethane) buffer, and high-dose barbiturates. Hyperventilation also helps reduce ICP. All measures work effectively for a short time only. Other approaches to control elevated ICP, including decompression surgery and hypothermia, have shown promising results. In the Heidelberg decompression surgery trial, mortality in surgically treated patients was significantly lower (32%) than in non-treated patients (76%) despite conventional treatment. Importantly, of the surviving treated patients, 66% were rated independent with only mild to moderate disability. Moderate hypothermia (33-36 degreesC) has recently been shown to be effective in severe MCA infarction. Hypothermia induction within 14 hours of ischemic injury and maintained for 72 hours significantly reduced ICP and mortality (44%).	Univ Klinikum Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany	Hacke, W (corresponding author), Univ Klinikum Heidelberg, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Steiner, Thorsten/L-2868-2018; Steiner, Thorsten/A-7391-2014; Hacke, Werner/ABE-8661-2020	Steiner, Thorsten/0000-0002-5080-8222; 			AKIOKA T, 1976, INTRACRANIAL PRESSUR, P219; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; BELL BA, 1987, LANCET, V1, P66; BOUMA GJ, 1992, J NEUROTRAUMA S1, V9, P333; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHIARA O, 1987, CRIT CARE MED, V15, P995, DOI 10.1097/00003246-198711000-00001; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; DORFLER A, 1996, J NEUROSURG, V85, P853; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; GARCIASOLA R, 1991, ACTA NEUROCHIR, V109, P114, DOI 10.1007/BF01403005; GRECO T, 1935, ARCH ITAL CHIR, V39, P757; GREENWOOD J, 1968, JOHNS HOPKINS MED J, V122, P254; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; IVAMOTO HS, 1974, STROKE, V5, P365, DOI 10.1161/01.STR.5.3.365; JENNETT B, 1975, LANCET, V1, P480; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KING AB, 1951, J NEUROSURG, V8, P536, DOI 10.3171/jns.1951.8.5.0536; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NAU R, 1992, EUR J CLIN PHARMACOL, V42, P181, DOI 10.1007/BF00278481; NUSSBAUM ES, 1991, NEUROSURGERY, V29, P62, DOI 10.1227/00006123-199107000-00010; OJEMANN RG, 1988, SURG MANAGEMENT CERE; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; Reid WL, 1940, SURGERY, V8, P756; RENGACHARY S, 1985, NEUROSURGERY, P1267; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SAITO I, 1987, STROKE, V18, P863, DOI 10.1161/01.STR.18.5.863; SCARCELLA G, 1956, J NEUROSURG, V13, P366; SCHNEIDER RC, 1952, J NEUROSURG, V9, P495, DOI 10.3171/jns.1952.9.5.0495; Schwab S, 1997, NEUROLOGY, V48, P1608, DOI 10.1212/WNL.48.6.1608; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHAW CM, 1959, ARCH NEUROL-CHICAGO, V1, P161; STEIGER HJ, 1991, ACTA NEUROCHIR, V111, P73, DOI 10.1007/BF01400491; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; Tsuruno Takashi, 1993, Neurological Surgery, V21, P823; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; YOUNG PH, 1982, SOUTHERN MED J, V75, P473, DOI 10.1097/00007611-198204000-00025	54	89	98	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	SEP 11	2001	57	5		2			S61	S68		10.1212/WNL.57.suppl_2.S61			8	Clinical Neurology	Neurosciences & Neurology	471PP	WOS:000170938000013	11552058				2021-06-18	
J	Friedman, JA; Ebersold, MJ; Quast, LM				Friedman, JA; Ebersold, MJ; Quast, LM			Post-traumatic cerebrospinal fluid leakage	WORLD JOURNAL OF SURGERY			English	Article							TEMPORAL BONE-FRACTURES; PROPHYLACTIC ANTIBIOTICS; MANAGEMENT; RHINORRHEA; METAANALYSIS; FISTULA; REPAIR; FOSSA	Posttraumatic cerebrospinal fluid (CSF) leakage frequently complicates skull base fractures. While most CSF leaks will cease without treatment, patients with persistent CSF leaks may be at increased risk for meningitis, and many will require surgical intervention. We reviewed the medical records of 51 patients treated between 1984 and 1998, with CSF leaks that persisted for 24 hours or longer after head trauma. Twenty-eight patients (53%) had spontaneous resolution of the leakage at an average of 5 days. Twenty-three patients (47%) required surgery. Eight patients (16%) had occult leaks presenting with recurrent meningitis at an average of 6.5 years posttrauma. Forty-three (84%) patients with CSF leaks had an associated skull fracture, most commonly involving the frontal sinus, while only 18 patients (35%) had parenchymal brain injury or extra-axial hematoma. Eight patients (16%) had delayed leaks at an average of 13 days posttrauma. Among patients with clinically evident CSF leakage the frequency of meningitis was 10% with antibiotic prophylaxis, and 21% without antibiotic prophylaxis. Thus, prophylactic antibiotic administration halved risk of meningitis. A variety of surgical approaches was used, with minimal morbidity. Three of 23 surgically treated patients (13%) required additional surgery for continued leakage. Patients with CSF leaks that persist greater than 24 hours are at risk for meningitis, and many will require surgical intervention. Prophylactic antibiotics may be effective and should be considered in this group of patients. Patients with skull fractures involving the skull base or frontal sinus should be followed for delayed leakage. Surgical outcome is excellent.	Mayo Clin & Mayo Fdn, Dept Neurol Surg, Rochester, MN 55905 USA	Ebersold, MJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol Surg, Mayo Bldg,E6B,200 1st St SW, Rochester, MN 55905 USA.						Anand Vijay K., 1995, Rhinology (Utrecht), V33, P212; APPELBAUM E, 1960, JAMA-J AM MED ASSOC, V173, P1818, DOI 10.1001/jama.1960.03020340036010; Brodie HA, 1997, ARCH OTOLARYNGOL, V123, P749; Brodie HA, 1997, AM J OTOL, V18, P188; CHANDLER JR, 1983, OTOLARYNG CLIN N AM, V16, P623; Choi D, 1996, BRIT J NEUROSURG, V10, P571, DOI 10.1080/02688699646880; CLEMENZA JW, 1995, J ORAL MAXIL SURG, V53, P1004, DOI 10.1016/0278-2391(95)90114-0; Frazee RC, 1988, POSTGRAD MED, V83, P273; JEFFERSON A, 1972, BRIT J SURG, V59, P585, DOI 10.1002/bjs.1800590802; Kaufman B A, 1990, Infect Dis Clin North Am, V4, P677; Lee D, 1998, LARYNGOSCOPE, V108, P816, DOI 10.1097/00005537-199806000-00008; LEECH PJ, 1973, LANCET, V1, P1013; Lewin W, 1964, Clin Neurosurg, V12, P237; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; MACGEE EE, 1970, J NEUROSURG, V33, P312, DOI 10.3171/jns.1970.33.3.0312; MCGUIRT WF, 1995, LARYNGOSCOPE, V105, P359, DOI 10.1288/00005537-199504000-00003; Mendizabal G R, 1992, Rev Laryngol Otol Rhinol (Bord), V113, P423; MINCY JE, 1966, J TRAUM, V6, P618, DOI 10.1097/00005373-196609000-00007; Ng M, 1998, ARCH OTOLARYNGOL, V124, P1125, DOI 10.1001/archotol.124.10.1125; OKADA J, 1991, SURG NEUROL, V35, P213, DOI 10.1016/0090-3019(91)90073-I; Ommaya AK, 1996, NEUROSURGERY, V2, P2773; Sethi D. S., 1996, Annals Academy of Medicine Singapore, V25, P724; SPETZLER RF, 1978, J NEUROSURG, V49, P393, DOI 10.3171/jns.1978.49.3.0393; Villalobos T, 1998, CLIN INFECT DIS, V27, P364, DOI 10.1086/514666	24	89	98	2	9	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	AUG	2001	25	8					1062	1066		10.1007/s00268-001-0059-7			5	Surgery	Surgery	460YF	WOS:000170337300016	11571972				2021-06-18	
J	Bondarenko, A; Chesler, M				Bondarenko, A; Chesler, M			Rapid astrocyte death induced by transient hypoxia, acidosis, and extracellular ion shifts	GLIA			English	Article						ischemia; BCECF; potassium; propidium iodide; extracellular pH	RAT SPINAL-CORD; PROPIDIUM IODIDE; INTRACELLULAR PH; NEURONAL DEATH; MEMBRANE INTEGRITY; SIMULATED ISCHEMIA; CALCIUM ACTIVITY; BRAIN ISCHEMIA; MOUSE NEURONS; CELL-DEATH	Death of astrocytes requires hours to days in injury models that use hypoxia, acidosis, or calcium paradox protocols. These methods do not incorporate the shifts in extracellular K+, Na+, Cl-, and Ca2+ that accompany acute brain insults. We studied astrocyte survival after exposure to hypoxic, acidic, ion-shifted Ringer (HAIR), with respective [Ca2+], [K+], [Na+], [Cl-], and [HCO3-] of 0.13, 65, 51, 75, and 13 mM (15% CO2/85% N-2, pH 6.6). Intracellular pH (pH(i)) was monitored with the fluorescent dye BCECF. Cell death was indicated by a steep fall in the pH-insensitive, 440-nm-induced fluorescence (F440) and was confirmed by propidium iodide staining. After 15-40-min HAIR exposure, reperfusion with standard Ringer caused death of most cultured (and acutely dissociated) astrocytes within 20 min. Cell death was not prevented if low Ca2+ was maintained during reperfusion. Survival fell with increased HAIR duration, elevated temperature, or absence of external glucose. Comparable durations of hypoxia, acidosis, or ion shifts alone did not lead to acute cell death, while modest loss was noted when acidosis was paired with either hypoxia or ion shifts. Severe cell loss required the triad of hypoxia, acidosis, and ion shifts. Intracellular pH was significantly higher in HAIR media, compared with solutions of low pH alone or with low pH plus hypoxia. These results indicate that astrocytes can be killed rapidly by changes in the extracellular microenvironment that occur in settings of traumatic and ischemic brain injury. GLIA 34:134-142, 2001. (C) 2001 Wiley-Liss, Inc.	NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA	Chesler, M (corresponding author), NYU, Sch Med, Dept Physiol & Neurosci, 550 1st Ave, New York, NY 10016 USA.		Bondarenko, Alexander I/B-3080-2013	Chesler, Mitchell/0000-0002-3189-8234	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34906] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034906] Funding Source: NIH RePORTER		Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BEVENSEE MO, 1995, J NEUROSCI METH, V58, P61, DOI 10.1016/0165-0270(94)00159-E; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; BONDARENKO A, 2000, SOC NEUR ABS, V26, P1893; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844; CHESLER M, 1991, BRAIN RES, V556, P71, DOI 10.1016/0006-8993(91)90548-A; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; DUGAN LL, 1995, J NEUROSCI, V15, P4545; Gido G, 1997, STROKE, V28, P206, DOI 10.1161/01.STR.28.1.206; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; Giffard RG, 2000, J NEUROSCI, V20, P1001, DOI 10.1523/JNEUROSCI.20-03-01001.2000; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HAUN SE, 1992, BRAIN RES, V593, P45, DOI 10.1016/0006-8993(92)91261-C; HERMAN B, 1988, FASEB J, V2, P146; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KELLEHER JA, 1993, STROKE, V24, P855, DOI 10.1161/01.STR.24.6.855; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMLEE MH, 1992, GLIA, V5, P56, DOI 10.1002/glia.440050109; KRAIG RP, 1985, BRAIN RES, V342, P281, DOI 10.1016/0006-8993(85)91127-8; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831; KRAIG RP, 1986, AM J PHYSIOL, V250, P348; Largo C, 1996, NEUROL RES, V18, P445; LITT L, 1985, J CEREBR BLOOD F MET, V5, P537, DOI 10.1038/jcbfm.1985.81; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Matsuda T, 1996, EUR J NEUROSCI, V8, P951, DOI 10.1111/j.1460-9568.1996.tb01582.x; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MORIYA T, 1994, J NEUROTRAUM, V11, P255, DOI 10.1089/neu.1994.11.255; NEDERGAARD M, 1991, J NEUROSCI, V11, P2489; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; Rose CR, 1998, J NEUROSCI, V18, P3554; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; SOCHOCKA E, 1994, BRAIN RES, V638, P21, DOI 10.1016/0006-8993(94)90628-9; STEWART PA, 1978, RESP PHYSIOL, V33, P9, DOI 10.1016/0034-5687(78)90079-8; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE FW, 1992, J NEUROSCI, V12, P1781; VONHANWEHR R, 1986, J NEUROCHEM, V46, P331; XU Y, 1991, STROKE, V22, P1303, DOI 10.1161/01.STR.22.10.1303; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1982, BRAIN RES, V253, P115, DOI 10.1016/0006-8993(82)90678-3; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3	55	89	92	0	9	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	APR 15	2001	34	2					134	142		10.1002/glia.1048			9	Neurosciences	Neurosciences & Neurology	429NH	WOS:000168523500007	11307162				2021-06-18	
J	Cummins, RA				Cummins, RA			The subjective well-being of people caring for a family member with a severe disability at home: a review	JOURNAL OF INTELLECTUAL & DEVELOPMENTAL DISABILITY			English	Article							CHRONIC CHILDHOOD ILLNESS; TRAUMATIC BRAIN INJURY; WOMENS MULTIPLE ROLES; LIFE SATISFACTION; DISABLED-CHILDREN; MENTALLY-ILL; PSYCHOLOGICAL DISTRESS; DEPRESSED-PATIENTS; CYSTIC-FIBROSIS; SOCIAL SUPPORT	This review concerns the life quality of people caring for a relative with a severe disability within their family. It involves the balance between the advantages such care brings to the care recipient and the costs borne by the family. A brief history indicates that the forces that encourage family care are minimally concerned with family welfare. Moreover, an analysis of both qualitative and quantitative data indicates that primary caregivers are at considerable risk of high stress, clinical depression, and abnormally low subjective quality of life. It is concluded that increased public expenditure directed to the care of people with severe disability is urgently required.	Deakin Univ, Sch Psychol, Melbourne, Vic 3125, Australia	Cummins, RA (corresponding author), Deakin Univ, Sch Psychol, Melbourne, Vic 3125, Australia.			Cummins, Robert/0000-0001-9014-7193			AMMERMAN RT, 1988, J FAMILY VIOLENCE, V3, P53; Archbold P G, 1980, J Gerontol Nurs, V6, P79; BAUMANIS D, 1970, CAN MENT HEALTH, V18, P23; BAUMGARTEN M, 1992, J CLIN EPIDEMIOL, V45, P61, DOI 10.1016/0895-4356(92)90189-T; BENTELSPACHER CE, 1994, FAM SOC-J CONTEMP H, V75, P287, DOI 10.1177/104438949407500504; BERGWEGER M, 1996, CARING ELDERLY PAREN; Bethoux F, 1996, INT J REHABIL RES, V19, P291, DOI 10.1097/00004356-199612000-00001; Bindoff HP, 1997, J FAMILY STUDIES, V3, P183; BOGGS EM, 1992, MENT RETARD, V30, P178; BOUMA R, 1990, J CLIN PSYCHOL, V46, P722, DOI 10.1002/1097-4679(199011)46:6<722::AID-JCLP2270460605>3.0.CO;2-6; BRANHOLM IB, 1992, SCAND J SOC MED, V20, P37; BRESLAU N, 1982, AM J DIS CHILD, V136, P682, DOI 10.1001/archpedi.1982.03970440026007; Browne G, 1996, Aust N Z J Ment Health Nurs, V5, P120; BURGENER SC, 1994, J RELIG HEALTH, V33, P175, DOI 10.1007/BF02354538; Christensen KA, 1998, HEALTH PSYCHOL, V17, P163, DOI 10.1037/0278-6133.17.2.163; Conoley JC, 1996, J LEARN DISABIL-US, V29, P662, DOI 10.1177/002221949602900610; Cummins R. A., 1997, COMPREHENSIVE QUALIT; Cummins RA, 1998, SOC INDIC RES, V43, P307, DOI 10.1023/A:1006831107052; CUMMINS RA, 1995, SOC INDIC RES, V35, P179, DOI 10.1007/BF01079026; Cummins RA, 1996, SOC INDIC RES, V38, P303, DOI 10.1007/BF00292050; CUMMINS RA, 2001, IN PRESS METHODOLOGI; DEIMLING GT, 1986, J GERONTOL, V41, P778, DOI 10.1093/geronj/41.6.778; Dyson LL, 1996, J LEARN DISABIL, V29, P280, DOI 10.1177/002221949602900306; FADDEN G, 1987, BRIT J PSYCHIAT, V150, P285, DOI 10.1192/bjp.150.3.285; FEINSTEIN C, 1986, ENTOURAGE, V1, P13; FENGLER AP, 1979, GERONTOLOGIST, V19, P175, DOI 10.1093/geront/19.2.175; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GOLODETZ A, 1969, MED CARE, V7, P385, DOI 10.1097/00005650-196909000-00006; Grant G, 1998, J INTELL DISABIL RES, V42, P58, DOI 10.1046/j.1365-2788.1998.00079.x; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; Hatton C, 1998, BRIT J SOC WORK, V28, P821; HERRMAN H, 1994, QUALITY LIFE ASSESSM, P131; Hodapp RM, 1998, J INTELL DISABIL RES, V42, P331, DOI 10.1046/j.1365-2788.1998.00148.x; HOLROYD J, 1986, J CLIN PSYCHOL, V42, P552, DOI 10.1002/1097-4679(198607)42:4<552::AID-JCLP2270420403>3.0.CO;2-8; Jenkins JH, 1999, BRIT J PSYCHIAT, V174, P31, DOI 10.1192/bjp.174.1.31; JOHNSON L, 1999, AGE             1026, P11; KNIGHT RG, 1998, AUSTR NZ J PUBLIC HL, V22, P96; KROPF NP, 1993, J GERONTOL SOC WORK, V21, P25; Lawenius M, 1996, SOC BEHAV PERSONAL, V24, P195, DOI 10.2224/sbp.1996.24.2.195; LAWTON MP, 1975, J GERONTOL, V30, P85, DOI 10.1093/geronj/30.1.85; LUBETSKY MJ, 1995, MENT RETARD, V33, P251; MARSH DT, 1996, PSYCHIATR REHABIL J, V20, P1; MOHIDE EA, 1993, DEPRESSION SOCIAL EN, P289; MORONEY RM, 1983, HOME HEALTH CARE SER, V3, P188; Nirje B., 1976, CHANGING PATTERNS RE, P231; NIRJE B, 1970, J MENTAL SUBNORM DEC, P64; Rosenvinge H, 1998, INT J GERIATR PSYCH, V13, P8, DOI 10.1002/(SICI)1099-1166(199801)13:1<8::AID-GPS717>3.3.CO;2-Z; Scheerenberger R. C., 1983, HIST MENTAL RETARDAT; SELZTER MM, 1995, J INTELLECTURAL DISA, V39, P408; SHANAS E, 1979, GERONTOLOGIST, V19, P169, DOI 10.1093/geront/19.2.169; SHERWOOD S, 1975, LONG TERM CARE HDB R, P3; Singer GHS, 1989, SUPPORT CAREGIVING F, P3; SINGHI PD, 1990, BRIT J MED PSYCHOL, V63, P173, DOI 10.1111/j.2044-8341.1990.tb01610.x; SMITH J, 1993, SOC PSYCH PSYCH EPID, V28, P11, DOI 10.1007/BF00797827; Spangenberg JJ, 1999, J PSYCHOL, V133, P253, DOI 10.1080/00223989909599738; Stainton T, 1998, J INTELLECT DEV DIS, V23, P57, DOI 10.1080/13668259800033581; Stengard E, 1997, NORD J PSYCHIAT, V51, P159, DOI 10.3109/08039489709109090; Stephens MAP, 1999, CURR DIR PSYCHOL SCI, V8, P149, DOI 10.1111/1467-8721.00035; Stuckey JC, 1996, GERONTOLOGIST, V36, P686, DOI 10.1093/geront/36.5.686; THOMPSON EH, 1982, FAM RELAT, V31, P379, DOI 10.2307/584170; TOWNSEND A, 1989, PSYCHOL AGING, V4, P393, DOI 10.1037/0882-7974.4.4.393; TRUTE B, 1995, J CHILD PSYCHOL PSYC, V36, P1225, DOI 10.1111/j.1469-7610.1995.tb01367.x; Tymchuk Alexander J., 1994, Australia and New Zealand Journal of Developmental Disabilities, V19, P111; Voepel-Lewis T, 1990, ANNA J, V17, P427; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Warfield ME, 1999, J DEV BEHAV PEDIATR, V20, P9, DOI 10.1097/00004703-199902000-00002; Weisz V, 1996, AM PSYCHOL, V51, P1239; Whitlatch CJ, 1997, J AGING HEALTH, V9, P222; WINEFIELD HR, 1993, SCHIZOPHRENIA BULL, V19, P619, DOI 10.1093/schbul/19.3.619; WINEFIELD HR, 1994, INT J STRESS MANAGE, V1, P283, DOI 10.1007/BF01857997; Winzer M., 1990, CHILDREN EXCEPTIONAL; Wolfensberger W., 1972, PRINCIPLE NORMALIZAT; WOOD V, 1969, J GERONTOL, V24, P465, DOI 10.1093/geronj/24.4.465; Yau MKS, 1999, BRIT J DEV DISABIL, V45, P38, DOI 10.1179/096979599799156028	74	89	89	0	11	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	1366-8250			J INTELLECT DEV DIS	J. Intellect. Dev. Dis.	MAR	2001	26	1					83	100		10.1080/13668250020032787			18	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	461LB	WOS:000170364800006					2021-06-18	
J	Drake, AI; Gray, N; Yoder, S; Pramuka, M; Llewellyn, M				Drake, AI; Gray, N; Yoder, S; Pramuka, M; Llewellyn, M			Factors predicting return to work following mild traumatic brain injury: A discriminant analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognition; mild traumatic brain injury; occupational functioning; outcome; return to work	MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; RATING-SCALE; CONCUSSION; SYMPTOMS; SEQUELAE; RECOVERY; PROGRAM; COMA	Studies of mild traumatic brain injury (MTBI) suggest that most individuals recover rapidly and return to their everyday activities. However, a percentage of MTBI patients report persistent problems with cognitive, physical, and emotional symptoms. There is also evidence that some experience changes in occupational functioning following MTBI. The current study used a stepwise discriminant function analysis (DFA) to examine the role of injury severity variables, cognitive performance, and ratings of symptoms of TBI in predicting work status following MTBI. Subjects included 121 MTBI patients who were all active-duty military personnel. The stepwise DFA revealed that age and three cognitive variables (verbal memory, verbal fluency, and a speed test of planning and strategy) were predictive of work status 3-15 months following a documented MTBI, correctly classifying work status 68.8% of the time. A cross-validation DFA was conducted, with a 66.1% correct classification rate. These findings highlight the importance of cognitive impairments in identifying those at risk for occupational impairment following MTBI.	USN, Med Ctr, Dept Neurosci, Def & Vet Head Injury Program, San Diego, CA 92152 USA	Drake, AI (corresponding author), USN, Med Ctr, Dept Neurosci, Def & Vet Head Injury Program, San Diego, CA 92152 USA.						Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Benton A.L., 1983, VERBAL FLUENCY MULTI; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BOHNEN N, 1992, NEUROSURGERY, V30, P692; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DELIS D, 1983, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; EKSTROM RB, 1976, MAP PLANNING TEST MA; EKSTRON RB, 1976, MAZE LERNING TEST MA; Fleming J, 1999, BRAIN INJURY, V13, P417; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gentilini M., 1989, MILD HEAD INJURY; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; GRONWALL D, 1989, MILD HEAD INJURY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Heaton R. K, 1981, WISCONSIN CARD SORTI; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1989, MILD HEAD INJURY; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS, 1989, MILD HEAD INJURY; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; PONSFORD J, 1994, BRIAN INJURY, V9, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R. M., 1989, MILD HEAD INJURY; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTHERFORD WH, 1989, MILD HEAD INJURY; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	55	89	89	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1103	1112		10.1097/00001199-200010000-00004			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800004	10970931				2021-06-18	
J	Guhring, H; Gorig, M; Ates, M; Coste, O; Zeilhofer, HU; Pahl, A; Rehse, K; Brune, K				Guhring, H; Gorig, M; Ates, M; Coste, O; Zeilhofer, HU; Pahl, A; Rehse, K; Brune, K			Suppressed injury-induced rise in spinal prostaglandin E-2 production and reduced early thermal hyperalgesia in iNOS-deficient mice	JOURNAL OF NEUROSCIENCE			English	Article						nitric oxide; inducible nitric oxide synthase; zymosan; thermal hyperalgesia; paw edema; spinal microdialysis; L-NIL; RE-2047; prostaglandins; cyclooxygenase	NITRIC-OXIDE SYNTHASE; CYCLOOXYGENASE-2 MESSENGER-RNA; TRAUMATIC BRAIN INJURY; PERIPHERAL INFLAMMATION; SECONDARY HYPERALGESIA; JOINT INFLAMMATION; UP-REGULATION; SUBSTANCE-P; RAT; EXPRESSION	It is widely accepted that peripheral injury increases spinal inducible cyclooxygenase (COX-2) expression and prostaglandin E-2 (PGE(2)) formation as key mediators of nociceptive sensitization. Here, we used inducible nitric oxide synthase (iNOS) gene-deficient (iNOS-/-) mice to determine the contribution of iNOS-derived nitric oxide (NO) to this process. iNOS-/- mice exhibited reduced thermal hyperalgesia after zymosan injection. Spinal NO and PGE2 formation both remained at baseline levels, in contrast to wild-type (wt) mice. In wt mice reduced hyperalgesia similar to that seen in iNOS-/- mice was induced by local spinal, but not by systemic treatment with the iNOS inhibitor L-NIL, suggesting that the reduced heat sensitization in iNOS-/- mice was attributable to the lack of spinal rather than peripheral iNOS. Two additional observations indicate that the antinociceptive effects of iNOS inhibition are dependent on a loss of stimulation of PG synthesis. First, intrathecal injection of the COX inhibitor indomethacin, which exerted pronounced antinociceptive effects in wt mice, was completely ineffective in iNOS-/- mice. Second, treatment with the NO donor RE-2047 not only completely restored spinal PG production and thermal sensitization in iNOS-/- mice but also its sensitivity to indomethacin. In both types of mice induction of thermal hyperalgesia was accompanied by similar increases in COX-1 and COX-2 mRNA expression. The stimulation of PG production by NO therefore involves an increase in enzymatic activity, rather than an alteration of COX gene expression. These results indicate that NO derived from spinal iNOS acts as a fast inductor of spinal thermal hyperalgesia.	Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany; Dept Pharmaceut Chem, D-14195 Berlin, Germany	Guhring, H (corresponding author), Dept Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.		Zeilhofer, Hanns Ulrich/A-4600-2008; ates, mehmet/P-4503-2019	Zeilhofer, Hanns Ulrich/0000-0001-6954-4629; ates, mehmet/0000-0002-8310-1979			Aley KO, 1998, J NEUROSCI, V18, P7008; AMIR S, 1991, EUR J PHARMACOL, V203, P125, DOI 10.1016/0014-2999(91)90800-6; Andrew D, 1999, J NEUROPHYSIOL, V82, P2649; Barker JE, 1998, BRAIN RES, V804, P1, DOI 10.1016/S0006-8993(98)00603-9; Beiche F, 1998, INFLAMM RES, V47, P482, DOI 10.1007/s000110050362; Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7; Bley KR, 1998, TRENDS PHARMACOL SCI, V19, P141, DOI 10.1016/S0165-6147(98)01185-7; BRUNE K, 1994, DRUGS, V5, P21; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen XJ, 1999, J NEUROPHYSIOL, V81, P963; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Deckert-Schluter M, 1998, J IMMUNOL, V160, P3427; DECKERTSCHLUTER M, 1995, IMMUNOLOGY, V85, P408; Dirig DM, 1999, BRIT J PHARMACOL, V126, P1333, DOI 10.1038/sj.bjp.0702427; Downen M, 1999, J NEUROPATH EXP NEUR, V58, P12, DOI 10.1097/00005072-199901000-00002; Ebersberger A, 1999, NEUROSCIENCE, V93, P775, DOI 10.1016/S0306-4522(99)00164-5; Ferreira SH, 1996, INFLAMM RES, V45, P499, DOI 10.1007/BF02311085; Goettl VM, 1996, PAIN, V67, P435, DOI 10.1016/0304-3959(96)03155-7; Gonzalez-Hernandez T, 1999, J NEUROSCI RES, V55, P198, DOI 10.1002/(SICI)1097-4547(19990115)55:2<198::AID-JNR7>3.0.CO;2-M; GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927; HADDAD EB, 1995, EUR J PHARM-ENVIRON, V293, P287, DOI 10.1016/0926-6917(95)00032-1; Hamalainen MM, 1997, NEUROSCIENCE, V80, P821, DOI 10.1016/S0306-4522(97)00124-3; Hamilton LC, 1998, BRIT J PHARMACOL, V125, P335, DOI 10.1038/sj.bjp.0702077; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hay C, 1997, NEUROREPORT, V8, P1249, DOI 10.1097/00001756-199703240-00038; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Ichitani Y, 1997, NEUROREPORT, V8, P2949, DOI 10.1097/00001756-199709080-00028; Inoue T, 1997, J NEUROL SCI, V153, P1, DOI 10.1016/S0022-510X(97)00188-3; KAWABATA A, 1994, BRIT J PHARMACOL, V112, P547, DOI 10.1111/j.1476-5381.1994.tb13108.x; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P1528, DOI 10.1097/00000542-199906000-00005; Lawand NB, 1997, NEUROREPORT, V8, P895, DOI 10.1097/00001756-199703030-00016; Lee Sunhee C., 1996, Methods (Orlando), V10, P31, DOI 10.1006/meth.1996.0075; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MacNaughton WK, 1998, INT J RADIAT BIOL, V74, P255, DOI 10.1080/095530098141645; MALMBERG AB, 1993, PAIN, V54, P291, DOI 10.1016/0304-3959(93)90028-N; MELLER ST, 1994, NEUROPHARMACOLOGY, V33, P1471, DOI 10.1016/0028-3908(94)90051-5; MINAMI T, 1994, PAIN, V57, P217, DOI 10.1016/0304-3959(94)90226-7; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; Osborne MG, 1999, BRIT J PHARMACOL, V126, P1840, DOI 10.1038/sj.bjp.0702508; REHSE K, 1995, ARCH PHARM, V328, P71, DOI 10.1002/ardp.19953280113; Reichner JS, 1999, AM J PATHOL, V154, P1097, DOI 10.1016/S0002-9440(10)65362-X; Sahnoun Z, 1998, THERAPIE, V53, P315; SALVEMINI D, 1994, J CLIN INVEST, V93, P1940, DOI 10.1172/JCI117185; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; Salvemini D, 1997, CELL MOL LIFE SCI, V53, P576, DOI 10.1007/s000180050074; Shen T Y, 1977, Adv Drug Res, V12, P90; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Urban MO, 1999, PAIN, V81, P45, DOI 10.1016/S0304-3959(98)00265-6; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; YAKSH TL, 1993, AGENT ACTION SUPPL, V41, P89; Yamamoto T, 1997, NEUROREPORT, V8, P2179, DOI 10.1097/00001756-199707070-00018; Yang LC, 1996, PAIN, V67, P345, DOI 10.1016/0304-3959(96)03106-5; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P357, DOI 10.1038/sj.bjp.0700892	56	89	93	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 1	2000	20	17					6714	6720		10.1523/JNEUROSCI.20-17-06714.2000			7	Neurosciences	Neurosciences & Neurology	348VJ	WOS:000089006900044	10964977	Green Published, Green Accepted, Bronze			2021-06-18	
J	Bernal-Sprekelsen, M; Bleda-Vazquez, C; Carrau, RL				Bernal-Sprekelsen, M; Bleda-Vazquez, C; Carrau, RL			Ascending meningitis secondary to traumatic cerebrospinal fluid leaks	AMERICAN JOURNAL OF RHINOLOGY			English	Article							FRONTAL SKULL BASE; MANAGEMENT; RHINORRHEA; DIAGNOSIS; LESIONS	Cerebrospinal fluid (CSF) leakage may cause immediate or delayed complications, such as ascending meningitis and brain abscess, potentially lethal complications that may appear years or decades after the trauma. Thus, the initial treatment of a CSF fistula may decisively influence long-term outcome. In a retrospective study including 1036 consecutive patients presenting with severe cranial trauma from May 1990 to March 1996, we identified 27 patients (2.6%) with CSF fistulas. Patients with a post-traumatic CSF leak were most commonly males between 15 and 40 years involved in a motor vehicle accident. The most common sites of injury were the frontal area and anterior skull base for those patients with rhinorrhea and the temporal bone for those patients with otorrhea. A transcranial repair was used for large cranial base defects (n = 10), while conservative treatment, comprised of bedrest, lumbar drainage, and medications, was used for smaller fistulas (n = 17). Four patients (40%) initially treated with a transcranial repair, and five patients (29%) initially treated conservatively, developed a meningitis. Therefore, neither the conservative approach nor the transcranial repair was able to prevent this considerable incidence of ascending meningitis. We believe that the high incidence of meningitis is not acceptable; thus, we are now evaluating early intervention using endoscopic techniques for the identification and/or repair of post-traumatic fistulas.	Hosp Clin Barcelona, Dept Otolaryngol, Barcelona, Spain	Bernal-Sprekelsen, M (corresponding author), Hosp Clin Barcelona, Serv ORL, C Villarroel 170, E-08036 Barcelona, Spain.		Bernal-Sprekelsen, Manuel/AAJ-7568-2021; Bernal-Sprekelsen, Manuel/AAG-4299-2021	Bernal-Sprekelsen, Manuel/0000-0001-8191-9833			Anand Vijay K., 1995, Rhinology (Utrecht), V33, P212; BERNAL M, 1994, CIRUGIA ENDOSCOPICA, P212; Choi D, 1996, BRIT J NEUROSURG, V10, P571, DOI 10.1080/02688699646880; Elverland Hans H., 1996, Tidsskrift for den Norske Laegeforening, V116, P3098; Gjuric M, 1998, HNO, V46, P205, DOI 10.1007/s001060050228; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; Kelley TF, 1996, NEUROSURGERY, V39, P743, DOI 10.1097/00006123-199610000-00019; KESSLER L, 1983, VERLETZUNGEN GESICHT; MESSERKLINGER W, 1972, HNO-WEGW FACHARZT PR, V20, P268; Moura-Ribeiro M V, 1992, Arq Neuropsiquiatr, V50, P199; Oberascher G, 1998, HNO, V46, P197, DOI 10.1007/s001060050225; Schick B, 1998, LARYNGO RHINO OTOL, V77, P144, DOI 10.1055/s-2007-996949; Sethi D. S., 1996, Annals Academy of Medicine Singapore, V25, P724; Simmen D, 1998, LARYNGO RHINO OTOL, V77, P264, DOI 10.1055/s-2007-996972; SIMON H, 1970, LARYN RHINOL OTOL, V59, P54; Spangenberg P, 1997, ANASTH INTENSIV NOTF, V32, P105, DOI 10.1055/s-2007-995018; Wax MK, 1997, OTOLARYNG HEAD NECK, V116, P442, DOI 10.1016/S0194-5998(97)70292-4	17	89	93	0	3	OCEAN SIDE PUBLICATIONS INC	PROVIDENCE	95 PITMAN ST, PROVIDENCE, RI 02906 USA	1050-6586			AM J RHINOL	Am. J. Rhinol.	JUL-AUG	2000	14	4					257	259		10.2500/105065800779954473			3	Otorhinolaryngology	Otorhinolaryngology	347VG	WOS:000088949400009	10979500				2021-06-18	
J	Beer, R; Franz, G; Schopf, M; Reindl, M; Zelger, B; Schmutzhard, E; Poewe, W; Kampfl, A				Beer, R; Franz, G; Schopf, M; Reindl, M; Zelger, B; Schmutzhard, E; Poewe, W; Kampfl, A			Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; Fas; Fas ligand; traumatic brain injury; TUNEL	TUMOR-NECROSIS-FACTOR; CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; CLOSED-HEAD INJURY; MULTIPLE-SCLEROSIS; MEMORY DEFICITS; MESSENGER-RNA; AMINO-ACIDS; TNF-ALPHA; RELEASE	Apoptotic cell death plays an important role in the cascade of neuronal degeneration after traumatic brain injury (TBI), but the underlying mechanisms are not fully understood. However, increasing evidence suggests that expression of Fas and its ligand (FasL) could play a major role in mediating apoptotic cell death in acute and chronic neurologic disorders. To further investigate the temporal pattern of Fas and Fast expression after experimental TBI in the rat, male Sprague Dawley rats were subjected to unilateral cortical impact injury. The animals were killed and examined for Fas and FasL protein expression and for immunohistologic analysis at intervals from 15 minutes to 14 days after injury. Increased Fas and FasL immunoreactivity was seen in the cortex ipsilateral to the injury site from 15 minutes to 72 hours after the trauma, respectively. Immunohistologic investigation demonstrated a differential pattern of Fas and FasL expression in the cortex, respectively: increased Fas immunoreactivity was seen in cortical astrocytes and neurons from 15 minutes to 72 hours after the injury. In contrast, increased expression of FasL was seen in cortical neurons, astrocytes, and microglia from 15 minutes to 72 hours after impact injury. Concurrent double-labeling examinations using terminal deoxynucleotidyl tranferase-mediated deoxyuridine-biotin nick end labeling identified Fas- and FasL-immunopostive cells with high frequency in the cortex ipsilateral to the injury site. In contrast, there was no evidence of Fas- and FasL-immunopositive cells in the hippocampus ipsilateral to the injury site up to 14 days after the trauma. Further, Fas and Fast immunoreactivity was absent in the contralateral cortex and hippocampus at all time points investigated. These results reveal induction of Fas and Fast expression in the cortex after TBI in the rat. Further, these data implicate an involvement of Fas and Fast in the pathophysiologic mechanism of apoptotic neurodegeneration after TBI. Last, these data suggest that strategies aimed to repress posttraumatic Fas- and Fast-induced apoptosis may open new perspectives for the treatment of TBI.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Dermatol, A-6020 Innsbruck, Austria	Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.		Reindl, Markus/ABE-5880-2020	Reindl, Markus/0000-0003-2817-1402			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Becher B, 1998, TRENDS NEUROSCI, V21, P114, DOI 10.1016/S0166-2236(97)01180-6; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cheema ZF, 1999, J NEUROSCI, V19, P1754; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; DSOUZA SD, 1996, J EXP MED, V181, P393; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fassbender K, 1999, J NEUROIMMUNOL, V93, P122, DOI 10.1016/S0165-5728(98)00210-0; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kokaia Z, 1998, NEUROSCIENCE, V84, P1113, DOI 10.1016/S0306-4522(97)00579-4; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mincheff M, 1998, VOX SANG, V74, P113, DOI 10.1046/j.1423-0410.1998.7420113.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NISHIMURA T, 1995, ADV SPACE RES, V16, P137, DOI 10.1016/0273-1177(95)00393-S; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, P494; RINK A, 1995, AM J PATHOL, V147, P1575; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Runic R, 1996, J CLIN ENDOCR METAB, V81, P3119, DOI 10.1210/jc.81.8.3119; Saas P, 1999, J IMMUNOL, V162, P2326; Shin SW, 1998, J NEUROCHEM, V71, P1773; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tachibana O, 1996, ACTA NEUROPATHOL, V92, P431, DOI 10.1007/s004010050542; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tarkowski E, 1999, STROKE, V30, P321, DOI 10.1161/01.STR.30.2.321; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	71	89	99	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2000	20	4					669	677		10.1097/00004647-200004000-00004			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	304CW	WOS:000086466000004	10779011	Bronze			2021-06-18	
J	Goforth, PB; Ellis, EF; Satin, LS				Goforth, PB; Ellis, EF; Satin, LS			Enhancement of AMPA-mediated current after traumatic injury in cortical neurons	JOURNAL OF NEUROSCIENCE			English	Article						glutamate; traumatic brain injury; AMPA receptor; desensitization; excitotoxicity; cortex	AMINO-ACID RECEPTORS; DEPENDENT PROTEIN-KINASE; RAT HIPPOCAMPAL SLICES; CENTRAL NERVOUS-SYSTEM; STRETCH-INDUCED INJURY; BRAIN INJURY; GLUTAMATE RECEPTORS; KAINATE RECEPTORS; SYNAPTIC TRANSMISSION; NEOCORTICAL NEURONS	Overactivation of ionotropic glutamate receptors has been implicated in the pathophysiology of traumatic brain injury. Using an in vitro cell injury model, we examined the effects of stretch-induced traumatic injury on the AMPA subtype of ionotropic glutamate receptors in cultured neonatal cortical neurons. Recordings made using the whole-cell patch-clamp technique revealed that a subpopulation of injured neurons exhibited an increased current in response to AMPA. The current-voltage relationship of these injured neurons showed an increased slope conductance but no change in reversal potential compared with uninjured neurons. Additionally, the EC50 values of uninjured and injured neurons were nearly identical. Thus, current potentiation was not caused by changes in the voltage-dependence, ion selectivity, or apparent agonist affinity of the AMPA channel. AMPA-elicited current could also be fully inhibited by the application of selective AMPA receptor antagonists, thereby excluding the possibility that current potentiation in injured neurons was caused by the activation of other, nondesensitizing receptors. The difference in current densities between control and injured neurons was abolished when AMPA receptor desensitization was inhibited by the coapplication of AMPA and cyclothiazide or by the use of kainate as an agonist, suggesting that mechanical injury alters AMPA receptor desensitization. Reduction of AMPA receptor desensitization after brain injury would be expected to further exacerbate the effects of increased postinjury extracellular glutamate and contribute to trauma-related cell loss and dysfunctional synaptic information processing.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA	Satin, LS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, Box 980524, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 T32 NSO 7288-13, NS 27214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214, T32NS007288] Funding Source: NIH RePORTER		Arai A, 1998, BRAIN RES, V799, P230, DOI 10.1016/S0006-8993(98)00446-6; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BERTOLINO M, 1993, RECEPTOR CHANNEL, V1, P267; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BOXALL AR, 1995, NEUROCHEM RES, V20, P605, DOI 10.1007/BF01694543; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dingledine R, 1999, PHARMACOL REV, V51, P7; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hatt H, 1999, NATURWISSENSCHAFTEN, V86, P177, DOI 10.1007/s001140050593; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; Jensen JB, 1998, NEUROCHEM INT, V32, P505, DOI 10.1016/S0197-0186(97)00130-7; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; KOH JY, 1990, J NEUROSCI, V10, P693; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Ohno K, 1998, NEUROCHEM INT, V32, P265, DOI 10.1016/S0197-0186(97)00098-3; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; PELLETIER MR, 1994, J NEUROPHYSIOL, V72, P1032; PERSSON K, 1995, AM J PHYSIOL-CELL PH, V269, pC1018; Povlishock JT, 1996, ACT NEUR S, V66, P81; RAMAN IM, 1992, NEURON, V9, P173, DOI 10.1016/0896-6273(92)90232-3; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Silver RA, 1996, J PHYSIOL-LONDON, V493, P167, DOI 10.1113/jphysiol.1996.sp021372; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; TRUSSELL LO, 1988, P NATL ACAD SCI USA, V85, P4562, DOI 10.1073/pnas.85.12.4562-a; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG LY, 1994, J PHYSIOL-LONDON, V475, P431, DOI 10.1113/jphysiol.1994.sp020083; WEBER JT, 1997, J NEUROTRAUM, V14, P778; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; ZORUMSKI CF, 1990, NEURON, V5, P61, DOI 10.1016/0896-6273(90)90033-C	61	89	90	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 1	1999	19	17					7367	7374		10.1523/JNEUROSCI.19-17-07367.1999			8	Neurosciences	Neurosciences & Neurology	233TL	WOS:000082442600016	10460243	Green Published, Bronze			2021-06-18	
J	Wrathall, JR; Li, W; Hudson, LD				Wrathall, JR; Li, W; Hudson, LD			Myelin gene expression after experimental contusive spinal cord injury	JOURNAL OF NEUROSCIENCE			English	Article						myelin; spinal cord injury; mRNA; proteolipid protein; myelin basic protein; protein zero; myelin transcription factor 1; in situ hybridization; Western analysis; immunocytochemistry	TRANSCRIPTION FACTOR-1 MYT1; DNA-BINDING PROTEIN; ZINC-FINGER; BASIC-PROTEIN; RAT-BRAIN; OLIGODENDROCYTES; APOPTOSIS; AXONS; CAT; REMYELINATION	After incomplete traumatic spinal cord injury (SCI), the spared tissue exhibits abnormal myelination that is associated with reduced or blocked axonal conductance. To examine the molecular basis of the abnormal myelination, we used a standardized rat model of incomplete SCI and compared normal uninjured tissue with that after contusion injury. We evaluated expression of mRNA for myelin proteins using in situ hybridization with oligonucleotide probes to proteolipid protein (PLP), the major protein in central myelin; myelin basic protein (MBP), a major component of central myelin and a minor component of peripheral myelin; and protein zero (PO), the major structural protein of peripheral myelin, as well as myelin transcription factor 1 (MYT1). We found reduced expression of PLP and MBP chronically after SCI in the dorsal, lateral, and ventral white matter both rostral and caudal to the injury epicenter. Detailed studies of PLP at 2 months after injury indicated that the density of expressing cells was normal but mRNA per cell was reduced. In addition, PO, normally restricted to the peripheral nervous system, was expressed both at the epicenter and in lesioned areas at least 4 mm rostral and caudal to it. Thus, after SCI, abnormal myelination of residual axons may be caused, at least in part, by changes in the transcriptional regulation of genes for myelin proteins and by altered distribution of myelin-producing cells. In addition, the expression of MYT1 mRNA and protein seemed to be upregulated after SCI in a pattern suggesting the presence of undifferentiated progenitor cells in the chronically injured cord.	Georgetown Univ, Dept Cell Biol, Div Neurobiol, Washington, DC 20007 USA; NINDS, Lab Dev Neurogenet, Bethesda, MD 20892 USA	Wrathall, JR (corresponding author), Georgetown Univ, Dept Cell Biol, Div Neurobiol, 3900 Reservoir Rd, Washington, DC 20007 USA.			Li, Wen/0000-0002-5543-4899	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035647, P01NS028130] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA051008] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28130, NS35647, R01 NS035647] Funding Source: Medline		Armstrong RC, 1997, J NEUROPATH EXP NEUR, V56, P772; ARMSTRONG RC, 1995, GLIA, V14, P303, DOI 10.1002/glia.440140407; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; BALENTINE JD, 1978, LAB INVEST, V39, P254; Bhat RV, 1996, GLIA, V17, P169; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BLIGHT AR, 1983, NEUROSCIENCE, V10, P1471, DOI 10.1016/0306-4522(83)90128-8; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; BUNGE RP, 1993, ADV NEUROL, V59, P75; CARSON JH, 1983, DEV BIOL, V96, P485, DOI 10.1016/0012-1606(83)90185-9; COOK JL, 1992, NEUROSCI LETT, V137, P56, DOI 10.1016/0304-3940(92)90297-K; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GLEDHILL RF, 1973, EXP NEUROL, V38, P472, DOI 10.1016/0014-4886(73)90169-6; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HAYES KC, 1994, J NEUROTRAUM, V11, P433, DOI 10.1089/neu.1994.11.433; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUDSON LD, 1990, SEMIN NEUROSCI, V2, P483; HUDSON LD, 1997, MOL SIGNALING REGULA, P182; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Peters A, 1991, FINE STRUCTURE NERVO; Richardson WD, 1997, DEV NEUROSCI-BASEL, V19, P58, DOI 10.1159/000111186; Rosenberg LJ, 1997, J NEUROTRAUM, V14, P823, DOI 10.1089/neu.1997.14.823; Salgado-Ceballos H, 1998, BRAIN RES, V782, P126; SHIBABUDDIN LS, 1997, EXP NEUROL, V148, P577; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Teng YD, 1997, J NEUROSCI, V17, P4359; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; ZELLER NK, 1985, J NEUROSCI, V5, P2955	46	89	91	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 1	1998	18	21					8780	8793					14	Neurosciences	Neurosciences & Neurology	132ED	WOS:000076616600023	9786985				2021-06-18	
J	Max, JE; Koele, SL; Smith, WL; Sato, Y; Lindgren, SD; Robin, DA; Arndt, S				Max, JE; Koele, SL; Smith, WL; Sato, Y; Lindgren, SD; Robin, DA; Arndt, S			Psychiatric disorders in children and adolescents after severe traumatic brain injury: A controlled study	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; pediatrics; psychopathology	HEAD-INJURY; DEPRESSION	Objective: To study psychiatric and behavioral morbidity associated with severe traumatic brain injury (TBI). Method: A consecutive series (n = 24) of children aged 5 through 14 years whet suffered a severe TBI were matched to subjects who sustained a mild TBI and to a second matched group who sustained an orthopedic injury with no evidence of TBI. Standardized psychiatric, behavioral, and neuroimaging assessments were conducted on average 2 years after injury. Results: Severe TBI was associated with a significantly higher rate of current."novel" psychiatric disorders (15/24; 63%) compared with children with mild TBI (5/24; 21%) and orthopedic injury (1/24; 4%). Higher effect sizes were evident for child and adolescent self-report of internalizing symptoms rather than externalizing symptoms, for parents' report of overall behavior and internalizing symptoms rather than externalizing symptoms, and for teachers' reports of overall behavior and externalizing symptoms rather than internalizing symptoms. Conclusions: Severe TBI is a profound risk factor for the development of a psychiatric disorder. Survivors should be assessed for organic personality syndrome, which is the most common psychiatric disorder after this type of injury.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA	Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Arndt, Stephan/A-6976-2013; Robin, Donald/F-2109-2010	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MHCRC43271, MH31593, MH40856] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R37MH031593, P30MH043271, R01MH031593, P50MH043271, R01MH040856] Funding Source: NIH RePORTER		Achenbach T. M., 1991, MANUAL YOUTH SELF RE; Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach T.M., 1991, MANUAL TEACHERS REPO; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KAY T, 1988, HEAD INJURY FAMILY I; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; McCubbin HI, 1980, FAMILY ASSESSMENT RE; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Shaffer D, 1975, Ciba Found Symp, P191; TEASDALE G, 1974, LANCET, V2, P81	22	89	94	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	AUG	1998	37	8					832	840		10.1097/00004583-199808000-00013			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	103ZY	WOS:000074988800013	9695445				2021-06-18	
J	Gillen, R; Tennen, H; Affleck, G; Steinpreis, R				Gillen, R; Tennen, H; Affleck, G; Steinpreis, R			Distress, depressive symptoms, and depressive disorder among caregivers of patients with brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; RELATIVES; FAMILY; PERSONALITY; INTERVIEW; RECOVERY; VALIDITY	Objective: To examine the prevalence and correlates of major depression in caregivers of individuals with moderate to severe traumatic brain injuries. Design: Repeated-measures design involving structured diagnostic interview and self-report of psychological distress administered on two occasions separated by 6 months. Setting: Three acute care rehabilitation hospitals. Subjects: Fifty-nine caregivers (39 mothers and 20 spouses) of individuals with moderate to severe brain injuries recruited from previous inpatient rosters. AU caregivers were currently residing with the person with traumatic brain injury. Main Outcome Measure: The Diagnostic Interview Schedule-Revised [DIS-R] was utilized to assess depression. The Symptom Checklist 90-Revised (SCL 90-R) measured general psychological distress. Results: Forty-seven percent of caregivers initially met diagnostic criteria for depression, and 43% met criteria 6 months later. Nearly two thirds of those who were Initially depressed continued to be depressed 6 months later, and 17% of those who were not depressed initially subsequently met criteria for depression. The best predictor of depression was a previous (pre-brain injury) depressive episode. Neither time since injury nor injury severity predicted diagnostic status, and spouses were no more likely to be depressed than were mothers. The SCL 90-R, including its depression scale, showed high specificity but low sensitivity in predicting diagnostic status. Conclusions: The prevalence of major depression is high in caregivers of individuals with brain injuries. Because depression may interfere with the capacity to provide care and contribute to the rehabilitation process, it is important for clinicians to carefully assess both the current and preaccident affective status of primary caregivers.	Sunnyview Hosp & Rehabil Ctr, Dept Psychol, Schenectady, NY 12308 USA; Univ Connecticut, Ctr Hlth, Dept Community Med & Hlth Care, Farmington, CT USA; Univ Wisconsin, Dept Psychol, Milwaukee, WI 53201 USA	Gillen, R (corresponding author), Sunnyview Hosp & Rehabil Ctr, Dept Psychol, 1270 Belmont Ave, Schenectady, NY 12308 USA.						Affleck G, 1997, PSYCHOSOM MED, V59, P95; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANHENSEL CS, 1987, J HEALTH SOC BEHAV, V28, P232; BOND M, 1984, CLOSED HEAD INJURY P; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS DN, 1984, CLOSED HEAD INJURY P; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Cadoret RJ, 1996, AM J PSYCHIAT, V153, P892; CAMPLAIR PS, 1990, COMMUNITY REINTEGRAT; Derogatis L., 1983, SCL 90R ADM SCORING; FAHY TJ, 1967, LANCET, V2, P475; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; KAMEROW DB, 1990, DEPRESSION PRIMARY C; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102, P110, DOI 10.1037/0021-843X.102.1.110; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LUTZKY SM, 1994, PSYCHOL AGING, V9, P513, DOI 10.1037/0882-7974.9.4.513; MAUSSCLUM N, 1981, J NEUROSURG NURS, V3, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MERIKANGAS KR, 1994, PSYCHOL MED, V24, P69, DOI 10.1017/S0033291700026842; Newmann JP, 1996, PSYCHOL AGING, V11, P112, DOI 10.1037/0882-7974.11.1.112; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Panting A., 1972, REHABILITATION, V38, P33; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REDINBAUGH EM, 1995, PSYCHOL AGING, V10, P358, DOI 10.1037/0882-7974.10.3.358; RIMEL RW, 1983, REHABILITATION HEAD; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Robins LN, 1985, DIAGNOSTIC INTERVIEW; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; STEIN PN, 1992, REHABIL PSYCHOL, V37, P121, DOI 10.1037/0090-5550.37.2.121; TENNEN H, 1995, J PERS SOC PSYCHOL, V68, P870, DOI 10.1037/0022-3514.68.5.870; TENNEN H, 1995, J PERS SOC PSYCHOL, V68, P895, DOI 10.1037/0022-3514.68.5.895; TENNEN H, 1985, TEST CRITIQUES, P3; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Wiseman EJ, 1996, J ADDICT DIS, V15, P43, DOI 10.1300/J069v15n02_04	42	89	90	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1998	13	3					31	43		10.1097/00001199-199806000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZT046	WOS:000074042200004	9582177				2021-06-18	
J	Rzigalinski, BA; Weber, JT; Willoughby, KA; Ellis, EF				Rzigalinski, BA; Weber, JT; Willoughby, KA; Ellis, EF			Intracellular free calcium dynamics in stretch-injured astrocytes	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; intracellular free calcium; intracellular calcium stores; traumatic brain injury; signal transduction; inositol trisphosphate; glutamate	TRAUMATIC BRAIN INJURY; CEREBRAL ENERGY-METABOLISM; AMINO-ACID RECEPTOR; GLUTAMATE RECEPTORS; GLIAL-CELLS; NEURONS; STORES; FURA-2; MODEL; FLUORESCENCE	We have previously developed an in vitro model for traumatic brain injury that simulates a major component of in vivo trauma, that being tissue strain or stretch. We have validated our model by demonstrating that it produces many of the posttraumatic responses observed in vivo. Sustained elevation of the intracellular free calcium concentration ([Ca2+](i)) has been hypothesized to be a primary biochemical mechanism inducing cell dysfunction after trauma. In the present report, we have examined this hypothesis in astrocytes using our in vitro injury model and fura-2 microphotometry. Our results indicate that astrocyte [Ca2+](i) is rapidly elevated after stretch injury, the magnitude of which is proportional to the degree of injury. However, the injury-induced [Ca2+](i) elevation is not sustained and returns to near-basal levels by 15 min postinjury and to basal levels between 3 and 24 h after injury. Although basal [Ca2+](i) returns to normal after injury, we have identified persistent injury-induced alterations in calcium-mediated signal transduction pathways. We report here, for the first time, that traumatic stretch injury causes release of calcium from inositol trisphosphate-sensitive intracellular calcium stores and may uncouple the stores from participation in metabotropic glutamate receptor-mediated signal transduction events. We found that for a prolonged period after trauma astrocytes no longer respond to thapsigargin, glutamate, or the inositol trisphosphate-linked metabotropic glutamate receptor agonist trans-(1 S,3R)1-amino-1,3-cyclopentanedicarboxylic acid with an elevation in [Ca2+](i). We hypothesize that changes in calcium-mediated signaling pathways, rather than an absolute elevation in [Ca2+](i), is responsible for some of the pathological consequences of traumatic brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Rzigalinski, BA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Castilho RF, 1996, MOL CELL BIOCHEM, V159, P105, DOI 10.1007/BF00420912; CHARLES AC, 1993, GLIA, V7, P134, DOI 10.1002/glia.440070203; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CONDORELLI DF, 1993, J NEUROCHEM, V60, P877, DOI 10.1111/j.1471-4159.1993.tb03232.x; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Elmoselhi AB, 1996, AM J PHYSIOL-CELL PH, V271, pC1652; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HANSSON E, 1995, FASEB J, V9, P343; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOLZWARTH JA, 1994, J NEUROSCI, V14, P1879; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; Lamb RG, 1997, J NEUROCHEM, V68, P1904; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; McIntosh TK, 1996, LAB INVEST, V74, P315; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MILLER S, 1995, ANN NY ACAD SCI, V757, P460, DOI 10.1111/j.1749-6632.1995.tb17506.x; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; PECHAN PA, 1993, NEUROSCI LETT, V149, P182; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SCHOEPP DD, 1992, NEUROSCI LETT, V145, P100, DOI 10.1016/0304-3940(92)90213-Q; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; YANO S, 1994, J BIOL CHEM, V269, P5428; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	60	89	94	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	1998	70	6					2377	2385					9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ZN457	WOS:000073647800016	9603202				2021-06-18	
J	Franzen, R; Schoenen, J; Leprince, P; Joosten, E; Moonen, G; Martin, D				Franzen, R; Schoenen, J; Leprince, P; Joosten, E; Moonen, G; Martin, D			Effects of macrophage transplantation in the injured adult rat spinal cord: A combined immunocytochemical and biochemical study	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						angiogenesis; axonal regeneration; CNS; macrophages; myelin; neural transplantation	CENTRAL-NERVOUS-SYSTEM; DELAYED WALLERIAN DEGENERATION; MYELIN-ASSOCIATED GLYCOPROTEIN; ROOT GANGLION NEURONS; NEURITE GROWTH; MONONUCLEAR PHAGOCYTES; AXONAL REGENERATION; TRAUMATIC INJURY; REACTIVE ASTROCYTES; SCHWANN-CELLS	Early and robust invasion by macrophages may be one of the reasons why axonal regeneration is more effective in the PNS than ill the CNS, Therefore, we have grafted autologous peritoneal macrophages labeled with fluorescent later; microspheres into spinal cord compression lesions, At various survival times, we have studied their effect on the expression, of neuronal (neurofilaments [NF], calcitonin gene-related peptide [CGRP], 5-hydroxytryptamine [5-HT]) and nonneuronal markers (myelin-associated: glycoprotein [MAG], glial fibrillary acidic protein [GFAP], laminin) by using semiquantitative Western blot and immunohistochemical techniques. After 1 month, we observed a significant decrease of the expression of MAG as well as an important invasion of the lesion site by neurites, chiefly peptidergic axons of presumed dorsal roof origin, in macrophage-grafted animals compared with controls, In addition, angiogenesis and Schwann cell infiltration were more pronounced after macrophage grafts, providing an increase in laminin, a favorable substrate for axonal regrowth. ;th. By using reverse transcription-polymerase, chain reaction (RT-PCR), mRNAs for tumor necrosis factor-alpha (TNF-alpha) were detected in the transplanted cells, whereas results were negative for nerve growth factor (NGF), neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), ol acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF). Thus, macrophage grafts: may represent an interesting strategy to promote axonal regeneration in the CNS, Our study suggests that they may exert their beneficial effects by degrading myelin products, which inhibit axonal regrowth th, and bg promoting a permissive extracellular matrix containing notably laminin. No evidence for a direct synthesis of neurotrophic factors by the transplanted macrophages was found in this study, but resident glial cells could secrete such factors as a result of stimulation by macrophage-released cytokines. (C) 1998 Wiley-Liss, Inc.	Univ Liege, Expt Neuropathol Lab, Liege, Belgium; Univ Liege, Dept Neurol, Liege, Belgium; Univ Liege, Dept Human Physiol & Pathophysiol, Liege, Belgium; Univ Liege, Dept Neurosurg, Liege, Belgium; Univ Utrecht, Neurol Res Inst, Utrecht, Netherlands	Schoenen, J (corresponding author), CHU Sart Tilman, Expt Neuropathol Lab, Tour Pathol,1, B-4020 Liege, Belgium.	jschoenen@chu.ulg.ac.be		MARTIN, Didier/0000-0001-7325-4958; Leprince, pierre/0000-0002-7233-6553			ARAUJO DM, 1992, DEV BIOL, V133, P309; AVELLINO AM, 1995, EXP NEUROL, V136, P183, DOI 10.1006/exnr.1995.1095; BEDI KS, 1992, EUR J NEUROSCI, V4, P193, DOI 10.1111/j.1460-9568.1992.tb00867.x; BERNSTEIN JJ, 1985, BRAIN RES, V327, P135, DOI 10.1016/0006-8993(85)91507-0; BISBY MA, 1990, BRAIN RES, V530, P117, DOI 10.1016/0006-8993(90)90666-Y; BROWN MC, 1994, EUR J NEUROSCI, V6, P420, DOI 10.1111/j.1460-9568.1994.tb00285.x; CHAMAK B, 1994, J NEUROSCI RES, V38, P221, DOI 10.1002/jnr.490380213; CHEN S, 1993, J COMP NEUROL, V333, P449, DOI 10.1002/cne.903330310; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLIN LB, 1995, BRAIN RES, V679, P274, DOI 10.1016/0006-8993(95)00249-P; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DAVID S, 1995, J NEUROSCI RES, V42, P594, DOI 10.1002/jnr.490420417; ELKABES S, 1995, J NEUROSCI, V16, P2505; FILBIN MT, 1995, CURR OPIN NEUROBIOL, V5, P588, DOI 10.1016/0959-4388(95)80063-8; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FRYER HJL, 1986, ANAL BIOCHEM, V153, P262, DOI 10.1016/0003-2697(86)90090-4; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GRIFFIN JW, 1992, J NEUROIMMUNOL, V40, P153, DOI 10.1016/0165-5728(92)90129-9; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; GUTH L, 1983, TRENDS NEUROSCI, P20; HIKAWA N, 1993, NEUROREPORT, V5, P41, DOI 10.1097/00001756-199310000-00010; Hikawa N, 1996, CELL MOL NEUROBIOL, V16, P517, DOI 10.1007/BF02150231; JAFFE EA, 1985, BLOOD, V65, P79; Jelsma Tony N., 1994, Current Opinion in Neurobiology, V4, P717, DOI 10.1016/0959-4388(94)90015-9; KIEFER R, 1995, INT J DEV NEUROSCI, V13, P331; LazarovSpiegler O, 1996, FASEB J, V10, P1296; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; LUDWIN SK, 1992, J NEUROL SCI, V109, P140, DOI 10.1016/0022-510X(92)90160-M; LUDWIN SK, 1991, J NEUROPATH EXP NEUR, V50, P330; MALLAT M, 1989, DEV BIOL, V133, P309, DOI 10.1016/0012-1606(89)90322-9; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MARTIN D, 1991, NEUROSCI LETT, V124, P44, DOI 10.1016/0304-3940(91)90818-E; Martin D, 1996, J NEUROSCI RES, V45, P588; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; MARTIN D, 1993, BRAIN RES BULL, V30, P507, DOI 10.1016/0361-9230(93)90285-J; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Ng WP, 1996, NEUROREPORT, V7, P861, DOI 10.1097/00001756-199603220-00005; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Ramon y Cajal S, 1928, DEGENERATION REGENER; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; SHIMOJO M, 1991, NEUROSCI LETT, V123, P229, DOI 10.1016/0304-3940(91)90937-O; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x	57	89	92	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	FEB 1	1998	51	3					316	327		10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J			12	Neurosciences	Neurosciences & Neurology	YV263	WOS:000071805700005	9486767				2021-06-18	
J	Stiell, IG; Wells, GA; Vandemheen, K; Laupacis, A; Brison, R; Eisenhauer, MA; Greenberg, GH; MacPhail, I; McKnight, RD; Reardon, M; Verbeek, R; Worthington, J; Lesiuk, H				Stiell, IG; Wells, GA; Vandemheen, K; Laupacis, A; Brison, R; Eisenhauer, MA; Greenberg, GH; MacPhail, I; McKnight, RD; Reardon, M; Verbeek, R; Worthington, J; Lesiuk, H			Variation in ED use of computed tomography for patients with minor head injury	ANNALS OF EMERGENCY MEDICINE			English	Article							ACUTE ANKLE INJURIES; TRAUMATIC INTRACRANIAL HEMATOMA; CLINICAL DECISION RULES; ACUTE KNEE INJURIES; SUBDURAL-HEMATOMA; SELECTION CRITERIA; DELAYED DIAGNOSIS; CT SCANS; RADIOGRAPHY; MANAGEMENT	Study objective: To determine the frequency of utilization, yield for brain injury, incidence of missed injury, and variation in the use of computed tomography (CT) for ED patients with minor head injury. Methods: This retrospective health records survey was conducted over a 12-month period in the EDs at seven Canadian teaching institutions. Included in this review were adult patients who sustained acute minor head injury, defined as witnessed loss of consciousness or amnesia and a Glasgow Coma Scale score of 13 or greater. Data were collected by research assistants who were trained to select cases and abstract data in a standardized fashion according to a resource manual. Subsequently, patient eligibility was reviewed by the study coordinator and principal investigator. Results: Of the 1,699 patients seen, 521 (30.7%) were referred for CT, and 418 (79.8%) of these scans were negative for any type of brain injury. Overall, 105 (6.2%) of these patients sustained acute brain injury, including 9 (.5%) with an epidural hematoma. Cochran's Q test for homogeneity demonstrated significant variation between the seven centers for rate of ordering CT (P<.0001), from a low of 15.9% to a high of 70.4%. All five cases of ''missed'' hematoma occurred at the institutions with the highest acid third highest rates of CT use. After controlling for possible differences in case severity and patient characteristics at each hospital, logistic regression analysis revealed that five of seven hospitals were significantly associated with use of CT (respective odds ratios [OR], .4, .5, .5, 3.2, and 4.7). Three of the centers (two with the highest ordering rates) showed significant heterogeneity in the ordering of CT among their attending staff physicians, from a low of 6.5% to a high of 80.0%. Conclusion: There was considerable variation among institutions and individual physicians in the ordering of CT for patients with minor head injury. Although emergency physicians were selective when ordering CT, the yield of radiography was very low at all hospitals. None of the cases of ''missed'' intracranial hematoma came from the lowest ordering institutions, indicating that patients may be managed safely with a selective approach to CT use, These findings suggest great potential for more standardized and efficient use of CT of the head, possibly through the use of a clinical decision rule.		Stiell, IG (corresponding author), OTTAWA CIVIC HOSP,LOEB RES INST,CLIN EPIDEMIOL UNIT,DIV EMERGENCY MED,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.			Stiell, Ian/0000-0002-2583-6408			*AM COLL SURG, 1993, ADV TRAUM LIF SUPP I; ANIS AH, 1995, ANN EMERG MED, V26, P422, DOI 10.1016/S0196-0644(95)70108-7; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; CARTER A, 1992, CAN MED ASSOC J, V147, P1649; Cook L S, 1994, Acad Emerg Med, V1, P227; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DEITCH D, 1989, NEUROLOGY, V39, P985, DOI 10.1212/WNL.39.7.985; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; DUUS BR, 1994, ANN EMERG MED, V23, P1279, DOI 10.1016/S0196-0644(94)70352-3; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR., 1987, CLINIMETRICS; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Goel V, 1996, PATTERNS HLTH CARE O; GRAHAM ID, 1996, MED DECIS MAKING, V16, P469; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; *HLTH SERV RES GRO, 1992, CAN MED ASSOC J, V146, P467; ISCOE NA, 1994, CAN MED ASSOC J, V150, P345; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LEVITT MA, 1994, ANN EMERG MED, V23, P1143; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MADDEN C, 1995, ACAD EMERG MED, V2, P248, DOI 10.1111/j.1553-2712.1995.tb03217.x; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; McCaig L F, 1994, Adv Data, P1; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MIKHAIL MG, 1992, AM J EMERG MED, V10, P24, DOI 10.1016/0735-6757(92)90119-I; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MORAN SG, 1994, AM SURGEON, V60, P533; *NAT CTR HLTH STAT, 1994, NAT HOSP AMB MED CAR; PITTS LH, 1991, ANN EMERG MED, V20, P1387, DOI 10.1016/S0196-0644(05)81089-3; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; RICHLESS LK, 1993, AM J EMERG MED, V11, P327, DOI 10.1016/0735-6757(93)90161-4; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; ROSEN P, 1992, EMERGENCY MED CONCEP; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1993, SURG NEUROL, V39, P269, DOI 10.1016/0090-3019(93)90003-J; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1995, ACAD EMERG MED, V2, P966, DOI 10.1111/j.1553-2712.1995.tb03123.x; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P611, DOI 10.1001/jama.275.8.611; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; STIELL IG, 1991, THESIS U OTTAWA OTTA; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TINTINALLI JE, 1992, EMERGENCY MED COMPRE; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WENNBERG JE, 1984, HLTH AFF MILLWOOD, V4, P6; YEALY D M, 1991, Emergency Medicine Clinics of North America, V9, P707	73	89	89	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUL	1997	30	1					14	22		10.1016/S0196-0644(97)70104-5			9	Emergency Medicine	Emergency Medicine	XG890	WOS:A1997XG89000003	9209219				2021-06-18	
J	Young, B; Ott, L; Kasarskis, E; Rapp, R; Moles, K; Dempsey, RJ; Tibbs, PA; Kryscio, R; McClain, C				Young, B; Ott, L; Kasarskis, E; Rapp, R; Moles, K; Dempsey, RJ; Tibbs, PA; Kryscio, R; McClain, C			Zinc supplementation is associated with improved neurologic recovery rate and visceral protein levels of patients with severe closed head injury	JOURNAL OF NEUROTRAUMA			English	Article						zinc supplementation; head injury; neurologic outcome; nutritional/metabolic status	COMA DATA-BANK; METHYL-D-ASPARTATE; SERUM-ZINC; CORTICAL-NEURONS; DEFICIENCY; BINDING; TRANSCRIPTION; IONS	Sixty-eight patients were entered into a randomized, prospective, double-blinded controlled trial of supplemental zinc versus standard zinc therapy to study the effects of zinc supplementation on neurologic recovery and nutritional/metabolic status after severe closed head injury. One month after injury, the mortality rates in the standard zinc group and the zinc-supplemented group were 26 and 12%, respectively. Glasgow Coma Scale (GCS) scores of the zinc-supplemented group exceeded the adjusted mean GCS score of the standard group at day 28 (p = 0.03). Mean motor GCS score levels of the zinc-supplemented group were significantly higher on days 15 and 21 than those of the control group (p = 0.005, p = 0.02). This trend continued on day 28 of the study (p = 0.09). The groups did not differ in serum zinc concentration, weight, energy expenditure, or total urinary nitrogen excretion after hospital admission. Mean 24-h urine zinc levels were significantly higher in the zinc-supplemented group at days 2 (p = 0.0001) and 10 (p = 0.01) after injury. Mean serum prealbumin concentrations were significantly higher in the zinc-supplemented group (p = 0.003) at 3 weeks after injury. A similar pattern was found for mean serum retinol binding protein level (p = 0.01). A significantly larger number of patients in the standard zinc group had craniotomies for evacuation of hematoma; thus a bias may have been present. The results of this study indicate that zinc supplementation during the immediate postinjury period is associated with improved rate of neurologic recovery and visceral protein concentrations for patients with severe closed head injury.	UNIV KENTUCKY, MED CTR, DEPT NEUROL, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT STAT, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT NUTR SCI, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT PHARM, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT TOXICOL, LEXINGTON, KY 40536 USA; VET ADM MED CTR, LEXINGTON, KY 40511 USA	Young, B (corresponding author), UNIV KENTUCKY, MED CTR, DEPT SURG, 800 ROSE ST, LEXINGTON, KY 40536 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR2602-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002602] Funding Source: NIH RePORTER		BATES J, 1981, AM J CLIN NUTR, V34, P1655; BAUDIER J, 1983, BIOCHEM BIOPH RES CO, V114, P1138, DOI 10.1016/0006-291X(83)90681-2; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; DAMASK MC, 1987, CRIT CARE CLIN, V3, P71; DRUMMOND RW, 1985, J PARENT ENTER NUTR, V9, P196; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FAURE H, 1991, BIOL TRACE ELEM RES, V30, P37, DOI 10.1007/BF02990340; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; HALLBOOK T, 1972, LANCET, V2, P780; HENNIG B, 1993, J NUTR, V123, P1003; HENNIG B, 1992, J NUTR, V122, P1242; HESKETH JE, 1982, INT J BIOCHEM, V14, P983, DOI 10.1016/0020-711X(82)90059-3; HULME EC, 1983, EUR J PHARMACOL, V94, P59, DOI 10.1016/0014-2999(83)90442-9; JIANG ZM, 1985, JPEN-PARENTER ENTER, V9, P196, DOI 10.1177/0148607185009002196; KAY RG, 1983, SURGICAL NUTRITION, P283; KOH JY, 1988, J NEUROSCI, V8, P2164; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LO MMS, 1983, J NEUROSCI, V3, P2270; LUISI B, 1992, NATURE, V356, P379, DOI 10.1038/356379a0; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; MCCLAIN CJ, 1985, PROG FOOD NUTR SCI, V9, P185; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; POWANDA MC, 1973, AM J PHYSIOL, V225, P399; POWANDA MC, 1980, P SOC EXP BIOL MED, V163, P296; SLEVIN JT, 1985, BRAIN RES, V334, P281, DOI 10.1016/0006-8993(85)90219-7; SLOMIANKA L, 1992, NEUROSCIENCE, V48, P325, DOI 10.1016/0306-4522(92)90494-M; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; WANNEMACHER RW, 1972, J INFECT DIS, V126, P77, DOI 10.1093/infdis/126.1.77; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; 1984, USP DI, V2, P1394	37	89	93	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	1996	13	1					25	34		10.1089/neu.1996.13.25			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TW167	WOS:A1996TW16700004	8714860				2021-06-18	
J	JACOBS, A; PUT, E; INGELS, M; BOSSUYT, A				JACOBS, A; PUT, E; INGELS, M; BOSSUYT, A			PROSPECTIVE EVALUATION OF TECHNETIUM-99M-HMPAO SPECT IN MILD AND MODERATE TRAUMATIC BRAIN INJURY	JOURNAL OF NUCLEAR MEDICINE			English	Article						TECHNETIUM-99M-HMPAO; TRAUMATIC BRAIN INJURY; SPECT	CEREBRAL BLOOD-FLOW; CLOSED-HEAD-INJURY; SEMIQUANTITATIVE ANALYSIS; COMPUTED-TOMOGRAPHY; INITIAL EXPERIENCE; PERFUSION; SEQUELAE; CT	We prospectively evaluated the contribution of Tc-99m-HMPAO SPECT in patients who have sustained acute, mild or moderate head trauma. Methods: Forty-two patients formed the first subgroup of moderate trauma (ModTr) and 25 patients formed the second subgroup of mild trauma (MilTr). All 67 patients underwent an initial SPECT (Tinit) within 4 wk after a closed cranial trauma. After a mean interval of 3 mo from the time of Tinit, all patients were clinically re-evaluated; those with an abnormal Tinit underwent a repeat SPECT (Trpt) as well. All SPECT studies were visually graded by agreement of three observers adjudging a score ranging from 0 (no lesions) to 4. Results: For the group as a whole (ModTr + MilTr), the following results could be derived: (1) in 32/33 Tinit negative cases, clinical symptoms had resolved; (2) the positive predictive value of Tinit was only 20/34 (59%); (3) the sensitivity for the repeat SPECT was 19/20 (95%). Conclusion: Our results show that: (1) SPECT alterations correlate well with the severity of the trauma; (2) a negative initial SPECT study is a reliable predictor of a favorable clinical outcome; (3) in cases with a positive initial SPECT, a follow-up consisting of a combination of SPECT and clinical data is necessary; (4) in patients suffering from postconcussive symptoms, SPECT offers an instrument to objectivate sequelae.	FREE UNIV BRUSSELS,DEPT NUCL MED,JETTE,BELGIUM	JACOBS, A (corresponding author), VIRGA JESSE HOSP,DEPT NUCL MED,STADSOMVAART 11,B-3500 HASSELT,BELGIUM.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; BECKER DP, 1988, CECIL TXB MED, P2239; BRITTON KE, 1991, RADIOACTIVE ISOTOPES IN CLINICAL MEDICINE AND RESEARCH, P235; DUCOURS JL, 1990, NUCL MED COMMUN, V11, P361, DOI 10.1097/00006231-199005000-00003; FUMEYA H, 1990, ACT NEUR S, V51, P283; GEORGE MS, 1991, NEUROACTIVATION NEUR, P29; GRAY BG, 1992, J NUCL MED, V33, P52; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; HOLBOURN AHS, 1943, LANCET, V2, P428; JACOBS A, 1993, NUCL MED COMMUN, V14, P702, DOI 10.1097/00006231-199308000-00011; JACOBS A, 1992, EUR J NUCL MED, V19, P728; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; PODREKA I, 1987, J NUCL MED, V28, P1657; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; ROPER SN, 1991, J NUCL MED, V32, P1684; RUTHERFORD WH, 1977, LANCET, V1, P1	20	89	90	0	0	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316	0161-5505			J NUCL MED	J. Nucl. Med.	JUN	1994	35	6					942	947					6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	NP288	WOS:A1994NP28800006	8195879				2021-06-18	
J	FAY, GC; JAFFE, KM; LIAO, SQ; MARTIN, KM; SHURTLEFF, HA; RIVARA, JB; WINN, HR; POLISSAR, NL				FAY, GC; JAFFE, KM; LIAO, SQ; MARTIN, KM; SHURTLEFF, HA; RIVARA, JB; WINN, HR; POLISSAR, NL			MILD PEDIATRIC TRAUMATIC BRAIN INJURY - A COHORT STUDY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; CHILDREN; SEQUELAE		CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,4800 SANDY POINT WAY NE,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT BEHAV SCI,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT PEDIAT,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT BIOSTAT,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,SCH SOCIAL WORK,SEATTLE,WA 98105; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA 98195; CHILDRENS HOSP & MED CTR,DEPT PSYCHIAT,SEATTLE,WA 98105				Shurtleff, Hillary/0000-0003-0959-2842	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Achenbach TM, 1986, MANUAL TEACHERS REPO; BIJUR PE, 1990, PEDIATRICS, V86, P337; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bruininks R.H., 1984, SCALES INDEPENDENT B; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Conover W.J., 1980, PRACTICAL NONPARAMET; DELIS DC, 1989, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P740; Jastak S, 1984, WIDE RANGE ACHIEVEME; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Miller R. G., 1981, SIMULTANEOUS STAT IN; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Wechsler D., 1974, MANUAL WECHSLER INTE; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; 1990, AM J DIS CHILD, V144, P627; 1985, ABBREVIATED INJURY S	29	89	89	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1993	74	9					895	901					7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	LX551	WOS:A1993LX55100001	8379832				2021-06-18	
J	TAFT, WC; YANG, KY; DIXON, CE; CLIFTON, GL; HAYES, RL				TAFT, WC; YANG, KY; DIXON, CE; CLIFTON, GL; HAYES, RL			HYPOTHERMIA ATTENUATES THE LOSS OF HIPPOCAMPAL MICROTUBULE-ASSOCIATED PROTEIN-2 (MAP2) FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CYTOSKELETON; MICROTUBULES; NEURONAL DEATH; PROTEASE; TEMPERATURE; TRAUMA	EXCITATORY AMINO-ACIDS; RAT-BRAIN; CALPAIN-I; FOREBRAIN ISCHEMIA; NEURONAL DAMAGE; TEMPERATURE; DEGRADATION; INHIBITOR; SPECTRIN; RELEASE	Traumatic brain injury (TBI) produces a tissue-specific decrease in protein levels of microtubule-associated protein 2 (MAP2), an important cross-linking component of the neuronal cytoskeleton. Because moderate brain hypothermia (30-degrees-C) reduces certain neurobehavioral deficits produced by TBI, we examined the efficacy of moderate hypothermia (30-degrees-C) in reversing the TBI-induced loss of MAP2 protein. Naive, sham-injured, and moderate (2.1 atm) fluid percussion-injured rats were assessed for MAP2 protein content 3 h post injury using quantitative immunoreactivity measurements. Parallel groups of sham-injured and fluid percussion-injured animals were maintained in moderate hypothermia (30-degrees-C), as measured by temporalis muscle temperature, for MAP2 quantitation 3 h post injury. No difference in MAP2 levels was observed between naive and sham-injured normothermic animals. Hypothermia alone had no effect on soluble MAP2 levels in sham-injured animals compared with normothermic sham-injured controls (88.0 +/- 7.3%; p > 0.10). Fluid percussion injury dramatically reduced MAP2 levels in he normothermic group (44.3 +/- 5.9%; p < 0.0005) compared with normothermic sham-injured controls. No significant reduction of MAP2 was seen in the hypothermic injured group (95.2 +/- 4.6%; compared with hypothermic sham-injured controls, p > 0.20). Although it is premature to infer any causal link, the data suggest that the attenuation of injury-induced MAP2 loss by hypothermia may contribute to its overall neuroprotective action.		TAFT, WC (corresponding author), UNIV TEXAS, HLTH SCI CTR, 6431 FANNIN, SUITE 7154, HOUSTON, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458] Funding Source: Medline		AVILA J, 1992, LIFE SCI, V50, P327, DOI 10.1016/0024-3205(92)90433-P; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dustin P., 1984, MICROTUBULES; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HARA H, 1990, J PHARMACOL EXP THER, V255, P906; HARA H, 1990, J CEREBR BLOOD F MET, V10, P646, DOI 10.1038/jcbfm.1990.117; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEIMANN R, 1985, J BIOL CHEM, V260, P2160; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; NORWOOD WI, 1982, AM J PHYSIOL, V243, pC62; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; TAFT W C, 1991, Society for Neuroscience Abstracts, V17, P164; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZIMMERMAN UJP, 1982, BIOCHEMISTRY-US, V21, P3977, DOI 10.1021/bi00260a012	45	89	91	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	1993	13	5					796	802		10.1038/jcbfm.1993.101			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	LT800	WOS:A1993LT80000008	8360286	Bronze			2021-06-18	
J	FERNAUDESPINOSA, I; NIETOSAMPEDRO, M; BOVOLENTA, P				FERNAUDESPINOSA, I; NIETOSAMPEDRO, M; BOVOLENTA, P			DIFFERENTIAL ACTIVATION OF MICROGLIA AND ASTROCYTES IN ANISOMORPHIC AND ISOMORPHIC GLIOTIC TISSUE	GLIA			English	Article						CNS INJURY; REACTIVE ASTROCYTES; IMMUNOCYTOCHEMISTRY	CENTRAL NERVOUS-SYSTEM; FIBRILLARY ACIDIC PROTEIN; ADULT-RAT-BRAIN; REACTIVE ASTROCYTES; WALLERIAN DEGENERATION; EXCITOTOXIC LESION; PRECURSOR PROTEIN; MAMMALIAN BRAIN; CELLS; ANTIBODIES	Reactive astrocytes and microglial cells are both involved in the formation of gliotic tissue. Using immunohistochemical markers, we have compared the response of both these cell types after two different kinds of damage in the brain: traumatic injury (anisomorphic gliosis) and neurotoxic induced lesion (isomorphic gliosis), in two distinct regions of the brain, the cortex and the hippocampus. We show that the time course and the relative contribution of astrocytes and microglial cells differ greatly in the two kinds of lesions. While in anisomorphic gliosis there is little activation of endogenous microglial cells independently of the brain region damaged, these cells contribute in large measure and for prolonged periods of time to the formation of isomorphic gliotic tissue. Astrocytes are quickly activated at the border of anisomorphic lesions, and after 3 days they already occupy an extensive portion of the brain parenchyma. However, after 1 month, they are found restricted to a thin strip at the lesion boundary. In contrast, after an isomorphic lesion, astrocytes become reactive around the site of neuronal cell loss but not at the site of the lesion itself. Only after 2 weeks do they totally invade the damaged region, persisting for at least 1 month. Such differences are observed independently of the brain region damaged. These results suggest that the cellular, and therefore the molecular, composition of gliotic tissue depends on the type of insult the CNS has suffered. (C) 1993 Wiley-Liss, Inc.	INST CAJAL,NEURAL PLASTIC GRP,C DOCTOR ARLE 37,E-28002 MADRID,SPAIN			Fernaud-Espinosa, Isabel/H-1875-2015	Fernaud-Espinosa, Isabel/0000-0003-2391-0704			AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BILLETT EE, 1984, BIOCHEM J, V221, P765, DOI 10.1042/bj2210765; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; BOVOLENTA P, 1984, DEV BIOL, V102, P248, DOI 10.1016/0012-1606(84)90189-1; BOVOLENTA P, 1993, IN PRESS EUR J NEURO; BOYA J, 1986, ACTA ANAT, V127, P142; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; CARD JP, 1988, NEURON, V1, P835, DOI 10.1016/0896-6273(88)90131-6; DAHL D, 1982, DIFFERENTIATION, V22, P185, DOI 10.1111/j.1432-0436.1982.tb01248.x; DENNISDONNINI S, 1984, NATURE, V307, P641; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; DRAGUNOW M, 1990, BRAIN RES, V527, P41, DOI 10.1016/0006-8993(90)91058-O; DUSART I, 1991, NEUROSCIENCE, V45, P541, DOI 10.1016/0306-4522(91)90269-T; GIULIAN D, 1991, J CELL BIOL, V112, P323, DOI 10.1083/jcb.112.2.323; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1986, J CELL BIOL, V102, P803, DOI 10.1083/jcb.102.3.803; GOLDMAN JE, 1991, GLIA, V4, P149, DOI 10.1002/glia.440040206; GRAEBER MB, 1988, J NEUROCYTOL, V17, P573, DOI 10.1007/BF01189811; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; GREENFIELD JG, 1958, NEUROPATHOLOGY, P1; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; KETTENMANN H, 1984, NEUROSCI LETT, V52, P25, DOI 10.1016/0304-3940(84)90345-8; LANGAN TJ, 1992, BRAIN RES, V577, P200, DOI 10.1016/0006-8993(92)90275-E; LINDSAY RM, 1986, ASTROCYTES CELL BIOL, V3, P231; MACVICAR BA, 1988, NEUROSCIENCE, V25, P721, DOI 10.1016/0306-4522(88)90272-2; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MARTY S, 1991, NEUROSCIENCE, V45, P529, DOI 10.1016/0306-4522(91)90268-S; MCGEER PL, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P587; MILLER RH, 1986, J NEUROSCI, V6, P22; MORENOFLORES MT, 1993, GLIA, V7, P146, DOI 10.1002/glia.440070204; MURABE Y, 1981, CELL TISSUE RES, V218, P75; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NIETOSAMPEDRO M, 1988, PHARM APPROACHES TRE, P331; NORTON WT, 1989, J NEUROSCI, V9, P769; OGAWA M, 1989, EXP NEUROL, V106, P187, DOI 10.1016/0014-4886(89)90093-9; OLNEY JW, 1978, KAINIC ACID TOOL NEU, P201; Paxinos G, 1986, RAT BRAIN STEREOTAXI; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; Reier P J, 1988, Adv Neurol, V47, P87; RIOHORTEGA DP, 1932, CYTOLOGY CELLULAR PA, V2, P481; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; SHAW G, 1981, EUR J CELL BIOL, V26, P68; SHIGEMATSU K, 1989, BRAIN RES, V501, P215, DOI 10.1016/0006-8993(89)90639-2; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SINGH VK, 1978, BRAIN RES, V155, P418, DOI 10.1016/0006-8993(78)91041-7; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; THOMAS WE, 1992, BRAIN RES REV, V17, P61; WILKIN GP, 1990, TRENDS NEUROSCI, V13, P43, DOI 10.1016/0166-2236(90)90065-I; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016	56	89	89	1	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0894-1491			GLIA	Glia	AUG	1993	8	4					277	291		10.1002/glia.440080408			15	Neurosciences	Neurosciences & Neurology	LP872	WOS:A1993LP87200007	8406684				2021-06-18	
J	BROOKE, MM; QUESTAD, KA; PATTERSON, DR; BASHAK, KJ				BROOKE, MM; QUESTAD, KA; PATTERSON, DR; BASHAK, KJ			AGITATION AND RESTLESSNESS AFTER CLOSED HEAD-INJURY - A PROSPECTIVE-STUDY OF 100 CONSECUTIVE ADMISSIONS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURY; PSYCHOMOTOR AGITATION; STATISTICS	SCALE	Agitation and restlessness are two of the most striking and problematic behaviors for patients with traumatic brain injury (TBI), their caregivers, and their families. These behaviors are often treated with physical and chemical restraints which have potentially harmful side effects. There are, however, few prospective studies which clearly define agitation and restlessness in a representative sample of TBI patients. Subjects for this study were 100 consecutive patients with traumatic, closed head injury (CHI) admitted to a regional Level I Trauma Center with a Glasgow Coma Scale score of less than 8, who had more than one hour of coma, and who required more than one week of hospitalization. Agitation was defined as episodic motor or verbal behavior which interfered with patient care or clearly required physical or chemical restraints to prevent damage to persons or property. This variable was rated on the Overt Aggression Scale, a 16-item scale, in four categories: verbal aggression; physical aggression against objects; physical aggression against self; or physical aggression directed at others. Systematic direct observations, caregiver interviews, and chart reviews were used to determine the frequency and duration of agitation. Patients were also monitored for restlessness, which was defined as behavior that interfered with staff or required some action by staff, such as change of activity, but either did not meet the severity criteria for agitation, or was continuous. Only 11 of the 100 subjects exhibited episodic agitation which met the criteria. Eight subjects were agitated for one week, one for two weeks, one for three weeks, and one for four weeks. Only one subject went directly from being unresponsive to being agitated. Restlessness, however, occurred in 35 patients. The results suggest that agitation is not frequently or predictably a phase of recovery from head injury. The precise definition and expected duration of these behaviors should be considered carefully before potentially harmful treatment is prescribed.	UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,SEATTLE,WA 98195	BROOKE, MM (corresponding author), TUFTS UNIV,SCH MED,DEPT REHABIL MED,136 HARRISON AVE,BOSTON,MA 02111, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR49-002570] Funding Source: Medline		CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALKMUS D, 1980, REHABILITATION HEAD; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	7	89	89	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1992	73	4					320	323		10.1016/0003-9993(92)90003-F			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HM910	WOS:A1992HM91000003	1554303				2021-06-18	
J	Shafiei, SS; Guerrero-Munoz, MJ; Castillo-Carranza, DL				Shafiei, Scott S.; Guerrero-Munoz, Marcos J.; Castillo-Carranza, Diana L.			Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage	FRONTIERS IN AGING NEUROSCIENCE			English	Article						tauopathy; tau oligomers; tau secretion; propagation; mitochondrial dysfunction	HEPARAN-SULFATE PROTEOGLYCANS; TRAUMATIC BRAIN-INJURY; V337M HUMAN TAU; ALZHEIMERS-DISEASE; IN-VIVO; NEUROFIBRILLARY TANGLES; EXTRACELLULAR TAU; ENDOGENOUS TAU; MOUSE MODEL; TRANSGENIC MICE	Aging has long been considered as the main risk factor for several neurodegenerative disorders including a large group of diseases known as tauopathies. Even though neurofibrillary tangles (NFTs) have been examined as the main histopathological hallmark, they do not seem to play a role as the toxic entities leading to disease. Recent studies suggest that an intermediate form of tau, prior to NFT formation, the tau oligomer, is the true toxic species. However, the mechanisms by which tau oligomers trigger neurodegeneration remain unknown. This review summarizes recent findings regarding the role of tau oligomers in disease, including release from cells, propagation from affected to unaffected brain regions, uptake into cells, and toxicity via mitochondrial dysfunction. A greater understanding of tauopathies may lead to future advancements in regards to prevention and treatment.	[Shafiei, Scott S.] Univ Texas Med Branch, Dept Neurol Neurosci & Cell Biol, Galveston, TX 77555 USA; [Guerrero-Munoz, Marcos J.] Hampton Univ, Dept Chem Engn, Hampton, VA 23668 USA; [Castillo-Carranza, Diana L.] Hampton Univ, Minor Mens Hlth, Hampton, VA 23668 USA	Castillo-Carranza, DL (corresponding author), Hampton Univ, Minor Mens Hlth, Hampton, VA 23668 USA.	diana.castillocarranza@hamptonu.edu		Castillo-Carranza, Diana/0000-0003-2511-949X	NIH National Institute for Minority Health & Health Disparities (NIMHD) award [4U54MD008621-04]	This work was supported by funds from NIH National Institute for Minority Health & Health Disparities (NIMHD) award 4U54MD008621-04. We thank Ms. Urmi Sengupta and Julia Gerson for contributing to the editing process.	Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; Calafate S, 2015, CELL REP, V11, P1176, DOI 10.1016/j.celrep.2015.04.043; Castillo-Carranza DL, 2014, J ALZHEIMERS DIS, V40, pS97, DOI 10.3233/JAD-132477; Castillo-Carranza DL, 2014, J NEUROSCI, V34, P4260, DOI 10.1523/JNEUROSCI.3192-13.2014; Castillo-Carranza Diana L, 2013, Front Biosci (Schol Ed), V5, P426; Christianson HC, 2013, P NATL ACAD SCI USA, V110, P17380, DOI 10.1073/pnas.1304266110; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Cowan CM, 2010, ACTA NEUROPATHOL, V120, P593, DOI 10.1007/s00401-010-0716-8; Danzer KM, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-42; David DC, 2005, J BIOL CHEM, V280, P23802, DOI 10.1074/jbc.M500356200; Davizon P, 2010, SEMIN THROMB HEMOST, V36, P857, DOI 10.1055/s-0030-1267039; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; Dennissen FJA, 2016, P NATL ACAD SCI USA, V113, P11597, DOI 10.1073/pnas.1603119113; Doeuvre L, 2009, J NEUROCHEM, V110, P457, DOI 10.1111/j.1471-4159.2009.06163.x; DuBoff B, 2012, NEURON, V75, P618, DOI 10.1016/j.neuron.2012.06.026; Dujardin S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100760; Dujardin S, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-14; Flach K, 2012, J BIOL CHEM, V287, P43223, DOI 10.1074/jbc.M112.396176; Gendreau KL, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00160; Gerson J, 2016, J NEUROTRAUM, V33, P2034, DOI 10.1089/neu.2015.4262; Gerson JE, 2014, ACS CHEM NEUROSCI, V5, P752, DOI 10.1021/cn500143n; Gerson JE, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-73; Gerson JE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00093; Goedert M, 2000, ANN NY ACAD SCI, V920, P74; Gomez-Ramos A, 2008, MOL CELL NEUROSCI, V37, P673, DOI 10.1016/j.mcn.2007.12.010; Gomez-Ramos A, 2009, EUR NEUROPSYCHOPHARM, V19, P708, DOI 10.1016/j.euroneuro.2009.04.006; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Holmes BB, 2014, J BIOL CHEM, V289, P19855, DOI 10.1074/jbc.R114.549295; Holmes BB, 2013, P NATL ACAD SCI USA, V110, pE3138, DOI 10.1073/pnas.1301440110; Hooper NM, 2011, J NEUROCHEM, V116, P721, DOI 10.1111/j.1471-4159.2010.06936.x; Hutton M, 2000, ANN NY ACAD SCI, V920, P63; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; Ihara Y, 2001, NEUROBIOL AGING, V22, P123, DOI 10.1016/S0197-4580(00)00200-1; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Khalyfa A, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-162; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; Kozlov MM, 1999, BIOPHYS J, V77, P604, DOI 10.1016/S0006-3495(99)76917-1; Kuchibhotla KV, 2014, P NATL ACAD SCI USA, V111, P510, DOI 10.1073/pnas.1318807111; LaPointe NE, 2009, J NEUROSCI RES, V87, P440, DOI 10.1002/jnr.21850; Lasagna-Reeves CA, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-56; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Maeda S, 2007, BIOCHEMISTRY-US, V46, P3856, DOI 10.1021/bi061359o; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Medina M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00113; Mirbaha H, 2015, J BIOL CHEM, V290, P14893, DOI 10.1074/jbc.M115.652693; Mondragon-Rodriguez S, 2012, J BIOL CHEM, V287, P32040, DOI 10.1074/jbc.M112.401240; Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Piccin A, 2007, BLOOD REV, V21, P157, DOI 10.1016/j.blre.2006.09.001; Pooler AM, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt214; Pooler AM, 2013, EMBO REP, V14, P389, DOI 10.1038/embor.2013.15; Pooler AM, 2010, BIOCHEM SOC T, V38, P1012, DOI 10.1042/BST0381012; Quintanilla RA, 2009, J BIOL CHEM, V284, P18754, DOI 10.1074/jbc.M808908200; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Rudinskiy N, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-63; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Sengupta U, 2015, BIOL PSYCHIAT, V78, P672, DOI 10.1016/j.biopsych.2014.12.019; Simoneau S, 2007, PLOS PATHOG, V3, P1175, DOI 10.1371/journal.ppat.0030125; Spillantini MG, 2000, NEUROGENETICS, V2, P193, DOI 10.1007/s100480050065; Spires TL, 2006, AM J PATHOL, V168, P1598, DOI 10.2353/ajpath.2006.050840; Tai HC, 2012, AM J PATHOL, V181, P1426, DOI 10.1016/j.ajpath.2012.06.033; Takashima A, 2013, J ALZHEIMERS DIS, V37, P565, DOI 10.3233/JAD-130653; Tanemura K, 2001, NEUROBIOL DIS, V8, P1036, DOI 10.1006/nbdi.2001.0439; Tanemura K, 2002, J NEUROSCI, V22, P133, DOI 10.1523/JNEUROSCI.22-01-00133.2002; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Tian Huilai, 2013, Int J Cell Biol, V2013, P260787, DOI 10.1155/2013/260787; van Horssen J, 2001, ACTA NEUROPATHOL, V102, P604; Ward SM, 2012, BIOCHEM SOC T, V40, P667, DOI 10.1042/BST20120134; Winston Charisse N, 2016, Alzheimers Dement (Amst), V3, P63, DOI 10.1016/j.dadm.2016.04.001; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528; Yamada K, 2014, J EXP MED, V211, P387, DOI 10.1084/jem.20131685; Yamada K, 2011, J NEUROSCI, V31, P13110, DOI 10.1523/JNEUROSCI.2569-11.2011; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010	94	88	91	5	16	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	APR 4	2017	9								83	10.3389/fnagi.2017.00083			9	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	EQ6ZZ	WOS:000398233600001	28420982	DOAJ Gold, Green Published			2021-06-18	
J	Sariaslan, A; Sharp, DJ; D'Onofrio, BM; Larsson, H; Fazel, S				Sariaslan, Amir; Sharp, David J.; D'Onofrio, Brian M.; Larsson, Henrik; Fazel, Seena			Long-Term Outcomes Associated with Traumatic Brain Injury in Childhood and Adolescence: A Nationwide Swedish Cohort Study of a Wide Range of Medical and Social Outcomes	PLOS MEDICINE			English	Article							PROFESSIONAL FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; PSYCHIATRIC-DISORDERS; YOUNG-CHILDREN; HEAD-INJURY; FOLLOW-UP; POPULATION; RISK; PREDICTORS; DISABILITY	Background Traumatic brain injury (TBI) is the leading cause of disability and mortality in children and young adults worldwide. It remains unclear, however, how TBI in childhood and adolescence is associated with adult mortality, psychiatric morbidity, and social outcomes. Methods and Findings In a Swedish birth cohort between 1973 and 1985 of 1,143,470 individuals, we identified all those who had sustained at least one TBI (n = 104,290 or 9.1%) up to age 25 y and their unaffected siblings (n = 68,268) using patient registers. We subsequently assessed these individuals for the following outcomes using multiple national registries: disability pension, specialist diagnoses of psychiatric disorders and psychiatric inpatient hospitalisation, premature mortality (before age 41 y), low educational attainment (not having achieved secondary school qualifications), and receiving means-tested welfare benefits. We used logistic and Cox regression models to quantify the association between TBI and specified adverse outcomes on the individual level. We further estimated population attributable fractions (PAF) for each outcome measure. We also compared differentially exposed siblings to account for unobserved genetic and environmental confounding. In addition to relative risk estimates, we examined absolute risks by calculating prevalence and Kaplan-Meier estimates. In complementary analyses, we tested whether the findings were moderated by injury severity, recurrence, and age at first injury (ages 0-4, 5-9, 6-10, 15-19, and 20-24 y). TBI exposure was associated with elevated risks of impaired adult functioning across all outcome measures. After a median follow-up period of 8 y from age 26 y, we found that TBI contributed to absolute risks of over 10% for specialist diagnoses of psychiatric disorders and low educational attainment, approximately 5% for disability pension, and 2% for premature mortality. The highest relative risks, adjusted for sex, birth year, and birth order, were found for psychiatric inpatient hospitalisation (adjusted relative risk [aRR] = 2.0; 95% CI: 1.9-2.0; 6,632 versus 37,095 events), disability pension (aRR = 1.8; 95% CI: 1.7-1.8; 4,691 versus 29,778 events), and premature mortality (aRR = 1.7; 95% CI: 1.6-1.9; 799 versus 4,695 events). These risks were only marginally attenuated when the comparisons were made with their unaffected siblings, which implies that the effects of TBI were consistent with a causal inference. A dose-response relationship was observed with injury severity. Injury recurrence was also associated with higher risks-in particular, for disability pension we found that recurrent TBI was associated with a 3-fold risk increase (aRR = 2.6; 95% CI: 2.4-2.8) compared to a single-episode TBI. Higher risks for all outcomes were observed for those who had sustained their first injury at an older age (ages 20-24 y) with more than 25% increase in relative risk across all outcomes compared to the youngest age group (ages 0-4 y). On the population level, TBI explained between 2%-6% of the variance in the examined outcomes. Using hospital data underestimates milder forms of TBI, but such misclassification bias suggests that the reported estimates are likely conservative. The sibling-comparison design accounts for unmeasured familial confounders shared by siblings, including half of their genes. Thus, residual genetic confounding remains a possibility but will unlikely alter our main findings, as associations were only marginally attenuated within families. Conclusions Given our findings, which indicate potentially causal effects between TBI exposure in childhood and later impairments across a range of health and social outcomes, age-sensitive clinical guidelines should be considered and preventive strategies should be targeted at children and adolescents.	[Sariaslan, Amir; Fazel, Seena] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England; [Sharp, David J.] Imperial Coll, Computat Cognit & Clin Neuroimaging Lab, London, England; [D'Onofrio, Brian M.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA; [Larsson, Henrik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Larsson, Henrik] Univ Orebro, Sch Med Sci, Orebro, Sweden	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England.	seena.fazel@psych.ox.ac.uk	Sharp, David J/A-2119-2013; Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365; Sariaslan, Amir/0000-0002-6151-3278	Wellcome TrustWellcome TrustEuropean Commission [095806]; Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); Swedish Research CouncilSwedish Research CouncilEuropean Commission [2010-3184, 2011-2492, 2013-5867]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD061817]; National Institute for Health Research (NIHR) ProfessorshipNational Institute for Health Research (NIHR) [NIHR-RP-011-048]; Shire; American Foundation for Suicide Prevention; Indiana Clinical and Translational Sciences Institute; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	The study was supported by the Wellcome Trust (095806), the Swedish Council for Working Life and Social Research, the Swedish Research Council (2010-3184; 2011-2492; 2013-5867), and the National Institute of Child Health and Human Development (HD061817). DJS is supported by a National Institute for Health Research (NIHR) Professorship (NIHR-RP-011-048). HL has served as a speaker for Eli-Lilly and Shire and has received a research grant from Shire; all outside the submitted work. BMD is receiving funding from the American Foundation for Suicide Prevention and the Indiana Clinical and Translational Sciences Institute, both outside of the submitted work. The funders were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript.	Allison P. D, 2009, FIXED EFFECTS REGRES; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carlin JB, 2005, INT J EPIDEMIOL, V34, P1089, DOI 10.1093/ije/dyi153; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; D'Onofrio BM, 2013, AM J PUBLIC HEALTH, V103, P46, DOI 10.2105/AJPH.2013.301252; Dahlqwist E., 2015, MODEL BASED ESTIMATI; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Ewing-Cobbs L, 2013, J INT NEUROPSYCH SOC, V19, P497, DOI 10.1017/S1355617713000210; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Fazel S, 2006, AM J PSYCHIAT, V163, P1397, DOI 10.1176/appi.ajp.163.8.1397; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gary KW, 2012, TRAUMATIC BRAIN INJU, P175; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Griffen J., 2014, HDB NEUROPSYCHOLOGY, P25; Guskiewicz Kevin, 2014, Neurosurgery, V75 Suppl 4, pS113, DOI 10.1227/NEU.0000000000000494; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hallden K., 2008, INT STANDARD CLASSIF; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lenroot RK, 2006, NEUROSCI BIOBEHAV R, V30, P718, DOI 10.1016/j.neubiorev.2006.06.001; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Narusyte J, 2014, EUR J PUBLIC HEALTH, V24, P106, DOI 10.1093/eurpub/ckt039; Narusyte J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023143; National Institute for Health and Care Excellence (NICE), 2014, HEAD INJ TRIAG ASS E; Nilsson AC., 1994, LAKARTIDNINGEN, V91, P603; Nudo RJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00887; *OECD, 2010, HLTH GLANC 2010; Organisation for Economic Co-operation and Development (OECD), 2014, SOC GLANC 2014 OECD; Orlovska S, 2014, AM J PSYCHIAT, V171, P463, DOI 10.1176/appi.ajp.2013.13020190; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Plomin R, 2015, MOL PSYCHIATR, V20, P98, DOI 10.1038/mp.2014.105; Polderman TJC, 2015, NAT GENET, V47, P702, DOI 10.1038/ng.3285; R Core Team, 2018, R LANG ENV STAT COMP; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Sariaslan A, 2014, BRIT J PSYCHIAT, V205, P286, DOI 10.1192/bjp.bp.113.136200; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Spira JL, 2014, J NEUROTRAUM, V31, P1823, DOI 10.1089/neu.2014.3363; StataCorp, 2015, Stata Statistical Software: Release 14.; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Thurman DJ, J CHILD NEUROL; von Knorring L, 2006, EUR PSYCHIAT, V21, P349, DOI 10.1016/j.eurpsy.2006.04.005; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018; World Health Organization, 2006, NEUR DIS PUBL HLTH C	62	88	88	3	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	AUG	2016	13	8							e1002103	10.1371/journal.pmed.1002103			18	Medicine, General & Internal	General & Internal Medicine	DW0UD	WOS:000383357400020	27552147	DOAJ Gold, Green Published			2021-06-18	
J	Fantini, S; Sassaroli, A; Tgavalekos, KT; Kornbluth, J				Fantini, Sergio; Sassaroli, Angelo; Tgavalekos, Kristen T.; Kornbluth, Joshua			Cerebral blood flow and autoregulation: current measurement techniques and prospects for noninvasive optical methods	NEUROPHOTONICS			English	Article						Cerebral perfusion; autoregulation; computed tomography perfusion; perfusion magnetic resonance imaging; transcranial Doppler; laser Doppler flowmetry; near-infrared spectroscopy; diffuse correlation spectroscopy; coherent hemodynamics spectroscopy	NEAR-INFRARED SPECTROSCOPY; TRANSCRANIAL DOPPLER ULTRASOUND; COHERENT HEMODYNAMICS SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; DIFFUSE CORRELATION SPECTROSCOPY; INTRACRANIAL-PRESSURE; ARTERIAL-PRESSURE; SUBARACHNOID HEMORRHAGE; CEREBROVASCULAR REACTIVITY; MATHEMATICAL-MODEL	Cerebral blood flow (CBF) and cerebral autoregulation (CA) are critically important to maintain proper brain perfusion and supply the brain with the necessary oxygen and energy substrates. Adequate brain perfusion is required to support normal brain function, to achieve successful aging, and to navigate acute and chronic medical conditions. We review the general principles of CBF measurements and the current techniques to measure CBF based on direct intravascular measurements, nuclear medicine, X-ray imaging, magnetic resonance imaging, ultrasound techniques, thermal diffusion, and optical methods. We also review techniques for arterial blood pressure measurements as well as theoretical and experimental methods for the assessment of CA, including recent approaches based on optical techniques. The assessment of cerebral perfusion in the clinical practice is also presented. The comprehensive description of principles, methods, and clinical requirements of CBF and CA measurements highlights the potentially important role that noninvasive optical methods can play in the assessment of neurovascular health. In fact, optical techniques have the ability to provide a noninvasive, quantitative, and continuous monitor of CBF and autoregulation. (C) 2016 Society of Photo-Optical Instrumentation Engineers (SPIE)	[Fantini, Sergio; Sassaroli, Angelo; Tgavalekos, Kristen T.] Tufts Univ, Dept Biomed Engn, 4 Colby St, Medford, MA 02155 USA; [Kornbluth, Joshua] Tufts Univ, Div Neurocrit Care, Dept Neurol, Sch Med, 800 Washington St,Box 314, Boston, MA 02111 USA	Fantini, S (corresponding author), Tufts Univ, Dept Biomed Engn, 4 Colby St, Medford, MA 02155 USA.	sergio.fantini@tufts.edu	Kornbluth, Joshua/U-7807-2019		NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA154774] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA154774] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid R, 2007, STROKE, V38, P1465, DOI 10.1161/STROKEAHA.106.473462; Agarwal N, 2008, J AFFECT DISORDERS, V110, P106, DOI 10.1016/j.jad.2008.01.013; Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Araki T, 2014, INT J GERIATR PSYCH, V29, P881, DOI 10.1002/gps.4074; Asenbaum S, 1998, J NUCL MED, V39, P613; Banaji M, 2005, MATH BIOSCI, V194, P125, DOI 10.1016/j.mbs.2004.10.005; Banaji M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000212; BARBER TW, 1970, ACTA NEUROL SCAND, V46, P85, DOI 10.1111/j.1600-0404.1970.tb05606.x; Bassan H, 2005, PEDIATR RES, V57, P35, DOI 10.1203/01.PDR.0000147576.84092.F9; Beevers G, 2001, BMJ-BRIT MED J, V322, P1043, DOI 10.1136/bmj.322.7293.1043; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bell RD, 2009, ACTA NEUROPATHOL, V118, P103, DOI 10.1007/s00401-009-0522-3; Berg RMG, 2016, SCAND J CLIN LAB INV, V76, P88, DOI 10.3109/00365513.2015.1091495; Bhatia A, 2007, INTENS CARE MED, V33, P1263, DOI 10.1007/s00134-007-0678-z; BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; Blokland JAK, 2002, EUR J RADIOL, V44, P70, DOI 10.1016/S0720-048X(02)00003-7; Boas DA, 1997, J OPT SOC AM A, V14, P192, DOI 10.1364/JOSAA.14.000192; BOGDAHN U, 1990, STROKE, V21, P1680, DOI 10.1161/01.STR.21.12.1680; Bor-Seng-Shu E, 2012, ARQ NEURO-PSIQUIAT, V70, P357, DOI 10.1590/S0004-282X2012000500010; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brickman AM, 2015, NEUROSCI LETT, V592, P54, DOI 10.1016/j.neulet.2015.03.005; Brown DW, 2002, PEDIATR RES, V51, P564, DOI 10.1203/00006450-200205000-00004; Buckley EM, 2014, NEUROPHOTONICS, V1, DOI 10.1117/1.NPh.1.1.011009; Budohoski KP, 2013, J CEREBR BLOOD F MET, V33, P449, DOI 10.1038/jcbfm.2012.189; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Burton VJ, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0464-4; Calamante F, 1999, J CEREBR BLOOD F MET, V19, P701, DOI 10.1097/00004647-199907000-00001; Caldwell M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126695; Calviere L, 2015, NEUROCRIT CARE, V23, P253, DOI 10.1007/s12028-015-0125-x; CARLSEN O, 1987, PHYS MED BIOL, V32, P1457, DOI 10.1088/0031-9155/32/11/007; Carlson AP, 2011, AM J NEURORADIOL, V32, P1315, DOI 10.3174/ajnr.A2522; Casati A, 2005, ANESTH ANALG, V101, P740, DOI 10.1213/01.ane.0000166974.96219.cd; Cebeci H, 2014, EUR J RADIOL, V83, P1914, DOI 10.1016/j.ejrad.2014.07.002; Charbel FT, 1999, J NEUROSURG, V91, P1050, DOI 10.3171/jns.1999.91.6.1050; CHEN RYZ, 1980, J APPL PHYSIOL, V49, P178; Chen XY, 2006, J NEUROPSYCH CLIN N, V18, P178, DOI 10.1176/appi.neuropsych.18.2.178; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper JA, 2011, J APPL PHYSIOL, V110, P1691, DOI 10.1152/japplphysiol.01458.2010; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; da Costa Leodante, 2015, Acta Neurochir Suppl, V120, P105, DOI 10.1007/978-3-319-04981-6_18; de Boorder MJ, 2004, STROKE, V35, P1350, DOI 10.1161/01.STR.0000128530.75424.63; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Detre JA, 1999, EUR J RADIOL, V30, P115, DOI 10.1016/S0720-048X(99)00050-9; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Dieterle T., 2012, SWISS MED WKLY, V142, P1; Dineen NE, 2010, J APPL PHYSIOL, V108, P604, DOI 10.1152/japplphysiol.01157.2009; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; Durduran T., 2004, THESIS; Durduran T, 2014, NEUROIMAGE, V85, P51, DOI 10.1016/j.neuroimage.2013.06.017; EDELMAN RR, 1994, RADIOLOGY, V192, P513, DOI 10.1148/radiology.192.2.8029425; EDWARDS AD, 1988, LANCET, V2, P770; ELWELL CE, 1994, J APPL PHYSIOL, V77, P2753; Essig M, 2013, AM J ROENTGENOL, V200, P24, DOI 10.2214/AJR.12.9543; Fabbri F, 2003, BRAIN RES, V992, P193, DOI 10.1016/j.brainres.2003.08.034; Fantini S, 2016, PROC SPIE, V9690, DOI 10.1117/12.2213139; Fantini S, 2014, PHYSIOL MEAS, V35, pN1, DOI 10.1088/0967-3334/35/1/N1; Fantini S, 2014, NEUROIMAGE, V85, P202, DOI 10.1016/j.neuroimage.2013.03.065; Ferrari M, 2012, NEUROIMAGE, V63, P921, DOI 10.1016/j.neuroimage.2012.03.049; Fog M, 1939, ARCH NEURO PSYCHIATR, V41, P260, DOI 10.1001/archneurpsyc.1939.02270140046003; Fredriksson I., 2007, LASER DOPPLER FLOWME; GARDNER RM, 1981, ANESTHESIOLOGY, V54, P227, DOI 10.1097/00000542-198103000-00010; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Girouard H, 2006, J APPL PHYSIOL, V100, P328, DOI 10.1152/japplphysiol.00966.2005; Golay Xavier, 2004, Top Magn Reson Imaging, V15, P10, DOI 10.1097/00002142-200402000-00003; Granata G, 2015, AUTOIMMUN REV, V14, P830, DOI 10.1016/j.autrev.2015.05.006; Hahn GH, 2011, PEDIATR RES, V70, P166, DOI 10.1203/PDR.0b013e3182231d9e; Han SJ, 2015, J CLIN NEUROSCI, V22, P1771, DOI 10.1016/j.jocn.2015.05.026; HANSON EJ, 1975, CIRC RES, V36, P18, DOI 10.1161/01.RES.36.1.18; Hecht N, 2013, J CEREBR BLOOD F MET, V33, P1000, DOI 10.1038/jcbfm.2013.42; Hecht N, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09148; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HOEDTRASMUSSEN K, 1966, CIRC RES, V18, P237; Hoeffner EG, 2004, RADIOLOGY, V231, P632, DOI 10.1148/radiol.2313021488; HOLMAN BL, 1972, J NUCL MED, V13, P916; Hori D, 2015, ANESTH ANALG, V121, P1187, DOI 10.1213/ANE.0000000000000930; Horsfield MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062588; Hosoda K, 2001, STROKE, V32, P1567, DOI 10.1161/01.STR.32.7.1567; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Imamura K, 2012, ACTA NEUROL SCAND, V126, P210, DOI 10.1111/j.1600-0404.2012.01652.x; Imholz BPM, 1998, CARDIOVASC RES, V38, P605, DOI 10.1016/S0008-6363(98)00067-4; Indelicato E, 2015, PARKINSONISM RELAT D, V21, P1393, DOI 10.1016/j.parkreldis.2015.10.018; INGVAR DH, 1961, LANCET, V2, P806, DOI 10.1016/S0140-6736(61)91092-3; Ishizu K, 1996, J NUCL MED, V37, P1600; JOBES DR, 1975, ANESTHESIOLOGY, V42, P30, DOI 10.1097/00000542-197501000-00006; JOHNSON DW, 1991, AM J NEURORADIOL, V12, P201; Johnson U, 2014, NEUROCRIT CARE, V21, P259, DOI 10.1007/s12028-014-9954-2; Kainerstorfer JM, 2015, J CEREBR BLOOD F MET, V35, P959, DOI 10.1038/jcbfm.2015.5; Kainerstorfer JM, 2014, BIOMED OPT EXPRESS, V5, P3403, DOI 10.1364/BOE.5.003403; Kainerstorfer JM, 2014, ACAD RADIOL, V21, P185, DOI 10.1016/j.acra.2013.10.012; KETY SS, 1945, AM J PHYSIOL, V143, P53; KETY SS, 1948, AM J PSYCHIAT, V104, P765, DOI 10.1176/ajp.104.12.765; KETY SS, 1951, PHARMACOL REV, V3, P1; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Kim MN, 2014, NEUROCRIT CARE, V20, P443, DOI 10.1007/s12028-013-9849-7; Kim S.- G., 1995, MAGN RESON MED, V37, P425; Kirkham SK, 2001, PHYSIOL MEAS, V22, P461, DOI 10.1088/0967-3334/22/3/305; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Koehler RC, 2009, TRENDS NEUROSCI, V32, P160, DOI 10.1016/j.tins.2008.11.005; Kolodjaschna J, 2005, INVEST OPHTH VIS SCI, V46, P636, DOI 10.1167/iovs.04-0717; Komoribayashi N, 2006, J CEREBR BLOOD F MET, V26, P878, DOI 10.1038/sj.jcbfm.9600244; KONTOS HA, 1981, ANNU REV PHYSIOL, V43, P397, DOI 10.1146/annurev.ph.43.030181.002145; Korfiatis P, 2014, APPL RADIOL, V43, P22; Kumar G, 2016, J NEUROSURG, V124, P1257, DOI 10.3171/2015.4.JNS15428; Kuo JR, 2013, J NEUROSCI METH, V214, P204, DOI 10.1016/j.jneumeth.2013.01.025; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lamy C, 2014, Handb Clin Neurol, V121, P1687, DOI 10.1016/B978-0-7020-4088-7.00109-7; LASSEN NA, 1988, J CEREBR BLOOD F MET, V8, pS13, DOI 10.1038/jcbfm.1988.28; LASSEN NA, 1985, J CEREBR BLOOD F MET, V5, P347, DOI 10.1038/jcbfm.1985.48; LASSEN NA, 1963, NEUROLOGY, V13, P719, DOI 10.1212/WNL.13.9.719; LASSEN NA, 1959, PHYSIOL REV, V39, P183; LASSEN NA, 1965, ACTA NEUROL SCAND, VS 41, P24; Latchaw RE, 2003, STROKE, V34, P1084, DOI 10.1161/01.STR.0000064840.99271.9E; Latka M, 2005, AM J PHYSIOL-HEART C, V289, pH2272, DOI 10.1152/ajpheart.01307.2004; Le Roux P., 2013, TXB NEUROINTENSIVE C, P127; Leal-Noval SR, 2010, INTENS CARE MED, V36, P1309, DOI 10.1007/s00134-010-1920-7; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lee SC, 2005, J CLIN NEUROSCI, V12, P520, DOI 10.1016/j.jocn.2004.07.016; Leung TS, 2007, APPL OPTICS, V46, P1604, DOI 10.1364/AO.46.001604; LEVEILLE J, 1989, J NUCL MED, V30, P1902; Li TQ, 2000, MAGN RESON IMAGING, V18, P503, DOI 10.1016/S0730-725X(00)00137-5; Lin BS, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0465-3; Lu J, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00199; Malinova V., 2015, J NEUROSURG, P1; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin GT, 2000, MED BIOL ENG COMPUT, V38, P319, DOI 10.1007/BF02347053; MATSUDA H, 1992, CLIN NUCL MED, V17, P581, DOI 10.1097/00003072-199207000-00011; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; McDonnell MN, 2013, PEERJ, V1, DOI 10.7717/peerj.65; MEIER P, 1954, J APPL PHYSIOL, V6, P731; Melot C, 1996, J CEREBR BLOOD F MET, V16, P1263, DOI 10.1097/00004647-199611000-00022; Mesquita RC, 2013, BIOMED OPT EXPRESS, V4, P978, DOI 10.1364/BOE.4.000978; Miller C, 2014, NEUROCRIT CARE, V21, P121, DOI 10.1007/s12028-014-0021-9; Minciotti P, 1997, ITAL J NEUROL SCI, V18, P21, DOI 10.1007/BF02106226; Mitsis GD, 2004, IEEE T BIO-MED ENG, V51, P1932, DOI 10.1109/TBME.2004.834272; Monden Y, 2012, CLIN NEUROPHYSIOL, V123, P1147, DOI 10.1016/j.clinph.2011.10.006; Moxham IM., 2014, S AFR J ANAESTH ANAL, V9, P33, DOI [10.1080/22201173.2003.10872990, DOI 10.1080/22201173.2003.10872990]; Nelson MR, 2010, MAYO CLIN PROC, V85, P460, DOI 10.4065/mcp.2009.0336; Nissen P, 2009, NEUROCRIT CARE, V11, P235, DOI 10.1007/s12028-009-9226-8; Novak V, 2004, BIOMED ENG ONLINE, V3, DOI 10.1186/1475-925X-3-39; Numan T, 2014, MED ENG PHYS, V36, P1487, DOI 10.1016/j.medengphy.2014.08.001; Ogedegbe G, 2010, CARDIOL CLIN, V28, P571, DOI 10.1016/j.ccl.2010.07.006; Olesen J, 1971, STROKE, V2, P519, DOI 10.1161/01.STR.2.6.519; Olufsen MS, 2002, AM J PHYSIOL-REG I, V282, pR611, DOI 10.1152/ajpregu.00285.2001; Orrison WW, 2011, CLIN RADIOL, V66, P566, DOI 10.1016/j.crad.2010.12.014; Ostergaard L, 2005, J MAGN RESON IMAGING, V22, P710, DOI 10.1002/jmri.20460; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Ouriel K, 1999, J VASC SURG, V29, P82, DOI 10.1016/S0741-5214(99)70362-9; Panerai R. B., 1993, Proceedings. Computers in Cardiology 1993 (Cat. No.93CH3384-5), P779, DOI 10.1109/CIC.1993.378369; PANERAI RB, 1995, STROKE, V26, P74, DOI 10.1161/01.STR.26.1.74; Panerai RB, 1996, IEEE T BIO-MED ENG, V43, P779, DOI 10.1109/10.508541; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; Payne SJ, 2006, MATH BIOSCI, V204, P260, DOI 10.1016/j.mbs.2006.08.006; Payne SJ, 2006, ANN BIOMED ENG, V34, P847, DOI 10.1007/s10439-006-9114-8; Payne SJ, 2011, BIOMED OPT EXPRESS, V2, P966, DOI 10.1364/BOE.2.000979; Peter L, 2014, IRBM, V35, P271, DOI 10.1016/j.irbm.2014.07.002; Pierro ML, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.2.026005; Pierro ML, 2014, NEUROIMAGE, V85, P222, DOI 10.1016/j.neuroimage.2013.03.037; Pinkham A, 2011, PSYCHIAT RES-NEUROIM, V194, P64, DOI 10.1016/j.pscychresns.2011.06.013; Pollard V, 1997, CRIT CARE MED, V25, P1700, DOI 10.1097/00003246-199710000-00020; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Proust F, 1999, STROKE, V30, P1091, DOI 10.1161/01.STR.30.5.1091; RAICHLE ME, 1983, J NUCL MED, V24, P790; RAICHLE ME, 1979, BRAIN RES REV, V1, P47, DOI 10.1016/0165-0173(79)90016-X; Reinhard M, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.9.097005; ROBERTS HC, 2001, SEM CEREBROVASC DIS, V1, P303; ROBERTS I, 1993, LANCET, V342, P1425, DOI 10.1016/0140-6736(93)92786-S; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; Rostami E, 2014, FRONT NEUROL, V5, P1; Rostami E, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00089; Sabri O, 1997, LANCET, V349, P1735, DOI 10.1016/S0140-6736(96)08380-8; Sahani D. V., 2010, INT SOC MAGNETIC RES, V18; Salibi PN, 2014, AM J ROENTGENOL, V202, P397, DOI 10.2214/AJR.12.10294; Sanderson ML, 2002, FLOW MEAS INSTRUM, V13, P125, DOI 10.1016/S0955-5986(02)00043-2; Sassaroli A, 2016, J THEOR BIOL, V389, P132, DOI 10.1016/j.jtbi.2015.11.001; SATO T, 1993, HYPERTENSION, V21, P866, DOI 10.1161/01.HYP.21.6.866; Schmidt B, 2009, J NEUROTRAUM, V26, P651, DOI 10.1089/neu.2008.0784; SCHMIDT JF, 1990, J CARDIOVASC PHARM, V15, P983, DOI 10.1097/00005344-199006000-00017; Scholkmann F, 2014, NEUROIMAGE, V85, P6, DOI 10.1016/j.neuroimage.2013.05.004; Seubert CN, 2013, TXB NEUROINTENSIVE C, P109; Shin JH, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790783; Sidtis JJ, 2012, J CEREBR BLOOD F MET, V32, P41, DOI 10.1038/jcbfm.2011.135; Smith M, 2011, PHILOS T R SOC A, V369, P4452, DOI 10.1098/rsta.2011.0242; Smith N.B., 2011, INTRO MED IMAGING PH; Soul JS, 2007, PEDIATR RES, V61, P467, DOI 10.1203/pdr.0b013e31803237f6; Soul JS, 2000, PEDIATR RES, V48, P445, DOI 10.1203/00006450-200010000-00005; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; STERN MD, 1975, NATURE, V254, P56, DOI 10.1038/254056a0; Sutherland BA, 2014, METHODS MOL BIOL, V1135, P237, DOI 10.1007/978-1-4939-0320-7_20; Tan CO, 2014, EXP PHYSIOL, V99, P3, DOI 10.1113/expphysiol.2013.072355; Tan CO, 2012, J APPL PHYSIOL, V113, P1194, DOI 10.1152/japplphysiol.00783.2012; Taussky P, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2011.12.FOCUS11280; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Togao O., 2016, NEUROONCOL, V18, P132; Torricelli A, 2014, NEUROIMAGE, V85, P28, DOI 10.1016/j.neuroimage.2013.05.106; Traystman RJ, 2004, J APPL PHYSIOL, V97, P1601, DOI 10.1152/classicessays.00023.2004; Tsalach A, 2015, BIOMED OPT EXPRESS, V6, P4871, DOI 10.1364/BOE.6.004871; Tsuji M, 2000, PEDIATRICS, V106, P625, DOI 10.1542/peds.106.4.625; Tsuji M, 1998, PEDIATR RES, V44, P591, DOI 10.1203/00006450-199810000-00020; Turowski B, 2015, CLIN NEURORADIOL, V25, P205, DOI 10.1007/s00062-015-0444-5; Tzeng YC, 2014, EUR J APPL PHYSIOL, V114, P545, DOI 10.1007/s00421-013-2667-y; Tzeng YC, 2011, J PHYSIOL-LONDON, V589, P3263, DOI 10.1113/jphysiol.2011.206953; Ursino M, 1998, AM J PHYSIOL-HEART C, V274, pH1715; Ursino M, 2000, AM J PHYSIOL-HEART C, V279, pH2439; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459; URSINO M, 1995, IEEE T BIO-MED ENG, V42, P529, DOI 10.1109/10.387192; URSINO M, 1988, ANN BIOMED ENG, V16, P379, DOI 10.1007/BF02364625; Ursino M, 1997, J APPL PHYSIOL, V82, P1256; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valotassiou V, 2015, J ALZHEIMERS DIS, V47, P773, DOI 10.3233/JAD-150068; VALVANO JW, 1984, J BIOMECH ENG-T ASME, V106, P192, DOI 10.1115/1.3138482; Vasic N, 2015, J PSYCHIATR NEUROSCI, V40, P412, DOI 10.1503/jpn.140246; Vavilala Monica S, 2002, Anesthesiol Clin North Am, V20, P247, DOI 10.1016/S0889-8537(01)00012-8; Verdecchia K, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.027007; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; Wagner BP, 2011, PEDIATR RES, V69, P436, DOI 10.1203/PDR.0b013e3182110177; Wagner BP, 2002, CRIT CARE MED, V30, P2014, DOI 10.1097/00003246-200209000-00010; WALOVITCH RC, 1989, J NUCL MED, V30, P1892; WESSELING KH, 1995, HOMEOSTASIS HLTH DIS, V36, P67; Wierenga CE, 2014, J ALZHEIMERS DIS, V42, pS411, DOI 10.3233/JAD-141467; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; Willie CK, 2012, J PHYSIOL-LONDON, V590, P3261, DOI 10.1113/jphysiol.2012.228551; Wilson EM, 1970, STROKE, V1, P348, DOI 10.1161/01.STR.1.5.348; Wintermark M, 2006, AM J NEURORADIOL, V27, P26; WOLFF J, 1994, ANESTHESIOLOGY, V81, P623, DOI 10.1097/00000542-199409000-00015; Wong EC, 1997, NMR BIOMED, V10, P237, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<237::AID-NBM475>3.0.CO;2-X; Wong EC, 1998, MAGNET RESON MED, V39, P702, DOI 10.1002/mrm.1910390506; Wong FY, 2008, PEDIATRICS, V121, pE604, DOI 10.1542/peds.2007-1487; Yousem DM, 2014, NEUROIMAG CLIN N AM, V24, P717, DOI 10.1016/j.nic.2014.07.007; Zazulia AR, 2010, J CEREBR BLOOD F MET, V30, P1883, DOI 10.1038/jcbfm.2010.135; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; ZIERLER KL, 1965, CIRC RES, V16, P309, DOI 10.1161/01.RES.16.4.309; ZIERLER KL, 1962, CIRC RES, V10, P393, DOI 10.1161/01.RES.10.3.393; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320; ZYGMUNT SC, 1995, ACTA NEUROCHIR, V135, P179, DOI 10.1007/BF02187765	245	88	89	2	19	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	2329-423X	2329-4248		NEUROPHOTONICS	Neurophotonics	JUL-SEP	2016	3	3							031411	10.1117/1.NPh.3.3.031411			31	Neurosciences; Optics	Neurosciences & Neurology; Optics	EF8MG	WOS:000390582600011	27403447	Green Published, Bronze			2021-06-18	
J	Losoi, H; Silverberg, ND; Waljas, M; Turunen, S; Rosti-Otajarvi, E; Helminen, M; Luoto, TM; Julkunen, J; Ohman, J; Iverson, GL				Losoi, Heidi; Silverberg, Noah D.; Waljas, Minna; Turunen, Senni; Rosti-Otajarvi, Eija; Helminen, Mika; Luoto, Teemu M.; Julkunen, Juhani; Ohman, Juha; Iverson, Grant L.			Recovery from Mild Traumatic Brain Injury in Previously Healthy Adults	JOURNAL OF NEUROTRAUMA			English	Article						outcome; traumatic brain injury; post-concussion syndrome; head injury; cognitive	QUALITY-OF-LIFE; POST-CONCUSSION SYMPTOMS; BNI FATIGUE SCALE; HEAD-INJURY; POSTCONCUSSION SYNDROME; RELIABILITY; METAANALYSES; IMPAIRMENT; GUIDELINES; VALIDITY	This prospective longitudinal study reports recovery from mild traumatic brain injury (MTBI) across multiple domains in a carefully selected consecutive sample of 74 previously healthy adults. The patients with MTBI and 40 orthopedic controls (i.e., ankle injuries) completed assessments at 1, 6, and 12 months after injury. Outcome measures included cognition, post-concussion symptoms, depression, traumatic stress, quality of life, satisfaction with life, resilience, and return to work. Patients with MTBI reported more post-concussion symptoms and fatigue than the controls at the beginning of recovery, but by 6 months after injury, did not differ as a group from nonhead injury trauma controls on cognition, fatigue, or mental health, and by 12 months, their level of post-concussion symptoms and quality of life was similar to that of controls. Almost all (96%) patients with MTBI returned to work/normal activities (RTW) within the follow-up of 1 year. A subgroup of those with MTBIs and controls reported mild post-concussion-like symptoms at 1 year. A large percentage of the subgroup who had persistent symptoms had a modifiable psychological risk factor at 1 month (i.e., depression, traumatic stress, and/or low resilience), and at 6 months, they had greater post-concussion symptoms, fatigue, insomnia, traumatic stress, and depression, and worse quality of life. All of the control subjects who had mild post-concussion-like symptoms at 12 months also had a mental health problem (i.e., depression, traumatic stress, or both). This illustrates the importance of providing evidence-supported treatment and rehabilitation services early in the recovery period.	[Losoi, Heidi; Waljas, Minna; Turunen, Senni; Rosti-Otajarvi, Eija; Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, POB 2000, FI-33521 Tampere, Finland; [Losoi, Heidi; Julkunen, Juhani] Univ Helsinki, Inst Behav Sci, Helsinki, Finland; [Silverberg, Noah D.] Univ British Columbia, GF Strong Rehab Ctr, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Helminen, Mika] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland; [Helminen, Mika] Pirkanmaa Hosp Dist, Ctr Sci, Tampere, Finland; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Charlestown Navy Yard, Charlestown, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Losoi, H (corresponding author), Tampere Univ Hosp, Dept Neurosci & Rehabil, POB 2000, FI-33521 Tampere, Finland.	heidi.losoi@gmail.com	Helminen, Mika T/I-3900-2016; Luoto, Teemu/W-6468-2018	Helminen, Mika T/0000-0001-5695-2084; Luoto, Teemu/0000-0002-7329-3284; Ohman, Juha/0000-0002-6592-1367; Iverson, Grant/0000-0001-7348-9570			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Army Individual Test Battery, 1944, MAN DIR SCOR; Ashley J, 1990, Health Trends, V22, P135; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beck AT., 1996, BECK DEPRESSION INVE, V2; Beseoglu K, 2013, BRIT J NEUROSURG, V27, P202, DOI 10.3109/02688697.2012.717984; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Brooks BL, 2009, DEMENT GERIATR COGN, V27, P439, DOI 10.1159/000215390; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Halstead WC, 1947, BRAIN INTELLIGENCE; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson GL, 2012, NEUROPSYCHOLOGICAL A, P360; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kristman VL, 2014, ARCH PHYS MED REH S3, V95, pS266; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mistridis P, 2015, EUR ARCH PSY CLIN N, V265, P407, DOI 10.1007/s00406-014-0571-z; Mitrushina M., 2005, HDB NORMATIVE DATA N; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Wagnild G M, 1993, J Nurs Meas, V1, P165; Waljas M, 2012, BRAIN INJURY, V26, P972, DOI 10.3109/02699052.2012.660511; Weathers F.W., 1993, 9 ANN C ISTSS SAN AN; Wechsler D., 2008, WECHSLER ADULT INTEL; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	54	88	88	1	58	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					766	776		10.1089/neu.2015.4070			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900007	26437675				2021-06-18	
J	Lynall, RC; Mauntel, TC; Padua, DA; Mihalik, JP				Lynall, Robert C.; Mauntel, Timothy C.; Padua, Darin A.; Mihalik, Jason P.			Acute Lower Extremity Injury Rates Increase after Concussion in College Athletes	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						MUSCULOSKELETAL INJURY RISK; POSTCONCUSSION DEFICITS; CONCUSSION; INJURY; COLLEGE ATHLETICS	STABILITY FOLLOWING CONCUSSION; SPORT-RELATED CONCUSSION; BALANCE CONTROL; POSTURAL STABILITY; FOOTBALL PLAYERS; HIGH-SCHOOL; GAIT; RECOVERY; ATTENTION; RISK	Dynamic postural control deficits and disrupted cortical pathways have been reported to persist beyond an athlete's return to activity after concussion, potentially increasing the risk of acute lower extremity musculoskeletal injury. Purpose This study aimed to investigate acute lower extremity musculoskeletal injury rates before and after concussion in athletes with concussion and their matched control. Methods College athletes with concussion (n = 44; age, 20.0 1.2 yr) were physician-diagnosed. Nonconcussed college athletes (n = 58; age, 20.5 1.3 yr) were matched to individuals with concussion. Acute lower extremity musculoskeletal injury data were collected for 2 yr (+/- 1 yr of the diagnosed concussion) using electronic medical records. Control participants' 2-yr window for exposure and musculoskeletal injury data were anchored to their match's concussion injury date. Pre- and postconcussion musculoskeletal injury rates were calculated for 90-, 180-, and 365-d periods for both study cohorts. Risk ratios were calculated to determine differences within and between groups for all periods. Results Within 1 yr after concussion, the group with concussion was 1.97 (95% confidence interval (CI), 1.19-3.28; P = 0.01) times more likely to have experienced an acute lower extremity musculoskeletal injury after concussion than before concussion and 1.64 times (95% CI, 1.07-2.51; P = 0.02) more likely to have experienced an acute lower extremity musculoskeletal injury after concussion than their matched nonconcussed cohort over the same period. Up to 180 d after concussion, the group with concussion was 2.02 (95% CI, 1.08-3.78; P = 0.02) times more likely to have experienced an acute lower extremity musculoskeletal injury after concussion than before concussion. Conclusions Previous literature has identified dynamic postural control deficits along with increased motor evoked potential latency and decreased amplitude after concussion, suggesting that the brain may be unable to effectively coordinate movement. Our findings underscore the need to explore functional movement and dynamic postural control assessments in postconcussion injury assessment protocols.	[Lynall, Robert C.; Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA; [Lynall, Robert C.; Mauntel, Timothy C.; Padua, Darin A.; Mihalik, Jason P.] Univ N Carolina, Dept Allied Hlth Sci, Sch Med, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA; [Mauntel, Timothy C.; Padua, Darin A.] Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA	Lynall, RC (corresponding author), Univ N Carolina, 2207 Stallings Evans Sports Med Ctr,Campus Box 87, Chapel Hill, NC 27599 USA.	rlynall@live.unc.edu	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640; Padua, Darin/0000-0002-9383-4236			Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Finch C F, 1999, J Sci Med Sport, V2, P42, DOI 10.1016/S1440-2440(99)80183-2; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Kristenson K, 2013, AM J SPORT MED, V41, P1419, DOI 10.1177/0363546513485358; LINDENFELD TN, 1994, AM J SPORT MED, V22, P364, DOI 10.1177/036354659402200312; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Pietrosimone BG, 2012, J ATHL TRAINING, V47, P621, DOI 10.4085/1062-6050-47.6.11; Plisky PJ, 2006, J ORTHOP SPORT PHYS, V36, P911, DOI 10.2519/jospt.2006.2244; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Zazulak BT, 2007, AM J SPORT MED, V35, P1123, DOI 10.1177/0363546507301585	30	88	88	1	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2015	47	12					2487	2492		10.1249/MSS.0000000000000716			6	Sport Sciences	Sport Sciences	CV8TX	WOS:000364561800001	26057941				2021-06-18	
J	Pearce, KL; Sufrinko, A; Lau, BC; Henry, L; Collins, MW; Kontos, AP				Pearce, Kelly L.; Sufrinko, Alicia; Lau, Brian C.; Henry, Luke; Collins, Michael W.; Kontos, Anthony P.			Near Point of Convergence After a Sport-Related Concussion: Measurement Reliability and Relationship to Neurocognitive Impairment and Symptoms	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; eye injuries; convergence insufficiency; neurocognitive impairment	EYE-MOVEMENT; INSUFFICIENCY; AREA; CLASSIFICATION; SPECIFICITY; SENSITIVITY; NEARPOINT; DEFICITS; NEURONS; IMPACT	Background: Convergence insufficiency (CI) is a common binocular vision deficit after a sport-related concussion (SRC). CI may result in visual discomfort and vision-mediated functional difficulties such as slowed reading and compromised attention, leading to impaired academic, work, and sport performance. Purpose: To test the reliability of repeated near point of convergence (NPC) measurements in a sample of athletes after an SRC; compare the symptoms and cognitive impairment of athletes with normal NPC to those with CI after an SRC; and explore the relationship among age, sex, learning disability, migraine history, and CI. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A total of 78 athletes (mean age, 14.31 2.77 years) who were seen a mean 5.79 5.63 days after an SRC were administered 3 trials of an NPC assessment, along with neurocognitive (Immediate Post-Concussion Assessment and Cognitive Testing [ImPACT]) and symptom assessments. Patients were divided into normal NPC (NPC 5 cm; n = 45) and CI (NPC >5 cm; n = 33) groups. Intraclass correlation coefficients (ICCs) and repeated-measures analyses of variance (ANOVAs) assessed the consistency of NPC across the 3 trials. The ANOVAs were employed to examine differences on neurocognitive composites and symptoms between the normal NPC and CI groups. Stepwise regressions (controlling for age and symptom scores on the Post-Concussion Symptom Scale [PCSS]) were conducted to evaluate the predictive utility of the NPC distance for neurocognitive impairment. Results: Groups did not differ on demographic or injury characteristics. NPC differed between trial 1 and trials 2 (P = .02) and 3 (P = .01) for the CI group but not the normal NPC group. Internal consistency was high across NPC measurements (ICC range, 0.95-0.98). Patients with CI performed worse on verbal memory (P = .02), visual motor speed (P = .02), and reaction time (P = .001, (2) = .13) and had greater total symptom scores (P = .02) after the injury. Results of hierarchical regression revealed that the NPC distance contributed significantly to the model for reaction time (P < .001). Conclusion: CI was common (similar to 42%) in athletes evaluated within 1 month after an SRC. Athletes with CI had worse neurocognitive impairment and higher symptom scores than did those with normal NPC. Clinicians should consider routinely screening for NPC as part of a comprehensive concussion evaluation to help inform treatment recommendations, academic accommodations, and referrals for vision therapy.	[Pearce, Kelly L.; Sufrinko, Alicia; Lau, Brian C.; Henry, Luke; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, Pittsburgh, PA USA	Kontos, AP (corresponding author), UPMC, Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication Disorders, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: This research was supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders, National Institutes of Health (1K01DC012332-01A1). M.W.C. is a cofounder and 10% shareholder of ImPACT Applications Inc.	Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Borsting Eric, 2005, Optometry, V76, P588, DOI 10.1016/j.optm.2005.07.007; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; COOPER J, 1978, J AM OPTOM ASSOC, V49, P673; Cooper J, 2012, OPTOMETRY, V83, P20; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; DAVIES CE, 1946, CAN MED ASSOC J, V55, P47; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Gamlin PD, 2000, NATURE, V407, P1003, DOI 10.1038/35039506; GNADT JW, 1995, J NEUROPHYSIOL, V73, P280; GRISHAM JD, 1988, AM J OPTOM PHYS OPT, V65, P448; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maples WC, 2007, OPTOMETRY VISION SCI, V84, P224, DOI 10.1097/OPX.0b013e3180339f44; MAYS LE, 1984, J NEUROPHYSIOL, V51, P1091; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGregor ML, 2014, PEDIATR CLIN N AM, V61, P621, DOI 10.1016/j.pcl.2014.03.010; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pierrot-Deseilligny C, 2004, CURR OPIN NEUROL, V17, P17, DOI 10.1097/00019052-200402000-00005; Prince SJD, 2000, J NEUROSCI, V20, P3387, DOI 10.1523/JNEUROSCI.20-09-03387.2000; Rambold H, 2004, NEUROLOGY, V62, P1850, DOI 10.1212/01.WNL.0000125331.95849.62; Rouse MW, 2002, OPTOMETRY VISION SCI, V79, P254, DOI 10.1097/00006324-200204000-00012; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Singman Eric L, 2014, Am Orthopt J, V64, P112, DOI 10.3368/aoj.64.1.112; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Zuckerman SL, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417735.94052.d6	39	88	88	0	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2015	43	12					3055	3061		10.1177/0363546515606430			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CX5RU	WOS:000365761000025	26453625	Green Accepted			2021-06-18	
J	Shultz, SR; Wright, DK; Zheng, P; Stuchbery, R; Liu, SJ; Sashindranath, M; Medcalf, RL; Johnston, LA; Hovens, CM; Jones, NC; O'Brien, TJ				Shultz, Sandy R.; Wright, David K.; Zheng, Ping; Stuchbery, Ryan; Liu, Shi-Jie; Sashindranath, Maithili; Medcalf, Robert L.; Johnston, Leigh A.; Hovens, Christopher M.; Jones, Nigel C.; O'Brien, Terence J.			Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury	BRAIN			English	Article						tau; MRI; DTI; protein phosphatase 2A; traumatic brain injury	PROTEIN PHOSPHATASE 2A; FLUID PERCUSSION INJURY; ABNORMALLY PHOSPHORYLATED-TAU; ALZHEIMER-DISEASE BRAIN; ANIMAL-MODEL; MOUSE-BRAIN; NEUROFIBRILLARY DEGENERATION; BEHAVIORAL DYSFUNCTION; REPEATED CONCUSSION; CELL-DEATH	Traumatic brain injury is a common and serious neurodegenerative condition that lacks a pharmaceutical intervention to improve long-term outcome. Hyperphosphorylated tau is implicated in some of the consequences of traumatic brain injury and is a potential pharmacological target. Protein phosphatase 2A is a heterotrimeric protein that regulates key signalling pathways, and protein phosphatase 2A heterotrimers consisting of the PR55 B-subunit represent the major tau phosphatase in the brain. Here we investigated whether traumatic brain injury in rats and humans would induce changes in protein phosphatase 2A and phosphorylated tau, and whether treatment with sodium selenate-a potent PR55 activator-would reduce phosphorylated tau and improve traumatic brain injury outcomes in rats. Ninety young adult male Long-Evans rats were administered either a fluid percussion injury or sham-injury. A proportion of rats were killed at 2, 24, and 72 h post-injury to assess acute changes in protein phosphatase 2A and tau. Other rats were given either sodium selenate or saline-vehicle treatment that was continuously administered via subcutaneous osmotic pump for 12 weeks. Serial magnetic resonance imaging was acquired prior to, and at 1, 4, and 12 weeks post-injury to assess evolving structural brain damage and axonal injury. Behavioural impairments were assessed at 12 weeks post-injury. The results showed that traumatic brain injury in rats acutely reduced PR55 expression and protein phosphatase 2A activity, and increased the expression of phosphorylated tau and the ratio of phosphorylated tau to total tau. Similar findings were seen in post-mortem brain samples from acute human traumatic brain injury patients, although many did not reach statistical significance. Continuous sodium selenate treatment for 12 weeks after sham or fluid percussion injury in rats increased protein phosphatase 2A activity and PR55 expression, and reduced the ratio of phosphorylated tau to total tau, attenuated brain damage, and improved behavioural outcomes in rats given a fluid percussion injury. Notably, total tau levels were decreased in rats 12 weeks after fluid percussion injury, and several other factors, including the use of anaesthetic, the length of recovery time, and that some brain injury and behavioural dysfunction still occurred in rats treated with sodium selenate must be considered in the interpretation of this study. However, taken together these data suggest protein phosphatase 2A and hyperphosphorylated tau may be involved in the neurodegenerative cascade of traumatic brain injury, and support the potential use of sodium selenate as a novel traumatic brain injury therapy.	[Shultz, Sandy R.; Zheng, Ping; Liu, Shi-Jie; Jones, Nigel C.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Melbourne Brain Ctr, Dept Med, Parkville, Vic 3050, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Stuchbery, Ryan; Hovens, Christopher M.] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic 3050, Australia; [Sashindranath, Maithili; Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [Johnston, Leigh A.] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic 3010, Australia	Shultz, SR (corresponding author), Univ Melbourne, Dept Med, Melbourne Brain Ctr, Off 1 02, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au	Sashindranath, Maithili/AAI-7408-2021; Medcalf, Robert L/E-9632-2011; Johnston, Leigh A/D-7102-2014	Sashindranath, Maithili/0000-0002-9712-4784; Johnston, Leigh A/0000-0002-5032-4674; Hovens, Christopher/0000-0002-0610-1289; Wright, David/0000-0002-7535-8651; O'Brien, Terence/0000-0002-7198-8621; Jones, Nigel/0000-0002-1080-8439	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1006077, 1062653]; Victorian Transport Accident Commission (Victorian Neurotrauma Initiative Grant) [DNP13]; Alzheimer's Australia Dementia Research Fund; Royal Melbourne Hospital Neuroscience Foundation; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); NHMRCNational Health and Medical Research Council of Australia; Helen Macpherson Smith Trust; Parkinson's VictoriaParkinson's UK; Perpetual Philanthropic Services	This study was funded by grants to T.O., C.H., N.J., M.S. and S.S. from the National Health and Medical Research Council (NHMRC #1006077 and #1062653), the Victorian Transport Accident Commission (Victorian Neurotrauma Initiative Grant #DNP13), the Alzheimer's Australia Dementia Research Fund, the Royal Melbourne Hospital Neuroscience Foundation, and the Canadian Institute of Health Research. Human brain tissues were received from the Victorian Brain Bank Network, supported by the Mental Health Research Institute, The Alfred, Victorian Forensic Institute of Medicine, The University of Melbourne and funded by NHMRC, Helen Macpherson Smith Trust, Parkinson's Victoria and Perpetual Philanthropic Services.	Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Avants BB, 2010, NEUROIMAGE, V49, P2457, DOI 10.1016/j.neuroimage.2009.09.062; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bolognin S, 2012, ACTA NEUROPATHOL, V123, P133, DOI 10.1007/s00401-011-0908-x; Bottiglieri T, 2012, J NEUROSCI, V32, P9173, DOI 10.1523/JNEUROSCI.0125-12.2012; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; Dong YL, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039386, 10.1371/journal.pone.0034435, 10.1371/journal.pone.0051643]; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jones NC, 2012, NEUROBIOL DIS, V45, P897, DOI 10.1016/j.nbd.2011.12.005; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Koh PO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054217; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Lee MJ, 2013, PROG NEUROBIOL, V105, P49, DOI 10.1016/j.pneurobio.2013.03.001; Li B, 2007, ACTA NEUROPATHOL, V113, P501, DOI 10.1007/s00401-007-0207-8; Liang ZH, 2009, J ALZHEIMERS DIS, V17, P531, DOI 10.3233/JAD-2009-1069; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Nunbhakdi-Craig V, 2007, J NEUROCHEM, V101, P959, DOI 10.1111/j.1471-4159.2007.04503.x; Oberg EA, 2012, J BIOL CHEM, V287, P43378, DOI 10.1074/jbc.M112.420281; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2014, NEUROTHERAPEUTICS, V11, P347, DOI 10.1007/s13311-014-0258-1; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Sontag E, 2007, J NEUROSCI, V27, P2751, DOI 10.1523/JNEUROSCI.3316-06.2007; Sontag JM, 2008, J NEUROSCI, V28, P11477, DOI 10.1523/JNEUROSCI.2816-08.2008; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun KJ, 2013, BRAIN RES, V1506, P132, DOI 10.1016/j.brainres.2013.02.011; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tournier JD, 2013, NMR BIOMED, V26, P1775, DOI 10.1002/nbm.3017; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; Whishaw IQ, 1995, HIPPOCAMPUS, V5, P595, DOI 10.1002/hipo.450050610; Xie HQ, 1998, J NEUROSCI RES, V53, P153, DOI 10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.3.CO;2-5; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Yao XQ, 2012, FEBS LETT, V586, P2522, DOI 10.1016/j.febslet.2012.06.018; Zheng P, 2014, MOL NEUROBIOL, V49, P1532, DOI 10.1007/s12035-013-8601-9; Zhou XW, 2008, NEUROBIOL DIS, V31, P386, DOI 10.1016/j.nbd.2008.05.013	77	88	90	1	24	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY 1	2015	138		5				1297	1313		10.1093/brain/awv053			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CH2DB	WOS:000353834100026	25771151	Green Published, Bronze			2021-06-18	
J	Lippa, SM; Fonda, JR; Fortier, CB; Amick, MA; Kenna, A; Milberg, WP; McGlinchey, RE				Lippa, Sara M.; Fonda, Jennifer R.; Fortier, Catherine B.; Amick, Melissa A.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina E.			Deployment-Related Psychiatric and Behavioral Conditions and Their Association with Functional Disability in OEF/OIF/OND Veterans	JOURNAL OF TRAUMATIC STRESS			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; STRUCTURED CLINICAL INTERVIEW; MENTAL-HEALTH PROBLEMS; PAIN; AFGHANISTAN; COMBAT; IRAQ; VALIDITY	Understanding the factors that influence veterans' functional outcome after deployment is critical to provide appropriately targeted care. Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) have been related to disability, but other psychiatric and behavioral conditions are not as well examined. We investigated the impact of deployment-related psychiatric and behavioral conditions on disability among 255 OEF/OIF/OND service members and veterans. Structured clinical interviews assessed TBI and the psychiatric conditions of depression, PTSD, anxiety, and substance use. Self-report questionnaires assessed disability and the behavioral conditions of sleep disturbance and pain. Over 90% of participants had a psychiatric and/or behavioral condition, with approximately half presenting with 3 conditions. Exploratory factor analysis revealed 4 clinically relevant psychiatric and behavioral factors which accounted for 76.9% of the variance: (a) depression, PTSD, and military mTBI (deployment trauma factor); (b) pain and sleep (somatic factor); (c) anxiety disorders, other than PTSD (anxiety factor); and (d) substance abuse or dependence (substance use factor). Individuals with the conditions comprising the deployment trauma factor were more likely to be substantially disabled than individuals with depression and PTSD, but no military mTBI, OR = 3.52; 95% CI [1.09, 11.37]. Depression, PTSD, and a history of military mTBI may comprise an especially harmful combination associated with high risk for substantial disability.	[Lippa, Sara M.; Fonda, Jennifer R.; Fortier, Catherine B.; Amick, Melissa A.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA; [Lippa, Sara M.; Fonda, Jennifer R.; Fortier, Catherine B.; Amick, Melissa A.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, GRECC, Boston, MA 02130 USA; [Lippa, Sara M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Fonda, Jennifer R.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Fortier, Catherine B.; Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Amick, Melissa A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA	McGlinchey, RE (corresponding author), VA Boston Healthcare Syst, TRACTS GRECC JP 182, 150 South Huntington Ave, Boston, MA 02130 USA.	regina_mcglinchey@hms.harvard.edu	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development (RR&D) Traumatic Brain Injury Center of Excellence [B6796-C]; VA CSR&D Merit Review Award; NIH NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG024898]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AT009430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG034258, K01AG024898] Funding Source: NIH RePORTER	This research was supported by the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development (RR&D) Traumatic Brain Injury Center of Excellence (B6796-C) and VA CSR&D Merit Review Award to Regina McGlinchey, and NIH NIA K01AG024898 to Catherine Fortier. We would like to thank Wally Musto for his championing of our work among military personnel and his tireless recruitment efforts on our behalf, as well as the entire TRACTS team for their assistance with data collection and management. We would also like to thank Drs. Patricia Dorn and Stuart Hoffman of VA RR&D for their support of our TBI CoE. Lastly, we would like to thank the anonymous reviewers of this manuscript for their thoughtful comments, which substantially strengthened the manuscript.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 2012, AN VA HLTH CAR UT OP; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Beder J, 2011, SOC WORK HEALTH CARE, V50, P515, DOI 10.1080/00981389.2011.554279; Blake D. D., 1990, BEHAV THER, V13, P187; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Erbes CR, 2011, J REHABIL RES DEV, V48, P1159, DOI 10.1682/JRRD.2010.11.0212; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; First M.B., 1996, STRUCTURED CLIN INTE; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Grafton KV, 2005, CLIN J PAIN, V21, P73, DOI 10.1097/00002508-200501000-00009; Guyker WM, 2013, MIL MED, V178, P377, DOI 10.7205/MILMED-D-12-00223; Higgins DM, 2014, PAIN MED, V15, P782, DOI 10.1111/pme.12388; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2014, ARCH CLIN NEUROPSYCH, V29, P236, DOI 10.1093/arclin/acu002; Lobbestael J, 2011, CLIN PSYCHOL PSYCHOT, V18, P75, DOI 10.1002/cpp.693; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P739, DOI 10.1002/da.20574; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2009, CLIN PSYCHOL REV, V29, P727, DOI 10.1016/j.cpr.2009.08.006; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Soberg HL, 2012, ARCH PHYS MED REHAB, V93, P765, DOI 10.1016/j.apmr.2011.08.050; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; U. S. Department of Defense, 2012, DEM PROF MIL COMM; UCLA Statistical Counseling Group, 2014, US PROC MLTTEST PER; United States Department of Veterans Affairs & Department of Defense, 2009, VA DOD CLIN PRACT GU; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Von Korff M, 2005, PSYCHOSOM MED, V67, P233, DOI 10.1097/01.psy.0000155662.82621.50; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; World Health Organisation (WHO), 2010, MEAS HLTH DIS MAN WH; World Health Organization, 2004, NEWSL NONC DIS MENT	49	88	88	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	FEB	2015	28	1					25	33		10.1002/jts.21979			9	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	CB9XF	WOS:000349986900004	25703936	Green Accepted			2021-06-18	
J	Mietto, BS; Mostacada, K; Martinez, AMB				Mietto, Bruno Siqueira; Mostacada, Klauss; Blanco Martinez, Ana Maria			Neurotrauma and Inflammation: CNS and PNS Responses	MEDIATORS OF INFLAMMATION			English	Article							SPINAL-CORD-INJURY; PERIPHERAL NERVOUS-SYSTEM; RESIDENT ENDONEURIAL MACROPHAGES; LEUKEMIA INHIBITORY FACTOR; NECROSIS-FACTOR-ALPHA; WALLERIAN DEGENERATION; AXON REGENERATION; SCHWANN-CELLS; NEUTROPHIL RECRUITMENT; FUNCTIONAL RECOVERY	Traumatic injury to the central nervous system (CNS) or the peripheral nervous system (PNS) triggers a cascade of events which culminate in a robust inflammatory reaction. The role played by inflammation in the course of degeneration and regeneration is not completely elucidated. While, in peripheral nerves, the inflammatory response is assumed to be essential for normal progression of Wallerian degeneration and regeneration, CNS trauma inflammation is often associated with poor recovery. In this review, we discuss key mechanisms that trigger the inflammatory reaction after nervous system trauma, emphasizing how inflammations in both CNS and PNS differ from each other, in terms of magnitude, cell types involved, and effector molecules. Knowledge of the precise mechanisms that elicit and maintain inflammation after CNS and PNS tissue trauma and their effect on axon degeneration and regeneration is crucial for the identification of possible pharmacological drugs that can positively affect the tissue regenerative capacity.	[Mietto, Bruno Siqueira; Mostacada, Klauss; Blanco Martinez, Ana Maria] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Neurodegeneracao & Reparo, Dept Patol,Fac Med, BR-21941550 Rio De Janeiro, RJ, Brazil	Martinez, AMB (corresponding author), Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Neurodegeneracao & Reparo, Dept Patol,Fac Med, BR-21941550 Rio De Janeiro, RJ, Brazil.	martinez@histo.ufrj.br	Mietto, Bruno/J-1261-2016; MARTINEZ, Ana/AAE-8358-2019	Mietto, Bruno/0000-0002-4172-2670; Reis, AlessanRSS/0000-0001-8486-7469			Ankeny DP, 2009, J CLIN INVEST, V119, P2990, DOI 10.1172/JCI39780; [Anonymous], 2014, NEUROSCIENCE; Arthur-Farraj PJ, 2012, NEURON, V75, P633, DOI 10.1016/j.neuron.2012.06.021; Baetas-da-Cruz W, 2009, J PERIPHER NERV SYST, V14, P84, DOI 10.1111/j.1529-8027.2009.00217.x; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Barrette B, 2008, J NEUROSCI, V28, P9363, DOI 10.1523/JNEUROSCI.1447-08.2008; Bastien D, 2014, EXP NEUROL, V258, P62, DOI 10.1016/j.expneurol.2014.04.006; Be'eri M, 1998, EUR J NEUROSCI, V10, P2707; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d; BISBY MA, 1990, BRAIN RES, V530, P117, DOI 10.1016/0006-8993(90)90666-Y; Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007; Bomze HM, 2001, NAT NEUROSCI, V4, P38; Boven LA, 2006, BRAIN, V129, P517, DOI 10.1093/brain/awh707; BROWN MC, 1992, J NEUROBIOL, V23, P521, DOI 10.1002/neu.480230507; Cafferty WBJ, 2001, J NEUROSCI, V21, P7161, DOI 10.1523/JNEUROSCI.21-18-07161.2001; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Caroleo MC, 2001, J NEUROIMMUNOL, V113, P193, DOI 10.1016/S0165-5728(00)00441-0; CHEN S, 1993, J COMP NEUROL, V333, P449, DOI 10.1002/cne.903330310; Chen ZL, 2003, J CELL BIOL, V163, P889, DOI 10.1083/jcb.200307068; Chen ZL, 2007, ANNU REV NEUROSCI, V30, P209, DOI 10.1146/annurev.neuro.30.051606.094337; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; David S, 2002, NEUROSCIENTIST, V8, P33, DOI 10.1177/107385840200800108; DAVID S, 1995, J NEUROSCI RES, V42, P594, DOI 10.1002/jnr.490420417; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; de Lima S, 2012, P NATL ACAD SCI USA, V109, P9149, DOI 10.1073/pnas.1119449109; Deumens R, 2010, PROG NEUROBIOL, V92, P245, DOI 10.1016/j.pneurobio.2010.10.002; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Dubovy P, 2011, ANN ANAT, V193, P267, DOI 10.1016/j.aanat.2011.02.011; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Elkabes S, 1996, J NEUROSCI, V16, P2508; Ferguson AR, 2008, J NEUROSCI, V28, P11391, DOI 10.1523/JNEUROSCI.3708-08.2008; FERNANDEZVALLE C, 1995, J NEUROCYTOL, V24, P667, DOI 10.1007/BF01179817; Ferraz LC, 2008, EUR J IMMUNOL, V38, P2762, DOI 10.1002/eji.200737986; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Filer A, 2009, ARTHRITIS RHEUM, V60, P1604, DOI 10.1002/art.24574; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; Gaudet AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-110; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Girolami EI, 2010, EXP NEUROL, V223, P173, DOI 10.1016/j.expneurol.2009.06.018; Goethals S, 2010, GLIA, V58, P1701, DOI 10.1002/glia.21041; Gosselin RD, 2008, CURR MED CHEM, V15, P2866, DOI 10.2174/092986708786242822; Griffin JW, 2010, EXP NEUROL, V223, P60, DOI 10.1016/j.expneurol.2009.12.033; Guertin AD, 2005, J NEUROSCI, V25, P3478, DOI 10.1523/JNEUROSCI.3766-04.2005; Gustavsson P, 2007, NEUROREPORT, V18, P669, DOI 10.1097/WNR.0b013e3280bef97b; Harkey H Louis 3rd, 2003, Anat Rec B New Anat, V271, P41, DOI 10.1002/ar.b.10012; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Inohara H, 1998, EXP CELL RES, V245, P294, DOI 10.1006/excr.1998.4253; Jeon SB, 2010, J IMMUNOL, V185, P7037, DOI 10.4049/jimmunol.1000154; Jessen KR, 2008, GLIA, V56, P1552, DOI 10.1002/glia.20761; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jung J, 2011, J NEUROSCI, V31, P2009, DOI 10.1523/JNEUROSCI.4537-10.2011; Juranek JK, 2013, DIABETES, V62, P931, DOI 10.2337/db12-0632; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim D, 2009, CURR TOP MICROBIOL, V336, P169, DOI 10.1007/978-3-642-00549-7_10; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Komori T, 2011, NEUROREPORT, V22, P911, DOI 10.1097/WNR.0b013e32834cd76a; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Lee H, 2006, BIOCHEM BIOPH RES CO, V350, P742, DOI 10.1016/j.bbrc.2006.09.108; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Leonhard C, 2002, EUR J NEUROSCI, V16, P1654, DOI 10.1046/j.1460-9568.2002.02236.x; Levy D, 2001, J NEUROPATH EXP NEUR, V60, P411, DOI 10.1093/jnen/60.5.411; Lopez-Vales R, 2008, BRAIN, V131, P2620, DOI 10.1093/brain/awn188; LUBINSKA L, 1977, BRAIN RES, V130, P47, DOI 10.1016/0006-8993(77)90841-1; Lutz AB, 2014, DEV CELL, V28, P7, DOI 10.1016/j.devcel.2013.12.002; Makwana M, 2005, FEBS J, V272, P2628, DOI 10.1111/j.1742-4658.2005.04699.x; MALBOUISSON AMB, 1985, J NEUROL SCI, V67, P307, DOI 10.1016/0022-510X(85)90155-8; Martinez AMB, 2000, BRAZ J MED BIOL RES, V33, P1477, DOI 10.1590/S0100-879X2000001200012; Martinez AMB, 1998, J SUBMICR CYTOL PATH, V30, P451; Martini R, 2008, GLIA, V56, P1566, DOI 10.1002/glia.20766; Maurer M, 2002, NEUROMUSCULAR DISORD, V12, P405, DOI 10.1016/S0960-8966(01)00302-9; Mautes AEM, 2000, PHYS THER, V80, P673, DOI 10.1093/ptj/80.7.673; Mietto B. S., 2011, ADV UNDERSTANDING NE; Mietto BS, 2013, EUR J NEUROSCI, V37, P1682, DOI 10.1111/ejn.12161; Mueller M, 2003, LAB INVEST, V83, P175, DOI 10.1097/01.LAB.0000056993.28149.BF; Mueller M, 2001, AM J PATHOL, V159, P2187, DOI 10.1016/S0002-9440(10)63070-2; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nadeau S, 2011, J NEUROSCI, V31, P12533, DOI 10.1523/JNEUROSCI.2840-11.2011; Narciso MS, 2009, EXP NEUROL, V217, P7, DOI 10.1016/j.expneurol.2009.01.008; Noble LJ, 2002, J NEUROSCI, V22, P7526; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407; PERRY VH, 1995, EUR J NEUROSCI, V7, P271, DOI 10.1111/j.1460-9568.1995.tb01063.x; Pineau I, 2009, GLIA, V57, P351, DOI 10.1002/glia.20763; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Popovich PG, 2012, EXP NEUROL, V233, P615, DOI 10.1016/j.expneurol.2010.11.016; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; REICHERT F, 1994, J NEUROSCI, V14, P3231; Ren Y, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/945034; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; ROTSHENKER S, 1992, J NEUROIMMUNOL, V39, P75, DOI 10.1016/0165-5728(92)90176-L; Rotshenker S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-109; Rotshenker S, 2009, J MOL NEUROSCI, V39, P99, DOI 10.1007/s12031-009-9186-7; Ruff RL, 2008, ANN NY ACAD SCI, V1142, P1, DOI 10.1196/annals.1444.004; Seijffers R, 2006, MOL CELL NEUROSCI, V32, P143, DOI 10.1016/j.mcn.2006.03.005; Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Stirling DP, 2009, J NEUROSCI, V29, P753, DOI 10.1523/JNEUROSCI.4918-08.2009; Stoll G, 2002, J PERIPHER NERV SYST, V7, P13, DOI 10.1046/j.1529-8027.2002.02002.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Thompson SWN, 1997, EUR J NEUROSCI, V9, P1244, DOI 10.1111/j.1460-9568.1997.tb01479.x; Trigueros SDA, 2003, MOL CELL NEUROSCI, V24, P753, DOI 10.1016/S1044-7431(03)00241-0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Vargas ME, 2010, P NATL ACAD SCI USA, V107, P11993, DOI 10.1073/pnas.1001948107; Wagner R, 1996, NEUROSCIENCE, V73, P625, DOI 10.1016/0306-4522(96)00127-3; Waller A, 1850, PHILOS T R SOC LOND, V140, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021, 10.1098/rstl.1850.0021]; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; WEKERLE H, 1986, EUR J IMMUNOL, V16, P1551, DOI 10.1002/eji.1830161214; Williams MR, 2011, TRENDS IMMUNOL, V32, P461, DOI 10.1016/j.it.2011.06.009; Winzeler AM, 2011, J NEUROSCI, V31, P6481, DOI 10.1523/JNEUROSCI.3004-10.2011; Ydens E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-176; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Yin YQ, 2009, P NATL ACAD SCI USA, V106, P19587, DOI 10.1073/pnas.0907085106; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; You SJ, 1997, GLIA, V20, P87, DOI 10.1002/(SICI)1098-1136(199706)20:2<87::AID-GLIA1>3.0.CO;2-1; Zedler S, 2006, CURR OPIN CRIT CARE, V12, P595, DOI 10.1097/MCC.0b013e3280106806; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X; Zhou H, 2009, J IMMUNOL, V183, P5244, DOI 10.4049/jimmunol.0901309	133	88	90	0	17	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2015	2015								251204	10.1155/2015/251204			14	Cell Biology; Immunology	Cell Biology; Immunology	CF9HC	WOS:000352874000001	25918475	DOAJ Gold, Green Published			2021-06-18	
J	Corrigan, JD; Cuthbert, JP; Harrison-Felix, C; Whiteneck, GG; Bell, JM; Miller, AC; Coronado, VG; Pretz, CR				Corrigan, John D.; Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Whiteneck, Gale G.; Bell, Jeneita M.; Miller, A. Cate; Coronado, Victor G.; Pretz, Christopher R.			US Population Estimates of Health and Social Outcomes 5 Years After Rehabilitation for Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; epidemiology; outcomes; prevalence; rehabilitation; traumatic brain injury	SYSTEMS NATIONAL DATABASE; MODEL SYSTEMS; REPRESENTATIVENESS; MORTALITY; SCALE; AGE	Objective: To estimate the number of adults in the United States from 2006 to 2012 who manifest selected health and social outcomes 5 years following a traumatic brain injury (TBI) that required acute inpatient rehabilitation. Design: Secondary data analysis. Setting: Acute inpatient rehabilitation facilities. Participants: Patients 16 years and older receiving acute inpatient rehabilitation for a primary diagnosis of TBI. Main Outcome Measures: Mortality, functional independence, societal participation, subjective well-being, and global outcome. Results: Annually from 2001 to 2007, an average of 13 700 patients aged 16 years or older received acute inpatient rehabilitation in the United States with a primary diagnosis of TBI. Approximately 1 in 5 patients had died by the 5-year postinjury assessment. Among survivors, 12% were institutionalized and 50% had been rehospitalized at least once. Approximately one-third of patients were not independent in everyday activities. Twenty-nine percent were dissatisfied with life, with 8% reporting markedly depressed mood. Fifty-seven percent were moderately or severely disabled overall, with 39% having deteriorated from a global outcome attained 1 or 2 years postinjury. Of those employed preinjury, 55% were unemployed. Poorer medical, functional, and participation outcomes were associated with, but not limited to, older age. Younger age groups had poorer mental and emotional outcomes. Deterioration in global outcome was common and not age-related. Conclusions: Significant mortality and morbidity were evident at 5 years postinjury. The deterioration in global outcomes observed regardless of age suggests that multiple influences contribute to poorer outcomes. Public health interventions intended to reduce post-acute inpatient rehabilitation mortality and morbidity rates will need to be multifaceted and age-specific.	[Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Whiteneck, Gale G.; Pretz, Christopher R.] Craig Hosp, Res Dept, Englewood, CO USA; [Bell, Jeneita M.; Coronado, Victor G.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Miller, A. Cate] Natl Inst Disabil & Rehabil Res, Dept Educ, Washington, DC USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu			US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; US Department of Education, Office of Special Education and Rehabilitative Services; National Institute on Disability and Rehabilitation Research (NIDRR); NIDRR; Traumatic Brain Injury (TBI) Model Systems National Data and Statistical Center [H133A110006]; TBI Model Systems Centers grant from the NIDRR to Ohio State University [H133A120086]	This research was supported by an interagency agreement between the US Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), and the US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research (NIDRR), with supplemental funding to the NIDRR-funded Traumatic Brain Injury (TBI) Model Systems National Data and Statistical Center (grant no. H133A110006). The study was also supported by a TBI Model Systems Centers grant from the NIDRR to Ohio State University (grant no. H133A120086). This article does not reflect the official policy or opinions of the CDC or HHS and does not constitute an endorsement of the individuals or their programs-by the CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. The TBI Model Systems National Database is supported by the NIDRR and created and maintained by the TBI Model Systems Centers program. This article is intended to promote the exchange of ideas among researchers and policy makers. The views expressed in it are part of ongoing research and analysis and do not necessarily reflect the position of the US Department of Education.	Battaglia M.P., 2000, P 25 ANN SAS US GROU; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Hammond FM, 2013, BRAIN INJ PROF, V10, P6; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Kalton G., 2003, J OFF STAT, V19, P81; Kolakowsky-Hayner SA, 2012, BRAIN INJURY, V26, P1328, DOI 10.3109/02699052.2012.706353; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, 2010, NAT HOSP DISCH SURV; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Rutherford GW, 2009, J HEAD TRAUMA REHAB, V24, P468, DOI 10.1097/HTR.0b013e3181c133d2; Substance Abuse and Mental Health Services Administration, 2009, NSDUH SERIES H, VH-36; Substance Abuse and Mental Health Services Administration, 2009, HHS PUBL, VSMA 09 4454; Szklo M, 2007, EPIDEMIOLOGY BASICS; TBI Model Systems National Data and Statistical Center, TRAUM BRAIN INJ MOD; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; UDS, 2014, UN DAT SYST MED REH; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2001, INT CLASS FUNCT DIS	25	88	88	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2014	29	6					E1	E9		10.1097/HTR.0000000000000020			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT7LI	WOS:000345117800001	24495919				2021-06-18	
J	Sun, Q; Wu, W; Hu, YC; Li, H; Zhang, DD; Li, S; Li, W; Li, WD; Ma, B; Zhu, JH; Zhou, ML; Hang, CH				Sun, Qing; Wu, Wei; Hu, Yang-Chun; Li, Hua; Zhang, Dingding; Li, Song; Li, Wei; Li, Wei-De; Ma, Biao; Zhu, Jian-Hong; Zhou, Meng-Liang; Hang, Chun-Hua			Early release of high-mobility group box 1 (HMGB1) from neurons in experimental subarachnoid hemorrhage in vivo and in vitro	JOURNAL OF NEUROINFLAMMATION			English	Article						HMGB1; SAH; Early brain injury	GLYCATION END-PRODUCTS; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; CELL DISTRIBUTION; LIVER ISCHEMIA; RECEPTOR; EXPRESSION; PROTEIN; RAT	Background: Translocation of high-mobility group box 1 (HMGB1) from nucleus could trigger inflammation. Extracellular HMGB1 up-regulates inflammatory response in sepsis as a late mediator. However, little was known about its role in subarachnoid hemorrhage-inducible inflammation, especially in the early stage. This study aims to identify whether HMGB1 translocation occurred early after SAH and also to clarify the potential role of HMGB1 in brain injury following SAH. Methods: Sprague-Dawley (SD) rats were randomly divided into sham group and SAH groups at 2 h, 12 h and on day 1, day 2. SAH groups suffered experimental subarachnoid hemorrhage by injection of 0.3 ml autoblood into the pre-chiasmatic cistern. Rats injected by recombinant HMGB1(rHMGB1) solution were divided into four groups according to different time points. Cultured neurons were assigned into control group and four hemoglobin (Hb) incubated groups. Mixed glial cells were cultured and stimulated in medium from neurons incubated by Hb. HMGB1 expression is measured by western blot analysis, real-time polymerase chain reaction (PCR), immunohistochemistry and immunofluorescence. Downstream nuclear factor kappa B (NF-kappa B) subunit P65 and inflammatory factor Interleukin 1 beta (IL-1 beta) were measured by western blot and real-time PCR, respectively. Brain injury was evaluated by cleaved caspase-3 staining. Results: Our results demonstrated HMGB1 translocation occurred as early as 2 h after experimental SAH with mRNA and protein level increased. Immunohistochemistry and immunofluorescence results indicated cytosolic HMGB1 was mainly located in neurons while translocated HMGB1 could also be found in some microglia. After subarachnoid injection of rHMGB1, NF-kappa B, downstream inflammatory response and cleaved caspase-3 were up-regulated in the cortex compared to the saline control group. In-vitro, after Hb incubation, HMGB1 was also rapidly released from neurons to medium. Incubation with medium from neurons up-regulated IL-1 beta in mixed glial cells. This effect could be inhibited by HMGB1 specific inhibitor glycyrrhizic acid (GA) treatment. Conclusion: HMGB1 was released from neurons early after SAH onset and might trigger inflammation as an upstream inflammatory mediator. Extracellular HMGB1 contributed to the brain injury after SAH. These results might have important implications during the administration of specific HMGB1 antagonists early in order to prevent or reduce inflammatory response following SAH.	[Sun, Qing; Wu, Wei; Hu, Yang-Chun; Li, Hua; Zhang, Dingding; Li, Wei; Ma, Biao; Zhu, Jian-Hong; Zhou, Meng-Liang; Hang, Chun-Hua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Li, Song; Li, Wei-De] Southern Med Univ Guangzhou, Dept Neurosurg, Sch Med, Jinling Hosp, Nanjing, Jiangsu, Peoples R China; [Hang, Chun-Hua] Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China.	hang_neurosurgery@163.com		Li, Hua/0000-0001-5893-535X; Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81371294]	The study was supported by the National Natural Science Foundation, China (81371294). The authors gratefully acknowledge the generous assistance of Dr Lin Zhu and Gen-Bao Feng.	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bera A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082282; Bianchi ME, 2009, SCIENCE, V323, P1683, DOI 10.1126/science.1172794; Chou SHY, 2012, J INVEST MED, V60, P1054, DOI 10.2310/JIM.0b013e3182686932; Evankovich J, 2010, J BIOL CHEM, V285, P39888, DOI 10.1074/jbc.M110.128348; Friedrich V, 2012, NEUROSCI LETT, V512, P6, DOI 10.1016/j.neulet.2012.01.036; Girard JP, 2007, CHEM BIOL, V14, P345, DOI 10.1016/j.chembiol.2007.04.001; Greenhalgh AD, 2012, DIS MODEL MECH, V5, P823, DOI 10.1242/dmm.008557; Hanafy KA, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-83; Hanafy KA, 2010, J NEUROL SCI, V291, P69, DOI 10.1016/j.jns.2009.12.023; Hu YC, 2014, INFLAMM RES, V63, P109, DOI 10.1007/s00011-013-0677-1; Jeon H, 2010, NEUROSCIENCE, V169, P1805, DOI 10.1016/j.neuroscience.2010.06.039; Jiang Y, 2012, J CLIN NEUROSCI, V19, P866, DOI 10.1016/j.jocn.2011.08.038; Kang SR, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/248592; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Krams M, 2003, STROKE, V34, P2543, DOI 10.1161/01.STR.0000092527.33910.89; Li H, 2014, BRAIN RES, V1543, P315, DOI 10.1016/j.brainres.2013.11.023; Li W, 2014, MOL NEUROBIOL, V49, P187, DOI 10.1007/s12035-013-8509-4; Li W, 2013, NEUROL SCI, V34, P847, DOI 10.1007/s10072-012-1131-9; Ma CX, 2009, CHINESE MED J-PEKING, V122, P1575, DOI 10.3760/cma.j.issn.0366-6999.2009.13.019; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Murakami K, 2011, TRANSL STROKE RES, V2, P72, DOI 10.1007/s12975-010-0052-2; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schuette AJ, 2013, WORLD NEUROSURG, V80, P264, DOI 10.1016/j.wneu.2012.10.049; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; Sun Q, 2013, MED HYPOTHESES, V81, P681, DOI 10.1016/j.mehy.2013.07.026; Sun Q, 2013, BRAIN RES, V1520, P134, DOI 10.1016/j.brainres.2013.05.010; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Tsung A, 2007, J EXP MED, V204, P2913, DOI 10.1084/jem.20070247; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; van Kralingen C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084269; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; You WC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/786242; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhou ML, 2007, INFLAMM RES, V56, P93, DOI 10.1007/s00011-006-6035-9	41	88	91	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUN 12	2014	11								106	10.1186/1742-2094-11-106			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AL7EQ	WOS:000339296400001	24924349	DOAJ Gold, Green Published			2021-06-18	
J	Caeyenberghs, K; Leemans, A; Leunissen, I; Gooijers, J; Michiels, K; Sunaert, S; Swinnen, SP				Caeyenberghs, K.; Leemans, A.; Leunissen, I.; Gooijers, J.; Michiels, K.; Sunaert, S.; Swinnen, S. P.			Altered structural networks and executive deficits in traumatic brain injury patients	BRAIN STRUCTURE & FUNCTION			English	Article						Diffusion tensor imaging; Graph theoretical analysis; Executive functioning; Structural network; Traumatic brain injury	DIFFUSE AXONAL INJURY; GRAPH-THEORETICAL ANALYSIS; WHITE-MATTER INTEGRITY; COGNITIVE CONTROL; BEHAVIOR RELATIONSHIPS; RESPONSE-INHIBITION; ANATOMICAL NETWORK; FIBER ORIENTATIONS; CEREBRAL-CORTEX; LESION PATIENTS	Recent research on traumatic brain injury (TBI) has shown that impairments in cognitive and executive control functions are accompanied by a disrupted neural connectivity characterized by white matter damage. We constructed binary and weighted brain structural networks in 21 patients with chronic TBI and 17 healthy young adults utilizing diffusion tensor tractography and calculated topological properties of the networks using a graph theoretical method. Executive function was assessed with the local global task and the trail making task, requiring inhibition, updating, and switching. The results revealed that TBI patients were less successful than controls on the executive tasks, as shown by the higher reaction times, higher switch costs, and lower accuracy rates. Moreover, both TBI patients and controls exhibited a small world topology in their white matter networks. More importantly, the TBI patients demonstrated increased shortest path length and decreased global efficiency of the structural network. These findings suggest that TBI patients have a weaker globally integrated structural brain network, resulting in a limited capacity to integrate information across brain regions. Furthermore, we showed that the white matter networks of both groups contained highly connected hub regions that were predominately located in the parietal cortex, frontal cortex, and basal ganglia. Finally, we showed significant correlations between switching performance and network property metrics within the TBI group. Specifically, lower scores on the switching tasks corresponded to a lower global efficiency. We conclude that analyzing the structural brain network connectivity provides new insights into understanding cognitive control changes following brain injury.	[Caeyenberghs, K.; Leunissen, I.; Gooijers, J.; Swinnen, S. P.] Katholieke Univ Leuven, Dept Kinesiol, Biomed Sci Grp, Movement Control & Neuroplast Res Grp, Louvain, Belgium; [Caeyenberghs, K.] Univ Ghent, Fac Med & Hlth Sci, Dept Phys Therapy & Motor Rehabil, B-9000 Ghent, Belgium; [Leemans, A.] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands; [Michiels, K.] Katholieke Univ Leuven Hosp, Dept Phys Med & Rehabil, Louvain, Belgium; [Sunaert, S.] Katholieke Univ Leuven, Biomed Sci Grp, Dept Imaging & Pathol, Louvain, Belgium	Caeyenberghs, K (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Phys Therapy & Motor Rehabil, De Pintelaan 185, B-9000 Ghent, Belgium.	Karen.Caeyenberghs@UGent.be	Gooijers, Jolien/AAH-9202-2020; Leemans, Alexander/A-1784-2011	Leemans, Alexander/0000-0002-9306-6126; Gooijers, Jolien/0000-0002-7569-7223; Leunissen, Inge/0000-0002-3977-3620; Caeyenberghs, Karen/0000-0001-7009-6843	Research Foundation-Flanders (FWO)FWO [G.0482.010, G.A114.11]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P6/29]	This work was supported by a grant from the Research Programme of the Research Foundation-Flanders (FWO) (G.0482.010 and G.A114.11) and Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a postdoctoral fellowship of the Research Foundation-Flanders (FWO).	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Bast T, 2007, REV NEUROSCIENCE, V18, P253; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrmann M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/j.conb.2004.03.012; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Carrera E, 2006, NEUROLOGY, V66, P1817, DOI 10.1212/01.wnl.0000219679.95223.4c; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Forstmann BU, 2012, NEUROIMAGE, V60, P370, DOI 10.1016/j.neuroimage.2011.12.044; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gilbert SJ, 2008, CURR BIOL, V18, pR110, DOI 10.1016/j.cub.2007.12.014; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Guilmette TJ, 1999, ASSESSMENT, V6, P33, DOI 10.1177/107319119900600104; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Ide JS, 2011, NEUROIMAGE, V54, P455, DOI 10.1016/j.neuroimage.2010.07.042; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; Iturria-Medina Y, 2011, CEREB CORTEX, V21, P56, DOI 10.1093/cercor/bhq058; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubat-Silman AK, 2002, BRAIN COGNITION, V50, P178, DOI 10.1016/S0278-2626(02)00502-X; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Leemans A., 2009, 17 ANN M INT SOC MAG, P3537; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Li Y, 2012, CEREB CORTEX, V12; Li YH, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000395; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; Niendam TA, 2012, COGN AFFECT BEHAV NE, V12, P241, DOI 10.3758/s13415-011-0083-5; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Patel TP, 2012, ANN BIOMED ENG, V40, P23, DOI 10.1007/s10439-011-0390-6; Gouveia PAR, 2007, BRAIN COGNITION, V63, P240, DOI 10.1016/j.bandc.2006.09.001; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schmahmann JD, 2007, CEREBELLUM, V6, P254, DOI 10.1080/14734220701490995; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Shu N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007228; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sporns O, 2004, NEUROINFORMATICS, V2, P145, DOI 10.1385/NI:2:2:145; Stoodley CJ, 2010, CORTEX, V46, P831, DOI 10.1016/j.cortex.2009.11.008; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Timmons SD, 2012, J NEUROSURG SCI, V56, P191; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2010, J NEUROSCI, V30, P15915, DOI 10.1523/JNEUROSCI.2874-10.2010; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Wen W, 2011, J NEUROSCI, V31, P1204, DOI 10.1523/JNEUROSCI.4085-10.2011	92	88	91	2	28	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	JAN	2014	219	1					193	209		10.1007/s00429-012-0494-2			17	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	283DM	WOS:000329225400014	23232826				2021-06-18	
J	Kalin, JH; Bergman, JA				Kalin, Jay H.; Bergman, Joel A.			Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; CONTAINING HYDROXAMIC ACIDS; TRAUMATIC BRAIN-INJURY; 2 CATALYTIC DOMAINS; HDAC INHIBITORS; CELL-MIGRATION; CANCER CELLS; HISTONE/PROTEIN DEACETYLASES; STRUCTURAL REQUIREMENTS; CYTOPLASMIC DEACETYLASE	This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated. The physiological pathways, protein-protein interactions, and non-histone substrates relating to different pathological conditions are discussed with regard to HDAC6. Furthermore, the compounds and methods used to modulate HDAC6 activity are profiled. The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the molecular tools available. Potential obstacles and future directions of HDAC6 research are also presented.	[Kalin, Jay H.; Bergman, Joel A.] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA	Kalin, JH (corresponding author), Johns Hopkins Univ, Dept Pharmacol, 725 N Wolfe St, Baltimore, MD 21205 USA.	jkalin1@jhmi.edu		Kalin, Jay/0000-0002-8747-6022			Abe T, 2008, CURR OPIN PHARMACOL, V8, P57, DOI 10.1016/j.coph.2007.12.002; Akimova T, 2012, BLOOD, V119, P2443, DOI 10.1182/blood-2011-10-292003; Aldana-Masangkay GI, 2011, LEUKEMIA LYMPHOMA, V52, P1544, DOI 10.3109/10428194.2011.570821; Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824; [Anonymous], 2010, J Natl Cancer Inst, V102, P219, DOI 10.1093/jnci/djq030; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Bardai FH, 2011, J NEUROSCI, V31, P1746, DOI 10.1523/JNEUROSCI.5704-10.2011; Bazzaro M, 2008, CLIN CANCER RES, V14, P7340, DOI 10.1158/1078-0432.CCR-08-0642; Beier UH, 2011, CURR OPIN IMMUNOL, V23, P670, DOI 10.1016/j.coi.2011.07.002; Bergman JA, 2012, J MED CHEM, V55, P9891, DOI 10.1021/jm301098e; Berry JM, 2008, EXPERT OPIN DRUG SAF, V7, P53, DOI [10.1517/14740338.7.1.53, 10.1517/14740338.7.1.53 ]; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Best JD, 2010, DRUG DISCOV TODAY, V15, P1008, DOI 10.1016/j.drudis.2010.10.006; Bieliauskas AV, 2008, CHEM SOC REV, V37, P1402, DOI 10.1039/b703830p; Bieliauskas AV, 2007, BIOORG MED CHEM LETT, V17, P2216, DOI 10.1016/j.bmcl.2007.01.117; Blair LP, 2012, DNA CELL BIOL, V31, pS49, DOI 10.1089/dna.2012.1654; Boyault C, 2007, GENE DEV, V21, P2172, DOI 10.1101/gad.436407; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bush EW, 2010, CIRC RES, V106, P272, DOI 10.1161/CIRCRESAHA.109.209338; Butler KV, 2008, CURR PHARM DESIGN, V14, P505; Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v; Calkins MJ, 2011, BBA-MOL BASIS DIS, V1812, P507, DOI 10.1016/j.bbadis.2011.01.007; Castro-Castro A, 2012, EUR J CELL BIOL, V91, P950, DOI 10.1016/j.ejcb.2012.07.001; Cecarini V, 2012, BBA-MOL BASIS DIS, V1822, P1741, DOI 10.1016/j.bbadis.2012.07.015; Chen SG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010848; Chen YT, 2012, CLIN EXP PHARMACOL P, V39, P751, DOI 10.1111/j.1440-1681.2012.05729.x; Chen Y, 2008, J MED CHEM, V51, P3437, DOI 10.1021/jm701606b; Chen YF, 2009, CHEMMEDCHEM, V4, P842, DOI 10.1002/cmdc.200800461; Choi SE, 2011, BIOORG MED CHEM LETT, V21, P6139, DOI 10.1016/j.bmcl.2011.08.027; Chuang DM, 2009, TRENDS NEUROSCI, V32, P591, DOI 10.1016/j.tins.2009.06.002; Cook C, 2012, HUM MOL GENET, V21, P2936, DOI 10.1093/hmg/dds125; d'Ydewalle C, 2012, INT J BIOCHEM CELL B, V44, P1299, DOI 10.1016/j.biocel.2012.04.020; d'Ydewalle C, 2012, TRAFFIC, V13, P771, DOI 10.1111/j.1600-0854.2012.01347.x; d'Ydewalle C, 2011, NAT MED, V17, P968, DOI 10.1038/nm.2396; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218; de Zoeten EF, 2011, MOL CELL BIOL, V31, P2066, DOI 10.1128/MCB.05155-11; Decker H, 2010, J NEUROSCI, V30, P9166, DOI 10.1523/JNEUROSCI.1074-10.2010; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Dickey CA, 2006, J NEUROSCI, V26, P6985, DOI 10.1523/JNEUROSCI.0746-06.2006; Dickson DW, 1999, BRAIN PATHOL, V9, P657; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Du H, 2010, P NATL ACAD SCI USA, V107, P18670, DOI 10.1073/pnas.1006586107; Fukushima N, 2009, J NEUROCHEM, V109, P683, DOI 10.1111/j.1471-4159.2009.06013.x; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Gibbs A, 2009, P NATL ACAD SCI USA, V106, P16663, DOI 10.1073/pnas.0908908106; Granger A, 2008, FASEB J, V22, P3549, DOI 10.1096/fj.08-108548; Greer JM, 2012, BIOL-TARGETS THER, V6, P307, DOI 10.2147/BTT.S24067; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hackanson B, 2012, LEUKEMIA RES, V36, P1055, DOI 10.1016/j.leukres.2012.02.026; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hammond JW, 2008, CURR OPIN CELL BIOL, V20, P71, DOI 10.1016/j.ceb.2007.11.010; Hammond JW, 2010, MOL BIOL CELL, V21, P572, DOI 10.1091/mbc.E09-01-0044; Hancock WW, 2012, ANN RHEUM DIS, V71, P46, DOI 10.1136/annrheumdis-2011-200593; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Heltweg B, 2004, J MED CHEM, V47, P5235, DOI 10.1021/jm0497592; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.02745; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hsieh TH, 2012, TOXICOL SCI, V128, P365, DOI 10.1093/toxsci/kfs163; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Inks ES, 2012, ACS CHEM BIOL, V7, P330, DOI 10.1021/cb200134p; Iyer A, 2010, BRIT J PHARMACOL, V159, P1408, DOI 10.1111/j.1476-5381.2010.00637.x; Jones P, 2008, BIOORG MED CHEM LETT, V18, P3456, DOI 10.1016/j.bmcl.2008.02.026; Jung KH, 2012, HEPATOLOGY, V56, P644, DOI 10.1002/hep.25699; Jung M, 2005, RADIAT RES, V163, P488, DOI 10.1667/RR3345; Kalin JH, 2012, CHEMMEDCHEM, V7, P425, DOI 10.1002/cmdc.201100522; Kalin JH, 2012, J MED CHEM, V55, P639, DOI 10.1021/jm200773h; Kaluza D, 2011, EMBO J, V30, P4142, DOI 10.1038/emboj.2011.298; Kamemura K, 2008, BIOCHEM BIOPH RES CO, V374, P84, DOI 10.1016/j.bbrc.2008.06.092; Kamemura K, 2012, FEBS LETT, V586, P1379, DOI 10.1016/j.febslet.2012.03.060; Kanno K, 2012, ONCOL REP, V28, P867, DOI 10.3892/or.2012.1898; Kawada J, 2009, J BIOL CHEM, V284, P17102, DOI 10.1074/jbc.M809090200; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kerr E, 2012, CELL DEATH DIFFER, V19, P1317, DOI 10.1038/cdd.2012.8; Kim C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042983; Kim D, 2008, NEURON, V60, P803, DOI 10.1016/j.neuron.2008.10.015; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Konsoula R, 2008, INT J PHARM, V361, P19, DOI 10.1016/j.ijpharm.2008.05.001; Konsoula Z, 2011, INT J RADIAT ONCOL, V79, P1541, DOI 10.1016/j.ijrobp.2010.11.057; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kozikowski AP, 2008, J MED CHEM, V51, P4370, DOI 10.1021/jm8002894; Kozikowski AP, 2007, J MED CHEM, V50, P3054, DOI 10.1021/jm070178x; Kozikowski AR, 2008, CHEMMEDCHEM, V3, P487, DOI 10.1002/cmdc.200700314; Lafarga V, 2012, EMBO J, V31, P856, DOI 10.1038/emboj.2011.466; Langley B, 2008, J NEUROSCI, V28, P163, DOI 10.1523/JNEUROSCI.3200-07.2008; Lee JY, 2010, J CELL BIOL, V189, P671, DOI 10.1083/jcb.201001039; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Lemon DD, 2011, J MOL CELL CARDIOL, V51, P41, DOI 10.1016/j.yjmcc.2011.04.005; Li GY, 2011, J NEUROL SCI, V304, P1, DOI 10.1016/j.jns.2011.02.017; Luxton GWG, 2007, DEV CELL, V13, P161, DOI 10.1016/j.devcel.2007.07.014; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Murphy PJM, 2005, J BIOL CHEM, V280, P33792, DOI 10.1074/jbc.M506997200; Myzak MC, 2007, EXP BIOL MED, V232, P227; Namdar M, 2010, P NATL ACAD SCI USA, V107, P20003, DOI 10.1073/pnas.1013754107; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Ontoria JM, 2009, J MED CHEM, V52, P6782, DOI 10.1021/jm900555u; Palijan A, 2009, J BIOL CHEM, V284, P30264, DOI 10.1074/jbc.M109.045526; Pan F, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003364; Parmigiani RB, 2008, P NATL ACAD SCI USA, V105, P9633, DOI 10.1073/pnas.0803749105; Penela P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003098; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Rao R, 2008, BLOOD, V112, P1886, DOI 10.1182/blood-2008-03-143644; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Rey M, 2011, EUR J CELL BIOL, V90, P128, DOI 10.1016/j.ejcb.2010.09.004; Rivieccio MA, 2009, P NATL ACAD SCI USA, V106, P19599, DOI 10.1073/pnas.0907935106; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365; Schafer S, 2008, BIOORGAN MED CHEM, V16, P2011, DOI 10.1016/j.bmc.2007.10.092; Schaefer S, 2009, CHEMMEDCHEM, V4, P283, DOI 10.1002/cmdc.200800196; Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Sigala R, 2007, CURR BIOL, V17, pR18, DOI 10.1016/j.cub.2006.11.036; Singh SV, 2009, CANCER RES, V69, P2117, DOI 10.1158/0008-5472.CAN-08-3502; Smil DV, 2009, BIOORG MED CHEM LETT, V19, P688, DOI 10.1016/j.bmcl.2008.12.045; Sternson SM, 2001, ORG LETT, V3, P4239, DOI 10.1021/ol016915f; Sung YM, 2013, EXP NEUROL, V239, P192, DOI 10.1016/j.expneurol.2012.10.005; Suzuki T, 2005, BIOORG MED CHEM LETT, V15, P331, DOI 10.1016/j.bmcl.2004.10.074; Suzuki T, 2004, BIOORG MED CHEM LETT, V14, P3313, DOI 10.1016/j.bmcl.2004.03.063; Suzuki T, 2003, BIOORG MED CHEM LETT, V13, P4321, DOI 10.1016/j.bmcl.2003.09.048; Suzuki T, 2006, J MED CHEM, V49, P4809, DOI 10.1021/jm060554y; Tapadar S, 2009, BIOORG MED CHEM LETT, V19, P3023, DOI 10.1016/j.bmcl.2009.04.058; Tran ADA, 2007, J CELL SCI, V120, P1469, DOI 10.1242/jcs.03431; True O, 2012, IMMUNOL CELL BIOL, V90, P78, DOI 10.1038/icb.2011.103; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033160; Welberg L, 2009, NAT REV DRUG DISCOV, V8, DOI 10.1038/nrd2934; Wickstrom SA, 2010, EMBO J, V29, P131, DOI 10.1038/emboj.2009.317; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Wittich S, 2002, J MED CHEM, V45, P3296, DOI 10.1021/jm0208119; Xia WL, 2010, CLIN EXP PHARMACOL P, V37, P253, DOI 10.1111/j.1440-1681.2009.05279.x; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644; Yao Tso-Pang, 2010, Genes Cancer, V1, P779; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang LX, 2010, AM J PHYSIOL-HEART C, V298, pH2154, DOI 10.1152/ajpheart.01015.2009; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033; Zhang XH, 2011, CNS NEUROSCI THER, V17, P590, DOI 10.1111/j.1755-5949.2011.00271.x; Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200; Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06; Zhao TC, 2007, CARDIOVASC RES, V76, P473, DOI 10.1016/j.cardiores.2007.08.010; Zhao TC, 2010, BBA-MOL CELL RES, V1803, P872, DOI 10.1016/j.bbamcr.2010.04.007; Zilberman Y, 2009, J CELL SCI, V122, P3531, DOI 10.1242/jcs.046813; Zou H, 2006, BIOCHEM BIOPH RES CO, V341, P45, DOI 10.1016/j.bbrc.2005.12.144; Zuo QQ, 2012, ONCOL REP, V27, P819, DOI 10.3892/or.2011.1553	154	88	91	3	49	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	AUG 22	2013	56	16					6297	6313		10.1021/jm4001659			17	Chemistry, Medicinal	Pharmacology & Pharmacy	207IZ	WOS:000323593400002	23627282				2021-06-18	
J	Kuczynski, A; Crawford, S; Bodell, L; Dewey, D; Barlow, KM				Kuczynski, Andrea; Crawford, Susan; Bodell, Lisa; Dewey, Deborah; Barlow, Karen M.			Characteristics of post-traumatic headaches in children following mild traumatic brain injury and their response to treatment: a prospective cohort	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							POSTCONCUSSION SYNDROME; CHILDHOOD HEADACHES; ICHD-II; CLASSIFICATION; ADOLESCENTS; CONCUSSION; EDITION	Aim Post-traumatic headaches (PTHs) following mild traumatic brain injury (mTBI) are common; however, few studies have examined the characteristics of PTHs or their response to treatment. The aims of this study were (1) to describe the clinical characteristics of PTH in a prospective cohort of children presenting to a paediatric emergency department with mTBI, and (2) to evaluate the response of PTH to treatment. Method The emergency department cohort was obtained from a prospective longitudinal cohort study of symptoms following mTBI (n=670; 385 males, 285 females) and a comparison group of children with extracranial injury (n=120; 61 males, 59 females). A retrospective chart review of a separate cohort of children from a brain injury clinic (the treatment cohort) treated for PTH was performed (n=44; 29 females, 15 males; mean age 14y 1mo, SD 3y 1mo). The median time since injury was 6.9months (range 1-29mo). The mean follow-up interval after treatment started was 5.5weeks (SD 4.3wks). Results Among the emergency department cohort (n=39; 20 males, 19 females; mean age 11y 1mo, SD 4y 3mo) 11% of children were symptomatic with PTHs at a mean of 15.8days (SD 11.6d) post injury. Three months post injury, 7.8% of children complained of headaches; of those, 56% had pre-existing headaches and 18% had experienced migraine before the injury. Although headache type varied, 55% met the criteria for migraine. A family or past medical history of migraine was present in 82% of cases. Among the treatment cohort, medications included amitriptyline, flunarizine, topiramate, and melatonin, with an overall response rate of 64%. Conclusion This is the first prospective cohort study to describe the clinical characteristics of PTHs following mTBI in children. Migraine was the most common headache type seen; other headaches included tension-type, cervicogenic, and occipital neuralgias, and 64% responded to treatment. Referral to a headache specialist should be considered, especially when the features are not typical of one of the primary headache disorders.	[Kuczynski, Andrea; Dewey, Deborah; Barlow, Karen M.] Univ Calgary, Calgary, AB, Canada; [Crawford, Susan; Bodell, Lisa; Dewey, Deborah; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Res Inst, Calgary, AB T3B 6A8, Canada	Barlow, KM (corresponding author), Alberta Childrens Prov Gen Hosp, C1-322 4888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	karen.barlow@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Dewey, Deborah/0000-0002-1323-5832; Barlow, Karen/0000-0003-2612-8507	Alberta Children's Hospital Foundation [RT34396]	This research was supported by the Alberta Children's Hospital Foundation (RT34396).	Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blaw M E, 1985, Pediatr Neurol, V1, P320, DOI 10.1016/0887-8994(85)90038-4; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hershey AD, 2005, HEADACHE, V45, P1288, DOI 10.1111/j.1526-4610.2005.00260.x; Hershey AD, 2002, HEADACHE, V42, P810, DOI 10.1046/j.1526-4610.2002.02185.x; Hershey AD, 2000, HEADACHE, V40, P539, DOI 10.1046/j.1526-4610.2000.00085.x; Kirk C, 2008, DEV MED CHILD NEUROL, V50, P422, DOI 10.1111/j.1469-8749.2008.02063.x; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Necajauskaite Olga, 2005, Medicina (Kaunas), V41, P100; Necajauskaite Olga, 2005, Medicina (Kaunas), V41, P457; Olesen J, 2005, REV NEUROL-FRANCE, V161, P689; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Price KE, 2011, CLIN PHARMACOL THER, V89, P867, DOI 10.1038/clpt.2011.47; RADANOV B, 1986, FORTSCHR NEUROL PSYC, V54, P375, DOI 10.1055/s-2007-1001942; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003	27	88	88	0	19	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUL	2013	55	7					636	641		10.1111/dmcn.12152			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	160HO	WOS:000320109900015	23560811				2021-06-18	
J	Boden, BP; Breit, I; Beachler, JA; Williams, A; Mueller, FO				Boden, Barry P.; Breit, Ilan; Beachler, Jason A.; Williams, Aaron; Mueller, Frederick O.			Fatalities in High School and College Football Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						football; fatalities; cardiac; brain	SICKLE-CELL TRAIT; SUDDEN-DEATH; AMERICAN FOOTBALL; CERVICAL-SPINE; INJURIES; SPORTS; YOUNG; CONCUSSION; STATEMENT; ASTHMA	Background: Fatalities in football are rare but tragic events. Purpose: The purpose was to describe the causes of fatalities in high school and college football players and potentially provide preventive strategies. Study Design: Descriptive epidemiology study. Methods: We reviewed the 243 football fatalities reported to the National Center for Catastrophic Sports Injury Research from July 1990 through June 2010. Results: Football fatalities averaged 12.2 per year, or 1 per 100,000 participants. There were 164 indirect (systemic) fatalities (average, 8.2 annually [or 0.7 per 100,000 participants]) and 79 direct (traumatic) fatalities (average, 4.0 annually [or 0.3 per 100,000 participants]). Indirect fatalities were 2.1 times more common than direct fatalities. The risk of a fatality in college compared with high school football players was 2.8 (95% CI, 0.7-8.2) times higher for all fatalities, 3.6 (95% CI, 2.5-5.3) times higher for indirect events, 1.4 (95% CI, 0.6-3.0) times higher for direct injuries, 3.8 (95% CI, 1.8-8.3) times higher for heat illness, and 66 (95% CI, 14.4-308) times higher for sickle cell trait (SCT) fatalities. Most indirect events occurred in practice sessions; preseason practices and intense conditioning sessions were vulnerable periods for athletes to develop heat illness or SCT fatalities, respectively. In contrast, most brain fatalities occurred during games. The odds of a fatality during the second decade, compared with the first decade of the study, were 9.7 (95% CI, 1.2-75.9) for SCT, 1.5 (95% CI, 0.8-2.9) for heat illness, 1.1 (95% CI, 0.8-1.7) for cardiac fatalities, and 0.7 (95% CI, 0.4-1.2) for brain fatalities. The most common causes of fatalities were cardiac failure (n = 100, 41.2%), brain injury (n = 62, 25.5%), heat illness (n = 38, 15.6%), SCT (n = 11, 4.5%), asthma and commotio cordis (n = 7 each, 2.9% each), embolism/blood clot (n = 5, 2.1%), cervical fracture (n = 4, 1.7%), and intra-abdominal injury, infection, and lightning (n = 3, 1.2% each). Conclusion: High school and college football have approximately 12 fatalities annually with indirect systemic causes being twice as common as direct blunt trauma. The most common causes are cardiac failure, brain injury, and heat illness. The incidence of fatalities is much higher at the college level for most injuries other than brain injuries, which were only slightly more common at the college level. The risk of SCT, heat-related, and cardiac deaths increased during the second decade of the study, indicating these conditions require a greater emphasis on diagnosis, treatment, and prevention.	[Boden, Barry P.; Breit, Ilan; Beachler, Jason A.; Williams, Aaron; Mueller, Frederick O.] Orthopaed Ctr, Rockville, MD 20850 USA	Boden, BP (corresponding author), Orthopaed Ctr, 9420 Key West Ave,300, Rockville, MD 20850 USA.	bboden@starpower.net					[Anonymous], 1987, Med Sci Sports Exerc, V19, P529; Becker JM, 2004, J ALLERGY CLIN IMMUN, V113, P264, DOI 10.1016/j.jaci.2003.10.052; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Boden BP, 2006, AM J SPORT MED, V34, P1223, DOI 10.1177/0363546506288306; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Carlsen KH, 2011, BRIT J SPORT MED, V45, P1266, DOI 10.1136/bjsports-2011-090591; Eichner ER, 2010, CURR SPORT MED REP, V9, P347, DOI 10.1249/JSR.0b013e3181fc73d7; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Howe AS, 2007, AM J SPORT MED, V35, P1384, DOI 10.1177/0363546507305013; Janda DH, 1992, CLIN J SPORT MED, V2, P172; Maron BJ, 2010, NEW ENGL J MED, V362, P917, DOI 10.1056/NEJMra0910111; Maron BJ, 2009, CIRCULATION, V119, P1085, DOI 10.1161/CIRCULATIONAHA.108.804617; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; Mitchell BL, 2007, J NATL MED ASSOC, V99, P300; Moffatt K, 2007, MED SCI SPORT EXER, V39, P899, DOI 10.1249/01.mss.0b013e31803d35e7; Mueller FO, 2010, FALL 1982 SPRING 201; Mueller FO, 1996, CATASTROPHIC INJURIE, P1; National Climatic Data Center, NOAA SAT INF SERV; National Collegiate Athletic Association, RESOURCES; National Federation of State High School Associations, PART DAT; Oller AR, 2010, J ATHL TRAINING, V45, P222, DOI 10.4085/1062-6050-45.3.222; Tao K, 2010, J EMERG MED, V38, P351, DOI 10.1016/j.jemermed.2008.07.030; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Torg J S, 1979, Am J Sports Med, V7, P127; Torg JS, 2002, J BONE JOINT SURG AM, V84A, P112, DOI 10.2106/00004623-200201000-00017; United States Census Bureau, CENS REG DIV US; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; Walsh KM, 2000, J ATHL TRAINING, V35, P471; Weather Underground Inc, WEATH UND	30	88	90	2	38	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2013	41	5					1108	1116		10.1177/0363546513478572			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	135OQ	WOS:000318298300024	23477766				2021-06-18	
J	Schoeler, M; Loetscher, PD; Rossaint, R; Fahlenkamp, AV; Eberhardt, G; Rex, S; Weis, J; Coburn, M				Schoeler, Marc; Loetscher, Philip D.; Rossaint, Rolf; Fahlenkamp, Astrid V.; Eberhardt, Georg; Rex, Steffen; Weis, Joachim; Coburn, Mark			Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury	BMC NEUROLOGY			English	Article						Neuroprotection; Traumatic brain injury; Dexmedetomidine	HIPPOCAMPAL ORGANOTYPIC CULTURES; INCOMPLETE CEREBRAL-ISCHEMIA; ALPHA(2A)-ADRENOCEPTOR SUBTYPE; SIGNALING PATHWAY; SLICE CULTURES; UNITED-STATES; HYPOTHERMIA; NEURONS; MILD; RATS	Background: The alpha(2)-adrenoreceptor agonist dexmedetomidine is known to provide neuroprotection under ischemic conditions. In this study we investigated whether dexmedetomidine has a protective effect in an in vitro model for traumatic brain injury. Methods: Organotypic hippocampal slice cultures were subjected to a focal mechanical trauma and then exposed to varying concentrations of dexmedetomidine. After 72 h cell injury was assessed using propidium iodide. In addition, the effects of delayed dexmedetomidine application, of hypothermia and canonical signalling pathway inhibitors were examined. Results: Dexmedetomidine showed a protective effect on traumatically injured hippocampal cells with a maximum effect at a dosage of 1 mu M. This effect was partially reversed by the simultaneous administration of the ERK inhibitor PD98059. Conclusion: In this TBI model dexmedetomidine had a significant neuroprotective effect. Our results indicate that activation of ERK might be involved in mediating this effect.	[Schoeler, Marc; Loetscher, Philip D.; Rossaint, Rolf; Fahlenkamp, Astrid V.; Eberhardt, Georg; Rex, Steffen; Coburn, Mark] Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, D-52074 Aachen, Germany; [Weis, Joachim] Rhein Westfal TH Aachen, Univ Hosp, Inst Neuropathol, D-52074 Aachen, Germany; [Rex, Steffen] Katholieke Univ Leuven, Univ Hosp, Dept Anesthesiol, B-3000 Louvain, Belgium	Coburn, M (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	mcoburn@ukaachen.de	Weis, Joachim/G-1984-2014	Weis, Joachim/0000-0003-3280-6773; Rex, Steffen/0000-0002-3536-9321; Coburn, Mark/0000-0002-7930-0270	Orion Corporation, Espoo, Finland; Orion Corporation	This study was supported by Orion Corporation, Espoo, Finland. RR received consultant fees from Orion Corporation, a company producing and marketing pharmaceuticals such as dexmedetomidine. All other authors declare that they have no competing interests.	Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dahmani S, 2008, ANESTHESIOLOGY, V108, P457, DOI 10.1097/ALN.0b013e318164ca81; Dahmani S, 2010, ANESTHESIOLOGY, V112, P373, DOI 10.1097/ALN.0b013e3181ca6982; Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539-200302000-00041; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; HOFFMAN WE, 1991, ANESTHESIOLOGY, V75, P328, DOI 10.1097/00000542-199108000-00022; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hua Y, 2010, J ANESTH, V24, P726, DOI 10.1007/s00540-010-0999-x; Laudenbach V, 2002, ANESTHESIOLOGY, V96, P134, DOI 10.1097/00000542-200201000-00026; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; Ma DQ, 2004, EUR J PHARMACOL, V502, P87, DOI 10.1016/j.ejphar.2004.08.044; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Mueller-Burke D, 2008, INT J DEV NEUROSCI, V26, P67, DOI 10.1016/j.ijdevneu.2007.08.015; MULLER D, 1993, DEV BRAIN RES, V71, P93, DOI 10.1016/0165-3806(93)90109-N; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; Paris A, 2006, ANESTH ANALG, V102, P456, DOI 10.1213/01.ane.0000194301.79118.e9; Roehl AB, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-97; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Sanders RD, 2010, ACTA ANAESTH SCAND, V54, P710, DOI 10.1111/j.1399-6576.2009.02177.x; Sato K, 2010, ACTA ANAESTH SCAND, V54, P377, DOI 10.1111/j.1399-6576.2009.02139.x; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TASKER RC, 1992, J NEUROSCI, V12, P4298; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toborek M, 2007, J CELL BIOCHEM, V100, P279, DOI 10.1002/jcb.21013; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043	29	88	103	0	23	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	APR 11	2012	12								20	10.1186/1471-2377-12-20			7	Clinical Neurology	Neurosciences & Neurology	943BJ	WOS:000304095100001	22494498	DOAJ Gold, Green Published			2021-06-18	
J	Bennett, RE; Mac Donald, CL; Brody, DL				Bennett, Rachel E.; Mac Donald, Christine L.; Brody, David L.			Diffusion tensor imaging detects axonal injury in a mouse model of repetitive closed-skull traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Diffusion tensor imaging; Traumatic brain injury; Axonal injury	AMYLOID PRECURSOR PROTEIN; HEAD TRAUMA; DEMYELINATION; DEGENERATION; WATER	Mild traumatic brain injuries (TBI) are common in athletes, military personnel, and the elderly, and increasing evidence indicates that these injuries have long-term health effects. However, the difficulty in detecting these mild injuries in vivo is a significant impediment to understanding the underlying pathology and treating mild TBI. In the following experiments, we present the results of diffusion tensor imaging (DTI) and histological analysis of a model of mild repetitive closed-skull brain injury in mouse. Histological markers used included silver staining and amyloid precursor protein (APP) immunohistochemistry to detect axonal injury, and Iba-1 immunohistochemistry to assess microglial activation. At 24 h post-injury, before silver staining or microglial abnormalities were apparent by histology, no significant changes in any of the DTI parameters were observed within white matter. At 7 days post-injury we observed a reduction in axial and mean diffusivity. Relative anisotropy at 7 days correlated strongly with the degree of silver staining. Interestingly. APP was not observed at any timepoint examined. In addition to the white matter alterations, mean diffusivity was elevated in ipsilateral cortex at 24 h but returned to sham levels by 7 days. Altogether, this demonstrates that DTI is a sensitive method for detecting axonal injury despite a lack of conventional APP pathology. Further, this reflects a need to better understand the histological basis for DTI signal changes in mild TBI. (c) 2012 Elsevier Ireland Ltd. All rights reserved.	[Bennett, Rachel E.; Mac Donald, Christine L.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069, P30 NS057105]; Burroughs Wellcome Career Award in the Biomedical SciencesBurroughs Wellcome Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057105, R01NS065069] Funding Source: NIH RePORTER	This work was supported by a NIH R01 NS065069 (Brody), a Burroughs Wellcome Career Award in the Biomedical Sciences (Brody), and an NIH Neuroscience Blueprint Core Grant to Washington University (P30 NS057105).	BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Le Bihan D, 2007, PHYS MED BIOL, V52, pR57, DOI 10.1088/0031-9155/52/7/R02; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	17	88	92	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	APR 4	2012	513	2					160	165		10.1016/j.neulet.2012.02.024			6	Neurosciences	Neurosciences & Neurology	929UD	WOS:000303090300012	22343314	Green Accepted			2021-06-18	
J	Savica, R; Parisi, JE; Wold, LE; Josephs, KA; Ahlskog, JE				Savica, Rodolfo; Parisi, Joseph E.; Wold, Lester E.; Josephs, Keith A.; Ahlskog, J. Eric			High School Football and Risk of Neurodegeneration: A Community-Based Study	MAYO CLINIC PROCEEDINGS			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; HEAD-INJURY; DISEASE; ROCHESTER; CONCUSSION; MINNESOTA; EVOLUTION	Objective: To assess whether high school football played between 1946 and 1956, when headgear was less protective than today, was associated with development of neurodegenerative diseases later in life. Methods: All male students who played football from 1946 to 1956 in the high schools of Rochester, Minnesota, plus a non-football-playing referent group of male students in the band, glee club, or choir were identified. Using the records-linkage system of the Rochester Epidemiology Project, we reviewed (from October 31, 2010, to March 30, 2011) all available medical records to assess later development of dementia, Parkinson disease (PD), or amyotrophic lateral sclerosis (ALS). We also compared the frequency of dementia, PD, or ALS with incidence data from the general population of Olmsted County, Minnesota. Results: We found no increased risk of dementia, PD, or ALS among the 438 football players compared with the 140 non-football-playing male classmates. Parkinson disease and ALS were slightly less frequent in the football group, whereas dementia was slightly more frequent, but not significantly so. When we compared these results with the expected incidence rates in the general population, only PD was significantly increased; however, this was true for both groups, with a larger risk ratio in the non-football group. Conclusion: Our findings suggest that high school students who played American football from 1946 to 1956 did not have an increased risk of later developing dementia, PD, or ALS compared with non-football-playing high school males, despite poorer equipment and less regard for concussions compared with today and no rules prohibiting head-first tackling (spearing). (C) 2012 Mayo Foundation for Medical Education and Research square Mayo Clin Proc. 2012;87(4):335-340	[Savica, Rodolfo; Parisi, Joseph E.; Josephs, Keith A.; Ahlskog, J. Eric] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Parisi, Joseph E.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Wold, Lester E.] Mayo Clin Hlth Syst, Dept Pathol, Austin, MN USA	Savica, R (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	savica.rodolfo@mayo.edu			Rochester Historical Society; Lourdes High School; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AG034676]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034676] Funding Source: NIH RePORTER	The authors thank all the personnel of the Rochester Historical Society and Lourdes High School for their help and support.Grant Support: The study was supported by National Institutes of Health Grant R01-AG034676, the Rochester Epidemiology Project (Principal Investigator: Walter A. Rocca, MD, MPH).	Abel EL, 2007, PERCEPT MOTOR SKILL, V104, P1251, DOI 10.2466/PMS.104.4.1251-1254; Bennett T, 1977, NFLS OFFICIAL ENCY H; Bower JH, 1999, NEUROLOGY, V52, P1214, DOI 10.1212/WNL.52.6.1214; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; CLARKE KS, 1979, MED SCI SPORT EXER, V11, P138; Edland SD, 2002, ARCH NEUROL-CHICAGO, V59, P1589, DOI 10.1001/archneur.59.10.1589; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; JUERGENS SM, 1980, NEUROLOGY, V30, P463, DOI 10.1212/WNL.30.5.463; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Levy ML, 2004, NEUROSURGERY, V55, P661; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482	23	88	89	2	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0025-6196	1942-5546		MAYO CLIN PROC	Mayo Clin. Proc.	APR	2012	87	4					335	340		10.1016/j.mayocp.2011.12.016			6	Medicine, General & Internal	General & Internal Medicine	930OC	WOS:000303147700008	22469346	Bronze, Green Published			2021-06-18	
J	Huang, CL; Han, XN; Li, X; Lam, E; Peng, WG; Lou, NH; Torres, A; Yang, MX; Garre, JM; Tian, GF; Bennett, MVL; Nedergaard, M; Takano, T				Huang, Chunlan; Han, Xiaoning; Li, Xi; Lam, Eric; Peng, Weiguo; Lou, Nanhong; Torres, Arnulfo; Yang, Meixiang; Garre, Juan Mauricio; Tian, Guo-Feng; Bennett, Michael V. L.; Nedergaard, Maiken; Takano, Takahiro			Critical Role of Connexin 43 in Secondary Expansion of Traumatic Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article							GAP-JUNCTION HEMICHANNELS; P2X(7) RECEPTOR; IMPROVES RECOVERY; MICROGLIAL CELLS; P2X7 RECEPTOR; ATP RELEASE; IN-VIVO; ASTROCYTES; EXPRESSION; BRAIN	Spinal cord injury (SCI) is often complicated by secondary injury as a result of the innate inflammatory response to tissue trauma and swelling. Previous studies have shown that excessive ATP release from peritraumatic regions contributes to the inflammatory response to SCI by activation of low-affinity P2X7 receptors. Because connexin hemichannels constitute an important route for astrocytic ATP release, we here evaluated the impact on post-traumatic ATP release of deletion of connexins (Cx30/Cx43) in astrocytes. In vivo bioluminescence imaging showed a significant reduction in ATP release after weight-drop injury in mice with deletion of Cx43 compared with Cx43-expressing littermates, both on a Cx30 knockout background. Moreover, astrogliosis and microglia activation were reduced in peritraumatic areas of those mice lacking Cx43; motor recovery was also significantly improved, and the traumatic lesion was smaller. Combined, these observations are consistent with a contribution by astrocytic hemichannels to post-traumatic ATP release that aggravates secondary injury and restrains functional recovery after experimental spinal cord injury. Connexins may thereby constitute a new therapeutic target in spinal cord injury.	[Takano, Takahiro] Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed,Dept Neurosurg, Rochester, NY 14642 USA; [Garre, Juan Mauricio; Bennett, Michael V. L.] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Takano, T (corresponding author), Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed,Dept Neurosurg, 601 Elmwood Ave, Rochester, NY 14642 USA.	nedergaard@urmc.rochester.edu; takahiro_takano@urmc.rochester.edu		Takano, Takahiro/0000-0002-6235-6673	New York State Spinal Cord Injury Research Board; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32DE007202, NS50350, NS038073]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE022743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078167, R01NS038073, R01NS075177] Funding Source: NIH RePORTER	This study was supported by the New York State Spinal Cord Injury Research Board and National Institutes of Health Grants T32DE007202, NS50350, and NS038073.	Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001; Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Cotrina ML, 2009, PURINERG SIGNAL, V5, P223, DOI 10.1007/s11302-009-9138-2; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cronin M, 2008, MOL CELL NEUROSCI, V39, P152, DOI 10.1016/j.mcn.2008.06.005; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Di Virgilio F, 1999, PROG BRAIN RES, V120, P355; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Garre JM, 2010, P NATL ACAD SCI USA, V107, P22659, DOI 10.1073/pnas.1013793107; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Iacobas DA, 2004, NEUROCHEM INT, V45, P243, DOI 10.1016/j.neuint.2003.12.008; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Lin JHC, 2008, J NEUROSCI, V28, P681, DOI 10.1523/JNEUROSCI.3827-07.2008; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; Naus CCG, 2000, BRAIN RES REV, V32, P259, DOI 10.1016/S0165-0173(99)00087-9; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Parpura V, 2004, NEUROCHEM INT, V45, P259, DOI 10.1016/j.neuint.2003.12.011; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Theis M, 2003, J NEUROSCI, V23, P766; Theis M, 2001, GENESIS, V29, P1, DOI 10.1002/1526-968X(200101)29:1<1::AID-GENE1000>3.0.CO;2-0; Theriault E, 1997, J COMP NEUROL, V382, P199; Tozaki-Saitoh H, 2008, J NEUROSCI, V28, P4949, DOI 10.1523/JNEUROSCI.0323-08.2008; Wallraff A, 2006, J NEUROSCI, V26, P5438, DOI 10.1523/JNEUROSCI.0037-06.2006; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082	33	88	89	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 7	2012	32	10					3333	3338		10.1523/JNEUROSCI.1216-11.2012			6	Neurosciences	Neurosciences & Neurology	905SV	WOS:000301295300008	22399755	Bronze, Green Accepted, Green Published			2021-06-18	
J	Ando, T; Xuan, WJ; Xu, T; Dai, TH; Sharma, SK; Kharkwal, GB; Huang, YY; Wu, QH; Whalen, MJ; Sato, S; Obara, M; Hamblin, MR				Ando, Takahiro; Xuan, Weijun; Xu, Tao; Dai, Tianhong; Sharma, Sulbha K.; Kharkwal, Gitika B.; Huang, Ying-Ying; Wu, Qiuhe; Whalen, Michael J.; Sato, Shunichi; Obara, Minoru; Hamblin, Michael R.			Comparison of Therapeutic Effects between Pulsed and Continuous Wave 810-nm Wavelength Laser Irradiation for Traumatic Brain Injury in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; HELIUM-NEON LASER; TERM NEUROLOGICAL DEFICITS; LEVEL LIGHT THERAPY; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; PROMOTES REGENERATION; FUNCTIONAL RECOVERY; MEMORY PERFORMANCE; ISCHEMIC-STROKE	Background and Objective: Transcranial low-level laser therapy (LLLT) using near-infrared light can efficiently penetrate through the scalp and skull and could allow non-invasive treatment for traumatic brain injury (TBI). In the present study, we compared the therapeutic effect using 810-nm wavelength laser light in continuous and pulsed wave modes in a mouse model of TBI. Study Design/Materials and Methods: TBI was induced by a controlled cortical-impact device and 4-hours post-TBI 1-group received a sham treatment and 3-groups received a single exposure to transcranial LLLT, either continuous wave or pulsed at 10-Hz or 100-Hz with a 50% duty cycle. An 810-nm Ga-Al-As diode laser delivered a spot with diameter of 1-cm onto the injured head with a power density of 50-mW/cm(2) for 12-minutes giving a fluence of 36-J/cm(2). Neurological severity score (NSS) and body weight were measured up to 4 weeks. Mice were sacrificed at 2, 15 and 28 days post-TBI and the lesion size was histologically analyzed. The quantity of ATP production in the brain tissue was determined immediately after laser irradiation. We examined the role of LLLT on the psychological state of the mice at 1 day and 4 weeks after TBI using tail suspension test and forced swim test. Results: The 810-nm laser pulsed at 10-Hz was the most effective judged by improvement in NSS and body weight although the other laser regimens were also effective. The brain lesion volume of mice treated with 10-Hz pulsed-laser irradiation was significantly lower than control group at 15-days and 4-weeks post-TBI. Moreover, we found an antidepressant effect of LLLT at 4-weeks as shown by forced swim and tail suspension tests. Conclusion: The therapeutic effect of LLLT for TBI with an 810-nm laser was more effective at 10-Hz pulse frequency than at CW and 100-Hz. This finding may provide a new insight into biological mechanisms of LLLT.	[Ando, Takahiro; Xuan, Weijun; Xu, Tao; Dai, Tianhong; Sharma, Sulbha K.; Kharkwal, Gitika B.; Huang, Ying-Ying; Wu, Qiuhe; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Ando, Takahiro; Obara, Minoru] Keio Univ, Dept Elect & Elect Engn, Yokohama, Kanagawa 223, Japan; [Xuan, Weijun; Xu, Tao; Dai, Tianhong; Kharkwal, Gitika B.; Huang, Ying-Ying; Wu, Qiuhe; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Xuan, Weijun] Tradit Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China; [Xu, Tao] Shanghai Jiao Tong Univ, Lab Anesthesiol, Shanghai 200030, Peoples R China; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Wu, Qiuhe] Shandong Univ, Jinan Cent Hosp, Dept Burns & Plast Surg, Jinan 250100, Peoples R China; [Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Sato, Shunichi] Natl Def Med Coll, Res Inst, Div Biomed Informat Sci, Tokorozawa, Saitama 359, Japan; [Hamblin, Michael R.] Harvard Univ, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02138 USA	Ando, T (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, Ying-ying/G-3153-2011; Huang, yingying/J-7329-2012; Dai, Tianhong/P-5961-2018; Hamblin, Michael R/H-2758-2019; Ando, Takahiro/R-8374-2019; Ando, Takahiro/H-5209-2019	Huang, Ying-ying/0000-0003-3066-6981; Huang, yingying/0000-0002-4038-0277; Dai, Tianhong/0000-0001-8960-8896; Hamblin, Michael R/0000-0001-6431-4605; Xu, Tao/0000-0001-5868-4079	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; Congressionally Directed Medical Research Program in Traumatic Brain Injury [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; Ministry of Education, Culture, Sport, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [10J04881] Funding Source: KAKEN; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health (NIH) grant R01AI050875 (to Dr. Hamblin), Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), Congressionally Directed Medical Research Program in Traumatic Brain Injury (W81XWH-09-1-0514) and Air Force Office of Scientific Research Military Photomedicine Program (FA9950-04-1-0079). Dr. Ando was supported in part by a Grant-in-Aid for the Global Center of Excellence for High-Level Global Cooperation for Leading-Edge Platform on Access Spaces from the Ministry of Education, Culture, Sport, Science and Technology, Japan, and a Grant-in-Aid for Research Fellows of the Japan Society for the Promotion of Science (JSPS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALEY KO, 1989, N-S ARCH PHARMACOL, V339, P306; ANDERS JJ, 1993, LASER SURG MED, V13, P72, DOI 10.1002/lsm.1900130113; Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brondon P, 2009, LASER SURG MED, V41, P222, DOI 10.1002/lsm.20740; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Castro-e-Silva O, 2003, LASER SURG MED, V32, P50, DOI 10.1002/lsm.10141; Davis PJ, 2007, METHODS NUMERICAL IN, Vxii, P612; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GREEN JD, 1954, J NEUROPHYSIOL, V17, P533; Hackett ML, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003437.pub3; Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950; Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826; Huang L, 2011, J CELL PHYSIOL, V226, P588, DOI 10.1002/jcp.22367; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu T, 1998, SCI LOW OWER LASER T; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Kharkwal GB, 2011, P SPIE; Kymplova J, 2003, J CLIN LASER MED SUR, V21, P35, DOI 10.1089/10445470360516725; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lin F, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-16; Lucki I, 2001, PSYCHOPHARMACOLOGY, V155, P315, DOI 10.1007/s002130100694; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Mayorga AJ, 2001, J PHARMACOL EXP THER, V298, P1101; McMarthy T, 2011, P SPIE; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3; Pastore D, 1996, BIOCHEM MOL BIOL INT, V39, P149; Porsolt RD, 2000, REV NEUROSCIENCE, V11, P53; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; PRIESTLEY T, 1994, MOL PHARMACOL, V46, P1191; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Sushko B S, 2007, Fiziol Zh, V53, P51; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; WINSON J, 1972, BEHAV BIOL, V7, P479, DOI 10.1016/S0091-6773(72)80210-4; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu Q, 2010, P SPIE; Wu SN, 2009, J CELL PHYSIOL, V218, P603, DOI 10.1002/jcp.21636; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Zhang Q, 2000, J BIOMED OPT, V5, P206, DOI 10.1117/1.429988	67	88	88	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2011	6	10							e26212	10.1371/journal.pone.0026212			9	Multidisciplinary Sciences	Science & Technology - Other Topics	837ID	WOS:000296186900034	22028832	DOAJ Gold, Green Published			2021-06-18	
J	Fevang, E; Lockey, D; Thompson, J; Lossius, HM				Fevang, Espen; Lockey, David; Thompson, Julian; Lossius, Hans Morten		Torpo Res Collaboration	The top five research priorities in physician-provided pre-hospital critical care: a consensus report from a European research collaboration	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article							EMERGENCY MEDICAL-SERVICES; ADVANCED LIFE-SUPPORT; INTERNATIONAL EMS SYSTEMS; TRAUMATIC BRAIN-INJURY; GOLDEN-HOUR; RESPONSE-TIME; PATIENT; SURVIVAL; PROGRAM; IMPACT	Background: Physician-manned emergency medical teams supplement other emergency medical services in some countries. These teams are often selectively deployed to patients who are considered likely to require critical care treatment in the pre-hospital phase. The evidence base for guidelines for pre-hospital triage and immediate medical care is often poor. We used a recognised consensus methodology to define key priority areas for research within the subfield of physician-provided pre-hospital critical care. Methods: A European expert panel participated in a consensus process based upon a four-stage modified nominal group technique that included a consensus meeting. Results: The expert panel concluded that the five most important areas for further research in the field of physician-based pre-hospital critical care were the following: Appropriate staffing and training in pre-hospital critical care and the effect on outcomes, advanced airway management in pre-hospital care, definition of time windows for key critical interventions which are indicated in the pre-hospital phase of care, the role of pre-hospital ultrasound and dispatch criteria for pre-hospital critical care services. Conclusion: A modified nominal group technique was successfully used by a European expert group to reach consensus on the most important research priorities in physician-provided pre-hospital critical care.	[Fevang, Espen; Lossius, Hans Morten] Norwegian Air Ambulance Fdn, Dept Res & Dev, Drobak, Norway; [Fevang, Espen] Stavanger Univ Hosp, Dept Anaesthesiol & Intens Care, Stavanger, Norway; [Lockey, David; Thompson, Julian] Royal London Hosp, London HEMS, London E1 1BB, England; [Lockey, David] Univ Bristol, Sch Clin Sci, Bristol, Avon, England; [Lossius, Hans Morten] Univ Bergen, Dept Surg Sci, Bergen, Norway	Fevang, E (corresponding author), Norwegian Air Ambulance Fdn, Dept Res & Dev, Drobak, Norway.	espen.fevang@norskluftambulanse.no	Di Bartolomeo, Stefano/K-1695-2016; Wisborg, Torben/H-5126-2011	Di Bartolomeo, Stefano/0000-0002-3468-9358; Wisborg, Torben/0000-0002-7213-8012; Fredriksen, Knut/0000-0002-9281-8007; Sandberg, Marten/0000-0002-4812-0103	Norwegian Air Ambulance Foundation (SNLA); SNLA	The entirety of this project and the consensus meeting were financed by the Norwegian Air Ambulance Foundation (SNLA), and the main author is on a research scholarship from SNLA. The authors would like to thank all members and involved staff from SNLA for making this study possible.	Ali J, 1997, J TRAUMA, V42, P1018, DOI 10.1097/00005373-199706000-00005; Ali J, 1998, WORLD J SURG, V22, P1192, DOI 10.1007/s002689900543; Ali J, 1998, J TRAUMA, V44, P588, DOI 10.1097/00005373-199804000-00005; Berger E, 2010, ANN EMERG MED, V56, p17A, DOI 10.1016/j.annemergmed.2010.09.012; Berlot G, 2006, CRIT CARE CLIN, V22, P457, DOI 10.1016/j.ccc.2006.03.009; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Blackwell TH, 2002, ACAD EMERG MED, V9, P288, DOI 10.1197/aemj.9.4.288; Botker MT, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-12; Breitkreutz R, 2010, RESUSCITATION, V81, P1527, DOI 10.1016/j.resuscitation.2010.07.013; Busch M, 2006, ACTA ANAESTH SCAND, V50, P754, DOI 10.1111/j.1399-6576.2006.01030.x; Butler DP, 2010, EMERG MED J, V27, P692, DOI 10.1136/emj.2009.087486; CALES RH, 1984, ANN EMERG MED, V13, P1, DOI 10.1016/S0196-0644(84)80375-3; Carley S, 2001, RESUSCITATION, V48, P47, DOI 10.1016/S0300-9572(00)00317-8; Carmont MR, 2005, POSTGRAD MED J, V81, P87, DOI 10.1136/pgmj.2004.021543; Chun Rosaleen, 2004, Prehosp Disaster Med, V19, P366; Davis DP, 2011, CRIT CARE, V15, DOI 10.1186/cc10039; DELBECQ AL, 1971, J APPL BEHAV SCI, V7, P466, DOI 10.1177/002188637100700404; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Dissmann PD, 2007, EMERG MED J, V24, P59, DOI 10.1136/emj.2006.038844; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Frederiksen CA, 2011, ACTA ANAESTH SCAND, V55, P126, DOI 10.1111/j.1399-6576.2010.02330.x; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; Garner Alan A, 2004, Emerg Med Australas, V16, P318, DOI 10.1111/j.1742-6723.2004.00636.x; Gillman LM, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-34; GOLD CR, 1987, ANN EMERG MED, V16, P797, DOI 10.1016/S0196-0644(87)80578-4; GOODMAN CM, 1987, J ADV NURS, V12, P729, DOI 10.1111/j.1365-2648.1987.tb01376.x; GUSS DA, 1989, ANN EMERG MED, V18, P1141, DOI 10.1016/S0196-0644(89)80048-4; Haut ER, 2011, ANN SURG, V253, P371, DOI 10.1097/SLA.0b013e318207c24f; Iirola TT, 2006, EUR J EMERG MED, V13, P335, DOI 10.1097/01.mej.0000224429.51623.fb; Isenberg DL, 2005, PREHOSPITAL DISASTER, V20, P265, DOI 10.1017/S1049023X0000265X; JANTZEN JPA, 1993, TXB TRAUMA ANESTHESI; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; JONES SE, 1991, ANN EMERG MED, V20, P857, DOI 10.1016/S0196-0644(05)81427-1; Jorgensen H, 2010, EUR J EMERG MED, V17, P249, DOI 10.1097/MEJ.0b013e328336adce; Knudsen L, 2011, ACTA ANAESTH SCAND, V55, P377, DOI 10.1111/j.1399-6576.2011.02400.x; Kruger AJ, 2010, RESUSCITATION, V81, P427, DOI 10.1016/j.resuscitation.2009.12.019; Kugler G, 2002, ADACOPTER AUFZEICHNU; KWAN I, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002245; Langhelle A, 2004, RESUSCITATION, V61, P9, DOI 10.1016/j.resuscitation.2003.12.008; Lecky F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001429.pub2; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Lockey D, 2009, RESUSCITATION, V80, P722, DOI 10.1016/j.resuscitation.2009.04.006; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; Lossius HM, 2011, CRIT CARE, V15, DOI 10.1186/cc9973; Lossius HM, 2002, ACTA ANAESTH SCAND, V46, P771, DOI 10.1034/j.1399-6576.2002.460703.x; Lyon RM, 2010, EMERG MED J, V27, P637, DOI 10.1136/emj.2009.087395; McManus John G, 2008, Am J Disaster Med, V3, P241; Meisler Rikke, 2009, Ugeskr Laeger, V171, P2548; Morrison CA, 2009, J SURG RES, V157, P115, DOI 10.1016/j.jss.2009.03.051; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Osterwalder JJ, 2003, J TRAUMA, V55, P355, DOI 10.1097/01.TA.0000034231.94460.1F; Pepe PE, 2009, CRIT CARE MED, V37, pS91, DOI 10.1097/CCM.0b013e318192154d; PEPE PE, 1993, ANN EMERG MED, V22, P17, DOI 10.1016/S0196-0644(05)80244-6; Polk JD, 2001, AVIAT SPACE ENVIR MD, V72, P432; Pons PT, 2005, ACAD EMERG MED, V12, P594, DOI 10.1197/j.aem.2005.02.013; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Price S, 2010, CURR OPIN CRIT CARE, V16, P211, DOI 10.1097/MCC.0b013e3283399d4c; RENNIE D, 1981, NEW ENGL J MED, V304, P665, DOI 10.1056/NEJM198103123041110; Ringburg A, 2009, PREHOSP EMERG CARE, V13, P28, DOI 10.1080/10903120802472012; Ringdal KG, 2008, SCAND J TRAUMA RESUS, V16, DOI 10.1186/1757-7241-16-7; Ryynanen OP, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-62; Sackman H., 1974, DELPHI CRITIQUE EXPE; Salomone JP, 2005, J TRAUMA, V58, P509, DOI 10.1097/01.TA.0000152807.63559.2E; Santora TA, 1996, AM J EMERG MED, V14, P564, DOI 10.1016/S0735-6757(96)90100-X; Schou J, 1997, Eur J Emerg Med, V4, P174, DOI 10.1097/00063110-199709000-00013; Seamon MJ, 2007, J TRAUMA, V63, P113, DOI 10.1097/TA.0b013e31806842a1; Simons R, 1999, J TRAUMA, V46, P811, DOI 10.1097/00005373-199905000-00008; Smith RM, 2009, INJURY, V40, pS23, DOI 10.1016/j.injury.2009.10.033; Snooks H, 2009, EMERG MED J, V26, P549, DOI 10.1136/emj.2008.065862; Sollid SJM, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-58; Taylor DM, 2008, PREHOSP EMERG CARE, V12, P42, DOI 10.1080/10903120701710389; Tazarourte K, 2011, ACTA ANAESTH SCAND, V55, P422, DOI 10.1111/j.1399-6576.2010.02372.x; Timmermann A, 2008, CURR OPIN ANESTHESIO, V21, P222, DOI 10.1097/ACO.0b013e3282f5f4f7; van der Velden MWA, 2008, EMERG MED J, V25, P444, DOI 10.1136/emj.2007.052662; VANDEVEN AH, 1972, AM J PUBLIC HEALTH N, V62, P337, DOI 10.2105/AJPH.62.3.337; Wang HE, 2007, ANN EMERG MED, V50, P643, DOI 10.1016/j.annemergmed.2007.08.004; Wang Henry E, 2004, Prehosp Emerg Care, V8, P366; Wigman LD, 2010, INJURY, V41, P1022, DOI DOI 10.1016/J.INJURY.2010.03.015; Williams MJ, 1997, J ACCID EMERG MED, V14, P81; Zalstein S, 1997, AUST NZ J SURG, V67, P593, DOI 10.1111/j.1445-2197.1997.tb04604.x	81	88	89	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	OCT 13	2011	19								57	10.1186/1757-7241-19-57			8	Emergency Medicine	Emergency Medicine	844GB	WOS:000296734600001	21996444	DOAJ Gold, Green Published			2021-06-18	
J	Chen, G; Fang, Q; Zhang, J; Zhou, D; Wang, Z				Chen, Gang; Fang, Qi; Zhang, Jian; Zhou, Dai; Wang, Zhong			Role of the Nrf2-ARE Pathway in Early Brain Injury After Experimental Subarachnoid Hemorrhage	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						early brain injury; subarachnoid hemorrhage; Nrf2	CEREBRAL-ISCHEMIA; RATS; SIMVASTATIN; EXPRESSION	The nuclear factor erythroid 2-related factor 2 and antioxidant-response element (Nrf2-ARE) pathway is a key regulator for modulating inflammation and oxidative damage, which are involved in the pathogenesis of early brain injury (EBI) after subarachnoid hemorrhage (SAH). Previous studies have demonstrated that Nrf2-ARE pathway play neural protective roles in traumatic brain injury, cerebral ischemia, and intracerebral hemorrhage models; however, it has not been investigated whether, and to what degree, the Nrf2-ARE pathway is induced by SAH, and the role of the Nrf2-ARE pathway in development of EBI following SAH remains unknown. Experiment 1 sought to investigate the time course of Nrf2-ARE activation in the cortex in the early stage of SAH. In experiment 2, we assessed the effect of sulforaphane (SUL; a specific Nrf2 activator) on regulation of the Nrf2-ARE pathway in the SAH model and evaluated the impact of SUL on EBI after SAH. The rat SAH model was used injection of 0.3 ml fresh arterial, nonheparinized blood into the prechiasmatic cistern over 20 sec. As a result, Nrf2 and its target gene product, heme oxygenase-1 (HO-1), were up-regulated in the cortex after SAH and peaked at 24 hr post-SAH. After intraperitoneal SUL administration, the elevated expression of Nrf2-ARE-related factors such as Nrf2, HO-1, NAD(P)H:quinone oxidoreductase 1 (NQO1), and glutathione S-transferase-alpha 1 (GST-alpha 1) was detected in the cortex at 48 hr following blood injection. In the SUL-treated group, early brain damage such as brain edema, blood brain barrier (BBB) impairment, cortical apoptosis, and motor deficits was significantly ameliorated compared with vehicle-treated SAH rats. Our results suggest that the Nrf2-ARE pathway is activated in the brain after SAH, playing a beneficial role in EBI development, possibly through inhibiting cerebral oxidative stress by inducing antioxidant and detoxifying enzymes. (C) 2011 Wiley-Liss, Inc.	[Chen, Gang; Zhang, Jian; Zhou, Dai; Wang, Zhong] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu Prov, Peoples R China; [Fang, Qi] Soochow Univ, Affiliated Hosp 1, Dept Neurol, Suzhou 215006, Jiangsu Prov, Peoples R China	Wang, Z (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu Prov, Peoples R China.	dr.daizhou@gmail.com; dr.zhongwang@gmail.com		Chen, Gang/0000-0002-0758-1907	Health Department of Jiangsu Province [RC2007081]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [20090460085]	Contract grant sponsor: 135 Grant from Health Department of Jiangsu Province; Contract grant number: RC2007081; Contract grant sponsor: China Postdoctoral Science Foundation; Contract grant number: 20090460085.	Ayer RE, 2008, ACTA NEUROCHIR SUPPL, V104, P33; Cahill J, 2009, STROKE, V40, pS86, DOI 10.1161/STROKEAHA.108.533315; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kong L, 2009, NEUROCHEM INT, V54, P172, DOI 10.1016/j.neuint.2008.08.013; Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.06-5097fje; Naga KK, 2007, NEUROL RES, V29, P877, DOI 10.1179/016164107X181842; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008; Prunell GF, 2005, NEUROSURGERY, V56, P1082, DOI 10.1227/01.NEU.0000157966.76590.39; Prunell GF, 2002, NEUROREPORT, V13, P2553, DOI 10.1097/00001756-200212200-00034; Prunell GF, 2004, NEUROSURGERY, V54, P426, DOI 10.1227/01.NEU.0000103670.09687.7A; Reddy PVB, 2010, NEUROCHEM INT, V56, P780, DOI 10.1016/j.neuint.2010.02.017; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; SHILL AY, 2003, J NEUROSCI, V23, P3394; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smeyne M, 2007, P NATL ACAD SCI USA, V104, P1977, DOI 10.1073/pnas.0610978104; Stringer JL, 2004, J COMP NEUROL, V471, P289, DOI 10.1002/cne.20048; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Wang Z, 2010, ANN CLIN LAB SCI, V40, P32; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	23	88	99	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2011	89	4					515	523		10.1002/jnr.22577			9	Neurosciences	Neurosciences & Neurology	731WX	WOS:000288142200005	21259333				2021-06-18	
J	Lippa, SM; Pastorek, NJ; Benge, JF; Thornton, GM				Lippa, Sara M.; Pastorek, Nicholas J.; Benge, Jared F.; Thornton, G. Matthew			Postconcussive Symptoms After Blast and Nonblast-Related Mild Traumatic Brain Injuries in Afghanistan and Iraq War Veterans	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Blast injury; Head injury; Concussion; Posttraumatic stress; Polytrauma; Neurobehavioral Symptom Inventory	POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; RAT-BRAIN; CONCUSSION; COMBAT; CARE; COMPLAINTS; METAANALYSIS; PERFORMANCE; MECHANISMS	Blast injury is common in current warfare, but little is known about the effects of blast-related mild traumatic brain injury (mTBI). Profile analyses were conducted investigating differences in self-reported postconcussive (PC) symptoms in 339 veteran outpatients with mTBI histories reporting current symptoms based on mechanism of injury (blast only, nonblast only, or both blast and nonblast), number of blast injuries, and distance from the blast. Veterans with any blast-related mTBI history were younger and reported higher posttraumatic stress symptoms than veterans with nonblast-related mTBI histories, with a marginally significant difference in posttraumatic stress symptom report between veterans reporting blast-related mTBI only and those reporting nonblast-related mTBI. The groups did not differ in terms of PC symptom severity or PC symptom cluster profiles. Among veterans with blast-related mTBI histories, PC symptom report did not vary by number of blast-related mTBIs or proximity to blast. Overall, posttraumatic stress symptoms accounted for a substantial portion of variance in PC symptom report. In veteran outpatients with remote mTBI histories who have enduring symptom complaints related to the mTBI, mechanism of injury did not clearly contribute to differential PC symptom severity or PC symptom cluster profile. Proximal rather than distal factors may be important intervention targets in returning symptomatic veterans with mTBI histories. (JINS, 2010, 16, 856-866.)	[Pastorek, Nicholas J.] Michael E DeBakey VA Med Ctr, ABPP CN, Houston, TX 77030 USA; [Lippa, Sara M.; Thornton, G. Matthew] Univ Houston, Dept Psychol, Houston, TX USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Benge, Jared F.] Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA	Pastorek, NJ (corresponding author), Michael E DeBakey VA Med Ctr, ABPP CN, 2002 Holcombe Blvd,RCL 117, Houston, TX 77030 USA.	nicholas.pastorek@va.gov		Benge, Jared/0000-0001-6201-3278	Department of Veterans AffairsUS Department of Veterans Affairs [B6812C]	The authors thank the Veterans who participated in this study. We also acknowledge the efforts of the Polytrauma Network Site team members at the Michael E. DeBakey VA Medical Center and the George E. Wahlen VA Medical Center for their assistance with data collection, especially Jennifer Romesser, Psy.D., and Maija Reblin, Ph.D. This material is based on work supported by the Office of Academic Affiliations, Department of Veterans Affairs. This work was supported in part by a Department of Veterans Affairs Center of Excellence grant (H.S.L., Grant number B6812C), Neurorehabilitation: Neurons to Networks Center for Rehabilitation Research. Dr. Pastorek had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The information in this manuscript and the manuscript itself has never been published either electronically or in print. No grant, pharmaceutical, or corporate funding was used in the preparation of this manuscript or collection of data. No conflicts of interest exist that might affect this manuscript. Portions of this study were previously presented at the Department of Veterans Affairs Evolving Paradigms II: The Journey Home Conference in Las Vegas, NV in September 2009.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; BRENNER LA, 2009, J HEAD TRAUMA REHABI; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Centers for Disease Control and Prevention, 2003, NAT CTR INJ PREV CON; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; *DEF BRAIN INJ CTR, 2009, BLAST REL MTBI FAQS; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; HOLLNAGEL H, 1980, Ugeskrift for Laeger, V142, P3071; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jakupcak M, 2008, J NERV MENT DIS, V196, P425, DOI 10.1097/NMD.0b013e31817108ed; Kashdan TB, 2006, BEHAV RES THER, V44, P1609, DOI 10.1016/j.brat.2005.12.003; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; LOFTUS EF, 1992, APPL COGNITIVE PSYCH, V6, P93, DOI 10.1002/acp.2350060202; MAYO A, 2006, EMERGEN MED, V7, P40; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Tabacknick B. G., 2001, USING MULTIVARIATE S; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2008, J REHABIL RES DEV, V45, P347, DOI 10.1682/JRRD.2007.05.0077; Weathers F., 1991, PTSD CHECKLIST MILIT; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; YEHUDA R, 1995, AM J PSYCHIAT, V152, P137	50	88	88	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2010	16	5					856	866		10.1017/S1355617710000743			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	670HA	WOS:000283410600015	20682086				2021-06-18	
J	Williams, WH; Mewse, AJ; Tonks, J; Mills, S; Burgess, CNW; Cordan, G				Williams, W. Huw; Mewse, Avril J.; Tonks, James; Mills, Sarah; Burgess, Crispin N. W.; Cordan, Giray			Traumatic brain injury in a prison population: Prevalence and risk for re-offending	BRAIN INJURY			English	Article						Prisoner health; traumatic brain injury; neuroepidemiology; head injury; behavioural disorder; epidemiology; neuropsychology	CRIMINAL BEHAVIOR; HEAD-INJURY; VIOLENT; ASSOCIATION; DYSFUNCTION; DISORDERS	Background: TBI can lead to cognitive, behavioural and emotional difficulties. Previous studies suggest that TBI is relatively elevated in offender populations. In this study the aims were to establish the rate of TBI of various severities in a representative sample of adult offenders and patterns of custody associated with TBI. Methods: A self-report survey of adult, male offenders within a prison. Of 453 offenders, 196 (43%) responded. Results: Over 60% reported 'Head Injuries'. Reports consistent with TBI of various severities were given by 65%. Of the overall sample, 16% had experienced moderate-to-severe TBI and 48% mild TBI. Adults with TBI were younger at entry into custodial systems and reported higher rates of repeat offending. They also reported greater time, in the past 5 years, spent in prison. Conclusions: These findings indicate that there is a need to account for TBI in the assessment and management of offenders.	[Williams, W. Huw] Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter EX4 4QG, Devon, England	Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter EX4 4QG, Devon, England.	w.h.williams@exeter.ac.uk		williams, huw/0000-0003-0670-2620; Tonks, James/0000-0003-3930-9294	UK Acquired Brain Injury Forum; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [Res-062-23-0135]	Research supported by grants to HW from: UK Acquired Brain Injury Forum and Economic and Social Research Council (Res-062-23-0135).	Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Birbaumer N, 2005, ARCH GEN PSYCHIAT, V62, P799, DOI 10.1001/archpsyc.62.7.799; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; BRADLEY L, REV PEOPLE MENTAL HL; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; *CDC, REP CTR DIS CONTR TR; DESOUZA C, 2003, BRAIN INJURY, V17, P39; Farrell M, 2002, BRIT J PSYCHIAT, V181, P393, DOI 10.1192/bjp.181.5.393; Fazel S, 2009, J NEUROL, V256, P1591, DOI 10.1007/s00415-009-5134-2; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Loza W, 2007, J INTERPERS VIOLENCE, V22, P1144, DOI 10.1177/0886260507303730; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; Mobbs D, 2007, PLOS BIOL, V5, P693, DOI 10.1371/journal.pbio.0050103; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; *NEW S WAL CHIEF H, REP NEW S WAL CHIEF; RAINE A, 1994, BIOL PSYCHIAT, V36, P365, DOI 10.1016/0006-3223(94)91211-4; Raine A, 1998, PSYCHOL CRIME LAW, V4, P107, DOI 10.1080/10683169808401752; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044	27	88	88	1	40	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	10					1184	1188		10.3109/02699052.2010.495697			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MJ	WOS:000283197100004	20642322				2021-06-18	
J	Twamley, EW; Allard, CB; Thorp, SR; Norman, SB; Cissell, SH; Berardi, KH; Grimes, EM; Stein, MB				Twamley, Elizabeth W.; Allard, Carolyn B.; Thorp, Steven R.; Norman, Sonya B.; Cissell, Shadha Hami; Berardi, Kelly Hughes; Grimes, Erin M.; Stein, Murray B.			Cognitive impairment and functioning in PTSD related to intimate partner violence	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Posttraumatic stress disorder; Trauma; Stress; Neuropsychological; Cognition; Domestic violence	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL FUNCTION; DISSOCIATIVE EXPERIENCES; VIETNAM VETERANS; CHILD-ABUSE; PERFORMANCE; ATTENTION; DEFICITS; IRAQ	Posttraumatic stress disorder (PTSD) has been associated with neuropsychological impairments across multiple domains, but consensus regarding the cognitive profile of PTSD has not been reached. In this Study of women with PTSD related to intimate partner violence (n = 55) and healthy, demographically similar comparison participants (NCs; n = 20), we attempted to control for many potential Confounds in PTSD samples. All participants were assessed with a comprehensive neuropsychological battery emphasizing executive functioning, including inhibition, switching, and abstraction. NCs outperformed PTSD participants on most neuropsychological measures, but the differences were significant only on speeded tasks (with and without executive functioning, components). The PTSD group's mean performance was within the average range on all neuropsychological tests. Within the PTSD group, more severe PTSD symptoms were associated with slower processing speed, and more severe dissociative symptoms were associated with poorer reasoning performance. These results Suggest that women with PTSD related to intimate partner violence demonstrate slower than normal processing speed, which is associated with the severity of psychiatric symptoms. We speculate that the cognitive slowing seen in PTSD may be attributable to reduced attention due to a need to allocate resources to cope with psychological distress Or unpleasant internal experiences. (JINS, 2009, 15, 879-887.)	[Twamley, Elizabeth W.; Allard, Carolyn B.; Thorp, Steven R.; Norman, Sonya B.; Cissell, Shadha Hami; Grimes, Erin M.; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Twamley, Elizabeth W.; Thorp, Steven R.; Norman, Sonya B.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Twamley, Elizabeth W.; Allard, Carolyn B.; Norman, Sonya B.; Berardi, Kelly Hughes] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA; [Thorp, Steven R.; Cissell, Shadha Hami; Grimes, Erin M.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Stein, Murray B.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA	Twamley, EW (corresponding author), Univ Calif San Diego, Dept Psychiat, 140 Arbor Dr 0851, San Diego, CA 92103 USA.	etwamley@ucsd.edu	Allard, Carolyn B./B-3521-2013; Thorp, Steven/AAT-7321-2020	Allard, Carolyn B./0000-0002-7803-2243; 	Veterans Affairs (VA) Merit ReviewUS Department of Veterans Affairs	This research Was Supported by a grant from the Veterans Affairs (VA) Merit Review Program to Murray B. Stein. The authors have no conflicts of interest.	American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132, DOI 10.1176/ajp.151.8.1132; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bremner JD, 2006, ANN NY ACAD SCI, V1071, P80, DOI 10.1196/annals.1364.008; Bremner JD, 2004, BIOL PSYCHIAT, V55, P612, DOI 10.1016/j.biopsych.2003.10.001; Breslau N, 2004, PSYCHOL MED, V34, P1205, DOI 10.1017/S0033291704002594; CARREY NJ, 1995, J AM ACAD CHILD PSY, V34, P1067, DOI 10.1097/00004583-199508000-00017; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Delis D. C., 2001, D KEFS EXAMINERS MAN; DePrince AP, 2004, PSYCHOL SCI, V15, P488, DOI 10.1111/j.0956-7976.2004.00706.x; DePrince AP, 1999, AM J CLIN HYPN, V41, P281, DOI 10.1080/00029157.1999.10404221; Evans DE, 2009, ADDICT BIOL, V14, P32, DOI 10.1111/j.1369-1600.2008.00130.x; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, P807, DOI 10.2466/pms.1989.68.3.807; First MB., 2002, STRUCTURED CLIN INTE; Freyd J.J., 1996, BETRAYAL TRAUMA LOGI; Freyd Jennifer J, 2005, J Trauma Dissociation, V6, P83, DOI 10.1300/J229v06n03_04; Freyd JJ, 1998, APPL COGNITIVE PSYCH, V12, pS91, DOI 10.1002/(SICI)1099-0720(199812)12:7<S91::AID-ACP599>3.0.CO;2-Z; GARCIA E, 2004, CAL PSYCH ASS ANN M; Geuze E, 2009, DEPRESS ANXIETY, V26, P7, DOI 10.1002/da.20476; Golier J, 2002, PSYCHIAT CLIN N AM, V25, P295, DOI 10.1016/S0193-953X(01)00004-1; Green MF, 2000, SCHIZOPHRENIA BULL, V26, P119, DOI 10.1093/oxfordjournals.schbul.a033430; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; JACKSON S., 2004, SEXUALITIES, V7, P233, DOI DOI 10.1177/1363460704042166; Kalechstein AD, 2003, J CLIN EXP NEUROPSYC, V25, P1186, DOI 10.1076/jcen.25.8.1186.16723; Koenen KC, 2009, AM J PSYCHIAT, V166, P50, DOI 10.1176/appi.ajp.2008.08030343; Kongs SK, 2000, WISCONSIN CARD SORTI; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Marvel CL, 2004, PSYCHIAT CLIN N AM, V27, P19, DOI 10.1016/S0193-953X(03)00106-0; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; PEREZ CM, 1994, CHILD ABUSE NEGLECT, V18, P617, DOI 10.1016/0145-2134(94)90012-4; Rey A., 1941, ARCH PSYCHOL, V28, P215; Saigh PA, 1997, BEHAV RES THER, V35, P429, DOI 10.1016/S0005-7967(96)00111-8; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seedat S, 2003, J NERV MENT DIS, V191, P115, DOI 10.1097/01.NMD.0000050940.16782.6B; Sheehan DV., 1983, ANXIETY DIS; Shucard JL, 2008, BIOL PSYCHOL, V79, P223, DOI 10.1016/j.biopsycho.2008.05.005; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stein MB, 2002, BIOL PSYCHIAT, V52, P1079, DOI 10.1016/S0006-3223(02)01414-2; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Stein MB, 1999, J TRAUMA STRESS, V12, P527, DOI 10.1023/A:1024775222098; Twamley EW, 2002, AM J PSYCHIAT, V159, P2013, DOI 10.1176/appi.ajp.159.12.2013; Twamley EW, 2004, PSYCHIAT RES, V126, P265, DOI 10.1016/j.psychres.2004.01.008; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Waller NG, 1996, PSYCHOL METHODS, V1, P300, DOI 10.1037/1082-989X.1.3.300; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029	54	88	92	0	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2009	15	6					879	887		10.1017/S135561770999049X			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	523ZV	WOS:000272114500008	19703324				2021-06-18	
J	Madri, JA				Madri, J. A.			MODELING THE NEUROVASCULAR NICHE: IMPLICATIONS FOR RECOVERY FROM INJURY	JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article; Proceedings Paper	13th International Congress of Histochemistry and Cytochemistry (ICHC 2008)	AUG 23-27, 2008	Gdansk, POLAND	Polish Soc Histochem & Cytochem		neurovascular niche; neural stem cell; hypoxia; endothelial cell; hydrogel; co-culture; recovery	NEURAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; BIRTH-WEIGHT INFANTS; NETWORKS IN-VIVO; VASCULAR NICHE; HIPPOCAMPAL NEUROGENESIS; AUTOCRINE FUNCTIONS; ANGIOGENIC FACTORS; S-NITROSYLATION; YOUNG ADULTHOOD	While survival from stroke, traumatic brain and spinal cord injuries, neurodegenerative diseases and hypoxia has improved over the past several years, treatments are limited and impacts of these injuries and diseases to patients, families and society can be devastating Recovery from these injuries is variable and involves in part an orchestrated angiogenesis and neurogenesis in the neurogenic zones (neurovascular niches) of the CNS In this focused review the roles of HIF-I alpha mediated responses to hypoxia in CNS neurovascular niches is discussed Using in vivo and in vitro murine models of sublethal hypoxia we mimicked the variable responses observed in the human population and correlated differences in baseline and hyoxia-induced induction of HIF-I alpha several downstream signaling components includind BDNF, VEGF, SDF-I, TrkB, Nrp-I, CXCR4 and NO with differences in survival as well as endothelial cell and neural stem cell survival and proliferation, providing insight into this important and timely problem and suggesting that optimizing of expression levels of some or all of these signaling components may have the potential of maximizing recovery following CNS injury.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37-HL28373, R01-HL51018] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS35476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL028373, R01HL051018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035476] Funding Source: NIH RePORTER		Antaya RJ, 2007, AM J DERMATOPATH, V29, P99, DOI 10.1097/01.dad.0000245636.39098.e5; Bassan H, 2006, PEDIATR NEUROL, V35, P85, DOI 10.1016/j.pediatrneurol.2006.03.005; Berchner-Pfannschmidt U, 2007, J BIOL CHEM, V282, P1788, DOI 10.1074/jbc.M607065200; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Chow J, 2001, DEV BRAIN RES, V130, P123, DOI 10.1016/S0165-3806(01)00220-6; Cooke RWI, 2006, ARCH DIS CHILD-FETAL, V91, pF293, DOI 10.1136/adc.2005.080192; Curristin SM, 2002, P NATL ACAD SCI USA, V99, P15729, DOI 10.1073/pnas.232568799; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Dragun P, 2008, J PHYSIOL PHARMACOL, V59, P441; Fagel DM, 2006, EXP NEUROL, V199, P77, DOI 10.1016/j.expneurol.2005.04.006; Ford MC, 2006, P NATL ACAD SCI USA, V103, P2512, DOI 10.1073/pnas.0506020102; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Iga J, 2007, PROG NEURO-PSYCHOPH, V31, P658, DOI 10.1016/j.pnpbp.2006.12.011; Kim H, 2004, J BIOL CHEM, V279, P33538, DOI 10.1074/jbc.M404115200; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; LI Q, 2009, AM J PATHOL     1008; Li Q, 2008, J NEUROSCI RES, V86, P1227, DOI 10.1002/jnr.21597; Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; MENT LR, 1991, STROKE, V22, P390, DOI 10.1161/01.STR.22.3.390; MENT LR, 1995, DEV BRAIN RES, V84, P142, DOI 10.1016/0165-3806(94)00168-Y; Ment LR, 1997, IN VITRO CELL DEV-AN, V33, P684; MENT LR, 1992, STROKE, V23, P1132, DOI 10.1161/01.STR.23.8.1132; Ment LR, 1997, DEV BRAIN RES, V100, P52, DOI 10.1016/S0165-3806(97)00012-6; Mompeo B, 2003, J NEUROCYTOL, V32, P123, DOI 10.1023/B:NEUR.0000005597.28053.2a; Mucha K, 2007, J PHYSIOL PHARMACOL, V58, P165; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Oishi K, 2004, J PHARMACOL SCI, V96, P208, DOI 10.1254/jphs.FP0040373; Ozturk H, 2007, RENAL FAILURE, V29, P249, DOI 10.1080/08860220601166289; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Paul David A, 2006, BMC Pediatr, V6, P2, DOI 10.1186/1471-2431-6-2; Rauch MF, 2008, J BIOMAT SCI-POLYM E, V19, P1469, DOI 10.1163/156856208786140409; Saigal S, 2006, JAMA-J AM MED ASSOC, V295, P667, DOI 10.1001/jama.295.6.667; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Sharma A, 2008, PSYCHO-ONCOLOGY, V17, P66, DOI 10.1002/pon.1191; Sheldon RA, 1998, BRAIN RES, V810, P114, DOI 10.1016/S0006-8993(98)00892-0; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Tsao PN, 2005, PEDIATR PULM, V39, P461, DOI 10.1002/ppul.20205; Tyson JE, 2005, JAMA-J AM MED ASSOC, V294, P371, DOI 10.1001/jama.294.3.371; Ward NL, 2007, J APPL PHYSIOL, V102, P1927, DOI 10.1152/japplphysiol.00909.2006; Ward NL, 2004, NEUROL RES, V26, P870, DOI 10.1179/016164104X3798; Warner-Schmidt JL, 2008, CURR OPIN PHARMACOL, V8, P14, DOI 10.1016/j.coph.2007.10.013; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Wurmser AE, 2004, SCIENCE, V304, P1253, DOI 10.1126/science.1099344	51	88	96	1	12	POLISH PHYSIOLOGICAL SOC	GRZEGORZECKA	JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLAND	0867-5910			J PHYSIOL PHARMACOL	J. Physiol. Pharmacol.	OCT	2009	60			4			95	104					10	Physiology	Physiology	562CK	WOS:000275026700013	20083857				2021-06-18	
J	Bar-Joseph, G; Guilburd, Y; Tamir, A; Guilburd, JN				Bar-Joseph, Gad; Guilburd, Yoav; Tamir, Ada; Guilburd, Joseph N.			Effectiveness of ketamine in decreasing intracranial pressure in children with intracranial hypertension Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article; Proceedings Paper	5th World Congress of Pediatric Critical Care	JUN, 2007	Geneva, SWITZERLAND			ketamine; sedation; intracranial pressure; child; intracranial hypertension; traumatic brain injury; cerebral perfusion pressure	CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID PRESSURE; INJURY PATIENTS; METABOLISM; ANESTHESIA; MIDAZOLAM; BRAIN; SEDATION; PIG	Object. Deepening sedation is often needed in patients with intracranial hypertension. All widely used sedative and anesthetic agents (opioids, benzodiazepines, propofol, and barbiturates) decrease blood pressure and may therefore decrease cerebral perfusion pressure (CPP). Ketamine is a potent, safe, rapid-onset anesthetic agent that does not decrease blood pressure. However, ketamine's use in patients with traumatic brain injury and intracranial hypertension is precluded because it is widely stated that it increases intracranial pressure (ICP). Based on anecdotal clinical experience, the authors hypothesized that ketamine does not increase-but may rather decrease-ICP. Methods. The authors conducted a prospective, controlled, clinical trial of data obtained in a pediatric intensive care unit of a regional trauma center. All patients were sedated and mechanically ventilated prior to inclusion in the study. Children with sustained, elevated ICP (> 18 mm Hg) resistant to first-tier therapies received a single ketamine dose (1-1.5 mg/kg) either to prevent further ICP increase during a potentially distressing intervention (Group 1) or as an additional measure to lower ICP (Group 2). Hemodynamic, ICP, and CPP values were recorded before ketamine administration, and repeated-measures analysis of variance was used to compare these values with those recorded every minute for 10 minutes following ketamine administration. Results. The results of 82 ketamine administrations in 30 patients were analyzed. Overall, following ketamine administration, ICP decreased by 30% (from 25.8 +/- 8.4 to 18.0 +/- 8.5 mm Hg) (p < 0.001) and CPP increased from 54.4 +/- 11.7 to 58.3 +/- 13.4 mm Hg (p < 0.005). In Group 1, ICP decreased significantly following ketamine administration and increased by > 2 mm Hg during the distressing intervention in only 1 of 17 events. In Group 2, when ketamine was administered to lower persistent intracranial hypertension, ICP decreased by 33% (from 26.0 +/- 9.1 to 17.5 +/- 9.1 mm Hg) (p < 0.0001) following ketamine administration. Conclusions. In ventilation-treated patients with intracranial hypertension, ketamine effectively decreased ICP and prevented untoward ICP elevations during potentially distressing interventions, without lowering blood pressure and CPP. These results refute the notion that ketamine increases ICP. Ketamine is a safe and effective drug for patients with traumatic brain injury and intracranial hypertension, and it can possibly be used safely in trauma emergency situations. (DOI: 10.3171/2009.1.PEDS08319)	[Bar-Joseph, Gad; Guilburd, Yoav; Tamir, Ada; Guilburd, Joseph N.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; [Bar-Joseph, Gad; Guilburd, Joseph N.] Rambam Med Ctr, Meyer Childrens Hosp, Haifa, Israel	Bar-Joseph, G (corresponding author), Rambam Med Ctr, Meyer Childrens Hosp, POB 9602, Haifa, Israel.	g_barjoseph@rambam.health.gov.il					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS34; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; AKESON J, 1993, ACTA ANAESTH SCAND, V37, P525, DOI 10.1111/j.1399-6576.1993.tb03759.x; AKESON J, 1993, ACTA ANAESTH SCAND, V37, P211, DOI 10.1111/j.1399-6576.1993.tb03703.x; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, V26, P458, DOI 10.1111/j.1399-6576.1982.tb01799.x; BJORKMAN S, 1992, J PHARMACOKINET BIOP, V20, P637, DOI 10.1007/BF01064423; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS71; Craven R, 2007, ANAESTHESIA, V62, P48, DOI 10.1111/j.1365-2044.2007.05298.x; CRUMRINE RS, 1975, ANESTHESIOLOGY, V42, P758, DOI 10.1097/00000542-197506000-00026; DAWSON B, 1971, ANESTH ANAL CURR RES, V50, P443; Dershwitz M., 2008, ANESTHESIOLOGY, P849; DUKE JC, 2003, TRAUMA, P329; ESCH JSA, 1978, ACTA NEUROCHIR, V45, P15; EVANS J, 1971, LANCET, V1, P40; EVERS AS, 2006, GOODMAN GILMANS PHAR, P341; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; Heard CMB, 2006, PEDIAT CRITICAL CARE, P1748; Holcomb HH, 2001, NEUROPSYCHOPHARMACOL, V25, P165, DOI 10.1016/S0893-133X(01)00229-9; JOHNSTON MN, 2003, EMERGENCY MED COMPRE, P858; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; Langsjo JW, 2003, ANESTHESIOLOGY, V99, P614, DOI 10.1097/00000542-200309000-00016; LEE TS, 2002, CURRENT CRITICAL CAR, P104; LIST WF, 1972, ANESTHESIOLOGY, V36, P98, DOI 10.1097/00000542-197201000-00023; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; OREN RE, 1987, STROKE, V18, P441, DOI 10.1161/01.STR.18.2.441; Ralston CS, 1999, PEDIAT NEUROSURGERY, P1; Reves JG, 2005, MILLERS ANESTHESIA, P317; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; SHERWOOD ER, 2008, SABISTON TXB SURG, P401; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; TREVOR AJ, 2006, BASIC CLIN PHARM, P395; Vishteh AG, 2004, YOUMANS NEUROLOGICAL, P1503; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021; ZIMMER GD, 2003, EMERGEN MED, P257	39	88	89	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUL	2009	4	1					40	46		10.3171/2009.1.PEDS08319			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	462VB	WOS:000267384000014	19569909				2021-06-18	
J	Ishrat, T; Sayeed, I; Atif, F; Stein, DG				Ishrat, Tauheed; Sayeed, Iqbal; Atif, Fahim; Stein, Donald G.			Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats	BRAIN RESEARCH			English	Article						Progesterone; Brain damage; Permanent MCAO; Functional recovery; Infarct volume	TRAUMATIC BRAIN-INJURY; ARTERY OCCLUSION; COGNITIVE DEFICITS; CELL-DEATH; STROKE; ALLOPREGNANOLONE; NEUROSTEROIDS; MICE; HYPERTHERMIA; MECHANISMS	Recent experimental evidence indicates that progesterone (PROG) protects against various models of brain injury, including ischemic stroke. Most human studies of pharmacologic treatments for acute cerebral stroke have failed despite initial success in animal models. To simulate better the typical human stroke without reperfusion, the present study was conducted to examine the efficacy of PROG on infarct volume and functional outcome in a permanent model of stroke, using direct cauterization of the middle cerebral artery (MCA). Twenty-four male adult Sprague-Dawley rats underwent pMCAO by electro-coagulation and sham operation. After induction of permanent MCA occlusion (pMCAO), the rats received an initial intraperitoneal injection of PROG (8 mg/kg) or vehicle at 1 h post-occlusion followed by subcutaneous injections at 6, 24 and 48 h. Functional deficits were tested on the rotarod and grip-strength meter at 24, 48 and 72 h after pMCAO. The rats were killed 72 h after surgery and isolated brain was sectioned into coronal slices and stained with 2, 3, 5-triphenyltetrazolium chloride (TTC). PROG-treated rats showed a substantial reduction (54.05%) in the volume of the infarct (% contralateral hemisphere) compared to vehicle controls. In addition there was a significant improvement in ability to remain on an accelerating rotarod and increased grip strength observed in the pMCAO rats treated with PROG compared to vehicle. Taken together, these data indicate that PROG is beneficial in one of the best-characterized models of stroke, and may warrant further testing in future clinical trials for human stroke. (C) 2008 Elsevier B.V. All rights reserved.	[Ishrat, Tauheed; Sayeed, Iqbal; Atif, Fahim; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, 1365B Clifton Rd NE, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS04851]; Rooms to Go Scholar award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048451] Funding Source: NIH RePORTER	This work was supported by NIH grants R01 NS04851 and Rooms to Go Scholar award. We acknowledge Leslie McCann for her help in manuscript preparation.	AGGARWAL R, 2008, PHARM PHARM, V60, P731; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1999, BRAIN RES, V833, P181, DOI 10.1016/S0006-8993(99)01528-0; BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; BITRAN D, 1995, J NEUROENDOCRINOL, V7, P171, DOI 10.1111/j.1365-2826.1995.tb00744.x; BIXO M, 1990, PSYCHONEUROENDOCRINO, V15, P159, DOI 10.1016/0306-4530(90)90025-5; Borlongan CV, 2008, REGEN MED, V3, P249, DOI 10.2217/17460751.3.3.249; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; DELCKER A, 1993, EUR ARCH PSY CLIN N, V242, P179, DOI 10.1007/BF02189960; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Feigin VL, 2005, LANCET, V365, P2160, DOI 10.1016/S0140-6736(05)66755-4; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gilmer LK, 2008, J NEUROTRAUM, V25, P593, DOI 10.1089/neu.2007.0477; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hankey GJ, 1999, ARCH NEUROL-CHICAGO, V56, P748, DOI 10.1001/archneur.56.6.748; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hunter AJ, 1998, TRENDS PHARMACOL SCI, V19, P59, DOI 10.1016/S0165-6147(97)01157-7; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kassem-Moussa H, 2002, ARCH NEUROL-CHICAGO, V59, P1870, DOI 10.1001/archneur.59.12.1870; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P570, DOI 10.1097/00004647-199805000-00012; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Luconi M, 1998, J CLIN ENDOCR METAB, V83, P877, DOI 10.1210/jc.83.3.877; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; Mergenthaler P, 2004, METAB BRAIN DIS, V19, P151, DOI 10.1023/B:MEBR.0000043966.46964.e6; MERRYMAN W, 1954, J CLIN ENDOCR METAB, V14, P1567, DOI 10.1210/jcem-14-12-1567; Muntner P, 2002, STROKE, V33, P1209, DOI 10.1161/01.STR.0000015031.57955.D1; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Reddy DS, 1997, BRAIN RES, V752, P61, DOI 10.1016/S0006-8993(96)01447-3; Reglodi D, 2003, BRAIN RES BULL, V59, P459, DOI 10.1016/S0361-9230(02)00962-0; Reglodi D, 2000, EXP NEUROL, V163, P399, DOI 10.1006/exnr.2000.7367; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Smith Sheryl S, 2004, Cleve Clin J Med, V71 Suppl 2, pS4; STEIN DG, HORMONES BR IN PRESS, V4; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	63	88	97	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 27	2009	1257						94	101		10.1016/j.brainres.2008.12.048			8	Neurosciences	Neurosciences & Neurology	420SI	WOS:000264309100011	19135987	Green Accepted			2021-06-18	
J	Vanderploeg, RD; Schwab, K; Walker, WC; Fraser, JA; Sigford, BJ; Date, ES; Scott, SG; Curtiss, G; Salazar, AM; Warden, DL				Vanderploeg, Rodney D.; Schwab, Karen; Walker, William C.; Fraser, Jamie A.; Sigford, Barbara J.; Date, Elaine S.; Scott, Steven G.; Curtiss, Glenn; Salazar, Andres M.; Warden, Deborah L.		Defense Vet Brain Injury Ctr Study	Rehabilitation of Traumatic Brain Injury in Active Duty Military Personnel and Veterans: Defense and Veterans Brain Injury Center Randomized Controlled Trial of Two Rehabilitation Approaches	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Rehabilitation; Treatment outcome	COGNITIVE REHABILITATION; HEAD-INJURY; UNITED-STATES; RATING-SCALE; DISABILITY; INTERVENTION; INTENSITY; EFFICACY; MODERATE; OUTCOMES	Objectives: To determine the relative efficacy of 2 different acute traumatic brain injury (TBI) rehabilitation approaches: cognitive didactic versus functional-experiential and secondarily to determine relative efficacy for different patient subpopulations. Design: Randomized, controlled, intent-to-treat trial comparing 2 alternative TBI treatment approaches. Setting: Four Veterans Administration acute inpatient TBI rehabilitation programs. Participants: Adult veterans or active duty military service members (N=360) with moderate to severe TBI. Interventions: One and a half to 2.5 hours of protoco specific cognitive-didactic versus functional-experiential rehabilitation therapy integrated into interdisciplinary acute Commission for Accreditation of Rehabilitation Facilities-accredited inpatient TBI rehabilitation programs with another 2 to 2.5 hours daily of occupational and physical therapy. Duration of protocol treatment varied from 20 to 60 days depending on the clinical needs and progress of each participant. Main Outcome Measures: The 2 primary outcome measures were functional independence in living and return to work and/or school assessed by independent evaluators at 1-year follow-up. Secondary outcome measures consisted of the FIM, Disability Rating Scale score, and items from the Present State Exam, Apathy Evaluation Scale, and Neurobehavioral Rating Scale. Results: The cognitive-didactic and functional-experiential treatments did not result in overall group differences in the broad 1-year primary outcomes. However, analysis of secondary outcomes found differentially better immediate posttreatment cognitive function (mean +/- SD cognitive FIM) in participants randomized to cognitive-didactic treatment (27.3 +/- 6.2) than to functional treatment (25.6 +/- 6.0, t(332)=2.56, P=.01). Exploratory subgroup analyses found that younger participants in the cognitive arm had a higher rate of returning to work or school than younger patients in the functional arm, whereas participants older than 30 years and those with more years of education in the functional arm had higher rates of independent living status at 1 year posttreatment than similar patients in the cognitive arm. Conclusions: Results from this large multicenter randomized controlled trial comparing cognitive-didactic and functional-experiential approaches to brain injury rehabilitation indicated improved but similar long-term global functional outcome. Participants in the cognitive treatment arm achieved better short-term functional cognitive performance than patients in the functional treatment arm. The current increase in war-related brain injuries provides added urgency for rigorous study of rehabilitation treatments. (http://ClinicalTrials.gov ID# NCT00540020.)	[Vanderploeg, Rodney D.; Curtiss, Glenn] James A Haley Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Curtiss, Glenn] James A Haley Vet Affairs Med Ctr, Def & Vet Brain Injury Ctr, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Curtiss, Glenn] Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Schwab, Karen; Fraser, Jamie A.; Warden, Deborah L.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Schwab, Karen; Warden, Deborah L.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Walker, William C.] Hunter H McGuire Vet Affairs Med Ctr, Def & Vet Brain Injury Ctr, Richmond, VA USA; [Walker, William C.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA; [Sigford, Barbara J.] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA; [Date, Elaine S.] Vet Affairs Palo Alto Hlth Care Syst, Comprehens Rehabil Ctr, Palo Alto, CA USA; [Date, Elaine S.] Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA; [Scott, Steven G.] James A Haley Vet Affairs Med Ctr, Polytrauma Rehabil Ctr, Phys Med & Rehabil Serv, Tampa, FL 33612 USA; [Scott, Steven G.] Univ S Florida, Coll Med, Dept Internal Med, Phys Med & Rehabil Sect, Tampa, FL 33612 USA; [Salazar, Andres M.] Oncovir Inc, Washington, DC USA	Vanderploeg, RD (corresponding author), James A Haley Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, 116B,13000 N Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020; Walker, William C/N-3162-2014				ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Barrett AM, 2007, AM J PHYS MED REHAB, V86, P423, DOI 10.1097/PHM.0b013e31805ba039; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Giles GM, 2006, J HEAD TRAUMA REHAB, V21, P168, DOI 10.1097/00001199-200603000-00009; GILES GM, 1993, BRAIN INJURY REHABIL; GILES GM, 1999, REHABILITATION SEVER; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Marin R.S., 1996, SEMIN CLIN NEUROPSYC, V1, P304, DOI [10.1053/SCNP00100304, DOI 10.1053/SCNP00100304]; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; *NAT CTR INJ PREV, 2008, TRAUM BRIN INJ; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Prigatano G., 1989, TRAUMATIC BRAIN INJU, P175; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SOHLBERE MM, 1989, INTRO COGNITIVE REHA; Sohlberg M. M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SOHLBERG MM, 1986, ATTENTION PROCESS TR; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spilker B., 1991, GUIDE CLIN TRIALS; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vanderploeg RD, 2006, J HEAD TRAUMA REHAB, V21, P179, DOI 10.1097/00001199-200603000-00010; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wing J. K., 1974, PRESENT STATE EXAMIN	49	88	88	0	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12					2227	2238		10.1016/j.apmr.2008.06.015			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	385GY	WOS:000261803900001	19061734				2021-06-18	
J	Wong, DK; Lurie, F; Wong, LL				Wong, David K.; Lurie, Fedor; Wong, Linda L.			The Effects of Clopidogrel on Elderly Traumatic Brain Injured Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Clopidogrel; Traumatic brain Injury; Elderly	PERCUTANEOUS CORONARY INTERVENTION; INTRACRANIAL HEMORRHAGE; ANTICOAGULATED PATIENTS; PREINJURY WARFARIN; ISCHEMIC EVENTS; ASPIRIN; MORTALITY; TRIAL; COMPLICATIONS; THERAPY	Background: Patients are living longer with cardiovascular disease managed with antiplatelet drugs. These seniors are asked to be more physically active and are prone to falls or injuries. Few have studied the mortality or morbidity from anticoagulants in patients with traumatic brain injuries (TBI). With the increasing use of clopidogrel in the elderly, studies on the consequences of TBI are warranted. Methods: This is a retrospective case-controlled study using a trauma data registry of 3,817 closed head trauma cases (2001-2005). Patients with preinjury use of clopidogrel, aspirin or warfarin, and evidence of traumatic intracranial bleeding were identified (n = 134). These were compared with a frequency-matched control group (n = 178) with similar age, gender, Glasgow Coma Scale, and Injury Severity Scores. Main outcome measure included mortality, hospital or intensive care unit duration, and discharge disposition. Results: Of 131 patients on anticoagulants, patients on clopidogrel (n = 21) were more likely to die (OR = 14.7; 95% CI: 2.3-93.6) and be discharged to an inpatient long-term facility (OR = 3.25; 95%CI: 1.06-9.96). Length of hospital stay and intensive care unit stay were not different from control. Mortality in aspirin patients (n = 90) and warfarin patients (n = 20) did not differ from control. Warfarin patients had increased hospital and ICU stay (10.6 and 5.3 days) when compared with the control (4.7 and 0.9 days, respectively). Conclusions: TBI patients on clopidogrel may have increased long-term disability and fatal consequences when compared with patients who are not on these drugs or on other anticoagulants. Patients on clopidogrel should be advised of safety when engaging in potentially dangerous activities to avoid the consequences of TBI.	Univ Hawaii, John A Burns Sch Med, Dept Surg, Honolulu, HI 96822 USA; Queens Med Ctr, Honolulu, HI USA	Wong, LL (corresponding author), 2226 Liliha St,Suite 402, Honolulu, HI 96817 USA.	hepatoma@aol.com		Lurie, Fedor/0000-0003-0644-0560			BARNES PM, 2000, ADV DATA VITAL HLTH, V333; Bhatt DL, 2001, CIRCULATION, V103, P363; Blackman D K, 1999, MMWR CDC Surveill Summ, V48, P1; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Coimbra R, 2005, J TRAUMA, V59, P374, DOI 10.1097/01.ta.000174728.46883.a4; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; DAWODU ST, 2007, TRAUMATIC BRAIN INJU; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Grabowski DC, 2004, JAMA-J AM MED ASSOC, V291, P2840, DOI 10.1001/jama.291.23.2840; HE W, 2005, 65 US CURRENT POPULA; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Keysor JJ, 2001, J GERONTOL A-BIOL, V56, pM412, DOI 10.1093/gerona/56.7.M412; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; *NAT CTR HLTH STAT, 2002, PUBL NAT CTR HLTH ST; *NAT CTR INJ PREV, WHAT IS TRAUM BRAIN; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.pu.08.050187.001345; Ringleb PA, 2004, STROKE, V35, P528, DOI 10.1161/01.STR.0000110221.54366.49; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Yusuf S, 2000, EUR HEART J, V21, P2033; TOP 200 DRUGS 2006 S	29	88	89	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2008	65	6					1303	1308		10.1097/TA.0b013e318185e234			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	383WV	WOS:000261706000021	19077618				2021-06-18	
J	Hilton, GD; Stoica, BA; Byrnes, KR; Faden, AI				Hilton, Genell D.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Faden, Alan I.			Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cell cycle activation; microglia; neurons; roscovitine; TBI	PROTEIN-KINASE INHIBITORS; CELL-CYCLE REGULATORS; IN-VITRO; DEATH; INJURY; EXPRESSION; APOPTOSIS; ISCHEMIA; NEUROPROTECTION; PROLIFERATION	Traumatic brain injury (TBI) causes both direct and delayed tissue damage. The latter is associated with secondary biochemical changes such as cell cycle activation, which leads to neuronal death, inflammation, and glial scarring. Flavopiridol-a cyclin-dependent kinase (CDK) inhibitor that is neither specific nor selective-is neuroprotective. To examine the role of more specific CDK inhibitors as potential neuroprotective agents, we studied the effects of roscovitine in TBI. Central administration of roscovitine 30 mins after injury resulted in significantly decreased lesion volume, as well as improved motor and cognitive recovery. Roscovitine attenuated neuronal death and inhibited activation of cell cycle pathways in neurons after TBI, as indicated by attenuated cyclin G1 accumulation and phosphorylation of retinoblastoma protein. Treatment also decreased microglial activation after TBI, as reflected by reductions in ED1, galectin-3, p22(PHOX), and Iba-1 levels, and attenuated astrogliosis, as shown by decreased accumulation of glial fibrillary acidic protein. In primary cortical microglia and neuronal cultures, roscovitine and other selective CDK inhibitors attenuated neuronal cell death, as well as decreasing microglial activation and microglial-dependent neurotoxicity. These data support a multifactorial neuroprotective effect of cell cycle inhibition after TBI-likely related to inhibition of neuronal apoptosis, microglial-induced inflammation, and gliosis-and suggest that multiple CDKs are potentially involved in this process.	[Stoica, Bogdan A.] Georgetown Univ, Sch Med, Dept Neurosci, Med Ctr, Washington, DC 20057 USA	Stoica, BA (corresponding author), Georgetown Univ, Sch Med, Dept Neurosci, Med Ctr, Res Bldg,Room WG18,3970 Reservoir Rd NW, Washington, DC 20057 USA.	stoicab@georgetown.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grant no. NS052568 to AIF.	Andreani A, 2000, ANTI-CANCER DRUG DES, V15, P447; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; BRENNER M, 1994, BRAIN PATHOL, V4, P245, DOI 10.1111/j.1750-3639.1994.tb00840.x; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Hamdane M, 2005, J CELL SCI, V118, P1291, DOI 10.1242/jcs.01724; Hashimoto M, 2005, NEUROREPORT, V16, P99, DOI 10.1097/00001756-200502080-00004; Ino H, 2001, J NEUROSCI, V21, P6086; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kubo A, 1999, CLIN CANCER RES, V5, P4279; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lam LT, 2001, GENOME BIOL, V2; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Maeda M, 2005, EXP NEUROL, V193, P350, DOI 10.1016/j.expneurol.2005.01.018; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Monaco EA, 2004, BIOCHEM PHARMACOL, V67, P1947, DOI 10.1016/j.bcp.2004.02.007; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; Newcomb EW, 2004, ANTI-CANCER DRUG, V15, P411, DOI 10.1097/01.cad.0000127332.06439.47; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Okamoto T, 1999, INT J MOL MED, V3, P517; Park DS, 2000, NEUROBIOL AGING, V21, P771, DOI 10.1016/S0197-4580(00)00220-7; Rashidian J, 2005, P NATL ACAD SCI USA, V102, P14080, DOI 10.1073/pnas.0500099102; Sakurai M, 2000, STROKE, V31, P200, DOI 10.1161/01.STR.31.1.200; Seo HR, 2006, CELL DEATH DIFFER, V13, P1475, DOI 10.1038/sj.cdd.4401822; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sultana R, 2007, NEUROCHEM RES, V32, P655, DOI 10.1007/s11064-006-9123-x; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tian DS, 2007, BRAIN RES, V1154, P206, DOI 10.1016/j.brainres.2007.04.005; Walther M, 2000, J NEUROSCI RES, V61, P430, DOI 10.1002/1097-4547(20000815)61:4<430::AID-JNR9>3.0.CO;2-3; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	46	88	88	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2008	28	11					1845	1859		10.1038/jcbfm.2008.75			15	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	366IB	WOS:000260472900009	18612315	Bronze, Green Accepted			2021-06-18	
J	Tierney, RT; Higgins, M; Caswell, SV; Brady, J; McHardy, K; Driban, JB; Darvish, K				Tierney, Ryan T.; Higgins, Michael; Caswell, Shane V.; Brady, Jessica; McHardy, Krista; Driban, Jeffrey B.; Darvish, Kurosh			Sex Differences in Head Acceleration During Heading While Wearing Soccer Headgear	JOURNAL OF ATHLETIC TRAINING			English	Article						head impact kinematics; concussion pathomechanics; brain injuries; football players	SEGMENT DYNAMIC STABILIZATION; BRAIN-INJURY; IMPACT; PERFORMANCE; CONCUSSIONS; STRENGTH	Context: Researchers have indicated that female soccer players may be at greater risk of concussion compared with their male counterparts. Soccer headgear is marketed for reducing head acceleration and risk of concussion. Objective: To determine the effect of sex and soccer headgear on head impact kinematics and dynamic stabilization during soccer heading. Design: Cross-sectional design. Setting: Research laboratory. Patients or Other Participants: Forty-four college-aged soccer players (29 women, 15 men). Intervention(s): Using a head impact model, participants performed 4 soccer headers under 3 headgear conditions (control, Head Blast Soccer Band, and Full90 Select Performance Headguard). Main Outcome Measure(s): Dependent variables assessed before soccer heading were head-neck anthropometrics and isometric neck muscle strength, and those assessed during soccer headers were resultant linear head acceleration, Head Injury Criteria (HIC36), and superficial neck muscle electromyography. Statistical analyses included multivariate and univariate analyses of variance with repeated measures, independent-samples t tests, appropriate follow-up analyses of variance and post hoc t tests, and Pearson product moment correlations (alpha = .05). Results: Head acceleration in women was 32% and 44% greater than in men when wearing the Head Blast (21.5 g versus 16.3 g) and Full90 Select (21.8 g versus 15.2 g), respectively (P < .05). Compared with men, women exhibited 10% greater head accelerations (20.2 g versus 18.2 g) during the control condition (P = .164). Conclusions: Female soccer players exhibited greater head accelerations than their male counterparts when wearing headgear. Our results are important clinically because they indicate that soccer headgear may not be an appropriate head injury prevention tool for all athletes.	[Tierney, Ryan T.] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Higgins, Michael] Towson Univ, Towson, MD USA; [Caswell, Shane V.] George Mason Univ, Manassas, VA USA	Tierney, RT (corresponding author), Temple Univ, Dept Kinesiol, 018 Pearson Hall, Philadelphia, PA 19122 USA.	rtierney@temple.edu	Driban, Jeffrey/H-3486-2019	Driban, Jeffrey/0000-0001-6098-4273; Darvish, Kurosh/0000-0002-6674-266X	Pennsylvania Athletic Trainers' Society; Eastern Athletic Trainers' Association; Mid-Atlantic Athletic Trainers' Association; Towson University	We thank the Pennsylvania Athletic Trainers' Society, Eastern Athletic Trainers' Association, Mid-Atlantic Athletic Trainers' Association, and Towson University (Faculty Research Development Grant) for funding this research.	Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Broglio SP, 2003, J ATHL TRAINING, V38, P220; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; Higgins M, 2007, J ATHL TRAINING, V42, P5; HIGGINS MJ, 2007, J ATHL TRAIN S2, V42, pS28; Hrysomallis C, 2004, J SCI MED SPORT, V7, P156, DOI 10.1016/S1440-2440(04)80005-7; Mansell J, 2005, J ATHL TRAINING, V40, P310; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Newman J A, 2000, Stapp Car Crash J, V44, P215; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; SCHANTZ P, 1983, ACTA PHYSIOL SCAND, V117, P219, DOI 10.1111/j.1748-1716.1983.tb07200.x; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; VERSACE J, 1993, BIOMECHANICS IMPACT, P309; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174	25	88	90	1	26	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2008	43	6					578	584		10.4085/1062-6050-43.6.578			7	Sport Sciences	Sport Sciences	377RN	WOS:000261268400003	19030135	Green Published			2021-06-18	
J	Fischer, C; Dailler, F; Morlet, D				Fischer, Catherine; Dailler, Frederic; Morlet, Dominique			Novelty P3 elicited by the subject's own name in comatose patients	CLINICAL NEUROPHYSIOLOGY			English	Article						P3; MMN; Novelty; Coma; Consciousness; Own name	MINIMALLY CONSCIOUS STATE; SOMATOSENSORY-EVOKED POTENTIALS; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; INVOLUNTARY ATTENTION; MISMATCH NEGATIVITY; NONTRAUMATIC COMA; ODDBALL PARADIGM; PREDICTIVE-VALUE; RESPONSES	Objective: To assess patterns of novelty P3 elicited by the subject's own name (SON) in comatose patients and to compare SON novelty P3 prognostic value with that of mismatch negativity (MMN). Methods: A passive oddball paradigm, previously validated in healthy subjects, including duration deviants and SON presented as a novel was applied in 50 severe comatose patients on average 20 days after coma onset. The outcome was assessed 3 months after coma onset. Results: MMN to deviants was found in 14/50 patients and a central-parietal P3 to SON was found in 21/50 patients. In 12 patients, a parietal component (P3b) was also clearly present in the late part of P3. Four patients showed an MMN but no P3. Eleven patients had a novelty P3. with a late parietal component for 5 of them, but no MMN. The presence of a P3 was highly correlated with awakening. Compared to MMN, P3 showed as large a specificity for awakening (0.85). It showed a much higher sensitivity (0.71 versus 0.42). All but one patient with P3b woke up. Conclusions: The use of novelty P3 elicited by SON increases the prognostic value of MMN alone and improves the assessment of comatose patients by demonstrating the activation of higher-level cognitive functions in some of them. It shows that unconsciously perceived stimuli are processed and activate brain areas similarly to consciously perceived stimuli. Significance: SON as a novel in an MMN design can be used to increase the prognostic value of ERPs in comatose patients and to assess unconscious cognitive processes in uncommunicative patients. (c) 2008 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Fischer, Catherine] Neurol Hosp Lyon, Hosp Civils Lyon, Clin Neurophysiol Unit, F-69677 Bron, France; [Fischer, Catherine; Morlet, Dominique] INSERM, U Brain Dynam & Cognit 821, F-69500 Bron, France; [Fischer, Catherine; Morlet, Dominique] Univ Lyon 1, F-69000 Lyon, France; [Dailler, Frederic] Neurol Hosp, Hosp Civils Lyon, Dept Intens Care, Lyon, France	Fischer, C (corresponding author), Neurol Hosp Lyon, Hosp Civils Lyon, Clin Neurophysiol Unit, 59 Blvd Pinel, F-69677 Bron, France.	catherine.fischer@chu-lyon.fr					Alho K, 1998, PSYCHOPHYSIOLOGY, V35, P211, DOI 10.1017/S004857729800211X; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; BASTUJI H, 1995, J CLIN NEUROPHYSIOL, V12, P155, DOI 10.1097/00004691-199503000-00006; BERLAD I, 1995, EVOKED POTENTIAL, V96, P472, DOI 10.1016/0168-5597(95)00116-A; Bernat E, 2001, CLIN NEUROPHYSIOL, V112, P159, DOI 10.1016/S1388-2457(00)00445-4; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; DEGIORGIO CM, 1993, ACTA NEUROL SCAND, V87, P423; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Escera C, 2000, AUDIOL NEURO-OTOL, V5, P151, DOI 10.1159/000013877; Escera C, 1998, J COGNITIVE NEUROSCI, V10, P590, DOI 10.1162/089892998562997; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fischer C, 2006, CRIT CARE MED, V34, P1520, DOI 10.1097/01.CCM.0000215823.36344.99; FISCHER C, 1994, NEUROSURGERY, V35, P45, DOI 10.1227/00006123-199407000-00007; Folmer RL, 1997, BRAIN LANG, V56, P306, DOI 10.1006/brln.1997.1828; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; GUTHRIE D, 1991, PSYCHOPHYSIOLOGY, V28, P240, DOI 10.1111/j.1469-8986.1991.tb00417.x; Holeckova I, 2006, BRAIN RES, V1082, P142, DOI 10.1016/j.brainres.2006.01.089; Holeckova I, 2008, BRAIN RES, V1189, P152, DOI 10.1016/j.brainres.2007.10.091; JENNETT B, 1975, LANCET, V1, P480; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; Melloni L, 2007, J NEUROSCI, V27, P2858, DOI 10.1523/JNEUROSCI.4623-06.2007; Muller HM, 1996, NEUROREPORT, V8, P221; Naccache L, 2005, CLIN NEUROPHYSIOL, V116, P988, DOI 10.1016/j.clinph.2004.10.009; Ofek E, 2005, CLIN NEUROPHYSIOL, V116, P2354, DOI 10.1016/j.clinph.2005.05.021; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Perrin F, 1999, CLIN NEUROPHYSIOL, V110, P2153, DOI 10.1016/S1388-2457(99)00177-7; PLOURDE G, 1991, ANESTH ANALG, V72, P342; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Reuter B M, 1989, Arch Psychol (Frankf), V141, P155; ROLLS ET, 1982, BRAIN, V105, P611, DOI 10.1093/brain/105.4.611; SIGNORINO M, 1995, LANCET, V345, P255, DOI 10.1016/S0140-6736(95)90252-X; SQUIRES KC, 1976, SCIENCE, V193, P1142, DOI 10.1126/science.959831; WOOD N, 1995, J EXP PSYCHOL LEARN, V21, P255, DOI 10.1037/0278-7393.21.1.255; WOODS DL, 1980, SCIENCE, V207, P655, DOI 10.1126/science.7352278; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	44	88	95	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	OCT	2008	119	10					2224	2230		10.1016/j.clinph.2008.03.035			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	373LW	WOS:000260974400013	18760663				2021-06-18	
J	Levin, HS; Hanten, G; Roberson, G; Li, XQ; Ewing-Cobbs, L; Dennis, M; Chapman, S; Max, JE; Hunter, T; Schachar, R; Luerssen, TG; Swank, P				Levin, Harvey S.; Hanten, Gerri; Roberson, Garland; Li, Xiaoqi; Ewing-Cobbs, Linda; Dennis, Maureen; Chapman, Sandra; Max, Jeffrey E.; Hunter, Till; Schachar, Russell; Luerssen, Thomas G.; Swank, Paul			Prediction of cognitive sequela based on abnormal computed tomography findings in children following mild traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						computed tomography; mild traumatic brain injury; predictive factor	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; HEAD-INJURY; WORKING-MEMORY; INHIBITION; VALIDITY; PERFORMANCE; MODEL	Object. The aim of this study was to determine whether the presence of intracranial pathophysiology on computed tomography (CT) scans obtained within 24 hours of mild traumatic brain injury (MTBI) in children adversely affects neuropsychological outcome during the 1st year postinjury. Methods. A prospective longitudinal design was used to examine the neuropsychological outcomes in children (ages 5-15 years) who had been treated for MTBI, which was defined as a loss of consciousness for up to 30 minutes and a lowest Glasgow Coma Scale (GCS) score of 13-15. Exclusion criteria included any preinjury neurological disorder. Outcome assessments were performed within 2 weeks and at 3, 6, and 12 months postinjury. Outcomes were compared between patients with MTBI whose postinjury CT scans revealed complications of brain pathophysiology (32 patients, CMTBI group) and those with MTBI but without complications (48 patients, MTBI group). Results. Significant interactions confirmed that the pattern of recovery over 12 months after injury differed depending on the intracranial pathology, presence and severity of injuries to body regions other than the head, preinjury attention-deficit hyperactivity disorder (ADHD), and socioeconomic status. Children in the CMTBI group had significantly poorer episodic memory, slower cognitive processing, diminished recovery in managing cognitive interference, and poorer performance in calculating and reading than patients in the MTBI group. Among the patients with mild or no extracranial injury, visuomotor speed was slower in those in the CMTBI group; and among patients without preinjury ADHD, working memory was worse in those in the CMTBI, group. Conclusions. Neuropsychological recovery during the 1st year following MTBI is related to the presence of radiographically detectable intracranial pathology. Children with intracranial pathology on acute CT performed more poorly in several cognitive domains when compared with patients whose CT findings were normal or limited to a linear skull fracture. Depending on the presence of preinjury ADHD and concomitant extracranial injury, working memory and visuomotor speed were also diminished in patients whose CT findings revealed complications following MTBI. Computed tomography within 24 hours postinjury appears to be useful for identifying children with an elevated risk for residual neuropsychological changes.	[Levin, Harvey S.; Hanten, Gerri; Roberson, Garland; Li, Xiaoqi] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Hunter, Till] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Luerssen, Thomas G.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Ewing-Cobbs, Linda; Swank, Paul] Univ Texas Houston, Sch Med, Dept Pediat, Houston, TX USA; [Hunter, Till] Texas Childrens Hosp, Houston, TX 77030 USA; [Chapman, Sandra] Univ Texas Dallas, Ctr Brainhlth, Dallas, TX 75230 USA; [Max, Jeffrey E.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Dennis, Maureen] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Schachar, Russell] Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	hlevin@bcm.edu		Schachar, Russell/0000-0002-2015-4395	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08 MH01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889] Funding Source: Medline		Alderson RM, 2007, J ABNORM CHILD PSYCH, V35, P745, DOI 10.1007/s10802-007-9131-6; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; Delis D, 1994, CALIFORNIA VERBAL LE; Donders J, 2004, J INT NEUROPSYCH SOC, V10, P482, DOI 10.1017/S1355617704104025; HOLLINGHSEAD AB, 1975, 4 FACTOR INDEX SOCIA; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Kane MJ, 2007, J EXP PSYCHOL LEARN, V33, P615, DOI 10.1037/0278-7393.33.3.615; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Littell R. C. G. A., 1996, SAS SYSTEM MIXED MOD; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Logan Gordon D., 1994, P189; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wechsler D, 1991, WISC 3 MANUAL; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woodcock R.W., 2001, WOODCOCK JOHNSON 3 T; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	46	88	88	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2008	1	6					461	470		10.3171/PED/2008/1/6/461			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	310IQ	WOS:000256522500011	18518697				2021-06-18	
J	Kemp, SPT; Hudson, Z; Brooks, JHM; Fuller, CW				Kemp, Simon P. T.; Hudson, Zoe; Brooks, John H. M.; Fuller, Colin W.			The epidemiology of head injuries in English professional rugby union	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						elite rugby; head injury; concussion; risk factors	AGREEMENT STATEMENT; CONCUSSION; FOOTBALL; PLAYERS; LEAGUE; PERFORMANCE; PROJECT; SEASONS; SPORTS	Objectives: To undertake a detailed epidemiological study of head injuries sustained by professional rugby union players in order to define their incidence, nature, severity, and causes. Design: A 3-season prospective cohort design. Setting: 13 English Premiership rugby union clubs. Participants: 757 male rugby union players. Main Outcome Measures: Anatomical location, diagnosis, severity (number of days unavailable for training and match play), injury incident, and incidence of match and training injuries (injuries/1000 player-hours). Risk Factors: Playing position, use of headgear, and activity. Results: The overall incidence of match head injury was 6.6 injuries/1000 player-hours, and each injury resulted, on average, in 14 days lost-time. The overall incidence of match concussions was 4.1 injuries/1000 player-hours resulting, on average, in 13 days lost-time. Concussion was the third most common match injury for all players. A large proportion of the players (48%) were able to return to play safely within 7 days. Match concussions were most commonly associated with tackling head-on (28%), collisions (20%), and being tackled head-on (19%). The midfield backs were the playing position at the greatest risk of sustaining a concussion. Only 42% of players were removed from the field of play immediately after a concussion. Foul play was reported by the player to be associated with match head injury in 17% of cases. Mouthguard and headgear usage was associated with a reduced incidence of concussive injury. The overall incidence of training head injury was 0.05 injuries/1000 player-hours, and the overall incidence of training concussions was 0.02 injuries/1000 player-hours. Conclusions: The results showed that rugby union players were exposed to a high risk of noncatastrophic head injury and concussion, particularly whilst tackling and being tackled head-on. In all, 48% of players sustaining a concussion were able to return to play in less than 7 days. The clinical challenge when assessing the potentially concussed player during a game is compounded by the current regulations regarding the permanent replacement of injured players. Injury prevention strategies should be focussed on minimizing the risk and force of direct contact to the head in the tackle.	[Kemp, Simon P. T.; Brooks, John H. M.] Rugby Football Union, Twickenham TW1 1DS, England; [Hudson, Zoe] Royal London Hosp, Ctr Sports & Exercise Med, London E1 1BB, England; [Fuller, Colin W.] Univ Nottingham, Ctr Sports Med, Nottingham NG7 2RD, England	Brooks, JHM (corresponding author), Rugby Football Union, Rugby House,Rugby Rd, Twickenham TW1 1DS, England.	johnbrooks@rfu.com		Brooks, John/0000-0003-2935-7858; Kemp, Simon/0000-0002-3250-2713			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Blignaut J B, 1987, Br J Sports Med, V21, P5; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Brooks JHM, 2005, BRIT J SPORT MED, V39, P288, DOI 10.1136/bjsm.2004.013391; COLLIE A, 2005, COGSPORT ERL USER MA; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Duthie G, 2003, SPORTS MED, V33, P973, DOI 10.2165/00007256-200333130-00003; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Gabbett TJ, 2005, AM J SPORT MED, V33, P428, DOI 10.1177/0363546504268407; Gabbett TJ, 2000, BRIT J SPORT MED, V34, P98, DOI 10.1136/bjsm.34.2.98; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; *INT RUGB BOARD, LAW GAM; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; KIRKWOOD BR, 2003, ESSENTIAL MED STAT, pCH16; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Marshall SW, 2002, INT J EPIDEMIOL, V31, P587, DOI 10.1093/ije/31.3.587; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2003.006338; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MCCRORY P, 2003, RUGBY FOOTBALL UNION; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; MCINTOSH AS, 1996, J SCI MED SPORT, V2; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; ORCHARD J, ORCHARD SPORTS INJUR; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; *RUGB FOOTB UN, 2004, COACH CONT RUGB; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	44	88	89	1	60	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2008	18	3					227	234		10.1097/JSM.0b013e31816a1c9a			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	298SG	WOS:000255706800002	18469563				2021-06-18	
J	Brown, CVR; Zada, G; Salim, A; Inaba, K; Kasotakis, G; Hadjizacharia, P; Demetriades, D; Rhee, P				Brown, Carlos V. R.; Zada, Gabriel; Salim, Ali; Inaba, Kenji; Kasotakis, Georgios; Hadjizacharia, Pantelis; Demetriades, Demetrios; Rhee, Peter			Indications for routine repeat head computed tomography (CT) stratified by severity of traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		blunt; trauma; head injury; traumatic brain injury; computed tomography	MANAGEMENT	Background: controversy exists as to the role of a routine repeat head computed tomography (CT) for patients with traumatic brain injury and an initially abnormal head CT. The specific aim of this study is to identify patients with head injuries who would benefit from a routine repeat head CT. Methods: This was a 2-year (2003 and 2004) prospective study of all patients with blunt trauma admitted to an urban, Level I trauma center that presented with an abnormal head CT. Results of initial head CT and indications for repeat head CT (routine vs. neurologic change) were recorded. Interventions were both medical (diuresis, hyperventilation, barbiturates) and surgical (intracranial pressure monitor placement or craniotomy). Patients were categorized by Glasgow Coma Scale (GCS) score as having mild (GCS 13-15), moderate (GCS 9-12), or severe (GCS <= 8) head injury. Results: There were 354 patients admitted with an initially abnormal head CT. The 37 (10%) patients who went directly to craniotomy and the 43 (12%) patients who died within 24 hours of admission were excluded from analysis. The remaining 274 patients (44 years old, 70% male, mean injury severity score = 19, mean GCS = 10) are the focus of this analysis. After admission, 163 patients underwent a total of 241 repeat CT scans. Of the repeat scans obtained, 102 scans (43%) were unchanged, 54 scans (22%) were better, and 85 scans (35%) were worse. Neurologic deterioration prompted 45 repeat scans (19%), and 196 repeat scans (81%) were obtained routinely after admission without change in neurologic status. The 45 CT scans obtained for neurologic change led to medical or surgical intervention in 38% (n = 17) of cases, whereas scans obtained led to an intervention in only two patients (1%). Both patients who underwent an intervention after a routine scan had a GCS score <= 8 at admission and at the time of routine repeat head CT. One patient had an intracranial pressure monitor placed and the other was taken for craniotomy. No patient with a mild or moderate traumatic brain injury underwent an intervention after a routine repeat head CT. Conclusions: Patients with any head injury (mild, moderate, or severe) should undergo a repeat head CT after neurologic deterioration, because it leads to intervention in over one-third of patients. Routine repeat head CT is indicated for patients with a GCS score :58, as results might lead to intervention without neurologic change.	Univ So Calif, Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA USA	Brown, CVR (corresponding author), 1200 N State St,Room 6341, Los Angeles, CA 90033 USA.	carlosbr@usc.edu		Kasotakis, George/0000-0002-7630-0742			Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; ROBERSON FC, 1979, SURG NEUROL, V12, P161; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	7	88	96	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2007	62	6					1339	1344		10.1097/TA.0b013e318054e25a			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	179YM	WOS:000247326600004	17563645				2021-06-18	
J	Knowles, SB; Marshall, SW; Bowling, JM; Loomis, D; Millikan, R; Yang, JZ; Weaver, NL; Kalsbeek, W; Mueller, FO				Knowles, Sarah B.; Marshall, Stephen W.; Bowling, J. Michael; Loomis, Dana; Millikan, Robert; Yang, Jinzhen; Weaver, Nancy L.; Kalsbeek, William; Mueller, Frederick O.			A prospective study of injury incidence among North Carolina high school athletes	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						athletic injuries; incidence; prospective studies; risk; sports; wounds and injuries	DISCRETIONARY PROTECTIVE EQUIPMENT; RISK-FACTORS; FOOTBALL; SPORTS; PATTERNS; CONCUSSION; COLLEGIATE; HEALTH; WOMEN; MEN	Sports-related injuries are an issue of concern in high school sports athletes. A prospective cohort study of injury risk factors was conducted from 1996 to 1999 among varsity high school athletes in 12 sports in 100 North Carolina high schools. Data were collected by trained school personnel. Unadjusted and adjusted incidence rates and rate ratios were estimated using Poisson regression models. The overall rate of injury was 2.08 per 1,000 athlete-exposures (95% confidence interval (CI): 1.79, 2.41). At 3.54 per 1,000 athlete-exposures (95% CI: 2.87, 4.37), football had the highest rate of injury of all sports. The adjusted rate ratio for athletes with a history of injury, compared with those without a prior injury, was 1.94 (95% CI: 1.69, 2.22). The injury rate rose with each year of playing experience (rate ratio = 1.06, 95% CI: 1.01, 1.12). In a subanalysis restricted to gender-comparable sports, boys had a higher rate of injury than did girls (rate ratio = 1.33, 95% CI: 0.99, 1.79). All other factors did not appear to be independent predictors of the injury rate. The influence of prior injury suggests that proper rehabilitation and primary prevention of the initial injury are important strategies for injury control.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Orthoped, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; St Louis Univ, Sch Publ Hlth, Dept Behav Sci & Hlth Educ, St Louis, MO 63103 USA; Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA USA	Knowles, SB (corresponding author), Palo Alto Med Fdn, Res Inst, 795 El Camino Real,Ames Bldg, Palo Alto, CA 94301 USA.	knowless@pamfri.org	Yang, Jingzhen/N-4786-2014; Loomis, Dana/AAE-3988-2019	Loomis, Dana/0000-0003-3297-5200; Marshall, Stephen/0000-0002-2664-9233			ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Arnason A, 2004, AM J SPORT MED, V32, p5S, DOI 10.1177/0363546503258912; Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501; *CDCP, 1996, SURG GEN REP PHYS AC; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; *DIV NUTR PHYS ACT, 2005, BMI BOD MASS IND BMI; GARRICK JG, 1978, PEDIATRICS, V61, P465, DOI 10.1542/peds.61.3.465; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel BE, 2003, AM J EPIDEMIOL, V157, P825, DOI 10.1093/aje/kwg050; Jones BH, 2000, AM J PREV MED, V18, P71, DOI 10.1016/S0749-3797(99)00169-5; Knapik JJ, 2001, MED SCI SPORT EXER, V33, P946, DOI 10.1097/00005768-200106000-00014; Levy P.S., 1999, WILEY S PRO STAT SUR, V3rd; MCLAIN LG, 1989, PEDIATRICS, V84, P446; *NAT FED STAT HIGH, 2005, PART SETS REC 6 STRA; *NAT FED STAT HIGH, 2005, 2003 2004 PART SUMM; Olson O C, 1979, Phys Sportsmed, V7, P75, DOI 10.1080/00913847.1979.11710899; Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; PRAGER BI, 1989, AM J SPORT MED, V17, P681, DOI 10.1177/036354658901700516; PRITCHETT JW, 1980, AM J SPORT MED, V8, P197, DOI 10.1177/036354658000800310; PRITCHETT JW, 1982, J BONE JOINT SURG AM, V64, P240, DOI 10.2106/00004623-198264020-00015; *RES TRIANL I, 2001, SUDAAN US MAN REL 8; ROBEY JM, 1971, J AMER MED ASSOC, V217, P184, DOI 10.1001/jama.217.2.184; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schulz MR, 2004, AM J SPORT MED, V32, P396, DOI 10.1177/0363546503261715; Stocker B D, 1997, J Ky Med Assoc, V95, P458; Turbeville SD, 2003, AM J SPORT MED, V31, P974, DOI 10.1177/03635465030310063801; Weaver NL, 1999, MED SCI SPORT EXER, V31, P176, DOI 10.1097/00005768-199901000-00027; Yang JZ, 2005, AM J PUBLIC HEALTH, V95, P1996, DOI 10.2105/AJPH.2004.050807; Yang JZ, 2005, AM J EPIDEMIOL, V161, P511, DOI 10.1093/aje/kwi077	33	88	89	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262	1476-6256		AM J EPIDEMIOL	Am. J. Epidemiol.	DEC 15	2006	164	12					1209	1221		10.1093/aje/kwj337			13	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	115DK	WOS:000242714800009	17012366				2021-06-18	
J	Wang, KKW; Larner, SF; Robinson, G; Hayes, RL				Wang, Kevin K. W.; Larner, Stephen F.; Robinson, Gillian; Hayes, Ronald L.			Neuroprotection targets after traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article						antagonist; hypothermia; inhibitor; neuroprotection; traumatic brain injury	RECEPTOR ANTAGONISTS; CELL-DEATH; PERMEABILITY TRANSITION; CALPAIN INHIBITORS; CASPASE INHIBITOR; CLINICAL-TRIALS; CYCLOSPORINE-A; RATS; ERYTHROPOIETIN; DISEASE	Purpose of review The scarcity of pharmacological neuroprotective treatments for traumatic brain injury is a concern being targeted on various fronts. This review examines the latest treatments under investigation. Recent findings In the last 12-18 months, no drug has completed phase III clinical trials as a clearly proven method to treat traumatic brain injury. While the drugs work in rodents, when they make it to clinical trial they have failed primarily due to negative side-effects. Those still in trial show promise, and even those rejected have undergone modifications and now show potential, e.g. second-generation N-methyl-D-aspartic acid and alpha-amino-3-hydroxy-methyl-4-isoxazolyl-propionic acid receptor antagonists, calpain inhibitors, and cyclosporine A analogues. Also, several drugs not previously given much attention, such as the antibiotic minocycline, estrogen and progesterone, and a drug already approved for other diseases, erythropoietin, are being examined. Finally, a treatment generating some controversy, but showing potential, is the application of hypothermia to the patients. Summary Clearly, finding treatments for traumatic brain injury is not going to be easy and is evidently going to require numerous trials. The good news is that we are closer to finding one or more methods for treating traumatic brain injury patients.	Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Banyon Biomarkers Inc, Alachua, FL USA	Wang, KKW (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, 100 S Newell Dr,Box 100256, Gainesville, FL 32610 USA.	kwang@psychiatry.ufl.edu		Wang, Kevin/0000-0002-9343-6473			Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cai SX, 2006, CURR TOP MED CHEM, V6, P651, DOI 10.2174/156802606776894465; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Chen HSV, 2006, J NEUROCHEM, V97, P1611, DOI 10.1111/j.1471-4159.2006.03991.x; Cooper GJ, 1996, J TRAUMA, V40, pS105, DOI 10.1097/00005373-199603001-00024; Davies A R, 2005, Crit Care Resusc, V7, P238; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Irazuzta J, 2005, INTENS CARE MED, V31, P146, DOI 10.1007/s00134-004-2462-7; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kreuter M, 2004, ARCH IMMUNOL THER EX, V52, P141; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; KURTZKE JF, 1992, CLIN NEUROLOGY, V4, P80; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Linton SD, 2005, J MED CHEM, V48, P6779, DOI 10.1021/jm050307e; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Matucz E, 2004, BRAIN RES, V1019, P210, DOI 10.1016/j.brainres.2004.05.098; Mcilvoy LH, 2005, AACN ADV CRIT CARE, V16, P488, DOI 10.1097/00044067-200510000-00006; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sairanen T, 2006, BRAIN, V129, P189, DOI 10.1093/brain/awh645; Seppelt I, 2005, Crit Care Resusc, V7, P233; Shirasaki Y, 2005, BIOORGAN MED CHEM, V13, P4473, DOI 10.1016/j.bmc.2005.04.059; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tanaka Ken-ichi, 2004, Nihon Shinkei Seishin Yakurigaku Zasshi, V24, P71; THRUMAN DJ, 2001, HEAD TRAUMA BASIC PR, P327; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Weiser T, 2002, CURR PHARM DESIGN, V8, P941, DOI 10.2174/1381612024607135; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2; Yang W, 2003, BRIT J PHARMACOL, V140, P402, DOI 10.1038/sj.bjp.0705450; Yu DY, 2006, IUBMB LIFE, V58, P429, DOI 10.1080/15216540600791555; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zhu M, 2006, NEUROSCIENCE, V141, P2019, DOI 10.1016/j.neuroscience.2006.05.011	60	88	91	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2006	19	6					514	519		10.1097/WCO.0b013e3280102b10			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	115XJ	WOS:000242766800002	17102687				2021-06-18	
J	McLeod, TCV; Barr, WB; McCrea, M; Guskiewicz, KM				McLeod, Tamara C. Valovich; Barr, William B.; McCrea, Michael; Guskiewicz, Kevin M.			Psychometric and measurement properties of concussion assessment tools in youth sports	JOURNAL OF ATHLETIC TRAINING			English	Article; Proceedings Paper	Rocky-Mountain-Athletic-Trainers'-Association District Meeting	MAR, 2004	Broomfield, CO	Rocky Mt Athlet Trainers Assoc		neuropsychological testing; brain injury; athletic injuries; reliability	MILD HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL TEST PROTOCOL; TEST-RETEST RELIABILITY; HIGH-SCHOOL; POSTURAL STABILITY; STANDARDIZED ASSESSMENT; NCAA CONCUSSION; RECOVERY; PERFORMANCE	Context: Establishing psychometric and measurement properties of concussion assessments is important before these assessments are used by clinicians. To date, data have been limited regarding these issues with respect to neurocognitive and postural stability testing, especially in a younger athletic population. Objective: To determine the test-retest reliability and reliable change indices of concussion assessments in athletes participating in youth sports. A secondary objective was to determine the relationship between the Standardized Assessment of Concussion (SAC) and neuropsychological assessments in young athletes. Design: We used a repeated-measures design to evaluate the test-retest reliability of the concussion assessments in young athletes. Correlations were calculated to determine the relationship between the measures. All subjects underwent 2 test sessions 60 days apart. Setting: Sports medicine laboratory and school or home environment. Patients or Other Participants: Fifty healthy young athletes between the ages of 9 and 14 years. Main Outcome Measure(s): Scores from the SAC, Balance Error Scoring System, Buschke Selective Reminding Test, Trail Making Test B, and Coding and Symbol Search subsets of the Wechsler Intelligence Scale for Children were used in the analysis. Results: Our test-retest indices for each of the 6 scores were poor to good, ranging from r =.46 to.83. Good reliability was found for the Coding and Symbol Search tests. The reliable change scores provided a way of determining a meaningful change in score for each assessment. We found a weak relationship (r <.36) between the SAC and each of the neuropsychological assessments; however, stronger relationships (r >.70) were found between certain neuropsychological measures. Conclusions: We found moderate test-retest reliability on the cognitive tests that assessed attention, concentration, and visual processing and the Balance Error Scoring System. Our results demonstrated only a weak relationship between performance on the SAC and the selected neuropsychological tests, so it is likely that these tests assess somewhat different areas of cognitive function. Our correlational findings provide more evidence for using the SAC along with a more complex neuropsychological assessment battery in the evaluation of concussion in young athletes.	AT Still Univ, Athlet Training Program, Arizona Sch Hlth Sci, Mesa, AZ 85206 USA; NYU, Sch Med, New York, NY USA; Waukesha Mem Hosp, Waukesha, WI USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ N Carolina, Chapel Hill, NC 27515 USA	McLeod, TCV (corresponding author), AT Still Univ, Athlet Training Program, Arizona Sch Hlth Sci, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	McLeod, Tamara/AAU-9435-2020	Guskiewicz, Kevin/0000-0002-8682-2130; Barr, William/0000-0001-7711-7758			ATWATER SW, 1990, PHYS THER, V70, P79, DOI 10.1093/ptj/70.2.79; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309; CLODFELTER CJ, 1987, CLIN NEUROPSYCHOL, V1, P243; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Duff K, 2001, ARCH CLIN NEUROPSYCH, V16, P461; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GARRETT HE, 1992, STAT PSYCHOL ED; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; McSweeny A., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2001, J ATHL TRAINING, V36, P288; Reitan RM., 1985, HALSTEAD REITAN NEUR; RIACH CL, 1987, DEV MED CHILD NEUROL, V29, P650; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Spreen O., 1998, COMPENDIUM NEUROPSYC; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wechsler D., 1991, WECHSLER INTELLIGENC; Westcott Sarah L., 1994, Physical and Occupational Therapy in Pediatrics, V14, P1, DOI 10.1300/J006v14n01_01	55	88	88	0	10	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2006	41	4					399	408					10	Sport Sciences	Sport Sciences	124QU	WOS:000243385800010	17273465				2021-06-18	
J	Liu, MC; Akle, V; Zheng, WR; Kitlen, J; O'Steen, B; Larner, SF; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW				Liu, Ming Cheng; Akle, Veronica; Zheng, Wenrong; Kitlen, Jason; O'Steen, Barbara; Larner, Stephen F.; Dave, Jitendra R.; Tortella, Frank C.; Hayes, Ronald L.; Wang, Kevin K. W.			Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						brain injury; cell death; demyelination; protease; proteolysis; proteomic	SPINAL-CORD-INJURY; GENE KNOCK-OUT; WHITE-MATTER; BREAKDOWN PRODUCTS; ALPHA-SPECTRIN; CATHEPSIN-B; II-SPECTRIN; PROTEOLYSIS; RAT; ACTIVATION	s Axonal injury is one of the key features of traumatic brain injury (TBI), yet little is known about the integrity of the myelin sheath. We report that the 21.5 and 18.5-kDa myelin basic protein (MBP) isoforms degrade into N-terminal fragments (of 10 and 8 kDa) in the ipsilateral hippocampus and cortex between 2 h and 3 days after controlled cortical impact (in a rat model of TBI), but exhibit no degradation contralaterally. Using N-terminal microsequencing and mass spectrometry, we identified a novel in vivo MBP cleavage site between Phe114 and Lys115. A MBP C-terminal fragment-specific antibody was then raised and shown to specifically detect MBP fragments in affected brain regions following TBI. In vitro naive brain lysate and purified MBP digestion showed that MBP is sensitive to calpain, producing the characteristic MBP fragments observed in TBI. We hypothesize that TBI-mediated axonal injury causes secondary structural damage to the adjacent myelin membrane, instigating MBP degradation. This could initiate myelin sheath instability and demyelination, which might further promote axonal vulnerability.	Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Ctr Neuroproteom & Biomarkers Res, Dept Psychiat, Gainesville, FL 32610 USA; Walter Reed Army Inst Res, Div Neurosci, Dept Neuropharmacol & Mol Biol, Silver Spring, MD USA	Liu, MC (corresponding author), Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Neurosci, L4-100F,POB 100256, Gainesville, FL 32610 USA.	liumc@mbi.ufl.edu; kwang@psychiatry.ufl.edu	Dave, Jitendra R/A-8940-2011; akle, veronica/AAD-7577-2019	Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049175-01] Funding Source: Medline		Akiyama K, 2002, J NEUROSCI RES, V68, P19, DOI 10.1002/jnr.10188; Asahi M, 2001, J NEUROSCI, V21, P7724; BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; BANIK NL, 1985, J NEUROCHEM, V45, P581, DOI 10.1111/j.1471-4159.1985.tb04026.x; BANIK NL, 1994, J NEUROSCI RES, V37, P489, DOI 10.1002/jnr.490370408; Bartholdi D, 1998, GLIA, V23, P278, DOI 10.1002/(SICI)1098-1136(199807)23:3<278::AID-GLIA10>3.0.CO;2-Q; BENUCK M, 1975, EUR J BIOCHEM, V52, P615, DOI 10.1111/j.1432-1033.1975.tb04033.x; BERLET HH, 1985, FEBS LETT, V179, P299, DOI 10.1016/0014-5793(85)80538-X; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BROSTOFF SW, 1974, J BIOL CHEM, V249, P559; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Hisahara S, 2003, NEUROSCI RES, V46, P387, DOI 10.1016/S0168-0102(03)00127-5; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Irving EA, 2001, ACTA NEUROPATHOL, V102, P627, DOI 10.1007/s004010100416; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; MARKS N, 1980, J NEUROSCI RES, V5, P217, DOI 10.1002/jnr.490050306; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Richter-Landsberg C, 2000, J NEUROSCI RES, V59, P11, DOI 10.1002/(SICI)1097-4547(20000101)59:1<11::AID-JNR2>3.0.CO;2-O; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Schaecher KE, 2001, NEUROCHEM RES, V26, P731, DOI 10.1023/A:1010903823668; Seyfried D, 1997, J NEUROSURG, V87, P716, DOI 10.3171/jns.1997.87.5.0716; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Sloane JA, 2003, J NEUROCHEM, V84, P157, DOI 10.1046/j.1471-4159.2003.01541.x; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; TSUBATA T, 1989, J BIOCHEM-TOKYO, V105, P23, DOI 10.1093/oxfordjournals.jbchem.a122611; Wang K K, 1997, Adv Pharmacol, V37, P117; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Waxman SG, 1998, NEW ENGL J MED, V338, P323, DOI 10.1056/NEJM199801293380610; WILLIAMS KR, 1986, J NEUROSCI RES, V15, P137, DOI 10.1002/jnr.490150203; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; YANAGISAWA K, 1988, J NEUROCHEM, V51, P803, DOI 10.1111/j.1471-4159.1988.tb01815.x	55	88	90	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2006	98	3					700	712		10.1111/j.1471-4159.2006.03882.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	063GV	WOS:000239007400007	16893416	Bronze			2021-06-18	
J	Casha, S; Yu, WR; Fehlings, MG				Casha, S; Yu, WR; Fehlings, MG			FAS deficiency reduces apoptosis, spares axons and improves function after spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						spinal cord injury; FAS; apoptosis; oligodendrocyte; neuroprotection	TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; COMPRESSION TRAUMA; WALLERIAN DEGENERATION; CONTUSION INJURY; GLIAL APOPTOSIS; UP-REGULATION; GRADED MODEL; IN-VITRO; RAT	After spinal cord injury (SCI), apoptosis of neurons and oligodendrocytes is associated with axonal degeneration and loss of neurological function. Recent data have suggested a potential role for FAS death receptor-mediated apoptosis in the pathophysiology of SCI. In this study, we examined the effect of FAS deficiency on SCI in vitro and in vivo. FAS(Lpr/lpr) mutant mice and wildtype background-matched mice were subjected to a T5-6 clip compression SCI, and complementary studies were done in an organotypic slice culture model of SCI. Post-traumatic apoptosis in the spinal cord, which was seen in neurons and oligodendrocytes, was decreased in the FAS-deficient mice both in vivo and in vitro particularly in oligodendrocytes. FAS deficiency was also associated with improved locomotor recovery, axonal sparing and preservation of oligodendrocytes and myelin. However, FAS deficiency did not result in a significant increase in surviving neurons in the spinal cord at 6 weeks after injury, likely reflecting the importance of other cell death mechanisms for neurons. We conclude that inhibition of the FAS pathway may be a clinically attractive neuroprotective strategy directed towards oligodendroglial and axonal preservation in the treatment of SCI and neurotrauma. (c) 2005 Elsevier Inc. All rights reserved.	Toronto Western Hosp, Krembil Neurosci Ctr, Spinal Program, Toronto, ON M5T 2S8, Canada; Univ Toronto, Inst Med Sci, Dept Surg, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Toronto Western Hosp, Krembil Neurosci Ctr, Spinal Program, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.	Michael.fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bjartmar C, 1999, J NEUROCYTOL, V28, P383, DOI 10.1023/A:1007010205037; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEMJEN D, 2004, NAT MED, V7, P7; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Ghirnikar RS, 2001, J NEUROSCI RES, V64, P582, DOI 10.1002/jnr.1110; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Joshi M, 2002, J NEUROTRAUM, V19, P191, DOI 10.1089/08977150252806956; Katoh K, 1996, NEUROSCI LETT, V216, P9; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Kim GM, 2001, J NEUROSCI, V21, P6617; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li GL, 2000, ACTA NEUROPATHOL, V100, P75, DOI 10.1007/s004010051195; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li XM, 2000, RESTOR NEUROL NEUROS, V17, P203; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nakatsuru S, 1999, PATHOL INT, V49, P974, DOI 10.1046/j.1440-1827.1999.00979.x; Ray SK, 2000, NEUROCHEM RES, V25, P1191, DOI 10.1023/A:1007631826160; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; Saito N, 2000, J NEUROTRAUM, V17, P173, DOI 10.1089/neu.2000.17.173; Sakurai M, 1998, BRAIN RES, V797, P23, DOI 10.1016/S0006-8993(98)00290-X; Sakurai M, 2000, STROKE, V31, P200, DOI 10.1161/01.STR.31.1.200; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Schmidt M, 2001, J IMMUNOL, V166, P1344, DOI 10.4049/jimmunol.166.2.1344; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Silvestris F, 2000, MOL MED, V6, P509, DOI 10.1007/BF03401791; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Ugolini G, 2003, J NEUROSCI, V23, P8526; Vidal S, 1998, J CLIN INVEST, V101, P696, DOI 10.1172/JCI1817; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yin XH, 1998, J NEUROSCI, V18, P1953, DOI 10.1523/jneurosci.18-06-01953.1998; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yoshino O, 2004, SPINE, V29, P1394, DOI 10.1097/01.BRS.0000129894.34550.48; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	51	88	98	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2005	196	2					390	400		10.1016/j.expneurol.2005.08.020			11	Neurosciences	Neurosciences & Neurology	987WG	WOS:000233547700020	16202410				2021-06-18	
J	Lu, KT; Wang, YW; Yang, JT; Yang, YL; Chen, HI				Lu, KT; Wang, YW; Yang, JT; Yang, YL; Chen, HI			Effect of interleukin-1 on traumatic brain injury - Induced damage to hippocampal neurons	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; IL-1; neuronal damage; rats; traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; CLOSED-HEAD INJURY; RECEPTOR ANTAGONIST; MESSENGER-RNA; GLUCOCORTICOIDS MODULATE; INFLAMMATORY CYTOKINES; CEREBRAL-ISCHEMIA; RAT HIPPOCAMPUS; MICE LACKING; IN-VITRO	Interleukin-1 (IL-1) has many roles in the brain in addition to mediating inflammatory processes in the glia, and has also been implicated in neurodegenerative disease. Traumatic brain injury (TBI) is one of the most prevalent causes of morbidity and mortality in young persons. We conducted a study to assess the effect of IL-1 on the TBI-induced death of hippocampal neurons. After TBI was induced in adult male Sprague-Dawley rats under anesthesia, we evaluated neuronal damage score through microscopic examination and Pulsinelli's grading system. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were used to measure the levels of IL-1 alpha and IL-1 beta in brain tissue at different points after the induction of TBI. Over a 4-day period, the specific sites of release of IL-1 alpha and IL-1 beta in the brain were elucidated by immunocytochemistry with double-labeling. TBI to the hippocampus was followed by disruption of the blood-brain barrier and severe neuronal loss. Levels of IL-1 alpha RNA and protein were significantly elevated at 3 h after TBI, peaked at 12 h, and remained elevated for 168 h. IL-1 beta RNA and protein expression were also elevated at 3 h after TBI, but remained so only for 48 h. Our findings indicate that the observed TBI-induced increases in IL-1 alpha and IL-1 beta occur largely through release of these cytokines from neurons and astrocytes, respectively. Intraventricular administration of antibodies to IL-1 alpha and IL-1 beta before TBI significantly attenuated the TBI-induced loss of hippocampal neurons. These results show that IL-1 alpha and IL-1 beta play important roles in the TBI-induced loss of hippocampal neurons.	Natl Chiayi Univ, Inst Biotechnol, Chiayi, Taiwan; Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Neurosurg, Chiayi, Taiwan; Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan	Yang, YL (corresponding author), Natl Chiayi Univ, Inst Biotechnol, 300 Univ Rd, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw	Yang, Jen-Tsung/C-3187-2011				Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CALDWELL J, 1995, BLOOD, V86, P3364, DOI 10.1182/blood.V86.9.3364.bloodjournal8693364; Chen CA, 2002, MOL PHYLOGENET EVOL, V23, P137, DOI 10.1016/S1055-7903(02)00008-8; Chen YM, 2001, GLIA, V33, P343, DOI 10.1002/1098-1136(20010315)33:4<343::AID-GLIA1033>3.0.CO;2-H; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GOSS JR, 1995, J NEUROCHEM, V64, P1351; GRAHAM DG, 1984, NEUROTOXICOLOGY, V5, P83; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; Grundy PL, 2001, BRAIN RES, V892, P386, DOI 10.1016/S0006-8993(00)03258-3; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Hartl R, 1997, ACT NEUR S, V70, P240; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; LANDFIELD PW, 1977, J GERONTOL, V32, P3, DOI 10.1093/geronj/32.1.3; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; Lukaszevicz AC, 2002, J CEREBR BLOOD F MET, V22, P289, DOI 10.1097/00004647-200203000-00006; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 2000, NEUROTRAUMA, V17, P143; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Reichert SA, 2001, J NEUROSCI, V21, P6608; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; RUDGE JS, 1989, EXP NEUROL, V103, P1, DOI 10.1016/0014-4886(89)90180-5; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; TOWER DB, 1973, J NEUROCHEM, V20, P269, DOI 10.1111/j.1471-4159.1973.tb12126.x; Tsao N, 2001, J MED MICROBIOL, V50, P812, DOI 10.1099/0022-1317-50-9-812; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com	51	88	93	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2005	22	8					885	895		10.1089/neu.2005.22.885			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	955LH	WOS:000231226900004	16083355				2021-06-18	
J	Wang, HE; Kupas, DF; Hostler, D; Cooney, R; Yealy, DM; Lave, JR				Wang, HE; Kupas, DF; Hostler, D; Cooney, R; Yealy, DM; Lave, JR			Procedural experience with out-of-hospital endotracheal intubation	CRITICAL CARE MEDICINE			English	Article						intubation (intratracheal); emergency medical services; clinical competence; resuscitation	RAPID-SEQUENCE INTUBATION; MEDICAL-SERVICES SYSTEM; TRAUMATIC BRAIN-INJURY; SUCCESS RATES; PARAMEDICS	Objective. Out-of-hospital rescuers likely need regular clinical experience to perform endotracheal intubation (ETI) in a safe and effective manner. We sought to determine the frequency of ETI performed by individual out-of-hospital rescuers. Design. Analysis of an administrative database of all emergency medical services (EMS) patient care reports in Pennsylvania. Setting: Commonwealth of Pennsylvania from January I to December 31, 2003. Subjects: EMS advanced life support rescuers (paramedics, prehospital nurses, and EMS physicians) who reported at least one patient contact during the study period. Interventions. None. Measurements. We calculated individual rescuer ETI frequency and opportunity. We evaluated relationships between ETI frequency and the number of patient contacts. We also examined the relationship with practice setting (air medical vs. ground rescuers and urban vs. rural rescuers). Main Results: In 1,544,791 patient care reports, 11,484 ETIs were reported by 5,245 out-of-hospital rescuers. The median ETI frequency was one (interquartile range, 0-3; range, 0-23). Of 5,245 rescuers, > 67% (3,551) performed two or fewer ETIs, and > 39% (2,054) rescuers did not perform any ETIs. The median number of ETI opportunities was three (interquartile range, 0-6; range, 0-76). ETI frequency was associated with patient volume (Spearman's rho = 0.67) and was higher for air medical (p = .006) and urban (p < .0001) rescuers. ETI frequency was not associated with response (Spearman's rho = -0.01) or transport (Spearman's rho = -0.06) times. Conclusions. Out-of-hospital ETI, an important and difficult resuscitation intervention, is an uncommon event for most rescuers.	Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15260 USA; Geisinger Hlth Syst, Dept Emergency Med, Danville, PA USA; Univ Pittsburgh, Off Emergency Med Serv, Dept Hlth, Harrisburg, PA USA; Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA	Wang, HE (corresponding author), Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15260 USA.			Kupas, Douglas/0000-0002-2183-4018; Hostler, David/0000-0002-7711-4001	AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08-HS13628] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS013628] Funding Source: NIH RePORTER		*ACCR COUNC GRAD M, EM MED GUID PROC RES; Burton John H, 2003, Prehosp Emerg Care, V7, P352, DOI 10.1080/10903120390936554; Charuluxananan Somrat, 2001, Journal of the Medical Association of Thailand, V84, pS251; *COUNC ACCR NURS A, 2004, ED PROGR STAND ACCR; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Filho G, 2002, ANESTH ANALG, V95, P411; Gabrielli Andrea, 2002, Curr Opin Crit Care, V8, P199, DOI 10.1097/00075198-200206000-00002; JACOBS LM, 1983, JAMA-J AM MED ASSOC, V250, P2175, DOI 10.1001/jama.250.16.2175; Jaeger K, 2000, RESUSCITATION, V43, P147, DOI 10.1016/S0300-9572(99)00124-0; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Luft HS, 1990, HOSP VOLUME PHYS VOL; Mizelle H Leland, 2002, Prehosp Emerg Care, V6, P472, DOI 10.1080/10903120290938184; National Highway Traffic Safety Administration, EM MED TECHN PAR NAT; O'Malley RN, 2001, ANN EMERG MED, V38, P441, DOI 10.1067/mem.2001.118018; Persse DE, 2003, RESUSCITATION, V59, P97, DOI 10.1016/S0300-9572(03)00178-3; Pollock M J, 1997, Prehosp Emerg Care, V1, P263; Ricketts T., 1998, DEFINITIONS RURAL HD; Sakles JC, 1998, ANN EMERG MED, V31, P325, DOI 10.1016/S0196-0644(98)70342-7; STEWART RD, 1984, CHEST, V85, P341, DOI 10.1378/chest.85.3.341; STEWART RD, 1984, ANN EMERG MED, V13, P1032, DOI 10.1016/S0196-0644(84)80064-5; STRATTON SJ, 1991, ANN EMERG MED, V20, P1314, DOI 10.1016/S0196-0644(05)81073-X; *USDHHS, MED PRIC NAT STANS P; Wang H E, 2001, Prehosp Emerg Care, V5, P10, DOI 10.1080/10903120190940254; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2003, RESUSCITATION, V58, P49, DOI 10.1016/S0300-9572(03)00058-3; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916	27	88	89	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2005	33	8					1718	1721		10.1097/01.CCM.0000171208.07895.2A			4	Critical Care Medicine	General & Internal Medicine	958ZS	WOS:000231487300006	16096447				2021-06-18	
J	Holshouser, BA; Tong, KA; Ashwal, S				Holshouser, BA; Tong, KA; Ashwal, S			Proton MR spectroscopic imaging depicts diffuse axonal injury in children with traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; ACUTE HEAD-INJURY; IN-VIVO; ADOLESCENTS; MODERATE; INFANTS; MILD	BACKGROUND AND PURPOSE: Diffuse axonal injury (DAI) after traumatic brain injury (TBI) is important in patient assessment and prognosis, yet they are underestimated with conventional imaging techniques. We used MR spectroscopic imaging (MRSI) to detect DAI and determine whether metabolite ratios are accurate in predicting long-term outcomes and to examine regional differences in injury between children with TBI and control subjects. METHODS: Forty children with TBI underwent transverse proton MRSI through the level of the corpus callosum within 1-16 days after injury. T2-weighted, fluid-attenuated inversion recovery, and susceptibility-weighted MR imaging was used to identify voxels as normal-appearing or as nonhemorrhagic or hemorrhagic injury. Neurologic outcome was evaluated at 6-12 months after injury. Metabolite ratios for total (all voxels), normal-appearing, and hemorrhagic brain were compared and used in a logistic regression model to predict long-term outcome. Total and regional metabolite ratios were compared with control data. RESULTS: A significant decrease in N-acetylaspartate (NAA)/creatine (Cr) and increase in choline (Cho)/Cr (evidence of DAI) was observed in normal-appearing (P <.05) and visibly injured (hemorrhagic) brain (P <.001) compared with controls. In normal-appearing brain NAA/Cr decreased more in patients with poor outcomes (1.32 +/- 0.54) than in those with good outcomes (1.61 +/- 0.50, P =.01) or control subjects (1.86 +/- 0.1, P =.00). In visibly injured brains, ratios were similarly altered in all patients. In predicting outcomes, ratios from normal-appearing and visibly-injured brain were 85% and 67% accurate, respectively. CONCLUSION. MRSI can depict injury in brain that appears normal on imaging and is useful for predicting long-term outcomes.	Loma Linda Univ, Dept Radiol, Neuroradiol Sect, Sch Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Div Child Neurol, Dept Pediat, Sch Med, Loma Linda, CA 92350 USA	Holshouser, BA (corresponding author), Loma Linda Univ, Med Ctr, MRI-B624,11234 Anderson St, Loma Linda, CA 92354 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; ASHWAL S, 2004, PEDIATR RES, V56, P1; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE JS, 2001, 87 SCI ASS ANN M RAD; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Ebel A, 2003, MAGN RESON IMAGING, V21, P113, DOI 10.1016/S0730-725X(02)00645-8; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Li BSY, 2002, MAGNET RESON MED, V47, P439, DOI 10.1002/mrm.10081; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pouwels PJW, 1999, PEDIATR RES, V46, P474, DOI 10.1203/00006450-199910000-00019; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robertson NJ, 2001, PEDIATR RES, V50, P692, DOI 10.1203/00006450-200112000-00011; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SHUTTER L, 2002, 1 JOINT S NAT INT NE; Signoretti S, 2002, ACT NEUR S, V81, P373; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	41	88	102	0	6	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2005	26	5					1276	1285					10	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	928XV	WOS:000229306100052	15891197				2021-06-18	
J	Laverty, PH; Leskovar, A; Breur, GJ; Coates, JR; Bergman, RL; Widmer, WR; Toombs, JP; Shapiro, S; Borgens, RB				Laverty, PH; Leskovar, A; Breur, GJ; Coates, JR; Bergman, RL; Widmer, WR; Toombs, JP; Shapiro, S; Borgens, RB			A preliminary study of intravenous surfactants in paraplegic dogs: Polymer therapy in canine clinical SCI	JOURNAL OF NEUROTRAUMA			English	Article						canine paraplegia; P 188; paraplegia; polyethylene glycol; polymer; spinal cord injury; surfactant	SPINAL-CORD-INJURY; HIGH-DOSE METHYLPREDNISOLONE; MOLECULAR REPAIR; RECOVERY; 4-AMINOPYRIDINE; MEMBRANES	Hydrophilic polymers, both surfactants and triblock polymers, are known to seal defects in cell membranes. In previous experiments using laboratory animals, we have exploited this capability using polyethylene glycol (PEG) to repair spinal axons after severe, standardized spinal cord injury (SCI) in guinea pigs. Similar studies were conducted using a related co-polymer Poloxamer 188 (P 188). Here we carried out initial investigations of an intravenous application of PEG or P 188 (3500 Daltons, 30 70 w/w in saline; 2 mL/kg I.V. and 2 mL/kg body weight or 300 mL P 188 per kg, respectively) to neurologically complete cases of paraplegia in dogs. Our aim was to first determine if this is a clinically safe procedure in cases of severe naturally occurring SCI in dogs. Secondarily, we wanted to obtain preliminary evidence if this therapy could be of clinical benefit when compared to a larger number of similar, but historical, control cases. Strict entry criteria permitted recruitment of only neurologically complete paraplegic dogs into this study. Animals were treated by a combination of conventional and experimental techniques within similar to72 h of admission for spinal trauma secondary to acute, explosive disk herniation. Outcome measures consisted of measurements of voluntary ambulation, deep and superficial pain perception, conscious proprioception in hindlimbs, and evoked potentials (somatosensory evoked potentials [SSEP]). We determined that polymer injection is a safe adjunct to the conventional management of severe neurological injury in dogs. We did not observe any unacceptable clinical response to polymer injection; there were no deaths, nor any other problem arising from, or associated with, the procedures. Outcome measures over the 6-8-week trial were improved by polymer injection when compared to historical cases. This recovery was unexpectedly rapid compared to these comparator groups. The results of this pilot trial provides evidence consistent with the notion that the injection of inorganic polymers in acute neurotrauma may be a simple and useful intervention during the acute phase of the injury.	Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Sch Vet Med, Dept Vet Clin Sci, W Lafayette, IN 47907 USA; Vet Teaching Hosp, Coll Vet Med, Dept Small Anim Med & Surg, College Stn, TX USA; Indiana Univ, Med Ctr, Dept Neurosurg, Indianapolis, IN USA; Purdue Univ, Coll Engn, Dept Biomed Engn, W Lafayette, IN 47907 USA	Borgens, RB (corresponding author), Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, 408 S Univ St, W Lafayette, IN 47907 USA.	cpr@purdue.edu					Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 2003, ADV ANAT EMBRYOLOGY, P1; CARPENTER CP, 1971, TOXICOL APPL PHARM, V18, P35, DOI 10.1016/0041-008X(71)90312-7; COATES JR, 1995, VET SURG, V24, P128, DOI 10.1111/j.1532-950X.1995.tb01307.x; Coates JR, 2000, VET CLIN N AM-SMALL, V30, P77, DOI 10.1016/S0195-5616(00)50004-7; Duerstock BS, 2002, J EXP BIOL, V205, P13; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HANSEN H J, 1952, Acta Orthop Scand Suppl, V11, P1; HAYES KC, 1993, PARAPLEGIA, V31, P216, DOI 10.1038/sc.1993.40; HOERLEIN BF, 1979, J AM ANIM HOSP ASSOC, V15, P535; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; PRINCIPE ANDREW H., 1968, J FORENSIC SCI, V13, P90; SHAFFER CB, 1947, J AM PHARM ASSOC SCI, V36, P152, DOI 10.1002/jps.3030360507; SHAFFER CB, 1948, AM J PHYSIOL, V152, P93, DOI 10.1152/ajplegacy.1947.152.1.93; SHAPIRO S, 2004, IN PRESS J NEUROSURG; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; SMYTH HF, 1947, J AM PHARM ASSOC SCI, V36, P157, DOI 10.1002/jps.3030360508; WORKING P, 1997, POLY ETHYLENE GLYCOL	34	88	91	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1767	1777		10.1089/neu.2004.21.1767			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400008	15684768				2021-06-18	
J	Brown, CVR; Weng, J; Oh, D; Salim, A; Kasotakis, G; Demetriades, D; Velmahos, GC; Rhee, P				Brown, CVR; Weng, J; Oh, D; Salim, A; Kasotakis, G; Demetriades, D; Velmahos, GC; Rhee, P			Does routine serial computed tomography of the head influence management of traumatic brain injury? - A prospective evaluation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						blunt trauma; head injury; traumatic brain injury; computed tomography	CRITICALLY-ILL PATIENTS; INTRAHOSPITAL TRANSPORT; ADMISSION; NEED	Background. Computed tomography (CT) of the head is the current standard for diagnosing intracranial pathology following blunt head trauma. It is common practice to repeat the head CT to evaluate any progression of injury. Recent retrospective reviews have challenged the need for serial head CT after traumatic brain injury (TBI). This study intends to prospectively examine the value of routine serial head CT after TBI. Methods. consecutive adult blunt trauma patients with an abnormal head CT admitted to an urban, Level I trauma center from January 2003 to September 2003 were prospectively studied. Variables collected included: initial head CT results, indication for repeat head CT (routine versus neurologic change), number and results of repeat head CT scans, and clinical interventions following repeat head CT. Results: Over the 9-month period, there were 128 patients admitted with an abnormal head CT after sustaining blunt trauma. The 16 patients who died within 24 hours and the 12 patients who went directly to craniotomy were excluded. The remaining 100 patients make up the study population. Abnormal head CT findings were subarachnoid hemorrhage (47%), intraparenchymal hemorrhage (37%), subdural hematoma (28%), contusion (14%), epidural hematoma (11%), intraventricular hemorrhage (3%), and diffuse axonal injury (2%). Overall, 32 patients (32%) had only the admission head CT, while 68 patients (68%) underwent 90 repeat CT scans. Of the repeat head CT scans, 81 (90%) were performed on a routine basis without neurologic change. The remaining 9 (10%) were performed for a change in Glasgow Coma Scale (n = 5), change in intracranial pressure (n = 1), change in Glasgow Coma Scale and intracranial pressure (n = 1), change in pupil size (n = 1), or sudden appearance of a headache (n = 1). Three patients had their care altered after repeat head CT: two underwent craniotomy and one was started on barbiturate therapy. All three patients had their repeat head CT after neurologic change (decrease in Glasgow Coma Scale in 2 and increase in intracranial pressure in 1). Conclusions. Serial head CT is common after TBI. Most repeat head CT scans are performed on a routine basis without neurologic change. Few patients with TBI have their management altered after repeat head CT, and these patients have neurologic deterioration before the repeat head CT. The use of routine serial head CT in patients without neurologic deterioration is not supported by the findings of this study.	Los Angeles Cty, Div Trauma & Crit Care, Dept Surg, Los Angeles, CA USA; Univ So Calif, Med Ctr, Los Angeles, CA USA	Brown, CVR (corresponding author), 1200 N State St,Room 9900, Los Angeles, CA 90033 USA.	carlosbr@usc.edu		Kasotakis, George/0000-0002-7630-0742; Oh, Daniel/0000-0002-2843-8077			ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Falimirski ME, 2003, J TRAUMA, V55, P1, DOI 10.1097/01.TA.0000071295.67263.A2; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; KAUPS KL, 2003, ANN M AM ASS SURG TR; Nakamura T, 2003, CHEST, V123, P159, DOI 10.1378/chest.123.1.159; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Stearley H E, 1998, Am J Crit Care, V7, P282; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; VALADKA AB, 2000, TRAUMA, P385; WADDELL G, 1975, BRIT MED J, V2, P417, DOI 10.1136/bmj.2.5968.417	16	88	90	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2004	57	5					939	943		10.1097/01.TA.0000149492.92558.03			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	878QD	WOS:000225660600003	15580014				2021-06-18	
J	Kreitschmann-Andermahr, I; Hoff, C; Saller, B; Niggemeier, S; Pruemper, S; Hutter, BO; Rohde, V; Gressner, A; Matern, S; Gilsbach, JM				Kreitschmann-Andermahr, I; Hoff, C; Saller, B; Niggemeier, S; Pruemper, S; Hutter, BO; Rohde, V; Gressner, A; Matern, S; Gilsbach, JM			Prevalence of pituitary deficiency in patients after aneurysmal subarachnoid hemorrhage	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							GROWTH-HORMONE DEFICIENCY; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; INTRACRANIAL ANEURYSMS; LAMINA TERMINALIS; GH DEFICIENCY; DIAGNOSIS; HYPOPITUITARISM; EMBOLIZATION; MANAGEMENT	After aneurysmal subarachnoid hemorrhage (SAH), patients frequently present with persistent bodily, psychosocial, and cognitive impairments that resemble those of patients with untreated partial or complete pituitary insufficiency. Because of these similarities, the authors hypothesized that aneurysmal SAH may cause pituitary dysfunction. Pituitary function testing was performed in 40 aneurysmal SAH patients between 12 and 72 months after the SAH. A combined TRH-LHRH-arginine test and the insulin tolerance test were performed on two separate days. Only 18 of 40 (45%) of the tested patients had normal pituitary function. Five of 40 exhibited isolated severe GH deficiency (GHD), and an additional three of 40 had severe GHD plus corticotroph deficiency. Isolated corticotroph deficiency was seen in 13 of 40 patients, and one patient showed isolated thyrotroph deficiency. All but one patient with corticotroph insufficiency were female. Patients with severe GHD had gained significantly more weight since their SAH than patients without GHD and exhibited a significantly higher body mass index. None of the clinical parameters indicative of a poor neurological outcome in aneurysmal SAH were related to pituitary insufficiency. In summary, neuroendocrine dysfunction was identified in a substantial portion of patients with previous aneurysmal SAH and should be borne in mind as a potential long-term sequel of the illness.	Univ Hosp Aachen, Dept Neurosurg, D-52074 Aachen, Germany; Univ Hosp Aachen, Endocrine Outpatient Clin, D-52074 Aachen, Germany; Univ Hosp Aachen, Dept Internal Med 3, Dept Med Psychol & Sociol, D-52074 Aachen, Germany; Univ Hosp Aachen, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany; Pfizer GmbH, D-76032 Karlsruhe, Germany	Kreitschmann-Andermahr, I (corresponding author), Univ Hosp Aachen, Dept Neurosurg, Pauwelsstr 30, D-52074 Aachen, Germany.	ilonka.kreitschmann@post.rwth-aachen.de					Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Brilstra EH, 2002, NEUROLOGIST, V8, P35, DOI 10.1097/00127893-200201000-00004; Brilstra EH, 1999, STROKE, V30, P470, DOI 10.1161/01.STR.30.2.470; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; Dhillo WS, 2002, EUR J ENDOCRINOL, V146, P231, DOI 10.1530/eje.0.1460231; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Freda PU, 1998, J CLIN ENDOCR METAB, V83, P3808, DOI 10.1210/jc.83.11.3808; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; Hutter BO, 1999, ACT NEUR S, V72, P157; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Komotar RJ, 2002, NEUROSURGERY, V51, P1403, DOI 10.1097/00006123-200212000-00010; KOVACS KJ, 1993, P NATL ACAD SCI USA, V90, P7681, DOI 10.1073/pnas.90.16.7681; Kreitschmann-Andermahr I, 2003, J NEUROL NEUROSUR PS, V74, P1133, DOI 10.1136/jnnp.74.8.1133; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P772, DOI 10.1136/jnnp.72.6.772; Ronkainen A, 2001, STROKE, V32, P2850, DOI 10.1161/hs1201.099711; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306; Wallymahmed ME, 1999, CLIN ENDOCRINOL, V51, P333	26	88	89	0	1	ENDOCRINE SOC	CHEVY CHASE	8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA	0021-972X			J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	OCT	2004	89	10					4986	4992		10.1210/jc.2004-0146			7	Endocrinology & Metabolism	Endocrinology & Metabolism	860EW	WOS:000224326300032	15472195	Bronze			2021-06-18	
J	Zhu, S; Li, MW; Figueroa, BE; Liu, AJ; Stavrovskaya, IG; Pasinelli, P; Beal, MF; Brown, RH; Kristal, BS; Ferrante, RJ; Friedlander, RM				Zhu, S; Li, MW; Figueroa, BE; Liu, AJ; Stavrovskaya, IG; Pasinelli, P; Beal, MF; Brown, RH; Kristal, BS; Ferrante, RJ; Friedlander, RM			Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice	JOURNAL OF NEUROSCIENCE			English	Article						creatine; ischemia; caspase; cytochrome c; neuroprotection; bioenergetics	NEURONAL CELL-DEATH; MOUSE MODEL; INJURY; MITOCHONDRIA; ATTENUATION; MINOCYCLINE; PROTECTS; MUTANT; BCL-2	Creatine mediates remarkable neuroprotection in experimental models of amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, and traumatic brain injury. Because caspase-mediated pathways are shared functional mechanistic components in these diseases, as well as in ischemia, we evaluated the effect of creatine supplementation on an experimental stroke model. Oral creatine administration resulted in a remarkable reduction in ischemic brain infarction and neuroprotection after cerebral ischemia in mice. Postischemic caspase-3 activation and cytochrome c release were significantly reduced in creatine-treated mice. Creatine administration buffered ischemia-mediated cerebral ATP depletion. These data provide the first direct correlation between the preservation of bioenergetic cellular status and the inhibition of activation of caspase cell-death pathways in vivo. An alternative explanation to our findings is that creatine is neuroprotective through other mechanisms that are independent of mitochondrial cell-death pathways, and therefore postischemic ATP preservation is the result of tissue spearing. Given its safety record, creatine might be considered as a novel therapeutic agent for inhibition of ischemic brain injury in humans. Prophylactic creatine supplementation, similar to what is recommended for an agent such as aspirin, may be considered for patients in high stroke-risk categories.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Nuerosurg,Neuroapoptosis Lab, Boston, MA 02115 USA; Bedford Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Burke Med Res Inst, White Plains, NY 10605 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurosci, New York, NY 10021 USA; Massachusetts Gen Hosp E, Dept Neurol, Day Neuromuscular Res Lab, Charlestown, MA 02129 USA; Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA	Friedlander, RM (corresponding author), Harvard Univ, Sch Med, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.	rfriedlander@rics.bwh.harvard.edu	Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219			Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Dedeoglu A, 2003, J NEUROCHEM, V85, P1359, DOI 10.1046/j.1471-4159.2003.01706.x; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Hausmann ON, 2002, SPINAL CORD, V40, P449, DOI 10.1038/sj.sc.3101330; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kristal BS, 1999, ANN NY ACAD SCI, V893, P321, DOI 10.1111/j.1749-6632.1999.tb07846.x; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tatsumi T, 2003, CARDIOVASC RES, V59, P428, DOI 10.1016/S0008-6363(03)00391-2; Wyss M, 2000, PHYSIOL REV, V80, P1107; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zhang WH, 2003, ANN NEUROL, V53, P267, DOI 10.1002/ana.10476; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zoghbi HY, 2002, TRENDS GENET, V18, P463, DOI 10.1016/S0168-9525(02)02729-4	27	88	95	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 30	2004	24	26					5909	5912		10.1523/JNEUROSCI.1278-04.2004			4	Neurosciences	Neurosciences & Neurology	833PZ	WOS:000222351900007	15229238	Bronze, Green Published			2021-06-18	
J	Singleton, RH; Povlishock, JT				Singleton, RH; Povlishock, JT			Identification and characterization of heterogeneous neuronal injury and death in regions of diffuse brain injury: Evidence for multiple independent injury phenotypes	JOURNAL OF NEUROSCIENCE			English	Article						cortex; fluorescence; hippocampus; horseradish peroxidase; neuron; necrosis; traumatic brain injury; diffuse brain injury	AMYLOID PRECURSOR PROTEIN; PLASMA-MEMBRANE DISRUPTIONS; AXONAL INJURY; HEAD-INJURY; HORSERADISH-PEROXIDASE; STRESS FAILURE; CYCLOSPORINE-A; FLUORO-JADE; CELL-DEATH; DAMAGE	Diffuse brain injury (DBI) is a consequence of traumatic brain injury evoked via rapid acceleration-deceleration of the cranium, giving rise to subtle pathological changes appreciated best at the microscopic level. DBI is believed to be comprised by diffuse axonal injury and other forms of diffuse vascular change. The potential, however, that the same forces can also directly injure neuronal somata in vivo has not been considered. Recently, while investigating DBI-mediated perisomatic axonal injury, we identified scattered, rapid neuronal somatic necrosis occurring within the same domains. Moving on the premise that these cells sustained direct somatic injury as a result of DBI, we initiated the current study, in which rats were intracerebroventricularly infused with various high-molecular weight tracers (HMWTs) to identify injury-induced neuronal somatic plasmalemmal disruption. These studies revealed that DBI caused immediate, scattered neuronal somatic plasmalemmal injury to all of the extracellular HMWTs used. Through this approach, a spectrum of neuronal change was observed, ranging from rapid necrosis of the tracer-laden neurons to little or no pathological change at the light and electron microscopic level. Parallel double and triple studies using markers of neuronal degeneration, stress, and axonal injury identified additional injured neuronal phenotypes arising in close proximity to, but independent of, neurons demonstrating plasmalemmal disruption. These findings reveal that direct neuronal somatic injury is a component of DBI, and diffuse trauma elicits a heretofore-unrecognized multifaceted neuronal pathological change within the CNS, generating heterogeneous injury and reactive alteration within both axons and neuronal somata in the same domains.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS045824] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS07288, NS045824, T32 NS007288, R01 NS045824] Funding Source: Medline		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Barros LF, 2002, BIOL RES, V35, P209; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; Conti AC, 1998, J NEUROSCI, V18, P5663; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Deurs B V, 1977, Brain Res, V124, P1; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Finnie JW, 2000, AUST VET J, V78, P775, DOI 10.1111/j.1751-0813.2000.tb10451.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KRISTENSSON K, 1977, ACTA NEUROPATHOL, V38, P143, DOI 10.1007/BF00688561; Lin C.A., 2001, MASS COMMUNICATION S, V4, P19, DOI DOI 10.1207/S15327825MCS0401_03; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MCNEIL PL, 1990, J CELL SCI, V96, P549; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; McNeil PL, 2001, CELL TISSUE RES, V304, P141, DOI 10.1007/s004410000286; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON C, 1993, BIOPHYS J, V65, P2277, DOI 10.1016/S0006-3495(93)81324-9; NOWAK TS, 1993, ANN NY ACAD SCI, V679, P142, DOI 10.1111/j.1749-6632.1993.tb18295.x; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Qian L, 1996, ACTA NEUROCHIR, V138, P90, DOI 10.1007/BF01411731; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RENNKE HG, 1979, J HISTOCHEM CYTOCHEM, V27, P1352, DOI 10.1177/27.10.41873; RINK A, 1995, AM J PATHOL, V147, P1575; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P37; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; TURNER PT, 1974, BRAIN RES, V74, P305, DOI 10.1016/0006-8993(74)90585-X; Vlahakis NE, 2000, J APPL PHYSIOL, V89, P2490; Vlahakis NE, 2002, AM J RESP CRIT CARE, V166, P1282, DOI 10.1164/rccm.200203-207OC; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAGATA Y, 1994, ENZYME MICROB TECH, V16, P99, DOI 10.1016/0141-0229(94)90070-1; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; YU QC, 1992, AM J PATHOL, V141, P1349	70	88	88	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 7	2004	24	14					3543	3553		10.1523/JNEUROSCI.5048-03.2004			11	Neurosciences	Neurosciences & Neurology	810PE	WOS:000220715400010	15071102	Green Published, Bronze			2021-06-18	
J	van Santbrink, H; Von der Brink, WA; Steyerberg, EW; Suazo, JAC; Avezaat, CJJ; Maas, AR				van Santbrink, H; Von der Brink, WA; Steyerberg, EW; Suazo, JAC; Avezaat, CJJ; Maas, AR			Brain tissue oxygen response in severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; brain tissue PO2; cerebral oxygenation; arterial pO(2); hyperventilation; pathophysiology; ischemia; outcome; prognosis	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; PARTIAL-PRESSURE; INTRACRANIAL HYPERTENSION; PERFUSION-PRESSURE; COMATOSE PATIENTS; REACTIVITY; VELOCITY; SATURATION	Objective. To investigate clinical relevance and prognostic value of brain tissue oxygen response (TOR: response of brain tissue pO(2) to changes in arterial pO(2)) in traumatic brain injury (TBI). Patients and methods. In a prospective cohort study TOR was investigated in 41 patients with severe TBI (Glasgow Coma Score less than or equal to8) in whom continuous monitoring of brain tissue oxygen pressure (PbrO(2)) was performed. TOR was investigated each day over a five day period for 15 minutes by increasing FiO(2) on the ventilator setting. FiO(2) was increased directly from baseline to 1.0 for a period of 15 minutes under stable conditions (145 tests). In 34 patients the effect of decreasing PaCO2 was evaluated on TOR by performing the same test after increasing inspiratory minute volume on the ventilator setting to 20% above baseline. Arterial blood gas analysis was performed before and after changing ventilator settings. Multimodality monitoring. including PbrO(2) was performed in all patients. Outcome at six months was evaluated according to the Glasgow Outcome Scale. For statistical analysis the Mann-whitney U-test was used for ordinally distributed variables, and the Chi-square test for categorical variables. Predictive value of TOR was analyzed in a multivariable model. Results. 145 tests were available for analysis. Baseline PbrO(2) varied from 4.0 to 50 mmHg at PaO2 values of 73-237 mmHg. At FiO(2) settings of 1.0. PbrO(2) varied from 9.1-200 mmHg and PaO2 from 196-499 mmHg. Three distinct patterns of response were noted: response type A is characterized by a sharp increase in PbrO(2), reaching a plateau within several minutes; type B by the absence of a plateau, and type C by a short plateau phase followed by a subsequent further increase in PbrO(2). Patterns characterized by a stable plateau (type A), considered indicative of intact regulatory mechanisms, were seen more frequently from 48 hours after injury on. If present within the first 24 hours after injury such a response was related to more favorable outcome (p = 0.06). Mean TOR of all tests was 0.73 +/- 0.59 with an median TOR of 0.58. Patients with an unfavourable outcome had a higher TOR (1.03 +/- 0.60) during the first 24 hours, compared to patients with a favorable outcome (0.61 +/- 0.51; p = 0.02). Multiple logistic regression analysis supported the independent predictive value of tissue oxygen response for unfavorable outcome (odds ratio 4.8). During increased hyperventilation, mean TOR decreased substantially from 0.75 +/- 0.54 to 0.65 +/- 0.45 (p = 0.06; Wilcoxon test). Within the first 24 hours after injury a decrease in TOR following hyperventilation was significantly related to poorer outcome (p = 0.01). Conclusions. Evaluation of TOR affords insight in (disturbances in) oxygen regulation after traumatic brain injury, is of prognostic value and may aid in identifying patients at (increased) risk for ischemia.	Erasmus MC, Dept Neurosurg, NL-3015 GD Rotterdam, Netherlands; Erasmus MC, Ctr Clin Decis Sci, NL-3015 GD Rotterdam, Netherlands; Isala Klin, Dept Neurosurg, Zwolle, Netherlands; Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands	Maas, AR (corresponding author), Erasmus MC, Dept Neurosurg, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; CHAN KH, 1992, NEUROSURGERY, V30, P697; Charoenchai C., 1997, Australian Journal of Grape and Wine Research, V3, P2, DOI 10.1111/j.1755-0238.1997.tb00109.x; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; ELLINGSEN I, 1987, ACTA PHYSIOL SCAND, V129, P157, DOI 10.1111/j.1748-1716.1987.tb08054.x; Fandino J, 1999, ACTA NEUROCHIR, V141, P825, DOI 10.1007/s007010050383; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GROLIMUND P, 1988, LANCET, V1, P1173; Ince C, 1999, CRIT CARE MED, V27, P1369, DOI 10.1097/00003246-199907000-00031; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471; Longhi L, 2002, ACT NEUR S, V81, P315; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MAAS AIR, 1993, ICP 8, P233; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARMAROU A, 1993, ACTA NEUROCHIR, P18; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; MEIZENSBERGER J, 1993, ACTA NCUROCHIR WIE S, V59, P58; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 2000, ZBL NEUROCHIR, V61, P181, DOI 10.1055/s-2000-15598; MILLER JD, 1992, NEUROSURGERY, V30, P518; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; RINGELSTEIN EB, 1986, KLIN WOCHENSCHR, V64, P194, DOI 10.1007/BF01713462; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P6; Siegemund M, 1999, INTENS CARE MED, V25, P1044, DOI 10.1007/s001340051011; STANDGAARD S, 1975, CEREBRAL CIRCULATION, P3; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	50	88	88	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUN	2003	145	6					429	438		10.1007/s00701-003-0032-3			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	703GK	WOS:000184271500002	12836066				2021-06-18	
J	Knoblach, SM; Nikolaeva, M; Huang, XL; Fan, L; Krajewski, S; Reed, JC; Faden, AI				Knoblach, SM; Nikolaeva, M; Huang, XL; Fan, L; Krajewski, S; Reed, JC; Faden, AI			Multiple caspases are activated after traumatic brain injury: Evidence for involvement in functional outcome	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; caspase; cysteine protease; mitochondria; neuron; trauma	SPINAL-CORD INJURY; CORTICAL IMPACT INJURY; NECROSIS-FACTOR-ALPHA; APOPTOTIC CELL-DEATH; CLOSED-HEAD INJURY; NEURONAL APOPTOSIS; CYTOCHROME-C; CEREBRAL-ISCHEMIA; GRANZYME-B; RAT-BRAIN	Caspase-3 is a cysteine protease that is strongly implicated in neuronal apoptosis. Activation of caspase-3 may be induced by at least two major initiator pathways: a caspase-8-mediated pathway activated through cell surface death receptors (extrinsic pathway), and a caspase-9-mediated pathway activated by signals from the mitochondria that lead to formation of an apoptosomal complex (intrinsic pathway). In the present studies, we compare the activation of caspases-3, -8, and -9 after lateral fluid-percussion traumatic brain injury (TBI) in rats. Inummoblot analysis identified cleaved forms of caspases-3 and -9, but not caspase-8, At 1, 12, and 48 h after injury. Immunocytochemistry specific for cleaved caspases-3 and -9 revealed their expression primarily in neurons. These caspases were also frequently localized in TUNEL-positive cells, some of which demonstrated morphological features of apoptosis. However, caspases-3 and -9 were also found in neurons that were not TUNEL-positive, and other TUNEL-positive cells did not show activated caspases. In contrast to caspases-3 or -9, caspase-8 expression was only minimally changed by injury. An increase in expression of this caspase was undetectable by immunoblotting methods, and appeared as positive immunostaining restricted to a few cells within the injured cortex. Treatment with the pan-caspase inhibitor z-VAD-fmk at 15 min after TBI improved performance on motor and spatial learning tests. These data suggest that several caspases may be involved in the pathophysiology of TBI and that pan-caspase inhibition strategies may improve neurological outcomes.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; Burnham Inst, La Jolla, CA 92037 USA	Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, EP-16,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036537, R01NS036821] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36821, NS36537] Funding Source: Medline		Allen JW, 1999, FASEB J, V13, P1875; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Buki A, 2000, J NEUROSCI, V20, P2825; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; deTorres C, 1997, NEUROSCI LETT, V230, P1, DOI 10.1016/S0304-3940(97)00445-X; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HUANG X, 2000, SOC NEUROSCIENCE SOC; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liao J, 2000, BIOTECHNIQUES, V28, P216, DOI 10.2144/00282bm05; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	69	88	92	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1155	1170		10.1089/08977150260337967			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400005	12427325				2021-06-18	
J	Singhal, A; Baker, AJ; Hare, GMT; Reinders, FX; Schlichter, LC; Moulton, RJ				Singhal, A; Baker, AJ; Hare, GMT; Reinders, FX; Schlichter, LC; Moulton, RJ			Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						human; inflammation; interleukin-1; interleukin-6; traumatic brain injury	TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; SOMATOSENSORY-EVOKED-POTENTIALS; FOCAL CEREBRAL-ISCHEMIA; FACTOR-ALPHA; RAT-BRAIN; INFLAMMATORY RESPONSE; TNF-ALPHA; MESSENGER-RNA; BARRIER FUNCTION	Acute inflammation plays a significant role in the pathophysiology of traumatic brain injury (TBI). However, the specific relationships between inflammatory mediators and patient outcome following TBI have not been fully established. In this study, we measured plasma and cerebrospinal fluid interleukin-1 (IL-1) and interleukin-6 (IL-6) concentrations in 36 patients, following severe TBI. Patients were monitored with continuous measurements of somatosensory-evoked potentials (SSEP) to derive an established surrogate outcome measurement, the 96-h evoked potential (SSEP96). Clinical outcomes were assessed at 3 months using the Glasgow Outcome Scale (GOS). Peak cerebrospinal fluid (CSF) IL-1 and IL-6 concentrations were significantly higher than those observed in the plasma [median 6.5 pg/mL (range 1.4-25.0) vs. 3.0 (0.8-7.6) for IL-1, and 650 (130-7,214) vs. 253 (52-1,506) for IL-6, p < 0.001 for both]. Peak CSF IL-6 levels correlated with SSEP96 (r = 0.42; p = 0.0133), and peak CSF IL-6 levels were higher with improved GOS (p = 0.024). Multiple regression analysis identified that age (p = 0.0072), pupillary abnormality (p = 0.021), the presence of mass lesion (p = 0.023), and peak CSF IL-6 concentrations (p = 0.026) were all statistically significant predictors of clinical outcome following TBI. These results suggest that peak CSF IL-6 concentrations correlate with improved outcome following TBI. This finding helps to characterize the inflammatory reaction associated with TBI and may help to develop improved treatment strategies for patients with TBI.	St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Toronto Western Res Inst, Cellular & Mol Biol Div, Toronto, ON, Canada	Baker, AJ (corresponding author), St Michaels Hosp, Cara Phelan Ctr Trauma Res, Rm 7086 Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.		Hare, Greg/AAM-5599-2021	Singhal, Ash/0000-0002-0061-9570			Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; AMADO JA, 1995, METABOLISM, V44, P812, DOI 10.1016/0026-0495(95)90198-1; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; Carlson NG, 1999, J IMMUNOL, V163, P3963; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; D'Arcangelo G, 2000, EUR J NEUROSCI, V12, P1241, DOI 10.1046/j.1460-9568.2000.00011.x; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/0304-3940(96)13116-5; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Fisher J, 2001, J NEUROIMMUNOL, V119, P1, DOI 10.1016/S0165-5728(01)00342-3; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hans VHJ, 1999, NEUROREPORT, V10, P409; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hermann DM, 1998, NEUROREPORT, V9, P1917, DOI 10.1097/00001756-199806010-00046; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Liu XH, 1999, J CEREBR BLOOD F MET, V19, P1099, DOI 10.1097/00004647-199910000-00006; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; Marz P, 1999, EUR J NEUROSCI, V11, P2995, DOI 10.1046/j.1460-9568.1999.00755.x; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MOULTON R, 1991, J TRAUMA, V31, P676, DOI 10.1097/00005373-199105000-00012; Moulton RJ, 1998, CAN J NEUROL SCI, V25, pS7, DOI 10.1017/S031716710003465X; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 1999, GLIA, V25, P343; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Savman K, 1998, PEDIATR RES, V43, P746; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Shuto T, 2001, NEUROREPORT, V12, P1081, DOI 10.1097/00001756-200104170-00043; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Stoll G, 2000, J NEURAL TRANSM-SUPP, P81; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; TARKOWSKI E, 1995, STROKE, V26, P1393, DOI 10.1161/01.STR.26.8.1393; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TOWFIGHI J, 1995, ACTA NEUROPATHOL, V90, P375, DOI 10.1007/BF00315011; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; Vege A, 1998, ACTA PAEDIATR, V87, P819, DOI 10.1080/080352598750013563; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	73	88	98	1	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2002	19	8					929	937		10.1089/089771502320317087			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	585JC	WOS:000177520800003	12225653				2021-06-18	
J	Beschorner, R; Nguyen, TD; Gozalan, F; Pedal, I; Mattern, R; Schluesener, HJ; Meyermann, R; Schwab, JM				Beschorner, R; Nguyen, TD; Gozalan, F; Pedal, I; Mattern, R; Schluesener, HJ; Meyermann, R; Schwab, JM			CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury	ACTA NEUROPATHOLOGICA			English	Article						traumatic brain injury; inflammation; immune response; CD14	TUMOR-NECROSIS-FACTOR; MICROGLIAL CELLS; DEPENDENT MECHANISMS; MONONUCLEAR-CELLS; NEGATIVE BACTERIA; GENE-EXPRESSION; UP-REGULATION; SOLUBLE CD14; EX-VIVO; LIPOPOLYSACCHARIDE	The immune response in the central nervous system (CNS) is under tight control of regulatory mechanisms, resulting in the establishment of immune privilege. CNS injury induces an acute inflammatory reaction, composed mainly of invading leukocytes and activated microglial cells/macrophages. The generation of this robust immune response requires binding of receptors such as CD14, a pattern recognition receptor of the immune system. CD14, a surface molecule of monocytic cells, is up-regulated after monocyte stimulation and is involved in cellular activation. To examine CD14 expression in human brain lesions we investigated sections of brains obtained at autopsy from 25 cases following closed traumatic brain injury (TBI) and 5 control brains by immunohistochemistry. Detection of CD14 in controls demonstrated constitutive expression by perivascular cells, but not in parenchymal microglial cells, equivalent to known expression pattern of ED2 in rats. Following TBI, numbers of CD14(+) cells in perivascular spaces and in the brain parenchyma increased in parallel within 1-2 days, both at the lesion and in adjacent perilesional areas. The number of CD14(+) cells in perivascular spaces and in the brain parenchyma reached maximum levels within 4-8 days and remained elevated until weeks after trauma. In contrast to activated parenchymal microglia/macrophages, resting parenchymal microglial cells lacked CD14. Thus, early CD14 expression constitutes an essential part of the acute inflammatory CNS response following trauma.	Heidelberg Univ, Inst Legal Med, Heidelberg, Germany; Univ Tubingen, Brain Res Inst, Sch Med, D-72076 Tubingen, Germany	Beschorner, R (corresponding author), Univ Tubingen, Brain Res Inst, Sch Med, Calwerstr 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X; Schwab, Jan/0000-0001-6784-4919			Abe M, 1999, J NEUROL, V246, P358, DOI 10.1007/s004150050363; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Antal-Szalmas P, 2000, CYTOMETRY, V41, P279, DOI 10.1002/1097-0320(20001201)41:4<279::AID-CYTO6>3.0.CO;2-B; ARDITI M, 1995, J IMMUNOL, V155, P3994; Asea A, 2000, NAT MED, V6, P435; Bauer J, 1996, HISTOCHEM J, V28, P83, DOI 10.1007/BF02331413; Becher B, 1996, GLIA, V18, P1; Becher B, 1996, J NEUROSCI RES, V45, P375; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Beyer M, 2000, GLIA, V31, P262, DOI 10.1002/1098-1136(200009)31:3<262::AID-GLIA70>3.0.CO;2-2; Bosco MC, 1997, J IMMUNOL, V159, P2922; Cauwels A, 1999, J IMMUNOL, V162, P4762; Chen KC, 1999, WIREL NETW, V5, P1, DOI 10.1023/A:1019157818476; DENTENER MA, 1993, J IMMUNOL, V150, P2885; Devitt A, 1998, NATURE, V392, P505; Dick AD, 1997, AIDS, V11, P1699, DOI 10.1097/00002030-199714000-00006; DICKSON DW, 1991, LAB INVEST, V64, P135; Dufour A, 1996, J NEUROL, V243, P666, DOI 10.1007/BF00878667; Fearns C, 1998, SHOCK, V9, P157, DOI 10.1097/00024382-199803000-00001; Frevert CW, 2000, J IMMUNOL, V164, P5439, DOI 10.4049/jimmunol.164.10.5439; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; GRAEBER MB, 1990, TRENDS NEUROSCI, V13, P366, DOI 10.1016/0166-2236(90)90020-B; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guillemin G, 1997, J NEUROSCI RES, V49, P576, DOI 10.1002/(SICI)1097-4547(19970901)49:5<576::AID-JNR8>3.3.CO;2-O; Han JH, 1998, PROG CLIN BIOL RES, V397, P157; HICKEY WF, 1987, P NATL ACAD SCI USA, V84, P2082, DOI 10.1073/pnas.84.7.2082; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Jersmann HPA, 2001, INFECT IMMUN, V69, P479, DOI 10.1128/IAI.69.1.479-485.2001; JORDAN FL, 1988, BRAIN RES REV, V13, P165, DOI 10.1016/0165-0173(88)90019-7; Kane JP, 1999, CIRCULATION, V99, P3210, DOI 10.1161/01.CIR.99.25.3210; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KRUGER C, 1991, CLIN EXP IMMUNOL, V85, P297; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; KUSUNOKI T, 1995, J EXP MED, V182, P1673, DOI 10.1084/jem.182.6.1673; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; LOPPNOW H, 1995, INFECT IMMUN, V63, P1020, DOI 10.1128/IAI.63.3.1020-1026.1995; Lucas R, 1997, J LEUKOCYTE BIOL, V61, P551; Manigold T, 2000, CYTOKINE, V12, P1788, DOI 10.1006/cyto.2000.0783; MATO M, 1986, ACTA NEUROPATHOL, V72, P117, DOI 10.1007/BF00685972; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Nockher WA, 1999, J NEUROIMMUNOL, V101, P161, DOI 10.1016/S0165-5728(99)00141-1; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; Postler E, 2000, J NEUROIMMUNOL, V108, P244, DOI 10.1016/S0165-5728(00)00283-6; Prinz M, 1999, J NEUROPATH EXP NEUR, V58, P1078, DOI 10.1097/00005072-199910000-00006; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Saito S, 2000, EUR J BIOCHEM, V267, P37, DOI 10.1046/j.1432-1327.2000.00956.x; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Schluesener HJ, 1998, ACTA NEUROPATHOL, V96, P575, DOI 10.1007/s004010050938; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Selvi E, 2000, ANN RHEUM DIS, V59, P399, DOI 10.1136/ard.59.5.399; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Streit Wolfgang J., 1995, P85; Su GL, 1999, J HEPATOL, V31, P435, DOI 10.1016/S0168-8278(99)80034-8; Su GL, 1995, CRIT REV IMMUNOL, V15, P201, DOI 10.1615/CritRevImmunol.v15.i3-4.10; Takeshita S, 1999, J INFECT DIS, V179, P508, DOI 10.1086/314600; THEELE DP, 1993, GLIA, V7, P5, DOI 10.1002/glia.440070104; Ulevitch RJ, 1999, NAT MED, V5, P144, DOI 10.1038/5504; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; ULVESTAD E, 1994, J NEUROPATH EXP NEUR, V53, P492, DOI 10.1097/00005072-199409000-00008; VASS K, 1986, ACTA NEUROPATHOL, V70, P149, DOI 10.1007/BF00691433; Verbon A, 2001, J IMMUNOL, V166, P3599, DOI 10.4049/jimmunol.166.5.3599; Wang PY, 1999, J BIOL CHEM, V274, P23235, DOI 10.1074/jbc.274.33.23235; Wang PY, 1998, J BIOL CHEM, V273, P24309, DOI 10.1074/jbc.273.38.24309; WILLIAMS K, 1992, J NEUROPATH EXP NEUR, V51, P538, DOI 10.1097/00005072-199209000-00009; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZIEGLERHEITBROCK HWL, 1994, EUR J IMMUNOL, V24, P1937, DOI 10.1002/eji.1830240835	80	88	92	1	12	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2002	103	6					541	549		10.1007/s00401-001-0503-7			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	557EE	WOS:000175894500002	12012085				2021-06-18	
J	Besenski, N				Besenski, N			Traumatic injuries: imaging of head injuries	EUROPEAN RADIOLOGY			English	Article						CT; MR; head injury; linear translation; diffuse axonal injury	BRAIN-STEM LESIONS; MECHANISM; MRI	Due to the forces of acceleration, linear translation, as well as rotational and angular acceleration, the brain undergoes deformation and distortion depending on the site of impact of traumatizing force direction, severity of the traumatizing force, and tissue resistance of the brain. Linear translation of accereration in a closed-head injury can run along the shorter diameter of the skull in latero-lateral direction causing mostly extra-axial lesions (subdural hematoma,epidural hematoma, subarachnoidal hemorrhage) or quite pronounced coup and countercoup contusions. Contusions are considerably less frequently present in medial or paramedial centroaxial blows (fronto-occipital or occipito-frontal). The centroaxial blows produce a different pattern of lesions mostly in the deep structures, causing in some cases a special category of the brain injury, the diffuse axonal injury (DAI). The brain stem can also be damaged, but it is damaged more often in patients who have suffered centroaxial traumatic force direction. Computed tomography and MRI are the most common techniques in patients who have suffered brain injury Computed tomography is currently the first imaging technique to be used after head injury, in those settings where CT is available. Using CT, scalp, bone, extra-axial hematomas, and parenchymal injury can be demonstrated. Computed tomography is rapid and easily performed also in monitored patients. It is the most relevant imaging procedure for surgical lesions. Computed tomography is a suitable method to follow the dynamics of lesion development giving an insight into the corresponding pathological development of the brain injury. Magnetic resonance imaging is more sensitive for all posttraumatic lesions except skull fractures and subarachnoidal hemorrhage, but scanning time is longer, and the problem with the monitoring of patients outside the MRI field is present. If CT does not demonstrate pathology as can adequately be explained to account for clinical state, MRI is warranted. Follow-up is best done with MRI as it is more sensitive to parenchymal changes. In routine MR protocol gradient-recalled-echo sequences should be included at any other time after a traumatic event since they are very sensitive in detection of hemosiderin as well as former hematoma without hemosiderin. The MR signal intensity varies depending on sequences and time scanning after trauma.	Univ Zagreb, Croatian Inst Brain Res, HR-10002 Zagreb, Croatia	Besenski, N (corresponding author), Univ Zagreb, Croatian Inst Brain Res, Salata 12, HR-10002 Zagreb, Croatia.	nada.besenski@hiim.hr					BESENSKI N, 1992, NEURORADIOLOGY, V34, P126, DOI 10.1007/BF00588158; BESENSKI N, 1995, NEURORADIOLOGY, V37, P207; Besenski N, 1996, NEURORADIOLOGY, V38, pS36; BESENSKI N, 1992, NEUROL CROATICA, V41, P33; Braun M, 2000, ANN FR ANESTH, V19, P296; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GEAN AD, 1994, IMAGING HEAD TRAUMA, P76; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gentry LR, 1991, NEUROIMAG CLIN N AM, V1, P411; GRCEVIC N, 1988, SCAND J REHABIL ME S, V17, P1; GRCEVIC N, 1984, INVESTIGATIONS NEURO; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; JADROSANTEL D, 1989, NEUROIMAGING, V2, P263; KIRCKPATRICK JB, 1988, FORENSIC NEUROPATHOL, P276; Leestma JE, 1988, FORENSIC NEUROPATHOL, P409; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; LINDENBERG R, 1957, ARCH PATHOL, V63, P23; MACPHERSON BCM, 1990, CLIN RADIOL, V42, P321, DOI 10.1016/S0009-9260(05)82145-2; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; PAVIC D, 1994, NEUROL CROATICA, V43, P3; ROSS PS, 1989, PEDIATR EMERG CARE, V5, P216; SELLIER K, 1963, Hefte Unfallheilkd, V76, P1; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tatalovic-Osterman L, 1991, Neurol Croat, V40, P231; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	32	88	99	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	JUN	2002	12	6					1237	1252		10.1007/s00330-002-1355-9			16	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	562LC	WOS:000176197400002	12042929				2021-06-18	
J	Knoller, N; Levi, L; Shoshan, I; Reichenthal, E; Razon, N; Rappaport, ZH; Biegon, A				Knoller, N; Levi, L; Shoshan, I; Reichenthal, E; Razon, N; Rappaport, ZH; Biegon, A			Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial	CRITICAL CARE MEDICINE			English	Article						head-trauma; HU-211; Glasgow Coma Scale; intracranial pressure; N-methyl-D-aspartate antagonist; antioxidant; anti-inflammatory	TRAUMATIC BRAIN INJURY; NEUROPROTECTANT; ANTAGONIST; MULTICENTER; EFFICACY; TERM; RAT	Objective: To establish the safety of intravenous dexanabinol in severe head injury. Design: Prospective, randomized, double-blind, placebo- (vehicle) controlled, multicenter, escalating dose study of a single administration of drug (48 or 150 mg) or vehicle (1 or 3 mL). Setting: All Israeli neurosurgical intensive care units (a total of six units). Patients: Sixty-seven patients, aged 16 - 65 yrs, Glasgow Coma Scale score of 4-8, injured within 6 hrs of treatment. Measurements and Main Results: Intracranial pressure, cerebral perfusion pressure, blood pressure, and heart rate were measured continuously in the intensive care unit, Adverse medical events were recorded and clinical outcome was assessed by the Glasgow outcome scale throughout a 6-month follow-up period. A highly significant reduction in the percentage of time with intracranial pressure >25, cerebral perfusion pressure <50, and systolic blood pressure <90 mm Hg was observed in the drug-treated group. The nature and incidence of adverse medical events were similar in the two groups. The percentage of patients achieving good neurologic outcome on the Glasgow outcome scale was 21% and 14% higher in the drug-treated group at 3 and 6 months, respectively. Statistical analysis of these differences by a logistic model using dose, entry Glasgow coma scale score, and computed tomograph as covariates yielded p values for the effect of treatment of .03 and .14 at 3 and 6 months, respectively. Conclusions: Dexanabinol was safe and well tolerated in severe head injury. The treated patients achieved significantly better intracranial pressure/cerebral perfusion pressure control without jeopardizing blood pressure. A trend toward faster and better neurologic outcome was also observed.	Chaim Sheba Med Ctr, Dept Neurosurg, Tel Hashomer, Israel; Rambam Med Ctr, Haifa, Israel; Hadassah Med Ctr, Dept Neurosurg, IL-91120 Jerusalem, Israel; Soroka Med Ctr, Dept Neurosurg, IL-84101 Beer Sheva, Israel; Ichilov Hosp, Dept Neurosurg, Tel Aviv, Israel; Beilinson Med Ctr, Dept Neurosurg, IL-49100 Petah Tiqwa, Israel; Pharmos Ltd, Rehovot, Israel	Knoller, N (corresponding author), Chaim Sheba Med Ctr, Dept Neurosurg, Tel Hashomer, Israel.		Rappaport, Zvi Harry/AAH-6024-2019	Rappaport, Zvi Harry/0000-0001-9479-3619			BAILEY I, 1992, Journal of Neurotrauma, V9, pS545; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; BIEGON A, 1993, AM SOC NEUR ABSTR, V19, P1485; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; GALLILY R, 1997, J PHARMACOL EXP THER, V83, P1; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; OTT I, 1998, NEUROINFLAMMATION ME, P221; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	24	88	91	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2002	30	3					548	554		10.1097/00003246-200203000-00009			7	Critical Care Medicine	General & Internal Medicine	531ZC	WOS:000174446300009	11990913				2021-06-18	
J	Coplin, WM; Cullen, NK; Policherla, PN; Vinas, FC; Wilseck, JM; Zafonte, RD; Rengachary, SS				Coplin, WM; Cullen, NK; Policherla, PN; Vinas, FC; Wilseck, JM; Zafonte, RD; Rengachary, SS			Safety and feasibility of craniectomy with duraplasty as the initial surgical intervention for severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Academic-Physiatrists	FEB, 1999	ORLANDO, FL	Assoc Acad Physiatrists		traumatic brain injury; craniectomy; brain swelling/edema; craniotomy; intracranial pressure; Glasgow Coma Scale; head injury; outcome; functional independence measure; Glasgow Outcome Scale; trauma	FUNCTIONAL INDEPENDENCE MEASURE; CLOSED-HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; INTRAVENTRICULAR HEMORRHAGE; HEMISPHERIC INFARCTION; CEREBRAL INFARCTION; MANAGEMENT; HEMICRANIECTOMY; MECHANISMS; CRANIOTOMY	Background: Decompressive craniectomy has historically served as a salvage procedure to control intracranial pressure after severe traumatic brain injury. We assessed the safety and feasibility of performing craniectomy as the initial surgical intervention. Methods: of 29 consecutive patients undergoing emergent decompression for severe traumatic brain injury with horizontal midline shift greater than explained by a removable hematoma, 17 had traditional craniotomy with or without brain resection and 12 underwent craniectomy. Results: The craniectomy group had lower Glasgow Coma Scale scores at surgery (median, 4 vs. 7; p = 0.04) and more severe radiographic injuries (using specific measures). Mortality, Glasgow outcome Scale scores, Functional Independence Measures, and length of stay in both the acute care setting and the rehabilitation phase were similar between the surgical groups, Conclusion Despite more severe injury severity, patients undergoing initial craniectomy had outcomes similar to those undergoing traditional surgery. A randomized evaluation of the effect of early craniectomy on outcome is warranted.	Wayne State Univ, Detroit Receiving Hosp, Dept Neurol, Detroit, MI USA; Wayne State Univ, Detroit Receiving Hosp, Dept Neurol Surg, Detroit, MI USA; Inst Rehabil, Dept Phys Med & Rehabil, Detroit, MI USA; Wayne State Univ, Med Ctr, Dept Radiol, Detroit, MI 48202 USA	Coplin, WM (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, 4201 St Antoine,8D, Detroit, MI 48201 USA.	wcoplin@med.wayne.edu		Cullen, Nora/0000-0001-6359-9418	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1-NS38905-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038905] Funding Source: NIH RePORTER		ALDRICH EF, 1993, BRAIN SURG COMPLICAT, P1283; Bouma G J, 1995, New Horiz, V3, P384; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Coplin WM, 1998, STROKE, V29, P1573, DOI 10.1161/01.STR.29.8.1573; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; Da Silva J A, 1976, Arq Neuropsiquiatr, V34, P232; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; GAAB MR, 1990, ACT NEUR S, V51, P326; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GERL A, 1980, Zentralblatt fuer Neurochirurgie, V41, P125; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jennett B, 1981, MANAGEMENT HEAD INJU; JENNETT B, 1992, PROGNOSIS NEUROLOGIC; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; KARLEN J, 1987, NEUROCHIRURGIA, V30, P35; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; Lubillo S, 1999, J NEUROSURG, V91, P581, DOI 10.3171/jns.1999.91.4.0581; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Munch E, 2000, NEUROSURGERY, V47, P315; PEREIRA WC, 1977, ARQ NEURO-PSIQUIAT, V35, P99, DOI 10.1590/S0004-282X1977000200002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prat R, 1998, ACTA NEUROCHIR, V140, P1257, DOI 10.1007/s007010050247; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; Schwab S, 1997, NEUROLOGY, V48, P412, DOI 10.1212/WNL.48.2.412; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; WRIGHT BC, 1992, RASCH ANAL BIG STEPS	52	88	94	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2001	50	6					1050	1059		10.1097/00005373-200106000-00013			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	442HD	WOS:000169278400017	11426120				2021-06-18	
J	Malaspina, D; Goetz, RR; Friedman, JH; Kaufmann, CA; Faraone, SV; Tsuang, M; Cloninger, CR; Nurnberger, JI; Blehar, MC				Malaspina, D; Goetz, RR; Friedman, JH; Kaufmann, CA; Faraone, SV; Tsuang, M; Cloninger, CR; Nurnberger, JI; Blehar, MC			Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							NEUROLOGIC SIGNS; HEAD-INJURY; RELATIVES; DEPRESSION; PSYCHOSIS; GENOTYPE; SEQUELAE; FAMILY; ONSET	Objective: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families with at least two biologically related first-degree relatives with schizophrenia, schizoaffective disorder, or bipolar disorder. Method: The Diagnostic Interview for Genetic Studies was used to determine history of traumatic brain injury and diagnosis for 1,275 members of multiplex bipolar disorder pedigrees and 565 members of multiplex schizophrenia pedigrees. Results: Rates of traumatic brain injury were significantly higher for those with a diagnosis of schizophrenia, bipolar disorder, and depression than for those with no mental illness. However, multivariate analysis of within-pedigree data showed that mental illness was related to traumatic brain injury only in the schizophrenia pedigrees. Independent of diagnoses, family members of those with schizophrenia were more likely to have had traumatic brain injury than were members of the bipolar disorder pedigrees. The members of the schizophrenia pedigrees also failed to show the gender difference for traumatic brain injury (more common in men than in women) that was expected and was present in the bipolar disorder pedigrees. Subjects with a schizophrenia diagnosis who were members of the bipolar disorder pedigrees land thus had less genetic vulnerability to schizophrenia) were less likely to have had traumatic brain injury (4.5%) than were subjects with schizophrenia who were members of the schizophrenia pedigrees land who had greater genetic vulnerability to schizophrenia) (19.6%). Conclusions: Members of the schizophrenia pedigrees, even those without a schizophrenia diagnosis, had greater exposure to traumatic brain injury com pared to members of the bipolar disorder pedigrees. Within the schizophrenia pedigrees, traumatic brain injury was associated with a greater risk of schizophrenia, consistent with synergistic effects between genetic vulnerability for schizophrenia and traumatic brain injury. Posttraumatic-brain-injury schizophrenia in mu[tip[ex schizophrenia pedigrees does not appear to be a phenocopy of the genetic disorder.	New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ, New York, NY 10027 USA; Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; Washington Univ, Dept Psychiat, St Louis, MO USA; NIMH, Bethesda, MD 20892 USA; Indiana Univ, Dept Psychiat, Indianapolis, IN 46204 USA	Malaspina, D (corresponding author), New York State Psychiat Inst, 722 W 168th St, New York, NY 10032 USA.		Cloninger, Claude/F-5357-2012; Faraone, Stephen/AAE-7334-2019; Faraone, Stephen V/O-7239-2018	Cloninger, Claude/0000-0003-3096-4807; Faraone, Stephen/0000-0002-9217-3982; Faraone, Stephen V/0000-0002-9217-3982; Nurnberger, John/0000-0002-7674-1767	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-46289, MH-50727] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH046289, P20MH050727] Funding Source: NIH RePORTER		ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; CLONINGER CR, 1994, AM J MED GENET, V54, P83, DOI 10.1002/ajmg.1320540202; CROW TJ, 1986, BRIT J PSYCHIAT, V149, P419, DOI 10.1192/bjp.149.4.419; CUMMINGS JL, 1985, BRIT J PSYCHIAT, V146, P184, DOI 10.1192/bjp.146.2.184; DAVISON K, 1983, PSYCHIAT DEV, V1, P1; Davison K, 1969, CURRENT PROBLEMS NEU, P113; DEMOL J, ENCEPHALE, V8, P17; FARMER AE, 1984, PSYCHIAT RES, V13, P109, DOI 10.1016/0165-1781(84)90054-4; FEDEROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GERSHON ES, 1987, ARCH GEN PSYCHIAT, V44, P314; GOETZ KL, 1986, J NERV MENT DIS, V74, P31; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KENDLER KS, 1986, AM J PSYCHIAT, V143, P279; Kinney DK, 1999, SCHIZOPHR RES, V35, P99, DOI 10.1016/S0920-9964(98)00121-2; KINNEY DK, 1986, ARCH GEN PSYCHIAT, V43, P665; KINNEY DK, 1991, PSYCHIAT RES, V39, P45, DOI 10.1016/0165-1781(91)90007-C; Kraepelin E., 1919, DEMENTIA PRAECOX PAR; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MAIER W, 1993, ARCH GEN PSYCHIAT, V50, P871; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NURNBERGER JI, 1994, ARCH GEN PSYCHIAT, V51, P849, DOI 10.1001/archpsyc.1994.03950110009002; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; PEARLSON GD, 1984, AM J PSYCHIAT, V141, P253; PLESS IB, 1995, PEDIATRICS, V95, P219; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; RUTHERFORD WH, 1977, LANCET, V1, P1; SILVER JM, 1993, 146TH AM PSYCH ASS A, P250; TAYLOR MA, 1992, AM J PSYCHIAT, V149, P22; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Violon A, 1988, Acta Neurochir Suppl (Wien), V44, P67; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; WOODS BT, 1991, BIOL PSYCHIAT, V30, P806, DOI 10.1016/0006-3223(91)90236-F	41	88	92	0	15	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	MAR	2001	158	3					440	446		10.1176/appi.ajp.158.3.440			7	Psychiatry	Psychiatry	408JL	WOS:000167323000016	11229986				2021-06-18	
J	Ashwal, S; Holshouser, BA; Shu, SK; Simmons, PL; Perkin, RM; Tomasi, LG; Knierim, DS; Sheridan, C; Craig, K; Andrews, GH; Hinshaw, DB				Ashwal, S; Holshouser, BA; Shu, SK; Simmons, PL; Perkin, RM; Tomasi, LG; Knierim, DS; Sheridan, C; Craig, K; Andrews, GH; Hinshaw, DB			Predictive value of proton magnetic resonance spectroscopy in pediatric closed head injury	PEDIATRIC NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; CORTICAL IMPACT INJURY; NERVOUS-SYSTEM INJURY; SHAKEN BABY SYNDROME; ACETYL-L-ASPARTATE; N-ACETYLASPARTATE; COMPUTED-TOMOGRAPHY; AXONAL INJURY; HYPOXIC ENCEPHALOPATHY; H-1-NMR SPECTROSCOPY	We studied 26 infants (1-18 months old) and 27 children (18 months or older) with acute nonaccidental (n = 21) or other forms (n = 32) of traumatic brain injury using clinical rating scales, a 15-point MRI scoring system, and occipital gray matter short-echo proton MRS. We compared the differences between the acutely determined variables (metabolite ratios and the presence of lactate) and 6- to 12-month outcomes. The metabolite ratios were abnormal (lower NAA/Cre or NAA/Cho; higher Cho/Cre) in patients with a poor outcome. Lactate was evident in 91% of infants and 80% of children with poor outcomes; none of the patients with a good outcome had lactate. At best, the clinical variables alone predicted the outcome in 77% of infants and 86% of children, and lactate alone predicted the outcome in 96% of infants and 96% of children. No further improvement in outcome prediction was observed when the lactate variable was combined with MRI ratios or clinical variables. The findings of spectral sampling in areas of brain not directly injured reflected the effects of global metabolic changes. Proton MRS provides objective data early after traumatic brain injury that can improve the ability to predict long-term neurologic outcome. (C) 2000 by Elsevier Science Inc, All rights reserved.	Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Div Child Neurol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Div Crit Care Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Div Forens Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Pediat Neurosurg, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Rehabil Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Pediat Surg, Loma Linda, CA 92350 USA	Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Coleman Pavil,11175 Campus St, Loma Linda, CA 92350 USA.						Aasly J, 1999, EPILEPSY RES, V35, P211, DOI 10.1016/S0920-1211(99)00011-X; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adelson PD, 1999, TRAUMATIC BRAIN INJU, P283; ARNOLD DL, 1994, ANN NEUROL, V36, P76, DOI 10.1002/ana.410360115; Ashwal S, 1997, J HEAD TRAUMA REHAB, V12, P13, DOI 10.1097/00001199-199708000-00004; Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; AULD KL, 1995, PEDIATR NEUROL, V12, P323, DOI 10.1016/0887-8994(95)00062-K; BECCA J, 1995, J PEDIATR, V126, P44; BECKER DP, 1990, NEUROLOGICAL SURGERY, P103; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BREITER SN, 1994, AM J NEURORADIOL, V15, P373; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; CASSIDY M, 1993, NEUROPEPTIDES, V24, P271, DOI 10.1016/0143-4179(93)90015-3; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; CHOE B, 1995, INVEST RADIOL, V8, P502; CHOI SC, 1996, NEUROTRAUMA, P779; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Dubowitz DJ, 1998, AM J NEURORADIOL, V19, P1617; ENEVOLDSEN EM, 1977, CLIN NEUROL NEUROSUR, V80, P213; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; FRAHM J, 1989, MAGNET RESON MED, V11, P47, DOI 10.1002/mrm.1910110105; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GENTRY LR, 1994, RADIOLOGY, V91, P1; Gotoh M, 1997, J NEUROCHEM, V69, P655; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; HOLMES G, 1982, ELECTROEN CLIN NEURO, V53, P60, DOI 10.1016/0013-4694(82)90106-7; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.0.CO;2-6; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ICHISE M, 1994, J NUCL MED, V35, P217; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JENNETT B, 1975, LANCET, V1, P480; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kochanek PM, 1999, TRAUMATIC BRAIN INJU, P233; Koura SS, 1998, ACT NEUR S, V71, P244; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Miller SL, 1996, NEUROCHEM RES, V21, P615, DOI 10.1007/BF02527761; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Novotny E, 1998, PEDIATR RES, V44, P1, DOI 10.1203/00006450-199807000-00001; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRAYER L, 1993, ACTA RADIOL, V34, P593; RANGO M, 1995, MAGNET RESON MED, V33, P595, DOI 10.1002/mrm.1910330503; RIVEROS N, 1984, BRAIN RES, V299, P393, DOI 10.1016/0006-8993(84)90727-3; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; ROSMAN P, 1999, PEDIAT NEUROLOGY PRI, P873; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUTTON LN, 1995, PEDIATR NEUROSURG, V22, P81, DOI 10.1159/000120881; TAYLOR DL, 1995, J NEUROCHEM, V65, P275; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21	80	88	91	0	2	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	AUG	2000	23	2					114	125		10.1016/S0887-8994(00)00176-4			12	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	364AG	WOS:000089869400002	11020636				2021-06-18	
J	Hanks, RA; Temkin, N; Machamer, J; Dikmen, SS				Hanks, RA; Temkin, N; Machamer, J; Dikmen, SS			Emotional and behavioral adjustment after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							BLUNT HEAD-INJURY; RELATIVES; SYMPTOMS; SEQUELAE; SCALE	Objectives: To examine emotional and behavioral adjustment and recovery over 1 year after traumatic brain injury (TBI), and to determine whether the difficulties, if present, are due to neurologic insult. Design: Longitudinal evaluation of adjustment from 1 month to 1 year after injury. Setting: Level I trauma center at a university hospital. Patients: One hundred fifty-seven consecutively hospitalized adults with TBI and 125 trauma controls with other system injuries evaluated at 1 and 12 months after injury. Main Outcome Measures: Katz Adjustment Scale (KAS). Results: The TBI group at 1 year follow-up demonstrated significant emotional and behavioral maladjustment, but such difficulties did not appear to be mediated by the brain injury, since the KAS scores for the TBI and trauma control groups were not significantly different. Those with moderate TBI reported greater difficulties than those with mild or severe injuries. Changes in adjustment over 1 year were common for both groups. Within the TBI group there was differential recovery: improvement in cognitive clarity, dysphoric mood, and emotional stability, but increased difficulties with anger management, antisocial behaviors, and self-monitoring, Conclusions: These results raise questions about commonly held beliefs that those with mild TBI report greater distress, and clarify some misconceptions regarding change in emotional and behavioral functioning over time. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Suite 555,261 Mack Ave, Detroit, MI 48201 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS006497] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS06497] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19643] Funding Source: Medline		BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burke J M, 1989, Brain Inj, V3, P35, DOI 10.3109/02699058909008071; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN S, 1977, J NERV MENT DIS, V165, P247, DOI 10.1097/00005053-197710000-00004; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KATZ M, 1963, PSYCHOL REP S, V4, P503; KLONOFF PS, 1984, RATINGS KATZ ADJUSTM; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Levin HS, 1989, MILD HEAD INJURY; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; Stevens J., 1996, APPL MULTIVARIATE ST; TEASDALE G, 1974, LANCET, V2, P81; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61	35	88	88	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1999	80	9					991	997		10.1016/S0003-9993(99)90049-7			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	234ZZ	WOS:000082515400002	10488997				2021-06-18	
J	Dixon, CE; Kraus, MF; Kline, AE; Ma, XC; Yan, HQ; Griffith, RG; Wolfson, BM; Marion, DW				Dixon, CE; Kraus, MF; Kline, AE; Ma, XC; Yan, HQ; Griffith, RG; Wolfson, BM; Marion, DW			Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain injury; amantadine; dopamine; rat	SENSORIMOTOR CORTEX INJURY; CLOSED-HEAD-INJURY; METHYLPHENIDATE TREATMENT; DOUBLE-BLIND; WORKING-MEMORY; RECOVERY; AMPHETAMINE; AGONIST; ABLATION; IMPACT	Amantadine, a dopamine agonist, is reported to have beneficial effects on the neurobehavioral sequelae of clinical brain injury. However, there are currently no published laboratory reports on its use in the assessment of functional or histopathological outcome following experimental traumatic brain injury (TBI). To this end, we examined the effects of daily amantadine treatment on functional recovery (motor and Morris water maze performance) and hippocampal neuronal survival following controlled cortical impact (CCI) injury (4 meters/sec, 2.7 mm tissue deformation). Male Sprague-Dawley rats were pretrained on motor performance tasks (beam balance and beam walking) one day prior to injury and tested on post-operative days 1-5. Additionally, all subjects were trained on the Morris water maze on post-operative days 14-18. Beginning one day after CCI injury or sham surgery, animals were injected once daily for 18 days with either amantadine (10 mg/kg, i.p.) or saline. The amantadine treatment regimen was ineffective in promoting motor recovery and increasing survival of hippocampal neurons in both the CA1 and CA3 regions following TBI, but did show improved swim latencies during the five days of water maze testing (Day 14 vs. Day 18, p < 0.01) when compared to saline controls. Mean (+/- SE) swim latencies on Day 18 were 15.12 +/- 2.8, 13.25 +/- 4. 18, 70.83 +/- 11.1, and 38.5 +/- 3.55 sec for the sham/saline, sham/amantadine, injured/saline, and injured/amantadine treatment groups, respectively. Thus, while the daily administration of amantadine exhibited a neutral effect on motor behavior, it produced a modest attenuation of water maze performance deficits. This latter finding is consistent with published clinical data suggesting a beneficial effect on functional outcome with amantadine therapy.	Univ Pittsburgh, Ctr Med, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Ctr Med, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021				ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; BAK IJ, 1972, J NEURAL TRANSM, V33, P45, DOI 10.1007/BF01244727; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BOND M, 1984, CLOSED HEAD INJURY P; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBKIN BH, 1993, ANN NEUROL, V33, P313, DOI 10.1002/ana.410330315; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FEENEY DM, 1998, CEREBROVASC DIS, P620; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; GRELAK RP, 1970, SCIENCE, V169, P203, DOI 10.1126/science.169.3941.203; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; JENNETT B, 1990, HDB CLIN NEUROLOGY, V57, P1; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; NISHINO K, 1991, FUNCTIONAL NEUROSURG, V30, P116; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH ML, 1995, NEUROSCIENCE, V67, P679, DOI 10.1016/0306-4522(95)00076-U; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Steele TD, 1996, ANN NY ACAD SCI, V777, P427, DOI 10.1111/j.1749-6632.1996.tb34457.x; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Von Voigtlander P F, 1971, Science, V174, P408, DOI 10.1126/science.174.4007.408; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004; Zafonte RD, 1998, BRAIN INJURY, V12, P617	67	88	88	0	8	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	4					285	294					10	Neurosciences	Neurosciences & Neurology	218EP	WOS:000081540500005					2021-06-18	
J	Schumacher, PA; Eubanks, JH; Fehlings, MG				Schumacher, PA; Eubanks, JH; Fehlings, MG			Increased calpain I mediated proteolysis, and preferential loss of dephosphorylated NF200, following traumatic spinal cord injury	NEUROSCIENCE			English	Article						calpain; neurofilament; nerve tissue proteins; spinal cord injury	NEUROFILAMENT PROTEINS; BRAIN INJURY; RAT-BRAIN; FOREBRAIN ISCHEMIA; SECONDARY INJURY; PROTEASE CALPAIN; INHIBITOR; PHOSPHORYLATION; DEGRADATION; CALCIUM	We investigated the hypothesis that the Ca2+-activared protease calpain is involved in the pathophysiology of spinal cord injury, and is linked to the proteolytic degradation of cytoskeletal proteins. We report here that levels of calpain I (mu-calpain)-mediated spectrin breakdown products are increased by 15 min post-injury, with peak levels reached by 2 h post-injury. The dephosphorylated form of the neurofilament protein NF200 is substantially lost over the same time-period. A 35-g compressive injury was applied to the midthoracic rat spinal cord for 1 min, and animals were killed at 15 min, 1, 2, 4, 8, 16, and 24 h post-injury. Calpain I-mediated spectrin breakdown products accumulated post-injury, with peak levels reached at 2 h, Secondly, we have demonstrated a progressive loss of the 200,000 mol. wt neurofilament protein NF200, a cytoskeletal calpain substrate, which began within 1-2 h post-injury. Densitometric analyses confirmed that loss of NF200 is a substrate-specific phenomenon, since (i) dephosphorylated NF200 was preferentially lost while phosphorylated NF200 was relatively spared, and (ii) actin, which is not a substrate for calpain, was relatively spared following spinal cord injury. Finally, we demonstrated calpain I-mediated spectrin breakdown within NF200-positive neuronal processes post-injury. We conclude that the accumulation of spectrin breakdown products is temporally and spatially correlated with loss of dephosphorylated NF200 after spinal cord injury. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Univ Toronto, Toronto Hosp, Western Div, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Hosp, Western Div, Res Inst, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Toronto, Toronto Hosp, Western Div, Playfair Neurosci Unit, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Eubanks, James/0000-0001-8595-2024; Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; Banik N L, 1984, Cent Nerv Syst Trauma, V1, P131; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BI XN, 1994, NEUROREPORT, V6, P61, DOI 10.1097/00001756-199412300-00017; CANER H, 1993, BRAIN RES, V607, P354, DOI 10.1016/0006-8993(93)91531-V; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CROALL DE, 1991, PHYSIOL REV, V71, P813; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; FEHLINGS MG, 1995, SPINE, V20, P2187, DOI 10.1097/00007632-199510001-00002; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; GOLL DE, 1991, J BIOL CHEM, V266, P8501; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HAPPEL RD, 1984, NEUROSCI LETT, V49, P279, DOI 10.1016/0304-3940(84)90302-1; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KISHIMOTO A, 1990, ADV SEC MESS PHOSPH, V24, P472; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PERLMUTTER LS, 1988, SYNAPSE, V2, P79, DOI 10.1002/syn.890020111; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; RIVLIN AS, 1979, J NEUROSURG, V50, P349, DOI 10.3171/jns.1979.50.3.0349; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1994, FASEB J, V8, P814; SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	49	88	92	1	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		1999	91	2					733	744		10.1016/S0306-4522(98)00552-1			12	Neurosciences	Neurosciences & Neurology	190RA	WOS:000079977200032	10366029				2021-06-18	
J	Bareyre, F; Wahl, F; McIntosh, TK; Stutzmann, JM				Bareyre, F; Wahl, F; McIntosh, TK; Stutzmann, JM			Time course of cerebral edema after traumatic brain injury in rats: Effects of riluzole and mannitol	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; fluid percussion; mannitol; rats; riluzole; traumatic brain injury	CLOSED-HEAD INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; BARRIER PERMEABILITY; GLUTAMATE RELEASE; CHANNEL BLOCKER; NMDA RECEPTORS; DAMAGE; CALCIUM; SODIUM; BLOOD	Brain trauma is the main cause of morbidity and mortality in young adults. One delayed events that occurs after a head trauma and compromises the survival of patients is cerebral edema. The present study examined first the occurrence of cerebral edema after a traumatic brain injury (TBI) induced by moderate fluid percussion in rats. Brain water content was measured from 1 h to 7 days posttrauma, in the hippocampus and cortex, on both ipsi-and contralateral hemispheres. Second, the effects of mannitol, an osmotic agent frequently used in the clinic, and riluzole, a neuroprotective compound, were investigated on regional edema formation. After TBI, the ipsilateral edema began early at 1-6 h, was maximal at 48 h and was resorbed by 5-7 days. No edema was observed in the contralateral hemisphere. Mannitol at 1 g/kg or vehicle was administered iv 15 min, 2 h and 4 h postinjury. At this dose, mannitol significantly attenuated the ipsilateral injured cortex edema measured at 6 h (p < 0.05). Riluzole at 4 and 8 mg/kg or vehicle was administered 15 min (IV) and 6 h, 24 h, and 30 h (SC) post-TBI. Riluzole at 4 x 4 mg/kg significantly reduced edema measured at 48 h, in the ipsilateral hippocampus (p < 0.05), whereas at 4 x 8 mg/kg, the reduction was observed in the hippocampus (p < 0.01) and the injured cortex (p < 0.05). Our results demonstrate that (1) cerebral edema begins early after the injury and is resorbed over 1 week; (2) mannitol could attenuate cerebral edema; and (iii) riluzole in addition to its neuroprotective effects reduces the brain edema. Thus, riluzole could be useful in human TBI treatment.	RHONE POULENC RORER SA,CTR NEURODEGENERAT DISORDERS,F-94400 VITRY SUR SEINE,FRANCE; UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104							Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BARBEITO L, 1996, J NEUROTRAUM, V13, P629; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Biros MH, 1996, AM J EMERG MED, V14, P27, DOI 10.1016/S0735-6757(96)90008-X; Bullock MR, 1996, J NEUROTRAUM, V13, P705; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Janis LS, 1996, NEUROSCI LETT, V214, P21, DOI 10.1016/S0304-3940(96)12873-1; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; LACOMBLEZ L, 1996, LANCET, V347, P1425, DOI DOI 10.1016/S0140-6736(96)91680-3; Mary V, 1995, NEUROSCI LETT, V201, P92, DOI 10.1016/0304-3940(95)12137-S; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McINTOSH T., 1988, NEUROL NEUR, P653; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Peluffo H, 1997, NEUROSCI LETT, V228, P207, DOI 10.1016/S0304-3940(97)00384-4; PETITO CK, 1979, J NEUROPATH EXP NEUR, V38, P222, DOI 10.1097/00005072-197905000-00003; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; SANDERSON KL, 1996, J NEUROTRAUM, V13, P626; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHAPIRA Y, 1991, ANESTH ANAG, V68, P5247; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, CRC S MEMBR, P235; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SMITH DH, 1993, J NEUROSCI, V13, P5383; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stewart-Wallace AM, 1939, BRAIN, V62, P426, DOI 10.1093/brain/62.4.426; Stutzmann J. M., 1997, CNS DRUG REV, V3, P83; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; STUTZMANN JM, 1993, NEURODEGENER DIS, P205; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOMINAGA T, 1995, CENTRAL NERVOUS SYST, P85; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; VODDI MD, 1995, J NEUROTRAUM, V12, P146; VONBERENBERG P, 1994, ACTA NEUROCHIR, V60, pS531; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	71	88	93	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1997	14	11					839	849		10.1089/neu.1997.14.839			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YK511	WOS:A1997YK51100003	9421455				2021-06-18	
J	Wade, DT; Crawford, S; Wenden, FJ; King, NS; Moss, NEG				Wade, DT; Crawford, S; Wenden, FJ; King, NS; Moss, NEG			Does routine follow up after bead injury help? A randomised controlled trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						randomised controlled trial; head injury; follow up service	MINOR HEAD-INJURY; GENERAL HEALTH; CONCUSSION; SYMPTOMS; MILD; QUESTIONNAIRE; EPIDEMIOLOGY	Objective-To evaluate the Medical Disability Society's 1988 recommendation that ''every patient attending hospital after a head injury should be registered and offered an outpatient follow up appointment'' by determining whether offering a routine follow up service to patients presenting to hospital with a head injury of any severity affects outcome six months later. Design-A randomised controlled trial design with masked assessment of outcome. Setting-A mixed rural and urban health district with a population of about 560 000. Patients-1156 consecutive patients resident in Oxfordshire aged between 16 and 65 years presenting over 13 months to accident and emergency departments or admitted to hospital and diagnosed as having a head injury of any severity, including those with other injuries. Interventions-Patients were registered and randomised to one of two groups. Both groups continued to receive the standard service offered by the hospitals, The early follow up group were approached at 7-10 days after injury and offered additional information, advice, support, and further intervention as needed. AU randomised patients were approached for follow up assessment six months after injury by independent clinicians blind to their group. Main outcome measures-Validated questionnaires were used to elicit ratings of post-concussion symptoms (the Rivermead postconcussion symptoms questionnaire), and changes in work, relationships, leisure, social, and domestic activities (the Rivermead head injury follow up questionnaire). Results-The two groups were comparable at randomisation. Data was obtained at six months on 226 of 577 ''control'' patients and 252 of 579 ''trial'' patients (59% were lost to follow up). There were no significant differences overall between the trial and control groups at follow up, but subgroup analysis of the patients with moderate or severe head injuries (posttraumatic amnesia greater than or equal to one hour, or admitted to hospital), showed that those in the early intervention group had significantly fewer difficulties with everyday activities (P = 0.03). Conclusions-The results from the 41% of patients followed up do not support the recommendation of offering a routine follow up to all patients with head injury, but they do suggest that routine follow up is most Likely to be beneficial to patients with moderate or severe head injuries. Some of those with less severe injuries do continue to experience difficulties and need access to services. A further trial is under way to lest these conclusions.		Wade, DT (corresponding author), RIVERMEAD REHABIL CTR,OXFORD HEAD INJURY SERV,ABINGDON RD,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1989, MILD HEAD INJURY; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GREENWOOD RJ, 1992, BRIT MED J, V308, P1199; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; MANDEL S, 1989, POSTGRAD MED, V85, P213; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Moss NE, 1996, DISABIL REHABIL, V18, P169, DOI 10.3109/09638289609166296; MOSS NEG, 1994, CLIN REHABIL, V8, P149; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9	29	88	89	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1997	62	5					478	484		10.1136/jnnp.62.5.478			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	WX623	WOS:A1997WX62300009	9153604	Bronze, Green Published			2021-06-18	
J	Matta, B; Menon, D				Matta, B; Menon, D			Severe head injury in the United Kingdom and Ireland: A survey of practice and implications for management	CRITICAL CARE MEDICINE			English	Article						brain; head injury; traumatic brain injury; head trauma; neurologic emergencies; coma; monitoring, transcranial Doppler ultrasonography; near-infrared spectroscopy; intracranial pressure; hyperventilation; sedation	CEREBRAL BLOOD-FLOW; PROLONGED NEUROMUSCULAR BLOCKADE; INCREASED INTRACRANIAL-PRESSURE; BRAIN INJURY; AGGRESSIVE TREATMENT; CLINICAL-TRIAL; HYPERVENTILATION; HYPERTENSION; ANESTHESIA; SUCCINYLCHOLINE	Objective: To study the current intensive care management of patients with severe head injury (defined as a Glasgow Coma Scale score of less than or equal to 8) in neurosurgical referral centers in the United Kingdom (UK) and Ireland. Data Collection: A questionnaire was sent to the directors of the 44 neurosurgical referral units identified from the UK Medical Directory. After 4 wks, a copy of the questionnaire was sent to all nonresponders, with a cover letter urging them to respond. The aim was to collect data regarding the characteristics of the intensive care units (ICU), sedation, monitoring modalities used, the treatment of intracranial hypertension, and general care of severely head-injured patients. Data Extraction: Forty completed questionnaires were returned. Only 35 (88%) centers provided care for the severely head-injured as defined in the questionnaire. Patients were managed in specialized neurosurgical ICUs in 66% of centers and in general ICUs in the remainder of the centers. The ICUs were coordinated by an anesthesiologist in 66% of instances and by a neurosurgeon in 23%. The mean number of beds per units was 7.9 (range 4 to 16), with 1:1 nurse/bed ratio and 5.5 nurses per bed (total number of nursing staff per bed) (range 2.75 to 8). Annual caseload varied between units with the majority of units (49%) receiving between 25 and 50 patients with severe head injury, 23% receiving between 50 and 100 patients with severe head injury, and 29% receiving >100 patients with severe head injury. There was considerable variability in both the nature of monitoring and therapy between centers. Although blood and central venous pressures were invasively monitored in >50% of the patients in 94% and 77% of the centers, respectively, intracranial pressure was only monitored routinely in 57% of the centers. Jugular venous bulb oximetry, transcranial Doppler ultrasonography, electroencephalography, and near-infrared spectroscopy were rarely used. Nearly all centers used propofol and midazolam for sedation, with morphine, fentanyl, and alfentanil as the main analgesics. Muscle relaxation was commonly used, with 40% of the centers employing it in 100% of their patients. Atracurium and vecuronium were the most commonly used agents. Only 68% of the centers had a protocol for the treatment of intracranial hypertension. Although hyperventilation to a PaCO2 of 26 to 30 torr (3.5 to 4.0 kPa) was the norm in the majority of centers (56%), two centers aimed for PaCO2 values (26 torr ((3.5 kPa). A quarter of the units did not aim for a cerebral perfusion pressure of >60 mm Hg. Mild hypothermia was rarely used and 14% of the centers continued to use corticosteroids for the treatment of intracranial hypertension as a result of head trauma. Conclusion: We conclude that there are wide variations in the management of the severely head injured patient in the UK and Ireland. Some of the therapies employed are not supported by available research findings. Rationalization (using rational management, i.e., based on good evidence) of the intensive care management of severe head injury with the development of widely accepted guidelines may result in an improvement in the quality of care of the head-injured patient.		Matta, B (corresponding author), ADDENBROOKES HOSP, DEPT ANAESTHESIA & NEUROSURG CRIT CARE, CAMBRIDGE, ENGLAND.						ALBANESE J, 1993, ANESTHESIOLOGY, V79, P493, DOI 10.1097/00000542-199309000-00012; ANDREWS PJD, 1995, ACTA ANAESTH SCAND, V39, P112, DOI 10.1111/j.1399-6576.1995.tb04287.x; ARTRU AA, 1992, J NEUROSURG ANESTH, V4, P99, DOI 10.1097/00008506-199204000-00005; BEDFORD RF, 1986, ANESTHESIA, P2253; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FABIAN TC, 1993, ARCH SURG-CHICAGO, V128, P185; FAHY BG, 1994, J NEUROSURG ANESTH, V6, P136; GEDEIT RG, 1993, CRIT CARE MED, V21, P1850, DOI 10.1097/00003246-199312000-00011; GHAR J, 1995, CRIT CARE MED, V23, P560; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GRIFFIN D, 1992, CHEST, V102, P510, DOI 10.1378/chest.102.2.510; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; LANIER WL, 1986, ANESTHESIOLOGY, V64, P551, DOI 10.1097/00000542-198605000-00003; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Marx W, 1989, J Neurosurg Anesthesiol, V1, P3, DOI 10.1097/00008506-198903000-00002; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; MATTA BF, 1994, ANESTH ANALG, V79, P745; MATTA BF, IN PRESS ANAESTHESIA; MAYBERG TS, 1993, ANESTHESIOLOGY, V78, P288, DOI 10.1097/00000542-199302000-00012; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MINTON MD, 1986, ANESTHESIOLOGY, V65, P165, DOI 10.1097/00000542-198608000-00006; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHAPIRA Y, 1992, ANESTH ANALG, V74, pS282; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; SPETZLER R F, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P212; STREBEL S, 1994, ANESTH ANALG, V78, P884; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; TODD MM, 1993, ANESTHESIOLOGY, V79, P139, DOI 10.1097/00000542-199307000-00020; TRINDLE MR, 1993, ANESTHESIOLOGY, V78, P454, DOI 10.1097/00000542-199303000-00008; WILSON JA, 1994, J NEUROSURG ANESTH, V6, P139; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H	45	88	92	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	1996	24	10					1743	1748		10.1097/00003246-199610000-00023			6	Critical Care Medicine	General & Internal Medicine	VM725	WOS:A1996VM72500024	8874315				2021-06-18	
J	LEWEN, A; LI, GL; NILSSON, P; OLSSON, Y; HILLERED, L				LEWEN, A; LI, GL; NILSSON, P; OLSSON, Y; HILLERED, L			TRAUMATIC BRAIN INJURY IN RAT PRODUCES CHANGES OF BETA-AMYLOID PRECURSOR PROTEIN IMMUNOREACTIVITY	NEUROREPORT			English	Article						APP; BETA-AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; AXONAL DAMAGE; GLUTAMATE; RAT	AMINO-ACIDS; HEAD-INJURY; DEPOSITION; DISEASE	beta-AMYLOID precursor protein immunoreactivity (APP) was studied after a mild compression contusion trauma to rat parietal cortex. Neurones in the periphery of the cortical lesion, i.e. tissue subjected to shear stress, showed markedly reduced immunoreactivity 1 and 3 days after injury. Numerous axons in the ipsilateral subcortical white matter and thalamus became immunoreactive. At 21 days, small rounded profiles appeared in the neuropil of the damaged cortex and in the thalamus. Thus, traumatic brain injury appears to induce several types of APP changes. The accumulation in neuronal processes is probably caused by disturbed axonal transport induced by trauma. Since APP is assumed to be excitoprotective, modulating intracellular Ca2+ responses, the decreased immunoreactivity noticed in the periphery of the lesion may render the neurones in this region more vulnerable to secondary injury mechanisms.	UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT NEUROPATHOL,S-75185 UPPSALA,SWEDEN	LEWEN, A (corresponding author), UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAULL RLM, 1985, RAT NERVOUS SYSTEM, P144; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1993, PROGR BRAIN RES, P237; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SMITH C, 1994, NEUROPATH APPL NEURO, V20, P322, DOI 10.1111/j.1365-2990.1994.tb00977.x	25	88	88	0	2	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	JAN 26	1995	6	2					357	360		10.1097/00001756-199501000-00032			4	Neurosciences	Neurosciences & Neurology	QG375	WOS:A1995QG37500033	7756628				2021-06-18	
J	JORGE, RE; ROBINSON, RG; STARKSTEIN, SE; ARNDT, SV				JORGE, RE; ROBINSON, RG; STARKSTEIN, SE; ARNDT, SV			INFLUENCE OF MAJOR DEPRESSION ON 1-YEAR OUTCOME IN PATIENTS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						DEPRESSION; TRAUMATIC BRAIN INJURY; OUTCOME; RECOVERY; EMOTIONAL DISORDER; BEHAVIORAL DISORDER; TRAUMATIC COMA DATA BANK	SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; RELATIVES VIEW; MOOD; SEQUELAE; COMA	The authors examine those factors that contributed to deterioration in social functioning, activities of daily living, or intellectual functioning during a 1-year period after traumatic brain injury (TBI). Fifty-two patients suffering an acute TBI were evaluated for existence and severity of mood disorders and impairment during their hospital stays and at 3-, 6-, and 12-month follow-up examinations. Patients whose scores on intellectual function, social function, or daily activities deteriorated during the 1-year period after trauma were considered to have a poor outcome. Eleven of 52 patients had a poor outcome in social function, which was associated with race, right-hemisphere lesions, intellectual impairment, and prolonged major depression. Seven of 52 patients had a poor outcome in daily activities, which was associated with a major depression of more than 6 months' duration and severity of Hamilton Depression Rating Scale scores. Eleven of these patients had a poor outcome in cognitive function, which was associated with cognitive impairment immediately after TBI. A major depression lasting more than 6 months was associated with deterioration of social functioning and activities of daily living during the 1-year period after TBI.	UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,MENTAL HLTH CLIN RES CTR,BIOSTAT CORE UNIT,IOWA CITY,IA; INST NEUROL INVEST RAUL CARREA,BUENOS AIRES,DF,ARGENTINA			Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021	Arndt, Stephan/0000-0003-0783-8204; 			BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LISHMAN WA, 1988, BR J PSYCHITRY, V153, P1460; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; PARIKH RM, 1990, ARCH NEUROL-CHICAGO, V47, P785, DOI 10.1001/archneur.1990.00530070083014; Prigatano G., 1985, NEUROPSYCHOLOGICAL R; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; Sartorius N, 1974, MEASUREMENT CLASSIFI; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397; 1987, DIAGNOSTIC STATISTIC	32	88	88	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1994	81	5					726	733		10.3171/jns.1994.81.5.0726			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	PN296	WOS:A1994PN29600011	7931619				2021-06-18	
J	CHERIAN, L; ROBERTSON, CS; CONTANT, CF; BRYAN, RM				CHERIAN, L; ROBERTSON, CS; CONTANT, CF; BRYAN, RM			LATERAL CORTICAL IMPACT INJURY IN RATS - CEREBROVASCULAR EFFECTS OF VARYING DEPTH OF CORTICAL DEFORMATION AND IMPACT VELOCITY	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; HEAD-INJURY; ISOFLURANE; RESPONSES	Intracranial pressure (ICP), blood pressure (BP), cerebral perfusion pressure (CPP), and cortical perfusion (LDF) of the contralateral parietal cortex were measured after cortical impact injury in 36 rats. Changes in these physiologic parameters were compared using analysis of variance to a group of 11 rats who received a sham impact. In one series of experiments, the velocity and duration of the impact injury were kept constant, and the severity of the injury was determined by varying the depth of cortical deformation from 2 to 3 mm. The peak pressure inside the skull was directly related to the depth of cortical deformation, and was 93 +/- 16, 182 +/- 18, and 268 +/- 57 mm Hg with the 2, 2.5, and 3 mm deformation, respectively, when the impact velocity was 5 m/sec. With the 2 mm depth injury, there was a transient decrease in BP (p < 0.05) and a 12% decrease in LDF after the impact. With the 2.5 mm depth injury, a small transient increase in ICP and decrease in BP and a 30% decrease in LDF occurred (p < 0.05). ICP then gradually increased throughout the 8 h experiment, becoming significantly greater than the sham-injured animals by 5 h after the impact. LDF gradually returned toward normal throughout the experiment. With the 3 mm depth injury, a marked transient increase in ICP (p < 0.05) and BP (p < 0.05) occurred immediately after the impact. The increase in BP lasted <5 min, and subsequently the BP decreased to approximately 50 mm Hg for the rest of the experiment. The initial marked increase in ICP lasted 15 min and then remained 5-10 mm Hg higher (p < 0.05) than in the sham-injured animals for the rest of the experiment. LDF decreased by an average of 50% (p < 0.05) immediately after the impact and remained lower than that of the sham-injured animals for the rest of the experiment. In another series of experiments, the depth of cortical deformation was kept constant at 2.5 mm, and the severity of the injury was determined by varying the velocity from 1 to 5 m/sec. The peak ICP was significantly related to the impact velocity, averaging 45 +/- 12, 66 +/- 9, and 182 +/- 18 mm Hg with the 1, 3, and 5 m/sec impact injuries, respectively. The 1 m/sec impact had no effect on ICP and only a transient decrease in BP. LDF was initially slightly decreased but, beginning at 4 h after the impact, increased to levels greater than for the sham-injured animals (p < 0.05). The 3 m/sec impact had no effect on ICP. BP and CPP were 10-15 mm Hg less than in the sham-injured animals throughout the experiment (p < 0.05). With the 5 m/sec impact, ICP was transiently increased for <15 min immediately after the impact. The ICP returned to preinjury levels by 30 min after the impact but then gradually increased throughout the rest of the experiment, becoming significantly greater than in the sham-injured animals by 5.5 h. BP and CPP were 10-15 mm Hg less than in the sham-injured animals throughout the experiment (p < 0.05). LDF immediately decreased by 30% (p < 0.05) and then gradually increased toward control values throughout the 8 h experiment. The cortical impact model of TBI reproduces many of the hemodynamic features of human head injury. Distinct cerebral hemodynamic patterns are related to both the depth of deformation and the velocity of the impact. This model may be useful for studying these manifestations of TBI.	BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030	CHERIAN, L (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01-HLB41960] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL041960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		BRYAN RM, 1993, 1993 NEUR SOC M; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1992, J NEUROTRAUM, V9, P383; CUCCHIARA RF, 1974, ANESTHESIOLOGY, V40, P571, DOI 10.1097/00000542-197406000-00011; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GELSEMA AJ, 1989, BRAIN RES, V482, P67, DOI 10.1016/0006-8993(89)90543-X; GOLDMAN H, 1991, J NEUROTRAUM, V8, P128; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Marmarou A, 1990, Adv Neurol, V52, P233; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	24	88	89	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1994	11	5					573	585		10.1089/neu.1994.11.573			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PR237	WOS:A1994PR23700010	7861449				2021-06-18	
J	GRATTAN, LM; BLOOMER, RH; ARCHAMBAULT, FX; ESLINGER, PJ				GRATTAN, LM; BLOOMER, RH; ARCHAMBAULT, FX; ESLINGER, PJ			COGNITIVE FLEXIBILITY AND EMPATHY AFTER FRONTAL-LOBE LESION	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						COGNITIVE FLEXIBILITY; EMPATHY; NEUROANATOMICAL VARIABLES	CLOSED-HEAD-INJURY; CARD SORTING TEST; DAMAGE; CONSEQUENCES; CHILDREN; BEHAVIOR	Although impairments in interpersonal behavior and cognitive flexibility are frequently associated with frontal lobe injury, the relationship between these deficits remains unknown. Social theories have emphasized the importance of flexible thinking for high-level social functioning, including perspective-taking capacities and empathy. We hypothesized that a positive correlation between measures of cognitive flexibility and empathy would be apparent after frontal lobe lesions in the dorsolateral, mesial or orbital sectors and possibly in a diverse group with frontal lobe damage. To test this hypothesis, 40 subjects with frontal or nonfrontal lobe lesions were compared on standardized measures of cognitive flexibility and empathy. Both groups showed similar quantitative alterations on the empathy measure, but responses of the frontal lesion group related these to greater discomfort in changing, novel, or ambiguous situations, while responses of the nonfrontal lesion group indicated reduced social self-confidence. Cognitive flexibility and empathy levels showed a similar pattern of variation in the nonfrontal lesion group, but not in the frontal lesion group because of marked differences among frontal lesion subgroups. Left and right dorsolateral lesions affected both cognitive flexibility and empathy (with a positive correlation after left dorsolateral lesions), while orbital lesions profoundly affected empathy only, and mesial lesions affected cognitive flexibility only. The findings support a model of functional-anatomic distinctions within the frontal lobe that encompasses cognitive and noncognitive mechanisms within a network of cerebral structures subserving complex social processes.	UNIV CONNECTICUT,DEPT EDUC PSYCHOL,STORRS,CT 06268; PENN STATE UNIV,COLL MED,DEPT MED,DIV NEUROL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,COLL MED,DEPT BEHAV SCI,UNIVERSITY PK,PA 16802; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033	GRATTAN, LM (corresponding author), UNIV MARYLAND,MED CTR,SCH MED,DEPT NEUROL,NEUROBEHAV DIAGNOST & RES LAB,22 S GREENE ST,BALTIMORE,MD 21201, USA.						ACKERLY SS, 1974, RES PUB ASS RES NERV, V27, P479; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P926; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; Benton A, 1989, MULTILINGUAL APHASIA; BRICKNER RM, 1952, AMA ARCH NEUROL PSY, V68, P293, DOI 10.1001/archneurpsyc.1952.02320210003001; BROTHERS L, 1989, AM J PSYCHIAT, V146, P10; CHLOPAN BE, 1985, J PERS SOC PSYCHOL, V48, P635, DOI 10.1037/0022-3514.48.3.635; Cummings JL, 1985, CLIN NEUROPSYCHIATRY; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAMASIO AR, 1989, LESION ANAL NEUROPSY; DAMASIO AR, 1985, CLIN NEUROPSYCHOLOGY, P339; DREWE E A, 1974, Cortex, V10, P159; Dymond R., 1950, J CONSULT PSYCHOL, V14, P43; Egan G., 1976, INTERPERSONAL LIVING; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V25, P1731; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.8.1120-1122; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1989, AM J PSYCHIAT, V146, P1521; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; GRATTAN LM, 1994, NEUROLOGY, V44, pA292; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; GREENSON RR, 1960, INT J PSYCHOANAL, V41, P418; GRIEF EB, 1973, J COUNS PSYCHOL, V20, P280; Guilford J.P., 1978, ALTERNATE USES MANUA; Harlow J. M., 1993, HIST PSYCHIATR, V4, P274, DOI [10.1177/0957154X9300401407, DOI 10.1177/0957154X9300401407]; Heaton R. K, 1981, WISCONSIN CARD SORTI; Hebb DO, 1940, ARCH NEURO PSYCHIATR, V44, P421, DOI 10.1001/archneurpsyc.1940.02280080181011; HERTEL PT, 1980, J EDUC PSYCHOL, V72, P133, DOI 10.1037/0022-0663.72.2.133; HOGAN R, 1969, J CONSULT CLIN PSYCH, V33, P307, DOI 10.1037/h0027580; JOHNSON JA, 1983, J PERS SOC PSYCHOL, V45, P1299, DOI 10.1037/0022-3514.45.6.1299; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lewis, 1954, PSYCHOMETRIKA, V19, P297; LEZAK MD, 1987, J HEAD TRAUMA REHABI, V29, P57; Mead George Herbert, 1934, MIND SELF SOC STANDP; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Milner B., 1964, FRONTAL GRANULAR COR; Mitchell J. V., 1985, 9 MENTAL MEASUREMENT, V1, P73; ODDY M, 1985, J NEUROL NEUROSUR PS, V133, P507; Pandya D. N., 1987, FRONTAL LOBES REVISI, P41; Piaget J., 1959, JUDGMENT REASONING C; PIERCE RM, 1972, J CLIN PSYCHOL, V28, P230, DOI 10.1002/1097-4679(197204)28:2<230::AID-JCLP2270280234>3.0.CO;2-9; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; PRIGATANO GP, 1987, NEUROPSYCHOLOGICAL R; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; Stuss D.T., 1986, FRONTAL LOBES; Tabachnick BG, 1983, USING MULTIVARIATE S; WINNE JF, 1961, J CLIN PSYCHOL MON S, P38; WVIDLAR DC, 1975, J PSYCHOL, V90, P237	53	88	89	0	17	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	OCT	1994	7	4					251	259					9	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	PY002	WOS:A1994PY00200002					2021-06-18	
J	WILLER, BS; ALLEN, KM; LISS, M; ZICHT, MS				WILLER, BS; ALLEN, KM; LISS, M; ZICHT, MS			PROBLEMS AND COPING STRATEGIES OF INDIVIDUALS WITH TRAUMATIC BRAIN INJURY AND THEIR SPOUSES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						FAMILY; HEAD INJURIES; MARRIAGE	SEVERE HEAD-INJURY; RECOVERY	A pilot investigation is reported on the problems and coping strategies of 20 married men and 11 married women with traumatic brain injury (TBI) and their able-bodied spouses. All injured subjects experienced severe head injury at least one and a half years earlier. A structured, small-group discussion process was used to elicit a prioritized list of problems and a similar list of coping strategies. Individuals with TBI and their spouses identified problems in living as most important; loss of employment and restrictions on autonomy were reported as the most problematic. Men with TBI placed priority on controlling their anger, whereas, women with TBI were concerned with their mood disorders, particularly depression. Women with TBI and able-bodied wives of men with TBI placed high priority on the use of support groups as a coping strategy. Men placed higher priority on individualistic approaches to adjustment, such as suppression of feelings. A number of testable hypotheses resulted from the pilot study.		WILLER, BS (corresponding author), SUNY BUFFALO,RES & TRAINING CTR TBI,197 FARBER HALL,3435 MAIN ST,BUFFALO,NY 14214, USA.						[Anonymous], 1980, INT CLASSIFICATION I; BENYISHAY Y, 1981, INT J REHABIL RES, V4, P208, DOI 10.1097/00004356-198106000-00012; BOND MR, 1980, J NEUROL NEUROSUR PS, V43, P798; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CRIPE LI, 1989, REHABIL PSYCHOL, V34, P93; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; Delbecq A.L., 1975, GROUP TECHNIQUES PRO; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Wood R. L., 1987, BRAIN INJURY REHABIL; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583	14	88	88	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1991	72	7					460	464					5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FP702	WOS:A1991FP70200003	2059116				2021-06-18	
J	Joy, MT; Ben Assayag, E; Shabashov-Stone, D; Liraz-Zaltsman, S; Mazzitelli, J; Arenas, M; Abduljawad, N; Kliper, E; Korczyn, AD; Thareja, NS; Kesner, EL; Zhou, M; Huang, S; Silva, TK; Katz, N; Bornstein, NM; Silva, AJ; Shohami, E; Carmichael, ST				Joy, Mary T.; Ben Assayag, Einor; Shabashov-Stone, Dalia; Liraz-Zaltsman, Sigal; Mazzitelli, Jose; Arenas, Marcela; Abduljawad, Nora; Kliper, Efrat; Korczyn, Amos D.; Thareja, Nikita S.; Kesner, Efrat L.; Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Katz, Noomi; Bornstein, Natan M.; Silva, Alcino J.; Shohami, Esther; Carmichael, S. Thomas			CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury	CELL			English	Article							CLOSED-HEAD INJURY; FUNCTIONAL RECOVERY; DENDRITIC SPINES; PREMOTOR CORTEX; PLASTICITY; REHABILITATION; MEMORY; AGE; REGENERATION; HEMIPARESIS	We tested a newly described molecular memory system, CCR5 signaling, for its role in recovery after stroke and traumatic brain injury (TBI). CCR5 is uniquely expressed in cortical neurons after stroke. Post-stroke neuronal knockdown of CCR5 in pre-motor cortex leads to early recovery of motor control. Recovery is associated with preservation of dendritic spines, new patterns of cortical projections to contralateral pre-motor cortex, and upregulation of CREB and DLK signaling. Administration of a clinically utilized FDA-approved CCR5 antagonist, devised for HIV treatment, produces similar effects on motor recovery post stroke and cognitive decline post TBI. Finally, in a large clinical cohort of stroke patients, carriers for a naturally occurring loss-of-function mutation in CCR5 (CCR5-Delta 32) exhibited greater recovery of neurological impairments and cognitive function. In summary, CCR5 is a translational target for neural repair in stroke and TBI and the first reported gene associated with enhanced recovery in human stroke.	[Joy, Mary T.; Mazzitelli, Jose; Arenas, Marcela; Abduljawad, Nora; Thareja, Nikita S.; Carmichael, S. Thomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Silva, Alcino J.] Univ Calif Los Angeles, Dept Neurobiol, Integrat Ctr Learning & Memory, Los Angeles, CA 90095 USA; [Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Integrat Ctr Learning & Memory, Los Angeles, CA 90095 USA; [Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychol, Integrat Ctr Learning & Memory, Los Angeles, CA 90095 USA; [Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Silva, Alcino J.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; [Ben Assayag, Einor; Kliper, Efrat; Bornstein, Natan M.] Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv, Israel; [Shabashov-Stone, Dalia; Liraz-Zaltsman, Sigal; Kesner, Efrat L.; Shohami, Esther] Hebrew Univ Jerusalem, Inst Drug Res, Dept Pharmacol, Jerusalem, Israel; [Ben Assayag, Einor; Korczyn, Amos D.; Bornstein, Natan M.] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Liraz-Zaltsman, Sigal] Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Tel Hashomer, Israel; [Liraz-Zaltsman, Sigal; Katz, Noomi] Ono Acad Coll, Inst Hlth & Med Profess, Kiryat Ono, Israel	Carmichael, ST (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.	scarmichael@mednet.ucla.edu	Joy, Mary Teena/S-9605-2018; Zhou, Miou/AAK-1515-2021	Joy, Mary Teena/0000-0002-3120-2022; Mazzitelli Perez, Jose/0000-0002-3896-3553; Joy, Mary Teena/0000-0003-4615-4067	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; American Heart FoundationAmerican Heart Association [16POST27710039]; United States-Israel Binational Science FoundationUS-Israel Binational Science Foundation [2011344]; Alzheimer's AssociationAlzheimer's Association [16-442861]; American Federation for Aging Research [RAG11482]	These studies were funded by Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (S.T.C., E.S., and A.J.S.), American Heart Foundation (16POST27710039, M.T.J.), United States-Israel Binational Science Foundation (2011344, E.B.A.), Alzheimer's Association (16-442861, EBA), and the American Federation for Aging Research (RAG11482, E.B.A.). We thank Rex Lee for dedicated technical assistance. We thank Dr. Greg Khitrov for technical assistance at UCLA MIC; Felicia Codrea, Jessica Scholes, and Jeff Calimlim at the UCLA FACS core (BSCRC); and Dr. Joanna Liliental at TASC core at Stanford University. We thank Sali Usher for her dedicated help in genetic analyses and Tal Adamit for comprehensive data collection from stroke patients at 3 months post stroke.	Adelson JD, 2012, NEURON, V73, P1100, DOI 10.1016/j.neuron.2012.01.020; Artzi M, 2013, EUR J RADIOL, V82, P1512, DOI 10.1016/j.ejrad.2013.05.029; Balkaya M, 2019, NEUROBIOL DIS, V126, P36, DOI 10.1016/j.nbd.2018.08.009; Barreto GE, 2012, EXP NEUROL, V238, P284, DOI 10.1016/j.expneurol.2012.08.015; Ben Assayag E, 2012, INT J STROKE, V7, P341, DOI 10.1111/j.1747-4949.2011.00652.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Brown CE, 2008, STROKE, V39, P1286, DOI 10.1161/STROKEAHA.107.498238; Brown CE, 2007, J NEUROSCI, V27, P4101, DOI 10.1523/JNEUROSCI.4295-06.2007; Caracciolo L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04445-9; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Clarkson AN, 2011, J NEUROSCI, V31, P3766, DOI 10.1523/JNEUROSCI.5780-10.2011; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Cramer SC, 2012, EUR J NEUROL, V19, P718, DOI 10.1111/j.1468-1331.2011.03615.x; Di Lazzaro V, 2010, CEREB CORTEX, V20, P1523, DOI 10.1093/cercor/bhp216; Doniger Glen M, 2006, Am J Alzheimers Dis Other Demen, V21, P28; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fisher M, 2009, AM J PSYCHIAT, V166, P805, DOI 10.1176/appi.ajp.2009.08050757; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fu M, 2012, NATURE, V483, P92, DOI 10.1038/nature10844; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Grafman Jordan, 2015, Handb Clin Neurol, V128, P795, DOI 10.1016/B978-0-444-63521-1.00049-2; Hammond MD, 2014, J NEUROSCI, V34, P3901, DOI 10.1523/JNEUROSCI.4070-13.2014; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Jorm AF, 2000, PSYCHOL MED, V30, P981, DOI 10.1017/S0033291799002299; Kantak SS, 2012, NEUROREHAB NEURAL RE, V26, P282, DOI 10.1177/1545968311420845; Lee S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0544-4; Li N, 2016, NATURE, V532, P459, DOI 10.1038/nature17643; Li S, 2015, NAT NEUROSCI, V18, P1737, DOI 10.1038/nn.4146; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Lucotte G, 1997, BIOMED PHARMACOTHER, V51, P469, DOI 10.1016/S0753-3322(97)82328-1; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Maayan S, 2000, GENES IMMUN, V1, P358, DOI 10.1038/sj.gene.6363690; Martin-Blondel G, 2016, NAT REV NEUROL, V12, P95, DOI 10.1038/nrneurol.2015.248; Middei S, 2012, LEARN MEMORY, V19, P330, DOI 10.1101/lm.025817.112; Moore DL, 2011, DEV NEUROBIOL, V71, P1186, DOI 10.1002/dneu.20934; Mostany R, 2010, J NEUROSCI, V30, P14116, DOI 10.1523/JNEUROSCI.3908-10.2010; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Overman JJ, 2012, P NATL ACAD SCI USA, V109, pE2230, DOI 10.1073/pnas.1204386109; Page SJ, 2012, ARCH PHYS MED REHAB, V93, P2373, DOI 10.1016/j.apmr.2012.06.017; Paterno R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0762-x; Posel C, 2016, JOVE-J VIS EXP, DOI 10.3791/53658; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schaechter JD, 2004, PROG NEUROBIOL, V73, P61, DOI 10.1016/j.pneurobio.2004.04.001; Shin JE, 2012, NEURON, V74, P1015, DOI 10.1016/j.neuron.2012.04.028; Sullivan KJ, 2011, STROKE, V42, P427, DOI 10.1161/STROKEAHA.110.592766; Tarasenko M, 2016, SCHIZOPHR RES, V172, P123, DOI 10.1016/j.schres.2016.01.019; Tennant Alan, 2013, Handb Clin Neurol, V110, P77, DOI 10.1016/B978-0-444-52901-5.00007-1; Vilkki J, 2008, NEUROSURGERY, V63, P198, DOI 10.1227/01.NEU.0000320382.21577.8E; Wagner JM, 2008, PHYS THER, V88, P652, DOI 10.2522/ptj.20070255; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; Wang L, 2016, P NATL ACAD SCI USA, V113, P2750, DOI 10.1073/pnas.1514682113; Watkins TA, 2013, P NATL ACAD SCI USA, V110, P4039, DOI 10.1073/pnas.1211074110; Xing SH, 2016, BRAIN, V139, P227, DOI 10.1093/brain/awv323; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhou M, 2016, ELIFE, V5, DOI 10.7554/eLife.20985	57	87	91	8	80	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	2019	176	5					1143	+		10.1016/j.cell.2019.01.044			28	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	HM2AK	WOS:000459257500016	30794775	Bronze, Green Accepted	Y	N	2021-06-18	
J	Kurowski, BG; Hugentobler, J; Quatman-Yates, C; Taylor, J; Gubanich, PJ; Altaye, M; Wade, SL				Kurowski, Brad G.; Hugentobler, Jason; Quatman-Yates, Catherine; Taylor, Jennifer; Gubanich, Paul J.; Altaye, Mekibib; Wade, Shari L.			Aerobic Exercise for Adolescents With Prolonged Symptoms After Mild Traumatic Brain Injury: An Exploratory Randomized Clinical Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescents; aerobic training; concussion; exercise; intervention; mild traumatic brain injury	SPORT-RELATED CONCUSSION; VESTIBULAR REHABILITATION; CEREBRAL AUTOREGULATION; POSTCONCUSSION SYNDROME; SYNAPTIC PLASTICITY; VOLUNTARY EXERCISE; DENTATE GYRUS; UP-REGULATION; CHILDREN; RECOVERY	Objective: To describe the methodology and report primary outcomes of an exploratory randomized clinical trial (RCT) of aerobic training for management of prolonged symptoms after a mild traumatic brain injury (mTBI) in adolescents. Setting: Outpatient research setting. Participants: Thirty adolescents between the ages of 12 and 17 years who sustained a mTBI and had between 4 and 16 weeks of persistent symptoms. Design: Partially blinded, pilot RCT of subsymptom exacerbation aerobic training compared with a full-body stretching program. Main Measures: The primary outcome was postinjury symptom improvement assessed by the adolescent's self-reported Post-Concussion Symptom Inventory (PCSI) repeated for at least 6 weeks of the intervention. Parent-reported PCSI and adherence are also described. Results: Twenty-two percent of eligible participants enrolled in the trial. Repeated-measures analysis of variance via mixed-models analysis demonstrated a significant group x time interaction with self-reported PCSI ratings, indicating a greater rate of improvement in the subsymptom exacerbation aerobic training group than in the full-body stretching group (F = 4.11, P = .044). Adherence to the home exercise programs was lower in the subsymptom exacerbation aerobic training group compared with the full-body stretching group (mean [SD] times per week = 4.42 [1.95] vs 5.85 [1.37], P < .0001) over the duration of the study. Conclusion: Findings from this exploratory RCT suggest subsymptom exacerbation aerobic training is potentially beneficial for adolescents with persistent symptoms after an mTBI. These findings and other recent research support the potential benefit of active rehabilitation programs for adolescents with persistent symptoms after an mTBI. Larger replication studies are needed to verify findings and improve generalizability. Future work should focus on determining the optimal type, timing, and intensity of active rehabilitation programs and characteristics of individuals most likely to benefit.	[Kurowski, Brad G.; Taylor, Jennifer; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA; [Hugentobler, Jason; Quatman-Yates, Catherine; Gubanich, Paul J.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Altaye, Mekibib] Cincinnati Childrens Hosp Med Ctr, Div Epidemiol & Biostat, Cincinnati, OH 45229 USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org	Quatman-Yates, Catherine/AAK-4507-2021; Quatman-Yates, Catherine/U-9580-2019		Cincinnati Children's Research Foundation Trustees Grant program; Ohio Department of Public Safety; National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683-01A1]; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [8 UL1 TR000077]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER	Funding for this study was supported in part by the Cincinnati Children's Research Foundation Trustees Grant program, Ohio Department of Public Safety, National Institute for Child Health and Human Development K23HD074683-01A1, and grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or other supporting agencies.	Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Borg G., 1985, INTRO BORGS RPE SCAL; Brooks GA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00408; Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; Chin LMK, 2015, J HEAD TRAUMA REHAB, V30, P382, DOI 10.1097/HTR.0000000000000062; Churchill JD, 2002, NEUROBIOL AGING, V23, P941, DOI 10.1016/S0197-4580(02)00028-3; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Cotman CW, 2002, EXERC SPORT SCI REV, V30, P75, DOI 10.1097/00003677-200204000-00006; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Davenport MH, 2012, EXERC SPORT SCI REV, V40, P153, DOI 10.1097/JES.0b013e3182553430; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; EAKIN BL, 1992, J PEDIATR-US, V120, P90, DOI 10.1016/S0022-3476(05)80608-0; Epp JR, 2007, NEUROSCIENCE, V149, P273, DOI 10.1016/j.neuroscience.2007.07.046; Eston R G, 1986, Br J Sports Med, V20, P27; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fogelman D, 2012, PM&R, V4, P908, DOI 10.1016/j.pmrj.2012.09.028; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lemka Malgorzata, 2005, Neurol Neurochir Pol, V39, pS42; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Lipsey M.W., 2001, PRACTICAL META ANAL; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P273, DOI 10.1080/87565641.2015.1067706; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Moreno MA, 2012, ARCH PEDIAT ADOL MED, V166, P296, DOI [10.1001/archpediatrics.2012.8, 10.1001/archpediatrics.2012.79]; Moreno MA, 2011, ARCH PEDIAT ADOL MED, V165, P376, DOI 10.1001/archpediatrics.2011.31; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rooks CR, 2010, PROG NEUROBIOL, V92, P134, DOI 10.1016/j.pneurobio.2010.06.002; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2004, J NEUROSCI RES, V76, P356, DOI 10.1002/jnr.20077; Vidal PG, 2012, PEDIATR ANN, V41, pE186, DOI 10.3928/00904481-20120827-10; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wilson DB, PRACTICAL METAANALYS; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Ylinen J, 2010, J REHABIL MED, V42, P344, DOI 10.2340/16501977-0527	81	87	88	2	43	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2017	32	2					79	89		10.1097/HTR.0000000000000238			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EN3YU	WOS:000395944700008	27120294	Green Accepted			2021-06-18	
J	O'Connor, KL; Baker, MM; Dalton, SL; Dompier, TP; Broglio, SP; Kerr, ZY				O'Connor, Kathryn L.; Baker, Melissa M.; Dalton, Sara L.; Dompier, Thomas P.; Broglio, Steven P.; Kerr, Zachary Y.			Epidemiology of Sport-Related Concussions in High School Athletes: National Athletic Treatment, Injury and Outcomes Network (NATION), 2011-2012 Through 2013-2014	JOURNAL OF ATHLETIC TRAINING			English	Article						injury surveillance; traumatic brain injuries; return to play	COLLEGIATE FOOTBALL PLAYERS; STATES HIGH-SCHOOL; RECURRENT CONCUSSION; RISK-FACTORS; ASSOCIATION; RATES; YOUTH; PERCEPTIONS; MANAGEMENT; CHILDREN	Context: Sports participation is one of the leading causes of concussions among nearly 8 million US high school student-athletes. Objective: To describe the epidemiology of sport-related concussion (SRC) in 27 high school sports during the 20112012 through 2013-2014 academic years. Design: Descriptive epidemiology study. Setting: Aggregate injury and exposure data from 27 sports in 147 high schools in the National Athletic Treatment, Injury and Outcomes Network (NATION). Patients or Other Participants: Boy and girl high school athletes during the 2011-2012 through 2013-2014 academic years. Main Outcome Measure(s): Sport-related concussion counts, percentages, rates per 10 000 athlete-exposures (AEs), rate ratios (RRs), and injury proportion ratios (IPRs) were reported with 95% confidence intervals (CIs). Rate ratios and IPRs with 95% CIs not containing 1.0 were considered significant. Results: Overall, 2004 SRCs were reported among 27 high school sports, for a rate of 3.89 per 10 000 AEs. Football had the highest SRC rate (9.21/10 000 AEs), followed by boys' lacrosse 6.65/10 000 AEs) and girls' soccer (6.11/10 000 AEs). The SRC rate was higher in competition than in practice (RR = 3.30; 95% CI = 3.02, 3.60). Among sex-comparable sports, the SRC rate was higher in girls than in boys (RR = 1.56; 95% CI = 1.34, 1.81); however, the proportion of SRCs due to player-to-player contact was higher in boys than in girls (IPR = 1.48; 95% CI = 1.27, 1.73). Common symptoms reported among all athletes with SRCs were headache (94.7%), dizziness (74.8%), and difficulty concentrating (61.0%). Only 0.8% of players with SRCs returned to play within 24 hours. The majority of athletes with SRCs (65.8%) returned to play between 7 and 28 days. More players had symptoms resolve after 7 days (48.8%) than less than a week (40.7%). Conclusions: Our findings provide updated high school SRC incidence estimates and further evidence of sex differences in reported SRCs. Few athletes with SRCs returned to play within 24 hours or a week. Most injured players returned after 7 days, despite a smaller proportion having symptoms resolve within a week.	[O'Connor, Kathryn L.; Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [Baker, Melissa M.; Dalton, Sara L.; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN USA; [Kerr, Zachary Y.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA	Kerr, ZY (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu		Van Pelt, Kathryn/0000-0002-5494-2357	National Athletic Trainers' Association Research and Education Foundation; Central Indiana Corporate Partnership Foundation; BioCrossroads	This study would not have been possible without the assistance of the many high school ATs who participated in the program. This project was funded by the National Athletic Trainers' Association Research and Education Foundation and the Central Indiana Corporate Partnership Foundation in cooperation with BioCrossroads. The content of this report is solely the responsibility of the authors and does not necessarily reflect the views of the National Athletic Trainers' Association Research and Education Foundation, Central Indiana Corporate Partnership Foundation, or BioCrossroads.	[Anonymous], 2013, RUL CHANG SAF GAM; Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Currie DW, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2447; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Institute of Medicine, 2013, SPORTS REL CONC YOUT, P1; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3; King H, 2015, J PHYS ACT HEALTH, V12, P1162, DOI 10.1123/jpah.2014-0356; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Kroshus E, 2015, HEALTH EDUC RES, V30, P1004, DOI 10.1093/her/cyv047; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McGuine TA, 2014, AM J SPORT MED, V42, P2470, DOI 10.1177/0363546514541926; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Membership statistics, 2015, MEMB STAT; Miyashita TL, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114554549; National Collegiate Athletic Association, NCAA FOOTB REC MAD R; National Federation of State High School Associations, 2015, NFHS HDB 2015 16; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Rowhani-Rahbar A, 2016, J NEUROTRAUM, V33, P784, DOI 10.1089/neu.2015.4100; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shields BJ, 2009, J ATHL TRAINING, V44, P586, DOI 10.4085/1062-6050-44.6.586; Soshnick S, 2014, FOOTBALL PARTICIPATI; Strauss B., 2015, NEW YORK TIMES; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	57	87	87	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2017	52	3					175	185		10.4085/1062-6050-52.1.15			11	Sport Sciences	Sport Sciences	ES0NE	WOS:000399222500004	28387555	Green Published, Bronze			2021-06-18	
J	Mokalled, MH; Patra, C; Dickson, AL; Endo, T; Stainier, DYR; Poss, KD				Mokalled, Mayssa H.; Patra, Chinmoy; Dickson, Amy L.; Endo, Toyokazu; Stainier, Didier Y. R.; Poss, Kenneth D.			Injury-induced ctgfa directs glial bridging and spinal cord regeneration in zebrafish	SCIENCE			English	Article							TISSUE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; ADULT ZEBRAFISH; ASTROCYTES; CELLS; SCAR; RAT	Unlike mammals, zebrafish efficiently regenerate functional nervous system tissue after major spinal cord injury. Whereas glial scarring presents a roadblock for mammalian spinal cord repair, glial cells in zebrafish form a bridge across severed spinal cord tissue and facilitate regeneration. We performed a genome-wide profiling screen for secreted factors that are up-regulated during zebrafish spinal cord regeneration. We found that connective tissue growth factor a (ctgfa) is induced in and around glial cells that participate in initial bridging events. Mutations in ctgfa disrupted spinal cord repair, and transgenic ctgfa overexpression or local delivery of human CTGF recombinant protein accelerated bridging and functional regeneration. Our study reveals that CTGF is necessary and sufficient to stimulate glial bridging and natural spinal cord regeneration.	[Mokalled, Mayssa H.; Dickson, Amy L.; Endo, Toyokazu; Poss, Kenneth D.] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; [Patra, Chinmoy; Stainier, Didier Y. R.] Max Planck Inst Heart & Lung Res, Dept Dev Genet, D-61231 Bad Nauheim, Germany; [Patra, Chinmoy] Agharkar Res Inst, Pune, Maharashtra, India	Poss, KD (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	kenneth.poss@duke.edu		Stainier, Didier/0000-0002-0382-0026	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32HL007101, R01 HL081674]; Max Planck SocietyMax Planck Society; Duke University School of Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007101, R01HL081674] Funding Source: NIH RePORTER	We thank A. Johnson, C. Eroglu, and M. Bagnat for discussions; N. Lee and K. Jones for technical and bioinformatics help; and the Duke University School of Medicine Zebrafish Shared Resource for animal care. Supported by NIH training grant T32HL007101 (M.H.M.), NIH grant R01 HL081674 (K.D.P.), the Max Planck Society (C.P. and D.Y.R.S.), and Duke University School of Medicine (K.D.P.). RNA sequencing data are archived at GEO (accession number GSE77025). The supplementary materials contain additional data. M.H.M. and K.D.P. are inventors on patent applications (62/159,413 and 62/398,781) submitted by Duke University that cover the use of Ctgf for spinal cord regeneration.	Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Becker T, 1997, J COMP NEUROL, V377, P577, DOI 10.1002/(SICI)1096-9861(19970127)377:4<577::AID-CNE8>3.0.CO;2-#; Conrad S, 2005, J NEUROSURG-SPINE, V2, P319, DOI 10.3171/spi.2005.2.3.0319; Goldshmit Y, 2012, J NEUROSCI, V32, P7477, DOI 10.1523/JNEUROSCI.0758-12.2012; Grotendorst GR, 2005, FASEB J, V19, P729, DOI 10.1096/fj.04-3217com; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hui SP, 2010, DEV DYNAM, V239, P2962, DOI 10.1002/dvdy.22438; Lin CY, 2012, J NEUROTRAUM, V29, P589, DOI 10.1089/neu.2011.2059; Liu YQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-141; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Raposo C, 2014, GLIA, V62, P1895, DOI 10.1002/glia.22676; Reimer MM, 2008, J NEUROSCI, V28, P8510, DOI 10.1523/JNEUROSCI.1189-08.2008; Robinson PM, 2012, INVEST OPHTH VIS SCI, V53, P8093, DOI 10.1167/iovs.12-10419; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Wang JH, 2011, DEVELOPMENT, V138, P3421, DOI 10.1242/dev.068601; Waselle L, 2009, MOL CELL NEUROSCI, V42, P315, DOI 10.1016/j.mcn.2009.08.004; White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268	19	87	90	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2016	354	6312					630	634		10.1126/science.aaf2679			5	Multidisciplinary Sciences	Science & Technology - Other Topics	EA8FD	WOS:000386869800052	27811277	Green Accepted, Bronze			2021-06-18	
J	Gracies, JM; Brashear, A; Jech, R; McAllister, P; Banach, M; Valkovic, P; Walker, H; Marciniak, C; Deltombe, T; Skoromets, A; Khatkova, S; Edgley, S; Gul, F; Catus, F; De Fer, BB; Vilain, C; Picaut, P				Gracies, Jean-Michel; Brashear, Allison; Jech, Robert; McAllister, Peter; Banach, Marta; Valkovic, Peter; Walker, Heather; Marciniak, Christina; Deltombe, Thierry; Skoromets, Alexander; Khatkova, Svetlana; Edgley, Steven; Gul, Fatma; Catus, France; De Fer, Beatrice Bois; Vilain, Claire; Picaut, Philippe		Int AbobotulinumtoxinA Adult Upper	Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial	LANCET NEUROLOGY			English	Article							TOXIN TYPE-A; BOTULINUM-TOXIN; REDUCING SPASTICITY; UPPER EXTREMITY; ASHWORTH SCALE; ARM SPASTICITY; TARDIEU SCALE; PLACEBO; INJECTION; NEUROTOXIN	Background Resistance from antagonistic muscle groups might be a crucial factor reducing function in chronic hemiparesis. The resistance due to spastic co-contraction might be reduced by botulinum toxin injections. We assessed the effects of abobotulinumtoxinA injection in the upper limb muscles on muscle tone, spasticity, active movement, and function. Methods In this randomised, placebo-controlled, double-blind study, we enrolled adults (aged 18-80 years) at least 6 months after stroke or brain trauma from 34 neurology or rehabilitation clinics in Europe and the USA. Eligible participants were randomly allocated in a 1: 1: 1 ratio with a computer-generated list to receive a single injection session of abobotulinumtoxinA 500 U or 1000 U or placebo into the most hypertonic muscle group among the elbow, wrist, or finger flexors (primary target muscle group [PTMG]), and into at least two additional muscle groups from the elbow, wrist, or finger flexors or shoulder extensors. Patients and investigators were masked to treatment allocation. The primary endpoint was the change in muscle tone (Modified Ashworth Scale [MAS]) in the PTMG from baseline to 4 weeks. Secondary endpoints were Physician Global Assessment (PGA) at week 4 and change from baseline to 4 weeks in the perceived function (Disability Assessment Scale [DAS]) in the principal target of treatment, selected by the patient together with physician from four functional domains (dressing, hygiene, limb position, and pain). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01313299. Findings 243 patients were randomly allocated to placebo (n=81), abobotulinumtoxinA 500 U (n=81), or abobotulinumtoxinA 1000 U (n=81). Mean change in MAS score from baseline at week 4 in the PTMG was -0.3 (SD 0.6) in the placebo group (n=79), -1.2 (1.0) in the abobotulinumtoxinA 500 U group (n=80; difference -0.9, 95% CI -1.2 to -0.6; p<0.0001 vs placebo), and -1.4 (1.1) in the abobotulinumtoxinA 1000 U group (n=79; -1.1, -1.4 to -0.8; p<0.0001 vs placebo). Mean PGA score at week 4 was 0.6 (SD 1.0) in the placebo group (n=78), 1.4 (1.1) in the abobotulinumtoxinA 500 U group (n=80; p=0.0003 vs placebo), and 1.8 (1.1) in the abobotulinumtoxinA 1000 U group (n=78; p<0.0001 vs placebo). Mean change from baseline at week 4 in DAS score for the principal target of treatment was -0.5 (0.7) in the placebo group (n=79), -0.7 (0.8) in the abobotulinumtoxinA 500 U group (n=80; p=0.2560 vs placebo), and -0.7 (0.7) in the abobotulinumtoxinA 1000 U group (n=78; p=0.0772 vs placebo). Three serious adverse events occurred in each group and none were treatment related; two resulted in death (from pulmonary oedema in the placebo group and a pre-existing unspecified cardiovascular disorder in the abobotulinumtoxinA 500 U group). Adverse events that were thought to be treatment related occurred in two (2%), six (7%), and seven (9%) patients in the placebo, abobotulinumtoxinA 500 U, and abobotulinumtoxinA 1000 U groups, respectively. The most common treatment-related adverse event was mild muscle weakness. All adverse events were mild or moderate. Interpretation AbobotulinumtoxinA at doses of 500 U or 1000 U injected into upper limb muscles provided tone reduction and clinical benefit in hemiparesis. Future research into the treatment of spastic paresis with botulinum toxin should use active movement and function as primary outcome measures.	[Gracies, Jean-Michel] Univ Paris Est Creteil, Hosp Albert Chenevier, Serv Reeduc Neurolocomotrice, EA 7377 BIOTN, F-94010 Creteil, France; [Brashear, Allison] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; [Jech, Robert] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Jech, Robert] Gen Fac Hosp, Prague, Czech Republic; [McAllister, Peter] New England Inst Neurol & Headache, Stamford, CT USA; [Banach, Marta] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland; [Valkovic, Peter] Comenius Univ, Dept Neurol 2, Bratislava, Slovakia; [Valkovic, Peter] Univ Hosp, Bratislava, Slovakia; [Walker, Heather] Univ N Carolina, Chapel Hill, NC USA; [Marciniak, Christina] Northwestern Univ, Chicago, IL 60611 USA; [Marciniak, Christina] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Deltombe, Thierry] Univ Cathol Louvain Namur, Ctr Hosp Univ Dinant Godinne, Serv Med Phys & Readaptat, Yvoir, Belgium; [Skoromets, Alexander] St Petersburg State Med Univ IP Pavlov, State Budgetary Educ Inst Higher Profess Educ, St Petersburg, Russia; [Khatkova, Svetlana] Fed State Hosp Treatments, Dept Neurol, Moscow, Russia; [Khatkova, Svetlana] Minist Hlth & Social Dev Russian Federat, Rehabil Ctr, Moscow, Russia; [Edgley, Steven] Univ Utah, Sch Med, Div Phys Med & Rehabil, Salt Lake City, UT USA; [Gul, Fatma] Univ Texas SW Med Ctr Dallas, Dallas, TX 75230 USA; [Catus, France] Assesoria Croissance, Santiago, Chile; [De Fer, Beatrice Bois; Vilain, Claire; Picaut, Philippe] Ipsen Innovat, Les Ulis, France	Gracies, JM (corresponding author), Univ Paris Est Creteil, Hosp Albert Chenevier, Serv Reeduc Neurolocomotrice, EA 7377 BIOTN, 51 Av Marechal Lattre Tassigny, F-94010 Creteil, France.	jean-michel.gracies@aphp.fr	Boyer, Francois Constant/P-4544-2016	Boyer, Francois Constant/0000-0003-1035-9108; Marciniak, Christina/0000-0003-3300-0050; remy-neris, olivier/0000-0001-6862-8433; Lejeune, Thierry/0000-0001-5741-7753; Jech, Robert/0000-0002-9732-8947	IpsenIpsen	The manuscript was written with editorial assistance from Martin Gilmour (ESP Bioscience, Crowthorne, UK), funded by Ipsen. The clinical research organisation responsible for the study was INC Research. We thank all the patients who participated in this study and their families; Pascale Cavillon (Ipsen) for study coordination; and the following research associates from study centres: G Stoquart and R Rak (both in Belgium), Y Angerova (Czech Republic), N Bayle and C M Loche (both in France), T Ialongo (Italy), A Botsina and A Korenko (both in Russia), J Benetin (Slovakia), M Pautler, C Dolezal, C McAllister, D Brown, G Kim, M D C Lichtenberger, A A Nmashie, R L Harvey, and Y Salem (all in the USA).	Alibiglou L, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-18; Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; Bhakta BB, 2000, J NEUROL NEUROSUR PS, V69, P217, DOI 10.1136/jnnp.69.2.217; Bohannon R. W., 1987, PHYS THER, V67, P206; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Brashear A, 2002, ARCH PHYS MED REHAB, V83, P1349, DOI 10.1053/apmr.2002.35474; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; Demetrios M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009689.pub2; Diong J, 2013, AM J PHYS MED REHAB, V92, P565, DOI 10.1097/PHM.0b013e318274605a; Francis HP, 2004, J NEUROL NEUROSUR PS, V75, P1547, DOI 10.1136/jnnp.2003.025551; Gracies JM, 2010, EUR J PHYS REHAB MED, V46, P411; Gracies JM, 2014, ARCH PHYS MED REHAB, V95, P1303, DOI 10.1016/j.apmr.2014.03.016; Gracies JM, 2010, ARCH PHYS MED REHAB, V91, P421, DOI 10.1016/j.apmr.2009.11.017; Gracies JM, 2005, MUSCLE NERVE, V31, P535, DOI 10.1002/mus.20284; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; Jost WH, 2014, J NEUROL SCI, V337, P86, DOI 10.1016/j.jns.2013.11.022; Kaji R, 2010, J NEUROL, V257, P1330, DOI 10.1007/s00415-010-5526-3; Kanovsky P, 2009, CLIN NEUROPHARMACOL, V32, P259, DOI 10.1097/WNF.0b013e3181b13308; Kinnear BZ, 2014, PHYS THER, V94, P1569, DOI 10.2522/ptj.20130408; Kinnear BZ, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-29; Lance JW., 1980, SPASTICITY DISORDERE, P185; Leonard CT, 2006, J REHABIL MED, V38, P243, DOI 10.1080/16501970600609808; Patrick E, 2006, CLIN REHABIL, V20, P173, DOI 10.1191/0269215506cr922oa; Picelli A, 2014, CLIN REHABIL, V28, P232, DOI 10.1177/0269215513497735; Rosales RL, 2012, NEUROREHAB NEURAL RE, V26, P812, DOI 10.1177/1545968311430824; Sheean G, 2010, EUR J NEUROL, V17, P74, DOI 10.1111/j.1468-1331.2010.03129.x; Simpson DM, 2008, NEUROLOGY, V70, P1691, DOI 10.1212/01.wnl.0000311391.00944.c4; Simpson DM, 2009, J NEUROL NEUROSUR PS, V80, P380, DOI 10.1136/jnnp.2008.159657; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Smith SJ, 2000, CLIN REHABIL, V14, P5, DOI 10.1191/026921500666642221; Turner-Stokes L, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002771; Ward AB, 2014, J REHABIL MED, V46, P504, DOI 10.2340/16501977-1817; Wissel J, 2009, J REHABIL MED, V41, P13, DOI 10.2340/16501977-0303; Yelnik AP, 2007, J NEUROL NEUROSUR PS, V78, P845, DOI 10.1136/jnnp.2006.103341	34	87	100	1	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2015	14	10					992	1001		10.1016/S1474-4422(15)00216-1			10	Clinical Neurology	Neurosciences & Neurology	CR2VI	WOS:000361188400010	26318836				2021-06-18	
J	Comstock, RD; Currie, DW; Pierpoint, LA; Grubenhoff, JA; Fields, SK				Comstock, R. Dawn; Currie, Dustin W.; Pierpoint, Lauren A.; Grubenhoff, Joseph A.; Fields, Sarah K.			An Evidence-Based Discussion of Heading the Ball and Concussions in High School Soccer	JAMA PEDIATRICS			English	Article							NEUROPSYCHOLOGICAL CONSEQUENCE; NEUROCOGNITIVE PERFORMANCE; POSTURAL CONTROL; SEX-DIFFERENCES; INJURIES; FEMALE; BRAIN; ACCELERATION; EPIDEMIOLOGY; IMPAIRMENT	IMPORTANCE Soccer, originally introduced as a safer sport for children and adolescents, has seen a rapid increase in popularity in the United States over the past 3 decades. Recently, concerns have been raised regarding the safety of soccer ball heading (when an athlete attempts to play the ball in the air with his or her head) given the rise in concussion rates, with some calling for a ban on heading among soccer players younger than 14 years. OBJECTIVES To evaluate trends over time in boys' and girls' soccer concussions, to identify injury mechanisms commonly leading to concussions, to delineate soccer-specific activities during which most concussions occur, to detail heading-related soccer concussion mechanisms, and to compare concussion symptom patterns by injury mechanism. DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of longitudinal surveillance data collected from 2005-2006 through 2013-2014 in a large, nationally representative sample of US high schools. Participants were boys and girls who were high school soccer players. EXPOSURES Concussions sustained during high school-sanctioned soccer games and practices. MAIN OUTCOMES AND MEASURES Mechanism and sport-specific activity of concussion. RESULTS Overall, 627 concussions were sustained during 1 393 753 athlete exposures (AEs) among girls (4.50 concussions per 10 000 AEs), and 442 concussions were sustained during 1 592 238 AEs among boys (2.78 concussions per 10 000 AEs). For boys (68.8%) and girls (51.3%), contact with another player was the most common concussion mechanism. Heading was the most common soccer-specific activity, responsible for 30.6% of boys' concussions and 25.3% of girls' concussions. Contact with another player was the most common mechanism of injury in heading-related concussions among boys (78.1%) and girls (61.9%). There were few differences in concussion symptom patterns by injury mechanism. CONCLUSIONS AND RELEVANCE Although heading is the most common activity associated with concussions, the most frequent mechanism was athlete-athlete contact. Such information is needed to drive evidence-based, targeted prevention efforts to effectively reduce soccer-related concussions. Although banning heading from youth soccer would likely prevent some concussions, reducing athlete-athlete contact across all phases of play would likely be a more effective way to prevent concussions as well as other injuries.	[Comstock, R. Dawn; Currie, Dustin W.; Pierpoint, Lauren A.] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA; [Comstock, R. Dawn; Grubenhoff, Joseph A.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Fields, Sarah K.] Univ Colorado, Dept Commun, Denver, CO 80202 USA	Comstock, RD (corresponding author), Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Mail Stop B119,13001E 17th Pl, Aurora, CO 80045 USA.	dawn.comstock@ucdenver.edu	Grubenhoff, Joseph A/H-9994-2019	Grubenhoff, Joseph A/0000-0001-5072-4064	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; National Operating Committee on Standards for Athletic Equipment; EyeBlack; DonJoy Orthotics; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172, R49CE000674] Funding Source: NIH RePORTER	This study was funded in part by grants R49/CE000674-01 and R49/CE001172-01 from the Centers for Disease Control and Prevention. Research funding was also provided by the National Federation of State High School Associations, National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack.	Adams AL, 2006, ACAD EMERG MED, V13, P571, DOI [10.1111/j.1553-2712.2006.tb01010.x, 10.1197/j.aem.2005.12.015]; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; [Anonymous], 2013 14 HIGH SCH ATH; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Brown S., 2007, Soccer and Society, V8, P366, DOI 10.1080/14660970701224640; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Current comment from the American College of Sports Medicine, 1993, MED SCI SPORTS EXERC, V25, P1; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Fields SK, 2011, FEMALE GLADIATORS GE; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gutierrez GM, 2014, PEDIATR EXERC SCI, V26, P33, DOI 10.1123/pes.2013-0102; Halloran JD, 2013, RISE RISE US WOMENS; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Sports Legacy Institute, SAF SOCC IN; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Teymouri M, 2012, ARCH TRAUMA RES, V1, P44, DOI [10.5812/atr.5307, 10.5812/atr.5399]; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; U.S. Census Bureau, 2014, CENS REG DIV US; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047	40	87	87	3	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	SEP	2015	169	9					830	837		10.1001/jamapediatrics.2015.1062			8	Pediatrics	Pediatrics	CR0CT	WOS:000360986500014	26168306	Bronze			2021-06-18	
J	Hernandez, F; Wu, LC; Yip, MC; Laksari, K; Hoffman, AR; Lopez, JR; Grant, GA; Kleiven, S; Camarillo, DB				Hernandez, Fidel; Wu, Lyndia C.; Yip, Michael C.; Laksari, Kaveh; Hoffman, Andrew R.; Lopez, Jaime R.; Grant, Gerald A.; Kleiven, Svein; Camarillo, David B.			Six Degree-of-Freedom Measurements of Human Mild Traumatic Brain Injury	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Mild traumatic brain injury (mTBI); Instrumented mouthguard; Six degree-of-freedom (6DOF) kinematics; Finite element model; Brain strain	DIFFUSE AXONAL INJURY; HEAD IMPACT; CEREBRAL CONCUSSION; FOOTBALL; ACCELERATION; SYSTEM; KINEMATICS; CLASSIFICATION; VALIDATION; PREDICTORS	This preliminary study investigated whether direct measurement of head rotation improves prediction of mild traumatic brain injury (mTBI). Although many studies have implicated rotation as a primary cause of mTBI, regulatory safety standards use 3 degree-of-freedom (3DOF) translation-only kinematic criteria to predict injury. Direct 6DOF measurements of human head rotation (3DOF) and translation (3DOF) have not been previously available to examine whether additional DOFs improve injury prediction. We measured head impacts in American football, boxing, and mixed martial arts using 6DOF instrumented mouthguards, and predicted clinician-diagnosed injury using 12 existing kinematic criteria and 6 existing brain finite element (FE) criteria. Among 513 measured impacts were the first two 6DOF measurements of clinically diagnosed mTBI. For this dataset, 6DOF criteria were the most predictive of injury, more than 3DOF translation-only and 3DOF rotation-only criteria. Peak principal strain in the corpus callosum, a 6DOF FE criteria, was the strongest predictor, followed by two criteria that included rotation measurements, peak rotational acceleration magnitude and Head Impact Power (HIP). These results suggest head rotation measurements may improve injury prediction. However, more 6DOF data is needed to confirm this evaluation of existing injury criteria, and to develop new criteria that considers directional sensitivity to injury.	[Hernandez, Fidel; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Wu, Lyndia C.; Yip, Michael C.; Laksari, Kaveh; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Hoffman, Andrew R.] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Lopez, Jaime R.] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kleiven, Svein] KTH Royal Inst Technol, Dept Neuron Engn, Stockholm, Sweden	Camarillo, DB (corresponding author), Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA.	dcamarillo@stanford.edu	Wu, Lyndia/AAQ-1106-2020	Wu, Lyndia/0000-0002-8236-032X; Hernandez, Fidel/0000-0002-6078-0518	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; David and Lucile Packard FoundationThe David & Lucile Packard Foundation [38454]; Child Health Research Institute of Stanford University; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR000093]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001085, UL1TR000093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB017611] Funding Source: NIH RePORTER	We thank the Stanford Department of Athletics (Palo Alto, CA) for enabling this research, notably Scott Anderson, Director of Athletic Training, and Mike Gleeson, Video Director. We thank Kevin Bui and Bradley Hammoor for work in processing the event video, Joseph Schooler for coordinating human subject protocols, and Maria Malone for device manufacturing and deployment. We thank X2 Biosystems (Seattle, WA) for early device prototypes and continual support. We thank Roy Englebrecht Promotions (Newport Beach, CA) and B Street Boxing (San Mateo, CA) for help with subject recruitment. The study was supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, David and Lucile Packard Foundation 38454, Child Health Research Institute of Stanford University, and NIH UL1 TR000093 for biostatistics consultation.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Bartsch A., 2013, ENV MONITORING, V1, P2; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bianchi A, 2015, IEEE T BIO-MED ENG, V62, P145, DOI 10.1109/TBME.2014.2342653; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Caccese V, 2016, EXP TECHNIQUES, V40, P413, DOI [10.1111/ext.12079, 10.1007/s40799-016-0046-4]; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Federal Motor Vehicle Safety Standards (FMVSS), 2014, 202A FMVSS 571, P531; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Gazzaniga M.S., 1998, COGNITIVE NEUROSCIEN; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1992, J EMERGENCY MED, V11, P5; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Higgins M, 2007, J ATHL TRAINING, V42, P5; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; Hosmer DW., 2013, APPL LOGISTIC REGRES, V3rd ed.; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kang YS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4005427; Kimpara H., 2011, INT J AUTOMOT ENG, V2, P13; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King A.I., 2003, IRCOBI C LISB PORT, P1; Kleinberger M., 1998, HEAD INJURY CRITERIA, V4405, P12; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; Moon D W, 1971, Med Sci Sports, V3, P44; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2012, ND00111M12 NOCSAE; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; NEWMAN JA, 2000, STAPP CAR CRASH J, V44, P362; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pincemaille Y, 1989, P 33 STAPP CAR CRASH, P177; Prasad P, 2008, STAPP CAR C, V52, P187; Prichep LS, 2012, IEEE T NEUR SYS REH, V20, P806, DOI 10.1109/TNSRE.2012.2206609; Qian H., 2008, P 10 IEEE C CONTR AU, P17; Reid S E, 1974, J Sports Med, V2, P86; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; TAKHOUNTS E, 2013, STAPP CAR CRASH J, V57, P1; Takhounts EG, 2008, STAPP CAR C, V52, P1; Ungerleider L., 1982, ANAL VISUAL BEHAV, P549; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Ward C., 1980, STAPP CAR CRASH J, V801304, P163; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	80	87	87	1	35	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	AUG	2015	43	8					1918	1934		10.1007/s10439-014-1212-4			17	Engineering, Biomedical	Engineering	CN2KM	WOS:000358249800018	25533767	Green Accepted			2021-06-18	
J	Davis, JS; Satahoo, SS; Butler, FK; Dermer, H; Naranjo, D; Julien, K; Van Haren, RM; Namias, N; Blackbourne, LH; Schulman, CI				Davis, James S.; Satahoo, Shevonne S.; Butler, Frank K.; Dermer, Harrison; Naranjo, Daniel; Julien, Katherina; Van Haren, Robert M.; Namias, Nicholas; Blackbourne, Lorne H.; Schulman, Carl I.			An analysis of prehospital deaths: Who can we save?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Death; wounds and injuries; emergency medical services; trauma	OPERATION-IRAQI-FREEDOM; COMBAT CASUALTY CARE; MAJOR LIMB TRAUMA; TOURNIQUET USE; PREVENTABLE DEATH; RURAL STATE; MORTALITY; BATTLEFIELD; OUTCOMES; INJURY	BACKGROUND: Since their inception in the late 1970s, trauma networks have saved thousands of lives in the prehospital setting. However, few recent works have been done to evaluate the patients who die in the field. Understanding the epidemiology of these deaths is crucial for trauma system performance evaluation and improvement. We hypothesized that specific patterns of injury could be identified and targeted for intervention. METHODS: Medical examiner reports in a large, urban county were reviewed including all trauma deaths during 2011 that were not transported to a hospital (i.e., died at the scene) or dead on arrival. Age, sex, date of death, mechanism, and list of injuries were recorded. An expert panel reviewed each case to determine the primary cause of death, and if the patient's death was caused by potentially survivable injuries or nonsurvivable injuries. RESULTS: A total of 512 patients were included. Patients were 80% male, died mostly of blunt (53%) and penetrating (46%) causes, and included 21% documented suicides. The leading cause of death was neurotrauma (36%), followed by hemorrhage (34%), asphyxia (15%), and combined neurotrauma/hemorrhage (15%). The anatomic regions most frequently injured were the brain (59%), chest (54%), and abdomen (35%). Finally, 29% of the patient deaths were classified as a result of potentially survivable injuries given current treatment options, mostly from hemorrhage and chest injuries. CONCLUSION: More than one of every five trauma deaths in our study population had potentially survivable injuries. In this group, chest injuries and death via hemorrhage were predominant and suggest targets for future research and implementation of novel prehospital interventions. In addition, efforts targeting suicide prevention remain of great importance. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Davis, James S.; Satahoo, Shevonne S.; Naranjo, Daniel; Julien, Katherina; Van Haren, Robert M.; Namias, Nicholas; Schulman, Carl I.] Univ Miami, Miller Sch Med, DeWitt Daughtry Dept Surg, Jackson Mem Hosp, Miami, FL 33101 USA; [Butler, Frank K.] Joint Trauma Syst San Antonio, Comm Tact Combat Casualty Care & Prehosp Trauma C, San Antonio, TX USA; [Blackbourne, Lorne H.] Brooke Army Med Ctr, Dept Surg, San Antonio, TX USA; [Butler, Frank K.] Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Bethesda, MD 20814 USA	Schulman, CI (corresponding author), Univ Miami, Miller Sch Med, DeWitt Daughtry Family Dept Surg, POB 016960 D-40, Miami, FL 33101 USA.	cschulman@med.miami.edu	Van Haren, Robert/T-8218-2019; Schulman, Carl/AAE-7448-2021	Namias, Nicholas/0000-0001-7021-2250; Schulman, Carl/0000-0001-8899-4350			Andersen RC, 2012, J AM ACAD ORTHOP SUR, V20, pS94, DOI 10.5435/JAAOS-20-08-S94; [Anonymous], 1976, Bull Am Coll Surg, V61, P15; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Beekley AC, 2008, J TRAUMA, V64, pS28, DOI 10.1097/TA.0b013e318160937e; Berbiglia L, 2013, AM SURGEON, V79, P764; Blackbourne LH, 1831, US ARMY MED DEP J, V2011, P6; Blackbourne Lorne H, 2008, US Army Med Dep J, P56; Blackbourne LH, 2010, J TRAUMA, V69, pS1, DOI 10.1097/TA.0b013e3181e4206f; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; Butler FK, 2012, J TRAUMA ACUTE CARE, V73, pS395, DOI 10.1097/TA.0b013e3182754850; Committee on Trauma and Committee on Shock, ACC DEATH DIS NEGL D; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Esposito TJ, 2003, J TRAUMA, V54, P663, DOI 10.1097/01.TA.0000058124.78958.6B; ESPOSITO TJ, 1995, J TRAUMA, V39, P955, DOI 10.1097/00005373-199511000-00022; Gerhardt Robert T, 2011, US Army Med Dep J, P82; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kotwal Russ S, 2013, J Spec Oper Med, V13, P77; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Kragh JF, 2008, J TRAUMA, V64, pS38, DOI 10.1097/TA.0b013e31816086b1; Kragh JF, 2009, ANN SURG, V249, P1, DOI 10.1097/SLA.0b013e31818842ba; Lee C, 2007, EMERG MED J, V24, P584, DOI 10.1136/emj.2007.046359; Maio RF, 1996, J TRAUMA, V41, P83, DOI 10.1097/00005373-199607000-00013; MAUGHON JS, 1970, MIL MED, V135, P8; Morrison JJ, 2013, ANN SURG, V257, P330, DOI 10.1097/SLA.0b013e31827eefcf; Niven Martin, 2010, Emerg Nurse, V18, P32; SALE JP, 1984, ANAESTHESIA, V39, P795, DOI 10.1111/j.1365-2044.1984.tb06527.x; Sanddal TL, 2011, J TRAUMA, V70, P970, DOI 10.1097/TA.0b013e3181fec9ba; Savage E, 2011, CAN J SURG, V54, pS14, DOI 10.1503/cjs.025011; Tarpey M, 2005, US ARMY MED DEP J, P38; Travis D, 2009, MIAMI DADE FIRE RESC; Trunkey DD., 1974, J AM COLL EMERG PHYS; Van Haren RM, 2012, J TRAUMA ACUTE CARE, V73, P1512, DOI 10.1097/TA.0b013e318270d40f	33	87	89	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2014	77	2					213	218		10.1097/TA.0000000000000292			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AN0EJ	WOS:000340255700006	25058244				2021-06-18	
J	Easter, JS; Bakes, K; Dhaliwal, J; Miller, M; Caruso, E; Haukoos, JS				Easter, Joshua S.; Bakes, Katherine; Dhaliwal, Jasmeet; Miller, Michael; Caruso, Emily; Haukoos, Jason S.			Comparison of PECARN, CATCH, and CHALICE Rules for Children With Minor Head Injury: A Prospective Cohort Study	ANNALS OF EMERGENCY MEDICINE			English	Article							CLINICAL DECISION RULES; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; 3 COUNTRIES; EMERGENCY; PREDICTION; MANAGEMENT; ASTHMA; RISK	Study objective: We evaluate the diagnostic accuracy of clinical decision rules and physician judgment for identifying clinically important traumatic brain injuries in children with minor head injuries presenting to the emergency department. Methods: We prospectively enrolled children younger than 18 years and with minor head injury (Glasgow Coma Scale score 13 to 15), presenting within 24 hours of their injuries. We assessed the ability of 3 clinical decision rules (Canadian Assessment of Tomography for Childhood Head Injury [CATCH], Children's Head Injury Algorithm for the Prediction of Important Clinical Events [CHALICE], and Pediatric Emergency Care Applied Research Network [PECARN]) and 2 measures of physician judgment (estimated of <1% risk of traumatic brain injury and actual computed tomography ordering practice) to predict clinically important traumatic brain injury, as defined by death from traumatic brain injury, need for neurosurgery, intubation greater than 24 hours for traumatic brain injury, or hospital admission greater than 2 nights for traumatic brain injury. Results: Among the 1,009 children, 21 (2%; 95% confidence interval [CI] 1% to 3%) had clinically important traumatic brain injuries. Only physician practice and PECARN identified all clinically important traumatic brain injuries, with ranked sensitivities as follows: physician practice and PECARN each 100% (95% CI 84% to 100%), physician estimates 95% (95% CI 76% to 100%), CATCH 91% (95% CI 70% to 99%), and CHALICE 84% (95% CI 60% to 97%). Ranked specificities were as follows: CHALICE 85% (95% CI 82% to 87%), physician estimates 68% (95% CI 65% to 71%), PECARN 62% (95% CI 59% to 66%), physician practice 50% (95% CI 47% to 53%), and CATCH 44% (95% CI 41% to 47%). Conclusion: Of the 5 modalities studied, only physician practice and PECARN identified all clinically important traumatic brain injuries, with PECARN being slightly more specific. CHALICE was incompletely sensitive but the most specific of all rules. CATCH was incompletely sensitive and had the poorest specificity of all modalities.	[Easter, Joshua S.; Bakes, Katherine; Caruso, Emily; Haukoos, Jason S.] Denver Hlth, Dept Emergency Med, Denver Emergency Ctr Children, Denver, CO 80204 USA; [Easter, Joshua S.; Bakes, Katherine; Caruso, Emily; Haukoos, Jason S.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA; [Easter, Joshua S.] Bon Secours St Marys Hosp, Dept Emergency Med, Richmond, VA USA; [Easter, Joshua S.] Univ Virginia, Dept Emergency Med, Charlottesville, VA USA; [Dhaliwal, Jasmeet; Miller, Michael] Denver Hlth Emergency Med Residency, Denver, CO USA; [Haukoos, Jason S.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA	Easter, JS (corresponding author), Denver Hlth, Dept Emergency Med, Denver Emergency Ctr Children, Denver, CO 80204 USA.	joshua_easter@bshsi.org			Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12HS019464, K02HS017526]; National Institutes of Health (NIH)/NCATS Colorado Clinical and Translational Science Institute [UL1 TR001082]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K02HS017526, K12HS019464] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI106057] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Dr. Easter (K12HS019464) and Dr. Haukoos (K02HS017526) had financial support from the Agency for Healthcare Research and Quality for the submitted work. Dr. Easter was also supported by National Institutes of Health (NIH)/NCATS Colorado Clinical and Translational Science Institute grant UL1 TR001082. No authors had financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years.	Bleeker SE, 2003, J CLIN EPIDEMIOL, V56, P826, DOI 10.1016/S0895-4356(03)00207-5; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hennelly KE, 2013, J PEDIATR-US, V162, P392, DOI 10.1016/j.jpeds.2012.07.018; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lyttle MD, 2013, EMERG MED J, V30, P790, DOI 10.1136/emermed-2012-201887; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Martin TP, 1997, ANN EMERG MED, V29, P459, DOI 10.1016/S0196-0644(97)70217-8; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Perry JJ, 2012, CAN J EMERG MED, V14, P83, DOI 10.2310/8000.2012.110552; Perry JJ, 2011, CAN J EMERG MED, V13, P19, DOI 10.2310/8000.2011.100269; Perry JJ, 2009, CAN J EMERG MED, V11, P516; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906	18	87	90	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2014	64	2					145	152		10.1016/j.annemergmed.2014.01.030			8	Emergency Medicine	Emergency Medicine	AM9PV	WOS:000340214400009	24635987	Green Accepted			2021-06-18	
J	Tan, KT; Huang, HH; Sun, CT				Tan, K. T.; Huang, H. H.; Sun, C. T.			Blast-wave impact mitigation using negative effective mass density concept of elastic metamaterials	INTERNATIONAL JOURNAL OF IMPACT ENGINEERING			English	Article						Blast-wave; Negative effective mass density; Elastic metamaterials; Wave propagation; Wave attenuation	TRAUMATIC BRAIN-INJURY; SIMULATION; MODULUS	This paper presents the use of elastic metamaterials for impact attenuation and blast-wave mitigation. Metamaterials represent a novel and emerging research area where materials exhibit exceptional properties not commonly found in natural materials. These unique properties are enacted by specifically designed microstructures. In this study, a single-resonator model and a dual-resonator microstructural design are proposed to exhibit negative effective mass density. The effect of negative effective mass density is explicitly confirmed by analysis of wave propagation using numerical simulations. Results evidently show that impact stress wave attenuation occurs over a wider frequency spectrum for the dual-resonator model as compared to the narrow band gap of a single-resonator design. Parametric studies of blast-wave simulation reveal that the mass and number of internal resonators have significant influence over the frequency range of blast-wave attenuation. The effectiveness and performance of the single-resonator and dual-resonator models on blast-wave mitigation are examined and discussed. Finally, practical ways to design and manufacture elastic metamaterials with negative effective mass density are presented and explored. (C) 2013 Elsevier Ltd. All rights reserved.	[Tan, K. T.; Sun, C. T.] Purdue Univ, Sch Aeronaut & Astronaut, W Lafayette, IN 47907 USA; [Huang, H. H.] Natl Taiwan Univ, Dept Engn Sci & Ocean Engn, Taipei 10617, Taiwan	Tan, KT (corresponding author), Purdue Univ, Sch Aeronaut & Astronaut, W Lafayette, IN 47907 USA.	kttan@purdue.edu		Tan, K.T./0000-0003-1266-6582	Agency for Science, Technology and Research (A*STAR, Singapore)Agency for Science Technology & Research (ASTAR); National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC-101-2218-E-002-013-MY3]; AFOSRUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9550-10-1-0061]	K.T. Tan gratefully appreciates the financial support provided by Agency for Science, Technology and Research (A*STAR, Singapore). H.H. Huang acknowledges the financial support from the National Science Council, Taiwan, grant NSC-101-2218-E-002-013-MY3. C.T. Sun would like to acknowledge the support by an AFOSR grant #FA9550-10-1-0061.	Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Chen JS, 2011, COMPOS STRUCT, V93, P2120, DOI 10.1016/j.compstruct.2011.02.007; Christou GA, 2012, INT J IMPACT ENG, V47, P48, DOI 10.1016/j.ijimpeng.2012.03.003; Dawson MA, 2009, INT J IMPACT ENG, V36, P1288, DOI 10.1016/j.ijimpeng.2009.03.008; Fang N, 2006, NAT MATER, V5, P452, DOI 10.1038/nmat1644; Grujicic M, 2013, MATER DESIGN, V51, P113, DOI 10.1016/j.matdes.2013.04.004; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Huang HH, 2011, J MECH PHYS SOLIDS, V59, P2070, DOI 10.1016/j.jmps.2011.07.002; Huang HH, 2009, INT J ENG SCI, V47, P610, DOI 10.1016/j.ijengsci.2008.12.007; Huang HH, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/1/013003; Lai Y, 2011, NAT MATER, V10, P620, DOI [10.1038/nmat3043, 10.1038/NMAT3043]; Li J, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.055602; Liu ZY, 2000, SCIENCE, V289, P1734, DOI 10.1126/science.289.5485.1734; Milton GW, 2007, P ROY SOC A-MATH PHY, V463, P855, DOI 10.1098/rspa.2006.1795; Nesterenko VF, GRANULAR MAT BASED T, V759; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Su ZB, 2008, INT J IMPACT ENG, V35, P336, DOI 10.1016/j.ijimpeng.2007.04.001; Sun CT, 2013, DEV NEGATIVE E UNPUB, P1; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tan KT, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4770370; Valentine J, 2008, NATURE, V455, P376, DOI 10.1038/nature07247; Wadley HNG, 2010, INT J IMPACT ENG, V37, P317, DOI 10.1016/j.ijimpeng.2009.06.006; Yao SS, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/4/043020	24	87	90	4	56	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0734-743X	1879-3509		INT J IMPACT ENG	Int. J. Impact Eng.	FEB	2014	64						20	29		10.1016/j.ijimpeng.2013.09.003			10	Engineering, Mechanical; Mechanics	Engineering; Mechanics	278TK	WOS:000328912500002					2021-06-18	
J	Piao, CS; Stoica, BA; Wu, JF; Sabirzhanov, B; Zhao, ZR; Cabatbat, R; Loane, DJ; Faden, AI				Piao, Chun-Shu; Stoica, Bogdan A.; Wu, Junfang; Sabirzhanov, Boris; Zhao, Zaorui; Cabatbat, Rainier; Loane, David J.; Faden, Alan I.			Late exercise reduces neuroinflammation and cognitive dysfunction after traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Exercise; Neurodegeneration; Inflammation; Neurogenesis	FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; VOLUNTARY EXERCISE; GENE-EXPRESSION; UP-REGULATION; ENVIRONMENTAL ENRICHMENT; LIMITS NEUROINFLAMMATION; MICROGLIAL ACTIVATION; MOTOR CORTEX; MOUSE-BRAIN	Delayed secondary biochemical and cellular changes after traumatic brain injury continue for months to years, and are associated with chronic neuroinflammation and progressive neurodegeneration. Physical activity can reduce inflammation and facilitate recovery after brain injury. Here, we investigated the time-dependent effects, and underlying mechanisms of post-traumatic exercise initiation on outcome after moderate traumatic brain injury using a well-characterized mouse controlled cortical impact model. Late exercise initiation beginning at 5 weeks after trauma, but not early initiation of exercise at 1 week, significantly reduced working and retention memory impairment at 3 months, and decreased lesion volume compared to non-exercise injury controls. Cognitive recovery was associated with attenuation of classical inflammatory pathways, activation of alternative inflammatory responses and enhancement of neurogenesis. In contrast, early initiation of exercise failed to alter behavioral recovery or lesion size, while increasing the neurotoxic pro-inflammatory responses. These data underscore the critical importance of timing of exercise initiation after trauma and its relation to neuroinflammation, and challenge the widely held view that effective neuroprotection requires early intervention. (C) 2013 Elsevier Inc. All rights reserved.	[Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA	Faden, AI (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348	Maryland Exercise and Robotics Center of Excellence (MERCE) Pilot Project Award [7RO1NS061839-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	We thank Titilola Akintola, Katherine Cardiff, Jeremy Bengson and Domenick Giordano for expert technical assistance. This work is supported by the Maryland Exercise and Robotics Center of Excellence (MERCE) Pilot Project Award and 7RO1NS061839-02, "Mechanisms and modulation of cell death in traumatic brain injury" to AIF.	Adkins DL, 2006, J APPL PHYSIOL, V101, P1776, DOI 10.1152/japplphysiol.00515.2006; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Bland DC, 2011, BRAIN INJURY, V25, P664, DOI 10.3109/02699052.2011.576306; Bland ST, 2001, BEHAV BRAIN RES, V126, P33, DOI 10.1016/S0166-4328(01)00243-1; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Clark RE, 2000, J NEUROSCI, V20, P8853; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Faden AI, 2011, ANN NEUROL, V70, P345, DOI 10.1002/ana.22555; Funk JA, 2011, BRAIN BEHAV IMMUN, V25, P1063, DOI 10.1016/j.bbi.2011.03.012; Galea I, 2005, GLIA, V49, P375, DOI 10.1002/glia.20124; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; JONES TA, 1994, J NEUROSCI, V14, P2140; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kelley MS, 1997, REV NEUROSCIENCE, V8, P147; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kobilo T, 2011, LEARN MEMORY, V18, P605, DOI 10.1101/lm.2283011; Komitova M, 2002, J CEREBR BLOOD F MET, V22, P852, DOI 10.1097/00004647-200207000-00010; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lalancette-Hebert M, 2012, J NEUROSCI, V32, P10383, DOI 10.1523/JNEUROSCI.1498-12.2012; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; Pajoohesh-Ganji A, 2012, BRAIN RES, V1475, P96, DOI 10.1016/j.brainres.2012.07.058; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; Petersen AMW, 2005, J APPL PHYSIOL, V98, P1154, DOI 10.1152/japplphysiol.00164.2004; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Qu M, 1998, NEUROSCIENCE, V85, P29, DOI 10.1016/S0306-4522(97)00656-8; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao VLR, 2002, J NEUROCHEM, V83, P1072, DOI 10.1046/j.1471-4159.2002.01208.x; Risedal A, 1999, J CEREBR BLOOD F MET, V19, P997, DOI 10.1097/00004647-199909000-00007; Rowntree S, 1997, EUR J NEUROSCI, V9, P2432, DOI 10.1111/j.1460-9568.1997.tb01660.x; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Ten VS, 2010, J NEUROSCI, V30, P2077, DOI 10.1523/JNEUROSCI.5249-09.2010; Tillerson JL, 2001, J NEUROSCI, V21, P4427, DOI 10.1523/JNEUROSCI.21-12-04427.2001; Van Keuren KR, 1998, BRAIN RES, V780, P56, DOI 10.1016/S0006-8993(97)01184-0; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; VANDERWOLF CH, 1994, BRAIN RES REV, V19, P264, DOI 10.1016/0165-0173(94)90015-9; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Witte OW, 1997, ADV NEUROL, V73, P207; Woods JA, 2005, BRAIN BEHAV IMMUN, V19, P369, DOI 10.1016/j.bbi.2005.04.007; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang HT, 2008, NEUROPSYCHOPHARMACOL, V33, P1611, DOI 10.1038/sj.npp.1301537; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	67	87	91	3	33	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2013	54						252	263		10.1016/j.nbd.2012.12.017			12	Neurosciences	Neurosciences & Neurology	132EZ	WOS:000318052000024	23313314	Green Accepted			2021-06-18	
J	Mayglothling, J; Duane, TM; Gibbs, M; McCunn, M; Legome, E; Eastman, AL; Whelan, J; Shah, KH				Mayglothling, Julie; Duane, Therese M.; Gibbs, Michael; McCunn, Maureen; Legome, Eric; Eastman, Alexander L.; Whelan, James; Shah, Kaushal H.			Emergency tracheal intubation immediately following traumatic injury: An Eastern Association for the Surgery of Trauma practice management guideline	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Guideline; endotracheal intubation; trauma; rapid sequence intubation	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; PREHOSPITAL ENDOTRACHEAL INTUBATION; CERVICAL-SPINE INJURY; POSITIVE-PRESSURE VENTILATION; NEUROMUSCULAR BLOCKING-AGENTS; IN-LINE STABILIZATION; BRAIN-INJURY; MACINTOSH LARYNGOSCOPE; AIRWAY MANAGEMENT	BACKGROUND: The ABCs of trauma resuscitation begin with the airway evaluation, and effective airway management is imperative in the care of a patient with critical injury. The Eastern Association for the Surgery of Trauma Practice Management Guidelines committee aimed to update the guidelines for emergency tracheal intubation (ETI) published in 2002. These guidelines were made to assist clinicians with decisions regarding airway management for patients immediately following traumatic injury. The goals of the work group were to develop evidence-based guidelines to (1) characterize patients in need of ETI and (2) delineate the most appropriate procedure for patients undergoing ETI. METHODS: A search of the National Library of Medicine and the National Institutes of Health MEDLINE database was performed using PubMed (www.pubmed.gov). RESULTS: The search retrieved English-language articles published from 2000 to 2012 involving patients who had sustained blunt trauma, penetrating trauma, or heat-related injury and had developed respiratory system insufficiency or required ETI in the immediate period after injury (first 2 hours after injury). Sixty-nine articles were used to construct this set of practice management guidelines. CONCLUSION: The data supported the formation of six Level 1 recommendations, four Level 2 recommendations, and two Level 3 recommendations. In summary, the decision to intubate a patient following traumatic injury is based on multiple factors, including the need for oxygenation and ventilation, the extent and mechanism of injury, predicted operative need, or progression of disease. Rapid sequence intubation with direct laryngoscopy continues to be the recommended method for ETI, although the use of airway adjuncts such as blind insertion supraglottic devices and video laryngoscopy may be useful in facilitating successful ETI and may be preferred in certain patient populations. There is no pharmacologic induction agent of choice for ETI; however, succinylcholine is the neuromuscular blockade agent recommended for rapid sequence intubation. (J Trauma Acute Care Surg. 2012;73: S333-S340. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Mayglothling, Julie; Duane, Therese M.; Whelan, James] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23298 USA; [Gibbs, Michael] Carolinas Med Ctr, Charlotte, NC 28203 USA; [McCunn, Maureen] Univ Penn, Philadelphia, PA 19104 USA; [Legome, Eric] Kings Cty Med Ctr, New York, NY USA; [Shah, Kaushal H.] Mt Sinai Med Ctr, New York, NY 10029 USA; [Eastman, Alexander L.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA	Mayglothling, J (corresponding author), Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23298 USA.	jmayglothling@mcvh-vcu.edu					Asai T, 2009, ANESTHESIOLOGY, V110, P898, DOI 10.1097/ALN.0b013e31819c45e5; Bair AE, 2002, J EMERG MED, V23, P131, DOI 10.1016/S0736-4679(02)00501-2; Baker CC, 2005, J TRAUMA, V58, P723; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Bathory I, 2009, ANAESTHESIA, V64, P1337, DOI 10.1111/j.1365-2044.2009.06075.x; Bernard Stephen, 2002, Emerg Med (Fremantle), V14, P406, DOI 10.1046/j.1442-2026.2002.00382.x; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Brown CA, 2010, ANN EMERG MED, V56, P83, DOI 10.1016/j.annemergmed.2010.01.033; Bukur M, 2011, J SURG RES, V170, pE117, DOI 10.1016/j.jss.2011.04.005; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; Bushra JS, 2004, ACAD EMERG MED, V11, P66, DOI 10.1197/S1069-6563(03)00586-4; Carassiti M, 2012, BRIT J ANAESTH, V108, P146, DOI 10.1093/bja/aer304; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Christensen EF, 2003, BRIT MED J, V327, P533, DOI 10.1136/bmj.327.7414.533; Clancy M, 2001, EMERG MED J, V18, P373, DOI 10.1136/emj.18.5.373; Combes X, 2006, ACAD EMERG MED, V13, P828, DOI 10.1197/j.aem.2006.02.016; Como JJ, 2005, J TRAUMA, V59, P912, DOI 10.1097/01.ta.0000187660.03742.a6; Cotton BA, 2008, ARCH SURG-CHICAGO, V143, P62, DOI 10.1001/archsurg.143.1.62; Cudnik MT, 2007, PREHOSP EMERG CARE, V11, P224, DOI 10.1080/10903120701205208; Cudnik MT, 2010, J EMERG MED, V38, P175, DOI 10.1016/j.jemermed.2008.01.022; Davis DP, 2007, PREHOSP EMERG CARE, V11, P1, DOI 10.1080/10903120601021093; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2003, ANN EMERG MED, V42, P697, DOI 10.1016/S0196-0644(03)00396-2; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Domeier RM, 2005, PREHOSP EMERG CARE, V9, P114; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Ellis DY, 2007, ANN EMERG MED, V50, P653, DOI 10.1016/j.annemergmed.2007.05.006; Enomoto Y, 2008, BRIT J ANAESTH, V100, P544, DOI 10.1093/bja/aen002; ESPOSITO TJ, 1995, J TRAUMA, V39, P955, DOI 10.1097/00005373-199511000-00022; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; Fields AM, 2009, J TRAUMA, V67, P867, DOI 10.1097/TA.0b013e3181b021c5; Filanovsky Y, 2010, CAN J EMERG MED, V12, P154; Franschman G, 2009, RESUSCITATION, V80, P1147, DOI 10.1016/j.resuscitation.2009.06.029; Guyette FX, 2007, PREHOSP EMERG CARE, V11, P473, DOI 10.1080/10903120701536958; Harris T, 2010, RESUSCITATION, V81, P810, DOI 10.1016/j.resuscitation.2010.02.023; Hassid VJ, 2008, J TRAUMA, V65, P1328, DOI 10.1097/TA.0b013e31818d07e4; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Hubble MW, 2010, PREHOSP EMERG CARE, V14, P377, DOI 10.3109/10903121003790173; Jensen JL, 2010, CAN J EMERG MED, V12, P135; Kaplan MB, 2006, J CLIN ANESTH, V18, P357, DOI 10.1016/j.jclinane.2006.01.002; KATSURADA K, 1973, SURGERY, V73, P191; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Komatsu R, 2008, BRIT J ANAESTH, V101, P863, DOI 10.1093/bja/aen288; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Koyama Y, 2011, ANAESTHESIA, V66, P895, DOI 10.1111/j.1365-2044.2011.06802.x; Kummer C, 2007, INJURY, V38, P27, DOI 10.1016/j.injury.2006.09.002; Lim HC, 2009, EUR J EMERG MED, V16, P68, DOI 10.1097/MEJ.0b013e328303e1c6; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Malik MA, 2008, BRIT J ANAESTH, V101, P723, DOI 10.1093/bja/aen231; Manoach S, 2007, ANN EMERG MED, V50, P236, DOI 10.1016/j.annemergmed.2007.01.009; Maruyama K, 2008, BRIT J ANAESTH, V101, P563, DOI 10.1093/bja/aen207; Maruyama K, 2008, BRIT J ANAESTH, V100, P120, DOI 10.1093/bja/aem313; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Miraflor E, 2011, J SURG RES, V170, P117; Muakkassa FF, 2010, J TRAUMA, V68, P1305, DOI 10.1097/TA.0b013e3181dcd137; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Ollerton JE, 2006, EMERG MED J, V23, P3, DOI 10.1136/emj.2004.020552; Patterson H, 2004, EMERG MED J, V21, P302, DOI 10.1136/emj.2003.006619; Platts-Mills TF, 2009, ACAD EMERG MED, V16, P866, DOI 10.1111/j.1553-2712.2009.00492.x; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Rajani Ravi R, 2009, Am J Surg, V198, P863, DOI 10.1016/j.amjsurg.2009.08.013; Reed MJ, 2005, EMERG MED J, V22, P99, DOI 10.1136/emj.2003.008771; Russell T, 2011, ANAESTH INTENS CARE, V39, P1098, DOI 10.1177/0310057X1103900619; Russi CS, 2008, INT J EMERG MED, V1, P135, DOI 10.1007/s12245-008-0023-5; Sakles JC, J EMER MED; Salomone JP, 2005, J TRAUMA, V59, P1145; Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37; SELLICK BA, 1961, LANCET, V2, P404; Sen A, 2005, EMERG MED J, V22, P887, DOI 10.1136/emj.2005.031716; Shafi S, 2005, J TRAUMA, V59, P1140, DOI 10.1097/01.ta.0000196434.88182.77; Sise MJ, 2009, J TRAUMA, V66, P32, DOI 10.1097/TA.0b013e318191bb0c; Stephens CT, 2009, ANESTH ANALG, V109, P866, DOI 10.1213/ane.0b013e3181ad87b0; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Stroumpoulis K, 2009, EUR J ANAESTH, V26, P218, DOI 10.1097/EJA.0b013e32831c84d1; Sun DA, 2005, BRIT J ANAESTH, V94, P381, DOI 10.1093/bja/aei041; Tallon John M, 2007, CJEM, V9, P101; Teixeira PGR, 2007, J TRAUMA, V63, P1338, DOI 10.1097/TA.0b013e31815078ae; Tumpach EA, 2009, PREHOSP EMERG CARE, V13, P324, DOI 10.1080/10903120902935322; Velmahos GC, 2003, AM SURGEON, V69, P891; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2011, RESUSCITATION, V82, P378, DOI 10.1016/j.resuscitation.2010.12.014; Warner KJ, 2009, J TRAUMA, V67, P45, DOI 10.1097/TA.0b013e3181a92a70; Weitzel N, 2004, J TRAUMA, V56, P1097, DOI 10.1097/01.TA.0000071294.21893.A4; Zamora JE, 2008, BRIT J ANAESTH, V101, P723	95	87	95	4	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2012	73			4			S333	S340		10.1097/TA.0b013e31827018a5			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	043VO	WOS:000311578300010	23114490	Bronze			2021-06-18	
J	De Beaumont, L; Tremblay, S; Poirier, J; Lassonde, M; Theoret, H				De Beaumont, Louis; Tremblay, Sebastien; Poirier, Judes; Lassonde, Maryse; Theoret, Hugo			Altered Bidirectional Plasticity and Reduced Implicit Motor Learning in Concussed Athletes	CEREBRAL CORTEX			English	Article						GABA system; neurophysiology; paired associative stimulation; sports concussion; synaptic plasticity; TMS	LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; GABA(B) RECEPTOR AGONIST; THETA-BURST STIMULATION; COGNITIVE IMPAIRMENT; UNAFFECTED HEMISPHERE; CORTICAL INHIBITION; SPORTS CONCUSSION; CORTEX	Persistent motor/cognitive alterations and increased prevalence of Alzheimer's disease are known consequences of recurrent sports concussions, the most prevalent cause of mild traumatic brain injury (TBI) among youth. Animal models of TBI demonstrated that impaired learning was related to persistent synaptic plasticity suppression in the form of long-term potentiation (LTP) and depression (LTD). In humans, single and repeated concussive injuries lead to lifelong and cumulative enhancements of gamma-aminobutyric acid (GABA)-mediated inhibition, which is known to suppress LTP/LTD plasticity. To test the hypothesis that increased GABAergic inhibition after repeated concussions suppresses LTP/LTD and contributes to learning impairments, we used a paired associative stimulation (PAS) protocol to induce LTP/LTD-like effects in primary motor cortex (M1) jointly with an implicit motor learning task (serial reaction time task, SRTT). Our results indicate that repeated concussions induced persistent elevations of GABA(B)-mediated intracortical inhibition in M1, which was associated with suppressed PAS-induced LTP/LTD-like synaptic plasticity. This synaptic plasticity suppression was related to reduced implicit motor learning on the SRTT task relative to normal LTP/LTD-like synaptic plasticity in unconcussed teammates. These findings identify GABA neurotransmission alterations after repeated concussions and suggest that impaired learning after multiple concussions could at least partly be related to compromised GABA-dependent LTP/LTD synaptic plasticity.	[De Beaumont, Louis; Tremblay, Sebastien; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ H2V 2S9, Canada; [De Beaumont, Louis; Poirier, Judes] McGill Univ, Douglas Mental Hlth Univ Inst, Montreal, PQ H4H 1R3, Canada; [Lassonde, Maryse; Theoret, Hugo] CHU St Justine, Montreal, PQ H3S 2G5, Canada	Theoret, H (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ H2V 2S9, Canada.	hugo.theoret@umontreal.ca		Tremblay, Sebastien/0000-0001-6251-9797; Theoret, Hugo/0000-0002-7458-8797	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Fonds de la recherche en sante du Quebec (FRSQ)Fonds de la Recherche en Sante du Quebec	Canadian Institute of Health Research (CIHR) awarded to M.L. and H.T.; Fonds de la recherche en sante du Quebec (FRSQ) awarded to H.T. and M.L.	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Antal A, 2004, EUR J NEUROSCI, V19, P2888, DOI 10.1111/j.1460-9568.2004.03367.x; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bruel-Jungerman E, 2007, NEUROSCIENTIST, V13, P492, DOI 10.1177/1073858407302725; Cheeran B, 2008, J PHYSIOL-LONDON, V586, P5717, DOI 10.1113/jphysiol.2008.159905; Cirillo J, 2009, J PHYSIOL-LONDON, V587, P5831, DOI 10.1113/jphysiol.2009.181834; Classen J, 1998, J NEUROPHYSIOL, V79, P1117; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Daskalakis ZJ, 2002, ARCH GEN PSYCHIAT, V59, P347, DOI 10.1001/archpsyc.59.4.347; Dave KR, 2005, J NEUROSCI RES, V82, P665, DOI 10.1002/jnr.20674; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Delvendahl I, 2010, CLIN NEUROPHYSIOL, V121, P594, DOI 10.1016/j.clinph.2009.09.034; Fatemi SH, 2000, MOL PSYCHIATR, V5, P654, DOI 10.1038/sj.mp.4000783; Fitzgerald PB, 2003, PSYCHIAT RES, V118, P197, DOI 10.1016/S0165-1781(03)00094-5; Frantseva MV, 2008, CEREB CORTEX, V18, P990, DOI 10.1093/cercor/bhm151; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Garvey MA, 2001, CLIN NEUROPHYSIOL, V112, P1451, DOI 10.1016/S1388-2457(01)00581-8; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kim YH, 2006, STROKE, V37, P1471, DOI 10.1161/01.STR.0000221233.55497.51; Kim YH, 2004, NEUROSCI LETT, V367, P181, DOI 10.1016/j.neulet.2004.05.113; Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuramoto N, 2007, NEURON, V53, P233, DOI 10.1016/j.neuron.2006.12.015; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liepert J, 1997, J NEURAL TRANSM, V104, P1207, DOI 10.1007/BF01294721; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McNamara RK, 1996, PHARMACOL BIOCHEM BE, V53, P303, DOI 10.1016/0091-3057(95)02025-X; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Nakagawa Y, 1997, BRAIN RES, V766, P101, DOI 10.1016/S0006-8993(97)00529-5; NIELSEN J, 1993, EUR J APPL PHYSIOL O, V66, P116, DOI 10.1007/BF01427051; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037; Perez MA, 2007, J NEUROSCI, V27, P1045, DOI 10.1523/JNEUROSCI.4128-06.2007; Perez-Pinzon MA, 2007, COMP BIOCHEM PHYS A, V147, P291, DOI 10.1016/j.cbpa.2006.08.032; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RAJJI TK, 2010, BRAIN STIMU IN PRESS; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Sanes JN, 2000, ANNU REV NEUROSCI, V23, P393, DOI 10.1146/annurev.neuro.23.1.393; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P333, DOI 10.1016/j.clinph.2006.10.014; Tang TTT, 2009, P NATL ACAD SCI USA, V106, P21395, DOI 10.1073/pnas.0910499106; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Willingham DB, 2000, MEM COGNITION, V28, P366, DOI 10.3758/BF03198552; WILLINGHAM DB, 1989, J EXP PSYCHOL LEARN, V15, P1047, DOI 10.1037/0278-7393.15.6.1047; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002; Ziemann U, 1998, ELECTROMYOGR MOTOR C, V109, P321, DOI 10.1016/S0924-980X(98)00023-X; Ziemann U, 2004, J NEUROSCI, V24, P1666, DOI 10.1523/JNEUROSCI.5016-03.2004; ZIEMANN U, 1993, NEUROSCI LETT, V156, P167, DOI 10.1016/0304-3940(93)90464-V; Ziemann U, 2008, BRAIN STIMUL, V1, P60, DOI 10.1016/j.brs.2007.08.003	89	87	89	0	51	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JAN	2012	22	1					112	121		10.1093/cercor/bhr096			10	Neurosciences	Neurosciences & Neurology	863TI	WOS:000298190500010	21572090	Bronze			2021-06-18	
J	Rivara, FP; Koepsell, TD; Wang, J; Temkin, N; Dorsch, A; Vavilala, MS; Durbin, D; Jaffe, KM				Rivara, Frederick P.; Koepsell, Thomas D.; Wang, Jin; Temkin, Nancy; Dorsch, Andrea; Vavilala, Monica S.; Durbin, Dennis; Jaffe, Kenneth M.			Disability 3, 12, and 24 Months After Traumatic Brain Injury Among Children and Adolescents	PEDIATRICS			English	Article						traumatic brain injury; disability; functional outcome	QUALITY-OF-LIFE; GENERIC CORE SCALES; POSTCONCUSSIVE SYMPTOMS; AFTER-DISCHARGE; RELIABILITY; OUTCOMES; HEAD; SEVERITY; VALIDITY; TERM	OBJECTIVE: To examine disability in children and adolescents after traumatic brain injury (TBI) across the spectrum of injury severity. METHODS: This was a prospective cohort study of children younger than 18 years treated for a TBI (n = 729) or an arm injury (n = 197) between March 1, 2007, and September 30, 2008. The main outcome measures were disability in health-related quality of life, adaptive skills, and participation in social and community activities 3, 12, and 24 months after injury compared with preinjury functioning. RESULTS: The health-related quality of life for children with moderate or severe TBI was lower at all follow-up times compared with baseline, but there was some improvement during the first 2 years after injury. Three months after injury, there was a substantial decrease in the level of activities in which children with moderate and severe TBI were able to participate; these activities improved at 12 and 24 months but were still significantly impaired. Communication and self-care abilities in children with moderate and severe TBI were lower at 3 months than at baseline and did not improve by 24 months. Children who met the definition of mild TBI but had an intracranial hemorrhage had lower quality-of-life scores at 3 months. CONCLUSIONS: Children with moderate or severe TBI and children with mild TBI who had intracranial hemorrhage had substantial long-term reduction in their quality of life, participation in activities with others, and ability to communicate and care for themselves. Pediatrics 2011; 128: e1129-e1138	[Rivara, Frederick P.; Koepsell, Thomas D.; Wang, Jin; Vavilala, Monica S.; Jaffe, Kenneth M.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Rivara, Frederick P.; Wang, Jin; Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Rivara, Frederick P.; Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Dorsch, Andrea] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98104 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA 19104 USA; [Durbin, Dennis] Univ Penn, Philadelphia, PA 19104 USA	Rivara, FP (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu			National Center for Injury Prevention and Control, CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025014] Funding Source: NIH RePORTER	This project was supported by the National Center for Injury Prevention and Control, CDC grant R49 CE 001021. The CDC had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bordignon KC, 2002, ARQ NEURO-PSIQUIAT, V60, P204, DOI 10.1590/S0004-282X2002000200004; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Gennarelli T.A., 2008, ABBREVIATED INJURY S; Guice KS, 2007, J TRAUMA, V63, pS68, DOI 10.1097/TA.0b013e31815acbb6; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Kirkwood MW, 2010, PEDIAT TRAUMATIC BRA; Koepsell TD, 2011, INCIDENCE D IN PRESS; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Marr AL., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meeske K, 2004, CANCER, V101, P2116, DOI 10.1002/cncr.20609; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Odetola FO, 2010, ARCH PEDIAT ADOL MED, V164, P277, DOI 10.1001/archpediatrics.2009.285; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wetherington CE, 2010, J PEDIATR PSYCHOL, V35, P662, DOI 10.1093/jpepsy/jsp081; World Health Organization, 2001, INT CLASS FUNCT DIS; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	57	87	88	0	14	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2011	128	5					E1129	E1138		10.1542/peds.2011-0840			10	Pediatrics	Pediatrics	843YO	WOS:000296714000011	22025592				2021-06-18	
J	Capaldi, VF; Guerrero, ML; Killgore, WDS				Capaldi, Vincent F., II; Guerrero, Melanie L.; Killgore, William D. S.			Sleep Disruptors Among Returning Combat Veterans From Iraq and Afghanistan	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; POOR SLEEP; DAYTIME SLEEPINESS; PREVALENCE; SYMPTOMS; INSOMNIA; QUALITY; ASSOCIATIONS; EXPERIENCES	Background: Post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) are common injuries among returning combat veterans from the wars in Iraq and Afghanistan. Although these combat injuries have been associated with increased sleep disruption, little is known about the nature and specificity of sleep problems within these common injury categories. Method: A retrospective chart review of 69 consecutive referrals to the Walter Reed Army Medical Center sleep clinic was conducted. All cases were active duty soldiers who had recently returned from combat deployment in Iraq or Afghanistan. Data from polysomnographically (PSG) recorded sleep stages, sleepiness scales, and documented medical diagnoses were extracted from medical records. Sleep data were compared across diagnoses of PTSD, TBI, and other clinical conditions. Results: As expected, clinical sleep disturbances, including rates of obstructive sleep apnea, excessive awakenings, daytime sleepiness, and hypoxia, were high for the sample as a whole. However, no differences across diagnostic groups were found. Differences were observed, however, on PSG measures of sleep quality, suggesting more frequent arousals from sleep among patients with PTSD and greater slow wave sleep among those with TBI. Except for REM latency, medication status had virtually no effect on sleep variables. Conclusions: Among recently redeployed combat veterans, clinically significant sleep disturbances and problems with sleep-disordered breathing are common but nonspecific findings across primary diagnoses of PTSD, TBI, major depression, and anxiety disorder, whereas more subtle differences in sleep architecture and arousals as measured by overnight PSG recordings were modestly, but significantly, effective at distinguishing among the diagnostic groups.	[Capaldi, Vincent F., II] Walter Reed Army Med Ctr, Washington, DC 20307 USA; [Guerrero, Melanie L.; Killgore, William D. S.] Walter Reed Army Inst Res, Silver Spring, MD 20910 USA; [Killgore, William D. S.] Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA	Capaldi, VF (corresponding author), Walter Reed Army Med Ctr, 6900 Georgia Ave NW, Washington, DC 20307 USA.			Killgore, William/0000-0002-5328-0208			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Amin MM, 2010, MIL MED, V175, P155; Anderer P, 2007, P ANN INT IEEE EMBS, P3994, DOI 10.1109/IEMBS.2007.4353209; Caldwell Barbara A, 2005, Issues Ment Health Nurs, V26, P721, DOI 10.1080/01612840591008294; Carlson KF, J HEAD TRAU IN PRESS; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Dezee KJ, 2005, J CLIN SLEEP MED, V1, P136; Flemons WW, 2002, NEW ENGL J MED, V347, P498, DOI 10.1056/NEJMcp012849; Germain A, 2004, J TRAUMA STRESS, V17, P477, DOI 10.1007/s10960-004-5796-6; Germain A, 2005, J ANXIETY DISORD, V19, P233, DOI 10.1016/j.janxdis.2004.02.001; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hukins Craig A, 2006, Neuropsychiatr Dis Treat, V2, P309, DOI 10.2147/nedt.2006.2.3.309; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Krakow B, 2004, J TRAUMA STRESS, V17, P257, DOI 10.1023/B:JOTS.0000029269.29098.67; Krakow B, 2001, BIOL PSYCHIAT, V49, P948, DOI 10.1016/S0006-3223(00)01087-8; Krakow B, 2006, J NERV MENT DIS, V194, P433, DOI 10.1097/01.nmd.0000221286.65021.e0; Krakow Barry, 2002, Sleep Breath, V6, P189; Kristo DA, 2005, CHEST, V127, P1654, DOI 10.1378/chest.127.5.1654; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; Loube DI, 1999, CHEST, V115, P1333, DOI 10.1378/chest.115.5.1333; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; O'Donnell T, 2004, NEUROPSYCHOBIOLOGY, V50, P273, DOI 10.1159/000080952; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Orr SP, 2002, PSYCHIAT CLIN N AM, V25, P271, DOI 10.1016/S0193-953X(01)00007-7; Pace-Schott EF, 2009, SLEEP, V32, P19; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Pole N, 2009, BIOL PSYCHIAT, V65, P235, DOI 10.1016/j.biopsych.2008.07.015; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Spoormaker VI, J PSYCHIAT IN PRESS; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Wahner-Roedler DL, 2007, GENDER MED, V4, P329, DOI 10.1016/S1550-8579(07)80062-3; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wessa M, 2007, AM J PSYCHIAT, V164, P1684, DOI 10.1176/appi.ajp.2007.07030525; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	44	87	88	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	AUG	2011	176	8					879	888		10.7205/MILMED-D-10-00440			10	Medicine, General & Internal	General & Internal Medicine	804TB	WOS:000293675800007	21882777	Bronze			2021-06-18	
J	De Beaumont, L; Mongeon, D; Tremblay, S; Messier, J; Prince, F; Leclerc, S; Lassonde, M; Theoret, H				De Beaumont, Louis; Mongeon, David; Tremblay, Sebastien; Messier, Julie; Prince, Francois; Leclerc, Suzanne; Lassonde, Maryse; Theoret, Hugo			Persistent Motor System Abnormalities in Formerly Concussed Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						traumatic brain injuries; transcranial magnetic stimulation; clinical neurophysiology; motor control; primary motor cortex	TRANSCRANIAL MAGNETIC STIMULATION; RAPID ALTERNATING MOVEMENTS; GABA(B) RECEPTOR AGONIST; TRAUMATIC BRAIN-INJURY; CORTICAL SILENT PERIOD; CEREBRAL CONCUSSION; POSTURAL CONTROL; LONG-TERM; APPROXIMATE ENTROPY; PARKINSONS-DISEASE	Context: The known detrimental effects of sport concussions on motor system function include balance problems, slowed motor execution, and abnormal motor cortex excitability. Objective: To assess whether these concussion-related alterations of motor system function are still evident in collegiate football players who sustained concussions but returned to competition more than 9 months before testing. Design: Case-control study. Setting: University laboratory. Patients or Other Participants: A group of 21 active, university-level football players who had experienced concussions was compared with 15 university football players who had not sustained concussions. Intervention(s): A force platform was used to assess center-of-pressure (COP) displacement and COP oscillation regularity (approximate entropy) as measures of postural stability in the upright position. A rapid alternating-movement task was also used to assess motor execution speed. Transcranial magnetic stimulation over the motor cortex was used to measure long-interval intracortical inhibition and the cortical silent period, presumably reflecting gamma-aminobutyric acid subtype B receptor mediated intracortical inhibition. Main Outcome Measure(S): COP displacement and oscillation regularity, motor execution speed, long-interval intracortical inhibition, cortical silent period. Results: Relative to controls, previously concussed athletes showed persistently lower COP oscillation randomness, normal performance on a rapid alternating-movement task, and more M1 intracortical inhibition that was related to the number of previous concussions. Conclusions: Sport concussions were associated with pervasive changes in postural control and more M1 intracortical inhibition, providing neurophysiologic and behavioral evidence of lasting, subclinical changes in motor system integrity in concussed athletes.	[De Beaumont, Louis; Tremblay, Sebastien; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada; [Mongeon, David; Messier, Julie; Prince, Francois; Leclerc, Suzanne] Univ Montreal, Dept Kinesiol, Montreal, PQ H3C 3J7, Canada; [Leclerc, Suzanne] Univ Montreal, Clin Med Sport, Montreal, PQ H3C 3J7, Canada	Theoret, H (corresponding author), Univ Montreal, Ctr Rech Neuropsychol & Cognit, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	hugo.theoret@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797			Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; Beuter A, 1999, ENVIRON RES, V80, P64, DOI 10.1006/enrs.1998.3885; Beuter A, 1999, J CLIN NEUROPHYSIOL, V16, P484, DOI 10.1097/00004691-199909000-00010; Cantello R, 2007, NEUROSCIENCE, V150, P64, DOI 10.1016/j.neuroscience.2007.08.033; Cavanaugh JT, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-42; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Duval C, 2001, EXP BRAIN RES, V139, P412, DOI 10.1007/s002210100780; Garvey MA, 2001, CLIN NEUROPHYSIOL, V112, P1451, DOI 10.1016/S1388-2457(01)00581-8; Geurts ACH, 2005, GAIT POSTURE, V22, P267, DOI 10.1016/j.gaitpost.2004.10.002; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kluger A, 1997, Int Psychogeriatr, V9 Suppl 1, P307, DOI 10.1017/S1041610297005048; Kluger A, 1997, J GERONTOL B-PSYCHOL, V52, pP28, DOI 10.1093/geronb/52B.1.P28; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Lang N, 2006, EPILEPSIA, V47, P813, DOI 10.1111/j.1528-1167.2006.00544.x; Laughton CA, 2003, GAIT POSTURE, V18, P101, DOI 10.1016/S0966-6362(02)00200-X; Macdonell RAL, 2001, NEUROLOGY, V57, P706, DOI 10.1212/WNL.57.4.706; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McNamara RK, 1996, PHARMACOL BIOCHEM BE, V53, P303, DOI 10.1016/0091-3057(95)02025-X; Moller B, 2007, NEUROREPORT, V18, P1503; Mohammadi B, 2006, MUSCLE NERVE, V33, P778, DOI 10.1002/mus.20531; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Nakagawa Y, 1997, BRAIN RES, V766, P101, DOI 10.1016/S0006-8993(97)00529-5; OKADA M, 1983, COMPUT BIOMED RES, V16, P59, DOI 10.1016/0010-4809(83)90007-1; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Pierantozzi M, 2004, BRAIN RES, V1028, P1, DOI 10.1016/j.brainres.2004.06.009; SHIMOYAMA I, 1990, ARCH NEUROL-CHICAGO, V47, P681, DOI 10.1001/archneur.1990.00530060095025; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.3.CO;2-O; Smith CD, 1999, NEUROLOGY, V53, P1458, DOI 10.1212/WNL.53.7.1458; Termoz N, 2008, GAIT POSTURE, V27, P463, DOI 10.1016/j.gaitpost.2007.05.015; Tinazzi M, 2005, NEUROSCI LETT, V378, P55, DOI 10.1016/j.neulet.2004.12.015; Watanabe M, 2002, INT REV CYTOL, V213, P1; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x	48	87	87	0	29	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAY-JUN	2011	46	3					234	240					7	Sport Sciences	Sport Sciences	770YC	WOS:000291123400003	21669091				2021-06-18	
J	Redell, JB; Zhao, J; Dash, PK				Redell, John B.; Zhao, Jing; Dash, Pramod K.			Altered Expression of miRNA-21 and Its Targets in the Hippocampus After Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						miR-21; Tiam1; TBI; apoptosis; ontology	EXCHANGE FACTOR TIAM1; GENE-EXPRESSION; MICRORNA-21 TARGETS; CELL-DEATH; IN-VIVO; INVASION; GROWTH; RAC; ACTIVATION; ONTOLOGY	Traumatic brain injury (TBI) initiates many different signaling cascades throughout the brain that impact both pathophysiological and neuroprotective processes. Cellular mechanisms that can modulate these processes may play an important role in determining the nature and extent of the damage suffered after TBI and therefore influence overall outcome after injury. MicroRNAs (miRNAs) are an important class of noncoding regulatory RNAs providing an epigenetic mechanism for the regulation of protein expression levels of target genes. We report that miR-21 expression is significantly up-regulated in the hippocampus after rodent TBI, with expression levels peaking by 3 days postinjury and returning to near sham levels by 15 days postinjury. In situ localization of miR-21 transcripts indicates widespread expression in normal brain, with a pronounced increase in expression after TBI evident throughout the cortex and hippocampus, including the dentate gyrus and CA3 cell layer. We used a combination of the miRanda, TargetScan, and PicTar prediction algorithms to identify 99 potential target genes that possess miR-21 binding sites within their 3' untranslated regions. Analysis of these genes' annotated Gene Ontology molecular function and biological process terms revealed an overrepresentation of genes involved in enzyme-linked receptor signaling, transcriptional regulation, and developmental processes. These results suggest that increased miR-21 expression in the hippocampus may influence multiple components of TBI pathophysiology. (C) 2010 Wiley-Liss, Inc.	[Redell, John B.; Zhao, Jing; Dash, Pramod K.] Univ Texas Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Med Sch, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; American Heart AssociationAmerican Heart Association; Mission Connect/TIRR Foundation; Gillson Longenbaugh Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078596] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant sponsor: American Heart Association; Contract grant sponsor: Mission Connect/TIRR Foundation; Contract grant sponsor: Gillson Longenbaugh Foundation.	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baek D, 2008, NATURE IN PRESS; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com; Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Carson JP, 2005, J MICROSC-OXFORD, V217, P275, DOI 10.1111/j.1365-2818.2005.01450.x; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Cottonham CL, 2010, J BIOL CHEM IN PRESS; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Grossmann S, 2007, BIOINFORMATICS, V23, P3024, DOI 10.1093/bioinformatics/btm440; Guillemot L, 2008, MOL BIOL CELL, V19, P4442, DOI 10.1091/mbc.E08-06-0558; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Knezevic H, 2008, J BIOL CHEM IN PRESS; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kunda P, 2001, J NEUROSCI, V21, P2361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Marquez RT, 2010, AM J PHYSIOL-GASTR L, V298, pG535, DOI 10.1152/ajpgi.00338.2009; Matsuo N, 2003, MOL CELL NEUROSCI, V24, P69, DOI 10.1016/S1044-7431(03)00122-2; Meng F, 2006, GASTROENTEROLOGY, V130, pA429; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Post S, 2008, ONCOGENE, V27, P2128; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Sathyan P, 2007, J NEUROSCI, V27, P8546, DOI 10.1523/JNEUROSCI.1269-07.2007; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Talotta F, 2008, ONCOGENE IN PRESS; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; Tolias KF, 2007, P NATL ACAD SCI USA, V104, P7265, DOI 10.1073/pnas.0702044104; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yaylaoglu MB, 2005, DEV DYNAM, V234, P371, DOI 10.1002/dvdy.20441; Zavadil J, 2007, CELLS TISSUES ORGANS, V185, P157, DOI 10.1159/000101316; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	66	87	89	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB	2011	89	2					212	221		10.1002/jnr.22539			10	Neurosciences	Neurosciences & Neurology	696QL	WOS:000285456400009	21162128	Green Accepted			2021-06-18	
J	Patel, AD; Gerzanich, V; Geng, ZH; Simard, JM				Patel, Ashish D.; Gerzanich, Volodymyr; Geng, Zhihua; Simard, J. Marc			Glibenclamide Reduces Hippocampal Injury and Preserves Rapid Spatial Learning in a Model of Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Caspase-3; Glibenclamide; Hippocampus; Morris water maze; Rapid spatial learning; Sp1; Sulfonylurea receptor 1 (SUR1); Traumatic brain injury	MORRIS WATER MAZE; FACTOR-KAPPA-B; ISCHEMIC-STROKE; DENTATE GYRUS; CORTICAL CONTUSION; PATTERN SEPARATION; ATP CHANNELS; PLACE CELLS; HEAD TRAUMA; RAT	Cognitive disturbances after traumatic brain injury (TBI) are frequent, even when neuroimaging shows no overt hemorrhagic or other abnormality. Sulfonylurea receptor 1 (SUR1) plays a key role in various forms of CNS injury, but its role in hippocampal dysfunction after mild to moderate TBI is unknown. To assess the hypothesis that postinjury SUR1 upregulation in the hippocampus is associated with a later disturbance in learning, we studied a rat model of cortical impact TBI calibrated to avoid primary and secondary hemorrhage in the underlying hippocampus. The transcription factor, specificity protein 1, which regulates expression of SUR1 and caspase-3, was activated in the hippocampus 15 minutes after injury. Upregulation of SUR1 protein and of Abcc8 (which encodes SUR1) messenger RNA was evident by 6 hours. To assess the role of SUR1, injured rats were administered vehicle or a low dose of the specific sulfonylurea inhibitor glibenclamide for 1 week. At 2 weeks, the increase in activated caspase-3 in the hilus of glibenclamide-treated rats was half of that in vehicle-treated rats. Testing for rapid learning in a Morris water maze at 4 weeks showed significantly better performance in glibenclamide-treated rats; performance inversely correlated with Fluoro-Jade staining for degenerated neurons in the hilus. We conclude that glibenclamide may have long-term protective effects on the hippocampus after mild-to-moderate TBI.	[Patel, Ashish D.; Gerzanich, Volodymyr; Geng, Zhihua; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu			Department of Veterans Affairs (Baltimore, MD)US Department of Veterans Affairs	This work was supported by a grant to J.M.S. from the Department of Veterans Affairs (Baltimore, MD).	Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; Bast T, 2009, PLOS BIOL, V7, P730, DOI 10.1371/journal.pbio.1000089; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Chen MK, 2001, J NEUROSCI, V21, P6512; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Corkin S, 2002, NAT REV NEUROSCI, V3, P153, DOI 10.1038/nrn726; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gerlai R, 1996, NEUROBIOL LEARN MEM, V66, P143, DOI 10.1006/nlme.1996.0055; Gerzanich V, 2003, CIRC RES, V93, P805, DOI 10.1161/01.RES.0000097872.69043.A0; Gribble FM, 2003, DIABETOLOGIA, V46, P875, DOI 10.1007/s00125-003-1143-3; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hernandez-Sanchez C, 1999, J BIOL CHEM, V274, P18261, DOI 10.1074/jbc.274.26.18261; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee I, 2004, NEURON, V42, P803, DOI 10.1016/j.neuron.2004.05.010; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Nakashiba T, 2008, SCIENCE, V319, P1260, DOI 10.1126/science.1151120; O'Reilly RC, 2001, PSYCHOL REV, V108, P311, DOI 10.1037//0033-295X.108.2.311; OLTON DS, 1979, NEUROPSYCHOLOGIA, V17, P669, DOI 10.1016/0028-3932(79)90042-3; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2007, BBA-MOL BASIS DIS, V1772, P947, DOI 10.1016/j.bbadis.2007.03.004; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Verstraeten SV, 2010, BBA-BIOMEMBRANES, V1798, P1739, DOI 10.1016/j.bbamem.2010.06.010; Whishaw IQ, 1996, HIPPOCAMPUS, V6, P513, DOI 10.1002/(SICI)1098-1063(1996)6:5<513::AID-HIPO4>3.0.CO;2-J; XIONG Y, 2010, J NEUROSURG     0521; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yamada K, 2005, J MOL CELL CARDIOL, V38, P945, DOI 10.1016/j.yjmcc.2004.11.020; Zawar C, 1999, J PHYSIOL-LONDON, V514, P327	65	87	91	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2010	69	12					1177	1190		10.1097/NEN.0b013e3181fbf6d6			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	686KN	WOS:000284695300001	21107131	Bronze			2021-06-18	
J	Castellanos, NP; Paul, N; Ordonez, VE; Demuynck, O; Bajo, R; Campo, P; Bilbao, A; Ortiz, T; Del-Pozo, F; Maestu, F				Castellanos, Nazareth P.; Paul, Nuria; Ordonez, Victoria E.; Demuynck, Olivier; Bajo, Ricardo; Campo, Pablo; Bilbao, Alvaro; Ortiz, Tomas; del-Pozo, Francisco; Maestu, Fernando			Reorganization of functional connectivity as a correlate of cognitive recovery in acquired brain injury	BRAIN			English	Article						brain injury; functional connectivity; magnetoencephalography; plasticity	GRAPH-THEORETICAL ANALYSIS; ALZHEIMERS-DISEASE; TUMOR PATIENTS; ALPHA-BAND; MEG; SYNCHRONIZATION; MODEL; REHABILITATION; DAMAGE; GAMMA	Cognitive processes require a functional interaction between specialized multiple, local and remote brain regions. Although these interactions can be strongly altered by an acquired brain injury, brain plasticity allows network reorganization to be principally responsible for recovery. The present work evaluates the impact of brain injury on functional connectivity patterns. Networks were calculated from resting-state magnetoencephalographic recordings from 15 brain injured patients and 14 healthy controls by means of wavelet coherence in standard frequency bands. We compared the parameters defining the network, such as number and strength of interactions as well as their topology, in controls and patients for two conditions: following a traumatic brain injury and after a rehabilitation treatment. A loss of delta- and theta-based connectivity and conversely an increase in alpha- and beta-band-based connectivity were found. Furthermore, connectivity parameters approached controls in all frequency bands, especially in slow-wave bands. A correlation between network reorganization and cognitive recovery was found: the reduction of delta-band-based connections and the increment of those based on alpha band correlated with Verbal Fluency scores, as well as Perceptual Organization and Working Memory Indexes, respectively. Additionally, changes in connectivity values based on theta and beta bands correlated with the Patient Competency Rating Scale. The current study provides new evidence of the neurophysiological mechanisms underlying neuronal plasticity processes after brain injury, and suggests that these changes are related with observed changes at the behavioural level.	[Castellanos, Nazareth P.; Ordonez, Victoria E.; Bajo, Ricardo; Campo, Pablo; del-Pozo, Francisco; Maestu, Fernando] Univ Politecn Madrid, Ctr Biomed Technol, Lab Cognit & Computat Neurosci, Madrid 28660, Spain; [Paul, Nuria; Ortiz, Tomas] Univ Complutense Madrid, Sch Med, Dept Psychiat & Med Psychol, E-28040 Madrid, Spain; [Demuynck, Olivier] Univ Politecn Madrid, Dept Signals Syst & Radiocomunicat, E-28040 Madrid, Spain; [Bilbao, Alvaro] Natl Ctr Brain Injury Treatment CEADAC, Madrid 28034, Spain; Univ Complutense Madrid, Dept Basic Psychol Cognit Sci 2, E-28040 Madrid, Spain	Castellanos, NP (corresponding author), Univ Politecn Madrid, Ctr Biomed Technol, Lab Cognit & Computat Neurosci, Campus Montegancedo 28660, Madrid 28660, Spain.	nazareth@pluri.ucm.es	Castellanos, Nazareth/AAA-8812-2020; Campo, Pablo/M-3317-2019; Campo, Pablo/I-8156-2012; Maestu, Fernando/E-3213-2012; maestu, fernando/M-7480-2019; POZO GUERRERO, FRANCISCO DEL/H-6668-2015	Campo, Pablo/0000-0003-4539-6857; Campo, Pablo/0000-0003-4539-6857; Maestu, Fernando/0000-0002-3195-0071; maestu, fernando/0000-0002-3195-0071; POZO GUERRERO, FRANCISCO DEL/0000-0001-9919-9125; Castellanos, Nazareth/0000-0002-3508-7316; Paul, Nuria/0000-0001-5462-6138	MADRI.B; Obra Social CajaMadrid; MAPFRE 2009; IMSERSO [07-2008]	MADRI.B (CAM i+d+I project), Obra Social CajaMadrid, MAPFRE 2009 and IMSERSO (07-2008).	AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Beason-Held LL, 2009, BRAIN IMAGING BEHAV, V3, P123, DOI 10.1007/s11682-008-9054-z; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; BOSMA I, 2009, NONLINEAR BIOMED PHY, V1, P3; Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034; Bressler SL, 2002, CURR DIR PSYCHOL SCI, V11, P58, DOI 10.1111/1467-8721.00168; Brookes MJ, 2005, NEUROIMAGE, V26, P302, DOI 10.1016/j.neuroimage.2005.01.050; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Butz M, 2009, FRONT COMPUT NEUROSC, V3, DOI 10.3389/neuro.10.010.2009; Campo P, 2010, NEUROIMAGE, V49, P2807, DOI 10.1016/j.neuroimage.2009.10.024; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cover KS, 2006, NEUROIMAGE, V29, P783, DOI 10.1016/j.neuroimage.2005.08.048; Cover KS, 2004, NEUROIMAGE, V22, P1432, DOI 10.1016/j.neuroimage.2004.04.016; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Douw L, 2008, EXP NEUROL, V212, P285, DOI 10.1016/j.expneurol.2008.03.013; EDOUARD L, 1893, RECREATIONS MATH, V3; Fingelkurts AA, 2007, HUM BRAIN MAPP, V28, P247, DOI 10.1002/hbm.20275; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; GASSER T, 1982, ELECTROEN CLIN NEURO, V53, P119, DOI 10.1016/0013-4694(82)90112-2; GLADSOJO J, 1999, NORMS LETT CATEGORY; Golden C., 1978, STROOP COLOUR WORD T; Gootjes L, 2006, NEUROIMAGE, V30, P245, DOI 10.1016/j.neuroimage.2005.09.015; Grinsted A, 2004, NONLINEAR PROC GEOPH, V11, P561, DOI 10.5194/npg-11-561-2004; Guggisberg AG, 2008, ANN NEUROL, V63, P193, DOI 10.1002/ana.21224; Hadjipapas A, 2005, CLIN NEUROPHYSIOL, V116, P1300, DOI 10.1016/j.clinph.2005.01.014; Halgren E, 2002, CEREB CORTEX, V12, P710, DOI 10.1093/cercor/12.7.710; Halligan P., 2005, EFFECTIVENESS REHABI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Huan NJ, 2004, J NEURAL ENG, V1, P142, DOI 10.1088/1741-2560/1/3/003; Jaakkola TS, 1999, ADV NEUR IN, V11, P487; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; Katz DI, 2006, COGNITIVE REHABILITA; Keller PE, 2006, J PSYCHOPHYSIOL, V20, P9, DOI 10.1027/0269-8803.20.1.9; Kilner JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004925; Kolb B., 1995, BRAIN PLASTICITY BEH; Korzeniewska A, 2003, J NEUROSCI METH, V125, P195, DOI 10.1016/S0165-0270(03)00052-9; Lee JH, 2006, J NEUROSCI, V26, P3330, DOI 10.1523/JNEUROSCI.3898-05.2006; Lehmann C, 2007, J NEUROSCI METH, V161, P342, DOI 10.1016/j.jneumeth.2006.10.023; Leocani L, 2006, NEUROL SCI, V27, pS27, DOI 10.1007/s10072-006-0542-x; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Maindonald J., 2007, DATA ANAL GRAPHICS U; Mallat S., 1999, WAVELET TOUR SIGNAL; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Murias M, 2007, BIOL PSYCHIAT, V62, P270, DOI 10.1016/j.biopsych.2006.11.012; NAKAMURA T, 2009, PLOS ONE, V14, P4; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Palva S, 2007, TRENDS NEUROSCI, V30, P150, DOI 10.1016/j.tins.2007.02.001; PERCIVAL DP, 1995, BIOMETRIKA, V82, P619, DOI 10.1093/biomet/82.3.619; PIVIK RT, 1993, PSYCHOPHYSIOLOGY, V30, P547, DOI 10.1111/j.1469-8986.1993.tb02081.x; PRIGATANO GP, 1991, AWARENESS DEFICITS B; Quigley M, 2001, AM J NEURORADIOL, V22, P294; REITAN RM, 1992, HALSTEADREITAN NEURO; Ripley B.D., 2007, PATTERN RECOGN; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; Rubinov M, 2009, AM J GERIAT PSYCHIAT, V17, P210, DOI 10.1097/JGP.0b013e318187137a; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Schnitzler A, 2005, NAT REV NEUROSCI, V6, P285, DOI 10.1038/nrn1650; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P90, DOI 10.1080/13854049608406667; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Stam CJ, 2006, NEUROIMAGE, V32, P1335, DOI 10.1016/j.neuroimage.2006.05.033; Stam CJ, 2010, J NEUROL SCI, V289, P128, DOI 10.1016/j.jns.2009.08.028; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; Stam CJ, 2002, J CLIN NEUROPHYSIOL, V19, P562, DOI 10.1097/00004691-200212000-00010; Stam CJ, 2007, HUM BRAIN MAPP, V28, P1178, DOI 10.1002/hbm.20346; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Tucha O, 2000, NEUROSURGERY, V47, P324, DOI 10.1097/00006123-200008000-00011; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; von Stein A, 2000, INT J PSYCHOPHYSIOL, V38, P301, DOI 10.1016/S0167-8760(00)00172-0; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILSON B, 1996, CASE STUDIES NEUROPS; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; Witte OW, 1997, ADV NEUROL, V73, P207	93	87	93	1	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2010	133		8				2365	2381		10.1093/brain/awq174			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	639NY	WOS:000280982700017	20826433	Green Accepted, Bronze			2021-06-18	
J	Raymont, V; Salazar, AM; Lipsky, R; Goldman, D; Tasick, G; Grafman, J				Raymont, V.; Salazar, A. M.; Lipsky, R.; Goldman, D.; Tasick, G.; Grafman, J.			Correlates of posttraumatic epilepsy 35 years following combat brain injury	NEUROLOGY			English	Article							PENETRATING HEAD-INJURY; POST-TRAUMATIC EPILEPSY; MECHANICAL INJURY; SEIZURES; SOFTWARE; GENETICS; GENES; RISK	Background: The Vietnam Head Injury Study (VHIS) is a prospective, longitudinal follow-up of 1,221 Vietnam War veterans with mostly penetrating head injuries (PHIs). The high prevalence (45%-53%) of posttraumatic epilepsy (PTE) in this unique cohort makes it valuable for study. Methods: A standardized multidisciplinary neurologic, cognitive, behavioral, and brain imaging evaluation was conducted on 199 VHIS veterans plus uninjured controls, some 30 to 35 years after injury, as part of phase 3 of this study. Results: The prevalence of seizures (87 patients, 43.7%) was similar to that found during phase 2 evaluations 20 years earlier, but 11 of 87 (12.6%) reported very late onset of PTE after phase 2 (more than 14 years after injury). Those patients were not different from patients with earlier-onset PTE in any of the measures studied. Within the phase 3 cohort, the most common seizure type last experienced was complex partial seizures (31.0%), with increasing frequency after injury. Of subjects with PTE, 88% were receiving anticonvulsants. Left parietal lobe lesions and retained ferric metal fragments were associated with PTE in a logistic regression model. Total brain volume loss predicted seizure frequency. Conclusions: Patients with PHI carry a high risk of PTE decades after their injury, and so require long-term medical follow-up. Lesion location, lesion size, and lesion type were predictors of PTE. Neurology (R) 2010;75:224-229	[Raymont, V.; Salazar, A. M.; Grafman, J.] Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Raymont, V.; Tasick, G.] Henry M Jackson Fdn, Natl Naval Med Ctr, Vietnam Head Injury Study, Bethesda, MD USA; [Raymont, V.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Lipsky, R.] Inova Fairfax Hosp, Inova Hlth Syst, Dept Neurosci, Falls Church, VA USA; [Goldman, D.] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA	Grafman, J (corresponding author), Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bldg 10,Room 7D43,MSC 1440, Bethesda, MD 20892 USA.	grafmanj@ninds.nih.gov	Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020	Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Lipsky, Robert/0000-0001-7753-1473; Grafman, Jordan H./0000-0001-8645-4457	United States Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); National Institute on Alcohol Abuse and Alcoholism intramural research programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); UD Department of Defense; US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); National Institute of Neurological Disorders and Stroke intramural research programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000301] Funding Source: NIH RePORTER	Dr. Raymont was supported by a project grant from the United States Army Medical Research and Material Command and administered by the Henry M. Jackson Foundation (DAMD17-01-1-0675). Dr. Salazar is CEO and Chairman of Oncovir, Inc., in which he owns stock; serves on the editorial board of the Journal of Neurology Neurosurgery & Psychiatry; and may accrue revenue on a patent re: Method for Preparation of large batches of Poly-ICLC. Dr. Lipsky serves as a field editor for Amino Acids and on the editorial board of CNS and Neurological Disorders-Drug Targets; may accrue revenue on a patents re: A Missense Variant (P10L) of the Melanopsin (OPN4) Gene in Seasonal Affective Disorder and re: Methods for detecting nucleic acid sequence variation; was supported by the National Institute on Alcohol Abuse and Alcoholism intramural research program; and receives research support from the UD Department of Defense. Dr. Goldman is supported by the National Institute on Alcohol Abuse and Alcoholism intramural research program. Ms. Tasick was supported by a project grant from the US Army Medical Research and Material Command and administered by the Henry M. Jackson Foundation (DAMD17-01-1-0675). Dr. Grafman is supported by the National Institute of Neurological Disorders and Stroke intramural research program; and serves as Coeditor of Cortex.	Aarabi B, 2000, Neurosurg Focus, V8, pe1; ADELOYE A, 1971, Clinical Radiology, V22, P312, DOI 10.1016/S0009-9260(71)80079-X; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1960, AFQT7A DEP DEF; Bazan N G, 1999, Adv Neurol, V79, P659; Benarroch EE, 2007, NEUROLOGY, V68, P612, DOI 10.1212/01.wnl.0000255669.83468.dd; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Crino PB, 2007, EPILEPSIA, V48, P42, DOI 10.1111/j.1528-1167.2007.01066.x; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Grafman J, 1992, Adv Neurol, V57, P369; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Gurnett CA, 2007, ARCH NEUROL-CHICAGO, V64, P324, DOI 10.1001/archneur.64.3.324; Helmstaedter C, 2001, CURR OPIN NEUROL, V14, P211, DOI 10.1097/00019052-200104000-00013; Jennett B, 1975, J R Coll Physicians Lond, V9, P231; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Noebels JL, 2003, ANNU REV NEUROSCI, V26, P599, DOI 10.1146/annurev.neuro.26.010302.081210; Pagni Carlo Alberto, 2006, Expert Rev Neurother, V6, P1223, DOI 10.1586/14737175.6.8.1223; PANTER SS, 1984, T ASSOC AM PHYSICIAN, V97, P56; Prince D A, 1999, Adv Neurol, V79, P665; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; RUSSELL WR, 1951, J NEUROL NEUROSUR PS, V14, P35, DOI 10.1136/jnnp.14.1.35; Salazar A, 1987, ADV EPILEPTOL, P267; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1999, AM ASS NEUROLOGICAL, P281; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Talairach J., 1988, COPLANAR STEREOTAXIC; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Wechsler D, 1997, WAIS 3 ADM SCORING M; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	40	87	91	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JUL 20	2010	75	3					224	229		10.1212/WNL.0b013e3181e8e6d0			6	Clinical Neurology	Neurosciences & Neurology	628ES	WOS:000280097900007	20644150	Green Published			2021-06-18	
J	Bell, RS; Mossop, CM; Dirks, MS; Stephens, FL; Mulligan, L; Ecker, R; Neal, CJ; Kumar, A; Tigno, T; Armonda, RA				Bell, Randy S.; Mossop, Corey M.; Dirks, Michael S.; Stephens, Frederick L.; Mulligan, Lisa; Ecker, Robert; Neal, Christopher J.; Kumar, Anand; Tigno, Teodoro; Armonda, Rocco A.			Early decompressive craniectomy for severe penetrating and closed head injury during wartime	NEUROSURGICAL FOCUS			English	Article						decompressive craniectomy; penetrating head injury; blast injury; Glasgow Outcome Scale	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; WOUNDS	Object. Decompressive craniectomy has defined this era of damage-control wartime neurosurgery. Injuries that in previous conflicts were treated in an expectant manner are now aggressively decompressed at the far-forward Combat Support Hospital and transferred to Walter Reed Army Medical Center (WRAMC) and National Naval Medical Center (NNMC) in Bethesda for definitive care. The purpose of this paper is to examine the baseline characteristics of those injured warriors who received decompressive craniectomies. The importance of this procedure will be emphasized and guidance provided to current and future neurosurgeons deployed in theater. Methods. The authors retrospectively searched a database for all soldiers injured in Operations Iraqi Freedom and Enduring Freedom between April 2003 and October 2008 at WRAMC and NNMC. Criteria for inclusion in this study included either a closed or penetrating head injury suffered during combat operations in either Iraq or Afghanistan with subsequent neurosurgical evaluation at NNMC or WRAMC. Exclusion criteria included all cases in which primary demographic data could not be verified. Primary outcome data included the type and mechanism of injury, Glasgow Coma Scale (GCS) score and injury severity score (ISS) at admission, and Glasgow Outcome Scale (GOS) score at discharge, 6 months, and 1-2 years. Results. Four hundred eight patients presented with head injury during the study period. In this population, a total of 188 decompressive craniectomies were performed (154 for penetrating head injury, 22 for closed head injury, and 12 for unknown injury mechanism). Patients who underwent decompressive craniectomies in the combat theater had significantly lower initial GCS scores (7.7 +/- 4.2 vs 10.8 +/- 4.0, p < 0.05) and higher ISSs (32.5 +/- 9.4 vs 26.8 +/- 11.8, p < 0.05) than those who did not. When comparing the GOS scores at hospital discharge, 6 months, and 1-2 years after discharge, those receiving decompressive craniectomies had significantly lower scores (3.0 +/- 0.9 vs 3.7 +/- 0.9, 3.5 +/- 1.2 vs 4.0 +/- 1.0, and 3.7 +/- 1.2 vs 4.4 +/- 0.9, respectively) than those who did not undergo decompressive craniectomies. That said, intragroup analysis indicated consistent improvement for those with craniectomy with time, allowing them, on average, to participate in and improve from rehabilitation (p < 0.05). Overall, 83% of those for whom follow-up data are available achieved a 1-year GOS score of greater than 3. Conclusions. This study of the provision of early decompressive craniectomy in a military population that sustained severe penetrating and closed head injuries represents one of the largest to date in both the civilian and military literature. The findings suggest that patients who undergo decompressive craniectomy had worse injuries than those receiving craniotomy and, while not achieving the same outcomes as those with a lesser injury, did improve with time. The authors recommend hemicraniectomy for damage control to protect patients from the effects of brain swelling during the long overseas transport to their definitive care, and it should be conducted with foresight concerning future complications and reconstructive surgical procedures. (DOI: 10.3171/2010.2.FOCUS1022)	[Bell, Randy S.; Mossop, Corey M.; Dirks, Michael S.; Stephens, Frederick L.; Mulligan, Lisa; Neal, Christopher J.; Armonda, Rocco A.] Univ Hlth Sci, Uniformed Serv, Bethesda, MD USA; [Bell, Randy S.; Mulligan, Lisa; Ecker, Robert; Neal, Christopher J.; Kumar, Anand; Armonda, Rocco A.] USN, Med Ctr, Dept Neurosurg, Bethesda, MD 20814 USA; [Tigno, Teodoro; Armonda, Rocco A.] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA; [Mossop, Corey M.; Dirks, Michael S.; Stephens, Frederick L.; Armonda, Rocco A.] Natl Capital Consortium Neurosurg Program, Washington, DC USA	Bell, RS (corresponding author), NAVMED MPT&E, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	randy.s.bell@us.army.mil			University of Texas, Medical Branch	The authors are thankful for the service of all neurosurgeons deployed during OIF and OEF. They also thank Dr. Alexander H. Vo, Ph. D., from the University of Texas, Medical Branch, for his support with statistical analysis.	Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bell RS, 2010, NEUROSURGERY, V66, P66, DOI 10.1227/01.NEU.0000361285.50218.A8; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; BELLAMY RF, 1984, MIL MED, V149, P55; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Cushing H, 1918, BRIT J SURG, V5, P558; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Manley GT, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS.JUNE09.INTRO; MATSON D, 1958, MANAGEMENT ACUTE CRA, V1; McNatt SA, 2005, NEUROSURGERY, V57, pE191, DOI [10.1227/01.NEU.0000175727.76530.94, 10.1227/01.NEU.0000164174.07281.F9]; Munch E, 2000, NEUROSURGERY, V47, P315; NAKAGAWA M, 2004, RSMC TOKYO TYPHOON C, V7, P10	17	87	93	1	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2010	28	5							E1	10.3171/2010.2.FOCUS1022			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	589ZU	WOS:000277193600001	20568925				2021-06-18	
J	Liu, MC; Akinyi, L; Scharf, D; Mo, JX; Larner, SF; Muller, U; Oli, MW; Zheng, WR; Kobeissy, F; Papa, L; Lu, XC; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW				Liu, Ming C.; Akinyi, Linnet; Scharf, Dancia; Mo, Jixiang; Larner, Stephen F.; Muller, Uwe; Oli, Monika W.; Zheng, Wenrong; Kobeissy, Firas; Papa, Linda; Lu, Xi-Chun; Dave, Jitendra R.; Tortella, Frank C.; Hayes, Ronald L.; Wang, Kevin K. W.			Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						biomarker; cell death; ischemia; diagnosis; stroke; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SPECTRIN BREAKDOWN PRODUCTS; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID; SURROGATE MARKERS; OUTCOME PREDICTION; SERUM BIOMARKER; S-100 PROTEIN; CALPAIN-I; NF-H	Ubiquitin C-terminal hydrolase-L1 (UCH-L1), also called neuronal-specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH-L1 was significantly elevated in cerebrospinal fluid (CSF) following controlled cortical impact (CCI) and middle cerebral artery occlusion (MCAO; model of ischemic stroke) in rats. Quantitative immunoblots of rat CSF revealed a dramatic elevation of UCH-L1 protein 48 h after severe CCI and as early as 6 h after mild (30 min) and severe (2 h) MCAO. A sandwich enzyme-linked immunosorbent assay constructed to measure UCH-L1 sensitively and quantitatively showed that CSF UCH-L1 levels were significantly elevated as early as 2 h and up to 48 h after CCI. Similarly, UCH-L1 levels were also significantly elevated in CSF from 6 to 72 h after 30 min of MCAO and from 6 to 120 h after 2 h of MCAO. These data are comparable to the profile of the calpain-produced alpha II-spectrin breakdown product of 145 kDa biomarker. Importantly, serum UCH-L1 biomarker levels were also significantly elevated after CCI. Similarly, serum UCH-L1 levels in the 2-h MCAO group were significantly higher than those in the 30-min group. Taken together, these data from two rat models of acute brain injury strongly suggest that UCH-L1 is a candidate brain injury biomarker detectable in biofluid compartments (CSF and serum).	[Liu, Ming C.; Larner, Stephen F.; Zheng, Wenrong; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Akinyi, Linnet; Scharf, Dancia; Mo, Jixiang; Muller, Uwe; Oli, Monika W.; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Diagnost Res & Dev Dept, Alachua, FL 32615 USA; [Kobeissy, Firas; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, McKnight Brain Inst, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Lu, Xi-Chun; Dave, Jitendra R.; Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD USA; [Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Wang, Kevin K. W.] Taipei Med Univ, Taipei, Taiwan	Wang, KKW (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	kwang@banyanbio.com	Dave, Jitendra R/A-8940-2011; Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0066]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01 A1, 2R44NS048685-02]; Florida State Center for Nano-Bio Sensors (CNBS) grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS048685, R01NS049175] Funding Source: NIH RePORTER	The authors would like to acknowledge the support of Department of Defense grant DAMD17-03-1-0066 (R. L. Hayes), NIH grants R01 NS049175-01 A1 (K. Wang) and 2R44NS048685-02 (K. K. Wang), and a Florida State Center for Nano-Bio Sensors (CNBS) grant (K. K. Wang). This article has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the true views of the Department of the Army or the Department of Defense. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals, and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 1996 edition. K. K. Wang and R. L. Hayes hold equity in Banyan Biomarkers, Inc., a company that commercializes technology for detecting brain injury biomarkers.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Choi DW, 2002, NAT NEUROSCI, V5, P1023, DOI 10.1038/nn930; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Elkind MSV, 2003, MT SINAI J MED, V70, P27; Ge PF, 2007, STROKE, V38, P3230, DOI 10.1161/STROKEAHA.107.487108; Hu BR, 2001, J CEREBR BLOOD F MET, V21, P865, DOI 10.1097/00004647-200107000-00012; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kwon J, 2005, BIOL REPROD, V73, P29, DOI 10.1095/biolreprod.104.037077; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Lincoln S, 1999, NEUROREPORT, V10, P427, DOI 10.1097/00001756-199902050-00040; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marin R, 2003, PHYSIOL BEHAV, V80, P167, DOI 10.1016/j.physbeh.2003.06.001; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Saigoh K, 1999, NAT GENET, V23, P47; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Sultana R, 2007, J ALZHEIMERS DIS, V11, P153; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; Wilkinson KD, 1997, FASEB J, V11, P1245; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zaremba J, 2001, ACTA NEUROL SCAND, V104, P288, DOI 10.1034/j.1600-0404.2001.00053.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	65	87	94	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2010	31	4					722	732		10.1111/j.1460-9568.2010.07097.x			11	Neurosciences	Neurosciences & Neurology	555XH	WOS:000274549500013	20384815	Green Accepted			2021-06-18	
J	Froelich, M; Ni, QH; Wess, C; Ougorets, I; Hartl, R				Froelich, Matteus; Ni, Quanhong; Wess, Christian; Ougorets, Igor; Hartl, Roger			Continuous hypertonic saline therapy and the occurrence of complications in neurocritically ill patients	CRITICAL CARE MEDICINE			English	Article						hypertonic saline; intracranial pressure; deep vein thrombosis; hypernatremia; sodium; intensive care; complications; renal failure; renal dysfunction; neurosurgery; deep vein thrombosis; treatment; traumatic brain injury; traumatic brain injury	POSTTRAUMATIC INTRACRANIAL HYPERTENSION; DURAL SINUS THROMBOSIS; TRAUMATIC BRAIN INJURY; INTENSIVE-CARE-UNIT; CEREBRAL-BLOOD-FLOW; SODIUM-CHLORIDE; HEMORRHAGIC-SHOCK; RENAL-FAILURE; HEAD-INJURY; MANNITOL	Objective: To evaluate potential side effects of continuous hypertonic 3% saline (CHS) as maintenance fluid in patients with brain injury. Methods: Retrospective chart analysis of prospectively collected data. Patients. Patients admitted to the neurosurgical Intensive care unit for >4 days with traumatic brain injury, stroke, or subarachnoid hemorrhage with a Glasgow Coma Scale <9 and elevated intracranial pressure (ICP) or at risk of developing elevated ICP were included. Based on physician preference, one group was treated with 3% CHS at a rate of 1.5 mL/kg/bw as maintenance fluid. The other group received 0.9% normal saline (NS). Two percent saline was used in the CHS group to wean patients off 3% CHS or when sodium was above 155. Data on serum sodium, blood urea nitrogen, creatinine, ICP, infection rate, length of stay, rates of deep vein thrombosis, and pulmonary emboli and dural thrombosis were collected prospectively. Results: One hundred seven patients in the CHS group and 80 in the NS group met the inclusion criteria. The incidence of moderate hypernatremia (Na >155 mmol/L) and severe hypernatremia (Na >160 mmol/L) was significantly higher in the CHS therapy group than in the NS group. No significant relationship between CHS infusion and renal dysfunction was found. Moderate and severe hypernatremia was associated with a higher risk of elevated blood urea nitrogen and creatinine levels. Acute renal failure was not seen in these patients. A total of 53.3% in the CHS group and in 16.3% in the NS group (p < 0.0001) had raised ICP (>25 mm Hg), consistent with the physicians decision to use CHS in patients with elevated ICP. Conclusions. CHS therapy was not associated with an increased rate of infection, deep vein thrombosis, or renal failure. However, there was a significant risk of developing hypernatremia. We conclude that CHS administration in patients with severe injuries is safe as long as sodium levels are carefully monitored. (Crit Care Med 2009; 37:1433-1441)	[Froelich, Matteus] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Froelich, Matteus; Wess, Christian; Ougorets, Igor; Hartl, Roger] Karolinska Inst, Div Clin CNS Res, Neurosurg Sect, Stockholm, Sweden; [Froelich, Matteus; Wess, Christian; Ougorets, Igor; Hartl, Roger] New York Presbyterian Hosp, Dept Neurol Surg, Weill Cornell Med Coll, New York, NY USA; [Ni, Quanhong] New York Presbyterian Hosp, Dept Publ Hlth, Weill Cornell Med Coll, New York, NY USA	Hartl, R (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.	roger@hartlmd.net					Abbott R, 2005, BRIT MED J, V331, P829, DOI 10.1136/bmj.331.7520.829; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS14; Bergada I, 2004, HORM RES, V61, P108, DOI 10.1159/000075374; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BICKELL WH, 1991, SURGERY, V110, P529; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Detry O, 2006, WORLD J GASTROENTERO, V12, P7405, DOI 10.3748/wjg.v12.i46.7405; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Dziedzic T, 2003, CLIN NEUROL NEUROSUR, V105, P87, DOI 10.1016/S0303-8467(02)00106-3; FINBERG L, 1963, JAMA-J AM MED ASSOC, V184, P187, DOI 10.1001/jama.1963.03700160063009; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GERBER JG, 1979, AM J PHYSIOL, V237, pF441; GOLDMAN JA, 1972, AM J OBSTET GYNECOL, V112, P1132, DOI 10.1016/0002-9378(72)90193-7; Gondim FDA, 2005, J NEUROSURG, V103, P444; GRANT PJ, 1985, THROMB RES, V40, P393, DOI 10.1016/0049-3848(85)90274-9; GROSS D, 1989, J TRAUMA, V29, P79, DOI 10.1097/00005373-198901000-00016; Hartl R, 1997, ACT NEUR S, V70, P126; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; HARTL R, 1995, SHOCK, V3, P274; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hartl Roger, 2004, Curr Neurol Neurosci Rep, V4, P481, DOI 10.1007/s11910-004-0073-x; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809; Himmelseher S, 2007, CURR OPIN ANESTHESIO, V20, P414, DOI 10.1097/ACO.0b013e3282eff9ea; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; HUDAK ML, 1989, AM J PHYSIOL, V257, pH912; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; Kamijo Y, 2003, J TOXICOL-CLIN TOXIC, V41, P359, DOI 10.1081/CLT-120022003; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; KRAUSZ MM, 1992, ARCH SURG-CHICAGO, V127, P93; Kuroda T, 1997, BURNS, V23, P338, DOI 10.1016/S0305-4179(96)00134-9; Laureno R, 1997, ANN INTERN MED, V126, P57, DOI 10.7326/0003-4819-126-1-199701010-00008; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; Ng KFJ, 2002, BRIT J ANAESTH, V88, P475, DOI 10.1093/bja/88.4.475; Palevsky PM, 1996, ANN INTERN MED, V124, P197, DOI 10.7326/0003-4819-124-2-199601150-00002; Perez-Perez AJ, 2002, AM J NEPHROL, V22, P573, DOI 10.1159/000065279; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Pinto FCG, 2006, J TRAUMA, V60, P758, DOI 10.1097/01.ta.0000214581.89316.73; Polderman KH, 1999, CRIT CARE MED, V27, P1105, DOI 10.1097/00003246-199906000-00029; PRIEN T, 1993, ZBL CHIR, V118, P257; PRIEN T, 1993, ZENTRALBL CHIR, V118, P264; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Raghavan M, 2006, NEUROCRIT CARE, V4, P179, DOI 10.1385/NCC:4:2:179; REED RL, 1991, J TRAUMA, V31, P8, DOI 10.1097/00005373-199101000-00002; Ruttmann TG, 1998, BRIT J ANAESTH, V80, P612; Ruttmann TG, 1996, BRIT J ANAESTH, V76, P412; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; Suarez JI, 1999, J NEUROSURG ANESTH, V11, P178, DOI 10.1097/00008506-199907000-00004; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Takefuji S, 2007, EXP NEUROL, V204, P88, DOI 10.1016/j.expneurol.2006.09.025; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Valadka AB, 2000, CRIT CARE MED, V28, P1245, DOI 10.1097/00003246-200004000-00069; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vikrant Sanjay, 2007, Clin Exp Nephrol, V11, P88, DOI 10.1007/s10157-006-0449-0; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wilder DM, 2002, THROMB RES, V107, P255, DOI 10.1016/S0049-3848(02)00335-3	76	87	91	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2009	37	4					1433	1441		10.1097/CCM.0b013e31819c1933			9	Critical Care Medicine	General & Internal Medicine	426HQ	WOS:000264699000036	19242317				2021-06-18	
J	Jayakumar, AR; Liu, ML; Moriyama, M; Ramakrishnan, R; Forbush, B; Reddy, PVB; Norenberg, MD				Jayakumar, Arumugam R.; Liu, Mingli; Moriyama, Mitsuaki; Ramakrishnan, Ramugounder; Forbush, Bliss, III; Reddy, Pichili V. B.; Norenberg, Michael D.			Na-K-Cl Cotransporter-1 in the Mechanism of Ammonia-induced Astrocyte Swelling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; ION-TRANSPORT; NA+-K+-2CL(-) COTRANSPORTER; HEPATIC-ENCEPHALOPATHY; PRIMARY CULTURES; BENZODIAZEPINE-RECEPTOR; GLUTAMATE TRANSPORTER; MOLECULAR-MECHANISMS; OXIDATIVE STRESS; TYROSINE KINASE	Brain edema and the consequent increase in intracranial pressure and brain herniation are major complications of acute liver failure (fulminant hepatic failure) and a major cause of death in this condition. Ammonia has been strongly implicated as an important factor, and astrocyte swelling appears to be primarily responsible for the edema. Ammonia is known to cause cell swelling in cultured astrocytes, although the means by which this occurs has not been fully elucidated. A disturbance in one or more of these systems may result in loss of ion homeostasis and cell swelling. In particular, activation of the Na-K-Cl cotransporter (NKCC1) has been shown to be involved in cell swelling in several neurological disorders. We therefore examined the effect of ammonia on NKCC activity and its potential role in the swelling of astrocytes. Cultured astrocytes were exposed to ammonia (NH4Cl; 5 mM), and NKCC activity was measured. Ammonia increased NKCC activity at 24 h. Inhibition of this activity by bumetanide diminished ammonia-induced astrocyte swelling. Ammonia also increased total as well as phosphorylated NKCC1. Treatment with cyclohexamide, a potent inhibitor of protein synthesis, diminished NKCC1 protein expression and NKCC activity. Since ammonia is known to induce oxidative/nitrosative stress, and antioxidants and nitric-oxide synthase inhibition diminish astrocyte swelling, we also examined whether ammonia caused oxidation and/or nitration of NKCC1. Cultures exposed to ammonia increased the state of oxidation and nitration of NKCC1, whereas the antioxidants N-nitro-L-arginine methyl ester and uric acid all significantly diminished NKCC activity. These agents also reduced phosphorylated NKCC1 expression. These results suggest that activation of NKCC1 is an important factor in the mediation of astrocyte swelling by ammonia and that such activation appears to be mediated by NKCC1 abundance as well as by its oxidation/nitration and phosphorylation.	[Jayakumar, Arumugam R.; Liu, Mingli; Moriyama, Mitsuaki; Ramakrishnan, Ramugounder; Reddy, Pichili V. B.; Norenberg, Michael D.] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; [Norenberg, Michael D.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; [Norenberg, Michael D.] Vet Affairs Med Ctr, Miami, FL 33101 USA; [Moriyama, Mitsuaki] Osaka Prefecture Univ, Lab Integrat Physiol Vet Sci, Osaka 5998531, Japan; [Forbush, Bliss, III] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu		Moriyama, Mitsuaki/0000-0001-8123-8835	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK063311]; Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK063311] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grant DK063311. This work was also supported by a Merit Review from the Department of Veterans Affairs. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Abbruscato TJ, 2004, J PHARMACOL EXP THER, V310, P459, DOI 10.1124/jpet.104.066274; Albrecht J, 1999, J NEUROL SCI, V170, P138, DOI 10.1016/S0022-510X(99)00169-0; Albrecht J, 2006, HEPATOLOGY, V44, P788, DOI 10.1002/hep.21357; Bender AS, 1996, NEUROCHEM RES, V21, P567, DOI 10.1007/BF02527755; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.3.CO;2-G; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chin SS, 1999, CURR EYE RES, V18, P254, DOI 10.1076/ceyr.18.4.254.5359; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619; ELLIOTT SJ, 1992, AM J PHYSIOL, V263, pH96; GREGORIOS JB, 1985, J NEUROPATH EXP NEUR, V44, P404, DOI 10.1097/00005072-198507000-00004; GREGORIOS JB, 1985, J NEUROPATH EXP NEUR, V44, P397, DOI 10.1097/00005072-198507000-00003; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; HANSSON E, 1986, NEUROCHEM RES, V11, P759, DOI 10.1007/BF00965202; Hazell AS, 1999, P SOC EXP BIOL MED, V222, P99, DOI 10.1046/j.1525-1373.1999.d01-120.x; Hertz L, 1994, HDB NEUROCHEMISTRY, P603; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Isaacks RE, 1999, NEUROCHEM RES, V24, P51, DOI 10.1023/A:1020928029845; ITZHAK Y, 1994, NEUROSCI LETT, V177, P35, DOI 10.1016/0304-3940(94)90038-8; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Juncos R, 2005, AM J PHYSIOL-RENAL, V288, pF982, DOI 10.1152/ajprenal.00348.2004; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kaplan MR, 1996, ANNU REV PHYSIOL, V58, P649, DOI 10.1146/annurev.ph.58.030196.003245; KIMELBERG HK, 1983, CELL MOL NEUROBIOL, V3, P1, DOI 10.1007/BF00734994; KIMELBERG HK, 1985, BRAIN RES, V361, P125, DOI 10.1016/0006-8993(85)91282-X; KIMELBERG HK, 1987, J PHYSIOL-PARIS, V82, P294; Kintner DB, 2007, AM J PHYSIOL-CELL PH, V292, pC1113, DOI 10.1152/ajpcell.00412.2006; Kintner DB, 2007, FRONT BIOSCI-LANDMRK, V12, P762, DOI 10.2741/2099; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Lenart B, 2004, J NEUROSCI, V24, P9585, DOI 10.1523/JNEUROSCI.2569-04.2004; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; MacVicar BA, 2002, GLIA, V37, P114, DOI 10.1002/glia.10023; Mallozzi C, 2001, FEBS LETT, V503, P189, DOI 10.1016/S0014-5793(01)02726-0; MARTINEZ A, 1968, ACTA NEUROPATHOL, V11, P82, DOI 10.1007/BF00692797; Mobasheri A, 1998, HISTOL HISTOPATHOL, V13, P893, DOI 10.14670/HH-13.893; Murthy CRK, 2001, J NEUROSCI RES, V66, P282, DOI 10.1002/jnr.1222; Nagaraja TN, 1998, AM J PHYSIOL-CELL PH, V274, pC883; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; NORENBERG MD, 1990, J NEUROPATH EXP NEUR, V49, P399, DOI 10.1097/00005072-199007000-00004; Norenberg MD, 1996, SEMIN LIVER DIS, V16, P245, DOI 10.1055/s-2007-1007237; Norenberg MD, 2004, METAB BRAIN DIS, V19, P313, DOI 10.1023/B:MEBR.0000043978.91675.79; Norenberg MD, 1997, GLIA, V21, P124; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; Norenberg MD, 2003, HEPATOLOGY, V37, P245, DOI 10.1053/jhep.2003.50087; Norenberg MD, 1998, METAB BRAIN DIS, V13, P319, DOI 10.1023/A:1020688925901; NORENBERG MD, 1977, LAB INVEST, V36, P618; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; NORENBERG MD, 1987, NEUROCHEM PATHOL, V6, P13, DOI 10.1007/BF02833599; NORENBERG MD, 2001, ASTROCYTES AGING BRA, P477; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Pichili VBR, 2007, GLIA, V55, P801, DOI 10.1002/glia.20499; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173; Rao KVR, 2003, J NEUROSCI RES, V74, P891, DOI 10.1002/jnr.10755; Rose CR, 1996, J PHYSIOL-LONDON, V491, P291, DOI 10.1113/jphysiol.1996.sp021216; Rose CR, 1998, J NEUROSCI, V18, P3554; Russell JM, 2000, PHYSIOL REV, V80, P211; Schomberg SL, 2003, J NEUROPHYSIOL, V89, P159, DOI 10.1152/jn.00229.2002; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; STAUB F, 1994, J NEUROTRAUM, V11, P679, DOI 10.1089/neu.1994.11.679; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Su G, 2000, AM J PHYSIOL-CELL PH, V279, pC1710; Sun DD, 1999, J NEUROPHYSIOL, V81, P1939; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; TAS PWL, 1987, BIOCHIM BIOPHYS ACTA, V903, P411, DOI 10.1016/0005-2736(87)90047-2; TAS PWL, 1986, NEUROSCI LETT, V70, P369, DOI 10.1016/0304-3940(86)90581-1; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Vaquero Javier, 2003, Ann Hepatol, V2, P12; WALZ W, 1992, CAN J PHYSIOL PHARM, V70, pS260, DOI 10.1139/y92-270; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; Yan YP, 2001, BRAIN RES, V911, P43, DOI 10.1016/S0006-8993(01)02649-X; Zhou BG, 1999, NEUROSCI LETT, V276, P145, DOI 10.1016/S0304-3940(99)00816-2	84	87	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2008	283	49					33874	33882		10.1074/jbc.M804016200			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	377UY	WOS:000261277700012	18849345	Green Published, Other Gold			2021-06-18	
J	Jones, KE; Puccio, AM; Harshman, KJ; Falcione, B; Benedict, N; Jankowitz, BT; Stippler, M; Fischer, M; Sauber-Schatz, EK; Fabio, A; Darby, JM; Okonkwo, DO				Jones, Kristen E.; Puccio, Ava M.; Harshman, Kathy J.; Falcione, Bonnie; Benedict, Neal; Jankowitz, Brian T.; Stippler, Martina; Fischer, Michael; Sauber-Schatz, Erin K.; Fabio, Anthony; Darby, Joseph M.; Okonkwo, David O.			Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						antiepileptic drug; posttraumatic seizure; seizure prophylaxis; traumatic brain injury	POSTTRAUMATIC SEIZURES; PREVENTION	Object. Current standard of care for patients with severe traumatic brain injury (TBI) is prophylactic treatment with phenytoin for 7 days to decrease the risk of early posttraumatic seizures. Phenytoin alters drug metabolism, induces fever, and requires therapeutic-level monitoring. Alternatively, levetiracetam (Keppra) does not require serum monitoring or have significant pharmacokinetic interactions. In the current study, the authors compare the EEG findings in patients receiving phenytoin with those receiving levetiracetam monotherapy for seizure prophylaxis following severe TBI. Methods. Data were prospectively collected in 32 cases in which patients received levetiracetam for the first 7 days after severe TBI and compared with data from a historical cohort of 41 cases in which patients received phenytoin monotherapy. Patients underwent 1-hour electroencephalographic (EEG) monitoring if they displayed persistent coma, decreased mental status, or clinical signs of seizures. The EEG results were grouped into normal and abnormal findings, with abnormal EEG findings further categorized as seizure activity or seizure tendency. Results. Fifteen of 32 patients in the levetiracetam group warranted EEG monitoring. In 7 of these 15 cases the results were normal and in 8 abnormal; 1 patient had seizure activity, whereas 7 had seizure tendency. Twelve of 41 patients in the phenytoin group received EEG monitoring, with all results being normal. Patients treated with levetiracetam and phenytoin had equivalent incidence of seizure activity (p = 0.556). Patients receiving levetiracetam had a higher incidence of abnormal EEG findings (p = 0.003). Conclusions. Levetiracetam is as effective as phenytoin in preventing early posttraumatic seizures but is associated with an increased seizure tendency on EEG analysis.	[Jones, Kristen E.; Puccio, Ava M.; Harshman, Kathy J.; Jankowitz, Brian T.; Stippler, Martina; Fischer, Michael; Sauber-Schatz, Erin K.; Fabio, Anthony; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15213 USA; [Falcione, Bonnie; Benedict, Neal] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; [Darby, Joseph M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Med Ctr, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu		Jones, Kristen/0000-0002-2007-028X; Fabio, Anthony/0000-0002-6808-4939	University of Pittsburgh Brain Trauma Research CenterUniversity of Pittsburgh [NIH P50NS30318]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER	This research was performed at the University of Pittsburgh Medical Center and was supported by the University of Pittsburgh Brain Trauma Research Center (NIH P50NS30318).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; JONES GL, 1983, MED RES REV, V3, P383, DOI 10.1002/med.2610030403; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Ramael S, 2006, EPILEPSIA, V47, P1128, DOI 10.1111/j.1528-1167.2006.00586.x; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sahin S, 2008, CLIN NEUROPHARMACOL, V31, P93, DOI 10.1097/WNF.0b013e31806ad6cb; Schierhout G, 2001, COCHRANE DB SYST REV, V4; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC	15	87	90	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E3	10.3171/FOC.2008.25.10.E3			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100003	18828701	Bronze, Green Accepted			2021-06-18	
J	Lai, Y; Chen, Y; Watkins, SC; Nathaniel, PD; Guo, F; Kochanek, PM; Jenkins, LW; Szabo, C; Clark, RSB				Lai, Yichen; Chen, Yaming; Watkins, Simon C.; Nathaniel, Paula D.; Guo, Fengli; Kochanek, Patrick M.; Jenkins, Larry W.; Szabo, Csaba; Clark, Robert S. B.			Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						ADP-ribosyltransferase; controlled cortical impact; electron transport chain; poly(ADP-ribose) polymerase; poly(ADP-ribose) synthetase; proteomics	APOPTOSIS-INDUCING FACTOR; POLY(ADP-RIBOSE) PAR POLYMER; INDUCED CELL-DEATH; NAD(+) DEPLETION; HEAT-SHOCK; DAMAGE; DNA; GLYCOHYDROLASE; STRESS; MICE	Poly-ADP-ribosylation is a post-translational modification performed by poly(ADP-ribose) polymerases (PARP), involved in many diverse cellular functions including DNA repair, transcription, and long-term potentiation. Paradoxically, PARP over-activation under pathologic conditions including traumatic brain injury (TBI) results in cell death. We previously demonstrated that intra-mitochondrial poly-ADP-ribosylation occurs following excitotoxic and oxidative injury in vitro. Here we sought to identify mitochondrial proteins modified by poly-ADP-ribosylation after TBI in vivo. Poly-ADP-ribosylation within mitochondria from injured brain after experimental TBI in rats was first verified using western blot and immuno-electron microscopy. Poly-ADP-ribosylated mitochondrial proteins identified using a targeted proteomic approach included voltage-dependent anion channel-1, mitofilin, mitochondrial stress proteins, and the electron transport chain components F1F0 ATPase, cytochrome c oxidase, and cytochrome c reductase. To examine the functional consequences of mitochondrial poly-ADP-ribosylation, isolated rat brain mitochondria were exposed to conditions of nitrosative stress known to activate PARP. PARP activation-induced reductions in State 3 respiration were prevented by the PARP-1 inhibitor 5-iodo-6-amino-1,2-benzopyrone or exogenous poly(ADP-ribose) glycohydrolase. As the effects of PARP activation on mitochondrial respiration appear regulated by poly(ADP-ribose) glycohydrolase, a direct effect of poly-ADP-ribosylation on electron transport chain function is suggested. These findings may be of relevance to TBI and other diseases where mitochondrial dysfunction occurs.	[Lai, Yichen; Chen, Yaming; Nathaniel, Paula D.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Safar Resuscitation Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Lai, Yichen; Chen, Yaming; Watkins, Simon C.; Nathaniel, Paula D.; Guo, Fengli; Kochanek, Patrick M.; Jenkins, Larry W.; Clark, Robert S. B.] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Watkins, Simon C.; Guo, Fengli] Univ Pittsburgh, Safar Resuscitation Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Safar Resuscitation Res, Dept Pediat, Pittsburgh, PA 15260 USA; [Szabo, Csaba] Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA; [Jenkins, Larry W.] Univ Pittsburgh, Safar Resuscitation Res, Dept Neurol Surg, Pittsburgh, PA USA	Clark, RSB (corresponding author), Univ Pittsburgh, Safar Resuscitation Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Szabo, Csaba/D-1882-2013	Kochanek, Patrick M/0000-0002-2627-913X; Lai, Yi-Chen/0000-0002-9450-5506; watkins, simon/0000-0003-4092-1552	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM060915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686, R01 HD045968] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM060915] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318] Funding Source: Medline		Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; BURZIO LO, 1981, BIOCHEM BIOPH RES CO, V103, P369, DOI 10.1016/0006-291X(81)91702-2; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Cohen-Armon M, 2004, SCIENCE, V304, P1820, DOI 10.1126/science.1096775; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; Cozzi A, 2006, J CEREBR BLOOD F MET, V26, P684, DOI 10.1038/sj.jcbfm.9600222; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; Druzhyna N, 2000, DIABETES, V49, P1849, DOI 10.2337/diabetes.49.11.1849; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Fossati S, 2006, BIOCHEM CELL BIOL, V84, P703, DOI 10.1139/O06-083; Gieffers C, 1997, EXP CELL RES, V232, P395, DOI 10.1006/excr.1997.3539; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Halmosi R, 2001, MOL PHARMACOL, V59, P1497; Hanai S, 2004, P NATL ACAD SCI USA, V101, P82, DOI 10.1073/pnas.2237114100; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; John GB, 2005, MOL BIOL CELL, V16, P1543, DOI 10.1091/mbc.E04-08-0697; Kim N, 2006, PROTEOMICS, V6, P1237, DOI 10.1002/pmic.200500291; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Koh DW, 2004, P NATL ACAD SCI USA, V101, P17699, DOI 10.1073/pnas.0406182101; Lai Y, 2005, J NEUROCHEM, V94, P360, DOI 10.1111/j.1471-4159.2005.03212.x; LAPLACA MC, 1998, J NEUROTRAUM, V15, P878; MASMOUDI A, 1993, BIOCHEM MOL BIOL INT, V29, P77; MASMOUDI A, 1988, J NEUROCHEM, V51, P188, DOI 10.1111/j.1471-4159.1988.tb04854.x; Navet R, 2007, J PROTEOME RES, V6, P25, DOI 10.1021/pr060064u; Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Poitras MF, 2007, NEUROSCIENCE, V148, P198, DOI 10.1016/j.neuroscience.2007.04.062; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Saunders PA, 1997, J NEUROCHEM, V69, P1820; Scovassi AI, 2004, FASEB J, V18, P1487, DOI 10.1096/fj.04-1841rev; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445; Virag L, 1998, J IMMUNOL, V161, P3753; Weeber EJ, 2002, J BIOL CHEM, V277, P18891, DOI 10.1074/jbc.M201649200; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	44	87	88	0	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	2008	104	6					1700	1711		10.1111/j.1471-4159.2007.05114.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	269DC	WOS:000253628700023	17996029				2021-06-18	
J	Onyszchuk, G; He, YY; Berman, NEJ; Brooks, WM				Onyszchuk, Gregory; He, Yong-Yue; Berman, Nancy E. J.; Brooks, William M.			Detrimental effects of aging on outcome from traumatic brain injury: A behavioral, magnetic resonance imaging, and histological study in mice	JOURNAL OF NEUROTRAUMA			English	Article						age; blood-brain barrier dysfunction; geriatric brain injury; neurodegenerative disorders; traumatic brain injury	CONTROLLED CORTICAL IMPACT; PROSPECTIVE MULTICENTER TRIAL; COGNITIVE DEFICITS; INTRACEREBRAL HEMORRHAGE; GENE-EXPRESSION; TRANSGENIC MICE; OLDER-ADULTS; SPINAL-CORD; EDEMA; RECOVERY	Considerable evidence indicates that outcomes from traumatic brain injury (TBI) are worse in the elderly, but there has been little preclinical research to explore potential mechanisms. In this study, we examined the age-related effects on outcome in a mouse model of controlled cortical impact (CCI) injury. We compared the responses of adult (5-6 months old) and aged (21-24 months old) male mice following a moderate lateral CCI injury to the sensorimotor cortex. Sensorimotor function was evaluated with the rotarod, gridwalk and spontaneous forelimb behavioral tests. Acute edema was assessed from hyperintensity on T2-weighted magnetic resonance images. Blood-brain barrier opening was measured using anti-mouse immunoglobulin G (IgG) immunohistochemistry. Neurodegeneration was assessed by amino-cupric silver staining, and lesion cavity volumes were measured from histological images. Indicators of injury were generally worse in the aged than the adult mice. Acute edema, measured at 24 and 48 h post-injury, resolved more slowly in the aged mice (p < 0.01). Rotarod recovery (p < 0.05) and gridwalk deficits (p < 0.01) were significantly worse in aged mice. There was greater (P < 0.01 at 3 days) and more prolonged post-acute opening of the blood-brain barrier in the aged mice. Neurodegeneration was greater in the aged mice (p < 0.01 at 3 days). In contrast, lesion cavity volumes, measured at 3 days post-injury, were not different between injured groups. These results suggest that following moderate controlled cortical impact injury, the aged brain is more vulnerable than the adult brain to neurodegeneration, resulting in greater loss of function. Tissue loss at the impact site does not explain the increased functional deficits seen in the aged animals. Prolonged acute edema, increased opening of the blood-brain barrier and increased neurodegeneration found in the aged animals implicate secondary processes in age-related differences in outcome.	[Onyszchuk, Gregory; He, Yong-Yue; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Dept Neurol, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Brooks, William M.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA	Brooks, WM (corresponding author), Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Dept Neurol, MailStop 1052,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	wbrooks@kumc.edu		brooks, william/0000-0001-6227-7636	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21 AG026482] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD02528] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039123] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026482] Funding Source: NIH RePORTER		BARTKOWSKI HM, 1985, J TRAUMA, V25, P192, DOI 10.1097/00005373-198503000-00004; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Benkovic SA, 2006, BRAIN RES, V1070, P215, DOI 10.1016/j.brainres.2005.11.065; Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; BRANTZAWADZKI M, 1984, AM J NEURORADIOL, V5, P125; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Felzien LK, 2001, BRAIN RES, V890, P137, DOI 10.1016/S0006-8993(00)03090-0; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; Gong Y, 2005, ACT NEUR S, V95, P425; Gong Y, 2004, STROKE, V35, P2571, DOI 10.1161/01.STR.0000145485.67827.d0; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; He W., 2005, CURRENT POPULATION R; Helmy A, 2007, CURR MED CHEM, V14, P1525, DOI 10.2174/092986707780831113; Jones E.G., 1985, THALAMUS; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Leblanc N, 2006, BRAIN COGNITION, V60, P208; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; Moor E, 2006, EXP GERONTOL, V41, P303, DOI 10.1016/j.exger.2005.12.006; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Muessel MJ, 2002, MOL BRAIN RES, V103, P12, DOI 10.1016/S0169-328X(02)00158-4; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Schuhmann MU, 2002, ACTA NEUROCHIR SUPPL, V81, P213; Schwarcz A, 2001, MAGN RESON MED, V46, P1246, DOI 10.1002/mrm.1324; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Suo Z., 2004, Current Drug Targets - Inflammation and Allergy, V3, P105, DOI 10.2174/1568010043483953; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; UNTERBERG A, 1994, ACTA NEUROCHIR, P431; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	64	87	91	1	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					153	171		10.1089/neu.2007.0430			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000008	18260798				2021-06-18	
J	Carone, DA				Carone, Dominic A.			Children with moderate/severe brain damage/dysfunction outperform adults with mild-to-no brain damage on the Medical Symptom Validity Test	BRAIN INJURY			English	Article						Effort testing; validity testing; mild traumatic brain injury; children; malingering	HEAD-INJURY; PERFORMANCE; SCALE; EXAGGERATION; CONCUSSION; CAPACITY; ISSUES	Primary objective: This study sought independent confirmation that the English computerized Medical Symptom Validity Test can be easily passed by children with moderate-to-severe brain injury/dysfunction (e.g. traumatic brain injury, stroke) and/or developmental disabilities. In addition, it was hypothesized that a higher percentage of such children would pass the MSVT compared to adults with mild traumatic brain injury or head injury (MTBI/HI) and would rate the task as easier. Methods: Thirty-eight children and 67 adults were administered the MSVT during an outpatient neuropsychological evaluation. Results: Two children (5%) failed the MSVT, whereas 14 (21%) of adults failed. Children performed significantly better on the MSVT and rated it as significantly easier compared to adults who failed the MSVT. There were no such differences when children were compared to adults who passed the MSVT. Conclusions: Findings independently validate the use of the MSVT with children and demonstrate symptom exaggeration in a sub-set of adult MTBI/HI patients.	[Carone, Dominic A.] SUNY Upstate Med Univ, Dept Phys Med & Rehabil, Neuropsychol Assessment Program, Syracuse, NY USA	Carone, DA (corresponding author), Univ Hosp, Neuropsychol Assessment Program, Dept Phys Med & Rehabil, 750 E Adams St, Syracuse, NY 13210 USA.	caroned@upstate.edu					American Psychological Association, 2002, AM PSYCHOL, V57, P1, DOI [10.1037/0003-066X.57.12.1060, DOI 10.1037/0003-066X.57.12.1060]; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck A.T., 1993; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; BRANDT J, 2001, VERBAL LEARNING TEST; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; CLARRIDGE C, MOTHER GETS 3 YEARS; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Delis DC, 2001, DELISKAPLAN EXECUTIV; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Green, 2004, GREENS MED SYMPTOM V; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 2007, PHYS MED REHABILITAT, V18, pvi; Green P., 2003, GREENS WORD MEMORY T; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2003, CLIN NEUROPSYCHOL, V17, P561, DOI 10.1076/clin.17.4.561.27937; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heubrock D, 2001, CHILD NEUROPSYCHOL, V7, P273, DOI 10.1076/chin.7.4.273.8738; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2006, APPL NEUROPSYCHOL, V13, P77, DOI 10.1207/s15324826an1302_3; Kaplan E., 2001, Boston naming test; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mantynen H, 2001, CHILD NEUROPSYCHOL, V7, P241, DOI 10.1076/chin.7.4.241.8739; Meyers J., 1996, REY COMPLEX FIGURE R; Meyers J., 1995, MEYERS SCORING SYSTE; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Polak A, 1999, DEV PSYCHOL, V35, P561, DOI 10.1037/0012-1649.35.2.561; Rey A, 1964, EXAMEN CLIN PSYCHOL; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; SCHMITZ B, 1993, J PERS SOC PSYCHOL, V64, P1010, DOI 10.1037/0022-3514.64.6.1010; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sheslow D., 2003, WIDE RANGE ASSESSMEN, V2nd; Slick D., 1997, VICTORIA SYMPTOM VAL; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1996, TEST MEMORY MALINGER; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	52	87	89	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					960	971	PII 905455478	10.1080/02699050802491297			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900007	19005888				2021-06-18	
J	Zhang, ZX; Guan, LX; Zhang, K; Zhang, Q; Dai, LJ				Zhang, Z-X; Guan, L-X; Zhang, K.; Zhang, Q.; Dai, L-J			A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury	CYTOTHERAPY			English	Article						mesenchymal stromal cells; transplantation; traumatic brain injury	FUNCTIONAL RECOVERY; MARROW; TRANSPLANTATION; NEURONS; RATS	Background There is increasing evidence of therapeutic benefits from bone marrow (BM)-derived mesenchymal stromal cells (MSC) in various animal models with neurologic disorders. It is of great interest to apply the approach to clinical patients, i.e. to take the investigations from laboratory bench to the patient's bedside. This clinical trial was performed to assess the safety and feasibility of a combined procedure to deliver autologous MSC to patients with traumatic brain injury. Methods MSC were isolated by BM aspiration and expanded in culture. Seven patients received autologous cell transplantation. A primary administration of 10(7)-10(9) cells was applied directly to the injured area during the cranial operation; a second dose of 10(8)-10(10) cells was infused intravenously. All patients were followed up regularly for 6 months. Results There was no immediate or delayed toxicity related to the cell administration within the 6-month follow-up period. Neurologic function was significantly improved at 6 months after cell therapy. Discussion The procedure used is safe and feasible at ordinary medical facilities without additional invasive procedures for the patient. The combined cell delivery procedure is expected to enhance the engraftment efficacy of transplanted cells at injured brain tissue, thereby promoting neurologic recover.	[Guan, L-X; Dai, L-J] Weifang Med Coll, Weifang Peoples Hosp, Cent Lab, Weifang 261041, Peoples R China; [Zhang, Z-X; Zhang, K.; Zhang, Q.] Weifang Med Coll, Weifang Peoples Hosp, Dept Neurosurg, Weifang 261041, Peoples R China; [Dai, L-J] Univ British Columbia, Dept Surg, Vancouver, BC V6T 1W5, Canada	Dai, LJ (corresponding author), Weifang Med Coll, Weifang Peoples Hosp, Cent Lab, Weifang 261041, Peoples R China.	longjundai@gmail.com					Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bakshi A, 2006, J NEUROTRAUM, V23, P55, DOI 10.1089/neu.2006.23.55; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KALLIS Y, 2007, GUT, V716, P24; Katakowski M, 2007, J CEREBR BLOOD F MET, V27, P669, DOI 10.1038/sj.jcbfm.9600390; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Mori K, 2005, J CEREBR BLOOD F MET, V25, P887, DOI 10.1038/sj.jcbfm.9600083; Moviglia GA, 2006, CYTOTHERAPY, V8, P202, DOI 10.1080/14653240600736048; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Strauer BE, 2005, J AM COLL CARDIOL, V46, P1651, DOI 10.1016/j.jacc.2005.01.069; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhang ZX, 2007, CELL BIOL INT, V31, P645, DOI 10.1016/j.cellbi.2006.11.025	20	87	88	3	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy		2008	10	2					134	139		10.1080/14653240701883061			6	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	279ZO	WOS:000254394900005	18368592				2021-06-18	
J	Silverberg, ND; Wertheimer, JC; Fichtenberg, NL				Silverberg, Noah D.; Wertheimer, Jeffrey C.; Fichtenberg, Norman L.			An effort index for the repeatable battery for the assessment of neuropsychological status (rbans)	CLINICAL NEUROPSYCHOLOGIST			English	Article							VERBAL-LEARNING TEST; TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; DETECTING POOR EFFORT; MILD HEAD-INJURY; SUBOPTIMAL PERFORMANCE; COGNITIVE IMPAIRMENT; MEMORY IMPAIRMENT; INCOMPLETE EFFORT; DIGIT SPAN	The present study aimed to dei,elop an internal vafidi j, indicator for a brief general purpose screening battery, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Two subtests of the RBANS were predicted to be relath,ely resilient to cognitive dy function on the basis of previous research. An Effort Index (EI) was created by combining them via a scaling system. The frequency of EI scores was first examined in a heterogenous clinical sample. A subsequent validation study showed good discriminability. In conclusion, the EI appears to he useful for detecting insufficient effort oil a screening battery.	Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; Wayne State Univ, Sch Med, Inst Rehabil, Detroit, MI USA	Silverberg, ND (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	noahsilverberg@hotmail.com					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; BAYLESS JD, 1995, ARCH CLIN NEUROPSYCH, V10, P297; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carey CL, 2004, CLIN NEUROPSYCHOL, V18, P234, DOI 10.1080/13854040490501448; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Duff K, 2003, CLIN NEUROPSYCHOL, V17, P351, DOI 10.1076/clin.17.3.351.18082; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GRIFFENSTEIN MF, 1994, PSYCHOL ASSESSMENT, V6, P218; Grohman K, 2004, EXP CLIN PSYCHOPHARM, V12, P200, DOI 10.1037/1064-1297.12.3.200; Iverson G L, 2001, Appl Neuropsychol, V8, P167, DOI 10.1207/S15324826AN0803_6; IVERSON GL, 1993, CRIM JUSTICE BEHAV, V20, P347, DOI 10.1177/0093854893020004003; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; King JH, 1998, J CLIN EXP NEUROPSYC, V20, P603, DOI 10.1076/jcen.20.5.603.1124; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Lee D, 2004, REHABIL PSYCHOL, V49, P167, DOI 10.1037/0090-5550.49.2.167; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/S15324826AN0804_6; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Norris MP, 1998, LAW HUMAN BEHAV, V22, P315, DOI 10.1023/A:1025706606774; Randolph C, 1998, REPEATABLE BATTERY A; Roberts C, 2003, INT J NEUROSCI, V113, P223, DOI 10.1080/00207450390162047; Serper MR, 2002, PSYCHIAT SERV, V53, P1527, DOI 10.1176/appi.ps.53.12.1527; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Silverberg N, 2005, J CLIN EXP NEUROPSYC, V27, P907, DOI 10.1080/13803390490919326; Slick D J, 2001, Appl Neuropsychol, V8, P185, DOI 10.1207/S15324826AN0803_9; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh T.N., 2003, J FORENSIC NEUROPSYC, V2, P69, DOI [DOI 10.1300/J151V02N03_04, 10.1300/J151v02n03_04]; Tombaugh TN, 1996, TEST MEMORY MALINGER; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D, 1997, WAIS 3 ADM SCORING M	50	87	87	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2007	21	5					841	854		10.1080/13854040600850958			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	210KO	WOS:000249455300009	17676548				2021-06-18	
J	Warner, KJ; Cuschieri, J; Copass, MK; Jurkovich, GJ; Bulger, EM				Warner, Keir J.; Cuschieri, Joseph; Copass, Michael K.; Jurkovich, Gregory J.; Bulger, Eileen M.			The impact of prehospital ventilation on outcome after severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		prehospital; intubation; traumatic brain injury; hyperventilation; outcome; target ventilation	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; ENDOTRACHEAL INTUBATION; CEREBRAL OXYGENATION; HYPERVENTILATION; HYPOVENTILATION; MODERATE; HYPOXIA; PERILS	Background: Prehospital intubation has been challenged on the grounds that it predisposes to hyperventilation, which is detrimental after traumatic brain injury (TBI), and impairs venous return in patients with hypovolemia. We sought to determine the incidence of hyperventilation among a cohort of trauma patients undergoing prehospital intubation and the impact of ventilation on outcome after severe TBI. Methods: Data were prospectively collected for all intubated trauma patients transported directly from the field for a period of 14 months (n = 574). An arrival P-CO2 < 30 mm Hg was termed severe hypocapnea and considered a marker of hyperventilation. Patients with a P-CO2 > 45 mm Hg were considered severely hypercapneic. Targeted ventilation was defined as a P-CO2 between 30 and 35 rum Hg based on the Brain Trauma Foundation guidelines. Results: The rate of severe hypocapnea was 18 % and women were more likely to be hyperventilated (p < 0.05). Patients with severe hypercapnia had higher Injury Severity Scores and were more likely hypotensive, hypoxic, and acidodic (p < 0.05). Patients in the targeted ventilation range were less likely to die than were those outside the range even after excluding the severe hypercapnea group (odds ratio, 0.57; 95% confidence interval, 0.33-0.99). This effect was even greater among patients with isolated TBI (odds ratio, 0.31; 95% confidence interval, 0.10-0.96). Conclusion: Targeted prehospital ventilation is associated with lower mortality after severe TBI.	Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Emergency Serv, Seattle, WA 98104 USA	Bulger, EM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Box 35976,325 9th Ave, Seattle, WA 98104 USA.	ebulger@u.washington.edu					Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Davis K, 2005, EUR J WOMENS STUD, V12, P5, DOI 10.1177/1350506805048851; Deakin CD, 2004, J TRAUMA, V57, P65, DOI 10.1097/01.TA.0000103984.70306.22; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marion DW, 2000, J TRAUMA, V48, P1032; Pepe PE, 2005, CURR OPIN CRIT CARE, V11, P212, DOI 10.1097/01.ccx.0000163650.80601.24; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wright J, FIM TM	20	87	88	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2007	62	6					1330	1336		10.1097/TA.0b013e31804a8032			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	179YM	WOS:000247326600002	17563643				2021-06-18	
J	Williams, AJ; Hartings, JA; Lu, XCM; Rolli, ML; Tortella, FC				Williams, Anthony J.; Hartings, Jed A.; Lu, Xi-Chun M.; Rolli, Michael L.; Tortella, Frank C.			Penetrating ballistic-like brain injury in the rat: Differential time courses of hemorrhage, cell death, inflammation, and remote degeneration	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; inflammation; military injury; models of injury; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; LATERAL FLUID PERCUSSION; MISSILE HEAD-INJURY; NEURONAL DEGENERATION; AXONAL INJURY; INTRACEREBRAL HEMORRHAGE; NEUROBEHAVIORAL OUTCOMES; NONCONVULSIVE SEIZURES; THERAPEUTIC WINDOW	Acute and delayed cerebral injury was assessed in a recently developed rat model of a penetrating ballistic-like brain injury (PBBI). A unilateral right frontal PBBI trajectory was used to induce survivable injuries to the frontal cortex and striatum. Three distinct phases of injury progression were observed. Phase I (primary injury, 0-6 h) began with immediate (< 5 min) intracerebral hemorrhage (ICH) that reached maximal volumetric size at 6 h (27.0 +/- 2.9 mm(3)). During Phase II (secondary injury, 6-72 h), a core lesion of degenerate neurons surrounding the injury track expanded into peri-lesional areas to reach a maximal volume of 69.9 +/- 6.1 mm(3) at 24 h. The core lesion consisted of predominately necrotic cell death and included marked infiltration of both neutrophils (24 h) and macrophages (72 h). Phase III (delayed degeneration, 3-7 days) involved the degeneration of neurons and fiber tracts remote from the core lesion including the thalamus, internal capsule, external capsule, and cerebral peduncle. Overall, different time courses of hemorrhage, lesion evolution, and inflammation were consistent with complementary roles in injury development and repair, providing key information about these mediators of primary, secondary, and delayed brain injury development. The similarities/differences of PBBI to other focal brain injury models are discussed.	Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 20910 USA	Williams, AJ (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, 503 Robert Grant Ave Bldg 503,Rm 2A40, Silver Spring, MD 20910 USA.	anthony.williams@na.amedd.army.mil		Hartings, Jed/0000-0001-8583-3471			ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Al-Abdulla NA, 2002, NEUROSCIENCE, V115, P7, DOI 10.1016/S0306-4522(02)00363-9; ALLEN IV, 1982, INJURY, V14, P183, DOI 10.1016/0020-1383(82)90057-2; AWASTHI D, 1991, SURG NEUROL, V36, P441, DOI 10.1016/0090-3019(91)90157-5; BELLAMY R, 1998, TXB MILITARY MED 1, V5, P107; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; BOYA J, 1986, ACTA ANAT, V127, P142; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BUTLER EG, 1945, J NEUROSURG, V2, P358, DOI 10.3171/jns.1945.2.4.0358; Butler TL, 2002, BRAIN RES, V929, P252, DOI 10.1016/S0006-8993(01)03371-6; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Carey ME, 1990, J NEUROTRAUM, V7, P13, DOI 10.1089/neu.1990.7.13; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; CLARK RK, 1994, BRAIN RES BULL, V35, P387, DOI 10.1016/0361-9230(94)90119-8; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLEMEDSON CJ, 1973, Z RECHTSMED, V73, P103, DOI 10.1007/BF01882332; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; FREYTAG E, 1963, ARCH PATHOL, V76, P215; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2005, J NEUROTRAUM, V22, P1201; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Hotz GA, 2000, BRAIN INJURY, V14, P649; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KIERNAN JA, 1999, HIST HISTOCHEMICAL M; Kotwica Z, 1989, Zentralbl Neurochir, V50, P68; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Marin R, 2003, PHYSIOL BEHAV, V80, P167, DOI 10.1016/j.physbeh.2003.06.001; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MOSHANG E, 2003, MODEL PENETRATING TR; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; Pintar F A, 2001, Biomed Sci Instrum, V37, P429; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Sapsford W, 2003, J R Army Med Corps, V149, P5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith Wade S, 2004, J Vasc Interv Radiol, V15, pS3; Soares HD, 1995, J NEUROSCI, V15, P8223; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Volgas DA, 2005, INJURY, V36, P380, DOI 10.1016/j.injury.2004.08.038; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEI H, 2006, ADV TECHN APPL COMB; Williams AJ, 2000, J PHARMACOL EXP THER, V294, P378; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2004, STROKE, V35, P1186, DOI 10.1161/01.STR.0000125721.10606.dc; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Williams AJ, 2003, J CEREBR BLOOD F MET, V23, P75, DOI 10.1097/01.WCB.0000039285.37737.C2; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang FY, 2002, J NEUROSURG, V97, P963, DOI 10.3171/jns.2002.97.4.0963	74	87	87	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2006	23	12					1828	1846		10.1089/neu.2006.23.1828			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	120AP	WOS:000243056100010	17184192				2021-06-18	
J	Schoenberg, MR; Dawson, KA; Duff, K; Patton, D; Scott, JG; Adams, RL				Schoenberg, Mike R.; Dawson, Kyra A.; Duff, Kevin; Patton, Doyle; Scott, James G.; Adams, Russell L.			Test performance and classification statistics for the Rey Auditory Verbal Learning Test in selected clinical samples	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Auditory Verbal Learning Test; RAVLT; memory; positive predictive power; test scores; diagnosis	MILD COGNITIVE IMPAIRMENT; QUALITY STANDARDS SUBCOMMITTEE; ALZHEIMERS-DISEASE; DIAGNOSTIC-ACCURACY; HIPPOCAMPAL VOLUME; PRACTICE PARAMETER; TEST AVLT; SENSITIVITY; DEMENTIA; SPECIFICITY	The Rey Auditory Verbal Learning Test [RAVLT; Rey, A. (1941). L'examen psychologique dans les cas d'encephalopathie traumatique. Archives de Psychologie, 28, 21] is a commonly used neuropsychological measure that assesses verbal learning and memory. Normative data have been compiled [Schmidt, M. (1996). Rey Auditory and Verbal Learning Test: A handbook. Los Angeles, CA: Western Psychological Services]. When assessing an individual suspected of neurological dysfunction, useful comparisons include the extent that the patient deviates from healthy peers and also how closely the subject's performance matches those with known brain injury. This study provides the means and S.D.'s of 392 individuals with documented neurological dysfunction [closed head TBI (n = 68), neoplasms (n = 57), stroke (n = 47), Dementia of the Alzheimer's type (n = 158), and presurgical epilepsy left seizure focus (n = 28), presurgical epilepsy right seizure focus (n = 34)] and 122 patients with no known neurological dysfunction and psychiatric complaints. Patients were stratified into three age groups, 16-35, 36-59, and 60-88. Data were provided for trials I-V, List B, immediate recall, 30-min delayed recall, and recognition. Classification characteristics of the RAVLT using [Schmidt, M. (1996). Rey Auditory and Verbal Learning Test: A handbook. Los Angeles, CA: Western Psychological Services] meta-norms found the RAVLT to best distinguish patients suspected of Alzheimer's disease from the psychiatric comparison group. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Hosp Cleveland, Case Med Ctr, Dept Neurol, Cleveland, OH 44106 USA; Cleveland State Univ, Dept Psychol, Cleveland, OH 44115 USA; Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Norman, OK 73019 USA	Schoenberg, MR (corresponding author), Univ Hosp Cleveland, Case Med Ctr, Dept Neurol, HH 5,11100 Euclid Ave, Cleveland, OH 44106 USA.	Michael.Schoenberg@uhhs.com	Schoenberg, Mike R/J-9018-2012	Schoenberg, Mike/0000-0003-1355-3651			Anastasi A, 1997, PSYCHOL TESTING, V7th; BIGLER ED, 1989, J CLIN PSYCHOL, V45, P277, DOI 10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M; Bolla-Wilson K, 1986, DEV NEUROPSYCHOL, V2, P203, DOI 10.1080/87565648609540342; BUTTERS N, 1985, NEUROPSYCHOLOGIA, V23, P729, DOI 10.1016/0028-3932(85)90080-6; Chen P, 2000, NEUROLOGY, V55, P1847, DOI 10.1212/WNL.55.12.1847; CROSSEN JR, 1994, J CLIN EXP NEUROPSYC, V16, P190, DOI 10.1080/01688639408402630; Davidoff G, 1990, Arch Clin Neuropsychol, V5, P77, DOI 10.1016/0887-6177(90)90009-E; Drebing CE, 1994, NEUROPSYCHOLOGY, V8, P31, DOI 10.1037/0894-4105.8.1.31; Estevez-Gonzalez A, 2003, INT J GERIATR PSYCH, V18, P1021, DOI 10.1002/gps.1010; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Gosche KM, 2002, NEUROLOGY, V58, P1476, DOI 10.1212/WNL.58.10.1476; GUILMETTE TJ, 1995, NEUROPSYCHOLOGY, V9, P338, DOI 10.1037/0894-4105.9.3.338; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Hoffmann M, 2004, ACTA NEUROL SCAND, V109, P14, DOI 10.1034/j.1600-0404.2003.00169.x; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Ivnik R. J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; Ivnik RJ, 2000, NEUROPSYCHOLOGY, V14, P163, DOI 10.1037/0894-4105.14.2.163; Ivnik RJ, 2001, CLIN NEUROPSYCHOL, V15, P114, DOI 10.1076/clin.15.1.114.1904; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P83; IVNIK RJ, 1994, NEUROPSYCHOLOGY, V8, P203; Jack CR, 1997, NEUROLOGY, V49, P786, DOI 10.1212/WNL.49.3.786; Jack CR, 1999, NEUROLOGY, V52, P1397, DOI 10.1212/WNL.52.7.1397; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Kurylo M, 2001, REHABIL PSYCHOL, V46, P247, DOI 10.1037/0090-5550.46.3.247; Laakso MP, 1998, NEUROBIOL AGING, V19, P23, DOI 10.1016/S0197-4580(98)00006-2; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LUCAS JA, 1998, CLIN NEUROPSYCHOLOGY; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MUNGAS D, 1983, J CONSULT CLIN PSYCH, V51, P848, DOI 10.1037/0022-006X.51.6.848; *NEUR ASS PAN, 1996, NEUROLOGY, V34, P592; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; OBrien JT, 1997, PSYCHOL MED, V27, P1267, DOI 10.1017/S0033291797005606; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Powell J B, 1991, Arch Clin Neuropsychol, V6, P241, DOI 10.1016/0887-6177(91)90001-P; QUERY WT, 1983, J CLIN PSYCHOL, V39, P136, DOI 10.1002/1097-4679(198301)39:1<136::AID-JCLP2270390125>3.0.CO;2-Q; RETZLAFF PD, 2001, CLIN GUIDE NEUROPSYC, P277; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Salmon DP, 2002, NEUROLOGY, V59, P1022, DOI 10.1212/WNL.59.7.1022; SAVAGE RM, 1992, ARCH CLIN NEUROPSYCH, V7, P407, DOI 10.1016/0887-6177(92)90153-E; Schmidt M., 1996, REY AUDITORY VERBAL; Simard S, 2003, BRAIN COGNITION, V53, P354, DOI 10.1016/S0278-2626(03)00142-8; SNYDER RPJ, 1998, CLIN NEUROPSYCHOLOGY; SQUIRE LR, 1986, BEHAV NEUROSCI, V100, P866, DOI 10.1037/0735-7044.100.6.866; Taylor E. M, 1959, PSYCHOL APPRAISAL CH, P423, DOI [10.4159/harvard.9780674367494, DOI 10.4159/HARVARD.9780674367494]; Tong BSK, 2002, BRAIN INJURY, V16, P987, DOI 10.1080/02699050210147202; TUOKKO H, 1995, J CLIN EXP NEUROPSYC, V17, P352, DOI 10.1080/01688639508405129; UCHIYAMA CL, 1995, ARCH CLIN NEUROPSYCH, V10, P133, DOI 10.1016/0887-6177(94)E0034-M; Unkenstein A.E., 1991, CLIN NEUROPSYCHOL, V5, P24; Vakil E, 2000, NEUROPSYCHOLOGIA, V38, P1, DOI 10.1016/S0028-3932(99)00058-5; VANDERPLOEG RD, 1995, ARCH CLIN NEUROPSYCH, V10, P225, DOI 10.1016/0887-6177(94)00042-O; Wechsler D, 1981, WESCHLER ADULT INTEL; WEINSTEIN A, 1998, CLIN NEURPSYCHOLOGY; Williamson DJG, 1996, NEUROPSYCHOLOGY CLIN; Wolfson D., 1993, HALSTEAD REITAN NEUR	57	87	97	2	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	OCT	2006	21	7					693	703		10.1016/j.acn.2006.06.010			11	Psychology, Clinical; Psychology	Psychology	112JR	WOS:000242522400010	16987634	Bronze			2021-06-18	
J	Tung, GA; Kumar, M; Richardson, RC; Jenny, C; Brown, WD				Tung, Glenn A.; Kumar, Monica; Richardson, Randal C.; Jenny, Carole; Brown, William D.			Comparison of accidental and nonaccidental traumatic head injury in children on noncontrast computed tomography	PEDIATRICS			English	Article						abuse; subdural hematoma; brain imaging; accidents; retinal hemorrhage	ACUTE SUBDURAL-HEMATOMA; SHAKEN IMPACT SYNDROME; YOUNG-CHILDREN; FINE-STRUCTURE; BABY SYNDROME; BRAIN-INJURY; CRANIAL MRI; CT FINDINGS; ABUSE; INFANTS	OBJECTIVE. Mixed-density convexity subdural hematoma and interhemispheric subdural hematoma suggest nonaccidental head injury. The purpose of this retrospective observational study is to investigate subdural hematoma on noncontrast computed tomography in infants with nonaccidental head injury and to compare these findings in infants with accidental head trauma for whom the date of injury was known. PATIENTS AND METHODS. Two blinded, independent observers retrospectively reviewed computed tomography scans with subdural hematoma performed on the day of presentation on 9 infant victims of nonaccidental head injury ( mean age: 6.8 months; range: 1 - 25 months) and on 38 infants ( mean age: 4.8 months; range: newborn to 34 months) with accidental head trauma (birth-related: 19; short fall: 17; motor vehicle accident: 2). RESULTS. Homogeneous hyperdense subdural hematoma was significantly more common in children with accidental head trauma ( 28 of 38 [74%]; nonaccidental head trauma: 3 of 9 [ 33%]), whereas mixed-density subdural hematoma was significantly more common in cases of nonaccidental head injury ( 6 of 9 [67%]; accidental head trauma: 7 of 38 [18%]). Twenty-two ( 79%) subdural hematomas were homogeneously hyperdense on noncontrast computed tomography performed within two days of accidental head trauma, one ( 4%) was homogeneous and isodense compared to brain tissue, one ( 4%) was homogeneous and hypodense, and four ( 14%) were mixed-density. There was no statistically significant difference in the proportion of interhemispheric subdural hematoma, epidural hematoma, calvarial fracture, brain contusion, or subarachnoid hemorrhage . CONCLUSIONS. Homogeneous hyperdense subdural hematoma is more frequent in cases of accidental head trauma; mixed-density subdural hematoma is more frequent in cases of nonaccidental head injury but may be observed within 48 hours of accidental head trauma. Interhemispheric subdural hematoma is not specific for inflicted head injury.	Rhode Isl Hosp, Dept Diagnost Imaging, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Pediat, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Neurol, Providence, RI 02903 USA; Brown Univ, Sch Med, Hasbro Childrens Hosp, Providence, RI 02912 USA	Tung, GA (corresponding author), Rhode Isl Hosp, Dept Diagnost Imaging, 593 Eddy St, Providence, RI 02903 USA.	gtung@lifespan.org		Richardson, Randal/0000-0003-3546-9266			Barnes PD, 2000, PEDIATR RADIOL, V30, P74, DOI 10.1007/s002470050018; BERGSTROM M, 1977, J COMPUT ASSIST TOMO, V1, P449, DOI 10.1097/00004728-197710000-00011; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Block R W, 1999, Curr Probl Pediatr, V29, P249; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; BRUCE DA, 1989, PEDIATR ANN, V18, P486; BRUCE DA, 1989, PEDIATR ANN, V18, P492; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Chabrol B, 1999, CHILD ABUSE NEGLECT, V23, P217, DOI 10.1016/S0145-2134(98)00128-8; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; Chen CY, 1999, NEURORADIOLOGY, V41, P711, DOI 10.1007/s002340050830; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; FRIEDE RL, 1978, AM J PATHOL, V92, P69; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hart BL, 1996, AM J FOREN MED PATH, V17, P217, DOI 10.1097/00000433-199609000-00008; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; KAO MC, 1983, J NEUROSURG, V58, P246, DOI 10.3171/jns.1983.58.2.0246; KAUFMAN HH, 1980, J COMPUT ASSIST TOMO, V4, P557, DOI 10.1097/00004728-198008000-00034; Krous HF, 1999, PEDIATR DEVEL PATHOL, V2, P497, DOI 10.1007/s100249900156; Lee HK, 1997, INT SOCIOL, V12, P353, DOI 10.1177/026858097012003005; MOLLER A, 1979, RADIOLOGY, V130, P149; NEW PFJ, 1976, RADIOLOGY, V121, P635, DOI 10.1148/121.3.635; NORMAN D, 1977, RADIOLOGY, V123, P335, DOI 10.1148/123.2.335; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Sargent S, 1996, J FORENSIC SCI, V41, P314; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; SMITH WP, 1981, AM J ROENTGENOL, V136, P543, DOI 10.2214/ajr.136.3.543; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P39, DOI 10.1007/BF00395197; Zouros A, 2004, J NEUROSURG, V100, P512, DOI 10.3171/ped.2004.100.5.0512	43	87	89	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	AUG	2006	118	2					626	633		10.1542/peds.2006-0130			8	Pediatrics	Pediatrics	069IW	WOS:000239440600024	16882816				2021-06-18	
J	Agha, A; Thompson, CJ				Agha, A; Thompson, CJ			Anterior pituitary dysfunction following traumatic brain injury (TBI)	CLINICAL ENDOCRINOLOGY			English	Article							GROWTH-HORMONE DEFICIENCY; BODY-COMPOSITION; HYPOGONADOTROPIC HYPOGONADISM; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; SPONTANEOUS-RECOVERY; ADULT PATIENTS; HEAD-INJURY; HYPOPITUITARISM; SEVERITY	Traumatic brain injury (TBI) is the commonest cause of death and disability in young adults living in industrialized countries. Several recent studies have convincingly shown that anterior hypopituitarism is a common complication of head trauma with a prevalence of at least 25% among long-term survivors. This is a much higher frequency than previously thought and suggests that most cases of post-traumatic hypopituitarism (PTHP) remain undiagnosed and untreated. These findings raise important questions about the potential contribution of PTHP to the high physical and neuropsychiatric morbidity seen in this group of patients. In this review, we examine the published reports on the neuroendocrine abnormalities in TBI patients and highlight new data that give novel insights into the natural history of this disorder. We discuss the potential contribution of PTHP to recovery and rehabilitation after injury and the need for the identification and the appropriate and timely management of hormone deficiencies to optimize patient recovery from head trauma, improve quality of life and avoid the long-term adverse consequences of untreated hypopituitarism.	Beaumont Hosp, Dept Endocrinol, Div Endocrinol & Diabet, Dublin 9, Ireland; RCSI, Sch Med, Dublin, Ireland	Agha, A (corresponding author), Beaumont Hosp, Dept Endocrinol, Div Endocrinol & Diabet, Beaumont Rd, Dublin 9, Ireland.	amaragha@yahoo.com					Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; ASA S, 2002, PITUITARY, P4; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P179, DOI 10.1111/j.1365-2265.1995.tb01860.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CITTADINI A, 1994, AM J PHYSIOL, V267, pE219; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; DANIEL PM, 1959, LANCET, V2, P927; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; Della Corte F, 1998, CRIT CARE MED, V26, P1419; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE SC, 1994, BRAIN INJURY, V8, P571; LEVITAN D, 1984, AM J NEPHROL, V4, P99, DOI 10.1159/000166785; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lissett CA, 2003, CLIN ENDOCRINOL, V59, P773, DOI 10.1046/j.1365-2265.2003.01884.x; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; *NIH, 1998, REH PERS TRAUM BRAIN, V16, P1; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SPRATT DI, 1992, J CLIN ENDOCR METAB, V75, P1562, DOI 10.1210/jc.75.6.1562; TEASDALE G, 1974, LANCET, V2, P81; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; World Health Organization, 1980, INT CLASS IMP DIS HA; YAUN XQ, 1991, NEUROENDOCRINOLOGY, V12, P209	66	87	94	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	MAY	2006	64	5					481	488		10.1111/j.1365-2265.2006.02517.x			8	Endocrinology & Metabolism	Endocrinology & Metabolism	034PR	WOS:000236943600002	16649964	Bronze			2021-06-18	
J	Staab, JP				Staab, JP			Chronic dizziness: the interface between psychiatry and neuro-otology	CURRENT OPINION IN NEUROLOGY			English	Article						anxiety; chronic dizziness; dysautonomia; migraine; traumatic brain injury	GENETIC-VARIATION; VESTIBULAR DYSFUNCTION; BEHAVIORAL-INHIBITION; VERTIGO; ANXIETY; POLYMORPHISM; ASSOCIATION; MIGRAINE; REHABILITATION; SYMPTOMS	Purpose of review This paper reviews the often-enigmatic relationships between dizziness and psychiatric symptoms. Psychiatric causes of dizziness, neuro-otologic causes of anxiety, underrecognized co-morbid conditions, and medical illnesses that masquerade as 'psychogenic' dizziness are examined. Key clinical features and data from recent treatment trials are presented with potential pathophysiologic mechanisms. Recent findings Investigations at the interface between psychiatry and neuro-otology have identified the distinguishing features of several clinical conditions that present with non-vertiginous dizziness, subjective imbalance, and psychiatric symptoms. The most common condition is chronic subjective dizziness; a refinement of earlier concepts of psychogenic dizziness, phobic postural vertigo, and space-motion phobia. Chronic subjective dizziness is consistent with advancing research on anxiety and somatoform disorders and offers greater insights into the relationships between neuro-otologic illnesses and anxiety. Migraine, post-concussional syndrome, and dysautonomias also cause persistent dizziness and may be misdiagnosed or malingering or psychogenic dizziness because they often present with comorbid psychiatric symptoms in the absence of identifiable vestibular deficits. Summary Recent research has defined the key features of several medical-psychiatric conditions that cause chronic dizziness, permitting greater diagnostic precision and insight into underlying pathophysiologic processes. Treatment studies have identified potentially effective interventions, which must be evaluated in controlled clinical trials.	Hosp Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; Univ Penn, Balance Ctr, Philadelphia, PA 19104 USA	Staab, JP (corresponding author), Hosp Univ Penn, Dept Psychiat, 3400 Spruce St,Founders Pavil F11-015, Philadelphia, PA 19104 USA.	jeffrey.staab@uphs.upenn.edu	Staab, Jeffrey/B-8792-2015	Staab, Jeffrey/0000-0002-1516-3131			American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Ballas CA, 2003, CNS SPECTRUMS, V8, P20, DOI 10.1017/S1092852900008245; Brandt T, 1996, NEUROLOGY, V46, P1515, DOI 10.1212/WNL.46.6.1515; Brantberg K, 2005, ACTA OTO-LARYNGOL, V125, P276, DOI 10.1080/00016480510003165; Brignole M, 2004, EUROPACE, V6, P467, DOI 10.1016/j.eupc.2004.08.008; Bronstein AM, 2004, J NEUROL, V251, P381, DOI 10.1007/s00415-004-0410-7; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; David SP, 2005, J NEUROSCI, V25, P2586, DOI 10.1523/JNEUROSCI.3769-04.2005; Erickson K, 2005, DEV PSYCHOBIOL, V47, P196, DOI 10.1002/dev.20086; Fox NA, 2005, ANNU REV PSYCHOL, V56, P235, DOI 10.1146/annurev.psych.55.090902.141532; Furman JM, 2005, J NEUROL NEUROSUR PS, V76, P1, DOI 10.1136/jnnp.2004.048926; Gallinat J, 2005, NEUROIMAGE, V26, P123, DOI 10.1016/j.neuroimage.2005.01.001; Godemann F, 2005, J PSYCHIATR RES, V39, P529, DOI 10.1016/j.jpsychires.2004.12.006; Godemann F, 2004, PSYCHOSOM MED, V66, P783, DOI 10.1097/01.psy.0000140004.06247.c9; Graff-Guerrero A, 2005, NEUROIMAGE, V25, P1197, DOI 10.1016/j.neuroimage.2004.12.020; Guerraz M, 2001, BRAIN, V124, P1646, DOI 10.1093/brain/124.8.1646; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Horii A, 2004, OTOL NEUROTOL, V25, P536, DOI 10.1097/00129492-200407000-00022; Huppert D, 2005, J NEUROL, V252, P564, DOI 10.1007/s00415-005-0699-x; Jacob RG, 2001, J ANXIETY DISORD, V15, P131, DOI 10.1016/S0887-6185(00)00047-5; Jacob RG, 2001, CURR OPIN NEUROL, V14, P41, DOI 10.1097/00019052-200102000-00007; Kalin Ned H, 2004, Psychopharmacol Bull, V38, P8; KAUFMAN KR, 2005, MED ENG PHYS    0722; KLEMENHAGEN KC, 2005, NEUROPSYCHOPHAR 0525; Longridge NS, 2005, OTOL NEUROTOL, V26, P695, DOI 10.1097/01.mao.0000178152.21634.6d; Mayou R, 2005, AM J PSYCHIAT, V162, P847, DOI 10.1176/appi.ajp.162.5.847; Neuhauser H, 2004, CEPHALALGIA, V24, P83, DOI 10.1111/j.1468-2982.2004.00662.x; Olsson CA, 2005, PSYCHIAT GENET, V15, P109, DOI 10.1097/00041444-200506000-00007; Pavlou M, 2004, J NEUROL, V251, P983, DOI 10.1007/s00415-004-0476-2; PERNA G, 2005, NEUROPSYCHOPHAR 0720; Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463; Schinka JA, 2004, MOL PSYCHIATR, V9, P197, DOI 10.1038/sj.mp.4001405; Schwartz CE, 2003, SCIENCE, V300, P1952, DOI 10.1126/science.1083703; Simon NM, 2005, PSYCHOSOMATICS, V46, P334, DOI 10.1176/appi.psy.46.4.334; Smoller JW, 2005, BIOL PSYCHIAT, V57, P1485, DOI 10.1016/j.biopsych.2005.02.018; Staab JP, 2005, ARCH OTOLARYNGOL, V131, P675, DOI 10.1001/archotol.131.8.675; Staab JP, 2004, LARYNGOSCOPE, V114, P1637, DOI 10.1097/00005537-200409000-00025; Staab JP, 2003, LARYNGOSCOPE, V113, P1714, DOI 10.1097/00005537-200310000-00010; Staab JP, 2002, LARYNGOSCOPE, V112, P1346, DOI 10.1097/00005537-200208000-00005; Staab JP, 2002, ARCH OTOLARYNGOL, V128, P554, DOI 10.1001/archotol.128.5.554; STAAB JP, 2005, ANN M E SECT AM LARY; Staab JR, 2005, PSYCHIAT ANN, V35, P330; Treleaven J, 2005, J REHABIL MED, V37, P224, DOI 10.1080/16501970510027989	43	87	97	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	FEB	2006	19	1					41	48		10.1097/01.wco.0000198102.95294.1f			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	013CT	WOS:000235387900007	16415676				2021-06-18	
J	Cater, HL; Sundstrom, LE; Morrison, B				Cater, Heather L.; Sundstrom, Lars E.; Morrison, Barclay, III			Temporal development of hippocampal cell death is dependent on tissue strain but not strain rate	JOURNAL OF BIOMECHANICS			English	Article						tolerance criteria; traumatic brain injury; hippocampus; diffuse axonal injury; viscous criterion	IN-VITRO; MECHANICAL STRETCH; BRAIN-INJURY; TOLERANCE CRITERION; NEURONAL SURVIVAL; SLICE CULTURES; MODEL; CALCIUM; DEFORMATION; NEURODEGENERATION	Deformation of brain tissue in response to mechanical loading of the head is the root-cause of traumatic brain injury (TBI). Even below ultimate failure limits, deformation activates pathophysiological cascades resulting in delayed cell death. Injury response of soft tissues, such as the chest and spinal cord, is dependent on the product of deformation and velocity, a parameter termed the viscous criterion. We set out to test if hippocampal cell death could be predicted by a similar combination of strain and strain rate and if the viscous criterion was valid for hippocampus. Quantitative prediction of the brain's biological response to mechanical stimuli is difficult to achieve in animal models of TBI, so we utilized an in vitro model of TBI based on hippocampal slice cultures. We quantified the temporal development of cell death after precisely controlled deformations for 30 combinations of strain (0.05-0.50) and strain rate (0.1-50 s(-1)) relevant to TBI. Loading conditions for a subset of cultures were verified by analysis of highspeed video. Cell death was found to be significantly dependent on time-post injury, on strain magnitude, and to a lesser extent, on anatomical region by a repeated-measures, three-way ANOVA. The responses of the CA1 and CA3 regions of the hippocampus were not statistically different in contrast to some in vivo TBI studies. Surprisingly, cell death was not dependent on strain rate leading us to conclude that the viscous criterion is not a valid predictor for hippocampal tissue injury. Given the large data set and extensive combinations of biomechanical parameters, predictive mathematical functions relating independent variables (strain, region, and time post-injury) to the resultant cell death were defined. These functions can be used as tolerance criteria to equip finite element models of TBI with the added capability to predict biological consequences. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Southampton, Div Clin Neurosci, Southampton SO16 7PX, Hants, England; Columbia Univ, Dept Biomed Engn, Neurotrauma & Repair Lab, New York, NY 10027 USA	Morrison, B (corresponding author), Univ Southampton, Div Clin Neurosci, Southampton SO16 7PX, Hants, England.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Brands D W, 2000, Stapp Car Crash J, V44, P249; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; *CDCP, 1999, TRAUM BRIAN INJ US R; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; KEARNEY P A, 1988, Journal of Neurotrauma, V5, P187, DOI 10.1089/neu.1988.5.187; King A. I., 2003, P IRCOBI C; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Laurent VM, 2003, ANN BIOMED ENG, V31, P1263, DOI 10.1114/1.1616932; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Lusardi TA, 2003, BIORHEOLOGY, V40, P401; LYMAN WD, 1992, BRAIN RES, V599, P34, DOI 10.1016/0006-8993(92)90849-5; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; MORRISON B, 2005, IN PRES J NEUROSCIEN; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Shreiber D.I., 1997, STAPP CAR CRASH J, V41, P277; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; SWANSON RA, 1993, J CEREBR BLOOD F MET, V13, P162, DOI 10.1038/jcbfm.1993.19; VIANO DC, 1988, J BIOMECH, V21, P387, DOI 10.1016/0021-9290(88)90145-5; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; Wang CCB, 2002, J BIOMECH ENG-T ASME, V124, P557, DOI 10.1115/1.1503795	47	87	87	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.		2006	39	15					2810	2818		10.1016/j.jbiomech.2005.09.023			9	Biophysics; Engineering, Biomedical	Biophysics; Engineering	111EH	WOS:000242433700009	16289515				2021-06-18	
J	Frankel, JE; Marwitz, JH; Cifu, DX; Kreutzer, JS; Englander, J; Rosenthal, M				Frankel, JE; Marwitz, JH; Cifu, DX; Kreutzer, JS; Englander, J; Rosenthal, M			A follow-up study of older adults with traumatic brain injury: Taking into account decreasing length of stay	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	65th Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	OCT, 2004	Phoenix, AZ	Amer Acad Phys Med & Rehabil		age; brain injuries; geriatrics; rehabilitation; treatment outcome	DISABILITY RATING-SCALE; FUNCTIONAL OUTCOMES; REHABILITATION; AGE; PATIENT	Objective: To examine age-related differences in rehabilitation outcomes following traumatic brain injury (TBI). Design: Retrospective collaborative study. Setting: Patients received acute neurotrauma and inpatient rehabilitation services at 1 of the 17 National Institute on Disability and Rehabilitation Research-designated Traumatic Brain Injury Model Systems (TBIMS) centers. Participants: A sample of 273 older patients (>= 55 y) admitted for TBI were taken from the TBIMS National Database. Older patients were matched with subjects 44 years of age or younger, based on severity of injury (Glasgow Coma Scale score, length of coma, intracranial pressure elevations). Due to decreasing length of stay (LOS), only patients admitted from 1996 through 2002 were included. Intervention: Inpatient interdisciplinary brain injury rehabilitation. Main Outcome Measures: Acute care LOS, inpatient rehabilitation LOS, admission and discharge FIM instrument and Disability Rating Scale (DRS) scores, FIM and DRS efficiency, acute and rehabilitative charges, and discharge disposition. Results: One-way analyses of variance demonstrated a statistically significant difference between older and younger patients with respect to LOS in rehabilitation but not for acute care. Total rehabilitative charges, and admission and discharge DRS and FIM scores also showed statistically significant differences between groups. Older patients progressed with significantly less efficiency on both the DRS and FIM scales. Significantly more charges were generated per unit for older patients to improve on the DRS scale, but not the FIM scale. Using chi-square analysis, a statistically significant difference in rate of discharge to home was identified between older (80.5%) and younger (94.4%) patients. Conclusions: Results in this study are similar to those in earlier studies with smaller sample sizes. Major differences observed include significantly slower and more costly progress in inpatient rehabilitation for older patients with TBI, as well as a significantly lower rate of discharge to community for older patients. However, even with decreasing LOS in both settings, community discharge rate is still encouraging for older patients with TBI.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr Traumat Brain Injury & Spinal Cor, Santa Clara, CA USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA	Cifu, DX (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980677,Med Coll Virginia Campus, Richmond, VA 23298 USA.	dcifu@mail2.vcu.edu		Cifu, David/0000-0003-1600-9387			Bagg S, 2002, STROKE, V33, P179, DOI 10.1161/hs0102.101224; Bodenheimer CF, 2004, ARCH PHYS MED REHAB, V85, pS23, DOI 10.1016/j.apmr.2004.03.009; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Ergeletzis D, 2002, AM J PHYS MED REHAB, V81, P881, DOI 10.1097/00002060-200212000-00001; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1997, ASSESSING MED REHABI, P103; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Miller RS, 2000, J TRAUMA, V48, P229, DOI 10.1097/00005373-200002000-00006; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schmidt SM, 2002, ARCH PHYS MED REHAB, V83, P894, DOI 10.1053/apmr.2002.33219; *STAT U NY, 1996, GUID UN DAT SET MED; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Worsowicz GM, 2004, ARCH PHYS MED REHAB, V85, pS3, DOI 10.1016/j.apmr.2004.03.005	26	87	88	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2006	87	1					57	62		10.1016/j.apmr.2005.07.309			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	003GT	WOS:000234670500010	16401439				2021-06-18	
J	Pullela, R; Raber, J; Pfankuch, T; Ferriero, DM; Claus, CP; Koh, SE; Yamauchi, T; Rola, R; Fike, JR; Noble-Haeusslein, LJ				Pullela, Ramadevi; Raber, Jacob; Pfankuch, Timothy; Ferriero, Donna M.; Claus, Catherine P.; Koh, Seong-Eun; Yamauchi, Toshihiro; Rola, Radoslaw; Fike, John R.; Noble-Haeusslein, Linda J.			Traumatic injury to the immature brain results in progressive neuronal loss, hyperactivity and delayed cognitive impairments	DEVELOPMENTAL NEUROSCIENCE			English	Article						traumatic brain injury; immature brain; cognitive function; delayed cell loss	HEAD-INJURY; ADULT-RAT; REGIONAL VULNERABILITY; SUPEROXIDE-DISMUTASE; SOCIAL-INTERACTION; ANIMAL-MODELS; MOUSE-BRAIN; TIME-COURSE; CELL LOSS; CHILDREN	The immature brain may be particularly vulnerable to injury during critical periods of development. To address the biologic basis for this vulnerability, mice were subjected to traumatic brain injury at postnatal day 21, a time point that approximates that of the toddler-aged child. After motor and cognitive testing at either 2 weeks (juveniles) or 3 months (adults) after injury, animals were euthanized and the brains prepared for quantitative histologic assessment. Brain-injured mice exhibited hyperactivity and age-dependent anxiolysis. Cortical lesion volume and subcortical neuronal loss were greater in brain-injured adults than in juveniles. Importantly, cognitive decline was delayed in onset and coincided with loss of neurons in the hippocampus. Our findings demonstrate that trauma to the developing brain results in a prolonged period of pathogenesis in both cortical and subcortical structures. Behavioral changes are a likely consequence of regional-specific neuronal degeneration. Copyright (c) 2006 S. Karger AG, Basel.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Oregon Hlth & Sci Univ, Dept Behav Neurosci, ONPRC, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Neurol, ONPRC, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Div Neurosci, ONPRC, Portland, OR 97201 USA	Noble-Haeusslein, LJ (corresponding author), 521 Parnassus Ave,Room C-224, San Francisco, CA 94143 USA.	noblelj@itsa.ucsf.edu	Rola, Radoslaw/AAQ-5587-2021; Rola, Radoslaw/V-6749-2018	Rola, Radoslaw/0000-0003-0613-6593; Rola, Radoslaw/0000-0003-0613-6593	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159, R21NS41246] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Conti AC, 1998, J NEUROSCI, V18, P5663; Crack PJ, 2001, J NEUROCHEM, V78, P1389, DOI 10.1046/j.1471-4159.2001.00535.x; de Bilbao F, 2000, EUR J NEUROSCI, V12, P921, DOI 10.1046/j.1460-9568.2000.00984.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Gonzalez LE, 2000, BRAIN RES, V887, P7, DOI 10.1016/S0006-8993(00)02931-0; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hicks R. R., 2000, Journal of Neurotrauma, V17, P969; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Jessberger S, 2003, EUR J NEUROSCI, V18, P2707, DOI 10.1111/j.1460-9568.2003.02986.x; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kesner RP, 2000, CURR OPIN NEUROBIOL, V10, P260, DOI 10.1016/S0959-4388(00)00067-2; Konrad K, 2003, COGNITIVE BRAIN RES, V16, P425, DOI 10.1016/S0926-6410(03)00057-0; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lacroix L, 2000, BEHAV NEUROSCI, V114, P1119, DOI 10.1037//0735-7044.114.6.1119; Lassalle JM, 2000, NEUROBIOL LEARN MEM, V73, P243, DOI 10.1006/nlme.1999.3931; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; Levin ED, 1998, BEHAV GENET, V28, P381, DOI 10.1023/A:1021673703129; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Max JE, 2003, J INT NEUROPSYCH SOC, V9, P815, DOI 10.1017/S1355617703960012; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Mizuguchi M, 1999, AM J PATHOL, V155, P1713, DOI 10.1016/S0002-9440(10)65486-7; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Peterson BS, 2000, ARCH GEN PSYCHIAT, V57, P364, DOI 10.1001/archpsyc.57.4.364; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; RADCLIFFE J, 1994, INT J DEV NEUROSCI, V12, P327, DOI 10.1016/0736-5748(94)90081-7; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rangel A, 2003, BRAIN RES, V992, P96, DOI 10.1016/j.brainres.2003.08.038; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Rustay NR, 2003, BEHAV BRAIN RES, V141, P237, DOI 10.1016/S0166-4328(02)00376-5; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shah AA, 2003, BRAIN RES, V969, P183, DOI 10.1016/S0006-8993(03)02299-6; SLOTNICK BM, 1975, STEREOTAXIC ATLAS MO; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Solanto MV, 2002, BEHAV BRAIN RES, V130, P65, DOI 10.1016/S0166-4328(01)00431-4; StubleyWeatherly L, 1996, BRAIN RES, V716, P29, DOI 10.1016/0006-8993(95)01589-2; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; WEINGARTEN J, 1999, PSYCHOSURGERY HUMAN; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Zilles K., 1985, RAT NERVOUS SYSTEM, P375	68	87	91	0	13	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					396	409		10.1159/000094166			14	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600017	16943663				2021-06-18	
J	Schmitz, TW; Rowley, HA; Kawahara, TN; Johnson, SC				Schmitz, TW; Rowley, HA; Kawahara, TN; Johnson, SC			Neural correlates of self-evaluative accuracy after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						fMRI; self-awareness; traumatic brain injury	ALZHEIMERS-DISEASE; BEHAVIORAL LIMITATIONS; FRONTOMEDIAN CORTEX; AWARENESS; FMRI; MIND; ANOSOGNOSIA; SCHIZOPHRENIA; UNAWARENESS; DYSFUNCTION	Individuals who have sustained a traumatic brain injury (TBI) often exhibit an array of cognitive deficits, yet perhaps most maladaptive of these sequelae is the frequent occurrence of reduced insight into one's own condition. In such cases, TBI individuals may overestimate their post-injury level of socio-cognitive functioning, leading to disparities between how they perceive themselves and what others observe. This functional MRI (fMRI) investigation examined the relationship between level of insight into one's post-injury condition (i.e. trait/ability status) and neural activation evoked during an fMRI task involving self-appraisal of one's traits and abilities. Twenty TBI patients (8-12 weeks post-injury, ER Glasgow Coma Scale Average = 10.9 +/- 2.8) were selected on the criterion that they overestimate their current trait/abilities (as detected on the patient competency rating scale, PCRS). fMRI activation on the self-appraisal task was compared between the TBI patients and 20 matched controls. For both groups, the fMRI task evoked activation at mid-line prefrontal and retrosplenial cortices. TBI patients exhibited greater signal change in the anterior cingulate, precuneus and right temporal pole. Subsequently, a linear regression analysis was conducted for the TBI group, with the PCRS and a measure of cognitive speed entered as predictor variables to determine the selective effect of insight on self-evaluative brain activation. A more accurate level of trait/ability-based insight was related to increased signal change in the right anterior dorsal prefrontal cortex (PFC). The results suggest that one's post-injury level of self-referential insight is related to a network inclusive of the medial and right dorsal PFC. (c) 2005 Elsevier Ltd. All rights reserved.	William S Middleton VA Med Ctr, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Madison, WI 53706 USA	Johnson, SC (corresponding author), William S Middleton VA Med Ctr, 2500 Overlook Terrace,11G, Madison, WI 53705 USA.	scj@medicine.wisc.edu		Johnson, Sterling/0000-0002-8501-545X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH65723] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER		ADAIR JC, 1995, NEUROLOGY, V45, P241, DOI 10.1212/WNL.45.2.241; Adair JC, 1995, NEUROLOGY, V45, P2195, DOI 10.1212/WNL.45.12.2195; BELYI B I, 1975, Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova, V75, P1793; BELYI BI, 1987, INT J NEUROSCI, V32, P799, DOI 10.3109/00207458709043334; Bondi MW, 2005, NEUROLOGY, V64, P501, DOI 10.1212/01.WNL.0000150885.00929.7E; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Craik FIM, 1999, PSYCHOL SCI, V10, P26, DOI 10.1111/1467-9280.00102; D'Argembeau A, 2005, NEUROIMAGE, V25, P616, DOI 10.1016/j.neuroimage.2004.11.048; Ferstl EC, 2002, NEUROIMAGE, V17, P1599, DOI 10.1006/nimg.2002.1247; Fink GR, 1996, J NEUROSCI, V16, P4275; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Flashman L. A., 1998, SEMINARS CLIN NEUROP, V3, P201; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Flashman LA, 2001, J NEUROPSYCH CLIN N, V13, P255, DOI 10.1176/appi.neuropsych.13.2.255; Flashman Laura A, 2002, Curr Psychiatry Rep, V4, P346, DOI 10.1007/s11920-002-0082-x; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fossati P, 2003, AM J PSYCHIAT, V160, P1938, DOI 10.1176/appi.ajp.160.11.1938; Francis W. N., 1982, FREQUENCY ANAL ENGLI; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Grady CL, 2003, J NEUROSCI, V23, P986, DOI 10.1523/jneurosci.23-03-00986.2003; GUSNARD DA, 2001, P NATL ACAD SCI USA, V20, P20; Heilman K.M.V.E., 1993, CLIN NEUROPSYCHOLOGY; Jenkinson M, 2003, MAGNET RESON MED, V49, P193, DOI 10.1002/mrm.10354; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Joseph R, 1999, PSYCHIATRY, V62, P138, DOI 10.1080/00332747.1999.11024862; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Miller BL, 2001, NEUROLOGY, V57, P817, DOI 10.1212/WNL.57.5.817; Northoff G, 2004, TRENDS COGN SCI, V8, P102, DOI 10.1016/j.tics.2004.01.004; Prigatano G., 1990, CLIN NEUROPSYCHOL, V4, P1; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Reddy H, 2000, BRAIN, V123, P2314, DOI 10.1093/brain/123.11.2314; REED BR, 1993, J CLIN EXP NEUROPSYC, V15, P231, DOI 10.1080/01688639308402560; Schmitz TW, 2004, NEUROIMAGE, V22, P941, DOI 10.1016/j.neuroimage.2004.02.018; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sperling RA, 2003, J NEUROL NEUROSUR PS, V74, P44, DOI 10.1136/jnnp.74.1.44; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; STUSS D, 2001, FRONTAL LOBES NEUROP; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Takahashi H, 2004, NEUROIMAGE, V23, P967, DOI 10.1016/j.neuroimage.2004.07.054; Turk DJ, 2003, ANN NY ACAD SCI, V1001, P65, DOI 10.1196/annals.1279.005; Turk DJ, 2002, NAT NEUROSCI, V5, P841, DOI 10.1038/nn907; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	56	87	90	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	5					762	773		10.1016/j.neuropsychologia.2005.07.012			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	032YQ	WOS:000236813200009	16154166				2021-06-18	
J	Giza, CC; Griesbach, GS; Hovda, DA				Giza, CC; Griesbach, GS; Hovda, DA			Experience-dependent behavioral plasticity is disturbed following traumatic injury to the immature brain	BEHAVIOURAL BRAIN RESEARCH			English	Article						complex environment; development; enriched environment; experience-dependent plasticity; fluid percussion injury; Morris water maze; pediatric; traumatic brain injury	FLUID-PERCUSSION INJURY; LONG-TERM POTENTIATION; RAT CEREBRAL-CORTEX; EARLY CORTICAL DAMAGE; ENVIRONMENTAL ENRICHMENT; SECONDARY ISCHEMIA; STATUS EPILEPTICUS; COGNITIVE FUNCTION; SPATIAL MEMORY; AMINO-ACIDS	Traumatic brain injury (TBI) is most prevalent in children and young adults. The long-term effects of pediatric TBI include cognitive and behavioral impairments; however, over time, it is difficult to distinguish individual variability in intellect and behavior from sequelae of early injury. Postnatal day (PND) 19 rats underwent lateral fluid Percussion (FP) injury followed by rearing in either standard (STD) or enriched environment (EE) conditions. The hypothesis was that the traditional enhancement of cognitive functioning following EE rearing would be attenuated when this rearing is preceded by TBI at PND 19. Thirty days after injury, Morris water maze (MWM) acquisition and subsequent probe trial retention were used to assess the behavioral effects of injury on experience-dependent plasticity induced by housing in EE at two different time windows. MWM acquisition demonstrated improvements following early EE rearing in both sham and injured animals: however, the degree of improvement was greater for uninjured animals. When EE rearing was delayed for 2 weeks after injury, the injury effect was absent and the effect of rearing even stronger. Memory testing in the early EE groups using a delayed probe trial showed an effect of injury and housing, with the sham EE animals benefiting the most. After the delayed EE, sham EE animals again showed more probe target hits, while FPEE animals did not, demonstrating an enduring memory deficit. These data confirm that early TBI has effects on experience-dependent plasticity resulting in long-term neurobehavioral deficits. In addition, the ability to benefit from environmental stimulation following TBI is dependent upon time after injury. (C) 2004 Elsevier B.V. All rights reserved.	Univ Calif Los Angeles, Brain Injury Res Ctr, David Geffen Sch Med, Dept Surg,Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Brain Res, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA	Giza, CC (corresponding author), Univ Calif Los Angeles, Brain Injury Res Ctr, David Geffen Sch Med, Dept Surg,Div Neurosurg, Room 18-228 NPI,Mail Code 703919, Los Angeles, CA 90095 USA.	cgiza@mednet.ucla.edu; ggriesbach@mednet.ucla.edu; dhovda@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS027544-09, NS30308, NS02197, R21 NS048535-01A1, NS27544, K08 NS002197-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002197, R01NS027544, R21NS048535, P50NS030308] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BURGESS JW, 1986, BEHAV BRAIN RES, V20, P1, DOI 10.1016/0166-4328(86)90096-3; Conti AC, 1998, J NEUROSCI, V18, P5663; CUMMINS RA, 1977, SCIENCE, V197, P692, DOI 10.1126/science.877587; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DeWitt D S, 1995, New Horiz, V3, P376; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; DIAMOND MC, 1975, BEHAV BIOL, V14, P163, DOI 10.1016/S0091-6773(75)90161-3; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; GURKOFF G, 2003, J NEUROTRAUMA, V20; Haas KZ, 2001, HIPPOCAMPUS, V11, P615, DOI 10.1002/hipo.1076; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HATTORI H, 1990, PEDIATR NEUROL, V6, P219, DOI 10.1016/0887-8994(90)90111-D; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KOLB B, 1988, BEHAV BRAIN RES, V28, P259, DOI 10.1016/0166-4328(88)90129-5; KOLB B, 1987, BEHAV BRAIN RES, V26, P47, DOI 10.1016/0166-4328(87)90015-5; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Kolb B, 2000, BRAIN RES, V882, P62, DOI 10.1016/S0006-8993(00)02828-6; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lado FA, 2000, MENT RETARD DEV D R, V6, P242, DOI 10.1002/1098-2779(2000)6:4<242::AID-MRDD3>3.3.CO;2-N; Malkasian D R, 1971, Int J Neurosci, V2, P161, DOI 10.3109/00207457109146998; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OSTEEN CL, 2002, J NEUROTRAUM, V19, P1384; OSTEEN CL, 2004, IN PRESS NEUROSCIENC; OSTEEN CL, 2000, RESTORATIVE NEUROL N, V16, P210; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sankar R, 1998, J NEUROSCI, V18, P8382; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VANGOOL WA, 1985, BEHAV NEURAL BIOL, V44, P454, DOI 10.1016/S0163-1047(85)90880-5; VENABLE N, 1988, BEHAV BRAIN RES, V31, P89, DOI 10.1016/0166-4328(88)90162-3; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Villablanca JR, 2000, NEUROSCIENCE, V95, P625; Weiner H. L., 2000, HEAD INJURY, P419; Williams BM, 2001, PHYSIOL BEHAV, V73, P649, DOI 10.1016/S0031-9384(01)00543-1; Yager JY, 1996, DEV BRAIN RES, V93, P143, DOI 10.1016/0165-3806(96)00026-0; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	71	87	90	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 10	2005	157	1					11	22		10.1016/j.bbr.2004.06.003			12	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	889NY	WOS:000226450900002	15617766				2021-06-18	
J	Mi, WQ; Beirowski, B; Gillingwater, TH; Adalbert, R; Wagner, D; Grumme, D; Osaka, H; Conforti, L; Arnhold, S; Addicks, K; Wada, K; Ribchester, RR; Coleman, MP				Mi, WQ; Beirowski, B; Gillingwater, TH; Adalbert, R; Wagner, D; Grumme, D; Osaka, H; Conforti, L; Arnhold, S; Addicks, K; Wada, K; Ribchester, RR; Coleman, MP			The slow Wallerian degeneration gene, Wld(S), inhibits axonal spheroid pathology in gracile axonal dystrophy mice	BRAIN			English	Article						axon; axonal spheroid; gracile axonal dystrophy; ubiquitin; Wallerian degeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; AMYLOID PRECURSOR PROTEIN; UBIQUITIN-PROTEASOME SYSTEM; CARBOXY-TERMINAL HYDROLASE; MULTIPLE-SCLEROSIS; TRANSGENIC MICE; CYTOSKELETAL PATHOLOGY; NERVE-TERMINALS; HIV-INFECTION; ANIMAL-MODEL	Axonal dystrophy is the hallmark of axon pathology in many neurodegenerative disorders of the CNS, including Alzheimer's disease, Parkinson's disease and stroke. Axons can also form larger swellings, or spheroids, as in multiple sclerosis and traumatic brain injury. Some spheroids are terminal endbulbs of axon stumps, but swellings may also occur on unbroken axons and their role in axon loss remains uncertain. Similarly, it is not known whether spheroids and axonal dystrophy in so many different CNS disorders arise by a common mechanism. These surprising gaps in current knowledge result largely from the lack of experimental methods to manipulate axon pathology. The slow Wallerian degeneration gene, Wld(S), delays Wallerian degeneration after injury, and also delays 'dying-back' in peripheral nervous system disorders, revealing a mechanistic link between two forms of axon degeneration traditionally considered distinct. We now report that Wld(S) also inhibits axonal spheroid pathology in gracile axonal dystrophy (gad) mice. Both gracile nucleus (P < 0.001) and cervical gracile fascicle (P = 0.001) contained significantly fewer spheroids in gad/Wld(S) mice, and secondary signs of axon pathology such as myelin loss were also reduced. Motor nerve terminals at neuromuscular junctions continued to degenerate in gad/Wld(S) mice, consistent with previous observations that Wld(S) has a weaker effect on synapses than on axons, and probably contributing to the fact that Wld(S) did not alleviate gad symptoms. Wld(S) acts downstream of the initial pathogenic events to block gad pathology, suggesting that its effect on axonal swelling need not be specific to this disease. We conclude that axon degeneration mechanisms are more closely related than previously thought and that a link exists in gad between spheroid pathology and Wallerian degeneration that could hold for other disorders.	Babraham Inst, Cambridge CB2 4AT, England; Univ Cologne, ZMMK, Cologne, Germany; Univ Cologne, Inst Genet, D-5000 Cologne, Germany; Univ Cologne, Dept Anat 1, Cologne, Germany; Univ Edinburgh, Div Neurosci, Edinburgh, Midlothian, Scotland; Natl Inst Neurosci, Dept Degenerat Neurol Dis, Tokyo, Japan; Kanagawa Childrens Med Ctr, Clin Res Inst, Yokohama, Kanagawa, Japan	Coleman, MP (corresponding author), Babraham Inst, Cambridge CB2 4AT, England.	michael.coleman@bbsrc.ac.uk	Gillingwater, Thomas/G-2880-2011	Adalbert, Robert/0000-0003-0782-1402; Gillingwater, Thomas/0000-0002-0306-5577; Ribchester, Richard/0000-0003-2670-6995			ADELBERT R, IN PRESS EUR J NEURO; Adle-Biassette H, 1999, NEUROPATH APPL NEURO, V25, P123; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Beirowski B, 2004, J NEUROSCI METH, V134, P23, DOI 10.1016/j.jneumeth.2003.10.016; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bomont P, 2000, NAT GENET, V26, P370; Brendza RP, 2003, J COMP NEUROL, V456, P375, DOI 10.1002/cne.10536; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bu BT, 2002, J NEUROSCI, V22, P6515; BUCKMASTER EA, 1995, EUR J NEUROSCI, V7, P1596, DOI 10.1111/j.1460-9568.1995.tb01155.x; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Edgar JM, 2004, J CELL BIOL, V166, P121, DOI 10.1083/jcb.200312012; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Ferri A, 2003, CURR BIOL, V13, P669, DOI 10.1016/S0960-9822(03)00206-9; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GEORGE R, 1994, J NEUROCYTOL, V23, P657, DOI 10.1007/BF01181641; Gillingwater TH, 2004, J CEREBR BLOOD F MET, V24, P62, DOI 10.1097/01.WCB.0000095798.98378.34; Gillingwater TH, 2002, J PHYSIOL-LONDON, V543, P739, DOI 10.1113/jphysiol.2002.022343; Gillingwater TH, 2001, J PHYSIOL-LONDON, V534, P627, DOI 10.1111/j.1469-7793.2001.00627.x; GLASS JD, 1993, J NEUROCYTOL, V22, P311, DOI 10.1007/BF01195555; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Hughes PM, 2003, J NEUROPATH EXP NEUR, V62, P1276, DOI 10.1093/jnen/62.12.1276; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; KIKUCHI T, 1990, ACTA NEUROPATHOL, V80, P145, DOI 10.1007/BF00308917; Kitada T, 1998, NATURE, V392, P605; Kornek B, 2001, BRAIN, V124, P1114, DOI 10.1093/brain/124.6.1114; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Kurihara LJ, 2001, HUM MOL GENET, V10, P1963, DOI 10.1093/hmg/10.18.1963; Laser H, 2003, J NEUROSCI RES, V74, P906, DOI 10.1002/jnr.10806; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lewis J, 2000, NAT GENET, V25, P402; Liberski PP, 1999, ACTA NEUROPATHOL, V97, P329, DOI 10.1007/s004010050995; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mi WQ, 2003, MUTAT RES-FUND MOL M, V526, P33, DOI 10.1016/S0027-5107(03)00011-3; Mi WQ, 2002, J NEUROSCI METH, V113, P215, DOI 10.1016/S0165-0270(01)00501-5; MIIKE T, 1986, ACTA NEUROPATHOL, V69, P117, DOI 10.1007/BF00687047; MIURA H, 1993, NEUROPATH APPL NEURO, V19, P41, DOI 10.1111/j.1365-2990.1993.tb00403.x; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MUKOYAMA M, 1989, ACTA NEUROPATHOL, V79, P294, DOI 10.1007/BF00294664; Norreel JC, 2001, EUR J NEUROSCI, V13, P1625, DOI 10.1046/j.0953-816x.2001.01535.x; ODA K, 1992, NEUROPATH APPL NEURO, V18, P265, DOI 10.1111/j.1365-2990.1992.tb00789.x; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Pan YA, 2003, J NEUROSCI, V23, P11479; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Raja F, 1997, ACTA NEUROPATHOL, V93, P184, DOI 10.1007/s004010050601; Saigoh K, 1999, NAT GENET, V23, P47; Sajadi A, 2004, CURR BIOL, V14, P326, DOI 10.1016//j.cub.2004.01.053; Samsam M, 2003, J NEUROSCI, V23, P2833; Sidman R. L., 1971, ATLAS MOUSE BRAIN SP; SUNG JH, 1981, J NEUROPATH EXP NEUR, V40, P37; Takahashi T, 1997, ACTA NEUROPATHOL, V94, P294, DOI 10.1007/s004010050707; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Wang MS, 2002, ANN NEUROL, V52, P442, DOI 10.1002/ana.10300; Wilson SM, 2002, NAT GENET, V32, P420, DOI 10.1038/ng1006; WUJEK JR, 1983, J NEUROSCI, V3, P243; YAMAZAKI K, 1988, P SOC EXP BIOL MED, V187, P209; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X	74	87	89	2	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2005	128		2				405	416		10.1093/brain/awh368			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	891UF	WOS:000226605800020	15644421	Bronze			2021-06-18	
J	Viano, DC; Pellman, EJ				Viano, DC; Pellman, EJ			Concussion in professional football: Biomechanics of the striking player - Part 8	NEUROSURGERY			English	Article						biomechanics; concussion; football; impact tolerances; neck injury; spearing; sport injury prevention	NECK-INJURY-REGISTRY; 4TH CERVICAL-VERTEBRAE; HYPEREXTENSION INJURIES; TACKLE FOOTBALL; SPINE INJURIES; 14-YEAR REPORT; HEAD; PATHOMECHANICS; QUADRIPLEGIA; FATALITIES	Objective: Concussive impacts in professional football were simulated in laboratory tests to determine the collision mechanics resulting in injury to the struck player and the biomechanics of the striking players, who were not concussed or neck-injured in the tackle. Methods: Twenty-seven helmet-to-helmet collisions were reconstructed in laboratory tests using Hybrid III dummies. The head impact velocity, direction, and kinematics matched game video. Translational and rotational head accelerations and six-axis upper neck loads and moments were used to evaluate how the striking player delivered the concussive blow. The neck injury criterion, Nij, was calculated to assess neck injury risks in the striking player. Results: The time-averaged impact force reached 6372 +/- 2486 N at 7.2 milliseconds because of 46.8 +/- 21.7 g head acceleration and 3524 +/- 1729 N neck compression force in the striking player. Fifty-seven percent of the load was contributed by neck compression. The striking players had their heads down and lined up in impact axis through their necks and torsos. This allowed momentum transfer with minimal neck bending and increased the effective mass of the striking player to 1.67 times that of the struck player at peak load. The impact caused 94.3 +/- 27.5 g head acceleration in the concussed players and 67.9 +/- 14.5 g without concussion (t = 2.06 , df = 25, P = 0.025). The striking player's Nij was greater than tolerance in 9 of 27 cases by exceeding the 4000 N neck compression limit. For these cases, the average neck compression force was 6631 +/- 997 N (range, 5210 - 8194 N). Nij was 1.25 +/- 0.16 for eight cases above the tolerance Nij = 1.0. In the NFL, striking players line up their heads, necks, and torsos to deliver maximum force is from acceleration of the striking player's head and torso load through the neck. Even though neck responses exceeded tolerance, no striking player experienced neck injury or concussion. A head-up stance at impact would reduce the torso inertial load in the collision and the risk of concussion in the struck player.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Committee, New York, NY USA; ProHLTH Care Assoc LLP, Lake Success, NY USA	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; BACKAITIS SH, 1994, HYBRID 3 1 HUMAN LIK; BISHOP PJ, 1986, 860201 SAE; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; CARTER DR, 1980, AM J SPORT MED, V8, P302, DOI 10.1177/036354658000800502; DIMASI FP, 1995, HS808282 DOT; Duff J F, 1974, J Sports Med, V2, P175; Eppinger R., 1999, DEV IMPROVED INJURY; FUNK FJ, 1975, CLIN ORTHOP RELAT R, P50, DOI 10.1097/00003086-197506000-00007; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Heck J F, 1996, J Athl Train, V31, P31; HECK J F, 1992, Journal of Athletic Training, V27, P120; Heck JF, 2004, J ATHL TRAINING, V39, P101; HECK JF, 1994, J ATHL TRAINING, V30, P63; Hodgson VR, 1980, P 24 STAPP CAR CRASH; HODGSON VR, 1983, 806434 DOT HS, P110; JARROD W, 2002, P 46 STAPP CAR CRASH; KING AI, 1995, BIOMEDICAL ENG HDB, P357; KLEINBERGER M, 1998, 19944059 NHTSA; KRAUS JF, 1984, ANNU REV PUBL HEALTH, V5, P163; Maroon J C, 1980, Clin Neurosurg, V27, P414; MCELHANEY J, 1979, SAE SP, V438; Mertz H. J., 1978, PHYS SPORTS MED, V6, P95, DOI [10.1080/00913847.1978.11948406, DOI 10.1080/00913847.1978.11948406]; MERTZ HJ, 1971, 15 STAPP CAR CRASH C; MUELLER FO, 1989, PHYSICIAN SPORTSMED, V17, P51, DOI 10.1080/00913847.1989.11709888; MUELLER FO, 1987, CLIN SPORT MED, V6, P185; *NCAA, 1976, FOOTB RUL CHANG RUL; NEWMAN JA, IN PRESS J BIOMECH; *NFSHSA, 1992, OFF FOOTB RUL, V15, P22; NIGHTINGALE RW, 1997, P 41 STAPP CAR CRASH, P451; *NOCSAE, 1996, 00196 NOCSAE; NUCKLEY DJ, 2002, P 46 STAPP CAR CRASH; Nusholtz G. S, 1981, P 25 STAPP CAR CRASH; NYQUIST GW, 1980, J BIOMECH ENG-T ASME, V102, P103, DOI 10.1115/1.3138204; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pintar FA, 1998, SPINE, V23, P1957, DOI 10.1097/00007632-199809150-00007; PINTAR FA, 1995, P 39 STAPP CAR CRASH; SANCES A, 1981, P 25 STAPP CAR CRASH; Schneider R., 1973, HEAD NECK INJURIES F; SHEA M, 1992, J ORTHOPAED RES, V10, P911, DOI 10.1002/jor.1100100621; *SOC AUT ENG, 1994, J1733 SAE; *SOC AUT ENG, 1980, J855 SAE; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TORG JS, 1990, AM J SPORT MED, V18, P50, DOI 10.1177/036354659001800109; TORG JS, 1987, CLIN SPORT MED, V6, P61; TORG JS, 1977, J BONE JOINT SURG AM, V59, P1015, DOI 10.2106/00004623-197759080-00003; TORG JS, 1987, CLIN SPORT MED, V6, P159; TORG JS, 1995, CLIN ORTHOP RELAT R, V321, P259; Yoganandan N, 1996, MED ENG PHYS, V18, P289, DOI 10.1016/1350-4533(95)00054-2	55	87	87	0	24	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2005	56	2					266	278		10.1227/01.neu.0000150035.54230.3C			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	895UO	WOS:000226889400017	15670375				2021-06-18	
J	Lister, JP; Blatt, GJ; DeBassio, WA; Kemper, TL; Tonkiss, J; Galler, JR; Rosene, DL				Lister, JP; Blatt, GJ; DeBassio, WA; Kemper, TL; Tonkiss, J; Galler, JR; Rosene, DL			Effect of prenatal protein malnutrition on numbers of neurons in the principal cell layers of the adult rat hippocampal formation	HIPPOCAMPUS			English	Article						stereology; nutrition; CA1; subiculum; hippocampus	SPATIAL-LEARNING DEFICITS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CA1 PYRAMIDAL CELLS; 4 AGE-GROUPS; DIFFERENTIAL VULNERABILITY; STEREOLOGICAL ESTIMATION; SUPEROXIDE-DISMUTASE; NEUROTROPHIC FACTOR; DENTATE GYRUS	Malnutrition has been associated with a variety of functional and anatomical impairments of the hippocampal formation. One of the more striking of these is widespread loss of hippocampal neurons in postnatally malnourished rats. in the present study we have investigated the effect of prenatal malnutrition on these same neuronal populations, neurons that are all generated during the period of the dietary restriction. In prenatally protein deprived rats, using design-based stereology, we have measured the regional volume and number of neurons in the hilus of the dentate gyrus and the pyramidal cell layers of CA3, CA2, CA1, and the subiculum of 90-day-old animals. These results demonstrated a statistically significant reduction of 20% in neuron numbers in the CA1 subfield, while numbers in the other subfields were unchanged. There was a corresponding significant reduction of 22% in the volume of the CA1 subfield and a significant 14% decrease in the volume of the pyramidal layer of the subiculum. The change in volume of the pyramidal layer of the subiculum without neuron loss may reflect loss of CA1 afferent input to the pyramidal layer. Although the effect of nutritional deprivation on the neuronal population appears to be different in pre- and postnatal malnutrition, both dietary paradigms highlight the vulnerability of key components of the hippocampal trisynaptic circuit (consisting of the dentate granule cell mossy fibers projection to CA3 pyramids and the CA3 projection to the CA1 pyramids), which is an essential circuit for memory and learning. (c) 2005 Wiley-Liss, Inc.	Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA USA; Boston Univ, Sch Med, Ctr Behav Dev & Mental Retardat, Boston, MA USA	Rosene, DL (corresponding author), Boston Univ, Sch Med, Dept Anat & Neurobiol, 715 Albany St W701, Boston, MA 02118 USA.	drosene@bu.edu	Rosene, Douglas L/G-1973-2015	Kemper, Thomas/0000-0002-4623-4094; DeBassio, William/0000-0002-0073-5627; Rosene, Douglas/0000-0001-8719-1441; Tonkiss, John/0000-0002-6498-7815	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD022539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG000001] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01-AG00001] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01-HD22539] Funding Source: Medline		Almeida SS, 1996, NEUROSCI BIOBEHAV R, V20, P389, DOI 10.1016/0149-7634(95)00054-2; Andrade JP, 1996, BRAIN RES, V718, P1; Andrade JP, 1996, NEUROSCI LETT, V211, P211, DOI 10.1016/0304-3940(96)12734-8; ANDRADE JP, 1995, J ANAT, V187, P379; Andrade JP, 1998, HIPPOCAMPUS, V8, P33, DOI 10.1002/(SICI)1098-1063(1998)8:1<33::AID-HIPO4>3.0.CO;2-8; BAYER SA, 1974, J COMP NEUROL, V158, P55, DOI 10.1002/cne.901580105; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BEDI KS, 1991, J COMP NEUROL, V311, P425, DOI 10.1002/cne.903110311; Bedi KS, 2003, NUTR NEUROSCI, V6, P141, DOI 10.1080/1028415031000098549; BOITANO JJ, 1980, PHYSIOL BEHAV, V25, P273, DOI 10.1016/0031-9384(80)90216-4; Bronzino JD, 1997, EXP NEUROL, V148, P317, DOI 10.1006/exnr.1997.6653; CINTRA L, 1990, BRAIN RES, V532, P271, DOI 10.1016/0006-8993(90)91769-D; Cintra L, 1997, HIPPOCAMPUS, V7, P184, DOI 10.1002/(SICI)1098-1063(1997)7:2<184::AID-HIPO5>3.0.CO;2-N; Cintra L, 1997, HIPPOCAMPUS, V7, P192, DOI 10.1002/(SICI)1098-1063(1997)7:2<192::AID-HIPO6>3.0.CO;2-P; Davies AM, 2003, EMBO J, V22, P2537, DOI 10.1093/emboj/cdg254; DEBASSIO WA, 1994, BRAIN RES BULL, V35, P57, DOI 10.1016/0361-9230(94)90216-X; DIAZCINTRA S, 1991, J COMP NEUROL, V310, P356, DOI 10.1002/cne.903100306; DIAZCINTRA S, 1994, BRAIN RES, V662, P117, DOI 10.1016/0006-8993(94)90803-6; GALLER JR, 1991, J NUTR, V121, P762; GALLER JR, 1996, NUTR PEDIAT, P196; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Granados-Rojas L, 2002, BRAIN RES, V933, P164, DOI 10.1016/S0006-8993(02)02314-4; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Hedreen JC, 1998, ANAT REC, V250, P366; JAY TM, 1989, BRAIN RES, V505, P337, DOI 10.1016/0006-8993(89)91464-9; JENNRICH R, 1988, BMDP STATISTICAL SOF, P483; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; Luebke J, 2000, SYNAPSE, V37, P23, DOI 10.1002/(SICI)1098-2396(200007)37:1&lt;23::AID-SYN3&gt;3.0.CO;2-Y; Lukoyanov NV, 2000, BEHAV BRAIN RES, V112, P85, DOI 10.1016/S0166-4328(00)00164-9; MATSUYAMA T, 1994, STROKE, V25, P1417, DOI 10.1161/01.STR.25.7.1417; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Mesquita RM, 2002, NEUROSCI LETT, V330, P155, DOI 10.1016/S0304-3940(02)00743-7; Morgane PJ, 2002, NEUROSCI BIOBEHAV R, V26, P471, DOI 10.1016/S0149-7634(02)00012-X; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nunez JL, 2003, ENDOCRINOLOGY, V144, P2350, DOI 10.1210/en.2002-220840; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Rapp PR, 1996, P NATL ACAD SCI USA, V93, P9926, DOI 10.1073/pnas.93.18.9926; Rasmussen T, 1996, NEUROBIOL AGING, V17, P143, DOI 10.1016/0197-4580(95)02032-2; ROSENE DL, 1986, J HISTOCHEM CYTOCHEM, V34, P1301, DOI 10.1177/34.10.3745909; ROSENE DL, 1987, CEREB CORTEX, P346; Rushmore J, 1998, HIPPOCAMPUS, V8, P380, DOI 10.1002/(SICI)1098-1063(1998)8:4<380::AID-HIPO6>3.0.CO;2-L; Shultz PL, 2002, PHARMACOL BIOCHEM BE, V73, P759, DOI 10.1016/S0091-3057(02)00907-3; STRUPP BJ, 1995, J NUTR, V125, pS2221, DOI 10.1093/jn/125.suppl_8.2221S; Tonkiss J, 2000, BEHAV PHARMACOL, V11, P437, DOI 10.1097/00008877-200009000-00001; TONKISS J, 1993, ANN NY ACAD SCI, V678, P215; Tonkiss J, 2003, NUTR NEUROSCI, V6, P379, DOI 10.1080/10284150310001624200; TONKISS J, 1990, BEHAV BRAIN RES, V40, P95, DOI 10.1016/0166-4328(90)90002-V; Tonkiss J, 2000, PHARMACOL BIOCHEM BE, V65, P105, DOI 10.1016/S0091-3057(99)00182-3; TONKISS J, 1990, PHYSIOL BEHAV, V48, P675, DOI 10.1016/0031-9384(90)90210-U; Tonkiss J, 1998, BEHAV PHARMACOL, V9, P49; TONKISS J, 1990, PHYSIOL BEHAV, V48, P73, DOI 10.1016/0031-9384(90)90263-4; Tuunanen J, 2000, EPILEPSY RES, V39, P171, DOI 10.1016/S0920-1211(99)00123-0; VANGROEN T, 1990, J COMP NEUROL, V302, P515, DOI 10.1002/cne.903020308; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilde GJC, 1997, J NEUROCHEM, V69, P883; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	57	87	88	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus		2005	15	3					393	403		10.1002/hipo.20065			11	Neurosciences	Neurosciences & Neurology	916YB	WOS:000228421600012	15669101				2021-06-18	
J	Sun, D; Colello, RJ; Daugherty, WP; Kwon, TH; McGinn, MJ; Harvey, HB; Bullock, MR				Sun, D; Colello, RJ; Daugherty, WP; Kwon, TH; McGinn, MJ; Harvey, HB; Bullock, MR			Cell proliferation and neuronal differentiation in the dentate gyrus in juvenile and adult rats following traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						BrdU; dentate gyrus; fluid percussion injury; hippocampus; neurogenesis; proliferation	FIBROBLAST-GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; FLUID-PERCUSSION MODEL; SUBVENTRICULAR ZONE; HIPPOCAMPAL NEUROGENESIS; GRANULE CELLS; FRONTAL LESIONS; NERVOUS-SYSTEM; IN-VIVO; AGE	It is well known that the cognitive functions of juveniles recover to a greater extent than adult patients following traumatic brain injury (TBI). The exact mechanisms underlying this age-related disparity are unknown; however, we speculate that this improved recovery in juveniles following TBI may be associated with an endogenous neurogenic response in the hippocampus. We, therefore, examined the effects of TBI on cellular proliferation and differentiation in the dentate gyrus (DG) of the hippocampus in juvenile and adult rats following lateral fluid percussion injury (FPI). The temporal profile of the injury-induced proliferative response was determined using BrdU labeling at varying survival times. The differentiation of these newly generated cells was investigated using cell-type specific markers. We found that, following injury, there was a significant increase in cell proliferation in the DG in both injured juveniles and adults at 2 days post injury when compared to shams. When comparing the extent of cell proliferation between juveniles and adults following TBI, the absolute number of cells generated in the subgranular zone (SGZ) was far greater in the juveniles. Moreover, the percentage of newly generated cells in the SGZ that differentiated into neurons was nearly two times higher in the juveniles as compared to adults. Conversely, more glial differentiation was observed in the DG of adult rats. These findings provide compelling evidence that age-related differences in the neurogenic response to injury may underlie the differences observed in cognitive recovery in juvenile mammals as compared to adults following TBI.	Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia, Richmond, VA 23298 USA	Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia, POB 980631, Richmond, VA 23298 USA.	dsun@hsc.vcu.edu					ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dong HX, 2003, J NEUROSCI, V23, P1742; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Gray WP, 2002, NEUROSCI LETT, V330, P235, DOI 10.1016/S0304-3940(02)00810-8; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Jiang W, 2003, BRAIN RES, V977, P141, DOI 10.1016/S0006-8993(03)02438-7; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2002, J NEUROSCI, V22, P5365; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kirn JR, 1999, J COMP NEUROL, V411, P487; KOLB B, 1991, BEHAV BRAIN RES, V43, P51, DOI 10.1016/S0166-4328(05)80051-8; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Markakis EA, 1999, J COMP NEUROL, V406, P449; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pencea V, 2001, J NEUROSCI, V21, P6706; PLATASALAMAN CR, 1991, PEPTIDES, V12, P653, DOI 10.1016/0196-9781(91)90115-6; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Seki T, 1995, NEUROREPORT, V6, P2479, DOI 10.1097/00001756-199512150-00010; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	54	87	93	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2005	22	1					95	105		10.1089/neu.2005.22.95			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	889OF	WOS:000226451600006	15665605				2021-06-18	
J	Wolf, OT; Fujiwara, E; Luwinski, G; Kirschbaum, C; Markowitsch, HJ				Wolf, OT; Fujiwara, E; Luwinski, G; Kirschbaum, C; Markowitsch, HJ			No morning cortisol response in patients with severe global amnesia	PSYCHONEUROENDOCRINOLOGY			English	Article						amnesic patients; salivary cortisol; ambulatory sampling; circadian rhythm; morning cortisol increase	STRESS; BURNOUT; MEMORY; TIME	Activity of the hypothalamus pituitary adrenal (HPA) axis is characterized by a pronounced circadian rhythm. An acute increase in cortisol. levels occurs after awakening in the morning with continuously declining levels over the course of the remaining day. The morning cortisol increase probably reflects an activational response of the HPA axis aimed at preparing the body for the day. Some studies found patterns of enhanced or blunted waking cortisol responses observed under chronic stress, burnout, or post traumatic stress disorder. The present study wanted to characterize the morning cortisol. response and the circadian cortisol day profile in a sample of six mate patients with severe amnesia due to hypoxia, herpes simplex encephalitis or closed head injury. Age and gender matched relatives or friends served as controls. Cortisol was measured from saliva samples collected at home on two consecutive days. The patients were woken up in the morning by their partners or caregivers. The morning cortisol increase typically observed in healthy subjects and also observed in the control group was absent in the amnesic patients. In contrast, a normal circadian day profile was found in the amnesic patients, with a pronounced circadian cortisol decrease. Further studies are needed to understand the neurological or psychological mechanisms leading to a missing morning cortisol response in amnesic patients. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Dusseldorf, Inst Expt Psychol, D-40225 Dusseldorf, Germany; Univ Bielefeld, D-4800 Bielefeld, Germany; Tech Univ Dresden, Dept Psychol, D-8027 Dresden, Germany	Wolf, OT (corresponding author), Univ Dusseldorf, Inst Expt Psychol, Geb 23-02,Ebene 01,Room 43,Univ Str 1, D-40225 Dusseldorf, Germany.	oliver.wolf@uni-duesseldorf.de	Fujiwara, Esther/F-8233-2011; Kirschbaum, Clemens/AAB-1752-2020	Fujiwara, Esther/0000-0003-4154-0145; Wolf, Oliver T./0000-0002-9320-2124			De Vente W, 2003, OCCUP ENVIRON MED, V60, P54, DOI 10.1136/oem.60.suppl_1.i54; Edwards S, 2001, PSYCHONEUROENDOCRINO, V26, P613, DOI 10.1016/S0306-4530(01)00015-4; Gold PW, 2002, BIOL PSYCHIAT, V52, P381, DOI 10.1016/S0006-3223(02)01480-4; Kunz-Ebrecht SR, 2004, PSYCHONEUROENDOCRINO, V29, P516, DOI 10.1016/S0306-4530(03)00072-6; Lupien SJ, 2001, BEHAV BRAIN RES, V127, P137, DOI 10.1016/S0166-4328(01)00361-8; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P627, DOI 10.1080/01688639308402586; Markowitsch HJ, 2003, NEUROIMAGE, V20, pS132, DOI 10.1016/j.neuroimage.2003.09.010; MARKOWITSCH HJ, 2000, PRINCIPLES BEHAV COG, P257; Nelson HE, 1982, NATL ADULT READING T; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; Pruessner JC, 1997, LIFE SCI, V61, P2539, DOI 10.1016/S0024-3205(97)01008-4; Pruessner JC, 1999, PSYCHOSOM MED, V61, P197, DOI 10.1097/00006842-199903000-00012; Rohleder N, 2004, BIOL PSYCHIAT, V55, P745, DOI 10.1016/j.biopsych.2003.11.018; Roozendaal B, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn766; Steptoe A, 2003, PSYCHOSOM MED, V65, P461, DOI 10.1097/01.PSY.0000035717.78650.A1; Tchiteya BM, 2003, PSYCHONEUROENDOCRINO, V28, P674, DOI 10.1016/S0306-4530(02)00050-1; Wust S, 2000, PSYCHONEUROENDOCRINO, V25, P707, DOI 10.1016/S0306-4530(00)00021-4	17	87	88	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	JAN	2005	30	1					101	105		10.1016/j.psyneuen.2004.05.001			5	Endocrinology & Metabolism; Neurosciences; Psychiatry	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	858TL	WOS:000224214700011	15358447				2021-06-18	
J	Chamelian, L; Feinstein, A				Chamelian, L; Feinstein, A			Outcome after mild to moderate traumatic brain injury: The role of dizziness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						dizziness; head injuries; rehabilitation; psychosocial aspects	MINOR HEAD-INJURY; BENIGN POSITIONAL VERTIGO; FOLLOW-UP; VESTIBULAR DAMAGE; ACUTE PREDICTORS; RATING-SCALE; RETURN; WORK; SEQUELAE; QUESTIONNAIRE	Objective: To assess the specific effect of dizziness on psychosocial outcome after mild to moderate traumatic brain injury (TBI). Design: Six-month cross-sectional study. Setting: An outpatient TBI clinic in a tertiary care referral center. Participants: A consecutive sample of 207 adults with mild to moderate TBI, 138 (66.7%) of whom had subjective complaint of posttraumatic dizziness. Interventions: Not applicable. Main Outcome Measures: Psychosocial indices (Glasgow Outcome Scale [GOS], General Health Questionnaire [GHQ], Rivermead Head Injury Follow-Up Questionnaire [RHFUQ], return to work status) were collected from dizzy and nondizzy patients. Results: Despite similar demographic, TBI, and global disability (GOS) profiles of both groups, psychosocial functioning (GHQ, RHFUQ, return to work) was significantly worse in dizzy subjects (P<.01 for all indices). A logistic regression analysis identified dizziness (P=.006), total GHQ (P=.001) and psychotropic and analgesic use (P=.05) as significant independent predictors of reemployment. Conclusions: Although dizziness was closely linked to psychologic distress at 6 months after head injury, it also emerged as an independent predictor of failure to return to work, suggesting that not all its adverse effects on outcome are psychologically mediated. Clinicians need to be alert to the presence of dizziness as an adverse prognostic indicator after mild to moderate TBI. (C) 2004 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Toronto, Toronto, ON, Canada	Feinstein, A (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	antfeinstein@aol.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Balaban CD, 2001, J ANXIETY DISORD, V15, P53, DOI 10.1016/S0887-6185(00)00042-6; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; BERMAN JM, 1978, J OTOLARYNGOL, V7, P237; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EAGGER S, 1992, J NEUROL NEUROSUR PS, V55, P383, DOI 10.1136/jnnp.55.5.383; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FROMMBERGER UH, 1994, ARCH INTERN MED, V154, P590; Furman JM, 2001, J ANXIETY DISORD, V15, P9, DOI 10.1016/S0887-6185(00)00040-2; GANNON RP, 1978, ARCH OTOLARYNGOL, V104, P404; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; JENNETT B, 1975, LANCET, V1, P480; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KROENKE K, 1993, J GEN INTERN MED, V8, P530, DOI 10.1007/BF02599633; KROENKE K, 1994, J GEN INTERN MED, V9, P684, DOI 10.1007/BF02599010; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHUTTY MS, 1991, ARCH PHYS MED REHAB, V72, P473; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; SULLIVAN M, 1993, ARCH INTERN MED, V153, P1479, DOI 10.1001/archinte.153.12.1479; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; TUOHIMAA P, 1978, ACTA OTO-LARYNGOL, V359, P5; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLSON GN, 1981, J LARYNGOL OTOL, V95, P1213, DOI 10.1017/S0022215100092057; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	54	87	87	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2004	85	10					1662	1666		10.1016/j.apmr.2004.02.012			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	861GS	WOS:000224404700016	15468028				2021-06-18	
J	Suh, SW; Garnier, P; Aoyama, K; Chen, YM; Swanson, RA				Suh, SW; Garnier, P; Aoyama, K; Chen, YM; Swanson, RA			Zinc release contributes to hypoglycemia-induced neuronal death	NEUROBIOLOGY OF DISEASE			English	Article						zinc; N-(6-methoxy-8-quinolyl)-paro-toluenesulfonamide; TSQ; hypoglycemia; glucose; hippocampus; neuron; insulin; poly (ADP-ribose) polymerase	POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; HISTOCHEMICALLY REACTIVE ZINC; HIPPOCAMPAL MOSSY FIBERS; TRAUMATIC BRAIN-INJURY; CELL-DEATH; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; GLYCEMIC CONTROL; FOCAL ISCHEMIA; CYCLOSPORINE-A	Neurons exposed to zinc exhibit activation of poly(ADP-ribose) polymerase-1 (PARP-1), an enzyme that normally participates in DNA repair but promotes cell death when extensively activated. Endogenous, vesicular zinc in brain is released to the extracellular space under conditions causing neuronal depolarization. Here, we used a rat model of insulin-induced hypoglycemia to assess the role of zinc release in PARP-I activation and neuronal death after severe hypoglycemia. Zinc staining with N-(6-methoxy-8-quinolyl)-para-toluenesulfonamide (TSQ) showed depletion of presynaptic vesicular zinc from hippocampal mossy fiber terminals and accumulation of weakly bound zinc in hippocampal CA1 cell bodies after severe hypoglycemia. Intracerebroventricular injection of the zinc chelator calcium ethylene-diamine tetraacetic acid (CaEDTA) blocked the zinc accumulation and significantly reduced hypoglycemia-induced neuronal death. CaEDTA also attenuated the accumulation of poly (ADP-ribose), the enzymatic product of PARP-1, in hippocampal neurons. These results suggest that zinc translocation is an intermediary step linking hypoglycemia to PARP-1 activation and neuronal death. (C) 2004 Elsevier Inc. All rights reserved.	Univ Calif San Francisco, Dept Neurol 127, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Swanson, RA (corresponding author), Univ Calif San Francisco, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.	ray@itsa.ucsf.edu		Garnier, Philippe/0000-0002-7877-3113; Swanson, Raymond/0000-0002-3664-5359	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41421] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041421] Funding Source: NIH RePORTER		ANIKSZTEJN L, 1987, BRAIN RES, V404, P58, DOI 10.1016/0006-8993(87)91355-2; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; AUER RN, 1989, CLIN NEUROPATHOL, V8, P63; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; AUER RN, 1993, BAILLIERE CLIN ENDOC, V7, P611, DOI 10.1016/S0950-351X(05)80210-1; AUER RN, 1984, DIABETES, V33, P1090, DOI 10.2337/diabetes.33.11.1090; BEAULIEU C, 1992, NEUROREPORT, V3, P861, DOI 10.1097/00001756-199210000-00010; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203; Davis EA, 1998, ARCH DIS CHILD, V78, P111, DOI 10.1136/adc.78.2.111; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; Frederickson CJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1659, DOI 10.1177/002215540205001210; FREDERICKSON CJ, 1992, J CHEM NEUROANAT, V5, P521, DOI 10.1016/0891-0618(92)90007-D; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Friberg H, 1998, J NEUROSCI, V18, P5151; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Kerchner GA, 2000, J PHYSIOL-LONDON, V528, P39, DOI 10.1111/j.1469-7793.2000.00039.x; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lee JM, 2002, NEUROSCIENCE, V115, P871, DOI 10.1016/S0306-4522(02)00513-4; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lincoln NB, 1996, DIABETES CARE, V19, P656, DOI 10.2337/diacare.19.6.656; Love S, 1999, NEUROPATH APPL NEURO, V25, P98; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PERRIN DD, 1979, IUPAC CHEM DATA SERI, V22, P399; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sheline CT, 2003, EUR J NEUROSCI, V18, P1402, DOI 10.1046/j.1460-9568.2003.02865.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 2001, NEUROREPORT, V12, P1523, DOI 10.1097/00001756-200105250-00044; Suh SW, 1999, J HISTOCHEM CYTOCHEM, V47, P969, DOI 10.1177/002215549904700715; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TAKATA TOY, 2002, SOC NEUR ABSTR, V28, P197; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; Virag L, 1999, BRIT J PHARMACOL, V126, P769, DOI 10.1038/sj.bjp.0702332; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; WIELOCH T, 1984, J NEUROCHEM, V43, P160, DOI 10.1111/j.1471-4159.1984.tb06692.x; Yin HZ, 2002, J NEUROSCI, V22, P1273, DOI 10.1523/JNEUROSCI.22-04-01273.2002; YING W, 2003, BIOCHEM BIOPH RES CO, V308, P89; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	58	87	93	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	AUG	2004	16	3					538	545		10.1016/j.nbd.2004.04.017			8	Neurosciences	Neurosciences & Neurology	841SF	WOS:000222951000007	15262265				2021-06-18	
